{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU"
  },
  "cells": [
    {
      "cell_type": "code",
      "source": [
        "!pip install langchain-community\n",
        "!pip install faiss-gpu"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0LFxwW3f_jhr",
        "outputId": "90355ba9-f6fa-4df0-e71a-2d4a1b26c235"
      },
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting langchain-community\n",
            "  Downloading langchain_community-0.3.12-py3-none-any.whl.metadata (2.9 kB)\n",
            "Requirement already satisfied: PyYAML>=5.3 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (6.0.2)\n",
            "Requirement already satisfied: SQLAlchemy<3,>=1.4 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.0.36)\n",
            "Requirement already satisfied: aiohttp<4.0.0,>=3.8.3 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (3.11.10)\n",
            "Collecting dataclasses-json<0.7,>=0.5.7 (from langchain-community)\n",
            "  Downloading dataclasses_json-0.6.7-py3-none-any.whl.metadata (25 kB)\n",
            "Collecting httpx-sse<0.5.0,>=0.4.0 (from langchain-community)\n",
            "  Downloading httpx_sse-0.4.0-py3-none-any.whl.metadata (9.0 kB)\n",
            "Requirement already satisfied: langchain<0.4.0,>=0.3.12 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.3.12)\n",
            "Requirement already satisfied: langchain-core<0.4.0,>=0.3.25 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.3.25)\n",
            "Requirement already satisfied: langsmith<0.3,>=0.1.125 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (0.2.3)\n",
            "Requirement already satisfied: numpy<2,>=1.22.4 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (1.26.4)\n",
            "Collecting pydantic-settings<3.0.0,>=2.4.0 (from langchain-community)\n",
            "  Downloading pydantic_settings-2.7.0-py3-none-any.whl.metadata (3.5 kB)\n",
            "Requirement already satisfied: requests<3,>=2 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (2.32.3)\n",
            "Requirement already satisfied: tenacity!=8.4.0,<10,>=8.1.0 in /usr/local/lib/python3.10/dist-packages (from langchain-community) (9.0.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (2.4.4)\n",
            "Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.3.2)\n",
            "Requirement already satisfied: async-timeout<6.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (4.0.3)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (24.3.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.5.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (6.1.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (0.2.1)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp<4.0.0,>=3.8.3->langchain-community) (1.18.3)\n",
            "Collecting marshmallow<4.0.0,>=3.18.0 (from dataclasses-json<0.7,>=0.5.7->langchain-community)\n",
            "  Downloading marshmallow-3.23.2-py3-none-any.whl.metadata (7.1 kB)\n",
            "Collecting typing-inspect<1,>=0.4.0 (from dataclasses-json<0.7,>=0.5.7->langchain-community)\n",
            "  Downloading typing_inspect-0.9.0-py3-none-any.whl.metadata (1.5 kB)\n",
            "Requirement already satisfied: langchain-text-splitters<0.4.0,>=0.3.3 in /usr/local/lib/python3.10/dist-packages (from langchain<0.4.0,>=0.3.12->langchain-community) (0.3.3)\n",
            "Requirement already satisfied: pydantic<3.0.0,>=2.7.4 in /usr/local/lib/python3.10/dist-packages (from langchain<0.4.0,>=0.3.12->langchain-community) (2.10.3)\n",
            "Requirement already satisfied: jsonpatch<2.0,>=1.33 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.25->langchain-community) (1.33)\n",
            "Requirement already satisfied: packaging<25,>=23.2 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.25->langchain-community) (24.2)\n",
            "Requirement already satisfied: typing-extensions>=4.7 in /usr/local/lib/python3.10/dist-packages (from langchain-core<0.4.0,>=0.3.25->langchain-community) (4.12.2)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.3,>=0.1.125->langchain-community) (0.28.1)\n",
            "Requirement already satisfied: orjson<4.0.0,>=3.9.14 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.3,>=0.1.125->langchain-community) (3.10.12)\n",
            "Requirement already satisfied: requests-toolbelt<2.0.0,>=1.0.0 in /usr/local/lib/python3.10/dist-packages (from langsmith<0.3,>=0.1.125->langchain-community) (1.0.0)\n",
            "Collecting python-dotenv>=0.21.0 (from pydantic-settings<3.0.0,>=2.4.0->langchain-community)\n",
            "  Downloading python_dotenv-1.0.1-py3-none-any.whl.metadata (23 kB)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2->langchain-community) (2024.12.14)\n",
            "Requirement already satisfied: greenlet!=0.4.17 in /usr/local/lib/python3.10/dist-packages (from SQLAlchemy<3,>=1.4->langchain-community) (3.1.1)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.3,>=0.1.125->langchain-community) (3.7.1)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->langsmith<0.3,>=0.1.125->langchain-community) (1.0.7)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->langsmith<0.3,>=0.1.125->langchain-community) (0.14.0)\n",
            "Requirement already satisfied: jsonpointer>=1.9 in /usr/local/lib/python3.10/dist-packages (from jsonpatch<2.0,>=1.33->langchain-core<0.4.0,>=0.3.25->langchain-community) (3.0.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.12->langchain-community) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.27.1 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.7.4->langchain<0.4.0,>=0.3.12->langchain-community) (2.27.1)\n",
            "Collecting mypy-extensions>=0.3.0 (from typing-inspect<1,>=0.4.0->dataclasses-json<0.7,>=0.5.7->langchain-community)\n",
            "  Downloading mypy_extensions-1.0.0-py3-none-any.whl.metadata (1.1 kB)\n",
            "Requirement already satisfied: sniffio>=1.1 in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.3,>=0.1.125->langchain-community) (1.3.1)\n",
            "Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio->httpx<1,>=0.23.0->langsmith<0.3,>=0.1.125->langchain-community) (1.2.2)\n",
            "Downloading langchain_community-0.3.12-py3-none-any.whl (2.5 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m2.5/2.5 MB\u001b[0m \u001b[31m48.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading dataclasses_json-0.6.7-py3-none-any.whl (28 kB)\n",
            "Downloading httpx_sse-0.4.0-py3-none-any.whl (7.8 kB)\n",
            "Downloading pydantic_settings-2.7.0-py3-none-any.whl (29 kB)\n",
            "Downloading marshmallow-3.23.2-py3-none-any.whl (49 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m49.3/49.3 kB\u001b[0m \u001b[31m4.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading python_dotenv-1.0.1-py3-none-any.whl (19 kB)\n",
            "Downloading typing_inspect-0.9.0-py3-none-any.whl (8.8 kB)\n",
            "Downloading mypy_extensions-1.0.0-py3-none-any.whl (4.7 kB)\n",
            "Installing collected packages: python-dotenv, mypy-extensions, marshmallow, httpx-sse, typing-inspect, pydantic-settings, dataclasses-json, langchain-community\n",
            "Successfully installed dataclasses-json-0.6.7 httpx-sse-0.4.0 langchain-community-0.3.12 marshmallow-3.23.2 mypy-extensions-1.0.0 pydantic-settings-2.7.0 python-dotenv-1.0.1 typing-inspect-0.9.0\n",
            "Collecting faiss-gpu\n",
            "  Downloading faiss_gpu-1.7.2-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (1.4 kB)\n",
            "Downloading faiss_gpu-1.7.2-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (85.5 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m85.5/85.5 MB\u001b[0m \u001b[31m8.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: faiss-gpu\n",
            "Successfully installed faiss-gpu-1.7.2\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.text_splitter import RecursiveJsonSplitter\n",
        "from langchain.document_loaders import PyPDFLoader, DirectoryLoader\n",
        "from langchain.embeddings import HuggingFaceEmbeddings\n",
        "from langchain.vectorstores import FAISS\n",
        "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
        "from langchain.docstore.document import Document"
      ],
      "metadata": {
        "id": "5q43WJxw_aGF"
      },
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import json"
      ],
      "metadata": {
        "id": "NrPoWcEw_aCj"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install python-Levenshtein"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ZOVc4kiz_Z9G",
        "outputId": "295508c5-cef9-4f77-917e-7ea24876ac40"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting python-Levenshtein\n",
            "  Downloading python_Levenshtein-0.26.1-py3-none-any.whl.metadata (3.7 kB)\n",
            "Collecting Levenshtein==0.26.1 (from python-Levenshtein)\n",
            "  Downloading levenshtein-0.26.1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (3.2 kB)\n",
            "Collecting rapidfuzz<4.0.0,>=3.9.0 (from Levenshtein==0.26.1->python-Levenshtein)\n",
            "  Downloading rapidfuzz-3.11.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (11 kB)\n",
            "Downloading python_Levenshtein-0.26.1-py3-none-any.whl (9.4 kB)\n",
            "Downloading levenshtein-0.26.1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (162 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m162.6/162.6 kB\u001b[0m \u001b[31m10.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading rapidfuzz-3.11.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (3.1 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m3.1/3.1 MB\u001b[0m \u001b[31m43.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: rapidfuzz, Levenshtein, python-Levenshtein\n",
            "Successfully installed Levenshtein-0.26.1 python-Levenshtein-0.26.1 rapidfuzz-3.11.0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import Levenshtein"
      ],
      "metadata": {
        "id": "jE1kVuQi_Lck"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def load_documents():\n",
        "    documents = []\n",
        "    for path in DATA_PATH:\n",
        "        with open(path, 'r', encoding=\"utf8\") as file:\n",
        "            text = json.load(file)\n",
        "\n",
        "            for articles in text:\n",
        "                doc = Document(\n",
        "                    page_content=articles['text'],\n",
        "                    metadata={\"source\": articles[\"link\"], \"title\": articles[\"title\"]},\n",
        "                )\n",
        "                documents.append(doc)\n",
        "\n",
        "    return documents"
      ],
      "metadata": {
        "id": "ewarHJXJ_LaB"
      },
      "execution_count": 6,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def filter_words_by_similarity(target_word, threshold=0.7):\n",
        "    \"\"\"\n",
        "    Filters words from the list based on similarity to the target word.\n",
        "\n",
        "    Args:\n",
        "        target_word (str): The reference word.\n",
        "        word_list (list): A list of words to compare.\n",
        "        threshold (float): Similarity threshold (0 to 1). Words with similarity <= threshold are ignored.\n",
        "\n",
        "    Returns:\n",
        "        list: A filtered list of words with similarity above the threshold.\n",
        "    \"\"\"\n",
        "    word_list = [\n",
        "                \"write acknowledgement\",\n",
        "                \"funding\",\n",
        "                \"supplementary data\",\n",
        "                \"author contribution\",\n",
        "                \"contributor information\",\n",
        "                \"study approval\",\n",
        "                \"associated data\",\n",
        "                \"conflict of interest\",\n",
        "                \"disclosure of potential conflict of interest\",\n",
        "                \"associated data\",\n",
        "                \"added value of study\",\n",
        "                \"implication of all available evidence\",\n",
        "                \"study funding\",\n",
        "                \"disclosure\",\n",
        "                \"history\",\n",
        "                \"what's new\",\n",
        "                \"declaration of interest\",\n",
        "                \"appendix\"\n",
        "               ]\n",
        "\n",
        "    for word in word_list:\n",
        "        # Compute normalized Levenshtein distance (1 - similarity)\n",
        "        similarity = 1 - Levenshtein.distance(target_word, word) / max(len(target_word), len(word))\n",
        "\n",
        "    return similarity\n"
      ],
      "metadata": {
        "id": "ffT1MSzk_LXm"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# Load research papers\n",
        "def load_paper(DATA_PATH_PDF):\n",
        "    documents = []\n",
        "    for path in DATA_PATH_PDF:\n",
        "        with open(path, 'r', encoding=\"utf8\") as file:\n",
        "            text = json.load(file)\n",
        "\n",
        "        for paper in text:\n",
        "\n",
        "            for key in paper.keys():\n",
        "\n",
        "                if key == \"sections\":\n",
        "                    for k in paper[key].keys():\n",
        "                        similarity = filter_words_by_similarity(k)\n",
        "\n",
        "                        if len(paper[key][k].split(\" \")) < 10 or similarity >= 0.7:\n",
        "                            continue\n",
        "                        hierarchy_level = \"top-level\" if key == \"abstract\" else (\n",
        "                            \"mid-level\" if key in [\"methods\", \"results\"] else \"fine-grained\"\n",
        "                        )\n",
        "                        try:\n",
        "                            doc = Document(\n",
        "                                page_content=paper[key][k],\n",
        "                                metadata={\n",
        "                                    \"title\": paper[\"title\"],\n",
        "                                    \"section\": k\n",
        "                                },\n",
        "                            )\n",
        "                        except Exception as e:\n",
        "                            print(e)\n",
        "                            continue\n",
        "                        documents.append(doc)\n",
        "\n",
        "                else:\n",
        "\n",
        "                    similarity = filter_words_by_similarity(key)\n",
        "\n",
        "                    if len(paper[key].split(\" \")) < 10 or similarity >= 0.7:\n",
        "                        continue\n",
        "                    hierarchy_level = \"top-level\" if key == \"abstract\" else (\n",
        "                        \"mid-level\" if key in [\"methods\", \"results\"] else \"fine-grained\"\n",
        "                    )\n",
        "                    try:\n",
        "                        doc = Document(\n",
        "                            page_content=paper[key],\n",
        "                            metadata={\n",
        "                                \"title\": paper[\"title\"],\n",
        "                                \"section\": key\n",
        "                            },\n",
        "                        )\n",
        "                    except Exception as e:\n",
        "                        print(e)\n",
        "                        continue\n",
        "                    documents.append(doc)\n",
        "\n",
        "\n",
        "\n",
        "    return documents"
      ],
      "metadata": {
        "id": "rur8Pa2-_U4O"
      },
      "execution_count": 8,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "DB_FAISS_PATH=\"vectorstores/db_faiss_research_5461_\""
      ],
      "metadata": {
        "id": "_SmQpAQS_XoA"
      },
      "execution_count": 14,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 15,
      "metadata": {
        "id": "0llQaWMD_AzZ"
      },
      "outputs": [],
      "source": [
        "def create_vector_db(documents):\n",
        "\n",
        "    text_splitter = RecursiveCharacterTextSplitter(chunk_size=550)\n",
        "\n",
        "    split_docs = text_splitter.split_documents(documents)\n",
        "\n",
        "    embeddings = HuggingFaceEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\",\n",
        "    model_kwargs = {'device': 'cuda:0'})\n",
        "\n",
        "    db = FAISS.from_documents(split_docs, embeddings)\n",
        "    db.save_local(DB_FAISS_PATH)\n",
        "\n",
        "\n",
        "if __name__ == \"__main__\":\n",
        "\n",
        "    DATA_PATH_PDF = [r\"/content/papers1.json\"]\n",
        "\n",
        "    text = load_paper(DATA_PATH_PDF)\n",
        "\n",
        "    #print(paper_docs)\n",
        "    create_vector_db(text)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import networkx as nx\n",
        "import matplotlib.pyplot as plt\n",
        "import spacy\n",
        "\n",
        "triplets1 = [\n",
        "    (\"Diabetes\", \"causes\", \"Neuropathy\"),\n",
        "    (\"Diabetes\", \"increases risk of\", \"Kidney Disease\"),\n",
        "    (\"Diabetes\", \"treated with\", \"Metformin\"),\n",
        "    (\"Diabetes\", \"managed by\", \"Lifestyle Changes\"),\n",
        "    (\"Kidney Disease\", \"leads to\", \"Dialysis Requirement\"),\n",
        "    (\"Kidney Disease\", \"caused by\", \"Hypertension\"),\n",
        "    (\"Hypertension\", \"increases risk of\", \"Heart Disease\"),\n",
        "    (\"Hypertension\", \"treated with\", \"ACE Inhibitors\"),\n",
        "    (\"Heart Disease\", \"leads to\", \"Heart Failure\"),\n",
        "    (\"Heart Disease\", \"caused by\", \"High Cholesterol\"),\n",
        "    (\"High Cholesterol\", \"treated with\", \"Statins\"),\n",
        "    (\"High Cholesterol\", \"linked to\", \"Obesity\"),\n",
        "    (\"Obesity\", \"causes\", \"Diabetes\"),\n",
        "    (\"Obesity\", \"managed by\", \"Exercise\"),\n",
        "    (\"Exercise\", \"reduces risk of\", \"Hypertension\"),\n",
        "    (\"Exercise\", \"recommended for\", \"Heart Health\"),\n",
        "    (\"Smoking\", \"causes\", \"Lung Cancer\"),\n",
        "    (\"Smoking\", \"increases risk of\", \"Heart Disease\"),\n",
        "    (\"Lung Cancer\", \"treated with\", \"Chemotherapy\"),\n",
        "    (\"Chemotherapy\", \"causes\", \"Fatigue\"),\n",
        "    (\"Fatigue\", \"managed by\", \"Physical Therapy\"),\n",
        "    (\"Physical Therapy\", \"recommended for\", \"Muscle Weakness\"),\n",
        "    (\"Muscle Weakness\", \"associated with\", \"Vitamin D Deficiency\"),\n",
        "    (\"Vitamin D Deficiency\", \"causes\", \"Osteoporosis\"),\n",
        "    (\"Osteoporosis\", \"leads to\", \"Bone Fractures\"),\n",
        "    (\"Bone Fractures\", \"treated with\", \"Calcium Supplements\"),\n",
        "    (\"Calcium Supplements\", \"recommended for\", \"Osteoporosis\"),\n",
        "    (\"Diabetes\", \"causes\", \"Retinopathy\"),\n",
        "    (\"Retinopathy\", \"treated with\", \"Laser Therapy\"),\n",
        "    (\"Laser Therapy\", \"used in\", \"Ophthalmology\"),\n",
        "    (\"Ophthalmology\", \"treats\", \"Vision Disorders\"),\n",
        "    (\"Kidney Disease\", \"linked to\", \"High Blood Pressure\"),\n",
        "    (\"High Blood Pressure\", \"causes\", \"Stroke\"),\n",
        "    (\"Stroke\", \"treated with\", \"Rehabilitation Therapy\"),\n",
        "    (\"Rehabilitation Therapy\", \"improves\", \"Motor Function\"),\n",
        "    (\"Motor Function\", \"affected by\", \"Nerve Damage\"),\n",
        "    (\"Nerve Damage\", \"caused by\", \"Diabetes\"),\n",
        "    (\"Heart Disease\", \"causes\", \"Chest Pain\"),\n",
        "    (\"Chest Pain\", \"diagnosed by\", \"ECG\"),\n",
        "    (\"ECG\", \"used in\", \"Cardiology\"),\n",
        "    (\"Cardiology\", \"treats\", \"Heart Disorders\"),\n",
        "    (\"Heart Disorders\", \"linked to\", \"Hypertension\"),\n",
        "    (\"Hypertension\", \"monitored by\", \"Blood Pressure Monitors\"),\n",
        "    (\"Blood Pressure Monitors\", \"recommended for\", \"Home Monitoring\"),\n",
        "    (\"Obesity\", \"linked to\", \"Sleep Apnea\"),\n",
        "    (\"Sleep Apnea\", \"managed by\", \"CPAP Machines\"),\n",
        "    (\"CPAP Machines\", \"improve\", \"Breathing Patterns\"),\n",
        "    (\"Breathing Patterns\", \"affected by\", \"Asthma\"),\n",
        "    (\"Asthma\", \"triggered by\", \"Airborne Allergens\"),\n",
        "    (\"Airborne Allergens\", \"include\", \"Pollen\"),\n",
        "    (\"Pollen\", \"causes\", \"Seasonal Allergies\"),\n",
        "    (\"Seasonal Allergies\", \"treated with\", \"Antihistamines\"),\n",
        "    (\"Antihistamines\", \"reduce\", \"Allergic Reactions\"),\n",
        "    (\"Allergic Reactions\", \"cause\", \"Skin Rashes\"),\n",
        "    (\"Skin Rashes\", \"treated with\", \"Topical Creams\"),\n",
        "    (\"Topical Creams\", \"recommended for\", \"Eczema\"),\n",
        "    (\"Eczema\", \"causes\", \"Skin Irritation\"),\n",
        "    (\"Skin Irritation\", \"managed by\", \"Moisturizers\"),\n",
        "    (\"Moisturizers\", \"reduce\", \"Dry Skin\"),\n",
        "    (\"Dry Skin\", \"linked to\", \"Dehydration\"),\n",
        "    (\"Dehydration\", \"caused by\", \"Heat Stroke\"),\n",
        "    (\"Heat Stroke\", \"managed by\", \"Rehydration Therapy\"),\n",
        "    (\"Rehydration Therapy\", \"prevents\", \"Electrolyte Imbalance\"),\n",
        "    (\"Electrolyte Imbalance\", \"causes\", \"Muscle Cramps\"),\n",
        "    (\"Muscle Cramps\", \"treated with\", \"Magnesium Supplements\"),\n",
        "    (\"Magnesium Supplements\", \"recommended for\", \"Muscle Health\"),\n",
        "    (\"Muscle Health\", \"improved by\", \"Exercise\"),\n",
        "    (\"Exercise\", \"recommended for\", \"Weight Management\"),\n",
        "    (\"Weight Management\", \"reduces risk of\", \"Diabetes\"),\n",
        "    (\"Diabetes\", \"causes\", \"Peripheral Neuropathy\"),\n",
        "    (\"Peripheral Neuropathy\", \"treated with\", \"Pain Relievers\"),\n",
        "    (\"Pain Relievers\", \"used for\", \"Chronic Pain\"),\n",
        "    (\"Chronic Pain\", \"managed by\", \"Physical Therapy\"),\n",
        "    (\"Physical Therapy\", \"improves\", \"Joint Mobility\"),\n",
        "    (\"Joint Mobility\", \"reduced by\", \"Arthritis\"),\n",
        "    (\"Arthritis\", \"treated with\", \"Anti-Inflammatory Drugs\"),\n",
        "    (\"Anti-Inflammatory Drugs\", \"reduce\", \"Joint Swelling\"),\n",
        "    (\"Joint Swelling\", \"causes\", \"Reduced Mobility\"),\n",
        "    (\"Reduced Mobility\", \"managed by\", \"Assistive Devices\"),\n",
        "    (\"Assistive Devices\", \"recommended for\", \"Elderly Patients\"),\n",
        "    (\"Elderly Patients\", \"at risk of\", \"Osteoporosis\"),\n",
        "    (\"Osteoporosis\", \"causes\", \"Fractures\"),\n",
        "    (\"Fractures\", \"treated with\", \"Bone Grafts\"),\n",
        "    (\"Bone Grafts\", \"used in\", \"Orthopedic Surgery\"),\n",
        "    (\"Orthopedic Surgery\", \"required for\", \"Severe Fractures\"),\n",
        "    (\"Severe Fractures\", \"lead to\", \"Reduced Quality of Life\"),\n",
        "    (\"Reduced Quality of Life\", \"improved by\", \"Rehabilitation Therapy\"),\n",
        "    (\"Rehabilitation Therapy\", \"supports\", \"Mental Health\"),\n",
        "    (\"Mental Health\", \"affected by\", \"Chronic Illness\"),\n",
        "    (\"Chronic Illness\", \"linked to\", \"Depression\"),\n",
        "    (\"Depression\", \"treated with\", \"SSRIs\"),\n",
        "    (\"SSRIs\", \"used for\", \"Anxiety Disorders\"),\n",
        "    (\"Anxiety Disorders\", \"cause\", \"Sleep Disturbances\"),\n",
        "    (\"Sleep Disturbances\", \"managed by\", \"Melatonin Supplements\"),\n",
        "    (\"Melatonin Supplements\", \"improve\", \"Sleep Quality\"),\n",
        "    (\"Sleep Quality\", \"linked to\", \"Mental Well-being\"),\n",
        "    (\"Mental Well-being\", \"improved by\", \"Exercise\"),\n",
        "    (\"Exercise\", \"benefits\", \"Cardiovascular Health\"),\n",
        "    (\"Cardiovascular Health\", \"enhanced by\", \"Heart-Healthy Diet\"),\n",
        "    (\"Heart-Healthy Diet\", \"reduces\", \"Cholesterol Levels\"),\n",
        "    (\"Cholesterol Levels\", \"monitored by\", \"Blood Tests\"),\n",
        "    (\"Blood Tests\", \"used to\", \"Diagnose Conditions\"),\n",
        "    (\"Conditions\", \"include\", \"Diabetes\"),\n",
        "]\n"
      ],
      "metadata": {
        "collapsed": true,
        "id": "XuuOFKYFAGmU"
      },
      "execution_count": 50,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "triplets = [('pwmscan', 'instance of', 'web server'), ('hematopoiesis', 'Positive_Correlation', 'epigenetic modification'), ('STAT1', 'Association', 'TFs'), ('H3K27 methyltransferase', 'Association', 'Ezh2'), ('gRNAs', 'Association', '165 bp starting oligonucleotide'), ('Sotorasib', 'Positive_Correlation', 'Sotorasib'), ('H3.1', 'Association', 'H2A'), ('Esrrb', 'Negative_Correlation', 'Dax1'), ('SERCA2a', 'Positive_Correlation', 'heart failure (HF)1'), ('galcanezumab', 'Positive_Correlation', 'CGRP'), ('schizophrenia', 'Positive_Correlation', 'Cariprazine'), ('TADs', 'Association', 'LADs'), ('MDM2', 'has part', 'p53'), ('STAT1', '', 'STAT1'), ('carbon dioxide', 'has part', 'carbon dioxide'), ('RP101988', 'Positive_Correlation', 'RP101988'), ('oprozomib', 'Positive_Correlation', 'HNSCC'), ('PMC Background Network', 'Association', 'epigenomic'), ('long noncoding RNA', 'Association', 'lncRNA'), ('methidiumpropyl-EDTA', 'uses', 'MPE-Fe(II)'), ('KRAS p.G12C mutation', 'Association', 'solid tumors'), ('RNF16834,39', 'Positive_Correlation', '53BP1'), ('epigenomic', 'Association', 'epigenomic'), ('CMT', 'Association', 'gene'), ('Christianson syndrome', 'Association', 'PMC'), ('β-dystroglycan', 'Association', 'DAPC'), ('RP101075', 'Positive_Correlation', 'RP101988'), ('topoisomerase 2', 'Positive_Correlation', 'AML'), ('lncRNA', 'subclass of', 'RNA'), ('hepatocellular carcinoma', 'Positive_Correlation', 'hepatocellular carcinoma'), ('α-synuclein at Serine 129', 'Positive_Synuclein at Serine 129', 'α-synuclein at Serine 129'), ('Rfc5p', 'Positive_Correlation', 'RF-C'), ('H3', 'Association', 'K36M'), ('CNEE', 'subclass of', 'CNEE'), ('Stratum 1', 'followed by', 'Stratum 3'), ('α-synuclein phosphorylation at Serine 129', 'Positive_Correlation', 'α-synuclein phosphorylation at Serine 129'), ('Wapl', 'Positive_Correlation', 'acetylation defects'), ('CardioClassifier', 'Positive_Correlation', 'cardiac conditions (ICCs)'), ('dopamine D3 receptor', 'Positive_Correlation', 'anxiolytic'), ('Pfh1', 'subclass of', 'Pif1'), ('pLGG', 'Positive_Correlation', 'Selumetinib'), ('Sansom', 'country of citizenship', 'Australia'), ('cisplatin', 'Positive_Correlation', 'oprozomib'), ('TAL1', 'Positive_Correlation', 'LSD1'), ('cariprazine', 'Positive_Correlation', 'antidepressant'), ('ATM', 'Positive_Correlation', 'NBS1'), ('PMC', 'Association', 'Metazoan'), ('BILAG', 'Positive_Correlation', 'Composite Lupus Assessment'), ('H2A', 'Association', 'DNA repair'), ('H2A', 'Positive_Correlation', 'DNA repair'), ('Level of evidence', 'has part', '3'), ('TAL1', 'Positive_Correlation', 'hematopoiesis'), ('Cabozantinib', 'Positive_Correlation', 'Cabozantinib'), ('Pediatric Quality of Life Inventory', 'Positive_Correlation', 'HFMSE'), ('anifrolumab', 'Positive_Correlation', 'IFN'), ('HEK-293', 'Association', 'HEK-293'), ('DNA replication fork', 'Association', 'DNA replication'), ('H3', 'Association', 'G34'), ('lncRNA', 'Association', 'long noncoding RNA'), ('oprozomib', 'Positive_Correlation', 'histone deacetylase inhibitor (HDACi) vorinostat entinostat'), ('RPCs', 'Association', 'Mrc1'), ('DNA polymerase α primase', 'connects with', 'MCM helicase'), ('solid tumor malignancies', 'Positive_Correlation', 'carfilzomib'), ('cardiomyopathy', '', 'cardiomyopathy'), ('migraine', 'Positive_Correlation', 'amitriptyline'), ('genome', 'connects with', 'chromatin'), ('QTcF', 'Association', 'QTcF'), ('53BP1', 'Association', 'DNA damage'), ('TcdB', 'Negative_Correlation', 'bezlotoxumab'), ('APA site detection', 'use', 'site detection')]"
      ],
      "metadata": {
        "id": "T8PeSQZ1P0iu"
      },
      "execution_count": 97,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "triplets = [\n",
        "    ('p53', 'Association', 'MDM2'),\n",
        "    ('RNA polymerase II', 'Association', '5S ribosomal RNA'),\n",
        "    ('LSD1', 'Positive_Correlation', 'p4.2 promoter'),\n",
        "    ('Preeclampsia', 'Association', 'hyperinflammatory'),\n",
        "    ('DNA damage', 'Positive_Correlation', 'H2A'),\n",
        "    ('Ezh2', 'Association', 'H3K27 methyltransferase'),\n",
        "    ('p53', 'Positive_Correlation', 'cancer'),\n",
        "    ('TMPDB', 'instance of', 'web site'),\n",
        "    ('FRDA', 'Association', 'Friedreich’s PsyNetataxia'),\n",
        "    ('erythropoiesis', 'Association', 'GATA-1'),\n",
        "    ('Gfi-1b', 'subclass of', 'hematopoietic factor'),\n",
        "    ('Ebola Virus Infection', 'Positive_Correlation', 'ZMapp'),\n",
        "    ('GATA-1', 'subclass of', 'hematopoietic factor'),\n",
        "    ('Pta1 Scaffold Protein', 'Association', 'Pta1 Scaffold Protein'),\n",
        "    ('pineal region', 'connects with', 'spinal cord'),\n",
        "    ('5S ribosomal RNA', 'Association', 'RNA polymerase II'),\n",
        "    ('cell cycle progression', 'Positive_Correlation', 'DNA replication'),\n",
        "    ('TAL1', 'Positive_Correlation', 'LSD1'),\n",
        "    ('Eco1', 'Association', 'sister chromatid cohesion'),\n",
        "    ('hyperinflammatory', 'Association', 'Preeclampsia'),\n",
        "    ('CGRP', 'Positive_Correlation', 'galcanezumab'),\n",
        "    ('K27M-H3', 'Positive_Correlation', 'HIST1H3B'),\n",
        "    ('HCNEs', 'subclass of', 'noncoding element'),\n",
        "    ('galcanezumab', 'Positive_Correlation', 'CGRP'),\n",
        "    ('hSET1', 'Association', 'TAL1'),\n",
        "    ('H3K4 methylation', 'Positive_Correlation', 'H3K4 methylation'),\n",
        "    ('TMPDB', 'field of work', 'TMPDB'),\n",
        "    ('GATA-1', 'Positive_Correlation', 'Gfi-1b'),\n",
        "    ('Hst 5', 'instance of', 'Histatin 5'),\n",
        "    ('thermosensitive growth', 'Positive_Correlation', 'thermosensitive growth'),\n",
        "    ('LSD1', 'Positive_Correlation', 'thymidine kniase minimal promoter'),\n",
        "    ('HCNEs', 'Association', 'GRBs'),\n",
        "    ('IDH1/2', 'Positive_Correlation', 'G34V/R-H3'),\n",
        "    ('UniPROBE', 'Association', 'JASPAR'),\n",
        "    ('cohesin acetylation', 'Positive_Correlation', 'cohesin acetylation'),\n",
        "    ('TAL1', 'Association', 'hematopoiesis'),\n",
        "    ('TAL1', 'Association', 'epigenetic modification'),\n",
        "    ('fork slowing', 'Positive_Correlation', 'H2A'),\n",
        "    ('C.albicans', 'parent taxon', 'C.albicans'),\n",
        "    ('Cannotatr', 'field of work', 'genomic'),\n",
        "    ('Pfh1', 'Association', '5S rRNA'),\n",
        "    ('STAT1', 'Association', 'interferon-gamma stimulationin vivo'),\n",
        "    ('1500 kb variant of chromosome XII', 'subclass of', 'chromosome XII'),\n",
        "    ('dystrophin', 'Association', 'DAPC'),\n",
        "    ('ATMIN', 'Association', 'ATM cofactor'),\n",
        "    ('TNF', 'Association', 'hematopoietic regulatory genes'),\n",
        "    ('p53', 'Positive_Correlation', 'MDM2'),\n",
        "    ('DNA helicase', 'Positive_Correlation', 'DNA damage'),\n",
        "    ('ZMapp', 'Positive_Correlation', 'Ebola Virus Infection'),\n",
        "    ('TF', 'Association', 'genomic regions'),\n",
        "    ('H3', 'Positive_Correlation', 'IDH1/2'),\n",
        "    ('histone histone H3', 'Association', 'histone histone histone H3.3 mutations'),\n",
        "    ('phosphoryl transfer reactions', 'Association', 'phosphoryl transfer reactions'),\n",
        "    ('DNA damage', 'Positive_Correlation', 'Pfh1'),\n",
        "    ('Amitriptyline', 'Positive_Correlation', 'Childhood and Adolescent Migraine'),\n",
        "    ('TAL1', 'Positive_Correlation', 'histone lysine demethylase LSD1'),\n",
        "    ('ATR', 'Positive_Correlation', 'PR-Set7'),\n",
        "    ('ATRXmutations', 'Association', 'histone H3'),\n",
        "    ('choroid plexus', 'has part', 'transthyretin'),\n",
        "    ('STAT1', '', 'STAT1'),\n",
        "    ('Anifrolumab', 'Positive_Correlation', 'Anti–Interferon‐α Receptor Monoclonal Antibody'),\n",
        "    ('Christianson syndrome', 'Association', 'NHE6'),\n",
        "    ('LADs', 'Association', 'LADs'),\n",
        "    ('H3', 'Positive_Correlation', 'G34V/R-H3'),\n",
        "    ('2-aminobenzamide', 'Positive_Correlation', 'Huntington’s disease (HD)'),\n",
        "    ('compound 106', 'Positive_Correlation', 'HDAC inhibitors'),\n",
        "    ('H3K27 methyltransferase', 'Association', 'Ezh2'),\n",
        "    ('TAL1', 'Positive_Correlation', 'p4.2 promoter'),\n",
        "    ('H3', 'Association', 'G34'),\n",
        "    ('transthyretin', 'Association', 'transthyretin'),\n",
        "    ('proteins', 'Positive_Correlation', 'mass spectrometry'),\n",
        "    ('Dur31p', 'Positive_Correlation', 'polyamine transporters'),\n",
        "    ('DNA polymerase', 'Positive_Correlation', 'H2A'),\n",
        "    ('histone H4 lysine 20', 'Association', 'ATR'),\n",
        "    ('Metazoan', 'Association', 'CNEs'),\n",
        "    ('GENCODE', 'Association', 'lncRNA'),\n",
        "    ('erythropoiesis', 'Association', 'MeCP1'),\n",
        "    ('JACUSA', 'field of work', 'RNA editing'),\n",
        "    ('protein carbonylation sites', 'Association', 'protein carbonylation sites'),\n",
        "    ('mast', 'Association', 'megakaryocytic'),\n",
        "    ('β-dystroglycan', 'Association', 'DAPC'),\n",
        "    ('eliglustat', 'Positive_Correlation', 'Gaucher disease type 1'),\n",
        "    ('TADs', 'subclass of', 'TADs'),\n",
        "    ('HDAC', 'Positive_Correlation', 'FRDA'),\n",
        "    ('mammary cellsin', 'Positive_Correlation', 'tumor metastasisin'),\n",
        "    ('β-1,3-glucans', 'Association', 'β-1,3-glucans'),\n",
        "    ('histone methyl-lysine binding', 'Association', '53BP1'),\n",
        "    ('lncRNA', 'Association', 'long noncoding RNA'),\n",
        "    ('Drosophila Ctf4', 'Association', 'cell cycle progression'),\n",
        "    ('long noncoding RNA', 'Association', 'lncRNA'),\n",
        "    ('lysine residues', 'Association', 'lysine residues'),\n",
        "    ('lncRNA', 'subclass of', 'prognostic'),\n",
        "    ('Christianson syndrome', 'Association', 'Christianson syndrome'),\n",
        "    ('QTcF', 'Association', 'QTcF'),\n",
        "    ('Gaucher disease type 1', 'Positive_Correlation', 'eliglustat'),\n",
        "    ('NBS1', 'Association', 'ATM cofactor'),\n",
        "    ('ZCCHC17', 'Association', 'Alzheimer’s disease'),\n",
        "    ('snoRNA termination', 'Positive_Correlation', 'RNA polymerase II C-terminal domain Ser5-P dephosphorylation'),\n",
        "    ('Swi1', 'Association', 'TIMELESS homolog'),\n",
        "    ('gynecological cancers', 'subclass of', 'cancers'),\n",
        "    ('CNEE', 'subclass of', 'CNEE'),\n",
        "    ('IDH', 'Positive_Correlation', 'K27M-H3'),\n",
        "    ('spinal cord', 'connects with', 'cerebellum'),\n",
        "    ('Cancer Genome Atlas', 'derivative work', 'TCGA2BED'),\n",
        "    ('ATR', 'Positive_Correlation', 'histone H4 lysine 20'),\n",
        "    ('TAL1', 'Positive_Correlation', 'hSET1'),\n",
        "    ('GATA-1', 'Association', 'hematopoietic factor'),\n",
        "    ('GATA-1', 'Positive_Correlation', 'TAL-1'),\n",
        "    ('K27M-H3', 'Positive_Correlation', 'IDH'),\n",
        "    ('HDAC inhibitors', 'Positive_Correlation', 'compound 106'),\n",
        "    ('webSDA', 'use', 'macromolecular diffusional association'),\n",
        "    ('RPCs', 'has part', 'Mrc1'),\n",
        "    ('Mrc1', 'Association', 'RPCs'),\n",
        "    ('themutSLoperon', 'Positive_Correlation', 'themutSLoperon'),\n",
        "    ('thermosensitive growth', 'Positive_Correlation', 'thermosensitive growth'),\n",
        "    ('hematopoiesis', 'Association', 'TAL1'),\n",
        "    ('Anifrolumab', 'Positive_Correlation', 'Anti–Interferon‐α Receptor Monoclonal Antibody'),\n",
        "    ('mass spectrometry', 'Positive_Correlation', 'proteins'),\n",
        "    ('JASPAR', 'Association', 'UniPROBE'),\n",
        "    ('ATRXandTP53mutations', 'Positive_Correlation', 'K27M-H3'),\n",
        "    ('MCM2-7', 'Association', 'DNA polymerase α'),\n",
        "    ('RPCs', 'Positive_Correlation', 'DNA damage checkpoint'),\n",
        "    ('breast cancer', 'Association', 'lncRNAs'),\n",
        "    ('MeCP1', 'Association', 'erythropoiesis'),\n",
        "    ('hepadnaviral cccDNA', 'subclass of', 'minichromosomes'),\n",
        "    ('cancer', 'Positive_Correlation', 'p53'),\n",
        "    ('UniPROBE', 'Association', 'UniPROBE'),\n",
        "    ('GRBs', 'Association', 'HCNEs'),\n",
        "    ('GAL4 reporter', 'Positive_Correlation', 'thymidine kniase minimal promoter'),\n",
        "    ('GATA-1', 'Positive_Correlation', 'MeCP1'),\n",
        "    ('p4.2 promoter', 'Positive_Correlation', 'LSD1'),\n",
        "    ('β-1,3-glucans', 'Positive_Correlation', 'β-1,3-glucans'),\n",
        "    ('α-sarcoglycan', 'Association', 'DAPC'),\n",
        "    ('LADs', 'Association', 'TADs'),\n",
        "    ('transthyretin', 'Association', 'choroid plexus'),\n",
        "    ('polyamine transporters', 'Positive_Correlation', 'polyamine transporters'),\n",
        "    ('thalamus', 'connects with', 'spinal cord'),\n",
        "    ('tRNA', 'Association', 'RNA polymerase II'),\n",
        "    ('DNA', 'Association', 'COUGER'),\n",
        "    ('protein carbonylation sites', 'Association', 'protein carbonylation sites'),\n",
        "    ('EBF1', 'Association', 'hematopoietic regulatory genes'),\n",
        "    ('cerebellum', 'connects with', 'spinal cord'),\n",
        "    ('lncRNA', 'Association', 'GENCODE'),\n",
        "    ('sister chromatid cohesion', 'Association', 'Eco1'),\n",
        "    ('RNA polymerase II', 'Association', 'tRNA'),\n",
        "    ('H3.3', 'Association', 'disease development'),\n",
        "    ('heart failure (HF)1', 'Positive_Correlation', 'SERCA2a'),\n",
        "    ('mast erythroid', 'Association', 'megakaryocytic'),\n",
        "    ('GATA-1', 'Association', 'erythroid differentiation'),\n",
        "    ('GATA-1', 'Positive_Correlation', 'ACF'),\n",
        "    ('DNA replication', 'Association', 'cell cycle progression'),\n",
        "    ('RPCs', 'Association', 'Mrc1'),\n",
        "    ('LSD1', 'Association', 'TAL1'),\n",
        "    ('Pfh1', 'Positive_Correlation', 'DNA damage'),\n",
        "    ('LIMT', 'Positive_Correlation', 'tumor metastasisin'),\n",
        "    ('TP53mutations', 'Association', 'histone H3'),\n",
        "    ('RNA polymerase II C-terminal domain Ser5-P dephosphorylation', 'Positive_Correlation', 'snoRNA termination'),\n",
        "    ('H3', 'Positive_Correlation', 'H3'),\n",
        "    ('genomic regions', 'Association', 'TF'),\n",
        "    ('tumor metastasisin', 'Positive_Correlation', 'mammary cellsin'),\n",
        "    ('cohesin', 'has part', 'Smc3'),\n",
        "    ('GATA-1', 'Positive_Correlation', 'WCRF'),\n",
        "    ('Topiramate', 'Positive_Correlation', 'Childhood and Adolescent Migraine'),\n",
        "    ('spinal cord', 'connects with', 'thalamus'),\n",
        "    ('DNA damage checkpoint', 'Positive_Correlation', 'chromosome replication'),\n",
        "    ('IEMs', 'Association', 'IEMs'),\n",
        "    ('MCM2-7 helicase to DNA polymerase α', 'connects with', 'MCM2-7 helicase to MCM2-7 helicase'),\n",
        "    ('TADs', 'Association', 'LADs'),\n",
        "    ('MCM2-7 helicase to DNA polymerase α', 'connects with', 'MCM2-7 helicase to DNA polymerase α'),\n",
        "    ('SERCA2a', 'Positive_Correlation', 'heart failure (HF)1'),\n",
        "    ('HIST1H3B', 'Positive_Correlation', 'K27M-H3'),\n",
        "    ('Mrc1', 'part of', 'RPCs'),\n",
        "    ('iPSC', 'Positive_Correlation', 'Friedreich’s PsyNetataxia'),\n",
        "    ('mitochondrial respiratory chain complexes I and IV', 'has part', 'mitochondrial respiratory chain complexes I and IV'),\n",
        "    ('PR-Set7', 'Positive_Correlation', 'ATR'),\n",
        "    ('Placebo', 'Positive_Correlation', 'Childhood and Adolescent Migraine'),\n",
        "    ('histone H3', 'Association', 'histone H3.3 wild type'),\n",
        "    ('ATM', 'Association', 'T cell development'),\n",
        "    ('gynecological cancers', 'Association', 'gynecological cancers'),\n",
        "    ('polyadenylation site analysis', 'subclass of', 'polyadenylation site analysis'),\n",
        "    ('JADE', 'field of work', 'Adverse Drug Events'),\n",
        "    ('HDAC', 'Positive_Correlation', 'Huntington’s disease (HD)'),\n",
        "    ('Ozanimod', 'Association', 'Ozanimod'),\n",
        "    ('TADs', 'Association', 'TADs'),\n",
        "    ('Friedreich’s PsyNetataxia', 'Positive_Correlation', 'iPSC'),\n",
        "    ('p53', 'Positive_Correlation', 'tumor suppressor'),\n",
        "    ('spinal cord', 'connects with', 'pineal region'),\n",
        "    ('HDAC1', 'Positive_Correlation', 'histone lysine demethylase LSD1'),\n",
        "    ('NanoStringNormCNV', 'based on', 'NanoString CNV'),\n",
        "    ('tumorigenesis', 'Association', 'tumorigenesis'),\n",
        "    ('LIMT', 'Positive_Correlation', 'mammary cellsin'),\n",
        "    ('NBS1', 'Association', 'ATM'),\n",
        "    ('GATA-1', 'Association', 'erythropoiesis'),\n",
        "    ('proteasome', 'Positive_Correlation', '@@@@@@@@p53'),\n",
        "    ('2-aminobenzamide', 'Positive_Correlation', 'FRDA'),\n",
        "    ('transthyretin', 'part of', 'choroid plexus'),\n",
        "    ('450 kb chromosome XII variant', 'subclass of', 'chromosome XII'),\n",
        "    ('STAT1', 'Association', 'STAT1'),\n",
        "    ('2-aminobenzamide', 'Positive_Correlation', 'neurodegenerative diseases'),\n",
        "    ('K27M-H3', 'Positive_Correlation', 'ATRXandTP53mutations'),\n",
        "    ('ATM', 'Positive_Correlation', 'NBS1'),\n",
        "    ('ASCIZ', 'Association', 'ATM cofactor'),\n",
        "    ('TCGA2BED', 'based on', 'Cancer Genome Atlas'),\n",
        "    ('GATA1', 'Association', 'hematopoietic regulatory genes'),\n",
        "    ('Pfh1', 'Association', 'Pfh1'),\n",
        "    ('TAL1', 'Positive_Correlation', 'thymidine kniase minimal promoter'),\n",
        "    ('H3', 'Association', 'K36M'),\n",
        "    ('MDM2', 'Positive_Correlation', 'p53'),\n",
        "    ('Smc3', 'part of', 'cohesin'),\n",
        "    ('Alzheimer’s disease', 'Association', 'ZCCHC17'),\n",
        "    ('53BP1', 'Association', 'histone methyl-lysine binding'),\n",
        "    ('RAPID', 'country', 'UK'),\n",
        "    ('H3', 'Association', 'K27M'),\n",
        "    ('megakaryocytic', 'Association', 'megakaryocytic'),\n",
        "    ('RG7112', 'Positive_Correlation', 'p53'),\n",
        "    ('DNA damage', 'Positive_Correlation', 'DNA helicase'),\n",
        "    ('CNEs', 'Association', 'Metazoan'),\n",
        "    ('themutSLoperon', 'Positive', 'themutSLoperon'),\n",
        "    ('breast cancer', 'Association', 'breast cancer')\n",
        "]\n"
      ],
      "metadata": {
        "id": "GthV7wcPFk70"
      },
      "execution_count": 96,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import re\n",
        "import numpy as np\n",
        "from transformers import pipeline\n",
        "from sklearn.preprocessing import MinMaxScaler\n",
        "from sentence_transformers import SentenceTransformer, util\n",
        "import networkx as nx\n",
        "\n",
        "# Initialize Hugging Face pipeline and sentence transformer model\n",
        "def initialize_models():\n",
        "    sentence_model = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
        "    return sentence_model\n",
        "\n",
        "sentence_model = initialize_models()\n"
      ],
      "metadata": {
        "id": "1s2A14gyB9_Z"
      },
      "execution_count": 98,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def extract_known_entities(query, graph):\n",
        "    \"\"\"Extract entities from the query using graph nodes.\"\"\"\n",
        "    return [node for node in graph.nodes if re.search(rf'\\b{node}\\b', query, re.IGNORECASE)]\n"
      ],
      "metadata": {
        "id": "MA9eVRb6CvUU"
      },
      "execution_count": 99,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def compute_relevance_score(graph, entity):\n",
        "    \"\"\"Assign relevance scores to relationships based on edge weights.\"\"\"\n",
        "    relevance_scores = {}\n",
        "    for neighbor in graph.neighbors(entity):\n",
        "        edge_data = graph.get_edge_data(entity, neighbor)\n",
        "        edge_weight = edge_data.get(\"weight\", 1)\n",
        "        relevance_scores[neighbor] = edge_weight\n",
        "    return relevance_scores\n"
      ],
      "metadata": {
        "id": "mCQJGgGeCyT1"
      },
      "execution_count": 100,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def expand_query_with_graph(graph, entities, synonym_model, max_hops=2):\n",
        "    \"\"\"\n",
        "    Expand query terms using graph traversal, relevance scoring, and synonym similarity.\n",
        "    \"\"\"\n",
        "    expanded_terms = {}\n",
        "    for entity in entities:\n",
        "        if entity in graph:\n",
        "            related_terms = {}\n",
        "            # Graph traversal\n",
        "            for neighbor, path_length in nx.single_source_shortest_path_length(graph, entity, cutoff=max_hops).items():\n",
        "                if neighbor != entity:\n",
        "                    relevance_scores = compute_relevance_score(graph, neighbor)\n",
        "                    total_score = sum(relevance_scores.values()) / (path_length + 1)  # Normalize by path length\n",
        "                    related_terms[neighbor] = total_score\n",
        "\n",
        "            # Synonym expansion\n",
        "            synonyms = synonym_model.encode([entity] + list(related_terms.keys()), convert_to_tensor=True)\n",
        "            similarity_scores = util.cos_sim(synonyms[0], synonyms[1:]).squeeze()\n",
        "            synonym_terms = {list(related_terms.keys())[i]: similarity_scores[i].item() for i in range(len(similarity_scores))}\n",
        "\n",
        "            # Combine and normalize scores\n",
        "            related_terms.update(synonym_terms)\n",
        "            scaler = MinMaxScaler()\n",
        "            scores = np.array(list(related_terms.values())).reshape(-1, 1)\n",
        "            normalized_scores = scaler.fit_transform(scores).flatten()\n",
        "            expanded_terms[entity] = {term: normalized_scores[i] for i, term in enumerate(related_terms.keys())}\n",
        "        else:\n",
        "            expanded_terms[entity] = {}\n",
        "    return expanded_terms\n"
      ],
      "metadata": {
        "id": "-KiXc3IpC04R"
      },
      "execution_count": 101,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def filter_redundancy_and_clustering(expanded_terms, sentence_model, min_community_size=1, add_relation_text=True):\n",
        "    \"\"\"\n",
        "    Filter redundant terms and perform clustering using sentence embeddings.\n",
        "\n",
        "    Parameters:\n",
        "    - expanded_terms (dict): Dictionary of entities with their related terms {entity: {term: score}}.\n",
        "    - sentence_model: SentenceTransformer model for generating embeddings.\n",
        "    - min_community_size (int): Minimum size for a cluster. Default is 1.\n",
        "    - add_relation_text (bool): Whether to format sentences with \"is related to\". Default is True.\n",
        "\n",
        "    Returns:\n",
        "    - dict: A dictionary of entities with their clustered, unique related terms.\n",
        "            Format: {entity: {cluster_index: [related terms]}}\n",
        "    \"\"\"\n",
        "    clustered_terms = {}\n",
        "\n",
        "    for entity, terms in expanded_terms.items():\n",
        "        # Prepare sentences for embedding\n",
        "        related_terms = list(terms.keys())\n",
        "        if add_relation_text:\n",
        "            sentences = [f\"{entity} is related to {term}\" for term in related_terms]\n",
        "        else:\n",
        "            sentences = [f\"{entity} is related to {term}\" for term in related_terms]\n",
        "\n",
        "        # Generate sentence embeddings\n",
        "        embeddings = sentence_model.encode(sentences, convert_to_tensor=True)\n",
        "\n",
        "        # Perform clustering using community detection\n",
        "        clusters = util.community_detection(embeddings, min_community_size=min_community_size)\n",
        "\n",
        "        # Map clusters back to terms\n",
        "        clustered_terms[entity] = {\n",
        "            f\"Cluster {i+1}\": [related_terms[idx] for idx in cluster]\n",
        "            for i, cluster in enumerate(clusters)\n",
        "        }\n",
        "\n",
        "    return clustered_terms\n",
        "\n"
      ],
      "metadata": {
        "id": "RWukfdcMC4Ll"
      },
      "execution_count": 102,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def generate_llm_prompt(query, clustered_terms):\n",
        "    \"\"\"\n",
        "    Combine the input query and clustered terms into a single, coherent context for LLM input.\n",
        "\n",
        "    Parameters:\n",
        "    - query (str): The original query, which can be any medical-related text.\n",
        "    - clustered_terms (dict): A dictionary of entities with their corresponding clustered terms.\n",
        "\n",
        "    Returns:\n",
        "    - str: A combined input text suitable for LLM processing.\n",
        "    \"\"\"\n",
        "    # Collect sentences from clustered terms\n",
        "    context_sentences = []\n",
        "    for entity, clusters in clustered_terms.items():\n",
        "        for cluster_sentences in clusters.values():\n",
        "            context_sentences.extend(cluster_sentences)\n",
        "\n",
        "    # Combine query and context\n",
        "    context = \" \".join(context_sentences)\n",
        "    combined_prompt = (\n",
        "        f\"query: \\\"{query}\\\" context: {context}\"\n",
        "    )\n",
        "\n",
        "    return combined_prompt\n"
      ],
      "metadata": {
        "id": "BV-YdEWSC7L7"
      },
      "execution_count": 103,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import google.generativeai as genai\n",
        "genai.configure(api_key=\"AIzaSyCMTLYDBSpDTofswPH2zZFmQ9sqp1IG3F4\")"
      ],
      "metadata": {
        "id": "kgkqsvRUC-r_"
      },
      "execution_count": 104,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "model = genai.GenerativeModel(\"gemini-1.5-flash\")\n",
        "\n",
        "def q_expansion(query):\n",
        "    entities = extract_known_entities(query, G)\n",
        "\n",
        "    # Step 1: Expand Query\n",
        "    expanded_entities = expand_query_with_graph(G, entities, sentence_model, max_hops=2)\n",
        "    print(\"### Expanded entities and terms:\")\n",
        "    for entity, terms in expanded_entities.items():\n",
        "        print(f\"{entity} - {terms}\")\n",
        "\n",
        "\n",
        "    # Step 2: Filter Redundancy and Perform Clustering\n",
        "    clustered_terms = filter_redundancy_and_clustering(expanded_entities, sentence_model)\n",
        "    print(f\"\\n ### Clustered: {clustered_terms}\")\n",
        "\n",
        "    # Step 3: Generate Refined Query Using LLM\n",
        "    input_prompt = generate_llm_prompt(query, clustered_terms)\n",
        "\n",
        "    # Step 4: Generate Expanded Query using Gemini\n",
        "    response = model.generate_content(f\"Expand the prompt: \\\"{input_prompt}\\\". Write in a paragraph, not points, and expand the question. (Less than 200 characters)\")\n",
        "\n",
        "    #OUTPUT\n",
        "    print(f\"Original Query: {query}\")\n",
        "    print(f\"Refined Query: {response.text}\")\n",
        "\n",
        "    return response.text"
      ],
      "metadata": {
        "id": "GDvGx_kCDBew"
      },
      "execution_count": 105,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 177
        },
        "id": "skBtFj7aDIpK",
        "outputId": "c210a4ab-a48d-4578-9065-250f8e4945b2"
      },
      "execution_count": 61,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What causes Alzihmers's Disease?\n",
            "Refined Query: What are the known risk factors and biological mechanisms contributing to the development of Alzheimer's disease?  Are there genetic predispositions, environmental influences, or lifestyle choices that increase the likelihood of its onset and progression?\n",
            "\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\"What are the known risk factors and biological mechanisms contributing to the development of Alzheimer's disease?  Are there genetic predispositions, environmental influences, or lifestyle choices that increase the likelihood of its onset and progression?\\n\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 61
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.vectorstores import FAISS\n",
        "from langchain.embeddings import HuggingFaceEmbeddings\n",
        "from sklearn.metrics.pairwise import cosine_similarity\n",
        "\n",
        "DB_FAISS_PATH = \"/content/vectorstores/db_faiss_research_5461_\"  # Path to your FAISS index\n",
        "\n",
        "def query_faiss_and_get_text(query, k=5):\n",
        "    \"\"\"\n",
        "    Query FAISS to retrieve the top k vectors and their associated text.\n",
        "\n",
        "    Args:\n",
        "        query (str): The query string to search for.\n",
        "        k (int): The number of top results to retrieve.\n",
        "\n",
        "    Returns:\n",
        "        list: A list of tuples containing the text (from the payload) and similarity score.\n",
        "    \"\"\"\n",
        "    # Load the FAISS index with dangerous deserialization explicitly enabled\n",
        "    embeddings = HuggingFaceEmbeddings(model_name=\"sentence-transformers/all-MiniLM-L6-v2\")\n",
        "    db = FAISS.load_local(DB_FAISS_PATH, embeddings, allow_dangerous_deserialization=True)\n",
        "\n",
        "    # Search the index for top k similar vectors\n",
        "    results = db.similarity_search_with_score(query, k)\n",
        "\n",
        "    # Extract the text and similarity scores\n",
        "    extracted_results = [(doc.page_content, score) for doc, score in results]\n",
        "\n",
        "    return extracted_results\n",
        "\n",
        "\n",
        "\n",
        "# Evaluate cosine similarity\n",
        "def evaluate_similarity_with_ground_truth(generated_responses, ground_truth):\n",
        "    scores = []\n",
        "    model_eval = SentenceTransformer('all-MiniLM-L6-v2')\n",
        "    for gen, truth in zip(generated_responses, ground_truth):\n",
        "        gen_embedding = model_eval.encode(gen, convert_to_tensor=True).cpu().numpy()\n",
        "        truth_embedding = model_eval.encode(truth, convert_to_tensor=True).cpu().numpy()\n",
        "        similarity = cosine_similarity(gen_embedding.reshape(1, -1), truth_embedding.reshape(1, -1))\n",
        "        scores.append(similarity[0][0])\n",
        "    return scores\n",
        "\n",
        "\n",
        "\n",
        "def main_function(query_text, top_k=10):\n",
        "    ans = []\n",
        "    query_expand = q_expansion(query_text)\n",
        "    results = query_faiss_and_get_text(query_expand, top_k)\n",
        "    #print(f\"Top {top_k} results for query: '{query_text}'\\n\")\n",
        "    for i, (text, score) in enumerate(results):\n",
        "        ans.append(text)\n",
        "\n",
        "    ans_combined = \" \".join(ans)\n",
        "    print(f\"Combined Answer: {ans_combined}\")\n",
        "    ans_resp = model.generate_content(f\"Given the question: \\\"{query_expand}\\\". Write in a paragraph, not points, and answer this question using this information \\\"{ans_combined}\\\". Generate a proper answer\")\n",
        "    return ans_resp.text\n",
        "\n",
        "\n"
      ],
      "metadata": {
        "collapsed": true,
        "id": "nM9bprdpGevx"
      },
      "execution_count": 106,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "with open('/content/training12b_new.json', 'r') as file:\n",
        "    data = json.load(file)"
      ],
      "metadata": {
        "id": "SddfBD9MGnVr"
      },
      "execution_count": 68,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "bioasq_dataset = pd.DataFrame(data)"
      ],
      "metadata": {
        "id": "NaS_4XUHIVbr"
      },
      "execution_count": 83,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "data = df.to_dict(orient='records')\n",
        "data[0]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "collapsed": true,
        "id": "fbyRpkjaJvC3",
        "outputId": "c409b05c-620e-4d56-8980-8e7cd62d0954"
      },
      "execution_count": 79,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'questions': {'body': 'Is Hirschsprung disease a mendelian or a multifactorial disorder?',\n",
              "  'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/15858239',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/20598273',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/15829955',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/6650562',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/12239580',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/21995290',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/15617541',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/23001136',\n",
              "   'http://www.ncbi.nlm.nih.gov/pubmed/8896569'],\n",
              "  'ideal_answer': [\"Coding sequence mutations in RET, GDNF, EDNRB, EDN3, and SOX10 are involved in the development of Hirschsprung disease. The majority of these genes was shown to be related to Mendelian syndromic forms of Hirschsprung's disease, whereas the non-Mendelian inheritance of sporadic non-syndromic Hirschsprung disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model.\"],\n",
              "  'concepts': ['http://www.disease-ontology.org/api/metadata/DOID:10487',\n",
              "   'http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006627',\n",
              "   'http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020412',\n",
              "   'http://www.disease-ontology.org/api/metadata/DOID:11372'],\n",
              "  'type': 'summary',\n",
              "  'id': '55031181e9bde69634000014',\n",
              "  'snippets': [{'offsetInBeginSection': 131,\n",
              "    'offsetInEndSection': 358,\n",
              "    'text': 'Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15829955',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 554,\n",
              "    'offsetInEndSection': 992,\n",
              "    'text': \"In this study, we review the identification of genes and loci involved in the non-syndromic common form and syndromic Mendelian forms of Hirschsprung's disease. The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease. The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model\",\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15617541',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 397,\n",
              "    'offsetInEndSection': 939,\n",
              "    'text': 'Coding sequence mutations in e.g. RET, GDNF, EDNRB, EDN3, and SOX10 lead to long-segment (L-HSCR) as well as syndromic HSCR but fail to explain the transmission of the much more common short-segment form (S-HSCR). Furthermore, mutations in the RET gene are responsible for approximately half of the familial and some sporadic cases, strongly suggesting, on the one hand, the importance of non-coding variations and, on the other hand, that additional genes involved in the development of the enteric nervous system still await their discovery',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12239580',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 941,\n",
              "    'offsetInEndSection': 1279,\n",
              "    'text': 'For almost all of the identified HSCR genes incomplete penetrance of the HSCR phenotype has been reported, probably due to modifier loci. Therefore, HSCR has become a model for a complex oligo-/polygenic disorder in which the relationship between different genes creating a non-mendelian inheritance pattern still remains to be elucidated',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12239580',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 129,\n",
              "    'offsetInEndSection': 358,\n",
              "    'text': ' Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15829955',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 851,\n",
              "    'offsetInEndSection': 1007,\n",
              "    'text': ' The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males.',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6650562',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 131,\n",
              "    'offsetInEndSection': 359,\n",
              "    'text': 'Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes.',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15829955',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 0,\n",
              "    'offsetInEndSection': 131,\n",
              "    'text': 'Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability.',\n",
              "    'beginSection': 'title',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20598273',\n",
              "    'endSection': 'title'},\n",
              "   {'offsetInBeginSection': 0,\n",
              "    'offsetInEndSection': 210,\n",
              "    'text': 'BACKGROUND: RET is the major gene associated to Hirschsprung disease (HSCR) with differential contributions of its rare and common, coding and noncoding mutations to the multifactorial nature of this pathology.',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21995290',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 151,\n",
              "    'offsetInEndSection': 376,\n",
              "    'text': 'In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance.',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15858239',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 0,\n",
              "    'offsetInEndSection': 83,\n",
              "    'text': \"Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.\",\n",
              "    'beginSection': 'title',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23001136',\n",
              "    'endSection': 'title'},\n",
              "   {'offsetInBeginSection': 715,\n",
              "    'offsetInEndSection': 818,\n",
              "    'text': \"The majority of the identified genes are related to Mendelian syndromic forms of Hirschsprung's disease\",\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15617541',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 151,\n",
              "    'offsetInEndSection': 375,\n",
              "    'text': 'In the etiology of Hirschsprung disease various genes play a role; these are: RET, EDNRB, GDNF, EDN3 and SOX10, NTN3, ECE1, Mutations in these genes may result in dominant, recessive or multifactorial patterns of inheritance',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15858239',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 417,\n",
              "    'offsetInEndSection': 615,\n",
              "    'text': 'On the basis of a skewed sex-ratio (M/F = 4/1) and a risk to relatives much higher than the incidence in the general population, HSCR has long been regarded as a sex-modified multifactorial disorder',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8896569',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 858,\n",
              "    'offsetInEndSection': 1012,\n",
              "    'text': 'The inheritance of Hirschsprung disease is generally consistent with sex-modified multifactorial inheritance with a lower threshold of expression in males',\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6650562',\n",
              "    'endSection': 'abstract'},\n",
              "   {'offsetInBeginSection': 820,\n",
              "    'offsetInEndSection': 992,\n",
              "    'text': \"The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model\",\n",
              "    'beginSection': 'abstract',\n",
              "    'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15617541',\n",
              "    'endSection': 'abstract'}]}}"
            ]
          },
          "metadata": {},
          "execution_count": 79
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 84,
      "metadata": {
        "id": "b7X5GjjSEHUu"
      },
      "outputs": [],
      "source": [
        "def get_required_fields(item: dict):\n",
        "    try:\n",
        "        question = item['body']\n",
        "        ans = item['ideal_answer']\n",
        "    except:\n",
        "        return 'Error: Could not find body or type'\n",
        "    return [question, ans]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 85,
      "metadata": {
        "id": "95tINXAmEZDj"
      },
      "outputs": [],
      "source": [
        "df = bioasq_dataset.questions.map(lambda item: get_required_fields(item))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 86,
      "metadata": {
        "id": "LP7_OTr7Ep61"
      },
      "outputs": [],
      "source": [
        "df = pd.DataFrame(df.tolist(), columns=['question', 'ideal_answer'])"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "type(df['ideal_answer'][0])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "p9PDygRrLIr1",
        "outputId": "e4c315bd-c482-45a1-c1a0-1baa0c74b611"
      },
      "execution_count": 92,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "list"
            ]
          },
          "metadata": {},
          "execution_count": 92
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "ques = df['question'].tolist()\n",
        "ans = df['ideal_answer'].tolist()\n",
        "score_cos = []\n",
        "for q, a  in zip(ques, ans):\n",
        "    try:\n",
        "        gen_resp = main_function(q, top_k=10)\n",
        "    except:\n",
        "        continue\n",
        "    score = evaluate_similarity_with_ground_truth([gen_resp], a)\n",
        "    score_cos.append(score)\n",
        "    print(score)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "collapsed": true,
        "id": "fo8EJXcyLMfH",
        "outputId": "dfa7e75e-f58e-40dd-edb4-a88c85561772"
      },
      "execution_count": 108,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Hirschsprung disease a mendelian or a multifactorial disorder?\n",
            "Refined Query: Hirschsprung disease's inheritance pattern is complex. While showing familial clustering suggesting a genetic component, its variable expressivity and incomplete penetrance challenge simple Mendelian inheritance.  Is it primarily caused by a single gene mutation, or is it a multifactorial disorder involving multiple genes and environmental factors?\n",
            "\n",
            "Combined Answer: Mutations of the RET gene in isolated and syndromic Hirschsprung's disease in human disclose major and modifier alleles at a single locus - PMC In Hirschsprung's disease (HSCR), a hypomorphic allele of a major gene, RET, accounts for most isolated (non‐syndromic) cases, along with other autosomal susceptibility loci under a multiplicative model. However, some syndromic forms of HSCR are monogenic entities, for which the disease causing gene is known. We thank the families and their referring clinical teams for participation and the Association Française de la Maladie de Hirschsprung for its support. This work was supported by grants from the GIS‐Maladies Rares and the Association Nationale pour la Recherche. CCHS - congenital central hypoventilation syndrome HSCR - Hirschsprung's disease MWS - Mowat‐Wilson syndrome SNP - single nucleotide polymorphism (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause Comprehensive literature review was performed to identify non-coding variants that are convincingly associated with Mendelian disease. We included only those variations and publications judged to provide plausible evidence of pathogenicity. First, the phenotypic abnormalities of the individual carrying the variant were assessed and a variant was included only if the disease association was regarded as plausible on the basis of evidence such as familial cosegregation or experimental validation, using techniques such as luciferase reporter settings or in projects dedicated to the characterization of novel disease-associated genes is only beginning to be tackled. The answer to this question is pressing, because only about 25%–40% of individuals with suspected Mendelian disease who are investigated in large-scale whole-exome screening programs actually receive a diagnosis.72, 73, 74, 75 Although non-coding mutations not detected by whole-exome analysis are unlikely to be the only cause for the lack of a diagnosis in these individuals, WGS puts us for the first time in the position 10, a member of the Sry family, is mutated in Dom, and its human homologue is disease causing in autosomal dominant Shah‐Waardenburg syndrome. A similar effect will be difficult to test in humans as a SOX10 mutation is rare while the penetrance of HSCR is high in carriers. However, the putative role of the RET gene could be further tested in syndromic HSCR entities frequent enough to allow the collection of large series of patients, namely cartilage‐hair hypoplasia, Bardet‐Biedl syndrome, and Down's syndrome. In relation to the MWS group of and that the defect underlying these mutations is misregulation of fgf8. It is therefore reasonable to speculate that FBXW4 has been incorrectly assigned as the disease gene in human split hand/foot malformation 3. The search for putative regulatory elements or previously unknown exons can generate target sequences to be re-sequenced in patient DNA. In one of the two cases that were characterized bioinformatically, otp, we searched for mapped human diseases at the edge of the otp GRB and found Hermansky-Pudlak Syndrome, type 2, a cell Causative mutations in neurodevelopmental disorders are frequently de novo, X-linked recessive or autosomal recessive. In contrast to prior literature reporting largely inherited mutations in NHE6, through prospective recruitment, here we discover seven highly deleterious de novo mutations in NHE6. An eighth mutation was found, in a three-generation pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a\n",
            "[0.7580568]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List signaling molecules (ligands) that interact with the receptor EGFR?\n",
            "Refined Query: Describe the diverse array of signaling molecules, or ligands, that bind to and activate the epidermal growth factor receptor (EGFR), including  EGF itself, along with other members of the ErbB family ligands like TGF-alpha and amphiregulin.  Consider both endogenous and exogenous ligands.\n",
            "\n",
            "Combined Answer: the basal‐like subtype are considered highly aggressive (Perou et al, 2000). While the former is driven by an amplified HER2 gene, a fraction of the basal subtype is characterized by relatively high abundance of the epidermal growth factor receptor (EGFR, a kin of HER2) (Carey et al, 2010; Foulkes et al, 2010). In line with driver functions, EGFR‐associated poor prognostic signatures are highly expressed in basal‐like tumors, and blocking EGFR using either kinase inhibitors or monoclonal antibodies effectively retards growth of basal‐like a short spike of E2F activity up-regulates cell-cycle genes at day 1. Finally, there is a group of motifs (TBP, FOS_FOS{B,L1}_JUN{B,D}, RXR{A,B,G}, HOX{A6,A7,B6,B7}, and GLI1..3) whose targets are progressively down-regulated across the differentiation time course. The targets of these motifs are generally enriched for extracellular proteins involved in cell adhesion, cell–cell junctions, and signaling. More specifically, targets of GLI1..3 involve genes from the TGF-beta pathway, targets of TBP involve nucleosomal and intermediate filament binding (Table S3 in the SI, the associated biology terms are manually summarized on the basis of gene terms enriched for each functional group). We further performed pathway and disease analyses in Ingenuity. The pathway analysis shows that ABPP 106 binders are mostly enriched in the EIF2 signaling pathway (p = 1.26 × 10–12). The molecules (shown in red), which are enriched in the EIF2 signaling pathway, are illustrated in Figure S4a in the SI. The top ranking categories (p < 1 × 10–5) are shown in Figure S4b in the SI. Numerous reports have of LIMT (Fig 2A), the migration and invasion results proposed the following scenario: EGF treatment downregulates LIMT, an inhibitor of cell migration and invasion, thereby enhancing motility of mammary cells. To test this model, we used a chemical inhibitor, U0126, which specifically blocks a major signaling pathway downstream of EGFR, the RAS‐to‐ERK pathway. We first confirmed blocking efficacy by assaying ERK phosphorylation (Fig 3C), as well as by measuring mRNA levels of EGR1, a downstream target of the RAS‐to‐ERK pathway (Fig EV3F). We also found an autoregulation pathway of Esrrb gene expression. The Esrrb gene contains four putative Esrrb-responsive elements (Esrrb-ERRE1 to -4) in its intron regions (see Fig. S5A in the supplemental material), and Esrrb-ERRE2 and Esrrb-ERRE4 had enhanced reporter activities in A3-1 ES cells (see Fig. S5B in the supplemental material). Of note, the enhancer activities of Esrrb-ERRE2 and Esrrb-ERRE4 were reduced by either knocking down endogenous Esrrb expression (see Fig. S5C and D in the supplemental material) or introducing mutations the enhancer activities of Esrrb-ERRE2 and Esrrb-ERRE4 were reduced by either knocking down endogenous Esrrb expression (see Fig. S5C and D in the supplemental material) or introducing mutations into the elements (see Fig. S5E and F in the supplemental material). A biotinylated DNA pulldown assay revealed that endogenous Esrrb associates with Esrrb-ERRE2 and Esrrb-ERRE4 (see Fig. S5G in the supplemental material). Taken together, these findings indicate that Esrrb is able to regulate its expression via Esrrb-ERRE2 and Esrrb-ERRE4 in ES cells. identified waves of transcription, similar to those observed with mRNAs (Fig 1B, right panel) and with miRNAs (Avraham et al, 2010). Unlike mRNA, the majority of lncRNAs exhibited downregulation in response to EGF stimulation. However, similar to mRNAs, many lncRNAs displayed very rapid responses; their down‐ or upregulation initiated as early as 20 min after stimulation (confirmed by use of quantitative PCR; Fig EV1). These early events are of special interest as they might represent immediate responses to EGF signaling, rather than later, To investigate functions of the Esrrb-Dax1 complex in ES cells, Dax1 RNAi was introduced into Esrrb-overexpressing ES A3-1 cells. Since the transfected cells have both overexpressed Esrrb and repressed Dax1, the expression levels of the two genes are unbalanced, and therefore the Esrrb-Dax1 complex would be disrupted in the cells. When we examined gene expression of the cells, the expression levels of endodermal marker genes (Gata4, Gata6, and Dab2), but not mesodermal (T) and ectodermal (Fgf5) genes, were significantly enhanced in Dax1 Because growth factors play essential roles in both mammary gland development and in breast cancer progression, and long noncoding RNAs (lncRNAs) are emerging as cardinal regulators of gene expression, we profiled epidermal growth factor (EGF) inducible expression of lncRNAs in normal mammary cells. A subset of the EGF‐inducible lncRNAs we identified correlated with clinical outcome of breast cancer patients. One of these, a highly conserved lncRNAs we called LIMT, is downregulated by EGF due to histone deacetylation at the respective promoter. in cell adhesion, cell–cell junctions, and signaling. More specifically, targets of GLI1..3 involve genes from the TGF-beta pathway, targets of TBP involve nucleosomal and intermediate filament cytoskeletal genes, and targets of the homeodomain motif (HOX{A6,A7,B6,B7}) are enriched for developmental genes and transcription factors. The genes in these pathways are most likely involved in the transition of the tissue from squamous to columnar epithelial that occurs during differentiation. Thus, in contrast to the methods used in the original\n",
            "[0.6707085]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the protein Papilin secreted?\n",
            "Refined Query: Determining whether the protein Papilin is secreted requires investigation into its cellular localization and mechanism of release.  Does it possess a signal peptide directing it to the endoplasmic reticulum, a necessary step for secretion?  Are there studies documenting its presence in extracellular fluids or conditioned media?\n",
            "\n",
            "Combined Answer: Cases of humans lacking either of the other two TH distributor proteins: albumin (Minchiotti et al., 2013) or thyroxine-binding globulin (Refetoff, 1989) have been described. Such people are apparently healthy and without overt clinical symptoms. However, no humans lacking TTR have been reported. In the 1990s the hypothesis was that because TTR is the only TH distributor protein synthesized in the brain, is secreted unidirectionally across the apical surface of the choroid plexus epithelial cells into the CSF, its role in the movement of TH proteins known as TH distributor proteins. Because THs are lipophilic they partition between the lipid phase and the aqueous phase with a ratio of 20,000:1 (Dickson et al., 1987). The binding of THs to TH distributor proteins prevents avid partitioning of THs into the lipid membranes of cells and ensures that there is a sufficiently large pool of TH circulating in the blood (Mendel et al., 1987). In humans, the main TH distributor proteins are albumin, transthyretin (TTR) and thyroxine-binding globulin (TBG), all of which are synthesized by with Aramchol. Purity and authentication of phHeps were assessed by measurement of secreted albumin and α1-Antitrypsin (AAT) by ELISA. CYP3A4 activity assay of the cells was evaluated using P450-Glo assay (Promega, WI, USA). Each of 3 experiments using phHep cells was performed in triplicate. it is known that THs enter cells via TH transmembrane transporters, which participate in the influx and efflux of THs into and out of cells. Several classes of TH transmembrane transporter proteins that belong to the family of solute carrier (Slc) transporters have been identified e.g. organic anion transporting polypeptides (OATPs), monocarboxylate transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters results were obtained at the secreted protein PSA level (Figure 3E). Knockdown of Uc.63+ did not affect the expression of AR and PSA in DU145 cells, which were shown to be AR-negative cells by western blot analysis (Supplementary Figure 7A, 7B). [although TTR mRNA has been detected in whole brain of sea bream (Santos and Power, 1999)]. The main protein synthesized and secreted by amphibian choroid plexus is a lipocalin (Achen et al., 1992), which could be the functional precursor of choroid plexus-derived TTR, as lipocalins are known to bind small hydrophobic molecules. That the choroid plexus specializes in the synthesis and secretion of TTR in such a great range of vertebrates is also suggestive of an important function. Furthermore, the amino acid sequence of TTRs across all and then captured using streptavidin beads. The captured proteins were subjected to extensive washing using harsh denaturing conditions prior to trypsin digestion and labeling of peptides from different samples with “heavy” or “light” isotopomeric dimethyl labels. Two of four experimental replicates were forward labeled, and the other two were reverse labeled (e.g., label swap). The “heavy” and “light” labeled samples were mixed and analyzed by LC–MS/MS. Searching tandem mass spectra through the sequence database identified peptides. TH circulating in the blood (Mendel et al., 1987). In humans, the main TH distributor proteins are albumin, transthyretin (TTR) and thyroxine-binding globulin (TBG), all of which are synthesized by the liver. In addition, a small fraction is distributed by lipoproteins including ApoB100 (Benvenga et al., 1989). The free hormone hypothesis states that it is the free hormone in blood (not the protein-bound hormone) that is important for biological activity (Mendel, 1989). Thus, THs must dissociate from the distributor proteins before they can Thyroid hormones are key players in regulating brain development. Thus, transfer of appropriate quantities of thyroid hormones from the blood into the brain at specific stages of development is critical. The choroid plexus forms the blood-cerebrospinal fluid barrier. In reptiles, birds and mammals, the main protein synthesized and secreted by the choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal Secreted PSA protein levels in cell culture supernatants were determined by LUMIPULSE Presto PSA (Fujirebio Inc., Tokyo, Japan) according to the manufacturer’s instructions. Serial dilutions of recombinant human PSA were used to plot the standard curve.\n",
            "[0.7238301]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are long non coding RNAs spliced?\n",
            "Refined Query: The question explores whether long non-coding RNAs (lncRNAs), a class of RNA molecules not translated into proteins, undergo splicing, a process where introns are removed from pre-mRNA to produce mature mRNA.  This clarifies if lncRNAs, like protein-coding genes,  are transcribed as precursor molecules requiring splicing before becoming functional.\n",
            "\n",
            "Combined Answer: human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with protein-coding genes (Supplemental Table S4; Supplemental Fig. S4). Finally, we have also identified 11 lncRNAs U12 introns (Alioto 2007) within the lncRNA catalog, of which eight belong to intergenic lncRNAs (lincRNAs) and three are in antisense of protein-coding introns. et al. 2009). In addition, >25% of lncRNA genes show evidence of alternative splicing with at least two different transcript isoforms per gene locus (Fig. 3D). The most highly spliced lncRNA gene is PCBP1-AS1 with 40 annotated isoforms. This human lncRNA gene is situated at a complex locus with major gene structure differences between human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with less exons, overall lncRNA transcripts are shorter than protein-coding (median 592 bp compared with 2453bp for protein-coding transcript; t-test, P-value <2.2 × 10−16) (Fig. 3C). Interestingly, the longest lncRNA is NEAT1, a single-exon lincRNA of 22.7 kb, which was recently shown to be necessary for the formation of nuclear paraspeckles (Sunwoo et al. 2009). In addition, >25% of lncRNA genes show evidence of alternative splicing with at least two different transcript isoforms per gene locus (Fig. 3D). The most highly spliced lncRNA gene is Most LncRNAs are spliced (98%), but they show a striking tendency to have only two exons (42% of lncRNA transcripts have only two exons compared with 6% of protein-coding genes) (Fig 3A). This does not seem to be an artifact of lncRNA's low expression, or poor annotation, since even subsets with experimental support for their 5′ and 3′ boundaries exhibit this effect (Fig. 3A). While lncRNA exons are slightly longer than those of protein-coding transcripts (medians 149 and 132 bp, respectively; t-test, P-value = 0.00014), introns from lncRNAs it could also reflect a higher rate of degradation (i.e., reduced stability) of lncRNAs compared with protein-coding genes. Because lncRNAs lack ORFs, and therefore have premature stop codons, degradation could occur through mechanisms such as translation-linked nonsense mediated decay (NMD) pathway, or translation-independent degradation pathways. On the other hand, the striking preponderance of single intron transcripts could also be a mechanism to escape NMD-like pathways. In any case, there is still a population of lncRNAs that are There is some evidence that transcripts thought to be purely noncoding lncRNAs may in fact encode proteins, in small or otherwise unrecognized ORFs (Chooniedass-Kothari et al. 2004; Kondo et al. 2010; Dinger et al. 2011). To assess the protein-coding status of the present lncRNAs catalog, we first used the program GeneID (Blanco et al. 2007) to (1) measure the protein-coding potential and (2) find the longest possible ORF in each lncRNA sequence. We compared the results in the set of GENCODE lncRNAs with (1) known protein-coding transcripts, in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. These elements are frequently found in genes post-transcriptionally regulated by alternative splicing events of exons with premature stop codons. Accordingly, the extreme genomic conservation has been associated to regulatory splicing events maintaining tightly regulated levels of RNA-binding proteins [4]. On the other hand, intergenic elements are frequently flanked by developmental genes, in particular for genes that with a small number of exceptions they exhibit minimal protein-coding capacity. The genomic structure of lncRNAs is very similar to that of protein-coding genes, although a surprisingly high proportion of the former are two-exon transcripts. Overall, we observe that while lncRNAs have exons of similar length to protein-coding mRNAs, they have fewer of them—in agreement with the recent findings of Cabili et al. (2011). One advantage of manual annotation of lncRNAs is that it provides accurate transcription start site, termination site, and some way were further categorized by those covering protein-coding exons (2411), introns (2784), or overlapping protein-coding (i.e., where the protein-coding transcript lies within an intron of the lncRNA) (167) (Fig. 1B). Note that transcripts intersecting protein-coding exons on the same strand were previously omitted from this analysis. The GENCODE lncRNA data set is larger than other available lncRNA data sets, and it shows limited intersect with them. A total of 42% (44 out of 96) of the long noncoding RNA database lncRNAdb (Amaral et The issue of whether lncRNA expression correlates with either neighboring (cis) or distal (trans) protein-coding genes has been a matter of debate in recent studies (Ørom et al. 2010; Cabili et al. 2011). We next analyzed whether any nonrandom coexpression patterns of lncRNA-mRNA exist in the ENCODE and HBM RNA-seq data.\n",
            "[0.6765995]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is RANKL secreted from the cells?\n",
            "Refined Query: The question explores whether receptor activator of nuclear factor kappa-B ligand (RANKL) is released by cells into the extracellular environment.  This necessitates understanding the cellular mechanisms of RANKL production, processing, and secretion, and whether it acts solely intracellularly or also exerts its effects in a paracrine or endocrine manner.\n",
            "\n",
            "Combined Answer: fifth most significant motif, PRDM1, which is an important developmental regulator in the B-cell and T-cell lineages and is required for the secretory pathway in B-cells (Martins and Calame 2008). PRDM1 activity increases, like that of IRF, across the entire time course, and these two regulators appear to share many of their predicted targets, including type 1 interferon pathway genes, the immunoproteasome (Seifert et al. 2010), ubiquitin conjugating enzymes, antigen peptide transporters, and MHC class I genes. These targets suggest that the 2d). This effect is consistent with impaired proteasomal degradation of I-κB, suggesting that, similar to bortezomib,17,18 carfilzomib and oprozomib-mediated inhibition of ex vivo OC activity may partially act through disruption of RANKL-induced NF-κB signaling. Together, these data demonstrate that epoxyketone-based PIs are capable of inhibiting OC resorptive function through multiple mechanisms. 2c) and reduced expression of αVβ3 integrin (Supplementary Table 1). OC-mediated resorption also requires functional signaling through a complex pathway involving mitogen-activated protein kinase (MAPK) and NF-κB45. PI treatment of human pre-OCs prevented RANKL-induced NF-κB activation, with the p65 subunit being retained in the cytoplasm (Figure 2d). This effect is consistent with impaired proteasomal degradation of I-κB, suggesting that, similar to bortezomib,17,18 carfilzomib and oprozomib-mediated inhibition of ex vivo OC activity may The presence of PIs during OB differentiation inhibited RANKL expression, yet only a modest trend toward increase of osteoprotegerin mRNA levels was observed (Figure 4e). In summary, PIs directly stimulated the transforming growth factor β and MAPK pathways and increased the activity of the UPR resulting in enhanced OB differentiation and matrix mineralization, while indirectly hindering OC stimulation through decreased OB expression of RANKL. complexity and satisfies the criteria for a prion-like domain [4,6]; an N-terminal autoregulatory domain, which suppresses transactivation at basal state [6]; a central methionine-rich domain, and so called multifunctional domain (MFD) implicated in the protein dimerisation, regulation of transactivation and subcellular localization of the protein [12]. In the nucleus, CREST was shown to be recruited to nuclear bodies of unknown origin [13]. More recently, CREST was identified in a screen for paraspeckle proteins [14]. The majority of 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux tissues (Mendel et al., 1989), TTR is responsible for much of the immediate delivery of THs to tissues (Robbins, 2000). THs have multiple mechanisms of action which can be grouped into “genomic” and “non-genomic” mechanisms of action. Non-genomic mechanisms include membrane-initiated mechanisms via binding to specific integrins (Davis et al., 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling to a TH distributor protein in blood, is in equilibrium with free T4 which is lipophilic, so partitions into the choroid plexus. Within the choroid plexus, the newly synthesized TTR by the epithelial cells binds to the T4 that entered the choroid plexus from the blood. Choroid plexus-derived TTR is 100% secreted into the CSF (not into the blood), so the TTR-T4 complex would be secreted into the CSF, followed by its distribution via the CSF to the brain tissue. Thus, the TTR synthesized by the choroid plexus is involved in moving T4 from the results were obtained at the secreted protein PSA level (Figure 3E). Knockdown of Uc.63+ did not affect the expression of AR and PSA in DU145 cells, which were shown to be AR-negative cells by western blot analysis (Supplementary Figure 7A, 7B). that STAT2,4,6 is the 11th most significant motif, indicating that STAT activity changes, affecting the level of its targets) and MHC class I genes. The latter are also predicted to be regulated by IRF1,2,7, which is confirmed by experimental data (Ten et al. 1993). ISMARA makes the novel predictions that both NFKB1/REL/RELA and IRF1,2,7 activate the fifth most significant motif, PRDM1, which is an important developmental regulator in the B-cell and T-cell lineages and is required for the secretory pathway in B-cells (Martins and Calame 2008).\n",
            "[0.54412335]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?\n",
            "Refined Query: Investigating epithelial ovarian cancer biomarkers, this query seeks to identify specific microRNAs (miRNAs) exhibiting differential expression patterns between cancerous and healthy ovarian tissues.  This exploration aims to determine which miRNAs could reliably indicate the presence or progression of the disease, aiding in early diagnosis and prognosis.\n",
            "\n",
            "Combined Answer: Breast cancer is a heterogeneous disease; hence, many efforts are being made to identify new drivers and classify tumors into increasing numbers of subtypes (Perou et al, 2000; Dawson et al, 2013). Thus, whereas initial profiling focused on finding histological characteristics and signatures of protein‐coding genes, more recent studies have found that the expression of microRNAs may also assist prognosis and classification (Dvinge et al, 2013). Importantly, the relatively high tissue specificity of lncRNAs promises a role for these noncoding and the HER2‐enriched subtypes. The unbiased screen identified several EGF‐responsive lncRNAs, which have previously been associated with cancer progression, demonstrating the suitability of our approach. For example, Neat1, which is overexpressed in advanced ovarian carcinoma and assists diagnosis (Pils et al, 2013), and LINC00472, high expression of which is correlated with reduced risk of relapse and death of breast cancer patients (Shen et al, 2015). Importantly, both lncRNAs were found to be early responders to EGF in our cellular model. that the expression of microRNAs may also assist prognosis and classification (Dvinge et al, 2013). Importantly, the relatively high tissue specificity of lncRNAs promises a role for these noncoding RNAs as drivers and biomarkers of breast cancer (Wang et al, 2011a). For example, a recent survey of 658 infiltrating ductal tumors reported that the lncRNA HOTAIR was significantly overexpressed in the HER2‐positive subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal‐like subgroup (Su et al, 2014). Herein, we introduce MiRduplexSVM can be used to identify the miRNA:miRNA* duplex of a miRNA gene given the hairpin sequence. The hairpin sequence does not need to be precisely defined; it may be generated by one of the numerous computational tools that predict miRNA genes [23–27]. Such an approach is useful when searching for novel miRNAs that may be involved in a particular phenotype. For example, we recently developed and used a miRNA gene finding tool to locate potential new miRNAs residing in cancer associated genomic regions [24]. Similar efforts have been phenotype. For example, we recently developed and used a miRNA gene finding tool to locate potential new miRNAs residing in cancer associated genomic regions [24]. Similar efforts have been reported in a number of other studies, where new miRNA genes were computationally predicted [26, 28]. In order to verify that a predicted miRNA gene/hairpin produces a functional miRNA however, a number of wet-lab experiments must be performed, requiring significant amount of time, money and effort [29]. MiRduplexSVM can provide reliable predictions about We next assessed the applicability of our method on two important problems: (a) the accurate identification of the opposite strand of a known miRNA, (b) the identification of high confidence potential miRNAs identified via deep sequencing or other methodologies. endometrial cancer can be detected early, but it does not reduce its incidence. Ovarian cancer is difficult to detect early, is the leading cause of gynecological cancer deaths. Early detection of molecular markers is the most effective method of GCs prevention; however the molecular mechanisms underlying GCs progression are not well characterized. Therefore, a better understanding of the molecular mechanisms involved in GCs development and progression will provide diagnostic and prognostic markers and potential targets for the therapeutic (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and mesenchymal cells (for results, see http://ismara.unibas.ch/supp/dataset5/averaged_report/). As discussed in the Supplemental Material and Supplemental Figure 21, ISMARA automatically inferred much of the key regulatory interactions between TFs and miRNAs involved in EMT (for a review, see Polyak and Weinberg 2009) using only the gene expression poor prognostic signatures are highly expressed in basal‐like tumors, and blocking EGFR using either kinase inhibitors or monoclonal antibodies effectively retards growth of basal‐like cancer cells (Hoadley et al, 2007; Ferraro et al, 2013). Using basal‐like untransformed cells, MCF10A, as a model system, data from our laboratory showed that both mRNAs and microRNAs exhibit dynamic changes in expression following EGF stimulation (Amit et al, 2007; Avraham et al, 2010; Kostler et al, 2013). We further demonstrated that the inducible mRNAs and To illustrate ISMARA’s ability to integrate the role of both TFs and miRNAs in the gene regulatory network, we took advantage of data from a system in which miRNAs are known to play important regulatory roles: the epithelial-to-mesenchymal transition (EMT). We applied ISMARA to expression measurements from epithelial and mesenchymal subpopulations (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and\n",
            "[0.71690965]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?\n",
            "Refined Query: Myasthenia gravis is characterized by muscle weakness due to impaired neuromuscular transmission.  Which acetylcholinesterase inhibitors, specifically, are clinically employed to improve this transmission by increasing acetylcholine availability at the neuromuscular junction, thereby alleviating symptoms of myasthenia gravis?\n",
            "\n",
            "Combined Answer: tend to decrease with strength training. We acknowledge, however, that our study design would have been stronger if we had ensured that the participants had elevated skeletal muscle myostatin before enrollment. However, we considered that a muscle biopsy might slow recruitment; moreover, because ActRIIs act as a pathway for multiple negative regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII blockade could induce muscle hypertrophy in a myostatin knockout mouse, proving that other molecules signal through those receptors (17). The magnitude of the anabolic response with bimagrumab treatment observed in this study was comparable with those reported in a prior study in patients with sarcopenia (18) and with reports on prior anabolic We report the first placebo-controlled, double-blind, randomized trial that investigated the effects of activin type II receptors blockade in patients with COPD and evidence of low body weight or muscle mass. Bimagrumab substantially increased thigh muscle volume and total lean body mass, but this did not translate into improved muscle function or functional performance. Antibody Resource for MANDSY106. The UCL MRC Neuromuscular Centre Biobank is also acknowledged. F.M. is supported by the Great Ormond Street Children's Charity. J.E.M. is funded by a Wellcome Trust University Award. All other authors except the listed those below do not report any disclosures. Prof Muntoni has served on scientific advisory boards for Genzyme, AVI BioPharma, Inc., GSK; he serves on the editorial board of Neuromuscular Disorders and Neuropediatrics; he receives research support from AVI BioPharma, Inc., the European Union, the for Genzyme, AVI BioPharma, Inc., GSK; he serves on the editorial board of Neuromuscular Disorders and Neuropediatrics; he receives research support from AVI BioPharma, Inc., the European Union, the MRC, the Wellcome Trust, the Association Française Contre les Myopathies (AFM), the Muscular Dystrophy Campaign, the GOSH Biomedical Research Centre and the Muscular Dystrophy Association USA, and funding for trials from AVI BioPharma, GSK, Trophos, and PTC. and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a clear list of candidate genes to investigate. than in the placebo group (P = 0.011, muscle spasms; P < 0.001, muscle tightness; Fisher exact test, two-sided); however, no other significant differences in AE incidence were observed between the bimagrumab and placebo groups. In addition, nasopharyngitis (12.1%, 4 of 33), sinusitis (9.1%, 3 of 33), and elevated liver enzymes (alanine aminotransferase, aspartate aminotransferase, or γ-glutamyl transpeptidase) (9.1%, 3 of 33) were reported only in the bimagrumab group. These AEs were mild and self-limited and resolved without treatment. This study was supported by the UK Department of Health and by the Medical Research Council to F.M. AVI Biopharma manufactured and supplied AVI-4658 for the study. The authors thank the patients who participated in this study and the charities Muscular Dystrophy Campaign, Action Duchenne, and the Duchenne Family Support Group for participating in the UK MDEX consortium (www.mdex.org.uk) which performed this study. We would like to thank in particular the members of the Scientific Advisory Board (see below) for their constructive criticism. The In patients with chronic obstructive pulmonary disease (COPD), locomotor muscle weakness is associated with a poor prognosis, worse health-related quality of life, and increased health care use. Although pulmonary rehabilitation can partially reverse skeletal muscle weakness in COPD, there is no drug approved for this purpose or to recover lost muscle mass. Myostatin and activin A are negative regulators of muscle mass that are increased in patients with COPD; myostatin and other regulators of muscle mass signal through the activin type II in intermuscular and subcutaneous fat. We have previously reported that reduced intermuscular and subcutaneous fat is a marker of anaerobic metabolism in COPD (49), and, thus, ActRII blockade may be of added value in such patients. In general, because muscle weakness is associated with impaired glucose tolerance in COPD (50), this effect could potentially be beneficial. To conclude, substantial gains in thigh muscle volume were observed after ActRII blockade using bimagrumab treatment, but these did not translate into improved muscle and\n",
            "[0.653308]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Has Denosumab (Prolia) been approved by FDA?\n",
            "Refined Query: I need more information to answer properly.  The prompt is incomplete.  To expand the question, I need to know what specific use or indication of Denosumab (Prolia) the query concerns.  The FDA approves medications for specific purposes, not generally.\n",
            "\n",
            "Combined Answer: to her institution, and provision of trial drugs from Agios, grant support and advisory board fees paid to her institution, and provision of trial drugs from Bayer and Bristol-Myers Squibb, grant support paid to her institution from Sanofi and Debio, and fees for serving on a steering committee paid to her institution from TARGET Pharma Solutions. We thank the patients, their families, the investigators, the site staff, and the trial teams; David W. Markby (Exelixis) for assistance with medical writing; and Karen O’Leary and Michael Raffin erenumab (78), and fremanezumab (79) have been reported elsewhere from clinical trials. The drug labels for these three drugs state similarly that, although the immunogenicity profiles do not demonstrate an impact of ADA development on efficacy or safety, the available data are too limited to make definitive conclusions (10,11,15). In addition, ADA development does not demonstrate an impact on the PK of galcanezumab (10). was based on the mechanism of action of anifrolumab and the assumption that demonstrating statistically significant benefit in the primary end point at a 2‐sided alpha level of 0.1 in either of the populations would provide sufficient preliminary evidence of efficacy to continue phase III studies in the appropriate population. A 2‐sided alpha level of 0.1 represents a 5% chance of declaring a positive study result when there is no treatment effect (risk of proceeding with an ineffective drug). The present study had a power of 88%, representing The protocol for this clinical trial was approved by Western Institutional Review Board (Puyallup, WA) and all enrolled subjects will provide informed consent before study participation. The study results will be widely disseminated at conference presentations and published in peer-reviewed journals. This was classified as a protocol deviation. The patient was included in the placebo group of the modified ITT population for the efficacy analyses, but in the anifrolumab 1,000‐mg group of the safety population for the safety analyses. Baseline characteristics (Table 1) were similar between groups, with the following exceptions: disease duration was shorter for the placebo group than for the anifrolumab groups (mean 90.6 months versus 95.9 months and 100.1 months), and fewer patients in the placebo group were receiving methotrexate (15.7% is needed. If this determination is made, the subject can be started on any preventative medication, but will not be informed of the study arm they were assigned. This may lead to the potential that the subject will re-start the same medication that they were taking during the study. An independent data and safety monitoring committee reviewed safety and efficacy during the trial. The trial was designed by the first and last authors in collaboration with the sponsor, and the authors and the sponsor were responsible for data collection and analysis. The authors vouch for the fidelity of the trial to the protocol and for the accuracy and completeness of the data. The first and last authors wrote the first draft of the manuscript in collaboration with the sponsor. Medical writing support was provided by the sponsor. drug). This combination of statistical risks was chosen to balance the continuation and discontinuation risks while maintaining a feasible phase IIb study. Further, to keep the sample size within reasonable limits, no adjustment was made for the multiplicity of testing the primary end point in the 2 populations. Therefore, the results of this study are clinically relevant, but are not definitive until prospectively replicated in larger studies with a more stringent alpha level and a more robust control for multiplicity. The anifrolumab dosages or increased through week 52 (Figure 2). Improvements in physician's global assessment at week 52 were also greater for the anifrolumab‐treated groups than for the placebo‐treated group (Table 2), with a greater effect observed in the 300‐mg treatment group compared with the 1,000‐mg treatment group. For all outcomes, the treatment effects observed in the overall population were driven by the IFN‐high subset (Table 2 and Figure 2). The study also assessed various measures of low disease activity. A SLEDAI‐2K score of ≤2 at week 52 was achieved The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo‐treated patients versus 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively. At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus\n",
            "[0.65480024]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List the human genes encoding for the dishevelled proteins?\n",
            "Refined Query: Identify the human genes responsible for the transcription and translation of the Dishevelled (DVL) protein family members.  Specify the gene names for each DVL isoform.\n",
            "\n",
            "Combined Answer: process term other than “biological process unknown.” The hox and irx families of developmental regulatory genes were excluded from the analysis because they are known to be kept together in large synteny blocks to maintain coregulation. We assigned a gene to a synteny block if that gene had one transcript with at least 95% of its coding sequence spanned by the synteny block and at least 50% of its coding sequence aligned, at the resolution of the net alignment track, to the syntenic locus in the human genome. occur at active TSSs regardless of whether they are annotated. We further characterized HOT regions at consensus promoters in terms of several quantitative genomic features associated with promoters (Additional file 1: Figure S5). Most known human promoters are enriched for GC content and especially CpG dinucleotides [21], and their sequences are typically under evolutionary constraint [22]. In addition, several histone modifications are associated with regulatory genome elements: histone 3 lysine 4 trimethylation (H3K4me3) is enriched at points. In the end this gave only one set derived from two replicates and two time points. Since our expressed gene set consisted of genes expressed at both 0 h and 96 h, the expressed genes were expected to be acetylated in at least one time point. For acetylation analysis we partitioned the genome into intergenic, intragenic and promoter regions. The promoter, in this case, was defined as 1,000 bp upstream and 1,000 bp downstream of the Ensembl TSS. The rest of the gene that was not part of the promoter region was categorized as intragenic. abundance of different forms of RNAPII (Additional file 1: Figure S18) and these results are largely confirmed in HiCap (Fig. 5g). These findings suggest that promoters can contact transcribed gene bodies. of MNase mapping are inheritable. In addition, we aligned the two original DHBV DNA sequences that were obtained from duck 5 and 6 for a possible relationship between sequence variations and a specific MNase pattern. Both variable areas marked in Fig. 5A were associated with a higher nucleotide substitution rate compared to the surrounding regions in the DHBV genome. The DNA covered by the line with an arrowhead in Fig. 5A encodes part of PreS and the overlapping spacer region of DHBV polymerase, and the two sequences were highly varied (there alcohol and were precipitated again as described above. The resulting DNA was used for sequencing. A detailed description of the other methodology and data analysis is provided in SI Materials and Methods. The data have been deposited in the Gene Expression Omnibus (accession no. GSE69098). We define developmental genes as genes with the following GO annotation: GO:0045165 (cell fate commitment), GO:0032502 (developmental process), GO:0030528 (transcription regulator activity), and GO:0003700 (transcription factor activity) as well as the descendant annotations as defined by the Open Biomedical Ontologies (version 1.2) [50]. For each model organism of interest (in this work we will focus exclusively on data from human and mouse), ISMARA relies on two precalculated resources: a genome-wide annotation of promoters and a comprehensive collection of transcription factor binding site (TFBS) predictions in all promoters (Fig. 1A,C). The genome-wide annotation of promoters in human and mouse, i.e., so-called “promoteromes,” were constructed primarily from deep sequencing data of transcription start sites (deepCAGE data) (de Hoon and Hayashizaki 2008) using Bayesian human-zebrafish synteny blocks. Synteny blocks were defined by joined zebrafish (danRer5) to human (hg18) high scoring (level 1) net alignments obtained from the UCSC Genome Browser [34]. We joined neighbor net alignments if they were separated by at most 450 kb in human and 150 kb in zebrafish. If multiple synteny blocks overlapped with the target gene - for example, in the case of zebrafish paralogs - we took the union of those synteny blocks as the primary synteny block to be used in the analysis. Following this procedure, we retrieved all terms from MESH and GENE ONTOLOGY in a given text passage. The annotator first pre-processes both the ontology terms and the text by tokenizing them, removing the stop words and stemming the remaining termsa. Then the term stems are mapped onto the text stems using the local sequence alignment algorithms [27]. Insertions, deletions and gaps are penalized. The information value of terms calculated over the whole ontology is also taken into account during the alignment process of ontology terms with text terms, in a similar manner as the inverse\n",
            "[0.40054533]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Name synonym of Acrokeratosis paraneoplastica.\n",
            "Refined Query: What is another name, or a synonym, for the skin condition Acrokeratosis paraneoplastica?  I need a concise, single-paragraph answer providing a synonym, not a list.\n",
            "\n",
            "Combined Answer: and irinotecan trial, the most common toxicities were grade 1 and 2 hypertension, fatigue, epistaxis, and grades 1–4 proteinuria.(27) These data contrast with the current study whereby only 6% (3/50) of patients had grade 3 neutropenia; 2% (1/50) had grade 4 lymphopenia and there were no grade 3 or 4 thrombocytopenia or anemia. There was no significant peripheral neuropathy or allergic reactions. As expected, grade 1 and 2 asymtommatic CPK elevation and grade 1 and 2 rashes were some of the most common attributable toxicities seen with The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). elevation, hypoalbuminemia, dyspnea, rash, duodenal ulcer, anemia, dry skin, fatigue and diarrhea. Rare grade 3 toxicities included elevated CPK (n=5), maculopapular rash (n=5), neutropenia (n=3), nausea (n=3), paronychia (n=3), acneiform rash (n=2), diarrhea (n=2), elevated ALT (n=1), decreased ejection fraction (n=1), gastric hemorrhage (n=1), headache (n=1), skin infection (n=1), tooth infection (n=1) and weight gain (n=1). There was only one grade 4 toxicity, lymphopenia. There were no treatment-realted deaths. Patient reported outcomes tissue content) in this sample. Despite the lack of confirmation, this patients had an imaging PR. No obvious additional pathogenic mutations beyond NF1 were identified in stratum 3 tumors. These small number of samples precluded any formal assessment of correlation with responses. The most common attributable toxicities on both strata were grade 1 and 2 CPK elevation, hypoalbuminemia, dyspnea, rash, duodenal ulcer, anemia, dry skin, fatigue and diarrhea (Table 2). Rare grade 3 toxicities included elevated CPK (n=5), maculopapular rash (n=5), atrophy resulting in legal blindness already during the first decade of life. In addition, all the patients developed progressive spastic paraparesis with severely limited walking accompanied by gradual foot deformities resulting in pes cavus suggesting underlying peripheral neuropathy. All three patients are already using splints to prevent further shortening of tendons while one has required surgical correction of feet deformities. On the last follow-up at the age of 17, 12, and 8 years, all three patients had esotropia, pes cavus, lower significant peripheral neuropathy or allergic reactions. As expected, grade 1 and 2 asymtommatic CPK elevation and grade 1 and 2 rashes were some of the most common attributable toxicities seen with selumetinib. Rashes were often mitigated with topical supportive care. There were some patients who did require selumetinib dose reductions (Table 3); however, responses did not appear minimized in those patients requiring dose reductions suggesting the RP2D is not necessary for response. Interestingly, on A9952, NF1 patients who were non-randomly inhibitor. Although not universally indicative of better clinical behavior, wild-type patients should perhaps be considered as atypical DIPG, and if coupled with atypical radiology and/or clinical presentation may warrant a different therapeutic approach. or corrective glasses. Ophthalmological examination at that time documented progressive bilateral optic nerve pallor particularly in the temporal optic disc parts. Disease progression was marked by a variable degree of intellectual disability ranging between mild-to-moderate intellectual disability with attention deficit and accompanied by severe optic atrophy resulting in legal blindness already during the first decade of life. In addition, all the patients developed progressive spastic paraparesis with severely limited walking accompanied by Three members of a large consanguineous Indian family (figure 1A), affected by axonal neuropathy (table 1) and optic atrophy, were identified at the London Royal Free Hospital. Case 3 was first seen at the age of 35 years and then again at the age of 51 years. She is the first cousin of Cases 1 and 2 and presented as a child with delayed milestones, later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were site leading to skipping of exon 2, the first coding exon (Figures 4b and c). Taken together, the main clinical features comprising a spectrum of C12orf65 defects corresponds to a triad of optic atrophy, peripheral neuropathy, and spastic paraparesis. Accordingly, C12orf65-related defects may be classified into three phenotypes distinguished by disease severity, mortality, and the lack or presence of associated intellectual disability (Table 2). The milder form is represented by the four subjects from family A in the current report and by the\n",
            "[0.6460651]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?\n",
            "Refined Query: The Vaughan-Williams classification categorizes anti-arrhythmic drugs based on their electrophysiological effects on the heart.  Could you list these classes and briefly describe their mechanisms of action?\n",
            "\n",
            "Combined Answer: a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. Details of the key features of CardioClassifier can be found in Table 2. Each variant is annotated for up to 17 computational criteria, with results output to a grid representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary CardioClassifier provides a simple-to-use web interface that takes as input either individual variant details or a single sample VCF (Supplementary Figure 1). Users select one of 11 cardiac disorders, and this determines which pre-specified validated disease genes are analysed. Where a diagnosis is uncertain (e.g. sudden cardiac death or complex cardiomyopathy), a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. allow distinguishing between commonly prescribed drugs of the selected cohort and those correlated with the selected diagnosis. If, for instance, published studies indicate a certain drug increases the risk of heart attacks, the JADE tool can list prescribed medication prior to hospital stays with the diagnosis heart attack. To assist the user selection of an interesting diagnosis, all diagnoses that are related to hospitalisations due to adverse drug events and drug-drug interactions are highlighted in red in the searchable list. able to add and remove evidence specific to the patient/family of interest. The strength of CardioClassifier is its disease-specificity. The ACMG/AMP rules are intentionally non-specific to allow adoption in any disease domain. To harness the full power of this framework, the rules need to be applied in a disease- and gene-specific manner25. We have defined criteria and thresholds for each ACMG/AMP rule that are specific to the disorder of interest, and demonstrate the power and effectiveness of this approach over a recently released data on prior observations (in health or disease), and integrates evidence according to the widely-adopted framework from ACMG/AMP. The tool is transparent, with all the information incorporated into interpreting each variant displayed along with the final classification. It is also flexible, and designed to be fully interactive, with the user able to add and remove evidence specific to the patient/family of interest. The strength of CardioClassifier is its disease-specificity. The ACMG/AMP rules are intentionally non-specific to allow CardioClassifier concordantly activated 137/157 rules (87.3%; Figure 3; Supplementary Table 3). The discrepancies fall across 3 rules; PP3 (in silico prediction algorithms; n=12), PS4 (prevalence in affected individuals statistically increased over controls; n=7) and PM5 (same amino acid residue as known Pathogenic variant; n=1). CardioClassifier imposes a more stringent threshold on PP3 (allowing only one of eight in silico prediction algorithms to be discordant), and differences in PS4 and PM5 are due to the increased availability of proband are attractive candidates for clinical studies. Therefore, we focused on the top 10%. Synergistic combinations with a measured score higher than 30 were classified as positive. In the negative class antagonistic, additive and low synergistic drug combinations were summarized. ozanimod exposures of the 0.5‐mg and 1‐mg QD regimens, respectively, currently being evaluated in ongoing development programs. All subjects were to have fasted for at least 10 hours before baseline ECG profiling and for 10 hours before dosing on days 1 to 14 and day 17. Discontinuation of a subject from the study was to be considered in the case of the following during treatment: an increase in QT/QTc interval to >500 milliseconds and/or of >60 milliseconds over baseline, any evidence for ventricular or supraventricular arrhythmia with or be activated when the evidence supporting the classification is unavailable, yet this evidence is often contained within the appropriate ClinVar submission. Full details of the rules activated by both tools are shown in Figure 3b. To ensure the higher sensitivity of CardioClassifier was not due to over-activating rules, we also tested a set of 67 ‘Benign’ and ‘Likely Benign’ variants from ClinVar across the same six ICCs. CardioClassifier identified 61/67 (91.0%) of these as Benign and the remaining 6 as VUS. Conversely, InterVar identified ability of the links within the CardioClassifier report to inform activation of the 61 case-level data points activated by the ClinGen team. These links allowed us to manually collate 50/61 (82.0%) individual data points (Supplementary Table 3) with differences again in the availability of proband data (6 PS4_supporting, 1 PS4_moderate, 1 PS2, 1 BS4 and 2 PP1_moderate). After addition of this clinical data, we reached an identical classification to the ClinGen team for 50/57 (87.7%) variants (Figure 3a).\n",
            "[0.643458]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the different isoforms of the mammalian Notch receptor?\n",
            "Refined Query: Mammalian Notch receptors exist in four distinct isoforms, Notch1, Notch2, Notch3, and Notch4.  These isoforms share a conserved overall structure but differ in their extracellular domains, influencing ligand binding and downstream signaling pathways, leading to diverse developmental outcomes.  What are the specific structural and functional differences between these isoforms, and how do these variations contribute to their distinct roles?\n",
            "\n",
            "Combined Answer: data show interactions between genes involved in the same developmental cascade and extend the concept of multistep control well known in metabolic pathways to a developmental pathway (fig 3). To our knowledge, similar examples remain uncommon. One worth mentioning is Alagille syndrome caused by heterozygous mutations of JAG1, a ligand for the Notch family of receptors. Jag+/− mice have a subtle ocular phenotype, while mice doubly heterozygous for a null allele of Jag1 and a hypomorphic allele of Notch2 have a more severe complex phenotype Notch family of receptors. Jag+/− mice have a subtle ocular phenotype, while mice doubly heterozygous for a null allele of Jag1 and a hypomorphic allele of Notch2 have a more severe complex phenotype closely resembling Alagille syndrome.32 In HSCR, genetic interactions between RET and genes encoding proteins of the endothelin signalling pathway (EDNRB and ET3) have been documented in both humans and mice.33,34,35 Altogether, RET plays a pivotal role in HSCR as the major gene in isolated HSCR and as a modifier gene in at least some syndromic gene (21). Another study demonstrated that hotspots of transcription factors in the early phase of adipogenesis are highly enriched in super-enhancer regions, which drive adipogenic-specific gene expression (22). Wang et al., found a large number of dynamic NOTCH1 (a master regulatory protein) sites in the super-enhancer regions (23). They observed that 83% of NOTCH1 sites overlap with H3K27ac ChIP-seq peaks and demonstrated the importance of Notch super-enhancer interaction in gene expression (23). Another study identified super-enhancers by role for protein-protein interaction. The C-terminal ligand-binding domain is similar to those of other nuclear receptors; however, a specific ligand of Dax1 has not been identified, and thus Dax1 is classified as an orphan nuclear receptor. Dax1 is specifically expressed in self-renewing ES cells (21). Expression of Dax1 is regulated by several transcription factors, including STAT3, Oct3/4, and LRH-1, in ES cells (21, 22). Dax1 associates with the POU-specific domain of Oct3/4; as a result, transcriptional activity of Oct3/4 is repressed by Nanog gene (29). Oct3/4 is able to bind to Dax1, as described in our previous study (20) as well as our current study. Here, we found that Esrrb interacts with Dax1 and that the first and third LXXLL motifs of Dax1 are crucial for the interaction. In particular, Esrrb associates with the third LXXLL motif of Dax1 rather than with the first LXXLL motif. We assume that Esrrb, Oct3/4, and Dax1 do not form a trimer complex. Instead, Esrrb or Oct3/4 is exclusively bound by Dax1. Dax1 is known to function as a transcriptional repressor (23, 35, 36). that 83% of NOTCH1 sites overlap with H3K27ac ChIP-seq peaks and demonstrated the importance of Notch super-enhancer interaction in gene expression (23). Another study identified super-enhancers by profiling BRD4 ChIP-seq signal in multiple cancer cells and found considerable loss of BRD4 at super-enhancer regions by treating cancer cells with the BET-bromodomain inhibiter JQ1 (16). Recently, a large-scale collaborative research project revealed highly asymmetric binding of BRD4 at super-enhancers in diffuse large B-cell lymphoma (DLBCL) cells suppressed followed by Oct3/4 repression; however, overexpression of Esrrb maintained expression of Dax1 even in the absence of Oct3/4, indicating that Dax1 is a direct downstream target of Esrrb and that Esrrb can regulate Dax1 expression in an Oct3/4-independent manner. We also found that the transcriptional activity of Esrrb was repressed by Dax1. Furthermore, we revealed that Oct3/4, Dax1, and Esrrb have a competitive inhibition capacity for each complex. These data, together with previous findings, suggest that Dax1 functions as a protein. Interaction of Dax1 and Esrrb was mediated through LXXLL motifs of Dax1 and the activation- and ligand-binding domains of Esrrb. Furthermore, Esrrb enhanced the promoter activity of the Dax1 gene via direct binding to Esrrb-binding site 1 (ERRE1, where “ERRE” represents “Esrrb-responsive element”) of the promoter. Expression of Dax1 was suppressed followed by Oct3/4 repression; however, overexpression of Esrrb maintained expression of Dax1 even in the absence of Oct3/4, indicating that Dax1 is a direct downstream target of Esrrb and Esrrb and Dax1 are known to be component molecules of the Oct3/4-centered transcription factor network in ES cells (18). Next, we confirmed the interaction between Dax1 and Esrrb and determined the interaction regions by using a MBP pulldown assay in mammalian HEK293 cells. To determine the Esrrb-binding region of Dax1, we prepared several truncated mutants of Dax1, including full-length Dax1 (amino acids 1 to 472), DNA-binding domain (DBD; amino acids 1 to 255), Q1a (amino acids 1 to 100), Q1b (amino acids 68 to 139), Q23e (amino acids 136 to We assume that Esrrb, Oct3/4, and Dax1 do not form a trimer complex. Instead, Esrrb or Oct3/4 is exclusively bound by Dax1. Dax1 is known to function as a transcriptional repressor (23, 35, 36). Transcriptional activities of Oct3/4 and Esrrb are inhibited by Dax1. As described previously, hyperactivation of Oct3/4 in ES cells leads to differentiation into primitive endoderm and mesoderm (10), and Dax1 inhibits the overactivation and contributes to retaining self-renewal (20). A similar relationship between Dax1 and Esrrb would be anticipated.\n",
            "[0.7022245]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the major characteristics of cellular senescence?\n",
            "Refined Query: Cellular senescence, a state of permanent cell cycle arrest, is characterized by a complex interplay of factors including altered morphology, senescence-associated secretory phenotype (SASP) production (releasing inflammatory molecules), genomic instability, and telomere shortening.  Understanding these hallmarks helps elucidate its roles in aging and disease.\n",
            "\n",
            "Combined Answer: genes. Lysosomes are responsible for the degradation of many macromolecules, including proteins, and increase in lysosomal mass is a well-known characteristic of aging and senescence in cells (Cuervo and Dice 2000; Kurz et al. 2000). In addition, evidence is increasing that a progressive decrease in the efficiency of autophagy and lysosomes with age plays a key role in aging-associated degenerative changes in mammals (Rubinsztein et al. 2011). Several recent findings support that SREBP TFs play a key role in these processes. SREBF1 expression plays a key role in aging-associated degenerative changes in mammals (Rubinsztein et al. 2011). Several recent findings support that SREBP TFs play a key role in these processes. SREBF1 expression increases with age in rat brains (Okamoto et al. 2006), SREBF1-mediated lipogenesis is involved in senescence (Kim et al. 2010), SREBF2 regulates autophagy (Seo et al. 2011), and SREBF activity is regulated by mTOR complex 1 (Peterson et al. 2011). It is remarkable that simply by contrasting motif activities in tissues from younger and older donors, maintenance can be a consequence of either reduced telomerase function or defects in other telomere-associated proteins that control chromosome end protection and/or replication (22). Telomerase null mutants die on extended outgrowth, accompanied by progressive telomere shortening. This phenotype is enhanced in rad52 mutants, which lack a compensatory recombinational pathway that maintains the telomere and hence cell viability (60). Clonal senesence was not observed in ctf18 or ctf18 rad52 mutants after 240 generations of outgrowth (data not ‘old’ samples for each motif (results at http://ismara.unibas.ch/supp/dataset1_IBM/averaged_age/averaged_report/). We found that only the SREBF motif is significantly differently regulated between old and young samples (Fig. 2D). The targets of SREBF are up-regulated in older tissues relative to the younger ones and are highly enriched for lysosomal genes. Lysosomes are responsible for the degradation of many macromolecules, including proteins, and increase in lysosomal mass is a well-known characteristic of aging and senescence in cells The transcription factor and tumor suppressor p53 is activated in response to a variety of cellular perturbations, in particular genotoxic stress, to prevent fixation of DNA damage and proliferation of cells with genetic defects (reviewed in [1]). Consequences of p53 activation include induction or repression of p53-responsive genes at the transcriptional level, resulting in cell cycle arrest, senescence, or apoptosis [2]. Due to this central function in preserving the genetic integrity of higher organisms p53 has been labeled the “guardian of level, resulting in cell cycle arrest, senescence, or apoptosis [2]. Due to this central function in preserving the genetic integrity of higher organisms p53 has been labeled the “guardian of the genome” [3]. Evasion of growth suppression is a hallmark of cancer [4], and disruption of the p53 pathway is considered to occur early during oncogenesis [5]. The activity of p53 is tightly regulated by post-translational modifications that affect its cellular localization and ability to bind DNA consensus sequences [6,7]. However, p53 is principally the genome in Pfh1-depleted cells might lead to widespread fork collapse and death when Swi1 is not there to protect them. Alternatively, death may arise from additive effects of DNA damage, as γ-H2A levels are elevated in both Pfh1-depleted (Fig. 7A–C) and swi1Δ cells (Rozenzhak et al. 2010). The synergism of Pfh1 and Swi1 depletion emphasizes the important role of Pfh1, as similarly severe growth effects are only seen in checkpoint-defective swi1Δ cells that are treated with a DNA-damaging agent (Noguchi et al. 2003). Because both Swi1 and cell cycle arrest. Coincident with the ATR-dependent cell cycle arrest, we find increased DNA damage that is specifically limited to late replicating regions of the Drosophila genome, suggesting that PR-Set7-mediated monomethylation of H4K20 is critical for maintaining the genomic integrity of late replicating domains. recombinational pathway that maintains the telomere and hence cell viability (60). Clonal senesence was not observed in ctf18 or ctf18 rad52 mutants after 240 generations of outgrowth (data not shown). Therefore it is likely that the short telomere phenotype is not due to an absence of telomerase. Interestingly, the synthetic dosage lethality screen described above revealed a synthetic interaction with rap1-5 in the presence of excess Ctf18p (Table 2). RAP1 encodes a transcriptional repressor-activator DNA binding protein with effects on both impacts on proliferation, senescence, or apoptosis. Similarly, the mutational profiles of cancer cells may bias CNVs toward forming in the vicinity of UCEs, possibly conferring selective advantage, whereas the profiles of healthy cells may avoid such disruptions. Whether the difference in UCE disruption by CNVs in cancer versus healthy cells is due to differences in mutational profiles, selective retention/loss of UCE-disrupting CNVs, or a combination of both, the dichotomy of CNV profiles with respect to UCEs between healthy and cancerous\n",
            "[0.6927812]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.26ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 958.34ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 833.54ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 733.16ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 881.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.76ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 580.72ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 404.02ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 781.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.40ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.96ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 710.53ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.96ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.34ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 956.78ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which MAP kinase phosphorylates the transcription factor c-jun?\n",
            "Refined Query: The transcription factor c-Jun's activation is crucial in various cellular processes.  Understanding its regulation necessitates identifying the specific mitogen-activated protein kinase (MAPK) isoform responsible for its phosphorylation.  Therefore, the question seeks to pinpoint which member of the MAPK family directly phosphorylates c-Jun.\n",
            "\n",
            "Combined Answer: a DNA-binding motif, such as the ETS family (ELF1, ETS1, GABPA, SPI1) and the E-box family (MYC, USF1, USF2). The AP-1 transcription factor is a heterodimer composed of a member of the JUN family and a member of either the FOS family or the ATF family [34]. However, in our analysis, FOS itself never clustered with a JUN family member, but JUN and JUND’s occupancy profiles were correlated with those of their alternative binding partners BATF, FOSL1, FOSL2, and ATF2, and to a lesser extent CEBPB and CEBPD, which are not documented to interact other than JunD. In a comparison of c-Fos versus c-Jun unique targets, we found E2F factors associated with c-Fos targets, consistent with the previously reported roles of c-Fos and E2Fs in the same signaling cascade that links Ras activity to cyclin A transcription (30). In the same comparison, TF Mitf was associated with c-Jun, consistent with their direct interaction and synergistic effects on gene regulation (31,32). In a comparison of Atf1 versus Atf3, Myc/Max/Mad TFs were found enriched in Atf3-unique targets; a potential interaction directly with JunD. However, it has very similar sequence preferences to Tgif2, a factor that has been shown to interact specifically with JunD (29). In the Fos-unique sequences, the most important features reflect the general specificity of Fos:Jun complexes, which might indicate that at those targets Fos binds together with AP-1 proteins other than JunD. In a comparison of c-Fos versus c-Jun unique targets, we found E2F factors associated with c-Fos targets, consistent with the previously reported roles of c-Fos and E2Fs in the same alterations in neurofibromin 1, a negative regulator of the MAPK pathway. Approximately 15–20% of NF1 patients will develop pLGG, most commonly within the optic pathway and brainstem.(13) Abnormal MAPK pathway activation is the most common genetic aberration in pLGG.(14–17) This is most often the result of activation of the BRAF oncogene either through a tandem duplication resulting in a KIAA1549-BRAF fusion or an activating point mutation, BRAFV600E.(18) Approximately 80–90% of pilocytic astrocytomas (PA), the most common pLGG, harbor the with proteins from the AP-1 subfamily (26,27); the exact identity of the GATA co-factor that might interact specifically with JunD remains to be determined. TF Sfpi1, associated with JunD-unique targets, is known to interact directly with JunD (28). TF Meis1 was also found to be associated with JunD-unique sequences. Meis1 is not known to interact directly with JunD. However, it has very similar sequence preferences to Tgif2, a factor that has been shown to interact specifically with JunD (29). In the Fos-unique sequences, the most important reflecting the specificity of the ATF/CREB subfamily (such as ‘Atf1_3026_contig8mers_v1_MAX’) are strongly associated with JunD-unique sequences, consistent with a direct interaction between JunD and ATF/CREB factors. GATA factors, also found to be important for distinguishing Fos- from JunD-unique targets, have been previously reported to interact with proteins from the AP-1 subfamily (26,27); the exact identity of the GATA co-factor that might interact specifically with JunD remains to be determined. TF Sfpi1, associated with JunD-unique selumetinib, MAPK pathway, BRAFV600E mutation and KIAA1549-BRAF fusion was undertaken. No date restrictions were employed. The data quality was robust and consistent verifying that abnormal Ras-MAP kinase-signaling is the most common genetic aberration in pLGG and that targeting of this pathway in cell lines and animal models led to tumor regression. Phase I clinical trials in both children and adults supported safety and preliminary efficacy of selumetinib, a non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. These detected some known binding partners and gene families as well as novel relationships among TFs. For example, subunits of multimeric complexes often had very similar binding profiles, such as NFE2 and MAFF or MAFK [28]; MAX and MYC or MXI1 [29,30], NFYA and NFYB [31,32]; and USF1 and USF2 [33]; to a lesser extent, so did family members that share a DNA-binding motif, such as the ETS family (ELF1, ETS1, GABPA, SPI1) and the E-box family (MYC, USF1, USF2). The AP-1 transcription factor is a heterodimer composed of a member of the JUN family and through a tandem duplication resulting in a KIAA1549-BRAF fusion or an activating point mutation, BRAFV600E.(18) Approximately 80–90% of pilocytic astrocytomas (PA), the most common pLGG, harbor the KIAA1549-BRAF fusion whereas BRAFV600E mutations are identified in approximately 10–20% of all pLGG.(19) Numerous drugs that target the MAPK pathway have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The mechanism. Treating C2C12 cells with RSV dramatically inhibited insulin-stimulated Akt, S6 kinase, and 4E-BP1 phosphorylation but had little effect on tyrosine phosphorylation of the insulin receptor and activation of the p44/42 MAPK signaling pathway. RSV treatment also partially blocked mTOR and S6 kinase phosphorylation in TSC1/2-deficient mouse embryonic fibroblasts, suggesting the presence of an inhibitory site downstream of TSC1/2. Knocking out PDK1 or suppressing AMP-activated protein kinase had little effect on leucine-stimulated mTOR\n",
            "[0.7791556]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the meaning of the acronym \"TAILS\" used in protein N-terminomics?\n",
            "Refined Query: In the field of protein N-terminomics, what does the acronym TAILS represent?  Specifically, I'm interested in its meaning within the context of identifying and characterizing protein N-termini.\n",
            "\n",
            "Combined Answer: accessible to the scientific community. In particular the Swiss-Prot component of UniProt is a high-quality, manually annotated, non-redundant protein sequence database which combines information extracted from scientific literature and biocurator-evaluated computational analysis. The aim of Swiss-Prot is to provide all known relevant information about a particular protein. Annotation is regularly reviewed to keep up with current scientific findings. The manual annotation of an entry involves detailed analysis of the protein sequence and of environment; molecular function, the elemental activities of a gene product at the molecular level, such as binding or catalysis; and biological process, operations or sets of molecular events with a defined beginning and end, pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. UniProt The Universal Protein Resource [56] (UNIPROT) provides the scientific community with a comprehensive, high-quality and freely accessible resource of protein sequence and functional information. Its protein knowledge Resource [56] (UNIPROT) provides the scientific community with a comprehensive, high-quality and freely accessible resource of protein sequence and functional information. Its protein knowledge base consists of two sections: Swiss-Prot, which is manually annotated and reviewed, and contains approximately 500 thousand sequences, and TrEMBL, which is automatically annotated and is not reviewed, and contains approximately 23 million sequences. The primary mission of UNIPROT is to support biological research by maintaining a stable, comprehensive, crystalized, including C-terminal fragments of the TcdA and TcdB CROP domains (12, 23–25). The structures of the TcdA/B CROPs display a recurring β-solenoid structural unit (defined herein as a “CROP unit”) containing one LR flanked by 2–3 SR β-hairpins on either side, consistent with the motifs uncovered through sequence analysis. Modeling based on a high-resolution structure of a peptide spanning the extreme C-terminal end of the TcdA CROP domain predicts an overall S-shaped elongated rodlike CROP domain for TcdA and a shorter the cytoplasm. Deletion of C-terminal part completely abolished the protein’s ability to aggregate. In contrast, CREST lacking the autoregulatory domain only (CR_dNT) or in combination with Met-rich domain (CR_dNT-Met) was distributed and aggregated in a very similar manner to the full-length protein, i.e. these variants were detected mainly in the nucleus where they formed multiple puncta (Figure 2F). However, for these two variants, cytoplasmic delocalisation was more pronounced and aggregation capacity was diminished compared to full-length GO term enrichment analysis i.e. they start from a user-supplied list of genes, but offer additional features to assist in interpretation of the results, typically visualization and clustering facilities. REVIGO is the tool of choice for users that wish to be able to quickly analyze their list of GO terms and see if the output fits their needs, without needing to install any software on their machine or to master complex input formats. Furthermore, REVIGO might appeal to users wanting to experiment with different visualization techniques and p-value by dividing this number by the number of random sets. In order to call a TFBS motif in the target promoters significantly over-represented, both p-values had to be lower than 0.01. For the phylogenetic fooprinting approach, we extracted the orthologous mouse region for each promoter from the UCSC genome browser human-mouse NET alignment [36], and then searched the alignments for TFBS motifs using an 80% score cut-off and an 80% identity cut-off. We also used the Clover [19] algorithm to detect TFBS motif over-representation. Clover is automatically annotated and is not reviewed, and contains approximately 23 million sequences. The primary mission of UNIPROT is to support biological research by maintaining a stable, comprehensive, fully classified, richly and accurately annotated protein sequence knowledge base, with extensive cross-references and querying interfaces freely accessible to the scientific community. In particular the Swiss-Prot component of UniProt is a high-quality, manually annotated, non-redundant protein sequence database which combines information of different CREST domains to its aggregation propensity, we produced a set of deletion constructs tagged with GFP at their N-terminus (Figure 2E) and expressed them in SH-SY5Y cells (Figure 2F). N-terminal autoregulatory domain (CR_NT) or C-terminal part of CREST (CR_CT) in isolation did not aggregate and were present both in the nucleus and in the cytoplasm. Deletion of C-terminal part completely abolished the protein’s ability to aggregate. In contrast, CREST lacking the autoregulatory domain only (CR_dNT) or in combination with Met-rich 2B), although formation of weakly CREST-positive nuclear caps could be observed, probably due to protein redistribution from the pool of not yet aggregated protein (Figure 2B, arrowheads). Using live cell imaging, we also demonstrated that nuclear CREST aggregates are characterized by time- and concentration-dependent fusion and growth (Additional file 2: Video S1). To explore CREST aggregation biochemically, we expressed untagged protein with subsequent sequential extraction in detergent-containing buffers (see Methods section for details).\n",
            "[0.6385273]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Do mutations of AKT1 occur in meningiomas?\n",
            "Refined Query: Investigating the prevalence and significance of AKT1 gene mutations in meningioma development and progression is crucial.  Are AKT1 mutations common in meningiomas?  If so, what subtypes are most affected, and is there a correlation between specific mutations and clinical outcomes?\n",
            "\n",
            "Combined Answer: of validated non-coding variants associated with Mendelian disease has not existed. Therefore, we performed detailed and comprehensive biocuration to identify experimentally or otherwise validated non-coding variants (<25 nucleotides) associated with Mendelian disease from the medical literature. The resulting 453 mutations were located in 5′ and 3′ UTRs, promoters, enhancers, large RNA genes, microRNA genes, and imprinting control regions (ICR) (Table 1, Table S6). To assess whether the regulatory Mendelian mutations differ from or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also gene panels in clinical practice. Five of the families with DOORS syndrome in our study have substitutions affecting the arginine at position 242, and two have substitutions affecting the arginine at position 40, suggesting that these residues are crucial in TBC1D24 function. Both are in a CpG island and affect CG dinucleotides. CpG nucleotides are more mutation-prone, which might explain mutation recurrence in individuals of different ethnic origins. Two patients also shared another recurrent mutation unique to DOORS (His336Glnfs*12). TBC1D24 previous reports on TBC1D24 mutations) to multi-systemic syndromic disorders such as DOORS syndrome. These emerging findings of both genotype-phenotype complexity and genetic pleiotropy lend support to the view that, with accumulating mutational data, the fuller coverage afforded by exome (or genome) sequencing might be more useful than targeted gene panels in clinical practice. Five of the families with DOORS syndrome in our study have substitutions affecting the arginine at position 242, and two have substitutions affecting the arginine at these tumors often also have TP53 and ATRX mutations but do not have IDH1 mutation 19, 25, 26. More recently, a subset of K27M+ DIPGs were found to also harbor missense mutations in the ACVR1 gene, encoding the activin A receptor type‐1 transmembrane protein, that lead to activation of the BMP‐TGFβ signaling pathway 6, 10, 27, 30. Other alterations occasionally found in K27M+ DIPGs include PIK3CA mutation, PDGFRA mutation or amplification, PPM1D mutation, and amplification of cell cycle genes including CCND1, CDK4 and CDK6 30, 31. The in 5′ and 3′ UTRs, promoters, enhancers, large RNA genes, microRNA genes, and imprinting control regions (ICR) (Table 1, Table S6). To assess whether the regulatory Mendelian mutations differ from non-deleterious variants, we compared the regulatory mutations based upon a set of genomic characteristics (attributes) representing typical indicators of variant functionality such as GC-content, conservation, histone modifications, DNase I accessibility, and overlap with enhancers and transcription factor binding sites. Additionally, Mendelian Comprehensive literature review was performed to identify non-coding variants that are convincingly associated with Mendelian disease. We included only those variations and publications judged to provide plausible evidence of pathogenicity. First, the phenotypic abnormalities of the individual carrying the variant were assessed and a variant was included only if the disease association was regarded as plausible on the basis of evidence such as familial cosegregation or experimental validation, using techniques such as luciferase reporter nature of the mutation (Wu et al. 2012). The K27M mutation is most often found in H3F3A (>70 %) with a few occurrences in HIST1H3B (∼20 %) and HIST1H3C mainly in younger patients with a median age of 10–11 years (Wu et al. 2012; Schwartzentruber et al. 2012; Sturm et al. 2012; Khuong-Quang et al. 2012; Wu et al. 2014; Fontebasso et al. 2014; Buczkowicz et al. 2014). Analysis of the DNA sequences for H3F3A and H3F3B illuminates why the K27M mutation is restricted to H3F3A, as K27 is coded by AAG in H3F3A and by AAA in H3F3B, requiring a single Our findings suggest that mutations in TBC1D24 seem to be an important cause of DOORS syndrome and can cause diverse phenotypes. Thus, individuals with DOORS syndrome without deafness and seizures but with the other features should still be screened for TBC1D24 mutations. More information is needed to understand the cellular roles of TBC1D24 and identify the genes responsible for DOORS phenotypes in individuals who do not have a mutation in TBC1D24. gene is similar to that observed in the European population (25%)3 in all groups except the Haddad group, where its frequency reaches 38.6% (χ2 = 11.73, p<0.001). However, a strict digenic model does not account for all cases and at least one more modifier gene (with or without the involvement of environmental factors) must be involved. Indeed, 16 patients with a PHOX2B alanine expansion and no predisposing RET haplotype had HSCR. Among these cases, one is known to harbour a heterozygous RET gene missense mutation P1039L,19 in addition to a de\n",
            "[0.80179036]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the main indications of lacosamide?\n",
            "Refined Query: What are the primary clinical uses and approved indications for the anticonvulsant medication lacosamide?  Specifically, in which neurological conditions is its use recommended?\n",
            "\n",
            "Combined Answer: MEDLINE (PubMed). #1 randomized controlled trial [pt] #2 controlled clinical trial [pt] #3 randomized [tiab] #4 placebo [tiab] #5 drug therapy [sh] #6 randomly [tiab] #7 trial [tiab] #8 groups [tiab] #9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 #10 animals [mh] NOT humans [mh] #11 #9 NOT #10 #12 epilepsy [mh] #13 seizures [mh] #14 (epilep* or seizu* or convuls*) [tw] #15 # 12 OR # 13 OR # 14 #16 losigame [sn] #17 losigam* [tw] #18 ADD137022 [tw] #19 LSG [tw] #20 #16 OR #17 OR #18 OR #19 #21 #11 AND #15 AND #20 epilepsy; losigamone is one of these drugs. We wanted to know whether losigamone was an effective and safe treatment for people with focal epilepsy. Study characteristics The evidence is current to February 2017. We found two trials assessing add‐on losigamone for focal epilepsy, which recruited a total of 467 participants aged over 18 years. Both trials assessed losigamone 1200 mg/day or 1500 mg/day as an add‐on therapy for focal epilepsy. Key results The results of this review showed that participants taking losigamone as an add‐on treatment In two double‐blind, placebo‐controlled, add‐on studies, losigamone has shown possible effects in people with focal epilepsy (Bauer 2001; Baulac 2003). One study tested losigamone at 1200 mg/day or 1500 mg/day, in addition to three standard anticonvulsants, in 264 people with focal epilepsy. They observed a dose‐dependent reduction of seizure frequency: 29.3% of participants receiving losigamone at 1500 mg/day had a 50% or greater reduction in seizure frequency, as compared to 17.2% in those receiving losigamone at 1200 mg/day and 11.8% in the Epilepsy is a common neurological disorder, affecting approximately 50 million people worldwide (Banerjee 2009; De Boer 2008). In low‐ and middle‐income countries, the median incidence of the disease is 68.7 per 100,000 population, which is higher than that in high‐income countries (43.4 per 100,000 population) (Kotsopoulos 2002). It is estimated that about 30% of patients have epilepsy that is refractory to one or more agents and they are considered to be drug‐resistant. These patients often need add‐on therapy with other antiepileptic drugs four‐week post‐treatment period for safety observations. A total of 264 people with focal epilepsy, who had also had one to three AEDs prior to the study, were randomly assigned to the losigamone or placebo group: 87 participants were randomized to losigamone 1200 mg/day, 92 to losigamone 1500 mg/day and 85 to placebo. The mean age of the study population was 35.7 years, the mean duration of the disease was 21 years, and the mean seizure frequency per month before randomization was 9.2 seizures. The percentage reduction in seizure frequency We included two studies that investigated the efficacy and safety of losigamone as an add‐on therapy for focal epilepsy (see Characteristics of included studies). The first study conducted in Germany by Bauer and colleagues (Bauer 2001) was a randomized, double‐blind, placebo‐controlled, add‐on study. The study lasted for 16 weeks and consisted of an eight‐week baseline phase and an eight‐week double‐blind treatment phase. A total of 203 people with focal epilepsy taking no more than three AEDs prior to the study were randomized to treatment As a result of the insufficient number of included trials with placebo‐controlled design, short‐term duration and uncertain quality in this review, it is difficult to give any recommendations for current clinical practice of losigamone as an add‐on therapy for focal epilepsy. In this review, results suggest that the higher dose of losigamone 1500 mg/day seems a better starting dose according to its efficacy in reducing seizure frequency, but it is associated with more dropouts due to adverse events. Furthermore, because both of the included Review question This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (2015, Issue 12) on 'Losigamone add‐on therapy for focal epilepsy'. We reviewed the evidence about the efficacy and safety of losigamone when used as an add‐on therapy for focal epilepsy. We found two studies. Background Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and for the favorable toxicity profiles and relatively low rates of peripheral neuropathy associated with epoxyketone PIs.24,53 This could permit more prolonged and intense dosing regimens, potentially increasing the efficacy of the drug. Bortezomib is dosed on a day 1, day 4 schedule, allowing for full recovery of proteasome activity between doses.38 In ongoing clinical trials, carfilzomib is dosed intravenously on two subsequent days; experimental evidence suggests that daily dosing is similarly well tolerated, although the necessity for in the losigamone‐treated group, and 11 participants dropped out in the placebo group. The second study conducted by Baulac and colleagues (Baulac 2003) was a multicenter, randomized, double‐blind, placebo‐controlled, add‐on study. The study lasted for 28 weeks and consisted of a 12‐week baseline period, a 12‐week double‐blind treatment phase and a four‐week post‐treatment period for safety observations. A total of 264 people with focal epilepsy, who had also had one to three AEDs prior to the study, were randomly assigned to the losigamone or\n",
            "[0.74559855]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which fusion protein is involved in the development of Ewing sarcoma?\n",
            "Refined Query: Ewing sarcoma's development is characterized by a specific chromosomal translocation.  Which fusion protein, resulting from this translocation, is the key driver of this cancer's pathogenesis?\n",
            "\n",
            "Combined Answer: rhabdomyosarcoma [47], Ewing sarcoma [48], and ALL [49]. Our results extend previous in vitro findings for Nutlin to RG7112, and they provide insight into the in vivo pattern of activity of RG7112 against p53 wild-type childhood cancer preclinical models. The pattern of in vitro activity of RG7112 against the cell line panel tested is consistent with p53-MDM2 interaction inhibition. Each of the p53 wild-type cell lines had rIC50 values < 1 µM, while only one p53 mutant cell line (Ramos-RA1) had a rIC50 value below 1 µM. The Ramos Burkitt rhabdomyosarcoma, Wilms, rhabdoid and Ewing sarcoma xenografts. For the ALL panel, there was 1 partial response, 5 complete responses and 1 maintained complete response. The ALL xenografts expressed the highest levels of p53 among the PPTP panels. The p53:MDM2 interaction is a priority target for pediatric evaluation given the high prevalence of p53 wild-type cancers in the childhood cancer setting. Previous results have shown that the MDM2 inhibitor Nutlin is active against cell lines derived from a number of pediatric cancers, including cell lines for neuroblastoma [44,45], osteosarcoma [46], rhabdomyosarcoma [47], Ewing sarcoma [48], and ALL [49]. Our results extend previous in vitro findings for Nutlin to RG7112, and they provide insight into the in vivo pattern of activity of RG7112 We thank F. Ochsenbein and C. Francastel for discussions, and S. Jounier and the Gene Identification team at CNG for technical help. We thank D. Reinberg for providing the H3K27me2/3 antibody, R. Feil for the JF1/Ms mouse strain, and N. Gilbert for probes. M.G.'s team is supported by the Association pour la Recherche sur le Cancer (ARC). S.D. acknowledges la Ligue Nationale Contre le Cancer for support (Equipe Labelisée). tumors is relatively stable, with cells being diploid and wild-type for p53 (Behjati et al. 2013). This suggests that these H3.3 mutations may not only be defined as oncogenic drivers because of their high frequency of occurrence but may also be important drivers for effecting tumorigenesis in these tumors. Mutations of H3.3 were also observed at low frequency in osteosarcoma (2 % containing G34R in H3F3A or H3F3B), conventional chondrosarcoma (1 % containing K36M in H3F3A), and clear cell chondrosarcoma (7 % containing K36M in H3F3B) (Behjati frequency in osteosarcoma (2 % containing G34R in H3F3A or H3F3B), conventional chondrosarcoma (1 % containing K36M in H3F3A), and clear cell chondrosarcoma (7 % containing K36M in H3F3B) (Behjati et al. 2013). Interestingly, although highly prevalent in pediatric glioblastoma, to date, no K27M mutations have been observed in bone or cartilage tumors, and the K36M mutant has not been found in glioblastoma. level, resulting in cell cycle arrest, senescence, or apoptosis [2]. Due to this central function in preserving the genetic integrity of higher organisms p53 has been labeled the “guardian of the genome” [3]. Evasion of growth suppression is a hallmark of cancer [4], and disruption of the p53 pathway is considered to occur early during oncogenesis [5]. The activity of p53 is tightly regulated by post-translational modifications that affect its cellular localization and ability to bind DNA consensus sequences [6,7]. However, p53 is principally for later steps in the chromosome cycle that support the maintenance of cohesion until anaphase remains to be seen. We note that neither CTF4 nor CTF18 is an essential gene, although cohesion and replication are essential functions. The synthetic lethality observed for double null cells is consistent with each making a complementary but nonoverlapping molecular contribution to the essential function they share. Whether this represents spatial, temporal, or biochemical differentiation awaits further study. The identification of polymerase κ, a or possibly K36me3 may tip the balance to activation of aberrant developmental programs contributing to tumorigenesis. Much progress has been made in our understanding of these histone mutants since their discovery, but there remains much to be done to develop therapies for pediatric HGG and for the skeletal and bone tumors. We anticipate that the development of additional model systems to interrogate the function of mutant H3 proteins together with insight from analysis of tumors will fuel the collaborative synergy between experts in cancer ([36] and below). Consequently, ectopic expression of Exd reproduces the endogenous nuclear distribution in the embryo [35], showing that Exd fusion proteins are not localized in all nuclei of abdA-expressing cells (Figure 2e). In conclusion, our genetic tools allow the expression of AbdA and Exd fusion proteins at levels and in places close to physiological conditions.\n",
            "[0.7405735]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List Hemolytic Uremic Syndrome Triad.\n",
            "Refined Query: Describe the characteristic triad of symptoms defining Hemolytic Uremic Syndrome (HUS).  What are the three key clinical manifestations that typically present in patients with this condition?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause Three patients had clinical symptoms and EEG findings suggestive of Lennox-Gastaut Syndrome according to the information available (Figure 3A). Patient 1 had tonic, tonic-clonic, myoclonic and clinical absence seizures and an EEG reporting 2–4 Hz slow spike-wave. Patient 6 had generalized tonic-clonic seizures and drop seizures as well as focal motor features with some seizures; the EEG showed bilateral frequent semi-rhythmic slow spike-and-wave discharges. Patient 11b had generalized seizures, in the form of tonic seizures and drop attacks, Rotor syndrome (RS; OMIM %237450) is a rare, benign hereditary conjugated hyperbilirubinemia, also featuring coproporphyrinuria and strongly reduced liver uptake of many diagnostic compounds, including cholescintigraphic tracers (1–6). RS is an autosomal recessive disorder that clinically resembles another conjugated hyperbilirubinemia, the Dubin-Johnson syndrome (DJS; OMIM #237500) (7, 8). In both RS and DJS, mild jaundice begins shortly after birth or in childhood. There are no signs of hemolysis, and routine hematologic and Multipoint nonparametric and parametric linkage analysis along with determination of the most likely haplotypes was performed with version 1.1.2 of Merlin software (52). Parametric linkage was carried out assuming an autosomal recessive mode of inheritance with a 1.00 constant, age-independent penetrance, 0.00 phenocopy rate, and 0.0001 frequency of disease allele. Results were visualized in version 1.032 of HaploPainter software (53) and in version 2.9.2 of R-project statistical software ( http://www.r-project.org/). Level III, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence. and irinotecan trial, the most common toxicities were grade 1 and 2 hypertension, fatigue, epistaxis, and grades 1–4 proteinuria.(27) These data contrast with the current study whereby only 6% (3/50) of patients had grade 3 neutropenia; 2% (1/50) had grade 4 lymphopenia and there were no grade 3 or 4 thrombocytopenia or anemia. There was no significant peripheral neuropathy or allergic reactions. As expected, grade 1 and 2 asymtommatic CPK elevation and grade 1 and 2 rashes were some of the most common attributable toxicities seen with survivors were only identified in the group of patients who are wild-type for this gene. Some of these patients had an atypical clinical presentation (longer duration of symptoms or atypical radiology) and thus were biopsied, demonstrating high grade histologic features. Despite high grade histology, this group of H3.3 wild-type patients did not follow the expected clinical course of what can be considered classic for children with DIPG, suggesting a potentially different clinical and molecular entity which should be added to the group of The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI Bilirubin, a breakdown product of heme, is normally glucuronidated and excreted by the liver into bile. Failure of this system can lead to a buildup of conjugated bilirubin in the blood, resulting in jaundice. The mechanistic basis of bilirubin excretion and hyperbilirubinemia syndromes is largely understood, but that of Rotor syndrome, an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8\n",
            "[0.79397845]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does physical activity influence gut hormones?\n",
            "Refined Query: How does the type, intensity, and duration of physical activity affect the secretion and levels of gut hormones like ghrelin, leptin, GLP-1, and PYY?  Does this influence vary based on individual factors like fitness level or diet?\n",
            "\n",
            "Combined Answer: exercise performance (34). Similar results were obtained by Yeh and colleagues, in an uncontrolled study (35), and by Ferreira and colleagues (36). Similarly, a small (n = 16) randomized study of growth hormone as an adjunct to rehabilitation demonstrated an LBM gain of slightly greater than 1 kg in favor of the treatment group without an improvement in exercise performance (37). Conversely, the appetite-stimulating hormone ghrelin, used as an adjunct to pulmonary rehabilitation, resulted in an increased 6MWD in a small randomized controlled in exercise performance (37). Conversely, the appetite-stimulating hormone ghrelin, used as an adjunct to pulmonary rehabilitation, resulted in an increased 6MWD in a small randomized controlled trial, although without a change in overall body weight, compared with placebo (38). Taken together with prior reports, the current data indicate that anabolic agents in isolation do not, in unselected patients with COPD, translate increased muscle mass into superior exercise performance. Although the anabolic response seen in this study was positive, Several prior interventions have attempted to improve functional performance in COPD by increasing skeletal muscle mass. Schols and colleagues performed a large three-way trial of nutrition with and without nandrolone, an anabolic steroid (33). They found that the nutrition plus nandrolone group gained LBM (mean, 1.6 kg vs. placebo), but the available data did not support any benefits on exercise performance (33). Casaburi and coworkers randomized 47 men to a four-way trial of testosterone against placebo with and without exercise training were observed with placebo (Week 4: +5.9% [SD, 3.4%] vs. 0.0% [3.3%], P < 0.001; Week 8: +7.0% [3.7%] vs. −0.7% [2.8%], P < 0.001; Week 16: +7.8% [5.1%] vs. −0.9% [4.5%], P < 0.001; Week 24: +5.0% [4.9%] vs. −1.3% [4.3%], P < 0.001). Over 24 weeks, 6-minute-walk distance did not increase significantly in either group. Adverse events in the bimagrumab group included muscle-related symptoms, diarrhea, and acne, most of which were mild in severity. Conclusions: Blocking the action of negative muscle regulators through the activin type II data did not support any benefits on exercise performance (33). Casaburi and coworkers randomized 47 men to a four-way trial of testosterone against placebo with and without exercise training (34). Although the treatment group gained 2.5 kg of LBM over placebo, the use of testosterone without exercise training increased strength but not endurance exercise performance (34). Similar results were obtained by Yeh and colleagues, in an uncontrolled study (35), and by Ferreira and colleagues (36). Similarly, a small (n = 16) randomized study of before dosing, and an average daily consumption of more than 20 kcal/kg and more than 0.6 g protein/kg, as confirmed by dietician’s evaluation (21). Exclusion criteria focused on conditions that would impact improvement in mobility (i.e., Medical Research Council dyspnea score of grade 5 or hospitalization 2 weeks before screening) or confound changes in muscle mass (i.e., drugs known to affect skeletal muscle size, such as an androgen or anti-androgen). A complete list of inclusion and exclusion criteria is available in the online agents in isolation do not, in unselected patients with COPD, translate increased muscle mass into superior exercise performance. Although the anabolic response seen in this study was positive, there are several possibilities why muscle-mass gains did not improve exercise performance in the population, and these may be insightful for the planning of future trials, given that other anabolic agents are emerging (39). First, in a proportion of patients with COPD, the basis of exercise limitation is breathlessness rather than skeletal muscle of future trials, given that other anabolic agents are emerging (39). First, in a proportion of patients with COPD, the basis of exercise limitation is breathlessness rather than skeletal muscle weakness (40, 41). Given the lack of effect of anabolic agents on lung function and gas exchange, one might not expect the former group to derive as much benefit as the latter. Second, exercise performance might only be improved when it is subnormal. Although the average 6MWD was reduced in the present study, the range of 6MWD baseline values was wide, 18; F5,35=0.39, P =.85; Table 1) and locomotor activity (day 22; F5,35=1.15, P =.35; Table 1) showed no significant difference between groups, indicating that effects of CUS on sucrose consumption were not due to experimental bias related to changes in drinking behavior or overall ambulatory activity, respectively. The potential effects of cariprazine on CUS-induced anxiety-like behaviors were also addressed in the same cohort of mice using the novelty-induced hypophagia test. ANOVA analysis indicated no significant effect of CUS or drug physiologic ability to exercise (e.g., bronchodilators) (42) and may be less responsive than a constant work rate exercise test (43). Fourth, gain in muscle mass may be a necessary but not sufficient condition for the delivery of improvements in whole-body exercise performance. Studies of isolated high-intensity training in COPD have shown that mitochondrial bioenergetic capacity can improve without mass gains (44), and it may be that concurrent exercise is required to demonstrate improved exercise capacity. Fifth, although we stratified by\n",
            "[-0.029016454]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the effects of depleting protein  km23-1 (DYNLRB1)  in a cell?\n",
            "Refined Query: Investigating the cellular consequences of reduced DYNLRB1 (km23-1) protein levels requires exploring its potential roles in various cellular processes.  What specific pathways or functions are disrupted by DYNLRB1 depletion, and what are the observable phenotypic changes at the cellular level, such as altered morphology, growth rate, or response to stress?\n",
            "\n",
            "Combined Answer: difference (Extended Data Fig. 4f). Furthermore, co-depletion of TIRR restored the formation of 53BP1 foci in RIF1-depleted cells (Fig. 4h) suggesting that the impact of RIF1 loss on 53BP1 foci is due to the complex with TIRR. PTIP depletion had no effect on 53BP1 foci formation (Fig. 4h). Together, these results suggest that RIF1 functions not only downstream of 53BP1 as an effector protein in DSB repair but also upstream to promote IR-induced 53BP1/TIRR dissociation and thereby facilitate 53BP1 recruitment to DSB sites. (Fig. 5i and Extended Data Fig. 9b, c), and this phenotype is ‘rescued’ by wild-type TIRR but not by the -TIRR mutant (K10E) that does not interact with 53BP1 (Fig. 5i). Together, our results suggested that TIRR influenced 53BP1 activity at multiple levels and broadly impacted DSB repair efficiency in cells. individual mutants revealed that K151E mutant continues to associate with 53BP1 in cells, while K10E mutation is sufficient to disrupt the interaction with 53BP1. We concluded that the residue K10 is crucial for the interaction with 53BP1. to DSBs. Depletion of TIRR destabilizes 53BP1 in the nuclear soluble fraction and also alters the DSB-induced protein complex centering 53BP1. These findings identify TIRR as a new factor that influences DSB repair utilizing a unique mechanism of masking the histone methyl-lysine binding function of 53BP1. and the Drosophila Rad51 or BRCA2 homolog had no impact on reducing the intensity of γ-H2A.v by immunofluorescence in our system (Supplementary Figure S9). Also, loss of Drosophila Suv4-20 had little if any impact on the cell cycle progression of Kc167 cells (Figure 1B) or animal survival (57). This may reflect the variability of the replicative stress response pathways across species, or likely a less essential role of H4K20me2 in Drosophila, despite it being the most abundant form of H4K20 (7). PR-Set7 is essential for development. Loss of both upstream of and downstream from the act1+ gene, only the increase at the upstream sites was significant (P-value<0.05). In contrast, Pfh1 depletion did not result in higher γ-H2A levels in the regions surrounding the gal1+ or ade6+ genes (Fig. 7D,E). Thus, reduced Pfh1 results in high γ-H2A levels specifically in those regions where replication fork progression is slowed in its absence. The fact that Pfh1 depletion did not increase γ-H2A levels at gal1+ or ade6+ provides additional support for our interpretation that Pfh1 acts at a subset We speculate that a subset of chromatin-associated 53BP1 remains inactive in cells (not phosphorylated/no association with effectors) even after DNA damage. Ectopic activation of RNF168 or loss of TIRR activates this subset leading to ‘hyper-active’ 53BP1 (see model in Extended Data Fig. 10). 53BP1 is a representative of Tudor domain-containing histone methyl-lysine readers such as SGF29, Spindlin1, UHRF1, and SHH140. These reader proteins are involved in the pathogenesis of various diseases and identifying small molecules that inhibit Loss of 53BP1 restores HR in Brca1-mutant cells 9–11, desensitizing them to PARPi. The minimal focus-forming region of 53BP1 (53BP1-FFR) required for localization of 53BP1 to DSBs includes an oligomerization domain, a tandem Tudor domain12, and the ubiquitin-dependent recruitment (UDR) motif13,14. The Tudor domain binds the dimethylated lysine 20 of histone H4 (H4-K20me2)15 while UDR binds the mono-ubiquitylated lysine 15 of histone H2A14. In response to DSBs, ATM phosphorylates 53BP116,17 and also initiates a signaling cascade which leads to 53BP1 and RIF1 recruitment are necessary for the dissociation of the TIRR–53BP1 complex. This allows 53BP1 localization to chromatin, and its function in DSB repair and CSR. Over-expression of TIRR blocks 53BP1 recruitment to DSBs and impairs CSR. Conversely, loss of TIRR destabilizes nuclear soluble 53BP1 and the association of 53BP1 with its binding partners is altered in these cells. Thus, TIRR has a dual role in regulating 53BP1 function, first by stabilizing 53BP1 and maintaining its sub-nuclear localization prior to DNA damage and of parental H4K20me1 levels, but rather the accumulation of nascent histone H4. To test this hypothesis, we examined the kinetics of the cell cycle arrest following PR-Set7 downregulation in synchronized cells (Figure 1C and D). Cells were synchronized in G1 by overexpressing the Drosophila p27 homolog, Dacapo (35), in the presence of control or PR-Set7 dsRNA. The cells were then released from the Dacapo-induced arrest and allowed to re-enter the cell cycle. In contrast to control cells, cells depleted for PR-Set7 exhibited no increase in\n",
            "[0.34737903]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Treatment of which disease was investigated in the MR CLEAN study?\n",
            "Refined Query: The MR CLEAN trial investigated the efficacy of a specific treatment for a particular cerebrovascular disease.  What was that disease, and what treatment's effectiveness was assessed in the study's design?\n",
            "\n",
            "Combined Answer: The protocol (available at NEJM.org) was approved by the ethics committee or institutional review board at each center, and the trial was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Written informed consent was obtained from every patient. An independent data and safety monitoring committee reviewed safety and efficacy during the trial. The trial was designed by the first and last authors in collaboration with the sponsor, and the C.A.C., K.J.S., B.T.D., S.T.I., D.C.D., D.A.N., and K.M.B. designed the trial. C.A.C., K.J.S., B.T.D., S.T.I., J.M., and D.C.D. conducted the trial. D.A.N. and K.M.B. performed the analysis of the data. C.A.C., D.A.N., F.B., and K.M.B. interpreted the data and wrote the manuscript. All authors critically revised and approved the final manuscript. An independent data and safety monitoring committee reviewed safety and efficacy during the trial. The trial was designed by the first and last authors in collaboration with the sponsor, and the authors and the sponsor were responsible for data collection and analysis. The authors vouch for the fidelity of the trial to the protocol and for the accuracy and completeness of the data. The first and last authors wrote the first draft of the manuscript in collaboration with the sponsor. Medical writing support was provided by the sponsor. to treatment arms. The Novartis Biostatistics Quality Assurance Group approved the randomization scheme. All participants, investigators, and sponsor representatives associated with the study were masked to treatment allocation. The study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles as laid down in the Declaration of Helsinki. All participants The protocol for this study was developed in accordance with the SPIRIT 2013 guidance for protocols of clinical trials.[15] the current standard of care were selected as trial sites by regional partners. Minimum requirements for the current standard of care included hemodynamic monitoring, the provision of intravenous fluids, laboratory testing, and the ability to deliver concomitant medications. The trial was approved by the NIAID institutional review board and applicable ethics boards in each site or country. Full details of trial design, conduct, and analyses can be found in the protocol and statistical analysis plan, available with the full text of this article The protocol and amendments were approved by the institutional review board or ethics committee at each participating site. The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All patients provided written informed consent. The study was designed by employees of Amgen (the main sponsor) in collaboration with the investigators. The data were collected by investigators and were analyzed by statisticians employed by Amgen. A ZMapp (Mapp Biopharmaceutical) was selected for an adaptive randomized, controlled trial design.9–11 A feature of this adaptive design was that an investigational agent that was subsequently shown to have activity against EVD could then be incorporated into an evolving standard of care, which was provided as the backbone of therapy in each trial group and against which newer agents could be tested. The primary objective was to determine whether the combination of ZMapp plus the current standard of care was both safe and superior to the current (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the originally planned 40 patient accrual was reached. Two factors led to this decision. The first was that accrual was slowing considerably, and the trial had been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule The protocol for this clinical trial was approved by Western Institutional Review Board (Puyallup, WA) and all enrolled subjects will provide informed consent before study participation. The study results will be widely disseminated at conference presentations and published in peer-reviewed journals.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish?\n",
            "Refined Query: What specific maternal factors, cytoplasmic determinants, or signaling pathways trigger the activation of zygotic genes in zebrafish embryos during the maternal-to-zygotic transition (MZT)?  How do these factors overcome repressive mechanisms present during oogenesis?\n",
            "\n",
            "Combined Answer: the zebrafish MZT to drive genome activation (Lee et al. 2013; Leichsenring et al. 2013). Furthermore, Pou5f3 and Sox2 are known to be pioneer factors instrumental in reprogramming differentiated cells to a pluripotent state (Soufi et al. 2012, 2015). Together, these data suggest that chromatin remodeling in the early embryo requires the function of multiple factors, and this activity facilitates the transition from the specified germ cells to the pluripotent cells of the early embryo. during the MZT. The coordinated function of multiple factors in determining chromatin structure and genome activation is not without precedent. It has recently been demonstrated that homologs of the core pluripotency factors, Nanog, Pou5f3 (previously known as Pou5f1 and Oct4), and Sox19B (a member of the SoxB1 family), act analogously to Zld during the zebrafish MZT to drive genome activation (Lee et al. 2013; Leichsenring et al. 2013). Furthermore, Pou5f3 and Sox2 are known to be pioneer factors instrumental in reprogramming differentiated which nurture the oocyte and ultimately are required for the development of the embryo prior to the activation of zygotic transcription [17]. During mid-oogenisis, stages 7-8, egg chambers will naturally degenerate if the egg chamber is defective and unable to support the subsequent growth of the oocyte and embryo [18]. This pre-vitellogenic check-point is triggered in egg chambers where CTF4 has been depleted and results in degeneration of 17.4% of the stage 7-8 egg chambers (n = 4/23) as compared to no degeneration observed in the wild-type between Zld binding and regions that require Zld for open chromatin is also evident at individual loci, such as dpn and sog (Fig. 1A, blue boxes). Furthermore, only 15% of those peaks that increase in accessibility in the absence of maternal Zld (zldM- differential) overlap with in vivo Zld-binding sites. Thus, both the Zld-binding sequence and in vivo Zld binding are enriched specifically in those regions that are more open in the control compared with zldM- embryos (yw differential). Together these data indicate that Zld is required to expressed. For this reason, the actual numbers of down-regulated genes in the zldM- embryos may be larger than reported. To independently verify these results, we repeated our gene expression analysis using published microarray data (Liang et al. 2008) and similarly demonstrated that those regions that require Zld for accessibility were enriched near genes that require Zld for expression (Supplemental Fig. S4). Zld influences expression of both a small number of genes expressed early in the MZT, as well as a large number of genes expressed at genes near regions that require Zld for open chromatin (differential, Zld-bound). However, the large amount of maternally supplied RNA in the early embryo masked any changes in expression of genes transcribed both maternally and zygotically. Thus, our RNA-seq only identified changes in gene expression for those genes that are exclusively zygotically expressed. For this reason, the actual numbers of down-regulated genes in the zldM- embryos may be larger than reported. To independently verify these results, we repeated our gene expression is required for somite development and hedgehog signaling in zebrafish [30] as well as vascular development in mammals [31]. Transgenesis [32] and enhancer trapping [6,10] experiments in zebrafish embryos showed previously that targets and bystanders have different spatiotemporal expression patterns. Here we have shown that the expression of target and bystander genes is also uncorrelated in a cell differentiation time course. Furthermore, we have provided support for the hypothesis that expressions of target genes are dependent on long-range is lost in zldM- embryos preferentially at those regions that depend on Zld for chromatin accessibility. These data show that Zld potentiates transcription factor binding through the establishment or maintenance of open chromatin, and this is likely to be important for Zld-mediated transcriptional activation (Fig. 7). The mechanism by which Zld establishes or maintains chromatin accessibility remains unknown. Unlike the pioneer factor FOXA1, which can bind open chromatin by binding through a winged-helix domain (Cirillo et al. 1998, 2002), the were highly enriched for promoter regions with ∼70% of these FAIRE peaks being localized to promoters (Fig. 2D). Promoters, especially of transcriptionally active genes, are known to be relatively nucleosome free in a wide variety of species (Lee et al. 2007; Schones et al. 2008; Weiner et al. 2010; Thomas et al. 2011; Valouev et al. 2011). In zebrafish, well-positioned nucleosome arrays appear at promoters during zygotic genome activation in a transcription-independent fashion, suggesting that active mechanisms may shape nucleosome occupancy that Zld-dependent early embryonic enhancers may be unique in that they rely only on Zld for chromatin accessibility. Although there are likely additional factors involved, our data demonstrate that later in development, Zld and GAF likely function together to define the chromatin landscape of the early embryo.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.54ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.23ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Exercise - {'Hypertension': 0.5724602081693839, 'Heart Health': 0.7839697731415147, 'Weight Management': 0.9999999999999999, 'Cardiovascular Health': 0.8566408621737275, 'Heart Disease': 0.436542328044943, 'ACE Inhibitors': 0.31360215426363636, 'Blood Pressure Monitors': 0.0, 'Diabetes': 0.6415735020034399, 'Heart-Healthy Diet': 0.6780790174181498}\n",
            "\n",
            " ### Clustered: {'Exercise': {'Cluster 1': ['Cardiovascular Health', 'Heart Health', 'Heart Disease', 'Heart-Healthy Diet', 'Hypertension'], 'Cluster 2': ['Blood Pressure Monitors'], 'Cluster 3': ['Weight Management'], 'Cluster 4': ['ACE Inhibitors'], 'Cluster 5': ['Diabetes']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 454.26ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1411.12ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Chronic Pain - {'Physical Therapy': 1.0, 'Muscle Weakness': 0.3667880560207335, 'Joint Mobility': 0.0}\n",
            "\n",
            " ### Clustered: {'Chronic Pain': {'Cluster 1': ['Physical Therapy', 'Joint Mobility'], 'Cluster 2': ['Muscle Weakness']}}\n",
            "Original Query: Are there web based self management strategies for chronic pain ?\n",
            "Refined Query: Given physical therapy focusing on joint mobility and muscle weakness for chronic pain management, are there web-based resources offering self-management strategies, such as exercise programs, pain tracking tools, or educational materials, to improve patient outcomes?\n",
            "\n",
            "Combined Answer: Relevant studies will be searched in the following electronic databases from their inception to June 10, 2019: PubMed, EMBASE, Cochrane Library, China Knowledge Resource Integrated Database, Weipu Database for Chinese Technical Periodicals, SinoMed, and Wanfang Database. The search terms include KOA, gonarthrosis, osteoarthrosis, osteoarthropathy, arthralgia, small needle knife, acupotomy, needle knife, and RCTs. The equivalent search words will be used in the Chinese databases. The detailed strategies for searching the PubMed database will be lean mass and bone density were assessed. Tests to assess mobility, muscle strength and power, and common daily tasks and a questionnaire to measure patients’ health status were used to quantify functional status. These included the 6-minute-walk test, which was performed to conform with the American Thoracic Society Guidelines (24), bilateral handgrip dynamometry, bilateral one-repetition maximum leg press to assess muscle strength (25), stair climbing time to assess lower limb muscle power (26), and the Timed Up and Go test (27). Maximum complications, symptomatic reherniation, and reoperation will be assessed at each follow-up visit. A schedule of patient assessments during the study is provided in Table 2. Back and leg pain severity will be separately assessed on a 100 mm visual analogue scale. Back disability will be evaluated with the ODI using a 0 to 100 scale where higher scores represent greater disability. Health utility will be evaluated with the EQ-5D questionnaire.[19] This patient-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, prediction of change in ambulatory function are helpful for individual treatment planning, including corticosteroid adjustment and rehabilitation in multidisciplinary care, which are imperative for alleviating muscle atrophy, skeletal deformities, and motor function deterioration [27,28]. Clinically, observations on strength loss (e.g., hip extension and ankle dorsiflexion) are typically used as the primary evaluation of ambulation loss in patients with DMD [29]. To compensate for muscle weakness, patients with DMD naturally develop The authors thank the patients who participated in this study and their parents/guardians and family members; and Cure SMA (formerly the Families of SMA) and Spinal Muscular Atrophy Foundation. Contributors: The authors also thank the people who contributed to this study: Rosangel Cruz (Columbia clinical site, coordinator); Sally Dunaway (Columbia clinical site, physical therapist); Nicole Holuba (Columbia clinical site, coordinator); Jonathan Marra (Columbia clinical site, coordinator); Douglas Sproule (Columbia clinical site, (Columbia clinical site, physical therapist); Nicole Holuba (Columbia clinical site, coordinator); Jonathan Marra (Columbia clinical site, coordinator); Douglas Sproule (Columbia clinical site, subinvestigator); Heather Allen (University of Utah, coordinator); Nicole Rausch (University of Utah, coordinator); Sandra Reyna (University of Utah, subinvestigator); Ai Sakonju (University of Utah, subinvestigator); Abby Smart (University of Utah, coordinator); Donata Viazzo-Trussel (University of Utah, physical therapist); Robert Graham (Boston with medical insurance that covers prolonged stay at a rehabilitation facility will opt to do so despite the surgeon recommending discharge straight to home. Fourth, we did not differentiate among discharge to home with no assistance, discharge to home with home health assistance, discharge to an acute inpatient rehabilitation facility, or discharge to a SNF. Most importantly, we found that half of our patients received intermediate scores, which accurately predicted outcome in only 65% of cases. We first assessed the predictive accuracy of pain severity, leg pain severity, and ODI. We will also obtain patient-level data from the EU Barricaid Controls for these variables from the study sponsor. We will then calculate propensity scores using binomial logistic regression to estimate the probability that patients would be enrolled in the US Barricaid trial. Propensity score adjustment using inverse probability of treatment weighting (IPTW) will be used to control for potential baseline covariate imbalances between study groups, thereby providing unbiased estimates of average have been conditionally approved for their potential effect on muscle strength and function [6]. Therefore, noninvasive approaches that reliably evaluate DMD are required to support different integrated care plans. Functional rating scales are commonly used for DMD assessment, including the 6 min walk test and the North Star Ambulatory Assessment [7,8]. These functional measures are limited to only ambulatory measurements and cannot provide quantitative and objective analyses of muscle tissues. Therefore, medical imaging techniques are a and outcome measures will serve as historical controls. Main outcomes will include back pain severity, leg pain severity, Oswestry Disability Index, health utility on the EuroQol-5 Dimension questionnaire, complications, symptomatic reherniation, and reoperation. Propensity score adjustment using inverse probability of treatment weighting will be used to adjust for differences in baseline patient characteristics between the US trial participants and European historical controls.\n",
            "[0.69946635]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Weaver syndrome similar to Sotos?\n",
            "Refined Query: Given the overlapping clinical features of Weaver and Sotos syndromes,  I'd like to understand the key distinguishing genetic and phenotypic differences.  How significant are these differences in terms of diagnosis and management?\n",
            "\n",
            "Combined Answer: data sources whilst interpreting a single genetic variant. The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recently released guidelines that aim to standardise variant interpretation2. These guidelines outline a set of evidence criteria to assess each variant against, along with how these might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, crucial step in broadening the availability of genetic testing for ICCs, and standardising variant interpretation in this field. Furthermore, we hope that in demonstrating the clinical utility of our disease-specific approach, we will encourage others to develop similar tools across other disease specialties. might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, with discordance in excess of 10%3. One key reason for this discordance is the structure of the ACMG/AMP guidelines, which are deliberately broad and lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 mutations are given in the appendix (pp 15–16). Some individuals without TBC1D24 mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In variants (SNVs) and insertion or deletions (indels), but also structural variants such as copy-number variants (CNVs) and translocations. Pilot studies have shown that WGS can reveal disease-causing variants missed by other genetic tests.3 In addition to interrogating more of the non-coding genome, WGS also has better coverage, even in exome regions.3 Therefore, WGS is best poised to investigate the relevance of nucleotide substitutions and other small non-coding variants (NCVs) in Mendelian disease, but substantial obstacles remain. We results. Many recent meta-studies of the efficacy of WES in diagnosing rare genetic diseases have revealed that its yield is usually less than 50%17. As such, for unsolved cases, researchers and clinicians are increasingly turning to WGS to identify candidate causal genes; however, the expansion into the rest of the genome causes a dramatic increase in the number of candidate variants. This is in part due to difficulties interpreting the effect of variants beyond the exome. As such, supplemental information regarding dysregulated candidate previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also Mendelian disorders. Overall, Genomiser is able to identify causal regulatory variants as the top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian disease. and gene information in close proximity to a focal SNP. For example, three significantly associated hits for the RL phenotype map to chromosome 1 and are in close proximity to the flowering regulator FLOWERING LOCUS T (FT; AT1G65480), as shown in Figure 6 and online using the easyGWAS Detailed SNP view: https://easygwas.ethz.ch/gwas/results/snp/detailed/57a7cf18-cb0f-408a-8954-49f94d1bfc47/Chr1/24338990/. FT shows remarkably little variation within its coding sequence. However, recent quantitative trait loci fine-mapping efforts have\n",
            "[0.5953853]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which enzyme is targeted by Evolocumab?\n",
            "Refined Query: Evolocumab is a monoclonal antibody used to lower cholesterol.  Which specific enzyme does it inhibit to achieve this cholesterol-lowering effect?\n",
            "\n",
            "Combined Answer: by reducing fibrogenesis, and addition of Aramchol to these cells did not rescue fibrogenic gene expression. Conversely, in LX-2 overexpressing SCD1, Aramchol no longer suppressed fibrogenic gene expression. The drug also induced genes in LX-2 that promote cholesterol efflux and inhibited ACAT2, which catalyses cholesterol synthesis. In phHeps, Aramchol also reduced SCD1 and increased PPARG mRNA expression. activity without affecting mRNA levels,8 but this is the first evidence of the induction of ABCA1 mRNA by Aramachol. Similarly, Aramchol induced ABCG1, which also mediates cholesterol and phosopholid efflux,21 and downregulated ACAT2, which catalyses the synthesis of cholesterol esters.22 These changes would further reduce intracellular cholesterol in HSCs. Importantly, increased cholesterol accumulation in HSCs accelerates liver fibrosis, and thus enhanced efflux through ABCA1 and ABCG1 induction while reducing ACAT2 may be additional levels, thereby attenuating activation.23 Indirectly, these findings also support the reliance of HSC activation on autophagy to generate lipids for energy to support cellular activation.4 Therefore, enhanced flux of cholesterol could deprive cells of an important energy source required to fuel the many pathways associated with HSC activation. Another interesting implication of these findings is the overlap in gene expression changes between effects of Aramchol and those inhibiting EMT, including hedgehog, which has been implicated in hepatic for both cholesterol biosynthesis and homeostasis were downregulated after 24 h of 10 μM Aramchol, and the downregulation of cholesterol biosynthesis persisted after 48 h of treatment. A full list of differentially expressed genes is available in Table S3. These findings support the possibility that the effect of Aramchol on cholesterol levels in HSCs may contribute to its antifibrotic activity. parallel pathways simultaneously through drugs that have multiple targets of action is an especially attractive strategy to prevent NASH development and progression.30 Interestingly, the antifibrotic effect of Aramchol is detectable in HSCs before changes in SCD1 mRNA, suggesting that in addition to downregulation of SCD1 there may be other mechanisms of the antifibrotic activity of the drug in this cell type. Indeed, the transcriptomic analysis in our study revealed the induction of ABCA1 and ABCG1 mRNAs, which encode cholesterol efflux In this randomized, controlled trial of a putative therapeutic agent for EVD, although the estimated effect of ZMapp appeared to be beneficial, the result did not meet the prespecified statistical threshold for efficacy. (Funded by the National Institute of Allergy and Infectious Diseases and others; PREVAIL II ClinicalTrials.gov number, NCT02363322.) filter. The filter was incubated for 1 h at room temperature with primary antibody. AR antibody (Thermo Fisher Scientific, MA, USA) and MMP2 antibody (Kyowa Pharma Chemical, Toyama, Japan) were used. Peroxidase-conjugated anti-mouse or anti-rabbit IgG was used in the secondary reaction. Immunocomplexes were visualized with an ECL Plus Western Blot Detection System (Amersham Biosciences, Piscataway, NJ, USA). β-Actin (Sigma-Aldrich, MO, USA) was detected as a loading control. of the antifibrotic activity of the drug in this cell type. Indeed, the transcriptomic analysis in our study revealed the induction of ABCA1 and ABCG1 mRNAs, which encode cholesterol efflux transporters. As increased free cholesterol accumulation in HSCs stimulates their activation, enhanced cholesterol efflux could reduce intracellular cholesterol levels, thereby attenuating activation.23 Indirectly, these findings also support the reliance of HSC activation on autophagy to generate lipids for energy to support cellular activation.4 in HSCs. Importantly, increased cholesterol accumulation in HSCs accelerates liver fibrosis, and thus enhanced efflux through ABCA1 and ABCG1 induction while reducing ACAT2 may be additional mechanisms by which Aramchol reduces HSC fibrogenesis.23 We performed GSEA to identify other cellular pathways responsive to Aramchol (Fig. 4A and B). Gene sets for both cholesterol biosynthesis and homeostasis were downregulated after 24 h of 10 μM Aramchol, and the downregulation of cholesterol biosynthesis persisted after 48 h of treatment. A full list were used at 1:1000 dilution and secondary antibodies at 1:5000. The following antibodies were used: ATM (Santa Cruz), ASCIZ (Millipore); p95 (known as NBS1) (NEB), β-actin (Sigma), pS15-p53 (Cell Signalling), pS824-KAP1 (Bethyl Labs), total p53 (Pab-421; CR-UK generated antibody) and HRP-conjugated goat anti-mouse or rabbit IgG (Sigma).\n",
            "[0.5925816]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are ultraconserved elements often transcribed?\n",
            "Refined Query: Ultraconserved elements (UCEs), highly similar across diverse species, are typically viewed as non-coding DNA.  However, their functional significance remains debated.  Do these regions, despite their sequence conservation, exhibit measurable transcription levels in various tissues and developmental stages?  What implications would transcription have for understanding their function?\n",
            "\n",
            "Combined Answer: lack a compelling explanation for why these sequences, called ultraconserved elements (UCEs), have been so extremely conserved for hundreds of millions of years – neither enhancers, nor transcription factor binding sites, nor promoters, nor protein coding regions require such a high level of conservation [1], [3]–[8]. Despite this, and because roughly half of UCEs are intronic and one third are intergenic, a popular expectation is that UCEs will be found to embody important regulatory activities; indeed, they are thought to be maintained by Ultraconservation came to light when Bejerano et al. reported that their comparison of the reference genomes of human, mouse, and rat had revealed an unexpected 481 orthologous genomic regions that are ≥200 bp in length and 100% identical in sequence [1], each of which is unique in the reference human genome [1], [2]. Ten years later, we still lack a compelling explanation for why these sequences, called ultraconserved elements (UCEs), have been so extremely conserved for hundreds of millions of years – neither enhancers, nor transcription an invaluable tool in the task of differentiating benign from pathogenic CNVs or, in other words, to evaluate which genes may be dose-sensitive or not. In this context, the real significance of the ultraconserved elements (UCEs) in the human genome remains an intriguing issue. There are 481 UCEs, defined as stretches of at least 200 base pairs of human DNA that match identically with corresponding regions in the mouse and rat genomes [2]. They are widely distributed in the genome (on all the chromosomes except chromosomes 21 and Y) and are Therefore, a better understanding of the molecular mechanisms involved in GCs development and progression will provide diagnostic and prognostic markers and potential targets for the therapeutic intervention of GCs. Ultraconserved elements (UCEs) are noncoding gene sequences with strict conserved across among humans, mice and rats. Emerging evidence demonstrates that UCEs can encode non–protein-coding RNAs (ncRNAs) serve as modulators of gene expression [1, 2]. Previous studies showed that transcribed ultraconserved elements (TUCEs) serve as based in the number of annotated RefSeq Genes [8], as well as in the more conservative Consensus Coding Sequence (CCDS) project [9]. As can be seen in Table 3, the UCEs-containing CNVs showed a lower than expected gene content, what allow us to reject this spurious association. Furthermore, this result is in good agreement with the previous report that non-exonic ultraconserved elements are often found in \"gene deserts\" [2]. It is worth mentioning that 88 of them were reported to be more than 100 kilobases away from any known gene. Conversely, UCEs are present in many genes encoding well-known RNA-binding proteins, while intergenic UCEs are preferentially flanked by developmental genes, particularly involved in early developmental tasks [2]. We found that both exonic and intergenic ultraconserved elements appear to be equally represented in the CNV regions associated to disease, what advocates for a dose-sensitive character of the nearby genes in either case. In summary, we have found that pathogenic CNVs show an enrichment of ultraconserved elements, conversely to benign CNVs. It genes, for instance by ultraconserved elements. Although our results did not reach significance (see Table 2), we have confirmed a depletion of UCEs among benign CNVs as previously described [7]. Derty and collaborators additionally found that most of the ultraconserved elements present in benign copy number variants overlapped exons. These exonic UCEs are present in many genes encoding well-known RNA-binding proteins, while intergenic UCEs are preferentially flanked by developmental genes, particularly involved in early developmental tasks Two new sets of ultraconserved elements were defined in this study: one between the reference genomes of cow, dog, and horse (builds: bosTau6, canFam2, and equCab2) and the other between the reference genomes of dog, mouse, and rat (builds: canFam2, mm9, and rn4). We also identified UCEs between human, mouse, and rat (builds: hg18, mm9, rn4), which are very similar to the UCEs identified in 2004 [1], although earlier builds were used to identify UCEs in that study. Pairwise alignments were found between each possible pair of genomes within the that non-exonic ultraconserved elements are often found in \"gene deserts\" [2]. It is worth mentioning that 88 of them were reported to be more than 100 kilobases away from any known gene. Conversely, those pathogenic CNVs that do not contain UCEs showed a strikingly higher than expected gene content. This result suggests that gene content and presence of UCEs might be complementary criteria of pathogenicity, that is, pathogenic CNVs tend to affect either a high number of genes or closely regulated genes near UCEs, many of them in \"gene have been evolutionarily conserved for 300 million years, before mammal and bird ancestors diverged [3]. Of the 481 ultraconserved elements, 111 overlap the mRNA of a known gene, 256 show no evidence of transcription, and for the remaining 114 the evidence for transcription is inconclusive. These elements are most often located either overlapping exons in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. These elements are frequently found in genes post-transcriptionally\n",
            "[0.4307411]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the methyl donor of DNA (cytosine-5)-methyltransferases?\n",
            "Refined Query: DNA (cytosine-5)-methyltransferases (DNMTs) catalyze the addition of a methyl group to cytosine in DNA.  What is the specific molecule that provides this methyl group, acting as the methyl donor in this enzymatic reaction?\n",
            "\n",
            "Combined Answer: KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Jacobsen, 2010). The plant specific DNA methyltransferase CHROMOMETHYLASE 3 (CMT3) binds to H3K9me2 and methylates cytosine residues at CHG sites (where H is A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS heterochromatin formation (Chen et al. 2008). Our results suggest that H3K36me3, in addition to H3K9me3, might also contribute to heterochromatin formation in mammalian cells. The recent finding that H3K36me3 stimulates the recruitment of DNA-methyltransferase DNMT3A onto nucleosomes is compatible with our hypothesis (Dhayalan et al. 2010). Interestingly, this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2), and the recently discovered CHROMOMETHYLASE 2 (CMT2) perform methylation in CHH contexts (Haag and Pikaard, 2011; Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry significantly by the absence of CMT3, the factor that methylates cytosine residues in CHG contexts at heterochromatic loci marked by H3K9me2 (Figure 2B). Since H2A.W localization does not depend on H3K9me2 or the associated CHG methylation, we tested the influence of other pathways responsible for DNA methylation. The loss of the de novo DNA methyltransferase DRM2 did not affect H2A.W nor heterochromatin organization (Figures S2G – S2I). In contrast, heterochromatin was partially dispersed in the absence of the CG methyltransferase MET1 or the over TEs and regions enriched in H3K9me2, while DNA methylation over gene bodies was not affected (Figure 4A). A notable up-regulation of the expression of CMT3 encoding the primary CHG DNA methyltransferase likely accounts for the increase in CHG methylation (Figure 4B). DNA methylation at CG and CHH sites was not significantly affected, suggesting a specific association of H2A.W with CHG methylation (Figure 4A). These results suggested the possibility that increased CHG methylation may compensate for the lack of H2A.W, resulting in has been observed previously in gene expression profiling studies [4,46]. Remarkably, the majority (>75%) of the hypermethylated genes present in all seven samples encoded for transcription factors, while the shared hypomethylated genes were spread among many different functional categories. Transcription factors play a central role in maintaining or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone deacetylase (NuRD) complex which is necessary for embryonic stem cell differentiation, it also directly interacts with DNMT1 and affects global DNA methylation status (17). LSD1 is the first of several protein lysine demethylases discovered. It specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 and functions as a transcriptional co-repressor (18, (DNMT1, 3A, 3B, 3L) and histone deacetylases (HDAC1 and HDAC2), to target genes (13–15). In addition, SALL4-mediated activation of Bmi-1, another important hematopoietic stem cell gene, involves methylation of lysine 4 of histone H3 (H3K4) at its promoter region (16). Based on recent discoveries, there seem to be various ways of cross-talking between histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. H3K36me3 could thus contribute to the establishment of a transcriptionally unfavorable chromatin conformation by recruiting (and perhaps stimulating) repressive complexes. In conclusion, this study demonstrated that trimethylated histone H3 at lysine 36 is specifically enriched in facultative and constitutive heterochromatin in mouse, and that this histone\n",
            "[0.5357456]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is peripheral neuroepithelioma related to Ewing sarcoma?\n",
            "Refined Query: Peripheral neuroepithelioma and Ewing sarcoma are both rare, aggressive tumors, but of different origins.  Are there any genetic, clinical, or histological overlaps warranting further investigation into a potential relationship, beyond their shared aggressive nature and pediatric prevalence?\n",
            "\n",
            "Combined Answer: rhabdomyosarcoma [47], Ewing sarcoma [48], and ALL [49]. Our results extend previous in vitro findings for Nutlin to RG7112, and they provide insight into the in vivo pattern of activity of RG7112 against p53 wild-type childhood cancer preclinical models. The pattern of in vitro activity of RG7112 against the cell line panel tested is consistent with p53-MDM2 interaction inhibition. Each of the p53 wild-type cell lines had rIC50 values < 1 µM, while only one p53 mutant cell line (Ramos-RA1) had a rIC50 value below 1 µM. The Ramos Burkitt no neuroblastoma (n=5) or osteosarcoma (n=6) models. Objective responses were observed in 5 solid tumor xenografts: maintained complete response (MCR) or complete response (CR) for a medulloblastoma and an alveolar rhabdomyosarcoma, respectively, and partial responses (PRs) for a Wilms tumor, rhabdoid tumor, and Ewing tumor xenograft (Figure 2). The MCR for the medulloblastoma (BT-50) was not statistically significant from the controls, as the untreated tumors did not have an event during the 6 weeks observation due to slow growth rate of this p53 mutations are less prevalent in pediatric compared with adult cancers [17], including glioma [18], neuroblastoma [19], sarcomas [8,20,21], Wilms tumor [22] and leukemia [23,24], suggesting that a larger proportion of pediatric patients may benefit from pharmacological unleashing of the wild-type p53 protein. However, p53 mutations are reported to occur at a higher frequency in relapsed patients with neuroblastoma [16,25] and acute lymphoblastic leukemia (ALL) [24,26], and where present have been associated with aggressive and The p53:MDM2 interaction is a priority target for pediatric evaluation given the high prevalence of p53 wild-type cancers in the childhood cancer setting. Previous results have shown that the MDM2 inhibitor Nutlin is active against cell lines derived from a number of pediatric cancers, including cell lines for neuroblastoma [44,45], osteosarcoma [46], rhabdomyosarcoma [47], Ewing sarcoma [48], and ALL [49]. Our results extend previous in vitro findings for Nutlin to RG7112, and they provide insight into the in vivo pattern of activity of RG7112 with neuropil‐like islands arising in the thoracic spinal cord of a 25‐year‐old woman (Figures 6A–C). This tumor contained neuropil‐like islands as highlighted by synaptophysin immunohistochemistry circumferentially surrounded by neoplastic astrocytes. Other areas of the tumor contained necrosis and microvascular proliferation, warranting classification as glioblastoma. As opposed to the vast majority of the diffuse gliomas with neuropil‐like islands that have been reported to date 18, this tumor lacked IDH1 mutant protein. One gliosarcoma rhabdomyosarcoma, Wilms, rhabdoid and Ewing sarcoma xenografts. For the ALL panel, there was 1 partial response, 5 complete responses and 1 maintained complete response. The ALL xenografts expressed the highest levels of p53 among the PPTP panels. adjacent to more anaplastic appearing areas composed of spindled cells with fascicular growth, brisk mitotic activity and loss of markers of glial differentiation such as GFAP and OLIG2 suggestive of sarcomatous transformation (Figures 6G–I). Another morphologic variant was a malignant glioma with epithelioid to rhabdoid features and ganglionic differentiation in the thoracic spinal cord of a 26‐year‐old man. The majority of this tumor was composed of loosely cohesive cells with eccentric nuclei and abundant eosinophilic cytoplasm, many of frequency in osteosarcoma (2 % containing G34R in H3F3A or H3F3B), conventional chondrosarcoma (1 % containing K36M in H3F3A), and clear cell chondrosarcoma (7 % containing K36M in H3F3B) (Behjati et al. 2013). Interestingly, although highly prevalent in pediatric glioblastoma, to date, no K27M mutations have been observed in bone or cartilage tumors, and the K36M mutant has not been found in glioblastoma. as glioblastoma, WHO grade IV (Figures 5C and D). Another notable glioblastoma arising in the thalamus of a 27‐year‐old woman demonstrated epithelioid features and also contained primitive neuroectodermal tumor (PNET)‐like foci (Figures 5E–H). Another interesting glioma variant we observed to harbor histone H3‐K27M mutation was a glioblastoma with neuropil‐like islands arising in the thoracic spinal cord of a 25‐year‐old woman (Figures 6A–C). This tumor contained neuropil‐like islands as highlighted by synaptophysin immunohistochemistry 26 deletions and duplications representing 200 patients with neurodevelopmental disorders [41]. An association between UCEs and disease was also demonstrated [42] in a study that assembled a database of ‘cancer-associated genomic regions’ from a literature search for terms associated with cancer [43], and several publications have highlighted possible roles for the transcription of specific UCEs in cancer [44]–[51]. In sum, the basis of ultraconservation remains unclear. Indeed, it has been suggested that UCEs represent nothing more than an\n",
            "[0.7180152]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which signaling pathway does sonidegib inhibit?\n",
            "Refined Query: Sonidegib's mechanism of action involves inhibiting a specific signaling pathway crucial in cancer development.  To be precise, which particular pathway, specifically which protein or receptor within that pathway, does sonidegib target and block to exert its anti-cancer effects?\n",
            "\n",
            "Combined Answer: resistance. Cancer cells often exhibit aberrant activation of signaling proteins and pathways that promote cellular survival and intrinsic resistance to proteasome inhibitors and other anti-cancer agents. In addition, because the proteasome regulates expression levels of a large number of proteins with diverse functions, proteasome inhibitors induce the expression of proteins with proapoptotic and antiapoptotic roles. Thus, bortezomib, carfilzomib, and oprozomib upregulate proapoptotic Bik and Noxa, which act to mediate the killing activities the MGH051 cell line was also sensitive to crizotinib (Fig. 3B). Accordingly, phosphorylation of ALK and downstream AKT and ERK were efficiently suppressed by crizotinib and ceritinib (Fig. 3C). This data suggests that cancers with acquired resistance to crizotinib without ALK resistant mutations may remain sensitive to ALK inhibition (please see Discussion). with studies showing that the UPR can attenuate the induction of inflammation as mediated by TFs of the NFkappaB family (Kaser et al. 2008; Kitamura 2011; Li et al. 2011). The induction of XBP1’s activity is not reflected in the expression of XPB1 itself, which is almost constant across the time course (Supplemental Fig. 20). This underscores that ISMARA infers a motif’s activity from the expression of its predicted targets and does not use the regulator’s own expression. Indeed, it has been established that XBP1 activity is regulated cell proliferation and apoptosis in colorectal cancer cell lines [3]. In bladder cancer tissues, upregulation of uc.8 was inversely related to grade and stage [16], but silence of uc.8 inhibited the proliferation, invasion and migration of cancer cells [17]. Uc.338 is an important oncogene which increased expression of MMP9 to improve invasion and migration of cancer cells in colorectal carcinoma [4], low- expression of uc.73 closely related with stage and grade of colorectal neoplasia [3]. Over-expression of uc.63 suppressed apoptosis of B (Fig. S2). Furthermore, in contrast to the parental cell lines, treatment of R-UMSCC-1 and R-Cal33 cells with the three proteasome inhibitors did not result in caspase-3 activation or cleavage of poly(ADP-ribose) polymerase (PARP; Fig. S3). We also examined whether the R-UMSCC-1 and R-Cal33 lines exhibited cross-resistance to conventional chemotherapy drugs and other targeting agents (Table 1; Fig. S1A and B). The chemotherapies most commonly used in the treatment of HNSCC are platinum-based or taxane compounds. Only modest 5-fold and 1.5-fold PI3K/AKT, MEK/ERK and mTOR signaling pathways at lower doses than crizotinib (Fig.1C and D). To further assess the cellular specificity of ceritinib, we determined the GI50 of ceritinib against a panel of tumor cell lines bearing different oncogenic drivers. Whereas ceritinib was potent against the two lung cancer cell lines with ALK-rearrangements, it was not potent against NSCLC or breast cancer cell lines driven by KRAS, EGFR, PI3K or HER2, with GI50s > 1μM (Fig.S1A). We next compared the efficacy of ceritinib and crizotinib in vivo using of sporadic ovarian cancer lacking BRCA1/2 silencing through methylation or mutations. Moreover, rucaparib was able to potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents independent of its activity as single agent. To show this, we tested the in vitro effects of rucaparib against a panel of 39 ovarian cancer cell lines, representing all histologic subtypes of the disease. We then sought to validate known and identify novel response markers. For this purpose, cell lines were characterized for BRCA1/2 promoter methylation and commonly used for the treatment of ovarian cancer. This was done both using cell lines that were either sensitive or resistant to single-agent rucaparib. To better understand observed synergies, we finally studied the effect of rucaparib on chemotherapy-induced apoptosis, DNA fragmentation, and γH2AX formation. Proteasome inhibitors, primarily bortezomib, and HDAC inhibitors have been shown to synergize against both hematologic and solid tumor malignancies, in models that are not acquired resistance models. Therefore, we sought to determine whether vorinostat, an inhibitor of class I and II HDACs, might synergize with carfilzomib against R-UMSCC-1 and R-Cal33, acting to overcome the acquired resistance to carfilzomib in these cell lines. As shown in Figure 1A and B, the combination of carfilzomib and vorinostat potently synergized to kill both of LIMT (Fig 2A), the migration and invasion results proposed the following scenario: EGF treatment downregulates LIMT, an inhibitor of cell migration and invasion, thereby enhancing motility of mammary cells. To test this model, we used a chemical inhibitor, U0126, which specifically blocks a major signaling pathway downstream of EGFR, the RAS‐to‐ERK pathway. We first confirmed blocking efficacy by assaying ERK phosphorylation (Fig 3C), as well as by measuring mRNA levels of EGR1, a downstream target of the RAS‐to‐ERK pathway (Fig EV3F).\n",
            "[0.7912929]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: In which phase of the cell cycle arrest is impaired in Fanconi anemia?\n",
            "Refined Query: Fanconi anemia (FA) is characterized by genomic instability.  The question asks which specific cell cycle checkpoint, such as G1/S, S, or G2/M, is primarily affected, leading to the characteristic cell cycle arrest and resulting FA phenotypes.\n",
            "\n",
            "Combined Answer: cells. The abundant class III morphology indicates the presence of many cells with altered progression through metaphase or anaphase. We conclude that an early mitotic delay underlies the G2 accumulation observed by flow cytometry. Early mitotic delay is often due to activation of either the DNA damage checkpoint or the spindle assembly checkpoint (reviewed in references 86 and 111). To investigate further, we constructed rad9Δ and mad2Δ mutants in a ctf18Δ background to remove the DNA damage and spindle assembly checkpoints, respectively. DNA activation of the spindle assembly checkpoint but, rather, appears to be augmented during mitotic arrest. In agreement, we have observed a marked reduction in the viability of ctf18 cells after a 3-h checkpoint-induced arrest. While the classic model of checkpoint function emphasizes the opportunity allowed for repair of an inducing lesion, in this case a checkpoint-induced delay favors removal of damaged cells from the dividing population. Interestingly, Kouprina et al. (53) noted a RAD9-dependent arrest in a ctf18 null mutant at 11°C. In Figure 5). Nevertheless, ctf4Δ cells have a major delay in cell cycle progression, a high rate of genome instability, and are defective in establishing cohesion between sister chromatids (Kouprina et al, 1992; Miles and Formosa, 1992a; Hanna et al, 2001). Cells can also survive in the laboratory without the RPC components Mrc1, Top1, Tof1 and Csm3, but like Ctf4 these proteins are important for preserving genome integrity during chromosome replication. Importantly, budding yeast cells lacking any two of the above factors are viable with one we propose that the 11°C observation reveals an additional physiological consequence. Perhaps at low temperature ctf18Δ cells accumulate defects that are detected by the DNA damage checkpoint. Paradoxically, Kouprina et al. (53) found that ctf18Δ rad9Δ cells exhibit increased (rather than decreased) viability at the nonpermissive temperature. We propose an explanation based on the observed sister chromatid cohesion defect. A delay induced by the RAD9-dependent checkpoint will probably augment the frequency of cohesion failure in ctf18Δ cells, (Figure 7A (i)). It seems that the inviability of cells lacking both Mrc1 and Ctf4 is unlikely to be due to the role of Mrc1 in checkpoint activation, as the mrc1-AQ allele that is defective in checkpoint activation but otherwise competent for replication (Osborn and Elledge, 2003) is viable in combination with ctf4Δ (Figure 7A (ii); Supplementary Figure 6). Previously, it was not possible to characterise why cells die in the absence of Mrc1 and Ctf4. To circumvent this problem, we made a strain in which the Ctf4 protein is fused at its amino the genome. As such, S-phase induced imbalances of UCEs could be used by a replicating cell to confirm that it is in S-phase and must continue to replicate its genome. If so, cells for which UCE dosage has been disrupted and, as suggested above, have also circumvented the deleterious consequences of aberrant UCE dosage, might be predisposed to continuously undergo replication and, hence, progress unrestrained through cell cycles. Of these, cells that are the most disrupted in UCE dosage, in other words enriched for the inclusion of UCEs in cell death in cohesion-defective cells, why do viable cohesion mutants exhibit aneuploidy? One potential explanation is that adaptation of the spindle assembly checkpoint allows at least some cells with separated chromosomes to progress through mitosis. Cohesion-defective mutants are frequently isolated in chromosome loss screens. Within a collection of viable chromosome loss mutants encompassing approximately 60 genes (91), alleles of six genes required for cohesion (CTF4, CTF7, CTF18, SMC1, MCD1, and SCC2) have been identified to date. This after arrest in early S-phase using HU. This revealed comparable amounts of Eco1 in all strains (Fig. 1c). Eco1 levels appeared slightly lower in ctf4Δ and ctf18Δ cells, but this is likely due to the difficulty of synchronizing these cells by HU treatment. Eco1 becomes unstable once cells progress out of S-phase into G2 (Borges et al. 2010; Lyons and Morgan 2011). We conclude that lower Smc3 acetylation in cohesion factor establishment mutant strains is unlikely explained by reduced Eco1 levels. The cohesion establishment factors appear to but like Ctf4 these proteins are important for preserving genome integrity during chromosome replication. Importantly, budding yeast cells lacking any two of the above factors are viable with one exception—simultaneous loss of Mrc1 and Ctf4 is lethal (Warren et al, 2004) and germinating mrc1Δ ctf4Δ spores usually die in the first few cell cycles (Figure 7A (i)). It seems that the inviability of cells lacking both Mrc1 and Ctf4 is unlikely to be due to the role of Mrc1 in checkpoint activation, as the mrc1-AQ allele that is defective in this case a checkpoint-induced delay favors removal of damaged cells from the dividing population. Interestingly, Kouprina et al. (53) noted a RAD9-dependent arrest in a ctf18 null mutant at 11°C. In contrast, at the normal growth temperature (30°C) we detected no appreciable RAD9 or MEC1 dependence of the preanaphase delay in ctf18Δ cells; therefore we propose that the 11°C observation reveals an additional physiological consequence. Perhaps at low temperature ctf18Δ cells accumulate defects that are detected by the DNA damage checkpoint.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 253.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.30ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Mutation of which gene is implicated in the familial isolated pituitary adenoma?\n",
            "Refined Query: Familial isolated pituitary adenoma (FIPA) is a rare inherited condition.  Research seeks to identify the specific gene mutations causing this predisposition to pituitary tumors.  Which gene(s) are most strongly implicated in the development of FIPA?\n",
            "\n",
            "Combined Answer: focal increase of CSF in the anterior temporal horns and in the lamina of the quadrigeminal cistern. The pituitary gland was normal. Chromosome analysis by array-CGH (a-CGH) revealed a 5.2-Mb deletion on chromosome 1p21.3p21.1 (chromosome 1:98,456,293-103,682,084 – hg19). a-CGH was performed using a Cytochip ISCA 180 K Oligo platform (BlueGnome Ltd.). a-CGH analysis of the parents revealed the de novo origin of the deletion. (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause of fgf8. Transposon insertions in Fbxw4 were determined to be causal in the mouse semidominant dactylaplasia mutation, in the absence of mutations in the coding sequence (Sidow et al. 1999). Fgf8 expression in the apical ectodermal ridge (AER) is not properly maintained in the mouse mutants, and this expression defect correlates well with the observed phenotype in both mouse dactylaplasia and the corresponding human genetic disease split hand/foot malformation 3 (OMIM#600095), which maps to the FGF8 GRB in the human genome (de Mollerat et al. the insertion closest to fgf8, also shows expression in the apical ectodermal ridge (AER) in the pectoral fin bud domain. The organization of regulatory elements around fgf8 has recently been assayed (Inoue et al. 2006), but our results suggest that there must be additional elements inside fbxw4. Hence, fgf8 and fbxw4 are part of the same GRB, and insertions over a 100-kb section of chromosome assume a partial or near complete fgf8 expression pattern, while the expression of fbxw4 is ubiquitous but weak (Supplemental Fig. S1). Pax6 is a gene and was associated with a younger age of onset of disease (Wu et al. 2014). These findings may point to a developmentally distinct cell of origin for ACVR1-associated tumors (Taylor et al. 2014b). Interestingly, while ACVR1 mutations suffice to increase proliferation of immortalized normal human astrocytes (Buczkowicz et al. 2014), mutations in the identical amino acids are found in the germline of individuals with the autosomal dominant congenital childhood disorder FOP (fibrodysplasia ossificans progressiva), who have no evidence of cancer and that the defect underlying these mutations is misregulation of fgf8. It is therefore reasonable to speculate that FBXW4 has been incorrectly assigned as the disease gene in human split hand/foot malformation 3. The search for putative regulatory elements or previously unknown exons can generate target sequences to be re-sequenced in patient DNA. In one of the two cases that were characterized bioinformatically, otp, we searched for mapped human diseases at the edge of the otp GRB and found Hermansky-Pudlak Syndrome, type 2, a cell identical amino acids are found in the germline of individuals with the autosomal dominant congenital childhood disorder FOP (fibrodysplasia ossificans progressiva), who have no evidence of cancer predisposition (Jones and Baker 2014; Taylor et al. 2014b). Thus, ACVR1 mutation likely provides a selective advantage in the presence of other critical mutations, but cannot initiate tumorigenesis, as supported by the failure of p53 null mouse astrocytes that express ACVR1 mutants to initiate tumorigenesis when implanted in the brain (Wu et al. de novo mutations (ie mutations were not found in the mother). Another notable finding was two separate recurrent mutations. The first was found at c.1498 c>t, p.R500X. This mutation was observed in two families not known to be related, and in one family this mutation was determined to occur de novo in a maternal carrier (Family 12, Figure 1). The mutation was carried in the mother of the proband with CS but not in the maternal grandparents. The same mutation was inherited in another proband (Family 9). The two families share a small haplotype their undifferentiated nature. This is in contrast with ApcNN teratomas where pluripotency markers were down-regulated. These results suggest that Tcf3 down-regulation in wild type ES cells is necessary but insufficient to fully inhibit neural differentiation, and that canonical Wnt signaling is still required for redirecting the differentiation towards non-neuroectodermal lineages. The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients).\n",
            "[0.6911999]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: which mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy?\n",
            "Refined Query: What specific Troponin C gene mutations have been linked to the development of hypertrophic cardiomyopathy (HCM)?  Are there specific genotype-phenotype correlations observed, and how prevalent are these mutations in HCM patients compared to the general population?\n",
            "\n",
            "Combined Answer: for the major cardiomyopathies; HCM, DCM and ARVC, defined as those occurring six or more times in the ACGV resource (reflecting a HCM case frequency of ~1/1000)9. There were 84 such recurrent variants in ACGV, together representing 39.5% (1,258/3,186) of all identified variants. We curated 63 that had not already been assessed by the expert panel. After manual curation of the literature and ClinVar for reports of segregation, de novo occurrence and functional characterisation, 34 variants were classified as Pathogenic, 13 as Likely Pathogenic variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants (TTNtv) in exons constitutively expressed in the heart are robustly associated with DCM15. Additionally, it is unclear that the mechanism of action for these variants is truly loss of function (LoF). Instead of scoring all TTNtv equally and assuming an underlying LoF mechanism, we only score TTNtv highly if they are in constitutive exons (proportion After manual curation of the literature and ClinVar for reports of segregation, de novo occurrence and functional characterisation, 34 variants were classified as Pathogenic, 13 as Likely Pathogenic and 7 as VUS (Supplementary Table 5; Supplementary Figure 4b). The annotations for these 120 variants, accounting for at least 40% of variants identified in Caucasian cardiomyopathy cases, are stored in CardioClassifier, ensuring these variants are correctly classified without further user-input. importance of disease and gene-specific annotations. CardioClassifier identified putatively disease-causing variants in 33.7% of 327 cardiomyopathy cases, comparable with leading ICC laboratories. Through addition of manually-curated data, variants found in over 40% of cardiomyopathy cases are fully annotated, without requiring additional user-input data. a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. Details of the key features of CardioClassifier can be found in Table 2. Each variant is annotated for up to 17 computational criteria, with results output to a grid representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary Inherited cardiac conditions (ICCs) represent a major health burden with a combined prevalence of ~1%1. Genetic testing is recommended to support the management of many ICCs, with roles in diagnosis (particularly valuable for identification of at-risk relatives), prognostication, and therapeutic stratification. The principle challenge in genetic testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data As well as publically available data for both cases and population controls, CardioClassifier incorporates data from three highly-curated in-house datasets sequenced with the Illumina TruSight Cardio sequencing panel1. Counts from 877 DCM, 327 HCM cases, and 1383 healthy volunteers, all rigorously phenotyped using cardiac MRI, are used to annotate variants in genes associated with these disorders. Some genomic regions, especially those that are repetitive or with high GC content, are not fully covered by standard exome sequencing used by major CardioClassifier provides a simple-to-use web interface that takes as input either individual variant details or a single sample VCF (Supplementary Figure 1). Users select one of 11 cardiac disorders, and this determines which pre-specified validated disease genes are analysed. Where a diagnosis is uncertain (e.g. sudden cardiac death or complex cardiomyopathy), a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. detect even with targeted investigation, as they often manifest later in life and exhibit incomplete penetrance. We have therefore modified PM2 so as not to inappropriately discard variants seen at very low frequencies in these reference datasets. In addition, we have created extensions to three ACMG/AMP rules, to enhance interpretation of ICC variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants associated with inherited cardiac conditions (Table 1). We look to continuously expand this list, focusing on curated genes robustly implicated in disease, emerging from community efforts such as ClinGen4. The classifier automatically assesses each variant for 17 rules across three distinct data categories, as defined by the ACMG/AMP guidelines2. It also consults an internal knowledge base of additional evidence, grouped by ACMG rule, either derived from community curation efforts or manually curated internally. The output is displayed on a\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 353.84ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Smoking - {'Lung Cancer': 1.0, 'Heart Disease': 0.4309104342976413, 'Chemotherapy': 0.46505238063046894, 'Heart Failure': 0.29200907550669486, 'High Cholesterol': 0.0, 'Chest Pain': 0.5499658559411191}\n",
            "\n",
            " ### Clustered: {'Smoking': {'Cluster 1': ['Heart Disease', 'Heart Failure', 'Chest Pain', 'Lung Cancer', 'High Cholesterol'], 'Cluster 2': ['Chemotherapy']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 579.97ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 505.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.35ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 655.97ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.46ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.52ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.56ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 632.90ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.22ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 680.10ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 580.12ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 579.92ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 681.73ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 505.24ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1032.63ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.92ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the method FASP used for?\n",
            "Refined Query: The method FASP, or Filter Aided Sample Preparation, is a technique used in proteomics.  Specifically, it's employed for efficient and rapid protein extraction and cleanup from complex samples like cell lysates, prior to mass spectrometry analysis.  Its speed and effectiveness make it a valuable tool in high-throughput proteomic studies.\n",
            "\n",
            "Combined Answer: Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide and protein global false discovery rate to < 1%: 99% protein confidence, 95% peptide confidence, and a minimum of two unique peptides per protein. dissociation (CID). Parameters for data processing were also followed as described previously [56]. Briefly, raw files containing MS2 data were extracted by Proteome Discoverer (version 1.3; Thermo Scientific) and uploaded to SEQUEST (version 1.20) and searched against a compiled database of the yeast protein sequences from S. cervisiae and S. pombe. Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide and data processing. FRET analysis is based on energy transfer between two fluorophores placed in close proximity, allowing real time detection of complex formation and dissociation. The detection of this energy transfer usually requires high levels of protein expression [13] and is crucially dependent of the distance between the donor and acceptor molecules [48]. This constrain may explain that FRET is mainly used to monitor conformational changes, processes of great importance in signalling [49]. Accordingly, FRET has only been used in the in FRDA, generally cannot be obtained as a pure population of cells and cannot be propagated to give rise to the required numbers of cells. The ABPP 106 probe and control probe were incubated with nuclear extracted proteins. Afterward, the bound probe was cross-linked to the protein using UV light, conjugated with biotin by using “Click” chemistry, and then captured using streptavidin beads. The captured proteins were subjected to extensive washing using harsh denaturing conditions prior to trypsin digestion and labeling of peptides from Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass spectrometry and data analysis. performed all WES data analysis and helped write portions of the paper. E.G. conceived the metPropagate method, performed metabolomics data processing, performed all metPropagate analyses and was the primary author of the paper. S.M. and C.vK. supervised the project and were involved in paper preparation. for 1 h at room temperature. Coverslips were mounted using DAPI Fluoromount-G (Southern Biotech). When staining for RPA or RAD51 foci, soluble proteins were preextracted as previously described34 prior to process to immunofluorescence. dbSUPER provides features to send data directly to the Cistrome analysis pipeline (50) to perform correlation analyses, gene expression analyses and motif discovery. Currently, Cistrome requires users to register to perform the analysis, so users will need to register and login at (http://cistrome.org/ap/) before loading data from our database to Cistrome. We thank members of the Guigó lab and the CRG Bioinformatics and Genomics Programme for many ideas and discussions, particularly Silvia Pérez-Lluch, Alessandra Breschi and Alexandre Esteban, in addition to Carlo Carolis of the CRG Biomolecular Screening & Protein Technologies Unit. We also acknowledge the administrative support of Romina Garrido. We acknowledge support of the Spanish Ministry of Economy and Competitiveness, ‘Centro de Excelencia Severo Ochoa 2013-2017’, SEV-2012-0208. This work was financially supported by the following grants: as shown in a previous study.7 While our primary interest is identification of targets of 106 that might be involved in regulation of the FXN gene in FRDA, an unbiased proteomic approach should also identify the broader targets of 106 and their interacting proteins. In the present study, we used a dimethyl stable isotope-labeling approach coupled with multidimensional protein identification technology (MudPIT)15 to quantitatively identify the proteins specifically captured by the ABPP 106 probe under nondenaturing conditions compared with the\n",
            "[0.73931026]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of extracellular signal-related kinases 1 and 2 (ERK1/2) proteins in craniosynostosis?\n",
            "Refined Query: How do extracellular signal-related kinases 1 and 2 (ERK1/2) influence the premature fusion of cranial sutures in craniosynostosis?  Are ERK1/2 involved in the cellular processes underlying abnormal bone growth and development leading to this condition?\n",
            "\n",
            "Combined Answer: selumetinib, MAPK pathway, BRAFV600E mutation and KIAA1549-BRAF fusion was undertaken. No date restrictions were employed. The data quality was robust and consistent verifying that abnormal Ras-MAP kinase-signaling is the most common genetic aberration in pLGG and that targeting of this pathway in cell lines and animal models led to tumor regression. Phase I clinical trials in both children and adults supported safety and preliminary efficacy of selumetinib, a non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. These cells expressing full-length CREST-GFP or CREST-Flag were exposed to sodium arsenite, thapsigargin or a prostaglandin 15d-PGJ2 to trigger SG formation by inducing oxidative stress, ER stress or inhibiting translation elongation factor eIF4E [21], respectively. In cells with small aggregates or diffuse staining in the nucleus all three stimuli led to weak but reproducible CREST recruitment to SGs visualised with SG markers TIAR, G3BP1 or FMRP (Figure 3A), which was facilitated by the emergence of typically nuclear CREST in the cytoplasm of This allowed us to propose a model whereby aggregation of FUS in the cytoplasm leads to its nuclear loss accompanied by depletion of other paraspeckle proteins, which in turn may disable protective paraspeckle assembly and contribute to neurodegeneration in FUSopathies. A similar scenario may occur in ALS cases caused by CREST mutations, where aggregating protein can sequester FUS (and perhaps other paraspeckle proteins) into aggregates and attenuate protective paraspeckle formation. We observed no overt phenotypes specific to identified utilized by most practitioners. The Pediatric Brain Tumor Consortium conducted a multi-institutional phase II study evaluating selumetinib (AZD6244, ARRY-142886), a MAP/ERK Kinase I/II inhibitor, in patients with recurrent, refractory or progressive pLGG assigned to numerous strata. The aim of the study was to evaluate the efficacy of selumetinib in these patients. led to weak but reproducible CREST recruitment to SGs visualised with SG markers TIAR, G3BP1 or FMRP (Figure 3A), which was facilitated by the emergence of typically nuclear CREST in the cytoplasm of stressed cells (Figure 3B). Only two CREST deletion mutants – those lacking N-terminal domains, namely CR_dNT and CR_dNT-Met, – were recruited in SGs, moreover, they were detected at higher levels within SGs compared to the full-length protein (Figure 3C,D and data not shown). This was likely due to their cytoplasmic redistribution rather than alterations in neurofibromin 1, a negative regulator of the MAPK pathway. Approximately 15–20% of NF1 patients will develop pLGG, most commonly within the optic pathway and brainstem.(13) Abnormal MAPK pathway activation is the most common genetic aberration in pLGG.(14–17) This is most often the result of activation of the BRAF oncogene either through a tandem duplication resulting in a KIAA1549-BRAF fusion or an activating point mutation, BRAFV600E.(18) Approximately 80–90% of pilocytic astrocytomas (PA), the most common pLGG, harbor the and differentiation by inducing OB-specific gene transcription.47 Likewise, MAPK signaling cascades through ERK (extracellular-signal-regulated kinase) (SRE) and JNK (c-Jun N-terminal kinase) (AP1) have been reported to upregulate Runx2 and Osterix, supporting osteogenic differentiation.48,49 Conversely, the activation of the unfolded protein response (UPR) is of particular importance in cells specialized to secrete proteins, such as plasma cells, endocrine cells and OBs. The IRE1-XBP1 pathway has been recently shown to promote OB Dysfunction of the paraspeckle has been recently implicated in pathogenesis of ALS [18,19]. Although the role of CREST in this nuclear body is not clear, it is unlikely to be essential for paraspeckle assembly because the majority of stable cell lines display normal paraspeckles despite very low levels of CREST expression. To further examine the involvement of CREST in these nuclear bodies, we used COS7 cells, which possess prominent paraspeckles. In the majority of cells displaying nuclear dot-like aggregates of CREST-Flag, these structures Our study presents evidence that CREST possesses three properties common to several proteins associated with ALS: i) high propensity to aggregate in cells; ii) recruitment into stress granules; and iii) ability to modulate paraspeckle integrity. There is a growing body of evidence that protein aggregation and altered function of SGs (and likely, paraspeckles) are important factors in ALS pathogenesis, and our observations also point to these processes as potential culprits for the development of pathological changes in ALS cases with CREST distribution in neuroblastoma SH-SY5Y and COS7 cells (Figure 1A, Additional file 1: Figure S1). In agreement with the results of the above study, we also observed formation of nuclear dot-like structures upon expression of tagged or untagged CREST (Figure 1A, Additional file 1: Figure S1). In cells with profound accumulation of CREST in the nucleus, the presence of the expressed protein in the cytoplasm and its cytoplasmic aggregation were also evident, particularly for CREST-GFP (Figure 1A, large + cyt panel, Additional file 1: Figure S1). To\n",
            "[0.64894]\n",
            "### Expanded entities and terms:\n",
            "Kidney Disease - {'Dialysis Requirement': 0.8161751562190629, 'Hypertension': 0.7070313195367597, 'High Blood Pressure': 0.5154116393100796, 'Heart Disease': 1.0, 'ACE Inhibitors': 0.0, 'Blood Pressure Monitors': 0.06499470261964702, 'Stroke': 0.07694194204351545}\n",
            "\n",
            " ### Clustered: {'Kidney Disease': {'Cluster 1': ['Hypertension', 'High Blood Pressure', 'Heart Disease', 'Blood Pressure Monitors', 'Stroke'], 'Cluster 2': ['Dialysis Requirement'], 'Cluster 3': ['ACE Inhibitors']}}\n",
            "Original Query: Are there any urine biomarkers for chronic kidney disease?\n",
            "Refined Query: Given the patient's hypertension, history of heart disease, and potential for dialysis, are there specific urine biomarkers that can reliably detect or predict the progression of chronic kidney disease, beyond standard blood tests, improving early intervention and management?\n",
            "\n",
            "Combined Answer: Correlation among continuous biomarkers were to be examined by Pearson or Spearman rank correlation coefficients. Both univariate and multivariate logistic regressions were to be performed to model the baseline prognostic factors on response, when appropriate. The generalized estimating equations to model were to be used to correlate discrete variables. Repeated measures analysis including mixed effects model were to be performed to analyze continuous biomarkers change over time. Time to progression (TTP) were estimated using the Kaplan-Meier Repeated measures analysis including mixed effects model were to be performed to analyze continuous biomarkers change over time. Time to progression (TTP) were estimated using the Kaplan-Meier method. Log-rank test was to be performed to test the difference in survival between prognostic groups. Regression analyses of survival data based on the Cox proportional hazards model was to be conducted on TTP. The proportional hazards assumptions were to be evaluated graphically and analytically, and regression diagnostics (e.g., martingale and higher than that in the pancreas (Figure 1B). In this sample set, the expression of Uc.63+ was significantly associated with high Gleason score (P = 0.007) and high prostate-specific antigen (PSA) level (P < 0.001) (Figure 1C). To further investigate the usefulness of Uc.63+ as a serum biomarker for PC, we examined the expression of Uc.63+ in the serum of 10 patients with benign prostatic hyperplasia (BPH), 24 patients with primary PC, and 45 patients with metastatic PC by droplet digital PCR (ddPCR). Representative images of ddPCR are shown upregulated in both PC tissues and cell lines. One recent study reported a T-UCR signature that was overexpressed in PC tissue through a microarray analysis using 57 PC and 7 non-neoplastic prostate tissues; however, Uc.63+ was not chosen as a hopeful candidate. The actual strategy we applied in this study was to validate the expression of 26 T-UCRs with qRT-PCR by referring to the signatures reported by Hudson et al [13], which enabled us to focus on Uc.63+, and its functional roles in PC were quite consistent with those determined in a in patients with mild or moderate renal impairment (10). For fremanezumab, a population PK analysis of integrated data from the fremanezumab clinical studies did not reveal a difference in the PK of fremanezumab in patients with mild hepatic impairment, relative to those with normal hepatic function (11). For erenumab, population PK analysis of integrated data from the erenumab clinical studies did not reveal a difference in the PK of erenumab in patients with mild or moderate renal impairment relative to those with normal renal function (15). a patient’s candidate gene list was ranked using a per-gene metabolomic score termed the “metPropagate score”, which represented the likely metabolic relevance of a particular gene to each patient. Per-gene metPropagate scores were generated by initializing a protein–protein functional linkage network with a metabolic “enrichment” score for each gene and propagating this score across the STRING network using a network propagation algorithm. To identify ideal biomarkers and therapeutic targets for PC, we first analyzed 26 candidate T-UCRs that were upregulated in PC based on a microarray analysis [13]. To validate the results obtained by a microarray analysis, we examined the expression of these 26 T-UCRs by quantitative real-time polymerase chain reaction (qRT-PCR) using 12 PC tissues and 8 non-neoplastic prostate tissues (Supplementary Figure 1). The mean expression level of each T-UCR was calculated, and the ratio of tumor/non-neoplastic prostate (T/N ratio) was determined prioritization approach, called metPropagate, that uses patient-specific metabolomic data to prioritize candidate genes in patients with suspected metabolic disorders. metPropagate uses untargeted metabolomic data and gene-metabolite interaction databases to identify proteins whose metabolic function are perturbed in a given patient. We then use this information to assign a score to each protein in a protein functional linkage network (STRING), and then propagate this evidence across the network12. Each patient’s set of candidate genes is not adequate to establish a genetic-based diagnosis. Using multiple types of personalized “-omic” data is a promising approach to address the evidence gap in support of an IEM diagnosis. While RNA profiling has been popular, it still leaves much to be desired with regards to diagnoses9. For patients suspected to have a metabolic disorder, integration of metabolomics data with WES/WGS data can provide direct evidence of a gene’s causality based on its implied metabolic dysfunction. For example, detection of the metabolite N-acetylmannosamine in data from the erenumab clinical studies did not reveal a difference in the PK of erenumab in patients with mild or moderate renal impairment relative to those with normal renal function (15). For galcanezumab, population PK analysis revealed that bilirubin, an indirect marker of hepatic function, did not influence the clearance of galcanezumab (10).\n",
            "[0.56856716]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is being measured with an accelerometer in back pain patients\n",
            "Refined Query: Accelerometers in back pain patients measure movement patterns, quantifying activity levels, posture changes, and the frequency and intensity of various body movements to assess pain behavior, functional limitations, and the impact of interventions.\n",
            "\n",
            "Combined Answer: complications, symptomatic reherniation, and reoperation will be assessed at each follow-up visit. A schedule of patient assessments during the study is provided in Table 2. Back and leg pain severity will be separately assessed on a 100 mm visual analogue scale. Back disability will be evaluated with the ODI using a 0 to 100 scale where higher scores represent greater disability. Health utility will be evaluated with the EQ-5D questionnaire.[19] This patient-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, from the EU Barricaid Controls, we developed a Cox proportional hazards model that included 15 variables including age, sex, body mass index, index level, smoking history, symptomatic reherniation by 3 months, back pain at baseline, back pain at 3 months, 3-month change in back pain, leg pain at baseline, leg pain at 3 months, 3-month change in leg pain, ODI at baseline, ODI at 3 months, and 3-month change in ODI. In multivariate analysis, symptomatic reherniation by 3 months and back pain severity at 3 months were independently associated backscattered analysis [11,13] to detect clues associated with muscle pathology. Recent studies have indicated that instantaneous frequency [14], envelope statistics [15], and information certainty [16] of ultrasound backscattered signals are sensitive to variations in tissue microstructures and beneficial for the assessment of DMD severity and ambulatory function. Notably, quantitative ultrasound analysis requires rigidly fixed settings or a dedicated system for hardware- and software-related reference values during scanning and data lean mass and bone density were assessed. Tests to assess mobility, muscle strength and power, and common daily tasks and a questionnaire to measure patients’ health status were used to quantify functional status. These included the 6-minute-walk test, which was performed to conform with the American Thoracic Society Guidelines (24), bilateral handgrip dynamometry, bilateral one-repetition maximum leg press to assess muscle strength (25), stair climbing time to assess lower limb muscle power (26), and the Timed Up and Go test (27). Maximum and outcome measures will serve as historical controls. Main outcomes will include back pain severity, leg pain severity, Oswestry Disability Index, health utility on the EuroQol-5 Dimension questionnaire, complications, symptomatic reherniation, and reoperation. Propensity score adjustment using inverse probability of treatment weighting will be used to adjust for differences in baseline patient characteristics between the US trial participants and European historical controls. Follow-up visits will occur at 4 weeks, 3 months, and 1 year posttreatment. Magnetic resonance imaging with axial and sagittal images of the lumbar spine, low-dose multiplanar computed tomography of the target level only, and x-rays will be performed during follow-up. Back pain severity, leg pain severity, ODI, EuroQol-5 Dimension (EQ-5D) questionnaire, complications, symptomatic reherniation, and reoperation will be assessed at each follow-up visit. A schedule of patient assessments during the study is provided in Table 2. Back and leg pain have been conditionally approved for their potential effect on muscle strength and function [6]. Therefore, noninvasive approaches that reliably evaluate DMD are required to support different integrated care plans. Functional rating scales are commonly used for DMD assessment, including the 6 min walk test and the North Star Ambulatory Assessment [7,8]. These functional measures are limited to only ambulatory measurements and cannot provide quantitative and objective analyses of muscle tissues. Therefore, medical imaging techniques are a examination to measure muscle size, structure, movement, and function [9]. To characterize tissues, ultrasound imaging biomarkers must be developed to identify neuromuscular disease severity and progression [10]. For example, muscle ultrasound quantification has been proposed by using either mean grayscale measurement of ultrasound B-scan [11,12] or backscattered analysis [11,13] to detect clues associated with muscle pathology. Recent studies have indicated that instantaneous frequency [14], envelope statistics [15], and information certainty device was utilized. Should the rates of symptomatic recurrence in the current study approximate those observed in the EU Barricaid Controls, this would provide sufficient evidence that the Barricaid device is effective in reherniation prevention not only in European patients, but also in a US population of high-risk lumbar discectomy patients. The results of this study will have important clinical and economic implications for all stakeholders involved in treating patients with lumbar discectomy in the US. lipid quantification (22). DXA was used to evaluate body composition and total and appendicular lean and fat mass. A calibration phantom was used to ensure consistency in DXA readings across study sites (23). Body positioning, including that of hands and feet, was standardized across sites. In addition to body composition, data regarding appendicular lean mass and bone density were assessed. Tests to assess mobility, muscle strength and power, and common daily tasks and a questionnaire to measure patients’ health status were used to quantify\n",
            "[0.46100765]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List the releases of JASPAR database\n",
            "Refined Query: Provide a comprehensive list of all released versions of the JASPAR database, including their release dates and any significant updates or changes implemented in each version.\n",
            "\n",
            "Combined Answer: latest JASPAR2014 release (25) and 368 TFs are from UniPROBE (26). TFs in JASPAR or UniPROBE without TFBS sequence information are not included in TFBSshape. Due to their different storage formats, sequence data from JASPAR and UniPROBE need to undergo different pre-processing steps prior to TFBS assembly and DNA shape prediction. it provides an interface for comparison of two TFBS shape profiles from the database and an interface for generating DNA shape data for user-uploaded TFBS sequences, which can also be compared to a TFBS shape profile in the database. Among the TFBS data derived from JASPAR and UniPROBE, 371 TFs are from JASPAR (29), including 149 TFs from the latest JASPAR2014 release (25) and 368 TFs are from UniPROBE (26). TFs in JASPAR or UniPROBE without TFBS sequence information are not included in TFBSshape. Due to their different storage formats, Here, we describe SNP2TFBS, which is an automatically generated comprehensive database of SNPs affecting one or several TFBSs from the JASPAR database (12). For each such SNP it provides the list of TFBSs (PWMs) affected, sorted by the magnitude of the effects. SNP2TFBS is a multiform resource, which is made available to users in three different ways: (i) as a collection of text files in various formats, (ii) via a web interface and (iii) as a collection of scripts enabling the user to regenerate the database from scratch, possibly with other This search was run for the original review on 1 May 2012. Subsequent searches were run on 30 January 2014, 16 February 2015, and 9 February 2017. For the latest update we searched the following databases. JASPAR curates TFBS sequence data derived from the literature in its sub-database JASPAR CORE (29). For TFs with available motif information, the TFBS sequences are provided in FASTA format, with the core binding site highlighted in upper-case letters and the flanking sequences in lower-case letters. Using this sequence data, TFBSshape derives DNA shape features for all nucleotide positions within the core binding site. This prediction is possible because TFBS sequences from JASPAR always contain the core binding sites, whereas their flanking We use two benchmark scenarios (Fig. 2) to compare JACUSA with other popular variant callers: REDItools, SAMtools/BCFtools, and MuTect. The gDNA vs. cDNA scenario works with all variant callers while the cDNA vs. cDNA comparison scenario could be only tested with SAMtools/BCFtools and JACUSA. Equally important, SAMtools/BCFtools and JACUSA are the only two variant callers that support replicates in our benchmark. More details on the benchmark setup and how others and our software were used are given in section 3.1 of the Additional file 1. into composite measures and observed 10−16% better average accuracy for JACUSA (see Fig. 4 c). This is even more pronounced for the F-score measure, where JACUSA is performing at least 20% better in all tested replicate scenarios (see Fig. 4 d). Additional results and details are given in Additional file 1: Section 3.4. A general overview on the single thread runtime of each tested software is shown in Additional file 1: Section 3.6. and siADAR RNA samples. Again, JACUSA overall predicts more sites in homozygous DNA positions and a greater proportion of A→G editing sites than SAMtools (83.0% vs 67.8%) in this RNA-RNA comparison scenario on HEK-293 RNA-seq data. These results were further corroborated by looking at an independent RNA-seq data set from Drosophila melanogaster heads. Herein, JACUSA reports the highest number of RNA editing sites (857 vs 674) with much higher precision (92.1% vs 86.3% of all RRD sites). In summary, JACUSA is a versatile software for the will accumulate rather than be replaced to preserve backward compatibility. Database updates will be managed similarly, although the user can alternatively specify the location of public or custom annotation VCFs that GenomeVIP can retrieve via FTP/HTTP or from Amazon cloud storage. Documentation, support, and further information is available through GitHub and the GenomeVIP home page at our Turnkey Variant Analysis Project website (http://tvap.genome.wustl.edu/tools/genomevip/). This section collects any data citations, data availability statements, or supplementary materials included in this article.\n",
            "[0.6104937]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List symptoms of the IFAP syndrome.\n",
            "Refined Query: Describe the common symptoms experienced by individuals diagnosed with Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome,  elaborating on their presentation and variability.\n",
            "\n",
            "Combined Answer: disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly The study was funded by MedImmune. All authors interpreted the data, critically reviewed the manuscript for important intellectual content, approved the final draft, and agreed to its submission. Publication of the article was contingent upon approval by MedImmune. Writing assistance was provided by Katie Alexander, PhD (QXV Communications, an Ashfield business, part of UDG Healthcare, Macclesfield, UK) and fully funded by MedImmune. 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI to report any subjective symptoms of EVD that they had had within the previous 24 hours. The symptoms reported by at least half the participants at trial entry were loss of appetite (72%), weakness (69%), fever (68%), fatigue (59%), and abdominal pain (50%) (Table S2 in the Supplementary Appendix). (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause In summary, we report a robust series of NHE6 mutations in twelve independently ascertained pedigrees within which we were able to characterize quantitatively core and secondary symptom presentations. Through this study we have proposed a core set of diagnostic criteria for CS and also generated a quantitative early guide to symptom presentation in order to help establish initial clinical expectations for families and clinicians. Based on current studies, CS may be among the most common X-linked developmental brain disorders.1 CS has broad chronic inflammation affecting multiple tissues including the gut [38,41]. This is, in some cases, due to abnormal T cell production that displays increased affinity for self-antigens. T cells from these patients are autoreactive and hence give rise to chronic inflammation. In addition, it was recently shown that unrepaired lesions in AT patients induce a type I interferon response, which leads to inflammatory manifestations [42]. However, the underlying genetic causes for such inflammatory diseases, including IBD, are largely not known. In This study included patients with spontaneous ICH admitted to our university hospital, between January 2007 and June 2009. Our hospital is the only one serving the population of about 300 000. Patients with ICD code I10.1-9 were identified from the National Hospital Discharge Register [10]. A research nurse, neurologists and a neuroradiologist validated the diagnosis by reviewing the medical records and CTs of these patients, respectively. Information about diabetes (diet or pharmacological treatment), treatment with antithrombotics (Aspirin, of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes of obesity and indicate targets for therapeutic intervention. These disorders include obesity syndromes such as Prader Willi syndrome and Bardet–Biedl syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic elevation, hypoalbuminemia, dyspnea, rash, duodenal ulcer, anemia, dry skin, fatigue and diarrhea. Rare grade 3 toxicities included elevated CPK (n=5), maculopapular rash (n=5), neutropenia (n=3), nausea (n=3), paronychia (n=3), acneiform rash (n=2), diarrhea (n=2), elevated ALT (n=1), decreased ejection fraction (n=1), gastric hemorrhage (n=1), headache (n=1), skin infection (n=1), tooth infection (n=1) and weight gain (n=1). There was only one grade 4 toxicity, lymphopenia. There were no treatment-realted deaths. Patient reported outcomes\n",
            "[0.5121316]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which gene is required for the efficient function of clopidogrel?\n",
            "Refined Query: Clopidogrel's effectiveness relies on its metabolism into an active form.  Which specific gene encodes the enzyme responsible for this crucial metabolic step, and thus dictates the efficiency of clopidogrel's antiplatelet action?\n",
            "\n",
            "Combined Answer: of PARP (Fig. 3). Further evidence of carfilzomib/vorinostat synergism in the acquired resistance models was obtained in clonogenic survival assays (Fig. 4A and B). Treatment of R-UMSCC-1 and R-Cal33 with carfilzomib plus vorinostat led to synergistic inhibition of colony formation at two different doses (constant ratio of drugs). of regulatory complexity characteristic of these target genes, which have the most complex spatiotemporal expression patterns of all metazoan genes [25,26]. Other striking features of the target genes are the long CpG islands that sometimes cover the whole gene (Figure 5), and a higher density of CpG dinucleotides around their most frequently used CTSS. Both the CpG island length and the existence of multiple promoters sets the target genes apart from other sets of genes, including genes in their immediate neighborhood with conserved synteny The activity of NFKB1/REL/RELA increases sharply in the first 45 min and slower afterward, until it reaches a steady activity after 3 h. The activity of the IRF1,2,7 motif increases steadily starting at 30 to 45 min after treatment until the end of the time course (Fig. 3A). As shown by NFKB1/REL/RELA’s local network figure (Fig. 3B and on the ISMARA results website), ISMARA predicts that IRF1 is activated directly at the level of transcription by these regulators, which is confirmed by the experimental literature (Harada et al. 1994). Other by reducing fibrogenesis, and addition of Aramchol to these cells did not rescue fibrogenic gene expression. Conversely, in LX-2 overexpressing SCD1, Aramchol no longer suppressed fibrogenic gene expression. The drug also induced genes in LX-2 that promote cholesterol efflux and inhibited ACAT2, which catalyses cholesterol synthesis. In phHeps, Aramchol also reduced SCD1 and increased PPARG mRNA expression. Proteasome inhibitors, primarily bortezomib, and HDAC inhibitors have been shown to synergize against both hematologic and solid tumor malignancies, in models that are not acquired resistance models. Therefore, we sought to determine whether vorinostat, an inhibitor of class I and II HDACs, might synergize with carfilzomib against R-UMSCC-1 and R-Cal33, acting to overcome the acquired resistance to carfilzomib in these cell lines. As shown in Figure 1A and B, the combination of carfilzomib and vorinostat potently synergized to kill both respectively, relative to the parental lines. Similarly, a high level of cross-resistance to oprozomib, as well as paclitaxel, was observed, whereas only moderate resistance to bortezomib (8- to 29-fold), and low level resistance to cisplatin (1.5- to 5-fold) was seen. Synergistic induction of apoptosis signaling and cell death, and inhibition of colony formation followed co-treatment of acquired resistance models with carfilzomib and the histone deacetylase inhibitor (HDACi) vorinostat. Synergism was also seen with other combinations, and R-Cal33, acting to overcome the acquired resistance to carfilzomib in these cell lines. As shown in Figure 1A and B, the combination of carfilzomib and vorinostat potently synergized to kill both R-UMSCC-1 cells and R-Cal33, as demonstrated by combination index (CI)47 values substantially lower than 1.0 at multiple different doses. However, despite the potency of this synergism, the resistance of these cells was not fully overcome, as efficacious killing by the combination required high nanomolar concentrations of carfilzomib. Nonetheless, Inspection of GRBs in a genome browser quickly reveals that many GRB target genes overlap with long CpG islands, and often with several of them. These CpG islands are not limited to the 5' end of the genes, but also occur in introns or internal exons of the gene; in some cases, the entire target gene is spanned by one or several CpG islands (see Figure 5 for examples). Since most CpG islands normally map to promoters and are usually the targets of regulation by methylation [11,12,20], this arrangement is rather unusual. These CpG islands are To determine the mechanism responsible for carfilzomib/vorinostat synergy in the acquired resistance models, we investigated the expression status of pro-apoptotic Bik protein. Bik is known to be upregulated in HNSCC cells following treatment with bortezomib, carfilzomib, or oprozomib, and plays an important role in mediating cell death by these proteasome inhibitors.8,34 However, as depicted in Figure 7, the R-UMSCC-1 and R-Cal33 resistance models demonstrated only modest, if any, upregulation of Bik when treated with either carfilzomib alone We thank members of the MacAlpine and Fox laboratories for suggestions and critical reading of the manuscript. We are grateful for bioinformatic advice and suggestions from Jeff Du and Jason A. Belsky.\n",
            "[0.62783706]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is valproic acid effective for glioblastoma treatment?\n",
            "Refined Query: Current research lacks conclusive evidence supporting valproic acid's efficacy as a standalone treatment for glioblastoma.  However, investigations explore its potential as an adjuvant therapy, possibly enhancing the effects of other treatments by modulating tumor cell behavior or overcoming drug resistance.  Further research is needed to determine its true clinical value in glioblastoma management.\n",
            "\n",
            "Combined Answer: Pediatric low-grade glioma (pLGG) is the most common central nervous system tumor in children.(1) The mainstay of therapy is a complete surgical resection as this can be curative; however, children for whom a gross total resection is not achievable often require additional therapy.(1, 2) There are multiple first-line chemotherapy regimens including combinations of carboplatin and vincristine (CV), combinations of thioguanine, procarbazine, lomustine and vincristine and vinblastine monotherapy.(3, 4) Five-year overall survival (OS) with preclinical study demonstrated remarkable efficacy with a novel small molecule inhibitor of the histone demethylase JMJD3 both in vitro and in vivo orthotopic xenograft models 14. A second group recently demonstrated therapeutic efficacy with the histone deacetylase inhibitor panobinostat both in vitro and in vivo orthotopic xenograft models 13. It is, thus, important to identify those gliomas with histone H3 mutations, given the prognostic significance and potential targeted therapy that will soon be in clinical trials for these patients. have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The Pediatric Preclinical Testing Program showed that selumetinib induced complete regression in a BRAFV600E xenograft glioma model.(20) Recently, the Pediatric Brain Tumor Consortium (PBTC) completed a phase I trial in 38 children with recurrent, refractory or progressive pLGG establishing the recommended phase II dose (RP2D) as 25 mg/m2/dose twice de Marseille, Marseille, France P.N. Munster, University of California, San Francisco, San Francisco, California S.S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta T.F. Burns, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh F. Meric-Bernstam, Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, University of Texas M.D. Anderson Cancer Center, Houston H. Henary, Amgen, Thousand Oaks, California J. Ngang, Amgen, Thousand Oaks, California G. five of these patients underwent a subsequent biopsy or resection demonstrating higher grade gliomas. These included two pontine gliomas originally classified as grade III that were upgraded to glioblastoma, a spinal glioma and a third ventricle glioma originally classified as grade II that were upgraded to glioblastoma, and a thalamic glioma originally classified as grade II that was upgraded to anaplastic astrocytoma. Given the prospective nature of this study without significant length of clinical follow‐up, the utility of assessing outcome glioblastoma in a 4‐year‐old boy, a thalamic glioblastoma in a 24‐year‐old woman, and a glioma in the lumbar spinal cord with grade II histologic features at time of initial biopsy but grade IV histologic features on subsequent resection. site of post‐translational modification in the histone H3 variants and leads to altered DNA methylation and gene expression profiles thought to drive gliomagenesis 3, 7, 15, 21, 26. Thus, there are ongoing efforts to study the efficacy of therapeutics targeting histone modifying enzymes for these midline gliomas with histone H3 mutations. A recent preclinical study demonstrated remarkable efficacy with a novel small molecule inhibitor of the histone demethylase JMJD3 both in vitro and in vivo orthotopic xenograft models 14. A second group Prior to initiation of this phase II clinical trial, all relevant pre-clinical and early phase clinical trial research in both adults and children evaluating glioma biology and MAPK pathway inhibition was considered. Between approximately April 2, 2013, and July 5, 2013, a thorough search of PubMed, specifically for pediatric low-grade glioma (pLGG), selumetinib, MAPK pathway, BRAFV600E mutation and KIAA1549-BRAF fusion was undertaken. No date restrictions were employed. The data quality was robust and consistent verifying that abnormal Ras-MAP valine substitution at codon 34 (G34R/V) was present in a subset of those pediatric nonmidline glioblastomas arising the cerebral hemispheres. Subsequent analyses have now demonstrated that histone H3‐K27M mutations are present in the majority of high grade infiltrative astrocytomas arising within midline structures (thalamus, pons and spinal cord) of both pediatric and young adult patients 1, 5, 9, 11, 12, 19, 20, 24, 26. Studies have shown that these diffuse midline gliomas with histone H3‐K27M mutation are associated with aggressive High-grade astrocytomas [anaplastic astrocytoma and glioblastoma (GBM)] are the most biologically aggressive form of cancer and a leading cause of cancer-related mortality and/or morbidity in the pediatric years [15, 19, 22]. They account for 20 % of all brain tumors in children and occur mainly supratentorially in the cortex or thalamus or in the brainstem where they are called diffuse intrinsic pontine gliomas (DIPGs). Cortical GBM can be amenable to complete surgical resection, however, up to 85 % will die within 2 years of diagnosis [3, 15,\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.40ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which antibiotics target peptidoglycan biosynthesis?\n",
            "Refined Query: What specific antibiotics inhibit peptidoglycan biosynthesis in bacterial cell walls?  This includes clarifying which enzymes in the pathway are targeted by these antibiotics and providing examples of the antibiotic classes involved.\n",
            "\n",
            "Combined Answer: Like C. albicans, β,(1–3)-D-glucans are major carbohydrate components of the outer cell wall of C. glabrata [24]. These cell surface moieties are recognition sites for the host immune system [25] and potential binding sites for antifungal drugs or peptides. The Candida biofilm matrix is also primarily comprised of β-1,3-glucans that sequester antifungal drugs and contribute to fluconazole resistance in the cells of the biofilm [26]–[28]. Therefore, it is possible that differences in cell surface or biofilm matrix glucans between C. albicans and lowest regions of the biofilm (Figures 4 A and 4 B). This is in contrast to other antifungal compounds such as flucytosine, fluconazole, amphotericin B, and voriconazole that have poor diffusion through fungal biofilms [39], thus bolstering potential therapeutic use of Hst 5 against fungal biofilms. In C. albicans Hst 5 initially binds to cell wall carbohydrates, then translocates to the cytoplasm through polyamine transporters, specifically Dur3 and Dur31 transporters. Unlike other pore forming antimicrobial compounds such as bactenecins, detergents and denaturing agents to remove non-covalently linked cell wall proteins (our unpublished data). Other carbohydrate or lipid cell wall components remain to be examined as possible binding sites for Hst 5 in C. glabrata. Among the known virulence factors of C. glabrata, biofilm formation is well studied and has become increasingly recognized as an important clinical problem [36]–[38]. The significantly higher levels of cell surface β-1,3-glucan in C. glabrata compared to C. albicans suggested that the secreted glucans in its biofilm (HyClone Laboratories), and 100 units/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Resistant cell lines (R-UMSCC-1 and R-Cal33) were maintained in the identical medium supplemented with 1 μM carfilzomib. Prior to the initiation of experiments involving treatment with different agents, the carfilzomib-resistant cells were cultured for 72 h in the absence of carfilzomib to prevent interference. as an important clinical problem [36]–[38]. The significantly higher levels of cell surface β-1,3-glucan in C. glabrata compared to C. albicans suggested that the secreted glucans in its biofilm matrix may contribute to its protection from Hst 5 similar to the role of β-1,3-glucan in fluconazole sequestration within C. albicans biofilms [26]. Indeed, we found significantly elevated matrix associated Hst 5 in C. glabrata biofilms at all depths of the biofilm compared with C. albicans biofilms (Figure 4). However, this did not result in in C. glabrata biofilms was three fold higher than the corresponding difference in β-1,3-glucan content (11% increase compared to C. albicans), pointing to additional matrix components other than glucans that could potentially bind Hst 5. We next examined the relative proportions of Hst 5 labeled cells within each region of the biofilm with the expectation that regions with high matrix associated Hst 5 would have less peptide available for diffusion and thus have reduced cell associated Hst 5. Surprisingly, the bottom regions (2.5 µm) of the drugs and contribute to fluconazole resistance in the cells of the biofilm [26]–[28]. Therefore, it is possible that differences in cell surface or biofilm matrix glucans between C. albicans and C. glabrata may alter initial Hst 5 binding to the fungal cells and/or biofilm matrix components of these two species. We and others found that Hst 5 fungicidal activity requires energy dependent translocation to the cytosol, so that cells treated with azide or cold do not take up Hst 5 and do not suffer consequential toxicity [20], [21], [29]. with protease inhibitors (10 mM NaPB, 1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 1 µg/ml aprotinin, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, and 1 µg/ml benzamidine) and processed using a FastPrep homogenizer at 4°C. Cell wall extracts and cytosolic proteins were normalized to total protein content using a BCA assay (Pierce). Candida cell wall proteins and cytosolic proteins (10 µg) were subjected to SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes, and visualized with streptavidin conjugated with horseradish peroxidase compared with C. albicans, but it did not reduce the percentage of Hst 5 positive fungal cells in the biofilm. Hst 5 enters C. albicans cell through polyamine transporters Dur3p and Dur31p that are uncharacterized in C. glabrata. C. glabrata strains expressing CaDur3 and CaDur31 had two-fold higher killing and uptake of Hst 5. Thus, neither C. glabrata cell surface or biofilm matrix β-1,3-glucan levels affected Hst 5 toxicity; rather the crucial rate limiting step is reduced uptake that can be overcome by expression of C. albicans Dur proteins reduced Hst 5 binding to C. glabrata may be the reason for its insensitivity. C. glabrata has higher surface levels of β-1,3-glucans as compared with C. albicans; however these differences did not account for reduced Hst 5 uptake and killing in C. glabrata. Similarly, the biofilm matrix of C. glabrata contained significantly higher levels of β-1,3-glucans compared with C. albicans, but it did not reduce the percentage of Hst 5 positive fungal cells in the biofilm. Hst 5 enters C. albicans cell through polyamine transporters Dur3p and Dur31p\n",
            "[0.42150337]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Fatigue - {'Physical Therapy': 0.40894165305290814, 'Muscle Weakness': 1.0, 'Joint Mobility': 0.0}\n",
            "\n",
            " ### Clustered: {'Fatigue': {'Cluster 1': ['Physical Therapy', 'Muscle Weakness'], 'Cluster 2': ['Joint Mobility']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.14ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.81ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Arthritis - {'Anti-Inflammatory Drugs': 0.0, 'Joint Swelling': 1.0}\n",
            "\n",
            " ### Clustered: {'Arthritis': {'Cluster 1': ['Anti-Inflammatory Drugs'], 'Cluster 2': ['Joint Swelling']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 807.13ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 604.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which technique is used for detection of EWS/FLI1 fusion transcripts?\n",
            "Refined Query: How are EWS/FLI1 fusion transcripts, specifically indicative of Ewing sarcoma, reliably detected?  What molecular techniques offer the best sensitivity and specificity for identifying this fusion in patient samples, considering both diagnostic and prognostic implications?\n",
            "\n",
            "Combined Answer: the MSP results validate the MethylCap-seq data, since the results obtained for all five fragments were consistent with the significant DMRs in all tumors, and Frag_01 appeared as part of the SCC-specific DMRs in the MethylCap-seq data. We thank F. Ochsenbein and C. Francastel for discussions, and S. Jounier and the Gene Identification team at CNG for technical help. We thank D. Reinberg for providing the H3K27me2/3 antibody, R. Feil for the JF1/Ms mouse strain, and N. Gilbert for probes. M.G.'s team is supported by the Association pour la Recherche sur le Cancer (ARC). S.D. acknowledges la Ligue Nationale Contre le Cancer for support (Equipe Labelisée). rhabdomyosarcoma, Wilms, rhabdoid and Ewing sarcoma xenografts. For the ALL panel, there was 1 partial response, 5 complete responses and 1 maintained complete response. The ALL xenografts expressed the highest levels of p53 among the PPTP panels. Atlas Research Network (TCGARN) et al. [76], Walter et al. [77], Beroukhim et al. [73], Bullinger et al. [78], Taylor et al. [79], TCGARN et al. [80], Curtis et al. [81], TCGARN et al. [82], TCGARN et al. [83], TCGARN et al. [84], Nik-Zainal et al. [85], Robinson et al. [86], Walker et al. [87], Zhang et al. [88], Holmfeldt et al. [89], TCGARN et al. [90], and Weischenfeldt et al. [91] representing 52 different forms of cancer, each including between 2 and 148 cancerCNA regions and covering 0.03% to 90.15% of the genome (Table S1). To avoid Next, we assessed clinical cohorts for expression of the EGF‐regulated lncRNAs from MCF10A cells. Two datasets of breast cancer patients were analyzed: The METABRIC dataset (Curtis et al, 2012) and several breast cancer cohorts integrated into a single dataset, called “Kaplan–Meier (KM) plotter” (Gyorffy et al, 2010). Each dataset includes ~2,000 breast cancer patients, who were followed for > 20 years from initial diagnosis. In addition to gene expression data, derived from either Illumina (Curtis et al, 2012) or Affymetrix (Gyorffy et al, between NFKB1/REL/RELA, IRF TFs, and PRDM1, or the prediction that MYBL1 is an upstream activator of RFX TFs in ciliogenesis. Moreover, the links to a genome browser view of the individual binding sites on the genome (Pachkov et al. 2007) allow for targeted validation of such individual regulatory interactions. There are many indications that the actions of miRNAs and TFs are tightly integrated (Cui et al. 2006; Hornstein and Shomron 2006; Zhou et al. 2007), and ISMARA’s incorporation of miRNA regulation allows for the automated identification and Tcf3 were selected for further analysis. Several stable ESC clones were generated which ectopically over-express miR-211 in an otherwise wild type background (Figure S7C). Western blot analysis showed that, unlike Sox11 and Sf3b1 (Figure S7D), Tcf3 protein level was decreased upon miR-211 ectopic expression (Figure 7D). To confirm that miR-211 directly targets Tcf3, we cloned the 3′ untranslated region (3′UTR) of the mouse Tcf3 gene in the pmirGLO reporter plasmid (Figure 7E) and performed a luciferase-based reporter assay. Transfection of genes predicted by all three programs. To narrow down the list of potential targets, qRT-PCR analysis was performed on wild type ESCs compared with ApcNN (Figure S7A) as well as on wild type ESCs treated with Wnt3a CM (Figure S7B). We excluded those predicted targets that showed up-regulation upon Wnt signaling. Based on these results Sox11, Sf3b1 and Tcf3 were selected for further analysis. Several stable ESC clones were generated which ectopically over-express miR-211 in an otherwise wild type background (Figure S7C). Western blot analysis all 5 fragments, with a p-value < 0.02 for CDKN2A and P < 0.0001 for the other four fragments (Figure 5B). Frag_01, Frag_02 and ZIC4 present a much lower P-value, indicating they may be better tumor markers than CDKN2A and RASSF1. We also observed that significant differences between SCC and ADC were only found for Frag_01 (Figure 5C). In conclusion, the MSP results validate the MethylCap-seq data, since the results obtained for all five fragments were consistent with the significant DMRs in all tumors, and Frag_01 appeared as part of the or recurrent genomic alterations in other pathways. When only FFPE tumor was available, DNA methylation array analysis for tumor subgrouping and generation of copy number plots as well as gene panel sequencing using a targeted neuro-oncology-specific gene set were performed.(23),(24) Putative alternative events (e.g. novel BRAF fusions) were detected based on a combination of gene panel data and copy number information. Alternative BRAF fusion genes were detected by integrating RNA sequence data and copy-number data inferred from exome\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 353.64ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 655.03ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 680.62ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 705.30ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 680.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.04ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.05ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 580.42ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 733.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 781.73ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.68ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the human selenoprotein that contains several Se-Cys residues?\n",
            "Refined Query: Selenoproteins are proteins containing selenocysteine (Sec or Se-Cys).  Identifying the human selenoprotein with multiple Sec residues requires a search through the known human selenoproteome, considering the number of Sec residues per protein as a key factor in the selection.\n",
            "\n",
            "Combined Answer: Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide and protein global false discovery rate to < 1%: 99% protein confidence, 95% peptide confidence, and a minimum of two unique peptides per protein. proximally associated with a given protein, and this DNA is sequenced and aligned to a reference assembly to create a genome-wide map of protein occupancy [9]. At each genome site occupied (though not necessarily bound directly) by a protein, ChIP-seq produces a tight cluster of read alignments, which can then be detected by software with high resolution. Previous ChIP-seq analyses have generally considered a single experiment at once, and have treated TF occupancy as a binary signal—present vs. absent. However, the particular strength of the The SNP2TFBS web interface can thus be used for prioritizing potential regulatory SNPs prior to a GWAS study for the sake of gaining statistical power. There are two ways of specifying genomic regions as search criteria: either by uploading a bed file or by specifying the start and end positions of genomic regions relative to a server-resident list of anchor points. Currently such lists are composed of promoters (transcription start sites) and ChIP-seq peak center positions. The user can thus restrict the query results to SNPs that fall into We tested for enrichment between the genomic locations of the ChIP-seq peaks with sixteen sets of genomic annotations (Table 1). The ChIP-seq data for Pfh1, Cdc20, and γ-H2A are available in GEO data set GSE59178 [39]. All peaks analyzed are available in S1 Table. We took the location of genes, coding sequences, essential genes, dubious genes, 3’ and 5’ UTRs, promoters, tRNAs, centromeres, 5S rRNAs, long terminal repeats, and the mating type loci from PomBase [68]. We also considered the locations of meiotic DSB hotspots [69], NDRs [70] using was set with exclusion after 1 times with an exclusion duration of 60 s. MS2 spectra were acquired with CID and a resolution of 60,000, AGC 5 × 104, maximum injection time 60 ms isolation window 1.6 Th as centroid spectra. Raw files were converted into mzXML data type and search using Sequest (against all human proteins reported by Uniprot) on an in-house data analysis tool developed by Steve P. Gygi (Harvard Medical School, Boston, USA). Unique peptides were imported into Skyline 3.5.0.9319 and transition lists for heavy and light fragments proteins with repeats [18], [19], [20], [21]. In addition to an enhanced positional resolution, ChIP-seq is more effective in mapping DNA-protein complexes located inside repetitive elements, where the ChIP-chip approach faces serious limitations due to cross-hybridization. The present re-analysis of ChIP-seq data extends the analysis of STAT1 binding for the first time to repetitive sequences. We furthermore show that ChIP-Seq data can be used to analyze the relation of in vivo interactions and extended sequence features such as spacing in human cells. The ENCODE data set [7,8] provides the first opportunity to study a large group of TFs together in human cells. These data come from the chromatin-immunoprecipitation sequencing (ChIP-seq) protocol: chromatin is crosslinked to preserve DNA-protein and protein-protein bonds, then a target-specific antibody is used to capture the DNA proximally associated with a given protein, and this DNA is sequenced and aligned to a reference assembly to create a genome-wide map of protein occupancy [9]. At each genome site occupied (though Morpholino Probes against HOTAIR were designed on three open regions detected by PARS-seq (ref) by Gene-Tools LLC (HOTAIR Morpho-1: GAGCAGCTCAAGTCCCCTGCATCCA, HOTAIR Morpho-2: GCACCCGCTCAGGTTTTTCCAGCGT, HOTAIR Morpho-3: TACATAAACCTCTGTTCTGTGAGTGC, Mock Morpho: CCTCTTACCTCAGTTACAATTTATA). All probes were biotinylated at the 3’ end. Antisense DNA probes were designed against HOTAIR full-length sequence using online designer at www.singlemoleculefish.com. All probes were compared with the human genome using the BLAT tool and probes returning extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified both HDAC3 and its partner protein NCoR1 by Western blot analysis. as shown in a previous study.7 While our primary interest is identification of targets of 106 that might be involved in regulation of the FXN gene in FRDA, an unbiased proteomic approach should also identify the broader targets of 106 and their interacting proteins. In the present study, we used a dimethyl stable isotope-labeling approach coupled with multidimensional protein identification technology (MudPIT)15 to quantitatively identify the proteins specifically captured by the ABPP 106 probe under nondenaturing conditions compared with the\n",
            "[0.66359943]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which package is available for analysing genomic interactions in R/Bioconductor?\n",
            "Refined Query: I need to analyze genomic interactions using R and Bioconductor.  Which package offers the best tools for this, considering tasks such as identifying interacting regions and visualizing interaction data?\n",
            "\n",
            "Combined Answer: We developed the annotatr Bioconductor package to flexibly and quickly summarize and plot annotations of genomic regions. The annotatr package reports all intersections of regions and annotations, giving a better understanding of the genomic context of the regions. A variety of graphics functions are implemented to easily plot numerical or categorical data associated with the regions across the annotations, and across annotation intersections, providing insight into how characteristics of the regions differ across the annotations. We Analyses were performed using R statistical computing environment (R Core Team 2017) and Bioconductor (Gentleman et al. 2004) packages (http://www.bioconductor.org/). Analyses details are presented in Supplemental Methods. RAPIDR is implemented in R and can be freely downloaded via CRAN from here: http://cran.r-project.org/web/packages/RAPIDR/index.html. Contact: kitty.lo@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online. cummeRbund (http://www.bioconductor.org/packages/release/bioc/html/cummeRbund.html) and biomaRt (http://www.bioconductor.org/packages/release/bioc/html/biomaRt.html) were used in combination with custom R scripts to perform quality assessment and further refine analysis results. Outside of the R ecosystem, BEDtools (Quinlan and Hall, 2010), implemented in C ++, intersects and aggregates genomic regions with annotations, and is very fast. However, its more general purpose means users must provide all annotations and manually generate plots. We developed annotatr, a Bioconductor package that reports all intersections of genomic regions with built-in genomic annotations for D. melanogaster (dm3 and dm6), H. Sapiens (hg19 and hg38), M. musculus (mm9 and mm10), R. norvegicus (rn4, rn5 and rn6), annotations imported from The R-package BBCAnalyzer, its source code, detailed documentation including a manual and a vignette with examples and exemplary data are freely available at http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: LGPL-3). Detailed documentation of the R-package BBCAnalyzer is provided in Additional file 1. The source code (written in R), a manual and a vignette with examples and exemplary data are freely available at the project’s homepage http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: The R-package BBCAnalyzer, its source code, detailed documentation including a manual and a vignette with examples and exemplary data are freely available at http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: LGPL-3). Detailed documentation of the R-package BBCAnalyzer is provided in Additional file 1. The source code (written in R), a manual and a vignette with examples and exemplary data are freely available at the project’s homepage http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: of trait-associated SNPs can be exploited to indicate whether a given genomic interval or intervals are likely to be functionally connected with certain phenotypes or diseases. Despite this importance, currently, there is no ready-to-use computational tool able to connect genomic intervals to phenotypes. Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs intergenic regions. Despite the great utilities, currently there is no off-the-shelf computational tool available to carry out this non-trivial test. To cater for this demand, we developed an R Bioconductor package named traseR, TRait-Associated SNP EnRichment analysis, which offers a turnkey solution for enrichment analysis of taSNPs. visualization method in leading to novel insight, we here provide a comparison the features of the two packages. Ultimately, the choice of the best software for a given purpose rests on the user. In addition to RedundancyMiner, in Table 1 we provide an overview of other, more remotely related software. In contrast to REVIGO, these tools perform GO term enrichment analysis i.e. they start from a user-supplied list of genes, but offer additional features to assist in interpretation of the results, typically visualization and clustering\n",
            "[0.5217825]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How many clinical trials for off-label drugs in neonates are cited in the literature.\n",
            "Refined Query: I need to know the precise number of published studies documenting clinical trials using medications off-label in neonates.  This requires a literature search encompassing all relevant medical journals and databases.\n",
            "\n",
            "Combined Answer: We also searched Chinese Clinical Trial Register, reference lists of included studies and review articles, and relevant journals from recent years. We contacted the pharmaceutical company that produced losigamone (Dr. Willmar Schwabe GmbH & Co.) to obtain relevant data. Published or unpublished randomized controlled trials (RCTs), with no language restrictions. For the latest update on 9 February 2017, we searched the Cochrane Epilepsy Specialized Register, CENTRAL and MEDLINE . We searched trials registers and contacted the manufacturer of losigamone and authors of included studies for additional information. We did not impose any language restrictions. This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011). The following strategy was used to search MEDLINE (OVID). 1. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab. 2. clinical trials as topic.sh. 3. trial.ti. 4. 1 or 2 or 3 5. exp animals/ not humans.sh. 6. 4 not 5 7. exp Epilepsy/ 8. exp Seizures/ 9. (epilep$ or seizure$ or convuls$).tw. 10. 7 or 8 or 9 11. (losigam$ or ADD137022).tw. or The original search on 1 May 2012 yielded a total of 29 potentially relevant articles (Cochrane Epilepsy Specialized Register: 5, CENTRAL: 8, MEDLINE: 16); we identified a further two relevant articles from reference lists of included studies. After reviewing the titles and abstracts we excluded 26 articles as they were not relevant or were obvious duplicate publications. Of the remaining five articles, we excluded three articles (Morris 1997; Runge 1993; Stefan 2001). Finally, two studies (Bauer 2001; Baulac 2003) were eligible to be included three entities are tightly connected, and their relation has also constituted the basis for research on how automated systems may support the design of clinical trial protocols and the validation of hypotheses, e.g., as was the case of the PONTE European project [40]. From this perspective, the selected resources were the following: Jochem for drugs, GENE ONTOLOGY and UNIPROT for targets, DISEASE ONTOLOGY for diseases, MESH as a general purpose domain dictionary, PUBMED and PUBMED CENTRAL for documents, and LINKED LIFE DATA for triples and other web locations. Mailings of the study introduction letter and brochure to academic and private pediatric practices may also be employed to ensure that private pediatric neurology practices are aware of the study. Individual sites may choose to conduct recruitment events to provide information to potential subjects and their parents. Recruitment events may also be conducted in tandem with professional society meetings to raise awareness of the trial among practitioners. These strategies may include the recruitment of additional For more than 150 years, the US National Library of Medicine (NLM) has provided access to the biomedical literature through the analytical efforts of human indexers. Since 1966, access has been provided in the form of electronically searchable document surrogates consisting of bibliographic citations, descriptors assigned by indexers from the Medical Subject Headings (MeSH®;) [1] controlled vocabulary and, since 1975, author abstracts for many citations. The MEDLINE®;/PubMed®; database (MEDLINE) contains over 23 million citations. It currently include a study introduction letter from the co-investigators, a study flyer, and study tear off pads. The flyer and tear off pads will be made available to study research sites for use in public places, medical practices, and research centers. Web postings will be developed for use on internet sites such as clinicaltrials.gov, the NINDS web site, and other web locations. Mailings of the study introduction letter and brochure to academic and private pediatric practices may also be employed to ensure that private pediatric neurology practices been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule was overly stringent as treatment discontinuation rates of 24 percent are reported(21), and would have been revised upward to keep the study open for accrual. To ensure timely dissemination of data, the decision was made to close the trial after 31 evaluable patients were accrued. Additional study limitations include a non-randomized study design\n",
            "[0.7379265]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are stress granules involved in the pathogenesis of Amyotrophic Lateral Sclerosis?\n",
            "Refined Query: Amyotrophic Lateral Sclerosis (ALS) pathogenesis is complex.  This query investigates the potential role of stress granules, cytoplasmic RNA-protein aggregates formed under cellular stress, in ALS disease mechanisms,  exploring whether their dysfunction or aberrant formation contributes to neuronal degeneration.\n",
            "\n",
            "Combined Answer: Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative condition characterized by aetiologically diverse pathomechanisms, which ultimately results in loss of upper and lower motor neurons, paralysis and death. In a rapidly growing group of genes mutated in ALS the most represented are the genes encoding proteins directly or indirectly involved in RNA metabolism [1-3]. Structural and functional studies of ALS-associated proteins and their disease-linked variants have significantly contributed to our current understanding of Our data indicate that CREST and certain other ALS-linked proteins share several features implicated in ALS pathogenesis, namely the ability to aggregate, be recruited to stress granules and alter paraspeckle integrity. A change in CREST levels in neurons which might occur under pathological conditions would have a profound negative effect on neuronal homeostasis. experimental evidence that CREST can be considered another member of the growing group of ALS-linked aggregation-prone proteins capable of recruitment to SGs and other RNA granules. Until very recently, members of this group were exclusively RNA-binding proteins. However, together with the report on profilin1 recruitment to SGs [54], our study links ALS aetiology with dysfunction of RNA granule components other than RNA-binding proteins. acknowledged to be contributory to ALS pathogenesis [3,34-38], and recently dysfunction of another RNA granule, the paraspeckle, has emerged as a possible factor in ALS pathology. Paraspeckles are built on a long non-coding RNA NEAT1 and recruit a subset of proteins, including FUS and to a lesser extent TDP-43 [14]. Functionally, this RNA granule is involved in the nuclear retention of specific RNAs [39], regulation of gene expression and possibly the cellular stress response [40,41]. Results of several studies suggest a role for paraspeckle Our study presents evidence that CREST possesses three properties common to several proteins associated with ALS: i) high propensity to aggregate in cells; ii) recruitment into stress granules; and iii) ability to modulate paraspeckle integrity. There is a growing body of evidence that protein aggregation and altered function of SGs (and likely, paraspeckles) are important factors in ALS pathogenesis, and our observations also point to these processes as potential culprits for the development of pathological changes in ALS cases with CREST A growing number of ALS-associated proteins have been shown to be the components of stress granules (SGs), cytoplasmic RNP foci assembled by cells in response to adverse conditions and facilitating translational shutdown under severe stress [20]. We examined CREST behaviour under various stresses and showed that CREST is also a resident of SGs. SH-SY5Y cells expressing full-length CREST-GFP or CREST-Flag were exposed to sodium arsenite, thapsigargin or a prostaglandin 15d-PGJ2 to trigger SG formation by inducing oxidative stress, ER stress or is involved in the nuclear retention of specific RNAs [39], regulation of gene expression and possibly the cellular stress response [40,41]. Results of several studies suggest a role for paraspeckle proteins and NEAT1 in ALS/FTLD disease pathogenesis [42-49]. Furthermore, it has been specifically demonstrated that paraspeckle assembly triggered by upregulated NEAT1 synthesis occurs in motor neurons at the early stage of ALS development, suggesting a protective role against various insults, which might be particularly important for motor neuron I123M, reduce depolarization-induced branching in cultured neurons [4]. In vivo effects of the other two mutations involving MFD and methionine-rich domain [5] have not been examined. Therefore, in current study we aimed to characterize the aspects of CREST structure and interactions relevant to ALS pathogenesis in vitro and in vivo, primarily its aggregation propensity and possible involvement in the formation of nuclear and cytoplasmic RNA granules. one ALS patient with CREST mutation also carried an amino acid substitution in OPTN gene [5]. It is plausible that in this case the presence of both mutations was necessary for manifestation of the clinical phenotype, providing another example in support of the emerging concept of ALS as an oligogenic disease [53]. In summary, our study provides experimental evidence that CREST can be considered another member of the growing group of ALS-linked aggregation-prone proteins capable of recruitment to SGs and other RNA granules. Until very upregulated NEAT1 synthesis occurs in motor neurons at the early stage of ALS development, suggesting a protective role against various insults, which might be particularly important for motor neuron welfare [18]. We have also established links between loss and gain of function of FUS protein and disrupted paraspeckle assembly in ALS-FUS [19]. This allowed us to propose a model whereby aggregation of FUS in the cytoplasm leads to its nuclear loss accompanied by depletion of other paraspeckle proteins, which in turn may disable protective\n",
            "[0.7497865]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does TGF-beta play a role in cardiac regeneration after myocardial infarction?\n",
            "Refined Query: Investigate the involvement of TGF-beta signaling pathways in the process of cardiac repair and regeneration following myocardial infarction.  Specifically, explore its effects on cardiomyocyte proliferation, fibrosis, and overall scar formation, considering both beneficial and detrimental roles.\n",
            "\n",
            "Combined Answer: Fibrocytes were treated without or with teprotumumab in combination with IGF-1 or TSH. Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes - PMC protein to cytosol. Immunofluorescence staining also revealed that TGF-β1 effectively removes Necl-2 from cell-cell interface. In addition, TGF-β1 reduces Necl-2 mRNA via down-regulating Necl-2 promoter activity. Mutational studies coupled with knockdown experiments have shown that TGF-β1-induced Necl-2 repression requires activation of Smad proteins. EMSA and ChIP assays further confirmed that TGF-β1 promotes the binding of Smad proteins onto MyoD and CCAATa motifs in vitro and in vivo. Taken together, TGF-β1 is a potent cytokine that in negative regulation. In addition, TGF-β1 promotes the formation of complex B where Smad proteins binds to, while it partly inhibits the formation of complex C where the positive regulator, NF-1, binds onto (Fig. 5F). The reduced amount of positive regulator bound to the respective motifs may also serve as another mechanism in mediating gene repression. Mutational studies have shown that single mutation of CCAATb motif abolish the effect of TGF-β1 on Necl-2 gene transcription (Fig. 4D), suggesting that CCAATb motif might also be involved in in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved in angiogenesis by regulating the expression of VEGF by means of intracellular signaling (40, 56). The inhibition of TGF-β1 signaling will lead to reduced endothelium-dependent vasodilation and increased endothelial cell apoptosis, suggesting that dysregulated TGF-β1 signaling may be involved in the pathogenesis of preeclampsia (40). A decline of VEGF treatment. As shown in Fig. 4D, single mutation of either MyoD, CCAATa or CCAATb motif abolished TGF-β1-induced Necl-2 gene repression. Also, the double and triple mutants exerted similar rebound effect. These results suggest that MyoD, CCAATa and CCAATb motifs might play important roles in TGF-β1-mediated Necl-2 gene repression. It is worth mentioning that concurrent mutation of MyoD, CCAATa and CCAATb caused no Necl-2 promoter activity, suggesting that these three motifs work in concert to drive the basal Necl-2 gene transcription. for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by stimulating the NO-cyclic guanosine monophosphate vascular relaxation pathway as well as by increasing the production of the calcium ion (Ca2+)i (53). An increase in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved supershift assays showed that Smad3 and Smad4 are the components of complex B when TGF-β1-treated nuclear extracts were used (Fig. 5F, lane 2 vs lanes 3 & 4). These results indicated that NF-1 is the transcription factor that normally binds to the MyoD and CCAATa motifs for basal gene transcription, while TGF-β1 induces the binding of Smad3 and Smad4 that negatively regulates Necl-2 gene transcription via competitive binding on MyoD and CCAATa motifs. In addition, ChIP assays were conducted to further confirm the in vivo interaction of Smad pair. Taken together, these results suggest that TGF-β1 induces the binding Smad3 and Smad4 to MyoD and CCAATa motifs in vitro and in vivo and thus exerts negative regulatory effect on Necl-2 gene transcription. proteins. EMSA and ChIP assays further confirmed that TGF-β1 promotes the binding of Smad proteins onto MyoD and CCAATa motifs in vitro and in vivo. Taken together, TGF-β1 is a potent cytokine that provides an effective mechanism in controlling Necl-2 expression in the testis via Smad-dependent gene repression and clathrin-mediated endocytosis.\n",
            "[0.68193364]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there a genetic component for happiness?\n",
            "Refined Query: Does happiness have a genetic basis, influencing our predisposition to experience positive emotions?  To what extent do inherited traits affect our overall happiness levels and resilience to life's stressors, compared to environmental influences and personal choices?\n",
            "\n",
            "Combined Answer: distribution, which in some cases may be too restrictive [34], we used the DESeqR package that is based on negative binomial distributions [34]. Using this approach, we fit four negative binomial generalized linear models for each gene: To test whether each factor has a significant impact on the expression of a given gene, the goodness of fit between the models were compared with likelihood-ratio χ2 tests. The results from comparing the fits of (3) to (1) and (3) to (2) are called the main effects of environment and genotype, respectively. For or from the father (two cases). These inherited CNVs were X-linked or associated to mild affectation in the carrier parent. Remarkably, 24 out of the 29 UCEs were contained in the rearrangements inherited from the father or originated in a paternally derived chromosome. However, this association might well be an indirect consequence of a higher proportion of deletions originated in the paternally derived chromosome. Both paternal and maternal deletions show a similar enrichment ratio for UCEs (3.9 and 3.0, respectively), while the paternal and Obesity is a complex disease that results from the interactions of a variety of hereditary and environmental factors. Heritability for obesity is high (typically 0.4 to 0.7) [1], comparable to that of other complex, polygenic diseases such as autism [2]. In most individuals, the genetic basis for obesity is complex and likely to involve the interaction of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes et al., 2017). In healthy individuals, some of the TMEM132D non-coding variants exhibit higher anxiety scores and larger volumetric estimates of the amygdala and hippocampus, key neural structures associated with fear and anxiety (Haaker et al., 2014). Furthermore, in cattle the TMEM132D locus appears to have undergone a selective sweep during domestication (Qanbari et al., 2014), and in the mouse, anterior cingulate cortex TMEM132D expression correlates with anxiety-related behaviour (Erhardt et al., 2011). Finally, mutations in TMEM132D are FM conceived the study, participated in its design and coordination and drafted the manuscript. SM participated in the molecular genetic studies and helped in the data collection. MR participated in the design of the study, in the data collection and performed the statistical analysis. SO participated in the molecular genetic studies. DB participated in the molecular genetic studies and in the draft of the manuscript. RQ participated in the molecular genetic studies. SM participated in the design of the study and helped to perform statistical Mikkelsen et al. 2007; Edmunds et al. 2008). The finding that H3K36me3 is highly enriched on the silenced, maternally inherited Snurf–Snrpn cluster was thus at first glance in contradiction with previous published studies. We verified that our ChIP experiments could reveal a preferentially enrichment of this mark in the coding regions of several control genes expressed in the brain (Supplemental Fig. S8). Therefore, the preferential enrichment of H3K36me3 on the maternally contributed imprinted region did not necessarily mean that it was (30), it fits that the genes proximal to active H3K27ac-positive enhancers reflect such a progenitor state. Conversely, genes proximal to H3K27ac-negative enhancer regions reflect the future more committed state of these cells, which again supports the notion that these enhancers exist in a predetermined state. The genome of each living organism contains thousands of genes, and the precise control of the timing and location of expression of these genes is key for normal development and homeostasis of each individual. Despite the oftentimes high genetic similarity between organisms, the source of phenotypic differences, for example between human and mouse, is thought to originate mainly from changes in how and when genes are expressed. This is partially determined by enhancers, that contribute to the control of gene expression. For decades, duplication enriched (i.e. above threshold) in Class 0. TN – rest of the genes which fall in Class 0. True positive rate (TPR) = sensitivity = TP/(TP + FN). False positive rate (FPR) = (1 – specificity) = FP/(FP+ TN). transformation has been demonstrated in large population based studies. As the headache frequency continues to increase there is a proportional increase in the likelihood of the development of chronic migraine and refractory headaches. This is becoming an increasingly impactful health concern(14, 15). The etiology of this worsening is complex, but may be related to both biological and psychological factors(16). As migraine is a genetically based disease, risk, especially in children, is based on the occurrence of the migraine related genes\n",
            "[0.7159058]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What enzyme is inhibied by Opicapone?\n",
            "Refined Query: Opicapone's mechanism of action involves inhibiting a specific enzyme.  Which enzyme does Opicapone inhibit, and what is the consequence of this inhibition on neurotransmitter metabolism?\n",
            "\n",
            "Combined Answer: 5-FU (Kano et al., 1996), Doxorubicin (Akutsu et al., 1995). Our predictions agree with those previous findings, given that the absolute value of the predicted synergy scores is low (with values of 1.48, −13.0, 0.12 and −10.2, respectively). Furthermore, Paclitaxel was combined with Etopside (Kano et al., 1999a) and Methotrexate (Kano et al., 1998b), resulting in additive/antagonistic effects, which agree with our predictions of synergy values of -19.75 and -23.42, respectively. Furthermore, two other experimental studies focused on Irinotecan and midostaurin as reference compounds. Quizartinib inhibited the growth of MOLM-13 cells with IC50 values of 1.6 nM (95% CI: 1.2–2.0) and 5.6 nM (95% CI: 3.8–8.1) in the absence and presence of FL, respectively (Figure 1A and 1D). Midostaurin inhibited the growth of MOLM-13 cells with IC50 values of 20.7 nM (95% CI: 13.8–31.2) and 63.7 nM (95% CI: 53.9–75.2) in the absence and presence of FL, respectively (Figure 1A and 1D). Consistent with previous reports, our findings demonstrate that the growth inhibitory effects of quizartinib and anhedonic-like behavior (Papp et al., 2014); however neural mechanisms underlying these effects are still unclear. In the current study, cariprazine significantly attenuated CUS-induced sucrose consumption in a novel environment in wild-type mice, demonstrating antidepressant-like activity that was comparable with the tricyclic antidepressant imipramine. Interestingly, the same antianhedonic-like actions of cariprazine were not observed in D3-KO mice, indicating that dopamine D3 receptors are required to mediate the antidepressant-like effects SERCA2a activity was determined using pyruvate/NADH-coupled reactions based assay, as previously described24. The activity of the Ca2+-ATPase was calculated as follows: Δabsorbance/6.22 × protein × time (in nmol ATP/mg protein × min). All assays were performed in triplicate. changes in GI viscosity, alterations in luminal metabolism or in systemic drug clearance, and direct physical or chemical interactions with the drug formulation (eg, changes in solubility and/or dissolution).11, 12, 13 The results of this study demonstrated an absence of a food effect on ozanimod and the major active metabolite RP101988. A food effect is considered demonstrable if the 90%CI for the ratio of population geometric means between fed and fasted treatment for Cmax and AUC does not meet the 80% to 125% bioequivalence criterion.13 with RS, however, lack ABCC2 mutations (14), and the mechanistic basis of RS is unknown. Organic anion transporting polypeptides (OATPs, genes: SLCOs) contain 12 plasma membrane–spanning domains and mediate sodium-independent cellular uptake of highly diverse compounds, including bilirubin glucuronide, bile acids, steroid and thyroid hormones, and numerous drugs, toxins, and their conjugates (15, 16). Human OATP1B1 and OATP1B3 localize to the sinusoidal membrane of hepatocytes and mediate the liver uptake of, among other compounds, many drugs CI: 53.9–75.2) in the absence and presence of FL, respectively (Figure 1A and 1D). Consistent with previous reports, our findings demonstrate that the growth inhibitory effects of quizartinib and midostaurin on MOLM-13 cells were attenuated in the presence compared with the absence of FL. In contrast, gilteritinib inhibited the growth of MOLM-13 cells with IC50 values of 15.5 nM (95% CI: 11.7–20.5) and 20.3 nM (95% CI: 14.7–28.0) in the absence and presence of FL, respectively, indicating that FL stimulation had little effect on the growth that concentrations well surpassing these doses are readily obtained following oral dosing of oprozomib.28,40 Importantly, peptide epoxyketones such as carfilzomib and oprozomib, specifically inhibit N-terminal threonine active proteasome subunits in contrast to dipeptide boronates that can also inhibit serine proteases. This difference may account for the favorable toxicity profiles and relatively low rates of peripheral neuropathy associated with epoxyketone PIs.24,53 This could permit more prolonged and intense dosing regimens, potentially which essentially results in blockade of D3 receptors (Freedman et al., 1994; Sautel et al., 1995; Kiss et al., 2010). In contrast, most other atypical antipsychotics have relatively lower affinities for the D3 receptor and in the presence of normal brain levels of dopamine are unable to block these receptors (Stahl, 2016). Furthermore, since D3 receptors are thought to be involved in the regulation of mood, cognition, and motivation (Gross and Drescher, 2012), compounds like cariprazine that exhibit high affinity and occupancy of these resulting in additive/antagonistic effects, which agree with our predictions of synergy values of -19.75 and -23.42, respectively. Furthermore, two other experimental studies focused on Irinotecan of which SN-38 is the active metabolite. In a combination with 5-FU on HT-29 an additive effect was observed (Guichard et al., 1997), which agrees with our prediction of −0.57 for 5-FU and SN-38 on HT-29. Furthermore, they investigated the combination Irinotecan with Oxaliplatin on HT-29, HCT-116 and SW-620 (Guichard et al., 2001). The highest\n",
            "[0.54993635]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What kind of affinity purification would you use in order to isolate soluble lysosomal proteins?\n",
            "Refined Query: To isolate soluble lysosomal proteins, which are prone to degradation,  a gentle affinity purification method is crucial.  What specific affinity tag (e.g., FLAG, HA, His) and corresponding resin would be most suitable, considering the lysosomal environment and potential interference from other cellular components?  How would the purification strategy be optimized to minimize protein loss and ensure high purity?\n",
            "\n",
            "Combined Answer: potassium acetate), and 1.5 g of ice-chilled glass beads (400 to 600 μm in diametet was added. The tubes were vortexed eight times for 30 s with 30-s intervals on ice. After 10 min on ice, the lysate was decanted into ice-chilled 15-ml Corex tubes and centrifuged for 20 min at 18,000 × g at 4°C. A 500-μl volume of clarified lysate was incubated with 25 μl of prewashed protein A-agarose beads at 4°C for 1 h. The beads were pelleted, and 450 μl of the lysate was transferred to a tube containing 7.5 μl of anti-myc antibody (Santa Cruz) and such as sucrose gradient centrifugation, gel filtration, and immunoprecipitation with different antibodies. The other difficulty was the overall instability of minichromosomes during the isolation: dissociation of some components with a lower binding affinity from minichromosomes might be inconsistent when comparing protein identifications of different purification preparations. Nevertheless, the results of nucleosome mapping on viral minichromosomes reported here will supply the initial framework information for the understanding of the purification, and the second round of carrier degradation is necessary to avoid substantial sample loss that leads to low-complexity libraries. Each sample was then individually assessed for fragment size distribution using an HS DNA chip (Bioanalyzer, Agilent). If short fragments were present in the library (<300 bp) (see Supplemental Fig. S21), another round of size selection was performed using a stringent volume ratio of AMPure XP beads to the sample of 0.8 X (volume of each sample was, prior to purification, adjusted with water to 30 µL). Following treatment, floating and attached cells were collected and lysed in lysis buffer (10 mM TRIS-HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 1% Triton X-100) containing protease inhibitor cocktail (1 tablet/10 mL; Roche Diagnostics Co.). Lysates were subjected to sonication and centrifugation, and the supernatants were transferred to new tubes. Bio-Rad Protein Assay dye concentrate (Bio-Rad) was used to determine protein concentrations in the lysates. Equivalent quantities of protein were electrophoresed on 10% or 12.5% SDS-PAGE gels and with 25 μl of prewashed protein A-agarose beads at 4°C for 1 h. The beads were pelleted, and 450 μl of the lysate was transferred to a tube containing 7.5 μl of anti-myc antibody (Santa Cruz) and incubated at 4°C for 2 h. Then 25 μl of prewashed protein A-agarose-conjugated beads was added, and the mixture was incubated for 1 h at 4°C. The beads were then washed successively seven times: four times with B60 adjusted to 100 mM potassium acetate and once each with B60 adjusted to 210, 240, or 270 mM potassium acetate. The beads were boiled in HU inhibitor (one tablet per 10 ml, Roche), and a protein phosphatase inhibitor cocktail (Sigma)] containing 20 mM N-ethylmaleimide. Lysates were cleared by centrifugation at 30,000 g for 20 min. Cell lysates were then immunoprecipitated with a flag-specific affinity matrix gel (Sigma) overnight at 4°C, after which the immunoprecipitates were washed in cold lysis buffer. The immunocomplexes were then resolved by SDS-PAGE, and immunoblot analysis was performed with an sSERCA2a-specific antibody. Fresh tissue extracts were prepared in lysis buffer were lysed by sonication and cleared extracts were incubated for 1 h at 4°C with anti-FLAG- (Sigma) or Ni-NTA agarose resin (Life Technologies) to purify FLAG- or His-fusion proteins, respectively. Proteins were eluted in lysis buffer containing 0.4 mg/ml of FLAG peptide (Sigma) (FLAG proteins) or 250 mM imidazole (His proteins) and dialyzed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 10% glycerol. For NMR spectroscopy and ITC measurements, TIRR-His was treated with benzonase (EMD Millipore) after cell lysis and upon binding to Ni-NTA resin, Cells were lysed in SDS buffer. Concentrations were determined by Bradford protein assay (Bio-Rad, Richmond, CA, USA) with BSA used as the standard. The lysates (40 μg) were solubilized in Laemmli sample buffer by boiling and then separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by electro-transfer onto a nitrocellulose filter. The filter was incubated for 1 h at room temperature with primary antibody. AR antibody (Thermo Fisher Scientific, MA, USA) and MMP2 antibody (Kyowa Pharma Chemical, Toyama, Japan) were are not clear. Complete elucidation of hepadnaviral minichromosome structures is still a challenge despite the fact that extensive efforts have been made. A main hurdle was a heavy contamination of host counterpartners during the process of isolation of viral minichromosomes, though different purification methods were employed in a tandem manner, such as sucrose gradient centrifugation, gel filtration, and immunoprecipitation with different antibodies. The other difficulty was the overall instability of minichromosomes during the isolation: Bio-Rad Protein Assay dye concentrate (Bio-Rad) was used to determine protein concentrations in the lysates. Equivalent quantities of protein were electrophoresed on 10% or 12.5% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked at room temperature for 1 h in TBST buffer (150 mM NaCl, 50 mM TRIS-HCl, pH 8.0, and 0.1% Tween 20) containing 5% nonfat milk, then probed overnight at 4 °C with primary antibodies directed against caspase-3 (AAP-113, Enzo Life Sciences, Inc.), PARP (9542S, Cell Signaling Technology\n",
            "[0.56731784]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the genes thought to be regulated by EWS/FLI?\n",
            "Refined Query: Investigating the transcriptional regulatory network of the EWS/FLI fusion oncoprotein in Ewing sarcoma is crucial.  This necessitates identifying the specific genes whose expression is directly or indirectly controlled by EWS/FLI, encompassing both upregulated and downregulated targets, and understanding the underlying mechanisms of this regulation.\n",
            "\n",
            "Combined Answer: rhabdomyosarcoma [47], Ewing sarcoma [48], and ALL [49]. Our results extend previous in vitro findings for Nutlin to RG7112, and they provide insight into the in vivo pattern of activity of RG7112 against p53 wild-type childhood cancer preclinical models. The pattern of in vitro activity of RG7112 against the cell line panel tested is consistent with p53-MDM2 interaction inhibition. Each of the p53 wild-type cell lines had rIC50 values < 1 µM, while only one p53 mutant cell line (Ramos-RA1) had a rIC50 value below 1 µM. The Ramos Burkitt Tables 2 and 3 show the motifs that are most consistently up-regulated or down-regulated in cancers, including miRNAs. As discussed in the Supplemental Material, many of the top disregulated motifs, such as HIF1A and hsa-miR-205 miRNA (Supplemental Fig. 17), are well-known in cancer biology, again supporting the accuracy of ISMARA’s predictions. Besides well-known oncogenes and tumor suppressors, ISMARA also makes several novel predictions of regulators consistently disregulated in cancers, including the TFs HAND1, KLF12, BPTF, FOXD3, and Next, we assessed clinical cohorts for expression of the EGF‐regulated lncRNAs from MCF10A cells. Two datasets of breast cancer patients were analyzed: The METABRIC dataset (Curtis et al, 2012) and several breast cancer cohorts integrated into a single dataset, called “Kaplan–Meier (KM) plotter” (Gyorffy et al, 2010). Each dataset includes ~2,000 breast cancer patients, who were followed for > 20 years from initial diagnosis. In addition to gene expression data, derived from either Illumina (Curtis et al, 2012) or Affymetrix (Gyorffy et al, We thank F. Ochsenbein and C. Francastel for discussions, and S. Jounier and the Gene Identification team at CNG for technical help. We thank D. Reinberg for providing the H3K27me2/3 antibody, R. Feil for the JF1/Ms mouse strain, and N. Gilbert for probes. M.G.'s team is supported by the Association pour la Recherche sur le Cancer (ARC). S.D. acknowledges la Ligue Nationale Contre le Cancer for support (Equipe Labelisée). region of the gene in A3-1 ES cells and found that the enhanced promoter activity of the region decreased by knocking down of Esrrb (Fig. 4C). These results suggest that Esrrb positively regulates the promoter activity of the Dax1 gene. To determine which ERRE sites are involved in regulation of Dax1 expression, we examined four reporter plasmids that included wild-type (WT), ERRE1-mutated (mutERRE1), ERRE2-mutated (mutERRE2), and ERRE1 and -2-mutated (mut ERRE1&2) promoters (Fig. 5A). As shown in Fig. 5B, enhanced promoter activity was Esrrb is a transcriptional regulator, and its recognition DNA sequence is known to be TCAAGGTCA (28). Interestingly, we discovered that the promoter region of the Dax1 gene contains two putative Esrrb binding sites, which we named Dax1-ERRE1 (−129 to −121) and Dax1-ERRE2 (−334 to −326) (Fig. 4A). This finding indicates that Dax1 not only is a protein-protein interaction partner of Esrrb but also is a downstream target of Esrrb. To explore this possibility, we first performed a luciferase reporter assay. When we examined the kb −2.1 promoter LRH-1 and SF-1 also regulate Dax1 gene expression in ES cells and adrenocortical carcinoma cells, respectively (22, 39), and the SF-1-mediated activation is repressed by Dax1 via binding to a hairpin structure in the promoter region (40). Here, we found that Dax1 is a downstream target gene of Esrrb. Esrrb recognized the ERRE1 of the Dax1 gene and enhanced the promoter activity, and the Esrrb-mediated activation of the Dax1 gene promoter was suppressed by Dax1 itself. In MCF7 breast cancer cells, expression of Dax1 is regulated by Esrrg, but between NFKB1/REL/RELA, IRF TFs, and PRDM1, or the prediction that MYBL1 is an upstream activator of RFX TFs in ciliogenesis. Moreover, the links to a genome browser view of the individual binding sites on the genome (Pachkov et al. 2007) allow for targeted validation of such individual regulatory interactions. There are many indications that the actions of miRNAs and TFs are tightly integrated (Cui et al. 2006; Hornstein and Shomron 2006; Zhou et al. 2007), and ISMARA’s incorporation of miRNA regulation allows for the automated identification that included wild-type (WT), ERRE1-mutated (mutERRE1), ERRE2-mutated (mutERRE2), and ERRE1 and -2-mutated (mut ERRE1&2) promoters (Fig. 5A). As shown in Fig. 5B, enhanced promoter activity was reduced when ERRE1, but not ERRE2, was mutated, suggesting that ERRE1 is required for the activation of the Dax1 promoter. Next, we performed a biotinylated DNA pulldown assay to look for an interaction of Esrrb with the Dax1-ERRE1 element. Nuclear extracts of undifferentiated ES cells were incubated with a biotin-labeled oligonucleotide carrying Besides well-known oncogenes and tumor suppressors, ISMARA also makes several novel predictions of regulators consistently disregulated in cancers, including the TFs HAND1, KLF12, BPTF, FOXD3, and ZNF143.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 354.06ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Do archaeal genomes contain one or multiple origins of replication?\n",
            "Refined Query: Archaeal genomes' replication initiation is a key area of study.  Unlike bacteria's single origin,  do archaea consistently exhibit a single origin of replication, or can multiple origins exist, potentially influencing their replication speed and regulation?\n",
            "\n",
            "Combined Answer: The genomic structure and organization of the repeated ribosomal DNA cluster (rRNA genes) have been studied extensively in many organisms, from Escherichia coli to humans. With respect to the number of rDNA genes, E.coli has seven, four of which are located fairly close to the origin of replication but are not continuous, whereas the rDNAs of most eukaryotic organisms are tandemly repeated at one or a few chromosomal loci and are present in many copies. In contrast, certain organisms routinely harbor extrachromosomal rRNA genes (1). The rRNA of throughout each chromosome. Our current understanding of eukaryotic DNA replication forks was inspired by earlier work with bacteria, in which chromosome replication is understood in much greater detail. In Escherichia coli, progression of DNA replication forks is dependent on the DnaB DNA helicase that unwinds the parental DNA duplex. The DnaB helicase is connected physically to a subset of the other replication factors to form a larger assembly called the replisome (Yao and O'Donnell, 2008). In addition to DnaB, the replisome includes the 6D, region analyzed indicated by bracket), indicating that Pfh1 does not promote replication genome-wide. These data also indicate that it is the Swi1-dependent protein complex at RTS1 that makes replication through this site Pfh1-sensitive. As controls for these experiments, we made swi1Δ variants of each strain. Unexpectedly, regardless of the presence or absence of the RuraR cassette, swi1Δ cells that were continuously depleted of Pfh1 by growth on thiamine plates were inviable (Fig. 6E; see the Discussion). than the shorter tRNA genes. The comprehensive analysis of sites of Pfh1 activity provided here demonstrates that, in addition to G4 motifs [39], there are many classes of hard-to-replicate sites that depend on Pfh1 for their proper replication. Many of these other sites, in particular RNA polymerase III transcribed genes, exhibit even stronger Pfh1-dependent effects than G4 motifs (Tables 1 and 2 and S3 Table). Altogether, Pfh1 supports DNA replication at thousands of diverse sites across the genome. the sites adjacent to the origins were similar to those of Cdc20 in the same cells; however, we could not detect a movement of Pfh1 from an origin to its adjacent region, as we detected for Cdc20 at ars3002. This may be due to the role of DNA polymerase ε in replication initiation [65], technical challenges, and/or stochastic origin usage in different cells in the synchronized population [66]. If Pfh1 were recruited only to Pfh1-dependent sites, we would have expected to see low binding to these Pfh1-independent sites compared to Cdc20. 2C). In addition, pausing at the other RFBs and converged forks was not increased in swi1Δ Pfh1-depleted cells (Fig. 2C). These data suggest that the protein complexes bound to the RFBs, rather than the RFB sequence, confer Pfh1 sensitivity to replication through these sites. In addition, replication intermediates were equally abundant in other regions of the rDNA fragment (denoted by bracket in schematic, Fig. 2C) in the presence or absence of Pfh1, suggesting that Pfh1 does not promote replication through all regions of the genome. et al, 2008). Archaea lack a direct equivalent to DNA polymerase α, but it is interesting to note that Sulfolobus GINS has been found to interact with Primase (Marinsek et al, 2006), suggesting that archaeal GINS might also serve to link MCM to Primase on the lagging strand template. Ctf4 is not essential for viability in budding yeast but is a key determinant of genome stability. Fission yeast cells lacking the Mcl1 protein that is orthologous to Ctf4 are unable to grow at high temperatures but are viable at 25 or 27°C (Williams and McIntosh, We used genome-wide assays to determine sites where replication and genome integrity are Pfh1-dependent. The most striking aspect of these data is the strong dependence of RNA polymerase III transcribed genes on Pfh1. 2D gel analyses showed previously that replication of five of five tested tRNA genes is Pfh1-dependent, and this dependence is seen regardless of whether replication is co-directional or opposite to the direction of transcription through the gene [35]. Here we show that close to 50% (80/171) of the tRNA genes bound Pfh1 (Table 1). in Pfh1-depleted cells (Fig. 3). As with tRNA genes, 5S rRNA genes were Pfh1-dependent regardless of the direction of replication through the gene. We propose that replication of all 169 tRNA and 33 5S rRNA genes is Pfh1-dependent. Based on the data presented here and in S. cerevisiae (Deshpande and Newlon 1996; Ivessa et al. 2000, 2003; Azvolinsky et al. 2009), we anticipate that RNA Pol III genes are hard to replicate in all eukaryotes, and Pif1 family helicases may also be important for their replication in more complex eukaryotes. Finally, Eukaryotic chromosomes replicate in a temporal order known as the replication-timing program1. In mammals, replication timing is cell-type-specific with at least half the genome switching replication timing during development, primarily in units of 400–800 kilobases (‘replication domains’), whose positions are preserved in different cell types, conserved between species, and appear to confine long-range effects of chromosome rearrangements2,3,4,5,6,7. Early and late replication correlate, respectively, with open and closed three-dimensional\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Conditions - {'Diabetes': 0.6726340238952433, 'Neuropathy': 0.30491226364146523, 'Kidney Disease': 0.28237135457322365, 'Metformin': 0.45907039765465335, 'Lifestyle Changes': 1.0000000000000002, 'Retinopathy': 0.23894733530402062, 'Peripheral Neuropathy': 0.0}\n",
            "\n",
            " ### Clustered: {'Conditions': {'Cluster 1': ['Neuropathy', 'Peripheral Neuropathy'], 'Cluster 2': ['Diabetes'], 'Cluster 3': ['Kidney Disease'], 'Cluster 4': ['Metformin'], 'Cluster 5': ['Lifestyle Changes'], 'Cluster 6': ['Retinopathy']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 807.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.93ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.46ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 908.05ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 908.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 887.08ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1110.20ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 680.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1063.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 659.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 812.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1110.23ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 731.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 983.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 807.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 634.77ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is hyperosmia\n",
            "Refined Query: What is hyperosmia, and how does this heightened sense of smell differ from a normal olfactory experience?  What are its potential causes, ranging from hormonal changes to neurological conditions, and how is it diagnosed and managed?\n",
            "\n",
            "Combined Answer: and psychological response patterns. Neuroimaging studies have demonstrated altered brainstem appearance with iron deposition as the presence of frequent migraine persists over time(23). Clinical and physiological assessments have demonstrated the increased hypersensitivity with lack of normal attenuation whether due to auditory, visual or sensory response patterns(24). As headache frequency persists, the ability of patients to cope with their headaches and daily life stressors is further compromised(25). This is further enhanced by the but may be related to both biological and psychological factors(16). As migraine is a genetically based disease, risk, especially in children, is based on the occurrence of the migraine related genes (genotypic expression)(17–19). As migraines become more frequent, it can be speculated that these genes have increased activity or influence on the pathways involved (phenotypic expression)(20–22). This results in a hypersensitive phenomenon that lowers the threshold for the occurrence of the next migraine. This hypersensitive phenomenon has been in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic symptoms. The mechanisms of action of preventative medication appear to reverse this hypersensitivity either through multiple re-uptake inhibition (AMI) or alteration of channel function and neurotransmission (TPM). If high frequency headaches are sustained, this increased hypersensitivity may result in long-term changes in neuroanatomy, neurophysiology, and psychological response patterns. Neuroimaging studies have demonstrated altered brainstem appearance with iron deposition as the presence of frequent migraine persists over time(23). have previously been published6 as well as in separate case reports2–4,19,20. Supplementary Table 1 summarizes the clinical characteristics of the patients and their previously identified genetic diagnoses. Patient inclusion criteria consisted of (1) a confirmed or potential neurodevelopmental disorder and (2) a metabolic phenotype. A metabolic phenotype could be reflected by (1) a pattern of abnormal metabolites in urine, blood or CSF, (2) abnormal results on biochemical functional studies or (3) typical abnormalities in clinical history or had the five features making the DOORS acronym; several had 2-oxoglutaric aciduria or a triphalangeal thumb. Further discussion on 2-oxoglutaric aciduria is provided in the appendix (p 20). Through a combination of careful clinical phenotyping and exome sequencing, we have identified the molecular basis of DOORS syndrome in about a third of individuals included in our cohort, or in half of the 18 families in which affected individuals had the five features making the DOORS acronym. We suggest that individuals without deafness and seizures but hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow involved (phenotypic expression)(20–22). This results in a hypersensitive phenomenon that lowers the threshold for the occurrence of the next migraine. This hypersensitive phenomenon has been supported by the observations that as patients' headaches become more frequent they may have increased photophobia, phonophobia, allodynia and promontory symptoms. The mechanisms of action of preventative medication appear to reverse this hypersensitivity either through multiple re-uptake inhibition (AMI) or alteration of channel function and start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, but myoclonic, partial, and absence seizures also occur.3 Neurological involvement—apart from the epilepsy, intellectual disability, and profound sensorineural hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a\n",
            "[0.6601457]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the number of long non coding RNAs in the human genome\n",
            "Refined Query: Determining the precise number of long non-coding RNAs (lncRNAs) in the human genome is challenging due to ongoing annotation efforts and varying detection methods.  The current estimates range widely, highlighting the complexities of lncRNA identification and characterization.  What are the most recent, reliable estimates and what factors contribute to the uncertainty?\n",
            "\n",
            "Combined Answer: The human genome contains many thousands of long noncoding RNAs (lncRNAs). While several studies have demonstrated compelling biological and disease roles for individual examples, analytical and experimental approaches to investigate these genes have been hampered by the lack of comprehensive lncRNA annotation. Here, we present and analyze the most complete human lncRNA annotation to date, produced by the GENCODE consortium within the framework of the ENCODE project and comprising 9277 manually annotated genes producing 14,880 transcripts. Our Kapranov et al. 2007; Findeiss et al. 2010). Among these, long noncoding RNAs are emerging as central players in cell biology. Likely outnumbering protein-coding transcripts, a small but rapidly growing number of them have been shown to participate in the epigenetic regulation of gene expression. The precise biological role of the vast majority, however, is still unknown. Here, we report on the generation and characterization of the largest catalog of lncRNAs to date. This catalog has been created through manual curation of available cDNA and 7, covers almost 85% of the human genome; therefore, we expect at least 2000 more lncRNA genes remain to be discovered with present annotation methods (Supplemental Fig. S15). Indeed, it is important to note that the transcripts originating from lncRNA gene loci represent only a fraction of the lncRNA world: ∼50% of the transcripts arising from protein-coding loci (i.e., sense-exonic transcripts) are also noncoding and have not been analyzed in the present study. While the function of the vast majority of lncRNAs is unknown, the full even slightly decreasing, across GENCODE versions (22,500 in version 3c, November 2009; 20,700 in version 7, April 2011), the number of lncRNA genes has substantially increased from 6000 to more than 10,000 during this period. It is not unlikely that lncRNA genes outnumber protein-coding genes in the human genome. The present annotation, version 7, covers almost 85% of the human genome; therefore, we expect at least 2000 more lncRNA genes remain to be discovered with present annotation methods (Supplemental Fig. S15). Indeed, it is important Long non-coding RNAs (lncRNAs) play integral roles in diverse biological processes including transcriptional regulation (Kino et al., 2010) and subnuclear structure formation (Naganuma and Hirose, 2013). The dysfunctions of many lncRNAs are associated with severe diseases such as diabetes and various cancers (Wapinski and Chang, 2011), and thus elucidating lncRNA functions is an important research topic. Although large-scale transcriptome analysis has revealed that more than 58 000 lncRNA genes are encoded by the human genome (Iyer et al., GENCODE lncRNA data set is larger than other available lncRNA data sets, and it shows limited intersect with them. A total of 42% (44 out of 96) of the long noncoding RNA database lncRNAdb (Amaral et al. 2011) are represented in GENCODE lncRNAs. We checked the same-strand overlap against recent lncRNA catalogs: GENCODE v7 lncRNAs contain 30% of Jia et al. (2010) lncRNAs, 33% of Cabili et al. (2011) (stringent) lincRNAs, 39% of Cabili et al. (2011) (all) lincRNAs, and 12% of vlincs (Supplemental Fig. S1; Kapranov et al. 2010). We also examined fused to a different protein domain [6]. These features make it possible to manipulate the numerous types of non-protein coding genomic elements that have so far resisted standard RNA interference (RNAi) techniques [6, 7]. The study of one gene class in particular, long non-coding RNAs (lncRNAs), has been hindered by a lack of effective loss-of-function tools [2]. Numerous yet poorly characterised, >40,000 lncRNAs have been discovered in the human genome, yet we understand the molecular function of <1 % [8]. This gap in understanding is There is some evidence that transcripts thought to be purely noncoding lncRNAs may in fact encode proteins, in small or otherwise unrecognized ORFs (Chooniedass-Kothari et al. 2004; Kondo et al. 2010; Dinger et al. 2011). To assess the protein-coding status of the present lncRNAs catalog, we first used the program GeneID (Blanco et al. 2007) to (1) measure the protein-coding potential and (2) find the longest possible ORF in each lncRNA sequence. We compared the results in the set of GENCODE lncRNAs with (1) known protein-coding transcripts, that with a small number of exceptions they exhibit minimal protein-coding capacity. The genomic structure of lncRNAs is very similar to that of protein-coding genes, although a surprisingly high proportion of the former are two-exon transcripts. Overall, we observe that while lncRNAs have exons of similar length to protein-coding mRNAs, they have fewer of them—in agreement with the recent findings of Cabili et al. (2011). One advantage of manual annotation of lncRNAs is that it provides accurate transcription start site, termination site, and Annotation of lncRNAs is made challenging by the low expression levels of these transcripts, which may lead to fragmentary annotation and poor definition of the transcript boundaries. Concerns have also been raised as to whether lncRNAs are independent transcripts, or whether they are simply unrecognized extensions of neighboring protein-coding transcripts (van Bakel et al. 2010). To test whether this is the case for the GENCODE lncRNAs, we used various high-throughput sequencing data produced in the context of the ENCODE project to search for\n",
            "[0.6437476]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the most known bacterium responsible for botulism (sausage-poisoning)?\n",
            "Refined Query: Botulism, a severe form of food poisoning, is primarily caused by a neurotoxin produced by bacteria.  Which specific species of *Clostridium* is most commonly associated with this condition, particularly in cases linked to improperly processed sausages?\n",
            "\n",
            "Combined Answer: Clostridium difficile is an anaerobic Gram-positive bacillus that infects the colon of susceptible patients, mainly in hospital settings but also increasingly in the community. C. difficile infections (CDI)4 are typified by severe diarrhea, pseudomembranous colitis, and in extreme cases colonic rupture, sepsis, and death (1). Current treatments for CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms that are “an immediate public health threat and that require urgent and aggressive action” (44). There is therefore a pressing need for new treatments against C. difficile, in particular ones that address the high rates of recurrence. The pathogenic nature of C. difficile results from production of two exotoxins, toxin A (TcdA) and toxin B (TcdB), palate. The diagnosis of strep throat is unlikely with symptoms of red eyes, hoarseness, runny nose, or mouth ulcers, and also less likely in the absence of fever. The etiology is usually infectious, with most cases being of viral origin. These cases are benign and self-limiting for the most part. Bacterial causes of pharyngitis are also self-limiting, but are concerning because of suppurative and nonsuppurative complications. Other causes include allergy, trauma, toxins, and neoplasia.3 The most common bacterial organism causing acute codified this practice with their recommendation that, “Nearly all severely malnourished children have bacterial infections when first admitted to hospital. Many have several infections caused by different organisms… Children with no apparent signs of infection and no complications should be given cotrimoxazole…orally twice daily for 5 days.” (WHO 1999) In fact, numerous recent studies have indeed confirmed this concern of severe bacterial infections in malnourished children who are hospitalized (Berkley et al. 2005; Noorani et al. 2005; (WHO 1999) In fact, numerous recent studies have indeed confirmed this concern of severe bacterial infections in malnourished children who are hospitalized (Berkley et al. 2005; Noorani et al. 2005; Babirekere-Iriso et al. 2006; Bachou et al. 2006; Brent et al. 2006; Maitland et al. 2006; Hill et al. 2007; Hossain et al. 2009). Over the last several years, a revolution in the case management of SAM has occurred with the introduction and widespread acceptance of ready-to-use therapeutic foods (RUTF) that allow for the management of Bacillus anthracis is a spore-forming, gram-positive bacterium that is the causative agent of anthrax. The major factors responsible for its pathogenesis are encoded on two virulence plasmids, pXO1 and pXO2 [1-4]. pXO1 contains the genes coding for the three secreted toxin proteins, protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid Malnutrition contributes to more than half of the 10 million child deaths worldwide (Bryce et al. 2005), many of which occur following an acute infectious insult. Children hospitalized with severe acute malnutrition (SAM) are traditionally treated with empiric antibiotics as part of their routine case management. The World Health Organization (WHO) codified this practice with their recommendation that, “Nearly all severely malnourished children have bacterial infections when first admitted to hospital. Many have several infections caused by problems, including two with suspected encephalitis. Infectious disease hospitalizations included: pneumonia; status epilepticus and possible viral encephalitis; and influenza B infection with myositis and possible encephalitis. A range of other medical problems were observed in only a single child and are listed in Supplementary Table 1. GI-related symptoms were prominent in the CS patients assessed. Half (50%) had gastroesophageal reflux disease (GERD), for which two patients (14% of total patients) required Nissen fundoplication. Many parents (71% of families) reported current and past feeding difficulties such as difficulty chewing and times where the patient refuses to eat. Feeding difficulties were also notable during the neonatal period with latching problems. Some parents also reported that their boys had history of swallowing difficulties (29%) including dysphagia, secreted in human parotid and submandibular-sublingual saliva in humans and higher primates [4]. Histatin 5 (Hst 5) is a proteolytic cleavage product of the larger Histatin 3 family member [5], [6]. Among Histatins, Hst 5 has the most potent fungicidal activity against pathogenic fungi including C. albicans and other medically important Candida species such as Candida kefyr, Candida krusei, and Candida parapsilosis (MIC50 10–20 µg/ml), as well as Cryptococcus neoformans and Aspergillus fumigatus (MIC50 5–6 µg/ml) [4], [7]–[9]. However, many\n",
            "[0.5472778]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the association of spermidine with α-synuclein neurotoxicity?\n",
            "Refined Query: Investigate the relationship between spermidine, a polyamine, and the neurotoxicity associated with α-synuclein aggregation, focusing on whether spermidine influences α-synuclein's aggregation, propagation, or downstream effects on neuronal health in neurodegenerative diseases like Parkinson's.\n",
            "\n",
            "Combined Answer: of α-synuclein and p-Ser-129 α-synuclein levels in primary cortical cultures from knock-out and wild-type littermates showed that α-synuclein phosphorylation was decreased by about 70%. A similar decrease was observed in soluble α-synuclein in 2–3-month-old cortices (Fig. 3, B and C). Kinase Assays—To prepare biotinylated α-synuclein substrate, a cysteine residue was introduced into the C terminus (141C-αSyn) of the recombinant α-synuclein expression construct previously described (11), using site-directed mutagenesis (QuikChange XL, Stratagene), and the resulting α-synuclein mutant was prepared (11). The C-terminal cysteine was biotinylated with maleimide-polyethylene glycol 2-biotin (Pierce). PLK1, -2, -3, and -4 (Carna Biosciences) or CK 2 (New England Biolabs) were mixed with 66 nm biotin-141C-α-synuclein (33 nm) and 0.2 cells. BI2536 was used to validate the role of PLK family members in α-synuclein phosphorylation in vivo. Mice were dosed intravenously with BI2536, the brains were collected, and the levels of total and p-Ser-129 α-synuclein in cortical extracts were measured by ELISA. As shown in Fig. 3A, consistent and significant inhibition of α-synuclein phosphorylation was observed. The effect of removal of the plk2 gene on α-synuclein levels was also investigated using PLK2 knock-out mice. Primary cortical cultures from a homozygous knock-out mouse were was observed. The effect of removal of the plk2 gene on α-synuclein levels was also investigated using PLK2 knock-out mice. Primary cortical cultures from a homozygous knock-out mouse were compared with those from wild-type (plk2+/+) littermates. Measurement of mRNA levels by qRT-PCR showed that PLK2 expression was completely ablated. Comparison of α-synuclein and p-Ser-129 α-synuclein levels in primary cortical cultures from knock-out and wild-type littermates showed that α-synuclein phosphorylation was decreased by about 70%. A similar Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System - PMC one 30 mg/kg dose of BI2536 or vehicle at a 5 ml/kg dose volume in 0.9% saline. Animals were euthanized by carbon dioxide 3 h after dosing. Brains were removed, rinsed in 0.9% saline, and separated into left and right hemispheres. The cortex was dissected from the right hemisphere, frozen on dry ice, and kept at –80 °C until used for quantitation of α-synuclein levels. ELISA Assay—Protein concentration of lysates was measured using the Micro BCA Kit (Pierce Biotechnology). Total α-synuclein and p-Ser-129 α-synuclein levels were each normalized have proposed that PLK2 has a critical role in maintaining dendritic spine stability (31) and modulating excitatory glutaminergic synaptic connections (32, 33). Thus, the involvement of PLK2 in α-synuclein phosphorylation provides a potential link between excitotoxic responses and Lewy pathology. Investigation of how the biology of PLK2 relates to the pathogenesis of PD and DLB should help clarify the role of synuclein phosphorylation in these diseases. Inhibition or Reduction of PLK2 Decreases α-Synuclein Phosphorylation—To establish the role of PLK2 in neurons, the effect of knockdown of PLK2 levels in human cortical cultures was investigated using shRNA in lentiviral vectors. As shown in Fig. 1, B and C, transduction with the PLK2 shRNA vectors caused substantial reduction of PLK2 message levels (by as much as 64%) and a parallel reduction of p-Ser-129 α-synuclein (as much as 78%). No effect was observed on PLK3 mRNA or total α-synuclein levels, and there was no cellular toxicity detected (7.5 nm) were added in the same reaction volume of buffer C (25 mm Hepes, pH 7.5, 0.8 m KF, 66 nm EDTA, 0.1% bovine serum albumin), and fluorescence intensity was measured. Uniform phosphorylation of the p-Ser-129 α-synuclein standard was confirmed by reverse phase-high pressure liquid chromatography and mass spectroscopy. The p-Ser-129 α-synuclein standard curve was obtained under the same conditions as for measurement of assay samples, without kinase. Unphosphorylated α-synuclein was added to keep the total synuclein constant at 33 nm. For so that almost all of the activity could be attributed to the transfected kinase. Good agreement was observed between inhibitor potencies in the presence and absence of overexpressed PLK2. In the absence of kinase transfection, the maximum inhibition of p-Ser-129 α-synuclein was around 60%. The remainder may be due to an additional kinase in these cells. BI2536 was used to validate the role of PLK family members in α-synuclein phosphorylation in vivo. Mice were dosed intravenously with BI2536, the brains were collected, and the levels of total\n",
            "[0.64122844]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List symptoms of 4H leukodystrophy.\n",
            "Refined Query: Describe the common symptoms of 4H leukodystrophy, focusing on their typical progression and presentation in affected individuals.  Provide a concise overview.\n",
            "\n",
            "Combined Answer: (550 iu/l; normal value < 200 iu/l). Normal early motor milestones were reported and no muscular dystrophy was ever reported in the family. His neurological examination was entirely normal at 15 years of age. Muscle biopsy showed slight fiber size variability (Supplementary Fig. 1a), and in some sections an increased number of central nuclei along with some densely stained hypercontracted fibers. Immunofluorescent analysis using a C-terminal antibody showed the presence of dystrophin at the membrane (Supplementary Fig. 1b) that western blot 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI may be confirmed by future neuropathologic studies. The paucity of white matter and leukomalacia reported on some MRI studies in the setting of developmental regression may also indicate axonal loss specifically. In this study, as in prior studies2, 14, 15, we report a high rate of prior diagnosis of AS (43%). Additionally, patients met symptom criteria of AS (93%) upon direct examination. The likeness of CS to AS is not apparent in all participants and the rate of NHE6 mutations in AS remains to be determined and may be low.13 Of 59 patients Duchenne muscular dystrophy (DMD), an X-linked recessive condition, is a rare genetic disorder caused by the absence of functional dystrophin proteins due to gene mutations [1]. The incidence of DMD is approximately 1 in 5000 male newborns [2]. Affected boys initially exhibit progressive muscle weakness of the lower proximal extremities [3]. The gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and We studied semiquantitatively three DAPC proteins, each one representative of one subcomplex of the DAPC, in four DMD patients, who received a single intramuscular (i.m.) administration of AVI-4658 at the higher dose of 0.9 mg. From the five patients treated at the higher dose, two with a missing nNOS-binding domain (carrying a deletion of exons 45–50) and two (carrying a deletion of exons 48–50) with an intact nNOS-binding domain in dystrophin, were selected for the study. All four patients demonstrated increased dystrophin expression after Three patients had clinical symptoms and EEG findings suggestive of Lennox-Gastaut Syndrome according to the information available (Figure 3A). Patient 1 had tonic, tonic-clonic, myoclonic and clinical absence seizures and an EEG reporting 2–4 Hz slow spike-wave. Patient 6 had generalized tonic-clonic seizures and drop seizures as well as focal motor features with some seizures; the EEG showed bilateral frequent semi-rhythmic slow spike-and-wave discharges. Patient 11b had generalized seizures, in the form of tonic seizures and drop attacks, start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, but myoclonic, partial, and absence seizures also occur.3 Neurological involvement—apart from the epilepsy, intellectual disability, and profound sensorineural hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a dystrophin expression in DMD boys receiving i.m. treatment with SSOs. In particular we observed a significant increase in the sarcolemmal expression of BDG and ASG expression after a single i.m. injection of the PMO AVI-4658 in all four patients studied (Figure 3). Importantly, nNOS expression was also significantly restored at the sarcolemma (Figures 2 and 3) but to a greater extent in patients with a deletion of exons 48–50 (33% increase), compared to patients with deletion of exons 45–50 (2% increase). The differences in sarcolemmal nNOS earlier images did not include that anatomical site. During the 4-year period, patient self-assessments indicated that mobility was not restricted before or during treatment for any patient, and no patient experienced a clinically significant change in bone pain. No new bone crises were reported. of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI (particularly after age 10). Low weight and cerebellar atrophy are key features, particularly with age, that distinguish CS from AS due to 15q11 locus anomalies. Another possible distinguishing feature is that epilepsy in AS may not occur in 100% of patients25, 28 whereas in CS, as the data currently stand, epilepsy occurs in all patients. Additional\n",
            "[0.49545914]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the extracellular core \"matrisome\"?\n",
            "Refined Query: What is the composition and function of the extracellular matrix (ECM) component known as the matrisome?  Specifically, what types of proteins (collagens, glycoproteins, proteoglycans) comprise it, and how does it contribute to tissue structure and cellular behavior?\n",
            "\n",
            "Combined Answer: (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton immediately beneath the sarcolemma. Regarding its important structural role, dystrophin connects the subsarcolemmal F-actin cytoskeleton to β-dystroglycan (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the binding site for actin is located at the N terminus.3 Second the rod domain contains 24 triple helical spectrin repeats with 4 interspersing hinge domains. Third, the cysteine-rich domain required for binding to BDG4,5,6 and fourth, the c-terminal domain that contains the syntrophin7 and dystrobrevin-binding sites8. The cysteine-rich domain consists of complex (DAPC),3 composed of three subcomplexes: (i) the sarcoglycans (α, β, γ, and δ), (ii) syntrophin, nNOS, and dystrobrevin, and (iii) BDG and α-dystroglycan. The absence of dystrophin and destabilization of the DAPC is thought to render muscle cells susceptible to stretch-induced damage and increased intracellular calcium influx, leading to a series of pathological processes responsible for skeletal and cardiac muscle fiber necrosis,9 inflammation and replacement of muscle with fibro-adipose tissue. Regarding the signaling function, version48,49. Although results with such constructs show that absence of ABD2 does not completely abrogate binding of dystrophin to actin, it is unlikely that absence of ABD1 completely disrupts the interaction between dystrophin and actin. Expression of transgenes deleted for ABD1 lessens the mdx phenotype and restores the costameric pattern of the M band and Z lines, suggesting that the link between dystrophin and the subsarcolemmal cytoskeleton involves more than an interaction with ABD150,51. In agreement with this, other members of the preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the extracellular matrix (Brieher and Yap, 2013; Ratheesh and Yap, 2012). We would like to thank Michael Reubens for plasmid construction and consultation on the manuscript, Catherine Gouge for assistance with the EdU incorporation studies, Tom Fink of the ECU Imaging Core for help with the SEMs. Denise Mayer of the ECU Core Genomics Facilities, East Carolina University for start-up funds, and the NIH (1R15GM093328-01) awarded to T.W.C. that all of the above proteins form a very large assembly called the replisome progression complex or RPC (Gambus et al, 2006). The RPC only exists during S-phase, occurs on chromatin, requires the prior loading of MCM2-7 at origins during G1-phase, and persists for as long as DNA replication forks are still present when nucleotide production is inhibited (Gambus et al, 2006). It thus appears that the RPC represents the fraction of MCM2-7 helicase that is present at DNA replication forks and is therefore likely to be a key component of the constructed using an automated tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). The array blocks were cut into 5-μm sections, and the sections were stained with hematoxylin and eosin to verify the presence of tumor cells. In all cases, tissue cores obtained from normal adjacent tissue served as internal controls. but, in eukaryotes, were previously thought to be restricted to choanoflagellate and sponge proteins (Pfam accession: PF00963) (Abedin and King, 2008; Nichols et al., 2012; Peer et al., 2009). These are not to be confused with the cohesin complex that regulates the separation of sister chromatids. Rather, cohesin domains are highly specialized protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria three sheets. Two of these sheets (composed of seven strands) contribute the immunoglobulin-like core of BIG domains. These seven strands are labelled ‘a’ to ‘g’ in Figure 1 and Supplementary Figure S3, following an established convention in the immunoglobulin fold (Bork et al., 1994). BIG domains have been described with diverse functions, usually relating to matrix, protein–ligand, or protein–protein interactions and are mainly extracellular (Mei et al., 2015; Ptak et al., 2014). Close 3D proximity and evolutionary conservation of four\n",
            "[0.5136111]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is GAGA associated with nucleosome-free regions (NFR)?\n",
            "Refined Query: Does the genomic distribution of GAGA factor binding sites show a statistically significant enrichment or depletion in nucleosome-free regions compared to nucleosome-occupied regions of the genome?\n",
            "\n",
            "Combined Answer: or related to this canonical Zld-binding site (Supplemental Table 1; ten Bosch et al. 2006; Liang et al. 2008; Harrison et al. 2011; Nien et al. 2011; Struffi et al. 2011). However, for the constitutively open Zld-bound peaks, there was a strong enrichment for GAGA motifs (Fig. 6B; Supplemental Table 1), suggesting that these regions may be occupied by GAGA factor (GAF; encoded by the gene Trithorax-like [Trl]) in addition to Zld (Wilkins and Lis 1997). Importantly, GAF binding is strongly correlated with chromatin accessibility, and GAGA of a pioneer factor. Unexpectedly, chromatin at a large subset of Zelda-bound regions remains open even in the absence of Zelda. The GAGA factor-binding motif and embryonic GAGA factor binding are specifically enriched in these regions. We propose that both Zelda and GAGA factor function to specify sites of open chromatin and together facilitate the remodeling of the early embryonic genome. by GAGA factor (GAF; encoded by the gene Trithorax-like [Trl]) in addition to Zld (Wilkins and Lis 1997). Importantly, GAF binding is strongly correlated with chromatin accessibility, and GAGA motifs are enriched in HOT regions (Lu et al. 1993; Kvon et al. 2012; Slattery et al. 2014). Because GAF-binding motifs are known to be enriched at promoters, it was possible that the identification of GAF-binding motifs in constitutive, Zld-bound peaks was a function of the fact that 39% of these peaks were in promoter regions compared with only 18% for regions had GAGA motifs in comparison to none of the differential, Zld-bound intergenic peaks (P < 10−8). These analyses demonstrate that the GAF-binding motif is specifically enriched in the constitutive, Zld-bound regions independently of where in the genome these peaks are located. Consistent with this sequence enrichment, GAF binding, as assayed by ChIP-seq in 0- to 8-h embryos (Negre et al. 2011), is enriched in those regions that are constitutively accessible and bound by Zld (constitutive, Zld-bound). Specifically, 52% (796/1537) of the differential, Zld-bound peaks for promoters, intergenic regions, intronic regions, and coding regions. We found that in all cases there was a significant enrichment of the GAF-binding motif in the constitutive, Zld-bound peaks. This enrichment was most significant at the intronic and intergenic peaks. Comparing GAGA motif enrichment in constitutive versus differential Zld-bound FAIRE peaks, we demonstrated that at intronic regions, 62% of constitutively accessible Zld-bound regions contained GAGA motifs, while only 25% of the introns that of regulatory elements to determine the role of Zelda in regulating regions of open chromatin in the early embryo. We demonstrate that Zelda is essential for hundreds of regions of open chromatin. This Zelda-mediated chromatin accessibility facilitates transcription-factor recruitment and early gene expression. Thus, Zelda possesses some key characteristics of a pioneer factor. Unexpectedly, chromatin at a large subset of Zelda-bound regions remains open even in the absence of Zelda. The GAGA factor-binding motif and embryonic GAGA factor ATAC-seq high-resolution regulatory nucleosome maps can be used to understand the relationship between nucleosomes and DNA binding factors. Using ChIP-seq data, we plotted the position of a variety of DNA binding factors with respect to the dyad of the nearest nucleosome. Unsupervised hierarchical clustering (Figure 3e) revealed major classes of binding with respect to the proximal nucleosome, including 1) a strongly nucleosome avoiding group of factors with binding events stereotyped at ~180 bases from the nearest nucleosome dyad (comprising versus differential Zld-bound FAIRE peaks, we demonstrated that at intronic regions, 62% of constitutively accessible Zld-bound regions contained GAGA motifs, while only 25% of the introns that depended on Zld for accessibility (differential, Zld-bound) contained the motif (P = 10−15). In intergenic regions, 20% of constitutively accessible Zld-bound regions had GAGA motifs in comparison to none of the differential, Zld-bound intergenic peaks (P < 10−8). These analyses demonstrate that the GAF-binding motif is specifically enriched in the billion reads) assays all nucleosomes, whereas reads generated from ATAC-seq (198 million paired reads) are concentrated at regulatory nucleosomes (Fig. 3b,c). Using our nucleosome calls, we further partitioned putative distal regulatory regions and TSSs into regions that were nucleosome free and regions that were predicted to be nucleosome bound. We note that TSSs were enriched for nucleosome free regions when compared to distal elements, which tend to remain nucleosome rich (Fig. 3d). These data suggest ATAC-seq can provide high-resolution We note that TSSs were enriched for nucleosome free regions when compared to distal elements, which tend to remain nucleosome rich (Fig. 3d). These data suggest ATAC-seq can provide high-resolution readout of nucleosome associated and nucleosome free regions in regulatory elements genome wide.\n",
            "[0.687255]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the plant DNA (cytosine-5) methyltransferase families?\n",
            "Refined Query: I'm interested in learning about the different families of plant enzymes that catalyze the methylation of cytosine at the 5 position.  Specifically, what are the known classifications of these plant DNA methyltransferases?\n",
            "\n",
            "Combined Answer: KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Jacobsen, 2010). The plant specific DNA methyltransferase CHROMOMETHYLASE 3 (CMT3) binds to H3K9me2 and methylates cytosine residues at CHG sites (where H is A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2), and the recently discovered CHROMOMETHYLASE 2 (CMT2) perform methylation in CHH contexts (Haag and Pikaard, 2011; Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry methylation are absolutely essential for plant life, although each pathway on its own is dispensable. The lethality observed in mutants deficient for both pathways likely results from a lack of heterochromatin integrity, which could impact cell division. In response to H2A.W depletion, we also observe a cross talk between these pathways as both CMT3 expression and CHG methylation increase in heterochromatin. In vitro micrococcal nuclease digestion data showed that nucleosomes containing H2A.W protect a longer stretch of DNA (162 bp) than for methylation (−792 to −64 from TSS), and Fw: 5′-aggttggagtgtagtggagtaattat-3′ and Re: 5′-caacacattaaaaaaccaaaacaaa-3′ for unmethylation (−793 to −63 from TSS). The products were analysed by agarose gel electrophoresis. visualized as dense structures called chromocentres by DAPI staining (Fransz et al., 2006). In Schizosaccharomyces pombe and mammals, heterochromatin is demarcated by histone H3 lysine 9 methylation (H3K9me3) (Jenuwein and Allis, 2001). Similarly, in Arabidopsis, heterochromatin is marked by H3K9me2, which is deposited by the histone methyltransferases KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry out diverse chromatin functions including transcription, DNA repair, and chromosome segregation (Bönisch and Hake, 2012; Millar, 2013; Szenker et al., 2011; Talbert and Henikoff, 2010). The vast majority of known histone variants are homologs of H2A and H3 histones. A phylogenetic analysis of histone families supports the notion that genes encoding chromocenters, indicating that H3K9me2 deposition does not require H2A.W (Figure S3B). The independent colocalization of H2A.W and H3K9me2 prompted us to examine the genetic interaction between these two marks of heterochromatin. In the H3K9 methyltransferase mutant kyp (Figure S3C), H3K9me2 is reduced but does not show a significant effect on plant growth (Jackson et al., 2002) as SUVH5 and 6 also contribute to H3K9me2 (Bernatavicute et al., 2008; Malagnac et al., 2002). We found that simultaneous mutation of KYP and H2.A.W in h2a.w.6, our method. Therefore, the use of 4D-CHAINS allows near-complete assignment of sidechain methyls without the need for site-specific labeling on a perdeuterated background33 (Supplementary Table 4). Second, autoNOE-Rosetta uses a highly parallelizable iterative algorithm run on a computer cluster to perform assignment of long-range NOEs alongside the structure determination process. The full pipeline takes approximately 10–12 days to execute for a typical protein sample, including the time needed for NMR data acquisition, and requires minimum methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of genes found to be aberrantly methylated in a wide variety of tumors [15-18], and epigenetic silencing of these genes has also been reported in NSCLC [19-22]. The great majority of DNA methylation studies are concentrated on the analysis of CpG islands located in the promoter areas of pre-selected genes. However, differentially methylated areas may be we look at protein-coding genes, we provide evidence that most of the promoter regions have differentially enriched histone-modification sites. Recently, the ChIPnorm approach has also been used to study histone methylation changes associated with leaf senescence in Arabidopsis [30]. Our approach is not restricted to the identification of differentially enriched sites nor is it limited to pairwise comparisons. A natural next step, therefore, is to apply it to more complex data (multiple cell types with multiple histone modifications, for\n",
            "[0.6986716]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 655.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 731.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is Genomicus?\n",
            "Refined Query: What exactly is Genomicus, and what is its purpose?  Is it a database, a software tool, or something else entirely?  What kind of genomic data does it handle, and how is it used in research or practical applications?\n",
            "\n",
            "Combined Answer: The functional units within GenomeVIP collectively implement variant analysis of genomic data (Fig. 2). They encompass sets of public tools most trusted and most often relied upon by investigators for their respective tasks. easily run tools like TREVA (Li et al. 2014), TOGGLE (Monat et al. 2015), HugeSeq (Lam et al. 2012), GotCloud (Jun et al. 2015), or Churchill (Kelly et al. 2015). Many systems also have more subtle aspects of designing a calculation, for example, manually discretizing genomic regions for parallelization (Afgan et al. 2010). GenomeVIP enables complete specification of job execution entirely by web-interface menu prompting, making it easier for users without considerable bioinformatics experience to undertake genomic analyses. as a free command-line tool as well as a library in C, Java, Perl and Python. It is particularly useful for manually examining local genomic features on the command line and enables genome viewers to support huge data files and remote custom tracks over networks. Availability and Implementation: http://samtools.sourceforge.net. Contact: hengli@broadinstitute.org to provide easy access to genomic regions of interest. The table browser enables data manipulation, downloads of multiple records and basic statistical analyses, which cannot be performed with the genome browser function. To visualize DNA shape annotations the user clicks on ‘Genome Browser’ in the navigation bar on the left of the GBshape homepage. On the Genome Browser Gateway page the user chooses an organism group, species genome, genome assembly, genome position and search terms of interest. After the ‘submit’ button is pressed, The functionality of GenomeVIP is provided through coordination among three central components: the user's web browser, the GenomeVIP server, and a cloud-computing resource (Fig. 1). The GBshape interface runs on a Linux-operated dual-core IBM server with Apache. GBshape consists of two major tools—a genome browser and a table browser. The genome browser provides a graphical representation of DNA shape annotations along with standard genome browser annotations. The genome browser also supports text and sequence search functions to provide easy access to genomic regions of interest. The table browser enables data manipulation, downloads of multiple records and basic statistical analyses, which cannot be performed with the sources, construction, and genome availability for all included annotations are provided in Supplementary Methods and Supplementary Table S1. The annotatr package consists of four modules that read, annotate, summarize and visualize genomic regions. The read module reads a BED6+ file, defined as BED6 and any number of numerical or categorical data columns (Supplementary Table S2). The annotate module reports the overlap of all input regions with all intersecting genomic annotations selected by the user, with a user-defined threshold overlap prediction platform was designed to be extendable by plug-ins of other whole-genome annotation programs (Figure 1). The results of high-throughput prediction programs are converted to the bigWig data format, which can be displayed in a genome browser. The platform was developed in C++ and runs on a high-performance computing cluster (HPCC). The GBshape database combines DNA shape data with standard UCSC Genome Browser annotations (19) and whole-genome sequence data. The sequences of 91 genomes (Supplementary Table S1) and corresponding meta data in tab-delimited attribute-value pair format, is released, and periodically updated at ftp://bioinf.iasi.cnr.it/. The availability in BED and in other supported standard formats (i.e., CSV, GTF, JSON, XML) of public genomic TCGA data permits to straightforwardly take full advantage of these very valuable data by reducing the time to be spent in managing them, and allows their seamless integration and comprehensive processing with available bioinformatics tools, such as GMQL. This possibility to globally consider genomic, epigenomic Associating regions of interest to genomic annotations is a standard part of many bioinformatics pipelines. The annotatr package improves upon existing annotation tools by returning all the genomic annotations associated with a region instead of artificially prioritizing one annotation type over another, giving a clearer picture of the biological complexities at play. In addition to tabular output of the annotations, annotatr's built-in plotting functions provide an easy and flexible way to summarize the annotations and view how data associated\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 379.13ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.58ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 555.48ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the COUGER tool?\n",
            "Refined Query: Can you provide more details about the \"COUGER\" tool?  I'm unfamiliar with this acronym.  Is it software, hardware, a methodology, or something else? Knowing its purpose or field of application would help me understand what it is.\n",
            "\n",
            "Combined Answer: to many implementations of classification algorithms, which provide an accuracy measure but no indication of what features drive the classification. Through its user-friendly and interactive design, the COUGER web tool makes it easy for users to understand and explore the contribution of individual features. with information about the importance of each co-factor feature, and the classification accuracy. Users can run COUGER through a web interface: http://couger.oit.duke.edu, or as a stand-alone Python software tool (available for download on the COUGER website). COUGER web runs under Apache2 (httpd.apache.org) with mod_wsgi on Debian 7.0 ‘Wheezy’ (www.debian.org). It was developed using the Django web framework (www.djangoproject.com), which is written in Python (www.python.org) and thus allowed direct integration with the COUGER source code. Input data is validated using Django forms module features. Also, part of the web functions are implemented with JavaScript and jQuery (jquery.com). each set of features and each type of classifier, COUGER computes median values for accuracy, sensitivity, specificity and precision, which are reported in separate files. In addition, it shows the classification accuracy (the fraction of true positives and true negatives in the test set) in a user-friendly format (Figure 2A). COUGER performs binary classification. The two classes are the DNA sequences under the ChIP-seq peaks for two paralogous TFs (TF1 and TF2), which the user can specify either in FASTA format or, for convenience, directly with ChIP-seq peak coordinates in ENCODE narrowPeak format, ENCODE broadPeak format, or even BED format. TF1- and TF2-specific sequences are defined by excluding the ChIP-seq peaks that overlap any peak of the other TF (Figure 1, Step 1). In order to avoid a potential classification bias toward one of the two classes, an equal COUGER takes as input two sets of genomic regions bound by (paralogous) TFs. Each set is specified in a separate, uncompressed file. Users can submit these files either in ENCODE narrowPeak format, ENCODE broadPeak format, BED format or in FASTA format. If the user provides FASTA files, COUGER will consider that the classes are predetermined and will start with Step 2 (Figure 1), so only the nucleotide sequences will be read (we note that in the absence of genomic coordinates, it is much harder and time-consuming to identify the overlapping COUGER uses support vector machine (SVM) (7) and random forest (RF) (8), two state-of-the-art classification algorithms with free software packages: LIBSVM (9) and Random Jungle (10). Both algorithms are highly accurate, can successfully handle high-dimensional data and are robust on data with highly correlated features. SVM is a non-probabilistic binary linear classifier with great performance on both linear and nonlinear classification problems. RF is an ensemble of multiple classification trees, which explicitly computes a measure of the will start with Step 2 (Figure 1), so only the nucleotide sequences will be read (we note that in the absence of genomic coordinates, it is much harder and time-consuming to identify the overlapping sequences between the two sets). For all other input formats, COUGER will start with Step 1 (Figure 1), removing from each set the sequences that have an overlap with any sequence from the other set. The resulting sets of sequences are reported by COUGER in FASTA format, and can be used to rerun the algorithms using different settings, such as of unique targets exceeds the threshold, then COUGER will run using only the top N sequences. These limitations do not apply to the stand-alone version of our framework. COUGER also requires a set of features that reflect the DNA binding specificities of putative co-factors. The current version of the web server offers six choices of such features for human and mouse data: ‘PBM data from UniPROBE’ (i.e. PBM 8-mer E-scores for 429 mammalian TFs from the UniPROBE database (12)), ‘PWMs from UniPROBE’ (i.e. PWMs derived from PBM data in UniPROBE of the putative co-factors. The identified co-factors are presented in a user-friendly output page, together with information that allows the user to understand and to explore the contributions of individual co-factor features. COUGER can be run as a stand-alone tool or through a web interface: http://couger.oit.duke.edu.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.90ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 581.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.06ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.61ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 509.16ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 733.07ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.31ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.76ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 682.51ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 705.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the gene MAOA epigenetically modified by methylation?\n",
            "Refined Query: Does methylation, a key epigenetic mechanism, alter the expression of the monoamine oxidase A (MAOA) gene?  This explores whether environmental factors influence MAOA activity through DNA methylation changes, impacting its role in neurotransmitter metabolism.\n",
            "\n",
            "Combined Answer: or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can has been observed previously in gene expression profiling studies [4,46]. Remarkably, the majority (>75%) of the hypermethylated genes present in all seven samples encoded for transcription factors, while the shared hypomethylated genes were spread among many different functional categories. Transcription factors play a central role in maintaining or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely tissues [7,9]. DNA methylation is a very stable epigenetic mark and next generation sequencing studies have recently shown that many genes are aberrantly methylated in cancer [10,11]. Tissue specific DNA methylation patterns are stabilized during embryonic development, and faithfully maintained through cell divisions [12-14]. Nevertheless, established methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of over TEs and regions enriched in H3K9me2, while DNA methylation over gene bodies was not affected (Figure 4A). A notable up-regulation of the expression of CMT3 encoding the primary CHG DNA methyltransferase likely accounts for the increase in CHG methylation (Figure 4B). DNA methylation at CG and CHH sites was not significantly affected, suggesting a specific association of H2A.W with CHG methylation (Figure 4A). These results suggested the possibility that increased CHG methylation may compensate for the lack of H2A.W, resulting in in the genome browsers. This broad view of DNA methylation in NSCLC will provide new opportunities for the identification of specific epigenetic markers of NSCLC that could, for instance, be used for early detection of the disease. The occurrence of methylated CpGs in the fragments selected for bisulfite sequencing showed a high quantitative correlation with the reads found by MethylCap-seq in the same area. In conjunction with the MethylCap-seq data on the fully methylated and fully unmethylated controls, this demonstrates that MethylCap-seq KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Jacobsen, 2010). The plant specific DNA methyltransferase CHROMOMETHYLASE 3 (CMT3) binds to H3K9me2 and methylates cytosine residues at CHG sites (where H is A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS significantly by the absence of CMT3, the factor that methylates cytosine residues in CHG contexts at heterochromatic loci marked by H3K9me2 (Figure 2B). Since H2A.W localization does not depend on H3K9me2 or the associated CHG methylation, we tested the influence of other pathways responsible for DNA methylation. The loss of the de novo DNA methyltransferase DRM2 did not affect H2A.W nor heterochromatin organization (Figures S2G – S2I). In contrast, heterochromatin was partially dispersed in the absence of the CG methyltransferase MET1 or the Carcinogenesis involves changes in gene expression that results in tumor specific gene and protein signatures. Such signatures have been used to classify different subtypes of cancers. Gene expression is partly regulated by the methylation state of CpG islands. Cancer tissue is characterized by an increased variability in DNA methylation patterns. DNA methylation profiling has been reported as a robust method to classify and subgroup tumors of different origin [1]. For most pediatric brain tumor diagnoses, methylation profiling can divide the with matched healthy lung tissues; the average correlation coefficient between the two was 0.83, indicating a generally high similarity in the methylation patterns of the matched tumor and lung samples (Figure 2B and Additional file 6). Collectively, these analyses establish the high reproducibility and specificity of the MethylCap-seq procedure that we used. To allow visual inspection of the methylation signal and DMRs, raw reads and log P-values of differential methylation were uploaded in the University of California, Santa Cruz (UCSC) methylation as an epigenetic regulatory mechanism. However, our data also reveal a high degree of hypermethylation outside promoter areas at intergenic regions, and at long distances from genes. This indicates that patterns of DNA methylation may play a role not only by silencing promoters of key tumor suppressor genes, but also by regulating gene expression in a more complex manner through distant regulatory elements such as insulators and enhancers. We found that satellite regions were particularly hypomethylated in the NSCLC tumors when\n",
            "[0.68672025]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which mutations of phopspholamban have been found in patients with cardiomyopathy?\n",
            "Refined Query: Investigate the specific phospholamban gene mutations identified in cardiomyopathy patient populations.  Detail the prevalence and phenotypic effects associated with these mutations, considering the various types of cardiomyopathy.\n",
            "\n",
            "Combined Answer: importance of disease and gene-specific annotations. CardioClassifier identified putatively disease-causing variants in 33.7% of 327 cardiomyopathy cases, comparable with leading ICC laboratories. Through addition of manually-curated data, variants found in over 40% of cardiomyopathy cases are fully annotated, without requiring additional user-input data. After manual curation of the literature and ClinVar for reports of segregation, de novo occurrence and functional characterisation, 34 variants were classified as Pathogenic, 13 as Likely Pathogenic and 7 as VUS (Supplementary Table 5; Supplementary Figure 4b). The annotations for these 120 variants, accounting for at least 40% of variants identified in Caucasian cardiomyopathy cases, are stored in CardioClassifier, ensuring these variants are correctly classified without further user-input. Inherited cardiac conditions (ICCs) represent a major health burden with a combined prevalence of ~1%1. Genetic testing is recommended to support the management of many ICCs, with roles in diagnosis (particularly valuable for identification of at-risk relatives), prognostication, and therapeutic stratification. The principle challenge in genetic testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants (TTNtv) in exons constitutively expressed in the heart are robustly associated with DCM15. Additionally, it is unclear that the mechanism of action for these variants is truly loss of function (LoF). Instead of scoring all TTNtv equally and assuming an underlying LoF mechanism, we only score TTNtv highly if they are in constitutive exons (proportion CardioClassifier provides a simple-to-use web interface that takes as input either individual variant details or a single sample VCF (Supplementary Figure 1). Users select one of 11 cardiac disorders, and this determines which pre-specified validated disease genes are analysed. Where a diagnosis is uncertain (e.g. sudden cardiac death or complex cardiomyopathy), a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also for the major cardiomyopathies; HCM, DCM and ARVC, defined as those occurring six or more times in the ACGV resource (reflecting a HCM case frequency of ~1/1000)9. There were 84 such recurrent variants in ACGV, together representing 39.5% (1,258/3,186) of all identified variants. We curated 63 that had not already been assessed by the expert panel. After manual curation of the literature and ClinVar for reports of segregation, de novo occurrence and functional characterisation, 34 variants were classified as Pathogenic, 13 as Likely Pathogenic a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. Details of the key features of CardioClassifier can be found in Table 2. Each variant is annotated for up to 17 computational criteria, with results output to a grid representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary detect even with targeted investigation, as they often manifest later in life and exhibit incomplete penetrance. We have therefore modified PM2 so as not to inappropriately discard variants seen at very low frequencies in these reference datasets. In addition, we have created extensions to three ACMG/AMP rules, to enhance interpretation of ICC variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and were inherited from an asymptomatic parent each time it could be tested. Subsequently, PHOX2B has been identified as the major disease causing gene in CCHS with a heterozygous de novo mutation in over 90% of the cases.11,23,24 Frameshift and missense mutations lying in the homeodomain of the protein are rare (11% in this series, fig 1) and\n",
            "[0.67710793]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the supplemental antioxidant in athletes?\n",
            "Refined Query: What supplemental antioxidants, beyond those obtained through a balanced diet, are commonly used by athletes to combat exercise-induced oxidative stress and potentially improve performance or recovery?\n",
            "\n",
            "Combined Answer: physiologic ability to exercise (e.g., bronchodilators) (42) and may be less responsive than a constant work rate exercise test (43). Fourth, gain in muscle mass may be a necessary but not sufficient condition for the delivery of improvements in whole-body exercise performance. Studies of isolated high-intensity training in COPD have shown that mitochondrial bioenergetic capacity can improve without mass gains (44), and it may be that concurrent exercise is required to demonstrate improved exercise capacity. Fifth, although we stratified by mitochondrial bioenergetic capacity can improve without mass gains (44), and it may be that concurrent exercise is required to demonstrate improved exercise capacity. Fifth, although we stratified by low muscle mass, we might have obtained greater focus on the population of interest had we made recent weight loss an inclusion criterion; however, unlike (for example) patients with cancer cachexia, most patients with COPD are not managed in secondary or tertiary care, so obtaining accurate sequential weight measures is difficult. An interesting data did not support any benefits on exercise performance (33). Casaburi and coworkers randomized 47 men to a four-way trial of testosterone against placebo with and without exercise training (34). Although the treatment group gained 2.5 kg of LBM over placebo, the use of testosterone without exercise training increased strength but not endurance exercise performance (34). Similar results were obtained by Yeh and colleagues, in an uncontrolled study (35), and by Ferreira and colleagues (36). Similarly, a small (n = 16) randomized study of Several prior interventions have attempted to improve functional performance in COPD by increasing skeletal muscle mass. Schols and colleagues performed a large three-way trial of nutrition with and without nandrolone, an anabolic steroid (33). They found that the nutrition plus nandrolone group gained LBM (mean, 1.6 kg vs. placebo), but the available data did not support any benefits on exercise performance (33). Casaburi and coworkers randomized 47 men to a four-way trial of testosterone against placebo with and without exercise training Oxidative stress—an imbalanced state of excessive production of reactive oxygen species (ROS) and diminished ROS scavenging ability in the cell—causes damage to cellular components. While all bio-molecules are prone to oxidative damage, proteins are particularly vulnerable and critical targets because most of the cellular functional-biomass is proteins (de Graff et al., 2016). Mild oxidative stress may cause simple oxidation/hydroxylation like reversible oxidation of methionine to methionine sulfoxide. However, more sustained/severe stress proteins (de Graff et al., 2016). Mild oxidative stress may cause simple oxidation/hydroxylation like reversible oxidation of methionine to methionine sulfoxide. However, more sustained/severe stress leads to carbonylation—an irreversible oxidative protein ‘damage’—a chemically diverse form of oxidative post-translational modification (PTM) wherein the side-chains of various amino acids are modified to diverse aldehydes, ketones, lactams and conjugates of advanced glycation (or lipid-peroxidation) end-products (AGEs/ALEs; Møller et al., 2011). exercise performance (34). Similar results were obtained by Yeh and colleagues, in an uncontrolled study (35), and by Ferreira and colleagues (36). Similarly, a small (n = 16) randomized study of growth hormone as an adjunct to rehabilitation demonstrated an LBM gain of slightly greater than 1 kg in favor of the treatment group without an improvement in exercise performance (37). Conversely, the appetite-stimulating hormone ghrelin, used as an adjunct to pulmonary rehabilitation, resulted in an increased 6MWD in a small randomized controlled in exercise performance (37). Conversely, the appetite-stimulating hormone ghrelin, used as an adjunct to pulmonary rehabilitation, resulted in an increased 6MWD in a small randomized controlled trial, although without a change in overall body weight, compared with placebo (38). Taken together with prior reports, the current data indicate that anabolic agents in isolation do not, in unselected patients with COPD, translate increased muscle mass into superior exercise performance. Although the anabolic response seen in this study was positive, between treatment arms. In fact, bimagrumab was proven effective in recovery from atrophy in animal models of steroid exposure (17), and a high likelihood of intercurrent exacerbation is not itself a barrier to anabolic drug therapy. A key rationale for this study was that myostatin levels are increased in the most disabled patients with COPD and tend to decrease with strength training. We acknowledge, however, that our study design would have been stronger if we had ensured that the participants had elevated skeletal muscle myostatin before agents in isolation do not, in unselected patients with COPD, translate increased muscle mass into superior exercise performance. Although the anabolic response seen in this study was positive, there are several possibilities why muscle-mass gains did not improve exercise performance in the population, and these may be insightful for the planning of future trials, given that other anabolic agents are emerging (39). First, in a proportion of patients with COPD, the basis of exercise limitation is breathlessness rather than skeletal muscle\n",
            "[0.56420505]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is glycyl-tRNA synthetase gene involved in the development of Charcot-Marie-Tooth disease?\n",
            "Refined Query: Investigating a potential link between mutations in the glycyl-tRNA synthetase gene and the pathogenesis of Charcot-Marie-Tooth disease requires exploring whether its dysfunction disrupts axonal protein synthesis or mitochondrial function, key factors in CMT development.\n",
            "\n",
            "Combined Answer: Charcot-Marie Tooth disease (CMT) forms a clinically and genetically heterogeneous group of disorders. Although a number of disease genes have been identified for CMT, the gene discovery for some complex form of CMT has lagged behind. The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but Inherited neuropathies are the most common genetic neurological disorders and affect ∼1 in 2500 individuals.1 Charcot–Marie Tooth (CMT) includes a group of hereditary disorders in which motor and sensory neuropathy is the sole or primary part of the disease. CMT is traditionally classified into two types based on electrophysiological and neuropathological criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and observed homology between CTF18 and RFC1 and the in vitro interactions observed between Ctf18p-9myc, Rfc3p, and Rfc4p. Interestingly, it has been demonstrated that RAD24, another RFC1 homolog, can also form a complex with the small RF-C subunits to facilitate alternative functions (31, 85). Early purification methods for generating a biochemically defined RF-C complex (promoting PCNA association with DNA) involved a variable species that migrated near the predicted molecular weight of Ctf18p. Therefore we analyzed an active purified fraction This work describes a mutation in the C12orf65 gene that causes recessive form of CMT6 and confirms the role of mitochondrial dysfunction in this complex axonal neuropathy. respiration rate and the reduction in mitochondrial membrane potential point to a global and uniform mitochondrial respiration dysfunction, consistent with other reports describing loss of function mutations in C12orf65 gene.17 CMT6 is a combination of two clinical processes caused by defective mitochondrial function that leads to axonal neuropathy and optic atrophy. The three genes identified in CMT6 confirm this and the phenotype is variable, a frequent finding in mitochondrial disorders. Overall CMT highlights the link between the axon and 183 patients. None of the patients harboured potentially pathogenic variants. To determine whether the truncating mutation induced mRNA nonsense-mediated decay, we tested the level of expression of C12orf65. This analysis showed that level of the C12orf65 mRNA was not reduced in the patients’ cells versus controls (data not shown). C12orf65 is a nuclear gene that encodes a mitochondrial matrix protein that appears to contribute to mitochondrial translation. Nonsense mutations in this have been found in patients with a mitochondrial disease strain. Interestingly, the results of previous experiments that used a proficient strain in the GO prevention system and examined the accumulation of His+, Met+, and Leu+ reversions showed that while most of the Met+ revertants were also His+, only less than 10% of His+ revertants were Met+ (41). This suggests that tRNA genes, particularly those for lysine and glutamine, are prone to oxidative damage. Even more interesting are the observations that deficiencies in the oxidative-damage prevention system affected the rate of the mutations to the tRNA gene rather than the genes themselves. Each of the four tRNA genes had robust Pfh1 binding compared with the no-tag control strain and the gal1+ gene (Fig. 1A), but Pfh1 binding to tRNA genes was not as high as to the RFBs, RTS1, or act1+ loci (Fig. 1A). We conclude that Pfh1 binds all of the tested sites, although some sites such as the rDNA, the mating type locus, act1+, histone, 5S, and tRNA genes have particularly high binding. and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a clear list of candidate genes to investigate. and optic atrophy. The three genes identified in CMT6 confirm this and the phenotype is variable, a frequent finding in mitochondrial disorders. Overall CMT highlights the link between the axon and mitochondrial dysfunction and suggested that this process is likely to be affected in other forms of acquired axonal dysfunction such as multiple sclerosis and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a\n",
            "[0.5840777]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there any software for automated analysis of FISH images?\n",
            "Refined Query: I need software capable of automating the analysis of fluorescence in situ hybridization (FISH) images.  This should include tasks like identifying and counting fluorescent signals, measuring signal intensity, and potentially classifying different signal patterns.  Are there any such programs available?\n",
            "\n",
            "Combined Answer: of acquisition were applied between the different genotypes. The number and intensity of the all pixels (for each embryo) were measured using the histogram function of the ImageJ Software. The quantification of fluorescence complementation was shown for each condition by boxplot representation using R-Software. Boxplot depicts: the smallest value, lower quartile, median (green line), upper quartile and largest value for each condition. Black points correspond to individual measures. Cerulean and mCherry BiFC signals were taken after identical as described in [62]. The probes were visualized using Fast Red staining (Roche) and the TSA-Kit (PerkinElmer) as in [62]. Imaging of double-fluorescent whole-mount in situ hybridizations was done using a Leica SPE confocal mircroscope with a 10× dipping lens. Images were assembled and processed using ImageJ and Adobe Photoshop. All confocal images displayed are Z-projections of stacks. Brightness and contrast were adjusted uniformly across the entire image. BiFC is a commonly used method in cultured cells and in plants for studying protein interactions. Surprisingly, this method remains rarely used in living animal embryos. In contrast, the visualization method based on fluorescence resonance energy transfer (FRET) has been more thoroughly used in animal models, although it requires complex instrumentation and data processing. FRET analysis is based on energy transfer between two fluorophores placed in close proximity, allowing real time detection of complex formation and dissociation. The USA). In order to quantify the BiFC signals, unsaturated images of ectodermal fluorescence were taken in embryos of the desired stage (with a minimum of 10 embryos by condition) using a LSM510 confocal microscope (Zeiss, Jena, Germany). For Venus fluorescence, filters were adjusted at 500 nm for excitation and 535 nm for emission. Identical parameters of acquisition were applied between the different genotypes. The number and intensity of the all pixels (for each embryo) were measured using the histogram function of the ImageJ Software. The or at 4°C overnight. Alexa Fluor-conjugated anti-mouse or anti-rabbit immunoglobulins (Molecular Probes, Life Technologies) were used as secondary antibodies (1:1000 in PBS/0.1% Triton-X100) and cell nuclei were visualized with DAPI. For RNA-FISH, a commercially available NEAT1 and MALAT1 probes (Stellaris® FISH Probes against human NEAT1 5′ segment and human MALAT1, Biosearch Technologies) was used according to the protocol provided by the manufacturer. Fluorescent images were taken using BX61 microscope (Olympus) and processed using CellF components at very high sensitivity and specificity as illustrated in artificially mixed human-mouse samples. This allows for maximum recovery of data from target tumours for more accurate variant calling and gene expression quantification. Given that no general use open source algorithm accessible to the bioinformatics community exists for the purposes of separating the two species data, the proposed Disambiguate tool presents a novel approach and improvement to performing sequence analysis of grafted samples. Both Python and C++ Invitrogen) was applied for counterstaining. Images from random fields were taken using a Nikon Eclipse E 800 microscope with an attached camera and using Spot Software from Diagnostic Instruments (Diagnostic Instruments). different cancer entities. However, all these tools focus their effort on assembling, analyzing, and visualizing cancer genomic data sets, but do not provide the investigator with a standard and easy accessible format for the TCGA data, which is seamlessly usable for the integration and analysis of these data. Moreover, although also other tools exist to manage and process TCGA data, generally they require programming skills to process the TCGA data, and mainly focus on the analysis and visualization of the most common data types provided by The automatic image segmentation algorithm was developed in the laboratory of Dr. Lin Yang. Evans Blue and H&E stained muscle image quantification contains two steps: 1) Machine learning based automatic detection of the geometric center of the muscle fibers10–12, and 2) a gradient vector field (GVF) snake based automatic segmentation that adopts color image gradients13–15. Briefly, this makes use of (a) machine learning based seed detection, in which image textures (intensity distribution patterns) are used as image features to distinguish RAPIDR is implemented in R and can be freely downloaded via CRAN from here: http://cran.r-project.org/web/packages/RAPIDR/index.html. Contact: kitty.lo@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online.\n",
            "[0.710714]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How do histone methyltransferases cause histone modification?\n",
            "Refined Query: Histone methyltransferases (HMTs) catalyze the addition of methyl groups to lysine or arginine residues on histone tails.  This process, histone methylation, alters chromatin structure and gene expression, impacting various cellular processes.  How precisely do specific HMTs target particular histone residues and influence downstream effects?\n",
            "\n",
            "Combined Answer: (DNMT1, 3A, 3B, 3L) and histone deacetylases (HDAC1 and HDAC2), to target genes (13–15). In addition, SALL4-mediated activation of Bmi-1, another important hematopoietic stem cell gene, involves methylation of lysine 4 of histone H3 (H3K4) at its promoter region (16). Based on recent discoveries, there seem to be various ways of cross-talking between histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone larvae (40). While it has been assumed that the essential function of the PR-Set7 methyltransferase is to monomethylate H4K20, it remains possible that it could target other critical proteins for methylation. Indeed, nonhistone targets of PR-Set7's catalytic activity have been identified in mammalian cells, including p53 (38) and PCNA (39), both of which are critical cell cycle regulators. Recently, McKay and colleagues developed a novel histone replacement system to directly assess the function of specific histone lysine residues in and H3.2) in transcribed regions, and its histone tail is highly enriched for covalent modifications or “marks” associated with transcriptionally active chromatin, such as tri-methylation of lysine 4 (K4me3) (McKittrick et al. 2004; Hake et al. 2006; Loyola et al. 2006). There is also conjecture over whether H3.3 is not just a marker for active regions, but whether it contributes to the transcriptional activity of loci enriched for this histone (Huang and Zhu 2014). This is in part due to its enrichment at regulatory regions such as promoters chromatin and translation. Histone lysine methylation has emerged as an important player in regulating gene expression and chromatin function [14]. K27 is a critical residue in all seven histone 3 variants and the subject of post-translational histone modifications as it can be both methylated and acetylated [2, 14, 20]. Acetylation may induce active transcription, while mono, bi or tri-methylation of K27 is associated with a repressive mark on chromatin and gene expression. Abrogation of acetylation and/or potential mimicry of a methylated this high level of expression, Ndn transcription occurs only from the paternally contributed chromosome, showing that the maternally inherited region is under the control of a potent transcription silencing mechanism (Gerard et al. 1999). We detected enrichment of dimethylated histone H3 at lysine 4 (H3K4me2) and acetylated histone H3 (H3Ac) on the active paternally contributed chromosome (Fig. 1B,C). We obtained a similar distribution for acetylated histone H4 (H4Ac) (Supplemental Fig. S2). The preferential enrichment of these histone marks significantly by the absence of CMT3, the factor that methylates cytosine residues in CHG contexts at heterochromatic loci marked by H3K9me2 (Figure 2B). Since H2A.W localization does not depend on H3K9me2 or the associated CHG methylation, we tested the influence of other pathways responsible for DNA methylation. The loss of the de novo DNA methyltransferase DRM2 did not affect H2A.W nor heterochromatin organization (Figures S2G – S2I). In contrast, heterochromatin was partially dispersed in the absence of the CG methyltransferase MET1 or the to date. The genome-wide histone acetylation data obtained in the same differentiation time-course allowed us to correlate the chromatin status of bystanders, targets and HCNEs with target gene expression. Our hypotheses can be summarized as follows: the apparently different responsiveness of GRB target genes and their immediate neighbors to (long-range) regulatory inputs will be reflected in the absence of correlation in expression between targets and bystander genes; HCNEs acting as enhancers of target genes at a particular point in time and bias; however, our findings support H3.3 as the major histone to be targeted in pediatric GBM and K27 the major residue affected in DIPG. H3.3 is the major histone to be loaded on chromatin during brain development. This histone variant is known to modulate specific chromatin changes and gene expression profiles and to be associated with active chromatin and translation. Histone lysine methylation has emerged as an important player in regulating gene expression and chromatin function [14]. K27 is a critical residue in all seven histone 3 this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. H3K36me3 could thus contribute to the establishment of a transcriptionally unfavorable chromatin conformation by recruiting (and perhaps stimulating) repressive complexes. In conclusion, this study demonstrated that trimethylated histone H3 at lysine 36 is specifically enriched in facultative and constitutive heterochromatin in mouse, and that this histone We recently mapped the location of nine histone modifications at four different developmental times spanning the MZT using ChIP-seq (Li et al. 2014) and demonstrated that acetylation of three different lysines on two different histones (H3K18, H3K27, and H4K8) correlated with Zld binding, especially early in development (Li et al. 2014). Thus we speculated that Zld-mediated chromatin accessibility might correlate with specific histone modifications. To further investigate the connection between chromatin accessibility and early gene expression,\n",
            "[0.73970926]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there an increased risk for cancer in Dyskeratosis Congenita?\n",
            "Refined Query: Dyskeratosis congenita (DC) is a rare genetic disorder.  Given its impact on telomere maintenance and cellular replication,  is there a significantly heightened risk of developing various cancers, and if so, which types are most prevalent among DC patients compared to the general population?\n",
            "\n",
            "Combined Answer: protein induced by exon skipping in the human. The lack of dystrophin in DMD leads to reduced levels of all DAPC proteins and even to the absence of nNOS from the sarcolemma.21,22,23,24,25 The importance of a dystrophin protein containing its functional domains is highlighted by patients with the missense mutation (C3340Y)4,26 within the BDG binding domain that develop a DMD phenotype even though considerable levels of dystrophin staining was visible at the sarcolemma. Another patient harboring a missense mutation (D3335H)27 had dystrophin in vitro leukaemia cell models (Ge et al, 2004; Cai et al, 2008; Song et al, 2009b). In our study, despite its identification as a pivotal key enzyme, dCK was not statistically correlated with DFS (P=0.965) or OS (P=0.852), according to univariate analyses. We also detected no meaningful significance in survival analyses using other candidates. The discrepancy between our results and those of previous studies may be attributable to the specialised role of dCK in the activity of anticancer drugs, and to the fact that other studies have employed discrepancy between our results and those of previous studies may be attributable to the specialised role of dCK in the activity of anticancer drugs, and to the fact that other studies have employed differently subtyped AML populations. Indeed, to screen outcome predictors, other research groups have employed mixed populations of AML patients treated with non-unified regimens, whereas in this study we used more focused populations in the aspect of disease type and chemotherapy regimen. Additionally, our previous in vitro study showing that dCK candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and were inherited from an asymptomatic parent each time it could be tested. Subsequently, PHOX2B has been identified as the major disease causing gene in CCHS with a heterozygous de novo mutation in over 90% of the cases.11,23,24 Frameshift and missense mutations lying in the homeodomain of the protein are rare (11% in this series, fig 1) and due to differences in mutational profiles, selective retention/loss of UCE-disrupting CNVs, or a combination of both, the dichotomy of CNV profiles with respect to UCEs between healthy and cancerous cells warrants further discussion. One explanation argues that even though cancer cells with disrupted UCE dosage may acquire a growth advantage, their presence is detrimental to the overall fitness of the individual. Hence, disruptions in UCE copy number such as those seen in cancer would not be predicted to endure in human populations, consistent patients presenting with an isolated, long segment form of HSCR, skewing of the sex ratio decreases when compared with the short segment form of HSCR. In relation to MWS, we observed a skewed male to female ratio of 2.5:1 among the 20 patients with HSCR (15 males, five females), in agreement with previous reports.10 RET had been considered as a candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and domain that develop a DMD phenotype even though considerable levels of dystrophin staining was visible at the sarcolemma. Another patient harboring a missense mutation (D3335H)27 had dystrophin protein expression, but despite this, a DMD phenotype. Similarly in-frame deletions affecting the actin-binding domain also cause a DMD phenotype.4,28,29 Therefore the functional properties of the restored dystrophin could be partly assessed by the quantification of the DAPC complex. This was shown briefly in animal models of DMD, as successful exon The allele frequencies for each SNP tested at the RET locus were similar in both CCHS and MWS groups and remained similar to the control European population in both subgroups.3 However, the distribution of alleles varied within the CCHS group according to the presence or absence of the HSCR phenotype (table 1). In the CCHS group, the frequency of the predisposing alleles at the RET locus was 39.7% in the group of patients with Haddad syndrome (CCHS+HSCR), and 21% in the group of patients with isolated CCHS irrespective of the mutation in the Duchenne muscular dystrophy (DMD), an X-linked recessive condition, is a rare genetic disorder caused by the absence of functional dystrophin proteins due to gene mutations [1]. The incidence of DMD is approximately 1 in 5000 male newborns [2]. Affected boys initially exhibit progressive muscle weakness of the lower proximal extremities [3]. The gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and aberrant activation of dNK cells, and excessive recruitment of innate immune cells are mainly responsible for disrupting the regulation of immunological balance in pregnancy (111). These will now be discussed in turn.\n",
            "[0.4718843]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does MicroRNA-21 (miR-21) contribute to cardiovascular disease?\n",
            "Refined Query: MicroRNA-21's role in cardiovascular disease is complex.  Does its upregulation in various cardiovascular pathologies, like myocardial infarction or atherosclerosis, directly contribute to disease progression through its established target genes?  What are the specific mechanisms involved, and are there therapeutic implications to targeting miR-21?\n",
            "\n",
            "Combined Answer: shown that miRNAs are dysregulated in obese adipose tissue [15]. Furthermore, during adipogenesis, miRNAs regulate fat cell development by accelerating or inhibiting adipocyte differentiation. In addition, miRNAs may regulate the commitment to the adipogenic lineage in multipotent stem cells and therefore govern the numbers of fat cells [16]. Ninety-two percent of the cases carrying 1p21.3 deletion present with ASD. miR-137 is a brain expressed miRNA [17, 18] that regulates several protein coding genes that are important for brain function, which also leads to obesity. However, the case herein presented and the patient recently reported by Pinto et al. [6] carried a deletion overlapping in the critical region only at the MIR137, which suggests that this is the gene underlying the phenotype of patients carrying deletions at 1p21.3. miRNAs are noncoding 21–23 nucleotide small RNAs that are highly conserved and involved in several biological processes, such as cell proliferation, apoptosis, cell differentiation and morphogenesis [8]. They regulate posttranscriptional processes via MIR137 is the key gene mediator of the syndromic obesity phenotype of patients with 1p21.3 microdeletions - PMC are highly conserved and involved in several biological processes, such as cell proliferation, apoptosis, cell differentiation and morphogenesis [8]. They regulate posttranscriptional processes via sequence-specific interactions with the untranslated regions (UTRs) of cognate messenger RNA targets [7, 9]. Each individual miRNA can regulate many mRNAs, and conversely, each mRNA can be targeted by a number of miRNAs. The involvement of miR-137 in obesity, ID and ASD could be explained at two different levels. First, miR-137 regulates a multitude that the miRNA miR137 is the mediator of the obesity, ASD and ID phenotype. Further studies are warranted to elucidate the molecular mechanisms by which miR-137 mediates the phenotype, both in the CNS and the adipose tissue. miR-130b. Additionally, Uc.63+ promoted docetaxel resistance by regulating the expression of AR. Furthermore, the expression of Uc.63+ in the serum was dramatically changed through the carcinogenesis and progression of PC from BPH to CRPC. Although additional studies will likely be needed to further advance our understanding of how Uc.63+ contributes to PC progression, the data presented here highlight the great potential of Uc.63+ as a serum biomarker and therapeutic target in patients with PC. for the investigation of their role in development. The conservation of synteny in these blocks around miRNA target genes indicates that these extended regulatory domains may be sensitive to chromosomal rearrangements resulting in position effect mutations and possibly harbor human disease breakpoints. MicroRNAs are small (18–27 nucleotides long), single stranded RNA molecules found in plants, animals, and some viruses. They are most known for controlling protein synthesis either by translation repression or mRNA degradation but they also promote histone modification and DNA methylation of promoter sites, which influence the expression of target genes [1, 2]. Their function is accomplished by binding to the target mRNA through sequence complementarity rules, usually in the 3′untranlated region (UTR) [3]. MicroRNA genes are typically Recent evidence suggests that T-UCRs act as endogenous competing RNAs, and miRNA is one of the key regulators of T-UCRs [16]. To identify the miRNAs that could potentially interact with Uc.63+, we used two online software programs: UCbase 2.0 and miRanda. We detected that miR-130b and miR-605 had complementary sequences of Uc.63+ (Figure 5A). Further validation study using qRT-PCR disclosed that the expression of miR-130b was robust both in PC tissues and in non-neoplastic prostate tissues, whereas miR-605 was not detectable in either of them its 3 UTR in a site-specific manner [27]. It is therefore likely that the core clinical features of obesity and ASD in patients carrying 1p21.3 deletion are both mediated by miR-137. The case herein described presents with clinical features not previously described in the 1p21.3 microdeletion syndrome, such as precocious puberty and bicuspid aortic valve, with mild stenosis of the aortic root. The boy carries a 1p21.3 deletion, which extends 5 Mb proximally to the SRO and includes a number of genes. PALMD and S1PR1 encode for proteins that are\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 279.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.00ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1109.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 606.07ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Arthritis - {'Anti-Inflammatory Drugs': 0.0, 'Joint Swelling': 1.0}\n",
            "\n",
            " ### Clustered: {'Arthritis': {'Cluster 1': ['Anti-Inflammatory Drugs'], 'Cluster 2': ['Joint Swelling']}}\n",
            "Original Query: Is CD84 genetically associated with arthritis?\n",
            "Refined Query: Given the context of anti-inflammatory drugs and joint swelling in arthritis,  investigate whether genetic variations in CD84 are associated with an increased risk, severity, or specific type of arthritis, and if so, what the nature of that association might be.\n",
            "\n",
            "Combined Answer: (see Supplementary Figure 6, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39962/abstract). No effect on complement C4 was observed. The median neutralization ratios of a 21‐gene type I IFN signature in the IFN‐high subpopulation at week 24 were 89.7 and 91.7 for the anifrolumab 300‐mg and anifrolumab 1,000‐mg groups, respectively. This degree of suppression was maintained until week 52. No neutralization in gene expression was observed with placebo. The rates of antidrug antibodies at any in the expression of rheumatoid arthritis risk genes with super-enhancer structures by treating T-cells with the Janus kinase (JAK) inhibitor tofacitinib (35). Additionally, disease-associated single nucleotide polymorphisms (SNPs) for autoimmune diseases such as rheumatoid arthritis have been found to be highly enriched in super-enhancer regions (35). The current research well characterized this biological phenomenon and effectively demonstrated the importance and potential application of super-enhancers as they can play key roles in cell Knee osteoarthritis (KOA) is one of the most common degenerative disease that causes disability in elderly people.[1–3] An epidemiological study showed that about 30% of all adults have radiological signs of osteoarthritis (OA), 8.9% of the adults population has clinical significant OA of the knee or hip.[4] And the probability of OA increases with age.[5] For Chinese population, it has the similar trend. A study based on Chinese nationwide population suggested 8.1% total incidence rate of symptomatic KOA and increasing prevalence of KOA with and Figure 3). Improvement in arthritis was also greater in patients receiving anifrolumab (Figure 3 and Supplementary Figure 4). In patients with ≥8 swollen and ≥8 tender joints at baseline, a ≥50% decrease in both the swollen and tender joint count was achieved in a greater percentage of anifrolumab‐treated patients than placebo‐treated patients (48.6% for placebo, 69.6% for anifrolumab 300 mg [P = 0.038], and 64.6% for anifrolumab 1,000 mg [P = 0.156]). Compared with placebo, greater proportions of patients in the anifrolumab 300‐mg group in the overall population were driven by the IFN‐high subset (Table 2 and Figure 2). The study also assessed various measures of low disease activity. A SLEDAI‐2K score of ≤2 at week 52 was achieved in 17.6% in the placebo group, 35.4% in the anifrolumab 300‐mg group (P = 0.004 versus placebo), and 32.7% in the anifrolumab 1,000‐mg group (P = 0.012 versus placebo) (see Supplementary Figure 4, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39962/abstract), and a score of 0 was achieved in such as an increased response in inducible immunologic feedback leading to a lower rate of response with the greater anifrolumab dosage, cannot be excluded. Biomarker studies to address this question are currently underway. The fact that greater efficacy was seen in all end points in patients with high baseline IFN gene signatures compared with those with low baseline IFN gene signatures supports the pathobiology of this treatment strategy. The lack of treatment effect in the IFN‐low subgroup was due to a greater response to placebo and disease-associated polymorphisms that reside outside of coding regions (31). Global enhancer identification across different tissues could identify subsets of these polymorphisms as enhancer elements, thus providing valuable insight into how some of these regions cause disease in a tissue-specific manner. the IFN‐high population were 19.7% for placebo, 52.0% for the anifrolumab 300‐mg group (P < 0.001), and 38.5% for the anifrolumab 1,000‐mg group (P = 0.013). No differences from placebo were seen in the patients with a low IFN gene signature at screening (IFN‐low subpopulation) at week 24 or week 52 (Table 2 and Figure 1). Consistent with the primary end point results, a greater percentage of patients receiving anifrolumab met criteria for SRI(4) response without the oral corticosteroid taper requirement (Table 2 and Figure 1), and the those with low baseline IFN gene signatures supports the pathobiology of this treatment strategy. The lack of treatment effect in the IFN‐low subgroup was due to a greater response to placebo and standard therapy and not to a lower response to anifrolumab, suggesting that the IFN‐high subgroup represents a subpopulation more likely to benefit from the addition of anifrolumab to standard therapy. The interpretation of the results in the IFN‐low subgroup is limited by its small size, and thus larger studies are needed to fully evaluate the data sources whilst interpreting a single genetic variant. The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recently released guidelines that aim to standardise variant interpretation2. These guidelines outline a set of evidence criteria to assess each variant against, along with how these might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories,\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 253.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 656.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1135.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 808.13ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 958.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Smoking - {'Lung Cancer': 1.0, 'Heart Disease': 0.4309104342976413, 'Chemotherapy': 0.46505238063046894, 'Heart Failure': 0.29200907550669486, 'High Cholesterol': 0.0, 'Chest Pain': 0.5499658559411191}\n",
            "\n",
            " ### Clustered: {'Smoking': {'Cluster 1': ['Heart Disease', 'Heart Failure', 'Chest Pain', 'Lung Cancer', 'High Cholesterol'], 'Cluster 2': ['Chemotherapy']}}\n",
            "Original Query: Is cytisine superior to nicotine replacement therapy for smoking cessation?\n",
            "Refined Query: Given the risks of heart disease, heart failure, chest pain, lung cancer, high cholesterol, and even chemotherapy, is cytisine a more effective and safer smoking cessation method than nicotine replacement therapy for patients with these conditions?\n",
            "\n",
            "Combined Answer: (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the originally planned 40 patient accrual was reached. Two factors led to this decision. The first was that accrual was slowing considerably, and the trial had been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule the study may be thought of as making a correct decision regarding a prevention medication using the algorithm described in the companion application. To assess the ability of our trial to meet this goal, we conducted a series of simulation studies. Each simulation consisted of 10,000 replications for each of 64 conditions defined by all possible combinations of plausible values for the true response rates in the three treatment groups: placebo (40%, 45%, 50%, 55%), AMI (50%, 60%, 70%, 80%), and TPM (50%, 70%, 85%, 95%). For each simulated to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many patients enrolled on the study had the option to revert to observation, and did not have the immediate threat of shortened survival as would be the case in metastatic disease, the incentive to remain on an agent that caused side effects was lower than in other settings. Despite that, a number of patients chose to remain on treatment for prolonged might die despite the use of generally effective medical countermeasures. This was one of the conclusions drawn from the JIKI trial of favipiravir in Guinea, for example, and was raised by several other studies as well.14–20 No major safety concerns were identified with the use of ZMapp. Despite the drawback of an intravenous infusion that had to be given three times over the course of a week, the full course of ZMapp was successfully administered 91% of the time to recipients who survived that first week of the trial. In considering both the be given three times over the course of a week, the full course of ZMapp was successfully administered 91% of the time to recipients who survived that first week of the trial. In considering both the choice of investigational drugs and the most appropriate trial design in which to study them, each group testing clinical research interventions during the 2014–2016 epidemic faced the unenviable task of having to weigh numerous exigencies accompanying the study of potential therapeutic interventions for a highly lethal infection, their own proper In the case of this trial, which was launched during the second half of the epidemic, we believed that a randomized, controlled design would be the most expedient and definitive means of establishing the absence of a harmful effect and of determining whether the very favorable preclinical data in support of ZMapp might actually translate directly into lives saved. The advantages of randomized studies have been discussed extensively by others.5,21–23 True confidence in the findings of studies of treatments with potentially small-to-moderate Administering drug combinations instead of monotherapy can lead to an increased efficacy compared to single drug treatments (Csermely et al., 2013; Jia et al., 2009). Furthermore, host toxicity and adverse side effects are likely reduced, since doses of drug combinations are typically lower than doses of single agents (Chou, 2006; O’Neil et al., 2016). Drug resistance can be decreased or even overcome through combination therapy (Huang et al., 2016; Kruijtzer et al., 2002; Tooker et al., 2007). Therefore, drug combinations are investigated accrual. To ensure timely dissemination of data, the decision was made to close the trial after 31 evaluable patients were accrued. Additional study limitations include a non-randomized study design and a small sample size. In conclusion, pazopanib resulted in significant response rates in renal cell carcinomas and pancreatic serous cystadenomas, and showed potential signs of efficacy in central nervous system and retinal hemangioblastomas, with a side effect profile consistent with that seen in other treatment settings. Pazopanib could be ZMapp (Mapp Biopharmaceutical) was selected for an adaptive randomized, controlled trial design.9–11 A feature of this adaptive design was that an investigational agent that was subsequently shown to have activity against EVD could then be incorporated into an evolving standard of care, which was provided as the backbone of therapy in each trial group and against which newer agents could be tested. The primary objective was to determine whether the combination of ZMapp plus the current standard of care was both safe and superior to the current not equivalent. It is also more focused on the efficacy of the acute treatment. Given the observations that preventative treatment has the potential to alter the efficacy of acute treatment, it is a worthwhile measure to obtain for secondary analysis.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 253.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 631.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which syndromes are associated with mutations in the EZH2 gene?\n",
            "Refined Query: What specific clinical syndromes or phenotypic features are linked to various mutations (missense, nonsense, indels, etc.) in the *EZH2* gene,  considering both the type and location of the mutation within the gene's structure?\n",
            "\n",
            "Combined Answer: The identification of high-frequency histone mutations in pediatric high-grade gliomas has given us an inroad to better understand and to treat these deadly tumors. Of particular interest is to determine how K27M mutation in a single copy of histone H3 can have a dominant effect on global H3K27 methylation and, in particular, how some genes escape these effects and accumulate K27me3. Is the mechanism of H3K27M blockage of EZH2 activity restricted to EZH2 or does it impact EZH1 also? What about for K36M mutants in chondroblastoma—are SETD2 or The mutational spectrum was composed of 9 single nucleotide variants (SNVs), 2 indels and 1 CNV deletion. All mutations were protein-truncating or splicing mutations. We identified two recurrent mutations (c.1498 c>t, p.R500X; and c.1710 g>a, p.W570X). Otherwise, all mutations were unique. In our study, seven of 12 mutations (58%) were de novo, in contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual although a powerful method to identify new genes linked to mendelian disorders, does have limitations. In a medical genetics clinical setting, exome sequencing has a diagnostic yield of 20–35%.38, 39 Some limitations are linked to the strategy of sequencing only exons: promoter mutations or deep intronic mutations affecting splicing will be missed. Other limitation are inherent to our study design; we did not analyse oligogenic inheritance (combination of one mutated allele in each of two or more genes) or synonymous exonic variants, which in the control group—ie, the 6503 exomes in the Exome Variant Server), 6645 genes had at least one rare or novel variant in at least one of fifteen samples. To restrict the list of candidate genes, we applied filtering based initially on an autosomal recessive inheritance, analysed genes mutated in several samples, and removed the false-positive variants (appendix p7). We visually compared the DOORS syndrome exome alignments to other exomes previously acquired for unrelated disorders,16, 17, 18, 19, 20 focusing initially on genes with a technologies. For example, in epilepsy, channelopathies were identified in the 1990s mostly with positional cloning and candidate gene sequencing.10 Next-generation sequencing, such as whole-exome sequencing, has accelerated the pace of the identification of epilepsy-associated genes. For instance, PPRT2 mutations were identified initially in paroxysmal kinesigenic dyskinesia, and are also seen in infantile seizures and febrile seizures.11, 12 In the past year, DEPDC5 mutations have been identified in various dominantly-inherited familial variants (appendix p7). We visually compared the DOORS syndrome exome alignments to other exomes previously acquired for unrelated disorders,16, 17, 18, 19, 20 focusing initially on genes with a recessive inheritance pattern (one homozygous mutation or two heterozygous mutations) and variants identified in the highest number of affected individuals. Most variants in genes identified in most exomes by our annotation pipeline proved to be false-positive variants on visualisation and comparison with control exomes (appendix p 7). We identified Some genes implicated in epilepsy seem capable of causing a wide variety of types of epilepsy, with greater or fewer additional neuropsychiatric features, and others have been associated with brain malformations or complex dysmorphic syndromes.31 However, phenotypic pleiotropy has rarely been reported to span the spectrum from seizures alone (eg, previous reports on TBC1D24 mutations) to multi-systemic syndromic disorders such as DOORS syndrome. These emerging findings of both genotype-phenotype complexity and genetic pleiotropy lend support results. Many recent meta-studies of the efficacy of WES in diagnosing rare genetic diseases have revealed that its yield is usually less than 50%17. As such, for unsolved cases, researchers and clinicians are increasingly turning to WGS to identify candidate causal genes; however, the expansion into the rest of the genome causes a dramatic increase in the number of candidate variants. This is in part due to difficulties interpreting the effect of variants beyond the exome. As such, supplemental information regarding dysregulated candidate or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also Likewise, somatic variants associated with cancer were not included. A total of 453 unique non-coding Mendelian disease-associated variants were identified (Table S6). Mutations were manually mapped to GRCh37, if necessary. Each variant was cataloged according to its sequence variant type (Table 1). The disease associated with the variant was mapped to an OMIM disease identifier, and the affected gene was encoded with an NCBI Entrez Gene identifier.\n",
            "[0.61253214]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which databases exist for experimentally determined topologies of α-helical transmembrane proteins ?\n",
            "Refined Query: I'm searching for databases specifically cataloging experimentally determined three-dimensional structures of alpha-helical transmembrane proteins.  What resources exist that compile this type of data?\n",
            "\n",
            "Combined Answer: TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are α-helical sequences, 17 β-stranded, and 9 α-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or Transmembrane (TM) proteins serve extremely important functions in life as pump, channel, receptor, energy transducer etc., and have been reported recently to share ∼20–30% of genes in a whole genome (1–4). Nevertheless, the number of three-dimensional (3D) structures with high-resolution is far below one hundred at present, in contrast to more than 18 000 3D structures for soluble proteins registered in PDB (5). It is because TM protein molecules are difficult to crystallize due to their amphiphilic characteristics—hydrophobic TM segments of well-characterized topology data to be used for training or tuning TM topology prediction methods. Thus, more high-quality TM topology data are required to evaluate the existing prediction methods more precisely. For this reason, we have constructed a transmembrane protein database, TMPDB (19,24,26) which is a collection of TM proteins with topologies based on definite experimental evidence such as X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, Asp (N)-linked glycosylation experiment and other than 18 000 3D structures for soluble proteins registered in PDB (5). It is because TM protein molecules are difficult to crystallize due to their amphiphilic characteristics—hydrophobic TM segments (TMSs) and hydrophilic loops. The functions of TM proteins, however, can be inferred rather easily from their TM topology (i.e., the number of TMSs, TMS position and orientation of TMS to the membrane lipid bilayer) without knowing their 3D structures because of rather simple structural characteristics (6). In this context, a number of TM topology We have collected 1074 articles reporting TM topology, by using MEDLINE (27) search with the keywords, ‘transmembrane’ and ‘topology’ (895 articles), by searching directly without using MEDLINE (46 articles), and by referring to the reference position line (RP) of the entries with the following annotations: ‘X-RAY CRYSTALLOGRAPHY’, ‘STRUCTURE BY NEUTRON DIFFRACTION’, ‘STRUCTURE BY ELECTRON CRYO-MICROSCOPY’, ‘STRUCTURE BY NMR’ or ‘TOPOLOGY’ in SWISS-PROT and TrEMBL (28) (133 articles). By checking the content of each collected article, we Figures S1–4 and Tables S1–5: protein quantification and functional analysis information. This material is available free of charge via the Internet at http://pubs.acs.org. position and orientation of TMS to the membrane lipid bilayer) without knowing their 3D structures because of rather simple structural characteristics (6). In this context, a number of TM topology prediction methods have been developed to determine the structure and function of TM proteins from their amino acid sequences (2,7–22). However, the proposed prediction methods have not attained the desired accuracies for this purpose. The recent reports of evaluating prediction performance by using experimentally-characterized TM topology datasets X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/. The latest release of TMPDB contains 302 TM protein sequences: 276 α-helical sequences (TMPDB_alpha dataset), 17 β-stranded sequences (TMPDB_beta dataset) and 9 α-helical sequences with short pore-forming α-helices buried in the membrane (e.g., aquaporin 1) (TMPDB_alpha-buried dataset). The dataset of TMPDB_alpha comprises 165 prokaryotic and 111 eukaryotic sequences while the TMPDB_beta dataset includes only prokaryotic sequences with topologies determined by X-ray diffraction. The TMPDB_alpha-buried dataset includes 6 prokaryotic and 3 The 3D structural ensembles of all four target proteins used in this study were calculated using the CYANA27 software suite, supplied with the same input datasets as with autoNOE-Rosetta. Depending on the size of each protein target, CYANA calculations required 45–90 min on 4 CPUs. The script with all parameters for CYANA calculations is available in the Supplementary Methods.\n",
            "[0.28746492]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which disease is characterized by congenital absence of intrinsic ganglion cells of the gastrointestinal tract?\n",
            "Refined Query: The congenital absence of intrinsic ganglion cells in the gastrointestinal tract defines a specific disease.  What is the name of this condition, characterized by the lack of these crucial nerve cells responsible for gut motility and function?\n",
            "\n",
            "Combined Answer: criteria—that is, the absence of enteric plexuses and increased acetylcholinesterase histochemical staining in nerve fibres. Molecularly proven CCHS and MWS patients were studied (fig 1). Our series of 143 CCHS patients11 included 44 with HSCR (20 female and 24 male; long segment, 22 cases; short segment, 12 cases; unknown length of the aganglionic tract, 10 cases). Our series of 30 MWS patients included 20 with HSCR (five female and 15 male; long segment, six cases; short segment, five cases; unknown length of the aganglionic tract, nine criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive NHE6 protein appears to be expressed in just about every cell and tissue type yet examined.31 Given this result, it is not surprising that somatic medical symptoms appear to represent a part of CS. A particularly notable symptom is gastroesophageal reflux. While GI symptoms are commonly reported in neurodevelopmental disorders such as Rett syndrome32 and 22q11.2 microdeletion syndrome33, the data that two patients in our cohort required surgery to correct extreme GERD raise the possibility that this GI condition may be related to CS. In Inherited neuropathies are the most common genetic neurological disorders and affect ∼1 in 2500 individuals.1 Charcot–Marie Tooth (CMT) includes a group of hereditary disorders in which motor and sensory neuropathy is the sole or primary part of the disease. CMT is traditionally classified into two types based on electrophysiological and neuropathological criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and and 22q11.2 microdeletion syndrome33, the data that two patients in our cohort required surgery to correct extreme GERD raise the possibility that this GI condition may be related to CS. In addition, relatively low weight, particularly as the boys develop, appears to be a common somatic symptom. This finding likely warrants further clinical and pre-clinical research. With regard to additional behavioral symptom patterns that should be emphasized, the hyperkinetic behavior in patients with CS seems fairly pervasive. Interestingly, the related chronic inflammation affecting multiple tissues including the gut [38,41]. This is, in some cases, due to abnormal T cell production that displays increased affinity for self-antigens. T cells from these patients are autoreactive and hence give rise to chronic inflammation. In addition, it was recently shown that unrepaired lesions in AT patients induce a type I interferon response, which leads to inflammatory manifestations [42]. However, the underlying genetic causes for such inflammatory diseases, including IBD, are largely not known. In Three members of a large consanguineous Indian family (figure 1A), affected by axonal neuropathy (table 1) and optic atrophy, were identified at the London Royal Free Hospital. Case 3 was first seen at the age of 35 years and then again at the age of 51 years. She is the first cousin of Cases 1 and 2 and presented as a child with delayed milestones, later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were such a scenario the wild-type T cells in ATMINΔLNBS1ΔL mice proliferate to fill an ‘empty space’. Yet we would argue against this since we do not observe spontaneous intestinal inflammation in NBS1ΔL mice that are as lymphopenic as ATMINΔLNBS1ΔL mice. Furthermore, spontaneous inflammation is not a general feature of lymphopenic mice and to our knowledge this is the first report of a DNA repair deficiency that leads to spontaneous colitis. ATM-deficient mice do not develop spontaneous systemic inflammation and yet the combinatorial loss of GI-related symptoms were prominent in the CS patients assessed. Half (50%) had gastroesophageal reflux disease (GERD), for which two patients (14% of total patients) required Nissen fundoplication. Many parents (71% of families) reported current and past feeding difficulties such as difficulty chewing and times where the patient refuses to eat. Feeding difficulties were also notable during the neonatal period with latching problems. Some parents also reported that their boys had history of swallowing difficulties (29%) including dysphagia, including in the spleen and intestine that results in the development of intestinal prolapses in approximately 30% of ATMINΔLNBS1ΔL mice. Moreover, in an in vivo experimental system for intestinal colitis, using DSS to mimic IBD, we report enhanced colitis, significantly and specifically, in ATMINΔLNBS1ΔL mice. Although we observe a tendency towards spontaneous T cell activation in mice lacking only NBS1, as indicated by increased antigen experienced cells in the spleen and increased proliferation of splenic T cells, this phenotype is not\n",
            "[0.49821442]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the disease in which patients are sensitive to DNA crosslinking agents, presenting with a high frequency of chromosomal aberrations?\n",
            "Refined Query: The query seeks to identify a disease characterized by extreme sensitivity to DNA crosslinking agents, resulting in a significantly elevated incidence of chromosomal abnormalities.  What specific genetic disorder or syndrome exhibits this clinical presentation?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific knowledge, to optimise variant interpretation and introduce consensus. Initiatives such as the Clinical Genome Resource (ClinGen)4, are working to define such disease- and gene-specific thresholds, although these are currently limited to pilot phases for specific gene-disease pairs. The introduction of guidelines, including the logic behind features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures. Families were excluded if the parents could not be contacted for consent or if DNA could not be obtained from the affected individual. Further exclusion criteria were autosomal dominant inheritance and the absence of both intellectual disability and seizures, criteria that have been used elsewhere.3 A clinical questionnaire was completed by the collaborating physician. DNA was disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, with discordance in excess of 10%3. One key reason for this discordance is the structure of the ACMG/AMP guidelines, which are deliberately broad and lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific We have defined criteria and thresholds for each ACMG/AMP rule that are specific to the disorder of interest, and demonstrate the power and effectiveness of this approach over a recently released genome-wide interpretation interface. Incorporation of disease-specific knowledge is limited by current data, and the power of this tool will increase over time as new data become available. On-going community initiatives, such as the Clinical Genome Resource (ClinGen), are defining consensus disease and gene-specific standards for modifications to pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this we returned abstracts containing mentions of clinically relevant mutations, the MeSH ‘Diseases Category’ was an essential component. We chose the MeSH terms ‘Mutation’ and ‘Polymorphism, Genetic’ to obtain abstracts that had been indexed as pertaining to genomic variation. The ‘Title/Abstract’ field was searched for terms identified to retrieve information pertaining to sequence type, mutation type and mutation location (see query later in the text). This strategy was chosen after reviewing example abstracts containing desired mutation Genomic DNA from 200 patients and their parents was purified by standard proteinase K/phenol-chloroform procedures. All the patients showed idiopathic mental retardation associated to congenital anomalies, non assignable to known syndromes after clinical examination by two specialists. Informed parental consent, as approved by our Hospital Review Board, was obtained prior to research studies. Patients C1 to C5 were studied by clone-based array CGH as reported elsewhere [11]. Patients M1 to M3 were detected in the initial screening for Autozygosity mapping on two affected cousins (Case 1 and Case 3) identified five homozygous chromosomal segments (>1 Mb), concordant in both cousins encompassing 15.8 Mb and containing 226 genes (NCBI build 37.2). Whole-exome sequencing was used to perform a comprehensive search for pathogenic mutations in both cousins. The target region was sequenced at an average sequence depth of 26.6 for all samples. To identify potential causal variants, we selected all coding variants in the homozygous regions present in both samples. Then, we filtered\n",
            "[0.3778323]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How is oprozomib administered?\n",
            "Refined Query: What are the methods of oprozomib administration?  Does it involve intravenous infusion, oral ingestion, or other routes?  What are the typical dosage regimens and frequency of administration for oprozomib?\n",
            "\n",
            "Combined Answer: Continuous or physiologic transient administration of carfilzomib or oprozomib is cytotoxic to human MM cells in vitro Under 48 h of continual drug incubation, carfilzomib and oprozomib exerted a cytotoxic effect on a panel of 10 human MM cell lines similar to bortezomib. In agreement with previous reports, the IC50 was approximately 2 nM for bortezomib, 3 nM for carfilzomib22 and 25 nM for oprozomib27 (Figure 1a). However, pharmacokinetic data indicate that in vivo exposure to drug is approximately 4 h following oral delivery of oprozomib28 (oprozomib schedule) and intravenous 10% Captisol in 10 mM citrate buffer, pH 3.5 (carfilzomib schedule). In Figure 5f, following 14 days of drug treatment, three doses of 1 mg/kg of RANKL were given intraperitoneally at 24 h intervals as described in Tomimori et al.34 Serum was collected 90 min after the final RANKL injection. PIs were administered to mice on the following weekly schedules: bortezomib (1 mg/kg intravenously days 1 and 4); carfilzomib (5 mg/kg for C57Bl/6, 3 mg/kg for KaLwRij, intravenously days 1 and 2); oprozomib (30 mg/kg by oral gavage once daily for 5 consecutive days followed by 2 days of rest). Vehicle mice were administered both oral 1% carboxy-methylcellulose (oprozomib schedule) and intravenous 10% Captisol in 10 mM citrate buffer, pH 3.5 (carfilzomib schedule). In Figure 5f, following 14 days of drug treatment, three doses of 1 mg/kg of 3 nM for carfilzomib22 and 25 nM for oprozomib27 (Figure 1a). However, pharmacokinetic data indicate that in vivo exposure to drug is approximately 4 h following oral delivery of oprozomib28 and approximately 1 h with intravenous administration of carfilzomib or bortezomib.22,38 To more accurately replicate this physiological situation in vitro, cells were transiently treated with oprozomib for 4 h and with carfilzomib or bortezomib for 1 h followed by an additional 48 h culture in drug-free media. Myeloma cell lines remained susceptible to In ongoing clinical trials, carfilzomib is dosed intravenously on two subsequent days; experimental evidence suggests that daily dosing is similarly well tolerated, although the necessity for intravenous delivery limits this use in practice.22,24,25 In current trials, oprozomib is dosed orally on five continuous days. While we demonstrate that single in vitro pulse treatments of oprozomib effectively exert anti-tumor, anti-OC, and pro-OB effects, the QDx5 repeated dosing schedule increases the overall period during which proteasome activity is been treated with bortezomib. Carfilzomib is currently undergoing extensive clinical testing in multiple myeloma, as well as evaluation in mantle cell lymphoma, T-cell lymphoma, large B-cell lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, acute lymphoblastic leukemia, small cell lung cancer, renal cell carcinoma, and advanced prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being evaluated in clinical trials of multiple myeloma and recurrent solid tumors (http://clinicaltrials.gov). Like carfilzomib, oprozomib is also active against bortezomib-resistant multiple myeloma cells.33 Thus, carfilzomib and oprozomib offer several unique advantages, including the ability to overcome acquired bortezomib resistance. Both carfilzomib markers of bone turnover showed that oprozomib inhibited bone resorption (Figure 7e) while enhancing bone formation (Figure 7f). In summary, these data demonstrate that orally administered oprozomib exerts in vivo anti-myeloma activity along with bone anti-catabolic and anabolic effects in mice bearing human MM. and function and inhibit OC formation and resorption equivalently to bortezomib in vitro and in vivo. Both drugs were effective at reducing myeloma burden and osteolytic bone destruction in mice bearing BM-disseminated myeloma. Collectively, our data demonstrate that carfilzomib and oprozomib effectively inhibit myeloma growth and shift the bone microenvironment from a catabolic to an anabolic state, with reduced toxicity24,28 and oral administration (in the case of oprozomib)26,27 being significant advantages to patients. cells were transiently treated with oprozomib for 4 h and with carfilzomib or bortezomib for 1 h followed by an additional 48 h culture in drug-free media. Myeloma cell lines remained susceptible to proteasome inhibition under short treatment conditions (Figure 1b), although increased doses were required to achieve similar efficacy (8 nM bortezomib, 6 nM carfilzomib and 50 nM oprozomib). Effective transient doses were still well below the maximum serum levels (Cmax) attained in patients (bortezomib: 0.162 μM (1.3 mg/m2 intravenous)39;\n",
            "[0.7637359]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is a Caveolae?\n",
            "Refined Query: What are caveolae, and what is their function in cell biology?  Describe their structure and how they differ from other membrane invaginations.  What roles do they play in processes like endocytosis and signal transduction?\n",
            "\n",
            "Combined Answer: Figures S1–4 and Tables S1–5: protein quantification and functional analysis information. This material is available free of charge via the Internet at http://pubs.acs.org. To unravel the TGF-β1-induced Necl-2 protein degradation pathway, various inhibitors were employed to block the proteasome and endocytoic degradation pathways which are the two major mechanisms reported for effective removal of cell junction molecules from cell-cell interface [32]. MG132 (a proteasome inhibitor), nystatin (an inhibitor of caveolin-dependent endocytosis) and CPZ (an inhibitor of clathrin-mediated endocytosis) were used prior to TGF-β1 treatment in order to screen the potential degradation pathway. Pretreatment of two different PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid capsule, which protects the bacterium from host phagocytosis [6]. The production of these virulence factors is highly dependent on an environment containing carbon dioxide and bicarbonate (CO2/HCO3, henceforth CO2). The relative concentrations of CO2 and bicarbonate are regulated enzymatically by carbonic anhydrase, as well as many other non-enzyme the origin of Metazoa. The striking concordance between the distribution of CNEs and topological organisation has far-reaching implications for understanding the nature and evolution of long-range regulation at developmental loci. Combining the concepts of GRBs and TADs leads to a model of regulatory domains with stronger predictive and explanatory power than either concept alone (Supplementary Fig. 12). The GRB model provides a framework for long-range regulation, in which the majority of regulatory elements within a GRB are dedicated to the provides specific early versus late differentiation functions in the context of distinct complexes (Figure 7). The model of different GATA-1 complexes executing specific tasks in different stages of erythroid differentiation suggests a dynamic aspect in the GATA-1 complex interactions during differentiation and also raises the prospect of dissecting the contribution of distinct GATA-1 interactions in erythropoiesis (i.e. essential versus dispensable) by selectively manipulating a specific GATA-1 complex at a time. is not mediated via ubiquitin-proteasome pathway or caveolin-dependent endocytosis. However, significant rebound in Necl-2 protein level was observed when CPZ was employed (Fig. 2D). Apart from the rebound of Necl-2 protein level, re-localization of Necl-2 at the cell-cell interface was observed in CPZ-pretreated cells in TGF-β1-treated group (Fig. 2E). Western blotting analysis and immunofluorescence staining unequivocally suggest that clathrin-mediated endocytosis possibly involves in TGF-β1-induced protein degradation. To further examine but, in eukaryotes, were previously thought to be restricted to choanoflagellate and sponge proteins (Pfam accession: PF00963) (Abedin and King, 2008; Nichols et al., 2012; Peer et al., 2009). These are not to be confused with the cohesin complex that regulates the separation of sister chromatids. Rather, cohesin domains are highly specialized protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria These references are in PubMed. This may not be the complete list of references from this article. These references are in PubMed. This may not be the complete list of references from this article. was spatially controlled within the tracheal system. Indeed, although fusion proteins are homogeneously expressed within all tracheal branches (as shown for two tracheal branches in the T2 segment, where no endogenous AbdA protein is present, Figures 7a-a'), BiFC is mostly visible in a main tracheal branch, the dorsal trunk (dt; quantification is shown in Figure 7a''). BiFC thus reveals the existence of a spatial control promoting AbdA/Exd assembly in the dt and/or avoiding AbdA/Exd interactions in other tracheal branches like the dorsal\n",
            "[0.5987843]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the roles of chromatin compartments in the eukaryotic nucleus?\n",
            "Refined Query: How do the distinct structural and functional domains within the eukaryotic nucleus, known as chromatin compartments (e.g., A and B compartments), influence gene expression, DNA replication, and genome organization and stability?\n",
            "\n",
            "Combined Answer: As part of the mouse ENCODE project, David Gilbert and colleagues study the relationship between replication timing and higher order chromatin domains in mouse and human. They find that boundaries of replication domains — domains within the genome which replicate at the same time — share a near one-to-one correlation with topology associated domains. These and other results reconcile cell-type specific sub-nuclear compartmentalization with developmentally stable chromosome domains and offer a unified model for large-scale chromosome structure Our results reconcile cell-type-specific sub-nuclear compartmentalization and replication timing with developmentally stable structural domains and offer a unified model for large-scale chromosome structure and function. These and other results reconcile cell-type specific sub-nuclear compartmentalization with developmentally stable chromosome domains and offer a unified model for large-scale chromosome structure and function. introduce the concept of chromatin assortativity (ChAs). This global measure identifies to what extent a property of a chromatin fragment is shared by fragments that interact preferentially with it. If a feature appears to be localized in specific well-connected areas of the network, it will be characterized by having high ChAs. Identifying features with high ChAs can thus lead us to candidates for factors that might mediate chromatin contacts. This would be an important step forward in elucidating the organizing principles inside the nucleus with lamina-associated domains (LADs)4,5,8,9. Recent Hi-C mapping has unveiled substructure within chromatin compartments called topologically associating domains (TADs) that are largely conserved in their positions between cell types and are similar in size to replication domains8,10. However, TADs can be further sub-stratified into smaller domains, challenging the significance of structures at any particular scale11,12. Moreover, attempts to reconcile TADs and LADs to replication-timing data have not revealed a common, underlying domain two major compartments, which correspond to open (compartment A) or closed chromatin (compartment B), which tend to self-associate within the nucleus31. TADs may switch compartment depending on the activity of genes within them23, and therefore it has been suggested that TADs form the ‘regulatory units’ of the genome32. The stability of TADs, the variation in their size and their ubiquitous presence across different metazoan phyla lead us to question how these domains relate to the regulatory domains of developmental genes. Given that our Moreover, cell-type-specific replication timing of TADs partitions the genome into two large-scale sub-nuclear compartments revealing that replication-timing transitions are indistinguishable from late-replicating regions in chromatin composition and lamina association and accounting for the reduced correlation of replication timing to LADs and heterochromatin. Our results reconcile cell-type-specific sub-nuclear compartmentalization and replication timing with developmentally stable structural domains and offer a unified model for large-scale for the absence of condensed heterochromatin in the central cell nucleus, we ectopically expressed H2A.W.6 using the promoter of FWA, which is specifically active in the central cell and the endosperm (Kinoshita et al., 2004). The chromatin of the central cell expressing pFWA-H2A.W.6-RFP showed domains of varying intensity with distinct zones of higher condensation (Figure 6B). We could distinguish two types of organization. A minor group of nuclei showed one or two strong patches of dense chromatin. The most representative class of central of discrete chromosomal domains was provided by [18] who showed that interactions between genome and nuclear lamina take place abundantly with CTCF sites preferentially demarcating the identified lamina associated domain borders. These data suggest that CTCF is an essential organiser of long-range chromatin interaction and transcription across species. In 2005, presence of a CTCF ortholog outside the vertebrates was reported for the first time [19]. This Drosophila CTCF had a binding site specificity similar to vertebrate CTCF and conveyed suggesting these regions are consistently insulated from neighbouring domains. The enrichment of CTCF at GRB and GRB-TAD boundaries, combined with the strength of interactions associated with GRBs, further suggests that these regions do not strongly interact with elements in adjacent domains. This is in addition to the association of GRBs with Polycomb-repressed chromatin and depletion of active euchromatin, which also promotes insulation from neighbouring regions, as described above. These features are reflective of the multiple mechanisms\n",
            "[0.66604]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the abnormal dosage of ultraconserved elements disfavored in cancer cells?\n",
            "Refined Query: Investigating the role of ultraconserved elements (UCEs) in cancer, this query asks whether deviations from their normal dosage—either increased or decreased copy number—are selected against in cancer cells.  Does maintaining typical UCE expression levels confer a selective advantage, or are dosage alterations tolerated or even beneficial for tumorigenesis?\n",
            "\n",
            "Combined Answer: Ultraconserved elements (UCEs) display a level of sequence conservation that has defied explanation. They are also dosage sensitive, being depleted from copy number variants (CNVs) in healthy cells. Here we address the process underlying this dosage sensitivity in order to gain insights into the way that UCE dosage affects cells. Our studies demonstrate that, in contrast to CNVs inherited by healthy individuals, cancer-specific CNVs are, as a rule, not depleted for UCEs and may even be enriched. Furthermore, by discovering that CNVs arising Abnormal Dosage of Ultraconserved Elements Is Highly Disfavored in Healthy Cells but Not Cancer Cells - PMC roles for the transcription of specific UCEs in cancer [44]–[51]. In sum, the basis of ultraconservation remains unclear. Indeed, it has been suggested that UCEs represent nothing more than an unexceptional tail end of a distribution of conservation [4]. Regardless, the apparent dosage sensitivity of UCEs remains intriguing, especially in light of the dosage sensitivity of many genomic functions whose importance has been well established [52]–[55]. Therefore, leaving aside the specific issue of ultraconservation, this report focuses on the a way that is disrupted in cancer cells. After examining CNVs over time in cell culture, we postulate that selection against UCE-disrupting CNVs in healthy cells acts rapidly, raising the surprising possibility of exploring in cell culture how UCE dosage sensitivity may explain ultraconservation. Our observations suggest that an understanding of the different responses of healthy and cancer cells to changes in UCE dosage could be harnessed to address genomic instabilities in cancer. continuously undergo replication and, hence, progress unrestrained through cell cycles. Of these, cells that are the most disrupted in UCE dosage, in other words enriched for the inclusion of UCEs in their CNVs, might be expected to show the strongest phenotype of unregulated growth and thus become cancerous. The enrichment of UCEs in many cancerCNA datasets may at first be difficult to reconcile with the depletion of UCEs from classicalCNVs, de nov°CNVs, somaticCNVs, and iPSCNVs; while cancer cells with abnormal UCE copy number appear an invaluable tool in the task of differentiating benign from pathogenic CNVs or, in other words, to evaluate which genes may be dose-sensitive or not. In this context, the real significance of the ultraconserved elements (UCEs) in the human genome remains an intriguing issue. There are 481 UCEs, defined as stretches of at least 200 base pairs of human DNA that match identically with corresponding regions in the mouse and rat genomes [2]. They are widely distributed in the genome (on all the chromosomes except chromosomes 21 and Y) and are lack a compelling explanation for why these sequences, called ultraconserved elements (UCEs), have been so extremely conserved for hundreds of millions of years – neither enhancers, nor transcription factor binding sites, nor promoters, nor protein coding regions require such a high level of conservation [1], [3]–[8]. Despite this, and because roughly half of UCEs are intronic and one third are intergenic, a popular expectation is that UCEs will be found to embody important regulatory activities; indeed, they are thought to be maintained by Therefore, a better understanding of the molecular mechanisms involved in GCs development and progression will provide diagnostic and prognostic markers and potential targets for the therapeutic intervention of GCs. Ultraconserved elements (UCEs) are noncoding gene sequences with strict conserved across among humans, mice and rats. Emerging evidence demonstrates that UCEs can encode non–protein-coding RNAs (ncRNAs) serve as modulators of gene expression [1, 2]. Previous studies showed that transcribed ultraconserved elements (TUCEs) serve as of cervical cancer has made great progress, but chemotherapy is still the main treatment for patients with advanced cervical cancer [9]. The main type of ovarian cancer includes serous, mucinous and endometrial, the survival rate of patients is still low although surgery and drug treatment progress for ovarian carcinomas [10]. Ultraconserved elements (UCEs) are noncoding DNA regions with strict conserved across among mice, rats, and humans. Transcribed UCEs can encode non–protein-coding RNAs (ncRNAs) serve as modulators of transcription and In recent decades, emerging evidence demonstrates that ultraconserved elements (UCEs) encoding noncoding RNAs serve as regulators of gene expression. Until now, the role of uc.189 in human cancers remains undefined and the clinical significance of uc.189 in gynecological cancers remains unknown. This study was to identify the prognostic value of uc.189 expression in gynecological cancers. Tissue microarrays were constructed with 243 samples including 116 cervical squamous cell carcinomas (CSCCs), 98 endometrial adenocarcinomas (EACs), 29\n",
            "[0.41344345]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does thyroid hormone regulate calcium transient in the myocardium? \n",
            "Refined Query: Investigating the precise role of thyroid hormone in modulating calcium handling within cardiomyocytes is crucial.  Does thyroid hormone directly influence the calcium transient amplitude, duration, or upstroke velocity, or does its effect manifest indirectly through other ion channels or signaling pathways?\n",
            "\n",
            "Combined Answer: Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, there is evidence for two mechanisms for THs to move out of the choroid plexus into the CSF: (i) secretion of TH bound to choroid plexus-derived TTR, and (ii) efflux of THs via TH transmembrane transporters. The relative quantitative contribution of each of these mechanisms during each stage of CNS development is currently unknown and should be From the above controversy regarding the importance of TTR synthesis by the choroid plexus, several points support the hypothesis that choroid plexus-derived TTR plays a role in the movement of THs from the blood to the brain and in distributing THs in the blood and CSF. These points include evolutionary, developmental, molecular and functional data. Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters - PMC 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. The structure of transthyretin has been highly conserved, implying strong selection pressure and an important function. In mammals, transthyretin binds T4 (precursor form of thyroid hormone) with higher affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about Thyroid hormones are key players in regulating brain development. Thus, transfer of appropriate quantities of thyroid hormones from the blood into the brain at specific stages of development is critical. The choroid plexus forms the blood-cerebrospinal fluid barrier. In reptiles, birds and mammals, the main protein synthesized and secreted by the choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal be considered euthyroid (Palha et al., 1994, 2000; Palha, 2002). However, this did not appear to correspond to the earlier data showing that choroid plexus-derived TTR was involved with movement of T4 from the blood into the brain (Dickson et al., 1987; Schreiber et al., 1990; Chanoine et al., 1992; Southwell et al., 1993). Soon thereafter, the regulation of neural stem cell cycle in the subventricular zone of adult rodent brain was shown to be dependent on TRα/TH by influencing both cell proliferation and apoptosis (Lemkine et al., 2005). Our current hypothesis for the movement of TH from the blood via the choroid plexus is depicted in Figure 1. In this Figure, T4 (major form of TH secreted by the thyroid gland) is depicted. It is worth noting that there is a higher concentration free T4 in CSF than in blood, so net movement of TH from the blood to the CSF is against this gradient. Therefore, it would not be surprising if several mechanisms for moving TH from the blood via the choroid plexus (and the blood-brain barrier) had evolved.\n",
            "[-0.077280134]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the biological roles proposed for proteins containing the SPRY domain?\n",
            "Refined Query: Investigate the diverse biological functions attributed to proteins incorporating the SPRY domain.  Explore the mechanisms by which this domain contributes to these roles, considering its involvement in protein-protein interactions and signaling pathways.\n",
            "\n",
            "Combined Answer: disassembly of the spliceosome (3), suggesting a common regulatory theme for complexes mediating multistep reactions. In summary, we have shown that the N terminus of Pta1 is important for CTD Ser5-P dephosphorylation, gene looping, snoRNA termination, and Ssu72 stability, and through the interaction with Ssu72, it also modulates the function of Pta1 in mRNA processing. These findings support a role for Pta1 in organizing the cleavage/polyadenylation complex and directing its activity. of Pta1 are involved in the Ssu72 (amino acids 26 to 300) and the Pti1 (amino acids 400 to 500) interactions. Furthermore, the Syc1 protein is almost identical to the C terminus of Ysh1 and can functionally substitute for this essential region (49). Our data suggest that Syc1 and Ysh1 both contact the C-terminal domain of Pta1, and as originally proposed by Nedea et al. (29), the simplest way to account for both proteins in holo-CPF would be the presence of two copies of Pta1 in the complex. In addition, we now show that Pta1 also interacts and facilitating transcription reinitiation by the interaction of the 5′ and 3′ ends of genes (1, 5, 6, 13, 39). The execution of these diverse functions requires that the CPFs interact differently with each other and with other factors depending on the job needed to be done. One of the proteins proposed to mediate these different interactions is the Pta1 subunit of the yeast CPFs and its metazoan homolog Symplekin. Of these, only SP1 is known to interact with NFYA/NFYB [64]. Other relationships between a motif set and TFs not annotated with it include one particular MAF motif with SPI1; the NRF1 motifs with ATF3; certain STAT motifs with ELF1, ETS1, SIX5, SPI1, and ZNF143; TAL1 motif with TCF3 and TCF12; and ZNF143 motif with ETS1 and SIX5. Of these relationships, all but the last can be explained by motif sequence similarity; no interaction among ZNF143, ETS1, and SIX5 is documented. Some of the most common motifs, the GC-rich EGR1 and SP1 sets, were KEGG and Biocarta pathways, Interpro and Smart protein domains, is shown in Table S1 in the SI (top ranking terms which have p < 1 × 10–18). We find that the most significant biological term associated with ABPP 106 binders across those analysis tools is acetylation, as would be expected. Other significant enrichment categories ranking on the top include ribonucleoprotein complex, RNA binding, RNA recognition motif, mRNA metabolic process, RNA splicing, mRNA processing, etc. The role of protein acetylation in these processes is beginning to be example, Pta1 phosphorylation by CKII and dephosphorylation by Glc7 modulate its function in poly(A) addition (16). Similarly, it has been reported that the sumoylation of Symplekin and/or CPSF-73 affects the assembly and the activity of the cleavage and polyadenylation complex (44). Ubiquitination of the splicing complex controls the assembly and disassembly of the spliceosome (3), suggesting a common regulatory theme for complexes mediating multistep reactions. In summary, we have shown that the N terminus of Pta1 is important for CTD Ser5-P proteins’ normal molecular functions, and their molecular dysfunction in disease, becomes more critical when sequence variants within functionally enigmatic genes are robustly associated with Mendelian or complex disease, or with cancer progression. Determining the molecular functions of such poorly characterized genes is all the more difficult when their protein sequences lack recognizable domains, because these otherwise can reliably provide structural and functional information through homology-based inference. Here, we shed much light on yeast-specific domains that interact with proteins such as Ssu72 or complexes such as APT that have not been described for metazoan cells. Unlike Pta1, symplekin is not tightly associated with any of the purified mammalian factors but clearly has a similar function in assembling diverse smaller complexes into larger ones. Symplekin is needed for the cleavage of the nonadenylated histone transcripts and performs this function as a component of heat-labile factor, a large complex that shares subunits with the CPFs CPSF and CstF (24). Symplekin and candidate partners have distinct and typical nuclear localisations, suggesting that the nuclear architecture has important roles in controlling Hox protein interactions and functions. It also illustrates the power of BiFC for deciphering unanticipated mechanisms regulating protein interactions within a proper physiological context. Finally, the variety of protein interactions visualized through BiFC indicates that the methodology could be used more globally [53] for screening for novel interacting partners in a developing organism. This the extended C-terminal domain that contains the conserved SPKK motif. This is consistent with previous in vitro studies of the function of the SPKK motif in other histone variants (Khadake and Rao, 1997). The SPKK motif binds preferentially to the minor groove of DNA at A/T rich sites (Churchill and Suzuki, 1989), which are generally enriched in satellite repeats of heterochromatin (Brutlag, 1980). During evolution, the SPKK motif not only became associated with H2A.W in seed plants but was also recruited to other histones, which are\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 379.21ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 883.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 936.26ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.38ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.34ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1010.56ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 711.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1189.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.06ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.04ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 836.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 655.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 833.18ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 732.17ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the suggested therapy for Mycobacterium avium infection?\n",
            "Refined Query: What specific therapeutic regimen is recommended for treating disseminated Mycobacterium avium complex (MAC) infection in an immunocompromised patient, considering factors like disease severity and drug resistance?  What are the first-line and alternative treatment options?\n",
            "\n",
            "Combined Answer: CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one recurrence and may require multiple rounds of treatment that can last several weeks to months, negatively impacting quality of life and costing the health care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms administration, as it requires patient visits to hospitals or clinics to receive the medication. As IM and SC dosing allows for self-administration, these routes are useful when effective treatment requires maintenance or chronic dosing. A limitation of IM and SC dosing is that large doses may not be feasible due to the solubility of IgG (∼100–150 mg/mL) and because larger injection volumes tend to cause more injection site pain. For these reasons, multiple injections must be given to achieve higher doses. The antibodies in Table 1 that Clostridium difficile is an anaerobic Gram-positive bacillus that infects the colon of susceptible patients, mainly in hospital settings but also increasingly in the community. C. difficile infections (CDI)4 are typified by severe diarrhea, pseudomembranous colitis, and in extreme cases colonic rupture, sepsis, and death (1). Current treatments for CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one Currently, about 350 million individuals worldwide are chronically infected with the hepatitis B virus (HBV). Of the infected people, 15 to 40% will develop severe sequelae in their lifetime, most notably liver cirrhosis and hepatocellular carcinoma (18). The treatment of chronic hepatitis B has been improved dramatically in the past 10 years, mainly due to the successful development and application of nucleoside(tide) drugs targeting HBV polymerase and interferon (9, 24). These treatment options delay disease progress by inhibiting viral mainly due to the successful development and application of nucleoside(tide) drugs targeting HBV polymerase and interferon (9, 24). These treatment options delay disease progress by inhibiting viral replication and modulating host immune functions in certain populations of HBV patients, but fail to cure the majority of HBV patients. A predominant reason for this failure is attributed to the persistence of viral covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes during the treatment with nucleoside(tide) analogs (8, 1-μl volume of anti-myc (sc-789) was added for a further 2-h incubation, followed by immune complex precipitation for 1 h using 10 μl of protein A-agarose beads (sc-2001; Santa Cruz). Following three washes (each with 1 ml of PBS–1% Triton X-100), the beads were resuspended in 20 μl of HU buffer (49) and boiled for 5 min. The entire supernatant was analyzed by SDS-PAGE (10% polyacrylamide). when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be translocation of enteric flora across the compromised intestinal mucosa. Moreover, resistant bacteria may exhibit enhanced virulence (Dancer 2004), further complicating a malnourished child’s chances for recovery. Amoxicillin was used in the standard protocol group because of its relatively broad-spectrum of activity, low cost, and current usage by diffusion or convection through the epithelium. Most antibodies are administered by the IV route because it allows for the antibody to be delivered rapidly with complete availability to the systemic circulation and can be given in larger volumes and doses compared to the IM or SC route. However, the IV route may not be as convenient as IM or SC administration, as it requires patient visits to hospitals or clinics to receive the medication. As IM and SC dosing allows for self-administration, these routes are useful when effective treatment to be receiving treatment with at least one of the following: oral prednisone (≤40 mg/day or equivalent), azathioprine (≤200 mg/day), an antimalarial, mycophenolate mofetil/mycophenolic acid (≤2.0 gm/day), or methotrexate (≤25 mg/week). Treatments for SLE had to be administered for at least 24 weeks prior to study entry and at stable dosages for ≥2 weeks (for prednisone and nonsteroidal antiinflammatory drugs) or ≥8 weeks (for other therapies) before screening. Biologic agents and protocol‐prohibited immunosuppressants had to be discontinued care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms that are “an immediate public health threat and that require urgent and aggressive action” (44). There is therefore a pressing need for new treatments against C. difficile, in particular ones that address the high rates of recurrence. The pathogenic nature of C. difficile results from production of two exotoxins, toxin A (TcdA) and toxin B (TcdB),\n",
            "[0.64059067]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the treatment of acute pericarditis?\n",
            "Refined Query: How is acute pericarditis, a condition characterized by inflammation of the pericardium, treated?  Describe the typical medical management, including both symptomatic relief and approaches to addressing the underlying cause.\n",
            "\n",
            "Combined Answer: 0.5 mg) and were transient and asymptomatic. Cardiac adverse events of special interest were infrequent and of comparable incidence between the study groups. These included short runs of nonsustained ventricular tachycardia (3 placebo subjects, 2 ozanimod subjects), transient and self‐limiting first‐degree AV block (1 ozanimod subject), and transient and self‐limiting second‐degree AV block, Mobitz type 1 (1 subject in each group). None of these cardiac events was temporally associated with the administration of moxifloxacin. Other were examined clinically using the Centor Criteria. They were also examined for other signs and symptoms such as petechiae over the palate and abdominal pain. All the patients had rapid strep tests and throat culture. No one was given any antibiotic till the culture results were obtained. All the observed data were obtained in another institutional review board–approved study, as mentioned above. as the occurrence of hypertension, ischemic heart disease, type 2 diabetes mellitus, obesity, and insulin resistance) has also been associated with increased circulating microparticles and subsequent systemic inflammation (38). The exact stimuli inducing inflammation in preeclamptic patients are, however, incompletely understood and various other possibilities exist (32, 39). For instance, an injured endothelium may release several factors thought to play a role in this systemic inflammatory response (40). These factors include result, the diagnosis is more secure. He also writes that although palatal petechiae are seen with streptococcal tonsillitis, they are not pathognomonic.5 However, in our study, 6 out of 8 patients with only palatal hemorrhages grew culture for group A β-hemolytic strep. Palatal hemorrhages may also accompany infectious mononucleosis, rubella (Forschheimer spots), roseola, viral hemorrhagic fevers, thrombocytopenia, and palatal trauma. In the setting of acute tonsillitis, treatment is recommended for all children who are antigen or culture The percentage of patients with serious adverse events was similar in the two groups: 37% in the group that received the current standard of care alone and 31% in the group that also received ZMapp (P = 0.62). Only one serious adverse event (hypertension) in ZMapp recipients was judged to be related to the infusion itself (Table S5 in the Supplementary Appendix). Adverse events related to ZMapp infusions were reported most commonly during the first infusion (25%) and decreased with subsequent infusions (11% with infusion 3). Fever (14% with palate. The diagnosis of strep throat is unlikely with symptoms of red eyes, hoarseness, runny nose, or mouth ulcers, and also less likely in the absence of fever. The etiology is usually infectious, with most cases being of viral origin. These cases are benign and self-limiting for the most part. Bacterial causes of pharyngitis are also self-limiting, but are concerning because of suppurative and nonsuppurative complications. Other causes include allergy, trauma, toxins, and neoplasia.3 The most common bacterial organism causing acute and 1 death during the study in a patient who received 1 dose of anifrolumab 1,000 mg. The patient had acute colitis with a rapidly deteriorating clinical course and had features of macrophage activation syndrome prior to death. No infectious agent was identified. Autopsy confirmed the cause of death to be acute colitis and revealed portal vein thrombosis and increased numbers of phagocytic macrophages in the bone marrow, consistent with macrophage activation syndrome. This was not considered related to the study drug by the investigator. the patients receiving placebo and 3.0% and 9.5% of the patients receiving anifrolumab 300 mg and anifrolumab 1,000 mg, respectively. The most frequently reported adverse events were headache, upper respiratory tract infection, nasopharyngitis, and urinary tract infection (Table 3). There was 1 death (due to sepsis syndrome) prior to randomization, and 1 death during the study in a patient who received 1 dose of anifrolumab 1,000 mg. The patient had acute colitis with a rapidly deteriorating clinical course and had features of macrophage CardioClassifier is an ICC-specific decision-support tool that integrates expertly curated computational annotations with case-specific data to generate fast, reproducible and interactive variant pathogenicity reports, according to best practice guidelines. in the placebo group. All patients responded promptly to antiviral treatment. One patient in the 300‐mg group discontinued treatment due to transverse myelitis with a positive PCR test for herpes zoster in the cerebrospinal fluid; the patient responded to antiviral and high‐dose corticosteroid treatment. The percentages of patients who were reported as developing influenza were greater in the anifrolumab 300‐mg group (6.1%) and anifrolumab 1,000‐mg group (7.6%) than in the placebo group (2.0%). Infusion‐related reactions were reported in 6\n",
            "[0.7349689]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the genetic basis of tuberous sclerosis?\n",
            "Refined Query: Tuberous sclerosis complex (TSC) is a genetic disorder.  What are the specific genes implicated, their normal functions, and how mutations in these genes (e.g., *TSC1* and *TSC2*) lead to the characteristic features of the disease, such as tumors and neurological abnormalities?\n",
            "\n",
            "Combined Answer: cerebellum. For rx3, the human ortholog RAX is embedded in a large syntenic block, and a cone-rod dystrophy (OMIM%600624) has been mapped to the area (Warburg et al. 1991). In the BARHL1 GRB, the far upstream TSC1 gene at 9q34 is implicated in tuberous sclerosis (OMIM#191100) and focal cortical dysplasia of Taylor (OMIM#607341), distinguished by epileptic seizures and likely caused by a neuronal migration defect (Wolf et al. 1995), which is consistent with the barhl1 expression pattern. However, the TSC1 ortholog was duplicated in teleosts cohort. We saw a wide variety of seizure types in our cohort of individuals with TBC1D24 mutations, including generalised tonic-clonic, complex partial, focal clonic seizures, and infantile spasms. Table 2, Table 3 list the clinical features of individuals with and without TBC1D24 mutations. Figure 2 shows photographs of the face, hands, feet, and radiographs. The mutations are listed in table 1 and shown in figure 3. The conservation of the affected residues and nucleotides is given in the appendix (p 17). In families with TBC1D24 mutations radiographs. The mutations are listed in table 1 and shown in figure 3. The conservation of the affected residues and nucleotides is given in the appendix (p 17). In families with TBC1D24 mutations and consanguinity, the mutations were homozygous and TBC1D24 was in a region of homozygosity as identified by SNP array or homozygosity mapping from exome data. The regions of homozygosity are given in the appendix (p 11). Because of the recessive nature of the disease and the presence of mutations predicted to lead to premature protein termination, mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without TBC1D24 mutations, we did not identify a mutated gene in common in these families (details on the regions identified are given in the appendix p 11). Analyses are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 26 families were included in the study. We did exome sequencing in the first 17 enrolled families; we screened for TBC1D24 by Sanger sequencing in subsequent families. We identified TBC1D24 mutations in 11 individuals from nine families (by exome sequencing in seven families, and Sanger sequencing in two families). 18 families had individuals with all five main features of DOORS syndrome, and TBC1D24 mutations were identified in half of these families. The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, all five main features of DOORS syndrome, and TBC1D24 mutations were identified in half of these families. The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, complex partial, focal clonic, and infantile spasms. Of the 18 individuals with DOORS syndrome from 17 families without TBC1D24 mutations, eight did not have seizures and three did not have deafness. In expression studies, some mutations abrogated TBC1D24 mRNA stability. We also detected Tbc1d24 expression in mouse phalangeal chondrocytes and genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also substantiate the role of this gene in various epilepsy syndromes, as is seen also with other epilepsy-related genes such as SCN1A, KCNQ2, and PRRT2. Moreover, our findings lend support to the idea of pleiotropy in epilepsy genetics because, although some mutations in TBC1D24 can cause mild epilepsy without other substantial associated features, for all TBC1D24 variants (from DOORS syndrome, the other associated epileptic disorders, and the Exome Variant Server), including population frequency, conservation scores and PolyPhen2 scores are in the appendix (p 8). Collectively, other coding variants in TBC1D24 were seen in the heterozygous state in 343 (5%) of 6503 of the Exome Variant Server cohort. We saw a wide variety of seizure types in our cohort of individuals with TBC1D24 mutations, including generalised tonic-clonic, complex partial, focal clonic seizures, and infantile spasms. data. The regions of homozygosity are given in the appendix (p 11). Because of the recessive nature of the disease and the presence of mutations predicted to lead to premature protein termination, we proposed that the mutations cause a loss of TBC1D24 function. We assessed this hypothesis in fibroblasts from a biopsy previously done for clinical reasons in individual 3, who was compound heterozygote for a splice site mutation and a frameshift mutation in trans. This frameshift mutation, because it is not in the last exon, is predicted to lead Our findings suggest that mutations in TBC1D24 seem to be an important cause of DOORS syndrome and can cause diverse phenotypes. Thus, individuals with DOORS syndrome without deafness and seizures but with the other features should still be screened for TBC1D24 mutations. More information is needed to understand the cellular roles of TBC1D24 and identify the genes responsible for DOORS phenotypes in individuals who do not have a mutation in TBC1D24.\n",
            "[0.63144296]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the molecular function of the Chd1 protein?\n",
            "Refined Query: The Chd1 protein is a chromatin remodeler.  To understand its molecular function, we need to explore precisely how it alters chromatin structure.  Specifically, what are its enzymatic activities and how do these activities impact gene expression and other cellular processes?\n",
            "\n",
            "Combined Answer: Katou et al. 2003; Warren et al. 2004; Bando et al. 2009). Their molecular mechanism of action is still poorly understood. Chl1 was one of the first identified budding yeast genes with a role in chromosome segregation. It encodes a DNA helicase, but little is known about its molecular function during DNA replication or in sister chromatid cohesion (Gerring et al. 1990; Hirota and Lahti 2000; Petronczki et al. 2004; Skibbens 2004). A putative link of Chl1 to lagging strand DNA synthesis has been derived from its ability to bind PCNA and Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and polymerase complexes provides a mechanism for the specificity of this tight and essential chromatin association. However, it is not yet clear how many distinct steps or molecular complexes operate in cohesion, which must incorporate sufficient flexibility to support both local and global dynamic chromatin restructuring events, including transcriptional responses, DNA repair, DNA replication, and mitotic chromosome condensation. It is to be anticipated that the protein complexes operating within mechanisms governing the establishment, Chromatin is made up of nucleosomes comprising histone octamers with a stable tetrameric core of histones H3 and H4, flanked by two more labile dimers of histone, H2A and H2B. Each histone octamer is wrapped by 147 bp DNA, which facilitates the compaction of genomic DNA and regulates access to regulatory factors (Workman and Kingston 1998). Chromatin is critical for the regulation of genome stability and for transcriptional control and its importance in disease has been highlighted by the frequent identification of mutations in histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone deacetylase (NuRD) complex which is necessary for embryonic stem cell differentiation, it also directly interacts with DNMT1 and affects global DNA methylation status (17). LSD1 is the first of several protein lysine demethylases discovered. It specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 and functions as a transcriptional co-repressor (18, KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Jacobsen, 2010). The plant specific DNA methyltransferase CHROMOMETHYLASE 3 (CMT3) binds to H3K9me2 and methylates cytosine residues at CHG sites (where H is A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can erythroid and megakaryocytic lineages (Pevny et al, 1995; Saleque et al, 2002). Chromatin remodeling and modification proteins also coeluted with GATA-1 (Table I) including the entire MeCP1 complex (Figure 1). MeCP1 consists of the methyl-DNA binding protein MBD2 (Feng and Zhang, 2001), p66/p68 (Feng et al, 2002) and the multi-subunit Mi-2/NuRD complex containing the nucleosome stimulated Mi-2β ATPase, the histone deacetylases HDAC1 and HDAC2 and other subunits of unknown function. The Mi2/NuRD and MeCP1 complexes are associated with genes to be rapidly transcribed or vice-versa (32–34). LSD1 is the first identified histone lysine-specific demethylase involved in removing mono- or dimethylated H3K4 (35). As a putative transcriptional repressor, LSD1 associates with multiple corepressor complexes including COREST and NURD complexes (36–38). Histone deacetylase activities of these complexes facilitate the LSD1 demethylase enzymatic activity on the chromatin template and therefore, enhance its repressive function (39). LSD1 regulates a variety of target genes that are We speculate that a subset of chromatin-associated 53BP1 remains inactive in cells (not phosphorylated/no association with effectors) even after DNA damage. Ectopic activation of RNF168 or loss of TIRR activates this subset leading to ‘hyper-active’ 53BP1 (see model in Extended Data Fig. 10). 53BP1 is a representative of Tudor domain-containing histone methyl-lysine readers such as SGF29, Spindlin1, UHRF1, and SHH140. These reader proteins are involved in the pathogenesis of various diseases and identifying small molecules that inhibit\n",
            "[0.69333285]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which drugs are included in the FEC-75 regimen?\n",
            "Refined Query: I need a more precise explanation of \"FEC-75 regimen\".  Is this a chemotherapy regimen?  If so, what type of cancer is it used to treat? Specifying the cancer type will allow for a more accurate and complete answer regarding the constituent drugs.\n",
            "\n",
            "Combined Answer: to docetaxel treatment and clinical outcome for patients that receive docetaxel treatment. To date, we have no clinical applications to predict the response to docetaxel chemotherapy in PC patients. The present results suggested that monitoring the expression of Uc.63+ in serum could potentially improve several steps of PC treatment, including the screening of PC patients using serum samples, and contribute to selection of the best treatment for PC patients: so-called “tailor-made treatment”. However, one concern is that the robust expression 1.1 criteria, and 19 (32.2%) had a confirmed partial response. Of the 5 patients who had a partial response that was never confirmed, 1 had long-term stable disease, whereas 4 had rapid disease progression (2 in target lesions and 2 in nontarget lesions). Rapid progression might suggest a high degree of tumor heterogeneity in these patients with late-stage disease or an early adaptation to treatment, as reported in a preclinical study with a precursor inhibitor.28 The molecular signature of the tumors from patient subgroups with distinct Houston, TX, USA Gregory N. Fuller, Pathology, UT MD Anderson Cancer Center, Houston, TX, USA Steven G. Waguespack, Endocrinology, UT MD Anderson Cancer Center, Houston, TX, USA Surena F. Matin, Urology, UT MD Anderson Cancer Center, Houston, TX, USA been treated with bortezomib. Carfilzomib is currently undergoing extensive clinical testing in multiple myeloma, as well as evaluation in mantle cell lymphoma, T-cell lymphoma, large B-cell lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, acute lymphoblastic leukemia, small cell lung cancer, renal cell carcinoma, and advanced prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being In contrast, the expression of Uc.63+ was significantly upregulated in the serum from PC patients compared with that from BPH patients. Moreover, we revealed that the expression of Uc.63+ in serum was remarkably upregulated in CRPC patients, and evaluation of its expression level in PC patients could be a useful biomarker for predicting the sensitivity to docetaxel treatment and clinical outcome for patients that receive docetaxel treatment. To date, we have no clinical applications to predict the response to docetaxel chemotherapy in PC A total of 707 patients were randomly assigned in a 2:1 ratio to receive cabozantinib (60 mg once daily) or matching placebo. Eligible patients had received previous treatment with sorafenib, had disease progression after at least one systemic treatment for hepatocellular carcinoma, and may have received up to two previous systemic regimens for advanced hepatocellular carcinoma. The primary end point was overall survival. Secondary end points were progression-free survival and the objective response rate. A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or rate; however, the designation of “minor response” was included as a response for patients with 25–50% reduction in 2-dimensional tumor measurements which would have been categorized as stable disease in our study. If this designation were included on the current study, the overall response rate would increase even further. Five-year OS and EFS with vinblastine were 93.2% ± 3.8%, and 42.3% ± 7.2%, respectively.(26) A PBTC phase II study of bevacizumab and irinotecan in 35 evaluable children with recurrent pLGG showed 2-year PFS of 47.8% (SE ± This randomized, phase 3 trial showed that cabozantinib treatment significantly prolonged survival in patients with previously treated advanced hepatocellular carcinoma. The median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo, with a hazard ratio for death of 0.76. Corresponding to this survival benefit, a longer duration of progression-free survival was also observed: the median progression-free survival was 5.2 months with cabozantinib and 1.9 months with placebo, with a hazard ratio for disease progression UT MD Anderson Cancer Center, Houston, TX, USA Justin A. Weldon, Departments of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA Ashley H. Woodson, 6, Clinical Cancer Genetics, UT MD Anderson Cancer Center, Houston, TX, USA Patrick G. Pilie, Departments of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA Gregory N. Fuller, Pathology, UT MD Anderson Cancer Center, Houston, TX, USA Steven G. Waguespack, Endocrinology, UT MD Anderson Cancer Center, Houston, TX, USA Surena F. Matin,\n",
            "[0.7917446]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Between which probes does the recurrent translocation breakpoint on chromosome 22 of neuroepithelioma lie?\n",
            "Refined Query: Neuroepitheliomas exhibit a recurrent translocation on chromosome 22.  Pinpointing the precise location of this breakpoint requires identifying the specific BAC or other genomic probes flanking the translocation site.  Which probes delineate this crucial breakpoint region on chromosome 22?\n",
            "\n",
            "Combined Answer: Based on the known consanguinity in these two families, we looked in each family for homozygous regions shared by the affected patients, yet not by their healthy siblings, using SNP arrays. We identified a single region on chromosome 12 spanning from 117 989 470 to 127 688 342 Mb and from 119 467 188 to 127 757 133 Mb (GRCh37/hg19) in families A and B, respectively (Figure 1, Supplementary Material). In family A, the 9.7-Mb region on chromosome 12 encompassed >100 protein-coding genes, and we elected to proceed with whole-exome sequencing in in the presence of Pfh1 (Fig. 4B). However, this pausing was increased threefold in Pfh1-depleted cells (Fig. 4B). Structures with the mobility of broken (Fig. 4B, fb) and converged (Fig. 4B, arrow) forks were also detected, but only in the absence of Pfh1 (Fig. 4B). We did not detect a bubble arc, suggesting that ORI2026 is either dormant or located outside the fragment being studied (Fig. 4B). Alternatively, this fragment could be replicated from forks initiating at ORI2027 (efficiency 37%). tRNAASN.05 is located on chromosome III between flanks are removed, and the TFBSs are assembled in the form of nnNNN … NNNnn using the remaining sequences. Here, the stretch of NNN … NNN represents the core binding site, and nn represents the 2-bp flanks required for predicting DNA shape features for the two NN positions at either end of the core binding site. If the portion of TFBSs with flanking sequence information is ≤50%, then no sequences are removed, and TFBSs are assembled in the form of NNN … NNN. In this case, DNA structural features cannot be predicted for the first and last two of GRBs. Following this, putative regions were split by the chromosome that they originated from in the query species to generate discrete regions of conserved synteny. Regions that did not contain a protein-coding gene were merged with adjacent regions if they were within 300 kb (for humans/mouse) or 50 kb (for Drosophila). All remaining regions not containing a protein-coding gene or having <10 CNEs was discarded, resulting in a set of putative GRBs. Our initial investigations found that segmenting CNE density using either a HMM or the We thank the UCSF Neuropathology BTRC Biomarkers Laboratory for developing and performing the immunohistochemical stain for histone H3‐K27M mutant protein. D.A.S. is supported by a Career Development Award from the UCSF Brain Tumor SPORE and an NIH Director's Early Independence Award (DP5 OD021403). fragments18; subsequent studies showed that such fragments are condensed heterochromatin19. Indeed we found repressed regions are depleted for short fragments and enriched for phased multi-nucleosomal inserts, consistent with their expected inaccessible state. These data suggest that ATAC-seq reveals differentially accessible forms of chromatin, which have been long hypothesized to exist in vivo2,20,21. To explore nucleosome positioning within accessible chromatin in the GM12878 cell line, we partitioned our data into reads generated from Nadeau and Taylor (1984) suggested a model of genome evolution in which evolutionary chromosomal breakpoints are distributed randomly throughout the mouse and human genomes, and postulated conserved blocks of synteny to be “relics of ancient linkage groups not yet disrupted by chromosome rearrangement.” In closely related genomes such as mouse and human, this may be partially true, but it is likely that in distantly related vertebrates, sufficient numbers of translocation events have occurred during evolution to rearrange all large chromosomal c>t transition leading to p.R500X, a protein truncating mutation in the putative eleventh transmembrane domain of the protein. In Family 12, this mutation appears likely de novo in the mother of the affected CS male (i.e. not found in the maternal grandparents). In Family 9, this mutation is inherited. These families do appear to share a haplotype around the mutation locus (Supplementary Table 4), which may be prone for recurrent mutation although further research will be necessary to clarify this. The mutation occurs at a CpG location in the All coordinates listed in this study are with reference to human genome build hg18. All start coordinates are 1-based. In this article, we described the RAPIDR package for NIPT of fetal aneuploidies. RAPIDR has been validated using >700 samples and delivers an acceptable level of specificity and sensitivity for T21, T18, T13 and monosomy X. The system requirement for RAPIDR is modest (Supplementary Text S3). Future work on RAPIDR will include evaluating strategies to detect sub-chromosomal abnormalities. Funding: This manuscript presents independent research funded by the National Institute for Health Research (NIHR) under the Program Grants for Applied\n",
            "[0.8342393]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does administration of triiodothyronine improve outcome following coronary artery bypass grafting?\n",
            "Refined Query: Investigating the impact of triiodothyronine administration on patient outcomes after coronary artery bypass grafting (CABG) surgery requires examining mortality, morbidity, length of hospital stay, and recovery rates in patients receiving T3 versus those receiving standard care.  Does supplemental T3 improve these post-operative parameters?\n",
            "\n",
            "Combined Answer: follow-up visit (postoperative day 105) divided by the sum of patients who return for the 3-month follow-up visit and all patients with confirmed symptomatic reherniation who fail to return for this visit. The propensity score-adjusted primary endpoint results will be descriptively reported for patients treated with the Barricaid device in each study, with no formal hypothesis testing. The difference in propensity score-adjusted 3-month reherniation risk between the US Barricaid trial participants and the EU Barricaid Controls will be reported identified within the first year.[26] Lastly, clinical outcomes during the first year after surgery are important metrics utilized by healthcare payers for making coverage decisions on new medical technologies. Another potential criticism of this study is a sample size of only 75 patients. This sample size was determined by calculating the minimum number of patients that would provide sufficient precision around the primary endpoint estimate. While formal noninferiority testing with patients in the US Barricaid Trial and the EU Barricaid and outcome measures will serve as historical controls. Main outcomes will include back pain severity, leg pain severity, Oswestry Disability Index, health utility on the EuroQol-5 Dimension questionnaire, complications, symptomatic reherniation, and reoperation. Propensity score adjustment using inverse probability of treatment weighting will be used to adjust for differences in baseline patient characteristics between the US trial participants and European historical controls. Using a Clopper-Pearson exact test, a sample size of 75 patients (70 evaluable at 3 months) produces a 2-sided 95% confidence interval ranging from 0.4% to 10.2% when the symptomatic reherniation rate is 3.0%. The primary endpoint will be calculated as the number of patients who experience symptomatic reherniation through the end of the 3-month follow-up visit (postoperative day 105) divided by the sum of patients who return for the 3-month follow-up visit and all patients with confirmed symptomatic reherniation who fail to return for this had a 3-year reherniation risk of 6.1%. In contrast, patients with early reherniation or 3-month back pain scores of 13/100 or higher had a 3-year reherniation risk of 22.6%. Additionally, the 1-year follow-up duration is clinically justified; among patients with a symptomatic reherniation through 3 years following Barricaid treatment, 60% were identified within the first year.[26] Lastly, clinical outcomes during the first year after surgery are important metrics utilized by healthcare payers for making coverage decisions on new medical score are currently being performed at MGH and could potentially improve the predictive accuracy of the RAPT for intermediate-risk patients. Further studies assessing the predictive accuracy of preoperative scoring systems such as RAPT at other institutions are warranted as well as studies assessing the effect of using RAPT to identify patients for targeted interventions in terms of length of stay, discharge disposition, clinical outcomes, and financial impact. in patient-reported outcomes will be evaluated with a mixed model analysis of variance. Categorical efficacy data will be evaluated as the number of patients with an event divided by the number of patients with follow-up data plus the number of patients with an event who miss the follow-up visit. Symptomatic reherniation and reoperation rates will be evaluated in a sensitivity analysis using Kaplan–Meier time-to-event methods. Missing data imputation will not be performed. and patients will continue in follow-up for 1 year after surgery. Although it could be argued that longer follow-up is needed in this relatively young patient population, the 3-month primary endpoint analysis is justified since early clinical outcomes in this patient population are highly predictive of long-term recurrence risk. Using 3-year data from the EU Barricaid Controls, we developed a Cox proportional hazards model that included 15 variables including age, sex, body mass index, index level, smoking history, symptomatic reherniation by potential group differences in important patient characteristics will be accounted for using propensity score methods. Thus, this observational study was appropriately designed to control for several important design factors that might have otherwise introduced bias into the results. The primary endpoint of this study will be evaluated at 3 months and patients will continue in follow-up for 1 year after surgery. Although it could be argued that longer follow-up is needed in this relatively young patient population, the 3-month primary endpoint and Prediction Tool (RAPT) is a preoperative survey constructed to predict discharge disposition after TJA [11]. It consists of six questions and generates a score from 1 to 12 with a low score indicating a higher risk for needing inpatient rehabilitation after TJA, including short-term nursing facilities (SNFs). The tool was developed and validated on data from an Australian cohort of 650 patients undergoing TJA. The cohort was split into two groups; data from the first 530 patients were used to develop the tool and data from the next 120\n",
            "[0.37783885]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the most widely used computational methods for the identification of CRMs (cis-regulatory modules)?\n",
            "Refined Query: What are the prevalent computational approaches used to identify cis-regulatory modules (CRMs) in genomic sequences, considering factors like accuracy, efficiency, and the types of genomic data they utilize (e.g., sequence conservation, transcription factor binding sites)?\n",
            "\n",
            "Combined Answer: Genome sequences were downloaded from the NCBI in FASTA format. Indexed versions for rapid scanning were generated for Bowtie (Langmead et al., 2009). The motif databases offered by PWMScan have been downloaded from the MEME Suite website (Bailey et al., 2009). LPMs have been converted to integer PWMs (see Supplementary Material). The input form of the PWMScan server is shown in Figure 1. The user chooses a genome assembly from a menu. Optionally, a BED file may be uploaded to restrict the search to genomic regions of particular interest, e.g. and inter-convertible. A PWM contains weights for each base at each motif position. By summing up weights at corresponding positions, a binding score can be computed for any base sequence of the same length as the PWM. Large collections of TF specificity matrices are nowadays available from public libraries such as JASPAR (Khan et al., 2017) or HOCOMOCO (Kulakovskiy et al., 2017). PWMScan is a web-server for rapid scanning of large genomes for high-scoring matches to a user-supplied or server-resident PWM. Compared to other web-based PWM ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs - PMC sequences of observed binding sites generally display a considerable variation, which may cause difficulties in the description of binding preferences using sequence motifs. Recent benchmarking studies confirmed that transcription factor binding sites (TFBS) prediction based on statistical motif discovery approaches is unreliable and thus remains a major bottleneck in the study of transcriptional regulatory regions [1], [2]. Identification of regulatory elements based on evolutionary conservation, also known as phylogenetic footprinting, has a major bottleneck in the study of transcriptional regulatory regions [1], [2]. Identification of regulatory elements based on evolutionary conservation, also known as phylogenetic footprinting, has the evident drawback of missing regulatory elements responsible for diversity among species. Therefore laboratory experiments assaying DNA-protein interactions in vivo remain indispensable. Especially massively parallel sequencing technologies in combination with chromatin immunoprecipitation (ChIP-seq) has proven a very powerful method to locate RAPIDR is implemented in R and can be freely downloaded via CRAN from here: http://cran.r-project.org/web/packages/RAPIDR/index.html. Contact: kitty.lo@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online. a pull-down menu. Alternatively, matrices can be entered into a text area or uploaded. Accepted motif types are: PFMs, LPMs, real or integer PWMs and IUPAC consensus sequences. PFMs can be entered in several formats, including TRANSFAC and JASPAR. All motif types have to be converted into integer PWMs for input to the genome search engines (see Supplementary Material). Default conversion parameters are proposed and can be changed by the user. For instance, real PWMs can be rescaled on input by a multiplication factor to ensure sufficient sophisticated computational approaches that are not available to most experimental researchers. Here we have presented ISMARA, a completely automated system that enables any researcher to apply sophisticated computational modeling, on data from their system of interest, and obtain concrete predictions on the key regulators acting in their system, their activities, their genome-wide targets, and so on. That the computational model at the core of ISMARA, i.e., motif activity response analysis, is a powerful method for reconstructing regulatory Transcription factors regulate gene expression by binding to specific short DNA sequences of 5–20 bp to regulate the rate of transcription of genetic information from DNA to messenger RNA. We present PWMScan, a fast web-based tool to scan server-resident genomes for matches to a user-supplied PWM or transcription factor binding site model from a public database. Today's high-throughput experiments measure the expression of thousands of genes simultaneously using microarrays, RNA-Seq or various proteomics approaches. ChIP-on-chip or ChIP-Seq experiments are used to determine the genome-wide DNA binding pattern of a specific protein, which may affect a large number of genes. New genomes are being sequenced at an ever-increasing pace and their genes characterized by homology-based annotation transfer. In order to interpret the results of such experiments, statistical testing for over- and\n",
            "[0.7719439]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which enzyme does MLN4924 inhibit?\n",
            "Refined Query: MLN4924 is a known inhibitor of a specific enzyme;  the question seeks to identify that target enzyme, clarifying its precise role in cellular processes.\n",
            "\n",
            "Combined Answer: may be important. To identify the targets of the 106 compound, we synthesized an activity-based profiling probe (ABPP) version of one of our HDAC inhibitors (106) and a control probe, which is a derivative of 106 lacking a 2-amino group in the HDAC inhibitor portion of the molecule.7,14 The control probe is far less active as an HDAC inhibitor as shown in a previous study.7 While our primary interest is identification of targets of 106 that might be involved in regulation of the FXN gene in FRDA, an unbiased proteomic approach should also MDC Systems Biology Network (MSBN) as a participant of the Helmholtz-Alliance on Systems Biology (to S.D.M.); Deutsche Forschungsgemeinschaft for a fellowship in the International Research Training Group Genomics and Systems Biology of Molecular Networks (GRK 1360 to M.J.). Federal Ministry for Education and Research (BMBF) and the Senate of Berlin, Berlin, Germany (to M.L. and C.D.). Funding for open access charge: MDC. Conflict of interest statement. None declared. writes all three methylation states at H3K36 whereas in mammals, each state of methylation is laid down by distinct enzymes suggesting extensive regulation of K36 methylation and its importance throughout evolution (Morris et al. 2005; Wagner and Carpenter 2012). Enzymes that modify K36 have been associated with various cancers. For example, SETD2 (the only enzyme that performs K36me2 to me3 modification) is mutated in renal carcinoma and breast cancer (Duns et al. 2010; Newbold and Mokbel 2010), and NSD2, which generates K36me2, has been individual mutants revealed that K151E mutant continues to associate with 53BP1 in cells, while K10E mutation is sufficient to disrupt the interaction with 53BP1. We concluded that the residue K10 is crucial for the interaction with 53BP1. Table S1). Combination of alternating recognition sites allows for higher degradation efficiency and reduces sequence repetitiveness. The two enzymes have recognition sites of lengths 27 and 18 bp, respectively, which even with some degeneracy allowed in the recognition site (Gimble and Wang 1996; Argast et al. 1998) makes their random occurrence in a transcriptome highly improbable. The two enzymes work at the same temperature and in the same buffer, so their digestion can be combined in a single step. A fraction of the synthesised carrier K36M) or by introduction of a mutation in a residue close to K36 (at G34) that may influence binding of writer or reader proteins at K36 (Schwartzentruber et al. 2012; Behjati et al. 2013; Lewis et al. 2013; Chan et al. 2013). Why G34 is targeted, but not other neighboring residues of K36 remains a mystery. It is conceivable that the introduction of a charged (R) or a bulky residue (W) in place of G34 might impact the accessibility or activity of enzymes that target K36 or alter the conformation of the tail leading to changes in nucleosomal results showing that MDM2 overexpression is common in ALL cell lines with wild-type p53 [52]. One interesting observation is that among the ALL xenografts ALL-19 had the lowest p53 and highest MDM2 expression and was the ALL line where RG7112 treatment resulted in low activity (based on EFS) and that did not score a CR or MCR (Figure 4). The PPTP previously tested serdemetan [53], which was initially developed as an inhibitor of MDM2 [54,55], and a comparison of results from both the in vitro and in vivo activity evaluations supports prior structures obtained using supervised assignments for the three target proteins, RTT, ms6282 and aLP, are better than or comparable to the convergence of structures obtained using 4D-CHAINS automated assignments, as expected (Table 1). Notably, for Enzyme I, autoNOE-Rosetta achieves a higher level of structural convergence using automated assignments due to enhanced resampling of the correct protein fold during the early stages of the autoNOE-Rosetta structure calculation process. Overall, our results suggest that the fully automated assignment calculations guided by both supervised or automated 4D-CHAINS assignments, and the resulting structural ensembles are very similar for all targets (Fig. 5; left column). For the largest target, the 27.3 kDa Enzyme I from Thermoanaerobacter tengcongensis, NOE contacts provided sufficient constraints to elucidate the structure of the individual domains, but the overall orientation of the two domains was not converged due to the lack of contacts at their interface (domain A, defined by residues 1–143 and domain B, defined by residues 144–248) extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified both HDAC3 and its partner protein NCoR1 by Western blot analysis.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 329.36ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?\n",
            "Refined Query: Investigating the interaction between phospholamban (PLN) and anti-apoptotic proteins is crucial.  Specifically, I'm looking for the identity of a protein known to both bind to PLN and possess anti-apoptotic properties.  What protein fulfills both these criteria?\n",
            "\n",
            "Combined Answer: To determine the mechanism responsible for carfilzomib/vorinostat synergy in the acquired resistance models, we investigated the expression status of pro-apoptotic Bik protein. Bik is known to be upregulated in HNSCC cells following treatment with bortezomib, carfilzomib, or oprozomib, and plays an important role in mediating cell death by these proteasome inhibitors.8,34 However, as depicted in Figure 7, the R-UMSCC-1 and R-Cal33 resistance models demonstrated only modest, if any, upregulation of Bik when treated with either carfilzomib alone it also inhibits PLK2 in the biochemical assay (Fig. 2, A and B). APMU (compound 3 in Johnson et al. (29)), which has good activity against PLK2 and -3 but is inactive against PLK1, inhibited α-synuclein phosphorylation in mouse cortical cultures. These results, together with the lower activity for PLK1 (Fig. 1A), suggest a limited role, if any, for PLK1 as an α-synuclein kinase. BI2536 has high potency and specificity for PLK family kinases (30) (see profiling results in supplemental Table S1). This compound inhibited up to 85–90% of resistance. Cancer cells often exhibit aberrant activation of signaling proteins and pathways that promote cellular survival and intrinsic resistance to proteasome inhibitors and other anti-cancer agents. In addition, because the proteasome regulates expression levels of a large number of proteins with diverse functions, proteasome inhibitors induce the expression of proteins with proapoptotic and antiapoptotic roles. Thus, bortezomib, carfilzomib, and oprozomib upregulate proapoptotic Bik and Noxa, which act to mediate the killing activities the expression of proteins with proapoptotic and antiapoptotic roles. Thus, bortezomib, carfilzomib, and oprozomib upregulate proapoptotic Bik and Noxa, which act to mediate the killing activities of these agents against HNSCC cells.8,34,49 At the same time, these agents also upregulate antiapoptotic Mcl-1 and phospho-STAT3 and promote pro-survival autophagy, which act to blunt the killing activities against these cells. In in vitro studies, co-targeting of Mcl-1, phospho-STAT3, or autophagy has been shown to reduce the intrinsic resistance of Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as CK2, which has been previously shown to phosphorylate α-synuclein (10). Phosphorylation at Ser-129 was measured with a fluorescence assay using an antibody specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent decreased synuclein phosphorylation were identified (26). Of the candidate kinases, PLK2 was of particular interest because the siRNAs against this enzyme provided the largest and most consistent decrease in α-synuclein phosphorylation. Importantly, PLK2, as well as the closely related PLK3, are expressed in brain (27, 28). PLK Family Members Directly Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as an average ratio (ABPP 106 versus control probe) greater than 1.5 with a p-value <0.05, and among those proteins 883 had an average ratio greater than 2 (Figure 3). HDAC1 and 2 were identified as 106-probe specific binders and were verified by Western blot analysis (Figure 4). HDAC1 and 2 were found to be significantly enriched in the ABPP 106 incubated samples. dependent on upregulation of proapoptotic Bik. By contrast, downregulation of MDR-1/P-gp, which was found to be overexpressed in the acquired resistance models, does not appear to play a role in the synergism between proteasome and HDAC inhibitors, since pretreatment with HDACi alone did not affect MDR-1/P-gp expression levels (data not shown). The overexpression of MDR-1/P-gp we observed in the acquired resistance models only partly explains the resistance of these cells. Only partial attenuation of carfilzomib resistance was seen when clonal density under different conditions and subsequently stained for alkaline phosphatase (AP) to evaluate the percentage of undifferentiated colonies. We found that, similar to the parental ApcNN cells, Tcf3-rescued clones show the highest colony forming capacity in the presence of LIF and Mek inhibitor (Figure 3D). Moreover, by applying the short term differentiation assay in N2B27 medium, we found that both ApcNN and their Tcf3-rescued counterparts retain expression of the pluripotency markers Nanog while fail to express the early evidence shows the two partners are not capable of binding each other alone, suggesting that a chaperone is required to enable binding, or that these interactions require both proteins to bind to a common intermediate or complex of intermediates. On the other hand, we find that in HOT promoters, FOS seems only rarely to perform its well-known role in the AP-1 heterodimer with JUN, generally supplanted by a FOSL or ATF protein, though of course FOS is known to have several alternate cofactors [34]. It should not be surprising that a TF with a\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.72ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.72ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 783.16ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.56ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 958.03ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 908.06ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1011.08ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 908.10ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 985.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 785.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Depression - {'SSRIs': 0.0, 'Anxiety Disorders': 1.0}\n",
            "\n",
            " ### Clustered: {'Depression': {'Cluster 1': ['SSRIs', 'Anxiety Disorders']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 581.35ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 859.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 834.64ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.33ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.42ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1286.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can DNA intercalators function as topoisomerase inhibitors?\n",
            "Refined Query: DNA intercalators, by inserting between DNA base pairs, can physically hinder the action of topoisomerases, enzymes that manage DNA supercoiling.  This raises the question: Do intercalators' steric hindrance directly inhibit topoisomerase activity, preventing DNA unwinding and religation, thereby acting as effective topoisomerase inhibitors, or are other mechanisms involved?\n",
            "\n",
            "Combined Answer: of double-strand DNA by TOP2B, as opposed to that by TOP2A, is more closely associated with the development of secondary malignancy after treatment with TOP2-targeting drugs such as etoposide and doxorubicin (Azarova et al, 2007). With regard to the case of cancer cells that escape from or resist anticancer drugs, one possibility is that reduced topoisomerase II levels occasionally allow the cells to survive from cytotoxic attack by maintaining their quiescence (Friche et al, 1991; Chen et al, 2011). Apart from relationship studies between a DNA-damaging agent, but not all and thus result in enhanced cytotoxicity. Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in an increase in apoptosis, DNA fragmentation, and yH2AX formation. The effect of topo-I inhibition is the induction of DNA SSBs (38), which are primarily repaired by the PARP-dependent BER pathway. In addition, it has been suggested that PARP inhibitors can enhance topo-I activity, which could sensitize cells to topoisomerase I poisons (39). The combination of topotecan with the of tumour chemoresistance to DNA-damaging agents in AML as well as other tumours (Chekerov et al, 2006; Chen et al, 2009; Coss et al, 2009). Some groups suggested no significant correlation between topoisomerase levels and treatment outcome at diagnosis (Kaufmann et al, 1994; McKenna et al, 1994). Another recent study indicated that a break of double-strand DNA by TOP2B, as opposed to that by TOP2A, is more closely associated with the development of secondary malignancy after treatment with TOP2-targeting drugs such as etoposide and We tested the association of these proteins with DNA and GATA-1 by treating nuclear extracts with DNase I. In contrast to MTA2, there were no topoisomerase I or PARP copurifying with GATA-1 after DNase I treatment (Supplementary Figure 2). Although it remains formally possible that interactions of GATA-1 with topoisomerase I or PARP are relevant and require DNA, on the basis of our DNase I results and on previous evidence by other groups describing topoisomerases as a common contaminant (Eberharter et al, 2001), we did not pursue these BER pathway. In addition, it has been suggested that PARP inhibitors can enhance topo-I activity, which could sensitize cells to topoisomerase I poisons (39). The combination of topotecan with the PARP inhibitor olaparib has recently been tested in a clinical phase I study in patients with advanced solid tumors (29). This trial showed enhanced topotecan-induced myelosuppression when combined with olaparib. Of note, our data also indicate that the most pronounced synergy was seen at low topotecan drug concentrations in vitro, which may imply of cccDNA and the slowly moving bands were the same after a heat denaturation (Fig. 6B, lane 2). This treatment converted nicked double-stranded circular and double-stranded linear DNA into single-stranded DNA. Supercoiled DNAs, however, were renatured and migrated in electrophoresis at the same mobility as their native forms after heat treatment. Second, treatment with Escherichia coli. topoisomerase I, which efficiently relaxes cccDNA with negatively superhelical turns, converted most of the cccDNA, including those slowly moving bands, into is required for forks to pause at protein–DNA barriers, the histone chaperone FACT, the type I topoisomerase Top1, and Mcm10 and Ctf4 that are known to bind DNA polymerase α (Homesley et al, 2000; Katou et al, 2003; Ricke and Bielinsky, 2004; Nedelcheva et al, 2005; Gambus et al, 2006). By purifying GINS from budding yeast cell extracts, we found that all of the above proteins form a very large assembly called the replisome progression complex or RPC (Gambus et al, 2006). The RPC only exists during S-phase, occurs on chromatin, requires the Second, treatment with Escherichia coli. topoisomerase I, which efficiently relaxes cccDNA with negatively superhelical turns, converted most of the cccDNA, including those slowly moving bands, into relaxed circular DNA and much less supercoiled cccDNA (Fig. 6B, lane 4). These results support the notion that the slowly moving species extracted from DHBV-positive duckling livers are cccDNA with less negatively superhelical turns. Since the number of superhelical turns in a cccDNA is equal to the number of bound nucleosomes on this molecule and require DNA, on the basis of our DNase I results and on previous evidence by other groups describing topoisomerases as a common contaminant (Eberharter et al, 2001), we did not pursue these further. in drug sensitivity against anthracyclines by distinct independent ways. Another possible explanation is that TOP2B/TOP2A ratio might be not relevant to a susceptibility against antitumour agents but to a biological feature of AML with good or poor outcome, empathising the value of the parameter as a predictive marker only. However, the functional and differential roles of both topoisomerases remain to be clearly elucidated. The reason for the differential regulation of their expression in AML cells will require elucidation in future studies.\n",
            "[0.7051369]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which diseases is microRNA 132 (miR-132) implicated in?\n",
            "Refined Query: Investigate the established and potential roles of microRNA-132 (miR-132) in human disease.  Explore its involvement in disease pathogenesis, progression, and potential as a diagnostic or therapeutic target.\n",
            "\n",
            "Combined Answer: miR-130b mimics than that in LNCaP Uc.63+#1 cells transfected with negative control (Figure 5G). Overexpression of miR-130b in LNCaP Uc.63+#1 cells downregulated the expression of MMP2 and migratory ability (Figure 5H, 5I). These results suggest that Uc.63+ may upregulate the expression of MMP2 through miR-130b interaction, which is most likely to contribute to the oncogenic role of Uc.63+. miR-130b mimics (target sequence ACUCUUUCCCUGUUGCACUAC, Thermo Fisher Scientific, MA, USA) was used for transfection of miR-130b. Transfection was performed with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA). Following the manufacture’s protocol. miR-130b. Additionally, Uc.63+ promoted docetaxel resistance by regulating the expression of AR. Furthermore, the expression of Uc.63+ in the serum was dramatically changed through the carcinogenesis and progression of PC from BPH to CRPC. Although additional studies will likely be needed to further advance our understanding of how Uc.63+ contributes to PC progression, the data presented here highlight the great potential of Uc.63+ as a serum biomarker and therapeutic target in patients with PC. T-UCRs with qRT-PCR by referring to the signatures reported by Hudson et al [13], which enabled us to focus on Uc.63+, and its functional roles in PC were quite consistent with those determined in a previous study on breast cancer [14]. One of the plausible explanations for the oncogenic role of Uc.63+ is thought to be an interaction with miR-130b that regulates MMP2. Several lines of study have provided evidence for an important role of the interaction between T-UCRs and miRNA in cancer biology. In this present study, we focused only on the and wound healing assay revealed that Uc.63+ was involved in cell growth and cell migration. miR-130b was predicted to have binding sites within the Uc.63+ sequence. The expression of miR-130b was significantly disturbed by the overexpression or knockdown of Uc.63+. We also showed that Uc.63+ regulated the expression of MMP2 via miR-130b regulation. Furthermore, overexpression of Uc.63+ increased the expression of AR and its downstream molecule PSA and promoted resistance to docetaxel through AR regulation. In patients treated with docetaxel, PC3 cells downregulated the expression of MMP2 by western blot analysis (Supplementary Figure 10B). To further verify that Uc.63+ was involved in the oncogenic role through miR-130b, we examined the overexpression of miR-130b in LNCaP Uc.63+#1 cells. qRT-PCR showed the expression of miR-130b was higher in LNCaP Uc.63+#1 cells transfected with miR-130b mimics than that in LNCaP Uc.63+#1 cells transfected with negative control (Figure 5G). Overexpression of miR-130b in LNCaP Uc.63+#1 cells downregulated the expression of MMP2 and migratory that regulates MMP2. Several lines of study have provided evidence for an important role of the interaction between T-UCRs and miRNA in cancer biology. In this present study, we focused only on the interaction between Uc.63+ and miR-130b, which would surely explain how Uc.63+ is involved in the regulation of PC cell migration and invasion but is not accountable enough for the interaction among Uc.63+ and PC cell growth. There could probably be a bunch of unknown miRNAs that are potentially regulated by Uc.63+, which may help to explain how in liver and the brain-specific role of hsa-miR-124, are well-known from the literature. However, all these results, including very specific predictions of the precise targets of each regulator, were obtained by a completely automated analysis of RNA-seq data from 16 human tissues, without any free parameters or specific processing of the data. Moreover, they constitute only a small selection of the predictions made by ISMARA. By default, ISMARA focuses on regulatory motifs that explain changes in expression levels across the input samples. or PC3 cells (Figure 5B). Furthermore, we investigated the expression of miR-130b in PC tissues and non-neoplastic prostate tissues by qRT-PCR and found that the expression of miR-130b inversely and significantly correlated with the expression of Uc.63+ (P = 0.002) (Figure 5C). There was significant downregulation of miR-130b in PC tissues compared with non-neoplastic prostate tissues (P = 0.002) (Figure 5D). To further investigate the interaction between Uc.63+ and miR-130b, we examined the effect of Uc.63+ deregulation on the expression of of miR-130b (Supplementary Figure 10A). It has been shown that matrix metallopeptidase 2 (MMP2) is a direct target of miR-130b [17]. Western blot analysis revealed that MMP2 was higher in LNCaP cells transfected with Uc.63+ expression vector than that in LNCaP cells transfected with empty vector (Figure 5F). As we expected, silencing of Uc.63+ in PC3 cells downregulated the expression of MMP2 by western blot analysis (Supplementary Figure 10B). To further verify that Uc.63+ was involved in the oncogenic role through miR-130b, we examined the\n",
            "[0.58619255]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the human glutamate transporters?\n",
            "Refined Query: Understanding the specific human glutamate transporters is crucial for neurological research.  This necessitates identifying the various transporter subtypes, their precise locations within the nervous system, and their roles in glutamate clearance, a process vital for preventing excitotoxicity.  Which specific proteins constitute these transporters and how they function are key questions.\n",
            "\n",
            "Combined Answer: It would be interesting to analyze the developmental profiles of TH transmembrane transporters in the choroid plexus (and in other blood-brain barrier structures) in non-mammalian vertebrates during development. The delivery of the requisite concentrations of THs to specific areas of the brain at each stage of CNS development is so important, that it would be understandable for evolution to have positively selected for more than one strategy for THs to enter the CNS. it is known that THs enter cells via TH transmembrane transporters, which participate in the influx and efflux of THs into and out of cells. Several classes of TH transmembrane transporter proteins that belong to the family of solute carrier (Slc) transporters have been identified e.g. organic anion transporting polypeptides (OATPs), monocarboxylate transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters TTR null mice have 36% T4 levels in their brain compared to wildtype mice (Palha et al., 1997). This implies that TTR is responsible for the other 64% of T4 moving into the brain. However, Mct8/Oatp1c1 double knock-out mice are cited as having only 10% TH concentration in their brains compared to wildtype mice (Muller and Heuer, 2014). However, careful analysis of the original paper reveals that only the forebrain (and not the entire brain) was analyzed for TH content (Mayerl et al., 2014). Furthermore, if TH transmembrane transporters are Most TH transmembrane transporters identified to date are promiscuous with respect to the range of metabolites they transport. Only MCT8 has been identified as being specific to transport of THs and their derivatives (Kinne et al., 2010). Intriguingly, there exists dramatic species-specificity in TH transmembrane transporters deficiency phenotypes. For example, human males with MCT8 mutations present with mental retardation (IQ <40), speech deficits and severe neurological abnormalities (known as the Allan-Herndon-Dudley syndrome), whereas transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters have been localized to the choroid plexus (Mayerl et al., 2012) and their distribution in the choroid plexus differs between species (Wirth et al., 2014). Most TH transmembrane transporters identified to date are promiscuous with respect to the range of metabolites they transport. Only MCT8 has been identified as being specific to transport of THs and and (ii) efflux of THs via TH transmembrane transporters. The relative quantitative contribution of each of these mechanisms during each stage of CNS development is currently unknown and should be investigated. Furthermore, perhaps the role played by choroid plexus-derived TTR is more significant in non-mammalian vertebrates than in mammals. It would be interesting to analyze the developmental profiles of TH transmembrane transporters in the choroid plexus (and in other blood-brain barrier structures) in non-mammalian vertebrates during this MR is predicted to have differential activity. We defined ‘synaptic’ genes using a pre-defined list of ‘synaptic’ genes from the Ingenuity database (Kramer et al., 2014). We curated this list using a broad definition that tagged any gene that was related to synaptic function (according to Ingenuity‘s filter), even if its protein product is not technically localized to the synapse. This relatively broad definition fit our purpose, as our goal was to identify MRs that drive synaptic and neurophysiologic dysfunction. Although a narrower is able to also facilitate Rab protein-mediated GTP hydrolysis is not known. Our findings implicate defective vesicular trafficking as the possible basis of the complex phenotype in individuals with DOORS syndrome in view of findings from previous studies in other TBC proteins (panel). The seizure phenotype present in all individuals with TBC1D24 mutations, and the studies in Drosophila, suggest a potential role for aberrant neurotransmitter release in the neurological manifestations of the disease. However, further studies in model organisms compared with wildtype mice? How do these data from TH transmembrane transporter and TTR null mice correlate with the data from Chanoine et al. (1992)? The quantitative contributions of the various mechanisms for TH moving across the blood-CSF barrier (the choroid plexus) and across the blood-brain barrier need to be investigated in greater detail. For example, human males with MCT8 mutations present with mental retardation (IQ <40), speech deficits and severe neurological abnormalities (known as the Allan-Herndon-Dudley syndrome), whereas MCT8 null mice are without an overt neurological phenotype (Kersseboom and Visser, 2011). The discovery of the suite of TH transmembrane transporters, particularly in the choroid plexus, was important in understanding how TTR null mice were without an overt phenotype. The difference in phenotype between MCT8 variant human males and MCT8 null mice,\n",
            "[0.62757766]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the functions of sorting nexin 27?\n",
            "Refined Query: Beyond simply asking what SNX27 *does*,  explore its specific roles in cellular processes.  Consider its involvement in membrane trafficking,  endocytosis,  or specific signaling pathways.  What are the consequences of SNX27 dysfunction?\n",
            "\n",
            "Combined Answer: oncogenic regions of the genome (Bender et al. 2013) may help stabilize the tumor phenotype. How these islands of PRC2 activity are maintained is clearly an interesting question and may be linked to disparate modes of PRC2 recruitment to different loci or to the use of alternate methyltransferases since to date there is no direct demonstration that EZH1 activity is similarly blocked by K27M. Loss of H3K27me3 in K27M expressing cells may also allow for an increase in H3K27Ac (Lewis et al. 2013). The presence of H3K27Ac distinguishes active al. 2012; Saratsis et al. 2014). Most intriguingly, many studies have shown a dominant effect of the K27M mutation, irrespective of whether found in H3.1 or H3.3, with a pronounced reduction in total H3K27 Me2 and Me3 in cells expressing one H3K27M mutant allele among 30 alleles encoding H3 isoforms (Lewis et al. 2013; Chan et al. 2013; Bender et al. 2013; Venneti et al. 2013). In vitro, a H3K27M peptide suffices to block PRC2 activity (Lewis et al. 2013; Brown et al. 2014). The most likely explanation is that K27M “poisons” PRC2, by these effects and accumulate K27me3. Is the mechanism of H3K27M blockage of EZH2 activity restricted to EZH2 or does it impact EZH1 also? What about for K36M mutants in chondroblastoma—are SETD2 or other K36 methyltransferases similarly dominantly blocked for function? It is also critical to determine the mechanism by which G34 mutations influence SETD2 function and how they and the K36M mutation contribute to tumorigenesis. Why are the mutations found in these tumors so predominant in H3.3? Is it linked to the nature of the replacement the precise role of TBC1D24 not only in the nervous system, but also in the skeletal system and other systems affected in DOORS syndrome. In Caenorhabditis elegans, C31H2.1 (a TBC1D24 orthologue) was implicated in synaptic function by an RNAi screen.35 In Drosophila, the orthologue Skywalker (Sky) enables endosomal trafficking in synaptic vesicles by facilitating GTP hydrolysis by Rab35, thus controlling synaptic vesicle rejuvenation and neurotransmitter release.36 Human TBC1D24 has low similarity to the Drosophila protein36 and neither could contribute to the deposition of this mark within the repressed Snurf–Snrpn domain. Several proteins that belong to the Setd2 family were recently involved in the deposition of H3K36me3 in mouse. In one study, Setd2 was identified as the major H3K36me3 HMT in MEFs (Edmunds et al. 2008). Another study identified Whsc1 as a second, potent H3K36me3 HMT (Nimura et al. 2009). We thus used a loss-of-function approach to test whether one of the proteins belonging to this family might be involved in H3K36me3 deposition within heterochromatin. cell clusters in the majority of mice that stained positive for Ki-67, which marks proliferating cells (Lewis et al. 2013). The apparent induction of proliferation by expression of K27M appears to be very cell type and developmental stage-specific as K27M did not induce proliferation in undifferentiated human ES cells or in primary human astrocytes (Funato et al. 2014) and indeed suppressed the proliferation of immortalized normal human astrocytes (Buczkowicz et al. 2014), suggesting that there is no driver effect on tumorigenesis of the K27M There is a growing belief that a substantial fraction of these SNPs affect gene regulation by altering transcription factor binding onto DNA though other mechanisms (e.g. ncRNA-mediated) cannot be excluded, and a recent study suggests that only a minority of regulatory SNPs act through TF binding (2). Knowing whether a SNP potentially disrupts or creates a new TFBS is thus of paramount importance for interpreting diverse results from human population studies. In particular, it will help elucidate the molecular mechanisms by which a SNP affects increase in the fraction of dying cells following knockdown of LOC282997 (aka PDCD4‐AS1, Fig EV3B), implying that the examined lncRNAs are not involved in cell survival or apoptosis. Since MCF10A cells adopt migratory phenotypes in response to EGF‐induced stimulation (Tarcic et al, 2012), we examined the effect of lncRNA knockdown on cellular motility. Firstly, we placed siRNA‐transfected cells in the upper compartment of Transwell migration chambers and determined their migration to the lower compartment, 20 h later, in the presence of EGF. that EZH1 activity is similarly blocked by K27M. Loss of H3K27me3 in K27M expressing cells may also allow for an increase in H3K27Ac (Lewis et al. 2013). The presence of H3K27Ac distinguishes active enhancers (Calo and Wysocka 2013; Vermunt et al. 2014); thus, an aberrant transcriptional program may be elicited through turning on of normally silent enhancers in K27M expressing cells, contributing to tumorigenesis. Therapeutic attempts by targeting methylation pathways have yielded encouraging results. GSKJ4, a pharmacological JMJD3 (a H3K27me3 the H3K9me3 reader, and Suz12 and Ezh2, two subunits of the PRC2 complex (Simon and Kingston 2009; Margueron and Reinberg 2011; Yang et al. 2012), were not altered significantly in these cells (Fig. 1B; Supplemental Fig. 1B). Together, these results reveal that the levels of H3K27me2/me3 are reduced in the H3.3K27M tumor cells, and the reduction is not due to a reduced level of Ezh2 or the PRC2 complex. To determine whether H3.3K27M mutation is the cause of global reduction in H3K27me2 and H3K27me3, we established 293T cell lines expressing\n",
            "[0.40907767]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Do orphan and gene related CpG islands follow power-law-like distributions?\n",
            "Refined Query: Investigating the frequency distribution of CpG islands associated with orphan genes and known genes, the question explores whether these distributions approximate a power law.  This examines if the abundance of CpG islands in relation to gene type follows a scale-free pattern.\n",
            "\n",
            "Combined Answer: island length compared to bystanders, non-target TFs and other CpG island genes (all p-values << 0.05). The comparisons of CpG island count and CpG island length to gene length ratio showed similar differences (Figure 6; Table S4 in Additional data file 2). Also, the density of CpG dinucleotides was elevated around the most used TSS of the target genes. We calculated the observed/expected ratio of CpG dinucleotides, a standard method to predict CpG islands, for the [-4000,+4000] bp regions around the most used CTSS of target genes, bystander CTSS. Both the CpG island length and the existence of multiple promoters sets the target genes apart from other sets of genes, including genes in their immediate neighborhood with conserved synteny (bystander genes), other genes with CpG island promoters, and non-GRB target transcription factor genes. Based on our previous whole-genome analyses [13], it is reasonable to expect a correlation between the number of TCs and CpG island length or CpG dinucleotide density, but the differences go deeper than that. Even though no CpG methylation is CpG islands (other CpG island genes set). We removed the TFs that were also GRB targets from the set of other TFs. Our initial TF gene set was based on the set described in Vaquerizas et al. [38]. Afterwards, we calculated total length, number of CpG islands and CpG island length to gene length ratio for our four sets of genes (targets, bystanders, other CpG island genes and other TF genes). We compared these distributions using a Wilcoxon test (rank sum test) in R, testing for the alternative hypothesis that the true shift when comparing two other CpG island genes and other TF genes). We compared these distributions using a Wilcoxon test (rank sum test) in R, testing for the alternative hypothesis that the true shift when comparing two given distributions was greater than 0. CpG scores were calculated for a 250 bp window sliding in 50 bp steps over 8,000 bp regions around the most used CTSS. The error bars for CpG scores are calculated by sampling procedures, similar to the calculation of error bars of TC densities. CpG scores were the observed number of CpG dinucleotides divided Figure 5 for examples). Since most CpG islands normally map to promoters and are usually the targets of regulation by methylation [11,12,20], this arrangement is rather unusual. These CpG islands are the same ones recently shown to coincide with genomic regions bound by repressor Polycomb group proteins [21]. We mapped CpG islands to bystander genes, target genes and TFs not predicted to be GRB targets (gene set 4 described above), and compared their total CpG island length, count and CpG island length to gene length ratio; 94% of the GRB genes, target genes and TFs not predicted to be GRB targets (gene set 4 described above), and compared their total CpG island length, count and CpG island length to gene length ratio; 94% of the GRB target genes and 75% of the bystanders overlapped with at least one CpG island. Furthermore, target genes have a significantly larger total CpG island length compared to bystanders, non-target TFs and other CpG island genes (all p-values << 0.05). The comparisons of CpG island count and CpG island length to gene length ratio showed similar We downloaded CpG island locations from the UCSC Genome Table Browser [36] and Ensembl gene boundaries from Biomart (Ensembl release 49) [37]. We extracted all CpG islands that overlapped with our genes of interest (target, bystander and other TF genes); additionally, we randomly selected 3,000 genes that were not GRB targets but overlapped CpG islands (other CpG island genes set). We removed the TFs that were also GRB targets from the set of other TFs. Our initial TF gene set was based on the set described in Vaquerizas et al. [38]. Inspection of GRBs in a genome browser quickly reveals that many GRB target genes overlap with long CpG islands, and often with several of them. These CpG islands are not limited to the 5' end of the genes, but also occur in introns or internal exons of the gene; in some cases, the entire target gene is spanned by one or several CpG islands (see Figure 5 for examples). Since most CpG islands normally map to promoters and are usually the targets of regulation by methylation [11,12,20], this arrangement is rather unusual. These CpG islands are conditions, but having no known function, deserve additional study. Although we point out above that many of the VCSG genes in the pathogenicity island are in operons, we do not suggest that operonic organization of genes is enriched within the pathogenicity island versus other regions. There is little reason to suggest such anenrichment, and the number of genes is too small to warrant a statistical analysis of their distribution. 4(b). The ratio of the number of genes in the VCSG on the extended pathogenicity island to the number of bp in the extended pathogenicity island is 3.08-fold higher than the ratio calculated with number of bp in pXO1 as a whole as the denominator. Further, the ratio of the number of genes in the VCSG on the extended pathogenicity island to the number of bp in the extended pathogenicity island is 444-fold higher than the ratio of the number of genes in the VCSG on the chromosome to the number of bp on the chromosome.\n",
            "[0.80209523]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the proportion of non canonical splice sites in the human genome?\n",
            "Refined Query: Determining the precise proportion of non-canonical splice sites in the human genome is challenging due to annotation limitations.  The question requires clarifying the definition of \"non-canonical\" (e.g.,  deviation from the GT-AG rule, specific sequence variations) and specifying the data source used for analysis (e.g.,  known transcripts, RNA-Seq data).  The answer will depend on these parameters.\n",
            "\n",
            "Combined Answer: et al. 2009). In addition, >25% of lncRNA genes show evidence of alternative splicing with at least two different transcript isoforms per gene locus (Fig. 3D). The most highly spliced lncRNA gene is PCBP1-AS1 with 40 annotated isoforms. This human lncRNA gene is situated at a complex locus with major gene structure differences between human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with (DNA-seq) [9] including whole genome and whole exome mutations, Gene expression (RNA-seq V1, RNA-seq V2) [10, 11], microRNA sequencing (miRNA-seq) [12], and their meta data (clinical and biospecimen information) [13], which are organized into three levels (1,2,3). In this work, we focus on data extracted from TCGA of level 2 for DNA-seq and of level 3 for the other types of experiments. These are publicly available and high level preprocessed data regarding gene, exon and splice junction expression quantifications, DNA-methylation sites, and First, the distribution of paired-end sequencing fragment sizes overlapping each chromatin state (http://www.ensembl.org/info/docs/funcgen/regulatory_segmentation.html) were computed. The distributions were then normalized to the percent maximal within each state and enrichment was computed relative to the genome-wide set of fragment sizes. Figure S2. From this signal we simply derive concordant and discordant genomic regions using configurable score thresholds tc and td respectively. A more detailed description of the individual algorithmic steps and their implementation is given in the Supplement. We evaluated our approach by calculating a set of concordant regions from N = 219 WGS datasets that were subjected to M = 3 different VC pipelines using samtools (SAMT, Li et al., 2009), GATK haplotype caller (GATK, DePristo et al., 2011) and platypus (PLAT, Rimmer et al., 2014). boundaries of protein-coding loci are difficult to predict due to unannotated alternatively spliced transcripts, we have defined the boundaries of protein-coding genes to be 5 kb upstream of the start codon and 30 kb downstream from the stop codon (Fig. 1A). For the analysis presented in this study, we removed transcripts shorter than 200 bp (n = 198) and also those containing at least one exon intersecting a protein-coding exon on the same strand (n = 594). This results in a final set of 14,880 transcripts originating from 9277 loci. We then zero correspond to a ‘neutral state’ where a decision could not be made due to contradictory or missing input data. In a subsequent step, the concordance scores for all other genomic position (i.e. all positions for which there is no call in any Ci,j) is calculated by interpolation. For this, we consider genomic windows of size 2·x+1, centred on each position pk from the ordered set of all polymorphic positions in Ci,j (we chose x = 1000 in this study). If the upstream polymorphic position pk−1 is contained in this window then we linearly with correlations below a minimum are flagged as poor quality. The second metric uses the restriction fragmentation controls to determine whether input DNA underwent appropriate enzymatic digestion and denaturation during sample preparation. According to NanoString guidelines, low probe ratios and low probe counts are indicative of incomplete digestion and denaturation, respectively, and lead to flagging by our software. The final metric relies on invariant controls (which map to autosomal regions likely to have neutral copy number of two). the peak locations 1,000 times in a manner that preserved the length, chromosome, and GC content of the regions. The number of randomized sets of peaks that obtain as many or more overlaps with the annotation (e.g., tRNA) as the actual peaks is the empirical p-value. If no random sets meet the level of overlap with the actual peaks, then the p-value is reported as < 0.001. We accounted for the testing of each set of ChIP-seq peaks with multiple genomic features using the Bonferroni correction. were interrupted by (stretches of) concordant calls within a genomic window that started 1000 bp upstream and ended 1000 bp downstream of the respective call. We then created a genomic partition by merging all such genomic windows that contained at least 10 such counts (see Supplement for further details). The respective genomic coverages of all used genomic partitions are depicted in Figure 2d. We plotted accuracy, false discovery rate (FDR) and negative prediction value (NPV) in Figure 2b. The Figure shows that our method achieves the by BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat), filtering out matches in the human genome that differed in length by more than 3 bp and were not unambiguously unique in the human genome. The hg18 orthologs of our new UCE sets were then used in our analyses. Coordinates for all UCEs are available in Table S2.\n",
            "[0.7671087]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List protein gel staining methods visualizing the entire protein set.\n",
            "Refined Query: I need a comprehensive list of protein gel staining techniques capable of visualizing the complete protein population, not just specific subsets, within a single gel.  What methods achieve total protein visualization?\n",
            "\n",
            "Combined Answer: Figures S1–4 and Tables S1–5: protein quantification and functional analysis information. This material is available free of charge via the Internet at http://pubs.acs.org. of hundreds to thousands of macromolecules, which can be used to study concentrated protein solutions, and to investigate macromolecular crowding, or other phenomena involving large numbers of macromolecules. [9] and Dronpa [10]). Protein interactions are visualized using a standard epifluorescence microscope and the analysis does not require complex data processing. Combining peptides of different fluorescent proteins for complementation (termed multicolour BiFC) expanded the number of protein interactions that could be simultaneously visualized [7,11,12]. BiFC is by now a widely used assay for testing the protein interaction status in cultured cells [13] and plants [14]. In contrast, only a handful studies have used the technology for the of anchor points. Currently such lists are composed of promoters (transcription start sites) and ChIP-seq peak center positions. The user can thus restrict the query results to SNPs that fall into promoter regions or overlap with an in vivo TFBS validated by a ChIP-seq experiment. There are five types of statistical plots posted on the output pages: (i) a histogram indicating the number of SNPs that affect the binding of 0, 1, 2, etc. factors (Figure 2), (ii) a plot showing the relative enrichment for different factors (Figure 2), (iii) the Steady-state levels of specific proteins were determined by Western blotting using mid-log-phase, whole-cell extracts as described previously using either 30 μg (see Fig. 1A, 2B, 4B, and 5B) (16) or 10 μg (see Fig. 3C) of total protein (33). Extracts were resolved on a sodium dodecyl sulfate (SDS)-10% polyacrylamide gel, and proteins were transferred onto either Immobilon-P polyvinylidene difluoride (Millipore) or nitrocellulose (Bio-Rad) membranes. Commercially available monoclonal antibodies were used to detect RNAP IIA (8WG16; Covance), CTD extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified both HDAC3 and its partner protein NCoR1 by Western blot analysis. used for detection. Protein loading was determined by standardization to β-tubulin (polyclonal antibody R43; a gift of D. Koshland). Anti-Orc3p monoclonal antibody (SB3) was a gift of B. Stillman (57). Film scans were obtained with a Hewlett-Packard 4c/T scanner and analyzed using NIH Image 1.61. Following treatment, floating and attached cells were collected and lysed in lysis buffer (10 mM TRIS-HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 1% Triton X-100) containing protease inhibitor cocktail (1 tablet/10 mL; Roche Diagnostics Co.). Lysates were subjected to sonication and centrifugation, and the supernatants were transferred to new tubes. Bio-Rad Protein Assay dye concentrate (Bio-Rad) was used to determine protein concentrations in the lysates. Equivalent quantities of protein were electrophoresed on 10% or 12.5% SDS-PAGE gels and Associating regions of interest to genomic annotations is a standard part of many bioinformatics pipelines. The annotatr package improves upon existing annotation tools by returning all the genomic annotations associated with a region instead of artificially prioritizing one annotation type over another, giving a clearer picture of the biological complexities at play. In addition to tabular output of the annotations, annotatr's built-in plotting functions provide an easy and flexible way to summarize the annotations and view how data associated antibody for 1 hour at room temperature. Proteins of interest were visualized by enhanced chemiluminescence using the ECL Prime Western Blotting Detection System (GE Healthcare), Western Lightning Plus-ECL (PerkinElmer), or Western Lightning Ultra (PerkinElmer), and detected with LAS-4000 (GE Healthcare) or LAS-4000EPUVmini (Fujifilm) and quantified using ImageQuant software (GE Healthcare) or Multi Gauge software (Fujifilm).\n",
            "[0.6009108]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What clinical use aptamers may have?\n",
            "Refined Query: Exploring the therapeutic and diagnostic potential of aptamers, this query investigates their specific clinical applications.  What diseases or conditions might benefit from aptamer-based treatments or diagnostic tools, and what are the limitations currently hindering broader clinical use?\n",
            "\n",
            "Combined Answer: Quantitative RT-PCR protocols (including the allele-specific assay) and primers used are described in the Supplemental Methods. (dT) and random primers was used. Then, DHBV cDNA was measured by real-time PCR and normalized with the cDNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a LightCycler 480 (Roche Diagnostics). Primers for DHBV real-time PCR amplification are 5′-TTTGGATAGGGCTAGGAGATTG-3′ (sense, nt 42 to 63) and 5′-AGGCGAGGGAGATCTATGGTG-3′ (antisense, nt 385 to 405). This set of primers measures the levels of PreC/C viral RNAs due to the position of amplification. Primers for duck GAPDH real-time PCR amplification are 5′-CATCGTGCACCACCAACTG-3′ were more efficacious than placebo, with the lower dosage showing greater numerical response rates at week 52 for many end points (Table 2). The fact that the degrees of IFN gene signature inhibition were similar with the low and high anifrolumab dosages supports a plateau effect rather than an inverse dosage response. However, other mechanisms, such as an increased response in inducible immunologic feedback leading to a lower rate of response with the greater anifrolumab dosage, cannot be excluded. Biomarker studies to address this question are clinically relevant, but are not definitive until prospectively replicated in larger studies with a more stringent alpha level and a more robust control for multiplicity. The anifrolumab dosages were selected based on pharmacokinetic and pharmacodynamic modeling and simulation from a previous study 18, 19. Both the 300‐mg and 1,000‐mg dosages were more efficacious than placebo, with the lower dosage showing greater numerical response rates at week 52 for many end points (Table 2). The fact that the degrees of IFN gene signature inhibition erenumab (78), and fremanezumab (79) have been reported elsewhere from clinical trials. The drug labels for these three drugs state similarly that, although the immunogenicity profiles do not demonstrate an impact of ADA development on efficacy or safety, the available data are too limited to make definitive conclusions (10,11,15). In addition, ADA development does not demonstrate an impact on the PK of galcanezumab (10). such as an increased response in inducible immunologic feedback leading to a lower rate of response with the greater anifrolumab dosage, cannot be excluded. Biomarker studies to address this question are currently underway. The fact that greater efficacy was seen in all end points in patients with high baseline IFN gene signatures compared with those with low baseline IFN gene signatures supports the pathobiology of this treatment strategy. The lack of treatment effect in the IFN‐low subgroup was due to a greater response to placebo and supports the conceptual linking of biomedical knowledge databases and the processing of the related resources. The idea behind the drug-target-disease triangle is based on the tight links that exist between these three entities. Any disease is associated with research on prognosis, diagnosis, symptoms, co-morbidities and incidence/prevalence. Towards investigating these aspects, there is a tight relation between a disease and targets, e.g., with regards to the development of animal models or the research in diagnostics, that can help the 16. The greater efficacy and broader impact demonstrated by anifrolumab are likely the result of achieving greater suppression of the type I IFN pathway. The positive results of the present study suggest that targeting IFNAR is a promising and novel therapeutic approach for patients with SLE whose disease does not respond to currently available therapies. primers (Table S2) designed with Methyl Primer Express Software 1.0 (Applied Biosystems) or MethPrimer software [57]. The PCR amplification was carried out using KAPA2G Robust HotStart Taq DNA polymerase (Kapa biosystems) and PCR conditions were: 95°C for 3 min and 39 cycles of 95°C for 15 s, 57 or 53°C for 15 sec and 72°C for 15 sec, followed by 10 min at 72°C. PCR products from Region A, B and D were employed in direct sequencing using ABI BigDye Terminator and ABI 3130×l genetic analyzer (Applied Biosystems). effective at distributing T4 to cells (see above), that it was thought to be crucial for survival, most probably due to the requirement of adequate amounts of TH for normal CNS development (Harms et al., 1991). There are cases of humans with mutations in TTR resulting in higher affinity for THs, including Gly6Ser (~12% of the population), Thr119Met, Ala109Thr, and Ala109Val (Refetoff et al., 1996 and references therein). Of these four variants, only Ala109Thr resulted in affected individuals consistently having elevated serum T4 levels (Moses\n",
            "[0.6242399]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 404.60ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 983.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.32ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 705.83ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 906.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of invadopodia in EMT?\n",
            "Refined Query: How do invadopodia, actin-rich cell protrusions, contribute to the epithelial-to-mesenchymal transition (EMT) process?  Specifically, what is their role in extracellular matrix degradation and cell migration, key features of EMT, and how does this influence cancer metastasis?\n",
            "\n",
            "Combined Answer: (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and mesenchymal cells (for results, see http://ismara.unibas.ch/supp/dataset5/averaged_report/). As discussed in the Supplemental Material and Supplemental Figure 21, ISMARA automatically inferred much of the key regulatory interactions between TFs and miRNAs involved in EMT (for a review, see Polyak and Weinberg 2009) using only the gene expression To illustrate ISMARA’s ability to integrate the role of both TFs and miRNAs in the gene regulatory network, we took advantage of data from a system in which miRNAs are known to play important regulatory roles: the epithelial-to-mesenchymal transition (EMT). We applied ISMARA to expression measurements from epithelial and mesenchymal subpopulations (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and Fig EV3C). Knockdown of only one lncRNA, LIMT, caused a similarly large, but opposite effect on migration (Figs 3A and EV3C). Consistent with this observation, knockdown of LIMT also increased the capacity of cells to invade through a layer of extracellular matrix (Fig 3B). To complement this loss‐of‐function approach, we created an MCF10A subline stably overexpressing LIMT (or eGFP as control; see Fig EV3D). As expected, ectopic expression of LIMT reduced migratory and invasive capacities (Fig 3A and B). To further validate the effect of LIMT preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the extracellular matrix (Brieher and Yap, 2013; Ratheesh and Yap, 2012). and/or conditional activation signals will shed light on underlying mechanisms of IRES control and elucidate potentially novel functions of dystrophin. An intriguing question is how the N-truncated isoform remains functional. A key cellular role for dystrophin is presumed to be transmitting the force of contraction across the sarcolemma to extracellular structures by serving as an important architectural bridge role between the F-actin cytoskeleton and the muscle plasma membrane41,42. Two regions within dystrophin are responsible for F-actin genetic program that broadly reduces fibrogenic activity by HSCs. Interestingly, 48 h of Aramchol reduced the expression of a gene set involved in epithelial-mesenchymal-transition (EMT; Fig. 4), a process in which epithelial cells acquire the phenotypic characteristics of mesenchymal cells, including increased motility and invasiveness. Quiescent liver cells express high levels of PPARG and low levels of Hedgehog (Hh) signalling components, while activated HSCs have increased Hh signalling that represses PPARG expression.26 The reduced (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton immediately beneath the sarcolemma. Regarding its important structural role, dystrophin connects the subsarcolemmal F-actin cytoskeleton to β-dystroglycan (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the in the setting of deletions within the ABD1 domain6,43–46. However, we note that most of these studies were performed with microdystrophin constructs lacking the ABD2 domain, which has been shown to enhance the interaction between ABD1 and actin47. Such miniproteins bind actin and modify actin dynamics in a different manner compared to the full length version48,49. Although results with such constructs show that absence of ABD2 does not completely abrogate binding of dystrophin to actin, it is unlikely that absence of ABD1 completely disrupts downregulate the respective transcript (Fig EV3E, see Materials and Methods). Consistent with the observations made with siRNAs and with overexpression of LIMT, MCF10A cells stably expressing shLIMT displayed remarkably increased migration and invasion relative to control cells (Fig 3A and B). Taken together with the ability of EGF to decrease expression of LIMT (Fig 2A), the migration and invasion results proposed the following scenario: EGF treatment downregulates LIMT, an inhibitor of cell migration and invasion, thereby enhancing motility these pathways are most likely involved in the transition of the tissue from squamous to columnar epithelial that occurs during differentiation. Thus, in contrast to the methods used in the original study (Ross et al. 2007), ISMARA predicts which regulators are directing various aspects of the differentiation process, including ciliogenesis, the innate immune response, and the transition from squamous to stratified epithelial. As far as we are aware, these predictions of the core regulatory network controlling mucociliary differentiation are\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.51ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.46ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is a mitochondrial nucleoid?\n",
            "Refined Query: Mitochondria, the powerhouses of cells, possess their own DNA, distinct from the nuclear genome.  This mitochondrial DNA, along with associated proteins and RNA molecules, is organized into structures called mitochondrial nucleoids.  What are the precise structural components and functional roles of these nucleoids?\n",
            "\n",
            "Combined Answer: also exist many cases where filtering worsened the trees significantly. Circular molecular structures are present, in abundance, in all domains of life: bacteria, archaea, and eukaryotes; and in viruses. They can be composed of both amino and nucleic acids. Exhaustive reviews can be found in [25] (proteins) and [26] (DNA). The most common examples of such structures in eukaryotes are mitochondrial DNA (mtDNA). mtDNA is generally conserved from parent to offspring and replication of mtDNA occurs frequently in animal cells [27]. This is key in of such structures in eukaryotes are mitochondrial DNA (mtDNA). mtDNA is generally conserved from parent to offspring and replication of mtDNA occurs frequently in animal cells [27]. This is key in phylogenetic analysis and the study of evolutionary relationships among species [11]. Several other example applications exist including MSA of viroid or viral genomes [28] and MSA of naturally-occurring circular proteins [29]. A fundamental assumption of all widely-used MSA techniques is that the left- and right-most positions of the input The two strands of the mtDNA molecule encode 13 polypeptides, 22 tRNAs, and 2 rRNAs. The translation machinery of transcribed mtDNA consists of aminoacyl-tRNA synthetases, ribosomal protein subunits, and translation initiation, elongation, and termination factors. Although all essential mammalian mitochondrial factors involved in the initiation and elongation of translation have been cloned and well distinguished, the steps involving the termination and release process are less characterized. The mitochondrial class I release factor family is DNA (RC DNA) that is transported into the nucleus from the cytoplasm, where viral DNA replication occurs within naked capsid particles (29). A small percentage of the cccDNA is converted from double-stranded linear DNA through a nonhomologous recombination that generates sequence variations around the joint region (39). In the nucleus, cccDNA exists as an individual minichromosome with a “beads-on-a-string” structure, which is revealed by electron microscopy (2, 25). Histones as well as nonhistone proteins either bind directly to the cccDNA or Muscle biopsy performed in two patients from family B (B.V-2- and B.V-3) revealed normal histology by light and electron microscopy. The enzymatic activities of the mtDNA-dependent respiratory chain complexes in isolated mitochondria from muscle tissue were partially affected; complex IV was reduced to 35 and 43% while complex I was mildly decreased to 57 and 70% in patient B.V-2 and patient B.V-3, respectively. Pfh1 is a multi-functional protein: in addition to its role in nuclear DNA replication, it promotes DNA repair and is essential for maintenance of mitochondrial (mt) DNA [34]. Consistent with Pfh1 having mt function, 8 of the 50 high confidence Pfh1 interaction proteins have mt annotations (Fig 6C; mt proteins are underlined in Table 3). This subset includes several proteins implicated in mtDNA replication, such as (1) Rim1, the mt single-strand DNA binding protein (MS analyses reveal that ScPif1 is also ScRim1-associated; [60]), (2) Rpo1, the (34,35). We have used GBshape to infer structural features of these nucleosome-bound sequences. We previously analyzed DNA shape features of 23 076 nucleosome-bound sequences from Saccharomyces cerevisae (34) and 25 654 from Drosophila melanogaster (35). We showed that analysis of shape profiles generated by the DNAshape and ORChID2 algorithms reveals a pronounced 10-bp periodicity in structural properties of nucleosomal DNA (14,18). The modENCODE consortium recently generated more extensive lists of nucleosome-bound sequences of much higher structural features: MGW, ProT, Roll and HelT using DNAshape predictions (14), and hydroxyl radical cleavage intensity derived from ORChID2 (18). To demonstrate the utility of GBshape we analyzed structural features of nucleosome binding sites and TSSs. The availability of DNA shape annotations for entire genomes will enable the integration of DNA structure into genome analyses that currently are based only on nucleotide sequence. is typically shortened resulting in premature death within the first two decades of life. Of note, enzyme assessment of mitochondrial OXPHOS complexes both in muscle and fibroblasts typically display reduced activities of complex I and complex IV regardless of phenotype severity. The exact role of C12orf65 in mitochondrial DNA translation is yet to be determined. C12orf65 is not directly participating in the translation machinery but is an auxiliary factor and was hypothesized to be involved in recycling of abortive peptidyl-tRNA in the a nuclear gene that encodes a mitochondrial matrix protein that appears to contribute to mitochondrial translation. Nonsense mutations in this have been found in patients with a mitochondrial disease associated with combined oxidative phosphorylation enzyme (OXPHOS) deficiency.17 Patients’ cells were analysed by BN-PAGE analysis to study mitochondrial respiratory chain protein complexes. This analysis showed a decreased activity of complex V as well as a defect in assembly and stability of complex V in the patient sample compared with controls\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 404.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Exercise - {'Hypertension': 0.5724602081693839, 'Heart Health': 0.7839697731415147, 'Weight Management': 0.9999999999999999, 'Cardiovascular Health': 0.8566408621737275, 'Heart Disease': 0.436542328044943, 'ACE Inhibitors': 0.31360215426363636, 'Blood Pressure Monitors': 0.0, 'Diabetes': 0.6415735020034399, 'Heart-Healthy Diet': 0.6780790174181498}\n",
            "\n",
            " ### Clustered: {'Exercise': {'Cluster 1': ['Cardiovascular Health', 'Heart Health', 'Heart Disease', 'Heart-Healthy Diet', 'Hypertension'], 'Cluster 2': ['Blood Pressure Monitors'], 'Cluster 3': ['Weight Management'], 'Cluster 4': ['ACE Inhibitors'], 'Cluster 5': ['Diabetes']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.60ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.03ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1008.22ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 680.91ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 983.52ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 908.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Proteomic analyses have revealed proteins associated with the triple-negative breast cancers. List some proposed proteins.\n",
            "Refined Query: Triple-negative breast cancer (TNBC) proteomic studies have identified numerous proteins potentially involved in its pathogenesis and progression.  What are some examples of proteins consistently implicated in TNBC research based on these analyses, and what are their proposed roles in the disease?\n",
            "\n",
            "Combined Answer: Breast cancer is a highly heterogeneous disease, the classification and understanding of which is still incomplete. Further in‐depth analysis of both protein‐coding and noncoding genes is vital to accelerate the resolution of these issues. 3D). This observation suggests that the RAS‐to‐ERK pathway mediates EGF‐induced downregulation of LIMT, as well as the consequent enhancement of cellular motility. Since high abundance of LIMT is associated with longer survival of advanced state breast cancer patients (Fig 2B and Appendix Fig S1), we tested the prediction that overexpression of LIMT would attenuate metastasis in vivo. For this, we established a derivative of the highly metastatic MDA‐MB‐231 triple negative breast cancer cell line, which stably expresses an ectopic LIMT (or TCGA2BED: extracting, extending, integrating, and querying The Cancer Genome Atlas - PMC positivity and ER negativity (Fig 6B–D and Appendix Fig S1). In conclusion and in line with the analyses of patient survival, we performed on additional cohorts, the loss of LIMT might coincide with the acquisition of aggressive features by breast cancers. In summary, by investigating a model system that simulates autocrine and stromal mechanisms controlling invasion of mammary tumor cells across tissue barriers, we identified several lncRNA molecules, the expression of which is altered in response to a growth factor and might predict disease contributing to the dataset may not represent the healthy state, having escaped the possible deleterious consequences of deleting or duplicating UCEs either because the mechanisms effecting such consequences were no longer in play or because the cells had acquired a means by which to circumvent them. With respect to cancerCNAs, it may be that they arise when the mechanisms producing deleterious consequences are disabled or circumvented, their positions potentially influenced by the density of genes with either pro- or anti-proliferative in hormone‐independent breast cancer and serves as a driver of mammary cell migration (Tarcic et al, 2012). Accordingly, we found that knockdown of LIMT enhanced cellular migration and invasion in vitro, as well as metastasis in vivo. Because lncRNAs such as ANRIL, SRG1 and Paupar might regulate in cis the expression of nearby genes (Martens et al, 2004; Kotake et al, 2011), we investigated whether LIMT's neighbors, namely the protein‐coding genes RHOF (positioned 1,579‐bp downstream of LIMT) and SETD1B (located on the opposite strand to LIMT, MEF2C [45], MTA3 [46], NFATC1 [47], PAX5 [48], PML [49], POU2F2 [50], RUNX3 [51], RXRA [52], SPI1 [53], STAT3 [54], STAT5A [55], TCF3 [56], and TCF12 [57], which are all known to be involved in the differentiation of lymphocyte lineages. This branch also included MEF2A, which, unlike its highly similar family member MEF2C, is not known to be involved in lymphocyte differentiation [58]. Thus, this analysis both recovered known functional relationships between TFs and discovered novel associations. To test whether protein-protein interactions of 44 cell lines representing cancer and non‐cancer cells from 15 tissues of human origin, including six breast cell lines. LIMT was found to be widely and differentially expressed, with relatively high expression in brain, blood, and several lung and mammary cell lines (Fig 5B). Next, we evaluated relations between LIMT and molecular subtypes of breast cancer, in two cohorts of patients: the Oslo2 cohort (Aure et al, 2014) and the larger, METABRIC dataset (Curtis et al, 2012). In line with the aforementioned lines of evidence, the lowest of SIX5 and ZNF143 were also correlated in multiple cell types despite no documented interaction. In fact, mammalian two-hybrid assays found no direct binding activity between these proteins [35]. One large branch in GM12878 included ATF2 [36], BATF [37], BCL3 [38], BCL11A [39], BCLAF1 [40], BHLHE40 [41], EBF1 [42], IRF4 [43], JUND [44], MEF2C [45], MTA3 [46], NFATC1 [47], PAX5 [48], PML [49], POU2F2 [50], RUNX3 [51], RXRA [52], SPI1 [53], STAT3 [54], STAT5A [55], TCF3 [56], and TCF12 [57], which are all known to be involved in the Atlas Research Network (TCGARN) et al. [76], Walter et al. [77], Beroukhim et al. [73], Bullinger et al. [78], Taylor et al. [79], TCGARN et al. [80], Curtis et al. [81], TCGARN et al. [82], TCGARN et al. [83], TCGARN et al. [84], Nik-Zainal et al. [85], Robinson et al. [86], Walker et al. [87], Zhang et al. [88], Holmfeldt et al. [89], TCGARN et al. [90], and Weischenfeldt et al. [91] representing 52 different forms of cancer, each including between 2 and 148 cancerCNA regions and covering 0.03% to 90.15% of the genome (Table S1). To avoid\n",
            "[0.5768525]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which signalling pathway is involved in Tuberous Sclerosis?\n",
            "Refined Query: Tuberous sclerosis complex (TSC) is characterized by dysregulation of which specific signaling pathway,  specifically focusing on the roles of  TSC1 and TSC2 proteins and their downstream effects on cell growth and proliferation?\n",
            "\n",
            "Combined Answer: cerebellum. For rx3, the human ortholog RAX is embedded in a large syntenic block, and a cone-rod dystrophy (OMIM%600624) has been mapped to the area (Warburg et al. 1991). In the BARHL1 GRB, the far upstream TSC1 gene at 9q34 is implicated in tuberous sclerosis (OMIM#191100) and focal cortical dysplasia of Taylor (OMIM#607341), distinguished by epileptic seizures and likely caused by a neuronal migration defect (Wolf et al. 1995), which is consistent with the barhl1 expression pattern. However, the TSC1 ortholog was duplicated in teleosts with the microtubule cytoskeleton, but no key regulators or regulatory interactions that drive these expression changes were identified. In contrast, applying ISMARA to this gene expression data set, we obtain the prediction that by far the most important regulatory motif in this system is RFX, whose activity is strongly increasing over the period from roughly day 4 to day 10 in all three donors (Fig. 4A) (http://ismara.unibas.ch/supp/dataset4/ismara_report/). The predicted targets of RFX are highly enriched in genes known to be associated a short spike of E2F activity up-regulates cell-cycle genes at day 1. Finally, there is a group of motifs (TBP, FOS_FOS{B,L1}_JUN{B,D}, RXR{A,B,G}, HOX{A6,A7,B6,B7}, and GLI1..3) whose targets are progressively down-regulated across the differentiation time course. The targets of these motifs are generally enriched for extracellular proteins involved in cell adhesion, cell–cell junctions, and signaling. More specifically, targets of GLI1..3 involve genes from the TGF-beta pathway, targets of TBP involve nucleosomal and intermediate filament did not have seizures and three did not have deafness. In expression studies, some mutations abrogated TBC1D24 mRNA stability. We also detected Tbc1d24 expression in mouse phalangeal chondrocytes and calvaria, which suggests a role of TBC1D24 in skeletogenesis. more mutation-prone, which might explain mutation recurrence in individuals of different ethnic origins. Two patients also shared another recurrent mutation unique to DOORS (His336Glnfs*12). TBC1D24 is a member of the Tre2–Bub2–Cdc16 (TBC) domain-containing RAB-specific GTPase-activating proteins, which coordinate Rab proteins and other GTPases for the proper transport of intracellular vesicles. TBC1D24 is the only TBC/RabGAP with a TLDc domain, which is thought to be involved in oxidative stress resistance and to have catalytic activity for controls (Student's t test p=0·024), confirming that the mRNA from both alleles undergoes NMD and thus showing a loss of TBC1D24 function. TBC1D24 protein from these fibroblasts could not be detected by western blot analysis (figure 3). We next assessed Tbc1d24 tissue expression. Tbc1d24 is known to be widely expressed, most highly in the brain (especially in pyramidal neurons), kidneys, and salivary and lacrimal glands.29, 30 In the brain, the regions with the highest expression levels are the hippocampus and the somatomotor areas of the is able to also facilitate Rab protein-mediated GTP hydrolysis is not known. Our findings implicate defective vesicular trafficking as the possible basis of the complex phenotype in individuals with DOORS syndrome in view of findings from previous studies in other TBC proteins (panel). The seizure phenotype present in all individuals with TBC1D24 mutations, and the studies in Drosophila, suggest a potential role for aberrant neurotransmitter release in the neurological manifestations of the disease. However, further studies in model organisms cohort. We saw a wide variety of seizure types in our cohort of individuals with TBC1D24 mutations, including generalised tonic-clonic, complex partial, focal clonic seizures, and infantile spasms. Table 2, Table 3 list the clinical features of individuals with and without TBC1D24 mutations. Figure 2 shows photographs of the face, hands, feet, and radiographs. The mutations are listed in table 1 and shown in figure 3. The conservation of the affected residues and nucleotides is given in the appendix (p 17). In families with TBC1D24 mutations all five main features of DOORS syndrome, and TBC1D24 mutations were identified in half of these families. The seizure types in individuals with TBC1D24 mutations included generalised tonic-clonic, complex partial, focal clonic, and infantile spasms. Of the 18 individuals with DOORS syndrome from 17 families without TBC1D24 mutations, eight did not have seizures and three did not have deafness. In expression studies, some mutations abrogated TBC1D24 mRNA stability. We also detected Tbc1d24 expression in mouse phalangeal chondrocytes and the proper transport of intracellular vesicles. TBC1D24 is the only TBC/RabGAP with a TLDc domain, which is thought to be involved in oxidative stress resistance and to have catalytic activity for unknown substrates.32, 33 The TLDc domain is also seen in the proteins encoded by the human genes OXR1, NCOA7, KIAA1609, and C20orf118, which do not share known functions. Mice without Oxr1 have oxidative stress-induced neurodegeneration,34 which suggests a possible link with the neurodegeneration seen in some individuals with TBC1D24 mutations.27 We\n",
            "[0.8151269]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can life style changes reduce oxidative stress\n",
            "Refined Query: Can lifestyle modifications, such as diet, exercise, and stress management, effectively mitigate oxidative stress and its associated health risks?  This explores the extent to which proactive changes can reduce cellular damage from free radicals.\n",
            "\n",
            "Combined Answer: Oxidative stress—an imbalanced state of excessive production of reactive oxygen species (ROS) and diminished ROS scavenging ability in the cell—causes damage to cellular components. While all bio-molecules are prone to oxidative damage, proteins are particularly vulnerable and critical targets because most of the cellular functional-biomass is proteins (de Graff et al., 2016). Mild oxidative stress may cause simple oxidation/hydroxylation like reversible oxidation of methionine to methionine sulfoxide. However, more sustained/severe stress proteins (de Graff et al., 2016). Mild oxidative stress may cause simple oxidation/hydroxylation like reversible oxidation of methionine to methionine sulfoxide. However, more sustained/severe stress leads to carbonylation—an irreversible oxidative protein ‘damage’—a chemically diverse form of oxidative post-translational modification (PTM) wherein the side-chains of various amino acids are modified to diverse aldehydes, ketones, lactams and conjugates of advanced glycation (or lipid-peroxidation) end-products (AGEs/ALEs; Møller et al., 2011). stress (20, 30). One assumption demonstrated here that supports these pathways is that the MMR system may be sequestered or turned off while cells experience significant oxidative damage. A major unanswered question is whether this stationary-phase process occurs in a subpopulation of the cells (30). (Fig 4E). We observed an increase in the expression of genes involved in the clearance of oxidative stress (Fig 4E). To validate this finding, we analysed the expression of selected genes involved in the detoxification of oxidative stress (Mt1, Mt2, Gpx4 and Pdia6) and confirmed their upregulation in the spleens of ATMINΔLNBS1ΔL mice (Fig 4F). In support of these findings, we measured ROS production in splenocytes and showed that ROS production was increased in all genotypes but additively so in ATMINΔLNBS1ΔL mice (Fig 4G). could be contributing to the systemic inflammatory response following local and systemic oxidative damage (176). Therefore, through the activation of TLR-4, bacterial stimuli may contribute to the oxidative, inflammatory, and metabolic stresses in preeclampsia (21). In this review, we strongly support the role of a dysregulated immune system in preeclampsia. Pro-inflammatory stimuli may be responsible for disrupting immune homeostasis in this disorder and we therefore suggest that preexisting systemic inflammation, likely caused by multiple are exacerbated by reactive oxygen species (ROS) in nondividing cells. Overall, our results support the proposal that starved cells have increased mutation frequencies that affect the production of adaptive mutants. Furthermore, the data presented here build on previously postulated pathways of mutagenesis in B. subtilis cells experiencing starvation stress (20, 30). One assumption demonstrated here that supports these pathways is that the MMR system may be sequestered or turned off while cells experience significant oxidative damage. A major Enlarged spleens from ATMINΔLNBS1ΔL mice contain activated, proliferating ATMIN/NBS1-proficient T cells as well as neutrophils. Since neutrophils are known to produce reactive oxygen species (ROS), we investigated the expression levels of genes involved in the oxidative stress response from the RNA sequencing data obtained from ATMINΔLNBS1ΔL mice (Fig 4E). We observed an increase in the expression of genes involved in the clearance of oxidative stress (Fig 4E). To validate this finding, we analysed the expression of selected genes involved in Oxidative stress and protein damage have been associated with over 200 human ailments including cancer, stroke, neuro-degenerative diseases and aging. Protein carbonylation, a chemically diverse oxidative post-translational modification, is widely considered as the biomarker for oxidative stress and protein damage. Despite their importance and extensive studies, no database/resource on carbonylated proteins/sites exists. As such information is very useful to research in biology/medicine, we have manually curated a data-resource (CarbonylDB) of The naturally occurring polyphenol resveratrol (RSV)3 has received great attention during the past few years due to its beneficial roles in longevity, cardioprotection, and immune regulation. How RSV exerts its biological function remains to be fully elucidated, but activation of the NAD+-dependent deacetylase Sirt1 has been suggested as an important mechanism for the life span extension and cancer prevention properties of RSV (1). Several targets of RSV such as AMP-activated protein kinase (AMPK), Akt, and NF-κB have also been identified involves other types of DNA lesions which are recognized by MMR but not oxidation-induced mutagenesis. Based on our results with B. subtilis ytkD mutT and ytkD mutM yfhQ mutants and the role the enzymes encoded by these genes play in preventing and/or repairing oxidation-induced DNA damage, it is possible to speculate that mutations in mRNA or DNA are exacerbated by reactive oxygen species (ROS) in nondividing cells. Overall, our results support the proposal that starved cells have increased mutation frequencies that affect the production of\n",
            "[0.26260573]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the relation between sweating and anaerobic threshold?\n",
            "Refined Query: How does the onset of sweating correlate with the physiological changes occurring at the anaerobic threshold during exercise?  Does increased sweating precede, coincide with, or lag behind the point at which lactate accumulation significantly increases?\n",
            "\n",
            "Combined Answer: acylcarnitines, amino acids, very long chain fatty acids, and transferrin isoelectric focusing, urinary organic acids, all of which were normal in the entire group of patients. Serum lactate was normal in all patients from family A, but showed mild-to-moderate increase (3.0–4.0 mmol/l, normal range <2.0 mmol/l) in patients from family B. in intermuscular and subcutaneous fat. We have previously reported that reduced intermuscular and subcutaneous fat is a marker of anaerobic metabolism in COPD (49), and, thus, ActRII blockade may be of added value in such patients. In general, because muscle weakness is associated with impaired glucose tolerance in COPD (50), this effect could potentially be beneficial. To conclude, substantial gains in thigh muscle volume were observed after ActRII blockade using bimagrumab treatment, but these did not translate into improved muscle and in neuromuscular disease, and difficulty in clearing secretions is a major cause of extubation failure in the ICU in such cases (48). Therefore, activin receptor blockade might be effective in these settings, but this, of course, requires further investigation. Another interesting secondary effect of bimagrumab treatment was a significant reduction in intermuscular and subcutaneous fat. We have previously reported that reduced intermuscular and subcutaneous fat is a marker of anaerobic metabolism in COPD (49), and, thus, ActRII blockade may be physiologic ability to exercise (e.g., bronchodilators) (42) and may be less responsive than a constant work rate exercise test (43). Fourth, gain in muscle mass may be a necessary but not sufficient condition for the delivery of improvements in whole-body exercise performance. Studies of isolated high-intensity training in COPD have shown that mitochondrial bioenergetic capacity can improve without mass gains (44), and it may be that concurrent exercise is required to demonstrate improved exercise capacity. Fifth, although we stratified by DMD. The Grad-CAM results indicate that boundary visibility, muscular texture clarity, and posterior shadowing are highlighted features in ultrasound imaging of the gastrocnemius recognized by the models for evaluating ambulatory function, as shown in the Results section. Recall that the echo intensity of ultrasound B-scans for normal muscles is relatively low, and dystrophic muscles behave similarly to hyperechoic tissue due to intramuscular fat infiltration and fibrosis [33,34]. In addition, fatty infiltration increases the strength of no effect of either treatment on any measure of muscle strength or mobility. In the bimagrumab group, there was a progressive increase over placebo in maximum static expiratory pressure (Figure 3); statistical significance was noted at Week 24 (P = 0.017). In addition, no statistically significant differences were recorded in spirometry parameters between both groups throughout the study (Table 2). No statistically significant difference was observed in 6-minute-walk distance (6MWD), stair climbing time, Timed Up and Go test, one-repetition tend to decrease with strength training. We acknowledge, however, that our study design would have been stronger if we had ensured that the participants had elevated skeletal muscle myostatin before enrollment. However, we considered that a muscle biopsy might slow recruitment; moreover, because ActRIIs act as a pathway for multiple negative regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII of future trials, given that other anabolic agents are emerging (39). First, in a proportion of patients with COPD, the basis of exercise limitation is breathlessness rather than skeletal muscle weakness (40, 41). Given the lack of effect of anabolic agents on lung function and gas exchange, one might not expect the former group to derive as much benefit as the latter. Second, exercise performance might only be improved when it is subnormal. Although the average 6MWD was reduced in the present study, the range of 6MWD baseline values was wide, All data generated or analysed during this study are included in this published article. All data generated or analysed during this study are included in this published article.\n",
            "[0.70428324]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Name monoclonal antibody against SLAMF7.\n",
            "Refined Query: What is the name of a monoclonal antibody specifically targeting the SLAMF7 protein?  I'm looking for a single antibody name, not a list.\n",
            "\n",
            "Combined Answer: (chicken polyclonal, a kind gift from Prof. Ronald Hay, Dundee); phosphorylated tau (mouse monoclonal, clone AT8, Thermo Scientific); beta-actin (mouse monoclonal, clone AC15, Sigma); alpha-tubulin (mouse monoclonal, clone DM1A, Sigma). Primary antibodies were used at 1:1,000 dilution for all applications. Commercially available primary antibodies against the following antigens were used: CREST (rabbit polyclonal, 12439-1-AP, Proteintech); FUS (mouse monoclonal against C-terminus, Santa Cruz, sc-47711; rabbit polyclonal, ab84078, Abcam); p54nrb (rabbit polyclonal C-terminal, Sigma); TIAR (mouse monoclonal, BD Biosciences); G3BP1 (mouse monoclonal, BD Biosciences); Dcp1a (rabbit polyclonal C-terminal, Sigma); anti-Flag M2 (mouse monoclonal, Sigma); PSPC1 (rabbit polyclonal C-terminal, Sigma); GFP (Living Colours® rabbit polyclonal, Clontech, used for detection. Protein loading was determined by standardization to β-tubulin (polyclonal antibody R43; a gift of D. Koshland). Anti-Orc3p monoclonal antibody (SB3) was a gift of B. Stillman (57). Film scans were obtained with a Hewlett-Packard 4c/T scanner and analyzed using NIH Image 1.61. were used at 1:1000 dilution and secondary antibodies at 1:5000. The following antibodies were used: ATM (Santa Cruz), ASCIZ (Millipore); p95 (known as NBS1) (NEB), β-actin (Sigma), pS15-p53 (Cell Signalling), pS824-KAP1 (Bethyl Labs), total p53 (Pab-421; CR-UK generated antibody) and HRP-conjugated goat anti-mouse or rabbit IgG (Sigma). BD Biosciences); Dcp1a (rabbit polyclonal C-terminal, Sigma); anti-Flag M2 (mouse monoclonal, Sigma); PSPC1 (rabbit polyclonal C-terminal, Sigma); GFP (Living Colours® rabbit polyclonal, Clontech, #632593); SMN (mouse monoclonal, BD Biosciences); cyclin A (rabbit polyclonal, Santa Cruz, sc-751); p80 coilin (mouse monoclonal, BD Biosciences); PML (chicken polyclonal, a kind gift from Prof. Ronald Hay, Dundee); phosphorylated tau (mouse monoclonal, clone AT8, Thermo Scientific); beta-actin (mouse monoclonal, clone AC15, Sigma); alpha-tubulin α- and β-Tubulin (Sigma), γH2AX (Millipore) 6×His (Clontech), GFP (Cell signaling) and ATM (Santa Cruz), rabbit antibodies were against TopBP1, RIF1, PTIP, 53BP1 and phosphoKAP1 (S824) (All Bethyl Laboratories), 53BP1 (Santa Cruz), RNF168 (Millipore), TIRR (Sigma), phospho53BP1 (T543), phospho53BP1 (S25/29), HMGA1, H3 (All Cell Signaling) and AID (generated by the Chaudhuri Lab) and rat antibody against RPA2 (Cell Signaling). The RIF1 antibody used in immunofluorescence is a kind gift of Lifeng Xu (University of California, USA). The following antibodies were used for Immunoblotting: SERCA2a (produced by 21st Century Biochemicals), GAPDH (Sigma), myc (Sigma), flag (Sigma), SUMO1 (Cell signaling), SUMO1 agarose resin (Santa Cruz Biotech), SUMO2/3 (MBL), Ubc9 (Boston Biochem), SENP1 (Pierce), PLN (Badrilla), RyR2 (Badrilla), NCX1 (Chemicon), GATA4 (Millipore), SRF (Millipore), anti-rabbit-HRP and anti-mouse-HRP secondary antibodies (Sigma). TcdA, as described by Greco et al. (12). We excluded the neutralizing antibody A26.8, which binds to the extreme C terminus of TcdA and for which no homologous epitope exists within peptide B2. The model reveals the distinct epitopes of each antibody and suggests that binding of bezlotoxumab is more likely to interfere with carbohydrate binding than binding of A20.1 and B39. This is in line with the fact that bezlotoxumab is a fully neutralizing antibody, whereas B39 is non-neutralizing (25) and A20.1 is poorly neutralizing (43). Although the binding activity, preventing the binding of the ligand to the antibody (71,72). Overall, these changes may alter the efficacy and toxicity profile of the antibody. Assays for immunogenicity are difficult to develop and verify, and a comparison of observed incidences of ADA formation across various detection assays is complicated by potential differences in assay sensitivity. It is expected that therapeutic antibodies will show some immunogenicity, and even completely human therapeutic antibodies have unique idiotypes and posttranslational onto either Immobilon-P polyvinylidene difluoride (Millipore) or nitrocellulose (Bio-Rad) membranes. Commercially available monoclonal antibodies were used to detect RNAP IIA (8WG16; Covance), CTD Ser5-P (H14; Covance), and the Rpb3 subunit of RNAP II (Neoclone). For the detection of differences in CTD Ser5-P levels, we have found that it is critical to use the H14 and 8WG16 antibodies at a 1/5,000 dilution. Monoclonal antibody against Pta1 and polyclonal antibodies against Ssu72 and other CPF and CF I subunits were described previously (25,\n",
            "[0.6913753]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the mode of action of bedaquiline?\n",
            "Refined Query: Explain bedaquiline's mechanism of action in treating tuberculosis.  Specifically, detail its target within the *Mycobacterium tuberculosis* bacteria and the resulting effect on bacterial growth and survival.\n",
            "\n",
            "Combined Answer: focus on elucidating structure-function relationships involved in carbohydrate binding for TcdB and how/whether such binding is truly the basis for toxin binding to host cells, as well as exploring the structural basis for binding/neutralization of TcdA to actoxumab, the other half of the important novel C. difficile therapy that is currently in phase III development for the prevention of recurrent CDI. and midostaurin as reference compounds. Quizartinib inhibited the growth of MOLM-13 cells with IC50 values of 1.6 nM (95% CI: 1.2–2.0) and 5.6 nM (95% CI: 3.8–8.1) in the absence and presence of FL, respectively (Figure 1A and 1D). Midostaurin inhibited the growth of MOLM-13 cells with IC50 values of 20.7 nM (95% CI: 13.8–31.2) and 63.7 nM (95% CI: 53.9–75.2) in the absence and presence of FL, respectively (Figure 1A and 1D). Consistent with previous reports, our findings demonstrate that the growth inhibitory effects of quizartinib and TcdB by blocking binding of TcdB to mammalian cells. Overall, our data are consistent with a model wherein a single molecule of bezlotoxumab neutralizes TcdB by binding via its two Fab regions to two epitopes within the N-terminal half of the TcdB CROP domain, partially blocking the carbohydrate binding pockets of the toxin and preventing toxin binding to host cells. in the presence of a 5-fold excess of antibody (Fig. 7) suggests that bezlotoxumab binding to TcdB does not lead to antibody-mediated cross-linking, supporting the notion that bezlotoxumab directly neutralizes the toxin rather than decreasing its effective concentration via the formation of large immune complexes. As noted previously, the preponderance of existing data suggests that TcdA binds to its target host cells through interactions of its CROP domain with specific carbohydrate moieties on the cell surface. Indeed, binding of specific in this system, they do not entirely rule out the possibility that bezlotoxumab binding to the TcdB CROP domain neutralizes toxin by a mechanism other than direct occlusion of the receptor binding pockets of TcdB. As noted above, carbohydrate binding has not been unequivocally demonstrated to be the basis for TcdB binding to the cell surface, nor has the CROP domain itself been confirmed to be the receptor binding domain of TcdB; indeed, recent data have challenged the notion that the CROP domain is the sole determinant of cell binding in both of structural and functional homology between the two toxins and on the observation that TcdB binds to carbohydrates that are structurally related to the known TcdA ligands. As shown in Figs. 3D and 5, a significant overlap exists between the bezlotoxumab epitopes and the carbohydrate binding pockets of TcdB. Furthermore, bezlotoxumab directly blocks binding of TcdB to Vero cells (Fig. 6). These observations support a mechanism whereby bezlotoxumab neutralizes TcdB through direct blockade of receptor binding at the sites located near E1 and These references are in PubMed. This may not be the complete list of references from this article. These references are in PubMed. This may not be the complete list of references from this article. surface of toxin-sensitive mammalian cells (10–16), and (ii) treatment with galactosidase abolishes TcdA binding (13–15). Evidence that the receptor for TcdB is also a carbohydrate is currently limited to the observation that this toxin is structurally highly homologous to TcdA (7, 17) and that it binds to carbohydrates that are structurally related to the TcdA ligands (10, 11). It is thought that toxin binding to receptor(s) on the cell surface occurs via the C-terminal domain of the toxins (known as the combined repetitive oligopeptide treatment with α-galactosidase (13–15). Furthermore, TcdA-induced cell rounding is significantly reduced in the presence of intact TcdA CROP domain (18). Although a formal demonstration that TcdB binds to cell surface carbohydrates via its CROP domain is still lacking, it is tempting to ascribe a similar mode of binding to TcdB based on the high level of structural and functional homology between the two toxins and on the observation that TcdB binds to carbohydrates that are structurally related to the known TcdA ligands. As shown in Figs. 3D\n",
            "[0.65564704]\n",
            "### Expanded entities and terms:\n",
            "Stroke - {'Rehabilitation Therapy': 0.7980541525037852, 'Motor Function': 0.9999999999999991, 'Mental Health': 0.0}\n",
            "\n",
            " ### Clustered: {'Stroke': {'Cluster 1': ['Rehabilitation Therapy'], 'Cluster 2': ['Motor Function'], 'Cluster 3': ['Mental Health']}}\n",
            "Original Query: Does helicobacter pylori infection increase risk for ischemic stroke?\n",
            "Refined Query: How does Helicobacter pylori infection, considering its systemic inflammatory effects, potentially influence the risk of ischemic stroke in patients undergoing rehabilitation therapy, impacting their motor function and mental health recovery?\n",
            "\n",
            "Combined Answer: that a patient in our US cohort needs a higher score than an Australian patient to not have a high risk of discharging to an inpatient rehabilitation facility (7 versus 6). Furthermore, our results indicate that a patient in our cohort needs a higher score to have a high chance of discharging home (10 versus 11). Perhaps these results reflect the difference in practice between the two countries in terms of use of inpatient rehabilitation facilities. This could be related to a number of factors such as patient preference, surgeon preference, the date of death was assessed from the National Cause of Death Register [14]. All patients with validated stroke diagnosis at the hospital are routinely registered in a National Stroke Register [15]. Modified Rankin Scale (mRS) [16] at three months as a measure of functional outcome was achieved from the three months follow-up questionnaire in this register. Eriksson et al. created a key to convert those self-reported answers into mRS [17]. Upon analysis of the functional outcome, patients with mRS of ≤ 3 were considered to have favorable (48.6% for placebo, 69.6% for anifrolumab 300 mg [P = 0.038], and 64.6% for anifrolumab 1,000 mg [P = 0.156]). Compared with placebo, greater proportions of patients in the anifrolumab 300‐mg group achieved a >3‐point improvement in the FACIT‐F scale, a ≥3.1‐point improvement in the physical component summary score of the SF‐36 health survey, and a ≥3.8‐point improvement in the mental component summary score of the SF‐36 health survey. However, none of these comparisons achieved statistical significance (Table 2). Assessments of biologic frailty and muscle wasting, however measured, is a well-established predictor of hospital admission due to acute exacerbation of COPD (4, 31, 32). We expected that our patients, who were selected to benefit from an anabolic agent, would have high rates of acute exacerbation, but it is reassuring that the rates of exacerbation did not differ significantly between treatment arms. In fact, bimagrumab was proven effective in recovery from atrophy in animal models of steroid exposure (17), and a high likelihood of intercurrent exacerbation is not the diagnosis by reviewing the medical records and CTs of these patients, respectively. Information about diabetes (diet or pharmacological treatment), treatment with antithrombotics (Aspirin, Clopidogrel, Dipyridamole), warfarin treatment, hypertension medication, smoking habit (current smoker/non smoker) on admission, and the time between onset of stroke and arrival to hospital, was retrieved from patient medical journal. Level of consciousness on admission was assessed according to the Reaction Level Scale (RLS 85 scale) [11,12]. The RLS between treatment arms. In fact, bimagrumab was proven effective in recovery from atrophy in animal models of steroid exposure (17), and a high likelihood of intercurrent exacerbation is not itself a barrier to anabolic drug therapy. A key rationale for this study was that myostatin levels are increased in the most disabled patients with COPD and tend to decrease with strength training. We acknowledge, however, that our study design would have been stronger if we had ensured that the participants had elevated skeletal muscle myostatin before could be contributing to the systemic inflammatory response following local and systemic oxidative damage (176). Therefore, through the activation of TLR-4, bacterial stimuli may contribute to the oxidative, inflammatory, and metabolic stresses in preeclampsia (21). In this review, we strongly support the role of a dysregulated immune system in preeclampsia. Pro-inflammatory stimuli may be responsible for disrupting immune homeostasis in this disorder and we therefore suggest that preexisting systemic inflammation, likely caused by multiple the patients receiving placebo and 3.0% and 9.5% of the patients receiving anifrolumab 300 mg and anifrolumab 1,000 mg, respectively. The most frequently reported adverse events were headache, upper respiratory tract infection, nasopharyngitis, and urinary tract infection (Table 3). There was 1 death (due to sepsis syndrome) prior to randomization, and 1 death during the study in a patient who received 1 dose of anifrolumab 1,000 mg. The patient had acute colitis with a rapidly deteriorating clinical course and had features of macrophage of 0.22 (P < 0.001). Regression modeling for recovery at up to 12 weeks demonstrated that none of these baseline factors were significantly predictive of recovery. Specifically, the effects of age, enrollment WHZ, and amoxicillin usage seen at 4 weeks were no longer significant. in the placebo group. All patients responded promptly to antiviral treatment. One patient in the 300‐mg group discontinued treatment due to transverse myelitis with a positive PCR test for herpes zoster in the cerebrospinal fluid; the patient responded to antiviral and high‐dose corticosteroid treatment. The percentages of patients who were reported as developing influenza were greater in the anifrolumab 300‐mg group (6.1%) and anifrolumab 1,000‐mg group (7.6%) than in the placebo group (2.0%). Infusion‐related reactions were reported in 6\n",
            "[0.7503783]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the major types of the motor speech disorder dysarthria?\n",
            "Refined Query: Dysarthria encompasses several motor speech disorders stemming from neurological damage.  What are the main categories of dysarthria, differentiating them by the underlying neuromuscular impairments affecting speech production?\n",
            "\n",
            "Combined Answer: hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow severity, mortality, and the lack or presence of associated intellectual disability (Table 2). The milder form is represented by the four subjects from family A in the current report and by the patients recently published by Shimazaki et al.3 This group displays a clinical phenotype dominated by ophthalmological impairment with slowly progressive optic neuropathy beginning within the first decade. Motor impairment due to both peripheral neuropathy and spasticity typically evolved within the second decade resulting in mild gait disturbance but, We are grateful to Johnathan Cooper-Knock for critical reading of the manuscript. This work was supported by Research Grants from Motor Neuron Disease Association (Buchman/Apr13/6096); Russian Scientific Fund (No. 14-14-01138); Russian Foundation for Basic Research (No.14-04-00796 and No.14-04-01243). AQ was supported by Erasmus studentship. 1991). In animal models of AD, early aberrations in synaptic physiology have been widely reported, and AD-associated synaptic structural abnormalities (such as altered dendritic spine morphology) have also been linked to neurophysiologic defects in AD animal models (see Pozueta et al., 2013 for a recent review). Faced with this evidence, multiple groups have proposed that synaptic dysfunction is central to the pathophysiology of AD (Gonatas et al., 1967; Teich et al., 2015). In an effort to identify master regulators of synaptic and impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2 hyper-intense lesions known to be associated with mitochondrial diseases. Although too early to conclude, life expectancy does not appear to be significantly reduced. A severe phenotype with dramatically deteriorating course was described by Antonicka et al,2 dominated by significant cognitive and motor impairment resulting in wheelchair dependence patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the current report who display, in addition to early onset optic neuropathy and esotropia, variable degree of intellectual disability and progressive motor impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2 (550 iu/l; normal value < 200 iu/l). Normal early motor milestones were reported and no muscular dystrophy was ever reported in the family. His neurological examination was entirely normal at 15 years of age. Muscle biopsy showed slight fiber size variability (Supplementary Fig. 1a), and in some sections an increased number of central nuclei along with some densely stained hypercontracted fibers. Immunofluorescent analysis using a C-terminal antibody showed the presence of dystrophin at the membrane (Supplementary Fig. 1b) that western blot Duchenne muscular dystrophy (DMD), an X-linked recessive condition, is a rare genetic disorder caused by the absence of functional dystrophin proteins due to gene mutations [1]. The incidence of DMD is approximately 1 in 5000 male newborns [2]. Affected boys initially exhibit progressive muscle weakness of the lower proximal extremities [3]. The gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and that were predicted to have differential activity in three or more of these six regions, as we are interested in finding MRs whose dysfunction may be generalizable to neurons throughout the brain in AD. For each MR that passed this threshold, we then calculated the average change in gene expression for each ‘synaptic’ gene across all regions where this MR is predicted to have differential activity. We defined ‘synaptic’ genes using a pre-defined list of ‘synaptic’ genes from the Ingenuity database (Kramer et al., 2014). We curated this list walking was achieved between 18 and 24 months of age, their gait was unsteady with both ataxia and spastic scissoring. In addition, hand tremor was noted on fine motor tasks in patient B.V-2. Esotropia either with or without nystagmus was initially recognized between the age of 1–4 years in all three patients, prompting either surgical repair or corrective glasses. Ophthalmological examination at that time documented progressive bilateral optic nerve pallor particularly in the temporal optic disc parts. Disease progression was marked by a\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.55ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is oxidative stress affected by FOXO expression?\n",
            "Refined Query: Investigating the relationship between FOXO transcription factor expression levels and the degree of oxidative stress within a cell or organism is crucial.  Does increased FOXO expression correlate with reduced oxidative stress due to its role in antioxidant defenses, or does it influence stress differently depending on the cellular context and specific FOXO isoform involved?\n",
            "\n",
            "Combined Answer: Oxidative stress—an imbalanced state of excessive production of reactive oxygen species (ROS) and diminished ROS scavenging ability in the cell—causes damage to cellular components. While all bio-molecules are prone to oxidative damage, proteins are particularly vulnerable and critical targets because most of the cellular functional-biomass is proteins (de Graff et al., 2016). Mild oxidative stress may cause simple oxidation/hydroxylation like reversible oxidation of methionine to methionine sulfoxide. However, more sustained/severe stress type [Fig. 2B (e.g., liver) and Fig. S4]. Furthermore, these particular genes correlated well with tissue-specific function [Fig. 2C (e.g., liver)]. Motif search analysis on conserved DNA sequence at these cell type-specific enhancers identified DNA binding motifs for the known enhancer regulators Foxa2 (P = 5.3E-18) in liver and PU.1 (P = 5.2E-06) in proB cells (7, 23) (Fig. S5). Examination of ChIP-Seq data (7, 24) confirmed that both Foxa2 and PU.1 occupy these enhancer regions in the corresponding adult tissues (P = 7.53E-147; Fig. 2A and (Fig 4E). We observed an increase in the expression of genes involved in the clearance of oxidative stress (Fig 4E). To validate this finding, we analysed the expression of selected genes involved in the detoxification of oxidative stress (Mt1, Mt2, Gpx4 and Pdia6) and confirmed their upregulation in the spleens of ATMINΔLNBS1ΔL mice (Fig 4F). In support of these findings, we measured ROS production in splenocytes and showed that ROS production was increased in all genotypes but additively so in ATMINΔLNBS1ΔL mice (Fig 4G). Zein et al. 2009). These observations suggest that the core regulatory network involved in ciliogenesis, with MYBL1 targeting RFX promoters and RFX TFs targeting FOXJ1, is conserved across multiple mammalian systems. As indicated in Figure 4B, ISMARA additionally predicts that, in this system, IRF1,2,7 up-regulates innate immune response genes, and a short spike of E2F activity up-regulates cell-cycle genes at day 1. Finally, there is a group of motifs (TBP, FOS_FOS{B,L1}_JUN{B,D}, RXR{A,B,G}, HOX{A6,A7,B6,B7}, and GLI1..3) whose targets are Enlarged spleens from ATMINΔLNBS1ΔL mice contain activated, proliferating ATMIN/NBS1-proficient T cells as well as neutrophils. Since neutrophils are known to produce reactive oxygen species (ROS), we investigated the expression levels of genes involved in the oxidative stress response from the RNA sequencing data obtained from ATMINΔLNBS1ΔL mice (Fig 4E). We observed an increase in the expression of genes involved in the clearance of oxidative stress (Fig 4E). To validate this finding, we analysed the expression of selected genes involved in stress (20, 30). One assumption demonstrated here that supports these pathways is that the MMR system may be sequestered or turned off while cells experience significant oxidative damage. A major unanswered question is whether this stationary-phase process occurs in a subpopulation of the cells (30). involves other types of DNA lesions which are recognized by MMR but not oxidation-induced mutagenesis. Based on our results with B. subtilis ytkD mutT and ytkD mutM yfhQ mutants and the role the enzymes encoded by these genes play in preventing and/or repairing oxidation-induced DNA damage, it is possible to speculate that mutations in mRNA or DNA are exacerbated by reactive oxygen species (ROS) in nondividing cells. Overall, our results support the proposal that starved cells have increased mutation frequencies that affect the production of significant motif (POU2F), only one of the three POU2F factors, POU2F2 (also known as OCT2), shows significant correlation of its mRNA level with motif activity, and it is the most highly expressed. This suggests that POU2F2 is mainly responsible for the motif activity in these tissues (Supplemental Figs. 7, 8). The fact that the correlation is positive also strongly suggests that POU2F2 acts as an activator. In contrast, whenever a negative correlation between motif activity and TF expression is observed, the TF most likely acts as a nondividing cells of B. subtilis. YtkD and MutT encode putative 8-oxo-dGTPases and may function in a cooperative manner to protect B. subtilis cells from the mutagenic effects of oxidative stress (8, 29). To investigate the role played by these proteins in the stationary-phase-induced mutagenesis of B. subtilis, we genetically disrupted ytkD and mutT in the YB955 strain. The rates of spontaneous mutation to rifampin resistance in this knockout strain were around 40 times higher than those of the parental strain (Table 2). Similarly, the Oxidative stress and protein damage have been associated with over 200 human ailments including cancer, stroke, neuro-degenerative diseases and aging. Protein carbonylation, a chemically diverse oxidative post-translational modification, is widely considered as the biomarker for oxidative stress and protein damage. Despite their importance and extensive studies, no database/resource on carbonylated proteins/sites exists. As such information is very useful to research in biology/medicine, we have manually curated a data-resource (CarbonylDB) of\n",
            "[0.6660324]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.34ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 909.22ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 983.22ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.12ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the treatment of subacute thyroiditis?\n",
            "Refined Query: Describe the medical management of subacute thyroiditis, including both symptomatic relief and approaches to address underlying inflammation and potential complications.  What are the typical treatment durations and expected outcomes?\n",
            "\n",
            "Combined Answer: patient data that were censored at data cutoff); in 10 of the 19 patients with a response, the response was ongoing as of the data cutoff date (Fig. 2A and 2B). Among patients who had a response, the duration of response was at least 3 months in 11 patients (57.9%), at least 6 months in 6 patients (31.6%), and at least 9 months in 5 patients (26.3%). The median duration of stable disease was 4.0 months (range, 1.4 to 10.9+). As of the data cutoff date, 14 patients (23.7%) were continuing treatment (Fig. 2A). The median progression-free in 3 treatment periods, each separated by a washout period of 7 days. The 3 conditions were fasted (treatment A), with a standard FDA high‐fat breakfast (treatment B), and with a low‐fat breakfast (treatment C). Eligible subjects were randomized (1:1:1) on the day before their first treatment period to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA). At the beginning of all 3 treatment periods, subjects were admitted to the clinical research unit (CRU) 1 day before dosing and remained in the CRU, under medical supervision, for 4 to be receiving treatment with at least one of the following: oral prednisone (≤40 mg/day or equivalent), azathioprine (≤200 mg/day), an antimalarial, mycophenolate mofetil/mycophenolic acid (≤2.0 gm/day), or methotrexate (≤25 mg/week). Treatments for SLE had to be administered for at least 24 weeks prior to study entry and at stable dosages for ≥2 weeks (for prednisone and nonsteroidal antiinflammatory drugs) or ≥8 weeks (for other therapies) before screening. Biologic agents and protocol‐prohibited immunosuppressants had to be discontinued was discontinued in 107 patients (82.9%); the most common reason for discontinuation was disease progression. As of the data cutoff date of June 1, 2020, 54 patients (41.9%) had died. The median duration of treatment was 3.9 months (range, 0 to 16.6). A total of 74 patients (57.4%) received treatment for 3 months or more, and 38 (29.5%) for 6 months or more. Baseline characteristics are summarized in Table 1 (with additional details in Table S1). The median age was 62 years (range, 33 to 83). Most of the enrolled patients were heavily those detected on thyroid epithelium (26–28). Antibodies directed against TSHR and/or IGF-1R may trigger signaling through these receptors and induce production of proinflammatory cytokines. Thus, targeting and blocking both proteins may constitute therapy for TAO. No definitive therapy for the disease currently exists; however, drugs targeting cytokines or B or T cells have been suggested as potential treatments (29, 30). Small molecule TSHR antagonists have been described recently (27, 31), as have TSHR-blocking antibodies (32). Teprotumumab of patients with NSCLC are shown in Figure 1B and Figure S4. Tumor shrinkage of any magnitude was observed in 42 patients (71.2%) at the first assessment, performed at week 6. The median time to response was 1.4 months (range, 1.1 to 9.5). The median duration of response was 10.9 months (range, 1.1+ to 13.6, with + indicating that the value includes patient data that were censored at data cutoff); in 10 of the 19 patients with a response, the response was ongoing as of the data cutoff date (Fig. 2A and 2B). Among patients who had a response, Once the subject has reached the end of the titration phase, either achieving the goal dose or the maximum dose within the extended titration window, they will continue this dose for a 16 week maintenance period. It is expected that no dosage adjustments will be made during this maintenance phase. If a subject does develop intolerable side effects and the site investigator feels that a dosage reduction is indicated, the subject will be weaned off of the study medication and enter the end of study analysis. Patients will continue to be evaluated (26.3%). The median duration of stable disease was 4.0 months (range, 1.4 to 10.9+). As of the data cutoff date, 14 patients (23.7%) were continuing treatment (Fig. 2A). The median progression-free survival for all patients with NSCLC was 6.3 months (range, 0.0+ to 14.9) (Fig. 2C). had stable disease, were still receiving treatment as of the data cutoff date. The median duration of response among all patients who had a response was 10.9 months. Nevertheless, some patients had disease progression shortly after an initial response. Twenty-four patients (40.7%) had at least one assessment of partial response according to RECIST 1.1 criteria, and 19 (32.2%) had a confirmed partial response. Of the 5 patients who had a partial response that was never confirmed, 1 had long-term stable disease, whereas 4 had rapid disease 498 children were treated according to the standard protocol with amoxicillin and 1955 were treated under the alternate protocol without antibiotics. The group of children treated with amoxicillin was slightly older and more stunted at baseline. The recovery rate for children who received amoxicillin was worse at 4 weeks (40% vs. 71%) but similar after up to 12 weeks of therapy (84% vs. 86%), compared to the children treated without antibiotics. Regression modeling indicated that this difference at 4 weeks was most strongly associated with the\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 302.73ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.03ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.24ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 883.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 781.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 863.14ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 609.40ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1083.53ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 933.66ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.64ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1236.30ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.96ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the tricarboxylic acid (TCA) cycle affected in inflammation?\n",
            "Refined Query: Inflammation significantly alters cellular metabolism.  Does the inflammatory response modulate the activity or regulation of the tricarboxylic acid (TCA) cycle, impacting its rate of ATP production and intermediary metabolite generation?\n",
            "\n",
            "Combined Answer: 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux treatment, and every 30 min for the next 4 h (Wada et al. 2009). Whereas the original study focused solely on nascent transcription, we here show that standard application of ISMARA to this data set (http://ismara.unibas.ch/supp/dataset3/ismara_report/) uncovers the transcription regulatory network involved in this inflammatory response in remarkable detail. The response of endothelial cells to TNF is known to be mediated by TFs of the NFkappaB family, GATA2, IRF1, and JUN (Inoue et al. 2006) TFs. TFs of the NFkappaB family in particular are with studies showing that the UPR can attenuate the induction of inflammation as mediated by TFs of the NFkappaB family (Kaser et al. 2008; Kitamura 2011; Li et al. 2011). The induction of XBP1’s activity is not reflected in the expression of XPB1 itself, which is almost constant across the time course (Supplemental Fig. 20). This underscores that ISMARA infers a motif’s activity from the expression of its predicted targets and does not use the regulator’s own expression. Indeed, it has been established that XBP1 activity is regulated of the metabolic syndrome (21). Obesity is a metabolic disorder characterized by systemic inflammation and an increased risk of developing preeclampsia. In obese individuals, adipose tissue is suggested to be a potent source of pro-inflammatory stimuli because of the ability of adipocytes to secrete the pro-inflammatory cytokines, such as TNF-α and IL-6 (21). Besides promoting inflammation, these cytokines also advance atherogenesis, the underlying pathological process in atherosclerosis (167). Atherosclerosis is an inflammatory disorder is sufficient to cause CO2-related induction of PA in B. anthracis[24], can interact with the pXO2-regulators AcpA and AcpB to upregulate the transcription of the capsule operon [25], and AtxA can engage in regulatory cross-talk with genes on the chromosome [26]. Although AtxA is known to have a strong synergistic relationship with CO2[15], its own transcription has been found to increase only slightly, if at all, in the presence of CO2[11,12,16], indicating that its regulatory function is linked to activation rather than to changes in its IL-6 and IL-8 may play roles in TAO and are induced by TSH in fibrocytes (13, 15). Untreated fibrocytes produce negligible IL-6. However, addition of bTSH increased the IL-6 concentration in culture medium by approximately 50-fold after 24 hours (13 ± 1 vs 643 ± 32 pg/mL; P < .0001; Figure 2A). Pretreatment with teprotumumab (24 hours) significantly reduced TSH-provoked IL-6 (643 ± 32 to 265 ± 30 pg/mL; P < .0001). Fibrocytes produce substantial IL-8 under basal (untreated) conditions. Like IL-6, IL-8 expression was also increased by bTSH (7595 reduced TSH-provoked IL-6 (643 ± 32 to 265 ± 30 pg/mL; P < .0001). Fibrocytes produce substantial IL-8 under basal (untreated) conditions. Like IL-6, IL-8 expression was also increased by bTSH (7595 ± 995 vs 70 911 ± 3429 pg/mL; P < .0001; Figure 2B). Teprotumumab significantly inhibited the induction by TSH of IL-8 (70 911 ± 3429 to 16 910 ± 11 199 pg/mL; P < .001). detail. The response of endothelial cells to TNF is known to be mediated by TFs of the NFkappaB family, GATA2, IRF1, and JUN (Inoue et al. 2006) TFs. TFs of the NFkappaB family in particular are crucial for the resulting inflammatory response (Kempe et al. 2005). Indeed, ISMARA infers that the two most significant motifs are IRF1,2,7 and NFKB1/REL/RELA. The activity of NFKB1/REL/RELA increases sharply in the first 45 min and slower afterward, until it reaches a steady activity after 3 h. The activity of the IRF1,2,7 motif increases steadily cytokines, specifically TNF-α and IL-6, generate widespread dysfunction of the maternal vascular endothelium that could result in hypertension (17). Increased pro-inflammatory cytokines also affect metabolic changes in preeclampsia. For instance, elevated levels of TNF-α induce insulin resistance and stimulate the adipocytes to release more free fatty acids (FFAs) (21, 165). Circulating levels of FFAs are increased in preeclampsia, contributing to insulin resistance and altered lipid metabolism in this disorder (165, 166). Several metabolic that attenuates experimental fibrosis in 2 animal models of NASH,6 as well as in a chemical-induced fibrosis model caused by thioacetamide.7 Aramchol targets stearoyl-CoA desaturase 1 (SCD1),8 the rate-limiting step in the synthesis of monounsaturated fatty acids (MUFAs), the major fatty acid of triglycerides, cholesteryl esters, and membrane phospholipids,9,10 through an unknown mechanism. Aramchol also increases metabolite flux through the trans-sulfuration pathway, leading to a rise in glutathione (GSH) and the GSH/glutathione disulfide\n",
            "[0.61206484]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the indications for treatment with anti-hepcidin?\n",
            "Refined Query: What specific clinical situations necessitate the use of anti-hepcidin therapies?  Are there particular patient profiles or disease severities that warrant this intervention, considering potential risks and benefits?\n",
            "\n",
            "Combined Answer: HCV without HBV; or other), geographic region (Asia or other), and evidence of extrahepatic spread of disease, macrovascular invasion, or both (yes or no). Patients received either a 60-mg tablet of cabozantinib or a matched placebo tablet to be taken orally once per day. Treatment interruptions and dose reductions (to 40 mg and then to 20 mg) were used to manage adverse events. Patients continued the assigned trial regimen as long as they had clinical benefit, as judged by the investigator, or until they had unacceptable toxic effects. Currently, about 350 million individuals worldwide are chronically infected with the hepatitis B virus (HBV). Of the infected people, 15 to 40% will develop severe sequelae in their lifetime, most notably liver cirrhosis and hepatocellular carcinoma (18). The treatment of chronic hepatitis B has been improved dramatically in the past 10 years, mainly due to the successful development and application of nucleoside(tide) drugs targeting HBV polymerase and interferon (9, 24). These treatment options delay disease progress by inhibiting viral HNSCC is the seventh leading cause of cancer deaths worldwide.48 Current therapy for HNSCC includes surgery, radiation, and/or chemotherapy. These treatment options often result in disfigurement, difficulty in speaking and swallowing, and cytotoxic side effects. Additionally, treatment success for late stage HNSCC is limited, with 5-y survival rates of roughly 50 percent. These grim facts highlight the need to develop new therapeutic approaches for the treatment of this disease. One potential approach involves the use of proteasome inhibitors, therapies. It is noteworthy that in an analysis of overall survival, the hazard ratio for death was 0.69 in patients with disease caused by HBV and 1.11 in patients with HCV, and the hazard ratio for death was 0.86 in patients of Asian race but 1.01 in patients enrolled in Asia. Further analyses are necessary to help understand these differences. The safety results for cabozantinib were consistent with results from an earlier phase 2 study involving patients with hepatocellular carcinoma26 and with the known safety profile of cabozantinib. The In this double-blind, phase 3 trial, patients were randomly assigned, in a 2:1 ratio, to receive cabozantinib or placebo. Randomization was performed at a central location through an interactive response system with the use of permuted blocks, stratified according to etiologic factor (hepatitis B virus [HBV], with or without hepatitis C virus [HCV]; HCV without HBV; or other), geographic region (Asia or other), and evidence of extrahepatic spread of disease, macrovascular invasion, or both (yes or no). Patients received either a 60-mg tablet of SHK performed experiments and analysed data; H-JK designed experiments, provided patient samples and clinical expertise; T-HL provided patient samples and performed experiments; W-SM provided patient samples and clinical information; H-JK provided patient samples and clinical data expertise; Y-KK provided valuable reagents; SYH performed experiments and analysed data; TSK designed and supervised the study, and wrote the manuscript. with Ara-C (N=14) or BH-AC (N=35) coupled with idarubicin. Four of the remaining patients were treated with Ara-C alone, and one received a regimen of Ara-C plus etoposide. After induction and subsequent consolidation chemotherapies, 33 patients (61.1%) received HSCT. Median DFS and OS periods for all populations were 521 (95% CI, 99–943) and 737 (95% CI, 222–1252) days, respectively. In a univariate analysis, we noted that HSCT resulted in prolonged patient survival (P<0.05). Patients with t(8;21) also evidenced better responses than the to be a major source of fibrogenic cells in hepatic fibrosis, the genetic similarities further reinforce the broad impact of Aramchol on HSC phenotype and function. Although the findings support a potential direct antifibrotic effect of Aramchol in NASH patients, further investigation is needed to understand the additional mechanisms besides SCD1 inhibition by which Aramchol exerts its antifibrotic effects in patients. Nonetheless, the compelling safety and tolerability of this agent, combined with early evidence of in vivo efficacy, reinforce The protocol for this study was developed in accordance with the SPIRIT 2013 guidance for protocols of clinical trials.[15] by which Aramchol exerts its antifibrotic effects in patients. Nonetheless, the compelling safety and tolerability of this agent, combined with early evidence of in vivo efficacy, reinforce its potential utility for the treatment of NASH and fibrosis.\n",
            "[0.15580204]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How many genera comprise the Flaviviridae family?\n",
            "Refined Query: Determining the precise number of genera within the Flaviviridae family is a complex question, as taxonomic classifications are subject to change based on ongoing research and viral discovery.  Therefore, a definitive answer requires consulting the most up-to-date virological databases and classifications.\n",
            "\n",
            "Combined Answer: program for phylogenetic analyses, was used to identify the similarity between the phylogenetic trees inferred using the original and refined datasets. A comparison with respect to the phylogenetic trees obtained using MUSCLE and RAxML was made between the alignment of the original datasets and that of the datasets produced by refining the A.B.C.rot datasets using MARS, BEAR, and Cyclope. The Robinson–Foulds (RF) metric was used to measure the distance between each pair of trees. The same parameter values were used for MARS: q=5, ℓ=50, and PH conceived the study, cloned the gene, generated the sequence databases and sets for phylogenetic analyses and wrote the manuscript except phylogeny. BM carried out and described the phylogenetic analyses. ES participated in design and coordination of the study and critically revised the manuscript. All authors read and approved the final manuscript. three published CTCF sequences from insects were incorporated [19,82]. An outgroup was not defined. Phylogenetic trees resulting from the alignments were computed using four different methods of tree reconstruction: maximum likelihood, neighbor joining, maximum parsimony, and a Bayesian analysis. At first, the optimal model of sequence evolution was determined by ProtTest version 1.4 [83] according to the Akaike Information Criterion. The resulting optimal model (WAG+I+G) was used for maximum likelihood (with 100 bootstrap replicates) as well the FlyBase website and integrated into easyGWAS (Attrill et al., 2016). For the species P. pacificus, a total of 149 samples with 2,135,350 SNPs were integrated (McGaughran et al., 2016). The data set comes with two binary and one categorical phenotypes, as well as four categorical covariates. datasets. Notice that, in particular with MUSCLE, we obtain an identical or less average pairwise distance in 8 out of 9 cases between the original and the refined datasets produced by using MARS, despite the fact that we had first randomly rotated all sequences (compare the A.B.C to the A.B.C.rot columns). RAxML [50], a maximum-likelihood-based program for phylogenetic analyses, was used to identify the similarity between the phylogenetic trees inferred using the original and refined datasets. A comparison with respect to the phylogenetic faster than Cyclope. A common reliability measure of MSAs is the computation of the transitive consistency score (TCS) [51]. The TCS has been shown to outperform existing programs used to identify structurally correct portions of an MSA, as well as programs which aim to improve phylogenetic tree reconstruction [8]. BEAR, Cyclope, and MARS were used to identify the best rotations for the sequences in the Viroids dataset; the output of each, as well as the unrotated dataset was then aligned using MUSCLE. The following TCS was computed for the using MUSCLE to align the sequences. Tables 2 and 3 show the results produced for Datasets 4–6 and 7–9, respectively. To evaluate the accuracy of MARS seven standard genetic measures were used: the length of the MSA; the number of polymorphic sites (PM sites); the number of transitions and transversions; substitutions, insertions, and deletions were also counted; as well as the average distance between each pair of sequences in the dataset (AVPD). correspondingly. DNA sequence changes in dominant viral species between adults and infected ducklings were not detected. These results indicate that although differences such as kinetics of virus replication, virus spreading, and liver microenvironments exist between adults and ducklings, overall minichromosome structures reflected by the patterns of MNase mapping are inheritable. In addition, we aligned the two original DHBV DNA sequences that were obtained from duck 5 and 6 for a possible relationship between sequence variations and a conditions, but having no known function, deserve additional study. Although we point out above that many of the VCSG genes in the pathogenicity island are in operons, we do not suggest that operonic organization of genes is enriched within the pathogenicity island versus other regions. There is little reason to suggest such anenrichment, and the number of genes is too small to warrant a statistical analysis of their distribution. With the high volume of data and computational challenges of alignment and kmer identification, new computational strategies are required to computationally separate the two species’ components for more accurate downstream analysis 1, especially for the reduction of variant calling artefacts. However, the two-species alignment approach proposed in Bradford et al. 1 excludes reads that align to both organisms, clearly dismissing a large portion of the data as evidenced in Table 1 when observing cross species alignment rates. Algorithms designed\n",
            "[0.7700569]\n",
            "### Expanded entities and terms:\n",
            "Smoking - {'Lung Cancer': 1.0, 'Heart Disease': 0.4309104342976413, 'Chemotherapy': 0.46505238063046894, 'Heart Failure': 0.29200907550669486, 'High Cholesterol': 0.0, 'Chest Pain': 0.5499658559411191}\n",
            "\n",
            " ### Clustered: {'Smoking': {'Cluster 1': ['Heart Disease', 'Heart Failure', 'Chest Pain', 'Lung Cancer', 'High Cholesterol'], 'Cluster 2': ['Chemotherapy']}}\n",
            "Original Query: Are reduced-nicotine cigarettes effective for smoking cessation?\n",
            "Refined Query: Given the risks of heart disease, lung cancer, and other conditions, are reduced-nicotine cigarettes a genuinely effective smoking cessation method, or do they simply delay quitting and maintain exposure to harmful chemicals?  Their impact on patients undergoing chemotherapy or those with heart failure is particularly important.\n",
            "\n",
            "Combined Answer: to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many patients enrolled on the study had the option to revert to observation, and did not have the immediate threat of shortened survival as would be the case in metastatic disease, the incentive to remain on an agent that caused side effects was lower than in other settings. Despite that, a number of patients chose to remain on treatment for prolonged (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the originally planned 40 patient accrual was reached. Two factors led to this decision. The first was that accrual was slowing considerably, and the trial had been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule In the case of this trial, which was launched during the second half of the epidemic, we believed that a randomized, controlled design would be the most expedient and definitive means of establishing the absence of a harmful effect and of determining whether the very favorable preclinical data in support of ZMapp might actually translate directly into lives saved. The advantages of randomized studies have been discussed extensively by others.5,21–23 True confidence in the findings of studies of treatments with potentially small-to-moderate This was a negative thorough QT/QTc study, demonstrating that ozanimod treatment, in doses of up to 2 mg/day, did not have a clinically relevant effect on cardiac repolarization. The upper bound of the 2‐sided 90%CI (or 95% 1‐sided confidence limit) of the ΔΔQTcF was below the 10‐millisecond regulatory threshold at all time points for the therapeutic and supratherapeutic doses of ozanimod. These results were confirmed by demonstrating assay sensitivity with the use of moxifloxacin as a positive control. Consistent with the lack of QTc effect, Although the trial was launched within weeks after the trial drug became available, the notable successes of numerous public health measures in reducing and aiming to extinguish EVD in the affected countries resulted in our not being able to attain the desired enrollment of 100 participants per group. As a consequence of early termination, the 95% credible intervals for the absolute difference in mortality and for the relative risk of death are wide: −34 to 6 percentage points and 0.29 to 1.24, respectively. In addition, although mortality confirmation of efficacy that bimagrumab is anabolic in patients with COPD. Options for demonstrating positive results from trials of anabolic medicines might include translating this anabolic effect into enhanced physical functioning by selecting populations with impaired exercise capacity and considering trials in combination with aerobic exercise programs. statistician and by the departmental and institutional protocol offices, we did not pursue a protocol modification for the toxicity stopping rule, and closed the study to permit efficacy analysis. Ten (32%) of 31 patients remained on 800mg pazopanib. Twelve (39%) of 31 patients dose reduced to 600mg PO daily and six (19%) of 31 patients to 400mg PO daily (Figure 3). The remaining patients came off study early without dose reduction due to patient preference/therapy intolerance. in and complete the trial. Other exclusion criteria included significant abnormalities detected by 12‐lead ECG or screening laboratory tests; history of alcoholism, drug abuse, or addiction within 24 months prior to screening; a positive serum result for the human immunodeficiency virus or hepatitis infection; use of tobacco‐ or nicotine‐containing products within 3 months of study initiation; and participation in any other investigational study within 90 days or 5 times the half‐life of the study drug, whichever was longer. Prior to dosing 2016). Drug resistance can be decreased or even overcome through combination therapy (Huang et al., 2016; Kruijtzer et al., 2002; Tooker et al., 2007). Therefore, drug combinations are investigated across various medical areas, such as cancer (Al-Lazikani et al., 2012), viral disease including human immunodeficiency virus (HIV) and hepatitis C virus infections (Clercq, 2007) as well as fungal (Chen et al., 2016; Groll and Tragiannidis, 2009) and bacterial infections (Tamma et al., 2012; Worthington and Melander, 2013). However, drug might die despite the use of generally effective medical countermeasures. This was one of the conclusions drawn from the JIKI trial of favipiravir in Guinea, for example, and was raised by several other studies as well.14–20 No major safety concerns were identified with the use of ZMapp. Despite the drawback of an intravenous infusion that had to be given three times over the course of a week, the full course of ZMapp was successfully administered 91% of the time to recipients who survived that first week of the trial. In considering both the\n",
            "[0.810575]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the Wnt protein modified by notum?\n",
            "Refined Query: Does the Notum protein directly or indirectly modify Wnt proteins?  This includes exploring potential enzymatic activity, such as palmitoylation, and resulting changes to Wnt's function, localization, or stability.\n",
            "\n",
            "Combined Answer: observed chromatin modifications downstream of Wnt signaling remains elusive, we found that the putative cis-acting element, if any, is not located in the 6.7 kb promoter region which was previously described to regulate Tcf3 expression in different cell types [31]. Further work is needed to identify and study these cis-acting elements which might be of potential interest for providing further insight into the transcriptional repression downstream of Wnt signaling. As an additional regulatory mechanism, we also described a novel Wnt-induced a large resource to study potential non-canonical functions of TERC RNA and telomerase (Table S2). It is known that TERT can bind to and co-activate Wnt target genes at chromatin (Park et al., 2009), and we hypothesized that TERC, as a component of the TERT complex, may also co-occupy some of the same genes. Unbiased analysis of the TERC-bound peaks revealed that one of the top three enriched Gene Ontology terms is Wnt receptor signaling pathway (p = 1.3 × 10-6), strongly supporting our initial hypothesis. We found that TERC occupied multiple was further confirmed by qRT-PCR and western blot analysis (Figure 2A and 2B; and Figure S1). Further qRT-PCR analysis revealed that the observed downregulation is specific for Tcf3 but not for other members of the Tcf/Lef family (Figure S2A). Whereas Tcf3 was down-regulated in both ApcNN and Apc Min/Min ESCs, the latter encode for the most severely truncated Apc mutant allele and therefore for a very high level of Wnt signaling, other members of the Tcf/Lef family were exclusively up-regulated in Apc Min/Min ESCs. Accordingly, Wnt activation revealed that one of the top three enriched Gene Ontology terms is Wnt receptor signaling pathway (p = 1.3 × 10-6), strongly supporting our initial hypothesis. We found that TERC occupied multiple Wnt genes directly, including Wnt11, which is transcriptionally induced by TERT overexpression in vivo (Choi et al., 2008). ChIRP-seq revealed a series of TERC binding peaks near the MYC gene, concordant with previously documented binding sites of TERT (Fig. 4C). Analysis of TERC-bound sequences identified an enriched cytosine rich sequence motif H2A.W carries an extended C-terminal tail with a conserved SPKK (in general T/SPXK) motif (Figure S1A) (Bönisch and Hake, 2012). The H2A.W variant class evolved and is highly conserved in seed bearing plants (i.e gymnosperms and the angiosperms) (Figure S2A). In Arabidopsis, the H2A.W family comprises three proteins H2A.W.6, H2A.W.7, and H2A.W.12, which are encoded by the genes HTA6, HTA7, and HTA12, respectively (Figure S1A). HTA6 is expressed at higher levels than the other two H2A.W homologs (Figure S2D) and was used for the ChIP-seq Wnt signaling, involves histone modifications at the Tcf3 promoter and the activation of miR-211, which post-transcriptionally stabilizes Tcf3 downregulation. Understanding the downstream effects of Wnt signaling in ESCs is of both fundamental and translational relevance, as it may be exploited to manipulate ESC differentiation towards specific cell lineages. with full-length Ctf4 and with Ctf4-ΔNT, but did not interact with the isolated WD40 domain itself. Taken together with the data described above, these findings indicate that Ctf4 binds GINS and the amino terminus of Pol1 through the region of the protein after the WD40 domain, whereas the WD40 domain probably has a separate function. truncated Apc mutant allele and therefore for a very high level of Wnt signaling, other members of the Tcf/Lef family were exclusively up-regulated in Apc Min/Min ESCs. Accordingly, Wnt activation achieved in wild type cells either by Wnt3a conditioned medium or by a GSK3-small molecule inhibitor (SB-216763), confirmed that Tcf3 down-regulation is a specific response to canonical Wnt signaling in mouse ESCs (Figure 2C, 2D, and 2E, and Figure S2B and S2C). Moreover, using a gradient of the GSK inhibitor SB-216763, we observed that unlike the would either express the WD40 domain alone (Ctf4-NT), or the remainder of the protein (Ctf4-ΔNT). Figure 8 shows that the truncated forms of Ctf4 were expressed to a similar level to the full-length protein, and as expected we found that Ctf4-ΔNT but not Ctf4-NT could interact with both GINS and Pol1 (note that these interactions are less efficient than seen with recombinant proteins, perhaps due to problems in subcellular localisation of the truncated Ctf4 proteins, or to cell cycle defects in the mutant strains, or to competition with other is a specific response to canonical Wnt signaling in mouse ESCs (Figure 2C, 2D, and 2E, and Figure S2B and S2C). Moreover, using a gradient of the GSK inhibitor SB-216763, we observed that unlike the canonical Wnt targets Axin2 and Cdx1, downregulation of Tcf3 required a higher Wnt signaling level, possibly explaining why Tcf3 downregulation is observed in ApcNN cells but not ApcTT or ApcNT ESCs (Figure 2F and Figure S1).\n",
            "[0.7561502]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List functions that are evaluated with the Full Outline of Unresponsiveness score?\n",
            "Refined Query: I need a list of functions or system calls whose execution time directly impacts the Full Outline of Unresponsiveness (FOU) score, a metric for system responsiveness.  Which functions, when slow or blocked, most significantly contribute to a poor FOU score?\n",
            "\n",
            "Combined Answer: into composite measures and observed 10−16% better average accuracy for JACUSA (see Fig. 4 c). This is even more pronounced for the F-score measure, where JACUSA is performing at least 20% better in all tested replicate scenarios (see Fig. 4 d). Additional results and details are given in Additional file 1: Section 3.4. A general overview on the single thread runtime of each tested software is shown in Additional file 1: Section 3.6. results calculation LCaF is first computed per instance and then averaged over all instances. Given the aforementioned descriptions, the winners of each batch were decided based on their performance in the Micro F-measure (MiF) from the family of flat measures, and the Lowest Common Ancestor F-measure (LCaF) from the family of hierarchical measures. For completeness, several other flat and hierarchical measures are reported for all participating systems [38], but which are not used for the selection of the winner. the individual, intersected, and combined filtered call sets, is plotted on receiver operating characteristic (ROC) curves (Fig. 4B). Comparison of unfiltered, novel calls reveals comparable TP but significantly different FP rates for VarScan and Strelka callers. Although Strelka's TP rates (ranging from 0.784 to 0.789) and FP rates (ranging from 0.011 to 0.016) did not appreciably change across the false-positives parameter landscape investigated, increasing the number of required variant-supporting reads (VSR) to four for filtering VarScan the accuracy measure and the F-score to evaluate the balance between precision and true positive rate (see Additional file 1: Section 3.2). The main difference between these performance measures is that the accuracy measure includes the number of true negatives. Of all tested methods, JACUSA scores the highest in terms of accuracy and F-score (see Fig. 3). The tradeoff between TPs and FPs can be nicely observed for the comparison of MuTect and REDItools. While REDItools shows a higher TPR (87,45% compared to 83,73% of MuTect, Fig. 3 a), the manage to perform better than the two baselines that were used in phase A. Note also that the systems did not respond to all the categories. For example, the MCTeam systems did not submit snippets throughout the task. Focusing on the specific categories, like concepts, for the Wishart system we observe that it achieves to have a balanced behavior with respect to the baselines (Table 8). This is evident from the F-measure which is superior to the values of the two baselines. This can be explained by the fact that the Wishart-S1 system responded a value accordingly. Thus, for the assessment of the systems participating in Task 1a, one flat and one hierarchical measure are used. Specifically, the flat micro-F1 measure is used which is a label-based measure [24]: where MiP and MiR are the micro-precision and micro-recall measures calculated as follows: where tpci,fpci and fnci are respectively the true positives, false positives and false negatives for class c i. From the family of hierarchical measures the Lowest Common Ancestor - F measure (LCaF) [25] is used: where the corresponding scores (see Supplementary Figs S4 and S5), (d) tissue/target specific mechanisms (see Fig. 5a) and (e) tissue/target coverage in the dataset (see Fig. 5b). Neither of these effects showed a clear association with performance. Therefore, we believe that these differences arise (f) from the fact that some biological mechanisms can be modelled better than others. This could be connected to the measurements that we can obtain from cell lines and whether they are able to capture these biological processes. Investigating (f) would require further Our computation platform is a high-end computer cluster, where each node has 32 Intel Broadwell cores and 512 GB memory. We compare the four APA site detection tools (i.e. TAPAS, IsoSCM, GETUTR and Cufflinks) on the simulated dataset with 50 million reads as considered in Section 3.1 based on sequential running time (i.e. using a single core) and peak memory usage. As shown in Supplementary Table S9, although TAPAS requires a significant amount of memory, its running time is comparable to that of the other three tools. We then compare the Real CPU runtime in seconds was reported over a single AMD Opteron CPU (2048 kb, 2600 MHz) with 512 GB of memory, running Ubuntu 12.04.5 LTS (Supplemental Figure 13). We observe that all algorithms implemented in easyGWAS, except for logistic regression, are at least as efficient as the tools to which we compared them. The results show that easyGWAS can compute GWAS with standard models such as linear regression within a few minutes for up to five million SNPs and up to 500 samples. More complex models, such as FaST-LMM or EMMAX, only take Fig. 3). The tradeoff between TPs and FPs can be nicely observed for the comparison of MuTect and REDItools. While REDItools shows a higher TPR (87,45% compared to 83,73% of MuTect, Fig. 3 a), the precision is slightly higher for MuTect (99,99% compared to 99.96% forREDItools, Fig. 3 b). SAMtools/BCFtools scores third in terms of TPR and achieves together with MuTect the highest precision of 99,99%. JACUSA takes advantage of replicate information and shows a steady increase in performance with the number of employed replicates.\n",
            "[0.36658213]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: For the constructions of which organs has 3D printing been tested?\n",
            "Refined Query: Beyond simple prototypes,  research explores the 3D printing of which human organs, specifically focusing on the viability and functional capabilities of printed tissues and structures for transplantation or therapeutic applications?\n",
            "\n",
            "Combined Answer: constructed using an automated tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). The array blocks were cut into 5-μm sections, and the sections were stained with hematoxylin and eosin to verify the presence of tumor cells. In all cases, tissue cores obtained from normal adjacent tissue served as internal controls. of what determines the three-dimensional (3D) structure and of its functional importance remains limited. Starting from the first papers modeling DNA as a polymer and the genome as a polymer globule [1, 2, 11], scientists have been looking for a connection between the chromatin contact configuration and the regulation of gene expression [12–14]. It is now accepted that gene regulation happens as much through distal enhancer elements as through proximal promoters and the distinction between promoters and enhancers has itself been put to the Advances in chromatin interaction mapping have allowed us to refine our vision of the genome, leading us to a more realistic, well organized tension globule picture with extrusions of chromatin loops [1, 2]. The resolution of available contact maps has increased from a megabase to less than a kilobase in just 5 years [3–10]. However, our understanding of what determines the three-dimensional (3D) structure and of its functional importance remains limited. Starting from the first papers modeling DNA as a polymer and the genome as a polymer Tibial metaphyses were scanned with a microCT-40 system (Scanco Medical, Wayne, PA, USA) as described previously.35 A three-dimensional cubical voxel model of bone was built and calculations were made for relative bone volume per total volume and trabecular number. intended to close the annular defect, and a bone anchor to secure the device to an adjacent vertebral body (Fig. 1). The occlusion component consists of a flexible polymer that is designed to prevent reherniation by physically blocking the annulus at the post-surgery defect to maintain hydrostatic pressure inside the nucleus pulposus,[18] and containing a platinum-iridium radiopaque marker to permit radiographic visualization. The anchor component is a saw-toothed titanium alloy that is secured into either the caudal-adjacent or Transmembrane (TM) proteins serve extremely important functions in life as pump, channel, receptor, energy transducer etc., and have been reported recently to share ∼20–30% of genes in a whole genome (1–4). Nevertheless, the number of three-dimensional (3D) structures with high-resolution is far below one hundred at present, in contrast to more than 18 000 3D structures for soluble proteins registered in PDB (5). It is because TM protein molecules are difficult to crystallize due to their amphiphilic characteristics—hydrophobic TM segments is used to calculate the percentage of specific expression (Table S3). Stable transgenic lines for all positive enhancer constructs were obtained. Images of transient/stable transgenic embryos were taken using an Olympus MVX10 fluorescence microscope with a Leica DC500 camera or a Leica SPE confocal microscope (10× dipping lens). Images were assembled and processed using ImageJ and Adobe Photoshop. All confocal images displayed are Z-projections of stacks. Hearts was prepared in Tissue-Tek OCT compound (Sakura Finetechnical) and sectioned into 6 μm slices (Microm HM560 Cryo-star, Thermo Scientific). The sections were stained with hematoxylin-eosin. 3D, three-dimensional; ChAs, chromatin assortativity; ChIA-PET, chromatin interaction analysis by paired-end tag sequencing; ChICAGO, Capture Hi-C Analysis of Genome Organization; HiC, high-throughput conformation capture; LCC, large connected component; mESC, mouse embryonic stem cell; O, other-end; P, promoter; PcG, Polycomb group; PCHi-C, promoter capture HiC; RNAPII, RNA polymerase II. Mice underwent TAC using a supraclavicular construction model as previously described26. TAC or sham surgery was performed in 8 weeks old male mice (BW: 18 – 22 g). Mice were anesthetized with intraperitoneal ketamine and placed on ventilator. A 2- to 3-mm longitudinal cut was made in the proximal portion of the sternum, allowing visualization of the aortic arch. The transverse aortic arch was ligated between the innominate and left common carotid arteries with an overlaying 27-gauge needle. The needle was immediately removed leaving a discrete\n",
            "[0.66440356]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is ospemifene effective for treatment of dyspareunia?\n",
            "Refined Query: Research suggests ospemifene, a selective estrogen receptor modulator (SERM), may alleviate dyspareunia, painful sexual intercourse.  However, its effectiveness compared to other treatments and the extent of its benefits require further investigation.  Are studies demonstrating efficacy robust enough to support widespread clinical use?\n",
            "\n",
            "Combined Answer: previously tested serdemetan [53], which was initially developed as an inhibitor of MDM2 [54,55], and a comparison of results from both the in vitro and in vivo activity evaluations supports prior findings that serdemetan and RG7112 likely have different mechanisms/targets. In vivo, although some of the xenografts (i.e., KT-10 and ALL-17) obtained consistent results between the two agents, there were many discrepancies between in vivo activity of the two drugs (e.g., OS-31, ALL-4, ALL-7 and ALL-8). Furthermore, in vitro sensitivity to that concentrations well surpassing these doses are readily obtained following oral dosing of oprozomib.28,40 Importantly, peptide epoxyketones such as carfilzomib and oprozomib, specifically inhibit N-terminal threonine active proteasome subunits in contrast to dipeptide boronates that can also inhibit serine proteases. This difference may account for the favorable toxicity profiles and relatively low rates of peripheral neuropathy associated with epoxyketone PIs.24,53 This could permit more prolonged and intense dosing regimens, potentially In order to properly determine the required sample size for the proposed trial, four applicable studies were identified. Three of these studies evaluated topiramate versus placebo(29–31) and one study examined amitriptyline in a clinical database(27, 28). Based on this review, there was an average response rate between 45% and 52% for the placebo group. There was generally more variability regarding the percentage of subjects on topiramate who achieve the primary endpoint – the average is 77%, but the effect ranges from 54% to 95% across The authors would like to thank the patients who participated in this trial, Gerald F. Cox, MD, PhD, Clinical Development at Genzyme, a Sanofi company, for critical review of the manuscript; Marianne B. Zajdel, a Senior Medical Writer contracted by Genzyme; and Lisa Underhill, MS, Director, Scientific Communications and Publications at Genzyme for editorial and administrative support. is commonly used for the treatment of schizophrenia and bipolar disorder, except that cariprazine has a greater affinity and selectivity for D3 vs. D2 receptors (Tadori et al., 2011; Ellenbroek and Cesura, 2015; Findlay et al., 2016; Stahl, 2016). Aripiprazole also has been shown to be effective as an adjunct treatment for major depressive disorder (Bourin et al., 2009; Lenze et al., 2015; Zhou et al., 2015). Our results show that administration of a high dose of aripiprazole produced an antidepressant-like response, but also induced increases Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated as add‐on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review. This is an update of a Cochrane review first published in 2012 (Cochrane Database of Systematic [Birmingham, AL (HEY)], Dr. Hiroaki Itamochi, Department of Obstetrics and Gynecology, Tottori University School of Medicine (Tottori, Japan; KK and KOC-7c), Dr. Beth Karlan, Cedars Sinai (Los Angeles, CA; OV2008, OVCA420, OVCA429, OVCA432, SKOV3), the Japanese Health Science Research Resources Bank, (Osaka, Japan; KURAMOCHI, MCAS, OVISE, OVKATE, OVMANA, OVSAHO, OVTOKO, RMG1, RMUGS, TYK-nu), and Dr. Simon P. Langdon, Edinburgh Cancer Research Center, University of Edinburgh (Edinburgh, United Kingdom; PE014, PEA2, PEO6). Detailed information The muscle biopsies were obtained during a single-blind, placebo-control dose escalation study (ClinicalTrials.gov, number NCT00159250), with primary outcome to test the safety and efficacy of an i.m. administration of a morpholino AO [eteplirsen (AVI-4658)] designed to skip dystrophin exon 51 in DMD patients.16 Seven DMD patients harboring deletions responsive to exon 51 skipping were investigated. Two patients received a dose of 0.09 mg eteplirsen into the extensor digitorum brevis whereas five patients received 0.9 mg; the contralateral This work was supported by grants PI040421 and PI080648 from the Fondo de Investigacion Sanitaria (Spanish Ministry of Health)/FEDER (Fondo Europeo de DEsarrollo Regional) and ACOMP/2009/216 (Conselleria d'Educació, Generalitat Valenciana). RQ and SM are supported by Fundación Bancaja fellowships. We want to thank the collaborative participation of all the families and referring clinicians to the development of this work. with vehicle-treated controls (Figure 3c). Of note, at equimolar concentrations, carfilzomib induced a significantly higher expression of Osterix and osteo-pontin as compared with bortezomib. In addition, all PIs induced modest but significant reductions in mRNA levels of the OB inhibitory protein Dkk-1 in pre-OBs (Figure 3c). In reporter assay systems, 24 h treatment of MC3T3-E1 osteoprogenitor cells with PIs enhanced the activity of Smad2/3/4, serum response element (SRE) and AP1 transcription factors (Figure 4a). Although transforming\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.09ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is pregabalin effective for treatment of patients with restless leg syndrome?\n",
            "Refined Query: Does pregabalin provide clinically significant relief from restless legs syndrome symptoms, such as  uncomfortable sensations and irresistible urges to move the legs,  in comparison to placebo or other established treatments, and what are the associated risks and side effects?\n",
            "\n",
            "Combined Answer: were observed with placebo (Week 4: +5.9% [SD, 3.4%] vs. 0.0% [3.3%], P < 0.001; Week 8: +7.0% [3.7%] vs. −0.7% [2.8%], P < 0.001; Week 16: +7.8% [5.1%] vs. −0.9% [4.5%], P < 0.001; Week 24: +5.0% [4.9%] vs. −1.3% [4.3%], P < 0.001). Over 24 weeks, 6-minute-walk distance did not increase significantly in either group. Adverse events in the bimagrumab group included muscle-related symptoms, diarrhea, and acne, most of which were mild in severity. Conclusions: Blocking the action of negative muscle regulators through the activin type II an AE, (33 [100%], in the bimagrumab group and 31 [91.2%] in the placebo group; Table E2). The three most commonly reported AEs with bimagrumab treatment were muscle spasms, tightness, or twitching (∼46–79%); diarrhea (21.2%); and acne (9.1%). Incidences of muscle spasms and muscle tightness were significantly higher in the bimagrumab group than in the placebo group (P = 0.011, muscle spasms; P < 0.001, muscle tightness; Fisher exact test, two-sided); however, no other significant differences in AE incidence were observed between the and Main Results: We assessed changes in thigh muscle volume (cubic centimeters) as the primary endpoint along with 6-minute-walk distance (meters), safety, and tolerability. Fifty-five (82.1%) patients completed the study. Thigh muscle volume increased by Week 4 and remained increased at Week 24 in bimagrumab-treated patients, whereas no changes were observed with placebo (Week 4: +5.9% [SD, 3.4%] vs. 0.0% [3.3%], P < 0.001; Week 8: +7.0% [3.7%] vs. −0.7% [2.8%], P < 0.001; Week 16: +7.8% [5.1%] vs. −0.9% [4.5%], P < 0.001; Week 24: +5.0% than 1.0% of patients in the cabozantinib group were palmar–plantar erythrodysesthesia, fatigue, decreased appetite, diarrhea, and nausea. Adverse events of any grade regardless of causality were reported in 99% of the patients in the cabozantinib group and in 92% in the placebo group, and adverse events of grade 3 or 4 were reported in 68% of the patients in the cabozantinib group and in 36% in the placebo group (Table 2). The most common grade 3 or 4 adverse events in the cabozantinib group were palmar–plantar erythrodysesthesia (17%, vs. 0% In order to properly determine the required sample size for the proposed trial, four applicable studies were identified. Three of these studies evaluated topiramate versus placebo(29–31) and one study examined amitriptyline in a clinical database(27, 28). Based on this review, there was an average response rate between 45% and 52% for the placebo group. There was generally more variability regarding the percentage of subjects on topiramate who achieve the primary endpoint – the average is 77%, but the effect ranges from 54% to 95% across but significant cognitive problems. She had a brisk jaw jerk and a pout reflex. Marked distal symmetrical weakness and wasting affecting the limbs. In contrast to her cousins, tone in her upper and lower limbs was reduced with severe distal weakness in upper and lower limbs. Upper limb reflexes were normal. Knee and adductor reflexes were abnormally brisk. Ankle and plantar reflexes were absent. She had a moderately severe thoracic scoliosis. Sensation was impossible to assess reliably due to cognition but was likely to be abnormal. As a crude strabismus, ophthalmoplegia, cerebellar dysfunction, seizures, or cranial nerve deficits. All the patients graduated regular high school with no behavioral abnormalities and had normal hearing studies. Nerve conduction velocity studies in the three older patients were consistent with severe bilateral sensory and motor peripheral neuropathy of the legs and sparing the arms. In two patients (A.IV-1, A.IV-4), lower limb action potentials were not evoked, whereas in one (A.IV-3) action potentials were severely reduced and associated with mild months with cabozantinib and 1.9 months with placebo (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.52; P<0.001), and the objective response rates were 4% and less than 1%, respectively (P = 0.009). Grade 3 or 4 adverse events occurred in 68% of patients in the cabozantinib group and in 36% in the placebo group. The most common high-grade events were palmar–plantar erythrodysesthesia (17% with cabozantinib vs. 0% with placebo), hypertension (16% vs. 2%), increased aspartate aminotransferase level (12% vs. 7%), fatigue than in the placebo group (P = 0.011, muscle spasms; P < 0.001, muscle tightness; Fisher exact test, two-sided); however, no other significant differences in AE incidence were observed between the bimagrumab and placebo groups. In addition, nasopharyngitis (12.1%, 4 of 33), sinusitis (9.1%, 3 of 33), and elevated liver enzymes (alanine aminotransferase, aspartate aminotransferase, or γ-glutamyl transpeptidase) (9.1%, 3 of 33) were reported only in the bimagrumab group. These AEs were mild and self-limited and resolved without treatment. We report the first placebo-controlled, double-blind, randomized trial that investigated the effects of activin type II receptors blockade in patients with COPD and evidence of low body weight or muscle mass. Bimagrumab substantially increased thigh muscle volume and total lean body mass, but this did not translate into improved muscle function or functional performance.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the biological role of expansins in fungi?\n",
            "Refined Query: Expansins are known to loosen plant cell walls, but do fungi, lacking cellulose-based walls, utilize similar proteins?  What specific roles, if any, do expansin-like proteins play in fungal cell wall dynamics, morphogenesis, or pathogenicity?\n",
            "\n",
            "Combined Answer: preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the extracellular matrix (Brieher and Yap, 2013; Ratheesh and Yap, 2012). protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria specialized in degrading cellulose (Adams et al., 2008; Artzi et al., 2017; Bras et al., 2016; Pinheiro et al., 2008; Tavares et al., 1997). Bacterial cohesin-dockerin rupture forces (>120 pN) are among the highest ever reported for a receptor-ligand system (Nash et al., 2016; Stahl et al., 2012). It is unclear whether the TMEM132 cohesin domain mediates Cell surface carbohydrates play an important role in protection and maintenance of fungal cells while serving as the point of contact with the host environment. Since we previously identified surface β-1,3-glucans as important for Hst 5 binding in C. albicans [21], we expected that this carbohydrate would also have a function in Hst 5 interactions with C. glabrata. However, despite higher surface levels of surface β-1,3-glucan in C. glabrata (Figure 3), we observed that blocking cell surface exposed polysaccharides in C. glabrata 10 reduced Like C. albicans, β,(1–3)-D-glucans are major carbohydrate components of the outer cell wall of C. glabrata [24]. These cell surface moieties are recognition sites for the host immune system [25] and potential binding sites for antifungal drugs or peptides. The Candida biofilm matrix is also primarily comprised of β-1,3-glucans that sequester antifungal drugs and contribute to fluconazole resistance in the cells of the biofilm [26]–[28]. Therefore, it is possible that differences in cell surface or biofilm matrix glucans between C. albicans for Hst 5 antifungal activity are its ability to bind to the fungal cell wall and sequential transportation into the cytosol. Among various C. albicans cell surface polysaccharides, we identified laminarins (beta-glucans) as primary surface binding moieties for Hst 5 [21], followed by Ssa1 and Ssa2 binding proteins within the cell wall [22], [23]. Like C. albicans, β,(1–3)-D-glucans are major carbohydrate components of the outer cell wall of C. glabrata [24]. These cell surface moieties are recognition sites for the host immune system [25] and treatment with α-galactosidase (13–15). Furthermore, TcdA-induced cell rounding is significantly reduced in the presence of intact TcdA CROP domain (18). Although a formal demonstration that TcdB binds to cell surface carbohydrates via its CROP domain is still lacking, it is tempting to ascribe a similar mode of binding to TcdB based on the high level of structural and functional homology between the two toxins and on the observation that TcdB binds to carbohydrates that are structurally related to the known TcdA ligands. As shown in Figs. 3D and found that they could interact (Zhou and Wang, 2004). We used libraries expressing random fragments of yeast proteins fused to the Gal4 transcriptional activation domain to screen through the two-hybrid assay for domains that interact with either the WD40 domain of Ctf4 (amino acids 1–383), or with the remainder of the protein (amino acids 461–927; Ctf4-ΔNT). The screen involving Ctf4-ΔNT identified 12 overlapping fragments from Pol1 that share a small region within the unique amino terminal domain of the Pol1 protein (Figure 6A). The same with some densely stained hypercontracted fibers. Immunofluorescent analysis using a C-terminal antibody showed the presence of dystrophin at the membrane (Supplementary Fig. 1b) that western blot revealed to be of a smaller molecular weight (~410kDa) (Fig. 1a), and mutational analysis revealed a deletion of exon 2 (Supplementary Fig. 1c–g). Peptide sequencing using tandem mass spectrometry (LC-MS/MS)19 confirmed the absence of any residues encoded by exons 1 through 5, consistent with translation initiation within exon 6 (Fig. 1b and but, in eukaryotes, were previously thought to be restricted to choanoflagellate and sponge proteins (Pfam accession: PF00963) (Abedin and King, 2008; Nichols et al., 2012; Peer et al., 2009). These are not to be confused with the cohesin complex that regulates the separation of sister chromatids. Rather, cohesin domains are highly specialized protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria in this system, they do not entirely rule out the possibility that bezlotoxumab binding to the TcdB CROP domain neutralizes toxin by a mechanism other than direct occlusion of the receptor binding pockets of TcdB. As noted above, carbohydrate binding has not been unequivocally demonstrated to be the basis for TcdB binding to the cell surface, nor has the CROP domain itself been confirmed to be the receptor binding domain of TcdB; indeed, recent data have challenged the notion that the CROP domain is the sole determinant of cell binding in both\n",
            "[0.8007375]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Depression - {'SSRIs': 0.0, 'Anxiety Disorders': 1.0}\n",
            "\n",
            " ### Clustered: {'Depression': {'Cluster 1': ['SSRIs', 'Anxiety Disorders']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1033.09ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 808.86ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Lung Cancer - {'Chemotherapy': 1.0, 'Fatigue': 0.0}\n",
            "\n",
            " ### Clustered: {'Lung Cancer': {'Cluster 1': ['Chemotherapy'], 'Cluster 2': ['Fatigue']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1159.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 960.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.30ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can a given genotype exhibit opposite fitness effects (beneficial and detrimental) within the same environment?\n",
            "Refined Query: Can a single genotype confer both advantageous and disadvantageous traits within a uniform environment?  This explores whether context-dependent gene expression or pleiotropic effects can lead to fitness outcomes that vary significantly depending on interacting factors, even without environmental shifts.\n",
            "\n",
            "Combined Answer: provided by independent GWAS, many of which were conducted on related traits, offers unique opportunities for comparing and integrating findings across experiments. This integration makes it possible to detect genes with pleiotropic effects on multiple traits and traits with a shared genetic basis and to replicate findings or increase statistical power in association mapping through meta-analyses of several studies (Franke et al., 2010; Chasman et al., 2011; Andreassen et al., 2013; Evangelou and Ioannidis, 2013; Pickrell et al., 2016). To Due to the factorial design of our experiment, the resulting data permit inferences to be made regarding the contributions of both genotype and environment to the responses of genes regulated by AtxA, CO2, or both. The results are consistent with a model in which AtxA is essential to stimulate expression greater than baseline and in which environments enriched in CO2 act to modulate the degree of that stimulation. Consistent with other studies, we found that the expression of atxA itself is not increased as significantly as the genes it the models were compared with likelihood-ratio χ2 tests. The results from comparing the fits of (3) to (1) and (3) to (2) are called the main effects of environment and genotype, respectively. For significance, the p-value cut-off for the main effects was set to 0.01 and we required a fold-change difference of at least 2 between conditions (i.e., WT and ΔAtxA or CO2 and air). The results from comparing the fits of (4) to (3) are called the interaction effects, and results were called significant when p-values were less than 0.01 and when there in Additional file 1: Tables S3-S9. Of the other interaction effects, we identified 17 genes with increased expression in conditions of the ΔAtxA genotype and air environment, 1 gene with increased expression in conditions of the ΔAtxA genotype and CO2 environment, and 23 genes with increased expression in conditions of the wildtype genotype and air environment. We did not perform systemic gene function analyses on the differentially expressed sets of genes, as is often the custom for microarray and RNA-seq analyses, because the number of of normalized intensity to the mean expression. Then, we summed up the squares of those ratios to get the total relative variation for each gene. Following this, we compared the relative expression variation of target genes and bystanders for each replicate time-course experiment using a Wilcoxon rank sum test, with the alternative hypothesis that the variation in the target gene set was larger than in the bystander gene set. distribution, which in some cases may be too restrictive [34], we used the DESeqR package that is based on negative binomial distributions [34]. Using this approach, we fit four negative binomial generalized linear models for each gene: To test whether each factor has a significant impact on the expression of a given gene, the goodness of fit between the models were compared with likelihood-ratio χ2 tests. The results from comparing the fits of (3) to (1) and (3) to (2) are called the main effects of environment and genotype, respectively. For of phenotypic values between the alleles, under the null hypothesis of equal distributions for both alleles. In a linear regression there is an implicit assumption that the phenotype is normally (Gaussian) distributed and that it can be modeled as a linear (additive) combination of a set of terms, where one term is the list of genotypes of a given SNP and other (optional) terms may include covariates to correct for confounders. Logistic regression makes a similar assumption about the additive effects of genotype and covariates, but unlike Other limitation are inherent to our study design; we did not analyse oligogenic inheritance (combination of one mutated allele in each of two or more genes) or synonymous exonic variants, which could be potentially deleterious. Finally, some limitations are technical—eg, GC-rich regions are difficult to sequence and map, coverage can vary from sample to sample, and reads in genes that have paralogues or homologues can also be difficult to map to the reference genome. Future strategies to identify the causative genes in individuals with DOORS and ΔAtxA or CO2 and air). The results from comparing the fits of (4) to (3) are called the interaction effects, and results were called significant when p-values were less than 0.01 and when there was a fold-change difference of at least 4 across genotype-environment pairings (i.e., between WT/CO2 and ΔAtxA/air, or between WT/air and ΔAtxA/CO2). The p-value was chosen to be relatively stringent to help account for the relatively small number of biological replicates per condition. All p-values were corrected for multiple comparisons by To graphically represent the frequency and location (genome vs. plasmid) of genes that respond to CO2 and AtxA, we generated modified volcano plots, which are scatter plots often used in gene expression studies [55] (Figure 4). These plots compare the p-values for significant interaction effects with the fold-expression differences between the conditions of WT/CO2 and ΔAtxA/air. Most of the chromosomally-located genes whose expression showed a significant interaction effect between genotype and environment did not show large fold-change\n",
            "[0.65366125]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Has the protein SETMAR (Metnase) a transposase domain?\n",
            "Refined Query: Does the protein SETMAR, also known as Metnase, possess a recognizable transposase domain within its amino acid sequence?  This requires examining its structural and functional domains to determine if it contains a region homologous to known transposase families, indicating its potential involvement in DNA transposition.\n",
            "\n",
            "Combined Answer: tool, the system has two components: first, a bipartite small RNA, or “guide RNA” (gRNA), designed to recognise a specific location in the genome; second, the Cas9 protein that binds the gRNA and is thereby recruited to the target site. The gRNA consists of a 20 nt targeting region that hybridises to genomic DNA upstream of a dinucleotide protospacer adjacent motif (PAM, here NGG), fused with a scaffold sequence recognised by Cas9 protein [3]. By engineering the gRNA targeting region, one may target virtually any complementary genomic locus complexity and satisfies the criteria for a prion-like domain [4,6]; an N-terminal autoregulatory domain, which suppresses transactivation at basal state [6]; a central methionine-rich domain, and so called multifunctional domain (MFD) implicated in the protein dimerisation, regulation of transactivation and subcellular localization of the protein [12]. In the nucleus, CREST was shown to be recruited to nuclear bodies of unknown origin [13]. More recently, CREST was identified in a screen for paraspeckle proteins [14]. The majority of We used BLAST to find homologous genes [36] and ClustalX to align homologous nucleotide sequences [37]. To search for conserved protein domains, NCBI’s Conserved Domain Database was used [38]. Additionally, we searched for the presence of gene operons in the virulence condition synergy group. Two adjacent genes were defined as in an operon if they had fully contiguous (i.e., non-zero) read mapping from the translation start site of the upstream gene to the translation stop site of the downstream gene in both WT/CO2 RNA samples [28]. genes whose fusion proteins were capable of conferring expression to three different GAL4-driven reporters: HIS3, ADE2, and the β-galactosidase gene (data not shown). Sequence analysis of the library plasmids indicated that they contained either RFC3 or RFC4, each present as full-length fusions. To investigate further, Rfc3p, Rfc4p, and Ctf18p-9myc were produced in vitro using a coupled transcription-translation system. Rfc3p and Rfc4p were radiolabeled using [35S]methionine. Unlabeled Ctf18-9myc product was incubated with each, in the captured during the transposition reaction. While extant methods such as DNase- and MNase-seq can provide some subsets of the information in ATAC-seq, they each require separate assays with large cell numbers, which increases the time, cost, and limits applicability to many systems. ATAC-seq also provides insert size “fingerprints” of biologically relevant genomic regions, suggesting that it capture information on chromatin compaction. We expect ATAC-seq to have broad applicability, significantly add to the genomics toolkit, and improve our carrier RNA (Supplemental Fig. S1A,B; Supplemental Table S1; see Methods for details). The synthetic gene is based on the Escherichia coli leucyl-tRNA synthetase sequence for two main reasons. First, we wanted to avoid mapping to eukaryotic genomes. Secondly, leucyl-tRNA synthetase is a housekeeping gene from a mesophilic species, and therefore its sequence is not expected to form strong secondary structures that would reduce its translation in vivo or reduce the efficiency of reverse transcription. We made this carrier selectively degradable if they had fully contiguous (i.e., non-zero) read mapping from the translation start site of the upstream gene to the translation stop site of the downstream gene in both WT/CO2 RNA samples [28]. Pseudogenes, defined by the NCBI annotations as non-functional on the basis of evolutionary comparisons, were not included in operons. assembly similar to DNA assembly techniques22 (Fig. 2). From N- to C-terminus of the protein sequence, series of aligned chains are merged to contigs with identical overlap of length L-1, where L is the length of the chains. A contig terminates if there is no overlap to extend or if it encounters an AAIG that is already part of it. Chains that cannot be merged to contigs are considered spurious and discarded. Finally, all contigs are aligned to the protein sequence. For an AAIG to be assigned to a given residue in the protein sequence, two ATAC-seq enables accurate inference of DNA binding factor occupancy genome-wide. We reasoned that DNA sequences directly occupied by DNA-binding proteins are protected from transposition; the resulting sequence “footprint” reveals the presence of the DNA-binding protein at each site, analogous to DNase digestion footprints24. At a specific CTCF binding site on chromosome 1, we observed a clear footprint (a deep notch of ATAC-seq signal), similar to footprints seen by DNase-seq25,26, at the precise location of the CTCF motif that coincides with As several protein motifs lying on both sides of the HD of AbdA could potentially interact with Exd [39], it was difficult to predict the best appropriate fusion insertion site in AbdA for BiFC with Exd. In order to test whether the choice of insertion sites could be predicted from the knowledge of the emplacement of known protein interaction domains, we performed BiFC between Exd and its well known nuclear translocation partner Hth. The domains required for Exd-Hth interactions have been well characterized and are located N-terminally in both\n",
            "[0.79630655]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is alternative splicing of apoptotic genes playing a role in the response to DNA or mitochondrial damage?\n",
            "Refined Query: Investigating whether alternative splicing modifies the expression or function of apoptotic genes following DNA or mitochondrial damage is crucial.  This could reveal novel mechanisms influencing cellular responses to genotoxic stress and potentially impacting disease pathogenesis.\n",
            "\n",
            "Combined Answer: and death as a child carry mutations in C12orf65 interrupting the RF-1 domain (p.L84X).17 Conversely, mutations sparing the RF-1 domain seem to cause a milder phenotype as reported in the cases presented here as well as in the SPG55 cases. Of note, the mutation site in our cases (p.V116X) would suggest a shorter protein as opposed to the SPG55 cases (p.R132X) and therefore a more severe phenotype. We also investigated mitochondrial function in patient cell lines and showed that this was impaired at multiple levels of mitochondrial function. (Fig 4E). We observed an increase in the expression of genes involved in the clearance of oxidative stress (Fig 4E). To validate this finding, we analysed the expression of selected genes involved in the detoxification of oxidative stress (Mt1, Mt2, Gpx4 and Pdia6) and confirmed their upregulation in the spleens of ATMINΔLNBS1ΔL mice (Fig 4F). In support of these findings, we measured ROS production in splenocytes and showed that ROS production was increased in all genotypes but additively so in ATMINΔLNBS1ΔL mice (Fig 4G). The transcription factor and tumor suppressor p53 is activated in response to a variety of cellular perturbations, in particular genotoxic stress, to prevent fixation of DNA damage and proliferation of cells with genetic defects (reviewed in [1]). Consequences of p53 activation include induction or repression of p53-responsive genes at the transcriptional level, resulting in cell cycle arrest, senescence, or apoptosis [2]. Due to this central function in preserving the genetic integrity of higher organisms p53 has been labeled the “guardian of Enlarged spleens from ATMINΔLNBS1ΔL mice contain activated, proliferating ATMIN/NBS1-proficient T cells as well as neutrophils. Since neutrophils are known to produce reactive oxygen species (ROS), we investigated the expression levels of genes involved in the oxidative stress response from the RNA sequencing data obtained from ATMINΔLNBS1ΔL mice (Fig 4E). We observed an increase in the expression of genes involved in the clearance of oxidative stress (Fig 4E). To validate this finding, we analysed the expression of selected genes involved in our group as well as others (36, 37) suggest that even in the presence of a functional homologous recombination path-way and a cell’s ability to conduct DNA DSB repair, the homologous recombination pathway may only be able to repair part of the additional damage introduced by PARP inhibition in homologous recombination proficient cells treated with a DNA-damaging agent, but not all and thus result in enhanced cytotoxicity. Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in an increase in apoptosis, DNA of ∼8 kb causing this disease was mapped in exons 14–15 of AP3B1 (Jung et al. 2006), which removes one of the HCNEs mapped in this study. While the AP3B1 mutation may have an effect on the disease phenotype, this finding suggests that the disease may be a compound phenotype of loss of function of AP3B1 and loss of specific regulatory input of OTP. Thus, as demonstrated by this case, establishment of human/teleost conserved synteny combined with fine mapping in the human genome can immediately produce strong candidate targets for human position was also apparent on the periphery, as indicated by a decrease in the total number of splenocytes in mice deficient for NBS1 (S3B Fig). Similarly, the relative percentage of CD4+, CD8+ and TCRβ+ T cells was dramatically reduced in the spleens of NBS1ΔL and ATMINΔLNBS1ΔL mice (S3B and S3C Fig). Since both ATM and NBS1 are required for the repair of DNA double-strand breaks, a process that occurs during VDJ recombination, we investigated whether recombination of the TCRβ locus was affected in NBS1ΔL and ATMINΔLNBS1ΔL mice. Southern blotting of p53 in the spleens of both NBS1ΔL and ATMINΔLNBS1ΔL mice (Fig 3D). Since p53 is stabilized upon phosphorylation, the total levels of p53 were also increased (Fig 3D). This data for NBS1 is in line with a previous report that show increased apoptosis in NBS1-deficient neuronal cells, which is dependent on p53 [43]. Having observed elevated DNA damage, activation, inflammation and proliferation in the spleens of ATMINΔLNBS1ΔL mice we next asked whether this could lead to neutrophil infiltration hence we stained for CD11b and Gr1 to identify in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. These elements are frequently found in genes post-transcriptionally regulated by alternative splicing events of exons with premature stop codons. Accordingly, the extreme genomic conservation has been associated to regulatory splicing events maintaining tightly regulated levels of RNA-binding proteins [4]. On the other hand, intergenic elements are frequently flanked by developmental genes, in particular for genes To test whether elevated DNA damage could be a contributing factor to T cell activation, we measured the presence of alkali-labile sites as well as DNA single- and double-strand breaks in splenic T cells using the alkali comet assay. We observed a significant contribution of ATMIN to suppress these types of lesions, as well as of NBS1 (Fig 3A and 3B). Indeed, splenic T cells isolated from ATMINΔLNBS1ΔL mice displayed an elevated amount of DNA lesions. DNA lesions were observed in YFP+ T cells but not YFP- T cells. DNA damage was also confirmed\n",
            "[0.60012776]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which oncogenes are able to induce cellular senescence?\n",
            "Refined Query: Investigating which oncogenes, when activated, trigger cellular senescence rather than uncontrolled proliferation is crucial for understanding cancer development.  This explores the paradoxical role of oncogenes in potentially halting tumorigenesis through senescence induction, a mechanism that could be exploited therapeutically.\n",
            "\n",
            "Combined Answer: level, resulting in cell cycle arrest, senescence, or apoptosis [2]. Due to this central function in preserving the genetic integrity of higher organisms p53 has been labeled the “guardian of the genome” [3]. Evasion of growth suppression is a hallmark of cancer [4], and disruption of the p53 pathway is considered to occur early during oncogenesis [5]. The activity of p53 is tightly regulated by post-translational modifications that affect its cellular localization and ability to bind DNA consensus sequences [6,7]. However, p53 is principally impacts on proliferation, senescence, or apoptosis. Similarly, the mutational profiles of cancer cells may bias CNVs toward forming in the vicinity of UCEs, possibly conferring selective advantage, whereas the profiles of healthy cells may avoid such disruptions. Whether the difference in UCE disruption by CNVs in cancer versus healthy cells is due to differences in mutational profiles, selective retention/loss of UCE-disrupting CNVs, or a combination of both, the dichotomy of CNV profiles with respect to UCEs between healthy and cancerous G.K. is supported by the Ligue Nationale Contre le Cancer (Equipes Labelisée), Agence Nationale pour la Recherche (ANR), Fondation Axa (Chair For Longevity Research), European Commission (ArtForce), Fondation pour la Recherche Médicale (FRM), Institut National du Cancer (INCa), Cancéropôle Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Immuno-Oncology. M.N.S., S.A., S.A.M., L.G. and M.C.M. are supported by Junta de Extremadura-Fondo Social Europeo, Ligue Nationale contre le Cancer, the Higher Education Commission (HEC) of The transcription factor and tumor suppressor p53 is activated in response to a variety of cellular perturbations, in particular genotoxic stress, to prevent fixation of DNA damage and proliferation of cells with genetic defects (reviewed in [1]). Consequences of p53 activation include induction or repression of p53-responsive genes at the transcriptional level, resulting in cell cycle arrest, senescence, or apoptosis [2]. Due to this central function in preserving the genetic integrity of higher organisms p53 has been labeled the “guardian of cancerCNA datasets may at first be difficult to reconcile with the depletion of UCEs from classicalCNVs, de nov°CNVs, somaticCNVs, and iPSCNVs; while cancer cells with abnormal UCE copy number appear unaffected or even advantaged, cells with abnormal UCE copy number may be disadvantaged in healthy individuals, this difference implying opposite impacts on proliferation, senescence, or apoptosis. Similarly, the mutational profiles of cancer cells may bias CNVs toward forming in the vicinity of UCEs, possibly conferring selective advantage, from growth advantages brought about by deletions or duplications of UCE-containing regions [45]–[50], [110]. This explanation is consistent with the observation that some transcribed UCEs can act as oncogenes [42], [47] or tumor suppressors [45] or, in the case of one UCE, intercellular signaling molecules within hepatocellular cancer [111]. An enrichment of UCEs in cancerCNVs could also be explained if UCE dosage were directly or indirectly implicated in cell cycle control. Here, we presume that cellular detection of UCE dosage is contributing to the dataset may not represent the healthy state, having escaped the possible deleterious consequences of deleting or duplicating UCEs either because the mechanisms effecting such consequences were no longer in play or because the cells had acquired a means by which to circumvent them. With respect to cancerCNAs, it may be that they arise when the mechanisms producing deleterious consequences are disabled or circumvented, their positions potentially influenced by the density of genes with either pro- or anti-proliferative LINC01089 (here renamed LncRNA Inhibiting Metastasis; LIMT), a highly conserved lncRNA, which is depleted in basal‐like and in HER2‐positive tumors, and the low expression of which predicts poor patient prognosis. Interestingly, EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. We also find that LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo. In conclusion, lncRNAs dynamically regulated by growth factors might act as novel drivers of itself, are amenable to analyses spanning just a few cell generations (Fig. 3). Excitingly, understanding the relative contributions of CNV formation and selection pressure to UCE depletion in healthy cells and loss of that depletion in cancer cells should help reveal how cancer cells differ from healthy cells and, perhaps, how we may mitigate cancer phenotypes by inducing cancer cells to more closely resemble healthy cells. Indeed, if we understand the mechanisms by which UCE depletion is established in healthy cells, be it through selection migration of cancer cells in colorectal carcinoma [4], low- expression of uc.73 closely related with stage and grade of colorectal neoplasia [3]. Over-expression of uc.63 suppressed apoptosis of B lymphoma cells and might be predict poor prognosis [18]. Uc.206 acts as a novel oncogene by targeting the P53 gene and promoting CC cell growth, which might be beneficial for cervical cancer therapy [5]. However, little is known about the expression level and biological role of uc.189 in gynecological carcinomas. This study is the first to\n",
            "[0.6231099]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is HbVar?\n",
            "Refined Query: What is HbVar, and what kind of information does this database contain?  Is it a public resource, and if so, how can researchers access and utilize its data for hematological studies?\n",
            "\n",
            "Combined Answer: In the TMPDB web page (http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/), the ‘Database Search’ is available with the use of gene name, PubMed (27) identifier (PMID), accession numbers of DDBJ (29), SWISS-PROT (28) and PIR (30), PDB (5) identifier, the number of TMS(s), or any combinations of those, over TMPDB or selected subset among the 6 TMPDB subsets. A returned search result will be displayed as a list of retrieved entry(ies) with a link to the complete database entry(ies). deal with huge amounts of cancer data, and to search, retrieve and extend them with additional information from well-known databases. Additionally, a freely accessible comprehensive FTP server, which contains all public available TCGA CNV, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1, V2) data converted into the BED format and the related meta data in tab-delimited attribute-value pair format, is released, and periodically updated at ftp://bioinf.iasi.cnr.it/. The availability in BED and in other supported standard formats (i.e., CSV, like RedoxDB (Sun et al., 2012) and MetOx DB (Jacques et al., 2015), it will help oxidative stress-related research in biology/medicine. The CarbonylDB resource provides a large curated dataset on the carbonylation sites in serum albumin–an important in vitro model protein for the study of oxidative protein damage (Maisonneuve et al., 2009; Ros, 2017). It also provides a much-needed large dataset for better prediction of carbonylation sites, which until now performs rather poorly mainly because of the lack of a good dataset (Weng et al., SHK performed experiments and analysed data; H-JK designed experiments, provided patient samples and clinical expertise; T-HL provided patient samples and performed experiments; W-SM provided patient samples and clinical information; H-JK provided patient samples and clinical data expertise; Y-KK provided valuable reagents; SYH performed experiments and analysed data; TSK designed and supervised the study, and wrote the manuscript. The dbSUPER database is freely available to the research community using the web link (http://bioinfo.au.tsinghua.edu.cn/dbsuper). Users are not required to register or login to access any feature available in the database. information from MESH, CHEBI, DRUGBANK, KEGG, HMDB, and CHEMIDPLUS. The included resources were chosen on the basis of free availability. They are downloadable terminology databases containing small molecules from human studies. Given the variety and the population of the different resources merged in Jochem, it is currently one of the largest publicly available biomedical resources for drugs and chemicals. Gene ontology The GENE ONTOLOGY [55] is currently the most successful case of ontology use in bioinformatics and provides a controlled the 1950s. It is accessible through the National Center for Biotechnology Information (NCBI). PUBMED CENTRAL is a digital archive of full-text biomedical and life science articles. The full text of all PubMed Central articles is freely available, but not for bulk download. As of July 2011, the archive contains approximately 2.2 million items, including articles, editorials and letters. Linked life data The LLF project [61] provides the LinkedLifeData platform. LinkedLifeData is a data warehouse that syndicates large volumes of heterogeneous 3 for the other types of experiments. These are publicly available and high level preprocessed data regarding gene, exon and splice junction expression quantifications, DNA-methylation sites, and genome-wide measurements of DNA mutations and copy number variations. Until June 2016, TCGA experimental and meta data were freely available at TCGA data portal. Recently, most of them have been moved to The Genomic Data Commons (GDC), which is a data sharing platform that promotes precision medicine in oncology (https://gdc.nci.nih.gov/) and where The R-package BBCAnalyzer, its source code, detailed documentation including a manual and a vignette with examples and exemplary data are freely available at http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: LGPL-3). Detailed documentation of the R-package BBCAnalyzer is provided in Additional file 1. The source code (written in R), a manual and a vignette with examples and exemplary data are freely available at the project’s homepage http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: The R-package BBCAnalyzer, its source code, detailed documentation including a manual and a vignette with examples and exemplary data are freely available at http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license: LGPL-3). Detailed documentation of the R-package BBCAnalyzer is provided in Additional file 1. The source code (written in R), a manual and a vignette with examples and exemplary data are freely available at the project’s homepage http://bioconductor.org/packages/release/bioc/html/BBCAnalyzer.html (license:\n",
            "[0.6436374]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can DMSO as an additive improve proteomic analysis results?\n",
            "Refined Query: Investigating whether dimethyl sulfoxide (DMSO), when added to samples prior to proteomic analysis, enhances the detection, identification, or quantification of proteins is crucial.  This includes exploring potential effects on protein solubility, reducing aggregation, and improving overall data quality.\n",
            "\n",
            "Combined Answer: dissociation (CID). Parameters for data processing were also followed as described previously [56]. Briefly, raw files containing MS2 data were extracted by Proteome Discoverer (version 1.3; Thermo Scientific) and uploaded to SEQUEST (version 1.20) and searched against a compiled database of the yeast protein sequences from S. cervisiae and S. pombe. Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide proteome analysis is particularly important. Dimethyl labeling provided a fast and straightforward quantification method17 to exclude the nonspecific binding proteins. Bantscheff and colleagues revealed HDAC complexes selectivity for 16 HDAC inhibitors by combining affinity capture and quantitative mass spectrometry. They found that the aminobenzamide inhibitors have preferred selectivity for the HDAC3-NCoR complex.33 HDAC3 was found to be a preferred cellular target of the 106 probe.7 However, HDAC3 was not identified in our data set although Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide and protein global false discovery rate to < 1%: 99% protein confidence, 95% peptide confidence, and a minimum of two unique peptides per protein. on the manuscript and Raymond Poot (CSC, London) for helpful discussions. We are grateful to Gerd Blobel (Children's Hospital of Philadelphia) for exchanging prepublication data. This work has been supported by the Netherlands Research Organization (NWO), the European Union (grant HPRN-CT-2000-00078), the NIH (grant RO1 HL 073455-01) and the Netherlands Proteomics Center. Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass spectrometry and data analysis. To determine enrichment of protein interactions within the network relative to the background proteome, NSAF (normalized spectrum abundance factor) values were calculated to take into account protein length and the total number of spectra present in each individual IP experiment. NSAF values were normalized to proteome abundance (PAX) values for S phase S. pombe (pax-db.org), and the NSAF/PAX ratio was mapped onto each node (node color). for generating high-quality models in a truly unsupervised manner. Therefore, our combined approach could be of great practical utility in both high-throughput structural determination projects34 and NMR-based screening for small-molecule and protein–protein interactions35. (www.glennmorris.org.uk/mabs.htm). The EU BIO-NMD project (n. 241665 to AF and CAS), and the Duchenne Parent Project Italy (DMD Diagnostics Project) to A.Ferlini, are acknowledged. Thanks are also due to Carmelo Rodolico (Department of Neuroscience, University of Messina, Italy), Paola Rimessi, Marina Fabbri and Matteo Bovolenta (University of Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass with multidimensional protein identification technology (MudPIT)15 to quantitatively identify the proteins specifically captured by the ABPP 106 probe under nondenaturing conditions compared with the control probe. The ABPP approach allows us to purify the 106 probe-specific targets with vigorous washing to reduce contaminating proteins. Dimethyl labeling and MudPIT provide powerful tools for defining the targets of the HDAC inhibitor 106 probe based on rigorous quantification to the control probe. In total, 4933 proteins were quantified and Figures S1–4 and Tables S1–5: protein quantification and functional analysis information. This material is available free of charge via the Internet at http://pubs.acs.org.\n",
            "[0.605562]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: The antibodies MK-3475 and CT-011 have shown promising results in treating malignancies. Which protein are they targeting?\n",
            "Refined Query: Given the promising anti-cancer effects of antibodies MK-3475 and CT-011,  identifying their shared protein target is crucial for understanding their mechanism of action and potential synergistic effects.  What specific protein do these antibodies bind to and inhibit?\n",
            "\n",
            "Combined Answer: TcdA, as described by Greco et al. (12). We excluded the neutralizing antibody A26.8, which binds to the extreme C terminus of TcdA and for which no homologous epitope exists within peptide B2. The model reveals the distinct epitopes of each antibody and suggests that binding of bezlotoxumab is more likely to interfere with carbohydrate binding than binding of A20.1 and B39. This is in line with the fact that bezlotoxumab is a fully neutralizing antibody, whereas B39 is non-neutralizing (25) and A20.1 is poorly neutralizing (43). Although the extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified both HDAC3 and its partner protein NCoR1 by Western blot analysis. ES cells were lysed using Cell Lysis Buffer (9803, Cell Signaling) and a cocktail of protease inhibitors (11836170001, Roche). Subsequently, NuPage LDS Sample Buffer (NP0008, Invitrogen) and DTT (1 mM) were added. Primary antibodies employed in western blot analysis included: Tcf3 (sc-8635, Santa Cruz); Sox2 (AF2018, R&D Systems); Sox11 (sc-20096, Santa Cruz); Oct4 (sc-5279, Santa Cruz); Dyrk1A G-19 (G2905, Santa Cruz); Sap155/Sf3b1 (D138-3, MBL); Nanog (AB5731, Milipore); β-actin (A5441, Sigma); β-tubulin (ab6046, Abcam). Lysates were loaded We thank Tom K Kerppola, Xavier Morin, Cédric Raoult, Stephane Zaffran, Manfred Frasch, Alain Vincent, Steve Kerridge, Michèle Crozatier, Ernesto Sanchez-Herrero, Dimitris Papadopoulos and the Bloomington stock centre for providing cDNAs, fly stocks and antibodies. We also thank Jonathan Ewbank and René Rezsohazy for their critical reading of the manuscript. This work was supported by the CNRS, grants from 'l'Association pour la Recherche contre le Cancer' (ARC), 'la Ligue Nationale Contre Le Cancer' (LNCC), 'l'Agence Nationale pour la α- and β-Tubulin (Sigma), γH2AX (Millipore) 6×His (Clontech), GFP (Cell signaling) and ATM (Santa Cruz), rabbit antibodies were against TopBP1, RIF1, PTIP, 53BP1 and phosphoKAP1 (S824) (All Bethyl Laboratories), 53BP1 (Santa Cruz), RNF168 (Millipore), TIRR (Sigma), phospho53BP1 (T543), phospho53BP1 (S25/29), HMGA1, H3 (All Cell Signaling) and AID (generated by the Chaudhuri Lab) and rat antibody against RPA2 (Cell Signaling). The RIF1 antibody used in immunofluorescence is a kind gift of Lifeng Xu (University of California, USA). We thank F. Ochsenbein and C. Francastel for discussions, and S. Jounier and the Gene Identification team at CNG for technical help. We thank D. Reinberg for providing the H3K27me2/3 antibody, R. Feil for the JF1/Ms mouse strain, and N. Gilbert for probes. M.G.'s team is supported by the Association pour la Recherche sur le Cancer (ARC). S.D. acknowledges la Ligue Nationale Contre le Cancer for support (Equipe Labelisée). for GATA-1 and FOG-1 binding (Figure 5A). The same sequence was also enriched for Mbd2 binding (Figure 5A), with similar results obtained with an antibody against Mi-2β (Supplementary Figure 4A). No binding of TAL-1 or Gfi-1b was observed in the GATA-2 sequences. Interestingly, the −3.4 kb, but not the −4.2 and −2.2 kb flanking sequence used as negative controls for GATA-1 binding, was enriched for FOG-1 and Mbd2 binding (Figure 5A and Supplementary Figure 4A), suggesting that the FOG-1/MeCP1 binding at −3.4 kb may reflect a very localized used for detection. Protein loading was determined by standardization to β-tubulin (polyclonal antibody R43; a gift of D. Koshland). Anti-Orc3p monoclonal antibody (SB3) was a gift of B. Stillman (57). Film scans were obtained with a Hewlett-Packard 4c/T scanner and analyzed using NIH Image 1.61. We are grateful to Lifeng Xu (University of California, USA) for RIF1 antibody and Simon Boulton (CRUK) for RIF1−/− MEFs. DC is supported by R01 AI101897-01 (NIAID) and R01CA142698-07 (NCI), Leukemia and Lymphoma Society Scholar Grant, Claudia Adams Barr Program for Innovative Cancer Research, DOD Ovarian Cancer Award, Breast SPORE Pilot Award, Robert and Deborah First Fund Award. GM is supported by NIH grants R01 CA132878 and R01 GM116829, and a Mayo Clinic Brain Cancer SPORE Program Pilot Award (P50 CA108961). JWH is supported by add were used at 1:1000 dilution and secondary antibodies at 1:5000. The following antibodies were used: ATM (Santa Cruz), ASCIZ (Millipore); p95 (known as NBS1) (NEB), β-actin (Sigma), pS15-p53 (Cell Signalling), pS824-KAP1 (Bethyl Labs), total p53 (Pab-421; CR-UK generated antibody) and HRP-conjugated goat anti-mouse or rabbit IgG (Sigma).\n",
            "[0.4871964]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?\n",
            "Refined Query: The human ASPH gene encodes aspartate beta-hydroxylase.  Are there known alternatively spliced isoforms of this gene resulting in different protein products with varying functions or properties?  If so, what are their sequences and functional differences?\n",
            "\n",
            "Combined Answer: of AS (93%) upon direct examination. The likeness of CS to AS is not apparent in all participants and the rate of NHE6 mutations in AS remains to be determined and may be low.13 Of 59 patients presenting with Angelman-like phenotypes one (1.8%) had NHE6 mutations.13 Also, Gilfillan et al.2 found 4 out of 73 patients with Angelman-like phenotypes had NHE6 mutations. As indicated by Gilfillan et al.2, the likeness of CS to AS is prominent enough to have important clinical relevance, i.e. all boys with non-15q11 AS should be tested for mutations Table S1). Combination of alternating recognition sites allows for higher degradation efficiency and reduces sequence repetitiveness. The two enzymes have recognition sites of lengths 27 and 18 bp, respectively, which even with some degeneracy allowed in the recognition site (Gimble and Wang 1996; Argast et al. 1998) makes their random occurrence in a transcriptome highly improbable. The two enzymes work at the same temperature and in the same buffer, so their digestion can be combined in a single step. A fraction of the synthesised carrier Stratagene, La Jolla, CA) was performed, and expression levels of target genes were normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primer sequences are listed in Table S1 in the supplemental material. No PCR products were amplified in non-RT samples (see Fig. S1 in the supplemental material). et al. 2012b), we showed that REST is involved in recruiting this mark during the differentiation of murine embryonic stem cells into pyramidal neurons, specifically at the neural progenitor state. With respect to the two acetylation marks, i.e., H3K9ac and H3K27ac, we find that the same two motifs, i.e., RFX and ATF/CREB, are most significant for both these marks (Fig. 5E,F). It is well known that ATF/CREB TFs can recruit histone acetylases (HATs), such as CREB binding protein (CREBBP) and EP300 (Yuan and Gambee 2001); and for RFX TFs it has (data not shown) and also a missense mutation (glycine to aspartate) in the region of the exchanger domain that was predicted to be highly deleterious by Polyphen-2.27 A second likely splice mutation was found in Family 6, a G to A transition in the last base of the intronic sequence upstream of the splice acceptor for exon 3. There was one genomic deletion discovered in the proband in Family 10 spanning from ChrX:135098247-135218938 (c.1237-557). This CNV deletion is predicted to delete exons 10 through 16 and the 3′-untranslated region in liver, kidney, stomach, and intestine (Kuo et al. 1990; Serfas and Tyner 1993), where it is essential for organ function (Pontoglio et al. 1996). Figure 2A also illustrates that the inferred motif activities are highly reproducible. In fact, motif activities are more reproducible than the expression profiles from which the motif activities were inferred (Supplemental Fig. 16). The reason for this high reproducibility of motif activities is that each motif, m, typically targets hundreds to thousands of promoters, and the inferred motif lines allowing expression of the corresponding AbdA and Exd fusion proteins under the UAS/Gal4 system were established. Importantly, all UAS constructs were inserted at the same genomic locus through the use of the phiC31-integrase system [26], ensuring comparable expression levels in the embryo. In order to be close to physiological conditions of expression, we generated an abdA-Gal4 driver by replacing a P- lacZ insertion in the abdA cis-regulatory sequences [28] by a P-Gal4 element (Figure 2a). This P-Gal4 insertion corresponds to an abdA Resource [56] (UNIPROT) provides the scientific community with a comprehensive, high-quality and freely accessible resource of protein sequence and functional information. Its protein knowledge base consists of two sections: Swiss-Prot, which is manually annotated and reviewed, and contains approximately 500 thousand sequences, and TrEMBL, which is automatically annotated and is not reviewed, and contains approximately 23 million sequences. The primary mission of UNIPROT is to support biological research by maintaining a stable, comprehensive, 13 and 14. With the possible exceptions of Families 3 and 7 all protein truncating mutations occurred prior to the end of the predicted transmembrane domains of the protein (Figure 4). Two mutations (17%) were splice mutations. Family 1 represented a g>a change in the first base of exon 9 which did result in a 20% reduction in the protein levels (data not shown) and also a missense mutation (glycine to aspartate) in the region of the exchanger domain that was predicted to be highly deleterious by Polyphen-2.27 A second likely splice mutation (Barrett et al., 2012). Alternative polyadenylation (cleavage) is very common in mammalian genes (Tian, 2005). According to the study in (Christine, 2016), more than half of human genes have alternative polyadenylation in their post-transcriptional process. Therefore, the analysis of alternative (or all) polyadenylation sites (APA sites) would be of great importance for the study of mammalian genes. The analysis of expressed sequence tags (ESTs) has provided genome-wide annotations of 3′ UTRs. Not only does this analysis show that mammalian\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 657.19ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What family do mDia proteins belong in?\n",
            "Refined Query: To what specific protein family do the mammalian Diaphanous-related formins (mDia proteins), a group of actin nucleating proteins, belong?  Clarify their classification within the broader formin family.\n",
            "\n",
            "Combined Answer: version48,49. Although results with such constructs show that absence of ABD2 does not completely abrogate binding of dystrophin to actin, it is unlikely that absence of ABD1 completely disrupts the interaction between dystrophin and actin. Expression of transgenes deleted for ABD1 lessens the mdx phenotype and restores the costameric pattern of the M band and Z lines, suggesting that the link between dystrophin and the subsarcolemmal cytoskeleton involves more than an interaction with ABD150,51. In agreement with this, other members of the preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the extracellular matrix (Brieher and Yap, 2013; Ratheesh and Yap, 2012). (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the binding site for actin is located at the N terminus.3 Second the rod domain contains 24 triple helical spectrin repeats with 4 interspersing hinge domains. Third, the cysteine-rich domain required for binding to BDG4,5,6 and fourth, the c-terminal domain that contains the syntrophin7 and dystrobrevin-binding sites8. The cysteine-rich domain consists of in the setting of deletions within the ABD1 domain6,43–46. However, we note that most of these studies were performed with microdystrophin constructs lacking the ABD2 domain, which has been shown to enhance the interaction between ABD1 and actin47. Such miniproteins bind actin and modify actin dynamics in a different manner compared to the full length version48,49. Although results with such constructs show that absence of ABD2 does not completely abrogate binding of dystrophin to actin, it is unlikely that absence of ABD1 completely disrupts Mutations from twelve families are represented on the NHE6 protein in Figure 4 and pedigrees are shown in Figure 1. Interestingly, in contrast to prior literature regarding NHE6 mutations wherein mutations have been largely inherited (Supplementary Table 2), a majority of mutations in our study (58%) were de novo. Families 1 through 7 had confirmed de novo mutations (ie mutations were not found in the mother). Another notable finding was two separate recurrent mutations. The first was found at c.1498 c>t, p.R500X. This mutation was observed in (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton immediately beneath the sarcolemma. Regarding its important structural role, dystrophin connects the subsarcolemmal F-actin cytoskeleton to β-dystroglycan (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the matrix and the actin-based cell cytoskeleton, with major roles in regulating changes in neuronal cell morphology, motility and migration. These findings should precipitate more detailed experimental and structural characterization of the TMEM132 family, and assist in formulating hypotheses concerning the cellular mechanisms by which sequence variants in these genes contribute to neurological disease. and sponge proteins, all five are both present and in the identical order in the three cadherin protein families—lefftyrins, coherins and hedglings—that were contained in the last common ancestor of choanoflagellates and metazoans (Abedin and King, 2008; Nichols et al., 2012) (Supplementary Fig. S2). The TMEM132 domain architecture is thus ancient, preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the Their ancient ancestry and their associations with neurological disease suggest that TMEM132 genes have been undeserving of their relative obscurity. Our identification of these proteins as CNS-expressed IG domain superfamily adhesion molecules now places them in a more appropriate perspective as a putative key connection between the extracellular matrix and the actin-based cell cytoskeleton, with major roles in regulating changes in neuronal cell morphology, motility and migration. These findings should precipitate more detailed experimental and/or conditional activation signals will shed light on underlying mechanisms of IRES control and elucidate potentially novel functions of dystrophin. An intriguing question is how the N-truncated isoform remains functional. A key cellular role for dystrophin is presumed to be transmitting the force of contraction across the sarcolemma to extracellular structures by serving as an important architectural bridge role between the F-actin cytoskeleton and the muscle plasma membrane41,42. Two regions within dystrophin are responsible for F-actin\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 353.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is nucleosome eviction ATP-dependent?\n",
            "Refined Query: Does the process of removing nucleosomes from DNA require the energy provided by ATP hydrolysis?  This explores the mechanistic details of nucleosome eviction, specifically whether ATP-dependent enzymes are necessary for this chromatin remodeling event.\n",
            "\n",
            "Combined Answer: CMT3 expression and CHG methylation increase in heterochromatin. In vitro micrococcal nuclease digestion data showed that nucleosomes containing H2A.W protect a longer stretch of DNA (162 bp) than nucleosomes containing H2A (146 bp) (Lindsey et al., 1991), suggesting that H2A.W prevents accessibility to DNA. Consistently, we find that H2A.W represses TE expression in synergistic action with H3K9me2. The acidic patch present in the histone core region of H2A affects the folding ability of nucleosome arrays (Kalashnikova et al., 2013). For identified hard-to-replicate sites as well as novel sites, such as nucleosome depleted regions (NDR). Second, we assayed binding and fork progression to determine if Pfh1 is nearby the replisome during S phase or, if it is recruited to its sites of action. These analyses revealed that Pfh1 and the leading strand DNA polymerase bind both Pfh1-sensitive and Pfh1-insensitive sites to a similar extent. Likewise, mass spectrometry (MS) found that Pfh1 interacts with many key replisome components. Together these data argue that Pfh1 is not just which have been long hypothesized to exist in vivo2,20,21. To explore nucleosome positioning within accessible chromatin in the GM12878 cell line, we partitioned our data into reads generated from putative nucleosome free regions of DNA, and reads likely derived from nucleosome associated DNA (see Methods and Supplementary Fig. 7). Using a simple heuristic that positively weights nucleosome associated fragments and negatively weights nucleosome free fragments (see Methods), we calculated a data track used to call nucleosome positions within folded chromatin fibers. In addition, chromatin fibers self-associate to form supramolecular oligomers that share many of the properties of large-scale structure in condensed chromosomes. These two reversible structural transitions rely on different types of nucleosome-nucleosome interactions (Hansen, 2002), and can be studied in a model system by analysing the magnesium-dependent solution-state properties of defined 12-mer nucleosomal arrays in vitro. To understand the mechanism of H2A.W in chromatin condensation in vitro, we tested whether pathways. In vitro nucleosome array experiments suggest that H2A.W causes higher order chromatin condensation by promoting chromatin fiber-to-fiber interactions. Finally, our findings further demonstrate that H2A.W is both necessary and sufficient for heterochromatin condensation in vivo. to MNase (see, for example, ref. 5). This property of MNase enables the identification of stable canonical nucleosomes in chromatin. However, there have also been reports of noncanonical chromatin particles that are more sensitive to MNase digestion than canonical nucleosomes. These noncanonical particles include “fragile” (MNase-sensitive) and salt-labile nucleosomes (see, for example, refs. 39–42), which have been seen at active promoters in vivo, as well as “prenucleosomes” (nonnucleosomal histone-DNA particles) (43), which have been mono-, di- and tri-nucleosome associated fragments. Transcribed and promoter flanking regions are enriched for longer multi-nucleosomal fragments, suggesting they may represent more compacted forms of chromatin. Finally, prior studies have shown that certain DNA sequences are refractory to nuclease digestion and released as large, multi-nucleosome-sized fragments18; subsequent studies showed that such fragments are condensed heterochromatin19. Indeed we found repressed regions are depleted for short fragments and enriched for phased analysing the magnesium-dependent solution-state properties of defined 12-mer nucleosomal arrays in vitro. To understand the mechanism of H2A.W in chromatin condensation in vitro, we tested whether H2A.W affects self-association or folding. We assembled nucleosome arrays with Arabidopsis H2A.1, H2A.W.6, or a truncated version of H2A.W.6 (H2A.W-CT) that lacks the C-terminal tail containing the SPKK motif (Figure 5). Because folding and self-association depend on the number of nucleosomes per array, the three types of arrays were closely matched heuristic that positively weights nucleosome associated fragments and negatively weights nucleosome free fragments (see Methods), we calculated a data track used to call nucleosome positions within regions of accessible chromatin22. An example locus (Fig. 3a) contains a putative bidirectional promoter with CAGE data showing two transcription start sites (TSS) separated by ~700bps. ATAC-seq reveals in fact two distinct nucleosome free regions, separated by a single well-positioned mononucleosome (Fig. 3a). Compared to MNase-seq23, ATAC-seq data are within 1 kb of an annotated RefSeq TSS. Cutting site analysis (Fig. 2A) revealed an oscillatory pattern with an amplitude that decays with the distance from the CTCF binding motif (Fig. 7A). This pattern is similar to that seen with MNase-seq (Fig. 7 B and C; see also refs. 10, 12, 48) and is consistent with the presence of positioned arrays of nucleosomes in the vicinity of CTCF binding sites. A fragment midpoint versus length plot (38) yielded a V-shaped pattern of depleted signals in the middle, indicating protection from cleavage by\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.20ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 604.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Name a method for enrichment of arginine-methylated peptides.\n",
            "Refined Query: Describe a method for isolating and enriching peptides specifically modified by arginine methylation from a complex biological sample, focusing on the key principles and techniques involved.  Consider the challenges presented by the low abundance of these modified peptides.\n",
            "\n",
            "Combined Answer: (Thermo Fisher Scientific) to identify a set of target peptides for the analysis of samples. Peptides were separated on a 35 cm microcapillary column with a 100 μm inner diameter and packed with ~0.5 cm Magic C4 resin (5 μm, 100 Å, Michrom Bioresources) and Accucore C18 resin (2.6 μm, 150 Å, Thermo Fisher Scientific). ~4 μl sample were loaded onto the column for each analysis and separated using a 40 min gradient of 7%–26% acetonitrile in 0.125% formic acid with a flow rate of 625 nl/min. MS1 spectra were acquired with the following our method. Therefore, the use of 4D-CHAINS allows near-complete assignment of sidechain methyls without the need for site-specific labeling on a perdeuterated background33 (Supplementary Table 4). Second, autoNOE-Rosetta uses a highly parallelizable iterative algorithm run on a computer cluster to perform assignment of long-range NOEs alongside the structure determination process. The full pipeline takes approximately 10–12 days to execute for a typical protein sample, including the time needed for NMR data acquisition, and requires minimum mutation to arginine. The synthesis of 13C-methyl alkylation reagent dimethylated 2-chloroethylamine and installation of dimethylated lysine analog followed previously reported protocols47,48. Briefly, two of the three cysteines in TIRR were mutated into serines. Each lysine of interest (K10, K151 and K205) was replaced by a cysteine and converted to the dimethylated lysine analogs KC10me2, KC151me2 and KC205me2. For the reductive alkylation of TIRR and the installation of dimethylated lysine analogs, excess reagent was eliminated by was set with exclusion after 1 times with an exclusion duration of 60 s. MS2 spectra were acquired with CID and a resolution of 60,000, AGC 5 × 104, maximum injection time 60 ms isolation window 1.6 Th as centroid spectra. Raw files were converted into mzXML data type and search using Sequest (against all human proteins reported by Uniprot) on an in-house data analysis tool developed by Steve P. Gygi (Harvard Medical School, Boston, USA). Unique peptides were imported into Skyline 3.5.0.9319 and transition lists for heavy and light fragments were reverse labeled (e.g., label swap). The “heavy” and “light” labeled samples were mixed and analyzed by LC–MS/MS. Searching tandem mass spectra through the sequence database identified peptides. Identified peptides were quantified by calculating the ratio of peptide abundances in the differentially labeled samples, and those changes were then extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified in an efficient and highly robust manner, yielding the correct assignments for at least 95% of residues and error rates of less than 1.5% (Supplementary Table 1). It is further worth noting that the vast majority of resonances corresponding to sidechain methyls, which are important probes in identifying the protein fold, are correctly assigned by our method. Therefore, the use of 4D-CHAINS allows near-complete assignment of sidechain methyls without the need for site-specific labeling on a perdeuterated background33 (Supplementary Table 4). Enrichment of methylated DNA was carried out using the MethylCap technique. DNA samples were sheared by sonication to obtain fragments between 200 and 800 bp. Methylated DNA capture was carried out using an adapted protocol from the MethylMiner Methylated DNA Enrichment kit (Invitrogen – Carlsbad, CA, USA). Two adaptations were made. Firstly, 20 μL of beads and 14 μL (7 μg) of MBD-biotin protein were used for 5 μg of sheared genomic DNA. Secondly, a single elution fraction was obtained by resuspending the beads in 200 μL of 1X binding/washing pairs were designed using MethPrimer software (Li and Dahiya, 2002), and are as follows: RRM2, Fw: 5′-ttagtttggtcgataaggagaatac-3′ and Re: 5′-taaaaaaacaatacgactttaacgc-3′ for methylation (305 to 566 from transcription start site, TSS), and Fw: 5′-tagtttggttgataaggagaatatgg-3′ and Re: 5′-aaaaaaacaatacaactttaacacc-3′ for unmethylation (306 to 565 from TSS); TOP2B, Fw: 5′-gatagtatggcgttgattgatagc-3′ and Re: 5′-tacttcaaaaacaaccttaacctcg-3′ for methylation (−679 to −476 from TSS), and Fw: 5′-tggatagtatggtgttgattgatagt-3′ and Re: peptides were analyzed by LC-MS/MS with the same MS1 settings as before, but without dynamic exclusion and targeting masses as determined and exported from Skyline51. MS2 spectra were collected at a resolution of 15,000, AGC 5 × 104, maximum injection time 120 ms, isolation window 1.6 Th and as centroid spectra. Precursor and fragment ions were assessed in Skyline and ratios of the different fractions determined. TIRR and 53BP1 quantity were determined from the most abundant fraction (400 mM) and approximated for the other fractions. extracts were separated on 4–12% SDS-PAGE gels and the 53BP1 bands excised for in-gel digestion. Bands were reduced with 10 mM DTT and alkylated with 50 mM iodoacetamide. Gel pieces were washed and destained, dried and digested overnight in trypsin. Digests were de-salted on C18 StageTips. Combined samples of light reference peptides and heavy sample peptides were analyzed by LC-MS/MS with the same MS1 settings as before, but without dynamic exclusion and targeting masses as determined and exported from Skyline51. MS2 spectra were collected at\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.16ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1058.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1083.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1361.48ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 937.18ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 656.05ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.07ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.10ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.76ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 606.40ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.71ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List causative genes for autosomal recessive forms of monogenic Parkinson's disease\n",
            "Refined Query: Identify all genes known to cause autosomal recessive inheritance of Parkinson's disease.  Provide a comprehensive list of these genes, acknowledging that the number may be limited compared to dominant forms.\n",
            "\n",
            "Combined Answer: Causative mutations in neurodevelopmental disorders are frequently de novo, X-linked recessive or autosomal recessive. In contrast to prior literature reporting largely inherited mutations in NHE6, through prospective recruitment, here we discover seven highly deleterious de novo mutations in NHE6. An eighth mutation was found, in a three-generation pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this before being input to Exomiser, which applied variant frequency filters to remove common variants, annotated functional impact against genes and then categorized by inheritance pattern: autosomal recessive, autosomal dominant and mitochondrial. In this study, gene scores from all inheritance patterns were combined. In the case where a single-gene harbored variants of more than one inheritance pattern, the variant with the highest variant prioritization ranking was retained for further analysis. The resulting list of genes was considered the for the mapping of human diseases it will be important to establish whether the implied disease gene is a GRB target gene or is, in fact, located in a GRB as a bystander with no functional relation to the regulatory inputs of the enhancers of the GRB. In such cases, it will be important to correlate GRB regulatory content with the disease phenotype and, if warranted, reassign the disease phenotype to the correct gene. Thus, important developmental genes are embedded in large GRBs, breakpoints or mutations within these GRBs may cause genetic are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause of DOORS syndrome is unknown.9 Strategies to identify disease-causing genes in inherited diseases have changed with the development and availability of new technologies. For example, in epilepsy, channelopathies were identified in the 1990s mostly with positional cloning and candidate gene sequencing.10 Next-generation sequencing, such as whole-exome Autozygosity mapping on two affected cousins (Case 1 and Case 3) identified five homozygous chromosomal segments (>1 Mb), concordant in both cousins encompassing 15.8 Mb and containing 226 genes (NCBI build 37.2). Whole-exome sequencing was used to perform a comprehensive search for pathogenic mutations in both cousins. The target region was sequenced at an average sequence depth of 26.6 for all samples. To identify potential causal variants, we selected all coding variants in the homozygous regions present in both samples. Then, we filtered Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a rare autosomal recessive disorder of unknown cause. We aimed to identify the genetic basis of this syndrome by sequencing most coding exons in affected individuals. Other limitation are inherent to our study design; we did not analyse oligogenic inheritance (combination of one mutated allele in each of two or more genes) or synonymous exonic variants, which could be potentially deleterious. Finally, some limitations are technical—eg, GC-rich regions are difficult to sequence and map, coverage can vary from sample to sample, and reads in genes that have paralogues or homologues can also be difficult to map to the reference genome. Future strategies to identify the causative genes in individuals with DOORS neurometabolic phenotypes achieved a diagnostic yield of 68%, identifying novel human disease genes and most importantly enabling targeted interventions in 44% of patients6. More broadly, published studies applying WES coupled with variant prioritization in patients with unexplained phenotypes are successful in identifying the underlying cause in 16 to 68% of patients6. The significant time and reasoning required to identify the causative gene after WES analysis has led to the development of a variety of variant prioritization algorithms.\n",
            "[0.71443474]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How does ranolazine affect calcium handling in the heart\n",
            "Refined Query: Ranolazine's impact on cardiac calcium handling is complex.  Does it primarily affect calcium influx through L-type calcium channels,  calcium release from the sarcoplasmic reticulum, or both?  How does this alteration influence contractility and action potential duration?\n",
            "\n",
            "Combined Answer: active metabolites and ΔΔQTcF. Although ozanimod blunted the observed diurnal increase in heart rate, excursions below predose heart rates were no greater than with placebo. Results demonstrate that ozanimod does not prolong the QTc interval or cause clinically significant bradycardia, supporting ozanimod's evolving favorable cardiac safety profile. 0.5 mg) and were transient and asymptomatic. Cardiac adverse events of special interest were infrequent and of comparable incidence between the study groups. These included short runs of nonsustained ventricular tachycardia (3 placebo subjects, 2 ozanimod subjects), transient and self‐limiting first‐degree AV block (1 ozanimod subject), and transient and self‐limiting second‐degree AV block, Mobitz type 1 (1 subject in each group). None of these cardiac events was temporally associated with the administration of moxifloxacin. Other This was a negative thorough QT/QTc study, demonstrating that ozanimod treatment, in doses of up to 2 mg/day, did not have a clinically relevant effect on cardiac repolarization. The upper bound of the 2‐sided 90%CI (or 95% 1‐sided confidence limit) of the ΔΔQTcF was below the 10‐millisecond regulatory threshold at all time points for the therapeutic and supratherapeutic doses of ozanimod. These results were confirmed by demonstrating assay sensitivity with the use of moxifloxacin as a positive control. Consistent with the lack of QTc effect, was combined with doxorubicin in 4 of 5 lines [mean combination index values ranged between 0.69 (95% CI, 0.56–0.82, P < 0.001) and 0.82 (95% CI, 0.49–1.15, P = 0.500); Fig. 2A]. Synergistic and additive interactions were observed when rucaparib was combined with carboplatin [mean combination index values ranged between 0.45 (95% CI, 0.22–0.68, P = 0.001) and 1.07 (95% CI, 0.94– 1.20, P = 0.240)] and paclitaxel [mean combination index values ranged between 0.73 (95% CI, 0.59–0.85, P < 0.001) and 1.00 (95% CI, 0.65–1.35, P = 0.980)]. In Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study - PMC no effect of either treatment on any measure of muscle strength or mobility. In the bimagrumab group, there was a progressive increase over placebo in maximum static expiratory pressure (Figure 3); statistical significance was noted at Week 24 (P = 0.017). In addition, no statistically significant differences were recorded in spirometry parameters between both groups throughout the study (Table 2). No statistically significant difference was observed in 6-minute-walk distance (6MWD), stair climbing time, Timed Up and Go test, one-repetition regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII blockade could induce muscle hypertrophy in a myostatin knockout mouse, proving that other molecules signal through those receptors (17). The magnitude of the anabolic response with bimagrumab treatment observed in this study was comparable with those reported in a prior study in patients with sarcopenia (18) and with reports on prior anabolic of the following during treatment: an increase in QT/QTc interval to >500 milliseconds and/or of >60 milliseconds over baseline, any evidence for ventricular or supraventricular arrhythmia with or without hemodynamic compromise or any advanced AV block, or symptomatic persistent bradycardia <35 bpm that required medical intervention. in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor desensitization, internalization, and degradation of the cardiac S1P1R have been proposed to explain the time‐related attenuation of heart‐rate effects.1, 17, 33 In a previous phase 1 single‐ascending‐dose and multiple‐ascending‐dose study with ozanimod, a mild dose‐dependent, first‐dose reduction in HR was observed, which was attenuated with an in the current study, ozanimod, which has even greater selectivity for S1P1R vs S1P3R (>10,000).1 Transient, dose‐dependent decreases in HR have been observed at treatment initiation of S1P receptor modulators in healthy subjects and in patients with multiple sclerosis. It appears that the negative chronotropic effects of S1P receptor agonists in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor\n",
            "[0.73243237]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the primary distinction between the Reverse Warburg effect and the conventional Warburg effect?\n",
            "Refined Query: The Warburg effect describes cancer cells' preference for glycolysis even with sufficient oxygen.  The reverse Warburg effect, however, posits that cancer-associated fibroblasts, not cancer cells themselves, primarily drive glycolysis, producing lactate which fuels cancer cell growth and proliferation.  This key difference lies in the *cellular source* of the enhanced glycolytic activity.\n",
            "\n",
            "Combined Answer: J.H. and E.K. contributed equally to this work. We thank P. Hieter and M. Mayer for valuable discussion and for sharing unpublished results. We also thank V. Larionov, J. Li, L. Hartwell, A. Straight, A. Murray, S. Gasser, D. Koshland, B. Lavoie, S. Gould, M. Basrai, S. Devine, R. Krishnan, and B. Stillman for sharing reagents and thoughts. We are additionally grateful to R. Skibbens and C. Grieder for comments on the manuscript. This work was supported by grants from the American Cancer Society and the NIH to F.S. We thank Jörg Bungert (University of Florida, Gainesville), Yoshihiro Nakatani (Dana-Farber Cancer Institute, Boston), Yang Shi (Harvard Medical School, Boston), and Eric So (The Institute of Cancer Research, London) for reagents and Jörg Bungert and Lizi Wu for helpful suggestions and comments on the manuscript. This work was supported by National Institutes of Health Grants HL090589 and HL091929 (to S.H.) and grants from the Bankhead-Coley Cancer Research Program (to S.H. and Y.Q). C.N. is supported by the Intramural Research Program, part by a Comprehensive Cancer Center Core Grant (P30 CA006927) at Fox Chase Cancer Center from the NIH, and Dr. Lito is supported in part by grants (1R01CA23074501 and 1R01CA23026701A1) from the NIH National Cancer Institute, by the Pew Charitable Trusts, and by the Damon Runyon Cancer Research Foundation. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. We thank the patients for G.K. is supported by the Ligue Nationale Contre le Cancer (Equipes Labelisée), Agence Nationale pour la Recherche (ANR), Fondation Axa (Chair For Longevity Research), European Commission (ArtForce), Fondation pour la Recherche Médicale (FRM), Institut National du Cancer (INCa), Cancéropôle Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Immuno-Oncology. M.N.S., S.A., S.A.M., L.G. and M.C.M. are supported by Junta de Extremadura-Fondo Social Europeo, Ligue Nationale contre le Cancer, the Higher Education Commission (HEC) of after inoculation, respectively. The growth rate of FL-expressing MOLM-13 tumors was not significantly different from that of mock MOLM-13 tumors. Further, plasma FL concentrations were detected in nude mice engrafted with FL-expressing cells but not mock cells (Figure 2B). Interestingly, plasma FL concentrations in FL-expressing tumor xenograft models on day 22 were similar to those observed in AML patients treated with chemotherapy and FLT3 inhibitor [21]. Next, we evaluated the antitumor activities of gilteritinib and quizartinib in these American Cancer Society [RSG-11-048-01-DMC to D.M.M.]; National Institutes of Health [T32-GM007092 to R.L.A., R01-DA036897 to R.J.D. and GM104097 to D.M.M.]. Funding for open access charge: National Institutes of Health [GM104097]. Conflict of interest statement. None declared. of the manuscript. This work was supported by the CNRS, grants from 'l'Association pour la Recherche contre le Cancer' (ARC), 'la Ligue Nationale Contre Le Cancer' (LNCC), 'l'Agence Nationale pour la Recherche' (ANR). but not mock cells. Further, the activities of the FLT3 downstream molecules were not significantly altered in FL-expressing cells compared to mock cells under the normal condition (Figure 2A). These cells were subcutaneously inoculated into the flank of mice and allowed to grow. Tumor volume and plasma FL concentrations were measured 18 and 22 days after inoculation, respectively. The growth rate of FL-expressing MOLM-13 tumors was not significantly different from that of mock MOLM-13 tumors. Further, plasma FL concentrations were detected in Buffalo, New York J.C. Krauss, University of Michigan, Ann Arbor Y. Kuboki, Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan J.C. Kuo, Scientia Clinical Research, Randwick, NSW, Australia A.L. Coveler, Department of Medicine, Division of Oncology, University of Washington, Seattle K. Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea T.W. Kim, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea F. Barlesi, itself, are amenable to analyses spanning just a few cell generations (Fig. 3). Excitingly, understanding the relative contributions of CNV formation and selection pressure to UCE depletion in healthy cells and loss of that depletion in cancer cells should help reveal how cancer cells differ from healthy cells and, perhaps, how we may mitigate cancer phenotypes by inducing cancer cells to more closely resemble healthy cells. Indeed, if we understand the mechanisms by which UCE depletion is established in healthy cells, be it through selection\n",
            "[0.31647936]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of per genes in circadian rhythm control?\n",
            "Refined Query: How do PER genes, specifically their protein products, interact within the molecular clockwork to regulate the cyclical expression of other clock genes and ultimately influence the organism's daily behavioral and physiological rhythms?\n",
            "\n",
            "Combined Answer: regulatory inputs will be reflected in the absence of correlation in expression between targets and bystander genes; HCNEs acting as enhancers of target genes at a particular point in time and space should have the corresponding chromatin domains in active state when they drive the expression of the target gene, which should be reflected by the presence of the corresponding epigenetic signatures; different responsiveness to long-range regulatory inputs will be reflected in different structural properties of the two classes of genes, that is, S5 in Additional data file 2). To test the hypothesis that target genes are expressed in a time-specific manner, we examined the variation in expression level of target and bystander genes across the time-course experiment. If target genes tended to be expressed only at specific time points, this would be evident by larger variation of expression in the time-course experiment, compared to genes that were constitutively expressed. We found that targets expressed in macrophage-differentiation showed significantly higher variation than expressed Topologically associating domains are stable units of replication-timing regulation - PMC The developmental program that generates a complex organism such as a human is executed via gene regulatory networks. Interactions between transcription factors (TFs) and target sites are the main edges of such networks as the regulatory output of such interactions determines the expression levels of target genes at a particular time point during development, in a given tissue and under specific conditions. The human genome contains hundreds of thousands of experimentally documented transcription factor binding sites (TFBSs) and perhaps a gene; distinct TFBS motif content; and mouse homologs of target genes having 'bivalent' histone marks. While the exact molecular mechanism of differential responsiveness remains unknown, the above properties enable identification of key regulatory features of genes responsive to long range regulation by HCNEs and provide a guide to monitoring their activity on multiple levels. Additionally, GRB target gene regulation is different from bystanders and possibly dependent on input from HCNEs even in terminal myeloid differentiation. The genome of each living organism contains thousands of genes, and the precise control of the timing and location of expression of these genes is key for normal development and homeostasis of each individual. Despite the oftentimes high genetic similarity between organisms, the source of phenotypic differences, for example between human and mouse, is thought to originate mainly from changes in how and when genes are expressed. This is partially determined by enhancers, that contribute to the control of gene expression. For decades, duplication events across a number of tissue-specific libraries and one time-course differentiation experiment. The time series experiment we used for this consists of six time points between 0 and 96 h of phorbol 12-myristate 13-acetate (PMA)-stimulated THP1 cells, modeling macrophage differentiation [16]; it is the only CAGE-based time series experiment to date. The genome-wide histone acetylation data obtained in the same differentiation time-course allowed us to correlate the chromatin status of bystanders, targets and HCNEs with target gene of target genes and allow for very precise and refined spatiotemporal patterns in different functional contexts. Since GRB target genes are central to developmental regulation, their expression should be robust and tightly coordinated even under varying external conditions. Most obviously, a large number of different promoter-enhancer pairings is needed because these genes have many different roles in time and space that require a complex switchboard of regulatory inputs arranged in a GRB. important organizational principle of mammalian genomes and represents a critical step towards understanding mechanisms regulating replication timing. Determining whether replication timing dictates chromatin structure within TADs to influence chromatin interactions or vice versa will be an important area of future investigation. KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Jacobsen, 2010). The plant specific DNA methyltransferase CHROMOMETHYLASE 3 (CMT3) binds to H3K9me2 and methylates cytosine residues at CHG sites (where H is A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS\n",
            "[0.41663224]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can sorafenib activate AMPK?\n",
            "Refined Query: Investigating whether the tyrosine kinase inhibitor sorafenib can activate AMP-activated protein kinase (AMPK) requires exploring potential indirect mechanisms, as sorafenib's primary targets are not directly involved in AMPK regulation.  Does sorafenib's effects on cellular metabolism or stress responses trigger AMPK activation?\n",
            "\n",
            "Combined Answer: 2E). These results suggest that inhibition of the PI3K/PDK1/Akt signaling pathway is dispensable for the negative regulation RSV-promoted of leucine-stimulated mTOR signaling. There is some evidence indicating that RSV could exert its biological effect by activation of AMPK (40, 41). Because activation of AMPK enhances TSC1/2 activity that down-regulates mTOR signaling (42, 43), it is possible that RSV inhibits leucine-stimulated mTOR signaling by activation of AMPK. However, we found that disruption of TSC1/2 expression or suppression of the mTOR signaling (42, 43), it is possible that RSV inhibits leucine-stimulated mTOR signaling by activation of AMPK. However, we found that disruption of TSC1/2 expression or suppression of the expression levels of AMPK had little effect on leucine-stimulated mTOR signaling in C2C12 cells or MEFs (Fig. 3), suggesting that RSV negatively regulates leucine-stimulated mTOR signaling by a mechanism independent of the AMPK signaling pathway. Consistent with this view, we found that RSV treatment markedly increased the association between mTOR and mechanism. Treating C2C12 cells with RSV dramatically inhibited insulin-stimulated Akt, S6 kinase, and 4E-BP1 phosphorylation but had little effect on tyrosine phosphorylation of the insulin receptor and activation of the p44/42 MAPK signaling pathway. RSV treatment also partially blocked mTOR and S6 kinase phosphorylation in TSC1/2-deficient mouse embryonic fibroblasts, suggesting the presence of an inhibitory site downstream of TSC1/2. Knocking out PDK1 or suppressing AMP-activated protein kinase had little effect on leucine-stimulated mTOR results website), ISMARA predicts that IRF1 is activated directly at the level of transcription by these regulators, which is confirmed by the experimental literature (Harada et al. 1994). Other predicted targets of NFKB1/REL/RELA that are also significantly up-regulated in this process are TNF receptor genes, components of the JAK-STAT pathway (note that STAT2,4,6 is the 11th most significant motif, indicating that STAT activity changes, affecting the level of its targets) and MHC class I genes. The latter are also predicted to be regulated studies also identified frequent up-regulation of receptor tyrosine kinases (RTKs) in DIPGs, in particular PDGFR-alpha, MET and IGF1R. These RTKs are also over-expressed in supratentorial GBM, albeit at much lower levels. These findings spearheaded several ongoing clinical trials targeting these RTKs, however, initial results show similarly the poor response rates to those seen to previous, more standard therapies [11]. This suggests that RTK-inhibition alone may not be sufficient to combat DIPG. We [23] and others [25] recently identified and differentiation by inducing OB-specific gene transcription.47 Likewise, MAPK signaling cascades through ERK (extracellular-signal-regulated kinase) (SRE) and JNK (c-Jun N-terminal kinase) (AP1) have been reported to upregulate Runx2 and Osterix, supporting osteogenic differentiation.48,49 Conversely, the activation of the unfolded protein response (UPR) is of particular importance in cells specialized to secrete proteins, such as plasma cells, endocrine cells and OBs. The IRE1-XBP1 pathway has been recently shown to promote OB pathway. We first confirmed blocking efficacy by assaying ERK phosphorylation (Fig 3C), as well as by measuring mRNA levels of EGR1, a downstream target of the RAS‐to‐ERK pathway (Fig EV3F). Ultimately, we measured RNA levels of LIMT and found that inhibiting the ERK pathway, using the MEK inhibitor, negated the decrease in abundance of LIMT (Fig 3D). This observation suggests that the RAS‐to‐ERK pathway mediates EGF‐induced downregulation of LIMT, as well as the consequent enhancement of cellular motility. Since high abundance of LIMT is mSIN1 (mammalian stress-activated protein kinase-interacting protein 1), Protor-1 (protein observed with Rictor-1), mLST8, and DEPTOR (8), functions as an Akt kinase that phosphorylates Ser473 of Akt in the “hydrophobic motif” that is essential for full activation of this kinase (8, 10). mTOR is activated by diverse upstream signals such as amino acids, insulin, and insulin-like growth factor-1. Although it is well established that insulin activates mTORC1 through the PI3K/Akt/TSC1/2 signaling pathway (11), the mechanism by which amino acids that future studies should incorporate functional outcomes such as visual acuity, quality of life and motor function, since these morbidities are more common than mortality.(19) Therefore, the activity of selumetinib is best evaluated in the context of toxicity, functional outcomes and QOL. As a MEK-1/2 inhibitor, selumetinib has the benefit of avoiding the adverse event of paradoxical activation of the MAPK pathway seen when BRAF-KIAA1549 aberrant pLGG tumors are treated with direct BRAF inhibitors.(30) Overall, the toxicity profile of (Fig. 2C), suggesting the presence of a distinct mechanism underlying the inhibitory effect of RSV on mTOR. We found that leucine activated mTOR signaling in C2C12 cells but had little effect on Akt activation (Fig. 2D). In addition, suppression of PDK1/Akt activity had little effect on leucine-stimulated S6K and 4E-BP1 phosphorylation (Figs. 2E). These results suggest that inhibition of the PI3K/PDK1/Akt signaling pathway is dispensable for the negative regulation RSV-promoted of leucine-stimulated mTOR signaling. There is some evidence\n",
            "[0.6201672]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?\n",
            "Refined Query: Imatinib, or Gleevec, is a targeted therapy used to treat chronic myelogenous leukemia (CML).  CML is often characterized by the Philadelphia chromosome, a genetic abnormality.  What specific tyrosine kinase, abnormally activated due to the Philadelphia chromosome, is the primary molecular target of Imatinib's inhibitory action in CML treatment?\n",
            "\n",
            "Combined Answer: databases [39] generated several matches. Consistent with the presumed DNA binding function of the protein, a putative RCC1 chromatin binding motif was detected near the C-terminus (AA 869 – 886) that is not present in other known CTCFs. Commonly found post-translational modifications like N-glycosylation (6 instances), N-myristoylation (14 instances), and phos-phorylation (22 instances, including cAMP-dependent kinase, Casein kinase II, Protein kinase C, and Tyrosine kinase sites) were also predicted for tsCTCF, the latter being consistent been treated with bortezomib. Carfilzomib is currently undergoing extensive clinical testing in multiple myeloma, as well as evaluation in mantle cell lymphoma, T-cell lymphoma, large B-cell lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, acute lymphoblastic leukemia, small cell lung cancer, renal cell carcinoma, and advanced prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being through a tandem duplication resulting in a KIAA1549-BRAF fusion or an activating point mutation, BRAFV600E.(18) Approximately 80–90% of pilocytic astrocytomas (PA), the most common pLGG, harbor the KIAA1549-BRAF fusion whereas BRAFV600E mutations are identified in approximately 10–20% of all pLGG.(19) Numerous drugs that target the MAPK pathway have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The of different ITD insertion sequences. Therefore, future studies should examine the efficacy of gilteritinib in the presence of FL using primary AML cells with various ITD mutations. Tyrosine kinase inhibitors are classified into 2 types based on their affinity to receptors. Type I inhibitors such as gilteritinib, midostaurin, and lestaurtinib bind to both the active and inactive forms of FLT3, while type II inhibitors such as quizartinib bind only to inactive FLT3. However, given that both type I and II inhibitors are affected by FL—with the A number of FLT3 inhibitors, including gilteritinib, midostaurin, quizartinib, and sorafenib, have been evaluated in clinical trials [12–15]. In 2017, the US Food and Drug Administration (FDA) and European Medicines Agency approved midostaurin for the treatment of adult patients with newly diagnosed AML with FLT3 mutation in combination with standard chemotherapy [16]. Gilteritinib is a selective FLT3 inhibitor that inhibits both FLT3-ITD and FLT3-TKD mutations, and is classified as an ATP-competitive type I inhibitor [17]. Based on a phase 3 kinase activation that is independent of FL, and occurs in approximately one-third of acute myeloid leukemia (AML) patients [4, 5]. In particular, in-frame duplications of 3 to >400 base pairs in the JMD, known as internal tandem duplications (ITDs), are the most common mutations, occurring in up to 30% of patients with AML, and are associated with poor prognosis [4–7]. Activating point mutations in the TKD are also observed in patients with AML, but at a lower frequency than ITD mutations [5, 8]. These activating mutations are oncogenic and for diagnosis and treatment, since each subtype presents with a distinctive prognosis [2] and the choice of therapeutic regimen is predominantly based on tumor subtype and staging parameters [3]. The development of personalized diagnostics and therapy is leading the way to a new era that may see us overcome some of the difficulties in treating complex diseases such as NSCLC. In the past decade, comparative gene expression profiles of tumors have been extensively studied [4-6], yielding useful insights into the molecular hallmarks of daunorubicin and idarubicin, indicating that a primary target of anthracycline is TOP2A (Gieseler et al, 1996). Microarray-based approach of diagnostic AML with normal cytogenetics showed that TOP2B expression was much higher in patients showing continuous CR than in refractory or relapsed patients after CR, although the researchers did not evidence a direct correlation between TOP2B expression and sensitivity to the induction chemotherapy (Vey et al, 2004). Therefore, our results imply the existence of a mechanism whereby high TOP2B assists efficacy of quizartinib may also be attenuated in the presence of FL in AML patients. Furthermore, single cell analysis of AML blasts in patients has revealed the presence of AML cells with FLT3-ITD co-expressing FLT3wt [27]. Therefore, the FL increase may be correlated with resistance to treatment with FLT3 inhibitors. Our results suggest that gilteritinib may overcome the FL increase and lengthen the duration of efficacy, although further research is needed to confirm this in patients. In this study, we investigated the inhibitory activity have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The Pediatric Preclinical Testing Program showed that selumetinib induced complete regression in a BRAFV600E xenograft glioma model.(20) Recently, the Pediatric Brain Tumor Consortium (PBTC) completed a phase I trial in 38 children with recurrent, refractory or progressive pLGG establishing the recommended phase II dose (RP2D) as 25 mg/m2/dose twice\n",
            "[0.28839806]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: When was empagliflozin FDA approved?\n",
            "Refined Query: I need to know the precise FDA approval date for the drug empagliflozin.  This includes the year and ideally, the month and day.  Was there a specific indication for approval at that time?\n",
            "\n",
            "Combined Answer: For the latest update on 9 February 2017, we searched the Cochrane Epilepsy Specialized Register, CENTRAL and MEDLINE . We searched trials registers and contacted the manufacturer of losigamone and authors of included studies for additional information. We did not impose any language restrictions. provide the actual date on which a medication was dispensed. In order to ensure a sufficient data quality we only considered patients whose year of birth and gender are documented in the database. To exclude children and patients whose year of birth was probably listed incorrectly we excluded patients younger than 20 or older than 99 years, respectively those born after 1987 or before 1908. To be able to analyse the hospitalisations due to ADEs we used a preliminary lead (February 14th 2006 to June 30th 2006) and one year time period (July 1st Eligible subjects were randomized to 1 of 2 groups: ozanimod (escalated from 0.25 to 2 mg over 14 days) or placebo (for 14 days). A single dose of moxifloxacin 400 mg or placebo was administered on days 2 and 17. The primary end point was the time‐matched, placebo‐corrected, baseline‐adjusted mean QTcF (ΔΔQTcF). A total of 113/124 (91.1%) subjects completed the study. The upper limits of the 2‐sided 90% confidence intervals for ΔΔQTcF for both ozanimod 1 and 2 mg were below the 10‐millisecond regulatory threshold. No QTcF >480 milliseconds or design,27 subjects in group 2 received ozanimod placebo QD for 14 days and were randomized (1:1) to receive a single dose of moxifloxacin 400 mg or placebo, alternatively, on days 2 and 17. The reasons for incorporating the nested crossover for the positive‐control moxifloxacin were to provide confirmation of assay sensitivity at the start and the end of the study, as discussed with the US Food and Drug Administration, and to allow a more efficient study design involving only 2 arms (and half the subjects) compared with the conventional 4‐arm a review of the event for determination of whether the event requires expedited reporting to the FDA. With the assistance of the data coordinators, the Independent Medical Monitor has the option of requesting additional information about any SAE. The IMM will complete a form for each review and this information will be entered into the data entry system. Safety will be assessed in two ways – both the percentage of subjects who experience any AE and the rate of AEs across the three groups will be compared, by body system, using standard The protocol for this clinical trial was approved by Western Institutional Review Board (Puyallup, WA) and all enrolled subjects will provide informed consent before study participation. The study results will be widely disseminated at conference presentations and published in peer-reviewed journals. to her institution, and provision of trial drugs from Agios, grant support and advisory board fees paid to her institution, and provision of trial drugs from Bayer and Bristol-Myers Squibb, grant support paid to her institution from Sanofi and Debio, and fees for serving on a steering committee paid to her institution from TARGET Pharma Solutions. We thank the patients, their families, the investigators, the site staff, and the trial teams; David W. Markby (Exelixis) for assistance with medical writing; and Karen O’Leary and Michael Raffin We also searched Chinese Clinical Trial Register, reference lists of included studies and review articles, and relevant journals from recent years. We contacted the pharmaceutical company that produced losigamone (Dr. Willmar Schwabe GmbH & Co.) to obtain relevant data. This search was run for the original review on 1 May 2012. Subsequent searches were run on 30 January 2014, 16 February 2015, and 9 February 2017. For the latest update we searched the following databases. 16.0 to 4000 pg/mL for RP101988, and 8.0 to 4000 pg/mL for RP101442. The interassay precision values were ≤5.57% for ozanimod, ≤6.22% for RP101988, ≤9.57% for RP101075, and ≤4.98% for RP101442. The accuracy (percentage bias) values ranged from −4.19% to −3.30% for ozanimod, −2.88% to 2.08% for RP101988, −4.17% to −0.10% for RP101075, and −3.75% to −1.00% for RP101442. For the plotting of mean plasma concentration‐time profiles, drug concentrations that were below the lower limit of quantification (LLOQ) of the assay were replaced with 0 and\n",
            "[0.7368471]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which R/bioconductor package is used for integrative genomics visualizations?\n",
            "Refined Query: I need a Bioconductor package recommendation for creating visualizations that integrate data from multiple genomic sources (e.g., gene expression, copy number variation).  Which package best suits this integrative genomics visualization need?\n",
            "\n",
            "Combined Answer: We developed the annotatr Bioconductor package to flexibly and quickly summarize and plot annotations of genomic regions. The annotatr package reports all intersections of regions and annotations, giving a better understanding of the genomic context of the regions. A variety of graphics functions are implemented to easily plot numerical or categorical data associated with the regions across the annotations, and across annotation intersections, providing insight into how characteristics of the regions differ across the annotations. We visualization method in leading to novel insight, we here provide a comparison the features of the two packages. Ultimately, the choice of the best software for a given purpose rests on the user. In addition to RedundancyMiner, in Table 1 we provide an overview of other, more remotely related software. In contrast to REVIGO, these tools perform GO term enrichment analysis i.e. they start from a user-supplied list of genes, but offer additional features to assist in interpretation of the results, typically visualization and clustering at play. In addition to tabular output of the annotations, annotatr's built-in plotting functions provide an easy and flexible way to summarize the annotations and view how data associated with the regions changes in different genomic contexts. The annotatr package thus enables fast exploration, more complete genomic contextualization of experiments, and more potential discoveries. [18] is a tool designed to view TCGA data from a gene-centric point of view, providing the user with a variety of interactive visualizations of TCGA data. Web-TCGA [19] is an online platform, which focuses on an integrated analysis and visualization of molecular cancer data sets allowing users to generate global molecular profiles across different cancer entities. However, all these tools focus their effort on assembling, analyzing, and visualizing cancer genomic data sets, but do not provide the investigator with a standard and easy Associating regions of interest to genomic annotations is a standard part of many bioinformatics pipelines. The annotatr package improves upon existing annotation tools by returning all the genomic annotations associated with a region instead of artificially prioritizing one annotation type over another, giving a clearer picture of the biological complexities at play. In addition to tabular output of the annotations, annotatr's built-in plotting functions provide an easy and flexible way to summarize the annotations and view how data associated [16] data portal is a comprehensive online archive to characterize genomic abnormalities in several cancer types including data from TCGA. The cBio Cancer Genomics Portal [17] is an open-access resource that provides visualization, analysis, and download of multidimensional cancer genomic data sets based on an R package and a web interface. GeneSpot [18] is a tool designed to view TCGA data from a gene-centric point of view, providing the user with a variety of interactive visualizations of TCGA data. Web-TCGA [19] is an online platform, which cummeRbund (http://www.bioconductor.org/packages/release/bioc/html/cummeRbund.html) and biomaRt (http://www.bioconductor.org/packages/release/bioc/html/biomaRt.html) were used in combination with custom R scripts to perform quality assessment and further refine analysis results. columns (Supplementary Table S2). The annotate module reports the overlap of all input regions with all intersecting genomic annotations selected by the user, with a user-defined threshold overlap between regions and annotations (Supplementary Table S3). The summarize module enables users to quickly compute summarized information of any numerical (Supplementary Table S4) or categorical data (Supplementary Table S5) over the annotations. The collective goal of the visualization module is to provide insight into modes of regulation, and to regions with built-in genomic annotations for D. melanogaster (dm3 and dm6), H. Sapiens (hg19 and hg38), M. musculus (mm9 and mm10), R. norvegicus (rn4, rn5 and rn6), annotations imported from the AnnotationHub R package or custom annotations for any organism. annotatr enables users to associate numerical or categorical data with regions, enabling better understanding of the underlying experiments via summarization and visualization functions. annotatr is fast, flexible and easily included in bioinformatics pipelines. sources, construction, and genome availability for all included annotations are provided in Supplementary Methods and Supplementary Table S1. The annotatr package consists of four modules that read, annotate, summarize and visualize genomic regions. The read module reads a BED6+ file, defined as BED6 and any number of numerical or categorical data columns (Supplementary Table S2). The annotate module reports the overlap of all input regions with all intersecting genomic annotations selected by the user, with a user-defined threshold overlap\n",
            "[0.59715885]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List symptoms of congenital toxoplasmosis triad.\n",
            "Refined Query: Describe the characteristic triad of symptoms seen in congenital toxoplasmosis.  What are the common clinical presentations of this condition in newborns?\n",
            "\n",
            "Combined Answer: 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). Affected subjects are three males and one female from a consanguineous family (Figure 1a). All were born after an uneventful pregnancy and delivery and had normal growth and development during their first years of life. Insidious symptoms, including visual impairment accompanied by progressive bilateral temporal optic disk pallor, were first noted at the age of 3–5 years (Figure 2a). Although bilateral optic atrophy was evident in all patients by the age of 5 years, there was significant intra-familial variability with visual acuity ranging in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Medical symptoms, particularly gastrointestinal symptoms, were common. Height and body mass index measures were below normal ranges in most participants. Behavioral symptoms included hyperkinetic behavior (100%) and a majority exhibited high pain threshold. Three members of a large consanguineous Indian family (figure 1A), affected by axonal neuropathy (table 1) and optic atrophy, were identified at the London Royal Free Hospital. Case 3 was first seen at the age of 35 years and then again at the age of 51 years. She is the first cousin of Cases 1 and 2 and presented as a child with delayed milestones, later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were\n",
            "[0.58169585]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 277.83ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1007.77ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.19ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1083.58ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 530.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1234.77ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.03ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1032.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1083.57ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 730.84ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1137.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1112.61ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 910.31ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 580.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.56ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 913.35ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 630.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 604.83ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the yeast Μac1 transcription factor induced upon copper deficiency?\n",
            "Refined Query: Does copper limitation in yeast cells trigger increased expression of the *MAC1* gene, leading to elevated levels of the Mac1 transcription factor?  This involves investigating *MAC1* mRNA and/or protein abundance under copper-deficient conditions compared to copper-replete controls.\n",
            "\n",
            "Combined Answer: as only 23% of all genes were Pfh1 associated. A recent paper suggested that association of proteins with highly expressed genes in S. cerevisiae might be an artifact of the ChIP assay [45]. This interpretation is unlikely for our S. pombe analyses as a non-ChIP method, 2D gel analysis of replication intermediates, also showed that replication of three of three tested highly expressed RNA polymerase II transcribed genes is Pfh1-dependent [35]. Also, the peak strength at the highly transcribed genes was elevated in Pfh1-depleted cells compared under the control of a copper-inducible metallothionein promoter did not increase the levels of H4K20me1 compared with control RNAi, presumably due to the rapid conversion of H4K20me1 to higher states of methylation (8). We only observed a very modest increase in PR-Set7 levels after overexpression of PR-Set7PIPm in asynchronous cells (Figure 1A). We hypothesize that multiple cell cycle-dependent mechanisms contribute to the regulation of Drosophila PR-Set7 levels, as we observed significant overexpression of PR-Set7PIPm in hydroxyurea (HU) (11), which places PTA1 expression under the control of the copper-inducible CUP1 promoter and integrates a heat-inducible degradation signal in frame with the Pta1 amino terminus at the PTA1 chromosomal locus. As shown previously (25), Pta1 was barely detectable after shifting this pta1-td strain to 37°C for 30 min and was totally degraded after 60 min (Fig. 1A). The depletion of Pta1 did not change the protein level of the tested CF I and CPF subunits except for that of Ssu72, which was significantly decreased upon the loss of Pta1 (Fig. 1A) amount (Supplemental Fig. S5A,C). We also assessed SLIC-CAGE-derived CTSS features from S. cerevisiae and M. musculus and compared them with features extracted using nAnT-iCAGE as a reference. First, nucleotide composition of all SLIC-CAGE-identified CTSSs reveals highly similar results to nAnT-iCAGE, independent of the total input RNA (Fig. 2C,G; Supplemental Fig. S2G,I). Furthermore, the composition of [−1,+1] dinucleotide initiators (where the +1 nucleotide represents the identified CTSS) also showed a highly similar pattern to the A recent study reported that highly transcribed S. cerevisiae genes are over-represented in ChIP experiments carried out with diverse nuclear proteins, suggesting that their presence might be a technical artifact caused by their high transcription rate [45]. The specific cause of the “hyper-ChIPability” of these regions has not been resolved. It has been proposed that, because highly transcribed genes are more accessible during the pull-down, they may be more likely to interact with beads or antibodies during the IP, and therefore be subject to near NDRs (p = 2.4x10-5; Fig 2C) and 62% of peaks near highly transcribed RNA polymerase II genes (p ≈ 0; Fig 2D) were significantly stronger in Pfh1-depleted cells. This effect was particularly striking at tRNA (p ≈ 0; Fig 2E) and 5S rRNA (p = 1.4x10-6; Fig 2F) genes, where over 97% of the peaks showed evidence of significantly elevated Cdc20 occupancy when cells were Pfh1-depleted compared to WT cells. These findings argue that these genomic features, all of which had significant Pfh1 occupancy in WT cells (Table 1), were particularly observed a slight increase in H4K20me1 levels relative to control RNAi when simultaneously depleting PR-Set7 and Suv4-20. This slight increase is likely due to differences between the rates of H4K20 monomethylation by PR-Set7 and subsequent dimethylation by Suv4-20. Overexpression of a stabilized PIP box mutant of PR-Set7 (F523A and F524A; PR-Set7PIPm) under the control of a copper-inducible metallothionein promoter did not increase the levels of H4K20me1 compared with control RNAi, presumably due to the rapid conversion of H4K20me1 to higher examine the consequences of exogenous DNA damage. However, there are a large number of sites throughout eukaryotic genomes, such as highly transcribed genes and stable protein complexes, that impede fork progression, and unlike lesions induced by exogenous damage, these obstacles are encountered in every S phase. Despite their importance, systematic identification of hard-to-replicate sites and the mechanisms that allow cells to cope with them have so far been addressed only in S. cerevisiae. Here we demonstrate that the sole S. pombe Pif1 libraries (Supplemental Figs. S9, S10, middle panels). We found there are no positional biases with regard to SLIC-CAGE-identified CTSSs and their expression values, independent of the total input RNA. As expected, a higher number of CTSSs identified in nAnT-iCAGE were absent from lower complexity S. cerevisiae SLIC-CAGE libraries derived from 1 and 2 ng total RNA (Supplemental Fig. S9A,B, middle panels). This was particularly evident in those CTSSs with expression values in the lower two quartiles (top two sections in each heat map). Further, over a range of growth conditions were bound by Pfh1 (Table 1), and 48% were sites of fork slowing and/or DNA damage in Pfh1-depeleted cells (Figs 2D and 3D; S2 and S3 Tables). The likelihood of Pfh1 association was significantly greater for highly expressed genes than expected from other RNA polymerase II expressed genes (p≈0; hypergeometric test) as only 23% of all genes were Pfh1 associated. A recent paper suggested that association of proteins with highly expressed genes in S. cerevisiae might be an artifact of the ChIP assay [45]. This\n",
            "[0.8105917]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the mechanism of DNA replication termination in vertebrates?\n",
            "Refined Query: Explain the precise molecular mechanisms by which DNA replication concludes in vertebrate cells, detailing the involvement of key proteins and the resolution of replication forks.\n",
            "\n",
            "Combined Answer: cells is a highly complex process that is still understood much less well than in prokaryotes. One reason for the greater complexity in eukaryotes is that DNA synthesis is coupled to other processes at replication forks, such as the establishment of cohesion between sister chromatids and the duplication of complex epigenetic patterns of histone modifications throughout each chromosome. Our current understanding of eukaryotic DNA replication forks was inspired by earlier work with bacteria, in which chromosome replication is understood in much throughout each chromosome. Our current understanding of eukaryotic DNA replication forks was inspired by earlier work with bacteria, in which chromosome replication is understood in much greater detail. In Escherichia coli, progression of DNA replication forks is dependent on the DnaB DNA helicase that unwinds the parental DNA duplex. The DnaB helicase is connected physically to a subset of the other replication factors to form a larger assembly called the replisome (Yao and O'Donnell, 2008). In addition to DnaB, the replisome includes the the integrity of the chromosomes, eukaryotic cells have evolved mechanisms that regulate the progression of DNA replication forks, monitor defects in DNA synthesis, and deal with problems when they occur (DePamphilis, 2006; Branzei and Foiani, 2007; Tourriere and Pasero, 2007; Aguilera and Gomez-Gonzalez, 2008). Chromosome replication in eukaryotic cells is a highly complex process that is still understood much less well than in prokaryotes. One reason for the greater complexity in eukaryotes is that DNA synthesis is coupled to other processes important organizational principle of mammalian genomes and represents a critical step towards understanding mechanisms regulating replication timing. Determining whether replication timing dictates chromatin structure within TADs to influence chromatin interactions or vice versa will be an important area of future investigation. due to coincidence of initiation events within their structural boundaries. Upon differentiation, TADs that switch replication timing acquire features associated with their new sub-nuclear compartment while their preexisting structural boundaries establish new compartment boundaries. The demonstration that TADs are units of regulation reveals an important organizational principle of mammalian genomes and represents a critical step towards understanding mechanisms regulating replication timing. Determining whether replication timing dictates in 18 human and 13 mouse cell types. We demonstrate that, collectively, replication domain boundaries share a near one-to-one correlation with TAD boundaries, whereas within a cell type, adjacent TADs that replicate at similar times obscure replication domain boundaries, largely accounting for the previously reported lack of alignment. Moreover, cell-type-specific replication timing of TADs partitions the genome into two large-scale sub-nuclear compartments revealing that replication-timing transitions are indistinguishable from a protein-kinase whose activity controls replication initiation, probably through modification of targets in the prereplication complex (64). CDC46 encodes an essential protein of the prereplication complex, components of which are proposed to remain associated with the replicative fork (2). These genetic interactions extend the list of interactions already identified through traditional synthetic lethality (24, 87) and support the idea that Ctf18p interacts with replication fork proteins in vivo. Reliable DNA replication during S-phase is vital for the sustainability of a cell and, ultimately, an organism. The proteins that assemble at licensed replication forks come together to form the Replisome Progression Complex (RPC). This complex must faithfully copy an organism's genome in the context of cell cycle regulation and chromatid segregation while at the same time safeguarding against DNA damage. In response to this highly integrated nature of the RPC, recent studies have generated models at the replication fork that link MCM helicase a unifying model in which TADs are stable regulatory units of replication timing (Fig. 4). In this ‘replication-domain model’, DNA synthesis begins within TADs that reside in the nuclear interior and contain features permissive for transcription. Meanwhile, replication gradually advances into adjacent later-replicating TADs that reside at the nuclear periphery or other repressive compartments and contain features associated with repressed transcription. This gradual progression forms a TTR that extends from the boundary separating early and can cause DNA double strand breaks (DSBs) that impair genome integrity and increase the risk of cancer and other disorders that are associated with genome instability. As many of the proteins involved in DNA replication are highly conserved, model organisms such as S. pombe provide genetically tractable systems to identify and characterize genes with important roles in genome preservation whose human orthologs might have similar functions. DNA replication is accomplished by the multi-subunit replisome, a complex that is assembled at and moves\n",
            "[0.62802386]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the different members/isoforms of the Ras oncogenes?\n",
            "Refined Query: I'm looking for a concise description of the various Ras gene family members and their isoforms, encompassing their distinct structures and functional variations contributing to oncogenesis.  What are the key differences between these isoforms?\n",
            "\n",
            "Combined Answer: The following additional data are available with the online version of this paper: a spreadsheet listing the gene sets used in this study (Additional data file 1); supplementary tables and figures (Additional data file 2). representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary Figure 2). The report is transparent, with all supporting evidence displayed along with links out to eight external resources that are commonly used for interpretation of ICC variants: the ExAC browser14, Ensembl, the UCSC genome browser, ClinVar, PubMed, Google, the Beacon Network (https://beacon-network.org) and the Atlas of Cardiac Genetic (R1–R3) segregated with RS: R1 in families CE1, CE2, and CE4; R2 in families CE3, A1, A2, and A3; and R3 in family P1 (Figure 4B; for genotyping details, see Methods). Intersection of these haplotypes defined a candidate genomic region spanning the SLCO1C1, SLCO1B3, SLCO1B1, SLCO1A2, and IAPP genes (Figure 4B). A parallel genome-wide copy number analysis detected a homozygous deletion within the SLCO1B3 gene in the R1 haplotype and a homozygous approximately 405-kb deletion encompassing SLCO1B3 and SLCO1B1 and the LST-3TM12 pseudogene in the form (S5P, S7P), in its actively elongating variant (S2P), or in any of its variants (RNAPII-8WG16, POLII). We compared the ChAs of the different RNAPII variants in the whole PCHi-C and HiCap networks. As was already noted, RNAPII-S2P, which denotes elongation of actively transcribed genes, shows higher ChAs than the other RNAPII variants in both datasets (Fig. 5b). These differences are robust to partial rewiring of the networks (see “Methods” and Additional file 1: Figure S16a). Figure 5c shows the corresponding abundance values, which are 41 paired samples were available. Both fragments differentiated between lung and tumor samples, whereas no methylation was detected in lung samples. ZIC4 showed methylation in more than 70% of the tumors, which is much higher than the 41% found for RASSF1. The findings for RASSF1 are in accordance with other studies [18]. Also, Frag_01 presented no amplification with the M primer set in the lung samples, in the Frag_02 M primer set only 5 out of 48 were amplified. In tumors, we observed fragment amplification in 29out of 48 samples for Frag_01 Based on the MethylCap-seq data, we generated a list of candidate DMRs and associated genes specific for NSCLC and its subtypes (Table 3). Several of these DMR-associated genes are known to be hypermethylated in NSCLC and other types of cancer, strongly supporting the validity of the data set reported here. For instance, the observed methylation rates of RASSF1 were in agreement with previously reported results [18]. In the MetylCap-seq data, hypermethylation of the genomic region where Frag_01 is located was most significant for the SCC to C to T transition by mechanisms involving deamination of a methylated cytosine.26 Family 9 has been reported previously in the literature as a US-based pedigree.15 In our study R500X represents approximately 16% of the mutations in CS. There are also two other reports of likely independent pedigrees with the R500X mutation.1, 2 Taking all these reports into account, conservatively R500X may represent up to 10% of mutations in the literature currently (at least three in total). Interestingly, we also discovered a second SNV (c.1710 g>a, RNA or protein. Its co-occurrence with the 405-kb R2 deletion in two asymptomatic family members (Table 1) indicates that a single functional SLCO1B3 allele can prevent RS. A search for copy number variations (CNVs) in existing databases and CNV genotyping of more than 2,300 individuals from various populations (see Supplemental Results) revealed additional heterozygous small and large deletions predicted to disrupt SLCO1B1 or SLCO1B3 function, including several approximately 400-kb deletions similar or identical to the R2 haplotype–linked sizes and positions of MNase bands on DHBV genome were roughly determined. Based on the estimated sizes and patterns of individual bands shown in different blots, 24 major MNase cleavage bands were named in an alphabetical way and marked on the right side of each blot in Fig. 4B as well as on a linearized DHBV genome in Fig. 4C. Because of different probes and restriction enzymes used in individual blots, individual bands or groups of bands with the same designations were located at different positions or were arranged in opposite orientations As a definition of genes, we used protein-coding genes among the RefSeq genes. When there were multiple isoforms for the same gene, we used the isoform with the highest transcript level from the RNA-seq data. This yielded 20,195 genes. These genes were used to generate the averaged profiles. For the heat maps, we excluded the following genes. We excluded NM_030207 that encodes murine Sfi1 from our analysis because it had aberrantly high MPE-seq and MNase-seq coverages. We also excluded genes with zero RNA-seq reads, as such genes also generally\n",
            "[0.72162914]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the  subcellular localization of ERAP2?\n",
            "Refined Query: Where within a cell is the endoplasmic reticulum aminopeptidase 2 (ERAP2) protein located?  Is it predominantly in the endoplasmic reticulum, or are there other subcellular compartments where it's also found?\n",
            "\n",
            "Combined Answer: HUVEC cells. Still, we found significant variability across the ChIP-seq data sets, and the targets from some ChIP-seq data sets had lower intersection with the other ChIP-seq data sets than ISMARA’s targets (Supplemental Fig. 19). This analysis shows that ISMARA’s genome-wide predictions can reach accuracies comparable to those obtained from a ChIP-seq study. Finally, the third most significant motif is XBP1, which is activated only after 2.5 h. Its predicted targets are highly over-represented for endoplasmic reticulum (ER) genes and genes study. Finally, the third most significant motif is XBP1, which is activated only after 2.5 h. Its predicted targets are highly over-represented for endoplasmic reticulum (ER) genes and genes involved in vesicle-mediated and Golgi transport, consistent with the fact that XBP1 is a major regulator of ER stress and the unfolded protein response (UPR) (Glimcher 2010). Moreover, several studies support that the UPR is a general characteristic resulting from inflammation or TNF activation in endothelial cells (Gargalovic et al. 2006; Civelek et al. ([36] and below). Consequently, ectopic expression of Exd reproduces the endogenous nuclear distribution in the embryo [35], showing that Exd fusion proteins are not localized in all nuclei of abdA-expressing cells (Figure 2e). In conclusion, our genetic tools allow the expression of AbdA and Exd fusion proteins at levels and in places close to physiological conditions. (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the binding site for actin is located at the N terminus.3 Second the rod domain contains 24 triple helical spectrin repeats with 4 interspersing hinge domains. Third, the cysteine-rich domain required for binding to BDG4,5,6 and fourth, the c-terminal domain that contains the syntrophin7 and dystrobrevin-binding sites8. The cysteine-rich domain consists of with multidimensional protein identification technology (MudPIT) to identify the proteins captured by the ABPP 106 probe. Nuclear proteins were extracted from FRDA patient iPSC-derived neural stem cells, and then were reacted with control and ABPP 106 probe. After reaction, the bound proteins were digested on the beads, and the peptides were modified using stable isotope-labeled formaldehyde to form dimethyl amine. The selectively bound proteins determined by mass spectrometry were subjected to functional and pathway analysis. Our findings with intracellular C-terminal Ser/Thr phosphatase-1 (PP1) docking (Hendrickx et al., 2009; Heroes et al., 2013) and WIRS (WAVE regulatory complex interacting receptor sequence) cytoplasmic motifs (Fig. 1 and Supplementary Fig. S1) (Chen et al., 2014). The latter is consistent with the reported co-localization of TMEM132D with actin filaments (Walser et al., 2011). Cell–cell junctions in the central nervous system (CNS) are maintained by a variety of transmembrane proteins that signal and physically link between the cytoskeletons of adjacent displayed similar association patterns at all three origins and their adjacent regions (Fig 5C–5E). We first examined the binding to ars3002 and its adjacent region ars3002_18kb (Fig 5C). Although Cdc20 bound in early S phase to ars3002, earlier than Pfh1, the peak binding for Cdc20 and Pfh1 was reached at 95 min (Fig 5C). Both proteins had their start of binding to ars3002_18kb at 80 min after release from G2 phase and their peak binding at 95 min (Fig 5C). Thus, Pfh1 and Cdc20 bound to the Pfh1-insensitive site located 18 kb downstream of to identify and document carbonylated proteins in different biological conditions. Further, knowing the exact site of carbonylation is important to understand the nature of oxidative damage, it’s mechanism, and downstream effects. Many studies have been conducted for large-scale identification of carbonylated proteins/sites in different organisms, cells and experimental conditions (Havelund et al., 2017; Maisonneuve et al., 2009). Consequently, it is essential to catalogue the known carbonylated proteins/sites for comparative analyses. A in Additional File 2. From the full set of 96 proteins in 5 cells, UniPeak detected 11,239 enriched regions (Table 1) of median size 136 bp (Additional file 1: Figure S3). Many of these appeared roughly evenly occupied by most proteins, with notable exceptions (Figure 2A). In particular, a large fraction of these regions were occupied only by the cohesin complex (CTCF, RAD21, SMC3), which, unlike canonical TFs, is known to bind insulator elements [12]. Cohesin-specific sites were less likely to be near a Pol II initiation site, and showed our laboratory.21 The statistical analysis among replicates was performed in the module “quantification compare” of IP2. Proteins with an average stable isotope ratio (ABPP 106 versus control probe) greater than 2 or greater than 1.5 with p < 0.05 were subjected to functional analysis in DAVID22 as well as Ingenuity.\n",
            "[0.8246834]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Have thyronamines  effects on fat tissue?\n",
            "Refined Query: Thyronamines, metabolites of thyroid hormones, are emerging as potential modulators of adipose tissue function.  Do they influence adipogenesis, lipolysis, or energy expenditure in fat cells, and what are the mechanisms involved in any observed effects?\n",
            "\n",
            "Combined Answer: 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form Direct involvement of either TSHR or IGF-1R in the pathogenesis of TAO remains uncertain (23, 24). TSHR is detectable on orbital fibroblasts, but the levels of this protein are vanishingly low until the cells are subjected to conditions favoring their differentiation into adipocytes (7, 25). In contrast, TSHR levels in fibrocytes approach or exceed those detected on thyroid epithelium (26–28). Antibodies directed against TSHR and/or IGF-1R may trigger signaling through these receptors and induce production of proinflammatory cytokines. Thus, noncoding RNAs in the energy control of the body is not fully understood, recently, the hypothalamic miR-103 has been shown to protect against hyperphagic obesity in mice [14]. Therefore, the role of miR-137 in the control of food intake or energy accumulation and expenditure in the CNS can be speculated. At a peripheral level, recent studies have shown that miRNAs are dysregulated in obese adipose tissue [15]. Furthermore, during adipogenesis, miRNAs regulate fat cell development by accelerating or inhibiting adipocyte differentiation. In studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave the mAb interferes with both IGF-1R- and TSHR-mediated actions. These findings are congruent with those reported earlier by Tsui et al (7), who demonstrated that 1H7, another IGF-1R-blocking mAb, could attenuate TSHR-initiated signaling in TAO orbital fibroblasts. A recent study by Kumar et al (8) confirmed these findings. Coupled with the current findings, it appears that IGF-1R plays an important role in regulating a component of the signaling conventionally attributed to TSHR in thyroid epithelial cells, orbital fibroblasts, and fibrocytes. From the above controversy regarding the importance of TTR synthesis by the choroid plexus, several points support the hypothesis that choroid plexus-derived TTR plays a role in the movement of THs from the blood to the brain and in distributing THs in the blood and CSF. These points include evolutionary, developmental, molecular and functional data. Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters - PMC of the metabolic syndrome (21). Obesity is a metabolic disorder characterized by systemic inflammation and an increased risk of developing preeclampsia. In obese individuals, adipose tissue is suggested to be a potent source of pro-inflammatory stimuli because of the ability of adipocytes to secrete the pro-inflammatory cytokines, such as TNF-α and IL-6 (21). Besides promoting inflammation, these cytokines also advance atherogenesis, the underlying pathological process in atherosclerosis (167). Atherosclerosis is an inflammatory disorder\n",
            "[0.81575185]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the names of anti-CD52 monoclonal antibody that is used for treatment of multiple sclerosis patients?\n",
            "Refined Query: What specific anti-CD52 monoclonal antibodies are approved or commonly used in the treatment regimens for multiple sclerosis patients, and are there any significant differences in their mechanisms of action or clinical applications?\n",
            "\n",
            "Combined Answer: toxins is protective both in animal models (29–32) and in humans (33) demonstrate that TcdA and TcdB are indeed the primary contributors to disease. Based on this premise, a combination of the two monoclonal antibodies actoxumab (also known as MK-3415, GS-CDA1, and MDX-066) and bezlotoxumab (also known as MK-6072, MBL-CDB1, and MDX-1388), specific for TcdA and TcdB, respectively, is currently in phase III development for the treatment of recurrent CDI. In phase II trials, the actoxumab/bezlotoxumab combination reduced the rate of recurrence Commercially available primary antibodies against the following antigens were used: CREST (rabbit polyclonal, 12439-1-AP, Proteintech); FUS (mouse monoclonal against C-terminus, Santa Cruz, sc-47711; rabbit polyclonal, ab84078, Abcam); p54nrb (rabbit polyclonal C-terminal, Sigma); TIAR (mouse monoclonal, BD Biosciences); G3BP1 (mouse monoclonal, BD Biosciences); Dcp1a (rabbit polyclonal C-terminal, Sigma); anti-Flag M2 (mouse monoclonal, Sigma); PSPC1 (rabbit polyclonal C-terminal, Sigma); GFP (Living Colours® rabbit polyclonal, Clontech, IgG exposure in the brain has been the focus of several investigations, and conflicting data have been reported (40–42). Galcanezumab shows limited distribution into the central nervous system and cerebrospinal fluid (43). For other monoclonal antibodies that bind CGRP, no data exists to our knowledge. While the central penetration of galcanezumab is low, a central effect cannot be definitively ruled out. For many neurodegenerative diseases, monoclonal antibodies are being developed suggesting that they can act centrally to mediate their were used at 1:1000 dilution and secondary antibodies at 1:5000. The following antibodies were used: ATM (Santa Cruz), ASCIZ (Millipore); p95 (known as NBS1) (NEB), β-actin (Sigma), pS15-p53 (Cell Signalling), pS824-KAP1 (Bethyl Labs), total p53 (Pab-421; CR-UK generated antibody) and HRP-conjugated goat anti-mouse or rabbit IgG (Sigma). administration, as it requires patient visits to hospitals or clinics to receive the medication. As IM and SC dosing allows for self-administration, these routes are useful when effective treatment requires maintenance or chronic dosing. A limitation of IM and SC dosing is that large doses may not be feasible due to the solubility of IgG (∼100–150 mg/mL) and because larger injection volumes tend to cause more injection site pain. For these reasons, multiple injections must be given to achieve higher doses. The antibodies in Table 1 that can lead to differences in binding to cell-associated receptors (20). The literature is limited regarding IgG subclass and its effect on PK/PD of monoclonal antibodies, and studies in this area are warranted to address this topic. The antibodies in Table 1 that modulate CGRP are of the IgG isotype and are either humanized or human antibodies. Therapeutic antibodies may be viewed by the body as foreign and activate immune responses that lead to anti-drug antibody (ADA) development that can bind to the therapeutic antibody. Many factors can influence the likelihood of ADA formation, including manufacturing process, antibody structure (i.e. derived from rodent, chimeric, humanized, human), dose, dosing frequency, route of administration (68–70), and patient factors such as immune status or genetics. The effect that ADA could have on the PK of an antibody is complex and difficult to Cells were washed with PBS containing 0.5% BSA and incubated for 30 minutes on ice with the following antibodies: anti-CD4 (RM-4.5; eBioscience), anti-CD8 (53.6.7; BD), anti-CD44 (IM.7; BD), anti-CD25 (PC61; BD), anti-CD62L (MEL14; Biolegend), anti-TCRβ (H57-597; eBioscience), anti-TCRγδ (BD), anti-CD69 (H1.2F3; eBioscience), anti-CD11b (M1/70; BD), anti-Gr1 (RB6-8C5; eBioscience) and anti-HSA (M1/69, eBioscience). Cells were then washed in PBS with 0.5% BSA and data was collected using a Fortessa cytometer (BD Bioscience) and analyzed using structure. The identification by SPR of high affinity and low affinity sites for bezlotoxumab binding to peptides B1 and B2 (with a single low affinity site in B3 and no binding to B4; see Table 2) suggests one of two distinct possibilities: (i) bezlotoxumab has distinct affinities for the two epitopes E1 and E2, with E2 corresponding to the low affinity site (because peptide B3 contains only this epitope), or (ii) the antibody binds to the two epitopes cooperatively, with the low affinity state identified by SPR corresponding to bezlotoxumab mg/mL) and because larger injection volumes tend to cause more injection site pain. For these reasons, multiple injections must be given to achieve higher doses. The antibodies in Table 1 that modulate CGRP administered by the SC route are galcanezumab, fremanezumab, and erenumab. The dose in a 1-mL injection is 120 mg for galcanezumab (10) and 70 mg or 140 mg for erenumab (15), and for fremanezumab (11) the dose in a 1.5-mL injection is 225 mg. Multiple injections of these antibodies are administered to achieve higher doses. Although antibody\n",
            "[0.6195621]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there a package in R/bioconductor for classification of alternative splicing?\n",
            "Refined Query: The question seeks to identify R packages, potentially within Bioconductor, specifically designed for the analysis and classification of alternative splicing events from RNA-Seq or similar high-throughput sequencing data.  Are there dedicated tools for identifying and categorizing different types of alternative splicing, such as exon skipping or intron retention?\n",
            "\n",
            "Combined Answer: et al. 2009). In addition, >25% of lncRNA genes show evidence of alternative splicing with at least two different transcript isoforms per gene locus (Fig. 3D). The most highly spliced lncRNA gene is PCBP1-AS1 with 40 annotated isoforms. This human lncRNA gene is situated at a complex locus with major gene structure differences between human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with from spliced read alignments, using the Ensembl e73 transcriptome as the reference as well as de novo assembly of transcript models. Differential expression was assessed with Cuffdiff v2.1.1 (http://www.nature.com/nbt/journal/v28/n5/full/nbt.1621.html). Transcriptome sets of all replicates for each sample group were combined with Cuffmerge. Finally, cummeRbund (http://www.bioconductor.org/packages/release/bioc/html/cummeRbund.html) and biomaRt (http://www.bioconductor.org/packages/release/bioc/html/biomaRt.html) were used in combination with in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. These elements are frequently found in genes post-transcriptionally regulated by alternative splicing events of exons with premature stop codons. Accordingly, the extreme genomic conservation has been associated to regulatory splicing events maintaining tightly regulated levels of RNA-binding proteins [4]. On the other hand, intergenic elements are frequently flanked by developmental genes, in particular for genes of the different constructs were generated by digesting the vector with BglII and HindIII. All plasmids constructs were sequence verified. The mouse U7 snRNA gene and smOPT sequence were designed, modified and cloned following the protocol described in2. Exonic splicing enhancer (ESE) and exonic splicing silencer (ESS) sequences were identified by Human Splicing Finder. Multiple U7snRNA constructs were cloned in tandem in a self-complementary AAV vector using a XbaI restriction site. All plasmids constructs were sequence verified. Both ITR and transcripts, genes and exons, respectively. Moreover, DEXSeq is designed for differential splicing (DS) rather than DE analysis (Liu et al., 2014; Soneson et al., 2016). The data is simulated for two conditions as follows. For condition 1, the expression profile created in Section 3.1 is taken as its initial expression profile. Genes with at least one major transcript (i.e. a transcript that has RPKM value greater than or equal to 1) in the expression profile are kept, similar to Yang and Jiang (2016). For these genes, only transcripts with in individual 3, who was compound heterozygote for a splice site mutation and a frameshift mutation in trans. This frameshift mutation, because it is not in the last exon, is predicted to lead to nonsense-mediated decay (NMD) of the mRNA.28 The splice donor mutation after exon five, because it is located five nucleotides away from a splice site (1206+5G→A), might or might not affect splicing efficiency. If it affects splicing efficiency, the mutation would lead to an aberrant protein-encoding mRNA, thus engaging NMD. To test for NMD, we did (6SG) residues are converted into C and A, respectively. These conversions mark the RBP binding site on the target RNA (11). The number of these mismatches therefore serves as a cross-link score. The other score addresses problems that may be encountered in a sequencing-based assay: we assign an entropy score based on the number and positions of distinct reads contributing to the cluster to guard against PCR or mapping artifacts. Finally, the pipeline automatically selects cutoffs on both quality scores by using the reverse complement of the (Cubillos et al., 2012). Polymorphisms in noncoding regions can also result in phenotypic variation, as demonstrated by a naturally occurring SNP affecting splicing of the FLC antisense transcript COOLAIR in some Arabidopsis accessions (Li et al., 2015). It is conceivable that additional examples will be identified in the future, making full use of whole-genome sequences from thousands of accessions. Interestingly, the three SNPs reported by easyGWAS for the RL phenotype are found to overlap within several noncoding RNAs downstream of FT on researchers and clinicians in the field supporting data-sharing initiatives, and facilitating direct ClinVar submission from CardioClassifier for the benefit of the ICC community is a development priority. A further limitation to CardioClassifier in its current form is the restricted prediction of impact on splicing. This arises for two main reasons; firstly, CardioClassifier uses the Ensembl variant effect predictor to annotate variants, which annotates bases within 8 base-pairs of the exon/intron boundary as splice-site, but will miss (DNA-seq) [9] including whole genome and whole exome mutations, Gene expression (RNA-seq V1, RNA-seq V2) [10, 11], microRNA sequencing (miRNA-seq) [12], and their meta data (clinical and biospecimen information) [13], which are organized into three levels (1,2,3). In this work, we focus on data extracted from TCGA of level 2 for DNA-seq and of level 3 for the other types of experiments. These are publicly available and high level preprocessed data regarding gene, exon and splice junction expression quantifications, DNA-methylation sites, and\n",
            "[0.76120734]\n",
            "### Expanded entities and terms:\n",
            "Depression - {'SSRIs': 0.0, 'Anxiety Disorders': 1.0}\n",
            "\n",
            " ### Clustered: {'Depression': {'Cluster 1': ['SSRIs', 'Anxiety Disorders']}}\n",
            "Original Query: Which brain structures have been investigated as potential targets for deep brain stimulation of patients suffering from major depression?\n",
            "Refined Query: Given the context of SSRIs and anxiety disorders,  research on deep brain stimulation (DBS) for major depressive disorder seeks to identify which brain structures, beyond those typically targeted, might offer improved treatment efficacy compared to current pharmacotherapies.  This includes investigating their interaction with serotonergic and other neurotransmitter systems involved in anxiety and depression.\n",
            "\n",
            "Combined Answer: Major depressive disorder is a common, chronic, recurring illness associated with significant functional and social impairment (Duric and Duman, 2013). Effective treatment of depression is challenging, with most patients failing to achieve remission after initial antidepressant treatment. As a result, antipsychotics are increasingly used as adjunct therapy to enhance antidepressant efficacy, especially since augmentation with atypical agents improves pharmacological and side effect profiles (Nelson and Papakostas, 2009). Although central following chronic treatment (Choi et al., 2014). The nucleus accumbens shell is one of the brain regions of particular interest where cariprazine produced this effect, and an increase in D3 receptor expression in this region has been proposed to be a common neurobiological mechanism of antidepressant treatments (Lammers et al., 2000). Cariprazine has demonstrated antidepressant-like activity in the chronic mild stress model in rats and was shown to reduce anhedonia-like behavior, a hallmark symptom of depression and negative symptoms of therapy to enhance antidepressant efficacy, especially since augmentation with atypical agents improves pharmacological and side effect profiles (Nelson and Papakostas, 2009). Although central nervous system mechanisms underlying antidepressant actions of atypical antipsychotics are still unclear, it has been proposed that a compound that exhibits high affinity and occupancy of both D2 and D3 dopamine receptors may be effective as a treatment for depressive disorders as well as the negative symptoms of schizophrenia. A dopamine D3 receptor these receptors have the highest density in rat and human ventral striatum (Sokoloff et al., 1990; Gurevich and Joyce, 1999), one of the core areas implicated in the pathology of schizophrenia as well as depression and anxiety. The potential involvement of dopamine D3 receptors in the effects of antidepressants was suggested by several preclinical studies demonstrating that administration of antidepressant drugs enhances D3 receptor gene expression and/or binding in distinct brain regions (Maj et al., 1998; Lammers et al., 2000). Cariprazine, In a mouse model of depression, cariprazine produces antidepressant-like activity through action on dopamine D3 receptors. Indeed, cariprazine reversed anhedonia-like and anxiety-like deficits in this chronic stress model. These results suggest that cariprazine has a unique and distinct dopamine D3 receptor-dependent mechanism of action that may be beneficial in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. has demonstrated antidepressant-like activity in the chronic mild stress model in rats and was shown to reduce anhedonia-like behavior, a hallmark symptom of depression and negative symptoms of schizophrenia (Papp et al., 2014); however, the mechanism of action underlying cariprazine’s antidepressant-like effects has not been elucidated. A previous study of cariprazine in dopamine D3 receptor-knockout (D3-KO) mice showed that cariprazine has D3 receptor-dependent positive/protective effects on cognitive function, suggesting that the efficacy D3 receptors are thought to be involved in the regulation of mood, cognition, and motivation (Gross and Drescher, 2012), compounds like cariprazine that exhibit high affinity and occupancy of these receptors could also potentially be useful in the treatment of depression and the negative symptoms of schizophrenia. This has been further supported by our previous studies showing that cariprazine has potent antidepressant-like, antipsychotic-like, and procognitive effects in rodent models (Gyertyán et al., 2011; Zimnisky et al., 2013; Papp et is commonly used for the treatment of schizophrenia and bipolar disorder, except that cariprazine has a greater affinity and selectivity for D3 vs. D2 receptors (Tadori et al., 2011; Ellenbroek and Cesura, 2015; Findlay et al., 2016; Stahl, 2016). Aripiprazole also has been shown to be effective as an adjunct treatment for major depressive disorder (Bourin et al., 2009; Lenze et al., 2015; Zhou et al., 2015). Our results show that administration of a high dose of aripiprazole produced an antidepressant-like response, but also induced increases high affinity and occupancy of both D2 and D3 dopamine receptors may be effective as a treatment for depressive disorders as well as the negative symptoms of schizophrenia. A dopamine D3 receptor strategy for treatment of depression or schizophrenia is based on the brain distribution and the putative role of D3 receptors (Gross and Drescher, 2012); these receptors have the highest density in rat and human ventral striatum (Sokoloff et al., 1990; Gurevich and Joyce, 1999), one of the core areas implicated in the pathology of schizophrenia as studies demonstrating that administration of antidepressant drugs enhances D3 receptor gene expression and/or binding in distinct brain regions (Maj et al., 1998; Lammers et al., 2000). Cariprazine, a novel, orally active antipsychotic agent that is a potent dopamine D2/D3 receptor partial agonist with preferential binding to D3 receptors, was recently approved by the U.S. Food and Drug Administration for the treatment of both schizophrenia and acute manic or mixed episodes associated with bipolar I disorder (Ágai-Csongor et al., 2012;\n",
            "[0.481529]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 504.17ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the association between moon cycle and rupture risk  of intracranial aneurysms?\n",
            "Refined Query: Investigate the potential correlation between the lunar cycle's gravitational pull and the risk of intracranial aneurysm rupture.  Does the changing gravitational force influence intracranial pressure, thereby increasing the likelihood of rupture during specific moon phases?\n",
            "\n",
            "Combined Answer: entry into the brain. However, it has been shown experimentally that there is no increase in BBB permeability during an aura phase of migraine and there is no disruption of the BBB during a glyceryl trinitrate-triggered migraine attack (47,48). The maximum haemorrhage width (W, transverse diameter), length (L, anteroposterior diameter) and height (H, craniocaudal diameter) were measured and the haemorrhage volume was estimated using the following formula (W x L x H x 0.5). Swirl sign was evaluated independently by 2 neuroradiologists (KAK, ES) experienced in stroke imaging. At the time of evaluation of swirl sign, the readers were blinded to the clinical data. One reader (KAK) has performed the same evaluation at two different occasions with 8- weeks interval. Swirl sign was defined attenuation of normal brain and an acute intraaxial haemorrhage might appear less dense than the brain [19]. Swirl sign was reported among 58% (26 out of 45) patients with of epidural hematomas and upon surgical exploration of 25 patients, 23 patients (92%) showed evidence of active bleeding [8]. Barras et al. [20] studied the shape and the density of ICHs and showed that large ICHs were significantly more irregular in shape, heterogeneous in density, and had greater growth. They concluded that density heterogeneity independently predicted ICH group of tumors, both morphologically and genetically. We identified no diffuse gliomas arising in the cerebral hemispheres and no midline pilocytic astrocytomas with histone H3‐K27M mutation. A subset of the diffuse midline gliomas we assessed was negative for histone H3‐K27M mutant protein. While some of these tumors had molecular features similar to those seen in glioblastomas arising in the cerebral hemispheres (eg, EGFR amplification, PTEN deletion), the majority lacked known glioma molecular alterations including EGFR amplification, IDH1 is low, a central effect cannot be definitively ruled out. For many neurodegenerative diseases, monoclonal antibodies are being developed suggesting that they can act centrally to mediate their effects (44–46). It has been hypothesized that a migraine attack could potentially disrupt the blood-brain barrier (BBB), allowing a mAb entry into the brain. However, it has been shown experimentally that there is no increase in BBB permeability during an aura phase of migraine and there is no disruption of the BBB during a glyceryl High-grade astrocytomas [anaplastic astrocytoma and glioblastoma (GBM)] are the most biologically aggressive form of cancer and a leading cause of cancer-related mortality and/or morbidity in the pediatric years [15, 19, 22]. They account for 20 % of all brain tumors in children and occur mainly supratentorially in the cortex or thalamus or in the brainstem where they are called diffuse intrinsic pontine gliomas (DIPGs). Cortical GBM can be amenable to complete surgical resection, however, up to 85 % will die within 2 years of diagnosis [3, 15, into the cerebrospinal fluid. The quantitative contribution of each route during development remains to be elucidated. This is part of a review series on ontogeny and phylogeny of brain barrier mechanisms. A majority (92%) of CS participants had histories of microcephaly with delayed trajectories of postnatal brain growth (Figure 2A). One participant provided a history of premature closure of cranial sutures. Disease and Stroke Clinical Research Consortium. The CHAMP Research Investigators: J. L. Aceves, MD, Scott and White Healthcare, Temple, TX; D. Arun, MD, Saint Louis University, St. Louis, MO; V.L. Atluru, MD, Winthrop University Hospital, Mineola, NY; S. K. Aurora, MD, Stanford Hospitals and Clinics, Palo Alto, CA; N.L. Bennett, MD, Preferred Clinical Research, Pittsburgh, PA; F.R. Berenson MD, Atlanta Headache Specialists, Atlanta, GA; J.L. Bickel, MD, Children's Mercy Hospital, Kansas City, MO; R.J. Bjork, MD, Colorado Springs Neurological Swirl sign in intracerebral haemorrhage: definition, prevalence, reliability and prognostic value - PMC\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.10ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 705.79ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 809.31ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Hypertension - {'Heart Disease': 0.8996163075278798, 'ACE Inhibitors': 0.403606615139032, 'Blood Pressure Monitors': 1.0, 'Heart Failure': 0.8646065258799878, 'High Cholesterol': 0.7708410551063214, 'Chest Pain': 0.6615752361245737, 'Home Monitoring': 0.0}\n",
            "\n",
            " ### Clustered: {'Hypertension': {'Cluster 1': ['Heart Disease', 'Heart Failure', 'High Cholesterol'], 'Cluster 2': ['Blood Pressure Monitors', 'Home Monitoring'], 'Cluster 3': ['ACE Inhibitors'], 'Cluster 4': ['Chest Pain']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1032.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 681.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How homoplasy affects phylogenetic reconstruction?\n",
            "Refined Query: Homoplasy, the independent evolution of similar traits in different lineages, complicates phylogenetic reconstruction by obscuring true evolutionary relationships.  Identical traits might arise convergently or through reversals, leading to inaccurate inferences of shared ancestry if not carefully considered during phylogenetic analysis.\n",
            "\n",
            "Combined Answer: ancient evolutionary history suggests that these genes should have properties similar to those of proteins with families of homologs, or domains shared across otherwise unrelated sequences. We looked for such families and found them to exist, although the common domains appear to be mostly degraded versions of common repeat elements (LINE, SINE, LTR). An analysis based on multiple sequence conservation suggests the secondary structures associated with these modules to be actively maintained through the course of evolution—a finding 2004) confirmed an ancient whole-genome duplication event, followed by loss of most of the duplicated genes. However, for the synteny comparisons between tetraodon and human genomes, these authors examined gene order, not underlying noncoding sequence similarity. It is important to note that synteny, as we have shown here, while typically defined as conserved gene linkage, is often rather the conservation of order of the underlying regulatory elements. The general rule for the destiny of GRBs after genome duplication seems to involve loss of [13]; and, therefore, heuristic techniques are commonly used [14–16], which may not always lead to optimal alignments. As a result, suboptimal alignments may lead to unreliable tree estimation during phylogenetic inference. To this end, several methods aimed to have shown that removing unreliable sites (columns) of an alignment may lead to better results [17]. Several discussions of existing filtering methods provide evidence that the removal of blocks in alignments of sufficient length leads to better phylogenetic trees. These filtering for a comprehensive review). Analysing multiple sequences simultaneously is fundamental in biological research and MSA has been found to be a popular method for this task. One main application of MSA is to find conserved patterns within protein sequences [9] and also to infer homology between specific groups of sequences [10]. MSA may also be used in phylogenetic tree reconstruction [11] as well as in protein structure prediction [12]. Using a generalisation of the dynamic-programming technique for pairwise sequence alignments works datasets. Notice that, in particular with MUSCLE, we obtain an identical or less average pairwise distance in 8 out of 9 cases between the original and the refined datasets produced by using MARS, despite the fact that we had first randomly rotated all sequences (compare the A.B.C to the A.B.C.rot columns). RAxML [50], a maximum-likelihood-based program for phylogenetic analyses, was used to identify the similarity between the phylogenetic trees inferred using the original and refined datasets. A comparison with respect to the phylogenetic ciona lineage (Table S2). These results show that the RRs ancestral sequences were very likely to have been coding at the split of the teleost-tetrapod lineages. We next investigated the evolutionary dynamics of these regions by analysing the similarity between the human coding exon and the orthologous regions in various lineages at both the amino-acid (AA) and nucleotide level. We found that the percentage identity at the nucleotide level is higher for the fish RRs, while the similarity at the AA level is higher for all other lineages, and topological organisation in the genomes of vertebrates and arthropods; with limited evidence available for echinoderms. These phyletic groups shared a common ancestor at ∼560 Mya, and while CNEs in these phyla show no conservation between them, they are highly predictive of the extent of the regulatory domains of homologous genes in both lineages. This association is observable at individual loci and genome-wide, independently of how topological organisation is represented. The genome of each living organism contains thousands of genes, and the precise control of the timing and location of expression of these genes is key for normal development and homeostasis of each individual. Despite the oftentimes high genetic similarity between organisms, the source of phenotypic differences, for example between human and mouse, is thought to originate mainly from changes in how and when genes are expressed. This is partially determined by enhancers, that contribute to the control of gene expression. For decades, duplication amino-acid (AA) and nucleotide level. We found that the percentage identity at the nucleotide level is higher for the fish RRs, while the similarity at the AA level is higher for all other lineages, including the fish coding paralog (Figure S6). Consistent with the alignment similarities, the ratio of non-synonymous compared to synonymous base pair changes (Ka/Ks) [33] is increased for the RRs compared to the coding homologs (see Materials and Methods and Figure S6). In accordance with the results obtained so far, these data further support revealed a high number of correlated positions (1100 in total; on average, five per kilobase of multiple sequence alignment) that may be interpreted as evidence of evolutionary conservation of RNA secondary structures. It is also worth pointing out that some of the families thus identified do not contain any identifiable repeat sequence, while others contain conserved structural elements. One such family is shown on Figure 4D along with its predicted fold and 10 identified compensatory mutations maintaining Watson-Crick base pairing, and\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.51ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 681.81ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which transcription factors are involved in E-cadherin repression during EMT?\n",
            "Refined Query: Epithelial-to-mesenchymal transition (EMT) involves the downregulation of E-cadherin.  Which specific transcription factors mediate this repression, and what are the signaling pathways and epigenetic modifications that regulate their activity during EMT?\n",
            "\n",
            "Combined Answer: (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and mesenchymal cells (for results, see http://ismara.unibas.ch/supp/dataset5/averaged_report/). As discussed in the Supplemental Material and Supplemental Figure 21, ISMARA automatically inferred much of the key regulatory interactions between TFs and miRNAs involved in EMT (for a review, see Polyak and Weinberg 2009) using only the gene expression To illustrate ISMARA’s ability to integrate the role of both TFs and miRNAs in the gene regulatory network, we took advantage of data from a system in which miRNAs are known to play important regulatory roles: the epithelial-to-mesenchymal transition (EMT). We applied ISMARA to expression measurements from epithelial and mesenchymal subpopulations (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and genetic program that broadly reduces fibrogenic activity by HSCs. Interestingly, 48 h of Aramchol reduced the expression of a gene set involved in epithelial-mesenchymal-transition (EMT; Fig. 4), a process in which epithelial cells acquire the phenotypic characteristics of mesenchymal cells, including increased motility and invasiveness. Quiescent liver cells express high levels of PPARG and low levels of Hedgehog (Hh) signalling components, while activated HSCs have increased Hh signalling that represses PPARG expression.26 The reduced these pathways are most likely involved in the transition of the tissue from squamous to columnar epithelial that occurs during differentiation. Thus, in contrast to the methods used in the original study (Ross et al. 2007), ISMARA predicts which regulators are directing various aspects of the differentiation process, including ciliogenesis, the innate immune response, and the transition from squamous to stratified epithelial. As far as we are aware, these predictions of the core regulatory network controlling mucociliary differentiation are Wnt signaling, involves histone modifications at the Tcf3 promoter and the activation of miR-211, which post-transcriptionally stabilizes Tcf3 downregulation. Understanding the downstream effects of Wnt signaling in ESCs is of both fundamental and translational relevance, as it may be exploited to manipulate ESC differentiation towards specific cell lineages. Figure 21, ISMARA automatically inferred much of the key regulatory interactions between TFs and miRNAs involved in EMT (for a review, see Polyak and Weinberg 2009) using only the gene expression data. histone marks (H3K4me3 and H3-acetylation) and the upregulation of miR-211, a novel Wnt-regulated microRNA that targets Tcf3 and attenuates early neural differentiation in mouse ESCs. Our data show for the first time that Wnt signaling down-regulates Tcf3 expression, possibly at both the transcriptional and post-transcriptional levels, and thus highlight a novel mechanism through which Wnt signaling inhibits neuro-ectodermal lineage differentiation in mouse embryonic stem cells. We provide evidence that Tcf3 down-regulation represents a main downstream effect through which Wnt signaling directs the differentiation of pluripotent ESCs towards non-neuroectodermal lineages. Moreover, we show that Wnt-mediated repression of Tcf3 involves epigenetic regulation associated with histone modifications and Wnt-mediated induction of miR-211. Our data demonstrate that Wnt signaling counteracts Tcf3 function at multiple levels, which ultimately ensures the delicate balance between self-renewal and differentiation in mouse ESCs. stably overexpressing LIMT (or eGFP as control; see Fig EV3D). As expected, ectopic expression of LIMT reduced migratory and invasive capacities (Fig 3A and B). To further validate the effect of LIMT on migration, we designed two shRNAs directed against different parts of the gene and show results for sh716, because it could more effectively downregulate the respective transcript (Fig EV3E, see Materials and Methods). Consistent with the observations made with siRNAs and with overexpression of LIMT, MCF10A cells stably expressing shLIMT for explaining differences in levels of a particular chromatin mark across tissues were often also highly significant for explaining mRNA expression differences. This was particularly the case for methylation of lysine 4 on histone H3 (H3K4me2, H3K4me3), for acetylation of histone H3 (H3K9ac, H3K27ac), and for trimethylation of lysine 36 on histone H3 (H3K36me3). For example, Figure 5A shows the activity profiles for these marks for the SNAI1..3 motif, which is recognized by the snail TFs (see Supplemental Fig. 22 for additional examples). As\n",
            "[0.73647565]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is desmin an intermediate filament protein involved in Dilated Cardiomyopathy (DCM)?\n",
            "Refined Query: Desmin, an intermediate filament protein crucial for maintaining sarcomeric structure, has been implicated in dilated cardiomyopathy (DCM).  This prompts the question:  To what extent does desmin dysfunction, such as mutations or abnormal expression, contribute to the pathogenesis of DCM and its clinical manifestations?\n",
            "\n",
            "Combined Answer: variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants (TTNtv) in exons constitutively expressed in the heart are robustly associated with DCM15. Additionally, it is unclear that the mechanism of action for these variants is truly loss of function (LoF). Instead of scoring all TTNtv equally and assuming an underlying LoF mechanism, we only score TTNtv highly if they are in constitutive exons (proportion a deletion of exons 45–50 and two of 48–50, that the shorter novel dystrophin induced by exon 51 skipping in DMD can restore components of the DAPC as indicated by the increase in ASG and BDG in dystrophin-positive fibers and the genotype-specific relocalization of nNOS to the sarcolemma. These data confirm that restored dystrophin maintains essential domains for its function and further suggest the potential of the PMO AVI-4658 to become a disease modifying drug for DMD. complex (DAPC),3 composed of three subcomplexes: (i) the sarcoglycans (α, β, γ, and δ), (ii) syntrophin, nNOS, and dystrobrevin, and (iii) BDG and α-dystroglycan. The absence of dystrophin and destabilization of the DAPC is thought to render muscle cells susceptible to stretch-induced damage and increased intracellular calcium influx, leading to a series of pathological processes responsible for skeletal and cardiac muscle fiber necrosis,9 inflammation and replacement of muscle with fibro-adipose tissue. Regarding the signaling function, protein induced by exon skipping in the human. The lack of dystrophin in DMD leads to reduced levels of all DAPC proteins and even to the absence of nNOS from the sarcolemma.21,22,23,24,25 The importance of a dystrophin protein containing its functional domains is highlighted by patients with the missense mutation (C3340Y)4,26 within the BDG binding domain that develop a DMD phenotype even though considerable levels of dystrophin staining was visible at the sarcolemma. Another patient harboring a missense mutation (D3335H)27 had dystrophin they indicate that the shortened dystrophin proteins produced by skipping exon 51 recapitulate protein expression observed in BMD patients with the relevant deletions. The restoration of sarcolemmal nNOS observed here may have further important implications, as nNOS expression counteracts vasoconstriction and focal ischemia following exercise, which cause additional damage in DMD muscle.10,34 Additionally, nNOS delocalization leads to nitrosative inhibition of muscle force in mdx mice,35 and this may cause further damage to the muscle. detect even with targeted investigation, as they often manifest later in life and exhibit incomplete penetrance. We have therefore modified PM2 so as not to inappropriately discard variants seen at very low frequencies in these reference datasets. In addition, we have created extensions to three ACMG/AMP rules, to enhance interpretation of ICC variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants 16/17 on the dystrophin molecule (encoded by exons 42–45) to be properly targeted to the sarcolemma.31,32,33 Patients with deletions of exons 45–50 lacks part of this region and the failure to restore nNOS at the sarcolemma is equivalent to that described in BMD patients with the equivalent in-frame deletions.32,33 These data are encouraging, as they indicate that the shortened dystrophin proteins produced by skipping exon 51 recapitulate protein expression observed in BMD patients with the relevant deletions. The restoration of sarcolemmal in red), which are enriched in the EIF2 signaling pathway, are illustrated in Figure S4a in the SI. The top ranking categories (p < 1 × 10–5) are shown in Figure S4b in the SI. Numerous reports have identified EIF2α and related proteins in the nucleus.28 Interestingly, pathogenesis of cardiomyopathy in a mouse model for FRDA correlates with the early and persistent eIF2α phosphorylation, which precedes activation of autophagy and apoptosis.29 The disease analysis shows that the “neurological disease” ranks at the top among the enriched disease with a substantial increase in DAPC and the restoration of nNOS to the sarcolemma, although the skipping in the mdx mouse only lacks the epitopes encoded by exon 23. None of these models have deletions equivalent to those studied in our patients in this study. Here, we show that restoration of the DAPC can be observed in the subset of myofibers showing dystrophin expression in DMD boys receiving i.m. treatment with SSOs. In particular we observed a significant increase in the sarcolemmal expression of BDG and ASG expression after a single i.m. α-sarcoglycan and nNOS expression (this latter protein only in the patient with a deletion 49–50, not in the one with a deletion of exons 45–50), as also found in this study. However, we did not quantify BDG and patients with a deletion 48–50 in the previous study.32 In summary, we prove now in a comprehensive study of four patients, two carrying a deletion of exons 45–50 and two of 48–50, that the shorter novel dystrophin induced by exon 51 skipping in DMD can restore components of the DAPC as indicated by the increase in ASG and BDG in\n",
            "[0.76055264]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is lambrolizumab effective for treatment of patients with melanoma ?\n",
            "Refined Query: Exploring the efficacy of lambrolizumab in treating melanoma requires examining its clinical trial data.  Specifically, what are the response rates, progression-free survival, and overall survival benefits observed in various melanoma stages and patient populations treated with lambrolizumab compared to standard therapies or other immunotherapies?\n",
            "\n",
            "Combined Answer: erenumab (78), and fremanezumab (79) have been reported elsewhere from clinical trials. The drug labels for these three drugs state similarly that, although the immunogenicity profiles do not demonstrate an impact of ADA development on efficacy or safety, the available data are too limited to make definitive conclusions (10,11,15). In addition, ADA development does not demonstrate an impact on the PK of galcanezumab (10). The primary study objective was to evaluate the efficacy and safety of pazopanib, with efficacy measured as objective response rate (ORR), which is the sum of complete responses (CRs) + partial responses (PRs). Secondary objectives included assessing growth rate over time in target lesions before and after pazopanib treatment, evaluating the need for surgical intervention in individuals who received pazopanib in comparison to rate prior to receipt of drug, and creating an annotated tissue resource from patients on study. All endpoints, 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. was based on the mechanism of action of anifrolumab and the assumption that demonstrating statistically significant benefit in the primary end point at a 2‐sided alpha level of 0.1 in either of the populations would provide sufficient preliminary evidence of efficacy to continue phase III studies in the appropriate population. A 2‐sided alpha level of 0.1 represents a 5% chance of declaring a positive study result when there is no treatment effect (risk of proceeding with an ineffective drug). The present study had a power of 88%, representing At the second planned interim analysis, the trial showed significantly longer overall survival with cabozantinib than with placebo. Median overall survival was 10.2 months with cabozantinib and 8.0 months with placebo (hazard ratio for death, 0.76; 95% confidence interval [CI], 0.63 to 0.92; P = 0.005). Median progression-free survival was 5.2 months with cabozantinib and 1.9 months with placebo (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.52; P<0.001), and the objective response rates were 4% and less than 1%, target of 60 patients, which was exceeded. Efficacy data were analyzed at each time point by analysis of covariance with a fixed effect for treatment (bimagrumab or placebo) and a continuous covariate for the baseline measurement. TMV data were log-transformed before analysis, but all results were back-transformed and reported on the original scale. Findings were considered statistically significant if a two-tailed P value was less than 0.05. 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed 32.2% of the patients with NSCLC had a confirmed response, and the majority (88.1%) had disease control for a few months or more with sotorasib, leading to a median progression-free survival of 6.3 months. Similarly, most patients in the colorectal cancer subgroup had disease control, with a median duration of stable disease of 5.4 months and median progression-free survival of 4.0 months. With current therapies, approximately 9 to 18% of patients with NSCLC have a response to second- or third-line therapies, with median progression-free was applied. The Cochran‐Armitage trend test of all treatment groups showed that the number of patients in whom the primary end point was achieved was greater for anifrolumab versus placebo in the modified ITT population (P = 0.072) and in the IFN‐high subpopulation, which included 75% of the patients (P = 0.034). In pairwise comparisons, both anifrolumab groups had greater response rates compared with placebo (17.6%). A response was achieved in 34.3% of the patients treated with anifrolumab 300 mg (P = 0.014 versus placebo) and in 28.8% of to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many patients enrolled on the study had the option to revert to observation, and did not have the immediate threat of shortened survival as would be the case in metastatic disease, the incentive to remain on an agent that caused side effects was lower than in other settings. Despite that, a number of patients chose to remain on treatment for prolonged\n",
            "[0.71865034]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List human diseases involving genomic imprinting.\n",
            "Refined Query: Describe human diseases resulting from disrupted genomic imprinting,  specifically detailing the genes affected and the resulting phenotypes.\n",
            "\n",
            "Combined Answer: imprinted region. Altogether, these data demonstrate that the potent transcriptional silencing mechanism that restrict gene expression on the maternal Snurf–Snrpn cluster is divergent from the mechanism that controls X inactivation. The involvement of H3K9me3 and H4K20me3 in the transcriptional silencing of imprinted genes was previously shown at the 0.5-Mb Igf2r cluster, as well as at the IC of other imprinted loci (Wu et al. 2006; Delaval et al. 2007; Regha et al. 2007; Pannetier et al. 2008). Interestingly, Barlow and colleagues showed that in gene silencing at this locus (Supplemental Fig. S4). We next analyzed the distribution of MacroH2A, a histone variant that is preferentially enriched on the inactive X chromosome and that could contribute to transcription silencing (Mietton et al. 2009). This analysis showed that MacroH2A was not enriched on the silenced imprinted interval (Supplemental Fig. S5). We also tested the distribution of H4K20me3, H3K9me3, and H3K79me3 histone marks in the postnatal (day 1) brain and found patterns very similar to those observed 3 d earlier, at in 5′ and 3′ UTRs, promoters, enhancers, large RNA genes, microRNA genes, and imprinting control regions (ICR) (Table 1, Table S6). To assess whether the regulatory Mendelian mutations differ from non-deleterious variants, we compared the regulatory mutations based upon a set of genomic characteristics (attributes) representing typical indicators of variant functionality such as GC-content, conservation, histone modifications, DNase I accessibility, and overlap with enhancers and transcription factor binding sites. Additionally, Mendelian silenced Snurf–Snrpn region, we would expect to detect RNAPII on the maternally contributed imprinted domain. Indeed, whereas the 3-Mb maternally contributed Snurf–Snrpn region was characterized as transcriptionally silent, we cannot exclude that transcription events could arise within this silenced region. We explored this hypothesis by performing ChIP experiments using chromatin prepared from E17 fetal brains, with antibody against the C-terminal domain of RNAPII. We then analyzed RNAPII enrichment within the imprinted region using our set are available in the Supplemental Methods. The 35 primer sets can discriminate the two parental alleles of all Snurf–Snrpn coding genes, four positions within the imprinting center, and a series of randomly chosen non-coding regions (Fig. 1A). Except for RNAPII ChIP experiments, we performed a pre-amplification step with the Thermoprime Taq polymerase (Abgene), using primers flanking the allelic differences (these primers amplify the JF1/Ms and C57BL/6 genomes with the same efficiency). This step improves mismatch detection (Shively et al. of validated non-coding variants associated with Mendelian disease has not existed. Therefore, we performed detailed and comprehensive biocuration to identify experimentally or otherwise validated non-coding variants (<25 nucleotides) associated with Mendelian disease from the medical literature. The resulting 453 mutations were located in 5′ and 3′ UTRs, promoters, enhancers, large RNA genes, microRNA genes, and imprinting control regions (ICR) (Table 1, Table S6). To assess whether the regulatory Mendelian mutations differ from parental crosses (i.e., C57BL/6 male × JF1/Ms female) and obtained the same distribution for all histone marks (H4K20me3 and H3K79me3 are shown in Supplemental Fig. S3). Hence, histone modifications segregate in opposite patterns that are dictated by the paternal or maternal origin of the imprinted genomic interval. H4K20me3 and H3K9me3 enrichment on the silent imprinted region is in accordance with the well-established role of these two modifications in heterochromatin and gene repression (Schotta et al. 2004). In contrast, we found that of heterochromatin-associated histone marks within the Snurf–Snrpn imprinted region is higher in brain than in liver cells. A comparison of the amount of mRNA expressed from the genes of this genomic interval in liver and brain revealed that they are expressed at much higher levels in the brain (Supplemental Fig. S7). In the light of the fact that PWS is a developmental, neurological syndrome, we propose the following hypothesis: Imprinting in this genomic interval is likely required for the proper dosage of one or several genes in the brain, imprinted region is enriched in H4K20me3, H3K9me3, H3K79me3, and H3K36me3 histone marks. Several of these marks—H3K9me3, H4K20me3, and H3K79me3—have been previously associated with heterochromatin formation and gene repression, which suggests that they could participate in gene silencing within the Snurf–Snrpn interval (Schotta et al. 2004; Jones et al. 2008). We demonstrated that H3K27me3, which contributes to gene silencing at the imprinted Kcnq1 cluster, as well as to X-chromosome inactivation (Plath et al. 2003; Lewis et al. 2004; PWS is a developmental, neurological syndrome, we propose the following hypothesis: Imprinting in this genomic interval is likely required for the proper dosage of one or several genes in the brain, during late gestation. We propose that in the brain, a high level of heterochromatin-associated histone marks on the maternal chromosome contributes to the establishment of an efficient heterochromatin barrier that prevents the recruitment of the transcription factors that are active on the paternally contributed chromosome. As the genes of the\n",
            "[0.3652614]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Why are insulators necessary in gene therapy vectors?\n",
            "Refined Query: Gene therapy vectors, delivering therapeutic genes, must avoid triggering immune responses or interacting non-specifically with cells. Insulators are crucial because they prevent the therapeutic gene from being silenced by surrounding chromosomal DNA or from activating nearby genes, ensuring controlled and targeted gene expression, maximizing therapeutic effect and minimizing off-target effects.\n",
            "\n",
            "Combined Answer: Chromatin insulation plays a profound role in regulating gene expression and is mediated by the binding of insulator proteins to specific DNA sequence elements. So far, in only a limited number of organisms insulator function has been demonstrated: in yeast [1-3], sea urchin [4,5], Drosophila (e. g. [6,7]), and vertebrates (e. g. [8,9]). D. melanogaster and vertebrates are the only metazoan systems where insulator binding proteins have been identified. In Drosophila, Suppressor of Hairy Wing [Su(Hw)], Boundary Element Associated Factors for normal development was also illustrated in vertebrates as its elimination in mice resulted in early embryonic lethality [22]. These reports from vertebrates and flies highlight the importance of chromatin insulation and insulator binding proteins on a global genomic scale in both systems (for recent reviews, see [13,23]). Moreover, the work about dCTCF showed that a key player of chromatin insulation is conserved from fly to man. We reasoned therefore that chromatin insulation might also be a relevant mechanism of regulating gene The understanding of such avoidances is becoming an interesting line of research (for recent studies, see [7, 8]). On the other hand, short words of nucleotides may be systematically avoided in large genomic regions or whole genomes for entirely different reasons, i.e. just because they play important signaling roles which confine their appearance only in specific positions: consensus sequences for the initiation of gene transcription and of DNA replication are well-known such oligonucleotides. Other such cases may be insulators, sequences reduced correlation in gene expression, consistent with the hypothesis that CTCF insulator sites partition the genome into independent domains of gene expression. A similar number of potential insulator sites was found by chromatin immunoprecipitation experiments (ChIP) against CTCF and, strikingly, the CTCF binding consensus motif deduced there was virtually identical to the enriched conserved element defined in the first study [17]. In addition, it was shown that the sites of CTCF-binding sequences in the human genome are highly conserved in proteins. In contrast, there is only one known insulator protein in vertebrates, CTCF, which is associated with all known insulators [10,11]. CTCF was initially described as a transcriptional regulator of the chicken c-myc proto-oncogene [12]. Besides its function as a transcription factor, CTCF is important for several other cellular processes, e. g. genomic imprinting, X-chromosome inactivation, control of DNA methylation state, or long-range chromatin interactions (for review see [13]). The link between CTCF and chromatin insulation was preserved synteny in vertebrates [6] and insects [7] are due to the requirement to keep such arrays of HCNEs in cis to their target genes. This has led us to formulate the concept of genomic regulatory blocks (GRBs), which are functional regulatory units on a chromosome that are spanned by HCNEs and contain the gene regulated by HCNEs (the target gene). Those HCNE arrays often span large genomic regions of low gene density (gene deserts), but are in other instances found in the introns of, or beyond, unrelated neighboring genes (which we will regulatory inputs will be reflected in the absence of correlation in expression between targets and bystander genes; HCNEs acting as enhancers of target genes at a particular point in time and space should have the corresponding chromatin domains in active state when they drive the expression of the target gene, which should be reflected by the presence of the corresponding epigenetic signatures; different responsiveness to long-range regulatory inputs will be reflected in different structural properties of the two classes of genes, that is, at different points in development and aging, and human diseases, including cancer, autoimmunity, and neuropsychiatric disorders are viable applications. In summary, we believe that the attractive combination of speed, simplicity and low input requirements of ATAC-seq will enable new gene regulatory insights into biology and medicine. Target genes within genomic regulatory blocks have distinct properties when compared to their neighboring bystander genes and different background gene sets. These properties can be summarized as follows (Figure 8): wide TC distribution around the TSS, indicating possible multiple promoter usage; large CpG islands sometimes spanning the entire gene; distinct TFBS motif content; and mouse homologs of target genes having 'bivalent' histone marks. While the exact molecular mechanism of differential responsiveness remains unknown, the above by pointing out that genomic variation could lead to the generation of enhancers in regions with no apparent regulatory function. As such variation may also lead to altered gene expression, more attention should be devoted to variation in so-called “neutral” DNA.\n",
            "[0.4649464]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which deficiency is the cause of restless leg syndrome?\n",
            "Refined Query: Restless legs syndrome (RLS) is a neurological disorder causing an irresistible urge to move the legs, often accompanied by uncomfortable sensations.  While the exact cause remains unknown,  research points to several potential deficiencies contributing to RLS, including iron, dopamine, and possibly others.  Which specific nutrient deficiency, or combination of deficiencies, is the primary underlying factor in the development of RLS is a key question in ongoing research.\n",
            "\n",
            "Combined Answer: appeared in a pes cavus position with a flexion contracture of the toes (Figure 2d), but the muscle strength remained normal. In addition, there was significant spastic paraparesis and generalized hyper-reflexia more prominent in the legs (both ankles and knees) with a bilateral plantar flexion response. In two patients (A.IV-1 and A.IV-4), mild distal sensory loss was evident in a stocking distribution in both legs. Gait abnormalities progressed very slowly allowing the three older patients independent, unaided walking at the age of 18, 20, neuropathy beginning within the first decade. Motor impairment due to both peripheral neuropathy and spasticity typically evolved within the second decade resulting in mild gait disturbance but, as a rule, preserved independent walking even throughout the fifth decade.3 Life expectancy is not anticipated to be shortened. Notably, none of these patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the but significant cognitive problems. She had a brisk jaw jerk and a pout reflex. Marked distal symmetrical weakness and wasting affecting the limbs. In contrast to her cousins, tone in her upper and lower limbs was reduced with severe distal weakness in upper and lower limbs. Upper limb reflexes were normal. Knee and adductor reflexes were abnormally brisk. Ankle and plantar reflexes were absent. She had a moderately severe thoracic scoliosis. Sensation was impossible to assess reliably due to cognition but was likely to be abnormal. As a crude One male and two females from a consanguineous family (Figure 1b) were evaluated. Following an uneventful pregnancy and labor, horizontal nystagmus was the first symptom observed in patient B.V-2 in the first months of life. Developmental milestones were globally delayed towards the end of the first year in all three patients. Although independent walking was achieved between 18 and 24 months of age, their gait was unsteady with both ataxia and spastic scissoring. In addition, hand tremor was noted on fine motor tasks in patient B.V-2. the legs and sparing the arms. In two patients (A.IV-1, A.IV-4), lower limb action potentials were not evoked, whereas in one (A.IV-3) action potentials were severely reduced and associated with mild decrease in conduction velocity, suggesting mainly axonal damage. Brain MRI studies done at the first and second decade of life were mostly normal in all the patients except for optic nerve atrophy, consistent with the clinical findings. Brain MR Spectroscopy (MRS) performed in patient A.IV-1 at the age of 20 years was normal and showed no distal sensory loss was evident in a stocking distribution in both legs. Gait abnormalities progressed very slowly allowing the three older patients independent, unaided walking at the age of 18, 20, and 23 years. Nevertheless, ankle contractures developed in two patients (A.IV-1, A.IV-4) and required daily use of ankle splints. There was no nystagmus, strabismus, ophthalmoplegia, cerebellar dysfunction, seizures, or cranial nerve deficits. All the patients graduated regular high school with no behavioral abnormalities and had normal hearing 4 years in three of the four patients, no further reduction in RNFL thickness was observed, consistent with a very slow progression of the optic neuropathy. By the second decade of life, affected individuals developed gait clumsiness and difficulties in regular sports activities. On examination, there was distal wasting of the calves and the feet appeared in a pes cavus position with a flexion contracture of the toes (Figure 2d), but the muscle strength remained normal. In addition, there was significant spastic paraparesis and generalized Rotor syndrome (RS; OMIM %237450) is a rare, benign hereditary conjugated hyperbilirubinemia, also featuring coproporphyrinuria and strongly reduced liver uptake of many diagnostic compounds, including cholescintigraphic tracers (1–6). RS is an autosomal recessive disorder that clinically resembles another conjugated hyperbilirubinemia, the Dubin-Johnson syndrome (DJS; OMIM #237500) (7, 8). In both RS and DJS, mild jaundice begins shortly after birth or in childhood. There are no signs of hemolysis, and routine hematologic and Three patients had clinical symptoms and EEG findings suggestive of Lennox-Gastaut Syndrome according to the information available (Figure 3A). Patient 1 had tonic, tonic-clonic, myoclonic and clinical absence seizures and an EEG reporting 2–4 Hz slow spike-wave. Patient 6 had generalized tonic-clonic seizures and drop seizures as well as focal motor features with some seizures; the EEG showed bilateral frequent semi-rhythmic slow spike-and-wave discharges. Patient 11b had generalized seizures, in the form of tonic seizures and drop attacks, hypsarrhythmia in infancy and later focal spikes (Patient 11a). EEG findings are summarized in Supplementary Table 1. At least four patients had clinical and EEG features consistent with epileptic encephalopathy, both Lennox-Gastaut Syndrome (Patients 1, 6 and 11b) and infantile spasms (Patient 11a), which are known to be often genetically mediated.24 Three patients had clinical symptoms and EEG findings suggestive of Lennox-Gastaut Syndrome according to the information available (Figure 3A). Patient 1 had tonic, tonic-clonic, myoclonic and\n",
            "[0.75123215]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What histone modification is recognized by the bromodomain?\n",
            "Refined Query: Bromodomains are protein domains that recognize and bind to specific acetylated lysine residues on histone tails.  The question asks which particular acetylation patterns, or combinations thereof, are preferentially bound by a bromodomain, considering there are many different bromodomains with varying specificities.\n",
            "\n",
            "Combined Answer: with lamina-associated domains (LADs)4,5,8,9. Recent Hi-C mapping has unveiled substructure within chromatin compartments called topologically associating domains (TADs) that are largely conserved in their positions between cell types and are similar in size to replication domains8,10. However, TADs can be further sub-stratified into smaller domains, challenging the significance of structures at any particular scale11,12. Moreover, attempts to reconcile TADs and LADs to replication-timing data have not revealed a common, underlying domain KEGG and Biocarta pathways, Interpro and Smart protein domains, is shown in Table S1 in the SI (top ranking terms which have p < 1 × 10–18). We find that the most significant biological term associated with ABPP 106 binders across those analysis tools is acetylation, as would be expected. Other significant enrichment categories ranking on the top include ribonucleoprotein complex, RNA binding, RNA recognition motif, mRNA metabolic process, RNA splicing, mRNA processing, etc. The role of protein acetylation in these processes is beginning to be Tudor domain which accommodates H4 dimethylated lysine 20 and to additional residues in the second Tudor domain (Fig. 2a, b). 53BP1 residues for which signal intensities were preferentially decreased are similar to those affected by interaction with an H4K20me2 peptide, indicating that H4K20me2 and TIRR binding surfaces on Tudor overlap even if there is no H4-like motif in TIRR. The interaction with TIRR is, however, more extensive as it involves residues from the second Tudor domain which do not interact with H4K20me2 (Fig. 2a). To extend AC: acetylation; CAGE: cap analysis of gene expression; CTSS: CAGE transcription start site; GRB: genomic regulatory block; HCNE: highly conserved non-coding element; TC: CAGE tag cluster; TF: transcription factor; TFBS: transcription factor binding site; TSS: transcription start site. for explaining differences in levels of a particular chromatin mark across tissues were often also highly significant for explaining mRNA expression differences. This was particularly the case for methylation of lysine 4 on histone H3 (H3K4me2, H3K4me3), for acetylation of histone H3 (H3K9ac, H3K27ac), and for trimethylation of lysine 36 on histone H3 (H3K36me3). For example, Figure 5A shows the activity profiles for these marks for the SNAI1..3 motif, which is recognized by the snail TFs (see Supplemental Fig. 22 for additional examples). As animals but also among more diverse eukaryotes, including members of the Coherin family in choanoflagellates and sponges (Nichols et al., 2012). The domain preceding the BIG domains was discovered as the first cohesin homology domain in vertebrates (HHpred E-value < 5 × 10−3) (Supplementary Fig. S5). Cohesin domains are found widely in prokaryotes but, in eukaryotes, were previously thought to be restricted to choanoflagellate and sponge proteins (Pfam accession: PF00963) (Abedin and King, 2008; Nichols et al., 2012; Peer et al., 2009). These both these marks (Fig. 5E,F). It is well known that ATF/CREB TFs can recruit histone acetylases (HATs), such as CREB binding protein (CREBBP) and EP300 (Yuan and Gambee 2001); and for RFX TFs it has also been established that they can recruit HATs at particular promoters (Masternak et al. 2003). Our results thus suggest that recruitment of HATs by TFs bound to ATF/CREB and RFX motifs make an important contribution to genome-wide histone acetylation at promoters. Moreover, the activity profiles of these motifs for H3K9ac and H3K27ac are highly It has been shown that histones H3 and H4 are hypoacetylated in the first intron of the inactivated frataxin gene, accompanied by trimethylation of lysine 9 of histone H3, which is a hallmark of heterochromatin.1,35 We found ABPP 106 probe specific proteins were mostly enriched in the category of acetylation in SP-PIR keywords across all the selected gene term enrichment analyses done in DAVID, indicating compound 106 may up-regulate frataxin gene transcription by selectively targeting proteins affecting acetylation. The transcription TFs bound to ATF/CREB and RFX motifs make an important contribution to genome-wide histone acetylation at promoters. Moreover, the activity profiles of these motifs for H3K9ac and H3K27ac are highly similar, suggesting that these two marks may be recruited through a common or highly overlapping pathways. Supplemental Figure 24 shows the most significant motifs for each of the other marks. Among the additional predictions made by ISMARA is that the PITX motif is associated with both mono- and dimethylation of lysine 4 of histone 3. This correlates with the acetylation state of HCNEs in the region. Additionally, target gene promoters have a distinct combination of activating and repressing histone modifications in mouse embryonic stem cell lines.\n",
            "[0.57870686]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What memory problems are reported in the \" Gulf war syndrome\"?\n",
            "Refined Query: Gulf War Syndrome is associated with a range of cognitive difficulties.  The question seeks to detail the specific memory impairments, such as short-term memory loss, long-term memory problems, or difficulties with recall and information processing, reported in individuals diagnosed with this condition.\n",
            "\n",
            "Combined Answer: al.4 described a potential progressive nature involving loss of cognitive and adaptive skills with aging. Further, there are clear regressions that appear to be associated with the CS. In our study, these appear to be associated with febrile illness and/or seizure, and can occur even in the first decade. In other studies, these regressions were generally described in later life past the first decade.3, 15, 16 A recurrent history involves loss of the ability to walk and loss of words or sounds. In addition to these clinical symptoms, there also This work was supported by National Institutes of Health [R03-AG048077 to A.F.T. and K08-AG049938 to A.F.T.]; and Alzheimer’s Association [NIRG-13-283742 to A.F.T.]. Conflict of Interest: none declared. percentile) with impaired academic abilities (WIAT-II reading and math, <1st percentile) and adaptive functioning in the extremely low range (ABAS-II, <1st percentile), consistent with her diagnosis of moderate intellectual disability. Another female carrier has been characterized as having mild ID and ADHD. She is also microcephalic with a head circumference of 50.9 (−3 SD). patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the current report who display, in addition to early onset optic neuropathy and esotropia, variable degree of intellectual disability and progressive motor impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2 Affected subjects are three males and one female from a consanguineous family (Figure 1a). All were born after an uneventful pregnancy and delivery and had normal growth and development during their first years of life. Insidious symptoms, including visual impairment accompanied by progressive bilateral temporal optic disk pallor, were first noted at the age of 3–5 years (Figure 2a). Although bilateral optic atrophy was evident in all patients by the age of 5 years, there was significant intra-familial variability with visual acuity ranging addition, a clear genotype–phenotype correlation is anticipated in which deleterious mutations which disrupt the GGQ-containing domain in the first coding exon are expected to result in a more severe phenotype, whereas down-stream C-terminal mutations may result in a more favorable phenotype, typically lacking cognitive impairment. One of the earliest events in Alzheimer’s disease (AD) is synaptic dysfunction (Scheff et al., 2007). In microscopic post-mortem studies, synaptic loss correlates strongly with pre-mortem cognitive status (DeKosky and Scheff, 1990), and serves as a better predictor of pre-mortem cognitive status than either plaque or tangle pathology (Terry et al., 1991). In animal models of AD, early aberrations in synaptic physiology have been widely reported, and AD-associated synaptic structural abnormalities (such as altered dendritic spine morphology) The authors wish to thank the patients and their families for participating in the WGS500 study. We are also grateful to Stefano Lise for helping with the variant calling and for discussions in an early phase of this project. We wish to thank Alistair Pagnamenta, Andy Rimmer, Heng Li and one anonymous reviewer for critically reading the manuscript and their insightful comments that greatly helped to improve this manuscript. We also wish to thank Heng Li for sharing his UM75 dataset. impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2 hyper-intense lesions known to be associated with mitochondrial diseases. Although too early to conclude, life expectancy does not appear to be significantly reduced. A severe phenotype with dramatically deteriorating course was described by Antonicka et al,2 dominated by significant cognitive and motor impairment resulting in wheelchair dependence convulsions, which spontaneously resolved at the age of 3 years. During a routine heart examination, a heart murmur was noticed, which prompted further tests. An echocardiogram showed a bicuspid aortic valve, with mild stenosis of the aortic root. At the age of 9, he attended the fifth year of primary school due to speech disorder and anxiety. Neuropsychiatric assessment revealed anxiety, normal non verbal cognitive function, specific language impairment and fine motor skills disturbances, requiring weekly psychomotricity sessions. His growth\n",
            "[0.8179196]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is cadasil syndrome a hereditary disease?\n",
            "Refined Query: CADASIL syndrome is a rare, inherited disorder affecting small blood vessels in the brain.  Is it exclusively inherited, meaning passed down through specific genes, or are there any other contributing factors influencing its development?\n",
            "\n",
            "Combined Answer: Inherited neuropathies are the most common genetic neurological disorders and affect ∼1 in 2500 individuals.1 Charcot–Marie Tooth (CMT) includes a group of hereditary disorders in which motor and sensory neuropathy is the sole or primary part of the disease. CMT is traditionally classified into two types based on electrophysiological and neuropathological criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. in order to help establish initial clinical expectations for families and clinicians. Based on current studies, CS may be among the most common X-linked developmental brain disorders.1 CS has broad implications to common neurologic and behavioral syndromes including epilepsy, intellectual disability, autism, regression and hyperactivity. criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive In the view of the association between ultraconserved elements and pathogenic dose variants, we therefore propose that these elements may be interpreted as hallmarks for dosage-sensitive genes, particularly for those genes whose gain or loss may be directly implied in neurodevelopmental disorders. Obviously, the presence of this kind of elements in CNVs of unknown consequences should be used with caution together with other pathogenicity criteria, such as the gene content or the mode of inheritance. This is an important issue given the current We found a highly significant enrichment of ultraconserved elements among pathogenic imbalances causing neurodevelopmental disorders. It can be therefore suggested that these elements, or their neighbouring genes, might be considered particularly sensitive to dose imbalances. It might be argued that the positive association between clinically relevant CNVs and UCEs merely reflects that pathogenic alterations preferentially affect gene-rich regions and, as an indirect consequence, they might contain more ultraconserved elements. In accordance, paroxysmal kinesigenic dyskinesia, and are also seen in infantile seizures and febrile seizures.11, 12 In the past year, DEPDC5 mutations have been identified in various dominantly-inherited familial focal epilepsies.13, 14 The precise role of each protein in the CNS has not been established. In a cohort of patients with a clinical diagnosis of DOORS syndrome, we sought to identify the genetic basis by whole-exome sequencing, aiming thus to provide improved diagnostic resolution and, eventually, a better understanding of the disorder. genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly inherited form of intellectual disability. One uniform and notable feature of CS is epilepsy. Conversations with parents indicate seizure control may represent one of the leading causes of concern in the family. In the current study, we report early age of onset of epilepsy and a mixture of seizure types. Further clinical and EEG analysis of the CS with cerebellar atrophy and a strong signal in the ansiform lobule of the cerebellum on T2-weighted and fluid-attenuated inversion recovery MRI.24 In an Italian family, compound heterozygous substitutions (Asp147His and Ala515Val) cause familial infantile myoclonic epilepsy (FIME [OMIM 605021]) in seven individuals with normal intellect and normal MRI, except for periventricular nodular heterotopia in one individual.25 A homozygous truncating mutation (969_970delGT, Ser324Thrfs*3) in exon 3 was identified in five Turkish individuals with a has an important role in the regulation of sprouting angiogenesis and vascular maturation. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development [29]. With regard to precocious puberty, we found two DECIPHER patients that carried deletions partially overlapping with our case and precocious puberty: case 260349, which presented with precocious puberty and specific learning disability and carrying a deletion at chr1:97,000,749–99,813,665; case 254871 presented with ASD, ID, precocious puberty and\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 429.53ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which neuroendocrine tumors are associated with specific tumor syndromes?\n",
            "Refined Query: Investigate the relationships between specific neuroendocrine tumor types (e.g., pancreatic,  carcinoid) and their associated paraneoplastic syndromes, focusing on the characteristic hormonal excesses or deficiencies causing clinical manifestations.\n",
            "\n",
            "Combined Answer: adjacent to more anaplastic appearing areas composed of spindled cells with fascicular growth, brisk mitotic activity and loss of markers of glial differentiation such as GFAP and OLIG2 suggestive of sarcomatous transformation (Figures 6G–I). Another morphologic variant was a malignant glioma with epithelioid to rhabdoid features and ganglionic differentiation in the thoracic spinal cord of a 26‐year‐old man. The majority of this tumor was composed of loosely cohesive cells with eccentric nuclei and abundant eosinophilic cytoplasm, many of differentiation in Tcf3 −/− teratomas when compared to wild type controls (Figure 5). However, high expression of the pluripotency markers Oct4 and Nanog was also observed in Tcf3 −/− teratomas (Figure 5). IHC analysis of Oct4 also showed that Tcf3 −/− teratomas are largely composed of undifferentiated, embryonic carcinoma (EC) -like cells, confirming their undifferentiated nature. This is in contrast with ApcNN teratomas where pluripotency markers were down-regulated. These results suggest that Tcf3 down-regulation in wild type ES cells is expression in a more complex manner through distant regulatory elements such as insulators and enhancers. We found that satellite regions were particularly hypomethylated in the NSCLC tumors when compared with lung tissues. Recently, Ting et al. [44] have shown that overexpression of satellite repeats is associated with different types of cancer. The observed hypomethylation of these regions in NSCLC would be compatible with their results. We also found that hypomethylated regions are often present in subtelomeric regions, in agreement with one of two (50%) arising in the pineal region, one of one (100%) arising in the midbrain, and one of one (100%) arising in the medulla. Two of these tumors (a glioblastoma in the thalamus of a 40‐year‐old woman and a glioblastoma in the hypothalamus of a 57‐year‐old man) had EGFR amplification and chromosome 10 deletions, similar to those more typically arising in the cerebral hemispheres. However, the molecular underpinnings of the rest of these tumors remains unknown, and none of the 19 tested cases had IDH1 mutation. Notably, three of these as glioblastoma. As opposed to the vast majority of the diffuse gliomas with neuropil‐like islands that have been reported to date 18, this tumor lacked IDH1 mutant protein. One gliosarcoma arising in the thalamus of an 11‐year‐old girl highlighted the spectrum of intratumoral variation that can be observed in diffuse midline gliomas with histone H3‐K27M mutation. Portions of this tumor were composed of ependymal‐like areas with solid growth, uniform ovoid nuclei, no mitotic activity, abundant dystrophic calcification, perivascular cerebellum. Patients with pontine tumors were younger (median = 7 years) than those with thalamic (median = 24 years) or spinal (median = 25 years) tumors. A wide morphologic spectrum was encountered including gliomas with giant cells, epithelioid and rhabdoid cells, primitive neuroectodermal tumor (PNET)‐like foci, neuropil‐like islands, pilomyxoid features, ependymal‐like areas, sarcomatous transformation, ganglionic differentiation and pleomorphic xanthoastrocytoma (PXA)‐like areas. In this series, histone H3‐K27M mutation was mutually File 11). These DMRs were classified by hyper- and hypomethylation and their genomic locations relative to genes (Figure 3B). We found that the ADC-specific DMRs had a genomic distribution similar to that observed for the DMRs present in all seven tumors, while for SCCs, DMRs within genes were concentrated in the gene body. SCC also presented considerably more subgroup-specific DMRs than ADC and ‘All-sample’; this could be explained by the notion that SCC is a relatively homogeneous tumor type. For the DMRs that fall in gene areas, we analyzed 26 deletions and duplications representing 200 patients with neurodevelopmental disorders [41]. An association between UCEs and disease was also demonstrated [42] in a study that assembled a database of ‘cancer-associated genomic regions’ from a literature search for terms associated with cancer [43], and several publications have highlighted possible roles for the transcription of specific UCEs in cancer [44]–[51]. In sum, the basis of ultraconservation remains unclear. Indeed, it has been suggested that UCEs represent nothing more than an tract, 10 cases). Our series of 30 MWS patients included 20 with HSCR (five female and 15 male; long segment, six cases; short segment, five cases; unknown length of the aganglionic tract, nine cases). We also studied a previously reported family where three members in two generations had tumours of the sympathetic nervous system of various grades at different ages (childhood in two cases and adulthood in one case).12 Most interestingly, HSCR occurred in two members of another branch of the family who were shown to carry the PHOX2B gene This study was performed in accordance with guidelines set forth by the institutional review board of the University of California, San Francisco (UCSF). For all tumors, formalin‐fixed paraffin‐embedded tumor tissue was prospectively examined from both UCSF in‐house and consults cases over a one‐year period. Hematoxylin and eosin (H&E) stained sections were reviewed for diagnostic assessment and determination of morphologic variation. Among the 47 K27M+ diffuse midline gliomas, 17 of the pediatric cases and 10 of the adult cases were resected\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.66ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1007.53ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1158.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1662.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 886.36ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1107.65ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 833.94ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1057.48ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 706.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.79ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.93ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1083.72ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which hormone abnormalities are common in Williams syndrome ?\n",
            "Refined Query: Williams syndrome is associated with various hormonal imbalances.  Specifically, what specific hormonal deficiencies or excesses, affecting which glands, are frequently observed in individuals with this genetic condition?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause of the syndrome, he reported the possibility of early mortality in affected males; however, this too requires verification through larger and longitudinal studies. Low numbers of men greater than 20 with CS could be either an issue of ascertainment, or alternatively, relate to an increased risk of mortality in CS. results. Many recent meta-studies of the efficacy of WES in diagnosing rare genetic diseases have revealed that its yield is usually less than 50%17. As such, for unsolved cases, researchers and clinicians are increasingly turning to WGS to identify candidate causal genes; however, the expansion into the rest of the genome causes a dramatic increase in the number of candidate variants. This is in part due to difficulties interpreting the effect of variants beyond the exome. As such, supplemental information regarding dysregulated candidate panels should consider comparison with a local dataset to identify platform specific errors. In addition to these in-house data, we display counts from published clinical cohorts for HCM9,20, DCM9,21, LQTS22 and Brugada syndrome23. These data are also used to assess individual variants for enrichment in cases over controls (rule PS4). patients presenting with an isolated, long segment form of HSCR, skewing of the sex ratio decreases when compared with the short segment form of HSCR. In relation to MWS, we observed a skewed male to female ratio of 2.5:1 among the 20 patients with HSCR (15 males, five females), in agreement with previous reports.10 RET had been considered as a candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and the predisposing alleles at the RET locus was 39.7% in the group of patients with Haddad syndrome (CCHS+HSCR), and 21% in the group of patients with isolated CCHS irrespective of the mutation in the PHOX2B gene (table 2). The difference was significant (χ2 = 11.73, p<0.001) and remained significant when CCHS patients harbouring an expansion of +5 alanines were excluded, as patients with CCHS and HSCR do not harbour a +5 alanine expansion (38.9% v 23.2%, p<0.02). When genotypes are considered, the odd ratios of HSCR for patients heterozygous The authors would like to thank the families for participating in this study. The authors would also like to thank Judith Nathanson and Heather M. Thompson for their help with figures. EMM has received a Career Award in Medical Science from the Burroughs Wellcome Fund and support from NIH NIGMS P20GM103645. This work was supported by a grant from the Simons Foundation (SFARI #239834 to EMM), and also generous support to EMM from the Nancy Lurie Marks Foundation. EMM has also received generous support from the newly-formed Christianson Syndrome (20–24, 41, 42), such risks are likely increased substantially in RS subjects. Their evident jaundice, however, may have been a warning sign for physicians to prescribe drugs with caution. The obligatory deficiency in two different, medium-sized genes explains the rarity of RS, with a roughly estimated frequency of about 1 in 106, although it might be several-fold lower or higher in different populations. Complete deficiency of either OATP1B1 or OATP1B3 alone will occur much more frequently but will not cause jaundice. For instance, the tract, 10 cases). Our series of 30 MWS patients included 20 with HSCR (five female and 15 male; long segment, six cases; short segment, five cases; unknown length of the aganglionic tract, nine cases). We also studied a previously reported family where three members in two generations had tumours of the sympathetic nervous system of various grades at different ages (childhood in two cases and adulthood in one case).12 Most interestingly, HSCR occurred in two members of another branch of the family who were shown to carry the PHOX2B gene of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes of obesity and indicate targets for therapeutic intervention. These disorders include obesity syndromes such as Prader Willi syndrome and Bardet–Biedl syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic\n",
            "[0.7359376]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: The secreted frizzled-related protein 3 (sFPR3) is altered in human cancers.\n",
            "Are its level found to increase or to decrease?\n",
            "Refined Query: Studies on sFRP3 expression in various human cancers show inconsistent results.  Some cancers exhibit elevated sFRP3 levels, while others demonstrate decreased levels compared to normal tissue.  The direction of change appears to be cancer-type dependent and possibly influenced by other factors.  A clear, universal trend of increased or decreased sFRP3 in all cancers is not established.\n",
            "\n",
            "Combined Answer: and 8 non-neoplastic prostate tissues (Supplementary Figure 1). The mean expression level of each T-UCR was calculated, and the ratio of tumor/non-neoplastic prostate (T/N ratio) was determined (Figure 1A). We identified 3 regions (Uc.3+, Uc.4+, and Uc.63+) that were significantly upregulated in PC tissues compared with non-neoplastic prostate tissues. We then analyzed the expression of these 3 regions in PC cell lines (LNCaP, DU145, and PC3) and revealed that the expression of Uc.63+ in PC cell lines was elevated compared with that in tissues. We then analyzed the expression of these 3 regions in PC cell lines (LNCaP, DU145, and PC3) and revealed that the expression of Uc.63+ in PC cell lines was elevated compared with that in non-neoplastic tissues. In contrast, the expression of Uc.3+ and Uc.4+ in PC cell lines was lower than that in the non-neoplastic prostate tissues (Supplementary Figure 2). Given these results, we decided to focus on Uc.63+. Then, we examined the expression of Uc.63+ in 14 types of normal tissue samples and 20 PC tissues from another cohort/sample set H3K27me3 is dramatically reduced in SF7761 cells compared with NSCs. H3K27me3 peaks detected in SF7761 cells spanned a larger chromatin region than those found in NSCs (Supplemental Fig. 5). Of the 2684 H3K27me3 peaks detected in SF7761 cells, 63% were unique to this cancer line in relation to NSCs. Surprisingly, these unique peaks had significantly more tagged density than corresponding peaks found in NSCs (Fig. 3A,D). These results indicate that the level of H3K27me3 at these loci, such as the long isoform of CDK6, is significantly elevated or PC3 cells (Figure 5B). Furthermore, we investigated the expression of miR-130b in PC tissues and non-neoplastic prostate tissues by qRT-PCR and found that the expression of miR-130b inversely and significantly correlated with the expression of Uc.63+ (P = 0.002) (Figure 5C). There was significant downregulation of miR-130b in PC tissues compared with non-neoplastic prostate tissues (P = 0.002) (Figure 5D). To further investigate the interaction between Uc.63+ and miR-130b, we examined the effect of Uc.63+ deregulation on the expression of pathogenesis of ovarian and breast cancer, and is part of the chromosome 8q24 prostate cancer risk locus [16]. The finding of these copy number changes in a subset of K27M-H3.3 mutants suggests that PDGFRA and MYC/PVT1 locus gains/amplifications are subsequent to K27M-H3.3 mutations. The addition of histone modifying agents to RTK inhibitors may thus be of therapeutic benefit in this group of patients. A clinically significant finding of this study is the fact that patients who harbor the K27M-H3.3 mutation have worse overall survival when There was a significant difference in Tumor grade (χ2 = 10.736, P = 0.001), nodal status (χ2 = 3.868, P = 0.049), TNM stage (χ2 = 12.318, P = 0.000) between patients with low/ unchanged versus high expression levels of uc.189 in CSCC. In EAC, unchanged/low versus high expression levels of uc.189 also showed a significant difference in tumor size (χ2 = 29.518, P = 0.000), tumor grade (χ2 = 36.993, P = 0.000), TNM stage (χ2 = 39.674, P = 0.002) and distant metastasis (χ2 = 40.462, P = 0.000). But no significant correlations between uc.189 activity of Oct3/4, since Dax1 associates with the DNA-binding domain of Oct3/4 (20). In the case of the Dax1-Esrrb complex, the association is not mediated through the DNA-binding domain of Esrrb, suggesting that Dax1 does not inhibit the DNA-binding capacity of Esrrb. Dax1 is a downstream target gene of STAT3 and Oct3/4 in ES cells (21). LRH-1 and SF-1 also regulate Dax1 gene expression in ES cells and adrenocortical carcinoma cells, respectively (22, 39), and the SF-1-mediated activation is repressed by Dax1 via binding to a hairpin patients. We provided the first evidence that T-UCRs can be detected in serum samples from cancer patients, suggesting that T-UCRs are more likely to be promising serum markers. Although PSA has been mainly used as a serum marker for PC, one of the issues with PSA is its low specificity in PC patients and false-positive results in BPH patients [22]. In contrast, the expression of Uc.63+ was significantly upregulated in the serum from PC patients compared with that from BPH patients. Moreover, we revealed that the expression of Uc.63+ in serum Notably, these modifications occur shortly after Wnt stimulation and it is plausible to think that the chromatin modifications within the Tcf3 locus can trigger the downregulation process of Tcf3 expression which can be stabilized further on via miR-211 function. Epigenetic regulation through histone modification or DNA methylation was also shown previously for other antagonists of Wnt signaling such as DACT3, sFRPs, WIF1 and DKK-1 in different cancer cells [48], [49], [50], [51]. Further experiments are required to clarify whether this mode with a view to identifying curative therapies. Our research team found that uc.189 expression was increased in 78.5% of cases (91/116) in CSCC, in EAC its expression was increased in 74.5% (73/98) and over-expression of uc.189 in 79.3% (23/29) of ovarian cystoadenocarcinomas. But in some cases of three types of female carcinomas, uc.189 expression is low or unchanged; this implies heterogeneous expression of uc.189 in a fraction of gynecological system cancers. Moreover, we showed for the first time that uc.189 expression is decreased in most\n",
            "[0.5656743]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Albumin depletion is a common first step for proteomic analysis of CSF fluid. What is the advantage and disadvantage of this procedure?\n",
            "Refined Query: Albumin depletion in cerebrospinal fluid (CSF) proteomics removes the highly abundant albumin, improving the detection of lower-abundance proteins of potential diagnostic significance.  However, this can lead to the loss of albumin-bound proteins, potentially obscuring  important biomarkers and biasing the results.\n",
            "\n",
            "Combined Answer: 2007). It was suggested that because the dissociation rate of T4 from albumin differs so significantly to that of T4 from TTR, and because the concentration of albumin in the CSF is significantly lower than that in the blood, that in the absence of TTR, albumin would be unlikely to distribute significant amounts of TH beyond the ependymal layer of the brain, resulting in the reduction of TH reaching the subventricular zone dur to a shallower TH gradient (Richardson et al., 2007). This study highlighted the importance of TTR in delivering THs is the only TH distributor protein synthesized in the brain, is secreted unidirectionally across the apical surface of the choroid plexus epithelial cells into the CSF, its role in the movement of TH from the blood into the CSF, its intermediate affinity for T4 (between those of albumin and thyroxine-binding globulin), and its role is being the most effective at distributing T4 to cells (see above), that it was thought to be crucial for survival, most probably due to the requirement of adequate amounts of TH for normal CNS development (Harms Cases of humans lacking either of the other two TH distributor proteins: albumin (Minchiotti et al., 2013) or thyroxine-binding globulin (Refetoff, 1989) have been described. Such people are apparently healthy and without overt clinical symptoms. However, no humans lacking TTR have been reported. In the 1990s the hypothesis was that because TTR is the only TH distributor protein synthesized in the brain, is secreted unidirectionally across the apical surface of the choroid plexus epithelial cells into the CSF, its role in the movement of TH The choroid plexus barrier ensures that the composition of the CSF is very different to that of the blood. For example, in adult mammals, the CSF has only about 0.5% total protein concentration compared to that in the blood (Brown et al., 2005) and the relative ratios of proteins in the blood compared to the CSF differ markedly. However, the total protein concentration in the CSF changes during development, peaking early in development and then gradually decreasing to adult levels (Saunders, 1992). For a comprehensive summary of the thus has a major influence on its composition (Cserr, 1971). In humans the total CSF is replaced about four times per day (Brown et al., 2005). In comparison to the blood, which mixes, the CSF has a pipeline type of flow which does not mix. Consequently, the composition of the CSF can vary depending on the site from which it is sampled (Cserr, 1971). The choroid plexus barrier ensures that the composition of the CSF is very different to that of the blood. For example, in adult mammals, the CSF has only about 0.5% total protein concentration on the manuscript and Raymond Poot (CSC, London) for helpful discussions. We are grateful to Gerd Blobel (Children's Hospital of Philadelphia) for exchanging prepublication data. This work has been supported by the Netherlands Research Organization (NWO), the European Union (grant HPRN-CT-2000-00078), the NIH (grant RO1 HL 073455-01) and the Netherlands Proteomics Center. electrochemiluminescence method; both methods were validated (PPD). SMN protein concentration was determined using an Erenna Immunoassay System validated for human CSF (Singulex, Inc., Alameda, CA). CSF elimination half-life was estimated for each individual using concentrations determined at 7 or 29 days and 9–14 months by using the following equation: where t1/2 is half-life in days; Ct and C0 are CSF concentrations at 9–14 months and 7 or 29 days, respectively; and (t0 − t) is time in days between measurements. Anne Connolly (data safety and monitoring board); Patti Dickson (data safety and monitoring board); Stephen Reingold (data safety and monitoring board); Sarah Hamren (Singulex, Inc., CSF SMN protein assay development and sample testing); Ali Vahad (Singulex, Inc., CSF SMN protein assay development and sample testing); and Maria Hovenden (Excel Scientific Solutions with funding from Biogen, editorial support based on input from the authors). To determine enrichment of protein interactions within the network relative to the background proteome, NSAF (normalized spectrum abundance factor) values were calculated to take into account protein length and the total number of spectra present in each individual IP experiment. NSAF values were normalized to proteome abundance (PAX) values for S phase S. pombe (pax-db.org), and the NSAF/PAX ratio was mapped onto each node (node color). In the present study, the targets of HDAC inhibitor ABPP 106 probe and interacting proteins have been identified in FRDA patient-derived neural stem cells by dimethyl labeling quantitative mass spectrometry combined with MudPIT. The ABPP approach, which allows the use of harsh protein denaturing conditions after the probes are cross-linked to the protein to remove noncovalently bound proteins, allowed us to purify either direct targets of 106 probe or interactors in close proximity to the direct targets of the native activity.32 The inactive\n",
            "[0.5633209]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How are lincRNA affecting the regulation of gene expression?\n",
            "Refined Query: Long intergenic non-coding RNAs (lincRNAs) are emerging as significant regulators of gene expression.  How do these transcripts, lacking protein-coding potential, influence processes like transcription, RNA processing, and translation?  What are the specific mechanisms involved, and how does their dysregulation contribute to disease?\n",
            "\n",
            "Combined Answer: Until very recently, RNA's main cellular role was assumed to be that of merely a messenger, mediating the transfer of information from DNA to proteins—the true effectors of biological function. This view has been altered, however, as a plethora of novel RNA species has been discovered (see, for instance, Carninci et al. 2005; Denoeud et al. 2007; Kapranov et al. 2007; Findeiss et al. 2010). Among these, long noncoding RNAs are emerging as central players in cell biology. Likely outnumbering protein-coding transcripts, a small but rapidly Long noncoding RNAs are key regulators of chromatin states for important biological processes such as dosage compensation, imprinting, and developmental gene expression (Kelley et al., 1999; Koziol and Rinn, 2010; Mercer et al., 2009; Pandey et al., 2008; Rinn et al., 2007; Wang et al., 2011; Zhao et al., 2008). The recent discovery of thousands of lincRNAs in association with specific chromatin modification complexes, such as Polycomb Repressive Complex 2 (PRC2) that mediates histone H3 lysine 27 trimethylation (H3K27me3), suggests broad roles Long non-coding RNAs (lncRNAs) play integral roles in diverse biological processes including transcriptional regulation (Kino et al., 2010) and subnuclear structure formation (Naganuma and Hirose, 2013). The dysfunctions of many lncRNAs are associated with severe diseases such as diabetes and various cancers (Wapinski and Chang, 2011), and thus elucidating lncRNA functions is an important research topic. Although large-scale transcriptome analysis has revealed that more than 58 000 lncRNA genes are encoded by the human genome (Iyer et al., We next focused our attention on pairwise correlations of expression involving neighboring genes (Supplemental Table S5). Several studies have demonstrated either positive (Kim et al. 2010; Ørom et al. 2010) or negative (Brockdorff et al. 1992; Nagano et al. 2008) regulation by intergenic lncRNAs (lincRNAs) of neighboring protein-coding genes. We found more positive (rs > 0.5) and more extreme positive (rs > 0.9) lncRNAs-mRNAs and mRNAs-mRNAs correlations in cis than in trans (Supplemental Table S5). But, in contrast to trans, we observed in al., 2008), but only at single gene locus at a time. The occupancy sites of most lincRNAs are not known, and the roles of lincRNAs in chromatin regulation have been mostly inferred from the indirect effects of lincRNA perturbation. Just as chromatin immunoprecipitation followed by microarray or deep sequencing (ChIP-chip or ChIP-seq, respectively) have greatly improved our understanding of protein-DNA interactions on a genomic scale, here we introduce a strategy to map long RNA occupancy genome-wide at high resolution, and apply this strategy et al. (2010) lncRNAs, 33% of Cabili et al. (2011) (stringent) lincRNAs, 39% of Cabili et al. (2011) (all) lincRNAs, and 12% of vlincs (Supplemental Fig. S1; Kapranov et al. 2010). We also examined the overlap with the Khalil et al. (2009) set of human lincRNAs; however, we could not perform an accurate intersection analysis due to their lack of strand information. Manual curation of the remaining genes in lncRNAdb reveals many that intersect with protein-coding genes and/or small RNAs. A full characterization of the GENCODE v7 lncRNA set can lincRNAs in association with specific chromatin modification complexes, such as Polycomb Repressive Complex 2 (PRC2) that mediates histone H3 lysine 27 trimethylation (H3K27me3), suggests broad roles for numerous lincRNAs in managing chromatin states in a gene-specific fashion (Khalil et al., 2009; Zhao et al., 2010). While some lincRNAs are thought to work in cis on neighboring genes, other lincRNAs work in trans to regulate distantly located genes. For instance, Drosophila ncRNAs roX1 and roX2 bind numerous regions on the X chromosome of to work in cis on neighboring genes, other lincRNAs work in trans to regulate distantly located genes. For instance, Drosophila ncRNAs roX1 and roX2 bind numerous regions on the X chromosome of male cells, and are critical for dosage compensation (Franke and Baker, 1999; Meller et al., 1997). However, the exact locations of their binding sites are not known at high resolution. Similarly, human lincRNA HOTAIR can affect PRC2 occupancy on hundreds of genes genome-wide (Gupta et al., 2010; Rinn et al., 2007; Tsai et al., 2010), but how al., 2010). The ChIRP-seq data indicate that it is the lack of PRC2, rather than the inactivation of HOTAIR function at chromatin, that is responsible for this epistatic interaction. Together, these experiments suggest that lincRNAs are surprisingly like sequence-specific transcription factors in dictating chromatin states, and again suggests the utility of ChIRP to generate mechanistic insights. by which LIMT regulates cellular migration and tumor progression is a matter of further investigation. Because LIMT, and especially its 5′ region, is one of only 29 lincRNAs that display very high sequence conservation throughout all vertebrates (Ulitsky et al, 2011), we assume that LIMT's function is shared by several species and that it requires a specific structure at the 5′ region. Presumably, physical interactions of LIMT with protein or RNA molecules regulate transcription of coding and noncoding genes involved in cellular motility. Some\n",
            "[0.66919875]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the protein encoded by the human gene GRIK?\n",
            "Refined Query: The human gene GRIK encompasses several subtypes (GRIK1, GRIK2, GRIK3, GRIK4, etc.).  Therefore, specifying which *GRIK* gene is being referenced is crucial to accurately identify the encoded protein.  Which specific GRIK gene's encoded protein are we interested in?\n",
            "\n",
            "Combined Answer: for the mapping of human diseases it will be important to establish whether the implied disease gene is a GRB target gene or is, in fact, located in a GRB as a bystander with no functional relation to the regulatory inputs of the enhancers of the GRB. In such cases, it will be important to correlate GRB regulatory content with the disease phenotype and, if warranted, reassign the disease phenotype to the correct gene. Thus, important developmental genes are embedded in large GRBs, breakpoints or mutations within these GRBs may cause genetic recently discovered set of genes crucial for normal gametogenesis (45 germline reprogramming-responsive genes or GRRs) (Hill et al. 2018), we found nine GRR genes in the PGC E11.5-specific 0_0 SOM class (Rad51c, Dazl, Slc25a31, Hormad1, 1700018B24Rik, Fkbp6, Stk31, Asz1, and Taf9b), three GRR genes in the PGC E11.5-specific 0_1 SOM class (Mael, Sycp, and Pnldc), and two in the ubiquitously expressed class 2_0 (D1Pas1 and Hsf2bp). Classes specific to mESC E14 cells or other ubiquitous classes did not contain any GRR genes. While the TSS sets. Both approaches resulted in a similar set of over-represented AT-rich motifs, including Nkx2-5, FOXL1, and Pdx1. Taken together, these findings indicate genuine AT-rich motif enrichment in CpG-rich promoters of GRB target genes. This suggests there is an intrinsic difference in nucleotide composition of GRB target promoters compared to various backgrounds. Another interesting feature of the GRB target promoters is that their corresponding mouse orthologs were mostly classified as 'bivalent promoters' in embryonic stem cells by Mikkelsen et al. [22]. Bivalent promoters have both repressive (H3K27me3) and active (H3K4me3) histone modifications in their promoter region. Around 70% (189 of 269) of GRB target orthologs have both repressive and active histone modifications of target genes and allow for very precise and refined spatiotemporal patterns in different functional contexts. Since GRB target genes are central to developmental regulation, their expression should be robust and tightly coordinated even under varying external conditions. Most obviously, a large number of different promoter-enhancer pairings is needed because these genes have many different roles in time and space that require a complex switchboard of regulatory inputs arranged in a GRB. We identified a set of 269 putative GRB target genes (see Materials and methods; Additional data file 1). A visual inspection of prominent GRB targets quickly revealed that they have a high density of tag clusters (TCs) around their start sites, determined in a 'conventional' way. We grouped CAGE tags into TCs when they overlapped by at least 1 bp and mapped to the same strand (see Materials and methods; Figure 1b); the goal of this clustering was for each cluster to correspond to an individual core promoter. Since many of the clusters were of tool, the system has two components: first, a bipartite small RNA, or “guide RNA” (gRNA), designed to recognise a specific location in the genome; second, the Cas9 protein that binds the gRNA and is thereby recruited to the target site. The gRNA consists of a 20 nt targeting region that hybridises to genomic DNA upstream of a dinucleotide protospacer adjacent motif (PAM, here NGG), fused with a scaffold sequence recognised by Cas9 protein [3]. By engineering the gRNA targeting region, one may target virtually any complementary genomic locus called genomic regulatory blocks (GRBs)3, 13, supports the idea that they are ensembles of regulatory elements that are involved in regulating these genes (Supplementary Fig. 1a). In addition to this target gene (or genes in the case of gene clusters) under developmental regulation, a GRB can harbour several other genes that are not detectably regulated by these elements (bystander genes). Target and bystander genes differ with respect to their promoter structure, patterns of epigenetic modification and range of biological functions3, 14, 15. Coding potential was calculated using an alignment‐free method, Coding‐Potential Assessment Tool (CPAT), which recognizes coding and noncoding transcripts from a large pool of candidates (Wang et al, 2013). Alongside, we used a reference catalog of human genes, which lists multiple protein‐coding sequences (N = 4,000) and lncRNAs (N = 4,000) (Cabili et al, 2011). and, if warranted, reassign the disease phenotype to the correct gene. Thus, important developmental genes are embedded in large GRBs, breakpoints or mutations within these GRBs may cause genetic disease, and subsequent fine mapping may result in the indictment of a bystander gene containing essential regulatory elements for a distant target gene. The bystander genes, although within reach of specific regulatory elements, are expressed in different patterns and thus are not specifically regulated by GRB regulatory content. How this apparent\n",
            "[0.17734987]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?\n",
            "Refined Query: Research on Lewy bodies, characteristic of Parkinson's disease, has focused on the post-translational modifications of alpha-synuclein.  Specifically, identifying which serine residue(s) of alpha-synuclein undergo phosphorylation within these protein aggregates is crucial to understanding disease pathogenesis.  Which specific alpha-synuclein serine residue has been consistently implicated in Lewy body phosphorylation?\n",
            "\n",
            "Combined Answer: Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of α-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent with complete phosphorylation of the 33 nm synuclein substrate (compare with the 33 nm p-Ser-129 (pS129) standard, Fig. 1A, inset). PLK1 had lower activity, comparable with that of CK2. To ensure that all enzymes were active, their abilities to phosphorylate another substrate, casein, were verified (supplemental Fig. S1). PLK4 had no measurable Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as CK2, which has been previously shown to phosphorylate α-synuclein (10). Phosphorylation at Ser-129 was measured with a fluorescence assay using an antibody specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent of α-synuclein and p-Ser-129 α-synuclein levels in primary cortical cultures from knock-out and wild-type littermates showed that α-synuclein phosphorylation was decreased by about 70%. A similar decrease was observed in soluble α-synuclein in 2–3-month-old cortices (Fig. 3, B and C). Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System - PMC (7.5 nm) were added in the same reaction volume of buffer C (25 mm Hepes, pH 7.5, 0.8 m KF, 66 nm EDTA, 0.1% bovine serum albumin), and fluorescence intensity was measured. Uniform phosphorylation of the p-Ser-129 α-synuclein standard was confirmed by reverse phase-high pressure liquid chromatography and mass spectroscopy. The p-Ser-129 α-synuclein standard curve was obtained under the same conditions as for measurement of assay samples, without kinase. Unphosphorylated α-synuclein was added to keep the total synuclein constant at 33 nm. For have proposed that PLK2 has a critical role in maintaining dendritic spine stability (31) and modulating excitatory glutaminergic synaptic connections (32, 33). Thus, the involvement of PLK2 in α-synuclein phosphorylation provides a potential link between excitotoxic responses and Lewy pathology. Investigation of how the biology of PLK2 relates to the pathogenesis of PD and DLB should help clarify the role of synuclein phosphorylation in these diseases. cells. BI2536 was used to validate the role of PLK family members in α-synuclein phosphorylation in vivo. Mice were dosed intravenously with BI2536, the brains were collected, and the levels of total and p-Ser-129 α-synuclein in cortical extracts were measured by ELISA. As shown in Fig. 3A, consistent and significant inhibition of α-synuclein phosphorylation was observed. The effect of removal of the plk2 gene on α-synuclein levels was also investigated using PLK2 knock-out mice. Primary cortical cultures from a homozygous knock-out mouse were so that almost all of the activity could be attributed to the transfected kinase. Good agreement was observed between inhibitor potencies in the presence and absence of overexpressed PLK2. In the absence of kinase transfection, the maximum inhibition of p-Ser-129 α-synuclein was around 60%. The remainder may be due to an additional kinase in these cells. BI2536 was used to validate the role of PLK family members in α-synuclein phosphorylation in vivo. Mice were dosed intravenously with BI2536, the brains were collected, and the levels of total In this study, we have shown that members of the PLK family, specifically PLK1, -2, and -3, phosphorylate Ser-129 of α-synuclein in vitro, suggesting that they are capable of acting as direct α-synuclein kinases. Studies with inhibitors additionally suggest that PLK2 and PLK3 are responsible for the majority of α-synuclein phosphorylation in cultured neurons and in mouse brain. PLK2-specific shRNA knockdown and genetic deletion of the plk2 gene in mice identify a role for this kinase in particular. Previous studies of PLK2 have identified\n",
            "[0.835023]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is paroxetine effective for treatment of premenstrual dysphoric disorder?\n",
            "Refined Query: Research suggests paroxetine, a selective serotonin reuptake inhibitor (SSRI), may be effective in treating Premenstrual Dysphoric Disorder (PMDD), a severe form of PMS.  However, its efficacy compared to other treatments and individual responses vary.  Is its effectiveness consistently demonstrated across studies, and what are the potential side effects and considerations before prescribing paroxetine for PMDD?\n",
            "\n",
            "Combined Answer: Major depressive disorder is a common, chronic, recurring illness associated with significant functional and social impairment (Duric and Duman, 2013). Effective treatment of depression is challenging, with most patients failing to achieve remission after initial antidepressant treatment. As a result, antipsychotics are increasingly used as adjunct therapy to enhance antidepressant efficacy, especially since augmentation with atypical agents improves pharmacological and side effect profiles (Nelson and Papakostas, 2009). Although central is commonly used for the treatment of schizophrenia and bipolar disorder, except that cariprazine has a greater affinity and selectivity for D3 vs. D2 receptors (Tadori et al., 2011; Ellenbroek and Cesura, 2015; Findlay et al., 2016; Stahl, 2016). Aripiprazole also has been shown to be effective as an adjunct treatment for major depressive disorder (Bourin et al., 2009; Lenze et al., 2015; Zhou et al., 2015). Our results show that administration of a high dose of aripiprazole produced an antidepressant-like response, but also induced increases following chronic treatment (Choi et al., 2014). The nucleus accumbens shell is one of the brain regions of particular interest where cariprazine produced this effect, and an increase in D3 receptor expression in this region has been proposed to be a common neurobiological mechanism of antidepressant treatments (Lammers et al., 2000). Cariprazine has demonstrated antidepressant-like activity in the chronic mild stress model in rats and was shown to reduce anhedonia-like behavior, a hallmark symptom of depression and negative symptoms of Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model - PMC (Bourin et al., 2009; Lenze et al., 2015; Zhou et al., 2015). Our results show that administration of a high dose of aripiprazole produced an antidepressant-like response, but also induced increases in total fluid consumption, which could be due to polydipsia and/or polyuria, potential side effects of some antipsychotic agents (Bersani et al., 2007; Meulendijks et al., 2010; Gandhi et al., 2016). In this regard, cariprazine has a more specific antidepressant-like effect that was independent of changes in overall liquid consumption. We found studies demonstrating that administration of antidepressant drugs enhances D3 receptor gene expression and/or binding in distinct brain regions (Maj et al., 1998; Lammers et al., 2000). Cariprazine, a novel, orally active antipsychotic agent that is a potent dopamine D2/D3 receptor partial agonist with preferential binding to D3 receptors, was recently approved by the U.S. Food and Drug Administration for the treatment of both schizophrenia and acute manic or mixed episodes associated with bipolar I disorder (Ágai-Csongor et al., 2012; therapy to enhance antidepressant efficacy, especially since augmentation with atypical agents improves pharmacological and side effect profiles (Nelson and Papakostas, 2009). Although central nervous system mechanisms underlying antidepressant actions of atypical antipsychotics are still unclear, it has been proposed that a compound that exhibits high affinity and occupancy of both D2 and D3 dopamine receptors may be effective as a treatment for depressive disorders as well as the negative symptoms of schizophrenia. A dopamine D3 receptor has demonstrated antidepressant-like activity in the chronic mild stress model in rats and was shown to reduce anhedonia-like behavior, a hallmark symptom of depression and negative symptoms of schizophrenia (Papp et al., 2014); however, the mechanism of action underlying cariprazine’s antidepressant-like effects has not been elucidated. A previous study of cariprazine in dopamine D3 receptor-knockout (D3-KO) mice showed that cariprazine has D3 receptor-dependent positive/protective effects on cognitive function, suggesting that the efficacy which essentially results in blockade of D3 receptors (Freedman et al., 1994; Sautel et al., 1995; Kiss et al., 2010). In contrast, most other atypical antipsychotics have relatively lower affinities for the D3 receptor and in the presence of normal brain levels of dopamine are unable to block these receptors (Stahl, 2016). Furthermore, since D3 receptors are thought to be involved in the regulation of mood, cognition, and motivation (Gross and Drescher, 2012), compounds like cariprazine that exhibit high affinity and occupancy of these In a mouse model of depression, cariprazine produces antidepressant-like activity through action on dopamine D3 receptors. Indeed, cariprazine reversed anhedonia-like and anxiety-like deficits in this chronic stress model. These results suggest that cariprazine has a unique and distinct dopamine D3 receptor-dependent mechanism of action that may be beneficial in the treatment of schizophrenia, bipolar disorder, and major depressive disorder.\n",
            "[0.5661318]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is known about thalidomide therapy and survival of glioblastoma patients?\n",
            "Refined Query: What clinical evidence exists regarding the efficacy of thalidomide, alone or in combination with other therapies, in extending the lifespan or improving the quality of life for patients diagnosed with glioblastoma?  Are there any ongoing or completed clinical trials investigating this?\n",
            "\n",
            "Combined Answer: glioblastoma in a 4‐year‐old boy, a thalamic glioblastoma in a 24‐year‐old woman, and a glioma in the lumbar spinal cord with grade II histologic features at time of initial biopsy but grade IV histologic features on subsequent resection. five of these patients underwent a subsequent biopsy or resection demonstrating higher grade gliomas. These included two pontine gliomas originally classified as grade III that were upgraded to glioblastoma, a spinal glioma and a third ventricle glioma originally classified as grade II that were upgraded to glioblastoma, and a thalamic glioma originally classified as grade II that was upgraded to anaplastic astrocytoma. Given the prospective nature of this study without significant length of clinical follow‐up, the utility of assessing outcome Pediatric low-grade glioma (pLGG) is the most common central nervous system tumor in children.(1) The mainstay of therapy is a complete surgical resection as this can be curative; however, children for whom a gross total resection is not achievable often require additional therapy.(1, 2) There are multiple first-line chemotherapy regimens including combinations of carboplatin and vincristine (CV), combinations of thioguanine, procarbazine, lomustine and vincristine and vinblastine monotherapy.(3, 4) Five-year overall survival (OS) with High-grade astrocytomas [anaplastic astrocytoma and glioblastoma (GBM)] are the most biologically aggressive form of cancer and a leading cause of cancer-related mortality and/or morbidity in the pediatric years [15, 19, 22]. They account for 20 % of all brain tumors in children and occur mainly supratentorially in the cortex or thalamus or in the brainstem where they are called diffuse intrinsic pontine gliomas (DIPGs). Cortical GBM can be amenable to complete surgical resection, however, up to 85 % will die within 2 years of diagnosis [3, 15, p53 mutations are less prevalent in pediatric compared with adult cancers [17], including glioma [18], neuroblastoma [19], sarcomas [8,20,21], Wilms tumor [22] and leukemia [23,24], suggesting that a larger proportion of pediatric patients may benefit from pharmacological unleashing of the wild-type p53 protein. However, p53 mutations are reported to occur at a higher frequency in relapsed patients with neuroblastoma [16,25] and acute lymphoblastic leukemia (ALL) [24,26], and where present have been associated with aggressive and ATRX loss was more commonly seen in the thalamic and spinal gliomas, p53 overexpression was more frequent in the thalamic (eight of 13 cases, 62%) vs. pontine (four of 12 cases, 33%) and spinal gliomas (one of five cases, 20%). No significant correlation between tumor grade and ATRX or p53 status was seen in this cohort. Of the 30 cases tested for IDH1‐R132H mutant protein, none were positive. Only one of the 18 cases tested for BRAF‐V600E mutant protein was positive, which was the exceptional glioma arising in the thalamus of a 5‐year‐old xanthoastrocytoma (PXA), including nuclear pleomorphism out of proportion to mitotic activity, dense reticulin network, eosinophilic granular bodies, and CD34 positive stellate cells. Of 15 cases assessed by FISH, none had EGFR amplification while four had loss of chromosome 10, including a pontine glioblastoma in an 11‐year‐old boy, a pontine glioblastoma in a 4‐year‐old boy, a thalamic glioblastoma in a 24‐year‐old woman, and a glioma in the lumbar spinal cord with grade II histologic features at time of initial biopsy but grade IV initiation of 36.4 months (range=4.4–50.48; IQR=21.72–45.59). In patients who have not progressed, the median follow-up since stopping selumetinib is currently 12.5 months (range=0–25.75; IQR= 6.64–21.38). Between August 28, 2013, and June 25, 2015, 26 eligible patients were enrolled on stratum 3. One of 26 (3.8%) eligible patients enrolled was not evaluable due the patient’s refusal to take any study drug, leaving 25 eligible and evaluable patients. Thirteen of 25 (52%) eligible and evaluable patients had an optic pathway glioma (OPG). Three loss of nuclear expression in 15 of 32 tested cases, including nine of 12 thalamic gliomas (75%), four of seven spinal gliomas (57%), and one of 13 pontine gliomas (8%). Of the 33 cases assessed, 14 demonstrated strong p53 immunoreactivity in the majority of tumor nuclei suggestive of TP53 gene mutation or other mechanism of p53 stabilization. Whereas ATRX loss was more commonly seen in the thalamic and spinal gliomas, p53 overexpression was more frequent in the thalamic (eight of 13 cases, 62%) vs. pontine (four of 12 cases, 33%) and spinal of existing hemangioblastomas demonstrated heterogeneous growth rates, with cerebellar and brainstem lesions growing faster than those in the spinal cord or cauda equina. Increased tumor burden or total tumor number detected was associated with male sex, longer follow-up, and genotype. Similar natural history data are available for renal cell carcinomas (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the\n",
            "[0.8570045]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is endostatin a proangiogenic factor?\n",
            "Refined Query: Endostatin, initially identified as an inhibitor of angiogenesis, has shown some conflicting research results.  Does its role extend beyond antiangiogenesis, potentially exhibiting proangiogenic effects under specific conditions or in certain contexts, thereby complicating its simple classification?\n",
            "\n",
            "Combined Answer: decline in NO, PIGF, and TGF-β1 levels, in concert with an increase of anti-angiogenic factors, deprives endothelial cells of support leading to endothelial dysfunction (8, 17, 22). Thus, endothelial dysfunction is a result of an antiangiogenic state in the placenta and contributes to the pathology of preeclampsia (Figure 1) (9, 52, 57). Immunological factors also play a role in the secretion of antiangiogenic factors. For instance, complement activation has been shown to stimulate monocytes to release antiangiogenic factors (20). Studies in factors also play a role in the secretion of antiangiogenic factors. For instance, complement activation has been shown to stimulate monocytes to release antiangiogenic factors (20). Studies in murine models of experimental pregnancy loss demonstrated that conditions of hypoxia and inflammation lead to the release of increased amounts of antiangiogenic factors and are therefore strong triggers of angiogenic dysregulation (20, 58). These studies and those in humans demonstrate that pregnancy complications, such as recurrent pregnancy loss for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by stimulating the NO-cyclic guanosine monophosphate vascular relaxation pathway as well as by increasing the production of the calcium ion (Ca2+)i (53). An increase in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved state (168). In a mouse model, injection of LPS induced increased expression of pro-inflammatory cytokines, such as TNF-α, monocyte chemoattractant protein-1, and IL-6 (169). In addition, endotoxin stimulates the expression of IL-1 and TNF-α in endothelial- and vascular smooth muscle cells (167, 170). IL-1 causes alterations in endothelial function, such as the induction of procoagulant activity that promotes blood clotting, that may play an important role in the vascular effects of inflammation and the pathogenesis of vascular diseases (170). endocytosis) and CPZ (an inhibitor of clathrin-mediated endocytosis) were used prior to TGF-β1 treatment in order to screen the potential degradation pathway. Pretreatment of two different doses of MG132 (Fig. 2B) or nystatin (Fig. 2C) could not abolish the effect of TGF-β1 on Necl-2 expression, indicating that TGF-β1-induced Necl-2 degradation is not mediated via ubiquitin-proteasome pathway or caveolin-dependent endocytosis. However, significant rebound in Necl-2 protein level was observed when CPZ was employed (Fig. 2D). Apart from the To unravel the TGF-β1-induced Necl-2 protein degradation pathway, various inhibitors were employed to block the proteasome and endocytoic degradation pathways which are the two major mechanisms reported for effective removal of cell junction molecules from cell-cell interface [32]. MG132 (a proteasome inhibitor), nystatin (an inhibitor of caveolin-dependent endocytosis) and CPZ (an inhibitor of clathrin-mediated endocytosis) were used prior to TGF-β1 treatment in order to screen the potential degradation pathway. Pretreatment of two different detail. The response of endothelial cells to TNF is known to be mediated by TFs of the NFkappaB family, GATA2, IRF1, and JUN (Inoue et al. 2006) TFs. TFs of the NFkappaB family in particular are crucial for the resulting inflammatory response (Kempe et al. 2005). Indeed, ISMARA infers that the two most significant motifs are IRF1,2,7 and NFKB1/REL/RELA. The activity of NFKB1/REL/RELA increases sharply in the first 45 min and slower afterward, until it reaches a steady activity after 3 h. The activity of the IRF1,2,7 motif increases steadily treatment, and every 30 min for the next 4 h (Wada et al. 2009). Whereas the original study focused solely on nascent transcription, we here show that standard application of ISMARA to this data set (http://ismara.unibas.ch/supp/dataset3/ismara_report/) uncovers the transcription regulatory network involved in this inflammatory response in remarkable detail. The response of endothelial cells to TNF is known to be mediated by TFs of the NFkappaB family, GATA2, IRF1, and JUN (Inoue et al. 2006) TFs. TFs of the NFkappaB family in particular are is not mediated via ubiquitin-proteasome pathway or caveolin-dependent endocytosis. However, significant rebound in Necl-2 protein level was observed when CPZ was employed (Fig. 2D). Apart from the rebound of Necl-2 protein level, re-localization of Necl-2 at the cell-cell interface was observed in CPZ-pretreated cells in TGF-β1-treated group (Fig. 2E). Western blotting analysis and immunofluorescence staining unequivocally suggest that clathrin-mediated endocytosis possibly involves in TGF-β1-induced protein degradation. To further examine factors and are therefore strong triggers of angiogenic dysregulation (20, 58). These studies and those in humans demonstrate that pregnancy complications, such as recurrent pregnancy loss (RPL), preterm birth, and preeclampsia, are associated with excessive complement activation, especially enhanced C5a synthesis, that promotes the secretion of the antiangiogenic factor sFlt-1 (20, 59). Activation of C5 contributes to fetal loss and adverse pregnancy outcomes by inducing a dysregulation of angiogenic factors and initiating a complex series of\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.46ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1084.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "SSRIs - {'Anxiety Disorders': 1.0000000000000002, 'Sleep Disturbances': 0.0}\n",
            "\n",
            " ### Clustered: {'SSRIs': {'Cluster 1': ['Anxiety Disorders'], 'Cluster 2': ['Sleep Disturbances']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.08ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1032.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1007.71ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 759.96ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 933.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 655.77ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1109.98ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 705.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.18ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.73ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Cholesterol Levels - {'Blood Tests': 1.0000000000000002, 'Diagnose Conditions': 0.0}\n",
            "\n",
            " ### Clustered: {'Cholesterol Levels': {'Cluster 1': ['Blood Tests', 'Diagnose Conditions']}}\n",
            "Original Query: Is there evidence that tomato juice lowers cholesterol levels?\n",
            "Refined Query: Given that blood tests diagnose cholesterol levels,  is there clinical evidence, specifically from controlled studies analyzing blood test results before and after tomato juice consumption, supporting a claim that tomato juice consumption demonstrably lowers cholesterol?\n",
            "\n",
            "Combined Answer: Blood samples were collected on days 2, 10, 14, and 17 at time 0 (predose) and at 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose. Additional blood samples were obtained at 48, 72, 96, and 120 hours after the last ozanimod dose on day 14. Plasma moxifloxacin concentrations were measured only if QTc assay sensitivity failed. Plasma concentrations of ozanimod and its active metabolites (RP101988, RP101075, and RP101442) were determined by a bioanalytical core laboratory (ICON Development Solutions, LLC, Whitesboro, New York) using a validated liquid Although we undertook an extensive and comprehensive search to minimize bias in the review process, we could not confirm whether other studies with negative findings exist, because trials with negative findings are not published as often as trials with positive findings (Hopewell 2009). In addition, we did not receive further unreported data from correspondence with the study authors. pulmonary, cardiovascular, gastrointestinal, neurologic, or psychiatric disorder. Also excluded were subjects with the presence or history of any abnormality or illness that, in the opinion of the study investigator, could affect the absorption, distribution, metabolism, or elimination of the study drug or could limit the subject's ability to participate in and complete the trial. Other exclusion criteria included significant abnormalities detected by 12‐lead ECG or screening laboratory tests; history of alcoholism, drug abuse, or addiction effect because the lower bound of the 90%CI for the ratio of geometric least‐squares means was outside the no‐effect boundary of 0.80 to 1.25 for the RP101075 Cmax. However, this minor change is not considered clinically meaningful because the extent of exposure (AUC0–t) of RP101075 was unaffected, and the lower Cmax of this minor active metabolite was not expected to have any effect on clinical safety or efficacy. Prior to the availability of the food‐effect study results, patients in the ozanimod phase 2 studies in RMS and UC were instructed levels, thereby attenuating activation.23 Indirectly, these findings also support the reliance of HSC activation on autophagy to generate lipids for energy to support cellular activation.4 Therefore, enhanced flux of cholesterol could deprive cells of an important energy source required to fuel the many pathways associated with HSC activation. Another interesting implication of these findings is the overlap in gene expression changes between effects of Aramchol and those inhibiting EMT, including hedgehog, which has been implicated in hepatic for both cholesterol biosynthesis and homeostasis were downregulated after 24 h of 10 μM Aramchol, and the downregulation of cholesterol biosynthesis persisted after 48 h of treatment. A full list of differentially expressed genes is available in Table S3. These findings support the possibility that the effect of Aramchol on cholesterol levels in HSCs may contribute to its antifibrotic activity. function. Few TEAEs of infection or elevated liver enzymes occurred, and they were evenly distributed between the study groups (infection: 3 placebo subjects, 2 ozanimod subjects; elevated liver enzymes: 1 placebo subject, 2 ozanimod subjects). All cases of elevated liver enzymes were detected at follow‐up visits that occurred ≥14 days after the last dose of study medication. All of these cases were transient and considered by the investigator to be unrelated to study medication. No clinically meaningful results of pulmonary function tests and these measurements were used to compare changes from baseline size. Laboratory testing included assessment of transaminase levels every two weeks for the first eight weeks and then monthly, as well as monthly complete blood counts, serum chemistries and kidney function tests. Adverse event monitoring included assessment of patient with history and physical exam every 12 weeks, as well as through direct communication with study team at any point during study if an adverse event occurred. Dose reductions to 600, 400 and 200mg by mouth per activity without affecting mRNA levels,8 but this is the first evidence of the induction of ABCA1 mRNA by Aramachol. Similarly, Aramchol induced ABCG1, which also mediates cholesterol and phosopholid efflux,21 and downregulated ACAT2, which catalyses the synthesis of cholesterol esters.22 These changes would further reduce intracellular cholesterol in HSCs. Importantly, increased cholesterol accumulation in HSCs accelerates liver fibrosis, and thus enhanced efflux through ABCA1 and ABCG1 induction while reducing ACAT2 may be additional This phase 1 study was designed to evaluate whether food consumption (high fat or low fat) has an effect on the systemic exposure of ozanimod or its active metabolites. Specific mechanisms of drug–food interactions include delays in gastric emptying, changes in gastrointestinal pH, increases in splanchnic blood flow or in the flow of bile salts, changes in GI viscosity, alterations in luminal metabolism or in systemic drug clearance, and direct physical or chemical interactions with the drug formulation (eg, changes in solubility and/or\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 404.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are there transposon-free regions in mammalian genomes?\n",
            "Refined Query: The question explores whether mammalian genomes contain any DNA segments completely devoid of transposable elements (transposons).  These elements are mobile genetic sequences that can proliferate within a genome, so regions lacking them are of interest for understanding genome organization and evolution.\n",
            "\n",
            "Combined Answer: We report evidence for a mechanism for the maintenance of long-range conserved synteny across vertebrate genomes. We found the largest mammal-teleost conserved chromosomal segments to be spanned by highly conserved noncoding elements (HCNEs), their developmental regulatory target genes, and phylogenetically and functionally unrelated “bystander” genes. Bystander genes are not specifically under the control of the regulatory elements that drive the target genes and are expressed in patterns that are different from those of the target genes. were found to be associated with transposon-free regions (TFRs) in the human genome; for instance, PAX6 and MIRN9-2 (Simons et al. 2006). However, we do not find such a correlation: we found two retroviral insertions within the third intron of pax6.2, with no detectable phenotype. On the other hand, the area around fgf8, which we found not to tolerate insertions in zebrafish (data not shown), contains evidence of numerous transposons in both human and fish genomes. Thus, while it is intriguing that developmental regulatory genes are associated or grammars. However, a linguistic analysis of the DNA needs to take into account many distinctive physical and biological characteristics of such sequences: The genome consists of coding regions that encode for polypeptide chains associated with biological functions as well as a plethora of regulatory and potentially functional non-coding regions, identified through multiple alignment of genomes of several organisms, and termed conserved non-coding elements (CNEs). In addition, it contains large non-coding regions most of which are not linked ubiquitously expressed genes that harbor HCNEs in their noncoding sequence will be retained in the detached segment, and the HCNEs will be lost from that segment. Any alternative explanations that would account for the observed disentangling of regulatory and protein-coding elements are highly improbable. Recently, early developmental regulators were found to be associated with transposon-free regions (TFRs) in the human genome; for instance, PAX6 and MIRN9-2 (Simons et al. 2006). However, we do not find such a correlation: we found two of TADs compared to those lacking evidence of this type of conservation (non-GRB-TADs) (Supplementary Fig. 8a and Supplementary Table 3) (see Supplementary Methods). Previously, it has been found that the regions surrounding key developmental genes are depleted of transposons46, suggesting that the regulation of these genes is sensitive to insertions. Indeed, GRBs sharply define regions depleted of transposons, with strong increases in the density of SINEs in their flanking regions (Fig. 4 and Supplementary Fig. 8b). Changes in SINE density Tn5, a prokaryotic transposase, on small numbers of unfixed eukaryotic nuclei would interrogate regions of accessible chromatin. Here we describe Assay for Transposase Accessible Chromatin followed by high-throughput sequencing (ATAC-seq). ATAC-seq uses Tn5 transposase to integrate its adapter payload into regions of accessible chromatin, whereas steric hindrance less accessible chromatin makes transposition less probable. Therefore, amplifiable DNA fragments suitable for high-throughput sequencing are preferentially generated at locations of Repetitive elements were obtained from the UCSC (University of California, Santa Cruz) Genome Browser77 for hg19 and dm3. We investigated both the distribution of different classes of transposons (LINEs, SINEs, DNA or LTRs). For visualisation using heatmaps the average coverage of elements within 5 kb bins in a 8 Mb window around the centre of hg19-galGal4 GRBs was calculated. For average profiles, retrotransposons per 10 kb were calculated by counting the number of retrotransposons occurring in overlapping 10 kb windows, with a step size of 1 of entire chromosomal loci by imposing long-range constraints on their structure and integrity. Whole-genome duplication can transiently relieve those constraints and enable neighboring genes to “escape” the gridlock imposed by long-range regulatory elements. Teleost genomes provide a fertile ground for studying this phenomenon in detail. of human DNA that match identically with corresponding regions in the mouse and rat genomes [2]. They are widely distributed in the genome (on all the chromosomes except chromosomes 21 and Y) and are often found in clusters. For unknown reasons, these regions are under a negative selection much stronger than that operating in coding sequences and have been evolutionarily conserved for 300 million years, before mammal and bird ancestors diverged [3]. Of the 481 ultraconserved elements, 111 overlap the mRNA of a known gene, 256 show no evidence Nadeau and Taylor (1984) suggested a model of genome evolution in which evolutionary chromosomal breakpoints are distributed randomly throughout the mouse and human genomes, and postulated conserved blocks of synteny to be “relics of ancient linkage groups not yet disrupted by chromosome rearrangement.” In closely related genomes such as mouse and human, this may be partially true, but it is likely that in distantly related vertebrates, sufficient numbers of translocation events have occurred during evolution to rearrange all large chromosomal\n",
            "[0.67877626]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are messenger RNA molecules epigenetically methylated?\n",
            "Refined Query: The question explores whether epigenetic modifications, specifically methylation, occur on messenger RNA (mRNA) molecules.  This investigates if mRNA methylation, beyond the typical post-transcriptional modifications, plays a regulatory role in gene expression, impacting mRNA stability, translation, or other cellular processes.\n",
            "\n",
            "Combined Answer: or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can has been observed previously in gene expression profiling studies [4,46]. Remarkably, the majority (>75%) of the hypermethylated genes present in all seven samples encoded for transcription factors, while the shared hypomethylated genes were spread among many different functional categories. Transcription factors play a central role in maintaining or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely family members. Taken together, site-specific RNA editing events may lead to amino acid substitutions by changing codons in coding sequences. Apart from its role in coding regions, RNA editing may also influence transcript splicing and structure and could have an effect on mRNA stability and nuclear export [2]. Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and It appears that SALL4 actively interacts with multiple epigenetic factors during transcriptional regulation, as we have shown earlier that SALL4 associates with a group of DNA methyltransferases during subsequent gene silencing. Competitive or compensative involvement of these epigenetic factors during specific SALL4 regulatory process may occur, because under LSD1 knockdown conditions, we monitored increased gene binding of DNMT1 and DNMT3L at SALL4 target genes. Here, it may be critical to consider that histone modification and DNA Developmental programs are controlled by transcription factors and chromatin regulators, which maintain specific gene expression programs through epigenetic modification of the genome. These regulatory events at enhancers contribute to the specific gene expression programs that determine cell state and the potential for differentiation into new cell types. Although enhancer elements are known to be associated with certain histone modifications and transcription factors, the relationship of these modifications to gene expression and The methylation state (none, mono-, di- or tri-methylation) of H4K20 has been linked to genome stability and cell cycle progression in a number of model systems (reviewed in (1)). To assess the impact of H4K20 methylation states on cell cycle progression in Drosophila Kc167 cells, we manipulated the levels of the H4K20 methyltransferases, PR-Set7 and Suv4-20 (Figure 1A). Depletion of the monomethyltransferase PR-Set7 with double-stranded RNA (dsRNA) mediated RNAi for 72 h resulted in a reduction of H4K20me1 levels compared with control RNAi. occur, because under LSD1 knockdown conditions, we monitored increased gene binding of DNMT1 and DNMT3L at SALL4 target genes. Here, it may be critical to consider that histone modification and DNA methylation cooperatively regulate chromatin structure and gene activity. For example, loss of LSD1 mediated by shRNA is found to suppress HDAC mRNA expressions in breast cancer cells (33). We have also verified the reduced mRNA levels of HDAC1 and HDAC2 after LSD1 knockdown in BM HSPCs. Further, their binding to SALL4·LSD1 co-occupied gene sites A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2), and the recently discovered CHROMOMETHYLASE 2 (CMT2) perform methylation in CHH contexts (Haag and Pikaard, 2011; Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry regulatory inputs will be reflected in the absence of correlation in expression between targets and bystander genes; HCNEs acting as enhancers of target genes at a particular point in time and space should have the corresponding chromatin domains in active state when they drive the expression of the target gene, which should be reflected by the presence of the corresponding epigenetic signatures; different responsiveness to long-range regulatory inputs will be reflected in different structural properties of the two classes of genes, that is,\n",
            "[0.6584543]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which genes are more frequently affected by somatic mutations in Chronic Lymphocytic Leukemia\n",
            "Refined Query: Investigating the frequency of somatic mutations in Chronic Lymphocytic Leukemia (CLL) requires identifying which genes exhibit the highest rates of alteration.  This involves analyzing genomic data from CLL patients to determine which genes are most commonly mutated, focusing on the types and frequency of these mutations.\n",
            "\n",
            "Combined Answer: and homopolymer repeat length. Further details on these three new filters are provided in Methods. GenomeVIP also provides dbSNP (NCBI v.142, GRChr37 and GRCh38) and a false-positive filter as high-level filters. These methods are based in part on published (Xu et al. 2014) best practices for these tools, our results in the ICGC-TCGA DREAM Somatic Mutation Calling challenge (http://www.synapse.org/#!Synapse:syn312572/wiki/58893), and our germline and somatic calling in the ICGC-TCGA Pan-Cancer Analysis of Whole Genomes Somatic Mutation Calling a clinical setting, e.g. CSN and CAVA [4], usually focus on the correct annotation of previously called variants. To our knowledge, there are no freely available variant calling tool that can use as input a list of likely mutations that should be considered with an especially low allelic frequency. Neither is it possible to perform a comparable analysis of positions where no variant is called, but the user is interested in the raw number of bases. As a consequence, a manual, time-consuming inspection of all sites where mutations are expected of automatic systems have been developed for extracting mutation mentions from the biomedical literature (Caporaso et al., 2007; McDonald et al., 2004) and some investigated further with respect to mutations’ associations with genes (Horn et al., 2004; Rebholz-Schuhmann et al., 2004), diseases (Doughty et al., 2011; Furlong et al., 2008; Yeniterzi and Sezerman, 2009) and other related information (Kanagasabai et al., 2007; Naderi and Witte, 2012). Despite different scopes, with regard to methods for mutation detection, most systems rely on respectively. The top three samples selected regarded white patients, who were current or current reformed smoker for 15 or less years, with age at the initial pathologic diagnosis of 69, 67 and 68 years, respectively, and presenting 95, 87 and 95% of tumor cells, respectively. Leveraging on GMQL and TCGA data in BED format, this last example query shows how to easily combine heterogeneous datasets to answer complex biomedical questions, such as to select DNA somatic mutations potentially relevant in altering the regulation of gene expression, Likewise, somatic variants associated with cancer were not included. A total of 453 unique non-coding Mendelian disease-associated variants were identified (Table S6). Mutations were manually mapped to GRCh37, if necessary. Each variant was cataloged according to its sequence variant type (Table 1). The disease associated with the variant was mapped to an OMIM disease identifier, and the affected gene was encoded with an NCBI Entrez Gene identifier. Motivation: Text-mining mutation information from the literature becomes a critical part of the bioinformatics approach for the analysis and interpretation of sequence variations in complex diseases in the post-genomic era. It has also been used for assisting the creation of disease-related mutation databases. Most of existing approaches are rule-based and focus on limited types of sequence variations, such as protein point mutations. Thus, extending their extraction scope requires significant manual efforts in examining new instances and variation is one of the major approaches for characterizing gene–disease relationships (Erdogmus and Sezerman, 2007; Schenck et al., 2012), with many study results subsequently reported in scientific publications. As such, text-mining mutation-related information from the literature has become an increasingly important task in many downstream bioinformatics applications, such as the curation of mutation-related biological databases (Gyimesi et al., 2012; Kuipers et al., 2012), the systematic study of biological effects of protein mutations study the dynamics of development, evolution or cancer progression (Bhang et al., 2015; Blundell and Levy, 2014; Levy et al., 2015; Lu et al., 2011; Nguyen et al., 2015), or as markers of engineered constructs to study genetic or protein–protein interactions (Jaffe et al., 2017; Schlecht et al., 2017). Errors in bar-seq analysis can have profound consequences on the biological interpretation of these assays. For example erroneous barcodes can inflate measures of the adaptive mutation rate (Levy et al., 2015), and undercounting of low frequency VariantTools [7], provide options for counting the number of bases and determining quality summaries at a selected set of positions. However, as the output is textual, programming one’s own solution for visualization is necessary. Altogether, this does not appear to be a satisfactory solution for clinical routine. In the use case of medical diagnostics, a tool performing detailed analyses of those locations where mutations are expected – but not always called – may prove to be very useful. Low allelic frequency and bad base quality may often 598, and 279, respectively. Applied on these samples, the described GMQL query found 271 DNA-seq samples with DNA somatic mutations close (within 2000 bp) to the 11,307 genes which were identified as both expressed and methylated. These somatic mutations found in the three samples with the highest number of such mutations were 108, 45, and 36, respectively. The top three samples selected regarded white patients, who were current or current reformed smoker for 15 or less years, with age at the initial pathologic diagnosis of 69, 67 and 68\n",
            "[0.22934166]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How effective is the dentritic cells treatment on cancer?\n",
            "Refined Query: The effectiveness of dendritic cell-based cancer therapies is a complex issue.  Research explores their ability to stimulate anti-tumor immune responses, but success varies widely depending on cancer type, treatment protocol, and patient factors.  What are the current clinical trial results and long-term efficacy data for different cancer indications?\n",
            "\n",
            "Combined Answer: Supported by Amgen; also supported in part by a Cancer Prevention Research Institute of Texas Precision Oncology Decision Support Core grant (RP150535)and Comprehensive Cancer Center Core Grants (P30 CA016672 and P30 CA008748) at Memorial Sloan Kettering Cancer Center from the National Institutes of Health (NIH). Dr. Denlinger is supported in part by a Comprehensive Cancer Center Core Grant (P30 CA006927) at Fox Chase Cancer Center from the NIH, and Dr. Lito is supported in part by grants (1R01CA23074501 and 1R01CA23026701A1) from the NIH form. These findings correspond to the similar inhibitory activity of gilteritinib against FLT3wt and FLT3-ITD. FL is reportedly involved in promoting the differentiation of hematopoietic progenitor cells into dendritic cells (DC) [31]. A potential downside of the inhibitory effect of gilteritinib on FLT3wt is that it may affect DC differentiation and immune function. However, gilteritinib has inhibitory activity against AXL, which has cancer immunosuppressive activity [17, 32]. The mechanism by which gilteritinib affects cancer immunity is part by a Comprehensive Cancer Center Core Grant (P30 CA006927) at Fox Chase Cancer Center from the NIH, and Dr. Lito is supported in part by grants (1R01CA23074501 and 1R01CA23026701A1) from the NIH National Cancer Institute, by the Pew Charitable Trusts, and by the Damon Runyon Cancer Research Foundation. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. We thank the patients for de Marseille, Marseille, France P.N. Munster, University of California, San Francisco, San Francisco, California S.S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta T.F. Burns, University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh F. Meric-Bernstam, Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, University of Texas M.D. Anderson Cancer Center, Houston H. Henary, Amgen, Thousand Oaks, California J. Ngang, Amgen, Thousand Oaks, California G. G.K. is supported by the Ligue Nationale Contre le Cancer (Equipes Labelisée), Agence Nationale pour la Recherche (ANR), Fondation Axa (Chair For Longevity Research), European Commission (ArtForce), Fondation pour la Recherche Médicale (FRM), Institut National du Cancer (INCa), Cancéropôle Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Immuno-Oncology. M.N.S., S.A., S.A.M., L.G. and M.C.M. are supported by Junta de Extremadura-Fondo Social Europeo, Ligue Nationale contre le Cancer, the Higher Education Commission (HEC) of discrepancy between our results and those of previous studies may be attributable to the specialised role of dCK in the activity of anticancer drugs, and to the fact that other studies have employed differently subtyped AML populations. Indeed, to screen outcome predictors, other research groups have employed mixed populations of AML patients treated with non-unified regimens, whereas in this study we used more focused populations in the aspect of disease type and chemotherapy regimen. Additionally, our previous in vitro study showing that dCK the LabEx Immuno-Oncology. M.N.S., S.A., S.A.M., L.G. and M.C.M. are supported by Junta de Extremadura-Fondo Social Europeo, Ligue Nationale contre le Cancer, the Higher Education Commission (HEC) of Pakistan, the LabEx Immuno-Oncology and the Association pour la Recherche sur le Cancer (ARC), respectively. C virus infections (Clercq, 2007) as well as fungal (Chen et al., 2016; Groll and Tragiannidis, 2009) and bacterial infections (Tamma et al., 2012; Worthington and Melander, 2013). However, drug combination effects can be adverse and even lead to shorter progression free survival of cancer patients (Hecht et al., 2009; Tol et al., 2009). Therefore, finding synergistic drug pairs for a particular cancer type is important for improving efficacy of anticancer treatment. Until recently, effective drug combinations were proposed based on clinical Among patients with other tumor types, 4 had a confirmed partial response (1 with pancreatic cancer, 1 with endometrial cancer, 1 with appendiceal cancer, and 1 with melanoma), 17 had stable disease, and 4 had progressive disease. The four responses lasted for 4.4, 6.9+, 2.7, and 5.6 months, respectively. Five patients were continuing treatment as of the data cutoff date (Table 3 and Fig. S6). Therapeutics, Phase I Clinical Trials Program, University of Texas M.D. Anderson Cancer Center, Houston H. Henary, Amgen, Thousand Oaks, California J. Ngang, Amgen, Thousand Oaks, California G. Ngarmchamnanrith, Amgen, Thousand Oaks, California J. Kim, Amgen, Thousand Oaks, California B.E. Houk, Amgen, Thousand Oaks, California J. Canon, Amgen, Thousand Oaks, California J.R. Lipford, Amgen, Thousand Oaks, California G. Friberg, Amgen, Thousand Oaks, California P. Lito, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New\n",
            "[0.5382283]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the mode of inheritance of nemaline myopathy?\n",
            "Refined Query: Nemaline myopathy exhibits genetic heterogeneity.  Explain the various modes of inheritance observed in different forms of this disease, detailing whether they are autosomal dominant, autosomal recessive, or X-linked, and mentioning any genes implicated.\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause Duchenne muscular dystrophy (DMD) is a progressive, severely disabling, and incurable X-linked recessive inherited disorder that affects 1 in 3,500 newborn boys and leads to death in the second or third decade of life.1 In patients with DMD, the open reading frame of the X-linked dystrophin gene, encoding dystrophin, is disrupted by deletions (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive the National Hospital for Neurology and Neurosurgery (NHNN), London. All patients were negative for known mutations in the following genes MFN2, MPZ, GJ1B, BSCL2 and NEFL. Additional 90 samples with axonal neuropathy and evidence of mitochondrial impairment on muscle biopsy were collected from the neurometabolic unit at the NHNN. Genomic DNA was purified from peripheral blood cells using standard procedures. might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, with discordance in excess of 10%3. One key reason for this discordance is the structure of the ACMG/AMP guidelines, which are deliberately broad and lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific Causative mutations in neurodevelopmental disorders are frequently de novo, X-linked recessive or autosomal recessive. In contrast to prior literature reporting largely inherited mutations in NHE6, through prospective recruitment, here we discover seven highly deleterious de novo mutations in NHE6. An eighth mutation was found, in a three-generation pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a atrophy,18 we assessed segregation of this mutation in the family. The deletion was homozygous in the affected cases, and either absent or heterozygous in the unaffected relatives (figure 3). To further investigate the presence of the mutation in patients with complex neuropathy, we sequenced the coding exons of C12orf65 in an additional cohort of 183 patients. None of the patients harboured potentially pathogenic variants. To determine whether the truncating mutation induced mRNA nonsense-mediated decay, we tested the level of expression of and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a clear list of candidate genes to investigate. Duchenne muscular dystrophy (DMD), an X-linked recessive condition, is a rare genetic disorder caused by the absence of functional dystrophin proteins due to gene mutations [1]. The incidence of DMD is approximately 1 in 5000 male newborns [2]. Affected boys initially exhibit progressive muscle weakness of the lower proximal extremities [3]. The gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly\n",
            "[0.8508947]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which syndrome is NHE6 associated with?\n",
            "Refined Query: Investigate the known genetic syndromes linked to mutations or dysfunction of the sodium/hydrogen exchanger 6 (NHE6) protein.  Are there any specific clinical presentations or phenotypes consistently associated with NHE6-related disorders?\n",
            "\n",
            "Combined Answer: Mutations from twelve families are represented on the NHE6 protein in Figure 4 and pedigrees are shown in Figure 1. Interestingly, in contrast to prior literature regarding NHE6 mutations wherein mutations have been largely inherited (Supplementary Table 2), a majority of mutations in our study (58%) were de novo. Families 1 through 7 had confirmed de novo mutations (ie mutations were not found in the mother). Another notable finding was two separate recurrent mutations. The first was found at c.1498 c>t, p.R500X. This mutation was observed in Our findings are important because they indicate that clinicians should be alert to considering mutations in NHE6 in a variety of presentations of neurodevelopmental disorders. Specifically, boys who present with new diagnoses of moderate to severe ID with seizures, language delays, and ataxia, with or without Angelman-like symptoms (AS), and with or without a pedigree consistent of X-linked ID, should be considered for NHE6 mutations. Finally, in twelve independent families we have discovered a robust allelic series of NHE6 mutations in CS. In this study, we prospectively ascertained 12 independent pedigrees, 14 affected boys in total, with mutations in NHE6. Interestingly, in contrast to prior literature, a majority of the pedigrees enrolled exhibited de novo mutations. Through quantitative study of clinical features in probands across these independent pedigrees (Supplementary Table 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected Twelve independent pedigrees (14 boys, ages 4 to 19) with mutations in NHE6 were administered standardized research assessments and mutations were characterized. Recently, Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na+/H+ Exchanger 6 (NHE6). We aimed to determine the diagnostic criteria and mutational spectrum for CS. Another possible distinguishing feature is that epilepsy in AS may not occur in 100% of patients25, 28 whereas in CS, as the data currently stand, epilepsy occurs in all patients. Additional medical and behavioral symptoms are notable, including GERD and high pain threshold. CS may be among the most common X-linked developmental brain disorders. In a large-scale sequencing project in 208 pedigrees with suspected X-linked intellectual disability, two protein-truncating mutations in NHE6 were found.1 These data place NHE6 among the top six genes will require larger studies to establish. The majority of mutations appear to be early truncating and/or splice mutations likely constituting loss of function mutations. Given our high discovery rate of de novo variants and prior publications, we anticipate that CS will constitute a spectrum of NHE6 mutations that may be either inherited or de novo. Our findings are important because they indicate that clinicians should be alert to considering mutations in NHE6 in a variety of presentations of neurodevelopmental disorders. Specifically, boys we determined that the variant found in NHE6 was unlikely to be pathogenic, and a distinct, likely causative mutation was found in a different gene (data not shown). The institutional review board (IRB) at Brown University and Lifespan Healthcare gave permission to perform this study and informed consent was obtained from all enrolled participants. Some aspects of the pedigrees are changed to assure anonymity. Information regarding phenotype of carriers is based on pedigree and family history. In summary, we report a robust series of NHE6 mutations in twelve independently ascertained pedigrees within which we were able to characterize quantitatively core and secondary symptom presentations. Through this study we have proposed a core set of diagnostic criteria for CS and also generated a quantitative early guide to symptom presentation in order to help establish initial clinical expectations for families and clinicians. Based on current studies, CS may be among the most common X-linked developmental brain disorders.1 CS has broad 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected males. These symptoms appear to be consistent regardless whether the mutation is inherited or de novo. These core diagnostic symptoms of CS (Table 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal\n",
            "[0.69619215]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is known about the reimbursement of Viagra\n",
            "Refined Query: What factors influence Viagra's reimbursement by insurance providers?  Are there specific medical criteria or limitations?  How does the cost vary depending on insurance coverage, dosage, and the patient's medical history?\n",
            "\n",
            "Combined Answer: increased health care costs and lost educational and work activities. Health care costs are 70% higher for a family with a migraineur than a non-migraine affected family, and direct medical costs for children with migraine are reported to be similar to those for adults(9). The majority of children with migraine continue to experience migraines into adulthood(10),] resulting in an annual economic impact in the U.S. of approximately $36 billion due to both direct medical costs and lost productivity(11). Preventing headaches may not only reduce based on two Canadian health claims databases [13], Hoffmann identified 70 studies based on German health claims data published from 1998 to 2007 with more than half of the studies being published from 2006 to 2007 [14]. However, limitations arise when health claims data are reused for clinical research. As to the JADE tool, the patients’ prescriptions are not fully covered: drugs administered or dispensed in hospitals and drugs which are not reimbursed by the insurance (e.g. over-the-counter drugs sold directly to a consumer without patients whose health insurance companies report the actual dispensing date for a drug. Therefore, the selection of patients was not random. Furthermore the prescribed dose and time period of the drug intake are not documented. In general, the quality of diagnoses documented for hospital stays needs to be questioned. For example, in a study conducted in Australia Sansom et al. suggest that only for a fraction of hospital stays related to adverse drug reactions a drug-related diagnosis has been documented [15]. However, in the Austrian payment (Devinsky 1999). As reported by the World Health Organization (WHO), the overall health burden due to epilepsy accounts for 0.5% of the global burden of disease; this can be considered as more than one‐third of the diabetes burden (1.3%) (WHO 2006). In Europe, the total annual costs of epilepsy are approximately EUR 15.5 billion (Pugliatti 2007). In China, about nine million people suffer from epilepsy; the overall annual costs are approximately USD 773 per patient, which represents half the average annual income (Hong 2009). adulthood(10),] resulting in an annual economic impact in the U.S. of approximately $36 billion due to both direct medical costs and lost productivity(11). Preventing headaches may not only reduce the frequency of the headaches, but also may results in improved effectiveness of acute medication. The majority of children and adolescents with migraine continue to experience migraines into adulthood(10). payers. Several studies have reported cost savings following Barricaid device implantation. Parker et al[28] reported that use of the Barricaid device resulted in a $2200 savings per person compared with lumbar discectomy alone. Ament et al[29] derived similar conclusions in which lumbar discectomy was $2100 less expensive when the Barricaid device was utilized. Should the rates of symptomatic recurrence in the current study approximate those observed in the EU Barricaid Controls, this would provide sufficient evidence that the Barricaid Eligible participants were women and men aged 18 through 55 years with a body weight of at least 50 kg and a body mass index of 18 to 30 kg/m2. Subjects were required to be in good health, as determined by no clinically significant findings from medical and surgical history, physical examination, and vital signs. Subjects agreed to use adequate contraception during the study and until 30 days after receiving the last dose of study drug and to comply with all study requirements. Excluded from participation were subjects who were pregnant or were performed with the use of a Bayesian approach, as described previously.10,11 In brief, a skeptical “prior” distribution was formulated for the treatment effect: smaller effects were more likely than larger ones, and results were equally likely to favor either group. This prior opinion was then revised on the basis of trial data, leading to a “posterior” probability distribution for treatment effect for computation of the probability that ZMapp plus the current standard of care results in lower 28-day mortality than the current standard of in most cases.[11] With almost half a million lumbar discectomies performed in the US per year,[27] and approximately 100,000 to 150,000 of these patients at high risk for recurrence based on annular defect size,[12] this poses a widespread, clinically important problem not only for affected individuals but also for physicians, hospitals, and healthcare payers. Several studies have reported cost savings following Barricaid device implantation. Parker et al[28] reported that use of the Barricaid device resulted in a $2200 savings per person (10 to 150 mg) without clear guidance to dose response effectiveness or adjustment by subject's weight. In order to address this short-coming, the effectiveness in an open-labeled dose finding study with 1 mg/kg/day was determined to have maximum effectiveness without any additional benefit beyond this dosing(27, 28). This dose has subsequently been used for clinical practice and in the drug + coping skills management of chronic migraine. Feedback from the AHS Pediatric section membership also indicated that this was the typical approach used\n",
            "[0.6734244]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Why is lock mass used in Orbitrap measurements?\n",
            "Refined Query: Orbitrap mass analyzers use a lock mass for accurate mass measurements.  This internal calibrant corrects for mass deviations caused by instrumental drift, ensuring high mass accuracy and reproducibility across measurements, crucial for reliable compound identification.\n",
            "\n",
            "Combined Answer: a Trace DSQ fast-scanning single-quadruple mass spectrometer (Thermo-Finnigan), and LC-MS analysis performed using an Orbitrap Elite high-resolution mass spectrometer (Thermo-Finnigan). Raw analyte intensity values (features) were calculated as the area under the chromatographic peak. Features underwent median-scaling and missing value imputation with the minimum detected intensity value and filtering which removed any feature not found in at least 10% of all samples. Each feature was assigned a z-score based on the intensity of the feature mm × 2.1 mm; 100 Angstroms; 1.8 micrometer), and an Agilent 6540 UHD accurate mass UHPLC-QTOF mass spectrometer with acquisition in positive and negative modes was used. The buffers in positive mode consisted of buffer A (0.1% (v/v) formic acid in water) and buffer B (0.1% (v/v) formic acid in water:methanol solution (1:99)); in negative mode, the buffers consisted of buffer A (10 mM acetic acid) and buffer B (10 mM acetic acid in water:methanol solution (1:99))11. Once MS data had been generated, the centwave and obiwarp methods in the XCMS were electrosprayed directly into a hybrid LTQ-Orbitrap mass spectrometer (ThermoFisher, San Jose, CA) with the application of a distal 2.4 kV spray voltage. A cycle of one full-scan mass spectrum (400–1600 m/z) followed by seven data-dependent MS/MS spectra at a 35% normalized collision energy was repeated continuously throughout each step of the multidimensional separation. scan and detected in the ion trap (ITMS). The same 5 ions underwent higher energy collision dissociation (HCD, at 32.5% energy) with detection in the orbitrap (FTMS). All Orbitrap data was searched using Sequest-Percolator under the software platform Proteome Discoverer 1.3 (Thermo) against the Swiss-Prot human protein sequence database (20121008) and filtered to a 1 % false discovery rate. A precursor mass tolerance of 10 ppm, and product mass tolerances of 0.02 Da for HCD-FTMS and 0.8 Da for CID-ITMS were used. All samples were analyzed Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass spectrometry and data analysis. structure-type predictions to bias the selection of 3- and 9-residue backbone fragments, excluding fragments derived from homologs to the target sequence present in the database. (3) Automated setup of autoNOE-Rosetta calculations for a range of restraint weight values. According to this general procedure, we performed two sets of calculations for each target using NOE peak lists that included either (i) amide to aliphatic (HCNH) only, or (ii) amide to aliphatic and aliphatic to aliphatic (HCNH+HCCH). To improve sampling for nEIt, NOEs were Blood plasma samples from 117 patients diagnosed with 21 different IEMs underwent three different types of untargeted metabolic screening: (1) gas chromatography coupled mass spectrometry (GC-MS), (2) liquid chromatography coupled mass spectrometry (LC-MS) in positive ion mode and (3) LC-MS in negative ion mode. GC-MS analysis was performed using a Trace DSQ fast-scanning single-quadruple mass spectrometer (Thermo-Finnigan), and LC-MS analysis performed using an Orbitrap Elite high-resolution mass spectrometer (Thermo-Finnigan). Raw analyte in-house data analysis tool developed by Steve P. Gygi (Harvard Medical School, Boston, USA). Unique peptides were imported into Skyline 3.5.0.9319 and transition lists for heavy and light fragments exported for use on the mass spectrometer. Cells were grown in K8 Lys and lyzed in hypotonic buffer [10mM Tris (pH 7.65), 1.5 mM MgCl2, 10 mM KCl]. Pellet nuclei were resuspended sequentially into 0.34 M sucrose buffer containing 150 mM, 250 mM and 400 mM NaCl. Extraction was performed 10 min on roller and nuclei were pelleted between each (www.glennmorris.org.uk/mabs.htm). The EU BIO-NMD project (n. 241665 to AF and CAS), and the Duchenne Parent Project Italy (DMD Diagnostics Project) to A.Ferlini, are acknowledged. Thanks are also due to Carmelo Rodolico (Department of Neuroscience, University of Messina, Italy), Paola Rimessi, Marina Fabbri and Matteo Bovolenta (University of Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass for IsoSCM, GETUTR and Cufflinks because it was used in (Kim et al., 2015b; Shenker et al., 2014). The numbers of TPs, FPs and true (i.e. annotated) APA sites (P) are used to calculate sensitivity (TPP) and precision (TPTP+FP). In the calculation of sensitivity, all TPs matching the same true APA site count as one TP. Among the 21 731 annotated APA sites, TAPAS identifies 16 866, 18 205 and 18 871 true APA sites on the 50, 100 and 150 million read datasets, respectively. For the other tools, IsoSCM identifies 11 790, 13 583 and 14 592 true APA\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 731.12ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Have gnotobiotic animal models been used for the study of bowel disease?\n",
            "Refined Query: Gnotobiotic animal models, with their defined gut microbiomes, offer valuable insights into bowel disease etiology.  Have these models, lacking the complexity of conventional microbiota, been effectively utilized to dissect the role of specific bacterial species or microbial communities in the pathogenesis of inflammatory bowel disease (IBD) or other bowel disorders?\n",
            "\n",
            "Combined Answer: analysis (Fig 7H). Assessment of the colitis score showed a severe inflammation of the intestine of ATMINΔLNBS1ΔL mice treated with DSS (Fig 7I). These data indicate that although a proportion of ATMINΔLNBS1ΔL mice develop spontaneous inflammation and colitis, these mice are prone to chemically induced colitis. colitis has similarities to human IBD hence is an ideal model to mimic this disease [48]. We treated control, ATMINΔL, NBS1ΔL, ATMINΔLNBS1ΔL and ATM-/- mice for 8 days with 2% DSS, at which point the control mice did not show any signs of weight loss. In striking contrast to ATMINΔL and NBS1ΔL, only the ATMINΔLNBS1ΔL mice were sensitive to DSS-induced colitis as apparent by the weight loss of approximately 20% in these mice over an 8-day period (Fig 7D). Our data also confirmed the reported mild sensitivity of ATM-/- to DSS induced colitis and the on the amount of RUTF needed to achieve recovery. Additionally, antibiotic resistance is increasing worldwide, and can be particularly problematic in developing countries where treatment options against resistant organisms are more limited (Nys et al. 2004; Okeke et al. 2005; Okeke et al. 2007). In the gut, resistant organisms rapidly develop when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be including in the spleen and intestine that results in the development of intestinal prolapses in approximately 30% of ATMINΔLNBS1ΔL mice. Moreover, in an in vivo experimental system for intestinal colitis, using DSS to mimic IBD, we report enhanced colitis, significantly and specifically, in ATMINΔLNBS1ΔL mice. Although we observe a tendency towards spontaneous T cell activation in mice lacking only NBS1, as indicated by increased antigen experienced cells in the spleen and increased proliferation of splenic T cells, this phenotype is not levels of the inflammatory cytokines Il-1β, Tnfα and Il17a in both unstimulated and stimulated IEL from ATMINΔLNBS1ΔL mice (Fig 7A–7C). Since only a proportion of ATMINΔLNBS1ΔL mice develop spontaneous colitis we assessed whether these mice would be more susceptible to chemically induced colitis with dextran sodium sulphate (DSS). The DSS model of colitis has similarities to human IBD hence is an ideal model to mimic this disease [48]. We treated control, ATMINΔL, NBS1ΔL, ATMINΔLNBS1ΔL and ATM-/- mice for 8 days with 2% DSS, at which point the against C. difficile, in particular ones that address the high rates of recurrence. The pathogenic nature of C. difficile results from production of two exotoxins, toxin A (TcdA) and toxin B (TcdB), that are thought to target colonocytes via similar mechanisms that ultimately lead to cell death and disruption of the trans-epithelial resistance that normally exists across the gut wall (3). Damage to the gut epithelium results in fluid leakage into the gut lumen and release of proinflammatory mediators, such as IL-1β, TNFα, and IL-8, leading to when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be translocation of enteric flora across the compromised intestinal mucosa. Moreover, resistant bacteria may exhibit enhanced virulence (Dancer 2004), further complicating a malnourished child’s chances for recovery. Amoxicillin was used in the standard protocol group because of its relatively broad-spectrum of activity, low cost, and current usage by normally exists across the gut wall (3). Damage to the gut epithelium results in fluid leakage into the gut lumen and release of proinflammatory mediators, such as IL-1β, TNFα, and IL-8, leading to an inflammatory response that includes recruitment of neutrophils and macrophages to the site of injury, further aggravating the disease (4). Extensive structural and functional work over the past several years has led to a basic understanding of the molecular events that lead to toxin-mediated cell death, as recently reviewed by Pruitt and Lacy A proportion of ATMINΔLNBS1ΔL mice became moribund and displayed systemic inflammation, which also involved the intestine since we observed the development of spontaneous intestinal prolapses. We histologically investigated the large intestine that was found to be thickened and inflamed (Fig 5A). Moreover, histological scoring of the spontaneously sick ATMINΔLNBS1ΔL mice revealed extensive inflammation of the intestine (Fig 5B). Since we observed an infiltration of CD3+ T cells to the large intestine (Fig 5C), we next aimed to address what type Clostridium difficile is an anaerobic Gram-positive bacillus that infects the colon of susceptible patients, mainly in hospital settings but also increasingly in the community. C. difficile infections (CDI)4 are typified by severe diarrhea, pseudomembranous colitis, and in extreme cases colonic rupture, sepsis, and death (1). Current treatments for CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1183.86ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.78ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.57ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is it possible to detect survivin protein expression in normal human adult tissues?\n",
            "Refined Query: Determining the presence and levels of survivin protein in healthy adult human tissues is crucial.  This inquiry investigates whether standard detection methods, like immunohistochemistry or Western blotting, can reliably identify survivin expression in various normal tissues, considering its known association with cancer and its potential for low-level expression even in non-cancerous states.\n",
            "\n",
            "Combined Answer: Lysates of ES cells were subjected to Western blot analysis using anti-Oct3/4 (sc-9081; Santa Cruz Biotechnology), anti-Dax1 (39984; Active Motif, CA), anti-Esrrb (PP-H6705-00; Perseus Proteomics, Tokyo, Japan), or anti-α-tubulin (MP Biomedicals, Solon, OH) antibodies followed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies (Millipore, Billerica, MA). The blot was visualized by using enhanced chemiluminescence reagents (PerkinElmer, Waltham, MA) with an LAS-1000 image analyzer (Fuji Film, Tokyo, Japan). An MBP pulldown extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified both HDAC3 and its partner protein NCoR1 by Western blot analysis. SGs, moreover, they were detected at higher levels within SGs compared to the full-length protein (Figure 3C,D and data not shown). This was likely due to their cytoplasmic redistribution rather than enhanced propensity for SG recruitment since fluorescence intensity ratio SG/cytoplasm was similar for CR_dNT and full-length protein (Figure 3D). It was not possible to establish if CR_dMFD was recruited to SGs due to its high aggregation propensity. These results indicate that CREST recruitment to SGs is restricted by its limited occurrence in for diagnosis and treatment, since each subtype presents with a distinctive prognosis [2] and the choice of therapeutic regimen is predominantly based on tumor subtype and staging parameters [3]. The development of personalized diagnostics and therapy is leading the way to a new era that may see us overcome some of the difficulties in treating complex diseases such as NSCLC. In the past decade, comparative gene expression profiles of tumors have been extensively studied [4-6], yielding useful insights into the molecular hallmarks of was not possible to establish if CR_dMFD was recruited to SGs due to its high aggregation propensity. These results indicate that CREST recruitment to SGs is restricted by its limited occurrence in the cytoplasm and that the presence of C-terminal domain (CT, aa. 317-396) and MFD is necessary and sufficient for SG targeting of CREST. Cytoplasmic aggregates of full-length CREST-GFP observed in a fraction of cells that also display large nuclear aggregates (similar to illustrated in Figure 1A) were negative for SG or P-body markers under basal Western blot analysis for PTEN was conducted as previously described (25). PTEN expression was detected, using a monoclonal anti-PTEN antibody (PTEN 7974; Santa Cruz Biotechnology). body markers. In SH-SY5Y cells with a diffuse/fine-granular nucleoplasmic distribution of CREST-GFP the protein was excluded from nucleolar region identified by ethidium bromide staining, was not enriched in SMN-positive Gems, coilin p80-positive Cajal bodies or PML bodies but we detected its enrichment around MALAT1-positive nuclear speckles (Figure 1B). CREST was reported to be a paraspeckle component [14]; we also observed CREST-GFP enrichment in paraspeckles visualized by NEAT1 FISH, but only in cells with low levels and diffuse CREST deletion variants lacking an autoregulatory domain, CR_dNT and CR_dNT-Met, unlike other deletion mutants, are highly enriched in paraspeckles regardless expression levels and can be readily recruited to actinomycin D-induced nucleolar caps (Figure 4C and data not shown). We next asked if CREST is able to recruit other paraspeckle proteins into its nuclear aggregates. Indeed, a core paraspeckle component, FUS, was efficiently sequestered into virtually all nuclear aggregates formed by CREST-Flag or CREST-GFP regardless their size and be a universal signature of cancerCNAs remains to be determined, the depletion of UCEs from one cancerCNA dataset (TCGARN 2013 [90]) suggesting that the story will be more complex, perhaps reflecting tissue or cancer specificity. At the least, our findings argue that the depletion of UCEs that characterizes many CNV datasets is unlikely to reflect an intrinsic inability, across all cell types, of CNVs to form in the vicinity of UCEs. with poor extraction or lack of growth of the tumour cells in the host. For RNA-seq, STAR aligned human (SRR387400) and mouse (SRR1930152) data was also analysed with very similar results. For the mouse sample Disambiguate displays again slightly more true and false positives compared to xenome but for SRR387400 xenome shows clearly more true positives.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 403.53ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List symptoms of Meigs' Syndrome.\n",
            "Refined Query: Describe the common symptoms experienced by individuals diagnosed with Meigs' syndrome,  providing a concise overview of their presentation.\n",
            "\n",
            "Combined Answer: 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI survivors were only identified in the group of patients who are wild-type for this gene. Some of these patients had an atypical clinical presentation (longer duration of symptoms or atypical radiology) and thus were biopsied, demonstrating high grade histologic features. Despite high grade histology, this group of H3.3 wild-type patients did not follow the expected clinical course of what can be considered classic for children with DIPG, suggesting a potentially different clinical and molecular entity which should be added to the group of 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected males. These symptoms appear to be consistent regardless whether the mutation is inherited or de novo. These core diagnostic symptoms of CS (Table 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). times as the replication machinery loses its place on the template; an insertion in one sequence paired with a reciprocal deletion in one other may be caused by unequal cross-over in meiosis; insertion of transposable elements--jumping genes--into a DNA sequence; insertion of DNA by retroviruses; and translocations of DNA between chromosomes [8]. The accurate identification of gaps is shown to be fundamental in various studies on disorders; for example, on Hajdu-Cheney syndrome [9], a disorder of severe and progressive bone loss. The focus of The authors would like to thank the families for participating in this study. The authors would also like to thank Judith Nathanson and Heather M. Thompson for their help with figures. EMM has received a Career Award in Medical Science from the Burroughs Wellcome Fund and support from NIH NIGMS P20GM103645. This work was supported by a grant from the Simons Foundation (SFARI #239834 to EMM), and also generous support to EMM from the Nancy Lurie Marks Foundation. EMM has also received generous support from the newly-formed Christianson Syndrome features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures. Families were excluded if the parents could not be contacted for consent or if DNA could not be obtained from the affected individual. Further exclusion criteria were autosomal dominant inheritance and the absence of both intellectual disability and seizures, criteria that have been used elsewhere.3 A clinical questionnaire was completed by the collaborating physician. DNA was\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.51ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 984.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1108.79ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.51ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Lung Cancer - {'Chemotherapy': 1.0, 'Fatigue': 0.0}\n",
            "\n",
            " ### Clustered: {'Lung Cancer': {'Cluster 1': ['Chemotherapy'], 'Cluster 2': ['Fatigue']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 781.58ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 805.68ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1183.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 861.03ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 780.68ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can we detect DNA strand asymmetries using dinucleotide relative abundance \"genomic signatures\"?\n",
            "Refined Query: Investigating whether dinucleotide relative abundance, as a genomic signature, allows for the detection of DNA strand asymmetries is the focus.  Can the biased occurrences of specific dinucleotides across the leading and lagging strands reveal underlying strand-specific processes or biases?\n",
            "\n",
            "Combined Answer: with correlations below a minimum are flagged as poor quality. The second metric uses the restriction fragmentation controls to determine whether input DNA underwent appropriate enzymatic digestion and denaturation during sample preparation. According to NanoString guidelines, low probe ratios and low probe counts are indicative of incomplete digestion and denaturation, respectively, and lead to flagging by our software. The final metric relies on invariant controls (which map to autosomal regions likely to have neutral copy number of two). Hence, the sequence bias of MPE-Fe(II) is substantially less than that of MNase, DNase I (Fig. S2F, based on data from ref. 22; also see refs. 23, 24), or the Tn5 transposase used in ATAC-seq (Fig. S2G, based on data from ref. 27). We also analyzed the distributions of all combinations of dinucleotides in the vicinity of the 5′ ends of the uniquely mapped reads (Fig. S3). The MPE-Fe(II) data revealed small peaks and troughs near the 5′ ends, but this effect was much less pronounced than that seen with MNase. Thus, the use of MPE-Fe(II) enables sets could be due to experimental bias: recent studies have found strong biases in ChIP-seq data for regions close to the TSS of highly expressed genes (33,34), which are oftentimes enriched in CG dinucleotides. (Indeed, many of the peaks unique to only one of the ChIP-seq replicates are close to TSSs.) Given that control experiments and replicate experiments reported in ENCODE were not performed at the same time, it is currently not possible to correct for this bias in the ChIP-seq data. We note, however, that for the TF pairs in our The understanding of such avoidances is becoming an interesting line of research (for recent studies, see [7, 8]). On the other hand, short words of nucleotides may be systematically avoided in large genomic regions or whole genomes for entirely different reasons, i.e. just because they play important signaling roles which confine their appearance only in specific positions: consensus sequences for the initiation of gene transcription and of DNA replication are well-known such oligonucleotides. Other such cases may be insulators, sequences between RNA-seq samples. This will sometimes lead to an overestimation of confidence in the base call vector x~ for the sample with higher coverage. We mitigate this phenomenon by adjusting the underlying read stacks. In essence, large coverage differences between a single nucleotide count vector D~homo and count vectors with two or more nucleotides D~hetero are evened out by replacing the original D~homo with a copy of D~hetero where all variant positions have been replaced by the reference nucleotide. Depending on the encountered read similar dinucleotide composition of dominant TSS initiators, independent of the amount of total RNA used, confirms that identification of the dominant TSSs is not obscured by PCR amplification (Fig. 2D,H, right panel; Supplemental Fig. S2M,O). The identified preferred initiators are pyrimidine-purine dinucleotides CA, TG, TA (S. cerevisiae) or CA, CG, TG (M. musculus) in accordance with the Inr element (YR) (Burke and Kadonaga 1997; Haberle and Lenhard 2016). These results confirmed the utility of SLIC-CAGE in uncovering authentic and denaturation, respectively, and lead to flagging by our software. The final metric relies on invariant controls (which map to autosomal regions likely to have neutral copy number of two). Low invariant probe counts are emblematic of low DNA input and can lead to inaccurate copy number calls. These samples are flagged. base substitutions in the sequenced cDNA reads. These base substitutions support target site identification at nucleotide-level resolution. For example, an incorporation of 4-thiouridine into RNA and subsequent cross-linking yields characteristic T → C base transitions in sequencing reads. RBPs binding sites from our own experiments are all based on the PAR-CLIP method and were processed in the same way (see ‘Materials and Methods’ section for details). Additionally, we collect and integrate target sites from published HITS-CLIP experiments from the + and the − strand of pulled down fragments [4]. The exact mapping of the ChIP fragment ends allows consequently for more accurate delineation of DNA regions that interact with the targeted protein. The other main task in the analysis of ChIP-seq data consists in the separation of ‘true signal’ from spurious background associated with ChIP or additional still uncharacterized experimental artifacts. Various approaches of ‘peak calling’ have been applied to determine loci with a clearly increased coverage of ChIP-seq reads. Some of RNA. We first assessed the presence of a TA dinucleotide around the −30 positions for all CTSSs identified by SLIC-CAGE for both 5 and 10 ng of input RNA. The dominant CTSSs were ordered by IQ-width of their corresponding tag cluster and extended to include 1 kb DNA sequence up- and downstream (Fig. 4E). The TA frequency is depicted in a heat map in Figure 4A for promoters ordered from sharp to broad for 10 ng of RNA and clearly recapitulates the patterns visible in the reference nAnT-iCAGE library (similarity of heat maps is assessed by\n",
            "[0.6972467]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the percentage of responders to tetrabenazine treatment for dystonia in children?\n",
            "Refined Query: What percentage of children with dystonia experience a clinically significant improvement in symptoms following treatment with tetrabenazine?  This should consider various outcome measures and account for the heterogeneity of dystonia presentations in children.\n",
            "\n",
            "Combined Answer: Rothner, MD, The Children's Hospital, The Cleveland Clinic, Cleveland, OH; J.I. Lopez, MD, Renown Neuroscience Institute, University of Nevada, Reno School of Medicine, Reno, Nevada; R. Simmons, MD, Schenectady Neurological Consultants, Schenectady, NY; M. Sowell, MD, University of Louisville Health Sciences Center, Louisville, KY; M. Victorio, MD, Akron Children's Hospital, Akron, OH; P. Winner, MD, Premiere Research Institute, West Palm Beach, FL; M. Yonker, MD, Phoenix Children's Medical Group, Phoenix, AZ. 498 children were treated according to the standard protocol with amoxicillin and 1955 were treated under the alternate protocol without antibiotics. The group of children treated with amoxicillin was slightly older and more stunted at baseline. The recovery rate for children who received amoxicillin was worse at 4 weeks (40% vs. 71%) but similar after up to 12 weeks of therapy (84% vs. 86%), compared to the children treated without antibiotics. Regression modeling indicated that this difference at 4 weeks was most strongly associated with the 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI up to 12 weeks of therapy (84% vs. 86%), compared to the children treated without antibiotics. Regression modeling indicated that this difference at 4 weeks was most strongly associated with the receipt of amoxicillin. MD, Dent Neurological Institute, Amherst, NY; H.R. Murali, MD, Marshfield Clinic, Marshfield, WI; A. Pakalnis, MD, Nationwide Children's Hospital, Columbus, OH; E.M. Pearlman, MD, Children's Hospital at Memorial University Medical Center, Savannah, GA; K.R. Ridel, MD, Josephson Wallack Munshower Neurology Research, Indianapolis, IN; A.D. Rothner, MD, The Children's Hospital, The Cleveland Clinic, Cleveland, OH; J.I. Lopez, MD, Renown Neuroscience Institute, University of Nevada, Reno School of Medicine, Reno, Nevada; R. Simmons, MD, Side effects experienced in at least 10 percent of patients are summarized in Table 3. Patients experienced fatigue, diarrhea or transaminitis at rates comparable to prior studies with pazopanib. Four (13%) of 31 patients discontinued treatment due to grade 3 or greater transaminitis (Table 2). Three (10%) of 31 additional patients discontinued treatment due to general intolerance to pazopanib, with a collection of grade 2 toxicities (Grade 2 back pain; Grade 2 diarrhea and fatigue; grade 2 abdominal pain, diarrhea, and fatigue) that were was similar to those treated with the alternate protocol without an antibiotic (86%). The rates of death and defaulting were similar between the two groups at both time points. Considering only the children who recovered after 4 weeks, the WHZ was significantly higher for children in the alternate protocol group, compared to those in the standard protocol group (−0.37 vs. −0.75, P < 0.0001). This difference was noted despite the fact that the baseline WHZ of these children was similar at enrollment (−1.63 vs. −1.59). To account for the many children suffer with functional morbidities such as visual disturbances, motor disabilities, poor quality of life (QOL) and neuropsychological deficits.(6–9) Classic chemotherapy exposes children to toxicities like myelosuppression, allergic reactions, peripheral neuropathy, constipation, secondary malignancies and infertility.(3) Although effective, radiotherapy increases the risk of secondary malignancy, ototoxicity, endocrinopathies and neurocognitive decline.(10, 11) Radiotherapy is often avoided in young children, especially those micronutrients, or antiparasitic treatments were routinely administered to children in either group. Caretakers were referred to their local health providers if there were any concerns for an acute illness such as malaria or diarrhea. Children returned at one- or two-week intervals for follow-up clinical and anthropometric assessments. Treatment with RUTF continued until the child’s WHZ was at least −2 and no peripheral edema was present. A minimum of 4 weeks of treatment was given; those that had recovered at the 4-week visit were discharged be unrecognized and thus under reported, future prospective studies will be required to evaluate this more completely in the pediatric population. A limitation of the current trial is that QOL and patient reported outcomes (PRO) were not assessed; however, there are some notable differences in the patients’ experience between selumetinib and chemotherapy. Selumetinib requires monthly, shorter clinic visits and is taken orally with no requirement for central line placement as compared to weekly CV, bi-monthly bevacizumab/irinotecan and weekly\n",
            "[0.87950855]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there any relationship between histone ubiquitylation and splicing?\n",
            "Refined Query: Recent research suggests a link between histone ubiquitylation, a post-translational modification affecting chromatin structure, and pre-mRNA splicing.  Does histone ubiquitylation directly or indirectly influence spliceosome assembly, splice site selection, or alternative splicing patterns?  Exploring this relationship could reveal novel mechanisms regulating gene expression.\n",
            "\n",
            "Combined Answer: in splicing, is required for assembly and function of the small interfering RISC, suggesting the role of Drosophila SmD1 in RNAi-mediated gene silencing besides its pre-mRNA splicing activity in posttranscriptional gene regulation.37 Proteins involved in the ribonucleoprotein complex and splicesome are enriched in the ABPP 106 probe specific proteins. Surprisingly, we found that the EIF2 signaling pathway and ribosome are also enriched, suggesting that the compound 106 may affect mRNA translation. There exists ample evidence in the literature in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. These elements are frequently found in genes post-transcriptionally regulated by alternative splicing events of exons with premature stop codons. Accordingly, the extreme genomic conservation has been associated to regulatory splicing events maintaining tightly regulated levels of RNA-binding proteins [4]. On the other hand, intergenic elements are frequently flanked by developmental genes, in particular for genes et al. 2009). In addition, >25% of lncRNA genes show evidence of alternative splicing with at least two different transcript isoforms per gene locus (Fig. 3D). The most highly spliced lncRNA gene is PCBP1-AS1 with 40 annotated isoforms. This human lncRNA gene is situated at a complex locus with major gene structure differences between human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and coding genes and in non-coding regions, including the 2-Mb long gene desert that extends between Ndn and Snrpn. We found pronounced allelic differences in histone modification distribution within the Snurf–Snrpn cluster. H3Ac and H3K4me2 were exclusively detected on the active, paternally contributed Snurf–Snrpn genomic interval. These marks were preferentially enriched in regions containing transcription units, which is reminiscent of the distribution of these histone modifications across the mouse and human genomes (Barski et al. 2007; complete human lncRNA annotation to date, produced by the GENCODE consortium within the framework of the ENCODE project and comprising 9277 manually annotated genes producing 14,880 transcripts. Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths. In contrast to protein-coding genes, however, lncRNAs display a striking bias toward two-exon transcripts, they are predominantly localized in the chromatin and Developmental programs are controlled by transcription factors and chromatin regulators, which maintain specific gene expression programs through epigenetic modification of the genome. These regulatory events at enhancers contribute to the specific gene expression programs that determine cell state and the potential for differentiation into new cell types. Although enhancer elements are known to be associated with certain histone modifications and transcription factors, the relationship of these modifications to gene expression and active paternally contributed chromosome (Fig. 1B,C). We obtained a similar distribution for acetylated histone H4 (H4Ac) (Supplemental Fig. S2). The preferential enrichment of these histone marks on the paternally contributed region is valid at all positions tested, including the IC, which is required for the expression of paternally contributed genes within the Snurf–Snrpn interval. H3K4me2 and H3Ac are, however, more strongly enriched at the level of active transcription units such as Snrpn, Ndn, Mkrn3, and Magel2. The distribution of these We recently mapped the location of nine histone modifications at four different developmental times spanning the MZT using ChIP-seq (Li et al. 2014) and demonstrated that acetylation of three different lysines on two different histones (H3K18, H3K27, and H4K8) correlated with Zld binding, especially early in development (Li et al. 2014). Thus we speculated that Zld-mediated chromatin accessibility might correlate with specific histone modifications. To further investigate the connection between chromatin accessibility and early gene expression, were preferentially enriched in regions containing transcription units, which is reminiscent of the distribution of these histone modifications across the mouse and human genomes (Barski et al. 2007; Mikkelsen et al. 2007). The presence of these “active” histone modifications suggests that the paternally inherited Snurf–Snrpn region has a classical euchromatic structure. Our biochemical analysis, which showed that this region has an open chromatin structure, supports this idea. We then focused our analysis on the mechanisms supporting the\n",
            "[0.35795504]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which disease can be treated with Delamanid?\n",
            "Refined Query: Delamanid is an anti-mycobacterial drug.  What specific disease, caused by *Mycobacterium tuberculosis*, is treatable with Delamanid, and what is its role in the treatment regimen?\n",
            "\n",
            "Combined Answer: care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms that are “an immediate public health threat and that require urgent and aggressive action” (44). There is therefore a pressing need for new treatments against C. difficile, in particular ones that address the high rates of recurrence. The pathogenic nature of C. difficile results from production of two exotoxins, toxin A (TcdA) and toxin B (TcdB), supports the conceptual linking of biomedical knowledge databases and the processing of the related resources. The idea behind the drug-target-disease triangle is based on the tight links that exist between these three entities. Any disease is associated with research on prognosis, diagnosis, symptoms, co-morbidities and incidence/prevalence. Towards investigating these aspects, there is a tight relation between a disease and targets, e.g., with regards to the development of animal models or the research in diagnostics, that can help the radiographs. The mutations are listed in table 1 and shown in figure 3. The conservation of the affected residues and nucleotides is given in the appendix (p 17). In families with TBC1D24 mutations and consanguinity, the mutations were homozygous and TBC1D24 was in a region of homozygosity as identified by SNP array or homozygosity mapping from exome data. The regions of homozygosity are given in the appendix (p 11). Because of the recessive nature of the disease and the presence of mutations predicted to lead to premature protein termination, been treated with bortezomib. Carfilzomib is currently undergoing extensive clinical testing in multiple myeloma, as well as evaluation in mantle cell lymphoma, T-cell lymphoma, large B-cell lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, acute lymphoblastic leukemia, small cell lung cancer, renal cell carcinoma, and advanced prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being was 4% (18 partial responses among 470 patients) in the cabozantinib group and less than 1% (1 partial response among 237 patients) in the placebo group (P = 0.009) (Table S4 in the Supplementary Appendix). Disease control (defined as a partial response or stable disease) was achieved in 64% of the patients (300 patients) in the cabozantinib group, as compared with 33% (79 patients) in the placebo group. Subgroup analyses of progression-free survival consistently favored cabozantinib, which showed the clinical activity of cabozantinib across CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one recurrence and may require multiple rounds of treatment that can last several weeks to months, negatively impacting quality of life and costing the health care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms cohort. We saw a wide variety of seizure types in our cohort of individuals with TBC1D24 mutations, including generalised tonic-clonic, complex partial, focal clonic seizures, and infantile spasms. Table 2, Table 3 list the clinical features of individuals with and without TBC1D24 mutations. Figure 2 shows photographs of the face, hands, feet, and radiographs. The mutations are listed in table 1 and shown in figure 3. The conservation of the affected residues and nucleotides is given in the appendix (p 17). In families with TBC1D24 mutations larger retrospective studies on the natural history and/or resection of von Hippel-Lindau related lesions had been published. We concluded that a major unmet need existed for larger prospective therapeutic studies in von Hippel-Lindau disease using systemic therapy to control von HippelLindau disease related lesions. was 28 days, and patients could be treated for up to 26 courses in the absence of unacceptable toxicity or tumor progression. Patients were taken off treatment if they met criteria for progressive disease as describe below or had unacceptable toxicity. Up to 2 dose reductions were allowed, however, re-escalation was not permitted. Dose modifying toxicities included any selumetinib-related adverse event that resulted in a delay of treatment > 7 days, any grade 4 non-hematologic toxicity, grade 3 non-hematologic toxicities and any grade 2 Pazopanib resulted in significant response rates in von HippelLindau disease, with an acceptable side effect profile. Pazopanib should be considered a treatment choice in patients with von Hippel-Lindau disease and growing lesions, or in patients with unresectable lesions where decrease in tumor size is desired.\n",
            "[0.7864148]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What was the aim of the COSS (Carotid Occlusion Surgery Study) clinical trial?\n",
            "Refined Query: The COSS trial's primary aim was to determine if carotid endarterectomy, a surgical procedure to remove plaque from the carotid artery, improved survival rates and reduced the risk of stroke compared to medical management alone in patients with symptomatic carotid stenosis.\n",
            "\n",
            "Combined Answer: analyses or manuscript preparation. CTEP provided input on study design, approved the trial and its amendments, served as the IND sponsor and reviewed the manuscript prior to submission. CTEP was not directly involved in patient enrollment, data collection, analyses or interpretation. AstraZeneca provided selumetinib and financial support for BRAF testing, CPK lab analyses, echocardiograms and ophthalmologic exams. AstraZeneca reviewed the manuscript; however, they did not have a direct role in trial design, patient recruitment, data for BRAF testing, CPK lab analyses, echocardiograms and ophthalmologic exams. AstraZeneca reviewed the manuscript; however, they did not have a direct role in trial design, patient recruitment, data collection, analyses or manuscript preparation. Only JF, AO and SW had access to the raw clinical data, and the corresponding author (JF) had full access to all of the data and the final responsibility to submit for publication. and outcome measures will serve as historical controls. Main outcomes will include back pain severity, leg pain severity, Oswestry Disability Index, health utility on the EuroQol-5 Dimension questionnaire, complications, symptomatic reherniation, and reoperation. Propensity score adjustment using inverse probability of treatment weighting will be used to adjust for differences in baseline patient characteristics between the US trial participants and European historical controls. (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the originally planned 40 patient accrual was reached. Two factors led to this decision. The first was that accrual was slowing considerably, and the trial had been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule for the analysis of differences in proportions,[20] which coincides with the planned primary endpoint analysis of this trial. We will verify the performance of the propensity score model by comparing the distribution of covariates between study groups before and after propensity score adjustment using the absolute average standardized difference (ASD) statistic. The ASD will be calculated as the difference in means or proportions between study groups divided by the pooled standard deviation. A negligible difference between treatment groups trial with the same device in Europe.[14] The design of this study and the conclusions to be drawn will be strengthened by the fact that patient eligibility criteria, surgical technique, device characteristics, and follow-up methodology including imaging and outcome reporting are comparable in the US Barricaid Trial and the EU Barricaid Controls. Further, potential group differences in important patient characteristics will be accounted for using propensity score methods. Thus, this observational study was appropriately designed to control for Two review authors (Xiao Y, Luo M) independently assessed the risk of bias of the included studies using the 'Risk of bias' tool recommended by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The 'Risk of bias' tool consists of six specific parameters: (1) sequence generation, (2) allocation concealment, (3) blinding, (4) incomplete outcome data, (5) selective outcome reporting and (6) other bias. For each entry, the judgment ('low risk' of bias, 'high risk' of bias, or 'unclear risk' of bias) was followed by a on placebo versus 70% of those in each of the treatment groups will achieve the primary endpoint. Clearly, smaller differences are important for the head-to-head comparison and it becomes much more difficult to define a minimum clinically meaningful effect (since one could argue that, assuming equal cost and safety profiles, any difference between two active treatments is clinically meaningful). Based on the review above, there is some preliminary evidence that suggests more than 85% of patients in the topiramate group may achieve the primary follow-up visit (postoperative day 105) divided by the sum of patients who return for the 3-month follow-up visit and all patients with confirmed symptomatic reherniation who fail to return for this visit. The propensity score-adjusted primary endpoint results will be descriptively reported for patients treated with the Barricaid device in each study, with no formal hypothesis testing. The difference in propensity score-adjusted 3-month reherniation risk between the US Barricaid trial participants and the EU Barricaid Controls will be reported outcome will involve a determination of whether a 50% or greater reduction in headache frequency was observed during the last 4 weeks of active treatment as compared with the headache frequency during the 4-week baseline period. The only exception will be that any subjects who must be removed from therapy prior to the completion of the 24-week treatment period will be considered `failures' with respect to the primary endpoint. The primary hypothesis will be assessed using a logistic regression model, adjusted for the two stratification\n",
            "[0.33020934]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the advantages of the top down mass spectrometric analysis of histones?\n",
            "Refined Query: Top-down mass spectrometry offers significant advantages in histone analysis by enabling the direct characterization of intact histone proteins, revealing post-translational modifications (PTMs) and their precise locations within the sequence, unlike bottom-up approaches. This detailed information is crucial for understanding histone function in gene regulation and chromatin structure.\n",
            "\n",
            "Combined Answer: a very high degree of conservation in vertebrates (Fig 5A, green rectangle). This observation hints that a cellular function of LIMT, such as recognition of other molecules, might localize to the transcript's 5′ region. Because LIMT is dynamically expressed in mammary cells, we predicted the presence of histone modifications at the 5′ region. Analyses of histone marks characteristic of transcriptionally active, open chromatin structures, such as H3K4Me3, in the vicinity of the transcription start site of LIMT, were consistent with an active Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and the TSS and found a strong and specific enrichment at the promoter (Fig. 5G). In addition, we observed a parallel enrichment of the core histones H2B and H3 in 101–140 bp subnucleosomal fragments by MPE-ChIP-seq (Fig. 5H). Hence, altogether, the MPE-seq and MPE-ChIP-seq data reveal that there are subnucleosome-sized histone-containing particles in the upstream promoter region of active genes and that the presence of these particles correlates with transcript levels of the corresponding genes. In the context of these data, it is useful to Transposition of native chromatin for multimodal regulatory analysis and personal epigenomics - PMC ChIPnorm: A Statistical Method for Normalizing and Identifying Differential Regions in Histone Modification ChIP-seq Libraries - PMC of histone marks characteristic of transcriptionally active, open chromatin structures, such as H3K4Me3, in the vicinity of the transcription start site of LIMT, were consistent with an active promoter (Fig 5A). To corroborate this observation, we investigated changes in tri‐acetylation of histone 3 (lysine 27; H3K27Ac), a marker of transcriptional activity. This was done by immunoprecipitating H3K27Ac from MCF10A cells, after stimulation with EGF. Profiling immunoprecipitated DNA fragments using deep sequencing detected an overall decrease in Histone H3 trimethylation at lysine 36 is associated with constitutive and facultative heterochromatin - PMC MPE-seq, a new method for the genome-wide analysis of chromatin structure - PMC bp), upstream promoter peaks of histones H2B and H3 were seen with both MPE-ChIP-seq as well as MNase Low-ChIP-seq (Fig. 5 C–F). It is notable that subnucleosomal chromatin particles (e.g., 101–140 bp) yielded a stronger histone ChIP signal in the upstream promoter region than nucleosome-sized chromatin particles. These findings suggest the existence of histone-containing subnucleosomal particles in the upstream promoter region. Heat maps of the ChIP-seq data further revealed that the intensity of the histone ChIP signal at the promoter tandem mass spectrometry (LC-MS/MS) (Fig. 1A). The majority of the polypeptides identified are involved in pathways that regulate chromatin structure and transcription. They fall into the following categories (Fig. 1A): (i) E12/E47 and HEB, known to heterodimerize with TAL1, (ii) LSD1 complex, possessing H3K4 HDM activity, (iii) transcription factors, some of them are known TAL1 binding partners, and (iv) ssDNA binding proteins, known as cofactors for LDB1 (23). We repeated the complex purification in Jurkat cells. Many of the TAL1-associated\n",
            "[0.42637238]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is situs inversus?\n",
            "Refined Query: What is situs inversus, a rare congenital condition affecting the position of internal organs?  Explain its causes, the different types (total vs. partial), and the potential health implications associated with this anatomical reversal.\n",
            "\n",
            "Combined Answer: 2, top). However, Fig. 4 shows that this lesion was not present 1 year later, and dark marrow at that location continued to improve beyond the level seen after 3 years of treatment. An asymptomatic infarction was also detected in the femoral condyle of a 49-year-old male patient, but it is not known if the lesion was present at baseline because earlier images did not include that anatomical site. During the 4-year period, patient self-assessments indicated that mobility was not restricted before or during treatment for any patient, and no The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). With treatment, the highest percentage of dark marrow reductions occurred in zones expected to be most recently infiltrated, the condyles and greater trochanter, whereas relatively few reductions were observed in the early infiltrated intertrochanteric region. Patients with marrow improvement tended to have more extensive marrow involvement, more severe splenomegaly, and lower hemoglobin levels at baseline than patients who did not show improvement (Table 2). Infiltration of vertebral marrow has previously been associated with splenomegaly shortening of tendons while one has required surgical correction of feet deformities. On the last follow-up at the age of 17, 12, and 8 years, all three patients had esotropia, pes cavus, lower limb hyper-reflexia, bilateral plantar flexion response, and wide-based, unsteady gait. Additionally, they had variable degree of kyphoscoliosis. Brain MRI was normal in one patient (B.V-1) at the age of 3 years and abnormal in the other two siblings showing a hypoplastic corpus calosum with absent rostrum and splenium (Figures 3a–c) and several small Three members of a large consanguineous Indian family (figure 1A), affected by axonal neuropathy (table 1) and optic atrophy, were identified at the London Royal Free Hospital. Case 3 was first seen at the age of 35 years and then again at the age of 51 years. She is the first cousin of Cases 1 and 2 and presented as a child with delayed milestones, later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow atrophy resulting in legal blindness already during the first decade of life. In addition, all the patients developed progressive spastic paraparesis with severely limited walking accompanied by gradual foot deformities resulting in pes cavus suggesting underlying peripheral neuropathy. All three patients are already using splints to prevent further shortening of tendons while one has required surgical correction of feet deformities. On the last follow-up at the age of 17, 12, and 8 years, all three patients had esotropia, pes cavus, lower we believe is inappropriate for ICCs which do not fit the important caveat of ‘full penetrance expected at an early age’. We do acknowledge, however, that InterVar was developed for severe congenital and very-early onset developmental disorders with nearly 100% penetrance. in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In brisk. Ankle and plantar reflexes were absent. She had a moderately severe thoracic scoliosis. Sensation was impossible to assess reliably due to cognition but was likely to be abnormal. As a crude estimate of visual acuity, they were able to watch television and recognise faces across the room and she could do needlework. Case 1 noted distal wasting and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular\n",
            "[0.68617624]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can SUMO affect calcium homeostasis?\n",
            "Refined Query: Does the small ubiquitin-like modifier (SUMO) system, through its post-translational modifications, influence intracellular calcium levels, calcium signaling pathways, or the expression/function of proteins involved in calcium homeostasis (e.g., calcium channels, pumps, or binding proteins)?\n",
            "\n",
            "Combined Answer: SR Ca2+ ATPase 2a (SERCA2a) is a critical ATPase responsible for Ca2+ re-uptake during excitation-contraction coupling. Impaired SR Ca2+ uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure (HF)1. Accordingly, restoration of SERCA2a expression by gene transfer has proven to be effective in improving cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most cellular process5. Here, we show that SERCA2a is SUMOylated at lysine 480 and 585 and that this SUMOylation is essential for preserving SERCA2a ATPase activity and stability. The levels of SUMO1 and SUMOylation of SERCA2a itself were greatly reduced in failing hearts. SUMO1 restitution by adeno-associated virus-mediated gene delivery maintained protein accompanied by decreased SERCA2a function. However, knockdown of SERCA2a resulted in severe contractile dysfunction both in vitro and in vivo, which was not rescued by overexpression of SUMO1. Taken together, our data show that SUMOylation is a critical post-translational modification that regulates SERCA2a function and provides a platform for the design of novel therapeutic strategies for HF. in isolated cardiomyocytes augmented contractility and accelerated Ca2+ decay. Transgene-mediated SUMO1 overexpression rescued pressure overload-induced cardiac dysfunction concomitantly with increased SERCA2a function. By contrast, down-regulation of SUMO1 using shRNA accelerated pressure overload-induced deterioration of cardiac function and was accompanied by decreased SERCA2a function. However, knockdown of SERCA2a resulted in severe contractile dysfunction both in vitro and in vivo, which was not rescued by overexpression of SUMO1. Taken and stability. The levels of SUMO1 and SUMOylation of SERCA2a itself were greatly reduced in failing hearts. SUMO1 restitution by adeno-associated virus-mediated gene delivery maintained protein abundance of SERCA2a and significantly improved cardiac function in HF mice. This effect was comparable to SERCA2a gene delivery. Moreover, SUMO1 overexpression in isolated cardiomyocytes augmented contractility and accelerated Ca2+ decay. Transgene-mediated SUMO1 overexpression rescued pressure overload-induced cardiac dysfunction concomitantly with Future studies will be needed to assess this possibility. The beneficial effects of HDAC inhibition in Huntington’s disease have been reviewed.12 In particular, HDAC inhibition can have positive effects in restoring global gene expression profiles,3,13 in ameliorating cytoskeletal defects12 and clearance of mutant Htt protein by the ubiquitin–proteosome system.2 Our current findings of diverse targets of the 2-aminobenzamides suggest that there are other potentially beneficial mechanisms of action, such as increased processing or translation To analyze SUMOylation within cells, Lipofectamine 2000 was used to transfect HEK293 cells with plasmids encoding WT or SERCA2a SUMOylation site mutants, along with flag-tagged SUMO1 and myc-tagged Ubc9. The cells were lysed by sonication in ice-cold lysis buffer [50 mM Tris-Cl pH 8.0, 150 mM NaCl, 0.1% Triton X-100, 10 mM EDTA, complete protease inhibitor (one tablet per 10 ml, Roche), and a protein phosphatase inhibitor cocktail (Sigma)] containing 20 mM N-ethylmaleimide. Lysates were cleared by centrifugation at 30,000 g for 20 min. Cell HNF1A was the most significant motif for the IBM2 data set, and its predicted activity is highly tissue-specific, being almost entirely restricted to liver and kidney (Fig. 2A; Supplemental Figs. 5, 6). The associated transcription factor hepatocyte nuclear factor 1 homeobox A (HNF1A) is relatively well-studied and indeed known to be mainly expressed in liver, kidney, stomach, and intestine (Kuo et al. 1990; Serfas and Tyner 1993), where it is essential for organ function (Pontoglio et al. 1996). Figure 2A also illustrates that the inferred Loss of 53BP1 restores HR in Brca1-mutant cells 9–11, desensitizing them to PARPi. The minimal focus-forming region of 53BP1 (53BP1-FFR) required for localization of 53BP1 to DSBs includes an oligomerization domain, a tandem Tudor domain12, and the ubiquitin-dependent recruitment (UDR) motif13,14. The Tudor domain binds the dimethylated lysine 20 of histone H4 (H4-K20me2)15 while UDR binds the mono-ubiquitylated lysine 15 of histone H2A14. In response to DSBs, ATM phosphorylates 53BP116,17 and also initiates a signaling cascade which leads to effect on translation of frataxin mRNA in addition to its documented effect on transcription of the FXN gene.6 Additionally, HDAC inhibition could have a positive effect on FXN mRNA splicing or stability, and this in turn could also result in the observed increases in frataxin protein on treatment of FRDA cells with 2-aminobenzamide HDAC inhibitors. Future studies will be needed to assess this possibility. The beneficial effects of HDAC inhibition in Huntington’s disease have been reviewed.12 In particular, HDAC inhibition can have positive\n",
            "[0.78330547]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the indication of Daonil (Glibenclamide)?\n",
            "Refined Query: Daonil (glibenclamide) is a medication used to manage what specific type of diabetes, and what are the key factors considered when determining its suitability for a patient?\n",
            "\n",
            "Combined Answer: We studied semiquantitatively three DAPC proteins, each one representative of one subcomplex of the DAPC, in four DMD patients, who received a single intramuscular (i.m.) administration of AVI-4658 at the higher dose of 0.9 mg. From the five patients treated at the higher dose, two with a missing nNOS-binding domain (carrying a deletion of exons 45–50) and two (carrying a deletion of exons 48–50) with an intact nNOS-binding domain in dystrophin, were selected for the study. All four patients demonstrated increased dystrophin expression after a deletion of exons 45–50 and two of 48–50, that the shorter novel dystrophin induced by exon 51 skipping in DMD can restore components of the DAPC as indicated by the increase in ASG and BDG in dystrophin-positive fibers and the genotype-specific relocalization of nNOS to the sarcolemma. These data confirm that restored dystrophin maintains essential domains for its function and further suggest the potential of the PMO AVI-4658 to become a disease modifying drug for DMD. α-sarcoglycan and nNOS expression (this latter protein only in the patient with a deletion 49–50, not in the one with a deletion of exons 45–50), as also found in this study. However, we did not quantify BDG and patients with a deletion 48–50 in the previous study.32 In summary, we prove now in a comprehensive study of four patients, two carrying a deletion of exons 45–50 and two of 48–50, that the shorter novel dystrophin induced by exon 51 skipping in DMD can restore components of the DAPC as indicated by the increase in ASG and BDG in the functionality of internally deleted dystrophins produced by exon skipping is already indicated by BMD patients carrying these in-frame deletions.32,33,38,39,40 The increased expression of DAPC proteins is an indirect sign of the appropriate assembly of the protein complex and suggests that restored dystrophin retains its fundamental functions. These data are also supported by limited data we have obtained in a recent open label, systemic intravenous dose escalation study using the PMO AVI-4658 (0.5, 1.0, 2.0, 4.0, 10, and 20 mg/kg) for This study was supported by the UK Department of Health and by the Medical Research Council to F.M. AVI Biopharma manufactured and supplied AVI-4658 for the study. The authors thank the patients who participated in this study and the charities Muscular Dystrophy Campaign, Action Duchenne, and the Duchenne Family Support Group for participating in the UK MDEX consortium (www.mdex.org.uk) which performed this study. We would like to thank in particular the members of the Scientific Advisory Board (see below) for their constructive criticism. The DAPC including nNOS, but the experiments that could confirm this presumption were outside the scope of the trial. We now report on the increased expression of DAPC proteins (ASG, BDG) and of nNOS in dystrophin-positive fibers in treated muscles of these patients, each of which is a component of a different subcomplex of the DAPC. This is despite the variable levels of dystrophin present in these fibers. AVI-4658 induced exon 51 skipping and increased expression of dystrophin with correct sarcolemmal localization. The two patients at the low dose showed exon skipping but not increased dystrophin expression. Following the 0.9 mg dose, muscle biopsies of cases 3–6, who received the high dose, demonstrated 44–79% of dystrophin-positive muscle fibers, relative to contralateral muscle background,16 and were subsequently analyzed for the restoration of the DAPC. For immunohistochemical detection, unfixed frozen serial transverse sections (7 µm) were the higher dose, the number of dystrophin-positive fibers ranged between 44% and 79% of total fibers, with dystrophin intensity levels on immunostained fibers reaching up to 42% (range 11–42) of the amount in healthy muscle. We reasoned that for the restored dystrophin to be functional, it should stabilize the assembly of proteins of the DAPC including nNOS, but the experiments that could confirm this presumption were outside the scope of the trial. We now report on the increased expression of DAPC proteins (ASG, BDG) and of nNOS in diseases with some metabolic features. We compare metPropagate to currently used metabolomics-based prioritization methods, in addition to a clinical phenotype-driven prioritization algorithm: Exomiser’s phenotype score in the hiPHIVE algorithm13. prescription of a drug combination that is a risky combination according to the Austria Codex, depend on socio-demographic parameters like age, gender and days the patient spent in hospital?”. The tool supports two basic evaluation steps: (i) Selection of a study cohort by specifying socio-demographic parameters and medical conditions. (ii) Execution of predefined statistical procedures using one or two ATC codes and a hospital diagnosis (ICD-10 Code) as input parameter. Three statistical procedures were implemented: Association rule learning,\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the most typical peptide sequence responsible for retrieval of endoplasmic reticulum (ER) lumenal proteins from the Golgi apparatus?\n",
            "Refined Query: Identifying the precise peptide sequence consistently mediating retrieval of ER lumenal proteins from the Golgi is challenging.  This question explores whether a single, dominant sequence exists or if multiple signals act redundantly, influencing ER retrieval efficiency.\n",
            "\n",
            "Combined Answer: HUVEC cells. Still, we found significant variability across the ChIP-seq data sets, and the targets from some ChIP-seq data sets had lower intersection with the other ChIP-seq data sets than ISMARA’s targets (Supplemental Fig. 19). This analysis shows that ISMARA’s genome-wide predictions can reach accuracies comparable to those obtained from a ChIP-seq study. Finally, the third most significant motif is XBP1, which is activated only after 2.5 h. Its predicted targets are highly over-represented for endoplasmic reticulum (ER) genes and genes were reverse labeled (e.g., label swap). The “heavy” and “light” labeled samples were mixed and analyzed by LC–MS/MS. Searching tandem mass spectra through the sequence database identified peptides. Identified peptides were quantified by calculating the ratio of peptide abundances in the differentially labeled samples, and those changes were then extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified KP and GK funded by the Institute of Bioinformatics, Johannes Kepler University Linz Austria. KCB and AB thank the European Research Commission (Starting Grant ERC-2013-StG 336159 MIXTURE) for funding. Conflict of Interest: none declared. and then captured using streptavidin beads. The captured proteins were subjected to extensive washing using harsh denaturing conditions prior to trypsin digestion and labeling of peptides from different samples with “heavy” or “light” isotopomeric dimethyl labels. Two of four experimental replicates were forward labeled, and the other two were reverse labeled (e.g., label swap). The “heavy” and “light” labeled samples were mixed and analyzed by LC–MS/MS. Searching tandem mass spectra through the sequence database identified peptides. dissociation (CID). Parameters for data processing were also followed as described previously [56]. Briefly, raw files containing MS2 data were extracted by Proteome Discoverer (version 1.3; Thermo Scientific) and uploaded to SEQUEST (version 1.20) and searched against a compiled database of the yeast protein sequences from S. cervisiae and S. pombe. Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide Many genes remain experimentally under-investigated not because they are functionally less important but because their discovery came relatively late (Pandey et al., 2014). Our ignorance of aspects of basic biology and disease thus is perpetuated by the serendipitous order by which genes were first characterized. The need to experimentally determine proteins’ normal molecular functions, and their molecular dysfunction in disease, becomes more critical when sequence variants within functionally enigmatic genes are robustly associated with locus (Anguita et al, 2004; Lahlil et al, 2004). The duality of GATA-1 as an activator and repressor has been reinforced by the recent microarray analysis of terminal erythroid differentiation following induction of GATA-1 expression (Welch et al, 2004). Despite all this information, important questions remain as to how can GATA-1 accommodate all these functions and interactions at the same time in erythroid cells? In addressing this, we have undertaken a biotinylation tagging–proteomics approach to characterize GATA-1 complexes from erythroid with cell proliferation functions, which become repressed with erythroid differentiation. Finally, our work demonstrates the utility of biotinylation tagging as an efficient approach for the rapid isolation and identification by mass spectrometry of multiple protein complexes. Resource [56] (UNIPROT) provides the scientific community with a comprehensive, high-quality and freely accessible resource of protein sequence and functional information. Its protein knowledge base consists of two sections: Swiss-Prot, which is manually annotated and reviewed, and contains approximately 500 thousand sequences, and TrEMBL, which is automatically annotated and is not reviewed, and contains approximately 23 million sequences. The primary mission of UNIPROT is to support biological research by maintaining a stable, comprehensive, Peptide sequencing using tandem mass spectrometry (LC-MS/MS)19 confirmed the absence of any residues encoded by exons 1 through 5, consistent with translation initiation within exon 6 (Fig. 1b and Supplementary Table 1). In a complementary approach, we examined DMD translation efficiency, promoter usage, and alternate splicing using muscle RNA isolated from a mild BMD patient with an exon 2 frameshift mutation (c.40_41del [p.Glu14ArgfsX17], referred to as FS) whose western blot also revealed expression of the same smaller molecular weight\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.65ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 881.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 883.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 731.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1184.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 605.19ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1490.19ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 580.09ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1511.12ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 830.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1082.60ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1158.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 855.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 756.04ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 881.48ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the treatment of neuropathic pain in children?\n",
            "Refined Query: What medications and non-pharmacological therapies are most effective for managing neuropathic pain in children, considering age-appropriate administration, potential side effects, and the diverse underlying causes of this pain?\n",
            "\n",
            "Combined Answer: the disease progression before many of the refractory aspects in adults become established(1). Effective early treatment should be expected to change this trajectory of morbidity and costs. Yet, research focused on treatment of pediatric migraine remains severely limited. Clinically, prevention medication is an option when migraine is disabling and/or occurring on a regular basis (e.g., 1×/week or more). The goal of prevention therapy is significant reduction of headache frequency and improvement in headache-related disability. However, no MD, Dent Neurological Institute, Amherst, NY; H.R. Murali, MD, Marshfield Clinic, Marshfield, WI; A. Pakalnis, MD, Nationwide Children's Hospital, Columbus, OH; E.M. Pearlman, MD, Children's Hospital at Memorial University Medical Center, Savannah, GA; K.R. Ridel, MD, Josephson Wallack Munshower Neurology Research, Indianapolis, IN; A.D. Rothner, MD, The Children's Hospital, The Cleveland Clinic, Cleveland, OH; J.I. Lopez, MD, Renown Neuroscience Institute, University of Nevada, Reno School of Medicine, Reno, Nevada; R. Simmons, MD, Rothner, MD, The Children's Hospital, The Cleveland Clinic, Cleveland, OH; J.I. Lopez, MD, Renown Neuroscience Institute, University of Nevada, Reno School of Medicine, Reno, Nevada; R. Simmons, MD, Schenectady Neurological Consultants, Schenectady, NY; M. Sowell, MD, University of Louisville Health Sciences Center, Louisville, KY; M. Victorio, MD, Akron Children's Hospital, Akron, OH; P. Winner, MD, Premiere Research Institute, West Palm Beach, FL; M. Yonker, MD, Phoenix Children's Medical Group, Phoenix, AZ. Children's Hospital Colorado, Aurora, CO; A.A. LeBel, MD, Boston Children's Hospital, Waltham, MA; D. Lebron, MD, Texas Children's Hospital, Houston, TX; S.L. Linder, MD, Dallas Pediatric Neurology Associates, Dallas, TX; K.J. Mack, MD, Mayo Clinic, Rochester, MN; H.G. Markley, MD, New England Regional Headache Center, Worcester, MA; J. W. McVige, MD, Dent Neurological Institute, Amherst, NY; H.R. Murali, MD, Marshfield Clinic, Marshfield, WI; A. Pakalnis, MD, Nationwide Children's Hospital, Columbus, OH; E.M. Pearlman, MD, Children's Hospital This study is an intent-to-treat, 3-arm, randomized, double-blinded, parallel group, placebo-controlled trial in order to simultaneously assess the impact of two medication therapies (AMI and TPM) for migraine prevention in children and adolescents. A total of 675 children and adolescents between 8 and 17 years old, inclusive, with migraine will be recruited from up to 40 sites across the U.S. Subjects will be randomized in a 2:2:1 fashion to receive either AMI (n=270), TPM (n=270), or placebo (n=135). Key endpoints will be headache frequency, and can have an impact on not only the patient, but the entire family as parents and guardians need to cope with the alterations of their lives when their child has a headache. Similarly, the pathophysiology of migraine can be presumed to be similar to adults. In children with the potential of early intervention with effective treatment may impact the disease progression before many of the refractory aspects in adults become established(1). Effective early treatment should be expected to change this trajectory of morbidity and costs. Yet, when they bring their children for headache treatment. The results will yield four possible practice recommendations: (1) topiramate first choice because it is superior to placebo and amitriptyline on primary outcome; (2) amitriptyline first choice because it is superior to placebo and topiramate on primary outcome; (3) both therapies possible first choice because both are superior to placebo but were not different on primary outcome; and (4) neither therapy first choice because neither are superior to placebo. If scenario (3) occurs, and a do not receive any prophylactic therapy despite the suffering and disability caused by this disease. Treatment practices vary widely even amongst headache specialists due to the absence of evidence based treatment results from clinical trials. Placebo-controlled clinical trials of prevention medications for pediatric migraine are necessary to establish solid evidence based early treatments. To address this deficit, the Childhood and Adolescent Migraine Prevention (CHAMP) Study (http://clinicaltrials.gov NCT01581281) was developed by the New York, NY; L.M. Frank, MD, Eastern Virginia Medical School, Norfolk, VA; P.J. Goadsby, MD, University of California-San Francisco Headache Center, San Francisco, CA; H.T. Jacobs, MD, University of Maryland School of Medicine, Baltimore, MD; M.A. Kabbouche, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; S. Kedia, MD, Children's Hospital Colorado, Aurora, CO; A.A. LeBel, MD, Boston Children's Hospital, Waltham, MA; D. Lebron, MD, Texas Children's Hospital, Houston, TX; S.L. Linder, MD, Dallas Pediatric Neurology Research, Pittsburgh, PA; F.R. Berenson MD, Atlanta Headache Specialists, Atlanta, GA; J.L. Bickel, MD, Children's Mercy Hospital, Kansas City, MO; R.J. Bjork, MD, Colorado Springs Neurological Associates, Colorado Springs, CO; H.K. Blume, MD, Seattle Children's Hospital, Seattle, WA; J.M. Cohen, MD, The Headache Institute at Roosevelt Hospital, New York, NY; L.M. Frank, MD, Eastern Virginia Medical School, Norfolk, VA; P.J. Goadsby, MD, University of California-San Francisco Headache Center, San Francisco, CA; H.T. Jacobs, MD, University of\n",
            "[0.6101493]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which phenomenon is known as the \"calcium paradox\" in the isolated perfused heart?\n",
            "Refined Query: In isolated perfused heart preparations, the \"calcium paradox\" describes the phenomenon of irreversible myocardial cell damage occurring when the heart is initially perfused with a calcium-free solution, followed by reperfusion with a normal calcium-containing solution.  What specific mechanisms underlie this detrimental effect?\n",
            "\n",
            "Combined Answer: 0.5 mg) and were transient and asymptomatic. Cardiac adverse events of special interest were infrequent and of comparable incidence between the study groups. These included short runs of nonsustained ventricular tachycardia (3 placebo subjects, 2 ozanimod subjects), transient and self‐limiting first‐degree AV block (1 ozanimod subject), and transient and self‐limiting second‐degree AV block, Mobitz type 1 (1 subject in each group). None of these cardiac events was temporally associated with the administration of moxifloxacin. Other a six month treatment period, due to the modest but persistent decrement in quality of life they experienced. Patient 1 on the swimmer’s plot is a case in point. Despite showing a CR in a renal cell carcinoma, the patient experienced grade 1 and 2 side effects from pazopanib they did not want to deal with on an ongoing basis. The patient discontinued therapy at the predetermined six-month mark and was observed. They experienced slow regrowth of a renal mass, and underwent a partial nephrectomy three years later. This patient is a good example This was a negative thorough QT/QTc study, demonstrating that ozanimod treatment, in doses of up to 2 mg/day, did not have a clinically relevant effect on cardiac repolarization. The upper bound of the 2‐sided 90%CI (or 95% 1‐sided confidence limit) of the ΔΔQTcF was below the 10‐millisecond regulatory threshold at all time points for the therapeutic and supratherapeutic doses of ozanimod. These results were confirmed by demonstrating assay sensitivity with the use of moxifloxacin as a positive control. Consistent with the lack of QTc effect, in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor desensitization, internalization, and degradation of the cardiac S1P1R have been proposed to explain the time‐related attenuation of heart‐rate effects.1, 17, 33 In a previous phase 1 single‐ascending‐dose and multiple‐ascending‐dose study with ozanimod, a mild dose‐dependent, first‐dose reduction in HR was observed, which was attenuated with an to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many patients enrolled on the study had the option to revert to observation, and did not have the immediate threat of shortened survival as would be the case in metastatic disease, the incentive to remain on an agent that caused side effects was lower than in other settings. Despite that, a number of patients chose to remain on treatment for prolonged SR Ca2+ ATPase 2a (SERCA2a) is a critical ATPase responsible for Ca2+ re-uptake during excitation-contraction coupling. Impaired SR Ca2+ uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure (HF)1. Accordingly, restoration of SERCA2a expression by gene transfer has proven to be effective in improving cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by stimulating the NO-cyclic guanosine monophosphate vascular relaxation pathway as well as by increasing the production of the calcium ion (Ca2+)i (53). An increase in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved complex (DAPC),3 composed of three subcomplexes: (i) the sarcoglycans (α, β, γ, and δ), (ii) syntrophin, nNOS, and dystrobrevin, and (iii) BDG and α-dystroglycan. The absence of dystrophin and destabilization of the DAPC is thought to render muscle cells susceptible to stretch-induced damage and increased intracellular calcium influx, leading to a series of pathological processes responsible for skeletal and cardiac muscle fiber necrosis,9 inflammation and replacement of muscle with fibro-adipose tissue. Regarding the signaling function, not have been feasible. Some patients also reported general intolerance to pazopanib, and several chose to discontinue study drug after a short treatment interval without attempting dose reduction. The rate of treatment discontinuation was similar to that seen in large phase III studies (21). These toxicity readouts provide a cautionary note and need to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many Hearts was prepared in Tissue-Tek OCT compound (Sakura Finetechnical) and sectioned into 6 μm slices (Microm HM560 Cryo-star, Thermo Scientific). The sections were stained with hematoxylin-eosin.\n",
            "[0.8142698]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there a crystal structure of the full-length of the flaviviridae NS5(Methyltransferase - RNA depended RNA Polymerase) ?\n",
            "Refined Query: Determining the complete crystal structure of the Flaviviridae NS5 protein, encompassing both its methyltransferase and RNA-dependent RNA polymerase domains, remains a significant challenge.  Existing structural data often covers only individual domains.  Are there any published crystal structures revealing the full-length protein's conformation, including the interaction between these two enzymatic domains?\n",
            "\n",
            "Combined Answer: of crystallographic contacts at levels of 67–86%, which are distributed across the entire protein fold (Fig. 6). Taken together, our results underpin that the automated 4D-CHAINS/autoNOE-Rosetta approach yields models that accurately capture the correct global fold as well as atomic features of the native structure. Overall, the convergence of structures obtained using supervised assignments for the three target proteins, RTT, ms6282 and aLP, are better than or comparable to the convergence of structures obtained using 4D-CHAINS automated calculations guided by both supervised or automated 4D-CHAINS assignments, and the resulting structural ensembles are very similar for all targets (Fig. 5; left column). For the largest target, the 27.3 kDa Enzyme I from Thermoanaerobacter tengcongensis, NOE contacts provided sufficient constraints to elucidate the structure of the individual domains, but the overall orientation of the two domains was not converged due to the lack of contacts at their interface (domain A, defined by residues 1–143 and domain B, defined by residues 144–248) DNA local bendability around a small histone octamer core (17, 42). In hepadnaviruses, considering the facts that viral RNA transcription is regulated by many cis and trans elements (6, 7, 13, 23) and that only a few copies of cccDNA minichromosomes, the transcription template, exist in each hepatocyte (41, 44), viral minichromosomes are expected to have a specific structure in terms of nucleosome positioning and other features to fulfill the complexity and efficiency of their functions. Besides the viral sequence that could be one of samples, assigned manually15. In addition, the use of evolutionary information in conjunction with NMR chemical shift data can be used to model protein targets in the 25–40 kDa range16–18. Finally, autoNOE-Rosetta performs automated assignment of long-range NOEs and structure refinement using iterations of parallel RASREC-Rosetta calculations19. In all these methods, the use of advanced conformational sampling methodologies enables protein structure determination using a sparse network of restraints20. However, a significant bottleneck remains all these methods, the use of advanced conformational sampling methodologies enables protein structure determination using a sparse network of restraints20. However, a significant bottleneck remains in establishing correct sidechain assignments at sufficient completeness levels to drive the automated assignment of long-range NOEs20. Moreover, the use of methyl-labeled samples requires extensive deuteration, which can be challenging for several biologically important systems21. Here we combine the powerful autoNOE-Rosetta approach with a new comparisons involve quantifying the levels of variation for each residue within and between defined groups so that the level of intragroup variation can be compared with the intergroup variation. Finally, the models in the crystallographic ensemble consisting of 51 aLP structures, used for Ensemblator analysis, were obtained from the CoDNaS28 database by searching for α-lytic protease and utilizing all the available X-ray structures. to have a specific structure in terms of nucleosome positioning and other features to fulfill the complexity and efficiency of their functions. Besides the viral sequence that could be one of determinants of nucleosome binding through nucleosome sequence preferences as described in other species, part of the uniqueness of the cccDNA minichromosome structure might be derived from the asymmetrical nature of the precursor of cccDNA, RC DNA. The asymmetries of RC DNA include a short RNA oligomer at the 5′ end of the plus-stranded DNA, a redundant table, we generate a TALOS52 file and perform empirical prediction of backbone torsion angles using TALOS-N53 for a given protein sequence. Based on the predicted chemical shift order parameter, we retain only the rigid regions of the structure. (2) Fragment selection54 from high-resolution structures in the PDB23. We use the TALOS-N φ, ψ and secondary structure-type predictions to bias the selection of 3- and 9-residue backbone fragments, excluding fragments derived from homologs to the target sequence present in the database. (3) Automated DNA shape analysis has been established in recent years as an approach that reveals determinants of protein-DNA binding specificity beyond the primary nucleotide sequence (1–4). Interactions between nucleotides within a binding site or its flanks are implicitly contained in the 3D structure of a DNA binding site. DNA shape is influenced by the core motif (5) and its flanking sequences (6) and therefore potentially characterizes binding sites with higher precision. In addition to taking into account interrelationships between nucleotide protists and bacteria (Table 1). We demonstrate the value of analyzing DNA shape annotations using GBshape by comparing the structural features of in vivo nucleosome binding sites from worm, fly and human (20) and the evolutionary conservation of DNA shape at transcription start sites (TSSs) across multiple Drosophila species (21). The GBshape database completes the family of DNA shape tools that includes DNAshape, a web server for high-throughput prediction of DNA shape features for up to 1 million base pairs (14), TFBSshape, a database of\n",
            "[0.6410244]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How do Hsp70 and Hsp110 affect mRNA stability?\n",
            "Refined Query: Investigate the mechanisms by which the molecular chaperones Hsp70 and Hsp110 influence the lifespan and translational efficiency of mRNA molecules.  Consider their roles in mRNA processing, degradation pathways, and interactions with RNA-binding proteins.\n",
            "\n",
            "Combined Answer: neurodegenerative disease.38 The ribosome binding and translation initiation as well as translation elongation and termination strongly influence mRNA stability in bacteria.39 In eukaryotes, translation is also linked to mRNA stability, suggesting a general model for cotranslational mRNA decay.40−42 It is possible that compound 106 could have a positive effect on translation of frataxin mRNA in addition to its documented effect on transcription of the FXN gene.6 Additionally, HDAC inhibition could have a positive effect on FXN mRNA splicing or acids (pta1-Δ75) causes thermosensitive growth, while the deletion of an additional 25 amino acids is lethal. The pta1-Δ75 mutant is defective for snoRNA termination, RNA polymerase II C-terminal domain Ser5-P dephosphorylation, and gene looping but is fully functional for mRNA 3′-end processing. Furthermore, different regions of Pta1 interact with the CPF subunits Ssu72, Pti1, and Ysh1, supporting the idea that Pta1 acts as a scaffold to organize CPF. The first 300 amino acids of Pta1 are sufficient for interactions with Ssu72, which is and DNA. Histone H3.1 differs from H3.2 by a single amino acid (Ser96 in H3.2), and H3.3 is distinguished by an additional four amino acid substitutions (Ser31, Ala87, Ile89, Gly90) (Franklin and Zweidler 1977) (Fig. 1a). These clustered amino acids that differ between H3.1 and H3.3 have been linked to the differential binding of chaperones (Tagami et al. 2004; Drane et al. 2010; Lewis et al. 2010; Wong et al. 2010), with specifically G90 of H3.3 promoting binding to DAXX (death-domain associated protein) (Elsasser et al. 2012). The DNA (Fig. 3A). However, this deletion caused a gene-specific defect in snoRNA termination (Fig. 3D), accumulation of the CTD Ser5-P form of RNAP II (Fig. 3C), and a defect in gene looping (Fig. 3E). These results suggest that a strong Pta1-Ssu72 interaction is required for these transcription-related activities. By examining the activity of the first 300 amino acids of Pta1 and Pta1 lacking this Ssu72 interaction domain, we were able to clarify the role of Pta1 and Ssu72 in mRNA 3′-end processing. Surprisingly, extracts from cells expressing only of ChAs in the two subnetworks include many promoter-specific histone modifications and chromatin factors, specifically H3K4me3 (typically denoting active promoters), HCFC1 (transcription activator complex), SIN3A (transcriptional repressor complex), KDM2A (H3K26 demethylase), NMYC, OGT (histone acetyl transferase complex), H3K4me2, and H3K9ac (denoting active promoters) [38]. Features that have slightly higher or equal ChAs in the P–O interactions include CBX3 (the HPγ implicated in elongation [44, 45]) and RNAPII-S2P. PCHi-C can only detect acids 1 to 75 of Pta1, this interaction can be weakened without affecting Ssu72 levels (Fig. 3C and 4A). Ssu72 is a CTD Ser-5 phosphatase, but this activity is not needed for Ssu72's function in pre-mRNA cleavage (25). The deletion of the first 75 amino acids of Pta1 also impaired growth at 39°C (Fig. 2D) but had no effect on mRNA 3′-end processing (Fig. 3A). However, this deletion caused a gene-specific defect in snoRNA termination (Fig. 3D), accumulation of the CTD Ser5-P form of RNAP II (Fig. 3C), and a defect in gene looping (Fig. 3E). This is an important feature as such small IRESs can be used in dicistronic vectors, where space is limited when packaged into viral vectors such as AAV. Although the precise molecular mechanism by which cellular IRESs modulate translation has not been defined in the literature, the requirement of ITAFs has been strongly suggested39. These cellular proteins act in trans to augment IRES activity. Almost all ITAFs have been shown to harbor RNA binding domains and have been hypothesized to act as RNA chaperones, helping the IRES primary sequence target RNAs. For example, Abdelmohsen et al. determined that lncRNA 7SL reduces p53 protein translation levels by binding TP53 mRNA (Abdelmohsen et al., 2014). Gong and Maquat also discovered that lncRNA 1/2-sbsRNAs inhibit the translation of the interaction target RNA through a Staufen1-mediated mRNA decay process (Gong and Maquat, 2011). These examples show that the identification of lncRNA–RNA interactions is an important step in characterizing lncRNA functions. Several sequencing-based technologies have been developed for the experimental proteins act in trans to augment IRES activity. Almost all ITAFs have been shown to harbor RNA binding domains and have been hypothesized to act as RNA chaperones, helping the IRES primary sequence attain appropriate conformational state intrinsic to its activity40. This is likely relevant to the loss of dystrophin IRES activity in the presence of an exon 2 duplication, which may ablate IRES function by formation of a complex secondary structure or cause the formation of an inhibitory uORF that interferes with ITAF access to the exon 5 IRES. it could also reflect a higher rate of degradation (i.e., reduced stability) of lncRNAs compared with protein-coding genes. Because lncRNAs lack ORFs, and therefore have premature stop codons, degradation could occur through mechanisms such as translation-linked nonsense mediated decay (NMD) pathway, or translation-independent degradation pathways. On the other hand, the striking preponderance of single intron transcripts could also be a mechanism to escape NMD-like pathways. In any case, there is still a population of lncRNAs that are\n",
            "[0.7628093]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is Prudent Diet?\n",
            "Refined Query: What constitutes a prudent diet?  This encompasses more than just weight loss; it involves a balanced intake of nutrients for optimal health, considering factors like individual needs, cultural preferences, and sustainability.  It's about making informed food choices to promote well-being.\n",
            "\n",
            "Combined Answer: thereby including less severe cases in this group. Since the two feeding programs operated independently, other unquantifiable variances in the teaching and nutritional counseling provided by the programs’ staff may also have developed over time and contributed to the differences seen in the outcomes between the two groups. Most of severely malnourished children in this study had kwashiorkor, and most were with mild edema, so the findings should not be generalized to populations where the predominant form of severe malnutrition is marasmus. In using natural log‐transformed data. The difference in least‐squares geometric means and the 90% confidence intervals (CIs) of the difference were back‐transformed to provide the treatment mean ratios (test:reference) for each primary PK parameter. The test formulations were high‐fat meal (treatment B) and low‐fat meal (treatment C), and the reference formulation was the fasted state (treatment A). The absence of a food effect was to be declared if the 90%CI for the ratio of the population geometric means between the fed and fasted states was All children aged 6–59 months with uncomplicated SAM who qualified for outpatient treatment (WHO 2007; Manary et al. 2008) and who presented to one of the malnutrition treatment clinics administered by the two organizations in Malawi’s Dowa, Chiradzulu, and Machinga districts between 2003 and 2005 were included in this study. These children were from rural, subsistence farming villages that consume monotonous maize-based diets. SAM was defined according to standard WHO guidelines consisting of weight-for-height Z-score (WHZ) ≤ −3 and/or the and generalizability. These exclusion criteria can be broadly grouped into: There are also several practical components that would lead to exclusion including the inability to swallow pills or the impression that the subject would likely be noncompliant with the study protocol. Although these exclusion criteria have some potential to lessen the “real world” applicability of the study, the practicality of including highly motivated subjects that are without complications, while still being representative of the vast majority of families that syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic features or other developmental abnormalities. Gaining insight into genetic causes through the study of obesity-related disorders has provided a more comprehensive picture of the mechanisms that control food intake and energy balance related to the development of obesity (e.g., SIM1). Deletions in chromosome 1p21.3 have been reported in a total of all PK parameters for ozanimod, RP101988, and RP101075 were similar under the 3 meal conditions. The 90% confidence intervals (CIs) for the ratios of geometric least‐squares mean (fed/fasted) were within the equivalence limits of 0.80 to 1.25 for area under the concentration–time curve from time 0 to infinity (AUC0–∞) and maximum plasma concentration (Cmax) for ozanimod, RP101988, and RP101075, except for the high‐fat effect on RP101075 Cmax (90%CI, 0.76–0.88). Given this lack of a food effect on the exposure of ozanimod and its active of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes of obesity and indicate targets for therapeutic intervention. These disorders include obesity syndromes such as Prader Willi syndrome and Bardet–Biedl syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic from rural, subsistence farming villages that consume monotonous maize-based diets. SAM was defined according to standard WHO guidelines consisting of weight-for-height Z-score (WHZ) ≤ −3 and/or the presence of bilateral pitting edema (WHO 1999). Children were only enrolled if they demonstrated a good appetite by direct observation of a test dose of approximately 30 g of RUTF by the clinical staff. Children who presented with poor appetite, altered mental status, compromised perfusion, or respiratory distress were excluded from home-based formulation was the fasted state (treatment A). The absence of a food effect was to be declared if the 90%CI for the ratio of the population geometric means between the fed and fasted states was contained within the default limits of 0.8 to 1.25 for both AUC0–∞ and Cmax. All statistical tabulations and analyses were performed using SAS, version 9.3 (SAS Institute, Cary, North Carolina). effect is considered demonstrable if the 90%CI for the ratio of population geometric means between fed and fasted treatment for Cmax and AUC does not meet the 80% to 125% bioequivalence criterion.13 Although an absence of the low‐fat food effect on the minor active metabolite RP101075 was established, it was not demonstrated for the high‐fat food effect because the lower bound of the 90%CI for the ratio of geometric least‐squares means was outside the no‐effect boundary of 0.80 to 1.25 for the RP101075 Cmax. However, this minor change is not\n",
            "[0.4834119]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of necroptosis in cancer therapy?\n",
            "Refined Query: Necroptosis, a programmed form of necrosis, is gaining attention in cancer therapy.  How does its regulated cell death mechanism contribute to, or hinder, anti-cancer treatment efficacy?  Are there specific cancers where targeting necroptosis shows promise, and what are the challenges in developing necroptosis-based therapies?\n",
            "\n",
            "Combined Answer: We have demonstrated that TGF-β1 reduces Necl-2 mRNA and protein levels at both transcriptional and post-translational levels. Using inhibitor and clathrin shRNA, we have revealed that TGF-β1 induces Necl-2 protein degradation via clathrin-dependent endocytosis. Endocytosis assays further confirmed that TGF-β1 accelerates the internalization of Necl-2 protein to cytosol. Immunofluorescence staining also revealed that TGF-β1 effectively removes Necl-2 from cell-cell interface. In addition, TGF-β1 reduces Necl-2 mRNA via down-regulating Necl-2 In addition, endocytosis assays further confirmed that TGF-β1 accelerates the kinetic of Necl-2 internalization and thus leads to Necl-2 degradation. Furthermore, immunofluorescence staining clearly revealed that Necl-2 was significantly declined from cell-cell interface upon TGF-β1 treatment, whereas Necl-2 remained at the cell-cell interface in the cells transfected with clathrin shRNA construct. These data suggest that TGF-β1 might perturb cell-cell interaction via internalizing Necl-2 from cell surface via endocytosis. Although this study levels were reduced by 35% and 60% respectively after 24 h TGF-β1 treatment. The reduction of Necl-2 protein levels was further confirmed by immunofluorescence staining on TGF-β1-treated cells. It is apparent that Necl-2 is localized at the cell-cell interface (Fig. 1D, upper panel). Upon TGF-β1 treatment, no fluorescence signal could be detected (Fig. 1D, lower panel), indicating that Necl-2 protein no longer exists at the cell-cell interface. These results clearly suggested that TGF-β1 is a potent negative regulator of Necl-2 expression. the internalization of Necl-2 as the level of biotinylated Necl-2 protein in cytosol was significantly increased upon TGF-β1 stimulation when compared to the corresponding control at 15 min and 30 min (Fig. 3C). At 60 min after exposure to TGF-β1, the level of cytosolic biotinylated Necl-2 protein declined accordingly, suggesting that TGF-β1 accelerates the endocytosis of Necl-2, followed by the degradation of endocytosed Necl-2 protein. Taken together, inhibitor treatment, shRNA approach and endocytosis assays have unequivocally demonstrated the endocytosis of Necl-2, followed by the degradation of endocytosed Necl-2 protein. Taken together, inhibitor treatment, shRNA approach and endocytosis assays have unequivocally demonstrated that TGF-β1 induces Necl-2 protein degradation via clathrin-dependent endocytosis. shown that Necl-2 remained at the cell-cell interface in TGF-β1-treated cells that were transfected with clathrin shRNA constructs, but not ctrl shRNA or sh-vector alone (Fig. 3B). To monitor the internalization process of Necl-2 protein upon TGF-β1 treatment, endocytosis assays were also performed. It is apparent that TGF-β1 significantly induced the internalization of Necl-2 as the level of biotinylated Necl-2 protein in cytosol was significantly increased upon TGF-β1 stimulation when compared to the corresponding control at 15 min and 30 TGF-β1 treatment. RT-PCR and real-time PCR analyses have shown that TGF-β1 caused no significant change on Necl-2 mRNA level in the presence of actinomycin D when compared to vehicle control (Fig. 4A and Fig. 4B). These results suggest that TGF-β1 down-regulates Necl-2 mRNA level is not mediated via altering the stability of Necl-2 transcript. To check whether TGF-β1 reduces Necl-2 mRNA level via gene transcription, a series of luciferase constructs having Necl-2 promoter region in different length were generated. Cells were transfected with the degradation of Necl-2 protein appeared on germ cells via clathrin-mediated endocytosis. Both inhibitor (CPZ) treatment (partially rebound in 1-hr CPZ incubation and completely rebound in 1.5-hr CPZ incubation) and shRNA knockdown studies have unequivocally demonstrated the involvement of clathrin in TGF-β1-mediated Necl-2 protein degradation. In addition, endocytosis assays further confirmed that TGF-β1 accelerates the kinetic of Necl-2 internalization and thus leads to Necl-2 degradation. Furthermore, immunofluorescence staining clearly protein to cytosol. Immunofluorescence staining also revealed that TGF-β1 effectively removes Necl-2 from cell-cell interface. In addition, TGF-β1 reduces Necl-2 mRNA via down-regulating Necl-2 promoter activity. Mutational studies coupled with knockdown experiments have shown that TGF-β1-induced Necl-2 repression requires activation of Smad proteins. EMSA and ChIP assays further confirmed that TGF-β1 promotes the binding of Smad proteins onto MyoD and CCAATa motifs in vitro and in vivo. Taken together, TGF-β1 is a potent cytokine that via its involvement in proper looping of Necl-2 promoter region. In short, there is a functional cooperation between MyoD and CCAATa motifs in initiating TGF-β1-mediated Necl-2 gene repression. Apart from TGF-β1-mediated Necl-2 gene repression, we also found that TGF-β1 reduces Necl-2 protein level via post-translational regulation. TGF-β1 promotes the degradation of Necl-2 protein appeared on germ cells via clathrin-mediated endocytosis. Both inhibitor (CPZ) treatment (partially rebound in 1-hr CPZ incubation and completely rebound in 1.5-hr\n",
            "[0.6028124]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can venlafaxine block NET and SERT?\n",
            "Refined Query: Venlafaxine's mechanism of action involves serotonin and norepinephrine reuptake inhibition.  The question asks to what extent, if any, venlafaxine blocks the norepinephrine transporter (NET) and the serotonin transporter (SERT),  considering its potency and selectivity for each transporter.\n",
            "\n",
            "Combined Answer: which essentially results in blockade of D3 receptors (Freedman et al., 1994; Sautel et al., 1995; Kiss et al., 2010). In contrast, most other atypical antipsychotics have relatively lower affinities for the D3 receptor and in the presence of normal brain levels of dopamine are unable to block these receptors (Stahl, 2016). Furthermore, since D3 receptors are thought to be involved in the regulation of mood, cognition, and motivation (Gross and Drescher, 2012), compounds like cariprazine that exhibit high affinity and occupancy of these TTR null mice have 36% T4 levels in their brain compared to wildtype mice (Palha et al., 1997). This implies that TTR is responsible for the other 64% of T4 moving into the brain. However, Mct8/Oatp1c1 double knock-out mice are cited as having only 10% TH concentration in their brains compared to wildtype mice (Muller and Heuer, 2014). However, careful analysis of the original paper reveals that only the forebrain (and not the entire brain) was analyzed for TH content (Mayerl et al., 2014). Furthermore, if TH transmembrane transporters are these receptors have the highest density in rat and human ventral striatum (Sokoloff et al., 1990; Gurevich and Joyce, 1999), one of the core areas implicated in the pathology of schizophrenia as well as depression and anxiety. The potential involvement of dopamine D3 receptors in the effects of antidepressants was suggested by several preclinical studies demonstrating that administration of antidepressant drugs enhances D3 receptor gene expression and/or binding in distinct brain regions (Maj et al., 1998; Lammers et al., 2000). Cariprazine, therapy to enhance antidepressant efficacy, especially since augmentation with atypical agents improves pharmacological and side effect profiles (Nelson and Papakostas, 2009). Although central nervous system mechanisms underlying antidepressant actions of atypical antipsychotics are still unclear, it has been proposed that a compound that exhibits high affinity and occupancy of both D2 and D3 dopamine receptors may be effective as a treatment for depressive disorders as well as the negative symptoms of schizophrenia. A dopamine D3 receptor resulting in additive/antagonistic effects, which agree with our predictions of synergy values of -19.75 and -23.42, respectively. Furthermore, two other experimental studies focused on Irinotecan of which SN-38 is the active metabolite. In a combination with 5-FU on HT-29 an additive effect was observed (Guichard et al., 1997), which agrees with our prediction of −0.57 for 5-FU and SN-38 on HT-29. Furthermore, they investigated the combination Irinotecan with Oxaliplatin on HT-29, HCT-116 and SW-620 (Guichard et al., 2001). The highest anhedonic-like behavior (Papp et al., 2014); however neural mechanisms underlying these effects are still unclear. In the current study, cariprazine significantly attenuated CUS-induced sucrose consumption in a novel environment in wild-type mice, demonstrating antidepressant-like activity that was comparable with the tricyclic antidepressant imipramine. Interestingly, the same antianhedonic-like actions of cariprazine were not observed in D3-KO mice, indicating that dopamine D3 receptors are required to mediate the antidepressant-like effects combinations of TH transmembrane transporters in the choroid plexus and at the blood-brain barrier, thereby partially compensating for the lack of choroid plexus-derived TTR in mice (but equivalent mechanisms lacking in humans). For example, Lat2 is synthesized in the choroid plexus of mice but not in the choroid plexus of humans (Wirth et al., 2009) or chickens (Darras et al., 2015). This may be an explanation for the mild phenotype of TTR null mice, yet the apparent absence of humans lacking TTR. For a more detailed discussion on the role of compared with wildtype mice? How do these data from TH transmembrane transporter and TTR null mice correlate with the data from Chanoine et al. (1992)? The quantitative contributions of the various mechanisms for TH moving across the blood-CSF barrier (the choroid plexus) and across the blood-brain barrier need to be investigated in greater detail. In a mouse model of depression, cariprazine produces antidepressant-like activity through action on dopamine D3 receptors. Indeed, cariprazine reversed anhedonia-like and anxiety-like deficits in this chronic stress model. These results suggest that cariprazine has a unique and distinct dopamine D3 receptor-dependent mechanism of action that may be beneficial in the treatment of schizophrenia, bipolar disorder, and major depressive disorder. affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave\n",
            "[0.7202625]\n",
            "### Expanded entities and terms:\n",
            "Arthritis - {'Anti-Inflammatory Drugs': 0.0, 'Joint Swelling': 1.0}\n",
            "\n",
            " ### Clustered: {'Arthritis': {'Cluster 1': ['Anti-Inflammatory Drugs'], 'Cluster 2': ['Joint Swelling']}}\n",
            "Original Query: Is Rheumatoid Arthritis more common in men or women?\n",
            "Refined Query: Given the context of anti-inflammatory drugs and joint swelling,  the question regarding the prevalence of rheumatoid arthritis needs clarification.  Specifically, is rheumatoid arthritis more prevalent in men or women, and does this prevalence differ based on the severity of joint swelling or response to anti-inflammatory treatment?\n",
            "\n",
            "Combined Answer: and Figure 3). Improvement in arthritis was also greater in patients receiving anifrolumab (Figure 3 and Supplementary Figure 4). In patients with ≥8 swollen and ≥8 tender joints at baseline, a ≥50% decrease in both the swollen and tender joint count was achieved in a greater percentage of anifrolumab‐treated patients than placebo‐treated patients (48.6% for placebo, 69.6% for anifrolumab 300 mg [P = 0.038], and 64.6% for anifrolumab 1,000 mg [P = 0.156]). Compared with placebo, greater proportions of patients in the anifrolumab 300‐mg group across a range of organ‐specific disease measures and patient‐reported outcomes. The percentage of patients with a baseline CLASI activity score of ≥10 who had a ≥50% reduction in this score by week 52 was greater for both anifrolumab dosages (63.0% for 300 mg [P = 0.013] and 58.3% for 1,000 mg [P = 0.077]) compared with placebo (30.8%) (Table 2 and Figure 3). Improvement in arthritis was also greater in patients receiving anifrolumab (Figure 3 and Supplementary Figure 4). In patients with ≥8 swollen and ≥8 tender joints at baseline, a ≥50% dosages were associated with higher rates of response in the BICLA compared with placebo (Table 2, Figure 2, and Supplementary Figure 3, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39962/abstract). The differentiation between placebo and anifrolumab occurred within 6 months and was maintained or increased through week 52 (Figure 2). Improvements in physician's global assessment at week 52 were also greater for the anifrolumab‐treated groups than for the placebo‐treated group (Table 2), in the overall population were driven by the IFN‐high subset (Table 2 and Figure 2). The study also assessed various measures of low disease activity. A SLEDAI‐2K score of ≤2 at week 52 was achieved in 17.6% in the placebo group, 35.4% in the anifrolumab 300‐mg group (P = 0.004 versus placebo), and 32.7% in the anifrolumab 1,000‐mg group (P = 0.012 versus placebo) (see Supplementary Figure 4, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39962/abstract), and a score of 0 was achieved in at baseline. Other efficacy measures included percentages of patients with ≥50% improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 27, 28 for patients with at least moderate skin involvement (CLASI ≥10); ≥50% improvement in swollen and tender joint count (28 joints assessed) for patients with ≥8 swollen and ≥8 tender joints at baseline; response in BILAG‐based Composite Lupus Assessment (BICLA) 29; modified SRIs requiring SLEDAI‐2K reductions of 5–8 points to be considered a responder; physician's global groups had greater response rates compared with placebo (17.6%). A response was achieved in 34.3% of the patients treated with anifrolumab 300 mg (P = 0.014 versus placebo) and in 28.8% of the patients treated with anifrolumab 1,000 mg (P = 0.063 versus placebo). The response rates in the IFN‐high subpopulation were 13.2% for the placebo group, 36.0% for the anifrolumab 300‐mg group (P = 0.004 versus placebo), and 28.2% for the anifrolumab 1,000‐mg group (P = 0.029 versus placebo) (see Supplementary Figure 2, available on the Arthritis & versus placebo) (see Supplementary Figure 4, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39962/abstract), and a score of 0 was achieved in 7.8% in the placebo group, 18.2% in the anifrolumab 300‐mg group (P = 0.033 versus placebo), and 19.2% in the anifrolumab 1,000‐mg group (P = 0.018 versus placebo). Major clinical response, defined as a BILAG 2004 score of C or better in all organ domains at week 24 with maintenance of this response through week 52, was achieved in 6.9%, 19.2% (P = Knee osteoarthritis (KOA) is one of the most common degenerative disease that causes disability in elderly people.[1–3] An epidemiological study showed that about 30% of all adults have radiological signs of osteoarthritis (OA), 8.9% of the adults population has clinical significant OA of the knee or hip.[4] And the probability of OA increases with age.[5] For Chinese population, it has the similar trend. A study based on Chinese nationwide population suggested 8.1% total incidence rate of symptomatic KOA and increasing prevalence of KOA with primary end point results, a greater percentage of patients receiving anifrolumab met criteria for SRI(4) response without the oral corticosteroid taper requirement (Table 2 and Figure 1), and the modified SRI responses, requiring 5‐, 6‐, 7‐, or 8‐point reductions in SLEDAI‐2K scores. Both anifrolumab dosages were associated with higher rates of response in the BICLA compared with placebo (Table 2, Figure 2, and Supplementary Figure 3, available on the Arthritis & Rheumatology web site at Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39962/abstract). Patients were randomized 1:1:1 to receive intravenous infusions of placebo, anifrolumab 300 mg, or anifrolumab 1,000 mg. Treatment was administered every 4 weeks with the final dose administered at week 48. The primary and secondary efficacy measures were assessed at week 24 and week 52, respectively. All patients were required to complete a 12‐week follow‐up period after administration of the final dose of the study drug. During the treatment\n",
            "[0.57478005]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is FINDbase?\n",
            "Refined Query: Can you provide a concise paragraph explaining what FINDbase is, including its purpose, functionality, and perhaps a brief mention of who uses it or what it's used for?\n",
            "\n",
            "Combined Answer: 1 miRBase (http://www.mirbase.org/) is a database of miRNA sequences and annotations. 2 Distances along the DNA are measured in base pairs (bp), i.e., number of nucleotides (or bases) present between two points of the DNA. In the TMPDB web page (http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/), the ‘Database Search’ is available with the use of gene name, PubMed (27) identifier (PMID), accession numbers of DDBJ (29), SWISS-PROT (28) and PIR (30), PDB (5) identifier, the number of TMS(s), or any combinations of those, over TMPDB or selected subset among the 6 TMPDB subsets. A returned search result will be displayed as a list of retrieved entry(ies) with a link to the complete database entry(ies). TMPDB will be updated continuously at least once every year to increase the number of entries as well to add other detailed experimental information from the referred articles, such as gene-fusion points, the accessibility for fused proteins, etc. Also, the next release of TMPDB on the web will support the display of the graphical image of TM topology and employ an SQL-based engine for more efficient and rapid database search. (i) as a collection of text files in various formats, (ii) via a web interface and (iii) as a collection of scripts enabling the user to regenerate the database from scratch, possibly with other filtering parameters or from other source files. DENdb allows users to perform multiple explorations of data, which span from simple browsing of the database to more customized queries that may include, for example, search for enhancers based on the simultaneous use of many criteria. DENdb queries can be customized by chromosome, coordinates range, cell-line, enhancer support, as well as the method that has generated the enhancer predictions. DENdb allows user to query enhancers that overlap with some genomic features or has a specific property. For example DENdb allows user to explore like RedoxDB (Sun et al., 2012) and MetOx DB (Jacques et al., 2015), it will help oxidative stress-related research in biology/medicine. The CarbonylDB resource provides a large curated dataset on the carbonylation sites in serum albumin–an important in vitro model protein for the study of oxidative protein damage (Maisonneuve et al., 2009; Ros, 2017). It also provides a much-needed large dataset for better prediction of carbonylation sites, which until now performs rather poorly mainly because of the lack of a good dataset (Weng et al., X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/. for each site it provides residue type/position, 21-mer flanking sequence, experimental information and PubMed reference number. Information on protein name, sequence and list of carbonylated sites with all relevant data, including solvent accessibility, is displayed when any protein ID is clicked. It provides a BLAST search-feature for easy database query using user-specified sequences. The entire resource can be downloaded as a tab delimited flat-file and associated sequences as a Fasta file in the download page. The CarbonylDB also provides The CarbonylDB web-interface (Fig. 1A) provides access to manually-curated experimentally-confirmed carbonylated proteins/sites. The data-resource can be searched using UniProt ID, protein name or other features or can be browsed for carbonylated protein/site. For each protein, it displays relevant information like species, number of sites, etc.; and for each site it provides residue type/position, 21-mer flanking sequence, experimental information and PubMed reference number. Information on protein name, sequence and list of carbonylated sites This section collects any data citations, data availability statements, or supplementary materials included in this article.\n",
            "[0.5811806]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can vitamin B1 deficiency cause encephalopathy?\n",
            "Refined Query: Does a deficiency in vitamin B1 (thiamine) directly lead to the development of Wernicke's encephalopathy,  and what are the specific mechanisms by which thiamine deficiency impacts brain function to cause this neurological condition?\n",
            "\n",
            "Combined Answer: the brain, resulting in the reduction of TH reaching the subventricular zone dur to a shallower TH gradient (Richardson et al., 2007). This study highlighted the importance of TTR in delivering THs to at least one of the two populations of neural stem cells in adult mammalian brain. Until then, all studies involving TTR null mice had been focussed on adult mice. However, it is well known that THs affect growth and development, particularly of the CNS (Morreale de Escobar et al., 1987). In severe cases, TH deficiency in human babies during We found a highly significant enrichment of ultraconserved elements among pathogenic imbalances causing neurodevelopmental disorders. It can be therefore suggested that these elements, or their neighbouring genes, might be considered particularly sensitive to dose imbalances. It might be argued that the positive association between clinically relevant CNVs and UCEs merely reflects that pathogenic alterations preferentially affect gene-rich regions and, as an indirect consequence, they might contain more ultraconserved elements. In accordance, (SRO) has been restricted to two genes: dihydropyrimidine dehydrogenase (DPYD) and microRNA 137 (MIR137). The DPYD encodes for the rate-limiting enzyme in the catabolism of the pyrimidine bases, and mutations in this gene cause DPYD deficiency (OMIM ♯274270), an autosomal recessive disease of variable severity typically characterized by the presence of childhood onset neurological problems, such as developmental delay and convulsions. MIR137 encodes for miR-137, a microRNA (miRNA) molecule involved in the post-transcriptional regulation of In the view of the association between ultraconserved elements and pathogenic dose variants, we therefore propose that these elements may be interpreted as hallmarks for dosage-sensitive genes, particularly for those genes whose gain or loss may be directly implied in neurodevelopmental disorders. Obviously, the presence of this kind of elements in CNVs of unknown consequences should be used with caution together with other pathogenicity criteria, such as the gene content or the mode of inheritance. This is an important issue given the current on adult mice. However, it is well known that THs affect growth and development, particularly of the CNS (Morreale de Escobar et al., 1987). In severe cases, TH deficiency in human babies during gestation results in stunted growth and mental retardation. Therefore, several aspects of growth known to be influenced by TH were examined during post-natal development in TTR null mice. The absence of TTR resulted in delays in several TH-regulated events including bone growth, CNS maturation, intestine and muscle development and in weaning (Monk et Future studies will be needed to assess this possibility. The beneficial effects of HDAC inhibition in Huntington’s disease have been reviewed.12 In particular, HDAC inhibition can have positive effects in restoring global gene expression profiles,3,13 in ameliorating cytoskeletal defects12 and clearance of mutant Htt protein by the ubiquitin–proteosome system.2 Our current findings of diverse targets of the 2-aminobenzamides suggest that there are other potentially beneficial mechanisms of action, such as increased processing or translation two were missense, one was a non-frameshift deletion and one was a nonsense mutation. The latter is a 1 bp deletion in C12orf65 gene, resulting in a premature stop codon (NM_001143905: c.346delG: p.V116X) (figure 1B). As mutations in C12orf65 have been recently described to cause a severe encephalomyopathy17 as well as spastic paraplegia and optic atrophy,18 we assessed segregation of this mutation in the family. The deletion was homozygous in the affected cases, and either absent or heterozygous in the unaffected relatives (figure 3). To gene expression levels of NHE6 are reduced in postmortem cortex as compared to control.6 Despite the clear neurodevelopmental components in CS and the likenesses to related developmental disorders such as autism and AS, there appear to be progressive aspects to the CS phenotype. Based on his observations in the original pedigree, Christianson et al.4 described a potential progressive nature involving loss of cognitive and adaptive skills with aging. Further, there are clear regressions that appear to be associated with the CS. In our study, Another study also found replication defects in rDNA in Pfh1-depleted cells (Steinacher et al. 2012). However, there are differences between the two studies. For example, Steinacher et al. (2012) saw heightened pausing at only one of the four rDNA Ter sites, while our data are best explained by increased pausing at all four Ter sites (Fig. 2C). These and other inconsistencies can be explained by methodological differences, as Steinacher et al. (2012) used the pfh1-mt* allele, which at 30°C provides more Pfh1 function than thiamine-grown in order to help establish initial clinical expectations for families and clinicians. Based on current studies, CS may be among the most common X-linked developmental brain disorders.1 CS has broad implications to common neurologic and behavioral syndromes including epilepsy, intellectual disability, autism, regression and hyperactivity.\n",
            "[0.6768422]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which methyl-CpG-binding protein when mutant becomes the hallmark for Rett syndrome?\n",
            "Refined Query: Rett syndrome is characterized by a mutation in a specific methyl-CpG-binding protein.  Which protein is this, and its mutation serves as the diagnostic hallmark of the disorder?\n",
            "\n",
            "Combined Answer: 10, a member of the Sry family, is mutated in Dom, and its human homologue is disease causing in autosomal dominant Shah‐Waardenburg syndrome. A similar effect will be difficult to test in humans as a SOX10 mutation is rare while the penetrance of HSCR is high in carriers. However, the putative role of the RET gene could be further tested in syndromic HSCR entities frequent enough to allow the collection of large series of patients, namely cartilage‐hair hypoplasia, Bardet‐Biedl syndrome, and Down's syndrome. In relation to the MWS group of Mutations of the RET gene in isolated and syndromic Hirschsprung's disease in human disclose major and modifier alleles at a single locus - PMC between MWS patients with and without HSCR (table 1). In family 1, a heterozygous G to T transversion at nucleotide 299 in exon 2 of the PHOX2B gene and changing an arginine into a leucine in the homeodomain of the protein (R100L) segregated in patients with an autonomic nervous system disorder and the obligate carrier (fig 2). No RET gene mutation could be identified in the two patients with HSCR who inherited the PHOX2B mutation from their mother and the hypomorphic RET allele from their father (fig 2, patients III 4 and III 6). In contrast, c>t transition leading to p.R500X, a protein truncating mutation in the putative eleventh transmembrane domain of the protein. In Family 12, this mutation appears likely de novo in the mother of the affected CS male (i.e. not found in the maternal grandparents). In Family 9, this mutation is inherited. These families do appear to share a haplotype around the mutation locus (Supplementary Table 4), which may be prone for recurrent mutation although further research will be necessary to clarify this. The mutation occurs at a CpG location in the around the mutation locus (Supplementary Table 4), which may be prone for recurrent mutation although further research will be necessary to clarify this. The mutation occurs at a CpG location in the genomic DNA, although not in a known CpG island or methylation hotspot; however, it remains formally possible that this C is methylated and prone to C to T transition by mechanisms involving deamination of a methylated cytosine.26 Family 9 has been reported previously in the literature as a US-based pedigree.15 In our study R500X represents NHE6 protein appears to be expressed in just about every cell and tissue type yet examined.31 Given this result, it is not surprising that somatic medical symptoms appear to represent a part of CS. A particularly notable symptom is gastroesophageal reflux. While GI symptoms are commonly reported in neurodevelopmental disorders such as Rett syndrome32 and 22q11.2 microdeletion syndrome33, the data that two patients in our cohort required surgery to correct extreme GERD raise the possibility that this GI condition may be related to CS. In To determine whether RET could be considered a modifier gene for the enteric phenotype on the background of a monogenic trait. Ret allele is known in mice, and a knock‐in mouse model leading to a +7 alanine expansion of Phox2b is being generated. The role of polymorphisms as modifiers of a disease phenotype is being increasingly recognised. Interestingly, Phox2b has recently been considered a putative modifier gene in Dom mice when considering the megacolon phenotype.30Sox 10, a member of the Sry family, is mutated in Dom, and its human homologue is disease causing in autosomal dominant Shah‐Waardenburg syndrome. A similar effect will be difficult to test in humans as In CCHS patients, the weak predisposing haplotype of the RET gene can be regarded as a quantitative trait, being a risk factor for the HSCR phenotype, while in MWS, for which the HSCR penetrance is high, the role of the RET predisposing haplotype is not significant. It seems likely that there are both RET dependent and RET independent HSCR cases. mutations are either de novo heterozygous deletions encompassing the gene or truncating mutations, both leading to a loss of function.25 A PHOX2B gene mutation appears necessary and sufficient for the CCHS phenotype to occur. Here we show that the RET gene acts as a modifier of the PHOX2B gene. Indeed, the frequency of the ATA haplotype of the RET gene is similar to that observed in the European population (25%)3 in all groups except the Haddad group, where its frequency reaches 38.6% (χ2 = 11.73, p<0.001). However, a strict digenic model does\n",
            "[0.6538496]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are epigenetic modifications implicated in cardiovascular development and disease?\n",
            "Refined Query: Investigate the role of epigenetic mechanisms, such as DNA methylation and histone modification, in the processes of normal cardiovascular development and the pathogenesis of cardiovascular diseases, including congenital heart defects and atherosclerosis.  Are specific epigenetic alterations causally linked to these conditions?\n",
            "\n",
            "Combined Answer: or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and has been observed previously in gene expression profiling studies [4,46]. Remarkably, the majority (>75%) of the hypermethylated genes present in all seven samples encoded for transcription factors, while the shared hypomethylated genes were spread among many different functional categories. Transcription factors play a central role in maintaining or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely Developmental programs are controlled by transcription factors and chromatin regulators, which maintain specific gene expression programs through epigenetic modification of the genome. These regulatory events at enhancers contribute to the specific gene expression programs that determine cell state and the potential for differentiation into new cell types. Although enhancer elements are known to be associated with certain histone modifications and transcription factors, the relationship of these modifications to gene expression and (DNMT1, 3A, 3B, 3L) and histone deacetylases (HDAC1 and HDAC2), to target genes (13–15). In addition, SALL4-mediated activation of Bmi-1, another important hematopoietic stem cell gene, involves methylation of lysine 4 of histone H3 (H3K4) at its promoter region (16). Based on recent discoveries, there seem to be various ways of cross-talking between histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone It appears that SALL4 actively interacts with multiple epigenetic factors during transcriptional regulation, as we have shown earlier that SALL4 associates with a group of DNA methyltransferases during subsequent gene silencing. Competitive or compensative involvement of these epigenetic factors during specific SALL4 regulatory process may occur, because under LSD1 knockdown conditions, we monitored increased gene binding of DNMT1 and DNMT3L at SALL4 target genes. Here, it may be critical to consider that histone modification and DNA any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can change chromatin structure, rendering DNA binding sites accessible or inaccessible to transcription factors leading to activation or silencing of genes important in cell differentiation and maintenance. It has been recently shown that hypermethylated genes found in lung tumors are associated with cellular morphogenetic differentiation [49]. These A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2), and the recently discovered CHROMOMETHYLASE 2 (CMT2) perform methylation in CHH contexts (Haag and Pikaard, 2011; Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry The methylation state of lysine 20 on histone H4 (H4K20) has been linked to chromatin compaction, transcription, DNA repair and DNA replication. Monomethylation of H4K20 (H4K20me1) is mediated by the cell cycle-regulated histone methyltransferase PR-Set7. PR-Set7 depletion in mammalian cells results in defective S phase progression and the accumulation of DNA damage, which has been partially attributed to defects in origin selection and activation. However, these studies were limited to only a handful of mammalian origins, and it remains tissues [7,9]. DNA methylation is a very stable epigenetic mark and next generation sequencing studies have recently shown that many genes are aberrantly methylated in cancer [10,11]. Tissue specific DNA methylation patterns are stabilized during embryonic development, and faithfully maintained through cell divisions [12-14]. Nevertheless, established methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of\n",
            "[0.7771965]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which deiodinases are present in skeletal  muscle?\n",
            "Refined Query: Skeletal muscle metabolism is significantly influenced by thyroid hormone.  To understand this regulation, identifying the specific deiodinases (types I, II, and/or III) present within skeletal muscle tissue is crucial.  Their presence dictates the local conversion of thyroxine (T4) to the active triiodothyronine (T3) and its further metabolism.\n",
            "\n",
            "Combined Answer: studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear transcription factors. T3 can bind TRs either in the cytoplasm and translocate into the nucleus, or bind TRs in the nucleus. T3 binding to TR hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. The structure of transthyretin has been highly conserved, implying strong selection pressure and an important function. In mammals, transthyretin binds T4 (precursor form of thyroid hormone) with higher affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then initiates transcription of genes that are positively regulated by THs. Some genes are negatively regulated by THs, whereby binding of T3 induces the opposite changes and turns off transcription. Thus, it is crucial that the appropriate concentration of THs is present in the critical regions of the brain at each stage of development, to ensure moves T3 into the brain? What could have been the selection pressure for the change to TTR from distributing T3 to distributing T4? One possibility could be a greater level of control, requiring an additional level of regulation (i.e., deiodination of T4 to T3) at the target site. For example, different regions of the brain generate different proportions of T3 by local deiodination (van Doorn et al., 1985). Two features that distinguish mammalian brains from non-mammalian brains that are regulated (at least in part) by thyroid hormones are the 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of T3 by local deiodination (van Doorn et al., 1985). Two features that distinguish mammalian brains from non-mammalian brains that are regulated (at least in part) by thyroid hormones are the corpus callosum which is heavily myelinated, and the highly developed cortex. The point here is that mammals may be the exception rather than the rule, when it comes to modes of TH entry into the CNS, so we should not just consider mammalian data. Furthermore, we have seen examples between eutherian species, of significant differences in TH transmembrane proteins in adult human blood varies greatly: TBG at 0.015 g/l, TTR at 0.25 g/l and albumin at 42 g/l. Traditionally it has been believed that in blood, TBG distributes about 75% of thyroid hormones, TTR distributes 15% and albumin transports about 10%. Because TBG binds about 75%, it is sometimes referred to as the “most important” thyroid hormone distributor. However, this is too simplistic, as the biological importance is related to the delivery of THs to cells, which is dependent on the dissociation rates of T3 and T4 from the distributor\n",
            "[0.63378376]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which genes are involved in patient response to warfarin?\n",
            "Refined Query: Investigating the genetic basis of warfarin responsiveness requires identifying specific genes influencing its metabolism (e.g., *CYP2C9*, *VKORC1*) and resulting in variable anticoagulation effects, impacting both efficacy and risk of bleeding.\n",
            "\n",
            "Combined Answer: Though the steps described above, an LC-MS metabolomics pipeline identified DAMs and a gene-based analysis pipeline identified a set of candidate genes. The primary goal of subsequent analysis was to determine whether metabolomic evidence could be used to prioritize the causative gene from this list of candidate genes. To do this, each gene in a patient’s candidate gene list was ranked using a per-gene metabolomic score termed the “metPropagate score”, which represented the likely metabolic relevance of a particular gene to each patient. such as the induction of procoagulant activity that promotes blood clotting, that may play an important role in the vascular effects of inflammation and the pathogenesis of vascular diseases (170). Innate recognition of LPS occurs through a receptor complex consisting of CD14, TLR-4, and myeloid differentiation factor 2 that recognizes pathogenic structures and subsequently induces an inflammatory response. Continuous activation of the innate immune system through TLRs by bacterial stimuli may disrupt immune homeostasis by the overproduction crucial step in broadening the availability of genetic testing for ICCs, and standardising variant interpretation in this field. Furthermore, we hope that in demonstrating the clinical utility of our disease-specific approach, we will encourage others to develop similar tools across other disease specialties. results. Many recent meta-studies of the efficacy of WES in diagnosing rare genetic diseases have revealed that its yield is usually less than 50%17. As such, for unsolved cases, researchers and clinicians are increasingly turning to WGS to identify candidate causal genes; however, the expansion into the rest of the genome causes a dramatic increase in the number of candidate variants. This is in part due to difficulties interpreting the effect of variants beyond the exome. As such, supplemental information regarding dysregulated candidate were more efficacious than placebo, with the lower dosage showing greater numerical response rates at week 52 for many end points (Table 2). The fact that the degrees of IFN gene signature inhibition were similar with the low and high anifrolumab dosages supports a plateau effect rather than an inverse dosage response. However, other mechanisms, such as an increased response in inducible immunologic feedback leading to a lower rate of response with the greater anifrolumab dosage, cannot be excluded. Biomarker studies to address this question metabolomic experiments due to the large number of annotated metabolites and detailed isotope, adduct and structural information available (Fig. 3a)11. To identify genes that may be causing perturbations in a single patient’s metabolome, metabolites with significantly higher or lower abundance than in controls, hereby referred to as DAMs, were mapped to HMDB genes, and statistical enrichment of DAMs among each group of gene-associated metabolites was assessed using a Fisher’s Exact Test. To generate a score that could be used to rank candidate Inborn errors of metabolism (IEMs) are the largest group of genetic diseases amenable to therapy, and are defined as any condition that leads to a disruption of a metabolic pathway, irrespective of whether it is associated with an abnormal biochemical test1. A growing understanding of metabolic and genetic phenotypes has resulted in the identification of at least 1015 well-characterized IEMs1. Identifying the causal gene has in turn provided insights and opportunities for interventions targeting downstream molecular or cellular of metabolomics data with WES/WGS data can provide direct evidence of a gene’s causality based on its implied metabolic dysfunction. For example, detection of the metabolite N-acetylmannosamine in cerebrospinal fluid can lend support to the identification of NANS as a causal gene4. These biochemical biomarkers can be detected individually (targeted metabolomics), or as part of a broader characterization of the metabolome (untargeted metabolomics). Recently, two separate untargeted metabolomics analysis pipelines were able to measure with non-unified regimens, whereas in this study we used more focused populations in the aspect of disease type and chemotherapy regimen. Additionally, our previous in vitro study showing that dCK performed a critical function in Ara-C resistance, but not in idarubicin resistance, of AML cells bolsters this discrepant observation (Song et al, 2009b). We also attempted to address the regulation mechanisms underlying the differential expression of marker genes between AML patients with good or poor outcomes. DNA methylation is a well-established such as an increased response in inducible immunologic feedback leading to a lower rate of response with the greater anifrolumab dosage, cannot be excluded. Biomarker studies to address this question are currently underway. The fact that greater efficacy was seen in all end points in patients with high baseline IFN gene signatures compared with those with low baseline IFN gene signatures supports the pathobiology of this treatment strategy. The lack of treatment effect in the IFN‐low subgroup was due to a greater response to placebo and\n",
            "[0.6615094]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the molecular weight of the protein angiogenin?\n",
            "Refined Query: Determining the precise molecular weight of angiogenin requires specifying the protein's isoform and considering post-translational modifications.  What is the expected molecular weight based on the amino acid sequence, and how might glycosylation or other modifications alter this calculated value?\n",
            "\n",
            "Combined Answer: amino acid sequence. Taken all the above into account, the weighted probability of assigning an AAIG from chain X to a specific residue in the protein sequence is given by Eq. 4. Since several different chains can be mapped at overlapping positions in the protein sequence, multiple AAIGs may correspond to each protein residue. For each position in the protein sequence, a confidence score (Cs) is computed for every AAIG corresponding to the given position by summing over all the chains as indicated in Eq. 5. In order to identify the correct that it is the free hormone in blood (not the protein-bound hormone) that is important for biological activity (Mendel, 1989). Thus, THs must dissociate from the distributor proteins before they can exert their effects. In human blood 99.97% of T4 and 99.70% of T3 is bound to the TH distributor proteins (Mendel, 1989). Of these, TBG has the highest affinity for T4 and T3 (1.0 × 1010 M−1 and 4.6 × 108 M−1, respectively), TTR has intermediate affinity (7.0 × 107 M−1 and 1.4 × 107 M−1, respectively) and albumin has the lowest affinity (7.0 × 105 S1a in the SI. GO analysis for biological processes showed that ABPP 106 binders are mostly enriched in the GO FAT category of translation elongation (p = 7.31 × 10–27). The top ranking categories (p < 1 × 10–9) are shown in Figure S1b in the SI. The SP-PIR keywords mostly enriched (p < 1 × 10–6) in our ABPP 106 binder set are shown in Figure S2 in the SI; 66.09% of the ABPP 106 binders belong to the category of acetylation, which makes the enrichment most significant (p = 1.25 × 10–194). The KEGG pathway analysis shows 16 significantly predictions obtained earlier. Each peptide is aligned to the protein sequence using the Needleman–Wunsch algorithm47. Many peptides are discarded at this stage due to alignment mismatches. For the aligned peptides, an alignment score Salign is computed using the BLOSUM90 similarity matrix48, which quantifies the importance of the alignment to a specific amino acid sequence. Taken all the above into account, the weighted probability of assigning an AAIG from chain X to a specific residue in the protein sequence is given by Eq. 4. Since several Peptide sequencing using tandem mass spectrometry (LC-MS/MS)19 confirmed the absence of any residues encoded by exons 1 through 5, consistent with translation initiation within exon 6 (Fig. 1b and Supplementary Table 1). In a complementary approach, we examined DMD translation efficiency, promoter usage, and alternate splicing using muscle RNA isolated from a mild BMD patient with an exon 2 frameshift mutation (c.40_41del [p.Glu14ArgfsX17], referred to as FS) whose western blot also revealed expression of the same smaller molecular weight structures obtained using supervised assignments for the three target proteins, RTT, ms6282 and aLP, are better than or comparable to the convergence of structures obtained using 4D-CHAINS automated assignments, as expected (Table 1). Notably, for Enzyme I, autoNOE-Rosetta achieves a higher level of structural convergence using automated assignments due to enhanced resampling of the correct protein fold during the early stages of the autoNOE-Rosetta structure calculation process. Overall, our results suggest that the fully automated assignment molecular weight (less than 60 kDa) filtered by the glomerulus can be influenced by renal impairment (65,66). Other organs including skin, muscle, and intestine also contribute to mAb degradation, thereby limiting major influences to mAb elimination due to liver injury or insufficiency. Dose adjustment of a mAb is usually not warranted in patients with renal or hepatic impairment (67). No dedicated clinical studies were conducted to evaluate the effect of hepatic impairment or renal impairment on the PK of monoclonal antibodies that modulate To further test our method in a fully unbiased manner we performed blind structure calculations for three additional protein targets, RTT29, 30, ms6282 and nEIt of sizes 133, 145 and 248 amino acids (aa), respectively (Table 1). To establish a baseline performance, we carried out CS-Rosetta calculations guided by chemical shifts alone15, as well as reference CYANA calculations using both input NOE datasets (HCNH+HCCH). With the exception of the smallest target (RTT), the resulting CS-Rosetta models failed to converge (Supplementary Figure 10) and, second, the consensus AAIG must have the higher confidence score for the given position (Fig. 2). Mapping of AAIGs to the protein sequence is accomplished by a succession of iterations that differ in three parameters used: (i) the length of chains built; (ii) a Z-score cutoff that controls the amino acid-type predictions to be considered per TOCSY AAIG when chains are translated to peptides; and (iii) the occupancy rate of connectivities between a TOCSY AAIG and all matched NOESY AAIGs. In the first iteration, stringent criteria are or Pathogenic, while CardioClassifier identified over double this number as clinically actionable (156/219) with a sensitivity of 71.2% (Supplementary Table 4). For both tools, sensitivity would be increased further through user addition of clinical and functional data. Despite the lower sensitivity of InterVar, there are occasions where the tool activates rules inappropriately in the absence of gene-specific knowledge. Firstly, InterVar activates PVS1 in the TTN gene, regardless of protein location, when it is recognised that truncating\n",
            "[0.7604972]\n",
            "### Expanded entities and terms:\n",
            "Diabetes - {'Neuropathy': 0.5892299010211162, 'Kidney Disease': 1.0, 'Metformin': 0.5926488076877152, 'Lifestyle Changes': 0.5093038951096769, 'Retinopathy': 0.546037930658053, 'Peripheral Neuropathy': 0.4446359120893055, 'Dialysis Requirement': 0.14286597088463343, 'Hypertension': 0.9419112688382072, 'High Blood Pressure': 0.5489428171131083, 'Laser Therapy': 0.062486448146711504, 'Pain Relievers': 0.0}\n",
            "\n",
            " ### Clustered: {'Diabetes': {'Cluster 1': ['Kidney Disease', 'Hypertension', 'Dialysis Requirement'], 'Cluster 2': ['Neuropathy', 'Peripheral Neuropathy'], 'Cluster 3': ['High Blood Pressure'], 'Cluster 4': ['Metformin'], 'Cluster 5': ['Lifestyle Changes'], 'Cluster 6': ['Retinopathy'], 'Cluster 7': ['Laser Therapy'], 'Cluster 8': ['Pain Relievers']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 379.33ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the gene mutated in the Gaucher disease?\n",
            "Refined Query: Gaucher disease is a lysosomal storage disorder.  What specific gene's mutation causes the deficiency in the enzyme glucocerebrosidase, leading to the accumulation of glucosylceramide and the resulting symptoms of Gaucher disease?\n",
            "\n",
            "Combined Answer: Skeletal complications are a major cause of morbidity in patients with Gaucher disease type 1 (GD1) [1–3]. In GD1, a genetic deficiency of acid β-glucosidase impairs the catabolism of glucosylceramide, resulting in intracellular, particularly intralysosomal, glycolipid accumulation [4]. Enlarged, lipid-laden macrophages known as “Gaucher cells” are observed in most tissues, but heavy infiltrations occur in spleen, liver, and bone marrow, giving rise to visceromegaly, cytopenia, and diverse skeletal lesions associated with mineral loss, manifestations of Gaucher disease. Additional data from an ongoing phase 3 randomized, controlled trial in treatment-naive adults with GD1 (ENGAGE) will provide further insight into the effect of eliglustat on hematologic, visceral, and bone parameters. to the appendicular skeleton, advancing in the lower extremity in a predictable sequence over time [1]. Focal collections of Gaucher cells may result in lytic lesions. The mechanistic link between marrow infiltration and the development of bony complications is not clear, but extensive Gaucher cell infiltration is associated with osteopenia, bone infarctions, avascular necrosis, lytic lesions, and pathological fractures [1, 5, 9]. Chronic bone pain and acute bone crises also often accompany skeletal disease in GD1 patients. Treatment of GD1 Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat - PMC The main limitations of this trial are the small number of patients, especially given the clinical heterogeneity of GD1; the uncontrolled study design of this proof-of-concept phase 2 trial; and the unblinded reviews of the bone images. However, this trial provides useful and objective information about the long-term effect of eliglustat on bone manifestations of Gaucher disease. Additional data from an ongoing phase 3 randomized, controlled trial in treatment-naive adults with GD1 (ENGAGE) will provide further insight into the effect of resonance (MR) imaging, areas of reduced bone marrow signal intensity (“dark marrow”) occur in T1-weighted sequences. Progressive accumulation of Gaucher cells displaces normal adipocytes from the marrow compartment [1, 7, 8], leading to abnormal quantities and distribution of “dark marrow.” This process begins in the axial skeleton and progresses to the appendicular skeleton, advancing in the lower extremity in a predictable sequence over time [1]. Focal collections of Gaucher cells may result in lytic lesions. The mechanistic link between was maintained in compliance with the Health Insurance Portability and Accountability Act. The main inclusion criteria were a diagnosis of GD1 confirmed by deficient acid β-glucosidase activity and Gaucher genotype, age 18 to 65 years, the presence of splenomegaly with anemia, and/or thrombocytopenia [16–18]. Patients could not have received ERT, miglustat, or corticosteroids within the previous year or bisphosphonates within the previous 3 months. The bone-related exclusion criteria were any new pathological bone involvement or bone crises in Eliglustat is an investigational oral substrate reduction therapy for Gaucher disease type 1 (GD1). Its skeletal effects were evaluated by prospective monitoring of bone mineral density (BMD), fractures, marrow infiltration by Gaucher cells, focal bone lesions, and infarcts during an open-label, multi-site, single-arm phase 2 trial (NCT00358150). of yellow marrow in bone could reflect the combined effect of eliglustat on Gaucher cell populations in the spleen (reducing hypersplenism) and bone marrow (restoring function to normal sites of hematopoiesis). This phase 2 study enrolled adult GD1 patients selected on the basis of an enlarged spleen (volume >10 MN) and the presence of either mild-to-moderate anemia or mild-to-severe thrombocytopenia, or both. Retrospective analyses of patients on ERT with imiglucerase have not consistently shown a correlation between marrow response and are observed in most tissues, but heavy infiltrations occur in spleen, liver, and bone marrow, giving rise to visceromegaly, cytopenia, and diverse skeletal lesions associated with mineral loss, ischemia, and marrow packing [5, 6]. Imaging of the skeleton provides a means of evaluating GD1 severity and monitoring responsiveness to treatment. On magnetic resonance (MR) imaging, areas of reduced bone marrow signal intensity (“dark marrow”) occur in T1-weighted sequences. Progressive accumulation of Gaucher cells displaces normal adipocytes from\n",
            "[0.7169181]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 353.56ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.83ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.88ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of lysine-specific demethylase 1 (LSD1) in hematopoiesis?\n",
            "Refined Query: Lysine-specific demethylase 1 (LSD1) is a histone demethylase implicated in gene regulation.  How does its enzymatic activity, specifically its demethylation of histone H3 at lysine 4 and 9, impact the various stages and lineages of hematopoiesis, including stem cell self-renewal, differentiation, and maturation of blood cell types?  What are the consequences of LSD1 dysregulation in hematopoietic development and disease?\n",
            "\n",
            "Combined Answer: status (17). LSD1 is the first of several protein lysine demethylases discovered. It specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 and functions as a transcriptional co-repressor (18, 19). Interestingly, LSD1 also appears to act as a central regulator for HSPC proliferation and differentiation. In a conditional gene knockdown model, LSD1 reduction was found to expand BM progenitor numbers by enhancing their proliferative behavior (20). Additionally, knockout of LSD1 resulted in derepression of stem and progenitor cell gene LSD1 is a lysine-specific histone demethylase that suppresses gene expression by converting dimethylated H3K4 to mono- and unmethylated H3K4 (18). LSD1 has been implicated in hematopoietic development and differentiation by its ability to activate or repress gene expression. It associates with hematopoietic specific repressors Gfi-1, Gfi-1b, and affects erythroid, megakaryocytic, and granulocytic differentiations (31). It is also shown to contribute to the activity of the Blimp-1-dependent repression complex during plasma cell differentiation of these complexes facilitate the LSD1 demethylase enzymatic activity on the chromatin template and therefore, enhance its repressive function (39). LSD1 regulates a variety of target genes that are required for cell survival, growth, and differentiation through its ability to modulate promoter chromatin structure (38, 40). Dysregulation of LSD1 function has been associated with genome instability and tumor metastasis (37, 40, 41). Interestingly, knock down of LSD1 in hematopoietic progenitors impairs differentiation of multiple hematopoietic histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone deacetylase (NuRD) complex which is necessary for embryonic stem cell differentiation, it also directly interacts with DNMT1 and affects global DNA methylation status (17). LSD1 is the first of several protein lysine demethylases discovered. It specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 and functions as a transcriptional co-repressor (18, Histone Lysine-specific Demethylase 1 (LSD1) Protein Is Involved in Sal-like Protein 4 (SALL4)-mediated Transcriptional Repression in Hematopoietic Stem Cells - PMC accompanied by a reversely changed histone 3 dimethylated lysine 4 at the same promoter regions. Finally, shRNA-mediated knockdown of LSD1 in hematopoietic precursor cells resulted in altered SALL4 downstream gene expression and increased cellular activity. Thus, our data revealed that histone demethylase LSD1 may negatively regulate SALL4-mediated transcription, and the dynamic regulation of SALL4-associated epigenetic factors cooperatively modulates early hematopoietic precursor proliferation. However, it remains unknown how TAL1/LSD1 interaction is regulated during hematopoiesis. During hematopoiesis, pluripotent HSCs are associated with both H3K4me3 and H3K27me3 to form so-called “bivalent domains” that facilitate differentiation into specific lineages by changing the relative level of specific modification and allow lineage-specific genes to be rapidly transcribed or vice-versa (32–34). LSD1 is the first identified histone lysine-specific demethylase involved in removing mono- or dimethylated H3K4 (35). As a putative demethylase LSD1 in erythroleukemia cells. LSD1 removes the methyl group from histone H3 lysine 4 of the TAL1 target genes and restricts TAL1 function in erythropoiesis (13). Upon induced erythroid differentiation, LSD1 may be released from the TAL1 complex and allow it to function as an activator, presumably recruiting coactivators for activating erythroid transcription programs (21) (Figure 7). Although the dramatically increase in hSET1 recruitment alone may be attributed to the elevation of H3K4me2 levels at the P4.2 promoter, The PKA genes to be rapidly transcribed or vice-versa (32–34). LSD1 is the first identified histone lysine-specific demethylase involved in removing mono- or dimethylated H3K4 (35). As a putative transcriptional repressor, LSD1 associates with multiple corepressor complexes including COREST and NURD complexes (36–38). Histone deacetylase activities of these complexes facilitate the LSD1 demethylase enzymatic activity on the chromatin template and therefore, enhance its repressive function (39). LSD1 regulates a variety of target genes that are The stem cell protein SALL4 plays a critical role in hematopoiesis by regulating the cell fate. In primitive hematopoietic precursors, it activates or represses important genes via recruitment of various epigenetic factors such as DNA methyltransferases, and histone deacylases. Here, we demonstrate that LSD1, a histone lysine demethylase, also participates in the trans-repressive effects of SALL4. Based on luciferase assays, the amine oxidase domain of LSD1 is important in suppressing SALL4-mediated reporter transcription. In freshly isolated\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.60ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Conditions - {'Diabetes': 0.6726340238952433, 'Neuropathy': 0.30491226364146523, 'Kidney Disease': 0.28237135457322365, 'Metformin': 0.45907039765465335, 'Lifestyle Changes': 1.0000000000000002, 'Retinopathy': 0.23894733530402062, 'Peripheral Neuropathy': 0.0}\n",
            "\n",
            " ### Clustered: {'Conditions': {'Cluster 1': ['Neuropathy', 'Peripheral Neuropathy'], 'Cluster 2': ['Diabetes'], 'Cluster 3': ['Kidney Disease'], 'Cluster 4': ['Metformin'], 'Cluster 5': ['Lifestyle Changes'], 'Cluster 6': ['Retinopathy']}}\n",
            "Original Query: For the treatment of which conditions can atypical neuroleptic drugs be used?\n",
            "Refined Query: Given the context of peripheral neuropathy, diabetes, kidney disease, metformin use, lifestyle changes, and retinopathy,  I want to know specifically which atypical neuroleptic drugs are used to treat any of these conditions, or any associated neuropathic pain.\n",
            "\n",
            "Combined Answer: significant peripheral neuropathy or allergic reactions. As expected, grade 1 and 2 asymtommatic CPK elevation and grade 1 and 2 rashes were some of the most common attributable toxicities seen with selumetinib. Rashes were often mitigated with topical supportive care. There were some patients who did require selumetinib dose reductions (Table 3); however, responses did not appear minimized in those patients requiring dose reductions suggesting the RP2D is not necessary for response. Interestingly, on A9952, NF1 patients who were non-randomly and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a clear list of candidate genes to investigate. neuropathy beginning within the first decade. Motor impairment due to both peripheral neuropathy and spasticity typically evolved within the second decade resulting in mild gait disturbance but, as a rule, preserved independent walking even throughout the fifth decade.3 Life expectancy is not anticipated to be shortened. Notably, none of these patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy - PMC start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, but myoclonic, partial, and absence seizures also occur.3 Neurological involvement—apart from the epilepsy, intellectual disability, and profound sensorineural hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a that about 30% of patients have epilepsy that is refractory to one or more agents and they are considered to be drug‐resistant. These patients often need add‐on therapy with other antiepileptic drugs (AEDs) (Schuele 2008). People with epilepsy often have psychosocial, behavioral and cognitive problems, and may place a heavy burden on society (Devinsky 1999). As reported by the World Health Organization (WHO), the overall health burden due to epilepsy accounts for 0.5% of the global burden of disease; this can be considered as more than Epilepsy is a common neurological disorder, affecting approximately 50 million people worldwide (Banerjee 2009; De Boer 2008). In low‐ and middle‐income countries, the median incidence of the disease is 68.7 per 100,000 population, which is higher than that in high‐income countries (43.4 per 100,000 population) (Kotsopoulos 2002). It is estimated that about 30% of patients have epilepsy that is refractory to one or more agents and they are considered to be drug‐resistant. These patients often need add‐on therapy with other antiepileptic drugs (p.R132X) and therefore a more severe phenotype. We also investigated mitochondrial function in patient cell lines and showed that this was impaired at multiple levels of mitochondrial function. Mitochondrial membrane potential as well as mitochondrial respiration rate were reduced; BN gel analysis showed a decrease in complex V activity as well as a defect in the assembly of the complex. These results highlight the importance of mitochondrial dysfunction in peripheral nerve disease and in optic atrophy. In peripheral nerve disease, the selectivity for D3 receptors, differentiate it from most atypical antipsychotic agents (including compounds with partial agonist as well as those with full antagonist properties at D2/D3 receptors) (Ellenbroek and Cesura, 2015; Stahl, 2016). Cariprazine is unique in its ability to bind D3 receptors with higher affinity than even dopamine itself, which essentially results in blockade of D3 receptors (Freedman et al., 1994; Sautel et al., 1995; Kiss et al., 2010). In contrast, most other atypical antipsychotics have relatively lower affinities pattern with mild delay. Full-field electroretinogram studies were normal on photopic and scotopic stimulation. In vivo optical coherent tomography (OCT) revealed general reduction in the retinal nerve fiber layer (RNFL) thickness, mainly on the temporal part of the optic disc, consistent with the temporal disc pallor (Figure 2c). When repeated after 4 years in three of the four patients, no further reduction in RNFL thickness was observed, consistent with a very slow progression of the optic neuropathy. By the second decade of life, affected\n",
            "[0.4819647]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the characteristics of  Andersen syndrome?\n",
            "Refined Query: Describe the key clinical features and genetic basis of Andersen-Tawil syndrome, including its impact on cardiac function, muscle tone, and skeletal development.  Are there variations in symptom severity?\n",
            "\n",
            "Combined Answer: criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. Details of the key features of CardioClassifier can be found in Table 2. Each variant is annotated for up to 17 computational criteria, with results output to a grid representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also The authors would like to thank the families for participating in this study. The authors would also like to thank Judith Nathanson and Heather M. Thompson for their help with figures. EMM has received a Career Award in Medical Science from the Burroughs Wellcome Fund and support from NIH NIGMS P20GM103645. This work was supported by a grant from the Simons Foundation (SFARI #239834 to EMM), and also generous support to EMM from the Nancy Lurie Marks Foundation. EMM has also received generous support from the newly-formed Christianson Syndrome which predicts a truncated protein lacking the C-terminal portion. In the second family, we studied three affected individuals who presented with early onset optic atrophy, peripheral neuropathy, and spastic gait in addition to moderate intellectual disability. Muscle biopsy in two of the patients revealed decreased activities of the mitochondrial respiratory chain complexes I and IV. In these patients, we identified a homozygous splice mutation, g.21043 T>A (c.282+2 T>A) which leads to skipping of exon 2. Our study broadens the phenotypic representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary Figure 2). The report is transparent, with all supporting evidence displayed along with links out to eight external resources that are commonly used for interpretation of ICC variants: the ExAC browser14, Ensembl, the UCSC genome browser, ClinVar, PubMed, Google, the Beacon Network (https://beacon-network.org) and the Atlas of Cardiac Genetic CCHS - congenital central hypoventilation syndrome HSCR - Hirschsprung's disease MWS - Mowat‐Wilson syndrome SNP - single nucleotide polymorphism Inherited cardiac conditions (ICCs) represent a major health burden with a combined prevalence of ~1%1. Genetic testing is recommended to support the management of many ICCs, with roles in diagnosis (particularly valuable for identification of at-risk relatives), prognostication, and therapeutic stratification. The principle challenge in genetic testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data\n",
            "[0.73947483]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How are induced pluripotent stem cells used in the study and treatment of cardiovascular diseases?\n",
            "Refined Query: How are induced pluripotent stem cells (iPSCs), derived from adult cells and reprogrammed to an embryonic-like state, utilized in research and therapy for cardiovascular diseases?  This encompasses their use in disease modeling, drug screening, and potential cell-based therapies for heart repair.\n",
            "\n",
            "Combined Answer: Embryonic stem cells (ESCs) are in vitro cultured cells derived from the preimplantation-stage embryo, which possess unconfined capacity for self-renewal and multi-lineage differentiation towards different embryonic germ layers. Pluripotency and self-renewal are two essential features of ESCs, which make them not only a very robust and suitable model for stem cell research, but also a promising source for regenerative medicine. Also, with the emergence of induced pluripotent stem cells (iPS) technology, understanding the basic mechanisms for UCEs. Finally, we show that it is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time, suggesting that depletion may be established through selection against UCE-disrupting CNVs without the requirement for meiotic divisions. become depleted for UCEs, we examine the relationship, over time, between UCEs and CNVs in induced pluripotent stem (iPS) cells. Our results suggest that CNVs that have deleted or duplicated UCEs may be selectively removed from cell populations and that this process may underlie the UCE-depleted profile of CNVs present in healthy, but not cancer, cells. the possibility that CNVs that arise somatically and are relatively newly formed are less likely to have established a CNV profile that is depleted for UCEs. Alternatively, lack of depletion for UCEs from cancer CNVs may reflect the diseased state. In support of this latter explanation, somatic CNVs that are not associated with disease are depleted for UCEs. Finally, we show that it is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time, suggesting that depletion may be established through Previous studies have shown that the bivalent chromatin conformation comprising H3K27me3 and H3K4me3 marks are reset in induced pluripotent stem (iPS) cells (28). To test whether enhancer elements are also reset we generated chromatin state maps for H3K4me1 in fibroblasts and fibroblast-derived iPS cells (Table S1). We used the iPS cell line that was previously shown to express all markers of pluripotency, give rise to fully developed embryos by tetraploid complementation, and contribute to the germ line (29). We found that enhancer model for stem cell research, but also a promising source for regenerative medicine. Also, with the emergence of induced pluripotent stem cells (iPS) technology, understanding the basic mechanisms governing the embryonic stem state becomes of great interest for safe clinical applications in regenerative medicine and stem cell programming. Among different signaling pathways, Wnt/β-catenin signaling has been shown to play a major role in maintaining self-renewal as well as in regulating ESCs differentiation [1], [2], [3],[4],[5],[6]. The that arise in healthy, as opposed to diseased, soma. We find that healthy somatic CNVs are depleted for UCEs, just as are CNVs inherited through the germline. This suggests that the profile of cancer specific CNVs reflects the diseased state, and not simply their somatic origin. Finally, to address how de novo and somatic CNVs of healthy individuals become depleted for UCEs, we examine the relationship, over time, between UCEs and CNVs in induced pluripotent stem (iPS) cells. Our results suggest that CNVs that have deleted or duplicated UCEs Pluripotency and self-renewal capacity are major characteristics of murine embryonic stem (ES) cells. Leukemia inhibitory factor (LIF) plays an important role for the self-renewal of ES cells, and depletion of LIF from ES cell culture medium leads to spontaneous differentiation of cells and results in a failure of self-renewal (1, 2). A large number of transcription factors function downstream of signaling by LIF, and several transcription factors, including STAT3, Oct3/4, Sox2, and Nanog, play crucial roles for pluripotency and self-renewal of Plk2–/– Mice—plk2–/– mice were prepared by Caliper Life Sciences. A plk2 targeting construct was designed to replace all 14 plk2 exons (deletion between sequences 5′-CAGCCAGCCGGCGCGTATTTAAAGC-3′ and 5′-AGCACGGGTTCCTGACACGTCAG-3′) with a Neo cassette (targeting vector FtNwCD, Caliper Life Sciences). This targeting construct was used to disrupt the plk2 gene in C57BL6 embryonic stem cells. These embryonic stem cells were injected into blastocysts and implanted into pseudo-pregnant females. Resulting germ line chimeras were crossed to C57BL/6N in the present study is shown in Figure 1b. Nuclear proteins were extracted from neural stem cells differentiated from Friedreich’s ataxia patient-derived iPS cells. We use neural stem cells as these cells are easily propagated and can give the required number of cells for the experiments. Differentiated neurons, the authentic cells that are affected in FRDA, generally cannot be obtained as a pure population of cells and cannot be propagated to give rise to the required numbers of cells. The ABPP 106 probe and control probe were incubated with\n",
            "[0.86948633]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?\n",
            "Refined Query: The Goldberg-Shprintzen syndrome is characterized by a distinct set of features.  I'm curious which specific additional disease or condition is frequently, or diagnostically, associated with this syndrome beyond its core symptoms.\n",
            "\n",
            "Combined Answer: hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI We contacted previous collaborators and physicians who had published case reports of individuals with DOORS syndrome. Patients were from 26 centres in 17 countries. Between Dec 1, 2010, and March 1, 2013, we enrolled identified individuals with DOORS syndrome who were assessed by clinical geneticists and had at least three of the five following features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures. Families were excluded if the The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a rare autosomal recessive disorder of unknown cause. We aimed to identify the genetic basis of this syndrome by sequencing most coding exons in affected individuals. Deafness, onychodystrophy, osteodystrophy, and mental retardation (DOOR or DOORS) syndrome (OMIM 220500) is a rare autosomal recessive disorder of unknown cause. Ronald Cantwell first described DOOR syndrome in 1975,1 noting that a few similarly affected individuals had been reported prior to that date. Qazi and colleagues suggested changing the name to DOORS syndrome to account for the presence of seizures in most individuals,2 and we use this term in this Article. The case reports of 32 affected individuals were reviewed by James and\n",
            "[0.6446736]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which protein is causing Netherton syndrome?\n",
            "Refined Query: Netherton syndrome is a rare genetic disorder characterized by ichthyosis, hair abnormalities, and atopic dermatitis.  Which specific protein deficiency or malfunction underlies this complex phenotype, leading to the characteristic skin and hair symptoms?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In the individuals without TBC1D24 mutations, eight did not have seizures and three did not have deafness (including one without seizures or deafness) and some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 mutations are given in the appendix (pp 15–16). Some individuals without TBC1D24 mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected males. These symptoms appear to be consistent regardless whether the mutation is inherited or de novo. These core diagnostic symptoms of CS (Table 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal In this study, we prospectively ascertained 12 independent pedigrees, 14 affected boys in total, with mutations in NHE6. Interestingly, in contrast to prior literature, a majority of the pedigrees enrolled exhibited de novo mutations. Through quantitative study of clinical features in probands across these independent pedigrees (Supplementary Table 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected\n",
            "[0.7159255]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Mutations in which gene and which protein are associated with Netherton syndrome?\n",
            "Refined Query: Netherton syndrome is a rare genetic disorder.  To understand its pathogenesis, identifying the specific gene mutation(s) responsible and the consequent affected protein is crucial. Which gene harbors these mutations, and what is the resulting protein dysfunction in Netherton syndrome?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause radiographs. The mutations are listed in table 1 and shown in figure 3. The conservation of the affected residues and nucleotides is given in the appendix (p 17). In families with TBC1D24 mutations and consanguinity, the mutations were homozygous and TBC1D24 was in a region of homozygosity as identified by SNP array or homozygosity mapping from exome data. The regions of homozygosity are given in the appendix (p 11). Because of the recessive nature of the disease and the presence of mutations predicted to lead to premature protein termination, or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a clear list of candidate genes to investigate. known functions. Mice without Oxr1 have oxidative stress-induced neurodegeneration,34 which suggests a possible link with the neurodegeneration seen in some individuals with TBC1D24 mutations.27 We saw no mutations in other TLDc domain encoding genes in this study. Several diseases have been associated with other aberrant Rab proteins and Rab-associated proteins. Some clinical overlap exists between DOORS syndrome and Martsolf syndrome (caused by mutations in RAB3GAP2 gene [OMIM 212720]; shared aspects include seizures, intellectual Rab-associated proteins. Some clinical overlap exists between DOORS syndrome and Martsolf syndrome (caused by mutations in RAB3GAP2 gene [OMIM 212720]; shared aspects include seizures, intellectual disability, abnormal toenails, and short phalanges), and other syndromes. We identified no mutations in RAB3GAP2. Further research is needed to establish the precise role of TBC1D24 not only in the nervous system, but also in the skeletal system and other systems affected in DOORS syndrome. In Caenorhabditis elegans, C31H2.1 (a TBC1D24 orthologue) disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly identified did not seem to affect portions of the protein predicted to interact with the TLDc domain, nor were they in the region that typically interacts with GTP in other TBC proteins (figure 3). Because TBC1D24 regulates Rab proteins and because of clinical overlap between DOORS syndrome and Martsolf syndrome, we also assessed RAB3GAP2. No RAB3GAP2 mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 mutations are given in the appendix (pp 15–16). Some individuals without TBC1D24 mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In and optic atrophy. The three genes identified in CMT6 confirm this and the phenotype is variable, a frequent finding in mitochondrial disorders. Overall CMT highlights the link between the axon and mitochondrial dysfunction and suggested that this process is likely to be affected in other forms of acquired axonal dysfunction such as multiple sclerosis and idiopathic neuropathy. From a genetic perspective, the combination of axonal neuropathy and CMT in any patient should alert the clinician to the possibility of a mitochondrial defect with a\n",
            "[0.4246064]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which disease of the central nervous system is characterized by the presence of Lewy bodies?\n",
            "Refined Query: What central nervous system disease is definitively diagnosed by the presence of Lewy bodies, intracellular protein aggregates, within neurons?  Are there variations in the presentation of this disease related to the location and density of these Lewy bodies?\n",
            "\n",
            "Combined Answer: MRs that drive synaptic dysfunction in AD. Aubry et al. identified MRs by region in six regions of brain, and each region had a separate list of MRs that are predicted to drive gene expression in AD brain tissue in that region (see Supplementary Methods for full details). With this initial list from Aubry et al., we first assembled a list of MRs that were predicted to have differential activity in three or more of these six regions, as we are interested in finding MRs whose dysfunction may be generalizable to neurons throughout the brain in not technically localized to the synapse. This relatively broad definition fit our purpose, as our goal was to identify MRs that drive synaptic and neurophysiologic dysfunction. Although a narrower focus limited to proteins actually localized to the synapse would be interesting, it was not the goal of this project. We then calculated the synaptic score for a given MR (SMR) with the following equation: where n is the number of synaptic genes that correlate with a given MR, ri is the Spearman‘s rank correlation between the MR and ith synaptic Indeed, in recent experimental studies in mouse models, impairments in neuronal arborization and synapse development were reported.12 It seems plausible that these defects in arborization and synapse development may represent the cellular correlates for the plateau in head circumference growth demonstrated in this study in patients. This hypothesis may be confirmed by future neuropathologic studies. The paucity of white matter and leukomalacia reported on some MRI studies in the setting of developmental regression may also indicate axonal loss have proposed that PLK2 has a critical role in maintaining dendritic spine stability (31) and modulating excitatory glutaminergic synaptic connections (32, 33). Thus, the involvement of PLK2 in α-synuclein phosphorylation provides a potential link between excitotoxic responses and Lewy pathology. Investigation of how the biology of PLK2 relates to the pathogenesis of PD and DLB should help clarify the role of synuclein phosphorylation in these diseases. Antibody Resource for MANDSY106. The UCL MRC Neuromuscular Centre Biobank is also acknowledged. F.M. is supported by the Great Ormond Street Children's Charity. J.E.M. is funded by a Wellcome Trust University Award. All other authors except the listed those below do not report any disclosures. Prof Muntoni has served on scientific advisory boards for Genzyme, AVI BioPharma, Inc., GSK; he serves on the editorial board of Neuromuscular Disorders and Neuropediatrics; he receives research support from AVI BioPharma, Inc., the European Union, the ZCCHC17 protein has not previously been studied in brain tissue, and so we examined which cell types express ZCCHC17. Immunohistochemistry at higher antibody concentrations stain mainly nucleus but also cytoplasm of cells throughout the grey matter (Supplementary Fig. S1A) and to a lesser extent white matter neuropil (Supplementary Fig. S1B). Although ZCCHC17 does not appear to be exclusively neuronal, it does stain neurons strongest. This is seen at lower antibody concentrations, where staining is limited to the nucleolus of large pyramidal We are grateful to Johnathan Cooper-Knock for critical reading of the manuscript. This work was supported by Research Grants from Motor Neuron Disease Association (Buchman/Apr13/6096); Russian Scientific Fund (No. 14-14-01138); Russian Foundation for Basic Research (No.14-04-00796 and No.14-04-01243). AQ was supported by Erasmus studentship. epileptic seizures and likely caused by a neuronal migration defect (Wolf et al. 1995), which is consistent with the barhl1 expression pattern. However, the TSC1 ortholog was duplicated in teleosts along with barhl1 and might be a developmental regulator itself, perhaps coregulated with barhl1 orthologs. The data presented in this paper suggest that for the mapping of human diseases it will be important to establish whether the implied disease gene is a GRB target gene or is, in fact, located in a GRB as a bystander with no functional relation IgG exposure in the brain has been the focus of several investigations, and conflicting data have been reported (40–42). Galcanezumab shows limited distribution into the central nervous system and cerebrospinal fluid (43). For other monoclonal antibodies that bind CGRP, no data exists to our knowledge. While the central penetration of galcanezumab is low, a central effect cannot be definitively ruled out. For many neurodegenerative diseases, monoclonal antibodies are being developed suggesting that they can act centrally to mediate their patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the current report who display, in addition to early onset optic neuropathy and esotropia, variable degree of intellectual disability and progressive motor impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2\n",
            "[0.72736526]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which deiodinase is known to be present in liver?\n",
            "Refined Query: The liver's role in thyroid hormone metabolism is significant.  Which specific type of deiodinase enzyme—type I, II, or III—is demonstrably present in hepatic tissue and what is its established function within the liver's overall contribution to thyroid hormone homeostasis?\n",
            "\n",
            "Combined Answer: of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear transcription factors. T3 can bind TRs either in the cytoplasm and translocate into the nucleus, or bind TRs in the nucleus. T3 binding to TR hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then initiates transcription of genes that are positively regulated by THs. Some genes are negatively regulated by THs, whereby binding of T3 induces the opposite changes and turns off transcription. Thus, it is crucial that the appropriate concentration of THs is present in the critical regions of the brain at each stage of development, to ensure transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. The structure of transthyretin has been highly conserved, implying strong selection pressure and an important function. In mammals, transthyretin binds T4 (precursor form of thyroid hormone) with higher affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about or chickens (Darras et al., 2015). This may be an explanation for the mild phenotype of TTR null mice, yet the apparent absence of humans lacking TTR. For a more detailed discussion on the role of TH transmembrane transporters, deiodinases and the establishment of TH gradients across membranes, see a comprehensive review by Schweizer and Kohrle (2013). The majority of current information on TH transmembrane transporters has been derived from only human and rodent data. A recent, comprehensive review on expression of TH transmembrane mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form (T4). About 80% of the active form (T3) is generated by deiodination of T4 to T3 in target tissues. In the blood, >99% of TH is bound to specific plasma proteins known as TH distributor proteins. Because THs are lipophilic they partition between the lipid phase and the aqueous phase with a ratio of 20,000:1 (Dickson et al., 1987). The binding of THs choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal fluid. Maximal transthyretin synthesis in the choroid plexus occurs just prior to the period of rapid brain growth, suggesting that choroid plexus-derived transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. The structure of transthyretin has been highly In this study, we have explored the potential activity of Aramchol, a drug currently in clinical trials for fatty liver disease, in blocking fibrosis, or scarring, by hepatic stellate cells, the principal collagen-producing (i.e. fibrogenic) cell type in liver injury. In both isolated human hepatic stellate cells and in a human hepatic stellate cell line, the drug suppresses the key fat-producing enzyme, stearoyl CoA desaturase 1 (SCD1), which leads to reduced expression of genes and proteins associated with hepatic fibrosis, while inducing the\n",
            "[0.45806322]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How is the sequence variability defined in antibodies?\n",
            "Refined Query: Antibodies exhibit sequence variability primarily within their antigen-binding regions (complementarity-determining regions or CDRs).  This variability, crucial for recognizing diverse antigens, arises from gene rearrangements, somatic hypermutation, and junctional diversification during B cell development.  How are these processes precisely defined and quantified, and how do they contribute to the overall antibody repertoire's diversity?\n",
            "\n",
            "Combined Answer: These preparations are derived from a cloned population of cells and have a unique structure, affinity, and specificity, which is in contrast to polyclonal antibodies that have a distribution of affinity and specificity resulting from antigen stimulation of genetically distinct cells (22). Humanized antibodies have the suffix “-zumab” and the amino acid sequence is ∼90% derived from a human DNA sequence, whereas human antibodies have the suffix “-umab” and 100% of the amino acid sequence is derived from a human DNA sequence. IgG are further Therapeutic antibodies may be viewed by the body as foreign and activate immune responses that lead to anti-drug antibody (ADA) development that can bind to the therapeutic antibody. Many factors can influence the likelihood of ADA formation, including manufacturing process, antibody structure (i.e. derived from rodent, chimeric, humanized, human), dose, dosing frequency, route of administration (68–70), and patient factors such as immune status or genetics. The effect that ADA could have on the PK of an antibody is complex and difficult to TcdA, as described by Greco et al. (12). We excluded the neutralizing antibody A26.8, which binds to the extreme C terminus of TcdA and for which no homologous epitope exists within peptide B2. The model reveals the distinct epitopes of each antibody and suggests that binding of bezlotoxumab is more likely to interfere with carbohydrate binding than binding of A20.1 and B39. This is in line with the fact that bezlotoxumab is a fully neutralizing antibody, whereas B39 is non-neutralizing (25) and A20.1 is poorly neutralizing (43). Although the site (because peptide B3 contains only this epitope), or (ii) the antibody binds to the two epitopes cooperatively, with the low affinity state identified by SPR corresponding to bezlotoxumab binding at a single epitope and the high affinity state corresponding to binding at both epitopes. The similar binding free energies calculated for the two epitopes (Table 3) supports the latter possibility. Taken together, the Western blotting, temperature-dependent fluorescence, SPR, HDX-MS (Fig. 2), and crystal structure (Fig. 3) data provide insight structure. The identification by SPR of high affinity and low affinity sites for bezlotoxumab binding to peptides B1 and B2 (with a single low affinity site in B3 and no binding to B4; see Table 2) suggests one of two distinct possibilities: (i) bezlotoxumab has distinct affinities for the two epitopes E1 and E2, with E2 corresponding to the low affinity site (because peptide B3 contains only this epitope), or (ii) the antibody binds to the two epitopes cooperatively, with the low affinity state identified by SPR corresponding to bezlotoxumab acid sequence is ∼90% derived from a human DNA sequence, whereas human antibodies have the suffix “-umab” and 100% of the amino acid sequence is derived from a human DNA sequence. IgG are further divided into four subclasses based on the structure of their heavy chains: IgG1, IgG2, IgG3, and IgG4. Structural differences among IgG heavy chains can lead to differences in binding to cell-associated receptors (20). The literature is limited regarding IgG subclass and its effect on PK/PD of monoclonal antibodies, and studies in this area are three sheets. Two of these sheets (composed of seven strands) contribute the immunoglobulin-like core of BIG domains. These seven strands are labelled ‘a’ to ‘g’ in Figure 1 and Supplementary Figure S3, following an established convention in the immunoglobulin fold (Bork et al., 1994). BIG domains have been described with diverse functions, usually relating to matrix, protein–ligand, or protein–protein interactions and are mainly extracellular (Mei et al., 2015; Ptak et al., 2014). Close 3D proximity and evolutionary conservation of four PCR amplification of the captured fragments [21] before performing the final base-pair sequencing. The sequenced data is binned to obtain a ChIP-seq library. To estimate the null distribution of a ChIP-seq library, we assume that the fragmented DNA from the sonicated whole cell is treated with an antibody that randomly captures fragments without any specificity. The bincounts of captured fragments then follow a binomial distribution. The captured fragments are amplified, sequenced, and binned to get the null distribution of the ChIP-seq in human cells. The ENCODE data set [7,8] provides the first opportunity to study a large group of TFs together in human cells. These data come from the chromatin-immunoprecipitation sequencing (ChIP-seq) protocol: chromatin is crosslinked to preserve DNA-protein and protein-protein bonds, then a target-specific antibody is used to capture the DNA proximally associated with a given protein, and this DNA is sequenced and aligned to a reference assembly to create a genome-wide map of protein occupancy [9]. At each genome site occupied (though In the past 10 years, the focus of biological research has shifted from individual genes and proteins toward the study of entire biological systems. One of the most important research issues is gene/protein and disease relationship analysis. Sequence variation plays the key role between gene and disease. Therefore, identifying sequence variation is one of the major approaches for characterizing gene–disease relationships (Erdogmus and Sezerman, 2007; Schenck et al., 2012), with many study results subsequently reported in scientific\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 454.29ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1536.48ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 810.22ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Mycobacterium avium less susceptible to antibiotics than Mycobacterium tuberculosis?\n",
            "Refined Query: Compared to Mycobacterium tuberculosis, does Mycobacterium avium exhibit reduced susceptibility to common antibiotic treatments, requiring higher dosages or alternative drug regimens for effective eradication?\n",
            "\n",
            "Combined Answer: (WHO 1999), may be complicating care in the home-based setting (WHO 2007), even without any definitive evidence that this is a necessary component of treatment (Alcoba et al. 2009; Bailey et al. 2009). The findings of this study must be considered preliminary; caution should be exercised in extrapolating these retrospective results to other settings. But these findings, together with growing evidence that the practice of administering routine antibiotics to vulnerable populations is ineffective and perhaps detrimental, highlight the need for antibiotic for this purpose, are becoming ineffective against the strains of bacteria that are found to be causing severe infections in this population of malnourished children (Manary et al. 2000; Madanitsa et al. 2009). Thus, while the constraints on the choice of antibiotics in resource-limited settings should not be underestimated, it is possible that a different routine antibiotic may have been of more benefit to these malnourished children. Home-based therapy for acute malnutrition is robust partly because children who live far from were significantly greater among children that did not receive amoxicillin for both kwashiorkor and marasmus. Nevertheless, despite these baseline differences between the two groups of children, regression modeling showed home-based therapy without antibiotics to be associated with a higher rate of recovery at 4 weeks and a similar rate at 12 weeks, compared to the group of children who all received amoxicillin for 1 week. This finding that the recovery rate with amoxicillin therapy is delayed has biological plausibility when considering the CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one recurrence and may require multiple rounds of treatment that can last several weeks to months, negatively impacting quality of life and costing the health care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms 498 children were treated according to the standard protocol with amoxicillin and 1955 were treated under the alternate protocol without antibiotics. The group of children treated with amoxicillin was slightly older and more stunted at baseline. The recovery rate for children who received amoxicillin was worse at 4 weeks (40% vs. 71%) but similar after up to 12 weeks of therapy (84% vs. 86%), compared to the children treated without antibiotics. Regression modeling indicated that this difference at 4 weeks was most strongly associated with the Currently, about 350 million individuals worldwide are chronically infected with the hepatitis B virus (HBV). Of the infected people, 15 to 40% will develop severe sequelae in their lifetime, most notably liver cirrhosis and hepatocellular carcinoma (18). The treatment of chronic hepatitis B has been improved dramatically in the past 10 years, mainly due to the successful development and application of nucleoside(tide) drugs targeting HBV polymerase and interferon (9, 24). These treatment options delay disease progress by inhibiting viral up to 12 weeks of therapy (84% vs. 86%), compared to the children treated without antibiotics. Regression modeling indicated that this difference at 4 weeks was most strongly associated with the receipt of amoxicillin. Clostridium difficile is an anaerobic Gram-positive bacillus that infects the colon of susceptible patients, mainly in hospital settings but also increasingly in the community. C. difficile infections (CDI)4 are typified by severe diarrhea, pseudomembranous colitis, and in extreme cases colonic rupture, sepsis, and death (1). Current treatments for CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be translocation of enteric flora across the compromised intestinal mucosa. Moreover, resistant bacteria may exhibit enhanced virulence (Dancer 2004), further complicating a malnourished child’s chances for recovery. Amoxicillin was used in the standard protocol group because of its relatively broad-spectrum of activity, low cost, and current usage by and the on the amount of RUTF needed to achieve recovery. Additionally, antibiotic resistance is increasing worldwide, and can be particularly problematic in developing countries where treatment options against resistant organisms are more limited (Nys et al. 2004; Okeke et al. 2005; Okeke et al. 2007). In the gut, resistant organisms rapidly develop when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.17ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Diabetes - {'Neuropathy': 0.5892299010211162, 'Kidney Disease': 1.0, 'Metformin': 0.5926488076877152, 'Lifestyle Changes': 0.5093038951096769, 'Retinopathy': 0.546037930658053, 'Peripheral Neuropathy': 0.4446359120893055, 'Dialysis Requirement': 0.14286597088463343, 'Hypertension': 0.9419112688382072, 'High Blood Pressure': 0.5489428171131083, 'Laser Therapy': 0.062486448146711504, 'Pain Relievers': 0.0}\n",
            "\n",
            " ### Clustered: {'Diabetes': {'Cluster 1': ['Kidney Disease', 'Hypertension', 'Dialysis Requirement'], 'Cluster 2': ['Neuropathy', 'Peripheral Neuropathy'], 'Cluster 3': ['High Blood Pressure'], 'Cluster 4': ['Metformin'], 'Cluster 5': ['Lifestyle Changes'], 'Cluster 6': ['Retinopathy'], 'Cluster 7': ['Laser Therapy'], 'Cluster 8': ['Pain Relievers']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.30ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 934.71ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.27ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1158.08ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Stroke - {'Rehabilitation Therapy': 0.7980541525037852, 'Motor Function': 0.9999999999999991, 'Mental Health': 0.0}\n",
            "Depression - {'SSRIs': 0.0, 'Anxiety Disorders': 1.0}\n",
            "\n",
            " ### Clustered: {'Stroke': {'Cluster 1': ['Rehabilitation Therapy'], 'Cluster 2': ['Motor Function'], 'Cluster 3': ['Mental Health']}, 'Depression': {'Cluster 1': ['SSRIs', 'Anxiety Disorders']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.19ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 933.34ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the inhibitors of histone methyltransferases?\n",
            "Refined Query: What specific chemical compounds or natural substances are known to inhibit the activity of histone methyltransferases (HMTs),  and what are their mechanisms of action?  This includes exploring both broad-spectrum and HMT-isoform-specific inhibitors.\n",
            "\n",
            "Combined Answer: larvae (40). While it has been assumed that the essential function of the PR-Set7 methyltransferase is to monomethylate H4K20, it remains possible that it could target other critical proteins for methylation. Indeed, nonhistone targets of PR-Set7's catalytic activity have been identified in mammalian cells, including p53 (38) and PCNA (39), both of which are critical cell cycle regulators. Recently, McKay and colleagues developed a novel histone replacement system to directly assess the function of specific histone lysine residues in Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and (DNMT1, 3A, 3B, 3L) and histone deacetylases (HDAC1 and HDAC2), to target genes (13–15). In addition, SALL4-mediated activation of Bmi-1, another important hematopoietic stem cell gene, involves methylation of lysine 4 of histone H3 (H3K4) at its promoter region (16). Based on recent discoveries, there seem to be various ways of cross-talking between histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. H3K36me3 could thus contribute to the establishment of a transcriptionally unfavorable chromatin conformation by recruiting (and perhaps stimulating) repressive complexes. In conclusion, this study demonstrated that trimethylated histone H3 at lysine 36 is specifically enriched in facultative and constitutive heterochromatin in mouse, and that this histone A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2), and the recently discovered CHROMOMETHYLASE 2 (CMT2) perform methylation in CHH contexts (Haag and Pikaard, 2011; Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry chromatin and translation. Histone lysine methylation has emerged as an important player in regulating gene expression and chromatin function [14]. K27 is a critical residue in all seven histone 3 variants and the subject of post-translational histone modifications as it can be both methylated and acetylated [2, 14, 20]. Acetylation may induce active transcription, while mono, bi or tri-methylation of K27 is associated with a repressive mark on chromatin and gene expression. Abrogation of acetylation and/or potential mimicry of a methylated histone methyl-lysine readers such as SGF29, Spindlin1, UHRF1, and SHH140. These reader proteins are involved in the pathogenesis of various diseases and identifying small molecules that inhibit interactions between histone methyl-lysine readers and their respective binding partners on chromatin has significant clinical relevance41. Here with TIRR, we have the first example of a bona fide cellular inhibitor of a histone methyl-lysine reader. This is also a unique mechanism by which the activity of this class of proteins maybe broadly A similar reduction in SET domain activity was seen for K9M and K36M, but interestingly, not K4M mutants, where lysines are targeted by distinct SET domain containing methyltransferases (Lewis et al. 2013; Herz et al. 2014). An interesting question is whether the stabilized binding of EZH2 to K27M can occur on soluble histone H3 prior to its incorporation into nucleosomes, as suggested by in vitro binding studies to peptides (Brown et al. 2014). If so, only EZH2 function would be blocked, whereas if EZH2 is bound to mutant chromatin, the Lys 36 of histone H3 can undergo mono-, di-, and tri-methylation as well as antagonistic acetylation at the same residue. Posttranslational modification of H3K36 is associated with active transcription, alternative splicing, dosage compensation, DNA replication, and DNA damage repair (Wagner and Carpenter 2012). In yeast, SET domain-containing 2 (Set2) writes all three methylation states at H3K36 whereas in mammals, each state of methylation is laid down by distinct enzymes suggesting extensive regulation of K36 methylation and its importance for explaining differences in levels of a particular chromatin mark across tissues were often also highly significant for explaining mRNA expression differences. This was particularly the case for methylation of lysine 4 on histone H3 (H3K4me2, H3K4me3), for acetylation of histone H3 (H3K9ac, H3K27ac), and for trimethylation of lysine 36 on histone H3 (H3K36me3). For example, Figure 5A shows the activity profiles for these marks for the SNAI1..3 motif, which is recognized by the snail TFs (see Supplemental Fig. 22 for additional examples). As\n",
            "[0.7232526]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the main characteristic of Amyotrophic Lateral Sclerosis?\n",
            "Refined Query: Amyotrophic Lateral Sclerosis (ALS) is primarily characterized by the progressive degeneration and death of motor neurons, leading to muscle weakness, atrophy, and eventually paralysis.  This ultimately affects the ability to control voluntary movements.\n",
            "\n",
            "Combined Answer: Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative condition characterized by aetiologically diverse pathomechanisms, which ultimately results in loss of upper and lower motor neurons, paralysis and death. In a rapidly growing group of genes mutated in ALS the most represented are the genes encoding proteins directly or indirectly involved in RNA metabolism [1-3]. Structural and functional studies of ALS-associated proteins and their disease-linked variants have significantly contributed to our current understanding of in ALS only slightly compromise the protein structure allowing normal development of the nervous system, but nevertheless are sufficient to trigger a severe neurodegenerative disorder in the adulthood. Our studies in vitro and in vivo suggested that altered protein stability and hence its increased levels may be behind this effect. Interestingly, one ALS patient with CREST mutation also carried an amino acid substitution in OPTN gene [5]. It is plausible that in this case the presence of both mutations was necessary for manifestation of the if CREST is indeed another protein whose aggregation leads to neurodegeneration. CREST is essential for the nervous system homeostasis as evidenced by the severe neurological phenotype of CREST deficient mice [6] as well as its high expression levels specifically in postmitotic neurons [9]. Therefore, it is highly likely that mutations identified in ALS only slightly compromise the protein structure allowing normal development of the nervous system, but nevertheless are sufficient to trigger a severe neurodegenerative disorder in the We are grateful to Johnathan Cooper-Knock for critical reading of the manuscript. This work was supported by Research Grants from Motor Neuron Disease Association (Buchman/Apr13/6096); Russian Scientific Fund (No. 14-14-01138); Russian Foundation for Basic Research (No.14-04-00796 and No.14-04-01243). AQ was supported by Erasmus studentship. Calcium-responsive transactivator (CREST) protein shares a set of structural and functional traits with other proteins associated with amyotrophic lateral sclerosis - PMC Our study presents evidence that CREST possesses three properties common to several proteins associated with ALS: i) high propensity to aggregate in cells; ii) recruitment into stress granules; and iii) ability to modulate paraspeckle integrity. There is a growing body of evidence that protein aggregation and altered function of SGs (and likely, paraspeckles) are important factors in ALS pathogenesis, and our observations also point to these processes as potential culprits for the development of pathological changes in ALS cases with CREST Our data indicate that CREST and certain other ALS-linked proteins share several features implicated in ALS pathogenesis, namely the ability to aggregate, be recruited to stress granules and alter paraspeckle integrity. A change in CREST levels in neurons which might occur under pathological conditions would have a profound negative effect on neuronal homeostasis. external or internal factor including mutation, could initiate aggregation of the protein in the nervous system, which in turn would affect CREST binding partners important for neuronal homeostasis. There are several reports of increased stability [29-31] and/or higher aggregation propensity [28,32,33] of ALS-associated TDP-43 mutants compared to non-mutated protein. Similarly, we have demonstrated that at least one of the ALS-linked mutations in CREST, Q388stop, affects protein stability and renders it more aggregate-prone. An opposite involved in RNA metabolism [1-3]. Structural and functional studies of ALS-associated proteins and their disease-linked variants have significantly contributed to our current understanding of the mechanisms of disease development and progression. Characterization of pathological signatures for each ALS-associated protein is crucial in delineating common pathways in the disease pathogenesis and eventually understanding how altered metabolism of proteins with diverse functions results in the same clinical phenotype. Recently, using exome impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2 hyper-intense lesions known to be associated with mitochondrial diseases. Although too early to conclude, life expectancy does not appear to be significantly reduced. A severe phenotype with dramatically deteriorating course was described by Antonicka et al,2 dominated by significant cognitive and motor impairment resulting in wheelchair dependence\n",
            "[0.63251054]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which genes are regulated by MEF-2 in the heart?\n",
            "Refined Query: Investigate the transcriptional regulation of cardiac genes by the myocyte enhancer factor 2 (MEF-2) family of transcription factors.  Identify specific genes whose expression is directly or indirectly controlled by MEF-2 in the context of cardiac development and function.\n",
            "\n",
            "Combined Answer: expression pattern of zebrafish c1orf61, while the nearest downstream gene, rhbg, has a different expression pattern (Fig. 5A; Supplemental Fig. S1). Both genes are embedded in an area with conserved synteny throughout vertebrates, and this interval also includes a gene encoding a myocyte enhancer factor 2d (mef2d). A paralog of mef2d, mef2c, is found on Chromosome 5 upstream of a gene desert that also harbors an miRNA gene, encoding human MIRN9-2/zebrafish mirn9-5. An insertion within this gene desert, ∼100 kb downstream from the miRNA, has Transcription factors (TFs) are proteins that regulate the expression of genes by binding the DNA at their regulatory elements (promoters or enhancers) and either preventing or facilitating the recruitment, in eukaryotes, of the transcription preinitiation complex (PIC). The PIC in turn recruits RNA polymerase II (Pol II) to the transcription start site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate found on Chromosome 5 upstream of a gene desert that also harbors an miRNA gene, encoding human MIRN9-2/zebrafish mirn9-5. An insertion within this gene desert, ∼100 kb downstream from the miRNA, has an expression pattern also resembling mirn9 (Fig. 5; Wienholds et al. 2005). In contrast, mef2c is expressed in somites and myotomes, and zgc:63626 in a widespread pattern (Supplemental Fig. S1). These results also show that miRNAs can be regulated by the same type of enhancers as are developmental regulatory genes, regardless of whether they are in gene expression. While the modification/translocation of those pre-existing elements has been shown to play an important functional role, they may only contribute to a fraction of the regulatory innovation. Indeed, recent findings using large-scale comparative analysis of regulatory features have shown that single binding sites can vary extensively between closely related species [14] or even between individuals of the same species [15]. Further supporting the flexibility of regulatory elements, tissue-specific enhancers such as heart between closely related species [14] or even between individuals of the same species [15]. Further supporting the flexibility of regulatory elements, tissue-specific enhancers such as heart enhancers have been shown to be poorly conserved [16] and examples of lineage/specie-specific enhancers have been described [17],[18]. Recently it has been reported that the genomic positions of tissue-specific enhancers of the yellow gene differ between Drosophila species [19]. Taken together, these results are suggesting that complete autonomous enhancer in the gene encoding G-coupled receptor MASS1 (for example, see Nakayama et al. 2002), which lies within the larger synteny block containing mirn9-5 and is ∼1.8 Mb upstream of MEF2C, but other cases remain unresolved. Expression of the mirn9 family is observed throughout the CNS and retina in zebrafish (Wienholds et al. 2005). It is interesting that both of these miRNAs are also near myocyte enhancer factor genes, which are also thought to be of developmental regulatory function. Why the miRNAs and the mefs are kept together is currently not family motifs along with Nkx2-5, MEF2A and SRY. Most of these motifs are bound by TFs that are GRB targets themselves. Forkhead TFs are major players in development: in the absence of Foxa2, mouse embryos can not develop further than embryonic day 8.5 and they lack notochord [28]. In addition, Nkx2-5 is essential for heart development [29] and MEF2A is required for somite development and hedgehog signaling in zebrafish [30] as well as vascular development in mammals [31]. Transgenesis [32] and enhancer trapping [6,10] experiments in zebrafish both of these miRNAs are also near myocyte enhancer factor genes, which are also thought to be of developmental regulatory function. Why the miRNAs and the mefs are kept together is currently not known, but it may be that they are regulated together, as mouse Mef2c and Mef2d are expressed in the telencephalon (Lyons et al. 1995). In the case of the gene desert containing zebrafish id1, annotation to the human genome reveals an orthologous relationship between zebrafish id1 and human ID1, even though their similarity at the protein level is SR Ca2+ ATPase 2a (SERCA2a) is a critical ATPase responsible for Ca2+ re-uptake during excitation-contraction coupling. Impaired SR Ca2+ uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure (HF)1. Accordingly, restoration of SERCA2a expression by gene transfer has proven to be effective in improving cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most validated by future experiments. Based on the similarity of their occupancy profiles, reproduced independently in multiple cell lines, we infer that ATF3 and USF1/USF2 may be part of a novel protein complex; furthermore, since DNA sequence motifs associated with USF1/2 are predictive of ATF3’s occupancy but not vice versa, we predict that USF1 or USF2 is the subunit of this complex that directly binds the promoter, while ATF3 is a cofactor recruited by USF1/2 despite having its own DNA-binding domain that is used in other complexes. By the\n",
            "[0.56609803]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there an association between TERT promoter mutation and survival of glioma patients?\n",
            "Refined Query: Investigating the correlation between the presence of TERT promoter mutations and overall survival rates in glioma patients requires analysis of patient cohorts with and without these mutations, comparing their survival times.  This would determine if TERT promoter mutations are prognostic indicators for glioma.\n",
            "\n",
            "Combined Answer: Pediatric glioblastomas (GBM) including diffuse intrinsic pontine gliomas (DIPG) are devastating brain tumors with no effective therapy. Here, we investigated clinical and biological impacts of histone H3.3 mutations. Forty-two DIPGs were tested for H3.3 mutations. Wild-type versus mutated (K27M-H3.3) subgroups were compared for HIST1H3B, IDH, ATRX and TP53 mutations, copy number alterations and clinical outcome. K27M-H3.3 occurred in 71 %, TP53 mutations in 77 % and ATRX mutations in 9 % of DIPGs. ATRX mutations were more frequent in older Cell Carcinoma (HNSC), Lung Adenocarcinoma (LUAD), and Brain Lower Grade Glioma (LGG), which count a total of 2,268, 1,096, 1,106, 1,180 and 1,024 samples (tissues), and 1,103, 540, 530, 583, 518 patients, respectively. Table 1 lists the number of included genomic experiments (identified by aliquot ids), samples, and patients for each kind of experiment type across all TCGA tumors; further details are in Additional file 6. As part of the clinical workup of these 47 diffuse midline gliomas with histone H3‐K27M mutation, a combination of additional molecular testing was variably performed including immunohistochemistry for ATRX, p53, IDH1‐R132H mutant protein and BRAF‐V600E mutant protein, as well as FISH for EGFR and PTEN genes (Table 2). ATRX immunostaining revealed loss of nuclear expression in 15 of 32 tested cases, including nine of 12 thalamic gliomas (75%), four of seven spinal gliomas (57%), and one of 13 pontine gliomas (8%). Of the 33 cases assessed, 14 modeling regulation in glioblastomas (Setty et al. 2012). In ISMARA, the effects of miRNA regulation have been incorporated into a completely automated procedure that can be applied to any expression data set. Specifically, we used miRNA target site predictions from TargetScan using preferential conservation scoring (PCT) (Friedman et al. 2009), which assigns target scores for 86 miRNA seed families to all RefSeq transcripts. To associate a target score Npm for miRNA seed family m targeting promoter p, we average TargetScan’s scores over all cord) of both pediatric and young adult patients 1, 5, 9, 11, 12, 19, 20, 24, 26. Studies have shown that these diffuse midline gliomas with histone H3‐K27M mutation are associated with aggressive clinical behavior and poor prognosis 19, 20, 26, including those tumors which demonstrate only low grade histologic features on biopsy 5. However, more recent studies have shown that thalamic gliomas in adult patients with histone H3‐K27M mutation might not be associated with worse prognosis than corresponding histone H3 wild‐type thalamic gliomas 1, studies have shown that thalamic gliomas in adult patients with histone H3‐K27M mutation might not be associated with worse prognosis than corresponding histone H3 wild‐type thalamic gliomas 1, 9, suggesting heterogeneity among this molecular subgroup of diffuse midline gliomas. Investigation has shown that this K27M mutation alters an important site of post‐translational modification in the histone H3 variants and leads to altered DNA methylation and gene expression profiles thought to drive gliomagenesis 3, 7, 15, 21, 26. Thus, there are probabilities of all predicted TFBSs for motif m in promoter p. When modeling expression levels in terms of regulatory sites using a linear model, it is relatively straightforward to extend the modeling to not only include effects of TFBSs but also the effects of miRNA regulation, e.g., as recently introduced in a supervised learning scheme for modeling regulation in glioblastomas (Setty et al. 2012). In ISMARA, the effects of miRNA regulation have been incorporated into a completely automated procedure that can be applied to any expression value of the gene ratio. Cox proportional hazards model was employed to investigate the influence of clinical factors against the prognostic gene markers. The details of this are provided in the figure legends. All statistic analyses were done by MS Office Excel program and SPSS 12.0 software (Chicago, IL, USA). A level of P<0.05 was regarded as statistically significant in this study. (P = 0.000, P = 0.000), there was a tendency towards a difference in TNM stage between patients with high versus low/ unchanged expression levels of uc.189 in CSCC (P = 0.083). The prognosis of CSCC patients with high expression of uc.189 was significantly poorer than that of CSCC patients with low/ unchanged uc.189 expression (P < 0.001; Figure 2). The median survival times were 43.45 months for high uc.189 expression and 72.47 months for low/unchanged uc.189 expression. Similarly, tumor node status (44.69 vs. 58.67 months; P < 0.01, n = 116) It is, thus, important to identify those gliomas with histone H3 mutations, given the prognostic significance and potential targeted therapy that will soon be in clinical trials for these patients. Genomic analysis of diffuse midline gliomas with histone H3‐K27M mutations (K27M+) has revealed a number of cooperating genetic alterations. In particular, these tumors often also have TP53 and ATRX mutations but do not have IDH1 mutation 19, 25, 26. More recently, a subset of K27M+ DIPGs were found to also harbor missense mutations in the ACVR1\n",
            "[0.63426304]\n",
            "### Expanded entities and terms:\n",
            "Arthritis - {'Anti-Inflammatory Drugs': 0.0, 'Joint Swelling': 1.0}\n",
            "\n",
            " ### Clustered: {'Arthritis': {'Cluster 1': ['Anti-Inflammatory Drugs'], 'Cluster 2': ['Joint Swelling']}}\n",
            "Original Query: Which JAK (Janus kinase) inhibitor is approved for treatment of rheumatoid arthritis?\n",
            "Refined Query: Given the context of anti-inflammatory drugs and joint swelling in rheumatoid arthritis,  I need a list of all Janus kinase (JAK) inhibitors approved by regulatory bodies (e.g., FDA, EMA) specifically for treating this condition.\n",
            "\n",
            "Combined Answer: in the expression of rheumatoid arthritis risk genes with super-enhancer structures by treating T-cells with the Janus kinase (JAK) inhibitor tofacitinib (35). Additionally, disease-associated single nucleotide polymorphisms (SNPs) for autoimmune diseases such as rheumatoid arthritis have been found to be highly enriched in super-enhancer regions (35). The current research well characterized this biological phenomenon and effectively demonstrated the importance and potential application of super-enhancers as they can play key roles in cell in the presence or absence of FL using the advanced ERK phospho-T202/Y204 detection system. Similar to our initial findings, this assay showed that while the presence of FL attenuated the effects of quizartinib, it did not affect those of gilteritinib (Figure 4B). Given that Fangli et al reported that activation of the MAPK pathway plays a crucial role in FL-dependent resistance to FLT3 inhibitors in FLT3wt and FLT3-ITD co-expressing 32D cells [26], we investigated whether trametinib, a potent and selective MEK inhibitor, recovers the efficacy linked the activation-induced deaminase (AID) off-targeting activity to the process of convergent transcription (33) and these AID targets are mainly grouped within super-enhancer and regulatory clusters (34). Very recently, Vahedi et al. found super-enhancers in T-cells by profiling p300 ChIP-seq signal and showed disproportionate alteration in the expression of rheumatoid arthritis risk genes with super-enhancer structures by treating T-cells with the Janus kinase (JAK) inhibitor tofacitinib (35). Additionally, disease-associated single erenumab (78), and fremanezumab (79) have been reported elsewhere from clinical trials. The drug labels for these three drugs state similarly that, although the immunogenicity profiles do not demonstrate an impact of ADA development on efficacy or safety, the available data are too limited to make definitive conclusions (10,11,15). In addition, ADA development does not demonstrate an impact on the PK of galcanezumab (10). results website), ISMARA predicts that IRF1 is activated directly at the level of transcription by these regulators, which is confirmed by the experimental literature (Harada et al. 1994). Other predicted targets of NFKB1/REL/RELA that are also significantly up-regulated in this process are TNF receptor genes, components of the JAK-STAT pathway (note that STAT2,4,6 is the 11th most significant motif, indicating that STAT activity changes, affecting the level of its targets) and MHC class I genes. The latter are also predicted to be regulated discrepancy between our results and those of previous studies may be attributable to the specialised role of dCK in the activity of anticancer drugs, and to the fact that other studies have employed differently subtyped AML populations. Indeed, to screen outcome predictors, other research groups have employed mixed populations of AML patients treated with non-unified regimens, whereas in this study we used more focused populations in the aspect of disease type and chemotherapy regimen. Additionally, our previous in vitro study showing that dCK Phase I clinical trials in both children and adults supported safety and preliminary efficacy of selumetinib, a non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. These data led to the development of this phase II efficacy trial of selumetinib in children with recurrent, refractory or progressive pLGG. the drugs and can be used as a prognostic indicator not only in leukaemias. One study using samples of Ara-C-treated AML patients indicated that high dCK and low NT5C expression were noted in the group with longer survival rates (Galmarini et al, 2003). Additionally, the roles of dCK, CDA and hENT1 were addressed in several studies employing in vitro leukaemia cell models (Ge et al, 2004; Cai et al, 2008; Song et al, 2009b). In our study, despite its identification as a pivotal key enzyme, dCK was not statistically correlated with DFS SHK performed experiments and analysed data; H-JK designed experiments, provided patient samples and clinical expertise; T-HL provided patient samples and performed experiments; W-SM provided patient samples and clinical information; H-JK provided patient samples and clinical data expertise; Y-KK provided valuable reagents; SYH performed experiments and analysed data; TSK designed and supervised the study, and wrote the manuscript. Relevant studies will be searched in the following electronic databases from their inception to June 10, 2019: PubMed, EMBASE, Cochrane Library, China Knowledge Resource Integrated Database, Weipu Database for Chinese Technical Periodicals, SinoMed, and Wanfang Database. The search terms include KOA, gonarthrosis, osteoarthrosis, osteoarthropathy, arthralgia, small needle knife, acupotomy, needle knife, and RCTs. The equivalent search words will be used in the Chinese databases. The detailed strategies for searching the PubMed database will be\n",
            "[0.90446925]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the mechanism used for synthesis of a highly functional N-truncated dystrophin isoform that attenuates dystrophinopathy?\n",
            "Refined Query: How is a shortened, highly functional dystrophin protein, lacking its N-terminus, synthesized to mitigate the effects of dystrophinopathy?  What specific genetic engineering or protein manipulation techniques are employed to achieve this attenuated isoform?\n",
            "\n",
            "Combined Answer: A novel DMD IRES results in a functional N-truncated dystrophin, providing a potential route to therapy for patients with 5’ mutations - PMC the higher dose, the number of dystrophin-positive fibers ranged between 44% and 79% of total fibers, with dystrophin intensity levels on immunostained fibers reaching up to 42% (range 11–42) of the amount in healthy muscle. We reasoned that for the restored dystrophin to be functional, it should stabilize the assembly of proteins of the DAPC including nNOS, but the experiments that could confirm this presumption were outside the scope of the trial. We now report on the increased expression of DAPC proteins (ASG, BDG) and of nNOS in (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton immediately beneath the sarcolemma. Regarding its important structural role, dystrophin connects the subsarcolemmal F-actin cytoskeleton to β-dystroglycan (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the We studied semiquantitatively three DAPC proteins, each one representative of one subcomplex of the DAPC, in four DMD patients, who received a single intramuscular (i.m.) administration of AVI-4658 at the higher dose of 0.9 mg. From the five patients treated at the higher dose, two with a missing nNOS-binding domain (carrying a deletion of exons 45–50) and two (carrying a deletion of exons 48–50) with an intact nNOS-binding domain in dystrophin, were selected for the study. All four patients demonstrated increased dystrophin expression after Skipping of dystrophin exon 51 has been shown to restore dystrophin expression in a subset of myofibers after a single i.m. injection of 2′OMe or PMO SSO in proof-of-principle clinical trials in DMD patients.16,17 After successful dystrophin restoration the important questions to address are the functional properties of the new-shortened dystrophin protein induced by exon skipping in the human. The lack of dystrophin in DMD leads to reduced levels of all DAPC proteins and even to the absence of nNOS from the sarcolemma.21,22,23,24,25 The Duchenne muscular dystrophy (DMD) is a progressive, severely disabling, and incurable X-linked recessive inherited disorder that affects 1 in 3,500 newborn boys and leads to death in the second or third decade of life.1 In patients with DMD, the open reading frame of the X-linked dystrophin gene, encoding dystrophin, is disrupted by deletions (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton 45–50) and two (carrying a deletion of exons 48–50) with an intact nNOS-binding domain in dystrophin, were selected for the study. All four patients demonstrated increased dystrophin expression after i.m. injection of the PMO SSO as reported previously.16 Dystrophin expression was not uniform in the biopsied muscle, being more pronounced in fascicles presumably adjacent to the needle track, as shown by adjacent positive and negative fascicles (Figure 2). In addition to the dystrophin staining identified by the antibody MANDYS106 (epitope in and/or conditional activation signals will shed light on underlying mechanisms of IRES control and elucidate potentially novel functions of dystrophin. An intriguing question is how the N-truncated isoform remains functional. A key cellular role for dystrophin is presumed to be transmitting the force of contraction across the sarcolemma to extracellular structures by serving as an important architectural bridge role between the F-actin cytoskeleton and the muscle plasma membrane41,42. Two regions within dystrophin are responsible for F-actin a deletion of exons 45–50 and two of 48–50, that the shorter novel dystrophin induced by exon 51 skipping in DMD can restore components of the DAPC as indicated by the increase in ASG and BDG in dystrophin-positive fibers and the genotype-specific relocalization of nNOS to the sarcolemma. These data confirm that restored dystrophin maintains essential domains for its function and further suggest the potential of the PMO AVI-4658 to become a disease modifying drug for DMD. protein induced by exon skipping in the human. The lack of dystrophin in DMD leads to reduced levels of all DAPC proteins and even to the absence of nNOS from the sarcolemma.21,22,23,24,25 The importance of a dystrophin protein containing its functional domains is highlighted by patients with the missense mutation (C3340Y)4,26 within the BDG binding domain that develop a DMD phenotype even though considerable levels of dystrophin staining was visible at the sarcolemma. Another patient harboring a missense mutation (D3335H)27 had dystrophin\n",
            "[0.64350617]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the newly identified DNA nucleases that can be used to treat thalassemia?\n",
            "Refined Query: Research is exploring novel DNA nucleases for thalassemia treatment.  What specific, recently discovered nucleases show promise in correcting the genetic defects underlying this disease, and what is the current status of their development and clinical application?\n",
            "\n",
            "Combined Answer: mutation rate of starved cells (3, 4, 36). On the other hand, while a mutM mutation did not affect the mutation rate of a mutT mutant, when combined with mutY a further enhancement in the mutation rate of starved mutY cells was observed (4). However, studies using adaptive mutagenesis with cells deficient in a full GO system have not been previously published. Several lines of evidence have implicated the MMR system in the repair of oxidative DNA damage (1, 45). The results described in this work support this idea since overexpression of the Results from this study support continued development of nusinersen for treatment of SMA. arrest occur in the next cell cycle with the accumulation of nascent nucleosomes containing unmodified H4K20 throughout the genome (Figure 7). DNA damage resulting from loss of PR-Set7 and H4K20 methylation was restricted to late replicating regions of the genome, suggesting a defect in the DNA replication program at the end of S phase. A paucity of activated origins has been shown to lead to DNA damage, fragile sites, and increased mutations in human cells due to the increased distances replication forks must traverse (44–46). However, unlike platform using HumanOmni1-Quad BeadChip (Illumina) according to the manufacturer's instructions, and analysed data using Illumina's GenomeStudio to look for insertions, deletions, and regions of homozygosity as well as haplotypes shared by affected siblings. Primers used for Sanger sequencing of the genomic DNA that encodes the complete coding sequence of TBC1D24 variant 1 (NCBI CCDS ID#55980.1) were generated with an online software ExonPrimer (see appendix p 6 for a list of primers). We generated amplicons with 10 ng of genomic DNA using screen, scanned with Typhoon 9410, and quantified by ImageQuant 5.2 software. Each indicated site on the thiamine-added 2D gel image was divided by the signal in the 1N spot in the same gel and then divided by the corresponding ratio for the “no thiamine” gel, setting the 0-h time point values as 1×. Quantitation is an average of at least two independent DNA preparations. Chromatin is made up of nucleosomes comprising histone octamers with a stable tetrameric core of histones H3 and H4, flanked by two more labile dimers of histone, H2A and H2B. Each histone octamer is wrapped by 147 bp DNA, which facilitates the compaction of genomic DNA and regulates access to regulatory factors (Workman and Kingston 1998). Chromatin is critical for the regulation of genome stability and for transcriptional control and its importance in disease has been highlighted by the frequent identification of mutations in transcriptionally silent in the fetal brain (Gerard et al. 1996). Hoxd11 was much more sensitive to DNase I digestion than silent Ndn (Fig. 4E). Thus, transcriptional silencing per se does not confer a chromatin structure resistant to nucleases. In summary, the presence of H4K20me3, H3K9me3, H3K79me3, and H3K36me3 at silent Ndn correlates with a chromatin structure that severely impairs DNA access to nucleases, whereas absence of these marks at the same locus correlates with an open chromatin structure, accessible to these enzymes. heterochromatin formation (Chen et al. 2008). Our results suggest that H3K36me3, in addition to H3K9me3, might also contribute to heterochromatin formation in mammalian cells. The recent finding that H3K36me3 stimulates the recruitment of DNA-methyltransferase DNMT3A onto nucleosomes is compatible with our hypothesis (Dhayalan et al. 2010). Interestingly, this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. and maintain gene repression. Supporting this hypothesis, Grewal and colleagues showed that, in fission yeast, mutations in Set2, which deposits H3K36me3, and Clr4, the HMTase responsible for the methylation of H3K9, resulted in cumulative defects in heterochromatin silencing, suggesting that the two enzymes act in parallel pathways to promote heterochromatin formation (Chen et al. 2008). Our results suggest that H3K36me3, in addition to H3K9me3, might also contribute to heterochromatin formation in mammalian cells. The recent finding that act to coordinate fork passage through cohesin rings with Okazaki fragment processing, e.g., to ensure lagging strand loop release upon cohesin encounter, or to ensure that loops do not exceed a maximum size. We therefore investigated the interplay between Ctf4 and Chl1, Okazaki fragment processing and sister chromatid cohesion. It has been reported that cells lacking Ctf4 show synthetic lethality with the dna2-2 mutation (Formosa and Nittis 1999; and data not shown). Dna2 is a nuclease-helicase involved in Okazaki fragment processing, whose\n",
            "[0.69959503]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does ziconotide bind to N-type calcium channels?\n",
            "Refined Query: Ziconotide, a peptide derived from the venom of the cone snail, is known to interact with voltage-gated calcium channels.  This question seeks to determine if its primary mechanism of action involves specific binding to N-type calcium channels, a subtype known to play a role in pain transmission.\n",
            "\n",
            "Combined Answer: Methods). Using our 12 rat RNA-seq profiles, we found that 233 of the 668 ZCCHC17 human regulon genes with an expressed rat homologue reached a significant correlation with ZCCHC17 in our rat data. Further analysis demonstrates that 81% of these identified genes in our rat data show the same sign of Spearman‘s rank correlation with ZCCHC17 in our human interactome (P-value < 2.2 × 10−16, binomial test; Supplementary Fig. S6A). In addition, across all of these 668 rat homologue genes, the correlation value of each ZCCHC17-target gene pair in et al., 2017; Ouyang, 2009). ZCCHC17 contains a zinc-finger (CCHC) domain and a nuclear localization signal, and microscopy has localized ZCCHC17 to the nucleus and nucleolus (Chang et al., 2003; Gueydan et al., 2002; Lin et al., 2017; Ouyang, 2009). Although there is no published experimental study of ZCCHC17 protein in brain tissue, a recent meta-analysis of RNA expression data from six previous gene expression studies of AD brain tissue included ZCCHC17 as one of the top 30 most reliably downregulated genes in AD (Li et al., 2015). interactome work has an associated Spearman‘s rank correlation value (Aubry et al., 2015). We tested the hypothesis that the Spearman‘s rank correlation between ZCCHC17 and each target gene in our human interactome is predictive of the identical Spearman‘s rank correlation in our rat data. Our human interactome was built using 193 samples (see Supplementary Methods). Using our 12 rat RNA-seq profiles, we found that 233 of the 668 ZCCHC17 human regulon genes with an expressed rat homologue reached a significant correlation with ZCCHC17 in our these targets are decreasing in AD. Using more conventional ontology analysis, ZCCHC17’s regulon also has a high representation of synaptic ontology groups (Supplementary Table S1). ZCCHC17 is a poorly understood protein that has been shown to interact with transcription factors (Chang et al., 2003; Joo et al., 2010) as well as splicing factors (Lin et al., 2017; Ouyang, 2009). ZCCHC17 contains a zinc-finger (CCHC) domain and a nuclear localization signal, and microscopy has localized ZCCHC17 to the nucleus and nucleolus (Chang et al., 2003; (1). CGRP is a 37-amino acid neuropeptide and a member of the calcitonin family, which includes calcitonin, adrenomedullin, amylin, and intermedin (2). It is expressed in both central and peripheral nervous systems, especially in dorsal root and trigeminal ganglions and their projections (3). Mammals express two isoforms, α-CGRP and β-CGRP, encoded by two distinct genes (4). The α-CGRP and β-CGRP are differentially regulated, differ in pharmacological profile, and have distinct physiological functions (5). During a migraine attack, CGRP of the subset of synaptic genes in the ZCCHC17 regulon. We first performed qPCR on three synaptic genes from our dataset that are predicted to have particularly strong positive correlations with ZCCHC17: SYT1, SYN2 and SV2B. qPCR for these three genes demonstrated statistically significant reductions in mRNA levels after ZCCHC17 knock-down (Fig. 3A and B). We then performed RNA-seq and discovered that a majority of the synaptic genes predicted to positively correlate with ZCCHC17 have reduced expression after ZCCHC17 knock-down. Of the 66 species and across multiple targets. Although the above findings are encouraging for our interactome analysis, one may still ask whether genes related to synaptic function are the most relevant net effect of ZCCHC17 knock-down. In other words, our computationally derived ZCCHC17 regulon is a fraction of the total number of genes that have changes in expression after ZCCHC17 knock-down. The ARACNe algorithm we used to establish the interactome is designed to detect only direct interactions between a transcriptional regulator and a target gene. domain into the cytosol (9), where it glucosylates and inactivates small GTPases, such as Rac and Rho, which play a critical role in maintaining cellular morphology and in multiple other aspects of cellular homeostasis. One aspect of toxin function that is still poorly understood is how TcdA and TcdB bind to host cells or, more specifically, what is the nature of the receptors to which the toxins bind. For TcdA, the receptor has been proposed to consist of a membrane-associated carbohydrate based on the following lines of evidence: (i) TcdA 3A and B). We then performed RNA-seq and discovered that a majority of the synaptic genes predicted to positively correlate with ZCCHC17 have reduced expression after ZCCHC17 knock-down. Of the 66 synaptic genes that positively correlate with ZCCHC17 in our interactome analysis with human expression data, 37 are significantly decreased in rat cortical cultures after ZCCHC17 knock-down (Supplementary Table S2). The above analysis suggests that ZCCHC17 has a relatively conserved function in neurons across species. To test this hypothesis genes, this is a fraction of the 775 total number of genes predicted to be regulated by ZCCHC17 in our human interactome analysis. We found that 668 of these 775 genes have a single unambiguous rat homologue that was also expressed at detectable levels in our rat cortical cultures (Supplementary Table S3). Each ZCCHC17-target interaction from our interactome work has an associated Spearman‘s rank correlation value (Aubry et al., 2015). We tested the hypothesis that the Spearman‘s rank correlation between ZCCHC17 and each target gene in our\n",
            "[0.5701637]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How is OCT3 associated with serotonin?\n",
            "Refined Query: How does the expression or function of the OCT3 transporter, specifically its role in serotonin uptake or metabolism, influence serotonin levels and signaling pathways in the brain and periphery?  Are there known interactions or regulatory effects between OCT3 and serotonergic systems?\n",
            "\n",
            "Combined Answer: and (ii) efflux of THs via TH transmembrane transporters. The relative quantitative contribution of each of these mechanisms during each stage of CNS development is currently unknown and should be investigated. Furthermore, perhaps the role played by choroid plexus-derived TTR is more significant in non-mammalian vertebrates than in mammals. It would be interesting to analyze the developmental profiles of TH transmembrane transporters in the choroid plexus (and in other blood-brain barrier structures) in non-mammalian vertebrates during It would be interesting to analyze the developmental profiles of TH transmembrane transporters in the choroid plexus (and in other blood-brain barrier structures) in non-mammalian vertebrates during development. The delivery of the requisite concentrations of THs to specific areas of the brain at each stage of CNS development is so important, that it would be understandable for evolution to have positively selected for more than one strategy for THs to enter the CNS. TTR null mice have 36% T4 levels in their brain compared to wildtype mice (Palha et al., 1997). This implies that TTR is responsible for the other 64% of T4 moving into the brain. However, Mct8/Oatp1c1 double knock-out mice are cited as having only 10% TH concentration in their brains compared to wildtype mice (Muller and Heuer, 2014). However, careful analysis of the original paper reveals that only the forebrain (and not the entire brain) was analyzed for TH content (Mayerl et al., 2014). Furthermore, if TH transmembrane transporters are Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters - PMC these receptors have the highest density in rat and human ventral striatum (Sokoloff et al., 1990; Gurevich and Joyce, 1999), one of the core areas implicated in the pathology of schizophrenia as well as depression and anxiety. The potential involvement of dopamine D3 receptors in the effects of antidepressants was suggested by several preclinical studies demonstrating that administration of antidepressant drugs enhances D3 receptor gene expression and/or binding in distinct brain regions (Maj et al., 1998; Lammers et al., 2000). Cariprazine, Kohrle (2013). The majority of current information on TH transmembrane transporters has been derived from only human and rodent data. A recent, comprehensive review on expression of TH transmembrane transporters during development in zebrafish, Xenopus tropicalis, chicken, and mouse (Darras et al., 2015) highlights how much is still unknown. Whilst the developing choroid plexus has only been analyzed for TH transmembrane transporters in a few species, interesting differences are emerging. For example, zebrafish choroid plexus does not transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters have been localized to the choroid plexus (Mayerl et al., 2012) and their distribution in the choroid plexus differs between species (Wirth et al., 2014). Most TH transmembrane transporters identified to date are promiscuous with respect to the range of metabolites they transport. Only MCT8 has been identified as being specific to transport of THs and it is known that THs enter cells via TH transmembrane transporters, which participate in the influx and efflux of THs into and out of cells. Several classes of TH transmembrane transporter proteins that belong to the family of solute carrier (Slc) transporters have been identified e.g. organic anion transporting polypeptides (OATPs), monocarboxylate transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters compared with wildtype mice? How do these data from TH transmembrane transporter and TTR null mice correlate with the data from Chanoine et al. (1992)? The quantitative contributions of the various mechanisms for TH moving across the blood-CSF barrier (the choroid plexus) and across the blood-brain barrier need to be investigated in greater detail. high affinity and occupancy of both D2 and D3 dopamine receptors may be effective as a treatment for depressive disorders as well as the negative symptoms of schizophrenia. A dopamine D3 receptor strategy for treatment of depression or schizophrenia is based on the brain distribution and the putative role of D3 receptors (Gross and Drescher, 2012); these receptors have the highest density in rat and human ventral striatum (Sokoloff et al., 1990; Gurevich and Joyce, 1999), one of the core areas implicated in the pathology of schizophrenia as\n",
            "[0.64634335]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1284.91ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.31ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 806.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.40ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 832.13ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.29ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.13ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1034.69ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1163.23ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 835.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can a peptide aptamer be used as protein inhibitor?\n",
            "Refined Query: The question explores the potential of peptide aptamers, short peptide sequences selected for high affinity binding to a target, to function as protein inhibitors.  Can their binding effectively disrupt the target protein's function, and if so, what are the limitations and advantages compared to other protein inhibitors?\n",
            "\n",
            "Combined Answer: the utility of such combinations in models of acquired resistance to proteasome inhibitors is largely unknown. We also demonstrated the generality of this approach for achieving synergism, as different combinations of carfilzomib or oprozomib with vorinostat or entinostat were all effective. The molecular basis for this synergism was found to be partially dependent on upregulation of proapoptotic Bik. By contrast, downregulation of MDR-1/P-gp, which was found to be overexpressed in the acquired resistance models, does not appear to play a role proteome analysis is particularly important. Dimethyl labeling provided a fast and straightforward quantification method17 to exclude the nonspecific binding proteins. Bantscheff and colleagues revealed HDAC complexes selectivity for 16 HDAC inhibitors by combining affinity capture and quantitative mass spectrometry. They found that the aminobenzamide inhibitors have preferred selectivity for the HDAC3-NCoR complex.33 HDAC3 was found to be a preferred cellular target of the 106 probe.7 However, HDAC3 was not identified in our data set although of HDAC inhibitors7 and is inhibited through a slow, tight-binding mechanism in contrast to the rapid-on/rapid-off inhibition mechanism observed for the hydroxamates TSA and SAHA,6,7 inhibition of other class I HDACs (HDACs 1 and 2) may also be involved in the beneficial effects of these compounds in FRDA and HD, and other HDAC interacting proteins may be important. To identify the targets of the 106 compound, we synthesized an activity-based profiling probe (ABPP) version of one of our HDAC inhibitors (106) and a control probe, which is a of Bik attenuated the synergy. The acquired resistance models also exhibited elevated levels of MDR-1/P-gp. Inhibition of MDR-1/P-gp with reversin 121 partially overcame carfilzomib resistance in R-UMSCC-1 and R-Cal33 cells. Collectively, these studies indicate that combining carfilzomib or oprozomib with HDAC or MDR-1/P-gp inhibitors may be a useful strategy for overcoming acquired resistance to these proteasome inhibitors. We next sought to determine whether our findings of synergism in the acquired resistance models would be extended to combinations of other proteasome inhibitors and other HDAC inhibitors. Oprozomib in combination with vorinostat also promoted synergistic killing of R-UMSCC-1 and R-Cal33 cells (Fig. 5A and B). Moreover, highly potent synergism was also observed when carfilzomib was combined with entinostat, a selective inhibitor of the class I HDACs HDAC1 and HDAC3 (Fig. 6A and B). These findings indicate that acquired proteasome inhibitor dependent on upregulation of proapoptotic Bik. By contrast, downregulation of MDR-1/P-gp, which was found to be overexpressed in the acquired resistance models, does not appear to play a role in the synergism between proteasome and HDAC inhibitors, since pretreatment with HDACi alone did not affect MDR-1/P-gp expression levels (data not shown). The overexpression of MDR-1/P-gp we observed in the acquired resistance models only partly explains the resistance of these cells. Only partial attenuation of carfilzomib resistance was seen when of colony formation followed co-treatment of acquired resistance models with carfilzomib and the histone deacetylase inhibitor (HDACi) vorinostat. Synergism was also seen with other combinations, including oprozomib plus vorinostat, or carfilzomib plus the HDACi entinostat. Synergism was accompanied by upregulation of proapoptotic Bik, and suppression of Bik attenuated the synergy. The acquired resistance models also exhibited elevated levels of MDR-1/P-gp. Inhibition of MDR-1/P-gp with reversin 121 partially overcame carfilzomib resistance in Attention to the PD effects of antibodies via the characterization of the interaction of the antibody and the soluble ligand is important, given that the soluble ligand is the active agent that elicits the pharmacological effect. When antibody is administered, the premise is that the ligand will bind to it and the free ligand concentration that is available to interact with the ligand receptor will be reduced. Theoretically, efficacy is driven by the magnitude and duration of the reduction in free ligand concentration (87). Galcanezumab, of a pharmacological response to a therapeutic intervention. Antibody drugs represent one of the fastest growing areas of drug development, and they often exhibit PK and PD properties that are more complex than those typically associated with small-molecule drugs (16). Antibody drugs that bind soluble ligands make up a large proportion of antibody therapeutics. As such, kinetics of both the antibody and the ligand are important for informing the pharmacological characteristics of the antibody drug. Pharmacokinetic/pharmacodynamic models that duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody–ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided.\n",
            "[0.5894157]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List inflammatory caspase proteins?\n",
            "Refined Query: Identify the specific caspase proteins known to be involved in inflammatory pathways, detailing their roles in the inflammatory cascade and associated diseases.\n",
            "\n",
            "Combined Answer: treatment, and every 30 min for the next 4 h (Wada et al. 2009). Whereas the original study focused solely on nascent transcription, we here show that standard application of ISMARA to this data set (http://ismara.unibas.ch/supp/dataset3/ismara_report/) uncovers the transcription regulatory network involved in this inflammatory response in remarkable detail. The response of endothelial cells to TNF is known to be mediated by TFs of the NFkappaB family, GATA2, IRF1, and JUN (Inoue et al. 2006) TFs. TFs of the NFkappaB family in particular are normally exists across the gut wall (3). Damage to the gut epithelium results in fluid leakage into the gut lumen and release of proinflammatory mediators, such as IL-1β, TNFα, and IL-8, leading to an inflammatory response that includes recruitment of neutrophils and macrophages to the site of injury, further aggravating the disease (4). Extensive structural and functional work over the past several years has led to a basic understanding of the molecular events that lead to toxin-mediated cell death, as recently reviewed by Pruitt and Lacy of these studies, MARA successfully inferred key regulators and their regulatory interactions ab initio. The applications in this work not only further confirm that in systems where key regulatory interactions are already known, ISMARA successfully infers them, but it also provides a large collection of novel regulatory predictions across different systems in human and mouse, e.g., novel regulators that are disregulated in cancers, novel regulatory interactions in the inflammatory response, and the core regulatory circuitry involved in such as the induction of procoagulant activity that promotes blood clotting, that may play an important role in the vascular effects of inflammation and the pathogenesis of vascular diseases (170). Innate recognition of LPS occurs through a receptor complex consisting of CD14, TLR-4, and myeloid differentiation factor 2 that recognizes pathogenic structures and subsequently induces an inflammatory response. Continuous activation of the innate immune system through TLRs by bacterial stimuli may disrupt immune homeostasis by the overproduction MEF2C [45], MTA3 [46], NFATC1 [47], PAX5 [48], PML [49], POU2F2 [50], RUNX3 [51], RXRA [52], SPI1 [53], STAT3 [54], STAT5A [55], TCF3 [56], and TCF12 [57], which are all known to be involved in the differentiation of lymphocyte lineages. This branch also included MEF2A, which, unlike its highly similar family member MEF2C, is not known to be involved in lymphocyte differentiation [58]. Thus, this analysis both recovered known functional relationships between TFs and discovered novel associations. To test whether protein-protein interactions detail. The response of endothelial cells to TNF is known to be mediated by TFs of the NFkappaB family, GATA2, IRF1, and JUN (Inoue et al. 2006) TFs. TFs of the NFkappaB family in particular are crucial for the resulting inflammatory response (Kempe et al. 2005). Indeed, ISMARA infers that the two most significant motifs are IRF1,2,7 and NFKB1/REL/RELA. The activity of NFKB1/REL/RELA increases sharply in the first 45 min and slower afterward, until it reaches a steady activity after 3 h. The activity of the IRF1,2,7 motif increases steadily extracts of E. coli cells that contained Pol1-NT and either full-length Ctf4, Ctf4-NT (the WD40 domain), or Ctf4-ΔNT. We isolated the various versions of Ctf4 through a six-histidine tag at the amino terminus of each protein, and used immunoblotting to determine whether they interacted with Pol1-NT. As shown in Figure 6B, Pol1-NT was able to interact with full-length Ctf4 and with Ctf4-ΔNT, but did not interact with the isolated WD40 domain itself. Taken together with the data described above, these findings indicate that Ctf4 binds GINS and 5b). As an exercise to consider how personal epigenomic maps may contain personalized regulatory information, we investigated ATAC-seq profile at the IL2 locus. IL-2 is a key cytokine that drives T-cell growth and functions in inflammatory and autoimmune diseases28. Furthermore, distinct drugs29–31 inhibit the activities of different transcription factors that bind putative IL2 enhancers in a context-dependent manner. In principle, one might wish to identify the causal transcription factor pathway in order to rationally target inhibition involves the disruption of the STAT3-EIF2AK2 complex as well as the phosphorylation of mitogen-activated protein kinase 8/c-Jun N-terminal kinase 1 (MAPK8/JNK1) and EIF2S1. These results reveal an unsuspected crosstalk between cellular metabolism (fatty acids), pro-inflammatory signaling (STAT3), innate immunity (EIF2AK2), and translational control (EIF2S1) that regulates autophagy. with studies showing that the UPR can attenuate the induction of inflammation as mediated by TFs of the NFkappaB family (Kaser et al. 2008; Kitamura 2011; Li et al. 2011). The induction of XBP1’s activity is not reflected in the expression of XPB1 itself, which is almost constant across the time course (Supplemental Fig. 20). This underscores that ISMARA infers a motif’s activity from the expression of its predicted targets and does not use the regulator’s own expression. Indeed, it has been established that XBP1 activity is regulated\n",
            "[0.46418095]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List invertebrates where ultraconserved elements have been identified.\n",
            "Refined Query: I need a list of invertebrate species in which ultraconserved elements (UCEs) have been identified and characterized through genomic studies.  This should cover a range of invertebrate phyla, if possible.\n",
            "\n",
            "Combined Answer: Two new sets of ultraconserved elements were defined in this study: one between the reference genomes of cow, dog, and horse (builds: bosTau6, canFam2, and equCab2) and the other between the reference genomes of dog, mouse, and rat (builds: canFam2, mm9, and rn4). We also identified UCEs between human, mouse, and rat (builds: hg18, mm9, rn4), which are very similar to the UCEs identified in 2004 [1], although earlier builds were used to identify UCEs in that study. Pairwise alignments were found between each possible pair of genomes within the based in the number of annotated RefSeq Genes [8], as well as in the more conservative Consensus Coding Sequence (CCDS) project [9]. As can be seen in Table 3, the UCEs-containing CNVs showed a lower than expected gene content, what allow us to reject this spurious association. Furthermore, this result is in good agreement with the previous report that non-exonic ultraconserved elements are often found in \"gene deserts\" [2]. It is worth mentioning that 88 of them were reported to be more than 100 kilobases away from any known gene. Conversely, lack a compelling explanation for why these sequences, called ultraconserved elements (UCEs), have been so extremely conserved for hundreds of millions of years – neither enhancers, nor transcription factor binding sites, nor promoters, nor protein coding regions require such a high level of conservation [1], [3]–[8]. Despite this, and because roughly half of UCEs are intronic and one third are intergenic, a popular expectation is that UCEs will be found to embody important regulatory activities; indeed, they are thought to be maintained by an invaluable tool in the task of differentiating benign from pathogenic CNVs or, in other words, to evaluate which genes may be dose-sensitive or not. In this context, the real significance of the ultraconserved elements (UCEs) in the human genome remains an intriguing issue. There are 481 UCEs, defined as stretches of at least 200 base pairs of human DNA that match identically with corresponding regions in the mouse and rat genomes [2]. They are widely distributed in the genome (on all the chromosomes except chromosomes 21 and Y) and are Ultraconservation came to light when Bejerano et al. reported that their comparison of the reference genomes of human, mouse, and rat had revealed an unexpected 481 orthologous genomic regions that are ≥200 bp in length and 100% identical in sequence [1], each of which is unique in the reference human genome [1], [2]. Ten years later, we still lack a compelling explanation for why these sequences, called ultraconserved elements (UCEs), have been so extremely conserved for hundreds of millions of years – neither enhancers, nor transcription that non-exonic ultraconserved elements are often found in \"gene deserts\" [2]. It is worth mentioning that 88 of them were reported to be more than 100 kilobases away from any known gene. Conversely, those pathogenic CNVs that do not contain UCEs showed a strikingly higher than expected gene content. This result suggests that gene content and presence of UCEs might be complementary criteria of pathogenicity, that is, pathogenic CNVs tend to affect either a high number of genes or closely regulated genes near UCEs, many of them in \"gene it becomes rather evident that the enrichment for ultraconserved elements is mainly due to the deletions (see Table 2). Deletions show a highly significant excess of UCEs, estimated in 3.6 times more frequent than expected. Conversely, the pathogenic gains of dose that we have detected in our series do not deviate significantly in the number of ultraconserved elements contained. The parental origin of the chromosome bearing the alteration could be determined in 21 cases through microsatellite segregation analyses. Ten rearrangements occurred from HT-SELEX data of Jolma et al. (14)), ‘PWMs from JASPAR CORE vertebrata’ (i.e. 205 PWMs from the JASPAR database (21)) and ‘PWMs from UniPROBE & HT-SELEX & JASPAR CORE vertebrata’ (all 876 PWMs from the three databases). COUGER also offers three choices for Drosophila melanogaster data: PWMs from TRANSFAC’ (i.e. 1226 PWMs from TRANSFAC database (13)), ‘PWMs from JASPAR CORE insecta’ (i.e. 131 PWMs from JASPAR database (21)) and ‘PWMs from TRANSFAC and JASPAR CORE insecta’ (all 1357 PWMs from the two databases). Another putative argument for a random association between pathogenic CNVs and UCEs might be derived from the fact that many UCEs appear clustered. However we found a similar number of isolated and clustered ultraconserved elements in our series (13 and 16, respectively). In fact, the isolated elements were over-represented as compared with clustered elements. In the 2.67% of the genome are present 10% of the isolated elements (13/131) and 4.6% of the clustered elements (16/350), what represent the respective enrichment ratios of 3.7 and 1.7. Item counts for the presence of ultraconserved elements, sno/miRNAs and genes in the regions encompassed by CNVs were performed through the UCSC Genome Browser [12], based on build hg18. The delimiting positions of all the ultraconserved elements, tracked in the hg16 version, were converted to built hg18 through the 'Convert' Feature http://genome.ucsc.edu/goldenPath/help/hgTracksHelp.html#Convert and compiled in an in-home excel sheet to facilitate visual inspection. In every case, a confirmation of the positions was performed by employing as\n",
            "[0.76310307]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which gene is most commonly associated with severe congenital and cyclic neutropenia?\n",
            "Refined Query: Severe congenital neutropenia (SCN) and cyclic neutropenia (CyN) are debilitating conditions characterized by low neutrophil counts.  Identifying the gene most frequently mutated in patients with these severe forms of neutropenia is crucial for understanding disease mechanisms and developing targeted therapies.  Which gene's mutations are most commonly implicated in SCN and CyN pathogenesis?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause may aggravate the severity and prognosis of the disease, but its occurrence seems to be dependent on the specific region of the mutation and its severity. As the disease is progressive and symptoms may appear later in the course, we suggest to include genetic analysis of C12orf65 in the diagnostic work-up of all patients with at least two of these three major features. disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly to C to T transition by mechanisms involving deamination of a methylated cytosine.26 Family 9 has been reported previously in the literature as a US-based pedigree.15 In our study R500X represents approximately 16% of the mutations in CS. There are also two other reports of likely independent pedigrees with the R500X mutation.1, 2 Taking all these reports into account, conservatively R500X may represent up to 10% of mutations in the literature currently (at least three in total). Interestingly, we also discovered a second SNV (c.1710 g>a, candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and were inherited from an asymptomatic parent each time it could be tested. Subsequently, PHOX2B has been identified as the major disease causing gene in CCHS with a heterozygous de novo mutation in over 90% of the cases.11,23,24 Frameshift and missense mutations lying in the homeodomain of the protein are rare (11% in this series, fig 1) and lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific knowledge, to optimise variant interpretation and introduce consensus. Initiatives such as the Clinical Genome Resource (ClinGen)4, are working to define such disease- and gene-specific thresholds, although these are currently limited to pilot phases for specific gene-disease pairs. The introduction of guidelines, including the logic behind around the mutation locus (Supplementary Table 4), which may be prone for recurrent mutation although further research will be necessary to clarify this. The mutation occurs at a CpG location in the genomic DNA, although not in a known CpG island or methylation hotspot; however, it remains formally possible that this C is methylated and prone to C to T transition by mechanisms involving deamination of a methylated cytosine.26 Family 9 has been reported previously in the literature as a US-based pedigree.15 In our study R500X represents we returned abstracts containing mentions of clinically relevant mutations, the MeSH ‘Diseases Category’ was an essential component. We chose the MeSH terms ‘Mutation’ and ‘Polymorphism, Genetic’ to obtain abstracts that had been indexed as pertaining to genomic variation. The ‘Title/Abstract’ field was searched for terms identified to retrieve information pertaining to sequence type, mutation type and mutation location (see query later in the text). This strategy was chosen after reviewing example abstracts containing desired mutation we did exome sequencing (table 1). All mutations were novel except for the frameshift mutation, seen in the heterozygous carrier state in two of 6118 individuals sequenced for that region in the June, 2013, release of the Exome Variant Server (EVS-v.0.0.20). This server provides variant frequency data for multiple exome studies done mostly in adults with various heart and lung diseases and controls, and individual phenotypes are not available. In view of the facts that mutations in this gene have been identified as the cause of some pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this\n",
            "[0.5957532]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: what is the role of TGFbeta in cardiac regeneration after myocardial injury?\n",
            "Refined Query: Myocardial injury, like that from a heart attack, triggers a complex healing response.  How does transforming growth factor beta (TGFβ), a pleiotropic cytokine, influence this process?  Does it promote or hinder cardiac regeneration, and what are the underlying mechanisms involved in its effects on cardiomyocyte survival, proliferation, and fibrosis?\n",
            "\n",
            "Combined Answer: for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by stimulating the NO-cyclic guanosine monophosphate vascular relaxation pathway as well as by increasing the production of the calcium ion (Ca2+)i (53). An increase in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved protein to cytosol. Immunofluorescence staining also revealed that TGF-β1 effectively removes Necl-2 from cell-cell interface. In addition, TGF-β1 reduces Necl-2 mRNA via down-regulating Necl-2 promoter activity. Mutational studies coupled with knockdown experiments have shown that TGF-β1-induced Necl-2 repression requires activation of Smad proteins. EMSA and ChIP assays further confirmed that TGF-β1 promotes the binding of Smad proteins onto MyoD and CCAATa motifs in vitro and in vivo. Taken together, TGF-β1 is a potent cytokine that in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved in angiogenesis by regulating the expression of VEGF by means of intracellular signaling (40, 56). The inhibition of TGF-β1 signaling will lead to reduced endothelium-dependent vasodilation and increased endothelial cell apoptosis, suggesting that dysregulated TGF-β1 signaling may be involved in the pathogenesis of preeclampsia (40). A decline of VEGF proteins. EMSA and ChIP assays further confirmed that TGF-β1 promotes the binding of Smad proteins onto MyoD and CCAATa motifs in vitro and in vivo. Taken together, TGF-β1 is a potent cytokine that provides an effective mechanism in controlling Necl-2 expression in the testis via Smad-dependent gene repression and clathrin-mediated endocytosis. Fibrocytes were treated without or with teprotumumab in combination with IGF-1 or TSH. Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes - PMC Transforming Growth Factor-β1 (TGF-β1) Regulates Cell Junction Restructuring via Smad-Mediated Repression and Clathrin-Mediated Endocytosis of Nectin-like Molecule 2 (Necl-2) - PMC produce factors associated with tissue remodeling and angiogenesis, e.g., MMP9 and VEGF (109). These macrophages are mostly of the immunomodulatory phenotype (M2) and contribute to the creation of a tolerogenic immune environment by producing immunosuppressive cytokines, such as IL-10 and IL-35, inducing expression of regulatory T cells (Tregs), phagocytosing apoptotic trophoblast cells to prevent the release of pro-inflammatory substances, and inhibiting the cytotoxic function of dNK cells (110). Decidual T cells are predominantly of the CD8+ Teprotumumab attenuates the actions of both IGF-1 and TSH in fibrocytes. Specifically, it blocks the induction of proinflammatory cytokines by TSH. These results provide, at least in part, the molecular rationale for interrogating the therapeutic efficacy of this antibody in TAO. TSH-provoked IL-6 and IL-8 expression in fibrocytes is mediated in part through the Akt pathway (22). Fibrocytes were treated with teprotumumab for 1 hour and treated with bTSH, and Akt phosphorylation was assessed. Teprotumumab partially blocked the effects of TSH on pAkt (S473) (density normalized to β-actin, 1.73 to 0.33; Figure 4). The mAb also blocked the expected increase in pAkt (S473) provoked by IGF-1 (Figure 4).\n",
            "[0.7422136]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List two chemotherapeutic agents that are used for treatment of Subependymal Giant Cell Astrocytoma\n",
            "Refined Query: What two chemotherapeutic agents are commonly employed in the treatment protocols for subependymal giant cell astrocytoma (SEGA),  considering the tumor's location and the patient's overall health?\n",
            "\n",
            "Combined Answer: aside from the use of mTOR inhibitors in tuberous sclerosis-associated subependymal giant cell astrocytoma which is a very rare entity in the pediatric population, selumetinib is one of the first prospectively-tested and successful molecularly-targeted agents in pLGG. These data provide a new alternative for patients with multiply recurrent pLGG. These data have also directly led to the development of two large multi-institutional prospective randomized phase III COG trials in previously untreated patients comparing selumetinib to standard findings do not alter therapy if the child presents with classic clinical and imaging features. However, biopsy may be helpful if biological information gleaned from the tissue may guide therapy or provide additional prognostic information. Despite aggressive therapeutic approaches and decades of clinical trials evaluating numerous chemotherapeutic and radiation therapy regimens, there has been no improvement in survival for children with GBM. The impediment to treatment is the invasive capacity of these high-grade astrocytomas within the Pediatric low-grade glioma (pLGG) is the most common central nervous system tumor in children.(1) The mainstay of therapy is a complete surgical resection as this can be curative; however, children for whom a gross total resection is not achievable often require additional therapy.(1, 2) There are multiple first-line chemotherapy regimens including combinations of carboplatin and vincristine (CV), combinations of thioguanine, procarbazine, lomustine and vincristine and vinblastine monotherapy.(3, 4) Five-year overall survival (OS) with our selumetinib data in recurrent pLGG patients compares favorably to the Fisher et al data following classic chemotherapy in previously untreated patients.(32) A limitation of these data are the small patient numbers and the lack of more standard visual acuity assessments such a Teller acuity cards and HOTV testing. To our knowledge, aside from the use of mTOR inhibitors in tuberous sclerosis-associated subependymal giant cell astrocytoma which is a very rare entity in the pediatric population, selumetinib is one of the first and radiation therapy regimens, there has been no improvement in survival for children with GBM. The impediment to treatment is the invasive capacity of these high-grade astrocytomas within the brain and their inherent resistance to adjuvant therapies. In addition, permanent damage inflicted to a developing brain by current life-saving therapies severely impacts the quality of life of surviving children [4, 8, 10]. A number of recent comprehensive studies have reported differences at both the copy number and expression levels that distinguish This prospective phase II trial was developed and conducted by PBTC investigators in collaboration with the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP). The trial enrolled children with recurrent, refractory or progressive pLGG to 6 unique strata separated by histology, location, NF1 status and BRAF aberration status. Herein we report on strata 1 and 3 which represent some of the most common patients with recurrent pLGG. Stratum 1 included children with World Health Organization (WHO) grade I pilocytic astrocytoma Pediatric low-grade glioma (pLGG) is the most common central nervous system tumor of childhood. Although overall survival is very good, many children suffer from multiple progressions and functional morbidities. There is no one universally accepted therapy for children with recurrent disease, however, standard cytotoxic chemotherapies are often utilized by most practitioners. The Pediatric Brain Tumor Consortium conducted a multi-institutional phase II study evaluating selumetinib (AZD6244, ARRY-142886), a MAP/ERK Kinase I/II inhibitor, in High-grade astrocytomas [anaplastic astrocytoma and glioblastoma (GBM)] are the most biologically aggressive form of cancer and a leading cause of cancer-related mortality and/or morbidity in the pediatric years [15, 19, 22]. They account for 20 % of all brain tumors in children and occur mainly supratentorially in the cortex or thalamus or in the brainstem where they are called diffuse intrinsic pontine gliomas (DIPGs). Cortical GBM can be amenable to complete surgical resection, however, up to 85 % will die within 2 years of diagnosis [3, 15, 1 and 2 non-pilocytic astrocytoma harboring either one of the two most common BRAF aberrations; and stratum 6, pLGG not associated with NF1 with tissue available for BRAF analyses that could not be classified into stratum 1, 2 or 5 due to inadequate tissue quality or assay failure. Data was analyzed by the PBTC Operations Biostatistical Data Management Core (OBDMC). The protocol was approved by each site’s local institutional review board (IRB). All patients and/or legal guardians provided written informed consent/assent as required by the through a tandem duplication resulting in a KIAA1549-BRAF fusion or an activating point mutation, BRAFV600E.(18) Approximately 80–90% of pilocytic astrocytomas (PA), the most common pLGG, harbor the KIAA1549-BRAF fusion whereas BRAFV600E mutations are identified in approximately 10–20% of all pLGG.(19) Numerous drugs that target the MAPK pathway have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The\n",
            "[0.6044629]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are integrins part of the extracellular matrix?\n",
            "Refined Query: Integrins are transmembrane receptors, not components of the extracellular matrix (ECM) itself.  The question explores whether integrins, which mediate cell-ECM interactions, should be considered part of the ECM due to their role in connecting cells to it.\n",
            "\n",
            "Combined Answer: fluid-phase or receptor-mediated endocytosis. The general pathway for IgG elimination after SC administration is shown in Figure 1. The contribution of different organs to mAb catabolism is estimated to be 33% for liver, 24% for skin, 16% for muscle, and 12% for intestine (50). An mAb is catabolized into peptides and amino acids primarily by the reticuloendothelial system, which consists of phagocytic cells such as macrophages and monocytes (51). Cells in the body have the ability to take up proteins or macromolecules from the surrounding receptor (i.e. FcRn) (24). FcRn is located in many tissues in adults such as endothelial cells of kidneys, liver, lungs, hepatocytes, intestinal macrophages, peripheral blood monocytes, and dendritic cells (25–27). Although FcRn is located in the GI epithelium, it appears that IgG is absorbed minimally in humans (28). FcRn functions within systemic tissues to protect IgG from degradation, and the receptor may be an important determinant of tissue disposition (see Distribution and Elimination sections) (23). The systemic absorption of an that significant extravasation occurs with antibodies by transcellular diffusion (33). The main processes in which endocytosis of antibodies can occur are phagocytosis, fluid-phase pinocytosis, and receptor-mediated endocytosis (34). Virtually all cells in the body have the ability to take up proteins and other macromolecules, including antibodies, from the surrounding fluid space via fluid-phase pinocytosis. Receptor-mediated endocytosis may occur following binding of antibodies to cell surface antigens or Fcy receptors, which are present on reticuloendothelial system, which consists of phagocytic cells such as macrophages and monocytes (51). Cells in the body have the ability to take up proteins or macromolecules from the surrounding fluid space via fluid phase endocytosis, from which the formed endosome is delivered to a lysosome where its content undergoes enzymatic degradation. A significant portion of IgG is rescued from lysosomal catabolism by FcRn (23,52,53). Within the acidified environment of the early endosome, IgG binds tightly to FcRn. The IgG–FcRn complexes are not et al., 2011). Cell–cell junctions in the central nervous system (CNS) are maintained by a variety of transmembrane proteins that signal and physically link between the cytoskeletons of adjacent cells. Many such proteins (e.g. CNTN, LRIG, NCAM, SEMA3 and SIGLEC families) contain one or more immunoglobulin (IG) superfamily domains (Rougon and Hobert, 2003). Here we identify TMEM132 molecules as novel IG domain containing proteins of the CNS. with intracellular C-terminal Ser/Thr phosphatase-1 (PP1) docking (Hendrickx et al., 2009; Heroes et al., 2013) and WIRS (WAVE regulatory complex interacting receptor sequence) cytoplasmic motifs (Fig. 1 and Supplementary Fig. S1) (Chen et al., 2014). The latter is consistent with the reported co-localization of TMEM132D with actin filaments (Walser et al., 2011). Cell–cell junctions in the central nervous system (CNS) are maintained by a variety of transmembrane proteins that signal and physically link between the cytoskeletons of adjacent A significant portion of IgG is rescued from lysosomal catabolism by FcRn (23,52,53). Within the acidified environment of the early endosome, IgG binds tightly to FcRn. The IgG–FcRn complexes are not delivered to the lysosome for catabolism but rather are sorted to the cell surface for fusion with the cell membrane. The receptor shows virtually no affinity for IgG at physiological pH and, upon fusion of the sorting vesicle with the cell membrane, IgG dissociates from the receptor and is released into blood or interstitial fluid. This from the surrounding fluid space via fluid-phase pinocytosis. Receptor-mediated endocytosis may occur following binding of antibodies to cell surface antigens or Fcy receptors, which are present on a variety of cells including monocytes, macrophages, B-lymphocytes, and platelets, and contribute to the movement of antibodies from blood to tissues (33). Convective transport through paracellular pores is considered to be the primary mechanism of antibody extravasation in tissues (35). Convective transport is driven by the hydrostatic pressure E1 (amino acids 1 to 211), E2 (activation domain [AD], amino acids 1 to 168), E3 (amino acids 169 to 433), E4 (ligand-binding domain [LBD], amino acids 212 to 433), E5 (amino acids 93 to 433), and E7 (DNA-binding domain [DBD], amino acids 93 to 211) (Fig. 3A). Dax1 was precipitated strongly with the full-length Esrrb, E3, and E4 regions and weakly with the E2 and E5 regions but not with the E1 and E7 regions (Fig. 3B), suggesting that Dax1 binds to the AD and LBD regions of Esrrb, but a part of the DBD region of Esrrb may act as an inhibition with the E2 and E5 regions but not with the E1 and E7 regions (Fig. 3B), suggesting that Dax1 binds to the AD and LBD regions of Esrrb, but a part of the DBD region of Esrrb may act as an inhibition domain for the association of Dax1 and Esrrb.\n",
            "[0.8358634]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Calcium homeostasis important in cardiac physiology and pathophysiology?\n",
            "Refined Query: Calcium homeostasis is crucial for normal heart function.  How does precise calcium handling within cardiomyocytes influence excitation-contraction coupling, and what disruptions in this process contribute to cardiac arrhythmias and heart failure?\n",
            "\n",
            "Combined Answer: SR Ca2+ ATPase 2a (SERCA2a) is a critical ATPase responsible for Ca2+ re-uptake during excitation-contraction coupling. Impaired SR Ca2+ uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure (HF)1. Accordingly, restoration of SERCA2a expression by gene transfer has proven to be effective in improving cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most in isolated cardiomyocytes augmented contractility and accelerated Ca2+ decay. Transgene-mediated SUMO1 overexpression rescued pressure overload-induced cardiac dysfunction concomitantly with increased SERCA2a function. By contrast, down-regulation of SUMO1 using shRNA accelerated pressure overload-induced deterioration of cardiac function and was accompanied by decreased SERCA2a function. However, knockdown of SERCA2a resulted in severe contractile dysfunction both in vitro and in vivo, which was not rescued by overexpression of SUMO1. Taken and stability. The levels of SUMO1 and SUMOylation of SERCA2a itself were greatly reduced in failing hearts. SUMO1 restitution by adeno-associated virus-mediated gene delivery maintained protein abundance of SERCA2a and significantly improved cardiac function in HF mice. This effect was comparable to SERCA2a gene delivery. Moreover, SUMO1 overexpression in isolated cardiomyocytes augmented contractility and accelerated Ca2+ decay. Transgene-mediated SUMO1 overexpression rescued pressure overload-induced cardiac dysfunction concomitantly with variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants (TTNtv) in exons constitutively expressed in the heart are robustly associated with DCM15. Additionally, it is unclear that the mechanism of action for these variants is truly loss of function (LoF). Instead of scoring all TTNtv equally and assuming an underlying LoF mechanism, we only score TTNtv highly if they are in constitutive exons (proportion complex (DAPC),3 composed of three subcomplexes: (i) the sarcoglycans (α, β, γ, and δ), (ii) syntrophin, nNOS, and dystrobrevin, and (iii) BDG and α-dystroglycan. The absence of dystrophin and destabilization of the DAPC is thought to render muscle cells susceptible to stretch-induced damage and increased intracellular calcium influx, leading to a series of pathological processes responsible for skeletal and cardiac muscle fiber necrosis,9 inflammation and replacement of muscle with fibro-adipose tissue. Regarding the signaling function, of the following during treatment: an increase in QT/QTc interval to >500 milliseconds and/or of >60 milliseconds over baseline, any evidence for ventricular or supraventricular arrhythmia with or without hemodynamic compromise or any advanced AV block, or symptomatic persistent bradycardia <35 bpm that required medical intervention. The mechanical properties of isolated ventricular cardiomyocytes were assessed using a video-based edge detection system (IonOptix) as previously described26. Generally, inosine is interpreted as guanosine by the translation machinery, which may lead to codon substitutions in protein-coding sequences. Almost 100% of the human GluA2 transcripts are edited at codon position 607 which leads to a substitution of glutamine (CAG codon) with arginine (CIG codon) in the polypeptide chain. The introduction of a positive charge reduces calcium permeability in the mammalian AMPA receptor. In human, aberrant editing of the Q/R sites has been associated with death of motor neurons [4]. However, the vast majority Cardiac Safety of Ozanimod, a Novel Sphingosine‐1‐Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study - PMC in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor desensitization, internalization, and degradation of the cardiac S1P1R have been proposed to explain the time‐related attenuation of heart‐rate effects.1, 17, 33 In a previous phase 1 single‐ascending‐dose and multiple‐ascending‐dose study with ozanimod, a mild dose‐dependent, first‐dose reduction in HR was observed, which was attenuated with an\n",
            "[0.57651794]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List available databases containing information about conserved noncoding elements.\n",
            "Refined Query: I need a list of databases that house information on conserved non-coding sequences,  specifically those  showing evolutionary conservation across species and potentially linked to regulatory functions.  Which databases are publicly available and readily searchable for this type of data?\n",
            "\n",
            "Combined Answer: identified through multiple alignment of genomes of several organisms, and termed conserved non-coding elements (CNEs). In addition, it contains large non-coding regions most of which are not linked to any particular function. All these genomic components appear to have many statistical features in common with natural languages [2]. A computational tool oriented towards the systematic search for avoided words is particularly useful for in silico genomic research analyses. The search for absent words is already undertaken in the recent past and or grammars. However, a linguistic analysis of the DNA needs to take into account many distinctive physical and biological characteristics of such sequences: The genome consists of coding regions that encode for polypeptide chains associated with biological functions as well as a plethora of regulatory and potentially functional non-coding regions, identified through multiple alignment of genomes of several organisms, and termed conserved non-coding elements (CNEs). In addition, it contains large non-coding regions most of which are not linked genomic nucleotide conservation, overlapping SNP database entries and overlapping repetitive elements. Clicking on an organism under the conservation column will direct the user to the UCSC genome browser location of the conserved editing site in the selected organism. Clicking on the reference column will direct the user to the PubMed abstract for the selected study. Users can download their search results as a tab-delimited text file by clicking on the ‘Download results’ button. A more detailed explanation of the results page can be found on thresholds of sequence similarity applied between the considered genomes: from 75 to 80 (the least conserved CNEs, which thus are expected to serve less demanding functional roles) to 95–100 which represent the extremely conserved non-coding elements (UCNEs or CNEs 95–100) [15]. The remaining two collections have been composed under different constraints and have been derived after alignment of genomes belonging to the Mammalian and Amniotic groups. In Tables 1 and 2, the last line shows the ratios formed by the numbers of avoided words of RAPIDR is implemented in R and can be freely downloaded via CRAN from here: http://cran.r-project.org/web/packages/RAPIDR/index.html. Contact: kitty.lo@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online. functional region within the gene (coding sequence, untranslated region, intron), associated repetitive element, conservation of editing to other species and the reference study in which the site was first identified. We designed a user-friendly web interface to query the database. The search page is displayed in Figure 1. Users must choose a species (human, mouse or fly) to search within. Users can filter their desired search using any combination of the listed annotations consisting of location in genome, gene, genic location conservation (chimpanzee, rhesus and/or mouse for human editing sites and human for mouse editing sites). To facilitate more detailed searches, we have made the entire database contents available as flat files on the Download web page. An example results page is displayed in Figure 2. The search parameters are repeated across the top of the page. Information about each editing site is displayed in a single row consisting of nine columns: chromosome, position, gene, strand, genic region, repetitive element, conservation, reference and editing in human and Drosophila. The set of TADs that are associated with high levels of noncoding conservation exhibit distinct properties compared to TADs devoid of extreme noncoding conservation. The close correspondence between extreme noncoding conservation and TADs suggests that these TADs are ancient, revealing a regulatory architecture conserved over hundreds of millions of years. query using user-specified sequences. The entire resource can be downloaded as a tab delimited flat-file and associated sequences as a Fasta file in the download page. The CarbonylDB also provides additional information on other oxidative modification databases and prediction tools for carbonylated proteins/sites. form a post-transcriptional regulatory code. We provide a database that supports the quest for deciphering this regulatory code. Within doRiNA, we are systematically curating, storing and integrating binding site data for RBPs and miRNAs. Users are free to take a target (mRNA) or regulator (RBP and/or miRNA) centric view on the data. We have implemented a database framework with short query response times for complex searches (e.g. asking for all targets of a particular combination of regulators). All search results can be browsed, inspected\n",
            "[0.13430148]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1712.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.02ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 983.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 858.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1109.66ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 958.63ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 983.23ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1159.98ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of ELMO1 gene in cell migration?\n",
            "Refined Query: ELMO1's role in cell migration is complex and multifaceted.  How does ELMO1, specifically its interaction with Dock180 and other proteins, regulate the  formation and activity of  cell migration machinery, such as  lamellipodia and filopodia, ultimately influencing cell motility and directional movement?\n",
            "\n",
            "Combined Answer: matrix and the actin-based cell cytoskeleton, with major roles in regulating changes in neuronal cell morphology, motility and migration. These findings should precipitate more detailed experimental and structural characterization of the TMEM132 family, and assist in formulating hypotheses concerning the cellular mechanisms by which sequence variants in these genes contribute to neurological disease. Their ancient ancestry and their associations with neurological disease suggest that TMEM132 genes have been undeserving of their relative obscurity. Our identification of these proteins as CNS-expressed IG domain superfamily adhesion molecules now places them in a more appropriate perspective as a putative key connection between the extracellular matrix and the actin-based cell cytoskeleton, with major roles in regulating changes in neuronal cell morphology, motility and migration. These findings should precipitate more detailed experimental but, in eukaryotes, were previously thought to be restricted to choanoflagellate and sponge proteins (Pfam accession: PF00963) (Abedin and King, 2008; Nichols et al., 2012; Peer et al., 2009). These are not to be confused with the cohesin complex that regulates the separation of sister chromatids. Rather, cohesin domains are highly specialized protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria the well-documented repressive properties of GATA-1 and FOG-1 interactions (Crispino et al, 1999; Fox et al, 1999; Letting et al, 2004; Pal et al, 2004). Only the slower migrating isoform of FOG-1 (Figure 3) interacts with the GATA-1/MeCP1 complex, providing a potential mechanism for the selective formation of the GATA-1/FOG-1/MeCP1 complex. We suggest that the separate GATA-1/FOG-1 complex without MeCP1 links GATA-1 with FOG-1 to transcriptional activation. For example, disruption of GATA-1 and FOG-1 interactions downregulates erythroid genes by Blobel and Weiss, 2001). Significantly, C-ZnF is essential for all in vivo GATA-1 functions, whereas N-ZnF is required for definitive, but not primitive, erythropoiesis (Shimizu et al, 2001). We addressed how the GATA-1 zinc-fingers mediated its multiple protein interactions by expressing in MEL cells biotin-tagged mutants lacking N-ZnF or C-ZnF followed by streptavidin pull-downs (Figure 3A–C). As described (Tsang et al, 1998), GATA-1 interaction with FOG-1 requires N-ZnF. Interactions of the MeCP1 members MTA2, Mbd2 and HDAC 1 also occur protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria specialized in degrading cellulose (Adams et al., 2008; Artzi et al., 2017; Bras et al., 2016; Pinheiro et al., 2008; Tavares et al., 1997). Bacterial cohesin-dockerin rupture forces (>120 pN) are among the highest ever reported for a receptor-ligand system (Nash et al., 2016; Stahl et al., 2012). It is unclear whether the TMEM132 cohesin domain mediates a short spike of E2F activity up-regulates cell-cycle genes at day 1. Finally, there is a group of motifs (TBP, FOS_FOS{B,L1}_JUN{B,D}, RXR{A,B,G}, HOX{A6,A7,B6,B7}, and GLI1..3) whose targets are progressively down-regulated across the differentiation time course. The targets of these motifs are generally enriched for extracellular proteins involved in cell adhesion, cell–cell junctions, and signaling. More specifically, targets of GLI1..3 involve genes from the TGF-beta pathway, targets of TBP involve nucleosomal and intermediate filament upregulated NEAT1 synthesis occurs in motor neurons at the early stage of ALS development, suggesting a protective role against various insults, which might be particularly important for motor neuron welfare [18]. We have also established links between loss and gain of function of FUS protein and disrupted paraspeckle assembly in ALS-FUS [19]. This allowed us to propose a model whereby aggregation of FUS in the cytoplasm leads to its nuclear loss accompanied by depletion of other paraspeckle proteins, which in turn may disable protective in induced MEL cells (Figure 2). Possibly, the two factors regulate common gene targets through distinct complexes and binding sites. Alternatively, the functions of GATA-1 with FOG-1 or Gfi-1b could be separate, for example, differentiation (FOG-1) versus proliferation arrest (Gfi-1b), with each function being essential for erythropoiesis. We also describe, for the first time, interactions of GATA-1 with the MeCP1 and ACF/WCRF complexes, linking GATA-1 to repressive functions (with MeCP1) and chromatin structure. Previous evidence linking with intracellular C-terminal Ser/Thr phosphatase-1 (PP1) docking (Hendrickx et al., 2009; Heroes et al., 2013) and WIRS (WAVE regulatory complex interacting receptor sequence) cytoplasmic motifs (Fig. 1 and Supplementary Fig. S1) (Chen et al., 2014). The latter is consistent with the reported co-localization of TMEM132D with actin filaments (Walser et al., 2011). Cell–cell junctions in the central nervous system (CNS) are maintained by a variety of transmembrane proteins that signal and physically link between the cytoskeletons of adjacent\n",
            "[0.7199613]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the biological role of K-48 linked protein ubiquitination?\n",
            "Refined Query: Explain the specific function of K48-linked polyubiquitin chains in targeting proteins for degradation via the proteasome.  Detail the process and its significance in cellular regulation.\n",
            "\n",
            "Combined Answer: example, Pta1 phosphorylation by CKII and dephosphorylation by Glc7 modulate its function in poly(A) addition (16). Similarly, it has been reported that the sumoylation of Symplekin and/or CPSF-73 affects the assembly and the activity of the cleavage and polyadenylation complex (44). Ubiquitination of the splicing complex controls the assembly and disassembly of the spliceosome (3), suggesting a common regulatory theme for complexes mediating multistep reactions. In summary, we have shown that the N terminus of Pta1 is important for CTD Ser5-P for interactions with the nuclease Ysh1) and promotes a Pta1 conformation (Form B) that favors cleavage and polyadenylation. The absence of Ssu72 leads to a different conformation (form A) that is inactive for 3′-end processing. Forming and breaking of the Pta1-Ssu72 contact may also work in concert with posttranslational modifications of Pta1. For example, Pta1 phosphorylation by CKII and dephosphorylation by Glc7 modulate its function in poly(A) addition (16). Similarly, it has been reported that the sumoylation of Symplekin and/or CPSF-73 end joining Ku complex, pKu70 and 80. In addition, Rqh1 (homolog of human BLM) DNA helicase and its two interacting partners, the topoisomerase Top3 and Rmi1, were Pfh1-associated. This highly conserved heterotrimeric complex has multiple functions, but is best known for suppressing DNA damage at hard-to-replicate sites, such as converged forks [63] and/or collapsed replication forks—functions relevant to those of Pfh1. Finally, six subunits of the 26 subunit RNA polymerase III complex were Pfh1-associated with high confidence (Rpc1, 2, 3, 4, and subsequent degradation by the proteasome [7–9]. Evidence for the importance of this pathway is the embryonic lethality of MDM2 knockout mice and their rescue by knocking out p53 [10,11]. Overexpression of MDM2 has also been frequently described in transformed cells that express wild-type p53 [12]. The feedback loop that regulates p53 degradation is based on p53-mediated transcriptional induction of MDM2, with an additional layer of regulation imposed by MDMX, a homolog of MDM2 that represses p53-mediated gene transactivation [13]. p53 The replisome is the multi-protein complex that is present at the replication fork as it moves through the chromosome. Multiple replisome components interacted with Pfh1 with high specificity (SAINT score ≥ 0.80; Fig 6C and Table 3). These proteins were: (1) five of the six subunits of the replicative helicase, the MCM complex (Mcm2 and Mcm4-7); (2) catalytic subunits of two of the three replicative polymerases (DNA Pol1 from DNA polymerase α; DNA Pol2/Cdc20, from DNA polymerase ε); (3) Pol12, the β subunit of DNA Pol1; (4) proliferating cell individual mutants revealed that K151E mutant continues to associate with 53BP1 in cells, while K10E mutation is sufficient to disrupt the interaction with 53BP1. We concluded that the residue K10 is crucial for the interaction with 53BP1. with the reported DNA repair functions of Pfh1 [34], we observed multiple repair proteins among the high confidence Pfh1 interactions (Table 3, italics), including Rad22, the S. pombe homolog of budding yeast Rad52, which is required for homologous recombination [61], Rad3, the ATR-like checkpoint kinase [62], and both subunits of the non-homologous end joining Ku complex, pKu70 and 80. In addition, Rqh1 (homolog of human BLM) DNA helicase and its two interacting partners, the topoisomerase Top3 and Rmi1, were Pfh1-associated. This highly fifth most significant motif, PRDM1, which is an important developmental regulator in the B-cell and T-cell lineages and is required for the secretory pathway in B-cells (Martins and Calame 2008). PRDM1 activity increases, like that of IRF, across the entire time course, and these two regulators appear to share many of their predicted targets, including type 1 interferon pathway genes, the immunoproteasome (Seifert et al. 2010), ubiquitin conjugating enzymes, antigen peptide transporters, and MHC class I genes. These targets suggest that the While the C terminus of Pta1 is clearly important for mRNA cleavage and polyadenylation (35, 47), the role of the N terminus had not been characterized. In this report, we found that the first 300 amino acids of Pta1 define an essential region needed for Ssu72 interactions and stability (Fig. 4A and 5B), although as shown by the deletion of amino acids 1 to 75 of Pta1, this interaction can be weakened without affecting Ssu72 levels (Fig. 3C and 4A). Ssu72 is a CTD Ser-5 phosphatase, but this activity is not needed for Ssu72's function in The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of MDM2, thereby impairing p53 function. Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule\n",
            "[0.85448104]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Could DNA (cytosine-5-)-methyltransferases serve as tumour markers?\n",
            "Refined Query: Investigating DNA cytosine-5-methyltransferases (DNMTs) as potential tumor markers warrants exploration.  Elevated DNMT activity is implicated in cancer development through aberrant DNA methylation.  Could specific DNMT isoforms or their expression levels serve as reliable indicators of tumor presence, type, or prognosis, potentially improving cancer diagnostics and treatment strategies?\n",
            "\n",
            "Combined Answer: tissues [7,9]. DNA methylation is a very stable epigenetic mark and next generation sequencing studies have recently shown that many genes are aberrantly methylated in cancer [10,11]. Tissue specific DNA methylation patterns are stabilized during embryonic development, and faithfully maintained through cell divisions [12-14]. Nevertheless, established methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of Carcinogenesis involves changes in gene expression that results in tumor specific gene and protein signatures. Such signatures have been used to classify different subtypes of cancers. Gene expression is partly regulated by the methylation state of CpG islands. Cancer tissue is characterized by an increased variability in DNA methylation patterns. DNA methylation profiling has been reported as a robust method to classify and subgroup tumors of different origin [1]. For most pediatric brain tumor diagnoses, methylation profiling can divide the identify genome-wide aberrant methylation patterns of NSCLC. Specific differentially methylated regions would be promising candidate molecular markers for non-invasive diagnostics using circulating tumor DNA, and increase the number of possible targets for epigenetic therapy. complex diseases such as NSCLC. In the past decade, comparative gene expression profiles of tumors have been extensively studied [4-6], yielding useful insights into the molecular hallmarks of carcinogenesis [7,8]. With the advent of next generation sequencing, genome-wide screening has become an attractive tool for profiling tumors versus lung tissues [7,9]. DNA methylation is a very stable epigenetic mark and next generation sequencing studies have recently shown that many genes are aberrantly methylated in cancer [10,11]. Tissue specific methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of genes found to be aberrantly methylated in a wide variety of tumors [15-18], and epigenetic silencing of these genes has also been reported in NSCLC [19-22]. The great majority of DNA methylation studies are concentrated on the analysis of CpG islands located in the promoter areas of pre-selected genes. However, differentially methylated areas may be regulation. We note that while some of the DMRs were associated with genes that had been previously reported to be differentially methylated in lung tumors, such as APCCDH13CDKN2ADAPKhMLH1HOX genes, OTX1HOX2 and many others [22,29-32], we also found DMRs which, to the best of our knowledge, have not been previously reported to be associated with methylation in NSCLC or other types of cancer. the cellular context [11], [12]. Based on this evidence, T-UCRs could provide useful markers to classify the characteristics of human cancer, diagnostic markers for some specific types of cancer, and predictive markers for drug sensitivity or prognosis of cancer patients. We previously showed that some T-UCRs are aberrantly expressed in PC and are silenced by DNA methylation [12]; however, further in-depth studies are needed to determine the complete picture of the biological function of T-UCRs in PC. In this study, we evaluated the expression or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can Genome-wide DNA methylation profiling of non-small cell lung carcinomas - PMC any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can change chromatin structure, rendering DNA binding sites accessible or inaccessible to transcription factors leading to activation or silencing of genes important in cell differentiation and maintenance. It has been recently shown that hypermethylated genes found in lung tumors are associated with cellular morphogenetic differentiation [49]. These\n",
            "[0.7121895]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which RNA polymerase is used for the replication of viroids?\n",
            "Refined Query: Viroids lack protein-coding genes; their replication relies entirely on the host cell's machinery.  This raises the question: which specific RNA polymerase, a host enzyme responsible for RNA synthesis, is utilized by viroids during their replication cycle?  Understanding this is crucial for clarifying viroid replication mechanisms.\n",
            "\n",
            "Combined Answer: we show that Pfh1 is required for efficient fork movement in the ribosomal DNA, the mating type locus, tRNA, 5S ribosomal RNA genes, and genes that are highly transcribed by RNA polymerase II. In addition, converged replication forks accumulated at all of these sites in the absence of Pfh1. The effects of Pfh1 on DNA replication are likely direct, as it had high binding to sites whose replication was impaired in its absence. Replication in the absence of Pfh1 resulted in DNA damage specifically at those sites that bound high levels of Pfh1 in and the replicative DNA polymerase bound to similar extents to both Pfh1-dependent and independent sites, suggesting that Pfh1 is proximal to the replication machinery during S phase. Consistent with this interpretation, Pfh1 co-purified with many key replisome components, including the hexameric MCM helicase, replicative DNA polymerases, RPA, and the processivity clamp PCNA in an S phase dependent manner. Thus, we conclude that Pfh1 is an accessory DNA helicase that interacts with the replisome and promotes replication and suppresses DNA than the shorter tRNA genes. The comprehensive analysis of sites of Pfh1 activity provided here demonstrates that, in addition to G4 motifs [39], there are many classes of hard-to-replicate sites that depend on Pfh1 for their proper replication. Many of these other sites, in particular RNA polymerase III transcribed genes, exhibit even stronger Pfh1-dependent effects than G4 motifs (Tables 1 and 2 and S3 Table). Altogether, Pfh1 supports DNA replication at thousands of diverse sites across the genome. and/or collapsed replication forks—functions relevant to those of Pfh1. Finally, six subunits of the 26 subunit RNA polymerase III complex were Pfh1-associated with high confidence (Rpc1, 2, 3, 4, 25 and 37), while four others were Pfh1-associated but had SAINT scores <0.8 (Rpc6, 0.71; Rpc9 and 10, 0.30; Rpc19, 0.76) [64]. This finding is probably related to RNA polymerase III transcribed genes being among the most potent replication impediments in Pfh1-depleted cells (Figs 2–4; see Discussion). We used genome-wide assays to determine sites where replication and genome integrity are Pfh1-dependent. The most striking aspect of these data is the strong dependence of RNA polymerase III transcribed genes on Pfh1. 2D gel analyses showed previously that replication of five of five tested tRNA genes is Pfh1-dependent, and this dependence is seen regardless of whether replication is co-directional or opposite to the direction of transcription through the gene [35]. Here we show that close to 50% (80/171) of the tRNA genes bound Pfh1 (Table 1). in Pfh1-depleted cells (Fig. 3). As with tRNA genes, 5S rRNA genes were Pfh1-dependent regardless of the direction of replication through the gene. We propose that replication of all 169 tRNA and 33 5S rRNA genes is Pfh1-dependent. Based on the data presented here and in S. cerevisiae (Deshpande and Newlon 1996; Ivessa et al. 2000, 2003; Azvolinsky et al. 2009), we anticipate that RNA Pol III genes are hard to replicate in all eukaryotes, and Pif1 family helicases may also be important for their replication in more complex eukaryotes. Finally, sites, but also sites whose replication is not Pfh1-dependent. The human genome encodes a Pfh1 homolog, hPIF1, and contains all of the same hard-to-replicate features that make fission yeast DNA replication dependent upon Pfh1. Thus, human cells likely also require replicative accessory DNA helicases to facilitate replication at hard-to-replicate sites, and hPIF1 is a good candidate for this role. DNA replication through hard-to-replicate sites, including both highly transcribed RNA Pol II and Pol III genes, requires the S. pombe Pfh1 helicase - PMC Replication forks encounter impediments as they move through the genome, including natural barriers due to stable protein complexes and highly transcribed genes. Unlike lesions generated by exogenous damage, natural barriers are encountered in every S phase. Like humans, Schizosaccharomyces pombe encodes a single Pif1 family DNA helicase, Pfh1. Here, we show that Pfh1 is required for efficient fork movement in the ribosomal DNA, the mating type locus, tRNA, 5S ribosomal RNA genes, and genes that are highly transcribed by RNA polymerase II. In helicase is connected physically to a subset of the other replication factors to form a larger assembly called the replisome (Yao and O'Donnell, 2008). In addition to DnaB, the replisome includes the DNA polymerase that works on the leading and lagging strand templates, the primase that initiates each new DNA molecule, and the γ-complex that loads the β-clamp that serves as a processivity factor for the DNA polymerase. Interactions between the components of the replisome serve to ensure that unwinding by DnaB is coordinated with efficient DNA\n",
            "[0.69052786]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List Parkin binding partners\n",
            "Refined Query: Identify and list the proteins known to directly interact with the Parkinson's disease-associated protein, Parkin,  specifying the type of interaction where possible (e.g., ubiquitination, phosphorylation).\n",
            "\n",
            "Combined Answer: Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of α-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical have proposed that PLK2 has a critical role in maintaining dendritic spine stability (31) and modulating excitatory glutaminergic synaptic connections (32, 33). Thus, the involvement of PLK2 in α-synuclein phosphorylation provides a potential link between excitotoxic responses and Lewy pathology. Investigation of how the biology of PLK2 relates to the pathogenesis of PD and DLB should help clarify the role of synuclein phosphorylation in these diseases. specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent with complete phosphorylation of the 33 nm synuclein substrate (compare with the 33 nm p-Ser-129 (pS129) standard, Fig. 1A, inset). PLK1 had lower activity, comparable with that of CK2. To ensure that all enzymes were active, their abilities to phosphorylate another substrate, casein, were verified (supplemental Fig. S1). PLK4 had no measurable this MR is predicted to have differential activity. We defined ‘synaptic’ genes using a pre-defined list of ‘synaptic’ genes from the Ingenuity database (Kramer et al., 2014). We curated this list using a broad definition that tagged any gene that was related to synaptic function (according to Ingenuity‘s filter), even if its protein product is not technically localized to the synapse. This relatively broad definition fit our purpose, as our goal was to identify MRs that drive synaptic and neurophysiologic dysfunction. Although a narrower about a particular protein. Annotation is regularly reviewed to keep up with current scientific findings. The manual annotation of an entry involves detailed analysis of the protein sequence and of the scientific literature. Disease ontology The DISEASE ONTOLOGY [57] contains data associating genes with human diseases, using established disease codes and terminologies. Approximately 8,000 inherited, developmental and acquired human diseases are included in the resource. The DISEASE ONTOLOGY semantically integrates disease and medical Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as CK2, which has been previously shown to phosphorylate α-synuclein (10). Phosphorylation at Ser-129 was measured with a fluorescence assay using an antibody specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent to identify functional protein interactions [53, 54]. By this metric, there were 50 high confidence Pfh1 protein associations that comprise the Pfh1 S phase interactome (Table 3 and S7 Table). Although five of the Pfh1 interacting proteins are uncharacterized, there is functional data for 45 of the 50 proteins. Table 3 lists these proteins. We also assessed the relative abundance of individual Pfh1 interacting proteins within the interaction network by calculating the normalized spectrum abundance factor (NSAF) for each protein relative to its any, for PLK1 as an α-synuclein kinase. BI2536 has high potency and specificity for PLK family kinases (30) (see profiling results in supplemental Table S1). This compound inhibited up to 85–90% of α-synuclein phosphorylation in the cortical cultures, with an EC50 in multiple assays of 50–100 nm. Because comparison of inhibitor potencies in cells and in vitro can be complicated by the ability of cells to exclude or accumulate different inhibitors, we compared the potency of inhibitors in HEK293 cells transfected with PLK2 (Fig. 2C) or with decreased synuclein phosphorylation were identified (26). Of the candidate kinases, PLK2 was of particular interest because the siRNAs against this enzyme provided the largest and most consistent decrease in α-synuclein phosphorylation. Importantly, PLK2, as well as the closely related PLK3, are expressed in brain (27, 28). PLK Family Members Directly Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as it also inhibits PLK2 in the biochemical assay (Fig. 2, A and B). APMU (compound 3 in Johnson et al. (29)), which has good activity against PLK2 and -3 but is inactive against PLK1, inhibited α-synuclein phosphorylation in mouse cortical cultures. These results, together with the lower activity for PLK1 (Fig. 1A), suggest a limited role, if any, for PLK1 as an α-synuclein kinase. BI2536 has high potency and specificity for PLK family kinases (30) (see profiling results in supplemental Table S1). This compound inhibited up to 85–90% of\n",
            "[0.29509807]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is generic name of drug Adempas?\n",
            "Refined Query: The medication Adempas is a brand-name drug; what is its generic name, the non-proprietary designation used in official drug compendia and by healthcare professionals when referring to the active ingredient?\n",
            "\n",
            "Combined Answer: of trial drugs, and printing and processing costs from AstraZeneca, grant support paid to her institution from Acceleron, grant support paid to her institution and provision of trial drugs from Adaptimmune, Eli Lilly, MedImmune, Celgene, Regeneron, Merck, Tekmira, Novartis, and Taiho, grant support and fees for serving on a steering committee paid to her institution, and provision of trial drugs from Agios, grant support and advisory board fees paid to her institution, and provision of trial drugs from Bayer and Bristol-Myers Squibb, grant Bortezomib was purchased from Selleckem (Houston, TX, USA). Carfilzomib and oprozomib were supplied by Onyx Pharmaceuticals. binding activity, preventing the binding of the ligand to the antibody (71,72). Overall, these changes may alter the efficacy and toxicity profile of the antibody. Assays for immunogenicity are difficult to develop and verify, and a comparison of observed incidences of ADA formation across various detection assays is complicated by potential differences in assay sensitivity. It is expected that therapeutic antibodies will show some immunogenicity, and even completely human therapeutic antibodies have unique idiotypes and posttranslational distinguished in later analysis. To identify hospital diagnoses which are associated with ADEs (and to highlight them in the tool) we used the ICD-10 codes listed by Stausberg and Hasford [10] and adapted the codes to the Austrian coding conditions. The Austria Codex [11], a register containing all drugs which are authorised in Austria, was used to identify potential drug-drug interactions between two prescriptions of a patient, which were taken at the same time according to our estimation. The Austrian pharmaceutical registration number (in to her institution, and provision of trial drugs from Agios, grant support and advisory board fees paid to her institution, and provision of trial drugs from Bayer and Bristol-Myers Squibb, grant support paid to her institution from Sanofi and Debio, and fees for serving on a steering committee paid to her institution from TARGET Pharma Solutions. We thank the patients, their families, the investigators, the site staff, and the trial teams; David W. Markby (Exelixis) for assistance with medical writing; and Karen O’Leary and Michael Raffin This was classified as a protocol deviation. The patient was included in the placebo group of the modified ITT population for the efficacy analyses, but in the anifrolumab 1,000‐mg group of the safety population for the safety analyses. Baseline characteristics (Table 1) were similar between groups, with the following exceptions: disease duration was shorter for the placebo group than for the anifrolumab groups (mean 90.6 months versus 95.9 months and 100.1 months), and fewer patients in the placebo group were receiving methotrexate (15.7% been treated with bortezomib. Carfilzomib is currently undergoing extensive clinical testing in multiple myeloma, as well as evaluation in mantle cell lymphoma, T-cell lymphoma, large B-cell lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, acute lymphoblastic leukemia, small cell lung cancer, renal cell carcinoma, and advanced prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being board fees from AstraZeneca, grant support from Astex, and fees for serving on a speakers’ bureau from Merrimack; Dr. Rimassa, receiving advisory board fees from Lilly, Bayer, Sirtex Medical, and Exelixis, consulting fees and travel support from ArQule and Ipsen, and lecture fees from AstraZeneca and AbbVie; Dr. Park, receiving advisory board fees from BMS, Midatech, and AstraZeneca, advisory board fees and honoraria from Ono and Eisai, and honoraria from Bayer; Dr. Blanc, receiving advisory board fees from Bayer, BMS, Lilly Oncology, Shire, 1mg/kg/day of alpha-methylprednisolone (PDN, M3781, Sigma) was administered by intraperitoneal injection (IP) for 3 weeks. Control animals received PBS. was shorter for the placebo group than for the anifrolumab groups (mean 90.6 months versus 95.9 months and 100.1 months), and fewer patients in the placebo group were receiving methotrexate (15.7% versus 19.2% and 24.0%). The anifrolumab 1,000‐mg group had a greater percentage of white patients than the anifrolumab 300‐mg and placebo groups (49.0% versus 35.4% and 40.2%, respectively).\n",
            "[0.54089254]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is known about Vancomycin dosing in neonates?\n",
            "Refined Query: What are the established pharmacokinetic and pharmacodynamic principles guiding vancomycin dosing in neonates, considering factors like age, weight, gestational age, renal function, and infection type?  What are the recommended dosing regimens and monitoring strategies to ensure efficacy and minimize toxicity?\n",
            "\n",
            "Combined Answer: the opportunity for participants to achieve a potential full dose of at least 70 mg/day or the equivalent of 2 mg/kg up to a maximum dose of 200 mg/day. The use of weight based dosing has several distinct advantages, while also adding complications to the study design. Weight-based dosing in pediatrics is common practice, taking into account the variability in size across developmental age, while allowing for a broad applicability of dosing beyond the age and size ranges utilized in the study. It also allows for personalization of dosing in variability in size across developmental age, while allowing for a broad applicability of dosing beyond the age and size ranges utilized in the study. It also allows for personalization of dosing in practice and provides a guideline for dosage initiation in practice. Weight-based dosing is complicated in real world application due to the availability of tablet size. Although an exact weight based dosing using powdered formulation with encapsulation would result in the most accurate determination of dosage, this would not be practical in the safe and effective therapeutic management of drugs in patients. Population PK principles are applied to understand the sources and correlates of variability in drug concentrations in a population of patients, which could have important implications for clinical dosing. Results from population PK analyses have been included in all drug labels from antibodies currently on the market. Pharmacodynamics is the relationship between the measured drug concentration and the resulting effect, including the time course and intensity of therapeutic and Resistant cell lines were established through exposure to gradually increasing concentrations of carfilzomib (Onyx Pharmaceuticals, Inc.) over a 12-mo time period. Cells were initially exposed to 30 nM carfilzomib and, finally, to 1 µM carfilzomib. The parental cell lines (P-UMSCC-1 and P-Cal33) were maintained in DMEM containing 10% fetal bovine serum (HyClone Laboratories), and 100 units/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Resistant cell lines (R-UMSCC-1 and R-Cal33) were maintained in the identical medium supplemented with (15). See Table 1 for a summary of the monoclonal antibodies that modulate CGRP. Pharmacokinetic (PK) and pharmacodynamic (PD) analyses are essential components of drug discovery and development. Pharmacokinetics is the study of the time-course of drug absorption, distribution, metabolism, and excretion, and these processes are applied to enable safe and effective therapeutic management of drugs in patients. Population PK principles are applied to understand the sources and correlates of variability in drug concentrations in a population of and CSF concentrations, consistent with literature reports indicating that CSF volume is similar in all children aged >2 years,21 and suggesting that fixed doses are appropriate in this pediatric population, with no dose scaling necessary. CSF and plasma drug levels were reasonably consistent with predicted values (within 2- to 3-fold) based on preclinical (monkey to human) CSF volume scaling. Dose-dependent mean peak plasma levels were observed within a few hours after dosing and then typically declined slowly ≤20 hours after intrathecal Age, body size/weight, sex, and ethnicity are demographic factors commonly examined using population PK analyses to understand their influence on drug exposure, efficacy, and safety to help guide clinical dosing regimens. Age may affect lymph flow rate and endocytosis rate, leading to reduced absorption, distribution, and/or elimination of a mAb (62). Pharmacokinetic studies show mixed results regarding the effect of age (80–84), but limited data exist in the young and elderly populations (85). Body weight is a commonly identified factor that is often considered when dosing topiramate. Feedback from the AHS Pediatric section membership also indicated that this was the typical approach used in current practice. To be consistent with the approach to dosing of amitriptyline in this trial as well as with clinical practice, a weight-based dosing plan was chosen that also allowed for maximizing the opportunity for participants to achieve a potential full dose of at least 70 mg/day or the equivalent of 2 mg/kg up to a maximum dose of 200 mg/day. The use of weight based dosing has several included children with any amount of edema, even cases that would be considered to have moderate or severe edema. Children in the standard protocol group were also provided with a 7-day supply of amoxicillin at a dose of approximately 60 mg/kg/day. Children treated under the alternate protocol were not given any antibiotics. No additional vitamins, micronutrients, or antiparasitic treatments were routinely administered to children in either group. Caretakers were referred to their local health providers if there were any concerns for an acute (HyClone Laboratories), and 100 units/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Resistant cell lines (R-UMSCC-1 and R-Cal33) were maintained in the identical medium supplemented with 1 μM carfilzomib. Prior to the initiation of experiments involving treatment with different agents, the carfilzomib-resistant cells were cultured for 72 h in the absence of carfilzomib to prevent interference.\n",
            "[0.5506762]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is single guide RNA part of the CRISPR/Cas9 tool or an inhibitor of its function?\n",
            "Refined Query: The CRISPR/Cas9 system relies on single guide RNA (sgRNA) to target specific DNA sequences.  Is sgRNA a fundamental component of this gene-editing tool, essential for its function, or does it somehow inhibit the Cas9 enzyme's activity?\n",
            "\n",
            "Combined Answer: use of a single starting oligonucleotide for cloning a dual gRNA expression vector, conferring both convenience and scalability. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a natural bacterial immunity system, with huge potential as a simple, cheap and versatile genome editing system [3]. Repurposed as an experimental tool, the system has two components: first, a bipartite small RNA, or “guide RNA” (gRNA), designed to recognise a specific location in the genome; second, the Cas9 protein that binds the gRNA and is adjacent motif (PAM, here NGG), fused with a scaffold sequence recognised by Cas9 protein [3]. By engineering the gRNA targeting region, one may target virtually any complementary genomic locus with moderate off-target effects [4]. As an effector protein, Cas9 may either be employed as a natural nuclease [1, 5], or else catalytically inactivated and fused to a different protein domain [6]. These features make it possible to manipulate the numerous types of non-protein coding genomic elements that have so far resisted standard RNA interference tool, the system has two components: first, a bipartite small RNA, or “guide RNA” (gRNA), designed to recognise a specific location in the genome; second, the Cas9 protein that binds the gRNA and is thereby recruited to the target site. The gRNA consists of a 20 nt targeting region that hybridises to genomic DNA upstream of a dinucleotide protospacer adjacent motif (PAM, here NGG), fused with a scaffold sequence recognised by Cas9 protein [3]. By engineering the gRNA targeting region, one may target virtually any complementary genomic locus approaches. Against this backdrop CRISPR-based deletion holds great promise as a tool for loss-of-function studies in non-coding RNAs and genomic elements [5, 17–20]. Two distinct gRNAs flanking the target region are introduced in combination with a catalytically active Cas9. The cellular non-homologous end-joining (NHEJ) mechanism repairs the resulting break [12], and in a certain proportion of cells, one or all alleles are correctly deleted. This approach is capable of removing regions from approximately 102 to 106 base pairs, and there is phenotype. Together these findings show that DECKO is a practical way of knocking out lncRNAs, within reach of a typical molecular biology laboratory, and there remains scope for further efficiency improvements in future. CRISPR genome editing enables us to directly observe the effect of genomic perturbations of gene regulatory elements. In the case of MALAT1, we have shown that CRISPR can be used to dissect gene regulatory sequences by demonstrating that the annotated upstream promoter of MALAT1 is largely irrelevant for correct gene which is presently hampered by the large size of the Cas9 protein and our limited understanding of optimal gRNA targeting [44]. A second consideration relates to annotation of target regions: lncRNA promoters are often poorly annotated [2], and a suitable DECKO library design strategy will have to flexible enough to maximise the likelihood of knocking out the correct region. First, pooled screening requires the delivery of a single viral particle per cell. In future experiments it will be necessary to demonstrate that DECKO functions efficiently when expressed from a single genomic integration, as opposed to multiple copies of transfected plasmid. This is related to the general challenge of improving CRISPR efficiency, which is presently hampered by the large size of the Cas9 protein and our limited understanding of optimal gRNA targeting [44]. A second consideration relates to annotation of target regions: lncRNA CRISPR can be used to delete genomic sequences, by cutting genomic DNA at two sites and relying on non-homologous end-joining (NHEJ) mechanism to repair the break (Fig. 1a). gRNAs are introduced to cells by a plasmid vector, either through transfection or viral infection. As it does not vary between experiments, the scaffold (constant region) sequence is encoded within the expression plasmid [23]. In contrast, the variable 20 nt target region must be generated in each experiment by the cloning of synthesised DNA fragment into the targeting efficiency, and (b) target site deletion depends on simultaneous cutting at two locations in one or more alleles by CRISPR, it is reasonable to expect that such bulk populations should contain a mixture of wild type, heterozygous and homozygous knockout cells. We transfected pDECKO plasmids into a variety of human cell lines in the presence of either cotransfected or stably-expressed catalytically-active Cas9 nuclease. Excision was tested qualitatively by genomic PCR using primers flanking the genomic target region, such that correctly deleted CRISPR guide RNAs were designed using http://crispr.mit.edu/. SgRNA targeting the ATM and TIRR locus were cloned in the pX458 vector carrying the pSpCas9(BB)-2A-GFP (Addgene #48138) or the pLentiGuide-puro vector (Addgene #52963). The following guide sequences were used (PAM). ATM: CTCTATCATGTTCTAGTTGA(CGG); TIRR guide 1: AGATGCAGATGCGTTTCGAC(GGG); TIRR guide 3: CAGTGCCAAGATGTCGACGG(CGG). Human TIRR and 53BP1 cDNAs were expressed at a moderate level by using the retroviral vector POZ45. Human TIRR cDNA were subcloned into retroviral vector pMIG\n",
            "[0.67212635]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 556.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 3150.52ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which bacteria caused plague?\n",
            "Refined Query: The bubonic plague, a historically devastating disease, is caused by bacteria.  Specifically, which species of *Yersinia* bacteria is responsible for this infection, and are there variations in the bacteria that cause different forms of plague?\n",
            "\n",
            "Combined Answer: of the bacterium to cross the host blood-brain barrier. Because BslA is an established virulence factor [44-46], it is not surprising that bslA transcripts are abundant relative to the flanking genes. The evidence that expression of pXO1_0123 and pXO1_0125 is coordinated with that of bslA suggests that they serve important functions, a suggestion that merits further study. We identified another region on pXO1 that contains several clusters of upregulated genes and these data are shown in Figure 2(c). Expression of the genes pXO1_0138, result, the diagnosis is more secure. He also writes that although palatal petechiae are seen with streptococcal tonsillitis, they are not pathognomonic.5 However, in our study, 6 out of 8 patients with only palatal hemorrhages grew culture for group A β-hemolytic strep. Palatal hemorrhages may also accompany infectious mononucleosis, rubella (Forschheimer spots), roseola, viral hemorrhagic fevers, thrombocytopenia, and palatal trauma. In the setting of acute tonsillitis, treatment is recommended for all children who are antigen or culture and pXO1_0125 are 441, 369, and 270 base pairs, respectively, which also provide room for potential promoters. Of note, none of these intergenic regions lacked reads, as would be the case if any transcripts terminated between the pXO1_0123, pXO1_0124, and pXO1_0125 genes. BslA mediates adhesion to host cells, and has been found to mediate the ability of the bacterium to cross the host blood-brain barrier. Because BslA is an established virulence factor [44-46], it is not surprising that bslA transcripts are abundant relative to the flanking thought to be an important signal for turning on virulence gene expression [7]. This CO2-induced response is mediated, at least in part, at the transcriptional level [8-11]. However, CO2 affects the transcription of many genes in other species of the B. cereus group; thus, it is unlikely that all of these genes are involved in anthrax-specific pathogenesis [12]. Parsing genes into pathogenic and non-pathogenic anthrax-specific subsets would help in identifying molecular virulence pathways in B. anthracis, which are not fully established tonsils or pharynx, palatal hemorrhages, and skin rash and complaints of abdominal pain. Acute bacterial pharyngitis in children is most commonly caused by group A β-hemolytic streptococci. According to Robert P. Blereau, MD, palatal petechiae are present along with exudative tonsillitis and cervical adenitis, and with a positive test or culture result, the diagnosis is more secure. He also writes that although palatal petechiae are seen with streptococcal tonsillitis, they are not pathognomonic.5 However, in our study, 6 out of 8 patients 4(b). The ratio of the number of genes in the VCSG on the extended pathogenicity island to the number of bp in the extended pathogenicity island is 3.08-fold higher than the ratio calculated with number of bp in pXO1 as a whole as the denominator. Further, the ratio of the number of genes in the VCSG on the extended pathogenicity island to the number of bp in the extended pathogenicity island is 444-fold higher than the ratio of the number of genes in the VCSG on the chromosome to the number of bp on the chromosome. and plasmid DNA were as described previously (2, 9, 34). B. subtilis strains were maintained on tryptose blood agar base medium (Difco Laboratories, Detroit, MI). Liquid cultures of B. subtilis strains were routinely grown in antibiotic medium no. 3 (A3) (Difco Laboratories, Detroit, MI) amended with different antibiotics. When required, neomycin (10 μg/ml), tetracycline (10 μg/ml), spectinomycin (100 μg/ml), chloramphenicol (5 μg/ml), rifampin (5 μg/ml), or isopropyl-β-d-thiogalactopyranoside (IPTG; 1.0 mM/ml) was added to the medium. E. coli Bacillus anthracis is a spore-forming, gram-positive bacterium that is the causative agent of anthrax. The major factors responsible for its pathogenesis are encoded on two virulence plasmids, pXO1 and pXO2 [1-4]. pXO1 contains the genes coding for the three secreted toxin proteins, protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid The bacterial strains used are listed in Table 1. B. subtilis YB955 is a prophage-“cured” strain that contains the hisC952 (CAG→TAG at position 952; amber mutation), metB5 (GAA→TAA at position 346; ochre mutation), and leuC427 (GGA→AGA at position 427; Gly to Arg) alleles (41, 46, 47). The procedures for transformation and isolation of chromosomal and plasmid DNA were as described previously (2, 9, 34). B. subtilis strains were maintained on tryptose blood agar base medium (Difco Laboratories, Detroit, MI). Liquid cultures of B. subtilis palate. The diagnosis of strep throat is unlikely with symptoms of red eyes, hoarseness, runny nose, or mouth ulcers, and also less likely in the absence of fever. The etiology is usually infectious, with most cases being of viral origin. These cases are benign and self-limiting for the most part. Bacterial causes of pharyngitis are also self-limiting, but are concerning because of suppurative and nonsuppurative complications. Other causes include allergy, trauma, toxins, and neoplasia.3 The most common bacterial organism causing acute\n",
            "[0.8195321]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.15ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1084.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 933.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1362.72ms\n",
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 833.62ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What kind of enzyme is encoded by the proto-oncogene ABL1?\n",
            "Refined Query: The proto-oncogene ABL1 encodes a non-receptor tyrosine kinase enzyme.  Understanding its specific enzymatic activity is crucial for comprehending its role in cellular signaling and its transformation into an oncogenic form.\n",
            "\n",
            "Combined Answer: identifies known key regulators ab initio. We also present a number of novel predictions including regulatory interactions in innate immunity, a master regulator of mucociliary differentiation, TFs consistently disregulated in cancer, and TFs that mediate specific chromatin modifications. as an activator of erythroid differentiation programs while its repressive activity has been linked to oncogenesis in T- cell lineage (8, 9, 21, 27, 28, 49). It has been suggested that inappropriate associations of transcription factors with histone modifying enzymes often lead to aberrant activation or repression of normal gene expression patterns and perturb cellular differentiation and proliferation that may eventually contribute to malignancies (21, 49). How is the dynamic interaction of TAL1 with corepressors and coactivators properly To determine the mechanism responsible for carfilzomib/vorinostat synergy in the acquired resistance models, we investigated the expression status of pro-apoptotic Bik protein. Bik is known to be upregulated in HNSCC cells following treatment with bortezomib, carfilzomib, or oprozomib, and plays an important role in mediating cell death by these proteasome inhibitors.8,34 However, as depicted in Figure 7, the R-UMSCC-1 and R-Cal33 resistance models demonstrated only modest, if any, upregulation of Bik when treated with either carfilzomib alone seen at the promoter region (Figure 3C) (See discussion). Due to the decrease in the LSD1 recruitment, the expression of TAL1Δ142-185 led to an increase in H3K4me2 at the enhancers and the proximal promoters of the pTα gene (Figure 3D) as well as the p21 gene (Figure S2C), a cell cycle-dependent kinase inhibitor that blocks the cell cycle during G1 to S phase transition and is also targeted by TAL1 (15, 30). As a control, the TAL1 mutants didn’t affect the level of H3K4me2 at the promoter of TAL1 activated target, Runx1 (Figure S2E). These harbors a splice donor site mutation, c.1747+1G→A, in intron 13 of SLCO1B3. If SLCO1B3 is still yielding functional mRNA, this would truncate OATP1B3 after amino acid 582, deleting the C-terminal one-and-a-half transmembrane domains. A nonsense mutation, c.757C→T, in exon 8 of R3-linked SLCO1B1 introduces a premature stop (p.R253X), truncating OATP1B1 before the C-terminal 7 transmembrane domains. All of these mutations would severely disrupt or annihilate proper protein expression and function. Moreover, they all showed consistent autosomal the TAL1-LSD1 interaction in T-ALL Jurkat cells (Figures 3 and 4), it will be interesting to know if PKA phosphorylation of TAL1 could facilitate TAL1’s ability to recruit coactivators during leukemogenesis. Although it is unknown whether a coactivator(s) is involved in the TAL1 mediated activation of CDK6 and NKX3.1 genes in leukemogenesis, our study identified an underlying mechanism by which phosphorylation regulated demethylase LSD1 recruitment controls the timing of erythroid differentiation and oncogenesis of T-cell leukemia. basolateral membranes of centrilobular hepatocytes stained crisply, as previously reported (31). Thus, the SLCO1B1 and SLCO1B3 mutations in each haplotype result in absence of a detectable signal for OATP1B protein in the liver. In family A2, a heterozygous splice donor site mutation, c.481+1G→T, in intron 5 of SLCO1B1 would result in dysfunctional RNA or protein. Its co-occurrence with the 405-kb R2 deletion in two asymptomatic family members (Table 1) indicates that a single functional SLCO1B3 allele can prevent RS. A search for copy number before the C-terminal 7 transmembrane domains. All of these mutations would severely disrupt or annihilate proper protein expression and function. Moreover, they all showed consistent autosomal recessive segregation with the RS phenotype in the investigated families (Table 1). No SLCO1A2 sequence variation was found in probands representing the 3 haplotypes, rendering involvement of OATP1A2 in RS unlikely. The severity of the identified mutations affecting SLCO1B3 and SLCO1B1 and their strict cosegregation with the RS phenotype indicate that Chromosomal rearrangements of ALK (anaplastic lymphoma kinase) are detected in 3–7% of NSCLCs (1, 2). These rearrangements result in constitutively active ALK fusion proteins with potent transforming activity (2, 3). Lung cancers with ALK rearrangements are highly sensitive to ALK tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to ALK kinase activity. Based on early phase studies, the multi-targeted tyrosine kinase inhibitor (TKI) crizotinib was approved by the FDA in 2011 to treat patients with advanced NSCLC changes and makes detailed predictions regarding their regulatory roles. These include predicted activities of the regulators across the samples, their genome-wide targets, enriched gene categories among the targets, and direct interactions between the regulators. Applying ISMARA to data sets from well-studied systems, we show that it consistently identifies known key regulators ab initio. We also present a number of novel predictions including regulatory interactions in innate immunity, a master regulator of mucociliary differentiation, TFs\n",
            "[0.48287505]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the mode of inheritance of Romano Ward long QT syndrome?\n",
            "Refined Query: Romano-Ward syndrome is a type of long QT syndrome.  How is this inherited?  Is it autosomal dominant, recessive, X-linked, or another mode of inheritance?  Clarifying the inheritance pattern is crucial for genetic counseling and risk assessment in families affected by this potentially life-threatening condition.\n",
            "\n",
            "Combined Answer: Inherited neuropathies are the most common genetic neurological disorders and affect ∼1 in 2500 individuals.1 Charcot–Marie Tooth (CMT) includes a group of hereditary disorders in which motor and sensory neuropathy is the sole or primary part of the disease. CMT is traditionally classified into two types based on electrophysiological and neuropathological criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause c>t transition leading to p.R500X, a protein truncating mutation in the putative eleventh transmembrane domain of the protein. In Family 12, this mutation appears likely de novo in the mother of the affected CS male (i.e. not found in the maternal grandparents). In Family 9, this mutation is inherited. These families do appear to share a haplotype around the mutation locus (Supplementary Table 4), which may be prone for recurrent mutation although further research will be necessary to clarify this. The mutation occurs at a CpG location in the or from the father (two cases). These inherited CNVs were X-linked or associated to mild affectation in the carrier parent. Remarkably, 24 out of the 29 UCEs were contained in the rearrangements inherited from the father or originated in a paternally derived chromosome. However, this association might well be an indirect consequence of a higher proportion of deletions originated in the paternally derived chromosome. Both paternal and maternal deletions show a similar enrichment ratio for UCEs (3.9 and 3.0, respectively), while the paternal and criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but until now, mutations in the recessive forms of disease have never been identified. Families were recruited by advertising and word-of-mouth among families. Pedigrees in which a diagnosis of Christianson syndrome was suspected or families with prior diagnoses were enrolled. Identified probands and the extended pedigree were enrolled, including all available parents, grandparents, aunts, uncles and unaffected siblings. The phenotype of the affected proband was considered to be consistent with Christianson syndrome if: 1) occurred in boys; 2) involved intellectual disability; 3) seizures; 4) ataxia; and 5) there was a plausible and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 In CCHS patients, the weak predisposing haplotype of the RET gene can be regarded as a quantitative trait, being a risk factor for the HSCR phenotype, while in MWS, for which the HSCR penetrance is high, the role of the RET predisposing haplotype is not significant. It seems likely that there are both RET dependent and RET independent HSCR cases. Charcot-Marie Tooth disease (CMT) forms a clinically and genetically heterogeneous group of disorders. Although a number of disease genes have been identified for CMT, the gene discovery for some complex form of CMT has lagged behind. The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but\n",
            "[0.76817787]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which histone modifications have been associated to alternative splicing?\n",
            "Refined Query: Investigate the specific histone modifications, such as methylation or acetylation of particular residues on H3 or H4, that correlate with or directly influence the process of alternative splicing, impacting the diversity of mRNA transcripts produced from a single gene.\n",
            "\n",
            "Combined Answer: Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and Zemach et al., 2013; Stroud et al., 2014). DNA methylation and H3K9me2 act together to silence genes and transposable elements (TEs) in Arabidopsis (Law and Jacobsen, 2010). Histone variants carry out diverse chromatin functions including transcription, DNA repair, and chromosome segregation (Bönisch and Hake, 2012; Millar, 2013; Szenker et al., 2011; Talbert and Henikoff, 2010). The vast majority of known histone variants are homologs of H2A and H3 histones. A phylogenetic analysis of histone families supports the notion that genes encoding Lys 36 of histone H3 can undergo mono-, di-, and tri-methylation as well as antagonistic acetylation at the same residue. Posttranslational modification of H3K36 is associated with active transcription, alternative splicing, dosage compensation, DNA replication, and DNA damage repair (Wagner and Carpenter 2012). In yeast, SET domain-containing 2 (Set2) writes all three methylation states at H3K36 whereas in mammals, each state of methylation is laid down by distinct enzymes suggesting extensive regulation of K36 methylation and its importance we look at protein-coding genes, we provide evidence that most of the promoter regions have differentially enriched histone-modification sites. Recently, the ChIPnorm approach has also been used to study histone methylation changes associated with leaf senescence in Arabidopsis [30]. Our approach is not restricted to the identification of differentially enriched sites nor is it limited to pairwise comparisons. A natural next step, therefore, is to apply it to more complex data (multiple cell types with multiple histone modifications, for for explaining differences in levels of a particular chromatin mark across tissues were often also highly significant for explaining mRNA expression differences. This was particularly the case for methylation of lysine 4 on histone H3 (H3K4me2, H3K4me3), for acetylation of histone H3 (H3K9ac, H3K27ac), and for trimethylation of lysine 36 on histone H3 (H3K36me3). For example, Figure 5A shows the activity profiles for these marks for the SNAI1..3 motif, which is recognized by the snail TFs (see Supplemental Fig. 22 for additional examples). As are typically under evolutionary constraint [22]. In addition, several histone modifications are associated with regulatory genome elements: histone 3 lysine 4 trimethylation (H3K4me3) is enriched at active promoters [13], while monomethylation (H3K4me1) is enriched at enhancers [23], and histone 3 lysine 27 acetylation (H3K27ac) is enriched at both active promoters [24,25] and active enhancers [17,25,26]. Consistent with active promoters, our consensus promoters showed higher GC content, CpG content, evolutionary constraint, H3K27ac, and active paternally contributed chromosome (Fig. 1B,C). We obtained a similar distribution for acetylated histone H4 (H4Ac) (Supplemental Fig. S2). The preferential enrichment of these histone marks on the paternally contributed region is valid at all positions tested, including the IC, which is required for the expression of paternally contributed genes within the Snurf–Snrpn interval. H3K4me2 and H3Ac are, however, more strongly enriched at the level of active transcription units such as Snrpn, Ndn, Mkrn3, and Magel2. The distribution of these coding genes and in non-coding regions, including the 2-Mb long gene desert that extends between Ndn and Snrpn. We found pronounced allelic differences in histone modification distribution within the Snurf–Snrpn cluster. H3Ac and H3K4me2 were exclusively detected on the active, paternally contributed Snurf–Snrpn genomic interval. These marks were preferentially enriched in regions containing transcription units, which is reminiscent of the distribution of these histone modifications across the mouse and human genomes (Barski et al. 2007; (DNMT1, 3A, 3B, 3L) and histone deacetylases (HDAC1 and HDAC2), to target genes (13–15). In addition, SALL4-mediated activation of Bmi-1, another important hematopoietic stem cell gene, involves methylation of lysine 4 of histone H3 (H3K4) at its promoter region (16). Based on recent discoveries, there seem to be various ways of cross-talking between histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone this high level of expression, Ndn transcription occurs only from the paternally contributed chromosome, showing that the maternally inherited region is under the control of a potent transcription silencing mechanism (Gerard et al. 1999). We detected enrichment of dimethylated histone H3 at lysine 4 (H3K4me2) and acetylated histone H3 (H3Ac) on the active paternally contributed chromosome (Fig. 1B,C). We obtained a similar distribution for acetylated histone H4 (H4Ac) (Supplemental Fig. S2). The preferential enrichment of these histone marks\n",
            "[0.44440663]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is phospholamban phosphorylated by Protein kinase A?\n",
            "Refined Query: Does Protein kinase A (PKA) directly phosphorylate phospholamban, and if so, at which specific serine residue(s)?  What are the downstream consequences of this phosphorylation on phospholamban's function and calcium handling in the heart?\n",
            "\n",
            "Combined Answer: known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases inhibited α-synuclein phosphorylation both in primary cortical cell cultures and in mouse brain in vivo. Finally, specific knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels. These results indicate that PLK2 plays a critical role SR Ca2+ ATPase 2a (SERCA2a) is a critical ATPase responsible for Ca2+ re-uptake during excitation-contraction coupling. Impaired SR Ca2+ uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure (HF)1. Accordingly, restoration of SERCA2a expression by gene transfer has proven to be effective in improving cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels. These results indicate that PLK2 plays a critical role in α-synuclein phosphorylation in central nervous system. (by as much as 64%) and a parallel reduction of p-Ser-129 α-synuclein (as much as 78%). No effect was observed on PLK3 mRNA or total α-synuclein levels, and there was no cellular toxicity detected by Alamar Blue assay, suggesting that the effect on phospho-α-synuclein was mediated by specific mRNA silencing (data not shown). We have compared the potency of selected kinase inhibitors against PLK2 in mouse primary cortical cultures with their potency in the biochemical PLK2 assay. Many of the studies investigating CK2 as an α-synuclein kinase Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of α-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical SERCA2a activity was determined using pyruvate/NADH-coupled reactions based assay, as previously described24. The activity of the Ca2+-ATPase was calculated as follows: Δabsorbance/6.22 × protein × time (in nmol ATP/mg protein × min). All assays were performed in triplicate. Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as CK2, which has been previously shown to phosphorylate α-synuclein (10). Phosphorylation at Ser-129 was measured with a fluorescence assay using an antibody specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent with complete phosphorylation of the 33 nm synuclein substrate (compare with the 33 nm p-Ser-129 (pS129) standard, Fig. 1A, inset). PLK1 had lower activity, comparable with that of CK2. To ensure that all enzymes were active, their abilities to phosphorylate another substrate, casein, were verified (supplemental Fig. S1). PLK4 had no measurable Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System - PMC structure and modulating the recruitment of RNA Pol II basal transcription machinery. In addition, there is another layer of regulation of TAL1 protein. Several threonine (Thr) and serine (Ser) residues of TAL1 can be phosphorylated by protein kinase B (Akt), mitogen activated protein kinase (MAPK), and protein kinase A (PKA) (17–20). In particular, serine 172 is phosphorylated in vitro and in vivo by PKA (18). Phosphorylation of this residue affects TAL1 target-dependent DNA recognition, therefore, potentially discriminating the DNA binding\n",
            "[0.6422664]\n",
            "### Expanded entities and terms:\n",
            "Chronic Pain - {'Physical Therapy': 1.0, 'Muscle Weakness': 0.3667880560207335, 'Joint Mobility': 0.0}\n",
            "\n",
            " ### Clustered: {'Chronic Pain': {'Cluster 1': ['Physical Therapy', 'Joint Mobility'], 'Cluster 2': ['Muscle Weakness']}}\n",
            "Original Query: Are there telemedicine applications for chronic pain management?\n",
            "Refined Query: Considering the context of physical therapy for joint mobility and muscle weakness,  are there effective telemedicine applications for remotely managing chronic pain, including tools for assessing movement limitations, providing exercise guidance, and monitoring patient progress?\n",
            "\n",
            "Combined Answer: complications, symptomatic reherniation, and reoperation will be assessed at each follow-up visit. A schedule of patient assessments during the study is provided in Table 2. Back and leg pain severity will be separately assessed on a 100 mm visual analogue scale. Back disability will be evaluated with the ODI using a 0 to 100 scale where higher scores represent greater disability. Health utility will be evaluated with the EQ-5D questionnaire.[19] This patient-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, lean mass and bone density were assessed. Tests to assess mobility, muscle strength and power, and common daily tasks and a questionnaire to measure patients’ health status were used to quantify functional status. These included the 6-minute-walk test, which was performed to conform with the American Thoracic Society Guidelines (24), bilateral handgrip dynamometry, bilateral one-repetition maximum leg press to assess muscle strength (25), stair climbing time to assess lower limb muscle power (26), and the Timed Up and Go test (27). Maximum have been conditionally approved for their potential effect on muscle strength and function [6]. Therefore, noninvasive approaches that reliably evaluate DMD are required to support different integrated care plans. Functional rating scales are commonly used for DMD assessment, including the 6 min walk test and the North Star Ambulatory Assessment [7,8]. These functional measures are limited to only ambulatory measurements and cannot provide quantitative and objective analyses of muscle tissues. Therefore, medical imaging techniques are a prediction of change in ambulatory function are helpful for individual treatment planning, including corticosteroid adjustment and rehabilitation in multidisciplinary care, which are imperative for alleviating muscle atrophy, skeletal deformities, and motor function deterioration [27,28]. Clinically, observations on strength loss (e.g., hip extension and ankle dorsiflexion) are typically used as the primary evaluation of ambulation loss in patients with DMD [29]. To compensate for muscle weakness, patients with DMD naturally develop the diaries will augment the calendar details. In addition to the comparison of baseline vs. the last 4 weeks of maintenance, a continuum assessment will be made through all stages of the study to determine a time course of responsiveness. Additional outcome measure will include disability changes as assessed by PedMIDAS at the time of randomization compared to the end of maintenance. Side effects and tolerability of study drug based on phone and face to face visit assessment throughout the study will additionally be evaluated. Safety analysis The authors thank the patients who participated in this study and their parents/guardians and family members; and Cure SMA (formerly the Families of SMA) and Spinal Muscular Atrophy Foundation. Contributors: The authors also thank the people who contributed to this study: Rosangel Cruz (Columbia clinical site, coordinator); Sally Dunaway (Columbia clinical site, physical therapist); Nicole Holuba (Columbia clinical site, coordinator); Jonathan Marra (Columbia clinical site, coordinator); Douglas Sproule (Columbia clinical site, (Aurora Scientific, Aurora, ON, Canada), and the foot is secured with tape. The TA muscle contractions were elicited by stimulating the sciatic nerve via bipolar platinum electrodes. Once the muscle is stabilized, the optimal length was determined by incremental stretching the muscle until the maximum twitch force was achieved. After a 3 minute rest period, the TA is stimulated at 50,100,150, and 200 Hz, allowing a 1 minute rest period between each stimulus to determine maximum tetanic force. Muscle length was measured. Following a 5 minute epidural steroid injection. Regardless of whether conservative treatment is undertaken, acute sciatica symptoms eventually subside in most patients.[3,4] In patients whose symptoms are resistant to conservative treatments, lumbar discectomy may be considered. Surgery typically results in faster symptom relief than continued conservative care[5] and this clinical advantage persists over longer term follow-up.[1] Consequently, lumbar discectomy has emerged as one of the most commonly performed spinal surgeries.[6] Among patients undergoing suture as close to the muscle as possible and the tendon is cut. The exposed muscle is constantly dampened with saline. Mice are then transferred to a thermal controlled platform and maintained at 37 degrees. The knee is secured to the platform with a needle through the patella tendon, the distal TA tendon suture to the level arm of the force transducer (Aurora Scientific, Aurora, ON, Canada), and the foot is secured with tape. The TA muscle contractions were elicited by stimulating the sciatic nerve via bipolar platinum electrodes. Once the with medical insurance that covers prolonged stay at a rehabilitation facility will opt to do so despite the surgeon recommending discharge straight to home. Fourth, we did not differentiate among discharge to home with no assistance, discharge to home with home health assistance, discharge to an acute inpatient rehabilitation facility, or discharge to a SNF. Most importantly, we found that half of our patients received intermediate scores, which accurately predicted outcome in only 65% of cases. We first assessed the predictive accuracy of\n",
            "[0.5579242]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is a P-body (processing body)?\n",
            "Refined Query: What are P-bodies, specifically their structure, function, and role in mRNA metabolism?  How are they formed, and what are the implications of their dysfunction in cellular processes and disease?\n",
            "\n",
            "Combined Answer: between P–P and P–O contacts (Fig. 5d). In the PCHi-C network we observe the ChAs for different phosphorylation states of RNAPII to vary widely in the P–O contacts (from close to 0.01 to 0.23, the third highest value overall), while all states have similar ChAs in the P–P contacts (ChAs range 0.21–0.22) (Fig. 5d; Additional file 1: Figure S16b). To understand this trend better, we also look at abundance of the different RNAPII variants in the different subnetworks (Additional file 1: Figure S16c). Whereas in the P–P subnetwork the abundance PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid capsule, which protects the bacterium from host phagocytosis [6]. The production of these virulence factors is highly dependent on an environment containing carbon dioxide and bicarbonate (CO2/HCO3, henceforth CO2). The relative concentrations of CO2 and bicarbonate are regulated enzymatically by carbonic anhydrase, as well as many other non-enzyme bias in datasets available in the literature. Therefore, we are unlikely to find features with higher ChAs in P–O versus P–P contacts, which would lie at the upper left corner above the diagonal in Fig. 3b. However, the features closer to the diagonal are features that are present in both P–P and P–O contacts. The PcG proteins and their associated histone marks are found very close to the diagonal on the comparative ChAs plot of Fig. 3b, suggesting that they are found at both P–P and P–O contacts, together with H3K36me3 and the cytosine identified hard-to-replicate sites as well as novel sites, such as nucleosome depleted regions (NDR). Second, we assayed binding and fork progression to determine if Pfh1 is nearby the replisome during S phase or, if it is recruited to its sites of action. These analyses revealed that Pfh1 and the leading strand DNA polymerase bind both Pfh1-sensitive and Pfh1-insensitive sites to a similar extent. Likewise, mass spectrometry (MS) found that Pfh1 interacts with many key replisome components. Together these data argue that Pfh1 is not just and Pfh1-insensitive sites to a similar extent. Likewise, mass spectrometry (MS) found that Pfh1 interacts with many key replisome components. Together these data argue that Pfh1 is not just recruited to its sites of action, but that it is in proximity to the replisome during DNA synthesis and functions as an accessory DNA helicase at all known classes of hard-to-replicate sites. These results inform our understanding of Pif1 helicases in higher eukaryotes, such as humans, which like S. pombe, encode only one Pif1 family helicase. Given that complexity that can influence the number of spectra acquired for a given protein within a sample. Normalizing NSAF values to PAX values, as described in [56], provides insight into proteins and functional protein classes that are enriched in the Pfh1 isolation relative to their abundances in the cellular proteome. These data are presented in Fig 6C, which also categorizes interacting proteins by function. and/or collapsed replication forks—functions relevant to those of Pfh1. Finally, six subunits of the 26 subunit RNA polymerase III complex were Pfh1-associated with high confidence (Rpc1, 2, 3, 4, 25 and 37), while four others were Pfh1-associated but had SAINT scores <0.8 (Rpc6, 0.71; Rpc9 and 10, 0.30; Rpc19, 0.76) [64]. This finding is probably related to RNA polymerase III transcribed genes being among the most potent replication impediments in Pfh1-depleted cells (Figs 2–4; see Discussion). in these experiments; however, it is well documented that ribosomes are assembled in nucleoli and many translation factors localize in the nucleus and participate in nuclear–cytoplasmic transport of mRNAs.25,26 Functional annotation of proteins binding ABPP 106, which combines the gene-term enrichment analysis done by GO, SP-PIR keywords, UP_SEQ_feature, KEGG and Biocarta pathways, Interpro and Smart protein domains, is shown in Table S1 in the SI (top ranking terms which have p < 1 × 10–18). We find that the most significant biological term the universally conserved Gly-Gly-Gln (GGQ) motif,7 which interacts with the large ribosomal subunit to release the polypeptide chain from the P-site bound peptidyl-tRNA. This GGQ-containing domain stretching from amino acid 57 to 121 in the human 166-residue full-length protein8 is not affected by the mutations that lead to a relatively mild phenotype. However, both in family B and in the previously described patients with the severe phenotype2 the mutation interrupts this highly conserved domain (Figure 4c). Possible explanations for the file 1: Figure S12H). The simulations show non-overlapping simulated ChAs distributions in the P–O subnetworks for the different RNAPII variants, whereas the corresponding distributions in the P–P subnetworks are highly overlapping. These results suggest a significant difference in the role of elongating polymerase between P–P and P–O contacts.\n",
            "[0.7397416]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the mechanism of action of decitabine?\n",
            "Refined Query: Decitabine's mechanism involves its incorporation into DNA, inhibiting DNA methyltransferases (DNMTs).  This leads to hypomethylation of DNA, reactivating tumor suppressor genes and ultimately impacting cell proliferation and inducing apoptosis in cancer cells.\n",
            "\n",
            "Combined Answer: or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can tissues [7,9]. DNA methylation is a very stable epigenetic mark and next generation sequencing studies have recently shown that many genes are aberrantly methylated in cancer [10,11]. Tissue specific DNA methylation patterns are stabilized during embryonic development, and faithfully maintained through cell divisions [12-14]. Nevertheless, established methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of heterochromatin formation (Chen et al. 2008). Our results suggest that H3K36me3, in addition to H3K9me3, might also contribute to heterochromatin formation in mammalian cells. The recent finding that H3K36me3 stimulates the recruitment of DNA-methyltransferase DNMT3A onto nucleosomes is compatible with our hypothesis (Dhayalan et al. 2010). Interestingly, this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. Notably, these modifications occur shortly after Wnt stimulation and it is plausible to think that the chromatin modifications within the Tcf3 locus can trigger the downregulation process of Tcf3 expression which can be stabilized further on via miR-211 function. Epigenetic regulation through histone modification or DNA methylation was also shown previously for other antagonists of Wnt signaling such as DACT3, sFRPs, WIF1 and DKK-1 in different cancer cells [48], [49], [50], [51]. Further experiments are required to clarify whether this mode methylation as an epigenetic regulatory mechanism. However, our data also reveal a high degree of hypermethylation outside promoter areas at intergenic regions, and at long distances from genes. This indicates that patterns of DNA methylation may play a role not only by silencing promoters of key tumor suppressor genes, but also by regulating gene expression in a more complex manner through distant regulatory elements such as insulators and enhancers. We found that satellite regions were particularly hypomethylated in the NSCLC tumors when this last study showed that the interaction between DNMT3A and H3K36me3 stimulates the methylase activity of DNMT3A in vitro, suggesting a cross talk between H3K36me3 and DNA methylation. H3K36me3 could thus contribute to the establishment of a transcriptionally unfavorable chromatin conformation by recruiting (and perhaps stimulating) repressive complexes. In conclusion, this study demonstrated that trimethylated histone H3 at lysine 36 is specifically enriched in facultative and constitutive heterochromatin in mouse, and that this histone antagonism and β-catenin/Tcf1 signaling [5]. In an attempt to elucidate the mechanisms underlying Tcf3 downregulation in the context of active Wnt signaling, we found that Tcf3 down-regulation does not require DNA methylation but is associated with alterations in histone marks at the core Tcf3 promoter region which are likely to regulate Tcf3 expression. Notably, these modifications occur shortly after Wnt stimulation and it is plausible to think that the chromatin modifications within the Tcf3 locus can trigger the downregulation process of histone modifiers and DNA methyltransferases. For example, the histone lysine-specific demethylase 1 (LSD1) has been shown not only to act as component of the nucleosome remodeling and histone deacetylase (NuRD) complex which is necessary for embryonic stem cell differentiation, it also directly interacts with DNMT1 and affects global DNA methylation status (17). LSD1 is the first of several protein lysine demethylases discovered. It specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 and functions as a transcriptional co-repressor (18, correlated with clinical outcome of breast cancer patients. One of these, a highly conserved lncRNAs we called LIMT, is downregulated by EGF due to histone deacetylation at the respective promoter. In agreement with this, LIMT is expressed at low levels in the basal‐like and in the HER2‐enriched, two relatively aggressive subtypes of breast cancer. Furthermore, LIMT was found to inhibit the migration of mammary cells and to reduce metastasis formation in vivo. enhancers in K27M expressing cells, contributing to tumorigenesis. Therapeutic attempts by targeting methylation pathways have yielded encouraging results. GSKJ4, a pharmacological JMJD3 (a H3K27me3 demethylase) inhibitor, leads to restoration of H3K27me3, leading to tumor cell lethality in vitro and a significant improvement in the survival of mice that carry tumors (Hashizume et al. 2014). A study by Brown et al. calls for alternative approaches by targeting different histone modification pathways to alter other posttranslational\n",
            "[0.6656139]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which gene is associated with the Mitchell-Riley syndrome?\n",
            "Refined Query: I need more information to answer your query about Mitchell-Riley syndrome.  Specifically, I require details on the genetic basis of this syndrome, as I don't currently possess that knowledge.  Please provide relevant research papers or databases.\n",
            "\n",
            "Combined Answer: < =60). This study also analyzed WES and LC/MS data from 11 patients genetically diagnosed through the TIDEX neurometabolic gene discovery project, hereby referred to as the “TIDEX project” (UBC IRB approval H12-00067) (Supplementary Table 1). Parents and caregivers provided written informed consent for the study. Details of this investigation have previously been published6 as well as in separate case reports2–4,19,20. Supplementary Table 1 summarizes the clinical characteristics of the patients and their previously identified genetic (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also Three members of a large consanguineous Indian family (figure 1A), affected by axonal neuropathy (table 1) and optic atrophy, were identified at the London Royal Free Hospital. Case 3 was first seen at the age of 35 years and then again at the age of 51 years. She is the first cousin of Cases 1 and 2 and presented as a child with delayed milestones, later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 two were missense, one was a non-frameshift deletion and one was a nonsense mutation. The latter is a 1 bp deletion in C12orf65 gene, resulting in a premature stop codon (NM_001143905: c.346delG: p.V116X) (figure 1B). As mutations in C12orf65 have been recently described to cause a severe encephalomyopathy17 as well as spastic paraplegia and optic atrophy,18 we assessed segregation of this mutation in the family. The deletion was homozygous in the affected cases, and either absent or heterozygous in the unaffected relatives (figure 3). To The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). Over a third of the patients (43%) were originally diagnosed with Angelman syndrome by clinicians. In this prospective study, clinical diagnostic criteria by Tan et al. 25 were utilized. Upon direct assessment, the majority of CS patients (93%) exhibit phenotypes similar to Angelman syndrome. For major criteria, all patients had ID and limited speech. Approximately 100% of patients had ataxia/unsteady gait (1 patient is currently non-ambulatory). For behavioral features, a majority were reported to have a happy disposition (100%) and unprovoked\n",
            "[0.66693944]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 379.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the mobile applications fields of use for patients ?\n",
            "Refined Query: Beyond basic appointment scheduling, how do mobile health apps benefit patients?  Consider applications in medication management, symptom tracking, telehealth consultations, mental health support, and chronic disease management.  What other areas significantly impact patient care and experience?\n",
            "\n",
            "Combined Answer: the diaries will augment the calendar details. In addition to the comparison of baseline vs. the last 4 weeks of maintenance, a continuum assessment will be made through all stages of the study to determine a time course of responsiveness. Additional outcome measure will include disability changes as assessed by PedMIDAS at the time of randomization compared to the end of maintenance. Side effects and tolerability of study drug based on phone and face to face visit assessment throughout the study will additionally be evaluated. Safety analysis with adjustment for the number of reports collected at each time point. Although there was a suggestion that the symptoms in the ZMapp recipients cleared more readily, these observations were confounded by the differential mortality in the two groups (i.e., patients who died no longer contributed to daily reports) and therefore a potential for bias, even though this effect should have favored the group that received the current standard of care alone. allow distinguishing between commonly prescribed drugs of the selected cohort and those correlated with the selected diagnosis. If, for instance, published studies indicate a certain drug increases the risk of heart attacks, the JADE tool can list prescribed medication prior to hospital stays with the diagnosis heart attack. To assist the user selection of an interesting diagnosis, all diagnoses that are related to hospitalisations due to adverse drug events and drug-drug interactions are highlighted in red in the searchable list. a contribution to the generation of hypotheses about ADEs and can help physicians in their daily work, especially while planning clinical trials. The Main Association of the Austrian Social Insurance Institutions provides the research database GAP-DRG [8] which contains dispensed medications, hospital stays and related diagnoses as well as sociodemographic attributes. In this work we describe JADE, a software tool that facilitates exploration of health claims data with regard to ADEs, which, in this project, are defined as any adverse event value) all favored the ZMapp group, credible intervals were even wider for these subgroups. If ZMapp did indeed confer some degree of therapeutic benefit, at least two main factors may have limited the magnitude of the mortality trend that we observed. Although trial patients were clinically symptomatic for only a few days before randomization, at enrollment they were probably 1 week or longer past their date of actual infection. This delay in initiating therapy exceeded the 5-day window within which ZMapp had been shown to provide 90% or patients whose health insurance companies report the actual dispensing date for a drug. Therefore, the selection of patients was not random. Furthermore the prescribed dose and time period of the drug intake are not documented. In general, the quality of diagnoses documented for hospital stays needs to be questioned. For example, in a study conducted in Australia Sansom et al. suggest that only for a fraction of hospital stays related to adverse drug reactions a drug-related diagnosis has been documented [15]. However, in the Austrian payment “real world” applicability of the study, the practicality of including highly motivated subjects that are without complications, while still being representative of the vast majority of families that seek care, are essential to a study's success. In many cases, the exclusion criteria would also exclude the use of the medications in the real world practice and thus can provide additional guidance to the choice of preventative medication. stays is shown. The support indicates the fraction of hospital stays before which a specific drug or drug combination was prescribed to the patient. A hospital stay is related to a diagnosis when documented as its main diagnosis or one of its additional diagnoses. The support is also shown for hospital stays not related to the selected diagnosis to allow distinguishing between commonly prescribed drugs of the selected cohort and those correlated with the selected diagnosis. If, for instance, published studies indicate a certain drug increases treated without antibiotics presented earlier in the course of their illness or attended treatment sites in closer proximity to their villages, improving their chances of recovery. The local health aides serving these sites may have been more proactive in recruiting caretakers in the community to bring children to the clinic for screening and treatment, thereby including less severe cases in this group. Since the two feeding programs operated independently, other unquantifiable variances in the teaching and nutritional counseling provided by After twelve years and two BioASQ Challenges it was a perfect time to look around and perform a reality check to determine if MTI was indeed still useful and relevant. In this paper we have presented several qualitative and quantitative reasons why we think that MTI is in fact still useful and relevant. The statistics on how much MTI is used by the indexers and by people outside of the US National Library of Medicine show that MTI usage continues to grow. The unbiased external review of MTI by the BioASQ Challenges where MTI provided two of the\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1235.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 933.15ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is CD99 encoded by MIC2 gene?\n",
            "Refined Query: The query asks if the CD99 cell surface glycoprotein is the protein product of the MIC2 gene.  Is the gene MIC2 responsible for the transcription and translation of CD99?  Clarification is needed to confirm this gene-protein relationship.\n",
            "\n",
            "Combined Answer: (Biorad) with the following gene specific primers: AID forward (GCCACCTTCGCAACAAGTCT), AID reverse (CCGGGCACAGTCATAGCAC), Imu forward (CTCTGGCCCTGCTTATTGTTG), Cmu reverse (GAAGACATTTGGGAAGGACTGACT), (GGCCCTTCCAGATCTTTGAG), CG1 reverse (GGATCCAGAGTTCCAGGTCACT). Relative gene expression was calculated according to the delta Ct method. affected by position effects among unaffected bystander genes. Mutations affecting expression of microRNAs in genetic disease have so far not been reported. However, since they can be target genes in GRBs, such cases may exist. In the case of the two GRBs described here that contain elements driving the transcriptional activity of microRNAs of the mirn9 family, there are human disease loci mapped to the area. In the case of mirn9-2, there is a cone rod dystrophy mapped to 1q12–1q24 (OMIM%605549), where so far no gene has been assigned. Close Full details can be found in SI Materials and Methods. Briefly, cells or tissues were chemically cross-linked and sonicated. After clearance, IPs were performed overnight using previously established antibodies (Abcam: H3K4me3 ab8580, H3K4me1 ab8895, H3K27ac ab4729, and H3 ab1791; Santa Cruz Biotechnology: Rfx1 sc-10652X and p300 sc-585). Samples were run using the GA2X genome sequencer (SCS v2.6, pipeline 1.5). Raw data are available online at the Gene Expression Omnibus ascension viewer series (accession nos. GSE24164, GSE24165, and Portions (1 μg) of circular pJH73.2 (CTF18-9myc), pJH78 (RFC3), or pJH79 (RFC4) were used as templates in a 50-μl linked transcription-translation system (Promega). A 24-μl volume of each product was used per immunoprecipitation in a final volume adjusted to 150 μl with 1× PBS–1% Triton X-100, and the mixtures were incubated for 2 h at 4°C. A 1-μl volume of anti-myc (sc-789) was added for a further 2-h incubation, followed by immune complex precipitation for 1 h using 10 μl of protein A-agarose beads (sc-2001; Santa Cruz). Following three map, we compared the genomic distribution of the same 89 transcription factors between GM12878 and proband CD4+ T-cells. Transcription factors that exhibit large variation in distribution between T-cells and B-cells are enriched for T-cell specific factors (Fig. 5d). This analysis shows NFAT is differentially regulating, while canonical CTCF occupancy is highly correlated within these two cell types (Fig. 5d). Supporting this interpretation, we note specific loci where NFAT is localized nearby to known T-cell specific genes such as CD28 and a we compared the predicted targets of NFKB1/REL/RELA with targets identified through ChIP-seq in lymphoblastoid cell lines derived from 10 individuals of African, European, and Asian ancestry (Kasowski et al. 2010). We find that almost two-thirds of the top 50 targets, >50% of the top 150 targets, and ∼40% of the top 300 targets are supported by ChIP-seq binding at the promoter (Supplemental Fig. 19). To put these numbers in perspective, we compared the validation of ISMARA’s targets with the variability in NFKB1/REL/RELA binding across adjacent motif (PAM, here NGG), fused with a scaffold sequence recognised by Cas9 protein [3]. By engineering the gRNA targeting region, one may target virtually any complementary genomic locus with moderate off-target effects [4]. As an effector protein, Cas9 may either be employed as a natural nuclease [1, 5], or else catalytically inactivated and fused to a different protein domain [6]. These features make it possible to manipulate the numerous types of non-protein coding genomic elements that have so far resisted standard RNA interference reporter gene expression (Figure S3E–F). For ccdc46RR, the deletion altered and massively reduced the reporter gene expression to a few cells in the hindbrain (Figure S3G). Only for fam44bRR did the deletion construct not abolish the original enhancer activity of the full construct (Figure S3H) and therefore fam44bRR was excluded from further analysis. These results demonstrate that three out of four RRs are necessary for enhancer activity. flanking genes (Figure S4). To further confirm this, we performed double fluorescent whole mount in situ hybridisation on stable transgenic lines by combining probes for the reporter and the flanking genes. In all cases, we identified at least one flanking gene that recapitulates key aspects of the expression pattern of the RR-driven reporter gene (Figure 3). In particular, both ttc29RR-driven GFP (Figure 3B) and the flanking gene pou4f2 (Figure 3A) are expressed in the optic tectum and retina (Figure 3C). dock9RR shows very specific enhancer occur at active TSSs regardless of whether they are annotated. We further characterized HOT regions at consensus promoters in terms of several quantitative genomic features associated with promoters (Additional file 1: Figure S5). Most known human promoters are enriched for GC content and especially CpG dinucleotides [21], and their sequences are typically under evolutionary constraint [22]. In addition, several histone modifications are associated with regulatory genome elements: histone 3 lysine 4 trimethylation (H3K4me3) is enriched at\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1008.33ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 984.39ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the main component of the Lewy bodies?\n",
            "Refined Query: Lewy bodies are abnormal aggregates found in the brains of individuals with Lewy body dementia and Parkinson's disease.  What is the primary protein constituent forming these characteristic intracellular inclusions?\n",
            "\n",
            "Combined Answer: protein [12]. In the nucleus, CREST was shown to be recruited to nuclear bodies of unknown origin [13]. More recently, CREST was identified in a screen for paraspeckle proteins [14]. The majority of ALS-associated proteins are characterized by high aggregation propensity, which is attributable to the presence of a prion-like domain in their structure [15]. The ability to aggregate reversibly is indispensable for their normal function in RNA-protein macromolecular complexes, such as RNA transport granules, stress granules, paraspeckles and have proposed that PLK2 has a critical role in maintaining dendritic spine stability (31) and modulating excitatory glutaminergic synaptic connections (32, 33). Thus, the involvement of PLK2 in α-synuclein phosphorylation provides a potential link between excitotoxic responses and Lewy pathology. Investigation of how the biology of PLK2 relates to the pathogenesis of PD and DLB should help clarify the role of synuclein phosphorylation in these diseases. Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of α-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical the presence of 4% SDS. However, similar to some other ALS-associated proteins that form non-amyloid aggregates, neither tagged nor untagged CREST formed SDS-resistant amyloidogenic species, as was evident from detection of only monomeric forms of the protein in semidenaturating detergent agarose gel (SDD-AGE) assay (Figure 2D). To assess the contribution of different CREST domains to its aggregation propensity, we produced a set of deletion constructs tagged with GFP at their N-terminus (Figure 2E) and expressed them in SH-SY5Y cells (Figure ZCCHC17 protein has not previously been studied in brain tissue, and so we examined which cell types express ZCCHC17. Immunohistochemistry at higher antibody concentrations stain mainly nucleus but also cytoplasm of cells throughout the grey matter (Supplementary Fig. S1A) and to a lesser extent white matter neuropil (Supplementary Fig. S1B). Although ZCCHC17 does not appear to be exclusively neuronal, it does stain neurons strongest. This is seen at lower antibody concentrations, where staining is limited to the nucleolus of large pyramidal concentration threshold of uncontrollable aggregation for mutated CREST. A similar scenario has been suggested for transformation of cytoplasmic RNA granules enriched in proteins with prion-like domains into proteinaceous inclusions in proteinopathies [22,23]. CREST also has a prion-like domain in its structure, and the latter was proposed to play a role both in physiological and pathological aggregation [15-17]. Since at present the nature of these CREST structures is unclear, in this study they are collectively referred as “aggregates” about a particular protein. Annotation is regularly reviewed to keep up with current scientific findings. The manual annotation of an entry involves detailed analysis of the protein sequence and of the scientific literature. Disease ontology The DISEASE ONTOLOGY [57] contains data associating genes with human diseases, using established disease codes and terminologies. Approximately 8,000 inherited, developmental and acquired human diseases are included in the resource. The DISEASE ONTOLOGY semantically integrates disease and medical and sponge proteins, all five are both present and in the identical order in the three cadherin protein families—lefftyrins, coherins and hedglings—that were contained in the last common ancestor of choanoflagellates and metazoans (Abedin and King, 2008; Nichols et al., 2012) (Supplementary Fig. S2). The TMEM132 domain architecture is thus ancient, preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the Identification of the three tandem BIG domains, then allowed our analyses to be focused on the TMEM132 family N-terminal region taking advantage of iterative profile-versus-sequence searches against the UniRef50 protein sequence database (Wu, 2006). These resulted in the identification of two additional domains, each of which is present not only in animals but also among more diverse eukaryotes, including members of the Coherin family in choanoflagellates and sponges (Nichols et al., 2012). The domain preceding the BIG domains was discovered as correlates well with the cranial shape phenotype and occasional cranial synostosis seen in affected individuals (table 2). TBC1D24 contains a TLDc domain and regulates Rab proteins. In our cohort, we identified no mutations in the other TLDc domain-containing genes by exome sequencing (appendix p 14). By homology modelling, the substitutions we identified did not seem to affect portions of the protein predicted to interact with the TLDc domain, nor were they in the region that typically interacts with GTP in other TBC proteins (figure 3).\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.78ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How does thyroid hormone regulate mitochondrial biogenesis in the myocardium?\n",
            "Refined Query: Thyroid hormone's impact on cardiac mitochondrial biogenesis is multifaceted.  How do its nuclear receptor interactions and subsequent gene expression changes specifically affect the expression of key regulators like PGC-1α and TFAM in cardiomyocytes, ultimately influencing mitochondrial number and function?\n",
            "\n",
            "Combined Answer: 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave From the above controversy regarding the importance of TTR synthesis by the choroid plexus, several points support the hypothesis that choroid plexus-derived TTR plays a role in the movement of THs from the blood to the brain and in distributing THs in the blood and CSF. These points include evolutionary, developmental, molecular and functional data. Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters - PMC of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear transcription factors. T3 can bind TRs either in the cytoplasm and translocate into the nucleus, or bind TRs in the nucleus. T3 binding to TR hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, there is evidence for two mechanisms for THs to move out of the choroid plexus into the CSF: (i) secretion of TH bound to choroid plexus-derived TTR, and (ii) efflux of THs via TH transmembrane transporters. The relative quantitative contribution of each of these mechanisms during each stage of CNS development is currently unknown and should be Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form Direct involvement of either TSHR or IGF-1R in the pathogenesis of TAO remains uncertain (23, 24). TSHR is detectable on orbital fibroblasts, but the levels of this protein are vanishingly low until the cells are subjected to conditions favoring their differentiation into adipocytes (7, 25). In contrast, TSHR levels in fibrocytes approach or exceed those detected on thyroid epithelium (26–28). Antibodies directed against TSHR and/or IGF-1R may trigger signaling through these receptors and induce production of proinflammatory cytokines. Thus, the mAb interferes with both IGF-1R- and TSHR-mediated actions. These findings are congruent with those reported earlier by Tsui et al (7), who demonstrated that 1H7, another IGF-1R-blocking mAb, could attenuate TSHR-initiated signaling in TAO orbital fibroblasts. A recent study by Kumar et al (8) confirmed these findings. Coupled with the current findings, it appears that IGF-1R plays an important role in regulating a component of the signaling conventionally attributed to TSHR in thyroid epithelial cells, orbital fibroblasts, and fibrocytes.\n",
            "[0.7682837]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the link between HOT regions and RNA polymerase recruitment?\n",
            "Refined Query: How do regions of high transcriptional activity (HOT regions) influence the recruitment and binding of RNA polymerase, the enzyme crucial for transcription initiation?  What specific mechanisms or factors mediate this relationship, and how does this contribute to differential gene expression?\n",
            "\n",
            "Combined Answer: We identified HOT regions by a comprehensive analysis of ChIP-seq data from 96 DNA-associated proteins in 5 human cell lines. Most HOT regions co-localize with RNA polymerase II binding sites, but many are not near the promoters of annotated genes. At HOT promoters, TF occupancy is strongly predictive of transcription preinitiation complex recruitment and moderately predictive of initiating Pol II recruitment, but only weakly predictive of elongating Pol II and RNA transcript abundance. TF occupancy varies quantitatively within human HOT site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate a multitude of signals that converge on them in the form of activating or repressing transcription factors. In invertebrates, some regulatory regions (\"high-occupancy target\", or HOT, regions) are occupied by a large number of transcription factors [1-6]. However, less is known about the interactions among TFs at HOT regions and how these Since transcription factors occupy regulatory elements in the genome, we expected HOT regions to align with these elements. We compared the positions of these HOT regions with those of known or inferred promoters, according to three lines of evidence. First, we detected initiating RNA polymerase II (serine 5-phosphorylated [18]; Pol II-S5P) enrichment sites from an independent UniPeak analysis, again using ENCODE ChIP-seq data. Second, we used a strand-specific UniPeak analysis to detect enriched regions from CAGE, a form of RNA-seq that Transcription-factor occupancy at HOT regions quantitatively predicts RNA polymerase recruitment in five human cell lines - PMC regions are not strongly enriched for the DNA-sequence motifs bound by the transcription factors that define them (Moorman et al. 2006; MacArthur et al. 2009; Gerstein et al. 2010; Roy et al. 2010). Instead, HOT regions are associated with open chromatin, suggesting that chromatin accessibility along with sequence motif enrichment drives the high transcription factor occupancy (Roy et al. 2010). In Drosophila, HOT regions are enriched for developmental enhancers that contain the canonical Zld-binding site, CAGGTAG, as well as for in vivo Zld Transcription factors (TFs) are proteins that regulate the expression of genes by binding the DNA at their regulatory elements (promoters or enhancers) and either preventing or facilitating the recruitment, in eukaryotes, of the transcription preinitiation complex (PIC). The PIC in turn recruits RNA polymerase II (Pol II) to the transcription start site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate also as new molecular protocols increase the signal-to-noise ratio of protein-associated DNA capture [67]. Assessing the relevance of this study to our understanding of transcriptional regulation, we found that about 40% of variance in initiating Pol II occupancy at HOT promoters can be explained by the entire set of available TF occupancy data in the cells with the most experiments. The predictive value is higher for PIC subunits, and much lower for elongating Pol II and transcript abundance. These results are also consistent with our different TFs to predict novel interactions, and used mechanistic evidence to infer which complex members directly bind DNA. Finally, we quantified the relationship between TF occupancy and several measures of gene expression at HOT promoters. our strictest definition finds several thousand HOT promoters, likely a considerable fraction of the active genes in any given cell line. Especially since there are far too few known DNA sequence motifs to account for all the TF occupancy at these sites, we propose that TFs collaborate combinatorially through protein-protein interactions to regulate Pol II recruitment (Figure 8), concordant with similar evidence from Drosophila enhancers [72]. Interactions of this nature have not previously been examined on such a large scale, due to the regions (\"high-occupancy target\", or HOT, regions) are occupied by a large number of transcription factors [1-6]. However, less is known about the interactions among TFs at HOT regions and how these interactions contribute combinatorially to the regulation of transcription, and until recently, insufficient data existed to search for HOT regions in human cells. The ENCODE data set [7,8] provides the first opportunity to study a large group of TFs together in human cells. These data come from the chromatin-immunoprecipitation sequencing\n",
            "[0.84128237]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List variants of the MC1R gene.\n",
            "Refined Query: I need a list of the known genetic variants of the melanocortin 1 receptor (MC1R) gene, including their common nomenclature (e.g., rs numbers) and, if possible, a brief description of their associated phenotypic effects on pigmentation.\n",
            "\n",
            "Combined Answer: for interpretation of ICC variants: the ExAC browser14, Ensembl, the UCSC genome browser, ClinVar, PubMed, Google, the Beacon Network (https://beacon-network.org) and the Atlas of Cardiac Genetic Variation (ACGV)9. The following additional data are available with the online version of this paper: a spreadsheet listing the gene sets used in this study (Additional data file 1); supplementary tables and figures (Additional data file 2). representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary Figure 2). The report is transparent, with all supporting evidence displayed along with links out to eight external resources that are commonly used for interpretation of ICC variants: the ExAC browser14, Ensembl, the UCSC genome browser, ClinVar, PubMed, Google, the Beacon Network (https://beacon-network.org) and the Atlas of Cardiac Genetic Entrez Gene, HGNC, UCSC, and miRBase). We also provide and maintain an automatically updated data repository with publicly available Copy Number Variation, DNA-methylation, DNA-seq, miRNA-seq, and RNA-seq (V1,V2) experimental data of TCGA converted into the BED format, and their associated clinical and biospecimen meta data in attribute-value text format. and genes. To our best knowledge, this work is the first attempt to identify various mutation types according to a standard nomenclature endorsed by the Human Genomic Variation Society (HGVS) for the description of sequence variants (mutations). Finally, similar to MutationFinder, along with a public tool for mutation extraction, we also contribute to the text-mining community a large corpus (500 PubMed abstracts) of manually annotated raw and normalized mutation mentions. A raw mutation extraction is normalized when individual mutation mirn9 family, there are human disease loci mapped to the area. In the case of mirn9-2, there is a cone rod dystrophy mapped to 1q12–1q24 (OMIM%605549), where so far no gene has been assigned. Close to mirn9-5 is Usher syndrome type II and febrile seizures at 5q14 (OMIM#605472 and #604352). Some cases of these diseases have been assigned to mutations in the gene encoding G-coupled receptor MASS1 (for example, see Nakayama et al. 2002), which lies within the larger synteny block containing mirn9-5 and is ∼1.8 Mb upstream of MEF2C, but other cDNA ENST00000370695. PCR primers for each exon are shown in Supplementary Table 3. Variants were identified by verifying the chromatogram using Chromas Lite software. All exons were screened in the proband; however, only the putative mutation was tested in relatives in the extended pedigree in order to discern the pattern of inheritance. All references to genomic coordinates are based on human genome build hg19 (www.genome.ucsc.edu). and the number of samples for the three races were 7, 20, and 209, respectively, whereas the corresponding numbers of distinct somatic mutations in the result samples were 1049, 1070, and 3227, respectively. In Fig. 4, we report a second GMQL query, which combines Copy Number Variation (CNV) and miRNA-seq data; it searches pairs of TCGA samples of these two data types that regard the same biospecimen, and returns the DNA copy number variations in each CNV sample that are within expressed microRNA (miRNA) genes in the paired miRNA-seq sample. Database of Genomic Variants47 (DGV), dbVar,48 and ISCA49 (study IDs nstd37, nstd45, nstd75) CNVs for every position in the human genome were counted for each position. All attributes are listed in Table S2. as well as qualitative and quantitative phenotypes. Resources, such as association result browser (http://www.ncbi.nlm.nih.gov/projects/gapplusprev/sgap_plus.htm) and NHGRI GWAS catalog (Welter et al., 2014), have been established to catalog all the trait-associated variants. Currently, the association result browser contains 44 124 association results (checked on October 10, 2015), which corresponds to 30 553 (autosomes plus chromosome X) unique trait-associated single nucleotide polymorphisms (taSNPs), linking to 573 diseases or phenotypes.\n",
            "[0.069878735]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the enzyme that degrades decapped mRNAs?\n",
            "Refined Query: Decapped mRNAs, lacking their 5' cap, are vulnerable to degradation.  Which specific enzyme, or enzyme complex, initiates this degradation process by targeting the absence of the 5' cap structure?\n",
            "\n",
            "Combined Answer: in a transcriptome highly improbable. The two enzymes work at the same temperature and in the same buffer, so their digestion can be combined in a single step. A fraction of the synthesised carrier RNA is capped using the Vaccinia Capping System (NEB) and mixed with uncapped carrier to achieve the desired capping percentage (Palazzo and Lee 2015). The percentage of capped RNAs in the carrier and its size distribution were optimized by performing the entire SLIC-CAGE protocol, starting by adding the synthetic carrier to the low-input sample to kit (Qiagen). A portion of carrier RNAs was capped using the Vaccinia Capping System and purified using an RNeasy Mini kit (Qiagen). The capping efficiency was estimated using RNA 5′ Polyphosphatase and Terminator 5′-Phosphate-Dependent Exonuclease, as only uncapped RNAs are de-phosphorylated and degraded, while capped RNAs are protected. Several carrier combinations were tested in SLIC-CAGE (Supplemental Tables S4, S5), and the final carrier used in SLIC-CAGE was comprised of 90% uncapped carrier and 10% capped carrier, both of varying length mouse model, in which we restored components of the dystrophin complex and corrected the pathologic and physiologic features of muscle injury. Most eukaryotic mRNAs are monocistronic and possess a specialized cap structure at their 5’ terminus, which is required for translation initiation as this is where scanning by the 40S ribosomal subunit begins32. Despite clear evidence for the cap-dependent 5' ◊ 3' scanning model of initiation, bioinformatic analysis has suggested that ~50% of human transcripts contain 5’UTR short upstream open reading Table S1). Combination of alternating recognition sites allows for higher degradation efficiency and reduces sequence repetitiveness. The two enzymes have recognition sites of lengths 27 and 18 bp, respectively, which even with some degeneracy allowed in the recognition site (Gimble and Wang 1996; Argast et al. 1998) makes their random occurrence in a transcriptome highly improbable. The two enzymes work at the same temperature and in the same buffer, so their digestion can be combined in a single step. A fraction of the synthesised carrier process includes three major steps: the addition of a 5′ cap, addition of a polyadenylation (polyA) tail and splicing. In particular, a polyA tail is added at the 3′ end of a pre-mRNA with the help of the polyadenylation process. More precisely, the polyadenylation process consists of two steps (Wahle and Kühn, 1997): cleavage near the 3′ end of a pre-mRNA and the addition of a polyA tail at the cleavage site. Certain cis-acting elements and trans-acting factors have been found in the literature that influence the choice of a particular polyA neurodegenerative disease.38 The ribosome binding and translation initiation as well as translation elongation and termination strongly influence mRNA stability in bacteria.39 In eukaryotes, translation is also linked to mRNA stability, suggesting a general model for cotranslational mRNA decay.40−42 It is possible that compound 106 could have a positive effect on translation of frataxin mRNA in addition to its documented effect on transcription of the FXN gene.6 Additionally, HDAC inhibition could have a positive effect on FXN mRNA splicing or acids 1 to 75 of Pta1, this interaction can be weakened without affecting Ssu72 levels (Fig. 3C and 4A). Ssu72 is a CTD Ser-5 phosphatase, but this activity is not needed for Ssu72's function in pre-mRNA cleavage (25). The deletion of the first 75 amino acids of Pta1 also impaired growth at 39°C (Fig. 2D) but had no effect on mRNA 3′-end processing (Fig. 3A). However, this deletion caused a gene-specific defect in snoRNA termination (Fig. 3D), accumulation of the CTD Ser5-P form of RNAP II (Fig. 3C), and a defect in gene looping (Fig. 3E). compared to other variants despite insignificant differences at mRNA level (Figure 6D). To assess if CREST mutations alter protein stability, we estimated the proteins’ half-lives using a pulse chase with cycloheximide. Overexpressed CREST was stable, with half-life of approximately 36 hours, without significant differences between the variants but again with the exception of Q388stop, which displayed increased stability (Figure 6E). The propensity of CREST mutants to aggregate was estimated using the sequential extraction protocol described factors, alternative cleavage sites can be formed for a pre-mRNA, resulting in more than one mRNA transcript from a single pre-mRNA containing 3′ untranslated regions (3′ UTRs) of different lengths. Note that a 3′ UTR is a suffix of an mRNA sandwiched between the stop codon and polyadenylation cleavage site of the mRNA. The length of a 3′ UTR as well as some sequence elements in the 3′ UTR such as AU-rich elements and GU-rich elements may have impact on mRNA stability, mRNA localization, protein translation, protein binding and translation may be required for high-quality libraries. We show that SLIC-CAGE libraries are of equivalent quality and complexity as nAnT-iCAGE libraries derived from 500- to 1000-fold more material (5 µg of total RNA, ∼106 cells). SLIC-CAGE extends the nAnT-iCAGE protocol through addition of the degradable carrier to the target RNA material of limited availability. Since the best CAGE protocol is not amenable to downscaling, the idea behind the carrier is to increase the amount of material to permit highly specific cap-trapper-based purification of\n",
            "[0.6357306]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which phenotypes are associated with heterozygous mutations of the BSCL2 gene?\n",
            "Refined Query: Investigate the phenotypic manifestations resulting from carrying one mutated copy of the BSCL2 gene.  Specifically, what observable characteristics or traits are linked to this heterozygous condition, considering the range of possible mutations?\n",
            "\n",
            "Combined Answer: mutations are either de novo heterozygous deletions encompassing the gene or truncating mutations, both leading to a loss of function.25 A PHOX2B gene mutation appears necessary and sufficient for the CCHS phenotype to occur. Here we show that the RET gene acts as a modifier of the PHOX2B gene. Indeed, the frequency of the ATA haplotype of the RET gene is similar to that observed in the European population (25%)3 in all groups except the Haddad group, where its frequency reaches 38.6% (χ2 = 11.73, p<0.001). However, a strict digenic model does groups of patients. Allele frequencies were estimated by the counting method and genotype and allele frequencies were compared by a χ2 test. We also compared the distribution of alleles for each SNP with the nature of the PHOX2B gene mutation. Haplotypes were determined by the family studies. In addition, direct sequencing on both DNA strands of the 21 exons and flanking introns of the RET gene was carried out in the two patients with HSCR in family 1, as previously described.16 We bred Phox2b+/− females and Ret+/− males in a C57/Bl6 ABCC2 mutation screening was performed in 8 probands representing all studied families as described previously (14). However, both in family B and in the previously described patients with the severe phenotype2 the mutation interrupts this highly conserved domain (Figure 4c). Possible explanations for the differences between the intermediate phenotype described for the patients in family B as compared with the severe phenotype in Antonicka et al2 may be related to the leakiness nature of the novel splice mutation, which retains some residual wild-type transcript with intact exon 2 (Figure 4b – lane 4) resulting in functional protein containing the GGQ 19% and 33% of the patients, respectively, have HSCR in addition to CCHS. Therefore, for an identical PHOX2B gene mutation, patients present CCHS with or without HSCR. Such a finding clearly indicates a role for modifier factors in the occurrence of the HSCR phenotype—allelic diversity is not the only satisfactory explanation. Concerning MWS, ZFHX1B mutations are either de novo heterozygous deletions encompassing the gene or truncating mutations, both leading to a loss of function.25 A PHOX2B gene mutation appears necessary and sufficient for one on each of two homologous chromosomes, physically interact and then undergo sequence comparison, wherein discrepancies in DNA sequence or copy number, or disruptions of genome organization that compromise interactions, would be sensed and result in loss of fitness through disease or reduced fertility [2], [25], [27]. Such a mechanism would, over time, tend to cull away variants in UCE sequence or copy number, maintaining the extreme DNA conservation that characterizes UCEs. Importantly, there is growing evidence for the potential of de novo mutations (ie mutations were not found in the mother). Another notable finding was two separate recurrent mutations. The first was found at c.1498 c>t, p.R500X. This mutation was observed in two families not known to be related, and in one family this mutation was determined to occur de novo in a maternal carrier (Family 12, Figure 1). The mutation was carried in the mother of the proband with CS but not in the maternal grandparents. The same mutation was inherited in another proband (Family 9). The two families share a small haplotype at an average sequence depth of 26.6 for all samples. To identify potential causal variants, we selected all coding variants in the homozygous regions present in both samples. Then, we filtered them by discarding (i) variants documented in the dbSNP and the 1000-Genomes Project and (ii) synonymous substitutions. Five variants passed these filters: two were missense, one was a non-frameshift deletion and one was a nonsense mutation. The latter is a 1 bp deletion in C12orf65 gene, resulting in a premature stop codon (NM_001143905: c.346delG: mutation was carried in the mother of the proband with CS but not in the maternal grandparents. The same mutation was inherited in another proband (Family 9). The two families share a small haplotype around the point mutations that is approximately 171kb long (Supplementary Table 4). We also observed a second recurrent mutation, c.1710 g>a, p.W570X, in Families 3 and 7. Here, the mutations were determined to be de novo in both families, although the families again share a haplotype around the point mutation spanning 260 kb. In total, we mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without TBC1D24 mutations, we did not identify a mutated gene in common in these families (details on the regions identified are given in the appendix p 11). Analyses are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24\n",
            "[0.49441892]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the target protein of the drug nivolumab?\n",
            "Refined Query: Nivolumab is a cancer immunotherapy drug;  what specific protein does it target to exert its anti-cancer effects?  Clarify whether the question seeks the protein's common name or its precise gene designation.\n",
            "\n",
            "Combined Answer: Cells were extracted in RIPA lysis buffer (NEB) supplemented with protease inhibitors (Sigma) and phosphatase inhibitors (Sigma, NEB). Western blots were performed using standard procedures. Protein samples were separated by SDS–PAGE (3–8% or 4–12% gradient gels; Invitrogen), and subsequently transferred onto nitrocellulose membranes. All primary antibodies were used at 1:1000 dilution and secondary antibodies at 1:5000. The following antibodies were used: ATM (Santa Cruz), ASCIZ (Millipore); p95 (known as NBS1) (NEB), β-actin (Sigma), pS15-p53 myelosuppression when combined with olaparib. Of note, our data also indicate that the most pronounced synergy was seen at low topotecan drug concentrations in vitro, which may imply that efficacy can be maintained even if a dose reduction of topotecan is required (29). Taken together, the present studies suggest that rucaparib sensitivity is not restricted to ovarian cancer with BRCA1/2 mutations and, furthermore, confirms the notion that PARP inhibitors may be able to potentiate cytotoxic treatment independent of their activity as single resistance. Cancer cells often exhibit aberrant activation of signaling proteins and pathways that promote cellular survival and intrinsic resistance to proteasome inhibitors and other anti-cancer agents. In addition, because the proteasome regulates expression levels of a large number of proteins with diverse functions, proteasome inhibitors induce the expression of proteins with proapoptotic and antiapoptotic roles. Thus, bortezomib, carfilzomib, and oprozomib upregulate proapoptotic Bik and Noxa, which act to mediate the killing activities Selumetinib is active against recurrent, refractory or progressive PA harboring common BRAF aberrations and NF1-associated pLGG. To our knowledge, this is one of the first prospectively tested and successful molecularly-targeted agents in pLGG. These data not only provide an alternative to standard chemotherapy for these subgroups of patients, but this success has led to an interest in exploring efficacy in patients as a first-line therapy. In fact, these data have directly led to the development of two Children’s Oncology Group phase III rucaparib with topotecan, synergistic interactions were observed across the entire concentration range (IC20–IC80). Importantly, however, the largest increase in rucaparib-induced enhanced growth inhibition was seen at lower topotecan concentrations (P = 0.018; Supplementary Fig. S6). We believe this is an important observation as data from a recent clinical trial show that due to an enhanced myelosuppression dose reductions are necessary in the clinical setting when combining topotecan with the PARP inhibitor olaparib (29). Nonetheless, these clinical trial show that due to an enhanced myelosuppression dose reductions are necessary in the clinical setting when combining topotecan with the PARP inhibitor olaparib (29). Nonetheless, these preclinical data suggest that significant antitumor activity may still be achievable despite a clinically necessary reduction in the dose of chemotherapy. restricted to ovarian cancer with BRCA1/2 mutations and, furthermore, confirms the notion that PARP inhibitors may be able to potentiate cytotoxic treatment independent of their activity as single agent. These findings support further clinical evaluation of rucaparib either as single agent or as adjunct to chemotherapy in the treatment of sporadic ovarian cancer. Multiple drug effect analyses were conducted to determine the nature of interactions between rucaparib and 5 chemotherapeutic agents most commonly used for the treatment of ovarian cancer: carboplatin, paclitaxel, doxorubicin, topotecan, and gemcitabine (Supplementary Fig. S4). These studies were conducted using 5 ovarian cancer cell lines with varying degrees of sensitivity toward single-agent rucaparib with IC50 values ranging between 3.9 μmol/L in A2780 and more than 15 μmol/L in MCAS or OV2008 cells. Synergistic interactions were observed were able to show that the drug interactions differed significantly between individual chemotherapeutic agents (P = 0.010). When adding rucaparib to chemotherapy, the benefit was most pronounced for topotecan, less so for doxorubicin or carboplatin, and the least for paclitaxel or gemcitabine (Supplementary Fig. S5). Moreover, when combining rucaparib with topotecan, synergistic interactions were observed across the entire concentration range (IC20–IC80). Importantly, however, the largest increase in rucaparib-induced enhanced growth for topotecan, synergistic, or additive for carboplatin, doxorubicin or paclitaxel, and additive for gemcitabine. Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in enhanced apoptosis, DNA fragmentation, and γH2AX formation. Importantly, rucaparib potentiated chemotherapy independent of its activity as a single agent. PARP inhibition may be a useful therapeutic strategy for a wider range of ovarian cancers bearing deficiencies in the homologous recombination pathway other than just BRCA1/2 mutations.\n",
            "[0.5492418]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: The CXCR2 receptor is targeted in cancer. Name five antagonists.\n",
            "Refined Query: The CXCR2 receptor's role in cancer progression makes it a promising therapeutic target.  Identify five specific antagonists used to inhibit CXCR2, detailing their mechanism of action if known, within a concise paragraph.\n",
            "\n",
            "Combined Answer: cells, R-Cal33 cells were less resistant to carfilzomib (64-fold) and oprozomib (32-fold) than R-UMSCC-1 cells (205-fold and 46-fold resistant to carfilzomib and oprozomib, respectively). It is interesting to note that R-UMSCC-1 cells, in contrast to R-Cal33 cells, also exhibited overexpression of Bcl-2 relative to parental cells. Thus, in the more resistant R-UMSCC-1 cells, the acquired resistance may reflect contributions from both MDR-1/P-gp and Bcl-2. This also suggests that inclusion of a pan-Bcl-2 inhibitor targeting both Bcl-2 and Mcl-1 study, ceritinib has exhibited dramatic activity in patients with ALK-rearranged NSCLC (13). In these studies, we find that ceritinib is a more potent ALK inhibitor than crizotinib, and has marked activity in crizotinib-naïve models of ALK-positive NSCLC, including H2228, H3122, Ba/F3 cell lines in vitro and MGH006 primary explants in vivo. To better characterize the activity of ceritinib in crizotinib resistance, we developed a variety of crizotinib-resistant models, including cell lines derived from biopsies from patients whose cancers had from crizotinib-resistant patient samples, demonstrate that the next generation ALK inhibitor ceritinib is active against most crizotinib resistant tumors. This is consistent with the marked clinical activity of ceritinib in ALK-positive NSCLC patients who progressed on crizotinib. As resistance to ceritinib has already been observed in the clinic, future studies will need to identify mechanisms of resistance to ceritinib other than mutations in the G1202 and F1174 residues in order to maximize the clinical benefit afforded by next generation MTD (750mg QD). We also evaluated the efficacy of ceritinib in a primary explant model derived from a crizotinib-naïve NSCLC tumor MGH006 (6). Treatment of these mice with 25 mg/kg ceritinib also led to tumor regressions (Fig.S1C). Altogether, these data demonstrate that ceritinib is potent against crizotinib-naïve ALK-rearranged cell lines and tumor models in vivo and in vitro. these crizotinib-resistant H2228 xenograft tumor models as well as one of the resistance models that did not harbor a resistance mutation nor ALK amplification (data not shown). While each was resistant to crizotinib at 100 mg/kg, ceritinib suppressed tumor growth in multiple resistance models (Fig.5A, B, C and D). In the wild-type and I1171T resistant models, ceritinib demonstrated impressive anti-tumor activity, while it was less active in the C1156Y resistant model and was inactive against the G1202R resistant model. This data is consistent tumors in vivo, we examined the efficacy of ceritinib against xenografts derived from MGH045 cells that harbor the L1196M resistance mutation. As shown in Figure 2E, treatment of MGH045 tumor bearing mice with low-dose ceritinib (25 mg/kg) was more effective than high-dose crizotinib in controlling tumor growth. These data demonstrate that ceritinib is active against cancers derived from patients with acquired resistance to crizotinib and is more potent than crizotinib against ALK-rearranged cancers harboring the L1196M and G1269A resistance resistance in androgen-independent DU145 cells. These results further support the notion that Uc.63+ is surely involved in modulation of the docetaxel sensitivity of PC cells through regulation of AR signaling. Docetaxel is the only well-established chemotherapeutic drug that provides a significant benefit to clinical outcome in CRPC patients [4]. To fully determine the machinery that controls docetaxel resistance in PC cells, further in-depth studies on which molecule in AR signaling is actually regulated by UC.63+ need to be elucidated; this were characterized by upregulation of Bcl-2, we also determined the impact of ABT-737, a small molecule inhibitor of Bcl-2/Bcl-XL, on the sensitivity of the resistant cells to carfilzomib. Cells were incubated with carfilzomib in the absence or presence of a nontoxic concentration of ABT-737 (2.5 μM). As shown in Figure 10, ABT-737 caused an approximately 50% reduction in the IC50 of R-UMSCC-1 cells for carfilzomib, but did not affect the sensitivity of R-Cal33 cells. This indicates that Bcl-2 upregulation can also play a role in acquired models, ceritinib demonstrated impressive anti-tumor activity, while it was less active in the C1156Y resistant model and was inactive against the G1202R resistant model. This data is consistent with the Ba/F3 models in which ceritinib was more potent against I1171T than the C1156Y and G1202R mutants (Fig. 4A). The studies shown herein provide evidence that ceritinib can overcome resistance in vivo, especially in tumors harboring wild-type, L1196M or I1171T ALK fusion genes at a dose that is predicted to be achievable in humans. Of note, it is Ceritinib has demonstrated impressive activity in the clinic in crizotinib-resistance patients (13). However, similar to other targeted therapy successes, despite initial and durable responses, tumors do develop resistance. We have now biopsied 11 cancers with acquired resistance to ceritinib (2 of which were from different sites from the same patient). As shown in Figure 6A, 5 of these biopsies revealed the development of mutations at either G1202 or F1174 in the ceritinib resistant cancers. In the patient, JFCR021, who had 2 sites of disease\n",
            "[0.6089477]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the genomic structure of the FAA (FANCA) gene?\n",
            "Refined Query: Describe the genomic organization of the FANCA gene, including its location on chromosome 16, the number and size of its exons and introns, and any known polymorphisms or variations affecting its structure.\n",
            "\n",
            "Combined Answer: UTR, and intronic regions, (2) are within 25 kb up- or down-stream of a gene, or (3) within predicted regulatory features from FANTOM546 or the Ensembl regulatory build.57 Candidate variants are assigned to the most phenotypically similar gene within the chromosomal topological domain,31 rather than simply taking the closest gene. We have previously shown that an assessment of regulatory boundaries formed by topological domains can improve the identification of candidate pathogenic copy-number variants.65 After this, any common variants (>1% BL and AA designed the study. AA, DF and JCB performed the analyses. HS, COD and YH designed and coordinated the FANTOM4 project and provided the CAGE and acetylation data. EA and XD provided data sets critical for the analysis. AA produced all the figures. AA, DF and BL wrote the manuscript with input from other coauthors. (>20 kb from a gene) variants that reside in predicted enhancers from the FANTOM5 consortium46 (downloaded on 8/7/15) or Ensembl regulatory feature build57 (downloaded Ensembl regulatory features dataset from Ensembl Biomart on 8/7/2015) are associated with the most phenotypically similar gene in the topologically associated domain (TAD)58 containing the enhancer. TADs are defined using Hi-C to identify higher-order chromatin interactions in the three-dimension organization of the genomes and they organize the genome into chromosome FANTOM4 consortium. When multiple detected probes mapped to one gene, we only considered the representative probe among them (as supplied by the microarray manufacturer), if any. We calculated the correlation of expression for each target gene and its bystander genes; we tested the significance of correlation using the alternative hypothesis that the association was positive. We also calculated the correlations of bystanders with each other for each GRB. For comparison of bystander pairs, we excluded the pairs potentially sharing a We thank Thomas S Becker and Christopher Previti for valuable discussion and feedback. AA, DF, and BL were supported by grants from Bergen Research Foundation (BFS) and the Young Future Research Leaders (YFF) program of the Norwegian Research Council (NFR) awarded to BL. JCB is supported by the EuTRACC, a EU Framework 6 program. The FANTOM4 project was supported by grants for the Genome Network Project from the Ministry of Education, Culture, Sports, Science and Technology, Japan (YH), Research Grant for the RIKEN Genome Exploration Research where there is little similarity between observed phenotypes and direct or inferred knowledge from disease and model organism databases. Note in this step, distal (>20 kb from a gene) variants that reside in predicted enhancers from FANTOM5 and Ensembl are associated with the most phenotypically similar gene in the topological domain containing the enhancer rather than simply taking the closest gene. Distal variants that do not reside in a predicted enhancer are removed, followed by the exclusion of any that are common (>1% minor allele enhancers were taken from the FANTOM5 project.46 Population-based features were computed by counting the number of rare (≤0.5% AF) and common (>0.5% AF) 1000 Genomes14 (release 5a of 05/02/2013) variants in a window of ±500 and using the ratio of rare variants (≤0.5%) and common variants (>0.5%) (zero if common variants are zero). Finally, overlapping Database of Genomic Variants47 (DGV), dbVar,48 and ISCA49 (study IDs nstd37, nstd45, nstd75) CNVs for every position in the human genome were counted for each position. All attributes are listed their activities, their genome-wide targets, and so on. That the computational model at the core of ISMARA, i.e., motif activity response analysis, is a powerful method for reconstructing regulatory interactions from high-throughput data has already been demonstrated, not only in its original application (The FANTOM Consortium et al. 2009), but in a substantial number of recent studies across a wide range of mammalian systems (Summers et al. 2010; Aceto et al. 2012; Arner et al. 2012; Arnold et al. 2012b; The FANTOM Consortium et al. 2012; used a p-value cutoff of 0.05 for detection, and kept only the probes detected at nine or more time-points in each replicate. Using a less stringent threshold may result in genes that are detected in few time-points, which could compromise the correlation analysis. We assigned one probe for each gene using the probe annotation provided by the FANTOM4 consortium. When multiple detected probes mapped to one gene, we only considered the representative probe among them (as supplied by the microarray manufacturer), if any. We calculated the called alternate alleles and the assigned genotypes. Finally, the ratios of the detected bases, deletions and insertions (additionally) are determined. Based on the ratios, up to six different calls are reported. A threshold may be set to ignore variants with a minor ratio. In the case of an available VCF file containing the called variants for every sample, the call – taking into account the reference allele, the alternate alleles and the genotype – is determined.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 304.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.92ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 956.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.05ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?\n",
            "Refined Query: Investigating vertebrate gene splicing, this query seeks to identify the most common non-canonical DNA sequences flanking introns.  Specifically, it asks which alternative splice site motifs, deviating from the consensus sequences at both the 5' (donor) and 3' (acceptor) splice junctions, appear most frequently across vertebrate genomes.\n",
            "\n",
            "Combined Answer: et al. 2009). In addition, >25% of lncRNA genes show evidence of alternative splicing with at least two different transcript isoforms per gene locus (Fig. 3D). The most highly spliced lncRNA gene is PCBP1-AS1 with 40 annotated isoforms. This human lncRNA gene is situated at a complex locus with major gene structure differences between human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with “splicing by overlap extension” approach [57]. For the deletion constructs, in all reporter gene constructs the sequence corresponding to the human exon (the putative RR) was spliced and the flanking genomic sequences were fused. Coordinates of the fused fragments are given in Table S3. The enhancer assay was performed as described in detail in [21]. In short, genomic sequences were cloned into a transgenesis-vector upstream of a zebrafish hsp70 minimal promoter and GFP reporter gene flanked by I-SceI Meganuclease sites using standard cloning in genes involved in RNA processing or in introns or nearby genes involved in the regulation of transcription and development. These elements are frequently found in genes post-transcriptionally regulated by alternative splicing events of exons with premature stop codons. Accordingly, the extreme genomic conservation has been associated to regulatory splicing events maintaining tightly regulated levels of RNA-binding proteins [4]. On the other hand, intergenic elements are frequently flanked by developmental genes, in particular for genes Several studies have reported distinct nucleosome positioning at exon–intron junctions (44–47). However, exon–intron junctions contain specific splice donor or acceptor DNA sequences that could affect the efficiency of DNA cleavage by MNase (Fig. 6A for 3′ splice sites and Fig. S6A for 5′ splice sites). Indeed, we observed sharp peaks of cutting by MNase at exon–intron junctions (Fig. 6B for 3′ splice sites and Fig. S6B for 5′ splice sites). This effect is also observed when naked genomic DNA was digested with MNase (Fig. 6C for 3′ splice sites of the different constructs were generated by digesting the vector with BglII and HindIII. All plasmids constructs were sequence verified. The mouse U7 snRNA gene and smOPT sequence were designed, modified and cloned following the protocol described in2. Exonic splicing enhancer (ESE) and exonic splicing silencer (ESS) sequences were identified by Human Splicing Finder. Multiple U7snRNA constructs were cloned in tandem in a self-complementary AAV vector using a XbaI restriction site. All plasmids constructs were sequence verified. Both ITR and human and mouse orthologs (Supplemental Fig. S3). The vast majority of lncRNA introns are flanked by canonical splices sites (GT/AG), and we find no differences in splicing signal usage compared with protein-coding genes (Supplemental Table S4; Supplemental Fig. S4). Finally, we have also identified 11 lncRNAs U12 introns (Alioto 2007) within the lncRNA catalog, of which eight belong to intergenic lncRNAs (lincRNAs) and three are in antisense of protein-coding introns. and elephant shark (Callorhinchus milii, kind gift from B. Venkatesh) using standard PCR methods. For the dock9 mouse and shark exon constructs, only the exon and 200 bp downstream sequence could be cloned. The 200 bp upstream sequence corresponds to a repeat and could not be amplified. The deletion-constructs were generated by applying a PCR-driven “splicing by overlap extension” approach [57]. For the deletion constructs, in all reporter gene constructs the sequence corresponding to the human exon (the putative RR) was spliced and the in individual 3, who was compound heterozygote for a splice site mutation and a frameshift mutation in trans. This frameshift mutation, because it is not in the last exon, is predicted to lead to nonsense-mediated decay (NMD) of the mRNA.28 The splice donor mutation after exon five, because it is located five nucleotides away from a splice site (1206+5G→A), might or might not affect splicing efficiency. If it affects splicing efficiency, the mutation would lead to an aberrant protein-encoding mRNA, thus engaging NMD. To test for NMD, we did in teleosts. We recovered two insertions on chromosome 7 in intron 3 of pax6.2, and one insertion ∼68 kb downstream from the transcriptional unit, in an intron of the downstream gene elp4 (Fig. 3B). These insertions show the expression pattern of pax6.2, suggesting that the cis-regulatory information driving pax6.2 is available inside elp4, while elp4 expression is much more widespread (Supplemental Fig. S1) and thus does not appear to be regulated specifically by the elements within its introns. We also mapped an insertion 116 kb downstream (data not shown) and also a missense mutation (glycine to aspartate) in the region of the exchanger domain that was predicted to be highly deleterious by Polyphen-2.27 A second likely splice mutation was found in Family 6, a G to A transition in the last base of the intronic sequence upstream of the splice acceptor for exon 3. There was one genomic deletion discovered in the proband in Family 10 spanning from ChrX:135098247-135218938 (c.1237-557). This CNV deletion is predicted to delete exons 10 through 16 and the 3′-untranslated region\n",
            "[0.56319165]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 958.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.90ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.90ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1511.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 807.17ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1738.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 805.77ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is microRNA(miRNA) 30 involved in post-ischemic cardiac remodeling?\n",
            "Refined Query: Does microRNA-30 modulate the processes of cardiac hypertrophy, fibrosis, and angiogenesis following myocardial ischemia, contributing to the overall post-ischemic remodeling of the heart?\n",
            "\n",
            "Combined Answer: To illustrate ISMARA’s ability to integrate the role of both TFs and miRNAs in the gene regulatory network, we took advantage of data from a system in which miRNAs are known to play important regulatory roles: the epithelial-to-mesenchymal transition (EMT). We applied ISMARA to expression measurements from epithelial and mesenchymal subpopulations (Scheel et al. 2011) (for results, see http://ismara.unibas.ch/supp/dataset5/ismara_report/) and used replicate averaging to identify regulators that explain the differences between epithelial and shown that miRNAs are dysregulated in obese adipose tissue [15]. Furthermore, during adipogenesis, miRNAs regulate fat cell development by accelerating or inhibiting adipocyte differentiation. In addition, miRNAs may regulate the commitment to the adipogenic lineage in multipotent stem cells and therefore govern the numbers of fat cells [16]. Ninety-two percent of the cases carrying 1p21.3 deletion present with ASD. miR-137 is a brain expressed miRNA [17, 18] that regulates several protein coding genes that are important for brain function, that the miRNA miR137 is the mediator of the obesity, ASD and ID phenotype. Further studies are warranted to elucidate the molecular mechanisms by which miR-137 mediates the phenotype, both in the CNS and the adipose tissue. genes. Both PLPPR4 and PLPPR5 encode for a lipid phosphate phosphatase enzyme specifically expressed in neurons and located in the membranes of outgrowing axons, important for axonal outgrowth during development and regenerative sprouting [30, 31]. In summary, with this study, we present a case carrying a novel 1p31.3 microdeletion, and we propose that the miRNA miR137 is the mediator of the obesity, ASD and ID phenotype. Further studies are warranted to elucidate the molecular mechanisms by which miR-137 mediates the phenotype, both in the lncRNAs). Because of the narrower dynamic range of lncRNAs, transcripts were considered dynamic if their fold change was > 1.5 (lncRNAs) or 2 (mRNAs) in at least one time point relative to time zero. Accordingly, the expression of 346 lncRNAs was affected by EGF (Fig 1B, left panel). Clustering the responsive lncRNAs according to peak expression times identified waves of transcription, similar to those observed with mRNAs (Fig 1B, right panel) and with miRNAs (Avraham et al, 2010). Unlike mRNA, the majority of lncRNAs exhibited downregulation noncoding RNAs in the energy control of the body is not fully understood, recently, the hypothalamic miR-103 has been shown to protect against hyperphagic obesity in mice [14]. Therefore, the role of miR-137 in the control of food intake or energy accumulation and expenditure in the CNS can be speculated. At a peripheral level, recent studies have shown that miRNAs are dysregulated in obese adipose tissue [15]. Furthermore, during adipogenesis, miRNAs regulate fat cell development by accelerating or inhibiting adipocyte differentiation. In Breast cancer is a heterogeneous disease; hence, many efforts are being made to identify new drivers and classify tumors into increasing numbers of subtypes (Perou et al, 2000; Dawson et al, 2013). Thus, whereas initial profiling focused on finding histological characteristics and signatures of protein‐coding genes, more recent studies have found that the expression of microRNAs may also assist prognosis and classification (Dvinge et al, 2013). Importantly, the relatively high tissue specificity of lncRNAs promises a role for these noncoding miR-130b mimics than that in LNCaP Uc.63+#1 cells transfected with negative control (Figure 5G). Overexpression of miR-130b in LNCaP Uc.63+#1 cells downregulated the expression of MMP2 and migratory ability (Figure 5H, 5I). These results suggest that Uc.63+ may upregulate the expression of MMP2 through miR-130b interaction, which is most likely to contribute to the oncogenic role of Uc.63+. that the expression of microRNAs may also assist prognosis and classification (Dvinge et al, 2013). Importantly, the relatively high tissue specificity of lncRNAs promises a role for these noncoding RNAs as drivers and biomarkers of breast cancer (Wang et al, 2011a). For example, a recent survey of 658 infiltrating ductal tumors reported that the lncRNA HOTAIR was significantly overexpressed in the HER2‐positive subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal‐like subgroup (Su et al, 2014). Herein, we introduce the different Apc-mutant ESCs for microRNA expression by using a miRNA array encompassing specific probes for all known mouse miRNAs [38] (data not shown). Of the different candidate miRNAs induced upon Wnt activation, mmu-miR-211 showed a Wnt dosage-dependent up-regulation among the different Apc-mutant ESCs (Figure 7A). Accordingly, activation of Wnt signaling in wild type ESCs either by Wnt3a conditioned medium (CM) or by GSK3 inhibition, confirmed that miR-211 is a novel Wnt-regulated microRNA in mouse embryonic stem cells (Figure 7B and\n",
            "[0.75178134]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List all clinical trials of the polypill.\n",
            "Refined Query: I need a comprehensive list of all registered clinical trials investigating the efficacy and safety of polypill regimens in preventing cardiovascular disease, specifying trial design,  outcomes measured, and current status (e.g., recruiting, completed).\n",
            "\n",
            "Combined Answer: We also searched Chinese Clinical Trial Register, reference lists of included studies and review articles, and relevant journals from recent years. We contacted the pharmaceutical company that produced losigamone (Dr. Willmar Schwabe GmbH & Co.) to obtain relevant data. An independent data and safety monitoring committee reviewed safety and efficacy during the trial. The trial was designed by the first and last authors in collaboration with the sponsor, and the authors and the sponsor were responsible for data collection and analysis. The authors vouch for the fidelity of the trial to the protocol and for the accuracy and completeness of the data. The first and last authors wrote the first draft of the manuscript in collaboration with the sponsor. Medical writing support was provided by the sponsor. The protocol for this clinical trial was approved by Western Institutional Review Board (Puyallup, WA) and all enrolled subjects will provide informed consent before study participation. The study results will be widely disseminated at conference presentations and published in peer-reviewed journals. (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the originally planned 40 patient accrual was reached. Two factors led to this decision. The first was that accrual was slowing considerably, and the trial had been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule The protocol for this study was developed in accordance with the SPIRIT 2013 guidance for protocols of clinical trials.[15] Published or unpublished randomized controlled trials (RCTs), with no language restrictions. of genes and biological functions that are connected to the disease. In parallel, the study of related drugs is crucial, because it can provide information on the pathways, mechanisms of action, efficacy and dosing, as well as for the design of clinical guidelines and clinical trials that aim at providing therapies to the disease. Hence, these three entities are tightly connected, and their relation has also constituted the basis for research on how automated systems may support the design of clinical trial protocols and the validation of three entities are tightly connected, and their relation has also constituted the basis for research on how automated systems may support the design of clinical trial protocols and the validation of hypotheses, e.g., as was the case of the PONTE European project [40]. From this perspective, the selected resources were the following: Jochem for drugs, GENE ONTOLOGY and UNIPROT for targets, DISEASE ONTOLOGY for diseases, MESH as a general purpose domain dictionary, PUBMED and PUBMED CENTRAL for documents, and LINKED LIFE DATA for triples the current standard of care were selected as trial sites by regional partners. Minimum requirements for the current standard of care included hemodynamic monitoring, the provision of intravenous fluids, laboratory testing, and the ability to deliver concomitant medications. The trial was approved by the NIAID institutional review board and applicable ethics boards in each site or country. Full details of trial design, conduct, and analyses can be found in the protocol and statistical analysis plan, available with the full text of this article to treatment arms. The Novartis Biostatistics Quality Assurance Group approved the randomization scheme. All participants, investigators, and sponsor representatives associated with the study were masked to treatment allocation. The study was conducted in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines for Good Clinical Practice, with applicable local regulations, and with the ethical principles as laid down in the Declaration of Helsinki. All participants\n",
            "[0.6741231]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is transvection?\n",
            "Refined Query: What exactly is meant by the term \"transvection\" and in what contexts, scientific fields, or disciplines is this term used?  Is there more than one meaning?  Provide a concise definition.\n",
            "\n",
            "Combined Answer: Movement of antibodies from the blood into the interstitial fluid of tissues is dependent on their limited ability to cross cell membranes. Extravasation of antibodies may occur by paracellular or transcellular movement by means of convective processes, diffusion, or endocytosis (33). Due to their large molecular weight and polarity, it is unlikely that significant extravasation occurs with antibodies by transcellular diffusion (33). The main processes in which endocytosis of antibodies can occur are phagocytosis, fluid-phase pinocytosis, and suture as close to the muscle as possible and the tendon is cut. The exposed muscle is constantly dampened with saline. Mice are then transferred to a thermal controlled platform and maintained at 37 degrees. The knee is secured to the platform with a needle through the patella tendon, the distal TA tendon suture to the level arm of the force transducer (Aurora Scientific, Aurora, ON, Canada), and the foot is secured with tape. The TA muscle contractions were elicited by stimulating the sciatic nerve via bipolar platinum electrodes. Once the (33). Convective transport through paracellular pores is considered to be the primary mechanism of antibody extravasation in tissues (35). Convective transport is driven by the hydrostatic pressure gradient between blood and tissues and is dependent on the gradient of osmotic pressure and the diameter and tortuosity of paracellular pores. Convection also plays a role in the distribution of antibodies within the interstitial fluid and facilitates the transport of antibodies out of the tissue as the interstitial fluid enters the lymphatic us with data to explore full text. MTI is also being considered to possibly expand its role by assisting with mapping OLDMEDLINE [36] terms to the latest version of the MeSH Vocabulary for citations originally printed in hardcopy indexes published prior to 1966, and the possibility of providing keywords for citations that normally would not be humanly indexed to provide additional access points that would assist in retrieval. diffusion or convection through the epithelium. Most antibodies are administered by the IV route because it allows for the antibody to be delivered rapidly with complete availability to the systemic circulation and can be given in larger volumes and doses compared to the IM or SC route. However, the IV route may not be as convenient as IM or SC administration, as it requires patient visits to hospitals or clinics to receive the medication. As IM and SC dosing allows for self-administration, these routes are useful when effective treatment 350 were mapped. For the insertions in this study, all transgenic lines with similar expression patterns were selected and the insertion sites identified. The flanking sequences of all insertions are listed in Supplemental Table S3. All experiments were in accordance with regulations for animal experimentation in Norway. years. MEDLINE Indexing has been used by librarians and researchers from its inception in 1879 by John Shaw Billings [3] and is currently used by an even larger community through PubMed [4]. PubMed uses the MEDLINE Indexing as part of their Automatic Term Mapping query expansion [5] and through their result filtering which depends on MEDLINE Indexing for determining species, sex, and ages [6]. Other recent examples of specific uses of MEDLINE Indexing include the results of TREC Genomics track (2003 – 2007) [7] and TREC Clinical Decision is converted by extracting the noun phrases and referencing them using a thesaurus of biomedical entities. Then the question is expanded by adding synonyms and relevant biomedical entities using the PolySearch tool [50]. The entities found by PolySearch are used to rank the retrieved set of concepts, articles, triples and snippets. In phase B of the task a similar approach to phase A is used in order to augment the set of given concepts. Extracted sentences from the retrieved documents are ranked according to the cosine similarity with respect either MTI or MTIFL. We used the descriptions for the various study categories found in the Funk and Reid [28] paper to correlate the appropriate MTI and MTIFL results to the proper historical study categories. We have also used these descriptions to identify equivalent categories from some of the other historical studies to fill in the results. For example: The definition of the “Descriptors (DESC)” category from Funk and Reid is equivalent to the “Checktags and Main Headings Only” category used in the Lancaster and Leonard studies. We do not (Fig. 2). Index-level reoperations will be defined as any surgical procedure performed at the level of the original herniation, regardless of side or reason, during follow-up. An independent imaging core laboratory will read imaging to assess device status and anatomical characteristics following the procedure. Key imaging variables will include Modic changes, Pfirrman grade, anterior and posterior ossification, spontaneous fusion, disc degeneration, herniation recurrence, annular tears/fissures, and device events such as device integrity,\n",
            "[0.3589167]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of probiotics in gastrointestinal disease?\n",
            "Refined Query: How do probiotics, live microorganisms, influence the prevention and treatment of gastrointestinal diseases like inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and infectious diarrhea?  What are the mechanisms by which they exert their effects, and what is the current evidence supporting their efficacy?\n",
            "\n",
            "Combined Answer: and the on the amount of RUTF needed to achieve recovery. Additionally, antibiotic resistance is increasing worldwide, and can be particularly problematic in developing countries where treatment options against resistant organisms are more limited (Nys et al. 2004; Okeke et al. 2005; Okeke et al. 2007). In the gut, resistant organisms rapidly develop when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be translocation of enteric flora across the compromised intestinal mucosa. Moreover, resistant bacteria may exhibit enhanced virulence (Dancer 2004), further complicating a malnourished child’s chances for recovery. Amoxicillin was used in the standard protocol group because of its relatively broad-spectrum of activity, low cost, and current usage by including in the spleen and intestine that results in the development of intestinal prolapses in approximately 30% of ATMINΔLNBS1ΔL mice. Moreover, in an in vivo experimental system for intestinal colitis, using DSS to mimic IBD, we report enhanced colitis, significantly and specifically, in ATMINΔLNBS1ΔL mice. Although we observe a tendency towards spontaneous T cell activation in mice lacking only NBS1, as indicated by increased antigen experienced cells in the spleen and increased proliferation of splenic T cells, this phenotype is not colitis has similarities to human IBD hence is an ideal model to mimic this disease [48]. We treated control, ATMINΔL, NBS1ΔL, ATMINΔLNBS1ΔL and ATM-/- mice for 8 days with 2% DSS, at which point the control mice did not show any signs of weight loss. In striking contrast to ATMINΔL and NBS1ΔL, only the ATMINΔLNBS1ΔL mice were sensitive to DSS-induced colitis as apparent by the weight loss of approximately 20% in these mice over an 8-day period (Fig 7D). Our data also confirmed the reported mild sensitivity of ATM-/- to DSS induced colitis Clostridium difficile is an anaerobic Gram-positive bacillus that infects the colon of susceptible patients, mainly in hospital settings but also increasingly in the community. C. difficile infections (CDI)4 are typified by severe diarrhea, pseudomembranous colitis, and in extreme cases colonic rupture, sepsis, and death (1). Current treatments for CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one antibiotic for this purpose, are becoming ineffective against the strains of bacteria that are found to be causing severe infections in this population of malnourished children (Manary et al. 2000; Madanitsa et al. 2009). Thus, while the constraints on the choice of antibiotics in resource-limited settings should not be underestimated, it is possible that a different routine antibiotic may have been of more benefit to these malnourished children. Home-based therapy for acute malnutrition is robust partly because children who live far from compared to the group of children who all received amoxicillin for 1 week. This finding that the recovery rate with amoxicillin therapy is delayed has biological plausibility when considering the clinical problem of antibiotic-associated diarrhea and the emerging knowledge of the way antibiotics disrupt the intestinal microbiome (Dethlefsen et al. 2008; Preidis et al. 2009). The marked difference in WHZ seen in the 4-week graduates also suggests that amoxicillin usage may be associated with delayed recovery. By 12 weeks, it is more likely that analysis (Fig 7H). Assessment of the colitis score showed a severe inflammation of the intestine of ATMINΔLNBS1ΔL mice treated with DSS (Fig 7I). These data indicate that although a proportion of ATMINΔLNBS1ΔL mice develop spontaneous inflammation and colitis, these mice are prone to chemically induced colitis. (WHO 1999) In fact, numerous recent studies have indeed confirmed this concern of severe bacterial infections in malnourished children who are hospitalized (Berkley et al. 2005; Noorani et al. 2005; Babirekere-Iriso et al. 2006; Bachou et al. 2006; Brent et al. 2006; Maitland et al. 2006; Hill et al. 2007; Hossain et al. 2009). Over the last several years, a revolution in the case management of SAM has occurred with the introduction and widespread acceptance of ready-to-use therapeutic foods (RUTF) that allow for the management of levels of the inflammatory cytokines Il-1β, Tnfα and Il17a in both unstimulated and stimulated IEL from ATMINΔLNBS1ΔL mice (Fig 7A–7C). Since only a proportion of ATMINΔLNBS1ΔL mice develop spontaneous colitis we assessed whether these mice would be more susceptible to chemically induced colitis with dextran sodium sulphate (DSS). The DSS model of colitis has similarities to human IBD hence is an ideal model to mimic this disease [48]. We treated control, ATMINΔL, NBS1ΔL, ATMINΔLNBS1ΔL and ATM-/- mice for 8 days with 2% DSS, at which point the\n",
            "[0.71183646]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the main symptom of Marfan syndrome patients?\n",
            "Refined Query: Marfan syndrome's most prominent symptom is typically skeletal abnormalities, manifesting as unusually long limbs, fingers, and toes, along with a tall and slender build.  However,  it's crucial to remember that the syndrome affects multiple systems.\n",
            "\n",
            "Combined Answer: males and females are equally affected and the long segment form of the disease is the most common.1,17 This is the case in the series we report, where there are 24 males and 20 females and where long segment HSCR occurred in the majority of cases for which the length of the aganglionic tract was known. However, it is worth mentioning that among patients presenting with an isolated, long segment form of HSCR, skewing of the sex ratio decreases when compared with the short segment form of HSCR. In relation to MWS, we observed a skewed male to previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. times as the replication machinery loses its place on the template; an insertion in one sequence paired with a reciprocal deletion in one other may be caused by unequal cross-over in meiosis; insertion of transposable elements--jumping genes--into a DNA sequence; insertion of DNA by retroviruses; and translocations of DNA between chromosomes [8]. The accurate identification of gaps is shown to be fundamental in various studies on disorders; for example, on Hajdu-Cheney syndrome [9], a disorder of severe and progressive bone loss. The focus of and that the defect underlying these mutations is misregulation of fgf8. It is therefore reasonable to speculate that FBXW4 has been incorrectly assigned as the disease gene in human split hand/foot malformation 3. The search for putative regulatory elements or previously unknown exons can generate target sequences to be re-sequenced in patient DNA. In one of the two cases that were characterized bioinformatically, otp, we searched for mapped human diseases at the edge of the otp GRB and found Hermansky-Pudlak Syndrome, type 2, a cell We contacted previous collaborators and physicians who had published case reports of individuals with DOORS syndrome. Patients were from 26 centres in 17 countries. Between Dec 1, 2010, and March 1, 2013, we enrolled identified individuals with DOORS syndrome who were assessed by clinical geneticists and had at least three of the five following features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures. Families were excluded if the and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14\n",
            "[0.55750406]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What species is associated with Tetrodotoxin?\n",
            "Refined Query: Tetrodotoxin, a potent neurotoxin, is famously associated with which species?  Are there multiple species known to harbor or produce this toxin, and if so, what are the key biological relationships between the toxin and these organisms?\n",
            "\n",
            "Combined Answer: surface of toxin-sensitive mammalian cells (10–16), and (ii) treatment with galactosidase abolishes TcdA binding (13–15). Evidence that the receptor for TcdB is also a carbohydrate is currently limited to the observation that this toxin is structurally highly homologous to TcdA (7, 17) and that it binds to carbohydrates that are structurally related to the TcdA ligands (10, 11). It is thought that toxin binding to receptor(s) on the cell surface occurs via the C-terminal domain of the toxins (known as the combined repetitive oligopeptide related to the TcdA ligands (10, 11). It is thought that toxin binding to receptor(s) on the cell surface occurs via the C-terminal domain of the toxins (known as the combined repetitive oligopeptide (CROP) domain) (12, 17–19), although recent data suggest that other domains within the toxins may also be involved in binding (20, 21). Analysis of the sequences of the TcdA and TcdB CROP domains shows that they consist of ∼20–30 short repeats (SRs) interspersed with a smaller number (seven in TcdA and four in TcdB) of homologous long repeats is the nature of the receptors to which the toxins bind. For TcdA, the receptor has been proposed to consist of a membrane-associated carbohydrate based on the following lines of evidence: (i) TcdA binds specifically to various galactose- and N-acetyl-glucose-containing carbohydrate molecules, including sugars known to be expressed on the extracellular surface of toxin-sensitive mammalian cells (10–16), and (ii) treatment with galactosidase abolishes TcdA binding (13–15). Evidence that the receptor for TcdB is also a carbohydrate is currently (1). CGRP is a 37-amino acid neuropeptide and a member of the calcitonin family, which includes calcitonin, adrenomedullin, amylin, and intermedin (2). It is expressed in both central and peripheral nervous systems, especially in dorsal root and trigeminal ganglions and their projections (3). Mammals express two isoforms, α-CGRP and β-CGRP, encoded by two distinct genes (4). The α-CGRP and β-CGRP are differentially regulated, differ in pharmacological profile, and have distinct physiological functions (5). During a migraine attack, CGRP domain into the cytosol (9), where it glucosylates and inactivates small GTPases, such as Rac and Rho, which play a critical role in maintaining cellular morphology and in multiple other aspects of cellular homeostasis. One aspect of toxin function that is still poorly understood is how TcdA and TcdB bind to host cells or, more specifically, what is the nature of the receptors to which the toxins bind. For TcdA, the receptor has been proposed to consist of a membrane-associated carbohydrate based on the following lines of evidence: (i) TcdA was completed by binary toxicophore features based on a set of toxicophores collected from the literature. Toxicophores are substructures which are known to be toxic (Singh et al., 2016). The chemical feature space was reduced by filtering out zero variance features. The final set of chemical features consists of 1309 ECFP_6, 802 physico-chemical and 2276 toxicophore features. The cell lines were described by their gene expression profile. The profiles of the untreated cells were downloaded from the ArrayExpress database (accession number: care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms that are “an immediate public health threat and that require urgent and aggressive action” (44). There is therefore a pressing need for new treatments against C. difficile, in particular ones that address the high rates of recurrence. The pathogenic nature of C. difficile results from production of two exotoxins, toxin A (TcdA) and toxin B (TcdB), supports the notion that multiple interactions with the cell surface are necessary for full binding/biological activity of the toxins (10). In further support of this, Just and co-workers (18) have previously shown that a peptide spanning the entire TcdA CROP domain efficiently competes with intact TcdA in a cell cytotoxicity assay, whereas a peptide spanning only the N-terminal half (three putative carbohydrate binding pockets) is unable to compete even at a high molar ratio. The binding motif of bezlotoxumab described here is distinct from local DNA topology of certain genomic regions [59]. Previous studies have found that the three AtxA-regulated toxin-encoding genes have distinct DNA curvature patterns, which is consistent with this hypothesis [48]. toxin gene transcription is not observed in atx4-null mutants. Here, we used two independent techniques to obtain evidence for additional CO2-induced atxA-regulated genes. First, total protein preparations from atxA4+ and atxA isolates grown in 5% CO2 and in air were examined by two-dimensional electrophoresis. Comparison of the resulting protein patterns indicated that synthesis of non-toxin proteins is influenced by growth in elevated CO2 and the toxin gene regulator, atxA. Second, we generated random transcriptional lacZ fusions in B.\n",
            "[0.54947007]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How is myotonic dystrophy inherited?\n",
            "Refined Query: Myotonic dystrophy, a progressive muscle disorder, has a unique inheritance pattern.  I'd like to know specifically if it's autosomal dominant or recessive, the likelihood of passing it on to children, and whether the severity varies depending on the parent's affected status.\n",
            "\n",
            "Combined Answer: (550 iu/l; normal value < 200 iu/l). Normal early motor milestones were reported and no muscular dystrophy was ever reported in the family. His neurological examination was entirely normal at 15 years of age. Muscle biopsy showed slight fiber size variability (Supplementary Fig. 1a), and in some sections an increased number of central nuclei along with some densely stained hypercontracted fibers. Immunofluorescent analysis using a C-terminal antibody showed the presence of dystrophin at the membrane (Supplementary Fig. 1b) that western blot Duchenne muscular dystrophy (DMD), an X-linked recessive condition, is a rare genetic disorder caused by the absence of functional dystrophin proteins due to gene mutations [1]. The incidence of DMD is approximately 1 in 5000 male newborns [2]. Affected boys initially exhibit progressive muscle weakness of the lower proximal extremities [3]. The gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and Duchenne muscular dystrophy (DMD) is a progressive, severely disabling, and incurable X-linked recessive inherited disorder that affects 1 in 3,500 newborn boys and leads to death in the second or third decade of life.1 In patients with DMD, the open reading frame of the X-linked dystrophin gene, encoding dystrophin, is disrupted by deletions (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive consent forms, and experiments were conducted according to the approved guidelines. A total of 85 participants aged between 2 and 24 years were recruited. The DMD diagnostics of each patient was confirmed through muscle biopsy or genetic testing. DMD was classified into four stages based on severity: normal control (n = 12; no history of weakness or neuromuscular disorders), stage 1 (n = 41; ambulatory), stage 2 (n = 20; early nonambulatory), and stage 3 (n = 12; late nonambulatory). The demographic data of participants and stage definitions Causative mutations in neurodevelopmental disorders are frequently de novo, X-linked recessive or autosomal recessive. In contrast to prior literature reporting largely inherited mutations in NHE6, through prospective recruitment, here we discover seven highly deleterious de novo mutations in NHE6. An eighth mutation was found, in a three-generation pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a Inherited neuropathies are the most common genetic neurological disorders and affect ∼1 in 2500 individuals.1 Charcot–Marie Tooth (CMT) includes a group of hereditary disorders in which motor and sensory neuropathy is the sole or primary part of the disease. CMT is traditionally classified into two types based on electrophysiological and neuropathological criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures. Families were excluded if the parents could not be contacted for consent or if DNA could not be obtained from the affected individual. Further exclusion criteria were autosomal dominant inheritance and the absence of both intellectual disability and seizures, criteria that have been used elsewhere.3 A clinical questionnaire was completed by the collaborating physician. DNA was or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a spectrum of deleterious mutations and that female carriers may exhibit intermediate neurocognitive symptoms, one might hypothesize that de novo mutations may be more highly deleterious and that inherited mutations may appear milder. However, from our data and the other mutations in the literature (Supplementary Table 2), this hypothesis does not\n",
            "[0.725343]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How do HBS1L-MYB intergenic variants regulate fetal hemoglobin?\n",
            "Refined Query: Investigating the precise mechanisms by which intergenic variants within the HBS1L-MYB locus influence fetal hemoglobin (HbF) expression in fetal erythropoiesis is crucial.  This requires understanding how these non-coding variants affect gene regulation, potentially through enhancer or repressor elements impacting  HBS1L and MYB transcription and subsequent HbF production.\n",
            "\n",
            "Combined Answer: a hexanucleotide sequence CANNTG termed E box to act as a regulator of transcription during hematopoiesis. TAL1 is required for specification and self-renewal of hematopoietic stem cells (HSCs), as well as for terminal differentiation of erythrocytes (6, 7). It is believed that TAL1 contributes mainly to transcriptional repression in early developmental stages and is then converted to an activator in complex with other erythroid specific transcription factors, such as GATA-1, LMO2, and LDB1, to activate erythroid specific transcription In support of this, genes that are associated with distal H3K27ac-enriched regions that are negative for H3K4me1 showed overall similar expression levels as proximal genes of enhancers enriched for both H3K27ac and H3K4me1 (P = 0.94). Furthermore, these data suggest that in addition to H3K4me1, distal H3K27ac sites that do not show significant H3K4me1 enrichment should also be considered as potential enhancer elements. It has previously been shown that enhancers that associate with promoters and support transcription of neighboring genes precursors but not in the P4.2 silenced CD34+ HSCs (Figure 7D) consistent with the ChIP data (Figure 7C). Thus, our data suggest that the levels of H3K4 methylations play an important role in p4.2 activation during erythroid differentiation. Together, our results reveal that the dynamic regulation of H3K4 demethylase and methyltransferase, perhaps by PKA mediated phosphorylation of TAL1, plays a critical role in controlling erythroid-specific gene transcription during hematopoiesis. for the mapping of human diseases it will be important to establish whether the implied disease gene is a GRB target gene or is, in fact, located in a GRB as a bystander with no functional relation to the regulatory inputs of the enhancers of the GRB. In such cases, it will be important to correlate GRB regulatory content with the disease phenotype and, if warranted, reassign the disease phenotype to the correct gene. Thus, important developmental genes are embedded in large GRBs, breakpoints or mutations within these GRBs may cause genetic networks in establishing cellular identity. H3K27ac is one of the modifications that were shown to be present at a subset of enhancers (16), yet its relevance was unclear. We establish the H3K27ac modification as an important mark for enhancer identification that can distinguish between active and inactive enhancer regions according to the expression of proximal genes and preferential eRNA production. Because distal H3K27ac-enriched regions are less abundant than distal H3K4me1-enriched regions, these data suggest that the amount of enhancers copies are used as starting material for variation in the binding site composition, which modifies the respective enhancer's activity [5]–[10]. Mobile genetic elements have also been shown to have regulatory activity [11],[12] or bear transcription factor binding sites (TFBSs) [13], and thus, their translocation can be associated with changes in gene expression. While the modification/translocation of those pre-existing elements has been shown to play an important functional role, they may only contribute to a fraction of the regulatory Guenther et al. 2007). We therefore expected H3K36me3 to be specifically enriched at the level of actively transcribed genes, which are only found on the paternally contributed chromosome within the Snurf–Snrpn interval. Strikingly, our ChIP analysis revealed a widespread H3K36me3 enrichment on the maternally inherited Snurf–Snrpn 3-Mb region (Fig. 2B). As for H4K20me3, H3K9me3, and H3K79me3 modifications, this maternal-specific enrichment for H3K36me3 was observed at all positions, including non-coding areas, known transcription units, as the potent regulatory roles of LSD1 on early hematopoiesis, detailed characterization of the gene expression profiles regulated specifically by SALL4 and LSD1 is awaited. As reported in our previous data (11), forced expression of SALL4 led to expansion of BM HSPCs, which is associated with dramatic up-regulation of HSPC-activating genes MEIS1 and HOX9A and down-regulation of apoptosis-inducing gene TNF and hematopoietic differentiation genes EBF1 and GATA1. Suppression of the latter factors was shown to be associated with an increased (13). Interestingly, TAL1 decreases its interaction with LSD1 during differentiation of erythroid cells and is switched to a transcriptional activator to activate erythroid specific p4.2 gene expression (13). Apparently, the dynamic regulation of TAL1 and its associated coregulators may determine the onset of the hematopoietic differentiation program. However, it remains unknown how TAL1/LSD1 interaction is regulated during hematopoiesis. During hematopoiesis, pluripotent HSCs are associated with both H3K4me3 and H3K27me3 to form so-called al, 2002) and of Gfi-1b overexpression inducing proliferation arrest and differentiation in erythroid progenitors (Garcon et al, 2005). Finally, we also tested the EKLF gene as an example of a gene that is activated during erythropoiesis. The EKLF enhancer sequence contains a GATA-E-box motif (Anderson et al, 1998), which is bound in vivo by GATA-1 independently of FOG-1 (Letting et al, 2004). Strong GATA-1 binding and a clear enrichment for TAL-1 binding were indeed detected at the EKLF enhancer (Figure 5F), thus providing a clear\n",
            "[0.77345216]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 353.81ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is statin use associated with improved outcomes after aneurysmal subarachnoid hemorrhage?\n",
            "Refined Query: Does the use of statins before or after aneurysmal subarachnoid hemorrhage (aSAH) correlate with improved patient outcomes, such as reduced mortality, better neurological function, or decreased vasospasm?  This explores the potential protective or therapeutic effects of statins in this critical neurological condition.\n",
            "\n",
            "Combined Answer: earlier than 2 h indicating that those patients survived the phase of active bleeding and upon arrival after 24 h their haemorrhages were often solid and clotted. Identification of patients with ongoing haemorrhage is of utmost importance in order to provide early and appropriate care and treatment. Apart from care in acute stroke unit, surgery in selected cases is so far the only recommended treatment. However, several ongoing pharmacological trials have focus on limiting hematoma growth in the acute phase [22]. Among the shortcomings of this study clearly falls within the meaningful range. Consistent with the intended biological mechanism of nusinersen, an increase in CSF SMN protein concentrations correlated well with the improvement in motor function. In addition, the study findings reaffirm the sensitivity of the HFMSE to detect change in functional motor outcome and inform the length of time that is required to observe improvement in motor function after treatment. Nusinersen dose levels for this first-in-human study were selected based on preclinical pharmacokinetic Disease and Stroke Clinical Research Consortium. The CHAMP Research Investigators: J. L. Aceves, MD, Scott and White Healthcare, Temple, TX; D. Arun, MD, Saint Louis University, St. Louis, MO; V.L. Atluru, MD, Winthrop University Hospital, Mineola, NY; S. K. Aurora, MD, Stanford Hospitals and Clinics, Palo Alto, CA; N.L. Bennett, MD, Preferred Clinical Research, Pittsburgh, PA; F.R. Berenson MD, Atlanta Headache Specialists, Atlanta, GA; J.L. Bickel, MD, Children's Mercy Hospital, Kansas City, MO; R.J. Bjork, MD, Colorado Springs Neurological One-month case fatality rate among patients with intracerebral haemorrhage (ICH) is high, 25–50% [1,2]. Haemorrhage volume is an important prognostic factor [3] and in one third of patients with ICH, there is an expansion of the hematoma volume during the first hours after ictus [4]. Identification of patients with ICH with a potential risk for hematoma expansion is crucial for planning of the treatment and prediction of the functional outcome. With the advent of computed tomography angiography (CTA) in the last decade, spot sign or contrast with Ara-C (N=14) or BH-AC (N=35) coupled with idarubicin. Four of the remaining patients were treated with Ara-C alone, and one received a regimen of Ara-C plus etoposide. After induction and subsequent consolidation chemotherapies, 33 patients (61.1%) received HSCT. Median DFS and OS periods for all populations were 521 (95% CI, 99–943) and 737 (95% CI, 222–1252) days, respectively. In a univariate analysis, we noted that HSCT resulted in prolonged patient survival (P<0.05). Patients with t(8;21) also evidenced better responses than the portion of intrathecally administered nusinersen rapidly transferred from the site of administration (CSF) into systemic circulation, with dose-dependent mean peak plasma levels observed within a few hours after dosing. After peaking, nusinersen plasma concentrations declined slowly ≤20 hours after intrathecal dosing, followed by a slower period of decline over the next 7 days. By 7 days postdose, concentrations in the 6-mg cohort had decreased to below the limit of quantification (1 ng/mL), and to <1% of the 20-hour postdose concentration in with agents that may disrupt vascular integrity was the potential for catastrophic intracranial or intraspinal hemorrhage. Two individuals with hemangioblastomas did experience hemorrhage while on or immediately after discontinuing pazopanib. The first individual had extensive, refractory hemangioblastomas, which were not deemed to be surgically resectable and experienced trauma while on treatment, leading to a bleed. Nonetheless we have to consider pazopanib as a potential contributor to the hemorrhagic event. The second individual head trauma while on treatment, with hemorrhage of a central nervous system hemangioblastoma, ultimately resulting in patient death. An additional patient who demonstrated progression in a central nervous system hemangioblastomas after two years of treatment also developed a central nervous system bleed after treatment discontinuation while awaiting surgical intervention. The patient underwent resection, followed by full recovery. No additional major toxicities were observed in this patient population. With 31 patients accrued, seven treatment as evidenced by increases in HFMSE score was observed following a single intrathecal dose of 9 mg nusinersen, with a 3.1-point mean increase from baseline at 3 months and a 5.8-point mean increase at 9–14 months. This improvement in motor function is not expected to occur as part of the disease process, as the predicted natural history trajectory of the HFMSE in type 2 and type 3 patients with SMA indicates stability over 1 year23 and a small decline over 2 years (−1 point).24 Though trials in patients with SMA evaluating other investigational dose selected for this clinical study (1 mg) was predicted to achieve the low end of this range, while the highest dose (9 mg) was predicted to achieve spinal cord tissue concentrations at the upper end of this range. However, no dose-limiting safety issues were identified in this study, suggesting that doses higher than the 9 mg tested in this study should be considered. The favorable risk-benefit profile from this first-in-human clinical study of nusinersen in children with SMA provides encouragement for further development of nusinersen for\n",
            "[0.81943136]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 479.65ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1715.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 886.93ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 907.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1083.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1637.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 932.64ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1159.32ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1335.71ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.78ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 958.06ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1012.09ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 961.16ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List angiocrine factors\n",
            "Refined Query: Provide a comprehensive list of known angiocrine factors, detailing their roles in angiogenesis and their source cells.  Specify if possible whether they are secreted proteins, lipids, or other molecules.\n",
            "\n",
            "Combined Answer: for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by stimulating the NO-cyclic guanosine monophosphate vascular relaxation pathway as well as by increasing the production of the calcium ion (Ca2+)i (53). An increase in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved in angiogenesis by regulating the expression of VEGF by means of intracellular signaling (40, 56). The inhibition of TGF-β1 signaling will lead to reduced endothelium-dependent vasodilation and increased endothelial cell apoptosis, suggesting that dysregulated TGF-β1 signaling may be involved in the pathogenesis of preeclampsia (40). A decline of VEGF are only weakly cytotoxic and are an important source of immunoregulatory cytokines, matrix metalloproteinases (MMPs), and angiogenic factors that promote key processes in placentation, such as extracellular matrix remodeling, trophoblast invasion, and angiogenesis (106–108). Decidual macrophages are present throughout pregnancy and similarly produce factors associated with tissue remodeling and angiogenesis, e.g., MMP9 and VEGF (109). These macrophages are mostly of the immunomodulatory phenotype (M2) and contribute to the creation of a various other possibilities exist (32, 39). For instance, an injured endothelium may release several factors thought to play a role in this systemic inflammatory response (40). These factors include pro-inflammatory cytokines, markers of oxidative stress, thrombomodulin, fibronectin, endothelin-1, and Von Willebrand factor (40, 41). Other placental factors, such as anti-angiogenic [soluble fms-like tyrosine kinase (sFlt-1)] factors secreted by placental cells can also be considered as possible stimuli, since these factors affect the decline in NO, PIGF, and TGF-β1 levels, in concert with an increase of anti-angiogenic factors, deprives endothelial cells of support leading to endothelial dysfunction (8, 17, 22). Thus, endothelial dysfunction is a result of an antiangiogenic state in the placenta and contributes to the pathology of preeclampsia (Figure 1) (9, 52, 57). Immunological factors also play a role in the secretion of antiangiogenic factors. For instance, complement activation has been shown to stimulate monocytes to release antiangiogenic factors (20). Studies in severity as well as the gestational age at the onset of the disorder (52). Preeclampsia is associated with decreased levels of vasodilators, such as nitric oxide (NO) and prostacyclin, as a result of the disproportionate increase in sFlt-1 and decrease in VEGF (Figure 1) and PIGF (53–55). The growth factor VEGF and its homolog, PIGF, are essential for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by The extensive angiogenesis that is characteristic of successful placentation is indirectly disrupted by placental ischemia/hypoxia in preeclampsia (1, 27, 51). Angiogenesis is critical for the improvement of placental circulation and blood flow by the formation of new vascular beds to enable vascular growth and development of the placenta (27). Placental factors, specifically pro-angiogenic [vascular endothelial growth factor (VEGF) and placental growth factor (PIGF)] and anti-angiogenic proteins, are responsible for placental growth, endothelium-dependent vasodilation and increased endothelial cell apoptosis, suggesting that dysregulated TGF-β1 signaling may be involved in the pathogenesis of preeclampsia (40). A decline of VEGF results in glomerular endotheliosis, a specific endothelial renal lesion presenting with proteinuria (21). In addition to low VEGF concentrations, a decline in NO, PIGF, and TGF-β1 levels, in concert with an increase of anti-angiogenic factors, deprives endothelial cells of support leading to endothelial dysfunction (8, 17, 22). Thus, endothelial had cerebellar hemangioblastomas, and eight had spinal hemangioblastomas. No response was seen in hemangioblastomas(18). A retrospective assessment of angiogenic receptor expression in renal cell carcinomas and hemangioblastomas was reported in the 2011 sunitinib study(17). Laser scanning cytometry was used to assess the expression levels of vascular endothelial growth factor receptor, platelet derived growth factor receptor, Tie2, fibroblast growth factor receptor 3, and phospho-fibroblast growth factor receptor substrate 2 (pFRS2). The factors also play a role in the secretion of antiangiogenic factors. For instance, complement activation has been shown to stimulate monocytes to release antiangiogenic factors (20). Studies in murine models of experimental pregnancy loss demonstrated that conditions of hypoxia and inflammation lead to the release of increased amounts of antiangiogenic factors and are therefore strong triggers of angiogenic dysregulation (20, 58). These studies and those in humans demonstrate that pregnancy complications, such as recurrent pregnancy loss\n",
            "[0.6374674]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is protein carbamylation?\n",
            "Refined Query: Protein carbamylation is a post-translational modification where a carbamoyl group (–NHCONH2) attaches to amino acid residues, particularly lysine. This process, often initiated by isocyanate, alters protein structure and function, potentially leading to cellular dysfunction and disease.  Understanding its mechanisms and consequences is crucial.\n",
            "\n",
            "Combined Answer: yet to be determined. C12orf65 is not directly participating in the translation machinery but is an auxiliary factor and was hypothesized to be involved in recycling of abortive peptidyl-tRNA in the mitoribosome.6 The entire group of the organellar release-factor family is characterized by the presence of a conserved peptidyl-hydrolase domain containing the universally conserved Gly-Gly-Gln (GGQ) motif,7 which interacts with the large ribosomal subunit to release the polypeptide chain from the P-site bound peptidyl-tRNA. This GGQ-containing proteins (de Graff et al., 2016). Mild oxidative stress may cause simple oxidation/hydroxylation like reversible oxidation of methionine to methionine sulfoxide. However, more sustained/severe stress leads to carbonylation—an irreversible oxidative protein ‘damage’—a chemically diverse form of oxidative post-translational modification (PTM) wherein the side-chains of various amino acids are modified to diverse aldehydes, ketones, lactams and conjugates of advanced glycation (or lipid-peroxidation) end-products (AGEs/ALEs; Møller et al., 2011). system.2 Our current findings of diverse targets of the 2-aminobenzamides suggest that there are other potentially beneficial mechanisms of action, such as increased processing or translation of mRNAs that are down-regulated by mutant Htt at the transcriptional level, among other possibilities suggested by the wide range of pathways identified as influenced by the 2-aminobenzamides. On a final note, the finding of a large number of targets of the 106 probe or interacting proteins could potentially raise concern for the use of 2-aminobenzamides the universally conserved Gly-Gly-Gln (GGQ) motif,7 which interacts with the large ribosomal subunit to release the polypeptide chain from the P-site bound peptidyl-tRNA. This GGQ-containing domain stretching from amino acid 57 to 121 in the human 166-residue full-length protein8 is not affected by the mutations that lead to a relatively mild phenotype. However, both in family B and in the previously described patients with the severe phenotype2 the mutation interrupts this highly conserved domain (Figure 4c). Possible explanations for the Tudor domain which accommodates H4 dimethylated lysine 20 and to additional residues in the second Tudor domain (Fig. 2a, b). 53BP1 residues for which signal intensities were preferentially decreased are similar to those affected by interaction with an H4K20me2 peptide, indicating that H4K20me2 and TIRR binding surfaces on Tudor overlap even if there is no H4-like motif in TIRR. The interaction with TIRR is, however, more extensive as it involves residues from the second Tudor domain which do not interact with H4K20me2 (Fig. 2a). To extend chromatin and translation. Histone lysine methylation has emerged as an important player in regulating gene expression and chromatin function [14]. K27 is a critical residue in all seven histone 3 variants and the subject of post-translational histone modifications as it can be both methylated and acetylated [2, 14, 20]. Acetylation may induce active transcription, while mono, bi or tri-methylation of K27 is associated with a repressive mark on chromatin and gene expression. Abrogation of acetylation and/or potential mimicry of a methylated Oxidative stress and protein damage have been associated with over 200 human ailments including cancer, stroke, neuro-degenerative diseases and aging. Protein carbonylation, a chemically diverse oxidative post-translational modification, is widely considered as the biomarker for oxidative stress and protein damage. Despite their importance and extensive studies, no database/resource on carbonylated proteins/sites exists. As such information is very useful to research in biology/medicine, we have manually curated a data-resource (CarbonylDB) of mutation to arginine. The synthesis of 13C-methyl alkylation reagent dimethylated 2-chloroethylamine and installation of dimethylated lysine analog followed previously reported protocols47,48. Briefly, two of the three cysteines in TIRR were mutated into serines. Each lysine of interest (K10, K151 and K205) was replaced by a cysteine and converted to the dimethylated lysine analogs KC10me2, KC151me2 and KC205me2. For the reductive alkylation of TIRR and the installation of dimethylated lysine analogs, excess reagent was eliminated by is typically shortened resulting in premature death within the first two decades of life. Of note, enzyme assessment of mitochondrial OXPHOS complexes both in muscle and fibroblasts typically display reduced activities of complex I and complex IV regardless of phenotype severity. The exact role of C12orf65 in mitochondrial DNA translation is yet to be determined. C12orf65 is not directly participating in the translation machinery but is an auxiliary factor and was hypothesized to be involved in recycling of abortive peptidyl-tRNA in the larvae (40). While it has been assumed that the essential function of the PR-Set7 methyltransferase is to monomethylate H4K20, it remains possible that it could target other critical proteins for methylation. Indeed, nonhistone targets of PR-Set7's catalytic activity have been identified in mammalian cells, including p53 (38) and PCNA (39), both of which are critical cell cycle regulators. Recently, McKay and colleagues developed a novel histone replacement system to directly assess the function of specific histone lysine residues in\n",
            "[0.61635154]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the cause of episodic ataxia type 6?\n",
            "Refined Query: Episodic ataxia type 6 (EA6) is a neurological disorder causing episodes of ataxia, or lack of muscle coordination.  What specific genetic mutations or underlying physiological mechanisms trigger these episodic attacks of incoordination in EA6 patients?\n",
            "\n",
            "Combined Answer: Our findings are important because they indicate that clinicians should be alert to considering mutations in NHE6 in a variety of presentations of neurodevelopmental disorders. Specifically, boys who present with new diagnoses of moderate to severe ID with seizures, language delays, and ataxia, with or without Angelman-like symptoms (AS), and with or without a pedigree consistent of X-linked ID, should be considered for NHE6 mutations. Finally, in twelve independent families we have discovered a robust allelic series of NHE6 mutations in CS. Another possible distinguishing feature is that epilepsy in AS may not occur in 100% of patients25, 28 whereas in CS, as the data currently stand, epilepsy occurs in all patients. Additional medical and behavioral symptoms are notable, including GERD and high pain threshold. CS may be among the most common X-linked developmental brain disorders. In a large-scale sequencing project in 208 pedigrees with suspected X-linked intellectual disability, two protein-truncating mutations in NHE6 were found.1 These data place NHE6 among the top six genes Causative mutations in neurodevelopmental disorders are frequently de novo, X-linked recessive or autosomal recessive. In contrast to prior literature reporting largely inherited mutations in NHE6, through prospective recruitment, here we discover seven highly deleterious de novo mutations in NHE6. An eighth mutation was found, in a three-generation pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a a large-scale sequencing project in 208 pedigrees with suspected X-linked intellectual disability, two protein-truncating mutations in NHE6 were found.1 These data place NHE6 among the top six genes that were found to have recurrent protein-truncating mutations, and suggest that CS may constitute approximately 1–2% of X-linked developmental brain disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume will require larger studies to establish. The majority of mutations appear to be early truncating and/or splice mutations likely constituting loss of function mutations. Given our high discovery rate of de novo variants and prior publications, we anticipate that CS will constitute a spectrum of NHE6 mutations that may be either inherited or de novo. Our findings are important because they indicate that clinicians should be alert to considering mutations in NHE6 in a variety of presentations of neurodevelopmental disorders. Specifically, boys In summary, we report a robust series of NHE6 mutations in twelve independently ascertained pedigrees within which we were able to characterize quantitatively core and secondary symptom presentations. Through this study we have proposed a core set of diagnostic criteria for CS and also generated a quantitative early guide to symptom presentation in order to help establish initial clinical expectations for families and clinicians. Based on current studies, CS may be among the most common X-linked developmental brain disorders.1 CS has broad Mutations from twelve families are represented on the NHE6 protein in Figure 4 and pedigrees are shown in Figure 1. Interestingly, in contrast to prior literature regarding NHE6 mutations wherein mutations have been largely inherited (Supplementary Table 2), a majority of mutations in our study (58%) were de novo. Families 1 through 7 had confirmed de novo mutations (ie mutations were not found in the mother). Another notable finding was two separate recurrent mutations. The first was found at c.1498 c>t, p.R500X. This mutation was observed in One of the identified targets of the 106 probe is the transcription elongation factor TCEB2. Interestingly, the gene encoding TCEB2 was found to be up-regulated by HDACi 106 in primary lymphocytes from Friedreich’s ataxia patients.30 TCEB2 is of interest since down regulation of FXN mRNA synthesis is the primary cause of FRDA, and transcription elongation as well as initiation has been shown to be affected by the GAA repeats.31 To validate TCEB2 as a bonafide target or target-interacting protein of the 106-probe, we used Western blotting of the atrophy,18 we assessed segregation of this mutation in the family. The deletion was homozygous in the affected cases, and either absent or heterozygous in the unaffected relatives (figure 3). To further investigate the presence of the mutation in patients with complex neuropathy, we sequenced the coding exons of C12orf65 in an additional cohort of 183 patients. None of the patients harboured potentially pathogenic variants. To determine whether the truncating mutation induced mRNA nonsense-mediated decay, we tested the level of expression of In this study, we prospectively ascertained 12 independent pedigrees, 14 affected boys in total, with mutations in NHE6. Interestingly, in contrast to prior literature, a majority of the pedigrees enrolled exhibited de novo mutations. Through quantitative study of clinical features in probands across these independent pedigrees (Supplementary Table 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected\n",
            "[0.61446774]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the main role of Ctf4 in dna replication?\n",
            "Refined Query: Ctf4's primary function in DNA replication isn't fully understood, but current research suggests it plays a crucial role in maintaining genome stability and accurate chromosome segregation by influencing sister chromatid cohesion and potentially assisting in replisome progression or stability.\n",
            "\n",
            "Combined Answer: sisters (108). The independent observation that both CTF4 and CTF18 possess functions important for sister chromatid cohesion strongly supports the concept that replication forks directly mediate molecular events important for sister chromatid cohesion. The proposed roles for CTF4 and CTF18 proteins in coupling S-phase DNA replication and cohesion do not preclude potential activities that are also important for cohesion maintenance. Several observations are consistent with roles for each of these proteins in cohesion establishment, such as 2004). While these factors are non-essential for viability, their absence leads to compromised sister chromatid cohesion. Several lines of evidence have linked these cohesion establishment factors to the DNA replication fork, though their specific requirement for cohesion establishment during S-phase, as opposed to cohesin loading onto chromosomes or maintaining sister chromatid cohesion, has formally been demonstrated only for the Ctf18 complex and Csm3 (Xu et al. 2007). Both Ctf4 and Ctf18 have been detected at DNA replication forks or maintaining sister chromatid cohesion, has formally been demonstrated only for the Ctf18 complex and Csm3 (Xu et al. 2007). Both Ctf4 and Ctf18 have been detected at DNA replication forks (Lengronne et al. 2006), where Ctf4 is an integral component of the replisome progression complex (Gambus et al. 2006). Ctf4 binds to DNA polymerase α/primase (Miles and Formosa 1992; Zhou and Wang 2004) and mediates its interaction with the GINS complex (Gambus et al. 2009; Tanaka et al. 2009). Ctf18 is part of a replication factor C (RFCCtf18) complex a role for sister chromatid cohesion regulation in many aspects of DNA metabolism. The requirement for CTF4 and CTF18 in cohesion identifies a role for these replication accessory proteins in high-fidelity chromosome segregation. The proposed intimate coupling between DNA synthesis and the establishment of sister chromatid cohesion by one or more DNA polymerase complexes provides a mechanism for the specificity of this tight and essential chromatin association. However, it is not yet clear how many distinct steps or molecular complexes operate CTF4 and CTF18 are required for high-fidelity chromosome segregation. Both exhibit genetic and physical ties to replication fork constituents. We find that absence of either CTF4 or CTF18 causes sister chromatid cohesion failure and leads to a preanaphase accumulation of cells that depends on the spindle assembly checkpoint. The physical and genetic interactions between CTF4, CTF18, and core components of replication fork complexes observed in this study and others suggest that both gene products act in association with the replication fork to The data described above show that the Ctf4 component of the RPC has an important function in maintaining a stable link between DNA polymerase α and the MCM2-7 helicase during chromosome replication. Budding yeast cells can survive without this stable connection, however, and both early and late origins are activated in the absence of Ctf4 (Supplementary Figure 5). Nevertheless, ctf4Δ cells have a major delay in cell cycle progression, a high rate of genome instability, and are defective in establishing cohesion between sister chromatids related to DNA synthesis. They also support a model in which sister chromatid cohesion defects may be among the consequences of mutations in other proteins that function at DNA replication forks. Although previous studies have suggested that Ctf4p and Ctf18p each play roles associated with DNA metabolism, these roles have not been defined. Intriguingly, CTF4 was isolated as a DNA polymerase α (Cdc17p) binding protein, and genetically interacts with with CDC17, RAD27, DNA2, and RFC1 (24). ctf4 mutants exhibited general properties consistent new contacts of cohesin with DNA during DNA replication, and whether Ctf4 shares this role, will be important questions to be addressed in the future. A better appreciation of where and when Ctf4 and Chl1 perform their role in sister chromatid cohesion establishment will be important to understand how cohesin establishes molecular links between sister chromatids. in the cell (21, 63). This view suggests that Ctf7p in S. cerevisiae acts together with a DNA polymerase activity. Finally, the novel polymerase κ protein family in budding yeast not only has a demonstrated requirement in replication of the genome but also plays a poorly understood role in establishing and/or maintaining robust cohesion between sisters (108). The independent observation that both CTF4 and CTF18 possess functions important for sister chromatid cohesion strongly supports the concept that replication forks directly mediate chromatid caused by compromised cohesion may lead to increased utilization of a homolog in recombinational DNA damage repair. This hypothesis may explain increased rates of mitotic recombination in cohesion-deficient mutants. Although not well understood, the association between cohesion and repair-recombination pathway activities strongly suggests a role for sister chromatid cohesion regulation in many aspects of DNA metabolism. The requirement for CTF4 and CTF18 in cohesion identifies a role for these replication accessory proteins in\n",
            "[0.7117231]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Could Arimidex (anastrozole) cause hot flashes?\n",
            "Refined Query: Arimidex, or anastrozole, is a medication used to treat hormone-receptor-positive breast cancer.  A common side effect of aromatase inhibitors like Arimidex is the occurrence of hot flashes.  I'm looking for information confirming whether this side effect is frequently reported and the severity typically experienced.\n",
            "\n",
            "Combined Answer: commonly used for the treatment of ovarian cancer. This was done both using cell lines that were either sensitive or resistant to single-agent rucaparib. To better understand observed synergies, we finally studied the effect of rucaparib on chemotherapy-induced apoptosis, DNA fragmentation, and γH2AX formation. the direct effect of T-UCRs on AR signaling and its downstream target PSA and the involvement of T-UCRs in the drug resistance of cancer cells. Several lines of evidence have shown that AR signaling modulates docetaxel sensitivity [15], [18], [19], and the recent CHAARTED clinical trial showed that patients with hormone-sensitive metastatic PC who received docetaxel chemotherapy given at the time of androgen deprivation therapy lived more than one year longer than patients who received androgen deprivation therapy alone [20]. We showed that (Bourin et al., 2009; Lenze et al., 2015; Zhou et al., 2015). Our results show that administration of a high dose of aripiprazole produced an antidepressant-like response, but also induced increases in total fluid consumption, which could be due to polydipsia and/or polyuria, potential side effects of some antipsychotic agents (Bersani et al., 2007; Meulendijks et al., 2010; Gandhi et al., 2016). In this regard, cariprazine has a more specific antidepressant-like effect that was independent of changes in overall liquid consumption. We found overcoming acquired resistance to carfilzomib/oprozomib, but several options, including combination(s) of these agents with an HDACi, an MDR-1/P-gp inhibitor, and/or a pan-Bcl-2 inhibitor should be considered. been treated with bortezomib. Carfilzomib is currently undergoing extensive clinical testing in multiple myeloma, as well as evaluation in mantle cell lymphoma, T-cell lymphoma, large B-cell lymphoma, Waldenstrom macroglobulinemia, acute myeloid leukemia, acute lymphoblastic leukemia, small cell lung cancer, renal cell carcinoma, and advanced prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being RP101988 is a substrate of P‐gp and breast cancer resistance protein (BCRP) drug transporters (data on file). Drug‐drug interaction studies showed that itraconazole, a strong inhibitor of CYP3A and P‐gp, had no effect on ozanimod exposure, whereas cyclosporine, a strong inhibitor of P‐gp and BCRP transporters, increased total agonist exposure (sum of ozanimod, RP101988, and RP101075) by approximately 50% (data on file). In contrast to ozanimod, fingolimod (an approved nonselective S1P receptor modulator) has produced mild but significant is commonly used for the treatment of schizophrenia and bipolar disorder, except that cariprazine has a greater affinity and selectivity for D3 vs. D2 receptors (Tadori et al., 2011; Ellenbroek and Cesura, 2015; Findlay et al., 2016; Stahl, 2016). Aripiprazole also has been shown to be effective as an adjunct treatment for major depressive disorder (Bourin et al., 2009; Lenze et al., 2015; Zhou et al., 2015). Our results show that administration of a high dose of aripiprazole produced an antidepressant-like response, but also induced increases prostate cancer (http://www.clinicaltrials.gov). Oprozomib is a structurally-related analog of carfilzomib that has the added benefit of being orally bioavailable.32 Currently, oprozomib is being evaluated in clinical trials of multiple myeloma and recurrent solid tumors (http://clinicaltrials.gov). Like carfilzomib, oprozomib is also active against bortezomib-resistant multiple myeloma cells.33 Thus, carfilzomib and oprozomib offer several unique advantages, including the ability to overcome acquired bortezomib resistance. Both carfilzomib Oprozomib (formerly known as ONX 0912 and PR-047) is an orally bioavailable analog of carfilzomib, which has been reported to have anti-tumor activity equivalent to carfilzomib in xenograft models of non-Hodgkin’s lymphoma and colorectal cancer,26 and also to exert anti-MM activity in vitro and in myeloma animal models.27 Its favorable pharmacologic profile and tolerability supports its further clinical development and Phase I clinical trials are underway.28 While epoxyketone-based PIs have been shown to stimulate bone formation29 and inhibit respectively, relative to the parental lines. Similarly, a high level of cross-resistance to oprozomib, as well as paclitaxel, was observed, whereas only moderate resistance to bortezomib (8- to 29-fold), and low level resistance to cisplatin (1.5- to 5-fold) was seen. Synergistic induction of apoptosis signaling and cell death, and inhibition of colony formation followed co-treatment of acquired resistance models with carfilzomib and the histone deacetylase inhibitor (HDACi) vorinostat. Synergism was also seen with other combinations,\n",
            "[0.8262386]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of Inn1 in cytokinesis?\n",
            "Refined Query: Investigate the precise function of the Inn1 protein during the cytokinesis phase of cell division.  Does it influence the formation of the contractile ring, membrane abscission, or other crucial cytokinetic processes?  What are the downstream effects of Inn1 dysfunction on cell division?\n",
            "\n",
            "Combined Answer: with the SWI/SNF remodeling complex in transcriptional activation (Kadam and Emerson, 2003). However, we did not observe these interactions in our GATA-1 purification from induced MEL cells or in immunoprecipitations (data not shown). Our observations on the interactions of GATA-1 (and FOG-1) with the MeCP1 complex add to previous reports linking MeCP1 (and the closely related NuRD complex) to transcription factors in hematopoiesis (Kim et al, 1999; O'Neill et al, 2000; Hutchins et al, 2002). The conditional knockout of Mi-2β in thymocytes its cofactors, ATMIN and NBS1. These cofactors compete for ATM binding and in doing so regulate ATM kinase activity. Whereas both ATM and NBS1 function in T cell development and in the maintenance of genomic stability within such cells, the role of ATMIN (and the contribution of ATMIN and NBS1) in T cell function is unknown. Here, we show that whereas NBS1 has distinct ATMIN-independent functions during VDJ recombination, loss of both cofactors resulted in exacerbated DNA damage, T cell hyperactivation, inflammation and an IBD phenotype. The mRNA that was synthesized in per-meiotic germ cells [17] . In this study, we have unraveled the potential mechanism on how Necl-2 transcription is terminated and how Necl-2 protein at the cell-cell interface is internalized and degraded. We found that TGF-β1 is a potent cytokine that mediates transcriptional repression of Necl-2 gene in GC-1 spg cells. Apparent, this could be an effective mechanism to terminate the transcription of Necl-2 gene in early pre-meiotic germ cells. It is of interest to point out that the existing Necl-2 mRNA spg cells. Apparent, this could be an effective mechanism to terminate the transcription of Necl-2 gene in early pre-meiotic germ cells. It is of interest to point out that the existing Necl-2 mRNA transcripts remain very stable even after TGF-β1 treatment in the actinomycin D study, which fits the hypothesis that the mRNA synthesized in early stage of germ cell development with long half-life may be used for protein translation in spermatids. In examining the details of transcriptional mechanism, we found that NF-1 interacts with both MyoD post-transcriptional and post-translational modification of cell junction proteins mediated by hormones and cytokines are crucial for the precise control of cell junction restructuring [2]–[4]. Cell junctions between Sertoli and germ cells are constituted by different types of junction protein complexes such as nectin-afadin and JAM-ZO-1 protein complexes [5], [6]. Recent animal studies have shown that knockout of individual junction proteins, including nectin-2, nectin-3, or JAM-C cause infertility in male mice, indicating that each of the the percentage difference between the Ymin value and the estimated starting cell number and either the control cell number (for agents with Ymin > starting cell number) or 0 (for agents with Ymin < estimated starting cell number). Relative I/O% values range between 100% (no treatment effect) to −100% (complete cytotoxic effect), with a Relative I/O% value of 0 being observed for a completely effective cytostatic agent. of RIF1 in RPE-1 and U2OS cells (Fig. 4h and Extended Data Fig. 4c, d) and deletion of RIF1 in RPE1 cells significantly diminished the formation of 53BP1 foci at low doses (2 Gy and 4 Gy) and early time points (15 min and 30 min) after IR (Extended Data Fig. 4e). The effect was relatively mild in MEFs RIF1−/− indicating a potential species-specific difference (Extended Data Fig. 4f). Furthermore, co-depletion of TIRR restored the formation of 53BP1 foci in RIF1-depleted cells (Fig. 4h) suggesting that the impact of RIF1 loss on 53BP1 foci is ChIP or additional still uncharacterized experimental artifacts. Various approaches of ‘peak calling’ have been applied to determine loci with a clearly increased coverage of ChIP-seq reads. Some of these methods include complex statistical approaches and data from ‘negative control’ experiments [5], [6], [7], [8], [9], [10], [11], [12]. STAT1 is a member of an intensively studied family of TFs with implications in the regulation of immune responses. In resting cells STAT1 is mainly located in the cytosol. Upon stimulation with the cytokine responses, DNA repair, DNA replication, and mitotic chromosome condensation. It is to be anticipated that the protein complexes operating within mechanisms governing the establishment, maintenance, and release of sister chromatid cohesion are just coming to light. complexes [5], [6]. Recent animal studies have shown that knockout of individual junction proteins, including nectin-2, nectin-3, or JAM-C cause infertility in male mice, indicating that each of the protein components indeed plays an indispensable role in cell adhesion during spermatogenesis [7]–[10]. Nectin-like molecule-2 (Necl-2) belongs to immunoglobulin superfamily. It has been also known as IGSF4A/TSLC1/RA175/SgIGSF/SynCAM/CADM1 due to its diverse functions in various tissues [11]–[16]. Necl-2 contains three immunoglobulin-like loops in\n",
            "[0.74806464]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which hormone deficiency is implicated in the Costello syndrome ?\n",
            "Refined Query: Costello syndrome is linked to a deficiency in which specific hormone, and how does this hormonal imbalance contribute to the characteristic features of the syndrome?\n",
            "\n",
            "Combined Answer: Cases of humans lacking either of the other two TH distributor proteins: albumin (Minchiotti et al., 2013) or thyroxine-binding globulin (Refetoff, 1989) have been described. Such people are apparently healthy and without overt clinical symptoms. However, no humans lacking TTR have been reported. In the 1990s the hypothesis was that because TTR is the only TH distributor protein synthesized in the brain, is secreted unidirectionally across the apical surface of the choroid plexus epithelial cells into the CSF, its role in the movement of TH TH circulating in the blood (Mendel et al., 1987). In humans, the main TH distributor proteins are albumin, transthyretin (TTR) and thyroxine-binding globulin (TBG), all of which are synthesized by the liver. In addition, a small fraction is distributed by lipoproteins including ApoB100 (Benvenga et al., 1989). The free hormone hypothesis states that it is the free hormone in blood (not the protein-bound hormone) that is important for biological activity (Mendel, 1989). Thus, THs must dissociate from the distributor proteins before they can Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form 10, a member of the Sry family, is mutated in Dom, and its human homologue is disease causing in autosomal dominant Shah‐Waardenburg syndrome. A similar effect will be difficult to test in humans as a SOX10 mutation is rare while the penetrance of HSCR is high in carriers. However, the putative role of the RET gene could be further tested in syndromic HSCR entities frequent enough to allow the collection of large series of patients, namely cartilage‐hair hypoplasia, Bardet‐Biedl syndrome, and Down's syndrome. In relation to the MWS group of patients presenting with an isolated, long segment form of HSCR, skewing of the sex ratio decreases when compared with the short segment form of HSCR. In relation to MWS, we observed a skewed male to female ratio of 2.5:1 among the 20 patients with HSCR (15 males, five females), in agreement with previous reports.10 RET had been considered as a candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver - PMC an autosomal recessive disorder characterized by conjugated hyperbilirubinemia, coproporphyrinuria, and near-absent hepatic uptake of anionic diagnostics, has remained enigmatic. Here, we analyzed 8 Rotor-syndrome families and found that Rotor syndrome was linked to mutations predicted to cause complete and simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3. These important detoxification-limiting proteins mediate uptake and clearance of countless drugs and drug conjugates across the sinusoidal Charcot-Marie Tooth disease (CMT) forms a clinically and genetically heterogeneous group of disorders. Although a number of disease genes have been identified for CMT, the gene discovery for some complex form of CMT has lagged behind. The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but until now, mutations in the recessive forms of disease have never been identified. candidate gene for CCHS and heterozygous missense mutations were identified in four Haddad cases and one CCHS case, respectively.18,19,20,21,22 Such mutations were found in a minority of patients and were inherited from an asymptomatic parent each time it could be tested. Subsequently, PHOX2B has been identified as the major disease causing gene in CCHS with a heterozygous de novo mutation in over 90% of the cases.11,23,24 Frameshift and missense mutations lying in the homeodomain of the protein are rare (11% in this series, fig 1) and\n",
            "[0.82679117]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List the components of a Replisome Progression Complex (RPC).\n",
            "Refined Query: Describe the core components of the Replisome Progression Complex (RPC), detailing the essential roles of each protein or protein complex in DNA replication.  Specifically, what are the key enzymes and accessory factors required for efficient and accurate replication fork movement?\n",
            "\n",
            "Combined Answer: Our data show for the first time that MCM2-7, GINS and DNA polymerase α all form part of a common complex at DNA replication forks. The demonstration that DNA polymerase α associates with the RPC thus represents an important step towards characterising the eukaryotic replisome. In the E. coli replisome, physical links between DNA helicase, DNA polymerase and primase regulate fork progression and allow unwinding to be coordinated with DNA synthesis. Our findings indicate that an important feature of the eukaryotic replisome will be that RPC that all of the above proteins form a very large assembly called the replisome progression complex or RPC (Gambus et al, 2006). The RPC only exists during S-phase, occurs on chromatin, requires the prior loading of MCM2-7 at origins during G1-phase, and persists for as long as DNA replication forks are still present when nucleotide production is inhibited (Gambus et al, 2006). It thus appears that the RPC represents the fraction of MCM2-7 helicase that is present at DNA replication forks and is therefore likely to be a key component of the Reliable DNA replication during S-phase is vital for the sustainability of a cell and, ultimately, an organism. The proteins that assemble at licensed replication forks come together to form the Replisome Progression Complex (RPC). This complex must faithfully copy an organism's genome in the context of cell cycle regulation and chromatid segregation while at the same time safeguarding against DNA damage. In response to this highly integrated nature of the RPC, recent studies have generated models at the replication fork that link MCM helicase The replisome is the multi-protein complex that is present at the replication fork as it moves through the chromosome. Multiple replisome components interacted with Pfh1 with high specificity (SAINT score ≥ 0.80; Fig 6C and Table 3). These proteins were: (1) five of the six subunits of the replicative helicase, the MCM complex (Mcm2 and Mcm4-7); (2) catalytic subunits of two of the three replicative polymerases (DNA Pol1 from DNA polymerase α; DNA Pol2/Cdc20, from DNA polymerase ε); (3) Pol12, the β subunit of DNA Pol1; (4) proliferating cell throughout each chromosome. Our current understanding of eukaryotic DNA replication forks was inspired by earlier work with bacteria, in which chromosome replication is understood in much greater detail. In Escherichia coli, progression of DNA replication forks is dependent on the DnaB DNA helicase that unwinds the parental DNA duplex. The DnaB helicase is connected physically to a subset of the other replication factors to form a larger assembly called the replisome (Yao and O'Donnell, 2008). In addition to DnaB, the replisome includes the important roles in genome preservation whose human orthologs might have similar functions. DNA replication is accomplished by the multi-subunit replisome, a complex that is assembled at and moves bi-directionally away from replication origins. Replicative helicases, such as the Escherichia coli DnaB and the eukaryotic hexameric MCM complex, are required to unwind the double helix to allow DNA polymerases access to the replication template. In addition, accessory helicases, such as the E. coli rep, dinG and UvrD proteins help the polymerase polymerase and primase regulate fork progression and allow unwinding to be coordinated with DNA synthesis. Our findings indicate that an important feature of the eukaryotic replisome will be that RPC components link the MCM helicase to other factors, such as DNA polymerase α that acts on the lagging strand template (Figure 10). Others have shown that Mrc1 is a prime candidate for a factor that couples MCM to DNA polymerase epsilon on the leading strand template (Lou et al, 2008), although this remains to be shown directly. Further is required for forks to pause at protein–DNA barriers, the histone chaperone FACT, the type I topoisomerase Top1, and Mcm10 and Ctf4 that are known to bind DNA polymerase α (Homesley et al, 2000; Katou et al, 2003; Ricke and Bielinsky, 2004; Nedelcheva et al, 2005; Gambus et al, 2006). By purifying GINS from budding yeast cell extracts, we found that all of the above proteins form a very large assembly called the replisome progression complex or RPC (Gambus et al, 2006). The RPC only exists during S-phase, occurs on chromatin, requires the contained all of the previously identified RPC components with the exception of Mcm10 (Figure 1; Supplementary Figure 1). Strikingly, however, the purified RPC material contained four additional proteins that were not detected in our previous experiments using cell extracts containing 300 or 700 mM potassium acetate. These factors comprised the four subunits of DNA polymerase α (Figure 1), indicating that a fraction of Pol α exists in a common complex with MCM2-7 and GINS at DNA replication forks. These findings imply that one role of the RPC helicase is connected physically to a subset of the other replication factors to form a larger assembly called the replisome (Yao and O'Donnell, 2008). In addition to DnaB, the replisome includes the DNA polymerase that works on the leading and lagging strand templates, the primase that initiates each new DNA molecule, and the γ-complex that loads the β-clamp that serves as a processivity factor for the DNA polymerase. Interactions between the components of the replisome serve to ensure that unwinding by DnaB is coordinated with efficient DNA\n",
            "[0.64852643]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the definition of minimal absent words?\n",
            "Refined Query: What precisely constitutes a \"minimal absent word\" in a given context, such as a text corpus or language model?  How is \"minimal\" defined—shortest length, fewest occurrences elsewhere, or something else?  And what constitutes \"absence\"—complete lack of any form, or simply infrequent use?\n",
            "\n",
            "Combined Answer: In [23], it is shown that all |A| minimal absent words of a word x of length n over an integer alphabet can be computed in time O(n+|A|) and space O(n). Computing minimal absent words and checking for each of them if it is an avoided word is the bottleneck for algorithms AvoidedWords and AllAvoidedWords. The result of [23] implies that for a word x of length n over an integer alphabet we can make both algorithms to require time O(n+|A|) and space O(n). We can do that by checking for each minimal absent word output by the algorithm whether it is [4] An absent word w of x is minimal if and only if all proper factors of w occur in x. We first show that the known asymptotic upper bound on the number of minimal absent words of a word is tight. Any absent ρ-avoided word w in x is a minimal absent word of x. [19] The upper bound O(σn) on the number of minimal absent words of a word of length n over an alphabet of size σ is tight if 2≤σ≤n. In Lemma 3, we showed that each absent ρ-avoided word is a minimal absent word. Thus, Routine AbsentAvoidedWords starts by computing all minimal absent words in x; this can be done in time and space O(n) for a fixed-sized alphabet or in time O(σn) for integer alphabets [4, 5]. Let <(i,j),α> be a tuple representing a minimal absent word in x, where for some minimal absent word w of length |w|>2, w=x[i…j]α, α∈Σ; this representation is clearly unique.  Intuitively, the idea is to check the length of every minimal absent word. If a tuple <(i,j),α> of length n over an integer alphabet we can make both algorithms to require time O(n+|A|) and space O(n). We can do that by checking for each minimal absent word output by the algorithm whether it is avoided, instead of storing a representation of them and then making the check. words over an integer alphabet and the expected length of the longest one. We also prove that the same asymptotic upper bound is tight for the number of ρ-avoided words of fixed length when the alphabet is sufficiently large. As shown subsequently, the set of absent ρ-avoided words is a subset of the set of minimal absent words of a word. Hence the tight asymptotic bounds for ρ-avoided words are based on the proof we provide for the tightness of the known asymptotic bound on minimal absent words and the tightness of this bound for minimal The upper bound O(σn) on the number of minimal absent words of fixed length of a word of length n over an alphabet of size σ is tight if n+1≤σ≤n. The number of ρ-avoided words in a word of length n over an alphabet of size 2≤σ≤n is O(σn) and this bound is tight. It is clear that if we just remove the condition on the length of each minimal absent word in Line 2 of AbsentAvoidedWords we then compute all absent ρ-avoided words in time O(σn). In order to compute all occurring ρ-avoided words in x it suffices by Lemma 4 to investigate the children of explicit nodes. We can thus traverse the suffix tree T(x) and for each explicit internal node, check for all of its children (explicit or integer alphabets. We also showed that the same asymptotic bound is tight for the number of minimal absent words of a fixed length if the alphabet is sufficiently large. Finally, we made available an implementation of our algorithm. Experimental results, using both real and synthetic data, show its efficiency and applicability in biological sequence analysis.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.68ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1309.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the most common CFTR mutation in Caucasians?\n",
            "Refined Query: Among individuals of Caucasian descent diagnosed with cystic fibrosis,  which specific cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation is statistically identified as the most prevalent?\n",
            "\n",
            "Combined Answer: pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this may be more highly deleterious and that inherited mutations may appear milder. However, from our data and the other mutations in the literature (Supplementary Table 2), this hypothesis does not appear to be substantiated.4 There is a statistical trend toward more regressions and earlier-onset regressions in the de novo group; however, this association will require larger studies to establish. The majority of mutations appear to be early truncating and/or splice mutations likely constituting loss of function mutations. Given our high discovery might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, with discordance in excess of 10%3. One key reason for this discordance is the structure of the ACMG/AMP guidelines, which are deliberately broad and lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific 19% and 33% of the patients, respectively, have HSCR in addition to CCHS. Therefore, for an identical PHOX2B gene mutation, patients present CCHS with or without HSCR. Such a finding clearly indicates a role for modifier factors in the occurrence of the HSCR phenotype—allelic diversity is not the only satisfactory explanation. Concerning MWS, ZFHX1B mutations are either de novo heterozygous deletions encompassing the gene or truncating mutations, both leading to a loss of function.25 A PHOX2B gene mutation appears necessary and sufficient for results. Many recent meta-studies of the efficacy of WES in diagnosing rare genetic diseases have revealed that its yield is usually less than 50%17. As such, for unsolved cases, researchers and clinicians are increasingly turning to WGS to identify candidate causal genes; however, the expansion into the rest of the genome causes a dramatic increase in the number of candidate variants. This is in part due to difficulties interpreting the effect of variants beyond the exome. As such, supplemental information regarding dysregulated candidate lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific knowledge, to optimise variant interpretation and introduce consensus. Initiatives such as the Clinical Genome Resource (ClinGen)4, are working to define such disease- and gene-specific thresholds, although these are currently limited to pilot phases for specific gene-disease pairs. The introduction of guidelines, including the logic behind ABCC2 mutation screening was performed in 8 probands representing all studied families as described previously (14). may aggravate the severity and prognosis of the disease, but its occurrence seems to be dependent on the specific region of the mutation and its severity. As the disease is progressive and symptoms may appear later in the course, we suggest to include genetic analysis of C12orf65 in the diagnostic work-up of all patients with at least two of these three major features. 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this development process, we compared rule activation in CardioClassifier to a set of variants manually curated as part of routine clinical service at the Royal Brompton Hospital (see Supplement). Full details of how each rule is parameterised can be found in the Supplement to this manuscript. As most large reference populations, such as ExAC, are not used. Even looking at the top 100 variants returned by Phen-Gen, the causative one was identified in only 31%–34% of samples. Phen-Gen uses its own model for predicted non-coding pathogenicity and is trained on positive sets of HGMD regulatory variants and GWAS hits and a neutral set of common (>30% allele frequency) variants using evolutionary conservation, function signals from ENCODE, and proximity to coding regions as properties. The issues discussed above with these positive sets not fully representing true disease-causing variants\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1057.88ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1259.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1386.23ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 833.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1484.63ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 856.64ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1208.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1058.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Simpson grading is used to describe resection of which brain tumor?\n",
            "Refined Query: The Simpson grading system categorizes the extent of resection for which specific type of brain tumor?  This system uses grades to describe how much of a tumor was surgically removed,  but which tumor type is this specifically applied to?\n",
            "\n",
            "Combined Answer: five of these patients underwent a subsequent biopsy or resection demonstrating higher grade gliomas. These included two pontine gliomas originally classified as grade III that were upgraded to glioblastoma, a spinal glioma and a third ventricle glioma originally classified as grade II that were upgraded to glioblastoma, and a thalamic glioma originally classified as grade II that was upgraded to anaplastic astrocytoma. Given the prospective nature of this study without significant length of clinical follow‐up, the utility of assessing outcome lesions. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to evaluate response, and was also modified to uncouple target organ systems, to allow each organ system to be evaluated separately. Summation of size was carried out separately for lesions in the kidney, pancreas, central nervous system (brain + spine), and retina, and these measurements were used to compare changes from baseline size. Laboratory testing included assessment of transaminase levels every two weeks for the first eight weeks and then monthly, as = 25 years) gliomas (Figure 1). Thirty‐four of these 47 patients underwent biopsy only, whereas 13 underwent resection (Table 2). Initial histologic diagnosis was diffuse astrocytoma (WHO grade II) in 10 cases, anaplastic astrocytoma (WHO grade III) in 14 cases and glioblastoma (WHO grade IV) in 23 cases. During the short period of clinical follow‐up, five of these patients underwent a subsequent biopsy or resection demonstrating higher grade gliomas. These included two pontine gliomas originally classified as grade III that were upgraded to glioblastoma in a 4‐year‐old boy, a thalamic glioblastoma in a 24‐year‐old woman, and a glioma in the lumbar spinal cord with grade II histologic features at time of initial biopsy but grade IV histologic features on subsequent resection. observed by the ‘probeMis’ command. MethPed is currently the only publically available tool for classification of pediatric brain tumors. The use of methylation profiling for classification of these tumors adds new and important knowledge in the clinical setting for choosing the optimal care and treatment of these patients and will therefore likely complement histopathological diagnoses in the near future [1, 2]. MethPed: an R package for the identification of pediatric brain tumor subtypes - PMC We developed an R package that implements the MethPed classifier, making it easily available and accessible. The package can be used for estimating the probability that an unknown sample belongs to each of nine pediatric brain tumor diagnoses/subgroups. [2]. The conditional probability matrix of the classification from the MethPed output can be observed by the ‘summary’ command in R. For visualization of the prediction, bar plots can be generated by using the ‘plot’ command (Fig. 2). If missing probes from the sample compared with the training data included with the package exist, these can be observed by the ‘probeMis’ command. MethPed is currently the only publically available tool for classification of pediatric brain tumors. The use of methylation profiling for classification of these pLGG align with results published for NF1 patients with plexiform neurofibromas. In the phase I plexiform neurofibroma trial, MRI volumetric imaging evaluated response. Approximately 70% of patients were considered partial responders, defined as a ≥20% tumor volume reduction, and the vast majority of patients showed some degree of tumor shrinkage.(22),(28) These volumetric response definitions differ from the classic bi-dimensional 50% shrinkage classically utilized to define a PR in pLGG and used on the current study, perhaps explaining the xanthoastrocytoma (PXA), including nuclear pleomorphism out of proportion to mitotic activity, dense reticulin network, eosinophilic granular bodies, and CD34 positive stellate cells. Of 15 cases assessed by FISH, none had EGFR amplification while four had loss of chromosome 10, including a pontine glioblastoma in an 11‐year‐old boy, a pontine glioblastoma in a 4‐year‐old boy, a thalamic glioblastoma in a 24‐year‐old woman, and a glioma in the lumbar spinal cord with grade II histologic features at time of initial biopsy but grade IV\n",
            "[0.5069704]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Where in the cell do we find the protein Cep135?\n",
            "Refined Query: The protein Cep135's cellular location is crucial to understanding its function.  Precisely pinpointing its subcellular localization, including specific organelles or structures,  is necessary to fully elucidate its role in cellular processes.  Where within the cell, such as the cytoplasm, nucleus, or a particular organelle, is Cep135 typically found?\n",
            "\n",
            "Combined Answer: with intracellular C-terminal Ser/Thr phosphatase-1 (PP1) docking (Hendrickx et al., 2009; Heroes et al., 2013) and WIRS (WAVE regulatory complex interacting receptor sequence) cytoplasmic motifs (Fig. 1 and Supplementary Fig. S1) (Chen et al., 2014). The latter is consistent with the reported co-localization of TMEM132D with actin filaments (Walser et al., 2011). Cell–cell junctions in the central nervous system (CNS) are maintained by a variety of transmembrane proteins that signal and physically link between the cytoskeletons of adjacent lies adjacent to the Ser/Thr PP1 docking (Hendrickx et al., 2009; Heroes et al., 2013) and WIRS cytoplasmic motifs (Fig. 1), the latter which is found in a variety of neurological and other proteins including protocadherins (Chen et al., 2014). The newly identified domains, and conserved domain architecture, of TMEM132 proteins now should facilitate detailed experimental investigation of these proteins' domain and molecular functions and how these are modulated by sequence variants. elp4 expression is much more widespread (Supplemental Fig. S1) and thus does not appear to be regulated specifically by the elements within its introns. We also mapped an insertion 116 kb downstream from pax6.1 with the corresponding expression pattern (Fig. 3B; Supplemental Fig. S1). However, although the conservation of synteny with mammalian and avian genomes suggests that this genomic area was duplicated in its entirety, neither of the downstream genes elp4 and immp1l was retained downstream from pax6.1. Thus, while the entire region of CenH3 is located at the centromere of each chromosome and is surrounded by pericentromeric chromatin that forms heterochromatin domains called chromocenters (Fang and Spector, 2005; Talbert et al., 2002; Fransz et al., 2002). Each H2A.W-RFP localized primarily to domains corresponding to the ten chromocenters, each containing a CENH3-GFP patch in its center (Figures 2A, S2B and S2C). H2A.W.7-RFP and H2A.W.12-RFP also colocalized with H3K9me2 (Figures S2E and S2F) as demonstrated for H2A.W.6 (Figures 2B WT row and 1D). In conclusion, all to help in early diagnosis and prognostic evaluation of gynecological cancers, even though the molecular function of uc.189 in those cancers remains unknown. Uc.189 may target to THAP11 according to detection of dual luciferase report system (data unpublished), then cause down-regulation of THAP11. We speculate that down-regulation of THAP11 could promote invasion and migration of cervical cancer Hela cells. In conclusion, our results indicate that gynecological system cancers, especially cases of CSCC and EAC with high uc.189 expression and sponge proteins, all five are both present and in the identical order in the three cadherin protein families—lefftyrins, coherins and hedglings—that were contained in the last common ancestor of choanoflagellates and metazoans (Abedin and King, 2008; Nichols et al., 2012) (Supplementary Fig. S2). The TMEM132 domain architecture is thus ancient, preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the To glean insights into the structural basis for the ability of ceritinib to maintain activity toward select crizotinib-resistant mutants, the structure of the ALK catalytic domain complexed with ceritinib was determined (Fig. 4B) (PDB 4MKC) and compared to the structure of the ALK catalytic domain bound to crizotinib (Fig. 4C) (PDB 2XP2)(16). As shown in Figure 4A, ceritinib retains potency towards the most common G1269A and L1196M crizotinib-resistant mutants. The co-crystal structure reveals that G1269 is situated just proximal to D1270 of ZF region of the invertebrate CTCFs is located on a large exon comprising ≥80% of the coding region while it is composed of seven short exons in vertebrates [32]. The 5'UTR, interrupted by an intron, is leading in frame to the translation start in both, Trichinella and Drosophila CTCF. However, unlike dCTCF the Trichinella gene carries a larger 3'UTR (1328 bp versus 320 bp) that is also present in vertebrate CTCFs (1413 bp for the chicken CTCF 3'UTR [33]). The central region of the protein contains ten C2H2 ZFs conserved in all reported CTCF The conserved region (corresponding to amino acids 127–239 of human TMEM132A) preceding the cohesin domain in TMEM132 is also evident in choanoflagellate and sponge proteins (HMMER E-value < 0.005) (Supplementary Fig. S6). Strikingly, despite each of the five TMEM132 domains (Fig. 1) being identified independently in these choanoflagellate and sponge proteins, all five are both present and in the identical order in the three cadherin protein families—lefftyrins, coherins and hedglings—that were contained in the last common ancestor of as shown in a previous study.7 While our primary interest is identification of targets of 106 that might be involved in regulation of the FXN gene in FRDA, an unbiased proteomic approach should also identify the broader targets of 106 and their interacting proteins. In the present study, we used a dimethyl stable isotope-labeling approach coupled with multidimensional protein identification technology (MudPIT)15 to quantitatively identify the proteins specifically captured by the ABPP 106 probe under nondenaturing conditions compared with the\n",
            "[0.22362153]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is delayed enhancement documented in patients with non-ischemic dilated cardiomyopathy?\n",
            "Refined Query: Does medical literature report the presence of delayed enhancement on cardiac MRI in patients diagnosed with non-ischemic dilated cardiomyopathy, and if so, what is the prevalence and significance of this finding?\n",
            "\n",
            "Combined Answer: 0.5 mg) and were transient and asymptomatic. Cardiac adverse events of special interest were infrequent and of comparable incidence between the study groups. These included short runs of nonsustained ventricular tachycardia (3 placebo subjects, 2 ozanimod subjects), transient and self‐limiting first‐degree AV block (1 ozanimod subject), and transient and self‐limiting second‐degree AV block, Mobitz type 1 (1 subject in each group). None of these cardiac events was temporally associated with the administration of moxifloxacin. Other Transthoracic echocardiography was performed using a Vivid 7000 equipped (GE healthcare) with a H13L transducer (14 MHz). Two-dimensional and M-mode images were obtained in the short-axis view. The heart rate (HR), left ventricular end-diastolic internal diameter (LVIDd), left ventricular end-systolic internal diameter (LVIDs) were measured over the course of at least three repeated cardiac cycles. The ejection fraction (EF) and fractional shortening (FS) were then calculated. variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants (TTNtv) in exons constitutively expressed in the heart are robustly associated with DCM15. Additionally, it is unclear that the mechanism of action for these variants is truly loss of function (LoF). Instead of scoring all TTNtv equally and assuming an underlying LoF mechanism, we only score TTNtv highly if they are in constitutive exons (proportion detect even with targeted investigation, as they often manifest later in life and exhibit incomplete penetrance. We have therefore modified PM2 so as not to inappropriately discard variants seen at very low frequencies in these reference datasets. In addition, we have created extensions to three ACMG/AMP rules, to enhance interpretation of ICC variants. Firstly, we have modified PVS1 for the titin (TTN) gene, which has a role in up to 20% of dilated cardiomyopathy (DCM) cases15. We have previously shown that only TTN truncating variants of the following during treatment: an increase in QT/QTc interval to >500 milliseconds and/or of >60 milliseconds over baseline, any evidence for ventricular or supraventricular arrhythmia with or without hemodynamic compromise or any advanced AV block, or symptomatic persistent bradycardia <35 bpm that required medical intervention. resolved by day 22), abdominal pain, and second‐degree atrioventricular block (Mobitz type 1). The atrioventricular block was asymptomatic, occurred on day 15 approximately 8 hours after the third dose following the high‐fat meal, and lasted approximately 2 hours with spontaneous reversion. was normal in one patient (B.V-1) at the age of 3 years and abnormal in the other two siblings showing a hypoplastic corpus calosum with absent rostrum and splenium (Figures 3a–c) and several small and tiny hyper-intense signals on T2 and FLAIR located in the pons, in both thalami nuclei, the anterior border of the fourth ventricle, the cortico-spinal tracts, above the third ventricle, and near the tectum (Figure 3d). These lesions did not enhance by gadolinium. In one patient, two consecutive MRI studies performed 18 months apart confirmed confirmation of reherniation based on MRI performed at an unscheduled visit due to patient symptoms, or imaging core lab confirmation of reherniation based on MRI performed at an scheduled visit in patients with ODI ≥40 and positive leg raise sign, or with an adverse event deemed related to reherniation, lumbar/leg pain, or a neurological event (Fig. 2). Index-level reoperations will be defined as any surgical procedure performed at the level of the original herniation, regardless of side or reason, during follow-up. An independent imaging reduced. A severe phenotype with dramatically deteriorating course was described by Antonicka et al,2 dominated by significant cognitive and motor impairment resulting in wheelchair dependence within the first decade and premature death. In addition, MRI was typically abnormal with widely distributed abnormal signals. In this form, life expectancy is typically shortened resulting in premature death within the first two decades of life. Of note, enzyme assessment of mitochondrial OXPHOS complexes both in muscle and fibroblasts typically display expansion is crucial for planning of the treatment and prediction of the functional outcome. With the advent of computed tomography angiography (CTA) in the last decade, spot sign or contrast extravasation has been shown to be an independent predictor of hematoma expansion [5]. However, CTA requires iodine contrast administration that might be harmful in older patients especially those with impairment of renal function. Therefore, scrutinizing plain CT for other possible signs that might have prognostic value is worthwhile for patients with\n",
            "[0.78446704]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which enzyme is inhibited by Varespladib?\n",
            "Refined Query: Varespladib is a drug;  what specific enzyme does it inhibit, and what is the mechanism of this inhibition?  A more precise answer than just naming the enzyme is desired.\n",
            "\n",
            "Combined Answer: established the foundation for the development of inhibitors suitable for clinical testing.16 Subsequently, Lito et al. and Patricelli et al. established the mechanism of KRASG12C inhibition (i.e., trapping the oncoprotein in its inactive state by blocking reactivation through nucleotide exchange).18,19 Sotorasib inhibits KRASG12C by a similar mechanism, but its potency and selectivity were enhanced through the optimization of novel interactions with a previously unexploited surface groove.20 The KRASG12C inhibitor sotorasib has the potential Losigamone is a newer AED that has been investigated as an add‐on therapy for focal seizures. When orally administered, losigamone is well absorbed through the gastrointestinal tract and reaches a peak plasma concentration within two to three hours of administration. Its plasma elimination half‐life is approximately four to seven hours (Luszczki 2009). In two double‐blind, placebo‐controlled, add‐on studies, losigamone has shown possible effects in people with focal epilepsy (Bauer 2001; Baulac 2003). One study tested losigamone at 1200 mg/day headache, somnolence, fatigue, ataxia, nausea, diplopia, abnormal vision and vertigo. No significant clinically pharmacokinetic interactions with other AEDs have been found, which allows the use of losigamone as an add‐on therapy (Bauer 2001; Baulac 2003). is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and often require treatment with two or more AEDs (add‐on therapy). In recent years, many newer AEDs have been investigated as add‐on therapy for focal epilepsy; losigamone is one of these drugs. We wanted to know whether losigamone was an effective and safe treatment for people with focal epilepsy. Study characteristics The evidence is current to E1 (amino acids 1 to 211), E2 (activation domain [AD], amino acids 1 to 168), E3 (amino acids 169 to 433), E4 (ligand-binding domain [LBD], amino acids 212 to 433), E5 (amino acids 93 to 433), and E7 (DNA-binding domain [DBD], amino acids 93 to 211) (Fig. 3A). Dax1 was precipitated strongly with the full-length Esrrb, E3, and E4 regions and weakly with the E2 and E5 regions but not with the E1 and E7 regions (Fig. 3B), suggesting that Dax1 binds to the AD and LBD regions of Esrrb, but a part of the DBD region of Esrrb may act as an inhibition 29.3% of participants receiving losigamone at 1500 mg/day had a 50% or greater reduction in seizure frequency, as compared to 17.2% in those receiving losigamone at 1200 mg/day and 11.8% in the placebo group (Baulac 2003). Generally, losigamone has been shown to be safe and well tolerated. The most commonly reported adverse events are dizziness, headache, somnolence, fatigue, ataxia, nausea, diplopia, abnormal vision and vertigo. No significant clinically pharmacokinetic interactions with other AEDs have been found, which allows the use of achieve near total occupancy and inhibition of KRASG12C over the entire dosing interval. The response with a daily dose of 960 mg appeared to be higher than that across all doses combined. The 960-mg daily dose was advanced to later confirmatory trials. To date, no dose-limiting toxic effects have been observed with sotorasib, even with extended treatment. The majority of patients had some toxic effects, although they were mainly of low-grade. Diarrhea, nausea, vomiting, fatigue, and elevations of aminotransferase levels were the most common of different ITD insertion sequences. Therefore, future studies should examine the efficacy of gilteritinib in the presence of FL using primary AML cells with various ITD mutations. Tyrosine kinase inhibitors are classified into 2 types based on their affinity to receptors. Type I inhibitors such as gilteritinib, midostaurin, and lestaurtinib bind to both the active and inactive forms of FLT3, while type II inhibitors such as quizartinib bind only to inactive FLT3. However, given that both type I and II inhibitors are affected by FL—with the for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review. This is an update of a Cochrane review first published in 2012 (Cochrane Database of Systematic Reviews 2012, Issue 6) and updated in 2015. Towards investigating these aspects, there is a tight relation between a disease and targets, e.g., with regards to the development of animal models or the research in diagnostics, that can help the researchers understand better the disease. The research on targets play a crucial role in turn for the study of sensitivity, selectivity, mutations of genes and biological functions that are connected to the disease. In parallel, the study of related drugs is crucial, because it can provide information on the pathways, mechanisms of action,\n",
            "[0.6507893]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which protein does empagliflozin inhibit?\n",
            "Refined Query: Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.  Therefore, the question should be clarified to ask which specific *transporter* protein empagliflozin inhibits, rather than simply \"which protein\".\n",
            "\n",
            "Combined Answer: it is known that THs enter cells via TH transmembrane transporters, which participate in the influx and efflux of THs into and out of cells. Several classes of TH transmembrane transporter proteins that belong to the family of solute carrier (Slc) transporters have been identified e.g. organic anion transporting polypeptides (OATPs), monocarboxylate transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters with RS, however, lack ABCC2 mutations (14), and the mechanistic basis of RS is unknown. Organic anion transporting polypeptides (OATPs, genes: SLCOs) contain 12 plasma membrane–spanning domains and mediate sodium-independent cellular uptake of highly diverse compounds, including bilirubin glucuronide, bile acids, steroid and thyroid hormones, and numerous drugs, toxins, and their conjugates (15, 16). Human OATP1B1 and OATP1B3 localize to the sinusoidal membrane of hepatocytes and mediate the liver uptake of, among other compounds, many drugs of DJS is in line with the generally accepted paradigm of normal hepatic bilirubin excretion, according to which a unidirectional elimination pathway is postulated: first, uptake of unconjugated bilirubin (UCB) from blood into hepatocytes; subsequent glucuronidation; and finally, secretion of bilirubin glucuronide into bile via ABCC2. Individuals with RS, however, lack ABCC2 mutations (14), and the mechanistic basis of RS is unknown. Organic anion transporting polypeptides (OATPs, genes: SLCOs) contain 12 plasma membrane–spanning domains and numerous drugs, toxins, and their conjugates (15, 16). Human OATP1B1 and OATP1B3 localize to the sinusoidal membrane of hepatocytes and mediate the liver uptake of, among other compounds, many drugs (15–19). Various SNPs in SLCO1B1 cause reduced transport activity and altered plasma and tissue levels of statins, methotrexate, and irinotecan in patients, potentially resulting in life-threatening toxicities (20–24). In a Slco1a/1b–/– mouse model recently generated by our group, the importance of Oatp1a/1b proteins in hepatic uptake and clearance transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters have been localized to the choroid plexus (Mayerl et al., 2012) and their distribution in the choroid plexus differs between species (Wirth et al., 2014). Most TH transmembrane transporters identified to date are promiscuous with respect to the range of metabolites they transport. Only MCT8 has been identified as being specific to transport of THs and Analogous to the mouse data for Oatp1a/1b (25), the extensive glucuronidation of bilirubin in Rotor subjects suggests that OATP1B1 and/or OATP1B3 are not strictly essential for uptake of UCB into the liver. Passive transmembrane diffusion is one likely candidate to take over this process, in hepatocytes and probably many other cell types as well (e.g., ref. 33), but we do not exclude that additional uptake transporters (perhaps OATP2B1) can also contribute to UCB uptake. However, OATP1B1 and/or OATP1B3 probably do contribute to hepatic UCB potentially resulting in life-threatening toxicities (20–24). In a Slco1a/1b–/– mouse model recently generated by our group, the importance of Oatp1a/1b proteins in hepatic uptake and clearance of drugs was confirmed, but the mice also displayed marked conjugated hyperbilirubinemia (25). We therefore hypothesized that sinusoidal Oatps in the normal, healthy mouse liver function in tandem with the sinusoidal efflux transporter Abcc3 to mediate substantial hepatic secretion and reuptake of bilirubin glucuronides and other conjugated compounds fluid-phase or receptor-mediated endocytosis. The general pathway for IgG elimination after SC administration is shown in Figure 1. The contribution of different organs to mAb catabolism is estimated to be 33% for liver, 24% for skin, 16% for muscle, and 12% for intestine (50). An mAb is catabolized into peptides and amino acids primarily by the reticuloendothelial system, which consists of phagocytic cells such as macrophages and monocytes (51). Cells in the body have the ability to take up proteins or macromolecules from the surrounding ligands and cell membrane-bound receptors (60). The liver and kidney are involved predominantly in the metabolism and elimination of small molecule drugs and can lead to changes in PK, possibly affecting the efficacy and toxicity profile in patients with renal and hepatic impairment. Although the liver and kidneys may contribute to catabolism of antibodies, in general, renal or hepatic impairment does not affect mAb elimination (61,62). The large size of a mAb (150 kDa) prevents efficient filtration through the glomerulus and mAb PK is proteins known as TH distributor proteins. Because THs are lipophilic they partition between the lipid phase and the aqueous phase with a ratio of 20,000:1 (Dickson et al., 1987). The binding of THs to TH distributor proteins prevents avid partitioning of THs into the lipid membranes of cells and ensures that there is a sufficiently large pool of TH circulating in the blood (Mendel et al., 1987). In humans, the main TH distributor proteins are albumin, transthyretin (TTR) and thyroxine-binding globulin (TBG), all of which are synthesized by\n",
            "[0.6663763]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What symptoms characterize the Muenke syndrome?\n",
            "Refined Query: Describe the typical symptoms manifested in individuals diagnosed with Muenke syndrome, focusing on the key clinical features that distinguish this condition from other craniosynostosis syndromes.\n",
            "\n",
            "Combined Answer: The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Three members of a large consanguineous Indian family (figure 1A), affected by axonal neuropathy (table 1) and optic atrophy, were identified at the London Royal Free Hospital. Case 3 was first seen at the age of 35 years and then again at the age of 51 years. She is the first cousin of Cases 1 and 2 and presented as a child with delayed milestones, later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 and 22q11.2 microdeletion syndrome33, the data that two patients in our cohort required surgery to correct extreme GERD raise the possibility that this GI condition may be related to CS. In addition, relatively low weight, particularly as the boys develop, appears to be a common somatic symptom. This finding likely warrants further clinical and pre-clinical research. With regard to additional behavioral symptom patterns that should be emphasized, the hyperkinetic behavior in patients with CS seems fairly pervasive. Interestingly, the related (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause criteria, where CMT1 defined as ‘demyelinating’ and CMT2 as ‘axonal’.2 CMT can be associated with a variety of additional clinical features. The association between hereditary motor and sensory neuropathy and optic atrophy, also known as CMT6 (OMIM #601152), has been reported in families with different modes of inheritance, comprising over 50 cases.3–8 The clinical manifestations of CMT6 consist of distal muscle weakness and wasting starting in the lower limb with reduced reflexes and glove and stocking sensory loss. There is progressive in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were remarkably similar with only mild deterioration of her clinical features. She had no dysmorphic features, but severe bilateral optic atrophy and static but significant cognitive problems. She had a brisk jaw jerk and a pout reflex. Marked distal symmetrical weakness and wasting affecting the limbs. In contrast to her cousins, tone in her upper and\n",
            "[0.6517896]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List all reported treatment options for anxiety in autism spectrum disorder.\n",
            "Refined Query: What established treatments, including medication and therapies, are documented in peer-reviewed research as effective for managing anxiety symptoms specifically within the autistic population?\n",
            "\n",
            "Combined Answer: water. Many children also sat with arms in flexed posture. The majority of patients displayed autistic symptoms. Six out of 14 (43%) patients were previously diagnosed with autism clinically. Three patients (1, 2 and 3) were assessed with the ADI-R and all met criteria for autism. Evident symptoms included absence of social play or interest in sharing, lack of a variety of facial expressions to communicate and poor eye contact. Patient 1 did not point to express interest, nod or shake his head to communicate. Patient 2 had the least severe Approximately 100% of patients had ataxia/unsteady gait (1 patient is currently non-ambulatory). For behavioral features, a majority were reported to have a happy disposition (100%) and unprovoked laughter (64%). For minor AS criteria, all had seizures and drooled, 92% were microcephalic, 64% had sleep problems and 29% reported a fascination with water. Many children also sat with arms in flexed posture. The majority of patients displayed autistic symptoms. Six out of 14 (43%) patients were previously diagnosed with autism clinically. Three sharing, lack of a variety of facial expressions to communicate and poor eye contact. Patient 1 did not point to express interest, nod or shake his head to communicate. Patient 2 had the least severe autistic symptoms of the patients directly assessed; yet he did not engage in play with other children. He regularly uses other’s hands as a tool (e.g. to turn a doorknob). Patient 3 had unusual preoccupations and sensory interests involving laundry baskets, metal objects and windows. We assessed nine patients with the SCQ. Patient scores ranged biologic level. A sizable proportion of boys with CS have received a previous diagnosis of autism, demonstrate autistic symptoms, and/or meet criteria for autism on standardized examinations. While we report here that a large percentage of patients who were tested using standardized assessments (ADI-R or SCQ) met criteria for autism, this result needs to be interpreted with caution given the challenges of observing a full range of autism symptoms in participants who are non-verbal and have low intellectual and adaptive functioning. However, in to turn a doorknob). Patient 3 had unusual preoccupations and sensory interests involving laundry baskets, metal objects and windows. We assessed nine patients with the SCQ. Patient scores ranged from 14 to 28, with an average score of 23.2 (autism cutoff score is 15). Eight out of nine participants tested (89%) met autism criteria. Parent responses consistently reported poor eye contact, use of a caregiver’s body parts as tools, unusual sensory interests and a lack of reciprocal play and/or social interest. contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Wild-type and D3-knockout mice were exposed to chronic unpredictable stress for up to 26 days, treated daily with vehicle, imipramine (20 mg/kg), aripiprazole (1 and 5 mg/kg), or cariprazine (0.03, 0.1, 0.2, and 0.4 mg/kg), and tested in behavioral assays measuring anhedonia and anxiety-like behaviors. samples from autistic individuals compared to matched controls [24, 25], suggesting that dysregulation of miRNAs could be related to autism. Furthermore, miR-137 has been recently implicated in ASD via a genome-wide meta-analysis that considered single nucleotide polymorphism data across five psychiatric disorders (ASD, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia), and found an association between mir-137 and both schizophrenia and ASD [26]. Lastly, Devanna and Vernes provided Review question This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (2015, Issue 12) on 'Losigamone add‐on therapy for focal epilepsy'. We reviewed the evidence about the efficacy and safety of losigamone when used as an add‐on therapy for focal epilepsy. We found two studies. Background Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated as add‐on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review. This is an update of a Cochrane review first published in 2012 (Cochrane Database of Systematic\n",
            "[0.44780734]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List adenosine A2A receptor antagonists that are used for Parkinson's disease treatment.\n",
            "Refined Query: What adenosine A2A receptor antagonists are currently approved or in clinical trials for treating Parkinson's disease symptoms, and what is their mechanism of action in improving motor function?\n",
            "\n",
            "Combined Answer: of adenosine residues [1]. Most functional editing sites described so far are found in transcripts for neuronal transporters and channel proteins in the brain [2]. Herein, editing is critical for normal brain development and function. Specifically, ADAR-mediated editing of the GluA2 subunit of the mammalian AMPA receptor is an essential event [3]. Generally, inosine is interpreted as guanosine by the translation machinery, which may lead to codon substitutions in protein-coding sequences. Almost 100% of the human GluA2 transcripts are edited Generally, inosine is interpreted as guanosine by the translation machinery, which may lead to codon substitutions in protein-coding sequences. Almost 100% of the human GluA2 transcripts are edited at codon position 607 which leads to a substitution of glutamine (CAG codon) with arginine (CIG codon) in the polypeptide chain. The introduction of a positive charge reduces calcium permeability in the mammalian AMPA receptor. In human, aberrant editing of the Q/R sites has been associated with death of motor neurons [4]. However, the vast majority are executed by two specific classes of RNA binding proteins (RBPs) that interact with their respective RNA targets: Adenosine deaminase acting on RNA (ADAR) catalyses A→I conversions, whereas APOBEC1 family members catalyse C→U conversions. ADAR mediates the more frequent A→I editing by binding to double-stranded RNA and subsequent hydrolytic deamination of adenosine residues [1]. Most functional editing sites described so far are found in transcripts for neuronal transporters and channel proteins in the brain [2]. Herein, editing is critical We report the first placebo-controlled, double-blind, randomized trial that investigated the effects of activin type II receptors blockade in patients with COPD and evidence of low body weight or muscle mass. Bimagrumab substantially increased thigh muscle volume and total lean body mass, but this did not translate into improved muscle function or functional performance. The trial was funded by a National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) PBTC U01 Grant: 2UM1CA081457 (UM1) and by the American Lebanese Syrian Associated Charities (ALSAC). ALSAC provides funding and infrastructure support for the OBDMC personnel but had no involvement in trial design, patient recruitment, data collection, analyses or manuscript preparation. CTEP provided input on study design, approved the trial and its amendments, served as the IND sponsor and reviewed the manuscript prior to submission. CTEP was Pharmaceuticals, Inc., Sarepta Therapeutics, Valerion Therapeutics, the NIH NINDS and NIAMS, Spinal Muscular Atrophy Foundation, Muscular Dystrophy Association, and the Slaney Family Fund for SMA. S. Iannaccone reports no disclosures relevant to the manuscript. J. Montes serves as a consultant to Ionis Pharmaceuticals, Inc. D. De Vivo has served as a consultant to Roche Pharmaceuticals, Ultragenyx Therapeutics, and Sarepta Therapeutics. He receives research support from the NIH, DOD, Colleen Giblin Foundation, Milestones for Children, Glut1 RNA editing is the post- or co-transcriptional modification of RNA nucleotides from their genome-encoded sequence. The most common type of editing in metazoans is the deamination of adenosine into inosine (A-to-I) catalyzed by the adenosine deaminase acting on RNA (ADAR) family of enzymes (1). ADAR enzymes bind double-stranded regions of RNA molecules and deaminate adenosine into inosine, which is subsequently recognized as guanosine by the cellular machinery. ADARs perform critical functions in the nervous system (2), and knockout of ADARs in Antibody Resource for MANDSY106. The UCL MRC Neuromuscular Centre Biobank is also acknowledged. F.M. is supported by the Great Ormond Street Children's Charity. J.E.M. is funded by a Wellcome Trust University Award. All other authors except the listed those below do not report any disclosures. Prof Muntoni has served on scientific advisory boards for Genzyme, AVI BioPharma, Inc., GSK; he serves on the editorial board of Neuromuscular Disorders and Neuropediatrics; he receives research support from AVI BioPharma, Inc., the European Union, the showed no significant difference from Bl6 controls (Fig. 6e). Despite the minimal (<3%) expression of dystrophin seen in some Dup2 muscles by PDN (Fig. 5c), treatment of the Dup2 muscles by PDN alone does not result in a significant amelioration in any of these measures of muscle physiology (Fig.6). Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial - PMC\n",
            "[0.6436038]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the clinical indication of cardiac T1 mapping magnetic resonance?\n",
            "Refined Query: Cardiac T1 mapping MRI assesses myocardial tissue characteristics.  Specifically, it helps diagnose conditions affecting myocardial composition, such as myocardial fibrosis, edema, and iron overload, by quantifying T1 relaxation times, aiding in the diagnosis and management of heart disease.\n",
            "\n",
            "Combined Answer: Inherited cardiac conditions (ICCs) represent a major health burden with a combined prevalence of ~1%1. Genetic testing is recommended to support the management of many ICCs, with roles in diagnosis (particularly valuable for identification of at-risk relatives), prognostication, and therapeutic stratification. The principle challenge in genetic testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data (“better,” “worse,” or “the same”) and were not blinded to patients or timepoints [19]. Images were assessed for quality and comparable anatomical sites at all time points and reviewer consensus was reported. Coronal spin-echo T1- and T2-weighted MR images of both femurs were obtained for assessment of focal marrow lesions, infarcts, and dark marrow. Marrow infiltration, or “dark marrow,” was evaluated on MR images using a modification of the Rosenthal method in which 11 anatomical zones in the lower extremity are numbered according to the The primary endpoint was stratum-specific objective response rate assessd by the local site and sustained for at least 8 weeks. Responses were based on 2-dimensional MRI evaluation. A complete response was defined as complete tumor disappearance on T2/fluid attenuation inversion recovery (FLAIR) images, no new lesions and disappearance of all enhancement on T1 post-contrast imaging. PR was defined as a ≥50% tumor reduction on T2/FLAIR. Stable disease (SD) was defined as neither sufficient increase or reduction to qualify as PR or progressive [7,8]. These functional measures are limited to only ambulatory measurements and cannot provide quantitative and objective analyses of muscle tissues. Therefore, medical imaging techniques are a crucial diagnostic tool for suspected muscular disorder. Among all imaging modalities, ultrasound imaging offers a real-time, noninvasive, and point-of-care examination to measure muscle size, structure, movement, and function [9]. To characterize tissues, ultrasound imaging biomarkers must be developed to identify neuromuscular disease severity and in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor desensitization, internalization, and degradation of the cardiac S1P1R have been proposed to explain the time‐related attenuation of heart‐rate effects.1, 17, 33 In a previous phase 1 single‐ascending‐dose and multiple‐ascending‐dose study with ozanimod, a mild dose‐dependent, first‐dose reduction in HR was observed, which was attenuated with an As well as publically available data for both cases and population controls, CardioClassifier incorporates data from three highly-curated in-house datasets sequenced with the Illumina TruSight Cardio sequencing panel1. Counts from 877 DCM, 327 HCM cases, and 1383 healthy volunteers, all rigorously phenotyped using cardiac MRI, are used to annotate variants in genes associated with these disorders. Some genomic regions, especially those that are repetitive or with high GC content, are not fully covered by standard exome sequencing used by major backscattered analysis [11,13] to detect clues associated with muscle pathology. Recent studies have indicated that instantaneous frequency [14], envelope statistics [15], and information certainty [16] of ultrasound backscattered signals are sensitive to variations in tissue microstructures and beneficial for the assessment of DMD severity and ambulatory function. Notably, quantitative ultrasound analysis requires rigidly fixed settings or a dedicated system for hardware- and software-related reference values during scanning and data have been conditionally approved for their potential effect on muscle strength and function [6]. Therefore, noninvasive approaches that reliably evaluate DMD are required to support different integrated care plans. Functional rating scales are commonly used for DMD assessment, including the 6 min walk test and the North Star Ambulatory Assessment [7,8]. These functional measures are limited to only ambulatory measurements and cannot provide quantitative and objective analyses of muscle tissues. Therefore, medical imaging techniques are a Internationally-adopted variant interpretation guidelines from the American College of Medical Genetics and Genomics (ACMG) are generic and require disease-specific refinement. Here we developed CardioClassifier (www.cardioclassifier.org), a semi-automated decision-support tool for inherited cardiac conditions (ICCs). The mechanical properties of isolated ventricular cardiomyocytes were assessed using a video-based edge detection system (IonOptix) as previously described26.\n",
            "[0.7176734]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 277.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1209.09ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1007.54ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1108.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1058.80ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2167.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 831.98ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1284.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1033.00ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1108.86ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1132.78ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1158.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1031.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does the protein mTOR regulate autophagy?\n",
            "Refined Query: The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase known to play a crucial role in cellular growth and metabolism.  Does mTOR's activity directly stimulate or inhibit autophagy, a cellular process essential for degrading damaged organelles and proteins, and how does this regulation affect cellular health and disease?\n",
            "\n",
            "Combined Answer: are involved in RSV-initiated beneficial function in cells. mTOR (mammalian target of rapamycin) is a member of the phosphatidylinositol 3-kinase (PI3K)-related protein kinase subfamily that plays a critical role in the regulation of various cellular events such as cell growth and proliferation (5, 6). mTOR exists in two distinct complexes, TORC1 and TORC2, which differ in subunit compositions and biological functions (7). The rapamycin-sensitive mTORC1, which consists of five components, including mTOR, Raptor (regulatory-associated protein RSV may indirectly promote the interaction between mTOR and DEPTOR by binding to an auxiliary protein. Similar to the latter model, rapamycin has been shown to impair the association between mTOR and Raptor through binding to FKBP12 (43). It is also possible that RSV may activate a signaling pathway that leads to a chemical modification of either mTOR or DEPTOR, thus promoting the interaction between these proteins. Further studies will be needed to test these possibilities. In summary, we have provided evidence showing that RSV inhibits and TORC2, which differ in subunit compositions and biological functions (7). The rapamycin-sensitive mTORC1, which consists of five components, including mTOR, Raptor (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with Sec13 protein 8; also known as GβL), PRAS40 (proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP domain-containing and mTOR-interactive protein) (8), regulates protein synthesis and cell growth by phosphorylating downstream target proteins such as p70 ribosomal S6K1 (S6 kinase 1) and the eukaryotic mechanism for the life span extension and cancer prevention properties of RSV (1). Several targets of RSV such as AMP-activated protein kinase (AMPK), Akt, and NF-κB have also been identified (2–4). However, it remains controversial as to whether activation of these signaling pathways is Sirt1-dependent and whether additional targets and mechanisms are involved in RSV-initiated beneficial function in cells. mTOR (mammalian target of rapamycin) is a member of the phosphatidylinositol 3-kinase (PI3K)-related protein kinase subfamily that plays a and mTOR-interactive protein) (8), regulates protein synthesis and cell growth by phosphorylating downstream target proteins such as p70 ribosomal S6K1 (S6 kinase 1) and the eukaryotic initiation factor 4E-BP1 (5, 9). The rapamycin-insensitive TORC2, which comprises six components, including mTOR, Rictor (rapamycin-insensitive companion of mTOR), mSIN1 (mammalian stress-activated protein kinase-interacting protein 1), Protor-1 (protein observed with Rictor-1), mLST8, and DEPTOR (8), functions as an Akt kinase that phosphorylates Ser473 of Akt at Ser473 (Fig. 2B), which is consistent with the finding that the binding of DEPTOR to mTOR suppresses both mTORC1 and mTORC2 activities (19). How RSV promotes the binding of DEPTOR to mTOR remains unknown. One possibility may be that RSV directly interacts with mTOR or DEPTOR, leading to enhanced interaction between these two proteins. Alternatively, RSV may indirectly promote the interaction between mTOR and DEPTOR by binding to an auxiliary protein. Similar to the latter model, rapamycin has been shown to impair the association between mTOR or DEPTOR, thus promoting the interaction between these proteins. Further studies will be needed to test these possibilities. In summary, we have provided evidence showing that RSV inhibits leucine-stimulated mTOR signaling via an Akt-independent mechanism. In addition, we have demonstrated that RSV enhances the interaction between mTOR and its negative regulator, DEPTOR, thus uncovering a novel mechanism by which RSV negatively regulates leucine-stimulated mTOR signaling in cells. (Fig. 2C), suggesting the presence of a distinct mechanism underlying the inhibitory effect of RSV on mTOR. We found that leucine activated mTOR signaling in C2C12 cells but had little effect on Akt activation (Fig. 2D). In addition, suppression of PDK1/Akt activity had little effect on leucine-stimulated S6K and 4E-BP1 phosphorylation (Figs. 2E). These results suggest that inhibition of the PI3K/PDK1/Akt signaling pathway is dispensable for the negative regulation RSV-promoted of leucine-stimulated mTOR signaling. There is some evidence mTOR signaling via a Sirt1-independent mechanism. In addition, we found that disruption of PDK1/Akt signaling and TSC1/2 expression has no significant effect on the inhibitory effect of RSV on leucine-stimulated mTOR activation. Furthermore, we found that RSV promotes the association between mTOR and DEPTOR, an inhibitor of mTOR, thus uncovering a novel mechanism by which RSV inhibits mTOR signaling. leucine-stimulated mTOR signaling by a mechanism independent of the AMPK signaling pathway. Consistent with this view, we found that RSV treatment markedly increased the association between mTOR and DEPTOR (Fig. 4B). Because the binding of DEPTOR to mTOR has been shown to inhibit mTOR activity (19, 44), this finding suggests that the enhanced interaction with DEPTOR could be a mechanism by which RSV inhibits insulin- and leucine-induced mTORC1 signaling. Consistent with this, suppressing DEPTOR expression levels by RNAi greatly diminished the\n",
            "[0.7215322]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the mains risk factors of metabolic syndrome?\n",
            "Refined Query: Metabolic syndrome is a cluster of conditions increasing the risk of heart disease, stroke, and diabetes.  What are the key underlying factors – such as abdominal obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels – that contribute to its development and progression?\n",
            "\n",
            "Combined Answer: fatty acids (FFAs) (21, 165). Circulating levels of FFAs are increased in preeclampsia, contributing to insulin resistance and altered lipid metabolism in this disorder (165, 166). Several metabolic disorders are also associated with systemic inflammation and, as discussed previously, there is pathological resemblance between preeclampsia and the components of the metabolic syndrome (21). Obesity is a metabolic disorder characterized by systemic inflammation and an increased risk of developing preeclampsia. In obese individuals, adipose tissue of the metabolic syndrome (21). Obesity is a metabolic disorder characterized by systemic inflammation and an increased risk of developing preeclampsia. In obese individuals, adipose tissue is suggested to be a potent source of pro-inflammatory stimuli because of the ability of adipocytes to secrete the pro-inflammatory cytokines, such as TNF-α and IL-6 (21). Besides promoting inflammation, these cytokines also advance atherogenesis, the underlying pathological process in atherosclerosis (167). Atherosclerosis is an inflammatory disorder have previously been published6 as well as in separate case reports2–4,19,20. Supplementary Table 1 summarizes the clinical characteristics of the patients and their previously identified genetic diagnoses. Patient inclusion criteria consisted of (1) a confirmed or potential neurodevelopmental disorder and (2) a metabolic phenotype. A metabolic phenotype could be reflected by (1) a pattern of abnormal metabolites in urine, blood or CSF, (2) abnormal results on biochemical functional studies or (3) typical abnormalities in clinical history or cytokines, specifically TNF-α and IL-6, generate widespread dysfunction of the maternal vascular endothelium that could result in hypertension (17). Increased pro-inflammatory cytokines also affect metabolic changes in preeclampsia. For instance, elevated levels of TNF-α induce insulin resistance and stimulate the adipocytes to release more free fatty acids (FFAs) (21, 165). Circulating levels of FFAs are increased in preeclampsia, contributing to insulin resistance and altered lipid metabolism in this disorder (165, 166). Several metabolic of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes of obesity and indicate targets for therapeutic intervention. These disorders include obesity syndromes such as Prader Willi syndrome and Bardet–Biedl syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic features or other developmental abnormalities. Gaining insight into genetic causes through the study of obesity-related disorders has provided a more comprehensive picture of the mechanisms that control food intake and energy balance related to the development of obesity (e.g., SIM1). Deletions in chromosome 1p21.3 have been reported in a total of uncontrolled severe hypertension, acute kidney injury, liver hematoma, liver rupture, and cardiac failure as well as severe complications also involving the fetus by possible abruption of placental membranes and stillbirth (5). A 12-fold increase in the risk of cardiovascular disease has been found in women with a history of preeclampsia and metabolic disease, highlighting a relationship between preeclampsia and cardiovascular disease (10). Preeclampsia is characterized by two major subtypes: the maternal subtype also known as the metabolic Obesity is a complex disease that results from the interactions of a variety of hereditary and environmental factors. Heritability for obesity is high (typically 0.4 to 0.7) [1], comparable to that of other complex, polygenic diseases such as autism [2]. In most individuals, the genetic basis for obesity is complex and likely to involve the interaction of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes inborn metabolic disorder. A search for RS subjects by part of the present group led to collaboration with another team already working on mapping of the RS gene(s). In an unbiased approach, scanning the whole genome, we mapped the genomic candidate intervals for RS in 11 RS index subjects from 8 different families, 4 Central European (CE1–CE4), 3 Saudi-Arabian (A1–A3), and 1 Filipino (P1) (Figure 4A and Supplemental Table 2). Homozygosity mapping identified a single genomic region on chromosome 12 for which 8 tested index subjects and no and IL-6 (21). Besides promoting inflammation, these cytokines also advance atherogenesis, the underlying pathological process in atherosclerosis (167). Atherosclerosis is an inflammatory disorder associated with endothelial dysfunction, similar to preeclampsia, and supports the hypothesis that a disrupted immune system, specifically a pro-inflammatory bias, is associated with metabolic disorders (167). Obese individuals thus have increased susceptibility to preeclampsia during pregnancy because of an already increased inflammatory response\n",
            "[0.61133844]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which multiple kinase inhibitors are used in cancer therapy?\n",
            "Refined Query: I'm looking for a list of FDA-approved multiple kinase inhibitors used in cancer treatment, specifying the types of cancer they target and if possible, mentioning any notable side effects.\n",
            "\n",
            "Combined Answer: We used a recently published large-scale oncology screen produced by Merck & Co. (O’Neil et al., 2016) to train our models. The dataset comprises 23 062 samples, where each sample consists of two compounds and a cell line. Thereby, the dataset covers 583 distinct combinations, each tested against 39 human cancer cell lines derived from 7 different tissue types (see Supplementary Table S1). Pairwise combinations were constructed from 38 diverse anticancer drugs (14 experimental and 24 approved, see Supplementary Table S2), of which 22 were finding synergistic drug pairs for a particular cancer type is important for improving efficacy of anticancer treatment. Until recently, effective drug combinations were proposed based on clinical experience. However, ‘trial-and-error’ is time-, labor- and cost-intensive. Furthermore, it might expose patients to unnecessary or even harmful treatment (Day and Siu, 2016; Pang et al., 2014). Another strategy to identify synergistic drug pairs without harming patients is high-throughput screening (HTS). A large number of measurements can be C virus infections (Clercq, 2007) as well as fungal (Chen et al., 2016; Groll and Tragiannidis, 2009) and bacterial infections (Tamma et al., 2012; Worthington and Melander, 2013). However, drug combination effects can be adverse and even lead to shorter progression free survival of cancer patients (Hecht et al., 2009; Tol et al., 2009). Therefore, finding synergistic drug pairs for a particular cancer type is important for improving efficacy of anticancer treatment. Until recently, effective drug combinations were proposed based on clinical that future studies should incorporate functional outcomes such as visual acuity, quality of life and motor function, since these morbidities are more common than mortality.(19) Therefore, the activity of selumetinib is best evaluated in the context of toxicity, functional outcomes and QOL. As a MEK-1/2 inhibitor, selumetinib has the benefit of avoiding the adverse event of paradoxical activation of the MAPK pathway seen when BRAF-KIAA1549 aberrant pLGG tumors are treated with direct BRAF inhibitors.(30) Overall, the toxicity profile of discrepancy between our results and those of previous studies may be attributable to the specialised role of dCK in the activity of anticancer drugs, and to the fact that other studies have employed differently subtyped AML populations. Indeed, to screen outcome predictors, other research groups have employed mixed populations of AML patients treated with non-unified regimens, whereas in this study we used more focused populations in the aspect of disease type and chemotherapy regimen. Additionally, our previous in vitro study showing that dCK et al., 2016) with more than 20 000 synergy measurements was performed, which offers the possibility to evaluate computational methods for predicting novel drug combinations. The dataset covers 38 drugs and 39 cancer cell lines. Therefore, the performed HTS covered 83% of the possible two drug combinations. Both experimental and approved drugs were tested. The used cancer cell lines originated from seven different tissue types. Previous methods were developed and optimized for small datasets. However, methods developed for limited data might Atlas Research Network (TCGARN) et al. [76], Walter et al. [77], Beroukhim et al. [73], Bullinger et al. [78], Taylor et al. [79], TCGARN et al. [80], Curtis et al. [81], TCGARN et al. [82], TCGARN et al. [83], TCGARN et al. [84], Nik-Zainal et al. [85], Robinson et al. [86], Walker et al. [87], Zhang et al. [88], Holmfeldt et al. [89], TCGARN et al. [90], and Weischenfeldt et al. [91] representing 52 different forms of cancer, each including between 2 and 148 cancerCNA regions and covering 0.03% to 90.15% of the genome (Table S1). To avoid The results reported here are based upon the data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We wish to thank Eleonora Cappelli, Paola Bertolazzi, Paolo Atzeni, and Riccardo Torlone for supporting this work. Chromosomal rearrangements of ALK (anaplastic lymphoma kinase) are detected in 3–7% of NSCLCs (1, 2). These rearrangements result in constitutively active ALK fusion proteins with potent transforming activity (2, 3). Lung cancers with ALK rearrangements are highly sensitive to ALK tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to ALK kinase activity. Based on early phase studies, the multi-targeted tyrosine kinase inhibitor (TKI) crizotinib was approved by the FDA in 2011 to treat patients with advanced NSCLC are addicted to ALK kinase activity. Based on early phase studies, the multi-targeted tyrosine kinase inhibitor (TKI) crizotinib was approved by the FDA in 2011 to treat patients with advanced NSCLC harboring ALK rearrangements (1). However, despite a high response rate of 60% in ALK-rearranged NSCLC, most patients develop resistance to crizotinib, typically within one to two years. Studies of ALK-rearranged lung cancers with acquired resistance to crizotinib have identified ALK fusion gene amplification and secondary ALK tyrosine kinase (TK)\n",
            "[0.6275304]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Has proteomics been used in the study of Pick's disease?\n",
            "Refined Query: Has proteomic analysis been employed to identify differentially expressed proteins in Pick's disease brain tissue or cerebrospinal fluid,  potentially revealing novel biomarkers or therapeutic targets for this neurodegenerative disorder?\n",
            "\n",
            "Combined Answer: We would like to thank the Department of Neuropathology, Heidelberg University and the Genomics and Proteomics Core Facility of the German Cancer Research Center (DKFZ) for their excellent technical support as well as one of their funding sources, A Kids’ Brain Tumour Cure PLGA Foundation. We would also like to acknowledge the Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748). 2) may also be involved in the beneficial effects of these compounds in FRDA and HD, and other HDAC interacting proteins may be impacted by the compound. To this end, we synthesized activity-based profiling probe (ABPP) versions of one of our HDAC inhibitors (compound 106), and in the present study we used a quantitative proteomic method coupled with multidimensional protein identification technology (MudPIT) to identify the proteins captured by the ABPP 106 probe. Nuclear proteins were extracted from FRDA patient iPSC-derived neural stem (www.glennmorris.org.uk/mabs.htm). The EU BIO-NMD project (n. 241665 to AF and CAS), and the Duchenne Parent Project Italy (DMD Diagnostics Project) to A.Ferlini, are acknowledged. Thanks are also due to Carmelo Rodolico (Department of Neuroscience, University of Messina, Italy), Paola Rimessi, Marina Fabbri and Matteo Bovolenta (University of Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass with multidimensional protein identification technology (MudPIT) to identify the proteins captured by the ABPP 106 probe. Nuclear proteins were extracted from FRDA patient iPSC-derived neural stem cells, and then were reacted with control and ABPP 106 probe. After reaction, the bound proteins were digested on the beads, and the peptides were modified using stable isotope-labeled formaldehyde to form dimethyl amine. The selectively bound proteins determined by mass spectrometry were subjected to functional and pathway analysis. Our findings Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative condition characterized by aetiologically diverse pathomechanisms, which ultimately results in loss of upper and lower motor neurons, paralysis and death. In a rapidly growing group of genes mutated in ALS the most represented are the genes encoding proteins directly or indirectly involved in RNA metabolism [1-3]. Structural and functional studies of ALS-associated proteins and their disease-linked variants have significantly contributed to our current understanding of on the manuscript and Raymond Poot (CSC, London) for helpful discussions. We are grateful to Gerd Blobel (Children's Hospital of Philadelphia) for exchanging prepublication data. This work has been supported by the Netherlands Research Organization (NWO), the European Union (grant HPRN-CT-2000-00078), the NIH (grant RO1 HL 073455-01) and the Netherlands Proteomics Center. involved in RNA metabolism [1-3]. Structural and functional studies of ALS-associated proteins and their disease-linked variants have significantly contributed to our current understanding of the mechanisms of disease development and progression. Characterization of pathological signatures for each ALS-associated protein is crucial in delineating common pathways in the disease pathogenesis and eventually understanding how altered metabolism of proteins with diverse functions results in the same clinical phenotype. Recently, using exome in ALS only slightly compromise the protein structure allowing normal development of the nervous system, but nevertheless are sufficient to trigger a severe neurodegenerative disorder in the adulthood. Our studies in vitro and in vivo suggested that altered protein stability and hence its increased levels may be behind this effect. Interestingly, one ALS patient with CREST mutation also carried an amino acid substitution in OPTN gene [5]. It is plausible that in this case the presence of both mutations was necessary for manifestation of the In an effort to better understand the molecular drivers of synaptic and neurophysiologic dysfunction in Alzheimer’s disease (AD), we analyzed neuronal gene expression data from human AD brain tissue to identify master regulators of synaptic gene expression. as shown in a previous study.7 While our primary interest is identification of targets of 106 that might be involved in regulation of the FXN gene in FRDA, an unbiased proteomic approach should also identify the broader targets of 106 and their interacting proteins. In the present study, we used a dimethyl stable isotope-labeling approach coupled with multidimensional protein identification technology (MudPIT)15 to quantitatively identify the proteins specifically captured by the ABPP 106 probe under nondenaturing conditions compared with the\n",
            "[0.7604687]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are there any urine biomarkers for bladder cancer diagnosis?\n",
            "Refined Query: Researching bladder cancer diagnosis often involves exploring urine biomarkers.  Are there currently established, reliable urine-based markers that can accurately detect bladder cancer, differentiating it from benign conditions, and improving early diagnosis rates?\n",
            "\n",
            "Combined Answer: To identify ideal biomarkers and therapeutic targets for PC, we first analyzed 26 candidate T-UCRs that were upregulated in PC based on a microarray analysis [13]. To validate the results obtained by a microarray analysis, we examined the expression of these 26 T-UCRs by quantitative real-time polymerase chain reaction (qRT-PCR) using 12 PC tissues and 8 non-neoplastic prostate tissues (Supplementary Figure 1). The mean expression level of each T-UCR was calculated, and the ratio of tumor/non-neoplastic prostate (T/N ratio) was determined upregulated in both PC tissues and cell lines. One recent study reported a T-UCR signature that was overexpressed in PC tissue through a microarray analysis using 57 PC and 7 non-neoplastic prostate tissues; however, Uc.63+ was not chosen as a hopeful candidate. The actual strategy we applied in this study was to validate the expression of 26 T-UCRs with qRT-PCR by referring to the signatures reported by Hudson et al [13], which enabled us to focus on Uc.63+, and its functional roles in PC were quite consistent with those determined in a higher than that in the pancreas (Figure 1B). In this sample set, the expression of Uc.63+ was significantly associated with high Gleason score (P = 0.007) and high prostate-specific antigen (PSA) level (P < 0.001) (Figure 1C). To further investigate the usefulness of Uc.63+ as a serum biomarker for PC, we examined the expression of Uc.63+ in the serum of 10 patients with benign prostatic hyperplasia (BPH), 24 patients with primary PC, and 45 patients with metastatic PC by droplet digital PCR (ddPCR). Representative images of ddPCR are shown algorithms for pre-processing, quality-control, normalization and copy number variation detection. A series of reporting and data visualization methods support exploratory analyses. To demonstrate its utility, we apply it to a new dataset of 96 genes profiled on 41 prostate tumour and 24 matched normal samples. and high uc.189 (HR, 0.067; 95% CI, 0.027–0.165; P = 0.000) predicted poor prognosis. Meanwhile, in multivariate analysis for EAC, stage, high uc.189 (HR, 0.015; 95% CI, 0.005–0.046; P = 0.000), and tumor grade predicted poor prognosis.These results showed the detection of uc.189 in tissues of gynecological oncology may provide new information to help in early diagnosis and prognostic evaluation of gynecological cancers, even though the molecular function of uc.189 in those cancers remains unknown. Uc.189 may target to THAP11 according to effect of selected false-positive filtering parameters, namely, the number of supporting reads and read mapping qualities (Methods). Calculations of true-positive (TP) and false-positive (FP) rates, based on unmasked regions of a known synthetically generated tumor's “truth” set (Ewing et al. 2015), for multiple combinations of parameter sets for the individual, intersected, and combined filtered call sets, is plotted on receiver operating characteristic (ROC) curves (Fig. 4B). Comparison of unfiltered, novel calls reveals comparable TP but calls while mitigating against a significant portion of false positives (Cantarel et al. 2014). This exercise also serves as a case study, showing the creation of expert knowledge and experience that investigators may wish to capture for subsequent analyses, such as maximizing sensitivity for discovery or specificity for diagnostic purposes. Users can then provide these optimal parameter values as previously described to perform a complete run. A similar approach was used to process WGS tumor/normal matched pairs from more than 10 different in human cancers, and some of the T-UCRs supposedly have functional roles in cancer biology, which implied that T-UCRs could provide valuable molecular markers and/or therapeutic targets. In the work presented here, we identified the signature of T-UCRs that were differentially expressed in PC and extensively studied T-UCR Uc.63+ as it was significantly upregulated in both PC tissues and cell lines. One recent study reported a T-UCR signature that was overexpressed in PC tissue through a microarray analysis using 57 PC and 7 non-neoplastic The results reported here are based upon the data generated by the TCGA Research Network: http://cancergenome.nih.gov/. We wish to thank Eleonora Cappelli, Paola Bertolazzi, Paolo Atzeni, and Riccardo Torlone for supporting this work. validation study using qRT-PCR disclosed that the expression of miR-130b was robust both in PC tissues and in non-neoplastic prostate tissues, whereas miR-605 was not detectable in either of them (data not shown). Therefore, we focused on miR-130b. A higher expression of miR-130b in LNCaP cells was detected in comparison with that in DU145 or PC3 cells (Figure 5B). Furthermore, we investigated the expression of miR-130b in PC tissues and non-neoplastic prostate tissues by qRT-PCR and found that the expression of miR-130b inversely and\n",
            "[0.54242355]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List types of avoided words in bacterial genomes\n",
            "Refined Query: What specific words or word patterns, representing potential artifacts or biases, are commonly avoided when analyzing and annotating bacterial genomes?  This includes considering both sequence-level and annotation-level avoidance.\n",
            "\n",
            "Combined Answer: tool oriented towards the systematic search for avoided words is particularly useful for in silico genomic research analyses. The search for absent words is already undertaken in the recent past and several results exist on the application and computation of such words [3–6]. However, words which may be present in a genome or in genomic sequences of a specific role (e.g., protein coding segments, regulatory elements, conserved non-coding elements etc.) but they are strongly underrepresented—as we can estimate on the basis of the frequency of bacterial genomes were considered. Also note that k might change when considering eukaryotic genomes, the complex dynamics and function of which might impose a more demanding analysis. The authors in [10–12] have studied the concept of unusual words—based on different definitions than the ones Brendel et al. use for expectation and variance—focusing on the factors of a string, whereas based on Brendel et al. definitions, we consider here any word over the alphabet. In an experiment with a prokaryote, we computed the set of avoided words for k=6 (hexamers) and ρ=-10 in the complete genome of Escherichia coli and sorted the output in increasing order of their deviation. The most avoided words were extremely enriched in self-complementary (palindromic) hexamers. In particular, within the output of 28 avoided words, 23 were self-complementary; and the 17 most avoided ones were all self-complementary. For comparison, we computed the set of avoided words for k=6 and ρ=-10 from an eukaryotic sequence: a segment identified through multiple alignment of genomes of several organisms, and termed conserved non-coding elements (CNEs). In addition, it contains large non-coding regions most of which are not linked to any particular function. All these genomic components appear to have many statistical features in common with natural languages [2]. A computational tool oriented towards the systematic search for avoided words is particularly useful for in silico genomic research analyses. The search for absent words is already undertaken in the recent past and length of avoided (or of overabundant) words of the nucleotide language was found to range from 3 to 5 (tri- to pentamers). The statistical significance of the avoided words was shown to reflect their biological importance. This work, however, was based on the very limited sequence data available at the time: only DNA sequences from two viral and one bacterial genomes were considered. Also note that k might change when considering eukaryotic genomes, the complex dynamics and function of which might impose a more demanding analysis. The authors of a specific role (e.g., protein coding segments, regulatory elements, conserved non-coding elements etc.) but they are strongly underrepresented—as we can estimate on the basis of the frequency of occurrence of their longest proper factors—may be of particular importance. They can be words of nucleotides which are hardly tolerated because they negatively influence the stability of the chromatin or, more generally, the functional genomic conformation; they can represent targets of restriction endonucleases which may be found in bacterial and On avoided words, absent words, and their application to biological sequence analysis - PMC example’ described above, these examples contain data a researcher would encounter in a real-life situation: very long, unintelligible lists of GO terms. The data sets cover diverse areas of the life sciences: example #1, a comparative analysis of predicted gene expression levels in bacteria and archaea [15]; example #2, finding putative targets for the cytostatic activity of a small molecule against cancer cell lines [16]; and example #3, gene expression profiling of aggressive breast cancer samples [17]. Data from the example #3 was used to influence the stability of the chromatin or, more generally, the functional genomic conformation; they can represent targets of restriction endonucleases which may be found in bacterial and viral genomes; or, more generally, they may be short genomic regions whose presence in wide parts of the genome are not tolerated for less known reasons. The understanding of such avoidances is becoming an interesting line of research (for recent studies, see [7, 8]). On the other hand, short words of nucleotides may be systematically avoided in large using both real and synthetic data, show its efficiency and applicability. Specifically, using our method we confirm that restriction endonucleases which target self-complementary sites are not found in eukaryotic sequences [8]. In addition, we apply our algorithm in the case of CNEs, which are classes of sequences whose functions in our genomes remain largely enigmatic [13, 14]. We observe interesting patterns of occurring avoided words within CNEs compared to CNE-like sequences (surrogates) that are in accordance with their distinct sequence\n",
            "[0.575695]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which gene(s) should be genotyped in order to prescribe the drug Cetuximab (anti-EGFR)?\n",
            "Refined Query: To effectively prescribe Cetuximab, a targeted therapy against EGFR, which gene(s), specifically within the EGFR pathway, should be genotyped to predict patient response and minimize adverse effects?  This includes considering both activating mutations and other relevant genetic markers impacting EGFR expression or function.\n",
            "\n",
            "Combined Answer: future studies will need to identify mechanisms of resistance to ceritinib other than mutations in the G1202 and F1174 residues in order to maximize the clinical benefit afforded by next generation ALK-targeted therapies. bound to ALK provides structural bases for this increased potency. However, we observed that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations were identified in 5 out of 11 biopsies from patients with acquired resistance to ceritinib. Altogether our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clinical data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease. models, ceritinib demonstrated impressive anti-tumor activity, while it was less active in the C1156Y resistant model and was inactive against the G1202R resistant model. This data is consistent with the Ba/F3 models in which ceritinib was more potent against I1171T than the C1156Y and G1202R mutants (Fig. 4A). The studies shown herein provide evidence that ceritinib can overcome resistance in vivo, especially in tumors harboring wild-type, L1196M or I1171T ALK fusion genes at a dose that is predicted to be achievable in humans. Of note, it is As shown in Figure 6A, 5 of these biopsies revealed the development of mutations at either G1202 or F1174 in the ceritinib resistant cancers. In the patient, JFCR021, who had 2 sites of disease biopsied, two different ceritinib resistant mutations were identified, underscoring the heterogeneity of resistance mechanisms that can be identified in a single patient (6). Of note, 2 of the patients had crizotinib-resistance mutations before enrolling on ceritinib (MGH011 –Fig.6B - and JFCR021) that our laboratory studies suggested would be sensitive of ceritinib varied depending on the specific ALK resistance mutation. For example, in Ba/F3 models, ceritinib was highly active against L1196M, G1269A, S1206Y and I1171T EML4-ALK mutants, and less active against the less common mutations, C1156Y, G1202R, 1151T-ins, L1152P and F1174C. It is notable that in the phase 1 study of ceritinib, 5 of 19 crizotinib-resistant tumors harbored resistance mutations at residues 1196, 1269 and 1206, with one tumor harboring both G1269A and 1151Tins. The patients harboring these resistance mutations all 5A). These findings may explain, at least in part, the finding that ceritinib is highly active in crizotinib resistant cancers with or without ALK resistance mutations. The initial interrogation of ceritinib resistant patient biopsies supports the notion that ceritinib is able to effectively suppress many crizotinib-resistance mutations, but the G1202R and F1174V/C mutants are resistant to ceritinib. It is noteworthy that in two cases the crizotinib resistance mutations, S1206Y and G1269A, were no longer observed in the ceritinib resistant To our knowledge, this is one of the first prospectively studied and successful molecularly-targeted agents in pLGG, providing a new alternative to children with NF1-associated pLGG and those with pLGG harboring the most common BRAF aberrations. These phase II data verified the findings seen in the phase I study and better delineated the specific subpopulations of pLGG patients most sensistive to selumetinib as well as further defined duration of response, visual outcomes and toxicity. To systematically assess the potency of ceritinib against ALK resistance mutations, we utilized Ba/F3 cells engineered to express wild type EML4-ALK or one of the 9 different resistance mutations. In this system, ceritinib was approximately 10-fold more potent against wild-type EML4-ALK than crizotinib. Whereas all these secondary mutations induced crizotinib resistance, ceritinib was potent in inhibiting the growth of Ba/F3 cells expressing four of the resistance mutations, including L1196M, G1269A, S1206Y and I1171T (Fig.4A, S3 and Table S1). patient (6). Of note, 2 of the patients had crizotinib-resistance mutations before enrolling on ceritinib (MGH011 –Fig.6B - and JFCR021) that our laboratory studies suggested would be sensitive to ceritinib. In the ceritinib resistant cancers, those mutations were no longer detected, but the G1202R mutation emerged (Fig. 6B). These findings are consistent with preclinical studies presented in this manuscript demonstrating the activity of ceritinib against G1269A and S1206Y crizotinib-resistance mutations, and its lack of potency against the to the elimination of tumor cells. It is also possible that this patient relapsed on crizotinib because of poor adherence to therapy or due to a stromal contribution. Similar findings were also observed in the H2228 xenograft model that developed resistance to crizotinib in vivo, did not develop an ALK mutation, and was sensitive to ceritinib (Fig. 5A). These findings may explain, at least in part, the finding that ceritinib is highly active in crizotinib resistant cancers with or without ALK resistance mutations. The initial interrogation of\n",
            "[0.5572759]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is signal transducer and activator of transcription-3 (STAT3) critical for tumor angiogenesis progression?\n",
            "Refined Query: Does the transcription factor STAT3 play a crucial role in the development and progression of tumor angiogenesis, specifically influencing the formation of new blood vessels that supply nutrients and oxygen to the tumor, thus contributing to its growth and metastasis?\n",
            "\n",
            "Combined Answer: A chemical screen designed to identify novel inducers of autophagy led to the discovery that signal transducer and activator of transcription 3 (STAT3) inhibitors can potently stimulate the autophagic flux. Although STAT3 is best known as a pro-inflammatory and oncogenic transcription factor, mechanistic analyses revealed that autophagy is regulated by the cytoplasmic, not nuclear, pool of STAT3. Cytoplasmic STAT3 normally interacts with the eukaryotic translation initiation factor 2, subunit 1α, 35kDa (EIF2S1/eIF2α) kinase 2/protein kinase, of transcription factors function downstream of signaling by LIF, and several transcription factors, including STAT3, Oct3/4, Sox2, and Nanog, play crucial roles for pluripotency and self-renewal of ES cells (3–5). Artificial activation of STAT3, which is achieved by 4-hydroxytamoxifen stimulation of nuclear localization of the STAT3-estrogen receptor fusion protein (STAT3ER), as well as forced expression of Nanog, accelerates the self-renewal in a LIF-independent manner (6–8). Oct3/4-deficient embryos develop to the blastocyst stage, but and osteoprogenitor cells in the BM leads to the overexpression of multiple OC activating factors including RANKL, MIP1-α, interleukin (IL)-3, osteopontin, IL-6 and vascular endothelial growth factor.1,2 In turn, OCs also support myeloma proliferation and survival by production of growth factors such as IL-6, osteopontin, BAFF and APRIL.1 Conversely, OB formation and activity is significantly reduced by tumoral production of OB inhibitory factors such as DKK-1, sFRP-2, sFRP-3, IL-7 and IL-3, and by direct myeloma and OB cell-to-cell for angiogenesis because of their pro-angiogenic activity that induces vascular permeability and promotes the proliferation and survival of epithelial cells (40). VEGF may cause vasodilation by stimulating the NO-cyclic guanosine monophosphate vascular relaxation pathway as well as by increasing the production of the calcium ion (Ca2+)i (53). An increase in (Ca2+)i promotes the binding to endothelial NO (eNOS) and subsequently increases eNOS activity and stimulates NO production (Figure 1) (53). Transforming growth factor (TGF)-β1 is involved Fms-like tyrosine kinase 3 (FLT3) is a member of the class III family of receptor tyrosine kinases expressed on early hematopoietic stem and progenitor cells, and plays an important role in hematopoiesis [1]. Wild-type FLT3 (FLT3wt) is activated by FLT3 ligand (FL), which promotes receptor dimerization, auto-phosphorylation, and cell proliferation via activation of its downstream signaling molecules, including STAT5, ERK1/2, and AKT [2]. FLT3 is made up of 5 functional domains: an immunoglobulin-like extracellular domain, a transmembrane and also similarly suppressed FLT3 downstream signaling molecules, including ERK1/2 and STAT5, even in the presence of FL in MOLM-13 cells. These findings may be clinically meaningful for several reasons. First, an FL increase has been observed in AML patients treated with a FLT3 inhibitor or chemotherapy [21]. The plasma concentrations of FL in the xenograft model established by inoculating FL-expressing MOLM-13 cells in our study were similar to those in AML patients [21]. In addition, detectable phosphorylation of FLT3wt, but not FLT3-ITD, by the cytoplasmic, not nuclear, pool of STAT3. Cytoplasmic STAT3 normally interacts with the eukaryotic translation initiation factor 2, subunit 1α, 35kDa (EIF2S1/eIF2α) kinase 2/protein kinase, RNA-activated (EIF2AK2/PKR), a sensor of double-stranded RNA. This interaction, which could be recapitulated using recombinant proteins in pull-down experiments, involves the catalytic domain of EIF2AK2 as well as the SH2 domain of STAT3, which can adopt a fold similar to that of EIF2S1. Thus, STAT3 may act as a competitive inhibitor of EIF2AK2. systems, 24 h treatment of MC3T3-E1 osteoprogenitor cells with PIs enhanced the activity of Smad2/3/4, serum response element (SRE) and AP1 transcription factors (Figure 4a). Although transforming growth factor β signaling exerts inhibitory effects in mature OBs,46 activity of Smad2/3 together with Smad4 promotes early osteoprogenitor commitment and differentiation by inducing OB-specific gene transcription.47 Likewise, MAPK signaling cascades through ERK (extracellular-signal-regulated kinase) (SRE) and JNK (c-Jun N-terminal kinase) (AP1) and the presence of mutant H3.3 or aberrantly modified H3 proteins (due to dominant effects of K27M or local effects of G34 mutant H3.3) at key regulatory elements may be critical to alteration of transcriptional programs leading to tumor initiation or progression. H3.3 is incorporated into promoters of developmentally regulated genes, and these loci bear both H3K27me3 and H3K4me3 marks, marking these promoters as “bivalent domains” poised for transcriptional induction (Bernstein et al. 2006; Goldberg et al. 2010; Banaszynski et al. 2013). Pluripotency and self-renewal capacity are major characteristics of murine embryonic stem (ES) cells. Leukemia inhibitory factor (LIF) plays an important role for the self-renewal of ES cells, and depletion of LIF from ES cell culture medium leads to spontaneous differentiation of cells and results in a failure of self-renewal (1, 2). A large number of transcription factors function downstream of signaling by LIF, and several transcription factors, including STAT3, Oct3/4, Sox2, and Nanog, play crucial roles for pluripotency and self-renewal of\n",
            "[0.81620735]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the physiological target for LeuRS translational quality control?\n",
            "Refined Query: Leucyl-tRNA synthetase (LeuRS) is crucial for accurate protein synthesis.  This question asks what specific cellular component or process LeuRS acts upon to ensure only correct leucine-charged tRNAs participate in translation, thus preventing errors in protein synthesis.\n",
            "\n",
            "Combined Answer: carrier RNA (Supplemental Fig. S1A,B; Supplemental Table S1; see Methods for details). The synthetic gene is based on the Escherichia coli leucyl-tRNA synthetase sequence for two main reasons. First, we wanted to avoid mapping to eukaryotic genomes. Secondly, leucyl-tRNA synthetase is a housekeeping gene from a mesophilic species, and therefore its sequence is not expected to form strong secondary structures that would reduce its translation in vivo or reduce the efficiency of reverse transcription. We made this carrier selectively degradable Having demonstrated new evidence for efficient alternate translation initiation using both ribosome profiling and protein analysis directly in patient muscle, we sought to characterize the elements contributing to the high translation efficiency. To determine whether exons 1 through 5 of DMD contain an IRES, we cloned the 5’ portion of the cDNA encompassing exons 1 through part of exon 6, beginning at the +4 position to exclude the native AUG initiation codon (c.4_c.369, referred as exon 1 to 6), into the dicistronic dual luciferase reporter The two strands of the mtDNA molecule encode 13 polypeptides, 22 tRNAs, and 2 rRNAs. The translation machinery of transcribed mtDNA consists of aminoacyl-tRNA synthetases, ribosomal protein subunits, and translation initiation, elongation, and termination factors. Although all essential mammalian mitochondrial factors involved in the initiation and elongation of translation have been cloned and well distinguished, the steps involving the termination and release process are less characterized. The mitochondrial class I release factor family is This is an important feature as such small IRESs can be used in dicistronic vectors, where space is limited when packaged into viral vectors such as AAV. Although the precise molecular mechanism by which cellular IRESs modulate translation has not been defined in the literature, the requirement of ITAFs has been strongly suggested39. These cellular proteins act in trans to augment IRES activity. Almost all ITAFs have been shown to harbor RNA binding domains and have been hypothesized to act as RNA chaperones, helping the IRES primary sequence To enable profiling of minute amounts of RNA, we set out to design a carrier RNA similar in size distribution and percentage of capped RNA to the cellular RNA, but whose cDNA will selectively degrade without affecting the cDNA originating from the sample. We constructed the synthetic gene used as a template for run-off in vitro transcription of the carrier RNA (Supplemental Fig. S1A,B; Supplemental Table S1; see Methods for details). The synthetic gene is based on the Escherichia coli leucyl-tRNA synthetase sequence for two main reasons. First, The C terminus of Pta1, which is conserved across eukaryotes, is involved in linking Pta1 to core CPF and is essential for mRNA cleavage and polyadenylation (29, 47). However, the role of its N terminus has not been defined. To address this question, we tested a series of N-terminal truncations (Fig. 2A) for their ability to support cell growth using the plasmid shuffle assay. Mutants lacking the first 25 (pta1 Δ1-25), 50 (pta1 Δ1-50), or 75 (pta1 Δ1-75) amino acids were viable when the wild-type PTA1 plasmid was counterselected on 5-FOA medium tool, the system has two components: first, a bipartite small RNA, or “guide RNA” (gRNA), designed to recognise a specific location in the genome; second, the Cas9 protein that binds the gRNA and is thereby recruited to the target site. The gRNA consists of a 20 nt targeting region that hybridises to genomic DNA upstream of a dinucleotide protospacer adjacent motif (PAM, here NGG), fused with a scaffold sequence recognised by Cas9 protein [3]. By engineering the gRNA targeting region, one may target virtually any complementary genomic locus assembly similar to DNA assembly techniques22 (Fig. 2). From N- to C-terminus of the protein sequence, series of aligned chains are merged to contigs with identical overlap of length L-1, where L is the length of the chains. A contig terminates if there is no overlap to extend or if it encounters an AAIG that is already part of it. Chains that cannot be merged to contigs are considered spurious and discarded. Finally, all contigs are aligned to the protein sequence. For an AAIG to be assigned to a given residue in the protein sequence, two to the first 39 nt, inclusive of the two in-frame AUGs (M124 and M128), and 10 additional nucleotides used for cloning purposes. T7 mediated RNA were generated from the different constructs and were used to perform rabbit reticulocyte lysate (RRL) translation assays (Fig. 2a). Size and integrity of the corresponding RNAs were checked using a formaldehyde agarose gel (Fig. 2b)22. Cap-independent translation activity (represented as the ratio of downstream FLuc to the RLuc luminescence) of the exons 1–5 of DMD results in a 1.5–1.7 fold increase Table S1). Combination of alternating recognition sites allows for higher degradation efficiency and reduces sequence repetitiveness. The two enzymes have recognition sites of lengths 27 and 18 bp, respectively, which even with some degeneracy allowed in the recognition site (Gimble and Wang 1996; Argast et al. 1998) makes their random occurrence in a transcriptome highly improbable. The two enzymes work at the same temperature and in the same buffer, so their digestion can be combined in a single step. A fraction of the synthesised carrier\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 379.48ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1410.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 937.02ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1108.32ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1058.30ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1635.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1182.91ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1032.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1033.46ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2164.15ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 912.14ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which gene test can be used for the X-linked myotubular myopathy?\n",
            "Refined Query: What specific genetic test, such as gene sequencing or deletion/duplication analysis, is most effective and commonly used to diagnose X-linked myotubular myopathy, targeting the *MTM1* gene?\n",
            "\n",
            "Combined Answer: testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data derived from the literature. Although existing tools aid collection of some of these data types, scientists and clinicians must often access multiple data sources whilst interpreting a single genetic variant. The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recently released guidelines data sources whilst interpreting a single genetic variant. The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recently released guidelines that aim to standardise variant interpretation2. These guidelines outline a set of evidence criteria to assess each variant against, along with how these might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, Inherited cardiac conditions (ICCs) represent a major health burden with a combined prevalence of ~1%1. Genetic testing is recommended to support the management of many ICCs, with roles in diagnosis (particularly valuable for identification of at-risk relatives), prognostication, and therapeutic stratification. The principle challenge in genetic testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data In our final evaluation experiment, we measured the performance of our genomic partition for predicting potential false positives/sequence artefacts. Following along the lines of Li (2014) we used variant calls derived from a WGS dataset of the CHM1hTERT (CHM1) cell line for this evaluation. As CHM1 is assumed to be haploid we considered all heterozygous variant calls as false positives. We downloaded the call sets from this publication that were prepared using two different mappers (bowtie2 [bt2] and bwa mem [mem]) and three different variant crucial step in broadening the availability of genetic testing for ICCs, and standardising variant interpretation in this field. Furthermore, we hope that in demonstrating the clinical utility of our disease-specific approach, we will encourage others to develop similar tools across other disease specialties. panels should consider comparison with a local dataset to identify platform specific errors. In addition to these in-house data, we display counts from published clinical cohorts for HCM9,20, DCM9,21, LQTS22 and Brugada syndrome23. These data are also used to assess individual variants for enrichment in cases over controls (rule PS4). and familial studies were done by microsatellite marker segregation analyses and commercial or home-made MLPA studies (primers and conditions available upon request). The CNVs detected with both kinds of arrays were collected together, defined by the distal ends of the first and last probe altered. It is worth to note that most benign and pathogenic CNVs were detected by the commercial oligonucleotides-based array because of its higher resolution and because it was applied to 95% patients. On the other hand, they can be considered method was deliberately sensitive but not specific, meaning that there are multiple false-positive variants identified. False-positive variant calls can be due to artifacts introduced by the next-generation technology used,15 poor coverage in GC-rich regions, bases missed by next-generation sequencing because of homopolymers or dinucleotide repeats, or mapping difficulties because of gene homologues or paralogues. The most efficient method to remove these false-positive variants is to visualise alignment files (binary alignment map files), disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also\n",
            "[0.8843045]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there a phylogenetic analysis for HIV?\n",
            "Refined Query: Numerous phylogenetic analyses exist for HIV, exploring its evolutionary history and relationships between different strains.  These studies are crucial for understanding viral transmission dynamics, drug resistance evolution, and vaccine development.  The question should specify which HIV subtype or region's phylogeny is of interest.\n",
            "\n",
            "Combined Answer: and also showed a high substitution rate between the two sequences (21 substitutions in the region, which is ∼320 bp in length). Although we had data of viral DNA sequences and MNase mapping for the two DHBV-positive ducks, we were unable to pinpoint or correlate a sequence variation with a specific MNase pattern. We thought that this might be due, at least partially, to the fact that MNase mapping here has a lower resolution compared to DNA sequencing and the fact that multiple substitutions are scattered in the regions. Moreover, it is 2016). Drug resistance can be decreased or even overcome through combination therapy (Huang et al., 2016; Kruijtzer et al., 2002; Tooker et al., 2007). Therefore, drug combinations are investigated across various medical areas, such as cancer (Al-Lazikani et al., 2012), viral disease including human immunodeficiency virus (HIV) and hepatitis C virus infections (Clercq, 2007) as well as fungal (Chen et al., 2016; Groll and Tragiannidis, 2009) and bacterial infections (Tamma et al., 2012; Worthington and Melander, 2013). However, drug are reported to be 7.0% through inference from mortality rate, whereas HIV rates are reported to be 15.0% and 16.5%, in Malawi’s Chiradzulu and Machinga districts, respectively, where children were treated without antibiotics (Oster 2007). Unfortunately, at the time these children were being treated, routine HIV testing was not readily available in this setting. Although the two feeding programs studied are designed and operated very similarly (with the exception of the use of antibiotics in the standard protocol group), the different baseline PH conceived the study, cloned the gene, generated the sequence databases and sets for phylogenetic analyses and wrote the manuscript except phylogeny. BM carried out and described the phylogenetic analyses. ES participated in design and coordination of the study and critically revised the manuscript. All authors read and approved the final manuscript. in the DHBV genome. The DNA covered by the line with an arrowhead in Fig. 5A encodes part of PreS and the overlapping spacer region of DHBV polymerase, and the two sequences were highly varied (there are 37 bp substitutions scattered in the region [∼260 bp in length]). Another region marked by an arrowhead in Fig. 5A encodes a part of viral polymerase and also showed a high substitution rate between the two sequences (21 substitutions in the region, which is ∼320 bp in length). Although we had data of viral DNA sequences and MNase mapping for datasets. Notice that, in particular with MUSCLE, we obtain an identical or less average pairwise distance in 8 out of 9 cases between the original and the refined datasets produced by using MARS, despite the fact that we had first randomly rotated all sequences (compare the A.B.C to the A.B.C.rot columns). RAxML [50], a maximum-likelihood-based program for phylogenetic analyses, was used to identify the similarity between the phylogenetic trees inferred using the original and refined datasets. A comparison with respect to the phylogenetic physiologic states at the time of enrollment. The greater degree of stunting and underweight among the children receiving amoxicillin may have been indicative of a higher prevalence of a chronic process such as HIV infection. However, the HIV rates in the Dowa district of Malawi, where children were treated by the standard protocol with amoxicillin, are reported to be 7.0% through inference from mortality rate, whereas HIV rates are reported to be 15.0% and 16.5%, in Malawi’s Chiradzulu and Machinga districts, respectively, where children were for a comprehensive review). Analysing multiple sequences simultaneously is fundamental in biological research and MSA has been found to be a popular method for this task. One main application of MSA is to find conserved patterns within protein sequences [9] and also to infer homology between specific groups of sequences [10]. MSA may also be used in phylogenetic tree reconstruction [11] as well as in protein structure prediction [12]. Using a generalisation of the dynamic-programming technique for pairwise sequence alignments works In the past 10 years, the focus of biological research has shifted from individual genes and proteins toward the study of entire biological systems. One of the most important research issues is gene/protein and disease relationship analysis. Sequence variation plays the key role between gene and disease. Therefore, identifying sequence variation is one of the major approaches for characterizing gene–disease relationships (Erdogmus and Sezerman, 2007; Schenck et al., 2012), with many study results subsequently reported in scientific conditions, but having no known function, deserve additional study. Although we point out above that many of the VCSG genes in the pathogenicity island are in operons, we do not suggest that operonic organization of genes is enriched within the pathogenicity island versus other regions. There is little reason to suggest such anenrichment, and the number of genes is too small to warrant a statistical analysis of their distribution.\n",
            "[0.646369]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the association between adiponectin and migraine?\n",
            "Refined Query: Explore the potential correlation between adiponectin levels (high or low) and the frequency, severity, or pathogenesis of migraine headaches.  Are there studies indicating a protective or risk-increasing effect of adiponectin in migraine sufferers?\n",
            "\n",
            "Combined Answer: When migraine becomes frequent prevention medication is indicated. There are no absolute criteria for when this transition occurs, but evidence from adult studies suggests that this should be considered when the average frequency reaches 1 headache per week(12, 13). When this threshold is reached, the likelihood of frequency progression and possible transformation has been demonstrated in large population based studies. As the headache frequency continues to increase there is a proportional increase in the likelihood of the development of migraine. Although this is less meaningful to the patient and family, the improvement in migraine features may be more highly correlated with an improvement in disability, functionality and response to acute medication. This proposed research approach has the added benefit to determine if a particular preventative medication has an impact on individual migraine components. It is limited, however, due to treatment response of acute medications that may prevent the expression of migraine features. This effect lessens to ability and robustness of migraine components. It is limited, however, due to treatment response of acute medications that may prevent the expression of migraine features. This effect lessens to ability and robustness of using migraine day and episode as outcome measures. The logic of migraine episode analysis is similar to headache episode analysis, with the added feature of quantifying and restricting the analysis to migraine specific features. in this trial, it is critically important to keep in mind that this study essentially provides three trials in one. Hence, the chosen sample size must allow adequate power for testing all three primary hypotheses of interest. For the two comparisons with placebo, the results of an NINDS Clinical Research Collaboration (CRC) survey demonstrates that the majority of responders felt that a minimum increase of 20% in the percentage of subjects achieving a 50% reduction in migraine frequency was clinically meaningful, and the threshold needed for transformation has been demonstrated in large population based studies. As the headache frequency continues to increase there is a proportional increase in the likelihood of the development of chronic migraine and refractory headaches. This is becoming an increasingly impactful health concern(14, 15). The etiology of this worsening is complex, but may be related to both biological and psychological factors(16). As migraine is a genetically based disease, risk, especially in children, is based on the occurrence of the migraine related genes will recruit 675 subjects between the ages of 8 and 17 years old, inclusive, who have migraine with or without aura or chronic migraine as defined by the International Classification of Headache Disorders, 2nd Edition, with at least 4 headaches in the 28 days prior to randomization. The subjects will be randomized in a 2:2:1 (amitriptyline: topiramate: placebo) ratio. Doses are weight based and will be slowly titrated over an 8 week period to a target dose of 1 mg/kg of amitriptyline and 2 mg/kg of topiramate. The primary outcome will be a 50% but may be related to both biological and psychological factors(16). As migraine is a genetically based disease, risk, especially in children, is based on the occurrence of the migraine related genes (genotypic expression)(17–19). As migraines become more frequent, it can be speculated that these genes have increased activity or influence on the pathways involved (phenotypic expression)(20–22). This results in a hypersensitive phenomenon that lowers the threshold for the occurrence of the next migraine. This hypersensitive phenomenon has been Each of these primary hypotheses will involve a comparison of headache frequency (percentage of days with any headache) between the last 4 weeks of treatment (weeks 20–24) and the 4-week baseline period. Study participants will be allowed to take acute pain medications, including over the counter medications and triptans. For each subject, the primary outcome will involve a determination of whether a 50% or greater reduction in headache frequency was observed during the last 4 weeks of active treatment as compared with the headache frequency criteria restrict the research subjects to a clearly definable group of pediatric patients with an established diagnosis using standardized international criteria, while broadening the headache frequency range to those patients that would be most likely to benefit from preventative treatment. As noted above, the impact of frequent migraine on a patient's life is one of the major decision factors in determining the necessity of preventative medication. The use of a readily applied, standardized, reliable, and validated disability assessment symptoms. The mechanisms of action of preventative medication appear to reverse this hypersensitivity either through multiple re-uptake inhibition (AMI) or alteration of channel function and neurotransmission (TPM). If high frequency headaches are sustained, this increased hypersensitivity may result in long-term changes in neuroanatomy, neurophysiology, and psychological response patterns. Neuroimaging studies have demonstrated altered brainstem appearance with iron deposition as the presence of frequent migraine persists over time(23).\n",
            "[0.72595906]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which phenomenon is described as oncogene addiction?\n",
            "Refined Query: Oncogene addiction describes a cancer's dependence on a specific oncogene for its survival and growth.  The question explores this phenomenon:  What characterizes a cancer's reliance on a single mutated gene, such that inhibiting that gene effectively halts tumor progression?\n",
            "\n",
            "Combined Answer: contributing to the dataset may not represent the healthy state, having escaped the possible deleterious consequences of deleting or duplicating UCEs either because the mechanisms effecting such consequences were no longer in play or because the cells had acquired a means by which to circumvent them. With respect to cancerCNAs, it may be that they arise when the mechanisms producing deleterious consequences are disabled or circumvented, their positions potentially influenced by the density of genes with either pro- or anti-proliferative due to differences in mutational profiles, selective retention/loss of UCE-disrupting CNVs, or a combination of both, the dichotomy of CNV profiles with respect to UCEs between healthy and cancerous cells warrants further discussion. One explanation argues that even though cancer cells with disrupted UCE dosage may acquire a growth advantage, their presence is detrimental to the overall fitness of the individual. Hence, disruptions in UCE copy number such as those seen in cancer would not be predicted to endure in human populations, consistent of which cancer is just one. Some diseased states may release cells from the dosage constraints of UCEs or even confer cellular advantages that outweigh the deleterious consequences of an imbalance of UCEs. Alternatively, release from the dosage constraints of UCEs may be a prerequisite or permissive step en route to disease. Our findings also highlight the possibility that some diseases associated with genomic instability involve instead, or in addition, a simple inability to cull away the normal burden of deleterious CNVs arising at a enriched for UCEs. This dichotomy may be explained by differences in the mutational landscapes and/or selective forces between healthy and cancer cells, with healthy cells displaying a bias against CNVs in the vicinity of UCEs, and cancer cells being biased toward disruption of UCEs by CNVs. Whether nondepletion and/or enrichment will prove to be a universal signature of cancerCNAs remains to be determined, the depletion of UCEs from one cancerCNA dataset (TCGARN 2013 [90]) suggesting that the story will be more complex, perhaps reflecting cancerCNA datasets may at first be difficult to reconcile with the depletion of UCEs from classicalCNVs, de nov°CNVs, somaticCNVs, and iPSCNVs; while cancer cells with abnormal UCE copy number appear unaffected or even advantaged, cells with abnormal UCE copy number may be disadvantaged in healthy individuals, this difference implying opposite impacts on proliferation, senescence, or apoptosis. Similarly, the mutational profiles of cancer cells may bias CNVs toward forming in the vicinity of UCEs, possibly conferring selective advantage, (Qanbari et al., 2014), and in the mouse, anterior cingulate cortex TMEM132D expression correlates with anxiety-related behaviour (Erhardt et al., 2011). Finally, mutations in TMEM132D are unusually frequent in small-cell lung cancer (Iwakawa et al., 2015; Peifer et al., 2012; Rudin et al., 2012) and in pancreatic cancer (Forbes et al., 2015). Disease mutations near, or functions of, TMEM132A or C have yet to be identified, although TMEM132A is thought to promote neuronal cell survival by regulating stress-related genes (Oh-hashi et al., 2003, the same patient. This strategy maximized the likelihood that our cancerCNA datasets reflect alterations that arose within the affected individuals' lifetimes and specifically in cancerous tissues, thereby minimizing inclusion of classicalCNVs. Additionally, as cancerCNAs that are recurrent in multiple patients are considered more likely to be causal “drivers” of disease, while non-recurrent ones are more likely to be merely “passengers” [73], we only included recurrent aberrations in our cancerCNA datasets, identified as such using the GISITC impacts on proliferation, senescence, or apoptosis. Similarly, the mutational profiles of cancer cells may bias CNVs toward forming in the vicinity of UCEs, possibly conferring selective advantage, whereas the profiles of healthy cells may avoid such disruptions. Whether the difference in UCE disruption by CNVs in cancer versus healthy cells is due to differences in mutational profiles, selective retention/loss of UCE-disrupting CNVs, or a combination of both, the dichotomy of CNV profiles with respect to UCEs between healthy and cancerous continuously undergo replication and, hence, progress unrestrained through cell cycles. Of these, cells that are the most disrupted in UCE dosage, in other words enriched for the inclusion of UCEs in their CNVs, might be expected to show the strongest phenotype of unregulated growth and thus become cancerous. The enrichment of UCEs in many cancerCNA datasets may at first be difficult to reconcile with the depletion of UCEs from classicalCNVs, de nov°CNVs, somaticCNVs, and iPSCNVs; while cancer cells with abnormal UCE copy number appear of the remaining population of cells is depleted of UCEs. In striking contrast to the situation in healthy cells, the CNVs of cancer cells are by and large not depleted of UCEs. This suggests an important and hitherto overlooked aspect of cancer genetics and invites the study of UCE depletion from CNVs into the realm of diseases that develop somatically, of which cancer is just one. Some diseased states may release cells from the dosage constraints of UCEs or even confer cellular advantages that outweigh the deleterious consequences of an\n",
            "[0.620988]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are there randomised controlled trials on sevoflurane?\n",
            "Refined Query: A more precise search would be:  \"What randomized controlled trials compare sevoflurane's efficacy and safety to other anesthetic agents or placebo in specific surgical procedures or patient populations?\"\n",
            "\n",
            "Combined Answer: be unrecognized and thus under reported, future prospective studies will be required to evaluate this more completely in the pediatric population. A limitation of the current trial is that QOL and patient reported outcomes (PRO) were not assessed; however, there are some notable differences in the patients’ experience between selumetinib and chemotherapy. Selumetinib requires monthly, shorter clinic visits and is taken orally with no requirement for central line placement as compared to weekly CV, bi-monthly bevacizumab/irinotecan and weekly toxicity assessments were completed every 4 weeks and prior to each subsequent cycle and were graded according to the Common Terminology Criteria for Adverse Events version 4.0. Dosing adherence was monitored through patient diaries and pill counts. Selumetinib was administered as capsules given orally at 25 mg/m2/dose twice daily. Each course was 28 days, and patients could be treated for up to 26 courses in the absence of unacceptable toxicity or tumor progression. Patients were taken off treatment if they met criteria for progressive This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011). The following strategy was used to search MEDLINE (OVID). 1. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab. 2. clinical trials as topic.sh. 3. trial.ti. 4. 1 or 2 or 3 5. exp animals/ not humans.sh. 6. 4 not 5 7. exp Epilepsy/ 8. exp Seizures/ 9. (epilep$ or seizure$ or convuls$).tw. 10. 7 or 8 or 9 11. (losigam$ or ADD137022).tw. or LP was performed under anesthesia/sedation per institutional guidelines. Before intrathecal injection of study drug, 5–6 mL of CSF was collected for analysis. Following injection, participants were observed for 24 hours. Follow-up visits were performed on days 8 and 29 for all participants and on day 85 for participants in the 6- and 9-mg dose groups. A second LP to collect CSF for safety and pharmacokinetics was performed on day 8 in the 1-, 3-, and 6-mg dose groups and on days 8 or 29 in the 9-mg dose group (n = 5 at each time point). These data have also directly led to the development of two large multi-institutional prospective randomized phase III COG trials in previously untreated patients comparing selumetinib to standard chemotherapy in both NF1-associated and sporadic pLGG, possibly re-defining the standard of care in pLGG. In these forthcoming COG studies, functional outcomes including VA, QOL, neuropsychological and PRO are included as both primary and secondary objectives. An independent data and safety monitoring committee reviewed safety and efficacy during the trial. The trial was designed by the first and last authors in collaboration with the sponsor, and the authors and the sponsor were responsible for data collection and analysis. The authors vouch for the fidelity of the trial to the protocol and for the accuracy and completeness of the data. The first and last authors wrote the first draft of the manuscript in collaboration with the sponsor. Medical writing support was provided by the sponsor. the current standard of care were selected as trial sites by regional partners. Minimum requirements for the current standard of care included hemodynamic monitoring, the provision of intravenous fluids, laboratory testing, and the ability to deliver concomitant medications. The trial was approved by the NIAID institutional review board and applicable ethics boards in each site or country. Full details of trial design, conduct, and analyses can be found in the protocol and statistical analysis plan, available with the full text of this article analyses or manuscript preparation. CTEP provided input on study design, approved the trial and its amendments, served as the IND sponsor and reviewed the manuscript prior to submission. CTEP was not directly involved in patient enrollment, data collection, analyses or interpretation. AstraZeneca provided selumetinib and financial support for BRAF testing, CPK lab analyses, echocardiograms and ophthalmologic exams. AstraZeneca reviewed the manuscript; however, they did not have a direct role in trial design, patient recruitment, data in selumetinib pharmacokinetics administered at the recommended phase II dose (RP2D). All secondary endpoints as they relate to Strata 1 and 3 are presented here. Similar information for Strata 2, 4, 5 and 6 will be reported elsewhere as the data become available. the study may be thought of as making a correct decision regarding a prevention medication using the algorithm described in the companion application. To assess the ability of our trial to meet this goal, we conducted a series of simulation studies. Each simulation consisted of 10,000 replications for each of 64 conditions defined by all possible combinations of plausible values for the true response rates in the three treatment groups: placebo (40%, 45%, 50%, 55%), AMI (50%, 60%, 70%, 80%), and TPM (50%, 70%, 85%, 95%). For each simulated\n",
            "[0.3667465]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: In which cells are gasdermins expressed?\n",
            "Refined Query: Gasdermins are pore-forming proteins crucial in pyroptosis.  I'm interested in understanding the specific cell types and tissues where various gasdermin family members (e.g., GSDMD, GSDME) are expressed, both constitutively and upon specific stimuli.\n",
            "\n",
            "Combined Answer: Bacillus anthracis is a spore-forming, gram-positive bacterium that is the causative agent of anthrax. The major factors responsible for its pathogenesis are encoded on two virulence plasmids, pXO1 and pXO2 [1-4]. pXO1 contains the genes coding for the three secreted toxin proteins, protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid capsule, which protects the bacterium from host phagocytosis [6]. The production of these virulence factors is highly dependent on an environment containing carbon dioxide and bicarbonate (CO2/HCO3, henceforth CO2). The relative concentrations of CO2 and bicarbonate are regulated enzymatically by carbonic anhydrase, as well as many other non-enzyme transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters have been localized to the choroid plexus (Mayerl et al., 2012) and their distribution in the choroid plexus differs between species (Wirth et al., 2014). Most TH transmembrane transporters identified to date are promiscuous with respect to the range of metabolites they transport. Only MCT8 has been identified as being specific to transport of THs and and zldM- embryos were from GSE11231 (Liang et al. 2008). Zld-binding sites were from GSE30757 (Harrison et al. 2011). Data for RNA Pol II binding during the MZT were obtained from GSE41703 (Chen et al. 2013). it is known that THs enter cells via TH transmembrane transporters, which participate in the influx and efflux of THs into and out of cells. Several classes of TH transmembrane transporter proteins that belong to the family of solute carrier (Slc) transporters have been identified e.g. organic anion transporting polypeptides (OATPs), monocarboxylate transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the binding site for actin is located at the N terminus.3 Second the rod domain contains 24 triple helical spectrin repeats with 4 interspersing hinge domains. Third, the cysteine-rich domain required for binding to BDG4,5,6 and fourth, the c-terminal domain that contains the syntrophin7 and dystrobrevin-binding sites8. The cysteine-rich domain consists of yeast-specific domains that interact with proteins such as Ssu72 or complexes such as APT that have not been described for metazoan cells. Unlike Pta1, symplekin is not tightly associated with any of the purified mammalian factors but clearly has a similar function in assembling diverse smaller complexes into larger ones. Symplekin is needed for the cleavage of the nonadenylated histone transcripts and performs this function as a component of heat-labile factor, a large complex that shares subunits with the CPFs CPSF and CstF (24). Symplekin Figures S1–4 and Tables S1–5: protein quantification and functional analysis information. This material is available free of charge via the Internet at http://pubs.acs.org. domain into the cytosol (9), where it glucosylates and inactivates small GTPases, such as Rac and Rho, which play a critical role in maintaining cellular morphology and in multiple other aspects of cellular homeostasis. One aspect of toxin function that is still poorly understood is how TcdA and TcdB bind to host cells or, more specifically, what is the nature of the receptors to which the toxins bind. For TcdA, the receptor has been proposed to consist of a membrane-associated carbohydrate based on the following lines of evidence: (i) TcdA GATA-1 was tagged by fusing of a small (23 aa) peptide sequence to its N-terminus. This tag is efficiently biotinylated by the bacterial BirA biotin ligase, which is coexpressed in stably transfected mouse erythroleukemic (MEL) cells, allowing a single-step purification of biotinylated GATA-1 using streptavidin beads under mild conditions (de Boer et al, 2003). Proteins copurified with GATA-1 from MEL cells chemically induced to undergo terminal differentiation were identified by mass spectrometry, classified according to Gene Ontology terms or\n",
            "[0.6969881]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Where in a protein can a signal sequence be found?\n",
            "Refined Query: Signal sequences, directing protein localization, are typically found at the N-terminus (beginning) of a polypeptide chain.  They're a short stretch of amino acids that precede the mature protein sequence.\n",
            "\n",
            "Combined Answer: type in that chain as shown in Eq. 3 to estimate the significance of each chain where L is the chain length and k the position in the chain. In principle, chains with higher occupancy rate of connectivities are more likely to be correct. Subsequently, the chains are used to generate a larger number of peptide sequence segments using the amino acid-type predictions obtained earlier. Each peptide is aligned to the protein sequence using the Needleman–Wunsch algorithm47. Many peptides are discarded at this stage due to alignment mismatches. For reference position of the cluster. TCs and their close surrounding genomic regions containing binding sites for the components of the pre-initiation complex (PIC) are regarded as core promoters; core promoters by definition do not contain tissue-specific or other context-specific binding sites, even though in rare known cases this may be possible. Individual, distinct TCs some distance apart are taken to correspond to separate, alternative promoters [13,17]. We then analyzed the distribution of TCs around four sets of genes. Set 1 comprises and mapped to the same strand (see Materials and methods; Figure 1b); the goal of this clustering was for each cluster to correspond to an individual core promoter. Since many of the clusters were of the broad type [13], we chose the most frequently used CAGE TSS (CTSS) position (that is, the one supported by the highest number of tags) as the reference position of the cluster. TCs and their close surrounding genomic regions containing binding sites for the components of the pre-initiation complex (PIC) are regarded as core promoters; core pre-mRNA and the addition of a polyA tail at the cleavage site. Certain cis-acting elements and trans-acting factors have been found in the literature that influence the choice of a particular polyA cleavage site (Barrett et al., 2012; Pichon et al., 2012). In particular, the 3′ end sequence of a pre-mRNA usually contains a AAUAAA hexamer (or some close variant). This hexamer is called the polyadenylation signal (PAS) and it usually appears 10–30 bps upstream of the cleavage site (Tian, 2005). The PAS serves as a binding site for the cleavage assembly similar to DNA assembly techniques22 (Fig. 2). From N- to C-terminus of the protein sequence, series of aligned chains are merged to contigs with identical overlap of length L-1, where L is the length of the chains. A contig terminates if there is no overlap to extend or if it encounters an AAIG that is already part of it. Chains that cannot be merged to contigs are considered spurious and discarded. Finally, all contigs are aligned to the protein sequence. For an AAIG to be assigned to a given residue in the protein sequence, two extrapolated to the protein level. This method will identify both direct targets of the 106 probe and proteins that interact with target proteins. For example, in our previous study7 we identified both HDAC3 and its partner protein NCoR1 by Western blot analysis. There are characteristic patterns of nucleosome occupancy and positioning that have been observed at transcriptional promoter regions (3, 4, 7, 8, 10). The area that is immediately upstream of the transcription start site (TSS) is often found to be depleted of canonical nucleosomes and is referred to as a nucleosome-free region (NFR) or a nucleosome-depleted region (NDR). Well-positioned nucleosomes are commonly seen downstream of the TSS in the transcribed region, and the precision of this positioning decays as distance from the TSS increases. According to the central dogma of molecular biology, the transcription process in eukaryotes synthesizes a pre-mRNA from the genomic sequence of a gene (Leavitt and Nirenberg, 2010). The pre-mRNA is then converted to a mature mRNA by the post-transcriptional process. Finally, this mature mRNA is translated into the corresponding protein. The post-transcriptional process includes three major steps: the addition of a 5′ cap, addition of a polyadenylation (polyA) tail and splicing. In particular, a polyA tail is added at the 3′ end of a pre-mRNA displayed similar association patterns at all three origins and their adjacent regions (Fig 5C–5E). We first examined the binding to ars3002 and its adjacent region ars3002_18kb (Fig 5C). Although Cdc20 bound in early S phase to ars3002, earlier than Pfh1, the peak binding for Cdc20 and Pfh1 was reached at 95 min (Fig 5C). Both proteins had their start of binding to ars3002_18kb at 80 min after release from G2 phase and their peak binding at 95 min (Fig 5C). Thus, Pfh1 and Cdc20 bound to the Pfh1-insensitive site located 18 kb downstream of termination rather than mRNA processing. Pta1 is known to physically interact with the Ssu72, Pti1, Syc1, and Glc7 subunits of APT (15, 16, 29, 49), but the domains of Pta1 responsible for these interactions had not been localized. The work described here adds to our knowledge of the APT architecture by showing that distinct, nonoverlapping regions of Pta1 are involved in the Ssu72 (amino acids 26 to 300) and the Pti1 (amino acids 400 to 500) interactions. Furthermore, the Syc1 protein is almost identical to the C terminus of Ysh1 and can\n",
            "[0.59370697]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Can FOXOs modulate longevity?\n",
            "Refined Query: The question explores the role of Forkhead box O (FOXO) transcription factors in regulating lifespan.  Do FOXO proteins directly influence longevity pathways, and if so, through what mechanisms?  Are their effects conserved across species?\n",
            "\n",
            "Combined Answer: We assume that Esrrb, Oct3/4, and Dax1 do not form a trimer complex. Instead, Esrrb or Oct3/4 is exclusively bound by Dax1. Dax1 is known to function as a transcriptional repressor (23, 35, 36). Transcriptional activities of Oct3/4 and Esrrb are inhibited by Dax1. As described previously, hyperactivation of Oct3/4 in ES cells leads to differentiation into primitive endoderm and mesoderm (10), and Dax1 inhibits the overactivation and contributes to retaining self-renewal (20). A similar relationship between Dax1 and Esrrb would be anticipated. is lost in zldM- embryos preferentially at those regions that depend on Zld for chromatin accessibility. These data show that Zld potentiates transcription factor binding through the establishment or maintenance of open chromatin, and this is likely to be important for Zld-mediated transcriptional activation (Fig. 7). The mechanism by which Zld establishes or maintains chromatin accessibility remains unknown. Unlike the pioneer factor FOXA1, which can bind open chromatin by binding through a winged-helix domain (Cirillo et al. 1998, 2002), the In S.cerevisiae, hyper-recombination in the rDNA cluster has been demonstrated to be a cause of aging in mother cells. In old mother cells which display a shortened life span, DNA circles containing a variable number of rDNA repeats (ERC) arise, suggesting that the ERCs are a cause of aging (15). A fob1 mutation was reported to result in a decreased rDNA recombination rate leading to a decreased amount of ERCs, and consequently an increased life span (16). The average life span of strains FY833 and ID-1 (harboring 610 and 1900 kb split plays a key role in aging-associated degenerative changes in mammals (Rubinsztein et al. 2011). Several recent findings support that SREBP TFs play a key role in these processes. SREBF1 expression increases with age in rat brains (Okamoto et al. 2006), SREBF1-mediated lipogenesis is involved in senescence (Kim et al. 2010), SREBF2 regulates autophagy (Seo et al. 2011), and SREBF activity is regulated by mTOR complex 1 (Peterson et al. 2011). It is remarkable that simply by contrasting motif activities in tissues from younger and older donors, An increase in chromosome number may result in a shorter life span. Thus, we examined the effect of an increased number of chromosomes on life span in strain YMH471 (34) harboring 21 chromosomes. The life span of this strain was found to be no different than that of wild type (data not shown). It has been established that trans-acting factors such as Fob1p and Sir2p are important for regulating copy number of rDNA, silencing and aging (16,17,22,30). Michel et al. (45) reported that short rDNA clones that arose from a single-step deletion event genes. Lysosomes are responsible for the degradation of many macromolecules, including proteins, and increase in lysosomal mass is a well-known characteristic of aging and senescence in cells (Cuervo and Dice 2000; Kurz et al. 2000). In addition, evidence is increasing that a progressive decrease in the efficiency of autophagy and lysosomes with age plays a key role in aging-associated degenerative changes in mammals (Rubinsztein et al. 2011). Several recent findings support that SREBP TFs play a key role in these processes. SREBF1 expression ‘old’ samples for each motif (results at http://ismara.unibas.ch/supp/dataset1_IBM/averaged_age/averaged_report/). We found that only the SREBF motif is significantly differently regulated between old and young samples (Fig. 2D). The targets of SREBF are up-regulated in older tissues relative to the younger ones and are highly enriched for lysosomal genes. Lysosomes are responsible for the degradation of many macromolecules, including proteins, and increase in lysosomal mass is a well-known characteristic of aging and senescence in cells a primary role in cell reprogramming. Additional properties have been shown for classical pioneer factors, including remaining bound to the mitotic chromosomes (i.e., bookmarking) and binding to nucleosomal DNA (Cirillo et al. 2002; Sekiya et al. 2009; Kadauke et al. 2012; Caravaca et al. 2013). It will be important to determine whether Zld shares these characteristics with other pioneer factors. Pioneer factors, such as FOXA1, can bind to closed chromatin and subsequently increase accessibility of the target site (Cirillo et al. 2002). not rule out the possibility that in ducklings those RNAs have a longer half-life. Differently from viral RNA, DHBV core protein and replicative intermediates were nearly equally detected in ducks and ducklings with some variations. Zein et al. 2009). These observations suggest that the core regulatory network involved in ciliogenesis, with MYBL1 targeting RFX promoters and RFX TFs targeting FOXJ1, is conserved across multiple mammalian systems. As indicated in Figure 4B, ISMARA additionally predicts that, in this system, IRF1,2,7 up-regulates innate immune response genes, and a short spike of E2F activity up-regulates cell-cycle genes at day 1. Finally, there is a group of motifs (TBP, FOS_FOS{B,L1}_JUN{B,D}, RXR{A,B,G}, HOX{A6,A7,B6,B7}, and GLI1..3) whose targets are\n",
            "[0.6800165]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which antibody is implicated in the Bickerstaff's brainstem encephalitis?\n",
            "Refined Query: Bickerstaff's brainstem encephalitis (BBE) is a neurological disorder linked to antibodies targeting specific proteins.  Which specific antibody, or antibodies, are most strongly implicated in the pathogenesis of BBE, and how does their presence contribute to the characteristic neurological symptoms?\n",
            "\n",
            "Combined Answer: which creates a barrier to mAb distribution in tissues following extravasation (36–39). The limited distribution of monoclonal antibodies to the brain has primarily been explained by tight junctions in the brain vascular endothelium, and plasma-to-brain concentration ratios are typically in the range of 500:1 (40). The role of FcRn in limiting IgG exposure in the brain has been the focus of several investigations, and conflicting data have been reported (40–42). Galcanezumab shows limited distribution into the central nervous system and is low, a central effect cannot be definitively ruled out. For many neurodegenerative diseases, monoclonal antibodies are being developed suggesting that they can act centrally to mediate their effects (44–46). It has been hypothesized that a migraine attack could potentially disrupt the blood-brain barrier (BBB), allowing a mAb entry into the brain. However, it has been shown experimentally that there is no increase in BBB permeability during an aura phase of migraine and there is no disruption of the BBB during a glyceryl Antibody Resource for MANDSY106. The UCL MRC Neuromuscular Centre Biobank is also acknowledged. F.M. is supported by the Great Ormond Street Children's Charity. J.E.M. is funded by a Wellcome Trust University Award. All other authors except the listed those below do not report any disclosures. Prof Muntoni has served on scientific advisory boards for Genzyme, AVI BioPharma, Inc., GSK; he serves on the editorial board of Neuromuscular Disorders and Neuropediatrics; he receives research support from AVI BioPharma, Inc., the European Union, the overlapping to an even larger extent with the epitopes of bezlotoxumab. As mentioned above, the two Fab regions of a single bezlotoxumab molecule bind to TcdB at two distinct sites, E1 and E2. Of the 18 bezlotoxumab-interacting residues in common between E1 and E2, only 10 are identical, although 6 of the 8 amino acids substitutions are conservative (Fig. 3D). The structural tolerance for binding exhibited by bezlotoxumab suggests that this antibody should bind to and neutralize toxins from various C. difficile strains, although this remains IgG exposure in the brain has been the focus of several investigations, and conflicting data have been reported (40–42). Galcanezumab shows limited distribution into the central nervous system and cerebrospinal fluid (43). For other monoclonal antibodies that bind CGRP, no data exists to our knowledge. While the central penetration of galcanezumab is low, a central effect cannot be definitively ruled out. For many neurodegenerative diseases, monoclonal antibodies are being developed suggesting that they can act centrally to mediate their NHE6 protein appears to be expressed in just about every cell and tissue type yet examined.31 Given this result, it is not surprising that somatic medical symptoms appear to represent a part of CS. A particularly notable symptom is gastroesophageal reflux. While GI symptoms are commonly reported in neurodevelopmental disorders such as Rett syndrome32 and 22q11.2 microdeletion syndrome33, the data that two patients in our cohort required surgery to correct extreme GERD raise the possibility that this GI condition may be related to CS. In fewer than 10 % of children surviving for more than 2 years [9, 13]. In addition, based on their infiltrative nature and location within the brainstem, DIPGs are often diagnosed clinically based on a combination of neurological signs, duration of symptoms and specific neuro-imaging findings. Currently, biopsy of these tumors is controversial as the findings do not alter therapy if the child presents with classic clinical and imaging features. However, biopsy may be helpful if biological information gleaned from the tissue may guide therapy or controls (Student's t test p=0·024), confirming that the mRNA from both alleles undergoes NMD and thus showing a loss of TBC1D24 function. TBC1D24 protein from these fibroblasts could not be detected by western blot analysis (figure 3). We next assessed Tbc1d24 tissue expression. Tbc1d24 is known to be widely expressed, most highly in the brain (especially in pyramidal neurons), kidneys, and salivary and lacrimal glands.29, 30 In the brain, the regions with the highest expression levels are the hippocampus and the somatomotor areas of the epileptic seizures and likely caused by a neuronal migration defect (Wolf et al. 1995), which is consistent with the barhl1 expression pattern. However, the TSC1 ortholog was duplicated in teleosts along with barhl1 and might be a developmental regulator itself, perhaps coregulated with barhl1 orthologs. The data presented in this paper suggest that for the mapping of human diseases it will be important to establish whether the implied disease gene is a GRB target gene or is, in fact, located in a GRB as a bystander with no functional relation problems, including two with suspected encephalitis. Infectious disease hospitalizations included: pneumonia; status epilepticus and possible viral encephalitis; and influenza B infection with myositis and possible encephalitis. A range of other medical problems were observed in only a single child and are listed in Supplementary Table 1.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Arthritis - {'Anti-Inflammatory Drugs': 0.0, 'Joint Swelling': 1.0}\n",
            "\n",
            " ### Clustered: {'Arthritis': {'Cluster 1': ['Anti-Inflammatory Drugs'], 'Cluster 2': ['Joint Swelling']}}\n",
            "Original Query: Which micro-RNAs have been associated in the pathogenesis of Rheumatoid Arthritis?\n",
            "Refined Query: Investigate the specific microRNAs implicated in rheumatoid arthritis pathogenesis, focusing on their roles in the inflammatory processes contributing to joint swelling and the potential for anti-inflammatory drug modulation of these microRNA activities.\n",
            "\n",
            "Combined Answer: in the expression of rheumatoid arthritis risk genes with super-enhancer structures by treating T-cells with the Janus kinase (JAK) inhibitor tofacitinib (35). Additionally, disease-associated single nucleotide polymorphisms (SNPs) for autoimmune diseases such as rheumatoid arthritis have been found to be highly enriched in super-enhancer regions (35). The current research well characterized this biological phenomenon and effectively demonstrated the importance and potential application of super-enhancers as they can play key roles in cell MicroRNAs are small (18–27 nucleotides long), single stranded RNA molecules found in plants, animals, and some viruses. They are most known for controlling protein synthesis either by translation repression or mRNA degradation but they also promote histone modification and DNA methylation of promoter sites, which influence the expression of target genes [1, 2]. Their function is accomplished by binding to the target mRNA through sequence complementarity rules, usually in the 3′untranlated region (UTR) [3]. MicroRNA genes are typically for the investigation of their role in development. The conservation of synteny in these blocks around miRNA target genes indicates that these extended regulatory domains may be sensitive to chromosomal rearrangements resulting in position effect mutations and possibly harbor human disease breakpoints. and deep sequencing are being used in combination with computational methods for the identification of novel miRNA genes and mature miRNAs [6–8]. These methods are particularly useful as they can provide a very sophisticated and accurate expression map for possible miRNA genes in the genome. However, they are also limited by their high cost as well as their tissue and condition specificity. Furthermore, identification of a small RNA sequence in deep sequencing data is not sufficient to categorize this molecule as a true, functional miRNA. As linked the activation-induced deaminase (AID) off-targeting activity to the process of convergent transcription (33) and these AID targets are mainly grouped within super-enhancer and regulatory clusters (34). Very recently, Vahedi et al. found super-enhancers in T-cells by profiling p300 ChIP-seq signal and showed disproportionate alteration in the expression of rheumatoid arthritis risk genes with super-enhancer structures by treating T-cells with the Janus kinase (JAK) inhibitor tofacitinib (35). Additionally, disease-associated single and wound healing assay revealed that Uc.63+ was involved in cell growth and cell migration. miR-130b was predicted to have binding sites within the Uc.63+ sequence. The expression of miR-130b was significantly disturbed by the overexpression or knockdown of Uc.63+. We also showed that Uc.63+ regulated the expression of MMP2 via miR-130b regulation. Furthermore, overexpression of Uc.63+ increased the expression of AR and its downstream molecule PSA and promoted resistance to docetaxel through AR regulation. In patients treated with docetaxel, served as internal controls. To quantify the level of miRNAs, TaqMan assays were performed as described previously [25] The expression values were normalized to the expression of the small RNA gene RNU6, and the relative quantification was determined using the ΔΔCt method as described previously [26]. Because lncRNAs might act as scaffolds or decoys, which interact with microRNAs (Poliseno et al, 2010; Yuan et al, 2014) and the epigenetic machinery (Rinn, 2014) to regulate transcription, we explored potential downstream targets of LIMT. To this end, we firstly manipulated the levels of LIMT in MCF10A cells, by means of either siRNA‐mediated knockdown or stable overexpression. We then profiled genomewide abundance of RNAs using Affymetrix microarrays. Analysis of the microarray screens identified 48 genes that undergo reciprocal expression Breast cancer is a heterogeneous disease; hence, many efforts are being made to identify new drivers and classify tumors into increasing numbers of subtypes (Perou et al, 2000; Dawson et al, 2013). Thus, whereas initial profiling focused on finding histological characteristics and signatures of protein‐coding genes, more recent studies have found that the expression of microRNAs may also assist prognosis and classification (Dvinge et al, 2013). Importantly, the relatively high tissue specificity of lncRNAs promises a role for these noncoding since many of the lncRNA probes were based on putative lncRNA annotations, we overlapped the position of each probe with RefSeq annotated ncRNAs. Only probes overlapping annotated RefSeq ncRNAs were retained for assessment of the effect of EGF stimulation on transcript abundance. The microarray dataset is accessible at the ArrayExpress database (E‐MTAB‐4822). In addition, we used DNA arrays to profile gene expression upon manipulation of LIMT levels. Twelve RNA samples, representing (i) knockdown of LIMT, (ii) knockdown using control siRNA\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.94ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1333.71ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are CD44 variants (CD44v) associated with poor prognosis of metastasis?\n",
            "Refined Query: The expression of various CD44 isoforms, particularly CD44 variants (CD44v), has been implicated in cancer progression and metastasis.  This raises the question:  Do specific CD44v patterns or levels correlate with reduced patient survival and increased metastatic potential across different cancer types?\n",
            "\n",
            "Combined Answer: size (χ2 = 29.518, P = 0.000), tumor grade (χ2 = 36.993, P = 0.000), TNM stage (χ2 = 39.674, P = 0.002) and distant metastasis (χ2 = 40.462, P = 0.000). But no significant correlations between uc.189 expression levels and other clinicopathologic variables, including age and depth of tumor invasion (all P > 0.05; Tables 3, 4). EAC patients with high uc.189 expression was dramatically poorer than that of EAC patients with low/unchanged uc.189 expression (P < 0.01; Figure 2). The median survival times were 43.52 months for high uc.189 expression and 72.99 months for low/unchanged uc.189 expression. Similarly, tumor node status (44.69 vs. 58.67 months; P < 0.01, n = 98) and distant metastasis (45.34 vs.54.61 months; P < 0.01, n = 98) also remained a significant predictor of poor survival from Table 5. In multivariate analysis for CSCC, tumor stage (HR, 5.825; 95% CI, H3K27me3 is dramatically reduced in SF7761 cells compared with NSCs. H3K27me3 peaks detected in SF7761 cells spanned a larger chromatin region than those found in NSCs (Supplemental Fig. 5). Of the 2684 H3K27me3 peaks detected in SF7761 cells, 63% were unique to this cancer line in relation to NSCs. Surprisingly, these unique peaks had significantly more tagged density than corresponding peaks found in NSCs (Fig. 3A,D). These results indicate that the level of H3K27me3 at these loci, such as the long isoform of CDK6, is significantly elevated (P = 0.000, P = 0.000), there was a tendency towards a difference in TNM stage between patients with high versus low/ unchanged expression levels of uc.189 in CSCC (P = 0.083). The prognosis of CSCC patients with high expression of uc.189 was significantly poorer than that of CSCC patients with low/ unchanged uc.189 expression (P < 0.001; Figure 2). The median survival times were 43.45 months for high uc.189 expression and 72.47 months for low/unchanged uc.189 expression. Similarly, tumor node status (44.69 vs. 58.67 months; P < 0.01, n = 116) There was a significant difference in Tumor grade (χ2 = 10.736, P = 0.001), nodal status (χ2 = 3.868, P = 0.049), TNM stage (χ2 = 12.318, P = 0.000) between patients with low/ unchanged versus high expression levels of uc.189 in CSCC. In EAC, unchanged/low versus high expression levels of uc.189 also showed a significant difference in tumor size (χ2 = 29.518, P = 0.000), tumor grade (χ2 = 36.993, P = 0.000), TNM stage (χ2 = 39.674, P = 0.002) and distant metastasis (χ2 = 40.462, P = 0.000). But no significant correlations between uc.189 distant metastasis (45.34 vs.54.61 months; P < 0.01, n = 98) also remained a significant predictor of poor survival from Table 5. In multivariate analysis for CSCC, tumor stage (HR, 5.825; 95% CI, 1.893–17.930; P = 0.002), grade (HR, 0.515; 95% CI, 0.271–0.978; P = 0.042), distant metastasis (HR, 0.298; 95% CI, 0.099–0.899; P = 0.032), and high uc.189 (HR, 0.067; 95% CI, 0.027–0.165; P = 0.000) predicted poor prognosis (Table 7). Moreover, in multivariate analysis for EAC, tumor status (HR,1.759; 95% CI, 1.084–2.854; P = 0.022), stage (HR, gene) and CDK6 (a group C gene). Using quantitative RT–PCR (qRT–PCR), we validated that the expression levels of OLIG2 in two cancer lines was higher than those in NSCs. Similarly, the expression of the long isoform of CDK6 (NM_001259) was significantly lower in both H3.3K27M patient lines relative to NSCs. In contrast, the expression of the short form of CDK6 (NM_001145306), in which no gain of H3K27me3 peak was detected by ChIP-seq (Fig. 3D), was not altered in DIPG patient cells (Fig. 4D). Kyoto Encyclopedia of Genes and Genomics (KEGG) of 44 cell lines representing cancer and non‐cancer cells from 15 tissues of human origin, including six breast cell lines. LIMT was found to be widely and differentially expressed, with relatively high expression in brain, blood, and several lung and mammary cell lines (Fig 5B). Next, we evaluated relations between LIMT and molecular subtypes of breast cancer, in two cohorts of patients: the Oslo2 cohort (Aure et al, 2014) and the larger, METABRIC dataset (Curtis et al, 2012). In line with the aforementioned lines of evidence, the lowest We thank Jörg Bungert (University of Florida, Gainesville), Yoshihiro Nakatani (Dana-Farber Cancer Institute, Boston), Yang Shi (Harvard Medical School, Boston), and Eric So (The Institute of Cancer Research, London) for reagents and Jörg Bungert and Lizi Wu for helpful suggestions and comments on the manuscript. This work was supported by National Institutes of Health Grants HL090589 and HL091929 (to S.H.) and grants from the Bankhead-Coley Cancer Research Program (to S.H. and Y.Q). C.N. is supported by the Intramural Research Program, The median survival times were 43.45 months for high uc.189 expression and 72.47 months for low/unchanged uc.189 expression. Similarly, tumor node status (44.69 vs. 58.67 months; P < 0.01, n = 116) and distant metastasis (45.34 vs.54.61 months; P < 0.01, n = 116) also remained a significant predictor of poor survival from Table 5. The prognosis of EAC patients with high uc.189 expression was dramatically poorer than that of EAC patients with low/unchanged uc.189 expression (P < 0.01; Figure 2). The median survival times were 43.52 months for\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1259.93ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1133.52ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Arthritis - {'Anti-Inflammatory Drugs': 0.0, 'Joint Swelling': 1.0}\n",
            "\n",
            " ### Clustered: {'Arthritis': {'Cluster 1': ['Anti-Inflammatory Drugs'], 'Cluster 2': ['Joint Swelling']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1057.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1132.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1737.22ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 881.66ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1140.84ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1159.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the typical alteration of the thyroid profile metabolism early after coronary artery bypass graft surgery?\n",
            "Refined Query: Following coronary artery bypass graft (CABG) surgery, how do thyroid hormone levels (T3, T4, TSH) typically change in the immediate postoperative period?  What factors contribute to these alterations, and are they clinically significant?\n",
            "\n",
            "Combined Answer: proteins in adult human blood varies greatly: TBG at 0.015 g/l, TTR at 0.25 g/l and albumin at 42 g/l. Traditionally it has been believed that in blood, TBG distributes about 75% of thyroid hormones, TTR distributes 15% and albumin transports about 10%. Because TBG binds about 75%, it is sometimes referred to as the “most important” thyroid hormone distributor. However, this is too simplistic, as the biological importance is related to the delivery of THs to cells, which is dependent on the dissociation rates of T3 and T4 from the distributor moves T3 into the brain? What could have been the selection pressure for the change to TTR from distributing T3 to distributing T4? One possibility could be a greater level of control, requiring an additional level of regulation (i.e., deiodination of T4 to T3) at the target site. For example, different regions of the brain generate different proportions of T3 by local deiodination (van Doorn et al., 1985). Two features that distinguish mammalian brains from non-mammalian brains that are regulated (at least in part) by thyroid hormones are the transthyretin moves thyroid hormones from blood into cerebrospinal fluid just prior to when thyroid hormones are required for rapid brain growth. The structure of transthyretin has been highly conserved, implying strong selection pressure and an important function. In mammals, transthyretin binds T4 (precursor form of thyroid hormone) with higher affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave From the above controversy regarding the importance of TTR synthesis by the choroid plexus, several points support the hypothesis that choroid plexus-derived TTR plays a role in the movement of THs from the blood to the brain and in distributing THs in the blood and CSF. These points include evolutionary, developmental, molecular and functional data. Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters - PMC studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, there is evidence for two mechanisms for THs to move out of the choroid plexus into the CSF: (i) secretion of TH bound to choroid plexus-derived TTR, and (ii) efflux of THs via TH transmembrane transporters. The relative quantitative contribution of each of these mechanisms during each stage of CNS development is currently unknown and should be affinity for T4 and T3 (1.0 × 1010 M−1 and 4.6 × 108 M−1, respectively), TTR has intermediate affinity (7.0 × 107 M−1 and 1.4 × 107 M−1, respectively) and albumin has the lowest affinity (7.0 × 105 M−1 and 1.0 × 105 M−1, respectively). Together, these three TH distributor proteins form a buffering network for free T4 in blood, which could help to protect against hypothyroidism (abnormally low levels of free TH in blood) or hyperthyroidism (abnormally high levels of free TH in blood) (Schreiber and Richardson, 1997). The older literature and\n",
            "[0.66620815]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which proteins are involved in actin bundling and filopodia formation and function?\n",
            "Refined Query: I'm investigating the specific proteins crucial for actin filament bundling within the context of filopodia.  This includes proteins responsible for both the initiation and maintenance of these structures, and their functional roles in cell motility and signaling.\n",
            "\n",
            "Combined Answer: structures by serving as an important architectural bridge role between the F-actin cytoskeleton and the muscle plasma membrane41,42. Two regions within dystrophin are responsible for F-actin binding: ABD1 (actin binding domain, spanning residues 15–237) and ABD2 (spanning residues 1468–2208). A number of studies have shown a lack of stability of dystrophin in the setting of deletions within the ABD1 domain6,43–46. However, we note that most of these studies were performed with microdystrophin constructs lacking the ABD2 domain, which has been preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the extracellular matrix (Brieher and Yap, 2013; Ratheesh and Yap, 2012). but, in eukaryotes, were previously thought to be restricted to choanoflagellate and sponge proteins (Pfam accession: PF00963) (Abedin and King, 2008; Nichols et al., 2012; Peer et al., 2009). These are not to be confused with the cohesin complex that regulates the separation of sister chromatids. Rather, cohesin domains are highly specialized protein-protein interaction modules that bind dockerin domains together forming the core that glues together the Cellulosome complex, a multi-enzymatic complex present in cellulolytic bacteria in the setting of deletions within the ABD1 domain6,43–46. However, we note that most of these studies were performed with microdystrophin constructs lacking the ABD2 domain, which has been shown to enhance the interaction between ABD1 and actin47. Such miniproteins bind actin and modify actin dynamics in a different manner compared to the full length version48,49. Although results with such constructs show that absence of ABD2 does not completely abrogate binding of dystrophin to actin, it is unlikely that absence of ABD1 completely disrupts and sponge proteins, all five are both present and in the identical order in the three cadherin protein families—lefftyrins, coherins and hedglings—that were contained in the last common ancestor of choanoflagellates and metazoans (Abedin and King, 2008; Nichols et al., 2012) (Supplementary Fig. S2). The TMEM132 domain architecture is thus ancient, preceding the emergence of early metazoans, and a repeated constituent of ancient cadherin domain-containing proteins with roles connecting the actin cytoskeleton with neighbouring cells and the and/or conditional activation signals will shed light on underlying mechanisms of IRES control and elucidate potentially novel functions of dystrophin. An intriguing question is how the N-truncated isoform remains functional. A key cellular role for dystrophin is presumed to be transmitting the force of contraction across the sarcolemma to extracellular structures by serving as an important architectural bridge role between the F-actin cytoskeleton and the muscle plasma membrane41,42. Two regions within dystrophin are responsible for F-actin with intracellular C-terminal Ser/Thr phosphatase-1 (PP1) docking (Hendrickx et al., 2009; Heroes et al., 2013) and WIRS (WAVE regulatory complex interacting receptor sequence) cytoplasmic motifs (Fig. 1 and Supplementary Fig. S1) (Chen et al., 2014). The latter is consistent with the reported co-localization of TMEM132D with actin filaments (Walser et al., 2011). Cell–cell junctions in the central nervous system (CNS) are maintained by a variety of transmembrane proteins that signal and physically link between the cytoskeletons of adjacent unappreciated cell adhesion molecules whose domain architecture has an early holozoan origin prior to the emergence of choanoflagellates and metazoa. The extra-cellular portions of TMEM132 proteins contain five conserved domains including three tandem immunoglobulin domains, and a cohesin domain homologue, the first such domain found in animals. These findings strongly predict a cellular adhesion function for TMEM132 family, connecting the extracellular medium with the intracellular actin cytoskeleton. matrix and the actin-based cell cytoskeleton, with major roles in regulating changes in neuronal cell morphology, motility and migration. These findings should precipitate more detailed experimental and structural characterization of the TMEM132 family, and assist in formulating hypotheses concerning the cellular mechanisms by which sequence variants in these genes contribute to neurological disease. Their ancient ancestry and their associations with neurological disease suggest that TMEM132 genes have been undeserving of their relative obscurity. Our identification of these proteins as CNS-expressed IG domain superfamily adhesion molecules now places them in a more appropriate perspective as a putative key connection between the extracellular matrix and the actin-based cell cytoskeleton, with major roles in regulating changes in neuronal cell morphology, motility and migration. These findings should precipitate more detailed experimental\n",
            "[0.63049424]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What does the SAGA complex acronym stands for?\n",
            "Refined Query: Could you please clarify the full meaning of the acronym SAGA, in the context of its use?  I'm interested in understanding what the letters in this complex acronym represent.\n",
            "\n",
            "Combined Answer: Conceptualization: Hanjun Qiu, Xiang Wang. Data curation: Zhixiong Zhu, Xiang Wang. Formal analysis: Hanjun Qiu, Zhuyi Si. Funding acquisition: Yueyi Wang. Investigation: Shirong Yang. Methodology: Hanjun Qiu, Dong Shen, Xuezong Wang, Chaojie Lu, Xu Kang. Project administration: Xiang Wang. Resources: Zhuyi Si, Xiang Wang. Software: Hanjun Qiu, Zhuyi Si, Yi Di. Supervision: Hanjun Qiu, Xiang Wang. Validation: Hanjun Qiu, Dong Shen, Yi Di, Xiang Wang. Visualization: Dong Shen, Yi Di, Xu Kang, Xiang Wang. Writing – original draft: Yi Di, Xiang terminologies and ontologies, relevant articles in English from designated article repositories, relevant snippets from the relevant articles, and relevant RDF triples (statements) from designated ontologies. The participating systems were allowed to return at most 100 concepts, 100 documents, 100 snippets and 1,000 RDF triples per question; (b) Phase B: The BIOASQ team released questions and gold (correct) relevant concepts, articles, snippets, and RDF triples (statements) from the benchmark datasets. The participating systems had to respond providing services in this industry, including information technology providers, and eventually everyone who will benefit from improved biomedical processes. On the way to this big goal, the first BIOASQ challenge facilitated a number of significant intermediate results. Primarily it facilitated a better understanding of the current semantic indexing and question answering technologies and their limitations. In addition, it enabled improved awareness of the biomedical community about the possibility of significant improvement of their work, statements from designated repositories. It was created by the BIOASQ biomedical expert team, using the BIOASQ annotation tool that will be described later. The task was organised in two phases; (a) Phase A: The BIOASQ team released questions from the benchmark datasets. The participating systems had to respond with relevant concepts from designated terminologies and ontologies, relevant articles in English from designated article repositories, relevant snippets from the relevant articles, and relevant RDF triples (statements) from designated also follow a similar approach [4,6]. Starting with a variety of data sources (lower right corner of the figure), semantic indexing and integration brings the data into a form that can be used to respond effectively to domain-specific questions. A semantic QA system associates ontology concepts with each question and uses the semantic index to retrieve relevant texts (documents or abstracts, e.g., from PUBMED or PUBMED CENTRAL) to retrieve pieces of structured information (e.g., Linked Open Data triples) and relevant documents (or abstracts, Besides the option to download output files, webSDA offers a convenient visualization of the results. An example is given in Figure 2. For the results of ‘SDA docking’, JSmol is used for visualization of the cluster representatives of the diffusional encounter complexes. This provides users with an easy way to view encounter complexes and decide which complexes to download for further analyses. For ‘SDA association’, the calculated association rate constants are plotted using the R language, enabling users to visualize calculated association B: The BIOASQ team released questions and gold (correct) relevant concepts, articles, snippets, and RDF triples (statements) from the benchmark datasets. The participating systems had to respond with “exact” answers, i.e., “yes” or “no” in the case of yes/no questions, named entities in the case of factoid questions, list of named entities in the case of list questions and nothing in the case of summary questions, and “ideal” answers (i.e., paragraph-sized summaries) for all types of questions. We call them “ideal” because it is what a human AC: acetylation; CAGE: cap analysis of gene expression; CTSS: CAGE transcription start site; GRB: genomic regulatory block; HCNE: highly conserved non-coding element; TC: CAGE tag cluster; TF: transcription factor; TFBS: transcription factor binding site; TSS: transcription start site. After the clustering procedure described above, the cluster representatives may be submitted to four different visualization procedures: scatterplots, a graph-based visualization, tree maps, and tag clouds. In drawing scatterplots (Fig. 2), the challenge lies in assigning x and y coordinates to each term so that more semantically similar GO terms are also closer in the plot. Here, we employ a multidimensional scaling procedure which initially places the terms using an eigenvalue decomposition of the terms' pairwise distance matrix. This is Rough Sets (JRS) symposium’s special event: Topical classification of biomedical articles, based on MESH concepts automatically assigned to articles by a tagger developed by the organisers [16]. (Ran in 2012.) Finally, the Special Interest Group on Biomedical Natural Language Processing (SIGBIOMED) of the Association for Computational Linguistics (ACL) organises the BioNLP annual workshops, which focus mostly on information extraction from biomedical documents (e.g., recognising named entities, particular relations between named entities, or\n",
            "[0.5628935]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the result of the interaction between TSC1 and PLK1?\n",
            "Refined Query: Investigate the functional consequences of TSC1 and PLK1 interaction.  Does their interplay influence cell cycle regulation, cell growth, or other cellular processes?  Describe the nature of this interaction – is it direct or indirect, stimulatory or inhibitory?\n",
            "\n",
            "Combined Answer: mechanism. Treating C2C12 cells with RSV dramatically inhibited insulin-stimulated Akt, S6 kinase, and 4E-BP1 phosphorylation but had little effect on tyrosine phosphorylation of the insulin receptor and activation of the p44/42 MAPK signaling pathway. RSV treatment also partially blocked mTOR and S6 kinase phosphorylation in TSC1/2-deficient mouse embryonic fibroblasts, suggesting the presence of an inhibitory site downstream of TSC1/2. Knocking out PDK1 or suppressing AMP-activated protein kinase had little effect on leucine-stimulated mTOR ApcNN cells confirmed that Tcf3 effectively reverses the expression pattern of several genes differentially expressed in ApcNN when compared to wild type ESCs (Figure S3). Since it has been previously reported that Tcf3 over-expression in wild type ESCs induces differentiation under self-renewing conditions [5], we first assessed whether over expressing Tcf3 in ApcNN ESCs induces similar effects in these cells. As reported above, ApcNN cells can grow in 1i medium (i.e. in LIF+Mek inhibitor) in the absence of GSK inhibitor (Figure 1C). To embryonic fibroblasts, suggesting the presence of an inhibitory site downstream of TSC1/2. Knocking out PDK1 or suppressing AMP-activated protein kinase had little effect on leucine-stimulated mTOR signaling. On the other hand, RSV significantly increased the association between mTOR and its inhibitor, DEPTOR. Furthermore, the inhibitory effect of RSV on leucine-stimulated mTOR signaling was greatly reduced in cells in which the expression levels of DEPTOR were suppressed by RNAi. Taken together, our studies reveal that RSV inhibits expressing Tcf3 in ApcNN ESCs induces similar effects in these cells. As reported above, ApcNN cells can grow in 1i medium (i.e. in LIF+Mek inhibitor) in the absence of GSK inhibitor (Figure 1C). To investigate whether Tcf3 can restore their dependency on the GSK inhibitor in serum-free culture, Tcf3-over expressing ApcNN cells were seeded at clonal density under different conditions and subsequently stained for alkaline phosphatase (AP) to evaluate the percentage of undifferentiated colonies. We found that, similar to the parental ApcNN it also inhibits PLK2 in the biochemical assay (Fig. 2, A and B). APMU (compound 3 in Johnson et al. (29)), which has good activity against PLK2 and -3 but is inactive against PLK1, inhibited α-synuclein phosphorylation in mouse cortical cultures. These results, together with the lower activity for PLK1 (Fig. 1A), suggest a limited role, if any, for PLK1 as an α-synuclein kinase. BI2536 has high potency and specificity for PLK family kinases (30) (see profiling results in supplemental Table S1). This compound inhibited up to 85–90% of by Dax1. Furthermore, we revealed that Oct3/4, Dax1, and Esrrb have a competitive inhibition capacity for each complex. These data, together with previous findings, suggest that Dax1 functions as a negative regulator of Esrrb and Oct3/4, and these molecules form a regulatory loop for controlling the pluripotency and self-renewal capacity of ES cells. 2E). These results suggest that inhibition of the PI3K/PDK1/Akt signaling pathway is dispensable for the negative regulation RSV-promoted of leucine-stimulated mTOR signaling. There is some evidence indicating that RSV could exert its biological effect by activation of AMPK (40, 41). Because activation of AMPK enhances TSC1/2 activity that down-regulates mTOR signaling (42, 43), it is possible that RSV inhibits leucine-stimulated mTOR signaling by activation of AMPK. However, we found that disruption of TSC1/2 expression or suppression of the we could not rule out that possibility that the recruitment of LSD1 to the pTα promoter is mediated in part through other transcription factors or mechanisms. On the other hand, TAL1 also activates a variety of genes affecting T-cell survival and growth, including CDK6, Runx1, and NKX3.1 (23, 48, 56). Given that PKA phosphorylation regulates the TAL1-LSD1 interaction in T-ALL Jurkat cells (Figures 3 and 4), it will be interesting to know if PKA phosphorylation of TAL1 could facilitate TAL1’s ability to recruit coactivators during individual mutants revealed that K151E mutant continues to associate with 53BP1 in cells, while K10E mutation is sufficient to disrupt the interaction with 53BP1. We concluded that the residue K10 is crucial for the interaction with 53BP1. a significant increase in apoptotic cells in the Dox-induced TAL1 KD Jurkat cells (Figure S3B, bottom blue color). Importantly, KD of TAL1 resulted in a strong derepression of pTαp21, and PTEN genes (Figure 6B). As a control, KD of TAL1 in Jurkat cells reduced its activated target Runx1 (48) and did not affect unrelated STIL expression (Figure S3C). We, therefore, tested whether the loss of TAL1 leads to a decrease in LSD1 recruitment at the pTα enhancer (Figure 6C), which may contribute to the derepression of the pTα gene in the induced KD\n",
            "[0.57848024]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the characteristics of the \"Universal Proteomics Standard 2\" (UPS2)?\n",
            "Refined Query: Describe the key features and composition of the Universal Proteomics Standard 2 (UPS2), including the number and types of proteins it contains, its intended use in proteomics experiments, and its advantages over previous standards.\n",
            "\n",
            "Combined Answer: dissociation (CID). Parameters for data processing were also followed as described previously [56]. Briefly, raw files containing MS2 data were extracted by Proteome Discoverer (version 1.3; Thermo Scientific) and uploaded to SEQUEST (version 1.20) and searched against a compiled database of the yeast protein sequences from S. cervisiae and S. pombe. Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide Ferrara), for their technical support. The Clinical Proteomics Mass Spectrometry core facility at Karolinska University Hospital and Science for Life Laboratory is acknowledged for assistance in mass spectrometry and data analysis. The raw data were extracted from the XCalibur data system format into MS1 and MS2 formats using in-house software. The peptides and proteins were identified by the Integrated Proteomics Pipeline - IP2 (Integrated Proteomics Applications, Inc., San Diego, CA. http://www.integratedproteomics.com/) using ProLuCID19 and DTASelect220 with a decoy database strategy. The protein false positive rate was controlled to be less than 1%. The searches were against EBI IPI Human protein database (version 3.87). Cysteine carboxyamidomethylation was set as a To determine enrichment of protein interactions within the network relative to the background proteome, NSAF (normalized spectrum abundance factor) values were calculated to take into account protein length and the total number of spectra present in each individual IP experiment. NSAF values were normalized to proteome abundance (PAX) values for S phase S. pombe (pax-db.org), and the NSAF/PAX ratio was mapped onto each node (node color). complexity that can influence the number of spectra acquired for a given protein within a sample. Normalizing NSAF values to PAX values, as described in [56], provides insight into proteins and functional protein classes that are enriched in the Pfh1 isolation relative to their abundances in the cellular proteome. These data are presented in Fig 6C, which also categorizes interacting proteins by function. our laboratory.21 The statistical analysis among replicates was performed in the module “quantification compare” of IP2. Proteins with an average stable isotope ratio (ABPP 106 versus control probe) greater than 2 or greater than 1.5 with p < 0.05 were subjected to functional analysis in DAVID22 as well as Ingenuity. probe and a second control probe, whose structures are shown in Figure 5a. Figure 5b clearly shows that TCEB2 is captured by both specific probes, but not by the control probe, providing validation of the proteomic analysis for TCEB2. Validation experiments for other identified targets is beyond the scope of the present study. Post-search validation of the SEQUEST data was conducted by an X! Tandem algorithm in Scaffold (version Scaffold_3_00_04; Proteome Software) using the following filter selections to reduce peptide and protein global false discovery rate to < 1%: 99% protein confidence, 95% peptide confidence, and a minimum of two unique peptides per protein. on the manuscript and Raymond Poot (CSC, London) for helpful discussions. We are grateful to Gerd Blobel (Children's Hospital of Philadelphia) for exchanging prepublication data. This work has been supported by the Netherlands Research Organization (NWO), the European Union (grant HPRN-CT-2000-00078), the NIH (grant RO1 HL 073455-01) and the Netherlands Proteomics Center. Resource [56] (UNIPROT) provides the scientific community with a comprehensive, high-quality and freely accessible resource of protein sequence and functional information. Its protein knowledge base consists of two sections: Swiss-Prot, which is manually annotated and reviewed, and contains approximately 500 thousand sequences, and TrEMBL, which is automatically annotated and is not reviewed, and contains approximately 23 million sequences. The primary mission of UNIPROT is to support biological research by maintaining a stable, comprehensive,\n",
            "[0.8106877]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which polyQ tract protein is linked to Spinocerebellar Ataxia type 2?\n",
            "Refined Query: Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disorder.  What specific protein with a polyglutamine (polyQ) tract is responsible for causing this inherited disease?  Identifying this protein is key to understanding SCA2 pathogenesis.\n",
            "\n",
            "Combined Answer: Recent studies have indicated that members of the 2-aminobenzamide class of histone deacetylase inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich’s ataxia (FRDA) and Huntington’s disease.1−3 In the case of FRDA, this disorder is caused by transcriptional repression of the nuclear FXN gene encoding the essential mitochondrial protein frataxin.4 Expansion of GAA·TTC triplet repeats in pathogenic FXN alleles cause gene silencing and a loss of frataxin protein in affected individuals. Currently there is no Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative condition characterized by aetiologically diverse pathomechanisms, which ultimately results in loss of upper and lower motor neurons, paralysis and death. In a rapidly growing group of genes mutated in ALS the most represented are the genes encoding proteins directly or indirectly involved in RNA metabolism [1-3]. Structural and functional studies of ALS-associated proteins and their disease-linked variants have significantly contributed to our current understanding of HDACi 106 has been shown to increase FXN mRNA levels in lymphoblast cell lines and in primary lymphocytes from Friedreich’s ataxia patients,9 and a related 2-aminobenzamide has shown similar efficacy in neuronal cells derived from FRDA patient iPSCs.11 The structures of the 106- and control probes are shown in Figure 1a, and the strategy applied in the present study is shown in Figure 1b. Nuclear proteins were extracted from neural stem cells differentiated from Friedreich’s ataxia patient-derived iPS cells. We use neural stem cells as these One of the identified targets of the 106 probe is the transcription elongation factor TCEB2. Interestingly, the gene encoding TCEB2 was found to be up-regulated by HDACi 106 in primary lymphocytes from Friedreich’s ataxia patients.30 TCEB2 is of interest since down regulation of FXN mRNA synthesis is the primary cause of FRDA, and transcription elongation as well as initiation has been shown to be affected by the GAA repeats.31 To validate TCEB2 as a bonafide target or target-interacting protein of the 106-probe, we used Western blotting of the and has completed a phase Ib clinical trial in FRDA patients, who show increases in FXN mRNA in circulating lymphocytes.11 In the case of Huntington’s disease (HD), a large body of evidence points to transcriptional dysregulation as one of the key features of this disease, and HDAC inhibitors have been the subject of intense investigation to counteract the transcription deficits in HD.12 We find that members of the 2-aminobenzamide class of HDAC inhibitors are beneficial in restoring normal transcriptional activity in both cellular and mouse Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich’s Ataxia Patient iPSC-Derived Neural Stem Cells - PMC respiratory chain complexes I and IV. In these patients, we identified a homozygous splice mutation, g.21043 T>A (c.282+2 T>A) which leads to skipping of exon 2. Our study broadens the phenotypic spectrum of C12orf65 defects and highlights the triad of optic atrophy, axonal neuropathy and spastic paraparesis as its key clinical features. In addition, a clear genotype–phenotype correlation is anticipated in which deleterious mutations which disrupt the GGQ-containing domain in the first coding exon are expected to result in a more severe cerebellum. For rx3, the human ortholog RAX is embedded in a large syntenic block, and a cone-rod dystrophy (OMIM%600624) has been mapped to the area (Warburg et al. 1991). In the BARHL1 GRB, the far upstream TSC1 gene at 9q34 is implicated in tuberous sclerosis (OMIM#191100) and focal cortical dysplasia of Taylor (OMIM#607341), distinguished by epileptic seizures and likely caused by a neuronal migration defect (Wolf et al. 1995), which is consistent with the barhl1 expression pattern. However, the TSC1 ortholog was duplicated in teleosts Future studies will be needed to assess this possibility. The beneficial effects of HDAC inhibition in Huntington’s disease have been reviewed.12 In particular, HDAC inhibition can have positive effects in restoring global gene expression profiles,3,13 in ameliorating cytoskeletal defects12 and clearance of mutant Htt protein by the ubiquitin–proteosome system.2 Our current findings of diverse targets of the 2-aminobenzamides suggest that there are other potentially beneficial mechanisms of action, such as increased processing or translation is able to also facilitate Rab protein-mediated GTP hydrolysis is not known. Our findings implicate defective vesicular trafficking as the possible basis of the complex phenotype in individuals with DOORS syndrome in view of findings from previous studies in other TBC proteins (panel). The seizure phenotype present in all individuals with TBC1D24 mutations, and the studies in Drosophila, suggest a potential role for aberrant neurotransmitter release in the neurological manifestations of the disease. However, further studies in model organisms\n",
            "[0.7059985]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the smallest known subviral pathogens of plants?\n",
            "Refined Query: What are the smallest plant pathogens smaller than viruses, considering viroids, virusoids, and satellite RNAs, and what are their defining characteristics and mechanisms of infection, given the ongoing research into subviral agents and their impact on plant health?\n",
            "\n",
            "Combined Answer: higher than that of ducks (Fig. 6C). As a control, GAPDH RNA in ducklings was 4- to 8-fold higher than that in ducks (Fig. 6C). Therefore, the ratio of DHBV PreC/C RNA to GAPDH RNA in ducklings was 2- to 3-fold higher than that of ducks. We inferred from these results that cccDNA in ducklings are associated with a higher level of viral RNAs but could not rule out the possibility that in ducklings those RNAs have a longer half-life. Differently from viral RNA, DHBV core protein and replicative intermediates were nearly equally detected in ducks CTCF-like sequences from other arthropods reinforces this finding (data not shown). Furthermore, we show that Xiphinema index, a basal plant parasitic nematode, contains CTCF. But BLAST searches indicated that a CTCF-like protein is not present in available plant genome sequences including Arabidopsis thaliana and grapevine (Vitis vinifera), a common host of Xiphinema index (not shown). Therefore, we assume that CTCF was originally present in nematodes. Our finding of a CTCF ortholog only in basal nematodes allows several possible scenarios small RNAs (tRNAs, miRNAs, snRNAs, and snoRNAs) map within the genic boundaries of 7% of all protein-coding genes, while 5% of small RNAs map within the boundaries of 4% of all lncRNAs. This does not necessarily rule out a propensity for lncRNAs to host small RNAs compared with protein-coding genes, because this analysis is biased by the greater number and length of protein-coding genes. To control for this, we computed the proportion of nucleotides in lncRNAs that overlap different classes of small RNAs, and compared it with similar data for It has been reported that the genome of several DNA viruses exists as an individual minichromosome in the nucleus of infected host cells. For long-term episomal maintenance of this viral structure from a parental cell to two daughter cells, viral DNA segregation must occur. This process involves “chromosome tethering” in many DNA viruses in which a viral protein binds to both a specific viral sequence, such as ori, and a host chromosome (15, 16, 19, 30). Such association enables the acentric viral minichromosome to utilize the chromosomal correspondingly. DNA sequence changes in dominant viral species between adults and infected ducklings were not detected. These results indicate that although differences such as kinetics of virus replication, virus spreading, and liver microenvironments exist between adults and ducklings, overall minichromosome structures reflected by the patterns of MNase mapping are inheritable. In addition, we aligned the two original DHBV DNA sequences that were obtained from duck 5 and 6 for a possible relationship between sequence variations and a miRNA molecule is more likely to be found in each strand of a hairpin, using an SVM based approach. It consists of two models, one specialized in plants, hereby termed MaturePred_Plants and one specialized in mammals, hereby named MaturePred_Mammals. We compare MiRduplexSVM with each model separately. Comparison to MiRduplexSVM is shown in Fig 3D (Plants), 3E (Mammals) and 3G (Plants: green line, Mammals: red line) for duplex prediction and Fig 4 (Plants: green lines, Mammals: red lines) for independent corner prediction. As evident from Fig H3/H4 antibodies, it was shown that the acetylation status of H3/H4 in cccDNA minichromosomes plays an important role in HBV RNA transcription (26). Besides host proteins that, as components of minichromosomes, are involved in cccDNA functions, the virally encoded proteins core and HBx have also been shown to bind to this structure and result in either a reduction of the nucleosomal spacing in HBV minichromosomes or an overall enhancement of HBV replication, respectively (1, 3, 43). In contrast to viral RNA transcription and its regulatory rAAV9/SERCA2a, rAAV9/shSUMO1 and rAAV9/scramble were produced using the two-plasmids protocol described by Zolotukhin et al27 with the following modifications: HEK293T cells (ATCC) were grown in triple flasks for 24 hours (DMEM, 10% FBS) prior to adding the calcium phosphate precipitate. After 72 hours, the virus was purified from benzonase-treated cell crude lysates over an iodixanol density gradient (Optiprep, Greiner Bio-One Inc), followed by heparin-agarose type I affinity chromatography (Sigma). Finally viruses were concentrated and the maintenance mechanism of cccDNA, it is important to obtain information of protein components bound at specific sites of viral minichromosomes. Though various host proteins as well as HBV core and X antigen have been reported to be associated with minichromosomes (1–3, 20, 25, 26), exact binding positions and mechanisms of action of these components are not clear. Complete elucidation of hepadnaviral minichromosome structures is still a challenge despite the fact that extensive efforts have been made. A main hurdle was a heavy contamination are not clear. Complete elucidation of hepadnaviral minichromosome structures is still a challenge despite the fact that extensive efforts have been made. A main hurdle was a heavy contamination of host counterpartners during the process of isolation of viral minichromosomes, though different purification methods were employed in a tandem manner, such as sucrose gradient centrifugation, gel filtration, and immunoprecipitation with different antibodies. The other difficulty was the overall instability of minichromosomes during the isolation:\n",
            "[0.7800159]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What causes Katayama Fever?\n",
            "Refined Query: What specific factors, including the type and quantity of Leptospira interrogans bacteria exposure and the individual's immune response, contribute to the development of Weil's disease, also known as Katayama fever?  What environmental conditions increase the risk of infection?\n",
            "\n",
            "Combined Answer: elevation, hypoalbuminemia, dyspnea, rash, duodenal ulcer, anemia, dry skin, fatigue and diarrhea. Rare grade 3 toxicities included elevated CPK (n=5), maculopapular rash (n=5), neutropenia (n=3), nausea (n=3), paronychia (n=3), acneiform rash (n=2), diarrhea (n=2), elevated ALT (n=1), decreased ejection fraction (n=1), gastric hemorrhage (n=1), headache (n=1), skin infection (n=1), tooth infection (n=1) and weight gain (n=1). There was only one grade 4 toxicity, lymphopenia. There were no treatment-realted deaths. Patient reported outcomes Towards investigating these aspects, there is a tight relation between a disease and targets, e.g., with regards to the development of animal models or the research in diagnostics, that can help the researchers understand better the disease. The research on targets play a crucial role in turn for the study of sensitivity, selectivity, mutations of genes and biological functions that are connected to the disease. In parallel, the study of related drugs is crucial, because it can provide information on the pathways, mechanisms of action, 1 and 2 CPK elevation, hypoalbuminemia, dyspnea, rash, duodenal ulcer, anemia, dry skin, fatigue and diarrhea (Table 2). Rare grade 3 toxicities included elevated CPK (n=5), maculopapular rash (n=5), neutropenia (n=3), nausea (n=3), paronychia (n=3), acneiform rash (n=2), diarrhea (n=2), elevated ALT (n=1), decreased ejection fraction (n=1), gastric hemorrhage (n=1), headache (n=1), skin infection (n=1), tooth infection (n=1) and weight gain (n=1). There was only one grade 4 toxicity, lymphopenia. All attributable toxicities and all grade 3 InterVar will categorise rare variants in these regions as ‘Likely Pathogenic’ when they are highly unlikely to be disease causing. Secondly, InterVar activates rule PP5 (reputable source identifies the variant as Pathogenic) for 89.5% of the variants as they are reported as ‘Pathogenic’ in ClinVar. The ACMG guidelines state that this rule should only be activated when the evidence supporting the classification is unavailable, yet this evidence is often contained within the appropriate ClinVar submission. Full details of the rules activated by and irinotecan trial, the most common toxicities were grade 1 and 2 hypertension, fatigue, epistaxis, and grades 1–4 proteinuria.(27) These data contrast with the current study whereby only 6% (3/50) of patients had grade 3 neutropenia; 2% (1/50) had grade 4 lymphopenia and there were no grade 3 or 4 thrombocytopenia or anemia. There was no significant peripheral neuropathy or allergic reactions. As expected, grade 1 and 2 asymtommatic CPK elevation and grade 1 and 2 rashes were some of the most common attributable toxicities seen with and the on the amount of RUTF needed to achieve recovery. Additionally, antibiotic resistance is increasing worldwide, and can be particularly problematic in developing countries where treatment options against resistant organisms are more limited (Nys et al. 2004; Okeke et al. 2005; Okeke et al. 2007). In the gut, resistant organisms rapidly develop when exposed to broad-spectrum antibiotics, often causing secondary infections that are difficult to treat; one of the primary routes of bacterial invasion in severe malnutrition is thought to be for lysine and glutamine, are prone to oxidative damage. Even more interesting are the observations that deficiencies in the oxidative-damage prevention system affected the rate of the mutations conferring a Leu+ phenotype in exponential growth but not the accumulation of Leu+ mutations in stationary phase. Considering the results obtained by examining the His+ and Met+ phenotypes, it could be speculated that the GO prevention system mediates mutagenic processes that are dependent and independent of growth and that those that result in a Leu+ immune cells contributing to excessive systemic inflammation, we suggest that bacterial endotoxin could also induce inflammatory responses as a predisposing factor to the oxidative damage and systemic inflammation in preeclampsia. problems, including two with suspected encephalitis. Infectious disease hospitalizations included: pneumonia; status epilepticus and possible viral encephalitis; and influenza B infection with myositis and possible encephalitis. A range of other medical problems were observed in only a single child and are listed in Supplementary Table 1. that may result in a preeclampsia-like syndrome (50). Ultimately, all of these secreted placental factors and stimuli, including bacterial endotoxin, are capable of disrupting the fine-tuned balance of the immune system and inducing a systemic inflammatory response.\n",
            "[0.48479214]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List clinical trials for prevention of sarcopenia\n",
            "Refined Query: I need a list of clinical trials investigating interventions aimed at preventing sarcopenia, the age-related loss of muscle mass and strength.  Specify any inclusion criteria if possible.\n",
            "\n",
            "Combined Answer: changes in muscle mass (i.e., drugs known to affect skeletal muscle size, such as an androgen or anti-androgen). A complete list of inclusion and exclusion criteria is available in the online supplementary (Table E1). Novartis Drug Supply Management produced a randomization list using a validated, automated system that randomly assigned participants to treatment arms. The Novartis Biostatistics Quality Assurance Group approved the randomization scheme. All participants, investigators, and sponsor representatives associated with the study were Overall, bimagrumab was safe and well tolerated in this sample of patients with COPD with lower-than-normal muscle mass. The three most commonly reported AEs with bimagrumab treatment—muscle spasms, tightness, and twitching; diarrhea; and acne—were also reported as mostly mild in severity in a recent study of older adults with sarcopenia (18). Physical frailty and muscle wasting, however measured, is a well-established predictor of hospital admission due to acute exacerbation of COPD (4, 31, 32). We expected that our patients, who were selected regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII blockade could induce muscle hypertrophy in a myostatin knockout mouse, proving that other molecules signal through those receptors (17). The magnitude of the anabolic response with bimagrumab treatment observed in this study was comparable with those reported in a prior study in patients with sarcopenia (18) and with reports on prior anabolic (6, 29). Future trials can be designed using either ORR or intervention rate as compared to historical or intra-patient controls as primary efficacy criteria. This study was stopped before the originally planned 40 patient accrual was reached. Two factors led to this decision. The first was that accrual was slowing considerably, and the trial had been open for three years. The second was that the trial met a prespecified toxicity stopping rule after 30 patients were accrued. The assessment of other trials using pazopanib indicated this rule mitochondrial bioenergetic capacity can improve without mass gains (44), and it may be that concurrent exercise is required to demonstrate improved exercise capacity. Fifth, although we stratified by low muscle mass, we might have obtained greater focus on the population of interest had we made recent weight loss an inclusion criterion; however, unlike (for example) patients with cancer cachexia, most patients with COPD are not managed in secondary or tertiary care, so obtaining accurate sequential weight measures is difficult. An interesting Indeed in a study of sarcopenic seniors who had both slow gait speed and reduced mass, bimagrumab did increase 6MWD and gait speed, suggesting this could be a model for future studies in COPD (18). Third, although the 6MWD is considered a useful stratification tool (31), it has been shown to be poorly responsive to interventions that improve the physiologic ability to exercise (e.g., bronchodilators) (42) and may be less responsive than a constant work rate exercise test (43). Fourth, gain in muscle mass may be a necessary but not sufficient tend to decrease with strength training. We acknowledge, however, that our study design would have been stronger if we had ensured that the participants had elevated skeletal muscle myostatin before enrollment. However, we considered that a muscle biopsy might slow recruitment; moreover, because ActRIIs act as a pathway for multiple negative regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII The primary study objective was to evaluate the efficacy and safety of pazopanib, with efficacy measured as objective response rate (ORR), which is the sum of complete responses (CRs) + partial responses (PRs). Secondary objectives included assessing growth rate over time in target lesions before and after pazopanib treatment, evaluating the need for surgical intervention in individuals who received pazopanib in comparison to rate prior to receipt of drug, and creating an annotated tissue resource from patients on study. All endpoints, gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and health management are useful strategies to prolong lifespan, improve quality of life, and reduce complications [4]. Several drugs, including corticosteroids, have been conditionally approved for their potential effect on muscle strength and function [6]. Therefore, noninvasive approaches that reliably evaluate DMD are required to support different was ≥5 responses in 25 subjects. All eligible subjects who initiated treatment were evaluable for the efficacy and toxicity objectives which were conducted per protocol. Eligible patients with available assessments or samples were also evaluable for the respective secondary objectives. This study is registered with ClinicalTrials.gov ( NCT01089101). All statistical analyses were conducted in SAS 9.4. Kaplan Meier estimator was utilized for PFS calculations, and if necessary, log-rank test or Cox Hazard model was used for comparisons. PFS was\n",
            "[0.36190528]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 403.88ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1233.70ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1132.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1686.84ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 931.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1258.38ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1082.24ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1687.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1464.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 933.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 982.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Sarcolipin a regulatory/inhibitory protein of the Calcium ATPase SERCA?\n",
            "Refined Query: Does sarcolipin, a small protein found in cardiac muscle, directly modulate or inhibit the activity of the sarcoplasmic reticulum calcium ATPase (SERCA) pump, impacting calcium handling and ultimately influencing cardiac contractility?\n",
            "\n",
            "Combined Answer: complex (DAPC),3 composed of three subcomplexes: (i) the sarcoglycans (α, β, γ, and δ), (ii) syntrophin, nNOS, and dystrobrevin, and (iii) BDG and α-dystroglycan. The absence of dystrophin and destabilization of the DAPC is thought to render muscle cells susceptible to stretch-induced damage and increased intracellular calcium influx, leading to a series of pathological processes responsible for skeletal and cardiac muscle fiber necrosis,9 inflammation and replacement of muscle with fibro-adipose tissue. Regarding the signaling function, SR Ca2+ ATPase 2a (SERCA2a) is a critical ATPase responsible for Ca2+ re-uptake during excitation-contraction coupling. Impaired SR Ca2+ uptake resulting from decreased expression and reduced activity of SERCA2a is a hallmark of heart failure (HF)1. Accordingly, restoration of SERCA2a expression by gene transfer has proven to be effective in improving cardiac function in HF patients2 as well as in animal models3. The small ubiquitin-related modifier (SUMO) can be conjugated to lysine residues of target proteins4, which is involved in most in isolated cardiomyocytes augmented contractility and accelerated Ca2+ decay. Transgene-mediated SUMO1 overexpression rescued pressure overload-induced cardiac dysfunction concomitantly with increased SERCA2a function. By contrast, down-regulation of SUMO1 using shRNA accelerated pressure overload-induced deterioration of cardiac function and was accompanied by decreased SERCA2a function. However, knockdown of SERCA2a resulted in severe contractile dysfunction both in vitro and in vivo, which was not rescued by overexpression of SUMO1. Taken the sarcolemma and provides further evidence for the functionality of this protein in vivo (Fig. 4f). Quantification of the number of EBD positive fiber confirms that expression of the IRES driven isoform results in significant protection of muscle fibers in these mice, from 14.7 ± 6.6% of myofibers in untreated Dup2 muscle to 2.8 ± 1.8% (U7-ACCA alone) or 0.65 ± 0.5% (in combination with PDN) (Fig. 6b). Normalized maximum hindlimb grip strength (Fig. 6c) in untreated Dup2 mice (2.22 ± 0.26 kg force (kgf) kg−1 mass of animal is significantly and/or conditional activation signals will shed light on underlying mechanisms of IRES control and elucidate potentially novel functions of dystrophin. An intriguing question is how the N-truncated isoform remains functional. A key cellular role for dystrophin is presumed to be transmitting the force of contraction across the sarcolemma to extracellular structures by serving as an important architectural bridge role between the F-actin cytoskeleton and the muscle plasma membrane41,42. Two regions within dystrophin are responsible for F-actin and stability. The levels of SUMO1 and SUMOylation of SERCA2a itself were greatly reduced in failing hearts. SUMO1 restitution by adeno-associated virus-mediated gene delivery maintained protein abundance of SERCA2a and significantly improved cardiac function in HF mice. This effect was comparable to SERCA2a gene delivery. Moreover, SUMO1 overexpression in isolated cardiomyocytes augmented contractility and accelerated Ca2+ decay. Transgene-mediated SUMO1 overexpression rescued pressure overload-induced cardiac dysfunction concomitantly with SERCA2a activity was determined using pyruvate/NADH-coupled reactions based assay, as previously described24. The activity of the Ca2+-ATPase was calculated as follows: Δabsorbance/6.22 × protein × time (in nmol ATP/mg protein × min). All assays were performed in triplicate. regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII blockade could induce muscle hypertrophy in a myostatin knockout mouse, proving that other molecules signal through those receptors (17). The magnitude of the anabolic response with bimagrumab treatment observed in this study was comparable with those reported in a prior study in patients with sarcopenia (18) and with reports on prior anabolic (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton immediately beneath the sarcolemma. Regarding its important structural role, dystrophin connects the subsarcolemmal F-actin cytoskeleton to β-dystroglycan (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the to a series of pathological processes responsible for skeletal and cardiac muscle fiber necrosis,9 inflammation and replacement of muscle with fibro-adipose tissue. Regarding the signaling function, dystrophin is involved in the localization of neuronal nitric oxide synthase (nNOS) a protein that directly interacts with dystrophin and syntrophin. nNOS regulates the blood flow in skeletal muscle according to its metabolic needs,10 and its lack at the sarcolemma is associated with ischemia following exercise, which is believed to cause\n",
            "[0.6716831]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the risk of developing acute myelogenous leukemia in Fanconi anemia?\n",
            "Refined Query: Individuals with Fanconi anemia (FA) face a significantly elevated risk of developing acute myelogenous leukemia (AML).  Understanding the precise risk percentage and factors influencing this increased susceptibility is crucial for proactive screening and management strategies in FA patients.\n",
            "\n",
            "Combined Answer: High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia - PMC Cytosine arabinoside-based chemotherapy coupled with anthracycline is currently the first-line treatment for acute myeloid leukaemia (AML), but diverse responses to the regimen constitute obstacles to successful treatment. Therefore, outcome prediction to chemotherapy at diagnosis is believed to be a critical consideration. Therapeutic effects of FLT3 inhibitors have been reported in acute myeloid leukemia (AML) with constitutively activating FLT3 mutations, including internal tandem duplication (ITD) and point mutation, which are found in approximately one-third of AML patients. One of the critical issues of treatment with FLT3 inhibitors in FLT3-mutated AML is drug resistance. FLT3 ligand (FL) represents a mechanism of resistance to FLT3 inhibitors, including quizartinib, midostaurin, and sorafenib, in AML cells harboring both wild-type and mutant FLT3 We obtained 54 BM MNCs from patients with the M2 subtype of AML at diagnosis; their details are described in Table 1. A total of 16 patients exhibited normal karyotype and 24 patients had t(8;21). Each of the others evidenced cytogenetically distinct abnormalities. For remission induction, a majority of the patients received standard chemotherapy with Ara-C (N=14) or BH-AC (N=35) coupled with idarubicin. Four of the remaining patients were treated with Ara-C alone, and one received a regimen of Ara-C plus etoposide. After induction and and 26–29% had grade 3/4 anemia.(3) On the published weekly vinblastine trial, the most common toxicities were hematologic. Eighteen of 50 (36%) patients had grade 4 neutropenia requiring dose reduction and 5 patients required red blood cell transfusions. Five patients with NF1 also had grade 3 peripheral neuropathy.(26) On the PBTC bevaicizumab and irinotecan trial, the most common toxicities were grade 1 and 2 hypertension, fatigue, epistaxis, and grades 1–4 proteinuria.(27) These data contrast with the current study whereby only 6% (3/50) recombination. Although 20% of the patients had germline or somatic BRCA1/2 mutations, an additional 11%, 6%, and 5% of the patients had epigenetic silencing of BRCA1, amplification of EMSY, or loss of PTEN expression, respectively. Moreover, an additional 7% of the patients had mutations in RAD51C, ATM, ATR, or Fanconi anemia genes (10). It is, however, currently not clear whether these aberrations all lead to a decrease in homologous recombination sufficient enough to cause sensitization of tumor cells toward PARP inhibitors. Indeed, the and TOP2A genes was correlated with treatment outcomes in AML patients treated with cytosine arabinoside-based chemotherapy in an independent manner. The finding may prove useful in the prediction of treatment responses in M2-subtype AML patients, and also expands the range of possible treatment choices for improved therapeutic efficacy. However, additional confirmatory studies in validation sets will be required in order to actualise the possible benefits illustrated by the results of this study. study was designed by employees of Amgen (the main sponsor) in collaboration with the investigators. The data were collected by investigators and were analyzed by statisticians employed by Amgen. A medical writer employed by Amgen provided the first draft of the manuscript and editorial assistance. All authors contributed to interpretation of the data and preparation of the manuscript and vouch for the completeness and accuracy of the data and the fidelity of the trial to the protocol. xenograft model established by inoculating FL-expressing MOLM-13 cells in our study were similar to those in AML patients [21]. In addition, detectable phosphorylation of FLT3wt, but not FLT3-ITD, has been observed using the plasma inhibitory activity assay with human plasma samples from patients administered quizartinib [28], suggesting that the efficacy of quizartinib may also be attenuated in the presence of FL in AML patients. Furthermore, single cell analysis of AML blasts in patients has revealed the presence of AML cells with FLT3-ITD Genes with distinct expression profiles such as TOP2B/TOP2A expression ratio at diagnosis can be employed for outcome prediction after the treatment with standard regimens in AML patients with M2 subtype.\n",
            "[0.70998657]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How many different mutations have been associated with Muenke syndrome?\n",
            "Refined Query: I'm researching Muenke syndrome.  Specifically, I need to know the precise number of distinct genetic mutations in the *FGFR3* gene that have been definitively linked to its development.  Could you provide this figure?\n",
            "\n",
            "Combined Answer: and that the defect underlying these mutations is misregulation of fgf8. It is therefore reasonable to speculate that FBXW4 has been incorrectly assigned as the disease gene in human split hand/foot malformation 3. The search for putative regulatory elements or previously unknown exons can generate target sequences to be re-sequenced in patient DNA. In one of the two cases that were characterized bioinformatically, otp, we searched for mapped human diseases at the edge of the otp GRB and found Hermansky-Pudlak Syndrome, type 2, a cell of fgf8. Transposon insertions in Fbxw4 were determined to be causal in the mouse semidominant dactylaplasia mutation, in the absence of mutations in the coding sequence (Sidow et al. 1999). Fgf8 expression in the apical ectodermal ridge (AER) is not properly maintained in the mouse mutants, and this expression defect correlates well with the observed phenotype in both mouse dactylaplasia and the corresponding human genetic disease split hand/foot malformation 3 (OMIM#600095), which maps to the FGF8 GRB in the human genome (de Mollerat et al. sequences in H3F3A and H3F3B, and R and V substitutions can be achieved with single point mutations. Similarly, G34R or V substitutions could be achieved by a single point mutation of any of the H3.1 genes, so other factors must determine the prevalence of H3F3A mutations in the tumors. G34 mutation is associated with global DNA hypomethylation, which is particularly pronounced in telomeric regions (Sturm et al. 2012). No G34R/V mutations were found in DIPG tumors, and the median age of G34 mutant tumor occurrence was older than for K27M we did exome sequencing (table 1). All mutations were novel except for the frameshift mutation, seen in the heterozygous carrier state in two of 6118 individuals sequenced for that region in the June, 2013, release of the Exome Variant Server (EVS-v.0.0.20). This server provides variant frequency data for multiple exome studies done mostly in adults with various heart and lung diseases and controls, and individual phenotypes are not available. In view of the facts that mutations in this gene have been identified as the cause of some pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this disorders. Similarly in a whole-exome sequencing project of multiplex, non-consanguineous pedigrees with ID, one in nineteen families exhibited a protein truncating mutation in NHE6.29 If we assume that between 1–3% of the world’s population is diagnosed with an intellectual disability, and approximately 10–20% of the causes are due to X-linked genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly phenotype in both mouse dactylaplasia and the corresponding human genetic disease split hand/foot malformation 3 (OMIM#600095), which maps to the FGF8 GRB in the human genome (de Mollerat et al. 2003). Fgf8 has been shown in the mouse to be the only Fgf family member expressed in the AER and necessary for normal limb development (Lewandoski et al. 2000). Intronic insertions in fbxw4 in zebrafish cause a semidominant adult pigment stripe pattern defect (Kawakami et al. 2002), which we also found with insertions CLGY1030, CLGY508, and CLGY667 FGF8, but has undergone deletion of fbxw4. Even though this gene was originally annotated as fgf17 (Reifers et al. 2000), it is more similar to fgf8 in sequence and expression pattern (for expression patterns of fgf8, fbxw4, fgf17a, and poll, see Supplemental Fig. S1). We propose that this gene should be annotated as fgf8.2, and the current fgf8 as fgf8.1. 2b]. The same age-associated distribution of ATRX mutation was identified across the entire GBM cohort including both DIPGs and supratentorial GBM [mean age 16.91 (±2.11) vs. 8.00 (±0.69) years, p < 0.0001 for ATRX mutant versus wild-type cases; Fig. 2c). mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without TBC1D24 mutations, we did not identify a mutated gene in common in these families (details on the regions identified are given in the appendix p 11). Analyses are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24\n",
            "[0.6954098]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How can the fetal Rhesus be determined with non-invasive testing?\n",
            "Refined Query: Currently, invasive procedures like amniocentesis determine fetal Rhesus factor (Rh).  Are there reliable, non-invasive methods, such as analyzing cell-free fetal DNA in maternal blood, to safely and accurately ascertain fetal Rh status early in pregnancy, avoiding the risks associated with invasive techniques?\n",
            "\n",
            "Combined Answer: Since the first demonstration of the use of cell-free DNA (cfDNA) to detect aneuploidy (Chiu et al., 2008; Fan et al., 2008), many groups around the world have reported large studies showing high sensitivities and specificities for the detection of trisomies 13, 18 and 21 (Jiang et al., 2012; Palomaki et al., 2011; Sehnert et al., 2011). In contrast to invasive methods such as amniocentesis, non-invasive prenatal testing (NIPT) uses cfDNA in maternal plasma and does not present a risk of miscarriage. Currently, outside the context of research acceptable level of test sensitivity can be reached with relatively short read lengths (36–52 bp) and modest coverage (2–10 million reads per sample) (Liang et al., 2013; Sehnert et al., 2011). Here, we present a flexible and robust R package for NIPT analysis called RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package). RAPIDR combines several analytical techniques that have been proposed for NIPT analysis and has been tested with a large sample set from the RAPID project (NIHR funded project to evaluate the use of NIPT). RAPID Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice. RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods. The input to RAPIDR is a set of sequence alignment files in the BAM format, and the outputs are calls for aneuploidy, including trisomies 13, 18, 21 and monosomy X as well as fetal sex. RAPIDR has been extensively tested with a large sample set as part to invasive methods such as amniocentesis, non-invasive prenatal testing (NIPT) uses cfDNA in maternal plasma and does not present a risk of miscarriage. Currently, outside the context of research studies, NIPT for aneuploidy is only available from commercial providers. To perform NIPT, cfDNA is extracted from maternal plasma and sequenced using short reads and high-throughput DNA sequencing. Sequenced reads are aligned to the reference human genome using a short read aligner. Aneuploidy is called if the number of reads mapped to each males, RAPIDR also estimates the fetal fraction using the method from Rava et al. (2014). Fetal fraction is an important determinant of NIPT sensitivity, but it cannot be measured directly using the protocol we described. RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy - PMC In this article, we described the RAPIDR package for NIPT of fetal aneuploidies. RAPIDR has been validated using >700 samples and delivers an acceptable level of specificity and sensitivity for T21, T18, T13 and monosomy X. The system requirement for RAPIDR is modest (Supplementary Text S3). Future work on RAPIDR will include evaluating strategies to detect sub-chromosomal abnormalities. Funding: This manuscript presents independent research funded by the National Institute for Health Research (NIHR) under the Program Grants for Applied placenta, intrauterine growth restriction (IUGR), and prematurity (7, 8). Adverse clinical conditions and maternal organ dysfunction associated with preeclampsia include renal insufficiency, liver involvement, neurological or hematological complications, and uteroplacental dysfunction (9). These conditions can progress to eclampsia, stroke, uncontrolled severe hypertension, acute kidney injury, liver hematoma, liver rupture, and cardiac failure as well as severe complications also involving the fetus by possible abruption of placental zX>−2, the sample is called female; if zX<−3, the sample is called as monosomy X; finally, if zX is between −2 and −3, then the sample sex is called as unknown (Fig. 1c). To improve the accuracy of fetal sex calling, we also excluded bins in chr Y with a high number of counts mapped from females, e.g. the pseudo-autosomal region of chr Y. For euploid males, RAPIDR also estimates the fetal fraction using the method from Rava et al. (2014). Fetal fraction is an important determinant of NIPT sensitivity, but it cannot be measured directly using blood to the placenta (21). The latter is termed placental ischemia/hypoxia and is associated with distortion of the placental villous architecture and increased oxidative stress (21). The subsequent uteroplacental insufficiency results in compromised blood flow to the uterus, resulting in pregnancies with increased perinatal morbidity and mortality (1). However, incomplete remodeling of the spiral arteries is not only associated with preeclampsia but is also found in IUGR and gestational hypertension (22, 28), suggesting that it is not the\n",
            "[0.75950146]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: DX-88 is investigational name of which drug?\n",
            "Refined Query: The investigational code name DX-88 is used in pre-clinical and clinical trials for a pharmaceutical drug.  Can you identify the actual, marketed name of this drug?\n",
            "\n",
            "Combined Answer: distinguished in later analysis. To identify hospital diagnoses which are associated with ADEs (and to highlight them in the tool) we used the ICD-10 codes listed by Stausberg and Hasford [10] and adapted the codes to the Austrian coding conditions. The Austria Codex [11], a register containing all drugs which are authorised in Austria, was used to identify potential drug-drug interactions between two prescriptions of a patient, which were taken at the same time according to our estimation. The Austrian pharmaceutical registration number (in Katie Alexander (Ionis Pharmaceuticals, Inc., clinical operations); Shannon Fine (Ionis Pharmaceuticals, Inc., clinical operations); Shannon Hall (Ionis Pharmaceuticals, Inc., pharmacokinetics analyses); Viola Kam (Ionis Pharmaceuticals, Inc., project manager); Katherine Kwoh (Ionis Pharmaceuticals, Inc., data manager); Dan Schultz (Ionis Pharmaceuticals, Inc., biostatistician); Celeste Vanderpool (Ionis Pharmaceuticals, Inc., clinical supplies); Shuting Xia (Ionis Pharmaceuticals, Inc., biostatistician); Mason Yamashita (Ionis dispensed prescriptions and information about hospital stays were combined in a separate database schema. For each hospital stay, exactly one main diagnosis and several additional diagnoses are documented as ICD-10 codes in the GAP-DRG database. Both main diagnoses and additional diagnoses were added to the hospital stays in the schema and are not distinguished in later analysis. To identify hospital diagnoses which are associated with ADEs (and to highlight them in the tool) we used the ICD-10 codes listed by Stausberg and Hasford [10] and Roche Pharmaceuticals, Inc., through the Cancer Therapy Evaluation Program (NCI), provided RG7112 and RG7112i to the PPTP. RG7112 was pre-formulated and provided to each consortium investigator in coded vials for blinded testing against a placebo control consisting of vehicle only, and administered orally (P.O.) at a dose of 100 mg/kg daily for 14 days, as recommended by the drug supplier. to identify potential drug-drug interactions between two prescriptions of a patient, which were taken at the same time according to our estimation. The Austrian pharmaceutical registration number (in German called “Pharmazentralnummer”) was used as an identifier for drugs which were mapped to Anatomical Therapeutic Chemical Classification System (ATC) codes for the later identification of a drug in the JADE tool. Drugs were considered to be relevant for a hospitalisation if prescribed less than 2 months prior to the date of hospital admission (Ionis Pharmaceuticals, Inc., biostatistician); Celeste Vanderpool (Ionis Pharmaceuticals, Inc., clinical supplies); Shuting Xia (Ionis Pharmaceuticals, Inc., biostatistician); Mason Yamashita (Ionis Pharmaceuticals, Inc., drug safety physician); Dawn McGuire, MD (independent medical monitor); Walter Bradley (data safety and monitoring board); Anne Connolly (data safety and monitoring board); Patti Dickson (data safety and monitoring board); Stephen Reingold (data safety and monitoring board); Sarah Hamren (Singulex, Inc., CSF SMN protein Pharmaceuticals, Inc., Sarepta Therapeutics, Valerion Therapeutics, the NIH NINDS and NIAMS, Spinal Muscular Atrophy Foundation, Muscular Dystrophy Association, and the Slaney Family Fund for SMA. S. Iannaccone reports no disclosures relevant to the manuscript. J. Montes serves as a consultant to Ionis Pharmaceuticals, Inc. D. De Vivo has served as a consultant to Roche Pharmaceuticals, Ultragenyx Therapeutics, and Sarepta Therapeutics. He receives research support from the NIH, DOD, Colleen Giblin Foundation, Milestones for Children, Glut1 This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011). The following strategy was used to search MEDLINE (OVID). 1. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab. 2. clinical trials as topic.sh. 3. trial.ti. 4. 1 or 2 or 3 5. exp animals/ not humans.sh. 6. 4 not 5 7. exp Epilepsy/ 8. exp Seizures/ 9. (epilep$ or seizure$ or convuls$).tw. 10. 7 or 8 or 9 11. (losigam$ or ADD137022).tw. or to her institution, and provision of trial drugs from Agios, grant support and advisory board fees paid to her institution, and provision of trial drugs from Bayer and Bristol-Myers Squibb, grant support paid to her institution from Sanofi and Debio, and fees for serving on a steering committee paid to her institution from TARGET Pharma Solutions. We thank the patients, their families, the investigators, the site staff, and the trial teams; David W. Markby (Exelixis) for assistance with medical writing; and Karen O’Leary and Michael Raffin CDI include vancomycin, metronidazole, and the recently approved antibiotic fidaxomicin (2). Despite excellent initial cure rates with these therapies, up to 30% of patients experience at least one recurrence and may require multiple rounds of treatment that can last several weeks to months, negatively impacting quality of life and costing the health care system at least $1 billion a year in the United States alone (2). For these reasons, the Centers for Disease Control have recently classified C. difficile as one of only three microorganisms\n",
            "[0.60097885]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What type of arrhythmia is known as bidirectional ventricular tachycardia (BDVT)?\n",
            "Refined Query: Bidirectional ventricular tachycardia (BDVT) is a rare and potentially life-threatening arrhythmia characterized by alternating premature ventricular contractions (PVCs) originating from opposite ventricular sites, resulting in a distinctive electrocardiogram pattern.  What specific subtype of ventricular tachycardia does this pattern represent and how does it differ from other forms of ventricular tachycardia?\n",
            "\n",
            "Combined Answer: CardioClassifier provides a simple-to-use web interface that takes as input either individual variant details or a single sample VCF (Supplementary Figure 1). Users select one of 11 cardiac disorders, and this determines which pre-specified validated disease genes are analysed. Where a diagnosis is uncertain (e.g. sudden cardiac death or complex cardiomyopathy), a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. seen in the equivalent residue of a paralogous gene). This analysis is currently restricted to the families of predominantly ion channel proteins associated with inherited arrhythmia syndromes for which this method has been previously validated16,17. We have previously shown paralogue annotation to be informative for over one third of novel SNVs17, and independent validation has shown a high specificity and PPV compared with other sources of evidence18,19. To determine the effect of these criteria on variant classification (before inclusion of of the following during treatment: an increase in QT/QTc interval to >500 milliseconds and/or of >60 milliseconds over baseline, any evidence for ventricular or supraventricular arrhythmia with or without hemodynamic compromise or any advanced AV block, or symptomatic persistent bradycardia <35 bpm that required medical intervention. variants from ClinVar identified as ‘Pathogenic’ or ‘Likely Pathogenic’ for LQTS from one or more submitter with at least one review status star, and compared CardioClassifier interpretations with and without paralogue data. Paralogue data were available for 11/48 (22.9%) variants and resulted in a potential change of class from variant of uncertain significance (VUS) to Likely Pathogenic for 63.6% (7/11) of these (Supplementary Table 2). After manual curation of the literature and ClinVar for reports of segregation, de novo occurrence and functional characterisation, 34 variants were classified as Pathogenic, 13 as Likely Pathogenic and 7 as VUS (Supplementary Table 5; Supplementary Figure 4b). The annotations for these 120 variants, accounting for at least 40% of variants identified in Caucasian cardiomyopathy cases, are stored in CardioClassifier, ensuring these variants are correctly classified without further user-input. and independent validation has shown a high specificity and PPV compared with other sources of evidence18,19. To determine the effect of these criteria on variant classification (before inclusion of any case-level or functional data that cannot be computationally predicted) we used 48 clinically curated (i.e. not literature only or research) missense variants from ClinVar identified as ‘Pathogenic’ or ‘Likely Pathogenic’ for LQTS from one or more submitter with at least one review status star, and compared CardioClassifier interpretations with chest was opened to expose the heart for an apical stab approach. In order to determine absolute ventricular volumes via admittance technology, myocardial and blood conductance were obtained prior to PV catheter placement in the left ventricle32. The inferior vena cava was transiently occluded to reduce ventricular preload to obtain load-independent pressure-volume relationships. Hemodynamic measurements were acquired and analyzed using IOX software (EMKAtech). a wider analysis can be performed for genes associated with a broader phenotype (e.g. all cardiomyopathies, or all arrhythmia syndromes; Table 1), or for all 40 ICC genes parameterised. Details of the key features of CardioClassifier can be found in Table 2. Each variant is annotated for up to 17 computational criteria, with results output to a grid representing the ACMG/AMP framework (Figure 1). The variant report is interactive, allowing a user to add additional case-level evidence to generate and refine a final classification (Supplementary or Pathogenic, while CardioClassifier identified over double this number as clinically actionable (156/219) with a sensitivity of 71.2% (Supplementary Table 4). For both tools, sensitivity would be increased further through user addition of clinical and functional data. Despite the lower sensitivity of InterVar, there are occasions where the tool activates rules inappropriately in the absence of gene-specific knowledge. Firstly, InterVar activates PVS1 in the TTN gene, regardless of protein location, when it is recognised that truncating for the major cardiomyopathies; HCM, DCM and ARVC, defined as those occurring six or more times in the ACGV resource (reflecting a HCM case frequency of ~1/1000)9. There were 84 such recurrent variants in ACGV, together representing 39.5% (1,258/3,186) of all identified variants. We curated 63 that had not already been assessed by the expert panel. After manual curation of the literature and ClinVar for reports of segregation, de novo occurrence and functional characterisation, 34 variants were classified as Pathogenic, 13 as Likely Pathogenic\n",
            "[0.71866053]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which genes have been found to be associated with restless leg syndrome\n",
            "Refined Query: What specific genes and their variants have been identified through genetic studies as having a statistically significant association with the development or severity of restless legs syndrome (RLS), and what is the current understanding of their roles in the underlying pathophysiology of the disorder?\n",
            "\n",
            "Combined Answer: Some genes implicated in epilepsy seem capable of causing a wide variety of types of epilepsy, with greater or fewer additional neuropsychiatric features, and others have been associated with brain malformations or complex dysmorphic syndromes.31 However, phenotypic pleiotropy has rarely been reported to span the spectrum from seizures alone (eg, previous reports on TBC1D24 mutations) to multi-systemic syndromic disorders such as DOORS syndrome. These emerging findings of both genotype-phenotype complexity and genetic pleiotropy lend support signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In the individuals without TBC1D24 mutations, eight did not have seizures and three did not have deafness (including one without seizures or deafness) and some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also technologies. For example, in epilepsy, channelopathies were identified in the 1990s mostly with positional cloning and candidate gene sequencing.10 Next-generation sequencing, such as whole-exome sequencing, has accelerated the pace of the identification of epilepsy-associated genes. For instance, PPRT2 mutations were identified initially in paroxysmal kinesigenic dyskinesia, and are also seen in infantile seizures and febrile seizures.11, 12 In the past year, DEPDC5 mutations have been identified in various dominantly-inherited familial between MWS patients with and without HSCR (table 1). In family 1, a heterozygous G to T transversion at nucleotide 299 in exon 2 of the PHOX2B gene and changing an arginine into a leucine in the homeodomain of the protein (R100L) segregated in patients with an autonomic nervous system disorder and the obligate carrier (fig 2). No RET gene mutation could be identified in the two patients with HSCR who inherited the PHOX2B mutation from their mother and the hypomorphic RET allele from their father (fig 2, patients III 4 and III 6). In contrast, genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also substantiate the role of this gene in various epilepsy syndromes, as is seen also with other epilepsy-related genes such as SCN1A, KCNQ2, and PRRT2. Moreover, our findings lend support to the idea of pleiotropy in epilepsy genetics because, although some mutations in TBC1D24 can cause mild epilepsy without other substantial associated features, are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 mutations are given in the appendix (pp 15–16). Some individuals without TBC1D24 mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In identified did not seem to affect portions of the protein predicted to interact with the TLDc domain, nor were they in the region that typically interacts with GTP in other TBC proteins (figure 3). Because TBC1D24 regulates Rab proteins and because of clinical overlap between DOORS syndrome and Martsolf syndrome, we also assessed RAB3GAP2. No RAB3GAP2 mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without the same pathway, an increase in enrolment and number of exomes or depth of exome sequencing, whole-genome sequencing, and analysis of exome data for copy-number variants. The phenotypic similarity between patients with and without TBC1D24 mutations is highly suggestive of genetic heterogeneity in DOORS syndrome. In this study, individuals with TBC1D24 mutations all had the five features of the DOORS acronym. However, other features were greatly variable, in terms of seizure types, pharmacoresponsiveness, brain-imaging abnormalities, cranial families with TBC1D24 mutations, one through additional exome sequencing and two by Sanger sequencing, totalling 11 affected individuals from nine families with confirmed mutations in the cohort of 26 families affected by DOORS syndrome (see table 1 for the TBC1D24 mutations identified and the appendix p 4 for analyses done on each family). Annotations for all TBC1D24 variants (from DOORS syndrome, the other associated epileptic disorders, and the Exome Variant Server), including population frequency, conservation scores and PolyPhen2 scores\n",
            "[0.3991186]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the circadian clock involved in ribosome biogenesis?\n",
            "Refined Query: Investigating the potential link between the circadian clock and ribosome biogenesis requires exploring whether the clock's regulatory mechanisms, such as transcription factors or signaling pathways, directly influence ribosome production, assembly, or degradation rates, thereby impacting protein synthesis rhythms.\n",
            "\n",
            "Combined Answer: analysis found 13 significant enrichment categories (Figure S3b in the SI) with the top category of control of gene expression by vitamin D receptor. The role of histone deacetylases in vitamin D-regulated gene expression is well established.23,24 The finding of ribosome-associated pathways is at first surprising since we used a nuclear extract in these experiments; however, it is well documented that ribosomes are assembled in nucleoli and many translation factors localize in the nucleus and participate in nuclear–cytoplasmic transport of increased according to decrease of rDNA copy number and consequently the synthesis of rRNA may be adjusted. In other words, artificially constructed rDNA chromosome was also normally regulated by Pol I-transcription machinery. the bacterial ICT1 homolog, YaeJ, the C-terminal tail functions as a sensor to discriminate between stalled and actively translating ribosomes. The mutations leading to a mild phenotype are expected to cause, in addition to a shortened C terminus, a less basic-charged tail, which may reduce the effectiveness of the interaction with the phosphate backbone of the ribosomal RNA that forms the walls of the ribosomal channel. In summary, our study delineates the broad spectrum of C12orf65 defects and establishes a distinct genotype–phenotype of ribosomal proteins in the nucleus is not surprising since ribosomes are assembled in nucleoli. It has been shown that abnormal control of eIF2 and eIF2B leads to CACH (childhood ataxia with central nervous system hypomyelination)/VWM (leukoencephalopathy with vanishing white matter) syndrome in young children, which is a severe autosomal recessive neurodegenerative disease.38 The ribosome binding and translation initiation as well as translation elongation and termination strongly influence mRNA stability in bacteria.39 In eukaryotes, and therefore it reflects the quality of the libraries. To confirm that WW dinucleotide periodicity reflects +1 nucleosome positioning in broad promoters, we assessed H3K4me3 data downloaded from ENCODE (Fig. 4F,G; Supplemental Fig. S16, H3K4me3 heat map; Supplemental Fig. S15D). H3K4me3-subtracted coverage reflects the well-positioned +1 nucleosome broad promoters (Fig. 4F,G) and localizes with WW periodicity specific for broad promoters (Fig. 4D). These results are in agreement with previously identified nucleosome positioning preferences we measured cohesin’s residence time on chromosomes using an assay based on the ‘anchor-away’ technique, as previously described (Haruki et al. 2008; Lopez-Serra et al. 2013). In brief, we fused the cohesin subunit Scc1 in tandem to GFP, for visualization, and to FRB, half of a pair of rapamycin-inducible protein interaction domains. The other half, FKBP12, was attached to the ribosomal protein Rpl13a. By hitchhiking onto Rpl13a while it shuttles through the nucleus during ribosome assembly, a freely diffusible nuclear protein is quickly of extrachromosomal rDNA circles (ERCs) (15) caused by recombination of the repeated sequence is promoted by FOB1 (16) and suppressed by SIR2 (11,17). Sinclair and Guarente (15) have shown that ERCs accumulate in aging yeast cells and that these circles can cause aging. rDNA transcription by Pol I is associated with a distinct crescent-shaped subnuclear structure, the nucleolus, which also appears to be the major site of ribosomal assembly. In a strain carrying a plasmid with a single rDNA unit transcribed by Pol I, the nucleolus was exon-exon junctions mapped exclusively to the known junctions between Dp427m exon 1 and exon 11, indicating that splicing of novel 5’ UTRs from alternate promoters did not contribute to exon 6 AUG usage. The distribution of ribosome footprints mapped on Dp427m exons 1 through 11 revealed normal levels of exon 1 AUG initiation, followed by premature termination in exon 2 and resumption of translation following the exon 6 in-frame AUG codons (Fig. 1f) that continued into the body of the DMD transcript (Supplementary Figs. 2b, c and d), nucleosome-bound and nucleosome-free positions in regulatory regions, and infer the positions of DNA binding proteins using “footprinting” in a B-cell line. Finally we demonstrate that this method is compatible with clinical timescales and standard blood draws by observing the open chromatin landscape of a healthy volunteer. A GC-enrichment in the region between the dominant TSS and 250 bp downstream from it indicates positioning of the +1 nucleosomes and is expected to be highly localized in broad promoters. This feature is again recapitulated by the 10-ng RNA input library (Fig. 4C; Supplemental Figs. S15C, S16; The FANTOM Consortium et al. 2014; Haberle et al. 2014; Haberle and Lenhard 2016). Furthermore, rotational positioning of the +1 nucleosomes is associated with WW periodicity (AA/AT/TA/TT dinucleotides) lined up with the dominant TSS. We examined WW\n",
            "[0.7460055]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.33ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Do the Sleeping Beauty or the piggyBac transposons have higher transposition efficiency?\n",
            "Refined Query: Comparing the transposition efficiencies of Sleeping Beauty and piggyBac transposons requires clarifying the specific experimental conditions.  Factors such as cell type, delivery method, and transposon design significantly influence transposition rates.  Therefore, a direct answer about which system is \"higher\" necessitates specifying these parameters.\n",
            "\n",
            "Combined Answer: of TADs compared to those lacking evidence of this type of conservation (non-GRB-TADs) (Supplementary Fig. 8a and Supplementary Table 3) (see Supplementary Methods). Previously, it has been found that the regions surrounding key developmental genes are depleted of transposons46, suggesting that the regulation of these genes is sensitive to insertions. Indeed, GRBs sharply define regions depleted of transposons, with strong increases in the density of SINEs in their flanking regions (Fig. 4 and Supplementary Fig. 8b). Changes in SINE density distributor. However, this is too simplistic, as the biological importance is related to the delivery of THs to cells, which is dependent on the dissociation rates of T3 and T4 from the distributor proteins and capillary transit times. To determine which of the three TH distributor proteins contributes most effectively to hormone delivery to tissues, the dissociation rates and the capillary transit times have to be considered. In brief, the dissociation rates for T4 and T3 from TBG are 0.018 and 0.16 s−1, respectively; from TTR are 0.094 and scores (see Supplementary Figs S4 and S5), (d) tissue/target specific mechanisms (see Fig. 5a) and (e) tissue/target coverage in the dataset (see Fig. 5b). Neither of these effects showed a clear association with performance. Therefore, we believe that these differences arise (f) from the fact that some biological mechanisms can be modelled better than others. This could be connected to the measurements that we can obtain from cell lines and whether they are able to capture these biological processes. Investigating (f) would require further careful analysis of the original paper reveals that only the forebrain (and not the entire brain) was analyzed for TH content (Mayerl et al., 2014). Furthermore, if TH transmembrane transporters are responsible for moving significant amounts of TH into and out of the choroid plexus, then why do TTR null mice have only 14% T4 in their choroid plexus compared with wildtype mice? How do these data from TH transmembrane transporter and TTR null mice correlate with the data from Chanoine et al. (1992)? The quantitative contributions of the various and that protein interactions are central to the developmental processes. Among the reasons that may explain this are technical constraints, such as the short time window characterizing worm and fly embryogenesis, and the sensitivity of the technique when fusion proteins are expressed at the same level as the endogenous proteins of interest, a prerequisite for drawing physiologically relevant conclusions. In this work, we question the suitability of the BiFC technology in conditions where proteins are expressed at physiological levels in the a Leu+ phenotype are not generated via oxidative damage in stationary phase. The results observed with the leu allele warrant further investigation and may involve the activation of the SOS response during exponential growth. Studies with E. coli and P. putida have shown that independent mutations in mutT and mutY but not in mutM did increase the mutation rate of starved cells (3, 4, 36). On the other hand, while a mutM mutation did not affect the mutation rate of a mutT mutant, when combined with mutY a further enhancement in the mutation from the strain YB955 on the generation of adaptive revertant colonies. To this end, a ytkD mutM yfhQ triple mutant was constructed in the genetic background B. subtilis YB955. As shown in Fig. 2, YB955 cells lacking a GO system had a dramatic propensity to increase the number of His and Met revertants during stationary phase. Specifically, with respect to the parental strain YB955, the ytkD mutM yfhQ mutant showed increases of around 22 and 50 times in the number of His and Met revertant colonies, respectively, generated during the stationary Constructs encoding human wild-type or mutant CREST, or lacZ in pUAST vector, were injected into w1118 embryos to produce transgenic flies as described previously [57,58]. At least three independent transformant lines were analyzed per construct. gmr-GAL4 and UAS-lacZ lines were obtained from the Bloomington Drosophila stock center. For immunoblot analysis, heads of 5-day-old flies were dissected and lysed in Laemmli sample buffer for SDS-PAGE containing 2% SDS. For external surface observation, 5-day-old flies were anesthetized with CO2 and and 48–72 h after laying) to generate germline clones. In parallel, y w FRT19A females were crossed with y w sn P{mini w+, ovoD1−26}25 FRT19A, hsFLP122/Y males, and the offspring were heat-shocked to serve as paired controls. Since only females with the desired germline clones should produce embryos, non-heat-shocked offspring from each cross were preserved and allowed to mature to check for escapers. Any crosses that produced embryos without heat-shock (escapers) were discarded. 350 were mapped. For the insertions in this study, all transgenic lines with similar expression patterns were selected and the insertion sites identified. The flanking sequences of all insertions are listed in Supplemental Table S3. All experiments were in accordance with regulations for animal experimentation in Norway.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.24ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Where does TORC1 sequester during heat stress?\n",
            "Refined Query: The cellular localization of the Target of Rapamycin Complex 1 (TORC1) is dynamically regulated.  Under heat stress conditions, does TORC1 relocalize to a specific subcellular compartment, such as the cytoplasm or nucleus, to mitigate stress-induced damage or regulate cellular responses?  Precisely pinpointing this sequestration is key to understanding its role in thermotolerance.\n",
            "\n",
            "Combined Answer: and TORC2, which differ in subunit compositions and biological functions (7). The rapamycin-sensitive mTORC1, which consists of five components, including mTOR, Raptor (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with Sec13 protein 8; also known as GβL), PRAS40 (proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP domain-containing and mTOR-interactive protein) (8), regulates protein synthesis and cell growth by phosphorylating downstream target proteins such as p70 ribosomal S6K1 (S6 kinase 1) and the eukaryotic and mTOR-interactive protein) (8), regulates protein synthesis and cell growth by phosphorylating downstream target proteins such as p70 ribosomal S6K1 (S6 kinase 1) and the eukaryotic initiation factor 4E-BP1 (5, 9). The rapamycin-insensitive TORC2, which comprises six components, including mTOR, Rictor (rapamycin-insensitive companion of mTOR), mSIN1 (mammalian stress-activated protein kinase-interacting protein 1), Protor-1 (protein observed with Rictor-1), mLST8, and DEPTOR (8), functions as an Akt kinase that phosphorylates Ser473 of Akt are involved in RSV-initiated beneficial function in cells. mTOR (mammalian target of rapamycin) is a member of the phosphatidylinositol 3-kinase (PI3K)-related protein kinase subfamily that plays a critical role in the regulation of various cellular events such as cell growth and proliferation (5, 6). mTOR exists in two distinct complexes, TORC1 and TORC2, which differ in subunit compositions and biological functions (7). The rapamycin-sensitive mTORC1, which consists of five components, including mTOR, Raptor (regulatory-associated protein the nucleus within 60 min of rapamycin addition (Lopez-Serra et al. 2013). Absence of either Ctf4 or Chl1 led only to a slight decrease in the stability of nuclear Scc1, when compared to the wild type, consistent with a role independent of promoting cohesin stability. However, ctf4 and chl1 deletions cause a less severe cohesion defect compared to eco1 inactivation. We therefore analyzed cells lacking Ctf18, a component of the Eco1-dependent pathway, that show a cohesion defect comparable to that of cells lacking Ctf4 or Chl1. Cohesin in (O'Reilly et al. 2012). We now added rapamycin and assessed the nuclear enrichment of Scc1-FRB-GFP in 10-min intervals. In wild type cells, Scc1 is stably bound to chromosomes and therefore retains nuclear localization throughout the experiment (Fig. 4b). As reported, after Eco1 depletion using an auxin-inducible degron, Scc1 was completely lost from the nucleus within 60 min of rapamycin addition (Lopez-Serra et al. 2013). Absence of either Ctf4 or Chl1 led only to a slight decrease in the stability of nuclear Scc1, when compared to the wild mrc1Δ cells, and the ctf4-td strain (td, temperature sensitive degron) were all able to grow at both 24 and 37°C in the presence or absence of the Ubr1 E3 ubiquitin ligase that induces ubiquitylation and degradation of the heat-inducible degron (Figure 7B). In contrast, the mrc1Δ ctf4-td strain was able to grow at 24 or 37°C in the absence of Ubr1, but was specifically unable to grow at 37°C in the presence of Ubr1 (Figure 7B). This indicated that we could use the mrc1Δ ctf4-td strain to analyse how cells die after removal of both Mrc1 and 67% among 39 species including D. rerio and X. tropicalis. The presence of an IRES within such a highly conserved region strongly suggests selective pressure favoring a programmed role for alternate translation initiation. The role of the IRES under normal conditions is unclear, but ongoing efforts to understand the relevant cell lineage-specific and/or conditional activation signals will shed light on underlying mechanisms of IRES control and elucidate potentially novel functions of dystrophin. An intriguing question is how the N-truncated ranging from 25 to 37°C was used to detect changes in maximum permissive growth temperature. A synthetic dosage lethal interaction was found with cdc2-1, cdc7-4, cdc17-1, and cdc46-1, each of which functions in an aspect of DNA synthesis. CDC2 and CDC17 encode catalytic subunits of polymerase δ and polymerase α, respectively (43). CDC7 encodes a protein-kinase whose activity controls replication initiation, probably through modification of targets in the prereplication complex (64). CDC46 encodes an essential protein of the prereplication stress (20, 30). One assumption demonstrated here that supports these pathways is that the MMR system may be sequestered or turned off while cells experience significant oxidative damage. A major unanswered question is whether this stationary-phase process occurs in a subpopulation of the cells (30). defect by including the temperature sensitive eco1-1 mutant in our analysis. Smc3 acetylation is much reduced in cells carrying this allele, even at the permissive temperature, and becomes close to undetectable at the restrictive temperature (Rowland et al. 2009). We synchronized cells in G1 and followed them through S-phase and into arrest in mitosis by nocodazole treatment at 23 °C, a permissive temperature for the eco1-1 allele (Fig. 2a). At the time of S-phase, Smc3 acetylation became detectable in eco1-1 cells, though at a greatly reduced\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1258.43ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1183.76ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1736.50ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 881.33ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1259.57ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1636.19ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 906.85ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1138.86ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1640.74ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 834.95ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the most common type of pediatric cerebellar tumor?\n",
            "Refined Query: Among children diagnosed with cerebellar tumors, what specific histological subtype is most frequently encountered?  This requires identifying the prevalent type, not just the general location within the cerebellum.\n",
            "\n",
            "Combined Answer: cerebellum. Patients with pontine tumors were younger (median = 7 years) than those with thalamic (median = 24 years) or spinal (median = 25 years) tumors. A wide morphologic spectrum was encountered including gliomas with giant cells, epithelioid and rhabdoid cells, primitive neuroectodermal tumor (PNET)‐like foci, neuropil‐like islands, pilomyxoid features, ependymal‐like areas, sarcomatous transformation, ganglionic differentiation and pleomorphic xanthoastrocytoma (PXA)‐like areas. In this series, histone H3‐K27M mutation was mutually There were 3 participants (33%) with documented cerebellar atrophy. MRI studies at sequential time points for one of these patients with moderate to severe atrophy of the cerebellar hemispheres and vermis, associated with regression – loss of the ability to walk, is shown in Figure 3B and C (arrow). Another patient had bilateral lesions in the inferior cerebellum with minimal volume loss. There were also notable findings regarding increases in ventricles as well as changes in white matter (Supplementary Table 1). (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Medical symptoms, particularly gastrointestinal symptoms, were common. Height and body mass index measures were below normal ranges in most participants. Behavioral symptoms included hyperkinetic behavior (100%) and a majority exhibited high pain threshold. follow the expected clinical course of what can be considered classic for children with DIPG, suggesting a potentially different clinical and molecular entity which should be added to the group of “atypical” DIPG when considering clinical trial design. These H3.3 wild-type tumors may be more heterogeneous in terms of histology and biological features than K27M-H3.3 tumors, and may perhaps, with larger numbers, be further divided into different sub-groups. One uncommon subgroup of H3.3 wild-type brainstem tumors which is hinted at by our series observed by the ‘probeMis’ command. MethPed is currently the only publically available tool for classification of pediatric brain tumors. The use of methylation profiling for classification of these tumors adds new and important knowledge in the clinical setting for choosing the optimal care and treatment of these patients and will therefore likely complement histopathological diagnoses in the near future [1, 2]. with cerebellar atrophy and a strong signal in the ansiform lobule of the cerebellum on T2-weighted and fluid-attenuated inversion recovery MRI.24 In an Italian family, compound heterozygous substitutions (Asp147His and Ala515Val) cause familial infantile myoclonic epilepsy (FIME [OMIM 605021]) in seven individuals with normal intellect and normal MRI, except for periventricular nodular heterotopia in one individual.25 A homozygous truncating mutation (969_970delGT, Ser324Thrfs*3) in exon 3 was identified in five Turkish individuals with a harboring histone H3‐K27M mutation. While all prior examples have been in pediatric and young adult patients, we found K27M+ gliomas in older adults up to 65 years of age. While nearly all prior examples of diffuse gliomas with histone H3‐K27M mutation have been located in the thalamus, pons or spinal cord, we also found examples arising in the third ventricle, hypothalamus, pineal region and cerebellum. Furthermore, we note that a wide morphologic spectrum can be encountered, with features overlapping nearly every known histologic variant of described in later life past the first decade.3, 15, 16 A recurrent history involves loss of the ability to walk and loss of words or sounds. In addition to these clinical symptoms, there also may be a neurodegenerative component to CS that involves at least the cerebellum and perhaps also regions within the brain stem. We find 33% of patients with MRI evidence of cerebellar atrophy, which corresponds frequently to loss in ability to walk. This finding was also corroborated at the biological level with regard to studies in a CS mouse model arising in the cerebral hemispheres. However, the molecular underpinnings of the rest of these tumors remains unknown, and none of the 19 tested cases had IDH1 mutation. Notably, three of these diffuse midline gliomas lacking histone H3‐K27M mutation had a history of prior radiation therapy. These included the only K27M negative DIPG in this study that occurred in a 15‐year‐old boy after receiving craniospinal irradiation at 5 years of age following resection of a medulloblastoma from the midline of the posterior fossa. The second patient was MethPed: an R package for the identification of pediatric brain tumor subtypes - PMC\n",
            "[0.66798925]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the E3 ubiquitin ligase of Hsp90?\n",
            "Refined Query: The heat shock protein 90 (Hsp90) chaperone machinery is regulated by ubiquitin-mediated proteolysis.  This question seeks to identify the specific E3 ubiquitin ligase responsible for targeting Hsp90 for degradation, a process crucial for cellular homeostasis.  Which E3 ligase(s) are involved in this regulatory pathway?\n",
            "\n",
            "Combined Answer: and DNA. Histone H3.1 differs from H3.2 by a single amino acid (Ser96 in H3.2), and H3.3 is distinguished by an additional four amino acid substitutions (Ser31, Ala87, Ile89, Gly90) (Franklin and Zweidler 1977) (Fig. 1a). These clustered amino acids that differ between H3.1 and H3.3 have been linked to the differential binding of chaperones (Tagami et al. 2004; Drane et al. 2010; Lewis et al. 2010; Wong et al. 2010), with specifically G90 of H3.3 promoting binding to DAXX (death-domain associated protein) (Elsasser et al. 2012). The DNA Figure 6). Previously, it was not possible to characterise why cells die in the absence of Mrc1 and Ctf4. To circumvent this problem, we made a strain in which the Ctf4 protein is fused at its amino terminus to the heat-inducible degron (Dohmen et al, 1994; Labib et al, 2000), allowing us to inactivate Ctf4 in a conditional manner. Control cells, mrc1Δ cells, and the ctf4-td strain (td, temperature sensitive degron) were all able to grow at both 24 and 37°C in the presence or absence of the Ubr1 E3 ubiquitin ligase that induces ubiquitylation of ChAs in the two subnetworks include many promoter-specific histone modifications and chromatin factors, specifically H3K4me3 (typically denoting active promoters), HCFC1 (transcription activator complex), SIN3A (transcriptional repressor complex), KDM2A (H3K26 demethylase), NMYC, OGT (histone acetyl transferase complex), H3K4me2, and H3K9ac (denoting active promoters) [38]. Features that have slightly higher or equal ChAs in the P–O interactions include CBX3 (the HPγ implicated in elongation [44, 45]) and RNAPII-S2P. PCHi-C can only detect or USF2 is the subunit of this complex that directly binds the promoter, while ATF3 is a cofactor recruited by USF1/2 despite having its own DNA-binding domain that is used in other complexes. By the same logic we also predict that SIX5 and ZNF143 are members of a novel complex in which ZNF143 is the DNA-binding subunit. In both cases, previous experimental evidence shows the two partners are not capable of binding each other alone, suggesting that a chaperone is required to enable binding, or that these interactions require both proteins to that also have high ChAs are H3K4me1, found on regulatory distal regulatory elements, and H3K36me3, marking transcribed gene bodies. On the other hand, H3K4me3, a modification associated with active promoters, is a very abundant mark (fourth most abundant, abundance = 0.12, mean of all features 0.02) but it has low ChAs (0.04). We verified that ChAs is robust to random removal of edges in the network, such that our results do not depend on the completeness and accuracy of the chromatin interaction network (see Additional file 1: Text S1 and (EDNRB and ET3) have been documented in both humans and mice.33,34,35 Altogether, RET plays a pivotal role in HSCR as the major gene in isolated HSCR and as a modifier gene in at least some syndromic HSCR entities. mrc1Δ cells, and the ctf4-td strain (td, temperature sensitive degron) were all able to grow at both 24 and 37°C in the presence or absence of the Ubr1 E3 ubiquitin ligase that induces ubiquitylation and degradation of the heat-inducible degron (Figure 7B). In contrast, the mrc1Δ ctf4-td strain was able to grow at 24 or 37°C in the absence of Ubr1, but was specifically unable to grow at 37°C in the presence of Ubr1 (Figure 7B). This indicated that we could use the mrc1Δ ctf4-td strain to analyse how cells die after removal of both Mrc1 and occupancy and H3K27me3, suggesting that HOTAIR may nucleate Polycomb domains. One prime example of this pattern is in the human HOXD locus, where HOTAIR is known to target PRC2 to silence multiple HOXD genes across 40 kilobases (Rinn et al., 2007). One of the high confidence HOTAIR ChIRP-seq peaks mapped to the intergenic region between HOXD3 and HOXD4, which corresponds to middle of a broad domain of H3K27me3 and SUZ12 occupancy loss upon HOTAIR depletion (Fig. 5C) (Rinn et al., 2007; Tsai et al., 2010). Endogenous HOTAIR in primary human (Tagami et al. 2004; Drane et al. 2010; Lewis et al. 2010; Wong et al. 2010), with specifically G90 of H3.3 promoting binding to DAXX (death-domain associated protein) (Elsasser et al. 2012). The DNA synthesis-coupled histones are encoded by unusual transcripts that lack introns and polyadenylation signals: histone H3.2 is encoded by three genes (HIST2H3A, HIST2H3C, and HIST2H3D), whereas H3.1 is encoded by ten genes clustered on chromosome 6. The DNA synthesis-independent H3.3 is expressed from only two genes, H3F3A on chromosome 1 and H3F3B group of features with positive ChAs in the P–P interactions, implying that these epigenomic features are found in promoters that contact each other, and negative ChAs in the P–O interaction network, implying that these features are usually not present on the other-end fragments that contact promoters. The features that have discordant signs of ChAs in the two subnetworks include many promoter-specific histone modifications and chromatin factors, specifically H3K4me3 (typically denoting active promoters), HCFC1 (transcription activator\n",
            "[0.65007174]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the major phycobiliproteins present in cyanobacteria?\n",
            "Refined Query: Cyanobacteria, also known as blue-green algae, utilize phycobiliproteins as their primary light-harvesting pigments.  Which specific phycobiliproteins, such as phycocyanin and phycoerythrin, are predominantly found in these organisms, and how might their relative abundance vary depending on environmental factors like light intensity and wavelength?\n",
            "\n",
            "Combined Answer: changes (Ka/Ks) [33] is increased for the RRs compared to the coding homologs (see Materials and Methods and Figure S6). In accordance with the results obtained so far, these data further support the hypothesis that (1) the RRs were ancestrally coding and (2) the fish RRs are under a selection acting at the nucleotide rather than at the AA level. These data suggest that the RRs were ancestrally not regulatory since the Ka/Ks ratio between human and shark or ciona would favour a selection acting at the AA level only. To test the nature Metazoan phylum: at the Six gene loci in the sea urchin Strongylocentrotus purpuratus, the regulatory landscapes defined by the span of promoter contacts identified using 4C45 closely correlates with lineage-specific CNE density at this locus (Supplementary Fig. 7b). These results show overwhelming evidence for a strong concordance between CNE density and topological organisation in the genomes of vertebrates and arthropods; with limited evidence available for echinoderms. These phyletic groups shared a common ancestor at ∼560 Mya, and while split Venus fragments. Again, the expression level of fusion constructs was verified to be close to endogenous AbdA expression levels (not shown). The red and blue fluorescent signals were visualised following their respective excitation wave lengths (see Methods). We found that BiFC with mCherry and Cerulean was weaker than BiFC with Venus (Figures 8a and 8b). This was mainly due to a weaker brightness of mCherry and Cerulean but it was also due to a higher level of non-specific fluorescent background in the Cerulean emission spectra Since its cloning in 1992 [1], the green fluorescent protein (GFP) from the jellyfish Aequorea victoria has become a potent tool in biology. GFP has been manipulated and modified and a set of derived fluorescent proteins showing different spectral properties and stabilities are now available. GFP proteins can tolerate peptide insertions without perturbing its fluorescence characteristics [2,3]. This led to the finding that split GFP fragments can reconstitute a functional fluorescent protein when fused to interacting peptides [4]. First applied level. These data suggest that the RRs were ancestrally not regulatory since the Ka/Ks ratio between human and shark or ciona would favour a selection acting at the AA level only. To test the nature (regulatory or non-regulatory) of the ancestral state at the tetrapod-teleost split, we further explored the enhancer activity of the exons homologous to the RRs in two independent lineages (mouse and elephant shark) as well as the coding paralog in fish (Figure 4). In none of the cases tested was an enhancer activity detectable (Figure 4 and Table AbdA: abdominalA; BiFC: bimolecular fluorescence complementation; CC: C-terminal fragment of Cerulean; CFP: cyan fluorescent protein; CN: N-terminal fragment of Cerulean; dt: dorsal trunk; EMSA: electrophoretic mobility shift assay; Exd: extradenticle; FRET: fluorescence resonance energy transfer; GFP: green FP; HD: homeodomain; Hth: homothorax; TALE: three amino acids insertion; PCR: polymerase chain reaction; Tsh: Teashirt; Bin: biniou; Ubx: ultrabithorax; YFP: yellow FP; VN: Venus; VN: N-terminal fragment of venus; VC: C-terminal fragment of (Millipore, Billerica, MA). The blot was visualized by using enhanced chemiluminescence reagents (PerkinElmer, Waltham, MA) with an LAS-1000 image analyzer (Fuji Film, Tokyo, Japan). An MBP pulldown assay was performed as described previously (20). Briefly, cell lysates were incubated overnight at 4°C with amylose resin. The beads were washed three times with a washing buffer (50 mM Tris-HCl [pH 7.5], 2 mM MgCl2, 150 mM NaCl), and the bound proteins were eluted by boiling in 2× sodium dodecyl sulfate (SDS) sample buffer and subjected to A (25 mm Hepes, pH 7.5, 50 mm NaCl, 2 mm dithiothreitol, 0.1 mg/ml bovine serum albumin). The kinase reaction was started by adding an equal volume of buffer B (25 mm Hepes, pH 7.5, 50 mm NaCl, 2 mm dithiothreitol, 0.2 mm ATP, 0.2 mm MgCl2) and incubated at 30 °C for 30 min. Europium cryptate-labeled p-Ser-129-specific11A5 antibody (2 nm) and streptavidin-allophycocyanin (7.5 nm) were added in the same reaction volume of buffer C (25 mm Hepes, pH 7.5, 0.8 m KF, 66 nm EDTA, 0.1% bovine serum albumin), and fluorescence intensity was measured. proliferation was quantified using the cell proliferation ELISA, BrdU colorimetric kit (Roche, NY, USA) according to the manufacturer’s instructions. Absorbance was measured at 370 nm with reference wavelength at 492 nm. USA), and held for 10 min in the dark. DAPI and GFP fluorescence were observed by fluorescence microscopy (BX61 Olympus, Japan) and photographed using a CCD camera (CCD-EX1; Universal Imaging Corporation, USA). DAPI and GFP images were merged using Photoshop (Adobe system). The shape and localization of the nucleolus were determined from an analysis of these images for at least 100 cells in each strain.\n",
            "[0.7698015]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is PLK2 involved in alpha-synuclein phosphorylation in the nervous system?\n",
            "Refined Query: Investigating the role of Polo-like kinase 2 (PLK2) in the phosphorylation of alpha-synuclein within neuronal cells is crucial to understanding its potential contribution to neurodegenerative diseases like Parkinson's, where aberrant alpha-synuclein phosphorylation is implicated.  Does PLK2 directly phosphorylate alpha-synuclein, or does it act indirectly via other kinases?\n",
            "\n",
            "Combined Answer: decreased synuclein phosphorylation were identified (26). Of the candidate kinases, PLK2 was of particular interest because the siRNAs against this enzyme provided the largest and most consistent decrease in α-synuclein phosphorylation. Importantly, PLK2, as well as the closely related PLK3, are expressed in brain (27, 28). PLK Family Members Directly Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as Several neurological diseases, including Parkinson disease and dementia with Lewy bodies, are characterized by the accumulation of α-synuclein phosphorylated at Ser-129 (p-Ser-129). The kinase or kinases responsible for this phosphorylation have been the subject of intense investigation. Here we submit evidence that polo-like kinase 2 (PLK2, also known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical In this study, we have shown that members of the PLK family, specifically PLK1, -2, and -3, phosphorylate Ser-129 of α-synuclein in vitro, suggesting that they are capable of acting as direct α-synuclein kinases. Studies with inhibitors additionally suggest that PLK2 and PLK3 are responsible for the majority of α-synuclein phosphorylation in cultured neurons and in mouse brain. PLK2-specific shRNA knockdown and genetic deletion of the plk2 gene in mice identify a role for this kinase in particular. Previous studies of PLK2 have identified known as serum-inducible kinase or SNK) is a principle contributor to α-synuclein phosphorylation at Ser-129 in neurons. PLK2 directly phosphorylates α-synuclein at Ser-129 in an in vitro biochemical assay. Inhibitors of PLK kinases inhibited α-synuclein phosphorylation both in primary cortical cell cultures and in mouse brain in vivo. Finally, specific knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels. These results indicate that PLK2 plays a critical role Polo-like Kinase 2 (PLK2) Phosphorylates α-Synuclein at Serine 129 in Central Nervous System - PMC Phosphorylate α-Synuclein—To confirm that PLK2 can directly phosphorylate α-synuclein, we examined the proteins in vitro. PLK2 was compared with the other members of the PLK family, as well as CK2, which has been previously shown to phosphorylate α-synuclein (10). Phosphorylation at Ser-129 was measured with a fluorescence assay using an antibody specific for phosphorylation at this residue (11); no other phosphorylation was observed by mass spectroscopy. PLK2 and -3 efficiently phosphorylated α-synuclein (Fig. 1A), with results consistent knockdown of PLK2 expression by transduction with short hairpin RNA constructs or by knock-out of the plk2 gene reduced p-Ser-129 levels. These results indicate that PLK2 plays a critical role in α-synuclein phosphorylation in central nervous system. (by as much as 64%) and a parallel reduction of p-Ser-129 α-synuclein (as much as 78%). No effect was observed on PLK3 mRNA or total α-synuclein levels, and there was no cellular toxicity detected by Alamar Blue assay, suggesting that the effect on phospho-α-synuclein was mediated by specific mRNA silencing (data not shown). We have compared the potency of selected kinase inhibitors against PLK2 in mouse primary cortical cultures with their potency in the biochemical PLK2 assay. Many of the studies investigating CK2 as an α-synuclein kinase was observed. The effect of removal of the plk2 gene on α-synuclein levels was also investigated using PLK2 knock-out mice. Primary cortical cultures from a homozygous knock-out mouse were compared with those from wild-type (plk2+/+) littermates. Measurement of mRNA levels by qRT-PCR showed that PLK2 expression was completely ablated. Comparison of α-synuclein and p-Ser-129 α-synuclein levels in primary cortical cultures from knock-out and wild-type littermates showed that α-synuclein phosphorylation was decreased by about 70%. A similar potency of selected kinase inhibitors against PLK2 in mouse primary cortical cultures with their potency in the biochemical PLK2 assay. Many of the studies investigating CK2 as an α-synuclein kinase have used the inhibitor DMAT. We also find that DMAT inhibits α-synuclein phosphorylation in mouse cortical cultures, with an EC50 around 30 μm. However, it also inhibits PLK2 in the biochemical assay (Fig. 2, A and B). APMU (compound 3 in Johnson et al. (29)), which has good activity against PLK2 and -3 but is inactive against PLK1, inhibited\n",
            "[0.8728404]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: In which kingdom do microsporidia belong, according to their current classification scheme?\n",
            "Refined Query: The current classification of microsporidia is a topic of ongoing debate.  To clarify, I need to know which classification scheme you are referring to—for example, are we considering the most recent phylogenetic analyses or a more traditional taxonomic system?  Determining their kingdom placement requires specifying the classification system used.\n",
            "\n",
            "Combined Answer: program for phylogenetic analyses, was used to identify the similarity between the phylogenetic trees inferred using the original and refined datasets. A comparison with respect to the phylogenetic trees obtained using MUSCLE and RAxML was made between the alignment of the original datasets and that of the datasets produced by refining the A.B.C.rot datasets using MARS, BEAR, and Cyclope. The Robinson–Foulds (RF) metric was used to measure the distance between each pair of trees. The same parameter values were used for MARS: q=5, ℓ=50, and 9) are designated «derived». This view of the Nematoda being divided into two major groups corresponds to their partition into the classes Enoplea (basal, paraphyletic) and Chromadorea (derived, monophyletic; see Discussion for further arguments supporting this view) [25,26]. three published CTCF sequences from insects were incorporated [19,82]. An outgroup was not defined. Phylogenetic trees resulting from the alignments were computed using four different methods of tree reconstruction: maximum likelihood, neighbor joining, maximum parsimony, and a Bayesian analysis. At first, the optimal model of sequence evolution was determined by ProtTest version 1.4 [83] according to the Akaike Information Criterion. The resulting optimal model (WAG+I+G) was used for maximum likelihood (with 100 bootstrap replicates) as well results [17]. Several discussions of existing filtering methods provide evidence that the removal of blocks in alignments of sufficient length leads to better phylogenetic trees. These filtering methods take a variety of mathematical and heuristic approaches. Most of the methods are fully automated and they remove entire columns of the alignment. A few of these programs, found in [18, 19], are based on site-wise summary statistics. Several filtering programs, found in [20–24], are based on mathematical models. However, experimental results [13]; and, therefore, heuristic techniques are commonly used [14–16], which may not always lead to optimal alignments. As a result, suboptimal alignments may lead to unreliable tree estimation during phylogenetic inference. To this end, several methods aimed to have shown that removing unreliable sites (columns) of an alignment may lead to better results [17]. Several discussions of existing filtering methods provide evidence that the removal of blocks in alignments of sufficient length leads to better phylogenetic trees. These filtering regions with built-in genomic annotations for D. melanogaster (dm3 and dm6), H. Sapiens (hg19 and hg38), M. musculus (mm9 and mm10), R. norvegicus (rn4, rn5 and rn6), annotations imported from the AnnotationHub R package or custom annotations for any organism. annotatr enables users to associate numerical or categorical data with regions, enabling better understanding of the underlying experiments via summarization and visualization functions. annotatr is fast, flexible and easily included in bioinformatics pipelines. datasets. Notice that, in particular with MUSCLE, we obtain an identical or less average pairwise distance in 8 out of 9 cases between the original and the refined datasets produced by using MARS, despite the fact that we had first randomly rotated all sequences (compare the A.B.C to the A.B.C.rot columns). RAxML [50], a maximum-likelihood-based program for phylogenetic analyses, was used to identify the similarity between the phylogenetic trees inferred using the original and refined datasets. A comparison with respect to the phylogenetic With the high volume of data and computational challenges of alignment and kmer identification, new computational strategies are required to computationally separate the two species’ components for more accurate downstream analysis 1, especially for the reduction of variant calling artefacts. However, the two-species alignment approach proposed in Bradford et al. 1 excludes reads that align to both organisms, clearly dismissing a large portion of the data as evidenced in Table 1 when observing cross species alignment rates. Algorithms designed PH conceived the study, cloned the gene, generated the sequence databases and sets for phylogenetic analyses and wrote the manuscript except phylogeny. BM carried out and described the phylogenetic analyses. ES participated in design and coordination of the study and critically revised the manuscript. All authors read and approved the final manuscript. containing homologous developmental genes are associated with the same type of conservation and structure in humans and Drosophila. Not only are regulatory elements in these regions under intense selective pressure, but the association between the boundaries of GRBs and TADs also suggests that the basic 3D structure of these loci has existed over hundreds of millions of years of evolution, at least back to the ancestor of chordates and arthropods. At even more distant timescales, the phenomenon of microsynteny has existed since early Metazoa\n",
            "[0.67709196]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the inheritance pattern of Emery-Dreifuss muscular dystrophy? \n",
            "Refined Query: Emery-Dreifuss muscular dystrophy (EDMD) exhibits what inheritance pattern?  Is it X-linked recessive, autosomal dominant, or another mode?  Clarify the specific gene(s) involved and how mutations affect inheritance.\n",
            "\n",
            "Combined Answer: Duchenne muscular dystrophy (DMD) is a progressive, severely disabling, and incurable X-linked recessive inherited disorder that affects 1 in 3,500 newborn boys and leads to death in the second or third decade of life.1 In patients with DMD, the open reading frame of the X-linked dystrophin gene, encoding dystrophin, is disrupted by deletions (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton Duchenne muscular dystrophy (DMD), an X-linked recessive condition, is a rare genetic disorder caused by the absence of functional dystrophin proteins due to gene mutations [1]. The incidence of DMD is approximately 1 in 5000 male newborns [2]. Affected boys initially exhibit progressive muscle weakness of the lower proximal extremities [3]. The gradual muscle tissue loss and motor function deterioration eventually lead to ambulation loss, with respiratory and cardiac failure at the end stage of the disease [4,5]. Multidisciplinary care and domain that develop a DMD phenotype even though considerable levels of dystrophin staining was visible at the sarcolemma. Another patient harboring a missense mutation (D3335H)27 had dystrophin protein expression, but despite this, a DMD phenotype. Similarly in-frame deletions affecting the actin-binding domain also cause a DMD phenotype.4,28,29 Therefore the functional properties of the restored dystrophin could be partly assessed by the quantification of the DAPC complex. This was shown briefly in animal models of DMD, as successful exon nNOS regulates the blood flow in skeletal muscle according to its metabolic needs,10 and its lack at the sarcolemma is associated with ischemia following exercise, which is believed to cause additional muscle tissue damage in DMD. Becker muscular dystrophy (BMD) is a milder allelic variant with mutations that maintain the dystrophin open reading frame. An internally shortened but partly functional dystrophin is consequently produced and as a result, BMD patients usually remain ambulant into late adulthood and have a normal life span.11 Using the DMD muscle transcript in the frameshifted patient FS. This decreased amount of translation is consistent with both the expected reduction in dystrophin level given the patient’s mild BMD phenotype, and with the amount of dystrophin seen in p.Trp3X patients4 and other 5’ mutation alleles (Fig. 1c). The saw-tooth RNA-Seq pattern observed in DMD introns 1 through 8 (Fig. 1e) confirmed that the major transcription start was located at the dystrophin muscle-specific promoter (Dp427m) and that DMD exons 1 through 7 underwent efficient protein induced by exon skipping in the human. The lack of dystrophin in DMD leads to reduced levels of all DAPC proteins and even to the absence of nNOS from the sarcolemma.21,22,23,24,25 The importance of a dystrophin protein containing its functional domains is highlighted by patients with the missense mutation (C3340Y)4,26 within the BDG binding domain that develop a DMD phenotype even though considerable levels of dystrophin staining was visible at the sarcolemma. Another patient harboring a missense mutation (D3335H)27 had dystrophin (~65%), duplications (~10%), point mutations (~10%), or other smaller rearrangements (15%).1 Dystrophin is a protein with both a structural and signaling role in muscle, localized to the cytoskeleton immediately beneath the sarcolemma. Regarding its important structural role, dystrophin connects the subsarcolemmal F-actin cytoskeleton to β-dystroglycan (BDG),2 which is associated with α-dystroglycan and in turn connects to proteins of the extracellular matrix (Figure 1). Dystrophin consists of four main functional units (Figure 1). First the Causative mutations in neurodevelopmental disorders are frequently de novo, X-linked recessive or autosomal recessive. In contrast to prior literature reporting largely inherited mutations in NHE6, through prospective recruitment, here we discover seven highly deleterious de novo mutations in NHE6. An eighth mutation was found, in a three-generation pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a A novel DMD IRES results in a functional N-truncated dystrophin, providing a potential route to therapy for patients with 5’ mutations - PMC a deletion of exons 45–50 and two of 48–50, that the shorter novel dystrophin induced by exon 51 skipping in DMD can restore components of the DAPC as indicated by the increase in ASG and BDG in dystrophin-positive fibers and the genotype-specific relocalization of nNOS to the sarcolemma. These data confirm that restored dystrophin maintains essential domains for its function and further suggest the potential of the PMO AVI-4658 to become a disease modifying drug for DMD.\n",
            "[0.89336526]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the mechanism of action of anticoagulant medication Dabigatran?\n",
            "Refined Query: How does the anticoagulant dabigatran prevent blood clot formation?  Explain its mechanism of action, detailing its specific target and the resulting physiological effect on the coagulation cascade.\n",
            "\n",
            "Combined Answer: such as the induction of procoagulant activity that promotes blood clotting, that may play an important role in the vascular effects of inflammation and the pathogenesis of vascular diseases (170). Innate recognition of LPS occurs through a receptor complex consisting of CD14, TLR-4, and myeloid differentiation factor 2 that recognizes pathogenic structures and subsequently induces an inflammatory response. Continuous activation of the innate immune system through TLRs by bacterial stimuli may disrupt immune homeostasis by the overproduction were characterized by upregulation of Bcl-2, we also determined the impact of ABT-737, a small molecule inhibitor of Bcl-2/Bcl-XL, on the sensitivity of the resistant cells to carfilzomib. Cells were incubated with carfilzomib in the absence or presence of a nontoxic concentration of ABT-737 (2.5 μM). As shown in Figure 10, ABT-737 caused an approximately 50% reduction in the IC50 of R-UMSCC-1 cells for carfilzomib, but did not affect the sensitivity of R-Cal33 cells. This indicates that Bcl-2 upregulation can also play a role in acquired To determine the mechanism responsible for carfilzomib/vorinostat synergy in the acquired resistance models, we investigated the expression status of pro-apoptotic Bik protein. Bik is known to be upregulated in HNSCC cells following treatment with bortezomib, carfilzomib, or oprozomib, and plays an important role in mediating cell death by these proteasome inhibitors.8,34 However, as depicted in Figure 7, the R-UMSCC-1 and R-Cal33 resistance models demonstrated only modest, if any, upregulation of Bik when treated with either carfilzomib alone Proteasome inhibitors, primarily bortezomib, and HDAC inhibitors have been shown to synergize against both hematologic and solid tumor malignancies, in models that are not acquired resistance models. Therefore, we sought to determine whether vorinostat, an inhibitor of class I and II HDACs, might synergize with carfilzomib against R-UMSCC-1 and R-Cal33, acting to overcome the acquired resistance to carfilzomib in these cell lines. As shown in Figure 1A and B, the combination of carfilzomib and vorinostat potently synergized to kill both a canalicular bilirubin glucuronide and xenobiotic export pump, thus disrupting bilirubin glucuronide excretion into bile (7, 8). Excretion of bilirubin glucuronides is then redirected into plasma by the action of ABCC3/MRP3, a homolog of ABCC2 that is present in the sinusoidal membrane and is upregulated in DJS (12, 13). The molecular mechanism of DJS is in line with the generally accepted paradigm of normal hepatic bilirubin excretion, according to which a unidirectional elimination pathway is postulated: first, uptake of unconjugated resistance. Cancer cells often exhibit aberrant activation of signaling proteins and pathways that promote cellular survival and intrinsic resistance to proteasome inhibitors and other anti-cancer agents. In addition, because the proteasome regulates expression levels of a large number of proteins with diverse functions, proteasome inhibitors induce the expression of proteins with proapoptotic and antiapoptotic roles. Thus, bortezomib, carfilzomib, and oprozomib upregulate proapoptotic Bik and Noxa, which act to mediate the killing activities as clinical evaluation of these agents proceeds. One approach that has proven successful for overcoming acquired resistance to bortezomib, a boronic acid-based dipeptide, is to utilize a structurally distinct proteasome inhibitor. Indeed, carfilzomib and oprozomib, both of which are epoxyketone proteasome inhibitors, have been shown to be active against patient multiple myeloma cells that have become bortezomib-resistant.26,30,31,33 Our results demonstrate that the converse also may be true. The models of acquired carfilzomib/oprozomib Acquired resistance to proteasome inhibitors also represents a very significant clinical problem, causing patients to become refractory to treatment. Although acquired resistance has primarily been studied with bortezomib in hematologic malignancies, it is anticipated that acquired resistance to carfilzomib and oprozomib will also be observed as clinical evaluation of these agents proceeds. One approach that has proven successful for overcoming acquired resistance to bortezomib, a boronic acid-based dipeptide, is to utilize a structurally focus on elucidating structure-function relationships involved in carbohydrate binding for TcdB and how/whether such binding is truly the basis for toxin binding to host cells, as well as exploring the structural basis for binding/neutralization of TcdA to actoxumab, the other half of the important novel C. difficile therapy that is currently in phase III development for the prevention of recurrent CDI. against patient multiple myeloma cells that have become bortezomib-resistant.26,30,31,33 Our results demonstrate that the converse also may be true. The models of acquired carfilzomib/oprozomib resistance we developed were found to exhibit only moderate resistance to bortezomib. These findings raise the possibility that patients who become refractory to frontline treatment with carfilzomib or oprozomib will retain responsiveness to bortezomib. Our studies also identified co-targeting of HDACs and the proteasome as a strategy for combating\n",
            "[0.6621355]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the effect of a defective CLN3 gene?\n",
            "Refined Query: How does a malfunctioning CLN3 gene impact the body, specifically concerning its role in cellular function and the resulting disease progression?  What are the observable symptoms and the overall health consequences of this genetic defect?\n",
            "\n",
            "Combined Answer: of ∼8 kb causing this disease was mapped in exons 14–15 of AP3B1 (Jung et al. 2006), which removes one of the HCNEs mapped in this study. While the AP3B1 mutation may have an effect on the disease phenotype, this finding suggests that the disease may be a compound phenotype of loss of function of AP3B1 and loss of specific regulatory input of OTP. Thus, as demonstrated by this case, establishment of human/teleost conserved synteny combined with fine mapping in the human genome can immediately produce strong candidate targets for human position ‘Benign’ and ‘Likely Benign’ variants from ClinVar across the same six ICCs. CardioClassifier identified 61/67 (91.0%) of these as Benign and the remaining 6 as VUS. Conversely, InterVar identified 41/67 (61.2%) as Benign with 22 as Likely Benign and 4 as VUS. Here InterVar activates BS2 when a variant is seen in the 1000 genomes dataset, which we believe is inappropriate for ICCs which do not fit the important caveat of ‘full penetrance expected at an early age’. We do acknowledge, however, that InterVar was developed for severe congenital DNA. In one of the two cases that were characterized bioinformatically, otp, we searched for mapped human diseases at the edge of the otp GRB and found Hermansky-Pudlak Syndrome, type 2, a cell migration and platelet defect (OMIM#608233) mapped to the AP3B1 gene at 5q14.1, which, as we have shown, contains HCNEs of the otp GRB. Recently, a microdeletion of ∼8 kb causing this disease was mapped in exons 14–15 of AP3B1 (Jung et al. 2006), which removes one of the HCNEs mapped in this study. While the AP3B1 mutation may have an effect on the at the DP stage of development. This novel finding differs from the developmental block reported by Saidi and colleagues [25] where the use of Lck-cre to mediate NBS1 deletion resulted in a T cell developmental block at the DN3 to DN4 stage [25]. The differences between the developmental block at DP and DN3-DN4 observed by Saidi and colleagues [25] could be due to the use of different cre lines, which delete with varying efficiency during T cell development, with CD2-cre appearing to delete target genes more efficiently. As with our findings to date. In fact, of the more than 100,000 Mendelian-disease-causing variants in ClinVar,5 the vast majority affect coding sequences or conserved splice sites. Accordingly, a large number of bioinformatics tools have been developed to predict the pathogenicity of sequence variants in these traditional categories.6 The “regulatory code” that determines whether and how a given genetic variant affects the function of a regulatory element remains poorly understood for most classes of regulatory variation. Thus, given our lack of understanding and its 3 UTR in a site-specific manner [27]. It is therefore likely that the core clinical features of obesity and ASD in patients carrying 1p21.3 deletion are both mediated by miR-137. The case herein described presents with clinical features not previously described in the 1p21.3 microdeletion syndrome, such as precocious puberty and bicuspid aortic valve, with mild stenosis of the aortic root. The boy carries a 1p21.3 deletion, which extends 5 Mb proximally to the SRO and includes a number of genes. PALMD and S1PR1 encode for proteins that are two were missense, one was a non-frameshift deletion and one was a nonsense mutation. The latter is a 1 bp deletion in C12orf65 gene, resulting in a premature stop codon (NM_001143905: c.346delG: p.V116X) (figure 1B). As mutations in C12orf65 have been recently described to cause a severe encephalomyopathy17 as well as spastic paraplegia and optic atrophy,18 we assessed segregation of this mutation in the family. The deletion was homozygous in the affected cases, and either absent or heterozygous in the unaffected relatives (figure 3). To (Table 2). A deleterious BRCA2 nonsense mutation (c.6952C>T, p.R2318X) was identified in the cell line KURAMOCHI and 2 BRCA1 missense mutations were found in the cell line KOC-7c (c.39T>A, p.N13K and c.395A>C, p.N132T). Furthermore, BRCA2 missense mutations were found in the cell lines MCAS (c.964A>C, p.K322Q), OVCA420 (c.6131G>A,pG2044D), and OVMANA (c.2275C>G, p.L759V). Because it is difficult to interpret the functional significance of missense mutations, we further characterized the predicted functional significance of these using both harbors a splice donor site mutation, c.1747+1G→A, in intron 13 of SLCO1B3. If SLCO1B3 is still yielding functional mRNA, this would truncate OATP1B3 after amino acid 582, deleting the C-terminal one-and-a-half transmembrane domains. A nonsense mutation, c.757C→T, in exon 8 of R3-linked SLCO1B1 introduces a premature stop (p.R253X), truncating OATP1B1 before the C-terminal 7 transmembrane domains. All of these mutations would severely disrupt or annihilate proper protein expression and function. Moreover, they all showed consistent autosomal p.W570X, in Families 3 and 7. Here, the mutations were determined to be de novo in both families, although the families again share a haplotype around the point mutation spanning 260 kb. In total, we observed 9 SNVs, 2 indels and 1 CNV deletion. The majority of mutations were protein truncations (10/12, 83%) and occurred in exons 1, 3, 11, 12, 13 and 14. With the possible exceptions of Families 3 and 7 all protein truncating mutations occurred prior to the end of the predicted transmembrane domains of the protein (Figure 4). Two mutations\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 277.97ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which genes are regulated by TRalpha2  in the heart?\n",
            "Refined Query: Investigate the transcriptional regulatory role of thyroid hormone receptor alpha 2 (TRα2) in the cardiac myocyte.  Specifically, identify target genes whose expression is directly or indirectly modulated by TRα2 in the heart, considering both activation and repression.\n",
            "\n",
            "Combined Answer: Transcription factors (TFs) are proteins that regulate the expression of genes by binding the DNA at their regulatory elements (promoters or enhancers) and either preventing or facilitating the recruitment, in eukaryotes, of the transcription preinitiation complex (PIC). The PIC in turn recruits RNA polymerase II (Pol II) to the transcription start site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then initiates transcription of genes that are positively regulated by THs. Some genes are negatively regulated by THs, whereby binding of T3 induces the opposite changes and turns off transcription. Thus, it is crucial that the appropriate concentration of THs is present in the critical regions of the brain at each stage of development, to ensure signal for the development of T thymocytes (30, 46). E-box motifs in the enhancer region of the pTα gene are required for its activation by E2A/HEB heterodimer in normal T-cell development and are occupied and repressed by TAL1 in Jurkat cells (Figure 3A) (46). Sequence comparison showed a 70.5% identity between mouse and human pTα enhancer sequences (Figure S1B). We further hypothesized that the TAL1 mutants that change TAL1’s ability to recruit LSD1 may affect T cell growth by altering the transcription of TAL1 target genes such as pTα and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux significant motif (POU2F), only one of the three POU2F factors, POU2F2 (also known as OCT2), shows significant correlation of its mRNA level with motif activity, and it is the most highly expressed. This suggests that POU2F2 is mainly responsible for the motif activity in these tissues (Supplemental Figs. 7, 8). The fact that the correlation is positive also strongly suggests that POU2F2 acts as an activator. In contrast, whenever a negative correlation between motif activity and TF expression is observed, the TF most likely acts as a From the above controversy regarding the importance of TTR synthesis by the choroid plexus, several points support the hypothesis that choroid plexus-derived TTR plays a role in the movement of THs from the blood to the brain and in distributing THs in the blood and CSF. These points include evolutionary, developmental, molecular and functional data. Therefore, it would follow that TTR synthesized by the choroid plexus would appear to have an important regulatory role in determining the delivery of thyroid hormones into the CSF. In conclusion, Self-renewal capacity and pluripotency, which are controlled by the Oct3/4-centered transcriptional regulatory network, are major characteristics of embryonic stem (ES) cells. Nuclear hormone receptor Dax1 is one of the crucial factors in the network. Here, we identified an orphan nuclear receptor, Esrrb (estrogen-related receptor beta), as a Dax1-interacting protein. Interaction of Dax1 and Esrrb was mediated through LXXLL motifs of Dax1 and the activation- and ligand-binding domains of Esrrb. Furthermore, Esrrb enhanced the promoter activity The developmental program that generates a complex organism such as a human is executed via gene regulatory networks. Interactions between transcription factors (TFs) and target sites are the main edges of such networks as the regulatory output of such interactions determines the expression levels of target genes at a particular time point during development, in a given tissue and under specific conditions. The human genome contains hundreds of thousands of experimentally documented transcription factor binding sites (TFBSs) and perhaps a\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 302.78ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1385.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List available methods for transmembrane protein topology prediction.\n",
            "Refined Query: Describe the computational and experimental methods used to predict the transmembrane topology of proteins, including their strengths and limitations in determining the number and orientation of transmembrane helices.\n",
            "\n",
            "Combined Answer: position and orientation of TMS to the membrane lipid bilayer) without knowing their 3D structures because of rather simple structural characteristics (6). In this context, a number of TM topology prediction methods have been developed to determine the structure and function of TM proteins from their amino acid sequences (2,7–22). However, the proposed prediction methods have not attained the desired accuracies for this purpose. The recent reports of evaluating prediction performance by using experimentally-characterized TM topology datasets of well-characterized topology data to be used for training or tuning TM topology prediction methods. Thus, more high-quality TM topology data are required to evaluate the existing prediction methods more precisely. For this reason, we have constructed a transmembrane protein database, TMPDB (19,24,26) which is a collection of TM proteins with topologies based on definite experimental evidence such as X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, Asp (N)-linked glycosylation experiment and other TMPDB is a database of experimentally-characterized transmembrane (TM) topologies. TMPDB release 6.2 contains a total of 302 TM protein sequences, in which 276 are α-helical sequences, 17 β-stranded, and 9 α-helical sequences with short pore-forming helices buried in the membrane. The TM topologies in TMPDB were determined experimentally by means of X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or than 18 000 3D structures for soluble proteins registered in PDB (5). It is because TM protein molecules are difficult to crystallize due to their amphiphilic characteristics—hydrophobic TM segments (TMSs) and hydrophilic loops. The functions of TM proteins, however, can be inferred rather easily from their TM topology (i.e., the number of TMSs, TMS position and orientation of TMS to the membrane lipid bilayer) without knowing their 3D structures because of rather simple structural characteristics (6). In this context, a number of TM topology of crystallographic contacts at levels of 67–86%, which are distributed across the entire protein fold (Fig. 6). Taken together, our results underpin that the automated 4D-CHAINS/autoNOE-Rosetta approach yields models that accurately capture the correct global fold as well as atomic features of the native structure. Overall, the convergence of structures obtained using supervised assignments for the three target proteins, RTT, ms6282 and aLP, are better than or comparable to the convergence of structures obtained using 4D-CHAINS automated Transmembrane (TM) proteins serve extremely important functions in life as pump, channel, receptor, energy transducer etc., and have been reported recently to share ∼20–30% of genes in a whole genome (1–4). Nevertheless, the number of three-dimensional (3D) structures with high-resolution is far below one hundred at present, in contrast to more than 18 000 3D structures for soluble proteins registered in PDB (5). It is because TM protein molecules are difficult to crystallize due to their amphiphilic characteristics—hydrophobic TM segments based on definite experimental evidence such as X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, Asp (N)-linked glycosylation experiment and other biochemical methods. TMPDB would serve the requirements of both bioinformaticians and biologists, as a test and/or training dataset, for improving the existing TM topology prediction methods and developing novel prediction methods with higher performance as well as for gaining better understanding of TM proteins. the structure determination process. The full pipeline takes approximately 10–12 days to execute for a typical protein sample, including the time needed for NMR data acquisition, and requires minimum supervision. In addition to recapitulating the correct protein fold, autoNOE-Rosetta models obtained using the 4D-CHAINS assignments show accurate placement of sidechains for most residues in the protein structure (Supplementary Table 5). Specifically, close inspection of sidechain conformations in the Rosetta ensembles computed using the We have collected 1074 articles reporting TM topology, by using MEDLINE (27) search with the keywords, ‘transmembrane’ and ‘topology’ (895 articles), by searching directly without using MEDLINE (46 articles), and by referring to the reference position line (RP) of the entries with the following annotations: ‘X-RAY CRYSTALLOGRAPHY’, ‘STRUCTURE BY NEUTRON DIFFRACTION’, ‘STRUCTURE BY ELECTRON CRYO-MICROSCOPY’, ‘STRUCTURE BY NMR’ or ‘TOPOLOGY’ in SWISS-PROT and TrEMBL (28) (133 articles). By checking the content of each collected article, we X-ray crystallography, NMR, gene fusion technique, substituted cysteine accessibility method, N-linked glycosylation experiment and other biochemical methods. TMPDB would be useful as a test and/or training dataset in improving the proposed TM topology prediction methods or developing novel methods with higher performance, and as a guide for both the bioinformaticians and biologists to better understand TM proteins. TMPDB and its subsets are freely available at the following web site: http://bioinfo.si.hirosaki-u.ac.jp/~TMPDB/.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.06ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Does GC content vary markedly within a given isochore?\n",
            "Refined Query: Isochores are genomic regions of relatively uniform GC content.  This raises the question:  how homogenous is this content *within* an isochore?  Do significant, localized variations in GC% exist, or is the GC content remarkably consistent throughout each isochore's length?\n",
            "\n",
            "Combined Answer: the observed association between two sets of genomic features, such as Pfh1 binding peaks and tRNA genes, was significantly greater than expected, we followed our previously described procedure for generating GC-content-aware empirical p-values [18, 39, 74]. In brief, we compared the observed number of overlaps to the number obtained when scrambling the peak locations 1,000 times in a manner that preserved the length, chromosome, and GC content of the regions. The number of randomized sets of peaks that obtain as many or more overlaps with the the peak locations 1,000 times in a manner that preserved the length, chromosome, and GC content of the regions. The number of randomized sets of peaks that obtain as many or more overlaps with the annotation (e.g., tRNA) as the actual peaks is the empirical p-value. If no random sets meet the level of overlap with the actual peaks, then the p-value is reported as < 0.001. We accounted for the testing of each set of ChIP-seq peaks with multiple genomic features using the Bonferroni correction. significant enrichment. In cases where normality was not observed, we noted this in the text and reported only the obs/exp ratio and the proportion of expected overlaps that were equal to, or more extreme than, the observed overlap. In analyses in which UCEs were segregated into exonic, intronic, and intergenic categories, random elements were drawn solely from the exonic, intronic, or intergenic portions of the genome. (Supplementary Section 6.1) confirms that discordant calls are located predominantly in regions with low sequence complexity and that their context composition differs significantly from concordant variants which could be utilized for the further characterization of problematic DNA regions and the improvement of variant filtering strategies. Note that our results are in good concordance with recently published research on sequence characteristics and polymorphism rates in the human genome, cf. Aggarwala and Voight (2016); Sahakyan and First, the distribution of paired-end sequencing fragment sizes overlapping each chromatin state (http://www.ensembl.org/info/docs/funcgen/regulatory_segmentation.html) were computed. The distributions were then normalized to the percent maximal within each state and enrichment was computed relative to the genome-wide set of fragment sizes. replicate experiments is driven mostly by Gata factors and by TFs that bind GC repeat regions (such as Zfp161 and E2F). Indeed, the nucleotide frequencies, in particular the GC content, play a major role in distinguishing between sequences unique to only one replicate. Supplementary Figure S6 shows the difference in GC% for all 20 pairs of paralogous TFs and 31 pairs of TF replicates. This difference correlates very well with the classification accuracy in the case of replicate experiments (Pearson correlation coefficient 0.706), but not in band for heterozygous clones. To avoid this resulting in misidentifying heterozygous clones as homozygous, we performed an additional 2nd PCR using a primer internal to the deleted region, which will only amplify wild type alleles (Fig. 5b and c). A band in the 2nd PCR, coupled with a short knockout band in the 1st PCR, thus indicates a heterozygous clone, as shown for the TFRC_B heterozygous clone (H) shown in Fig. 5b and c. Target fragment inversion is also a commonly observed event in experiments of this type [38, 39]. Such events will be ReliableGenome: annotation of genomic regions with high/low variant calling concordance - PMC transcripts with incorrect APA sites. GETUTR and IsoSCM have the worst performance in the experiment (in term of precision). While the performance of GETUTR is consistent with the results in (Kim et al., 2015b), it is reported in (Shenker et al., 2014) that IsoSCM performs well when the sequencing depth is 500 reads/kb or more. Note that the sequencing depths for our 50, 100 and 150 million read datasets are in fact 326, 652 and 977 reads/kb, respectively. However, the simulation study in (Shenker et al., 2014) assumed the abundance is Every position in the genome was annotated with 26 numeric features. Conservation scores PhastCons and PhyloP42 for 9 primates, 32 mammals, and 45 vertebrates multi-species alignments were derived from UCSC.43 GERP++ element scores and the corresponding p values were downloaded from the GERP44 website on June 6, 2015. CpG and G/C content as well as the observed to expected CpG ratio were downloaded directly from the UCSC table browser45 on June 6, 2015. The GC content in the human genome (hg19) in a range of ±75 nt for every position was\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 277.97ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1410.36ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1912.87ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 882.11ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1285.47ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1309.52ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1184.36ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1209.93ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1182.60ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the properties of super-enhancers?\n",
            "Refined Query: Describe the defining characteristics that distinguish super-enhancers from typical enhancers.  Consider their size, genomic location, associated histone modifications, transcription factor binding, and the resulting transcriptional output they drive.\n",
            "\n",
            "Combined Answer: as an enhancer marker to identify enhancers in hESC (13) and mESC (14), and these enhancers were further grouped into active and poised enhancers. Recently a small set of enhancers spanning large regions of the genome in a clustered manner were named as super-enhancers (SEs). These enhancers are occupied by high levels of Mediator complex, master transcription factors and coactivators (15,16). Super-enhancers drive cell-type-specific gene expression programs and many disease-associated sequence variations are preferentially enriched in these Super-enhancers are clusters of transcriptional enhancers that drive cell-type-specific gene expression and are crucial to cell identity. Many disease-associated sequence variations are enriched in super-enhancer regions of disease-relevant cell types. Thus, super-enhancers can be used as potential biomarkers for disease diagnosis and therapeutics. Current studies have identified super-enhancers in more than 100 cell types and demonstrated their functional importance. However, a centralized resource to integrate all these findings is not The dbSUPER database also contains associated genes for all the super-enhancers. These transcriptionally active genes were assigned to super-enhancers using a simple proximity rule. It is known that enhancers tend to loop and associate with target genes in order to activate their transcription (40), while most of these interactions occur within a distance of ≈50 kb of the enhancer (41). Hence, all transcriptionally active genes (TSSs) were assigned to super-enhancers within a 50 kb window. This approach identified a large proportion of true More systematic and comprehensive studies will lead to better understanding of super-enhancer formation, find key features and make accurate predictions genome-wide. The above mentioned studies have generated a large amount of data by profiling ChIP-seq signal for Mediator complex (Med1), master transcription factors (MyoD, T-bet and C/EBPα) (15), H3K27ac (17,24,29), BRD4 (16,24) and p300 (35) in different tissue and cell types. The data produced by most of these studies are shared with the public in the literature. However, a centralized between 10, 25, 50 and 100 using the ‘records per page’ dropdown menu. The tabular data can be filtered using the search box on the top right and the user can sort the data based on any field of interest. Details about each super-enhancer can be viewed by clicking the super-enhancer ID. Besides the general details about the super-enhancer, this also lists details about the associated gene, such as information like gene symbol, chromosome, transcription start site, transcription end site, strand and number of exons for the gene. Furthermore, other one contains information about super enhancers for human and mouse (37). To enhance the capacity of users to analyse the enhancer information, we developed DENdb, a database of computationally predicted human enhancers. DENdb is an on-line archive of enhancer regions obtained by five prediction methods and currently covers 15 different ENCODE cell-lines. The prediction methods we used all rely on ChIP-seq histone modification marks data obtained by ENCODE experiments. DENdb provides users the utility to explore some aspects of gene of super-enhancer concept can be found elsewhere (15,16,38). The current version of the dbSUPER database was developed using the hg19 assembly for the human genome and the mm9 assembly for the mouse genome. For any data that were not available in this assembly, we adjusted the coordinates using the liftOver tool (39). ChIP-seq data for various chromatin regulators and coactivators including p300 (10) were used for enhancer identification. However, super-enhancers are separated from a list of enhancers based on ChIP-seq occupancy for certain (35). The current research well characterized this biological phenomenon and effectively demonstrated the importance and potential application of super-enhancers as they can play key roles in cell identity and human disease. The concept of super-enhancers is still evolving but has already gained extensive attention in the research community. More systematic and comprehensive studies will lead to better understanding of super-enhancer formation, find key features and make accurate predictions genome-wide. The above mentioned studies have a distance of ≈50 kb of the enhancer (41). Hence, all transcriptionally active genes (TSSs) were assigned to super-enhancers within a 50 kb window. This approach identified a large proportion of true enhancer/promoter interactions in embryonic stem cells (42). In cases where experimentally verified enhancer-gene assignments were available, genes were assigned to enhancers based on those studies (17). Current studies have identified super-enhancers in more than 100 cell types and demonstrated their functional importance. However, a centralized resource to integrate all these findings is not currently available. We developed dbSUPER (http://bioinfo.au.tsinghua.edu.cn/dbsuper/), the first integrated and interactive database of super-enhancers, with the primary goal of providing a resource for assistance in further studies related to transcriptional control of cell identity and disease. dbSUPER provides a responsive and user-friendly web\n",
            "[0.7470827]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the inheritance pattern of Li–Fraumeni syndrome?\n",
            "Refined Query: Li-Fraumeni syndrome (LFS) is inherited in an autosomal dominant pattern.  This means only one mutated copy of the TP53 gene, inherited from either parent, is sufficient to cause the syndrome, resulting in a high risk of various cancers.\n",
            "\n",
            "Combined Answer: recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but until now, mutations in the recessive forms of disease have never been identified. are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 mutations are given in the appendix (pp 15–16). Some individuals without TBC1D24 mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In identified did not seem to affect portions of the protein predicted to interact with the TLDc domain, nor were they in the region that typically interacts with GTP in other TBC proteins (figure 3). Because TBC1D24 regulates Rab proteins and because of clinical overlap between DOORS syndrome and Martsolf syndrome, we also assessed RAB3GAP2. No RAB3GAP2 mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without Von Hippel-Lindau disease is an autosomal dominant hereditary cancer syndrome that affects approximately one in 35,000 live births per year(1). The primary manifestations of von Hippel-Lindau disease include retinal, cerebellar and spinal hemangioblastomas, renal cysts and clear cell renal cell carcinomas, pancreatic cysts and pancreatic neuroendocrine tumors, pheochromocytomas, endolymphatic sac tumors of the middle ear, and epididymal or round ligament cysts(1). von HippelLindau disease arises due to germline mutations in the eponymous VHL and was associated with a younger age of onset of disease (Wu et al. 2014). These findings may point to a developmentally distinct cell of origin for ACVR1-associated tumors (Taylor et al. 2014b). Interestingly, while ACVR1 mutations suffice to increase proliferation of immortalized normal human astrocytes (Buczkowicz et al. 2014), mutations in the identical amino acids are found in the germline of individuals with the autosomal dominant congenital childhood disorder FOP (fibrodysplasia ossificans progressiva), who have no evidence of cancer 10, a member of the Sry family, is mutated in Dom, and its human homologue is disease causing in autosomal dominant Shah‐Waardenburg syndrome. A similar effect will be difficult to test in humans as a SOX10 mutation is rare while the penetrance of HSCR is high in carriers. However, the putative role of the RET gene could be further tested in syndromic HSCR entities frequent enough to allow the collection of large series of patients, namely cartilage‐hair hypoplasia, Bardet‐Biedl syndrome, and Down's syndrome. In relation to the MWS group of and a group of individuals when the relationship between the individuals is known. This model can effectively quantify the association of a genetic variant to the phenotype (fixed effect), while correcting for the familial structure in the data (random effect). However, the LMM has gained popularity in recent years in GWAS when there is no pedigree of the individuals. Although it may be tempting to assume that the individuals in a study are unrelated, that is, it may be a requirement in the collection or recruiting process, it is still identical amino acids are found in the germline of individuals with the autosomal dominant congenital childhood disorder FOP (fibrodysplasia ossificans progressiva), who have no evidence of cancer predisposition (Jones and Baker 2014; Taylor et al. 2014b). Thus, ACVR1 mutation likely provides a selective advantage in the presence of other critical mutations, but cannot initiate tumorigenesis, as supported by the failure of p53 null mouse astrocytes that express ACVR1 mutants to initiate tumorigenesis when implanted in the brain (Wu et al. mutations were identified in families without TBC1D24 mutations (appendix p 14). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without TBC1D24 mutations, we did not identify a mutated gene in common in these families (details on the regions identified are given in the appendix p 11). Analyses are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes BMP4 and OGDH. Interpretation Our findings suggest that mutations in TBC1D24 are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also\n",
            "[0.732493]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which pituitary adenoma is common cause of infertility is women?\n",
            "Refined Query: Infertility in women can stem from various pituitary adenomas.  Which specific type of pituitary adenoma is most frequently implicated as a cause of female infertility?\n",
            "\n",
            "Combined Answer: focal increase of CSF in the anterior temporal horns and in the lamina of the quadrigeminal cistern. The pituitary gland was normal. Chromosome analysis by array-CGH (a-CGH) revealed a 5.2-Mb deletion on chromosome 1p21.3p21.1 (chromosome 1:98,456,293-103,682,084 – hg19). a-CGH was performed using a Cytochip ISCA 180 K Oligo platform (BlueGnome Ltd.). a-CGH analysis of the parents revealed the de novo origin of the deletion. Esrrb (estrogen-related receptor beta) is a member of the nuclear hormone receptor superfamily and belongs to subfamily 3 (estrogen receptor type). In mice, Esrrb-deficient embryos are embryonically lethal at embryonic day 10.5 (E10.5) because of placental hypoplasia, suggesting that Esrrb is involved in placental formation (31). Complementation analysis of placental defects of the Esrrb-deficient embryo with wild-type tetraploid embryos revealed that Esrrb-deficient mice mature to adults, but the number of germ cells is significantly reduced The main common malignant neoplasms of female reproductive system are endometrial carcinoma, cervical and ovarian cancer. Endometrial carcinoma is generally found early, but the prognosis of patients’ with recurrence and metastasis in this cancer is significantly poor [8]. With the wide application of cervical cytological screening, prevention of cervical cancer has made great progress, but chemotherapy is still the main treatment for patients with advanced cervical cancer [9]. The main type of ovarian cancer includes serous, mucinous and or maternogenic (36). The different phenotypes of preeclampsia can thus either be placentogenic, which usually occurs in early pregnancy with association of poor placentation and different severities of IUGR, or maternogenic, which occurs late in pregnancy with no relation to placental insufficiency or IUGR (37). The metabolic syndrome (defined as the occurrence of hypertension, ischemic heart disease, type 2 diabetes mellitus, obesity, and insulin resistance) has also been associated with increased circulating microparticles and subsequent by a pro-inflammatory environment that ensures adequate repair of the uterine epithelium and removal of cellular debris that accumulates secondary to embryo implantation (114). The second and third trimester are times of rapid fetal growth and development and the predominant immunological profile in the feto-maternal interface is anti-inflammatory (114). Progesterone, estradiol, prostaglandin D2, and leukemic inhibitory factor all promote the development of this Th2 profile (104, 105). The immunological effect of progesterone is mediated (114). Progesterone, estradiol, prostaglandin D2, and leukemic inhibitory factor all promote the development of this Th2 profile (104, 105). The immunological effect of progesterone is mediated through a protein called P-induced blocking factor, which induces dominant Th2 cytokine production and immune modulation in aid of maternal tolerance toward the fetus (115). A Th2 bias in pregnancy modulates cell-mediated immunity, which is responsible for the increased susceptibility of pregnant women to bacterial LPS and intracellular pathogenesis of, which nurture the oocyte and ultimately are required for the development of the embryo prior to the activation of zygotic transcription [17]. During mid-oogenisis, stages 7-8, egg chambers will naturally degenerate if the egg chamber is defective and unable to support the subsequent growth of the oocyte and embryo [18]. This pre-vitellogenic check-point is triggered in egg chambers where CTF4 has been depleted and results in degeneration of 17.4% of the stage 7-8 egg chambers (n = 4/23) as compared to no degeneration observed in the wild-type pedigree (Family 12), to be de novo in the mother although inherited in the proband. These de novo (and recent) mutations constitute greater than 50% of pedigrees in our cohort (Figure 1). Given a spectrum of deleterious mutations and that female carriers may exhibit intermediate neurocognitive symptoms, one might hypothesize that de novo mutations may be more highly deleterious and that inherited mutations may appear milder. However, from our data and the other mutations in the literature (Supplementary Table 2), this hypothesis does not The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). and preeclampsia, suggesting that inadequate immune recognition and tolerance contributed to pregnancy complications in these women (97, 98). In addition, preeclamptic pregnancies have reduced levels of progesterone along with reduced levels of immunomodulators, such as IDO and TRAIL, and soluble CD30, a member of the tumor necrosis superfamily of receptors and a marker of T-helper (Th)2 polarization (99–101). These findings, in addition to those of epidemiological studies, support the hypothesis that immune maladaptation play a role in the\n",
            "[0.6622899]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of mismatched uracil glycosylase (Mug) in DNA repair?\n",
            "Refined Query: Mismatched uracil glycosylase (MUG) plays a crucial role in base excision repair (BER) by specifically targeting and removing uracil bases from DNA.  Uracil's presence, often resulting from cytosine deamination, can lead to mutations if left uncorrected.  MUG's activity is vital for maintaining genomic integrity.\n",
            "\n",
            "Combined Answer: of the reads, if added through template-free activity of the reverse transcriptase, was resolved within CAGEr’s standard workflow designed to remove Gs that do not map to the genome: (1) If the first nucleotide is G and a mismatch, i.e., it does not map to the genome, it is removed from the read; or (2) if the first nucleotide is G and it matches, it is retained or removed according to the percentage of mismatched G. Sample replicates and reads from different lanes were merged prior to the final analysis as presented in Supplemental Material that FACT and Pfh1 might act synergistically to promote replication through hard-to-replicate sites. Four mismatch repair (MMR) proteins, Msh1, 2, 3 and 6, were also Pfh1-associated. The Msh2/6 and Msh2/3 heterodimers interact directly with DNA for the recognition of base pair mismatches. Because MMR and DNA replication are strongly coupled in budding yeast, MMR proteins are proposed to track with the replisome and hence can also be considered replisome components [57, 58]. Additional replisome components were present in the Pfh1-GFP repair pathway, the base excision repair (BER) pathway (3). PARP is a nuclear protein that senses and binds to DNA single-strand breaks (SSB) and subsequently activates the BER pathway by recruiting additional repair factors (4). When PARP is inhibited, persistent SSBs become DNA DSB during DNA synthesis via collapsed replication forks (5, 6). To repair DSBs, the cell preferentially uses homologous recombination, which is usually considered error proof. If the cell cannot initiate homologous recombination, as is the case with BRCA1/2-mutant that cells lacking Ctf4 show synthetic lethality with the dna2-2 mutation (Formosa and Nittis 1999; and data not shown). Dna2 is a nuclease-helicase involved in Okazaki fragment processing, whose function overlaps with that of the flap endonuclease Fen1 (Budd and Campbell 1997). Human Fen1, in turn, has been shown to be required for sister chromatid cohesion (Farina et al. 2008). If the synthetic growth defect of ctf4Δ with dna2-2 is due to Dna2’s role in Okazaki fragment processing, we would expect a similar synthetic interaction between CRISPR can be used to delete genomic sequences, by cutting genomic DNA at two sites and relying on non-homologous end-joining (NHEJ) mechanism to repair the break (Fig. 1a). gRNAs are introduced to cells by a plasmid vector, either through transfection or viral infection. As it does not vary between experiments, the scaffold (constant region) sequence is encoded within the expression plasmid [23]. In contrast, the variable 20 nt target region must be generated in each experiment by the cloning of synthesised DNA fragment into the targeting is required for forks to pause at protein–DNA barriers, the histone chaperone FACT, the type I topoisomerase Top1, and Mcm10 and Ctf4 that are known to bind DNA polymerase α (Homesley et al, 2000; Katou et al, 2003; Ricke and Bielinsky, 2004; Nedelcheva et al, 2005; Gambus et al, 2006). By purifying GINS from budding yeast cell extracts, we found that all of the above proteins form a very large assembly called the replisome progression complex or RPC (Gambus et al, 2006). The RPC only exists during S-phase, occurs on chromatin, requires the approaches. Against this backdrop CRISPR-based deletion holds great promise as a tool for loss-of-function studies in non-coding RNAs and genomic elements [5, 17–20]. Two distinct gRNAs flanking the target region are introduced in combination with a catalytically active Cas9. The cellular non-homologous end-joining (NHEJ) mechanism repairs the resulting break [12], and in a certain proportion of cells, one or all alleles are correctly deleted. This approach is capable of removing regions from approximately 102 to 106 base pairs, and there is our group as well as others (36, 37) suggest that even in the presence of a functional homologous recombination path-way and a cell’s ability to conduct DNA DSB repair, the homologous recombination pathway may only be able to repair part of the additional damage introduced by PARP inhibition in homologous recombination proficient cells treated with a DNA-damaging agent, but not all and thus result in enhanced cytotoxicity. Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in an increase in apoptosis, DNA engaged in protein interactions between the MCM DNA helicase, the GINS complex and the DNA polymerase α/primase complex. Chl1 in turn might contribute to Ctf4 recruitment during S-phase. If the replisome passes through cohesin rings during DNA replication, it is conceivable that an altered replisome geometry in the absence of Ctf4 could lead to difficulties with cohesion establishment. Instead of traversing through the ring, the oncoming replication fork might displace or break cohesin. An alternative scenario for the establishment of sister regions. Due to lack of nutrient auxotrophies, Cg10, Cg30, and Cg32 could not be used for making insertional DUR mutants. Instead, C. glabrata BG14 strain [33] was used for insertion of CaDUR3 and CaDUR31 since it is auxotrophic for the selection marker uridine and we found that this strain was similar to Cg10 in Hst 5 binding as well as its low sensitivity to Hst 5 as shown below. Expression levels of CaDUR3 and CaDUR31 in C. glabrata expressing C. albicans DUR genes were examined by RT-PCR (Figure 5). Both C. albicans DUR3 and DUR31 genes\n",
            "[0.7363056]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the cardiac effects of thyronamines?\n",
            "Refined Query: Describe the impact of thyronamines on the heart, including effects on heart rate, contractility, and rhythm.  Consider both positive and negative inotropic and chronotropic effects,  and mention any influence on cardiac electrophysiology.\n",
            "\n",
            "Combined Answer: in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor desensitization, internalization, and degradation of the cardiac S1P1R have been proposed to explain the time‐related attenuation of heart‐rate effects.1, 17, 33 In a previous phase 1 single‐ascending‐dose and multiple‐ascending‐dose study with ozanimod, a mild dose‐dependent, first‐dose reduction in HR was observed, which was attenuated with an dose‐escalation day to determine whether reduction in HR was attenuated with increasing dose. Drug concentrations and heart‐rate data in this study will be combined with those of other studies (with steady‐state data) for modeling and simulation. Transient and self‐limiting first‐ and second‐degree AV block occurred rarely in the current study and with a similar incidence in the ozanimod and placebo groups. active metabolites and ΔΔQTcF. Although ozanimod blunted the observed diurnal increase in heart rate, excursions below predose heart rates were no greater than with placebo. Results demonstrate that ozanimod does not prolong the QTc interval or cause clinically significant bradycardia, supporting ozanimod's evolving favorable cardiac safety profile. in the current study, ozanimod, which has even greater selectivity for S1P1R vs S1P3R (>10,000).1 Transient, dose‐dependent decreases in HR have been observed at treatment initiation of S1P receptor modulators in healthy subjects and in patients with multiple sclerosis. It appears that the negative chronotropic effects of S1P receptor agonists in humans are mediated by S1P1R through activation of G‐protein–coupled inwardly rectifying potassium channels on cardiac myocytes, which reduce excitability and decrease firing rate.16, 33 Receptor confirming the effectiveness of the dose‐escalation regimen employed in this TQT study. Starting dose escalation at 0.25 mg appeared to attenuate first‐dose effects on HR on day 1 and during the dose‐escalation period when higher doses were administered. Telemetry monitoring in this study was performed to evaluate the heart‐rate effect on each dose‐escalation day to determine whether reduction in HR was attenuated with increasing dose. Drug concentrations and heart‐rate data in this study will be combined with those of other studies (with 0.5 mg) and were transient and asymptomatic. Cardiac adverse events of special interest were infrequent and of comparable incidence between the study groups. These included short runs of nonsustained ventricular tachycardia (3 placebo subjects, 2 ozanimod subjects), transient and self‐limiting first‐degree AV block (1 ozanimod subject), and transient and self‐limiting second‐degree AV block, Mobitz type 1 (1 subject in each group). None of these cardiac events was temporally associated with the administration of moxifloxacin. Other Twenty‐four‐hour cardiac telemetry was used to characterize the effect of ozanimod on HR. Daily mean predose baseline HRs were similar for the study groups (ie, between 59 and 71 bpm throughout all dose‐escalation days). The mean hourly HRs during the 24‐hour monitoring period on each dose‐escalation day are presented in Figure 4. Mean HR in the ozanimod‐treated subjects was consistently lower than that in the placebo‐treated subjects. On day 1, the maximum difference from placebo in HR was 8.1 bpm and was observed at hour 10. On day 5, the of the following during treatment: an increase in QT/QTc interval to >500 milliseconds and/or of >60 milliseconds over baseline, any evidence for ventricular or supraventricular arrhythmia with or without hemodynamic compromise or any advanced AV block, or symptomatic persistent bradycardia <35 bpm that required medical intervention. (sum of ozanimod, RP101988, and RP101075) by approximately 50% (data on file). In contrast to ozanimod, fingolimod (an approved nonselective S1P receptor modulator) has produced mild but significant prolongation of the QTc interval.12 Understanding the mechanistic basis of this QT prolongation is important for the development of improved therapeutic agents in the S1P receptor modulator class. In mice, S1P3 receptors are expressed in cardiac Purkinje fibers, and their activation is associated with blockade of ventricular conduction. therapeutic agents in the S1P receptor modulator class. In mice, S1P3 receptors are expressed in cardiac Purkinje fibers, and their activation is associated with blockade of ventricular conduction. Fingolimod‐induced cardiac abnormalities are not observed in S1P3 knockout mice and are reversed in wild‐type mice with a selective S1P3 antagonist.13 In human TQT studies, results with fingolimod and 2 other S1P receptor‐targeting agents in development (ponesimod and siponimod) support a potential relationship between activity at S1P3R and QT\n",
            "[0.46630684]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Matuzumab has been tested for treatment of which cancers?\n",
            "Refined Query: A literature search is needed to determine the specific cancer types in which the monoclonal antibody Matuzumab has undergone clinical trials or been used therapeutically.  The goal is to identify the range of cancers targeted by this drug in research and potentially approved treatments.\n",
            "\n",
            "Combined Answer: in assay sensitivity. It is expected that therapeutic antibodies will show some immunogenicity, and even completely human therapeutic antibodies have unique idiotypes and posttranslational modifications or impurities associated with the manufacturing process that may trigger an immune response (72–75). The immunogenicity of galcanezumab (76,77), erenumab (78), and fremanezumab (79) have been reported elsewhere from clinical trials. The drug labels for these three drugs state similarly that, although the immunogenicity profiles do not erenumab (78), and fremanezumab (79) have been reported elsewhere from clinical trials. The drug labels for these three drugs state similarly that, although the immunogenicity profiles do not demonstrate an impact of ADA development on efficacy or safety, the available data are too limited to make definitive conclusions (10,11,15). In addition, ADA development does not demonstrate an impact on the PK of galcanezumab (10). that bind to soluble ligands, target-mediated elimination may also occur (58,59). Galcanezumab exhibits linear PK and exposure increases proportionally with doses between 1 and 600 mg (10). For fremanezumab, dose proportionality, based on population PK, was observed between 225 mg to 900 mg (11). It is worthy to note that antibodies can target soluble ligands and cell membrane-bound receptors (60). The liver and kidney are involved predominantly in the metabolism and elimination of small molecule drugs and can lead to changes in PK, possibly of high galcanezumab concentrations. These data are supportive evidence to address a common misconception that if high antibody concentrations are present (i.e. excess of antibody relative to the ligand) then the ligand should be completely bound to the antibody. Figure 4 illustrates the results from a simulation using the developed model to show the predicted effect of galcanezumab on free CGRP relative to baseline when galcanezumab is administered monthly for 5 months at doses of 5, 50, 120, 240, and 300 mg, and 240 mg as a loading dose The PK and PD properties of an antibody are complex and differ from small molecule drugs. To understand how antibodies can affect the extent and duration of free ligand concentrations, the dose and PK of the antibody, and the kinetics of the ligand and the antibody–ligand complex, are important factors to consider. The PK/PD model developed for galcanezumab is a tool that serves as a mechanistic explanation based on free CGRP for galcanezumab therapeutic effects and was used to help justify dose regimens in clinical efficacy trials. duration of free ligand concentrations, it is important to consider the dose and pharmacokinetics of an antibody, and the kinetics of the ligand and antibody–ligand complex. Insights regarding the pharmacokinetic/pharmacodynamic properties of galcanezumab as a probe antibody drug and calcitonin gene-related peptide as its binding ligand regarding its clinical outcomes are provided. is available to interact with the ligand receptor will be reduced. Theoretically, efficacy is driven by the magnitude and duration of the reduction in free ligand concentration (87). Galcanezumab, eptinezumab, and fremanezumab are antibodies that bind to the soluble ligand CGRP (Table 1). Galcanezumab and fremanezumab are approved in the US for the preventive treatment of migraine, and eptinezumab is currently in Phase 3 development. During drug development of antibodies, measurements of total (free + bound) or free ligand concentrations have 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively. At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P < 0.001] and 41.2% [P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P = 0.002] and 44.7% [P = 0.015], respectively), major clinical response (BILAG 2004 C or better in all organ domains from understanding of modulation of CGRP following antibody administration is required to comprehend the pharmacology of antibodies that bind CGRP. As such, an evaluation of the PK/PD properties of galcanezumab as a probe antibody drug and CGRP as its binding ligand provides insights regarding their clinical interaction and therapeutic outcome. Therapeutic antibodies may be viewed by the body as foreign and activate immune responses that lead to anti-drug antibody (ADA) development that can bind to the therapeutic antibody. Many factors can influence the likelihood of ADA formation, including manufacturing process, antibody structure (i.e. derived from rodent, chimeric, humanized, human), dose, dosing frequency, route of administration (68–70), and patient factors such as immune status or genetics. The effect that ADA could have on the PK of an antibody is complex and difficult to\n",
            "[0.5936259]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the synonyms of prostate-specific antigen?\n",
            "Refined Query: I need more context to understand what kind of synonyms are being sought.  Are we looking for synonyms for \"prostate-specific antigen\" as a medical term,  in a casual setting, or in a specific scientific context?  Clarifying the intended use will help identify appropriate synonyms.\n",
            "\n",
            "Combined Answer: higher than that in the pancreas (Figure 1B). In this sample set, the expression of Uc.63+ was significantly associated with high Gleason score (P = 0.007) and high prostate-specific antigen (PSA) level (P < 0.001) (Figure 1C). To further investigate the usefulness of Uc.63+ as a serum biomarker for PC, we examined the expression of Uc.63+ in the serum of 10 patients with benign prostatic hyperplasia (BPH), 24 patients with primary PC, and 45 patients with metastatic PC by droplet digital PCR (ddPCR). Representative images of ddPCR are shown tissues. We then analyzed the expression of these 3 regions in PC cell lines (LNCaP, DU145, and PC3) and revealed that the expression of Uc.63+ in PC cell lines was elevated compared with that in non-neoplastic tissues. In contrast, the expression of Uc.3+ and Uc.4+ in PC cell lines was lower than that in the non-neoplastic prostate tissues (Supplementary Figure 2). Given these results, we decided to focus on Uc.63+. Then, we examined the expression of Uc.63+ in 14 types of normal tissue samples and 20 PC tissues from another cohort/sample set upregulated in both PC tissues and cell lines. One recent study reported a T-UCR signature that was overexpressed in PC tissue through a microarray analysis using 57 PC and 7 non-neoplastic prostate tissues; however, Uc.63+ was not chosen as a hopeful candidate. The actual strategy we applied in this study was to validate the expression of 26 T-UCRs with qRT-PCR by referring to the signatures reported by Hudson et al [13], which enabled us to focus on Uc.63+, and its functional roles in PC were quite consistent with those determined in a higher expression of Uc.63+ in the serum of CRPC patients than that in hormone-dependent PC patients (Figure 1E). To clarify the localization of Uc.63+, we performed in situ hybridization of Uc.63+ in PC tissues and found that robust expression of Uc.63+ was observed in the nucleus in PC tissues, whereas the expression of Uc.63+ was rarely detected in non-neoplastic prostate tissues (Figure 1F). and 8 non-neoplastic prostate tissues (Supplementary Figure 1). The mean expression level of each T-UCR was calculated, and the ratio of tumor/non-neoplastic prostate (T/N ratio) was determined (Figure 1A). We identified 3 regions (Uc.3+, Uc.4+, and Uc.63+) that were significantly upregulated in PC tissues compared with non-neoplastic prostate tissues. We then analyzed the expression of these 3 regions in PC cell lines (LNCaP, DU145, and PC3) and revealed that the expression of Uc.63+ in PC cell lines was elevated compared with that in For qRT-PCR, 20 PC tissue samples and 8 non-neoplastic prostate tissue samples were used (Supplementary Table 1). The non-neoplastic prostate tissue samples were obtained at biopsy or autopsy, as described as previously [24]. The samples were immediately frozen in liquid nitrogen and stored at -80°C until use. For ddPCR, 5-mL serum samples collected from 79 patients, including 10 with BPH, 24 with localized PC, 18 with hormone-dependent PC, and 27 with CRPC, were used (Supplementary Table 2). The Institutional Review Board of Hiroshima Figure 2). Given these results, we decided to focus on Uc.63+. Then, we examined the expression of Uc.63+ in 14 types of normal tissue samples and 20 PC tissues from another cohort/sample set by qRT-PCR. Among these normal tissue samples, the highest expression of Uc.63+ was found in the pancreas. However, the expression of Uc.63+ in PC tissues was higher than that in the pancreas (Figure 1B). In this sample set, the expression of Uc.63+ was significantly associated with high Gleason score (P = 0.007) and high prostate-specific antigen (PSA) To identify ideal biomarkers and therapeutic targets for PC, we first analyzed 26 candidate T-UCRs that were upregulated in PC based on a microarray analysis [13]. To validate the results obtained by a microarray analysis, we examined the expression of these 26 T-UCRs by quantitative real-time polymerase chain reaction (qRT-PCR) using 12 PC tissues and 8 non-neoplastic prostate tissues (Supplementary Figure 1). The mean expression level of each T-UCR was calculated, and the ratio of tumor/non-neoplastic prostate (T/N ratio) was determined serum of 10 patients with benign prostatic hyperplasia (BPH), 24 patients with primary PC, and 45 patients with metastatic PC by droplet digital PCR (ddPCR). Representative images of ddPCR are shown in Supplementary Figure 3. ddPCR analysis determined that significantly higher expression of Uc.63+ was detected in metastatic PC than in BPH and primary PC (Figure 1D). Moreover, the expression of Uc.63+ was significantly elevated in the serum from primary PC compared with that in the serum from BPH (Supplementary Figure 4). The expression of that exists in the biomedical domain is a challenging task for traditional search engines, which largely rely on term (keyword) indexing. Obtaining the required information is made even more difficult by non-standard terminology and the ambiguity of the technical terms involved. Therefore, indexing at the semantic (concept) level, rather than at the level of keywords only, is particularly important. Biomedical concept taxonomies or, more generally, ontologies are abundant and they provide concept inventories that can be used in semantic\n",
            "[0.7331016]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the lipid droplet used for in the cell?\n",
            "Refined Query: Lipid droplets, intracellular organelles composed primarily of neutral lipids, serve crucial roles in cellular energy storage, lipid metabolism, and membrane biogenesis.  Their functions extend beyond simple fat storage, influencing diverse cellular processes.\n",
            "\n",
            "Combined Answer: against a gradient and required metabolic energy (Rao, 1981). Yet some researchers missed these publications and believed that because THs could avidly partition into cell membranes, they could diffuse across the membrane as a mode of entry into cells. For a history of hypotheses about TH entry into cells, see (Hennemann et al., 2001). Currently, it is known that THs enter cells via TH transmembrane transporters, which participate in the influx and efflux of THs into and out of cells. Several classes of TH transmembrane transporter proteins 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of the antifibrotic activity of the drug in this cell type. Indeed, the transcriptomic analysis in our study revealed the induction of ABCA1 and ABCG1 mRNAs, which encode cholesterol efflux transporters. As increased free cholesterol accumulation in HSCs stimulates their activation, enhanced cholesterol efflux could reduce intracellular cholesterol levels, thereby attenuating activation.23 Indirectly, these findings also support the reliance of HSC activation on autophagy to generate lipids for energy to support cellular activation.4 levels, thereby attenuating activation.23 Indirectly, these findings also support the reliance of HSC activation on autophagy to generate lipids for energy to support cellular activation.4 Therefore, enhanced flux of cholesterol could deprive cells of an important energy source required to fuel the many pathways associated with HSC activation. Another interesting implication of these findings is the overlap in gene expression changes between effects of Aramchol and those inhibiting EMT, including hedgehog, which has been implicated in hepatic The first publication on TH transport that indicated an energy-dependent process for TH uptake into cells was in 1954 (Christensen et al., 1954) but was “lost” in the literature for decades. In the 1970s Rao demonstrated that TH entry into cells was temperature-dependent, saturable, high-affinity, and low-capacity, ligand specific, could transport against a gradient and required metabolic energy (Rao, 1981). Yet some researchers missed these publications and believed that because THs could avidly partition into cell membranes, they could transporters (MCTs) and L-type amino acid transporters (LATs), and actively participate in entry and exit of THs into and out of cells (Visser et al., 2011). Several TH transmembrane transporters have been localized to the choroid plexus (Mayerl et al., 2012) and their distribution in the choroid plexus differs between species (Wirth et al., 2014). Most TH transmembrane transporters identified to date are promiscuous with respect to the range of metabolites they transport. Only MCT8 has been identified as being specific to transport of THs and cells (HSCs) are a resident perisinusoidal mesenchymal cell type that contributes to liver homeostasis, but during injury they transdifferentiate from a quiescent to an activated state, with loss of vitamin A-containing lipid droplets and increased production of collagen and other extracellular matrix constituents.3 The mechanistic link between loss of lipids in HSCs and the development of hepatic fibrosis is not well understood, but is thought to involve consumption of fatty acids by increased autophagy.4 Activation of HSCs drives hepatic droplet generator (Bio-Rad). Amplification was performed at 95°C for 10 min, followed by 40 cycles at 94°C for 30 s and 40 cycles at 57°C for 1 min using a C1000 Touch thermocycler (Bio-Rad). After amplification, the droplets were read on a QX100 droplet reader (Bio-Rad) and analyzed with QuantaSoft software V1.7.4 (Bio-Rad). The QuantaSoft software measured the number of positive versus negative droplets. Their ratio was then fitted to a Poisson distribution to determine the copy number of the target molecule as copies/μL. reticuloendothelial system, which consists of phagocytic cells such as macrophages and monocytes (51). Cells in the body have the ability to take up proteins or macromolecules from the surrounding fluid space via fluid phase endocytosis, from which the formed endosome is delivered to a lysosome where its content undergoes enzymatic degradation. A significant portion of IgG is rescued from lysosomal catabolism by FcRn (23,52,53). Within the acidified environment of the early endosome, IgG binds tightly to FcRn. The IgG–FcRn complexes are not Aramchol is a fatty acid-bile acid conjugate that reduces liver fat content and is being evaluated in a phase III clinical trial for non-alcoholic steatohepatitis (NASH). Aramchol attenuates NASH in mouse models and decreases steatosis by downregulating the fatty acid synthetic enzyme stearoyl CoA desaturase 1 (SCD1) in hepatocytes. Although hepatic stellate cells (HSCs) also store lipids as retinyl esters, the impact of Aramchol in this cell type is unknown.\n",
            "[0.6691911]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.21ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Stroke - {'Rehabilitation Therapy': 0.7980541525037852, 'Motor Function': 0.9999999999999991, 'Mental Health': 0.0}\n",
            "\n",
            " ### Clustered: {'Stroke': {'Cluster 1': ['Rehabilitation Therapy'], 'Cluster 2': ['Motor Function'], 'Cluster 3': ['Mental Health']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1461.17ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is flibanserin effetive for Hypoactive Sexual Desire Disorder? \n",
            "Refined Query: How effective is flibanserin in treating hypoactive sexual desire disorder (HSDD) in women, considering both its efficacy and potential side effects?  Are the benefits significant enough to outweigh the risks for a substantial portion of the population diagnosed with HSDD?\n",
            "\n",
            "Combined Answer: epilepsy; losigamone is one of these drugs. We wanted to know whether losigamone was an effective and safe treatment for people with focal epilepsy. Study characteristics The evidence is current to February 2017. We found two trials assessing add‐on losigamone for focal epilepsy, which recruited a total of 467 participants aged over 18 years. Both trials assessed losigamone 1200 mg/day or 1500 mg/day as an add‐on therapy for focal epilepsy. Key results The results of this review showed that participants taking losigamone as an add‐on treatment respectively (Figure 3D). In addition, midostaurin inhibited the growth of FLT3wt- and FLT3-ITD-expressing Ba/F3 cells with IC50 values of 28.5 nM (95% CI: 23.5–34.5) and 4.2 nM (95% CI: 3.7–4.7), respectively (Figure 3D). These results indicate that gilteritinib had similar inhibitory action on FLT3wt and FLT3-ITD, while quizartinib and midostaurin had more potent inhibitory action on FLT3-ITD than on FLT3wt. The similar inhibitory potency against FLT3wt and FLT3-ITD suggests that FL has no effect on the efficacy of gilteritinib. acceptable safety profile, for the ozanimod HCl 0.5‐ and 1‐mg once‐daily regimens.14, 15 In RADIANCE Part‐A, a phase 2 randomized, placebo‐controlled trial among 258 patients with RMS, the number of gadolinium‐enhancing lesions in weeks 12 through 24 (primary end point) was significantly lower for patients on once‐daily doses of ozanimod HCl 0.5 or 1 mg than for placebo recipients. The mean cumulative number of total gadolinium‐enhancing lesions was 1.5 (standard deviation, 3.7) with ozanimod HCl 0.5 mg and 1.5 (3.4) with ozanimod 1 mg Review question This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (2015, Issue 12) on 'Losigamone add‐on therapy for focal epilepsy'. We reviewed the evidence about the efficacy and safety of losigamone when used as an add‐on therapy for focal epilepsy. We found two studies. Background Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and over placebo across a broad range of global disease activity measures. In the whole modified ITT population, 25.5% of the placebo group achieved SRI(4) response with sustained reduction of oral corticosteroids, compared with 51.5% in the anifrolumab 300‐mg group (P < 0.001) and 38.5% in the anifrolumab 1,000‐mg group (P = 0.048). Response rates in the IFN‐high population were 19.7% for placebo, 52.0% for the anifrolumab 300‐mg group (P < 0.001), and 38.5% for the anifrolumab 1,000‐mg group (P = 0.013). No differences from placebo were seen in We included two studies that investigated the efficacy and safety of losigamone as an add‐on therapy for focal epilepsy (see Characteristics of included studies). The first study conducted in Germany by Bauer and colleagues (Bauer 2001) was a randomized, double‐blind, placebo‐controlled, add‐on study. The study lasted for 16 weeks and consisted of an eight‐week baseline phase and an eight‐week double‐blind treatment phase. A total of 203 people with focal epilepsy taking no more than three AEDs prior to the study were randomized to treatment in the losigamone‐treated group, and 11 participants dropped out in the placebo group. The second study conducted by Baulac and colleagues (Baulac 2003) was a multicenter, randomized, double‐blind, placebo‐controlled, add‐on study. The study lasted for 28 weeks and consisted of a 12‐week baseline period, a 12‐week double‐blind treatment phase and a four‐week post‐treatment period for safety observations. A total of 264 people with focal epilepsy, who had also had one to three AEDs prior to the study, were randomly assigned to the losigamone or poor prognosis [4–7]. Activating point mutations in the TKD are also observed in patients with AML, but at a lower frequency than ITD mutations [5, 8]. These activating mutations are oncogenic and render a state of “oncogene addiction” in this disease [5, 9–11]. Therefore, FLT3 is considered a promising drug target in AML patients with FLT3 mutations. A number of FLT3 inhibitors, including gilteritinib, midostaurin, quizartinib, and sorafenib, have been evaluated in clinical trials [12–15]. In 2017, the US Food and Drug Administration (FDA) effect on the PK of galcanezumab (10). For fremanezumab, a population PK analysis assessing effects of age, race, sex, and weight was conducted, and no dose adjustments are recommended (11). The PK of erenumab were not affected by age, gender, race, or subtypes of migraine spectrum (episodic or chronic migraine) based on population PK analysis (15). is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and often require treatment with two or more AEDs (add‐on therapy). In recent years, many newer AEDs have been investigated as add‐on therapy for focal epilepsy; losigamone is one of these drugs. We wanted to know whether losigamone was an effective and safe treatment for people with focal epilepsy. Study characteristics The evidence is current to\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.55ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2740.70ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which dediodinases are present in kidney?\n",
            "Refined Query: The human kidney expresses several deiodinases, enzymes crucial for thyroid hormone metabolism.  Which specific isoforms of these enzymes (e.g., DIO1, DIO2, DIO3) are found in the kidney, and what are their relative abundances and functional roles in renal physiology?\n",
            "\n",
            "Combined Answer: studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux of THs from cells. For genomic actions of THs within the cell nucleus, T4 can be deiodinated to T3 (considered the “active” form of TH). The family of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear of deiodinases can either activate (e.g., T4 to T3) or inactivate (e.g., T3 to T2; T4 to rT3) THs within the cell (Darras et al., 2015). T3 exerts genomic effects by binding to TRs which are nuclear transcription factors. T3 can bind TRs either in the cytoplasm and translocate into the nucleus, or bind TRs in the nucleus. T3 binding to TR hetero-dimer complexes on thyroid response elements in the promotor of specific genes causes dissociation of co-repressor proteins and association of co-activator proteins. The resulting complex then mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form (T4). About 80% of the active form (T3) is generated by deiodination of T4 to T3 in target tissues. In the blood, >99% of TH is bound to specific plasma proteins known as TH distributor proteins. Because THs are lipophilic they partition between the lipid phase and the aqueous phase with a ratio of 20,000:1 (Dickson et al., 1987). The binding of THs Thyroid hormones (THs) are key players in regulating development of the brain. Insufficient THs during prenatal development in humans can lead to cretinism and mental retardation, whereas insufficient THs in adult life can result in fatigue, lethargy, mental impairment, weight gain, cold intolerance and in severe cases, clinical depression. THs act mainly by regulating transcription of specific genes. THs are synthesized in the thyroid gland and are secreted into the blood. Most of the TH secreted from the thyroid gland is the precursor form affinity than T3 (active form of thyroid hormone). In all other vertebrates, transthyretin binds T3 with higher affinity than T4. As mammals are the exception, we should not base our thinking about the role of transthyretin in the choroid plexus solely on mammalian data. Thyroid hormone transmembrane transporters are involved in moving thyroid hormones into and out of cells and have been identified in many tissues, including the choroid plexus. Thyroid hormones enter the choroid plexus via thyroid hormone transmembrane transporters and leave proteins in adult human blood varies greatly: TBG at 0.015 g/l, TTR at 0.25 g/l and albumin at 42 g/l. Traditionally it has been believed that in blood, TBG distributes about 75% of thyroid hormones, TTR distributes 15% and albumin transports about 10%. Because TBG binds about 75%, it is sometimes referred to as the “most important” thyroid hormone distributor. However, this is too simplistic, as the biological importance is related to the delivery of THs to cells, which is dependent on the dissociation rates of T3 and T4 from the distributor 2005, 2011; Lin et al., 2012); cytosolic kinase-initiated interactions which have non-genomic effects on glucose metabolism (Moeller et al., 2006, 2011) and rapid activation of kinases in signaling cascades in mitochondria resulting in altered fatty acid metabolism (Sayre and Lechleiter, 2012). The genomic pathway, which is generally better known and studied, involves thyroid hormone receptors (TRs). Free (unbound) THs enter target cells via the TH transmembrane transporters (Hennemann et al., 2001), which are responsible for influx and efflux in liver, kidney, stomach, and intestine (Kuo et al. 1990; Serfas and Tyner 1993), where it is essential for organ function (Pontoglio et al. 1996). Figure 2A also illustrates that the inferred motif activities are highly reproducible. In fact, motif activities are more reproducible than the expression profiles from which the motif activities were inferred (Supplemental Fig. 16). The reason for this high reproducibility of motif activities is that each motif, m, typically targets hundreds to thousands of promoters, and the inferred motif of T3 by local deiodination (van Doorn et al., 1985). Two features that distinguish mammalian brains from non-mammalian brains that are regulated (at least in part) by thyroid hormones are the corpus callosum which is heavily myelinated, and the highly developed cortex. The point here is that mammals may be the exception rather than the rule, when it comes to modes of TH entry into the CNS, so we should not just consider mammalian data. Furthermore, we have seen examples between eutherian species, of significant differences in TH transmembrane Thyroid hormones are key players in regulating brain development. Thus, transfer of appropriate quantities of thyroid hormones from the blood into the brain at specific stages of development is critical. The choroid plexus forms the blood-cerebrospinal fluid barrier. In reptiles, birds and mammals, the main protein synthesized and secreted by the choroid plexus is a thyroid hormone distributor protein: transthyretin. This transthyretin is secreted into the cerebrospinal fluid and moves thyroid hormones from the blood into the cerebrospinal\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.66ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2342.04ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1339.01ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1460.57ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1184.89ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1260.38ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which trancription factor activates the betalain pathway?\n",
            "Refined Query: The betalain pathway, responsible for the vibrant red and yellow pigments in plants like beetroot, is regulated by transcription factors.  Identifying the specific transcription factor(s) that initiate and control the expression of genes involved in betalain biosynthesis is crucial for understanding pigment production and manipulating it for biotechnological applications.  Which transcription factor(s) play this key role?\n",
            "\n",
            "Combined Answer: Transcription factors (TFs) are proteins that regulate the expression of genes by binding the DNA at their regulatory elements (promoters or enhancers) and either preventing or facilitating the recruitment, in eukaryotes, of the transcription preinitiation complex (PIC). The PIC in turn recruits RNA polymerase II (Pol II) to the transcription start site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate The precise spatial and temporal regulation of gene expression remains poorly understood despite an increasing number of species with nearly complete genome sequences available. Proteins which regulate the expression of genes by binding to specific DNA sequences in the vicinity of their targets have been termed transcription factors (TFs). The nucleotide sequences of observed binding sites generally display a considerable variation, which may cause difficulties in the description of binding preferences using sequence motifs. Recent benchmarking published on the specific roles of β-catenin and Tcf3 in these processes [4], [5], [6], [44]. In the classical Wnt model, Tcf factors bind DNA and repress gene expression in the absence of active Wnt signaling. Activating the signaling pathway leads to the binding of β-catenin to Tcf proteins thus converting them from transcriptional repressors to transcriptional activators. Among the four members of Tcf/Lef family, Tcf3 seems to be different as its repressor function is not directly affected by Wnt signaling. In this perspective, two modes of site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate a multitude of signals that converge on them in the form of activating or repressing transcription factors. In invertebrates, some regulatory regions (\"high-occupancy target\", or HOT, regions) are occupied by a large number of transcription factors [1-6]. However, less is known about the interactions among TFs at HOT regions and how these The developmental program that generates a complex organism such as a human is executed via gene regulatory networks. Interactions between transcription factors (TFs) and target sites are the main edges of such networks as the regulatory output of such interactions determines the expression levels of target genes at a particular time point during development, in a given tissue and under specific conditions. The human genome contains hundreds of thousands of experimentally documented transcription factor binding sites (TFBSs) and perhaps a developmental stages and is then converted to an activator in complex with other erythroid specific transcription factors, such as GATA-1, LMO2, and LDB1, to activate erythroid specific transcription programs during differentiation (8, 9). Several studies have shown that TAL1 could function either as a transcription activator or as a repressor in a context dependent fashion. TAL1 represses transcription by recruiting ETO2, mSin3A, HDAC1/2 or LSD1. In contrast, it potentiates transcription by interacting with p300 and p300/CBP associated factor confirms that HNF1A targets genes involved in the metabolism of drugs and xenobiotics. To gain insight in the transcription regulatory networks that control expression profiles, it is of particular interest to identify direct regulatory connections between the TFs themselves. In ISMARA, a direct regulatory interaction from motif m to m′ is predicted when motif m is predicted to target a promoter of one of the TFs associated with m′. To visualize the predicted direct regulatory interactions between regulators, ISMARA provides, for each motif m, transcription factors [22] in Drosophila melanogaster. Importantly, these latter studies were only undertaken in adults. The absence of BiFC applications in the embryos of these model organisms might appear somewhat surprising, given that they have been extensively used to address questions relating to mechanisms underlying developmental control, and that protein interactions are central to the developmental processes. Among the reasons that may explain this are technical constraints, such as the short time window characterizing worm and fly to the proliferation arrest that accompanies terminal erythroid differentiation. The myc gene has also been shown to be a GATA-1 target gene in G1E cells (Rylski et al, 2003; Welch et al, 2004). We found GATA-1 binding to both promoters in induced MEL cells but we could not detect binding of FOG-1 or Mbd2 to the same sequences (Figure 5D and E). By contrast, Gfi-1b (absent from all other genes tested) was found binding to both promoters (Figure 5D and E), suggesting a role for the GATA-1/Gfi-1b complex in the repression of genes associated can make a substantial contribution to the study of gene regulatory networks. The applications we presented highlighted several of ISMARA’s advantages. First, by inferring a regulator’s activity from the behavior of its targets, ISMARA does not rely on changes in a TF’s expression to infer activity changes and readily detects activity changes due to alternative splicing, post-translation modifications, changes in cellular localization, etc. Second, when motif activity is transcriptionally regulated, comparing motif activity with TF expression\n",
            "[0.55459374]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: List common symptoms of patients with the DOORS syndrome.\n",
            "Refined Query: Describe the common clinical presentation of individuals diagnosed with DOORS syndrome, detailing the range of symptoms typically observed across patients.  Focus on the most frequently reported manifestations.\n",
            "\n",
            "Combined Answer: We contacted previous collaborators and physicians who had published case reports of individuals with DOORS syndrome. Patients were from 26 centres in 17 countries. Between Dec 1, 2010, and March 1, 2013, we enrolled identified individuals with DOORS syndrome who were assessed by clinical geneticists and had at least three of the five following features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures. Families were excluded if the Through a search of available case studies and communication with collaborators, we identified families that included at least one individual with at least three of the five main features of the DOORS syndrome: deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures. Participants were recruited from 26 centres in 17 countries. Families described in this study were enrolled between Dec 1, 2010, and March 1, 2013. Collaborating physicians enrolling participants obtained clinical information and DNA samples from the the name to DOORS syndrome to account for the presence of seizures in most individuals,2 and we use this term in this Article. The case reports of 32 affected individuals were reviewed by James and colleagues in 2007,3 and five others have been published since that report.4, 5, 6, 7, 8 Seizures, present in most patients with DOORS syndrome, usually start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, Deafness, onychodystrophy, osteodystrophy, and mental retardation (DOOR or DOORS) syndrome (OMIM 220500) is a rare autosomal recessive disorder of unknown cause. Ronald Cantwell first described DOOR syndrome in 1975,1 noting that a few similarly affected individuals had been reported prior to that date. Qazi and colleagues suggested changing the name to DOORS syndrome to account for the presence of seizures in most individuals,2 and we use this term in this Article. The case reports of 32 affected individuals were reviewed by James and previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic had the five features making the DOORS acronym; several had 2-oxoglutaric aciduria or a triphalangeal thumb. Further discussion on 2-oxoglutaric aciduria is provided in the appendix (p 20). Through a combination of careful clinical phenotyping and exome sequencing, we have identified the molecular basis of DOORS syndrome in about a third of individuals included in our cohort, or in half of the 18 families in which affected individuals had the five features making the DOORS acronym. We suggest that individuals without deafness and seizures but Systematic review We searched PubMed and the references of included papers for articles published from Jan 1, 1970, to March 1, 2013. We used the following search terms: “DOOR syndrome”, “DOORS syndrome”, “deafness and onychodystrophy”, “TBC1D24”, “2-oxoglutaric aciduria”, “2-oxoglutarate”, “epilepsy”, and “exome sequencing”. We retrieved all previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, included in our cohort, or in half of the 18 families in which affected individuals had the five features making the DOORS acronym. We suggest that individuals without deafness and seizures but with the other features should still be screened for TBC1D24 mutations because we are only beginning to understand the genetic causation of DOORS syndrome: the discovery of TBC1D24 mutations in a patient with an appropriate phenotype confirms the diagnosis of DOORS syndrome, but more cases need to be studied to establish the full clinical use of TBC1D24 The genetic basis of DOORS syndrome: an exome-sequencing study - PMC some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from DOORS syndrome (table 2). All individuals with TBC1D24 mutations had all five features making the DOORS acronym. If we stratify based on this strict definition of DOORS syndrome, TBC1D24 mutations were seen in nine of 18 families.\n",
            "[0.6786873]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the most well-accepted method for Down syndrome non-invasive prenatal diagnosis?\n",
            "Refined Query: Given the current state of non-invasive prenatal testing (NIPT), what screening method is most widely considered accurate and reliable for detecting Down syndrome in a fetus,  considering factors such as sensitivity, specificity, and accessibility?\n",
            "\n",
            "Combined Answer: acceptable level of test sensitivity can be reached with relatively short read lengths (36–52 bp) and modest coverage (2–10 million reads per sample) (Liang et al., 2013; Sehnert et al., 2011). Here, we present a flexible and robust R package for NIPT analysis called RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package). RAPIDR combines several analytical techniques that have been proposed for NIPT analysis and has been tested with a large sample set from the RAPID project (NIHR funded project to evaluate the use of NIPT). RAPID males, RAPIDR also estimates the fetal fraction using the method from Rava et al. (2014). Fetal fraction is an important determinant of NIPT sensitivity, but it cannot be measured directly using the protocol we described. In this article, we described the RAPIDR package for NIPT of fetal aneuploidies. RAPIDR has been validated using >700 samples and delivers an acceptable level of specificity and sensitivity for T21, T18, T13 and monosomy X. The system requirement for RAPIDR is modest (Supplementary Text S3). Future work on RAPIDR will include evaluating strategies to detect sub-chromosomal abnormalities. Funding: This manuscript presents independent research funded by the National Institute for Health Research (NIHR) under the Program Grants for Applied Since the first demonstration of the use of cell-free DNA (cfDNA) to detect aneuploidy (Chiu et al., 2008; Fan et al., 2008), many groups around the world have reported large studies showing high sensitivities and specificities for the detection of trisomies 13, 18 and 21 (Jiang et al., 2012; Palomaki et al., 2011; Sehnert et al., 2011). In contrast to invasive methods such as amniocentesis, non-invasive prenatal testing (NIPT) uses cfDNA in maternal plasma and does not present a risk of miscarriage. Currently, outside the context of research to invasive methods such as amniocentesis, non-invasive prenatal testing (NIPT) uses cfDNA in maternal plasma and does not present a risk of miscarriage. Currently, outside the context of research studies, NIPT for aneuploidy is only available from commercial providers. To perform NIPT, cfDNA is extracted from maternal plasma and sequenced using short reads and high-throughput DNA sequencing. Sequenced reads are aligned to the reference human genome using a short read aligner. Aneuploidy is called if the number of reads mapped to each Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice. RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods. The input to RAPIDR is a set of sequence alignment files in the BAM format, and the outputs are calls for aneuploidy, including trisomies 13, 18, 21 and monosomy X as well as fetal sex. RAPIDR has been extensively tested with a large sample set as part zX>−2, the sample is called female; if zX<−3, the sample is called as monosomy X; finally, if zX is between −2 and −3, then the sample sex is called as unknown (Fig. 1c). To improve the accuracy of fetal sex calling, we also excluded bins in chr Y with a high number of counts mapped from females, e.g. the pseudo-autosomal region of chr Y. For euploid males, RAPIDR also estimates the fetal fraction using the method from Rava et al. (2014). Fetal fraction is an important determinant of NIPT sensitivity, but it cannot be measured directly using RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy - PMC several analytical techniques that have been proposed for NIPT analysis and has been tested with a large sample set from the RAPID project (NIHR funded project to evaluate the use of NIPT). RAPID validation results can be found in the Supplementary Material (Supplementary Figs S1–S4, Supplementary Text S1 and Supplementary Tables S1 and S2). depth strategy. A number of factors influence test performance, for example the fetal fraction (i.e. the proportion of reads originating from the fetus), and other technical parameters such as read length and coverage (Fan and Quake, 2010). The choice of sequencing parameters needs to be balanced against costs. Previous studies have shown that an acceptable level of test sensitivity can be reached with relatively short read lengths (36–52 bp) and modest coverage (2–10 million reads per sample) (Liang et al., 2013; Sehnert et al., 2011). Here,\n",
            "[0.76675606]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is the H3K4me3 histone mark related to transcriptional initiation or elongation?\n",
            "Refined Query: The histone mark H3K4me3 is strongly associated with transcriptional regulation.  However, its precise role in either initiation or elongation, or both, requires further clarification.  Does H3K4me3 primarily mark promoters signifying transcriptional readiness, or does it also play a significant role in the process of elongation itself?\n",
            "\n",
            "Combined Answer: an unexpected result because this histone modification is considered an “active” mark. Indeed, H3K36me3 was generally associated with transcriptionally active regions in yeast and mammals (Bannister et al. 2005; Vakoc et al. 2006; Barski et al. 2007; Guenther et al. 2007; Mikkelsen et al. 2007). More precisely, H3K36me3 was found to accumulate in the 3′ region of transcribed genes and to correlate with elongation of transcription. The link between H3K36me3 and transcription elongation is, however, not universal, since this modification was not and H3.2) in transcribed regions, and its histone tail is highly enriched for covalent modifications or “marks” associated with transcriptionally active chromatin, such as tri-methylation of lysine 4 (K4me3) (McKittrick et al. 2004; Hake et al. 2006; Loyola et al. 2006). There is also conjecture over whether H3.3 is not just a marker for active regions, but whether it contributes to the transcriptional activity of loci enriched for this histone (Huang and Zhu 2014). This is in part due to its enrichment at regulatory regions such as promoters could erase histone acetylation generated before or during the passage of elongating RNAPII. Interestingly, set2 and rpd3S mutants display aberrant intragenic transcription initiation events, which strongly suggests that a role of Rpd3S, and by extension H3K36me3, could be to prevent transcription initiation from intragenic cryptic promoters (Carrozza et al. 2005; Joshi and Struhl 2005). Thus, H3K36me3 could be involved immediately after a transcription event in the establishment of a chromatin state repressive to (intragenic) transcription. that promoter–enhancer contacts are preformed, conserved across tissues and developmental stages, and associated with paused RNAPII [64]. Further experiments will be needed to assess the role of elongation in these processes. The many interactions we have observed between promoters and gene body fragments without the H3K4me1 enhancer mark cannot be easily explained. It could be speculated that these contacts are joining two promoters while both genes are being transcribed, such that each promoter could come in contact with the body of any of loci bear both H3K27me3 and H3K4me3 marks, marking these promoters as “bivalent domains” poised for transcriptional induction (Bernstein et al. 2006; Goldberg et al. 2010; Banaszynski et al. 2013). H3.3 is required for establishment of the H3K27me3 mark in these domains (Banaszynski et al. 2013), and it is easy to envisage that a switch to K27Ac or possibly K36me3 may tip the balance to activation of aberrant developmental programs contributing to tumorigenesis. Much progress has been made in our understanding of these histone mutants since of histone marks characteristic of transcriptionally active, open chromatin structures, such as H3K4Me3, in the vicinity of the transcription start site of LIMT, were consistent with an active promoter (Fig 5A). To corroborate this observation, we investigated changes in tri‐acetylation of histone 3 (lysine 27; H3K27Ac), a marker of transcriptional activity. This was done by immunoprecipitating H3K27Ac from MCF10A cells, after stimulation with EGF. Profiling immunoprecipitated DNA fragments using deep sequencing detected an overall decrease in We next analyzed the distribution of trimethylated histone H3 at lysine 36 (H3K36me3) within the Snurf–Snrpn region. H3K36me3 has been mapped on the genome of several organisms, revealing that the deposition of this mark on chromatin is highly correlated with transcription elongation (Bannister et al. 2005; Vakoc et al. 2006; Barski et al. 2007; Guenther et al. 2007). We therefore expected H3K36me3 to be specifically enriched at the level of actively transcribed genes, which are only found on the paternally contributed chromosome within the 3′ region of transcribed genes and to correlate with elongation of transcription. The link between H3K36me3 and transcription elongation is, however, not universal, since this modification was not detected in a subset of actively transcribed genes in Drosophila (Filion et al. 2010). In the present study, we show that H3K36me3 is associated with facultative heterochromatin within the imprinted Snurf–Snrpn cluster. We also provide evidence that H3K36me3 is enriched within pericentromeric regions, which shows that this mark is associated with reduced the H3Ac and H3K4me3 activating marks but had no effect on the H3K27me3 and H3K9me3 repressing marks (Figure S6). These data demonstrate a correlation between Tcf3 expression and histone modifications in its promoter suggesting that Wnt signaling might regulate Tcf3 expression through epigenetic mechanisms. However, the mediator of this regulation still remains elusive. (TSS)) of those genes which are over-expressed in NP cells, and more NP enriched differential regions in the promoter region of genes which are over-expressed in ES cells. Note however that we do not expect a high correlation in such a test, as H3K27me3 modification of histone H3 is only one of several mechanisms of gene repression. We are also aware of recent work that questions the exclusively repressive role of H3K27me3 in gene regulation. Young et al. 2011 [27] identified a new subclass of H3K27me3-marked genes, which are highly expressed.\n",
            "[0.83753693]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What does polyadenylate-binding protein 4 (PABP4) bind to?\n",
            "Refined Query: Describe the specific RNA sequences, proteins, or other molecules that polyadenylate-binding protein 4 (PABP4) interacts with, focusing on the nature of these interactions and their functional significance in cellular processes.\n",
            "\n",
            "Combined Answer: catalytic subunit of DNA polymerase α (Miles and Formosa, 1992b), although the nature of the interaction between Ctf4 and DNA polymerase α is not well understood. A later study combined Ctf4 in a two-hybrid assay with the first 550 amino acids of Pol1 that comprise a unique amino terminal region, before the exonuclease and polymerase domains, and found that they could interact (Zhou and Wang, 2004). We used libraries expressing random fragments of yeast proteins fused to the Gal4 transcriptional activation domain to screen through the and found that they could interact (Zhou and Wang, 2004). We used libraries expressing random fragments of yeast proteins fused to the Gal4 transcriptional activation domain to screen through the two-hybrid assay for domains that interact with either the WD40 domain of Ctf4 (amino acids 1–383), or with the remainder of the protein (amino acids 461–927; Ctf4-ΔNT). The screen involving Ctf4-ΔNT identified 12 overlapping fragments from Pol1 that share a small region within the unique amino terminal domain of the Pol1 protein (Figure 6A). The same that the Ctf4 protein (and Ctf4-ΔNT) behaves as a multimer, and this is true of the endogenous protein in yeast extracts as well the purified recombinant protein (A Gambus and K Labib, unpublished data). One of the original studies to identify Ctf4 showed that it could be isolated from a yeast extract using an affinity column bearing the Pol1 catalytic subunit of DNA polymerase α (Miles and Formosa, 1992b), although the nature of the interaction between Ctf4 and DNA polymerase α is not well understood. A later study combined Ctf4 in a The formation of the polyadenylated 3′ ends of eukaryotic mRNA requires that several different factors come together to recognize the polyadenylation signals on the mRNA precursor and, in temporal sequence, cleave at the poly(A) site and then synthesize a poly(A) tail of the correct length. In addition, the activity of this large complex must be coordinated with that of other nuclear complexes involved in transcription, splicing, acquisition of export factors, and confirmation that the final mRNP has been correctly processed and assembled. CPFs pre-mRNA and the addition of a polyA tail at the cleavage site. Certain cis-acting elements and trans-acting factors have been found in the literature that influence the choice of a particular polyA cleavage site (Barrett et al., 2012; Pichon et al., 2012). In particular, the 3′ end sequence of a pre-mRNA usually contains a AAUAAA hexamer (or some close variant). This hexamer is called the polyadenylation signal (PAS) and it usually appears 10–30 bps upstream of the cleavage site (Tian, 2005). The PAS serves as a binding site for the cleavage the species examined, it is not likely mediated through the highly conserved WD40 domain found in the N terminus of the protein. Instead, the C terminal portion of the protein has been implicated in interaction with the CMG complex [4]. We demonstrate that Drosophila Ctf4 interacts with Mcm2, Polymerase alpha primase, and members of the GINS complex. These interactions are consistent with a central role for Ctf4 in coordinating the helicase-polymerase association during S phase. It has been reported in budding yeast that Ctf4 interacts only These interactions are consistent with a central role for Ctf4 in coordinating the helicase-polymerase association during S phase. It has been reported in budding yeast that Ctf4 interacts only with the GINS complex via interaction with Sld5 [23]. Drosophila Ctf4 appears to be different in that it interacts with the Psf1 and Psf2 subunits of the GINS complex. Given the structural similarities between the subunits of the GINS complex [24] it is not unreasonable to speculate that specific subunit association of Ctf4 may be fluid over at 25°C efficiently cleaved and polyadenylated the RNA, but extracts from cells after the shift to 37°C were not functional in this coupled reaction (Fig. 1B, left). The poly(A) addition step can be studied separately from cleavage using RNA that ends at the GAL7 poly(A) site. Compared to cells grown at 25°C, levels of polyadenylation markedly decreased in extracts prepared from cells 15 min after the shift to 37°C, and very little adenylated product could be detected after 60 min (Fig. 1B, right). We conclude that Pta1 is important for both process includes three major steps: the addition of a 5′ cap, addition of a polyadenylation (polyA) tail and splicing. In particular, a polyA tail is added at the 3′ end of a pre-mRNA with the help of the polyadenylation process. More precisely, the polyadenylation process consists of two steps (Wahle and Kühn, 1997): cleavage near the 3′ end of a pre-mRNA and the addition of a polyA tail at the cleavage site. Certain cis-acting elements and trans-acting factors have been found in the literature that influence the choice of a particular polyA Recent investigations into Ctf4 have placed it as an integral member of the DNA replication machinery with respect to coordinating helicase and polymerase activity. Here with lay the groundwork for studying the role of this protein within the context of a multicellular metazoan. We have found that this highly conserved protein interacts with a member of the Mcm2-7 helicase, members of the GINS complex, and DNA pol alpha. Moreover, we demonstrate efficient RNAi knockdown of CTF4 in Drosophila and use these animals to show that CTF4 is required\n",
            "[0.6494765]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the average diameter of intermediate filaments?\n",
            "Refined Query: Determining the average diameter of intermediate filaments is challenging due to variations depending on the specific protein composition and cellular context.  What is the range of diameters typically observed, and what factors influence this variability?  Are there significant differences between filament types?\n",
            "\n",
            "Combined Answer: We used fragments that are 141–190 bp in length for this analysis because this range is comparable to the length of DNA that accommodates a single nucleosome. We determined that the use of the middle 60 bp of such fragments (see Fig. 2A for details) results in optimal smoothing and resolution of the data. We thus assigned each nucleotide in the middle 60 bp of each fragment a value of 1. For each position, we calculated the sum of the values. We then normalized this sum by dividing with the genomic average [i.e. (the total number of reads that of the measurements was determined by plotting this experiment against another. The log base 2 of average ratios of two forward-labeling and two reverse-labeling experiments are shown in Figure 2. The slope of the calculated best fit to the data is 0.9449 (with an R2 of 0.7617), indicating that the ratio for each protein in the forward- and reverse-labeled measurements were largely similar (Figure 2). About 77% of the proteins (1987) have ratios (ABPP 106 versus control probe) greater than 1. A total of four replicates were performed; 3003 from opposite strands were shifted by this value and added together for a unified, strand-independent profile. Regions with a low Pearson correlation between the two strands’ density profiles were discarded as artifacts. measurements were largely similar (Figure 2). About 77% of the proteins (1987) have ratios (ABPP 106 versus control probe) greater than 1. A total of four replicates were performed; 3003 proteins were quantified in at least two of the replicates, and this set was used for further analysis. One thousand two hundred and thirty-one proteins have an average ratio (ABPP 106 versus control probe) greater than 1.5 with a p-value <0.05, and among those proteins 883 had an average ratio greater than 2 (Figure 3). HDAC1 and 2 were identified as 60 bp of each fragment a value of 1. For each position, we calculated the sum of the values. We then normalized this sum by dividing with the genomic average [i.e. (the total number of reads that are in the 141–190 bp range) × 60/(the genome size)] to obtain the Nucleosome Positioning Index. The Fragment Positioning Index for DNA fragments in different size ranges (50–100 bp, 101–140 bp, 141–160 bp, and 161–190 bp) was obtained by the same method except for the normalization factor. When plots for DNA fragments in different size ranges were three sheets. Two of these sheets (composed of seven strands) contribute the immunoglobulin-like core of BIG domains. These seven strands are labelled ‘a’ to ‘g’ in Figure 1 and Supplementary Figure S3, following an established convention in the immunoglobulin fold (Bork et al., 1994). BIG domains have been described with diverse functions, usually relating to matrix, protein–ligand, or protein–protein interactions and are mainly extracellular (Mei et al., 2015; Ptak et al., 2014). Close 3D proximity and evolutionary conservation of four size ranges (50–100 bp, 101–140 bp, 141–160 bp, and 161–190 bp) was obtained by the same method except for the normalization factor. When plots for DNA fragments in different size ranges were presented in the same graph as in Fig. 3 J–L, we used the total number of reads that are in the 50–190 bp range instead of the total number of reads that are in the 141–190 bp range for normalization. When plots for DNA fragments in a specific size range were presented as in Fig. 5 C–F, the total number of reads that are in the specific size range for the lengths that could be obtained from mononucleosomes) and assigned each nucleotide in the middle 60 bp of each fragment a value of 1. Then, for each position, the sum of the values normalized to the genome-wide average was plotted as the Nucleosome Positioning Index (Nucleosome Positioning Analysis and Fig. 2A). The peaks thus obtained would generally be expected to indicate the positions of nucleosomes or nucleosome-like species. Comparison of the MPE-seq data with the MNase-seq data at standard or low (MNase Low; Fig. 1B) concentrations of The 3D structural ensembles of all four target proteins used in this study were calculated using the CYANA27 software suite, supplied with the same input datasets as with autoNOE-Rosetta. Depending on the size of each protein target, CYANA calculations required 45–90 min on 4 CPUs. The script with all parameters for CYANA calculations is available in the Supplementary Methods. we used 1.6 × 10-3and 2.4 × 10-5, respectively--the ones observed in AT [24]. Since, in practice, insertions occur less frequently than deletions, 42% of the inserted gaps were insertions and 58% deletions--also observed in AT [24]. For the length of the inserted gaps, we used the distribution of gap lengths shown in Figure 3, which is consistent with other studies on gap distributions (cf. [9,22,23]). Since the queries were simulated, we were able to know the exact location of the fragments of the reference sequence they were derived from\n",
            "[0.68210185]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Elaborate on the association between Genomic Regulatory Blocks (GRBs) and target genes\n",
            "Refined Query: How do Genomic Regulatory Blocks (GRBs), encompassing clusters of regulatory elements, physically and functionally interact with their target genes to influence gene expression?  Consider the mechanisms involved and the spatial relationship between GRBs and their regulated genes.\n",
            "\n",
            "Combined Answer: called genomic regulatory blocks (GRBs)3, 13, supports the idea that they are ensembles of regulatory elements that are involved in regulating these genes (Supplementary Fig. 1a). In addition to this target gene (or genes in the case of gene clusters) under developmental regulation, a GRB can harbour several other genes that are not detectably regulated by these elements (bystander genes). Target and bystander genes differ with respect to their promoter structure, patterns of epigenetic modification and range of biological functions3, 14, 15. elements in cis with the gene under long-range regulation12. We should emphasise that in regulatory genomics conservation of synteny corresponds to the conservation of collinear arrangement of genes and other conserved sequences between the genomes of two species. This syntenic organisation of clusters of CNEs around key developmental genes, called genomic regulatory blocks (GRBs)3, 13, supports the idea that they are ensembles of regulatory elements that are involved in regulating these genes (Supplementary Fig. 1a). In addition to this power than either concept alone (Supplementary Fig. 12). The GRB model provides a framework for long-range regulation, in which the majority of regulatory elements within a GRB are dedicated to the control of its target gene9, 11, with other genes not responding to long-range regulation despite being located close to regulatory elements8, 57. Target and bystander genes appear to exhibit distinct features that may help to explain this specificity (see Akalin et al. for a list of putative target genes)14, 15. Topological organisation data Developmental genes in metazoan genomes are surrounded by dense clusters of conserved noncoding elements (CNEs). CNEs exhibit unexplained extreme levels of sequence conservation, with many acting as developmental long-range enhancers. Clusters of CNEs define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks (GRBs). Their function and distribution around important regulatory genes raises the question of how they relate to 3D conformation of these loci. Here, of target genes and allow for very precise and refined spatiotemporal patterns in different functional contexts. Since GRB target genes are central to developmental regulation, their expression should be robust and tightly coordinated even under varying external conditions. Most obviously, a large number of different promoter-enhancer pairings is needed because these genes have many different roles in time and space that require a complex switchboard of regulatory inputs arranged in a GRB. preserved synteny in vertebrates [6] and insects [7] are due to the requirement to keep such arrays of HCNEs in cis to their target genes. This has led us to formulate the concept of genomic regulatory blocks (GRBs), which are functional regulatory units on a chromosome that are spanned by HCNEs and contain the gene regulated by HCNEs (the target gene). Those HCNE arrays often span large genomic regions of low gene density (gene deserts), but are in other instances found in the introns of, or beyond, unrelated neighboring genes (which we will and, if warranted, reassign the disease phenotype to the correct gene. Thus, important developmental genes are embedded in large GRBs, breakpoints or mutations within these GRBs may cause genetic disease, and subsequent fine mapping may result in the indictment of a bystander gene containing essential regulatory elements for a distant target gene. The bystander genes, although within reach of specific regulatory elements, are expressed in different patterns and thus are not specifically regulated by GRB regulatory content. How this apparent characterized by the absence of a well-defined single transcription start site (TSS); instead, the transcription from them can start from multiple sites within a range of several dozen to several hundred nucleotides. In this work we set out to investigate general transcriptional initiation properties of genes in genomic regulatory blocks, including differences in expression and promoter structure between the target and bystander genes in GRBs, and to discuss possible underlying causes for their differential responsiveness. We approach this by with nearby GRB target genes is one of the main motivations for this study). Set 3 comprises other CpG island-overlapping genes outside GRBs; since most GRB target and bystander genes have CpG island-type promoters, genes elsewhere in the genome with the same general type of promoters should provide a general picture of their typical behavior). Set 4 comprises other (non-GRB, non-target) transcription factor (TF) genes; since most GRB target genes are TFs [1], this set serves as a control to exclude the possibility that certain transcriptional This study provides a detailed survey of promoter properties of GRB targets and offers insight into their behavior during a differentiation time-course. GRB target genes show evidence of the existence of multiple promoters that span a large region when compared to several other gene sets. Multiple promoters might be instrumental in achieving the level of regulatory complexity characteristic of these target genes, which have the most complex spatiotemporal expression patterns of all metazoan genes [25,26]. Other striking features of the target\n",
            "[0.77411187]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which therapeutic interventions for sarcopenia have been  applied\n",
            "Refined Query: What specific therapeutic interventions, including exercise regimens, nutritional strategies, and pharmacological treatments, have been practically applied in clinical settings to address sarcopenia, and what is the current evidence supporting their efficacy and safety?\n",
            "\n",
            "Combined Answer: of the anabolic response with bimagrumab treatment observed in this study was comparable with those reported in a prior study in patients with sarcopenia (18) and with reports on prior anabolic agents used in COPD (33, 34). In individuals with sarcopenia, 16 weeks of treatment with bimagrumab resulted in mean peak increases of +8.0% in TMV and of +6.0% in LBM (18), compared with +7.8% and +3.1%, respectively, in the present study with patients with COPD. Overall, bimagrumab was safe and well tolerated in this sample of patients with COPD with lower-than-normal muscle mass. The three most commonly reported AEs with bimagrumab treatment—muscle spasms, tightness, and twitching; diarrhea; and acne—were also reported as mostly mild in severity in a recent study of older adults with sarcopenia (18). Physical frailty and muscle wasting, however measured, is a well-established predictor of hospital admission due to acute exacerbation of COPD (4, 31, 32). We expected that our patients, who were selected regulators of muscle mass, it is unlikely that the observed increases in TMV and LBM were entirely mediated by blocking the effects of myostatin. In fact, a preclinical study demonstrated that ActRII blockade could induce muscle hypertrophy in a myostatin knockout mouse, proving that other molecules signal through those receptors (17). The magnitude of the anabolic response with bimagrumab treatment observed in this study was comparable with those reported in a prior study in patients with sarcopenia (18) and with reports on prior anabolic The primary study objective was to evaluate the efficacy and safety of pazopanib, with efficacy measured as objective response rate (ORR), which is the sum of complete responses (CRs) + partial responses (PRs). Secondary objectives included assessing growth rate over time in target lesions before and after pazopanib treatment, evaluating the need for surgical intervention in individuals who received pazopanib in comparison to rate prior to receipt of drug, and creating an annotated tissue resource from patients on study. All endpoints, Indeed in a study of sarcopenic seniors who had both slow gait speed and reduced mass, bimagrumab did increase 6MWD and gait speed, suggesting this could be a model for future studies in COPD (18). Third, although the 6MWD is considered a useful stratification tool (31), it has been shown to be poorly responsive to interventions that improve the physiologic ability to exercise (e.g., bronchodilators) (42) and may be less responsive than a constant work rate exercise test (43). Fourth, gain in muscle mass may be a necessary but not sufficient mitochondrial bioenergetic capacity can improve without mass gains (44), and it may be that concurrent exercise is required to demonstrate improved exercise capacity. Fifth, although we stratified by low muscle mass, we might have obtained greater focus on the population of interest had we made recent weight loss an inclusion criterion; however, unlike (for example) patients with cancer cachexia, most patients with COPD are not managed in secondary or tertiary care, so obtaining accurate sequential weight measures is difficult. An interesting and Main Results: We assessed changes in thigh muscle volume (cubic centimeters) as the primary endpoint along with 6-minute-walk distance (meters), safety, and tolerability. Fifty-five (82.1%) patients completed the study. Thigh muscle volume increased by Week 4 and remained increased at Week 24 in bimagrumab-treated patients, whereas no changes were observed with placebo (Week 4: +5.9% [SD, 3.4%] vs. 0.0% [3.3%], P < 0.001; Week 8: +7.0% [3.7%] vs. −0.7% [2.8%], P < 0.001; Week 16: +7.8% [5.1%] vs. −0.9% [4.5%], P < 0.001; Week 24: +5.0% need for surgical intervention in individuals who received pazopanib in comparison to rate prior to receipt of drug, and creating an annotated tissue resource from patients on study. All endpoints, including safety, were assessed by intent-to-treat. to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many patients enrolled on the study had the option to revert to observation, and did not have the immediate threat of shortened survival as would be the case in metastatic disease, the incentive to remain on an agent that caused side effects was lower than in other settings. Despite that, a number of patients chose to remain on treatment for prolonged which cause additional damage in DMD muscle.10,34 Additionally, nNOS delocalization leads to nitrosative inhibition of muscle force in mdx mice,35 and this may cause further damage to the muscle. Therefore the restoration of nNOS to the sarcolemma in DMD patients should lead to additional benefit, as their muscles are expected to be better protected from additional damage by these two nNOS-related mechanisms.34,35 Further clinical research on BMD and other neuromuscular disorders with a loss of nNOS is needed in order to quantify the clinical\n",
            "[0.40170208]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the genetic basis of progeria?\n",
            "Refined Query: Progeria, characterized by premature aging, arises from genetic mutations.  Specifically, what genes are implicated, what types of mutations occur within these genes, and how do these alterations at the molecular level lead to the accelerated aging phenotype observed in progeria patients?\n",
            "\n",
            "Combined Answer: mutation was carried in the mother of the proband with CS but not in the maternal grandparents. The same mutation was inherited in another proband (Family 9). The two families share a small haplotype around the point mutations that is approximately 171kb long (Supplementary Table 4). We also observed a second recurrent mutation, c.1710 g>a, p.W570X, in Families 3 and 7. Here, the mutations were determined to be de novo in both families, although the families again share a haplotype around the point mutation spanning 260 kb. In total, we genes [2]. Functional studies suggested that these elements show a tissue-specific in vivo enhancer activity in a mouse transgenic reporter assay that tended to recapitulate aspects of the expression pattern found in genes that were in their proximity [5]. On the other hand, the removal of four of these UCEs, located near genes that exhibit marked phenotypes in murine models, failed to reveal any overt variation of growth, longevity, pathology or metabolism. As the authors concluded, these results indicate that extreme sequence constraint does The proband is a ten-year-old male and the first-born child of healthy non-consanguineous parents. The family history was unremarkable for neurological disorders, behavioral problems, and congenital anomalies. He was born at 39 weeks of gestation via elective caesarian section. His birth weight was 2800 g (10-25th centile) and his length, occipital frontal circumference and APGAR scores were not reported but were said to be normal. At birth, no medical problems were recorded. Postnatally, his growth was normal; global psychomotor delay was gene expression levels of NHE6 are reduced in postmortem cortex as compared to control.6 Despite the clear neurodevelopmental components in CS and the likenesses to related developmental disorders such as autism and AS, there appear to be progressive aspects to the CS phenotype. Based on his observations in the original pedigree, Christianson et al.4 described a potential progressive nature involving loss of cognitive and adaptive skills with aging. Further, there are clear regressions that appear to be associated with the CS. In our study, For example, instead of whole genomes, one could use clinical exome data containing at least some part of the regulatory genome such as UTR or proximal promoter sequences. Additionally, the software requires at least one Human Phenotype Ontology64 (HPO) term that describes the clinical abnormalities of the individual being investigated. As shown in Figure 3, Genomiser first of all identifies and scores the genes that have the most similar phenotypes to the phenotypic profile under investigation represented using the HPO terms. This scoring enrichment nor depletion for those who are 60 or over (92 regions, 35.51% of the genome, P = 0.044, obs/exp = 0.921). Hence, the enrichment of UCEs in the Forsberg 2012 [64] dataset is unlikely to be explained simply by the age of the subjects. Instead, our observations may reflect technical differences, such as sample selection and size, tissue-specificity of the mechanisms underlying depletion or enrichment of UCEs in CNVs, or the possibility of some somaticCNVs representing tissues that are diseased, even if not diagnosed. Alternatively, a ‘old’ samples for each motif (results at http://ismara.unibas.ch/supp/dataset1_IBM/averaged_age/averaged_report/). We found that only the SREBF motif is significantly differently regulated between old and young samples (Fig. 2D). The targets of SREBF are up-regulated in older tissues relative to the younger ones and are highly enriched for lysosomal genes. Lysosomes are responsible for the degradation of many macromolecules, including proteins, and increase in lysosomal mass is a well-known characteristic of aging and senescence in cells The genome of each living organism contains thousands of genes, and the precise control of the timing and location of expression of these genes is key for normal development and homeostasis of each individual. Despite the oftentimes high genetic similarity between organisms, the source of phenotypic differences, for example between human and mouse, is thought to originate mainly from changes in how and when genes are expressed. This is partially determined by enhancers, that contribute to the control of gene expression. For decades, duplication (30), it fits that the genes proximal to active H3K27ac-positive enhancers reflect such a progenitor state. Conversely, genes proximal to H3K27ac-negative enhancer regions reflect the future more committed state of these cells, which again supports the notion that these enhancers exist in a predetermined state. de novo mutations (ie mutations were not found in the mother). Another notable finding was two separate recurrent mutations. The first was found at c.1498 c>t, p.R500X. This mutation was observed in two families not known to be related, and in one family this mutation was determined to occur de novo in a maternal carrier (Family 12, Figure 1). The mutation was carried in the mother of the proband with CS but not in the maternal grandparents. The same mutation was inherited in another proband (Family 9). The two families share a small haplotype\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.24ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1361.68ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1208.73ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1409.26ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which enzyme is involved in the maintenance of DNA (cytosine-5-)-methylation?\n",
            "Refined Query: The maintenance of cytosine-5 methylation patterns in DNA during replication is crucial for epigenetic inheritance.  Which enzyme, specifically, is responsible for copying these methylation marks onto the newly synthesized DNA strand, ensuring the pattern is passed on to daughter cells?\n",
            "\n",
            "Combined Answer: position marked with b), in which case, replication moves through the gene in the same direction as transcription. The signal at this site was about threefold higher in Pfh1-depleted (+12 h thiamine) compared with nondepleted cells. We also detected pausing in Pfh1-depleted cells at the position expected for the 5S rRNA gene if it is replicated from forks initiating at ORI3046 (Fig. 3A,B, position marked with a). In this case, forks move in the opposite direction as transcription through the 5S gene. At this site, pausing was 32-fold higher is associated with the enrichment of γ-H2A.v in late replicating domains, suggesting that H4K20 methylation is critical in maintaining the integrity of late replicating sequences. H4K20 is the most common histone target for post-translational modification. The vast majority (>80%) of H4K20 exists in the dimethyl state (7); therefore, every cell cycle the bulk of nascent histone H4 deposited during DNA replication needs to undergo monomethylation by PR-Set7 and subsequent di- or tri- methylation by Suv4-20. The conserved PIP-box mediating the or modifying cell fate, either in normal processes such as development and cell differentiation, or in cancer. Mechanisms of epigenetic regulation via DNA methylation are not yet completely understood; several factors such as DNA methyltransferases, chromatin remodelling proteins and DNA-binding transcription factors are involved [47,48]. Therefore, any perturbation that leads to a decrease in the expression status of those factors may disrupt important pathways for maintenance of the differentiated cellular state. Aberrant methylation can KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and Jacobsen, 2010). The plant specific DNA methyltransferase CHROMOMETHYLASE 3 (CMT3) binds to H3K9me2 and methylates cytosine residues at CHG sites (where H is A or C or T) (Du et al., 2012; Lindroth, 2001). In addition, DNA methylation in CG contexts is carried out by METHYLTRANSFERASE 1 (MET1) (Finnegan and Dennis, 1993; Law and Jacobsen, 2010). DOMAINS tissues [7,9]. DNA methylation is a very stable epigenetic mark and next generation sequencing studies have recently shown that many genes are aberrantly methylated in cancer [10,11]. Tissue specific DNA methylation patterns are stabilized during embryonic development, and faithfully maintained through cell divisions [12-14]. Nevertheless, established methylation patterns can be reprogrammed, with tumor cells undergoing DNA demethylation and de novo methylation through mechanisms not yet completely understood. CDKN2A and RASSF1 are examples of activated origins has been shown to lead to DNA damage, fragile sites, and increased mutations in human cells due to the increased distances replication forks must traverse (44–46). However, unlike in mammalian cells, deregulation of H4K20 methylation did not impair origin activation in Drosophila. In mammalian cells, tethering of PR-Set7 to the DNA promotes the locus-specific recruitment of replication factors and pre-RC assembly (presumably via increased levels of H4K20me2 and ORC stabilization) (11,19,20). However, given that almost all Histone post-translational modifications (PTMs) regulate almost all DNA-templated processes including DNA replication, transcription and DNA repair. Deregulation of these epigenetic histone modifications has the potential to lead to catastrophic consequences at both the cellular and organismal level. One such epigenetic mark, methylation of histone H4 lysine 20 (H4K20), is critical for maintaining genome stability, and its deregulation impacts transcription, chromatin compaction, DNA repair, cell cycle progression and DNA replication [(reviewed visualized as dense structures called chromocentres by DAPI staining (Fransz et al., 2006). In Schizosaccharomyces pombe and mammals, heterochromatin is demarcated by histone H3 lysine 9 methylation (H3K9me3) (Jenuwein and Allis, 2001). Similarly, in Arabidopsis, heterochromatin is marked by H3K9me2, which is deposited by the histone methyltransferases KRYPTONITE (KYP), SUVH5 and 6 (Bernatavichute et al., 2008; Jackson et al., 2002; Malagnac et al., 2002). DNA methylation plays an important function in regulating heterochromatin (Law and a previously unidentified origin is located in this EcoRV DNA fragment. Although there was little evidence for pausing at the 5S rRNA gene in the presence of Pfh1 (−thiamine), there were two sites of discrete pausing in Pfh1-depleted cells. One pause mapped to the site expected if the gene was replicated by forks initiating at ORI3047 (Fig. 3A,B, position marked with b), in which case, replication moves through the gene in the same direction as transcription. The signal at this site was about threefold higher in Pfh1-depleted (+12 h thiamine) arrest occur in the next cell cycle with the accumulation of nascent nucleosomes containing unmodified H4K20 throughout the genome (Figure 7). DNA damage resulting from loss of PR-Set7 and H4K20 methylation was restricted to late replicating regions of the genome, suggesting a defect in the DNA replication program at the end of S phase. A paucity of activated origins has been shown to lead to DNA damage, fragile sites, and increased mutations in human cells due to the increased distances replication forks must traverse (44–46). However, unlike\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.02ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1461.17ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1360.51ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1439.20ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Osteoporosis - {'Bone Fractures': 0.9999999999999998, 'Fractures': 0.6379515536869338, 'Calcium Supplements': 0.0, 'Bone Grafts': 0.3788330996160021}\n",
            "\n",
            " ### Clustered: {'Osteoporosis': {'Cluster 1': ['Bone Fractures', 'Fractures', 'Bone Grafts', 'Calcium Supplements']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1812.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 936.81ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1561.34ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which disease phenotypes are associated to PRPS1 mutations?\n",
            "Refined Query: Investigate the phenotypic spectrum of diseases linked to PRPS1 gene mutations.  Specifically, what clinical manifestations and disease characteristics are observed in individuals carrying these mutations?\n",
            "\n",
            "Combined Answer: these variants is truly loss of function (LoF). Instead of scoring all TTNtv equally and assuming an underlying LoF mechanism, we only score TTNtv highly if they are in constitutive exons (proportion spliced in (PSI) > 0.9), and we reduce the strength of evidence by one level from very strong to strong (coded as PVS1_strong). We also extended PS1 and PM5 to utilise known disease-causing variants in related genes/proteins (paralogues) to identify residues intolerant to variation16 (Figure 2c). Where nothing is known about variants at the pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this The mutational spectrum was composed of 9 single nucleotide variants (SNVs), 2 indels and 1 CNV deletion. All mutations were protein-truncating or splicing mutations. We identified two recurrent mutations (c.1498 c>t, p.R500X; and c.1710 g>a, p.W570X). Otherwise, all mutations were unique. In our study, seven of 12 mutations (58%) were de novo, in contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual Motivation: Text-mining mutation information from the literature becomes a critical part of the bioinformatics approach for the analysis and interpretation of sequence variations in complex diseases in the post-genomic era. It has also been used for assisting the creation of disease-related mutation databases. Most of existing approaches are rule-based and focus on limited types of sequence variations, such as protein point mutations. Thus, extending their extraction scope requires significant manual efforts in examining new instances and may be more highly deleterious and that inherited mutations may appear milder. However, from our data and the other mutations in the literature (Supplementary Table 2), this hypothesis does not appear to be substantiated.4 There is a statistical trend toward more regressions and earlier-onset regressions in the de novo group; however, this association will require larger studies to establish. The majority of mutations appear to be early truncating and/or splice mutations likely constituting loss of function mutations. Given our high discovery DNA. In one of the two cases that were characterized bioinformatically, otp, we searched for mapped human diseases at the edge of the otp GRB and found Hermansky-Pudlak Syndrome, type 2, a cell migration and platelet defect (OMIM#608233) mapped to the AP3B1 gene at 5q14.1, which, as we have shown, contains HCNEs of the otp GRB. Recently, a microdeletion of ∼8 kb causing this disease was mapped in exons 14–15 of AP3B1 (Jung et al. 2006), which removes one of the HCNEs mapped in this study. While the AP3B1 mutation may have an effect on the one homozygous mutation or two heterozygous mutations were added to the 1000 Genomes VCF file. For these experiments, the phenotypic (HPO) annotations for the corresponding disease in OMIM were taken on 8/7/2015 from the annotation files of the HPO team. To measure the ability of Genomiser to detect known disease-gene associations, we repeated the analysis with incomplete (maximum of three HPO annotations), noisy (two random HPO terms added), and imprecise (two of the original HPO annotations replaced by the more general parent terms in the testing across all diseases is the interpretation of identified sequence variants. This requires evaluation of data from diverse sources, including clinical observations, computational data and data derived from the literature. Although existing tools aid collection of some of these data types, scientists and clinicians must often access multiple data sources whilst interpreting a single genetic variant. The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recently released guidelines c>t transition leading to p.R500X, a protein truncating mutation in the putative eleventh transmembrane domain of the protein. In Family 12, this mutation appears likely de novo in the mother of the affected CS male (i.e. not found in the maternal grandparents). In Family 9, this mutation is inherited. These families do appear to share a haplotype around the mutation locus (Supplementary Table 4), which may be prone for recurrent mutation although further research will be necessary to clarify this. The mutation occurs at a CpG location in the PS1 and PM5 to utilise known disease-causing variants in related genes/proteins (paralogues) to identify residues intolerant to variation16 (Figure 2c). Where nothing is known about variants at the equivalent residue of the same gene, we use high confidence variants (i.e. same reference allele and M-coffee mapping score >3) as evidence if they affect the equivalent residue in a paralogue (with the same reference allele), either with the same substitution (rule PS1_moderate - Equivalent amino acid change as an established pathogenic variant in\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 378.73ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is indicated the use of antioxidant supplements in patients at risk for coronary artery disease?\n",
            "Refined Query: Should antioxidant supplements be recommended for individuals exhibiting risk factors for coronary artery disease?  The question explores whether evidence supports their preventative use in mitigating cardiovascular events.\n",
            "\n",
            "Combined Answer: active metabolites and ΔΔQTcF. Although ozanimod blunted the observed diurnal increase in heart rate, excursions below predose heart rates were no greater than with placebo. Results demonstrate that ozanimod does not prolong the QTc interval or cause clinically significant bradycardia, supporting ozanimod's evolving favorable cardiac safety profile. into lives saved. The advantages of randomized studies have been discussed extensively by others.5,21–23 True confidence in the findings of studies of treatments with potentially small-to-moderate effects on mortality is often enhanced by well-performed randomized trials; in their absence, there is a greater risk that such treatment effects may be masked by selection bias and confounding. Although a major strength of the PREVAIL II trial was its randomized design, its weaknesses include an open-label as opposed to double-blind design (i.e., completed the study. The upper limits of the 2‐sided 90% confidence intervals for ΔΔQTcF for both ozanimod 1 and 2 mg were below the 10‐millisecond regulatory threshold. No QTcF >480 milliseconds or postdose change in QTcF of >60 milliseconds was observed. There was no evidence of a positive relationship between concentrations of ozanimod and its active metabolites and ΔΔQTcF. Although ozanimod blunted the observed diurnal increase in heart rate, excursions below predose heart rates were no greater than with placebo. Results demonstrate that This was a negative thorough QT/QTc study, demonstrating that ozanimod treatment, in doses of up to 2 mg/day, did not have a clinically relevant effect on cardiac repolarization. The upper bound of the 2‐sided 90%CI (or 95% 1‐sided confidence limit) of the ΔΔQTcF was below the 10‐millisecond regulatory threshold at all time points for the therapeutic and supratherapeutic doses of ozanimod. These results were confirmed by demonstrating assay sensitivity with the use of moxifloxacin as a positive control. Consistent with the lack of QTc effect, 72.9%; placebo, 76.1%). The number of subjects who discontinued the study due to TEAEs was similar for each group (4 ozanimod subjects [6.5%], 3 placebo subjects [4.8%]). There were no serious TEAEs. Incidences of the most common TEAEs and cardiac adverse events of special interest are shown in Table 5. The most common TEAE was site reaction caused by the ECG electrode tape. The incidence of specific TEAEs was similar for the study groups, with the exception of orthostatic hypotension, which occurred in 5 ozanimod subjects (8.1%) and 1 placebo There were no potential biases from the review authors in the review process. In the preparation of this review, two review authors independently read and screened trials retrieved for inclusion, independently completed data extraction and assessed the quality of included trials to minimize potential biases. No conflict of interests were found in relation to the review authors of this review. Relevant studies will be searched from the databases of PubMed, EMBASE, Cochrane Library, China Knowledge Resource Integrated Database, Weipu Database for Chinese Technical Periodicals, SinoMed, and Wanfang Database from their inception to June 10, 2019. Two researchers will independently select studies, collect data, and assess the methodology quality by the Cochrane risk of bias tool. was not expected to have any effect on clinical safety or efficacy. Prior to the availability of the food‐effect study results, patients in the ozanimod phase 2 studies in RMS and UC were instructed to take ozanimod in fasting conditions. Results of the ozanimod phase 2 studies in RMS and UC showed clinical benefit, along with an acceptable safety profile, for the ozanimod HCl 0.5‐ and 1‐mg once‐daily regimens.14, 15 In RADIANCE Part‐A, a phase 2 randomized, placebo‐controlled trial among 258 patients with RMS, the number of Two review authors (Xiao Y, Luo M) independently assessed the risk of bias of the included studies using the 'Risk of bias' tool recommended by the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The 'Risk of bias' tool consists of six specific parameters: (1) sequence generation, (2) allocation concealment, (3) blinding, (4) incomplete outcome data, (5) selective outcome reporting and (6) other bias. For each entry, the judgment ('low risk' of bias, 'high risk' of bias, or 'unclear risk' of bias) was followed by a the supratherapeutic dose (2 mg) than at the therapeutic dose (1 mg). PK results in this study also showed that the active metabolites (RP101988 and RP101075) exhibit PK properties similar to those of ozanimod. The International Conference on Harmonisation E14 Guidance recommends assessment of QTc prolongation by the study drug at multiples of the anticipated maximum therapeutic exposure to mimic exposure that may occur under circumstances that might augment potential toxicity (eg, drug‐food or drug‐drug interactions involving metabolic\n",
            "[0.72684157]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the main functions of the human HuR (ELAVL1) protein in fibroblasts?\n",
            "Refined Query: What are the key roles of the human HuR (ELAVL1) protein in regulating gene expression, mRNA stability, and translation within fibroblast cells?  Specifically, how does HuR influence fibroblast function and behavior?\n",
            "\n",
            "Combined Answer: in the trans-repressive effects of SALL4. Based on luciferase assays, the amine oxidase domain of LSD1 is important in suppressing SALL4-mediated reporter transcription. In freshly isolated adult mouse bone marrows, both SALL4 and LSD1 proteins are preferentially expressed in undifferentiated progenitor cells and co-localize in the nuclei. Further sequential chromatin immunoprecipitation assay confirmed that these two factors share the same binding sites at the promoter regions of important hematopoietic regulatory genes including EBF1, GATA1, their primitive cell phenotypes (Fig. 6), reinforcing that LSD1 may act as a key controller for HSPC proliferation and differentiation. One function of LSD1 in HSPCs may be to contribute not only to activity of the SALL4-dependent repression network, but also to influence SALL4 expression directly, as SALL4 mRNA levels were substantially increased after LSD1 knockdown (Fig. 6E). Additionally, increased enrichment of SALL4 after LSD1 knockdown at the SALL4·LSD1 co-binding sites of different downstream gene promoters also supported this notion HOXD4, which corresponds to middle of a broad domain of H3K27me3 and SUZ12 occupancy loss upon HOTAIR depletion (Fig. 5C) (Rinn et al., 2007; Tsai et al., 2010). Endogenous HOTAIR in primary human fibroblasts also bound the same sites (four of four tested, including in HOXD), as indicated by ChIRP-qPCR (Fig. S4). HOTAIR occupancy sites are significantly enriched for genes that gain PRC2 occupancy in a HOTAIR-dependent manner in the same cell type, or become de-repressed when endogenous HOTAIR is depleted (Gupta et al., 2010; Tsai et al., 2010) The regulation of gene activity on the RNA level has been at the heart of intensive research efforts since the description of the operon (1). Post-transcriptional regulation is highly versatile and adaptable by controlling RNA availability in cellular time and space. Messenger RNA stability, transport, storage and translation are largely determined by the interaction of mRNA with microRNAs (miRNAs) and RNA-binding proteins (RBPs). We have just begun to understand the extent and dynamics of transcriptome-wide binding events that lead to the activity. Also, enhancer activities of ERRE2 and ERRE4 regions of the Esrrb gene, where Esrrb directly binds, were repressed by overexpression of Dax1 in ES cells (Fig. 7C and D). These data suggest that Dax1 functions as a negative regulator of Esrrb. sequential chromatin immunoprecipitation assay confirmed that these two factors share the same binding sites at the promoter regions of important hematopoietic regulatory genes including EBF1, GATA1, and TNF. In addition, studies from both gain- and loss-of-function models revealed that SALL4 dynamically controls the binding levels of LSD1, which is accompanied by a reversely changed histone 3 dimethylated lysine 4 at the same promoter regions. Finally, shRNA-mediated knockdown of LSD1 in hematopoietic precursor cells resulted in altered SALL4 Loss of 53BP1 restores HR in Brca1-mutant cells 9–11, desensitizing them to PARPi. The minimal focus-forming region of 53BP1 (53BP1-FFR) required for localization of 53BP1 to DSBs includes an oligomerization domain, a tandem Tudor domain12, and the ubiquitin-dependent recruitment (UDR) motif13,14. The Tudor domain binds the dimethylated lysine 20 of histone H4 (H4-K20me2)15 while UDR binds the mono-ubiquitylated lysine 15 of histone H2A14. In response to DSBs, ATM phosphorylates 53BP116,17 and also initiates a signaling cascade which leads to and Sanger sequencing to confirm mutations. We did expression studies in human fibroblasts from one individual by real-time PCR and western blot analysis, and in mouse tissues by immunohistochemistry and real-time PCR. interesting implication of these findings is the overlap in gene expression changes between effects of Aramchol and those inhibiting EMT, including hedgehog, which has been implicated in hepatic fibrosis through its effects on HSCs. EMT has largely been studied in neoplasia, but its contribution to organ fibrosis is unproven. Although EMT is not likely to be a major source of fibrogenic cells in hepatic fibrosis, the genetic similarities further reinforce the broad impact of Aramchol on HSC phenotype and function. Although the findings support and the enhanced activity was repressed by Dax1 in HEK293 cells (Fig. 7A). Similarly, promoter activity was stimulated by Esrrb and the activity was suppressed by Dax1 in A3-1 ES cells (Fig. 7B). Unlike the case of HEK293 cells, Dax1 promoter activity was suppressed by Dax1 itself in A3-1 ES cells, indicating that Dax1 represses endogenous Esrrb transcriptional activity. Also, enhancer activities of ERRE2 and ERRE4 regions of the Esrrb gene, where Esrrb directly binds, were repressed by overexpression of Dax1 in ES cells (Fig. 7C and D). These\n",
            "[0.5750338]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which kinases does baricitinib inhibit?\n",
            "Refined Query: Baricitinib is a Janus kinase (JAK) inhibitor;  however,  specifying which JAK isoforms (JAK1, JAK2, JAK3, TYK2) it inhibits with greatest potency and selectivity is crucial for understanding its mechanism of action and therapeutic effects, and potential side effects.  Therefore,  a precise answer requires detail on the relative inhibition strengths against each isoform.\n",
            "\n",
            "Combined Answer: that future studies should incorporate functional outcomes such as visual acuity, quality of life and motor function, since these morbidities are more common than mortality.(19) Therefore, the activity of selumetinib is best evaluated in the context of toxicity, functional outcomes and QOL. As a MEK-1/2 inhibitor, selumetinib has the benefit of avoiding the adverse event of paradoxical activation of the MAPK pathway seen when BRAF-KIAA1549 aberrant pLGG tumors are treated with direct BRAF inhibitors.(30) Overall, the toxicity profile of in the presence or absence of FL using the advanced ERK phospho-T202/Y204 detection system. Similar to our initial findings, this assay showed that while the presence of FL attenuated the effects of quizartinib, it did not affect those of gilteritinib (Figure 4B). Given that Fangli et al reported that activation of the MAPK pathway plays a crucial role in FL-dependent resistance to FLT3 inhibitors in FLT3wt and FLT3-ITD co-expressing 32D cells [26], we investigated whether trametinib, a potent and selective MEK inhibitor, recovers the efficacy through a tandem duplication resulting in a KIAA1549-BRAF fusion or an activating point mutation, BRAFV600E.(18) Approximately 80–90% of pilocytic astrocytomas (PA), the most common pLGG, harbor the KIAA1549-BRAF fusion whereas BRAFV600E mutations are identified in approximately 10–20% of all pLGG.(19) Numerous drugs that target the MAPK pathway have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The role in FL-dependent resistance to FLT3 inhibitors in FLT3wt and FLT3-ITD co-expressing 32D cells [26], we investigated whether trametinib, a potent and selective MEK inhibitor, recovers the efficacy of quizartinib in the presence of FL. We confirmed that treatment with trametinib to inhibit the MAPK pathway abolished the FL-dependent resistance to quizartinib (Figure 4C and Supplementary Figure 2). Therefore, these results indicate that the inhibitory effect of gilteritinib on the FLT3wt-MAPK pathway is crucial for overcoming FL-dependent of different ITD insertion sequences. Therefore, future studies should examine the efficacy of gilteritinib in the presence of FL using primary AML cells with various ITD mutations. Tyrosine kinase inhibitors are classified into 2 types based on their affinity to receptors. Type I inhibitors such as gilteritinib, midostaurin, and lestaurtinib bind to both the active and inactive forms of FLT3, while type II inhibitors such as quizartinib bind only to inactive FLT3. However, given that both type I and II inhibitors are affected by FL—with the selumetinib, MAPK pathway, BRAFV600E mutation and KIAA1549-BRAF fusion was undertaken. No date restrictions were employed. The data quality was robust and consistent verifying that abnormal Ras-MAP kinase-signaling is the most common genetic aberration in pLGG and that targeting of this pathway in cell lines and animal models led to tumor regression. Phase I clinical trials in both children and adults supported safety and preliminary efficacy of selumetinib, a non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. These to both the active and inactive forms of FLT3, while type II inhibitors such as quizartinib bind only to inactive FLT3. However, given that both type I and II inhibitors are affected by FL—with the exception of gilteritinib—we propose that selectivity against FLT3wt and FLT3-ITD may be more important than the inhibitors’ classification type. The crystal structure of the complex formed between FLT3 and gilteritinib was obtained using the kinase domain of FLT3wt, including the JMD, which has been reported to bind to the active site of FLT3 and inhibitors.8,34 However, as depicted in Figure 7, the R-UMSCC-1 and R-Cal33 resistance models demonstrated only modest, if any, upregulation of Bik when treated with either carfilzomib alone or vorinostat alone. In contrast, co-treatment of the cells with carfilzomib and vorinostat resulted in markedly enhanced upregulation of Bik relative to that seen with either agent alone. To determine whether Bik upregulation was important for synergism by the drug combination, R-Cal33 cells were transfected with a nonspecific siRNA or with siRNA directed Phase I clinical trials in both children and adults supported safety and preliminary efficacy of selumetinib, a non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. These data led to the development of this phase II efficacy trial of selumetinib in children with recurrent, refractory or progressive pLGG. have been developed. Selumetinib (AZD6244, ARRY-142886) (Wilmington, DE, USA) is a selective and potent orally-available non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. The Pediatric Preclinical Testing Program showed that selumetinib induced complete regression in a BRAFV600E xenograft glioma model.(20) Recently, the Pediatric Brain Tumor Consortium (PBTC) completed a phase I trial in 38 children with recurrent, refractory or progressive pLGG establishing the recommended phase II dose (RP2D) as 25 mg/m2/dose twice\n",
            "[0.6805323]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there evidence to suggest that triiodothyronine has neuroprotective properties in traumatic brain injury?\n",
            "Refined Query: Research exploring the neuroprotective effects of triiodothyronine (T3) following traumatic brain injury (TBI) is needed.  Does existing evidence, from in vitro, in vivo, or clinical studies, suggest T3 can mitigate neuronal damage, improve functional outcomes, or reduce secondary injury processes after TBI?\n",
            "\n",
            "Combined Answer: be considered euthyroid (Palha et al., 1994, 2000; Palha, 2002). However, this did not appear to correspond to the earlier data showing that choroid plexus-derived TTR was involved with movement of T4 from the blood into the brain (Dickson et al., 1987; Schreiber et al., 1990; Chanoine et al., 1992; Southwell et al., 1993). Soon thereafter, the regulation of neural stem cell cycle in the subventricular zone of adult rodent brain was shown to be dependent on TRα/TH by influencing both cell proliferation and apoptosis (Lemkine et al., 2005). entry into the brain. However, it has been shown experimentally that there is no increase in BBB permeability during an aura phase of migraine and there is no disruption of the BBB during a glyceryl trinitrate-triggered migraine attack (47,48). moves T3 into the brain? What could have been the selection pressure for the change to TTR from distributing T3 to distributing T4? One possibility could be a greater level of control, requiring an additional level of regulation (i.e., deiodination of T4 to T3) at the target site. For example, different regions of the brain generate different proportions of T3 by local deiodination (van Doorn et al., 1985). Two features that distinguish mammalian brains from non-mammalian brains that are regulated (at least in part) by thyroid hormones are the is low, a central effect cannot be definitively ruled out. For many neurodegenerative diseases, monoclonal antibodies are being developed suggesting that they can act centrally to mediate their effects (44–46). It has been hypothesized that a migraine attack could potentially disrupt the blood-brain barrier (BBB), allowing a mAb entry into the brain. However, it has been shown experimentally that there is no increase in BBB permeability during an aura phase of migraine and there is no disruption of the BBB during a glyceryl symptoms. The mechanisms of action of preventative medication appear to reverse this hypersensitivity either through multiple re-uptake inhibition (AMI) or alteration of channel function and neurotransmission (TPM). If high frequency headaches are sustained, this increased hypersensitivity may result in long-term changes in neuroanatomy, neurophysiology, and psychological response patterns. Neuroimaging studies have demonstrated altered brainstem appearance with iron deposition as the presence of frequent migraine persists over time(23). synthesis by the choroid plexus was involved in the movement of TH from the blood into the CSF were published in 1987. 125I-T4 was injected into the blood of rats and was detected in various brain structures: initially it accumulated in the choroid plexus to ~250% the level in blood. Thereafter, 125I-T4 accumulated in the CSF, after which it began to appear in the cortex and striatum of the brain. However, when the analogous experiment was repeated using 125I-T3, there was no specific accumulation of 125I-T3 in the choroid plexus. This was of T3 by local deiodination (van Doorn et al., 1985). Two features that distinguish mammalian brains from non-mammalian brains that are regulated (at least in part) by thyroid hormones are the corpus callosum which is heavily myelinated, and the highly developed cortex. The point here is that mammals may be the exception rather than the rule, when it comes to modes of TH entry into the CNS, so we should not just consider mammalian data. Furthermore, we have seen examples between eutherian species, of significant differences in TH transmembrane head trauma while on treatment, with hemorrhage of a central nervous system hemangioblastoma, ultimately resulting in patient death. An additional patient who demonstrated progression in a central nervous system hemangioblastomas after two years of treatment also developed a central nervous system bleed after treatment discontinuation while awaiting surgical intervention. The patient underwent resection, followed by full recovery. No additional major toxicities were observed in this patient population. With 31 patients accrued, seven treatment the short term differentiation assay in N2B27 medium, we found that both ApcNN and their Tcf3-rescued counterparts retain expression of the pluripotency markers Nanog while fail to express the early differentiation markers Fgf5 (Figure 3E). Hence, constitutive Wnt signaling prevents differentiation in a short-term assay despite the ectopic Tcf3 expression. We then asked whether rescuing Tcf3 expression in ApcNN cells could affect the neural differentiation potential of these cells. To this aim, we applied the in vitro neural differentiation regulation of neural stem cell cycle in the subventricular zone of adult rodent brain was shown to be dependent on TRα/TH by influencing both cell proliferation and apoptosis (Lemkine et al., 2005). Consequently, it was hypothesized that if TTR was involved in the delivery of THs to the neural stem cell niche, then this population of cells in TTR null mice would be affected. Indeed, TTR null mice were shown to have reduced apoptosis of neural stem cells in the subventricular zone compared to wildtype mice. Furthermore, the level of apoptosis\n",
            "[0.6949599]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Lysine-specific demethylase 1 (LSD1) a critical regulator of hematopoiesis?\n",
            "Refined Query: Investigate the role of Lysine-specific demethylase 1 (LSD1) in hematopoietic stem cell maintenance, differentiation, and proliferation.  Determine if LSD1's enzymatic activity is essential for normal blood cell development and whether its dysregulation contributes to hematological malignancies.\n",
            "\n",
            "Combined Answer: of these complexes facilitate the LSD1 demethylase enzymatic activity on the chromatin template and therefore, enhance its repressive function (39). LSD1 regulates a variety of target genes that are required for cell survival, growth, and differentiation through its ability to modulate promoter chromatin structure (38, 40). Dysregulation of LSD1 function has been associated with genome instability and tumor metastasis (37, 40, 41). Interestingly, knock down of LSD1 in hematopoietic progenitors impairs differentiation of multiple hematopoietic LSD1 is a lysine-specific histone demethylase that suppresses gene expression by converting dimethylated H3K4 to mono- and unmethylated H3K4 (18). LSD1 has been implicated in hematopoietic development and differentiation by its ability to activate or repress gene expression. It associates with hematopoietic specific repressors Gfi-1, Gfi-1b, and affects erythroid, megakaryocytic, and granulocytic differentiations (31). It is also shown to contribute to the activity of the Blimp-1-dependent repression complex during plasma cell differentiation status (17). LSD1 is the first of several protein lysine demethylases discovered. It specifically removes histone H3K4me2 to H3K4me1 or H3K4me0 and functions as a transcriptional co-repressor (18, 19). Interestingly, LSD1 also appears to act as a central regulator for HSPC proliferation and differentiation. In a conditional gene knockdown model, LSD1 reduction was found to expand BM progenitor numbers by enhancing their proliferative behavior (20). Additionally, knockout of LSD1 resulted in derepression of stem and progenitor cell gene Histone Lysine-specific Demethylase 1 (LSD1) Protein Is Involved in Sal-like Protein 4 (SALL4)-mediated Transcriptional Repression in Hematopoietic Stem Cells - PMC studies further addressed that LSD1 plays a critical role in inhibiting HSPC gene expression programs and restraining progenitor proliferation, and LSD1 deficiency resulted in severe granulocytic and erythroid differentiation (20, 21). We report that reduction of LSD1 stimulated the HSPC subpopulation from cultured bone marrows cells and preserved their primitive cell phenotypes (Fig. 6), reinforcing that LSD1 may act as a key controller for HSPC proliferation and differentiation. One function of LSD1 in HSPCs may be to contribute not only to demethylase LSD1 in erythroleukemia cells. LSD1 removes the methyl group from histone H3 lysine 4 of the TAL1 target genes and restricts TAL1 function in erythropoiesis (13). Upon induced erythroid differentiation, LSD1 may be released from the TAL1 complex and allow it to function as an activator, presumably recruiting coactivators for activating erythroid transcription programs (21) (Figure 7). Although the dramatically increase in hSET1 recruitment alone may be attributed to the elevation of H3K4me2 levels at the P4.2 promoter, The PKA strong deacetylase and demethylase activities (Figs. 2C and 3E), the difference of these complexes in regulating TAL1 and LSD1 functions in normal or malignant hematopoiesis is currently unknown. Nevertheless, protein–protein interactions between LSD1 and its associated components control its enzymatic activity and substrate specificity. It is possible that the unknown components in the TAL1/LSD1 complex may be specifically required for controlling the action of TAL1 or LSD1 during hematopoiesis. The deletion of LSD1 perturbs hematopoietic accompanied by a reversely changed histone 3 dimethylated lysine 4 at the same promoter regions. Finally, shRNA-mediated knockdown of LSD1 in hematopoietic precursor cells resulted in altered SALL4 downstream gene expression and increased cellular activity. Thus, our data revealed that histone demethylase LSD1 may negatively regulate SALL4-mediated transcription, and the dynamic regulation of SALL4-associated epigenetic factors cooperatively modulates early hematopoietic precursor proliferation. The stem cell protein SALL4 plays a critical role in hematopoiesis by regulating the cell fate. In primitive hematopoietic precursors, it activates or represses important genes via recruitment of various epigenetic factors such as DNA methyltransferases, and histone deacylases. Here, we demonstrate that LSD1, a histone lysine demethylase, also participates in the trans-repressive effects of SALL4. Based on luciferase assays, the amine oxidase domain of LSD1 is important in suppressing SALL4-mediated reporter transcription. In freshly isolated However, it remains unknown how TAL1/LSD1 interaction is regulated during hematopoiesis. During hematopoiesis, pluripotent HSCs are associated with both H3K4me3 and H3K27me3 to form so-called “bivalent domains” that facilitate differentiation into specific lineages by changing the relative level of specific modification and allow lineage-specific genes to be rapidly transcribed or vice-versa (32–34). LSD1 is the first identified histone lysine-specific demethylase involved in removing mono- or dimethylated H3K4 (35). As a putative\n",
            "[0.71087307]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is K-63 linked protein ubiquitination related to proteasomal degradation?\n",
            "Refined Query: Does K63-linked polyubiquitination, a non-canonical ubiquitination type,  influence protein degradation via the proteasome, or does it instead regulate other cellular processes?\n",
            "\n",
            "Combined Answer: example, Pta1 phosphorylation by CKII and dephosphorylation by Glc7 modulate its function in poly(A) addition (16). Similarly, it has been reported that the sumoylation of Symplekin and/or CPSF-73 affects the assembly and the activity of the cleavage and polyadenylation complex (44). Ubiquitination of the splicing complex controls the assembly and disassembly of the spliceosome (3), suggesting a common regulatory theme for complexes mediating multistep reactions. In summary, we have shown that the N terminus of Pta1 is important for CTD Ser5-P in polyadenylation (Tian, 2005). These U-rich or U/G-rich elements serve as the binding sites for the cleavage stimulation factor (CstF). In addition, some auxiliary elements upstream of the PAS and downstream of the cleavage site may enhance the polyadenylation process (Tian, 2005). Due to the interactions between these cis elements and polyadenylation factors, alternative cleavage sites can be formed for a pre-mRNA, resulting in more than one mRNA transcript from a single pre-mRNA containing 3′ untranslated regions (3′ UTRs) of different [5]. The activity of p53 is tightly regulated by post-translational modifications that affect its cellular localization and ability to bind DNA consensus sequences [6,7]. However, p53 is principally regulated by its high rate of turnover and degradation mediated by the E3 ubiquitin ligase, MDM2 (mouse double minute 2), which catalyzes p53 ubiquitination and subsequent degradation by the proteasome [7–9]. Evidence for the importance of this pathway is the embryonic lethality of MDM2 knockout mice and their rescue by knocking out p53 [10,11]. close variant). This hexamer is called the polyadenylation signal (PAS) and it usually appears 10–30 bps upstream of the cleavage site (Tian, 2005). The PAS serves as a binding site for the cleavage and polyadenylation specificity factor (CPSF). U-rich or U/G-rich elements located 20–40 bps downstream of the cleavage site are also involved in polyadenylation (Tian, 2005). These U-rich or U/G-rich elements serve as the binding sites for the cleavage stimulation factor (CstF). In addition, some auxiliary elements upstream of the PAS and fifth most significant motif, PRDM1, which is an important developmental regulator in the B-cell and T-cell lineages and is required for the secretory pathway in B-cells (Martins and Calame 2008). PRDM1 activity increases, like that of IRF, across the entire time course, and these two regulators appear to share many of their predicted targets, including type 1 interferon pathway genes, the immunoproteasome (Seifert et al. 2010), ubiquitin conjugating enzymes, antigen peptide transporters, and MHC class I genes. These targets suggest that the writes all three methylation states at H3K36 whereas in mammals, each state of methylation is laid down by distinct enzymes suggesting extensive regulation of K36 methylation and its importance throughout evolution (Morris et al. 2005; Wagner and Carpenter 2012). Enzymes that modify K36 have been associated with various cancers. For example, SETD2 (the only enzyme that performs K36me2 to me3 modification) is mutated in renal carcinoma and breast cancer (Duns et al. 2010; Newbold and Mokbel 2010), and NSD2, which generates K36me2, has been 2014; Jha and Strahl 2014; Pai et al. 2014; Pfister et al. 2014). H3K36me3 may promote DNA repair pathways such as mismatch repair since H3K36me3 recruits the mismatch recognition complex hMutSα onto chromatin through association of the hMSH6 PWWP (Pro-Trp-Trp-Pro) domain with H3K36me3 (Li et al. 2013). H3K36 modification (methylation or acetylation) may also impact the choice of DNA repair pathway between nonhomologous end-joining (NHEJ) and homologous recombination (HR) (Pai et al. 2014), and H3K36 methylation status has also been implicated Figure 6). Previously, it was not possible to characterise why cells die in the absence of Mrc1 and Ctf4. To circumvent this problem, we made a strain in which the Ctf4 protein is fused at its amino terminus to the heat-inducible degron (Dohmen et al, 1994; Labib et al, 2000), allowing us to inactivate Ctf4 in a conditional manner. Control cells, mrc1Δ cells, and the ctf4-td strain (td, temperature sensitive degron) were all able to grow at both 24 and 37°C in the presence or absence of the Ubr1 E3 ubiquitin ligase that induces ubiquitylation for interactions with the nuclease Ysh1) and promotes a Pta1 conformation (Form B) that favors cleavage and polyadenylation. The absence of Ssu72 leads to a different conformation (form A) that is inactive for 3′-end processing. Forming and breaking of the Pta1-Ssu72 contact may also work in concert with posttranslational modifications of Pta1. For example, Pta1 phosphorylation by CKII and dephosphorylation by Glc7 modulate its function in poly(A) addition (16). Similarly, it has been reported that the sumoylation of Symplekin and/or CPSF-73 end joining Ku complex, pKu70 and 80. In addition, Rqh1 (homolog of human BLM) DNA helicase and its two interacting partners, the topoisomerase Top3 and Rmi1, were Pfh1-associated. This highly conserved heterotrimeric complex has multiple functions, but is best known for suppressing DNA damage at hard-to-replicate sites, such as converged forks [63] and/or collapsed replication forks—functions relevant to those of Pfh1. Finally, six subunits of the 26 subunit RNA polymerase III complex were Pfh1-associated with high confidence (Rpc1, 2, 3, 4,\n",
            "[0.66571295]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Could transcription factors act as cell-cell signalling molecules?\n",
            "Refined Query: Transcription factors, typically intracellular regulators of gene expression, could potentially function as cell-cell signaling molecules under specific conditions.  This raises the question of their secretion mechanisms, extracellular stability, and the presence of specific receptors on target cells capable of mediating their signaling effects.\n",
            "\n",
            "Combined Answer: The precise spatial and temporal regulation of gene expression remains poorly understood despite an increasing number of species with nearly complete genome sequences available. Proteins which regulate the expression of genes by binding to specific DNA sequences in the vicinity of their targets have been termed transcription factors (TFs). The nucleotide sequences of observed binding sites generally display a considerable variation, which may cause difficulties in the description of binding preferences using sequence motifs. Recent benchmarking Transcription factors (TFs) are proteins that regulate the expression of genes by binding the DNA at their regulatory elements (promoters or enhancers) and either preventing or facilitating the recruitment, in eukaryotes, of the transcription preinitiation complex (PIC). The PIC in turn recruits RNA polymerase II (Pol II) to the transcription start site (TSS) to synthesize an RNA transcript. This is a primary mechanism for the regulation of gene expression in response to environmental stimuli or developmental programs. Promoters must integrate Most transcription factors (TFs) belong to protein families that share a common DNA binding domain and have very similar DNA binding preferences. However, many paralogous TFs (i.e. members of the same TF family) perform different regulatory functions and interact with different genomic regions in the cell. A potential mechanism for achieving this differential in vivo specificity is through interactions with protein co-factors. Computational tools for studying the genomic binding profiles of paralogous TFs and identifying their putative The developmental program that generates a complex organism such as a human is executed via gene regulatory networks. Interactions between transcription factors (TFs) and target sites are the main edges of such networks as the regulatory output of such interactions determines the expression levels of target genes at a particular time point during development, in a given tissue and under specific conditions. The human genome contains hundreds of thousands of experimentally documented transcription factor binding sites (TFBSs) and perhaps a of these studies, MARA successfully inferred key regulators and their regulatory interactions ab initio. The applications in this work not only further confirm that in systems where key regulatory interactions are already known, ISMARA successfully infers them, but it also provides a large collection of novel regulatory predictions across different systems in human and mouse, e.g., novel regulators that are disregulated in cancers, novel regulatory interactions in the inflammatory response, and the core regulatory circuitry involved in and bystander genes is also uncorrelated in a cell differentiation time course. Furthermore, we have provided support for the hypothesis that expressions of target genes are dependent on long-range enhancer input by showing that HCNEs having active chromatin domains are significantly associated with the expression of the target gene, consistent with being in an 'active' state and able to serve as regulatory inputs by binding TFs. The distinct response of the target genes and their dependency on long-range regulation might be explained by the being in an 'active' state and able to serve as regulatory inputs by binding TFs. The distinct response of the target genes and their dependency on long-range regulation might be explained by the distinct motif content and sequence composition of their promoters. We showed recently that GRB target genes in Drosophila differ from the neighboring genes in the type and motif content of their core promoters [7], which might explain their differential responsiveness to long-range regulation. A similar mechanism, involving the motifs we have found in a substantial number of recent studies across a wide range of mammalian systems (Summers et al. 2010; Aceto et al. 2012; Arner et al. 2012; Arnold et al. 2012b; The FANTOM Consortium et al. 2012; Hasegawa et al. 2012; Pérez-Schindler et al. 2012; Eisele et al. 2013; Meier-Abt et al. 2013; Tiwari et al. 2013a,b; Vervoort et al. 2013). In each of these studies, MARA successfully inferred key regulators and their regulatory interactions ab initio. The applications in this work not only further confirm that in systems where key regulatory sequence-specific DNA binding by repressor element-1 silencing transcription factor (REST; also known as NRSF, for neuron-restrictive silencer factor) (Fig. S8), which had been previously examined by MNase-sEq. (10). These results indicate that MPE-seq can potentially be used to detect the binding of sequence-specific factors to chromatin. CAGE tag mapping of transcription start sites across different human tissues shows that genomic regulatory blocks have unique features that are the likely cause of their ability to respond to regulatory inputs from very long distances.\n",
            "[0.37565303]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Magnetic beads has been used in numerous applications. List some coatings used.\n",
            "Refined Query: Magnetic beads, used extensively in various applications like bioseparations and diagnostics, require surface coatings to enhance their functionality.  What specific coating materials, such as polymers, ligands, or other functional groups, are commonly employed to modify the surface properties of these beads for different applications?\n",
            "\n",
            "Combined Answer: bead solution, and the beads were washed with PBS (1 mL, twice, prior to use). The supernatant was removed, and the beads were washed with 0.2% SDS in PBS (1 mL, twice), 6 M urea (1 mL, twice), and PBS (1 mL, three times); the resulting beads were eluted with 60 μL SDS loading buffer at 90 °C; 20 μL aliquots were loaded onto three separate SDS polyacrylamide gels, and subjected to Western blotting. Each membrane was immunostained with antibodies to HDAC1, HDAC2, and HDAC3 (all from Abcam), respectively, followed by antirabbit IgG–horseradish were captured by magnets (Invitrogen) and washed five times with 40x beads volume of wash buffer (2x SSC, 0.5% SDS, add DTT and PMSF fresh). After last wash buffer was removed carefully with P-10 pipette so that no trace volume was left behind. Beads are now poised for different elution protocols depending on downstream assays. the solutions from each well were transferred to separate Eppendorf tubes and centrifuged to precipitate proteins, which were then washed with cold methanol (1 mL, twice), dried, resuspended in 1 mL of 0.2% SDS in PBS, and then incubated with 0.8 mL of magnetic streptavidin beads (Invitrogen) for 2 h. The supernatant was removed from the original bead solution, and the beads were washed with PBS (1 mL, twice, prior to use). The supernatant was removed, and the beads were washed with 0.2% SDS in PBS (1 mL, twice), 6 M urea (1 mL, twice), and Santa Cruz); Oct4 (sc-5279, Santa Cruz); Dyrk1A G-19 (G2905, Santa Cruz); Sap155/Sf3b1 (D138-3, MBL); Nanog (AB5731, Milipore); β-actin (A5441, Sigma); β-tubulin (ab6046, Abcam). Lysates were loaded on 10% SDS-PAGE (BIO-RAD System), and transferred onto Immobilon-FL PVDF membrane (IPFL00010, Millipore). Blocking was performed at room temperature using LI-COR Blocking buffer (Part#927-40000) diluted 1∶1 with PBS. Incubation with the first antibody was performed overnight at 4°C. Blots were subsequently incubated with fluorescent-labeled ice cold high-salt buffer (20 mM Tris, 300 mM NaCl, 1% Triton-X100) and bound complexes were eluted from beads by boiling for 5 min at 100°C in SDS-PAGE loading buffer. To remove beads, samples were centrifuged at 13000 × g for 5 min. Samples were then analyzed by Western blotting. For input 10% of final IP sample was loaded. was diluted in ChIP dilution buffer (with 0.15% SDS) and incubated with BSA-blocked protein-A/G Sepharose beads (Amersham) and 5 µg antibody overnight at 4°C. Antibodies used in this study include: H3K4me3 (Abcam, Ab8580-50), H3K27me3 (Upstate, 07-449), H3K9me3 (Abcam, Ab8898-100), H3Ac (Millipore #06-599) Beads were washed with buffer 1 (0.1% SDS, 0.1% deoxycholate, 1% Triton-X 100, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM Hepes pH 7.6), buffer 2 (0.1% SDS, 0.1% deoxycholate, 1% Triton-X 100, 0.5 M NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM Hepes potassium acetate) were optimized for efficiency of Pfh1-GFP purification. Cell lysate was homogenized using a PT 10–35 Poyltron (Kinematica) for 3 sets of 10 seconds (30 seconds total) with 1 minute on ice in between each set. Insoluble material from the cell lysate was removed by centrifugation at 8000 rpm (9265 x g) for 10 minutes at 4°C. For immunoaffinity purification of Pfh1-GFP, the cell lysate supernatant was incubated for 30 minutes at 4°C with approximately 20 mg of M-270 epoxy magnetic beads (Invitrogen Dynal) conjugated with 50 μg old mice by negative selection using anti-CD43 magnetic beads (Miltenyi Biotec) according to the manufacturer’s protocol. 2×106 B cells were plated at a density of 1×106 cells/ml and were immediately stimulated with 30 μg/ml LPS (Sigma) plus mouse 25 μg/ml IL-4 (R&D systems). Following stimulation for either 24 h or 48 h, media was aspirated, leaving approximately 1 ml of media per well of a 6-well dish, and retroviruses were added. 6-well dishes were spun at 2000×g for 90 min at 32°C, after which viral supernatants were aspirated and fresh B with 25 μl of prewashed protein A-agarose beads at 4°C for 1 h. The beads were pelleted, and 450 μl of the lysate was transferred to a tube containing 7.5 μl of anti-myc antibody (Santa Cruz) and incubated at 4°C for 2 h. Then 25 μl of prewashed protein A-agarose-conjugated beads was added, and the mixture was incubated for 1 h at 4°C. The beads were then washed successively seven times: four times with B60 adjusted to 100 mM potassium acetate and once each with B60 adjusted to 210, 240, or 270 mM potassium acetate. The beads were boiled in HU purification of Pfh1-GFP, the cell lysate supernatant was incubated for 30 minutes at 4°C with approximately 20 mg of M-270 epoxy magnetic beads (Invitrogen Dynal) conjugated with 50 μg of in-house developed rabbit polyclonal anti-GFP [51]. Following incubation, the beads were collected and washed six times with 1ml of lysis buffer. Proteins were eluted from the beads by incubation with 40 μl of 1x LDS sample buffer (Life Technologies) by shaking for 10 minutes at room temperature, followed by 10 minutes at 70°C. Eluted proteins were alkylated\n",
            "[0.34589624]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 328.42ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1436.62ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1335.37ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1335.10ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1259.66ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which gene harbors the mutation T790M?\n",
            "Refined Query: The EGFR gene is known to harbor the T790M mutation, a common resistance mechanism in non-small cell lung cancer.  Which specific EGFR exon contains this substitution (T790M) and what are the clinical implications of this mutation?\n",
            "\n",
            "Combined Answer: of breast cancer, in two cohorts of patients: the Oslo2 cohort (Aure et al, 2014) and the larger, METABRIC dataset (Curtis et al, 2012). In line with the aforementioned lines of evidence, the lowest expression of LIMT in both cohorts corresponded to patients diagnosed with basal‐like cancer (Fig 6A and Appendix Fig S1), an aggressive tumor frequently associated with high EGFR expression and mutations in the downstream pathways (Hoadley et al, 2007; Foulkes et al, 2010). Similarly, low expression of LIMT was noted in the other aggressive patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been detected in crizotinib-resistant cancers (4, 6-10). In approximately one-third of crizotinib-resistant tumors, there is evidence of activation of bypass signaling tracts such as EGFR or c-KIT (6, 9). In the remaining one-third of crizotinib-resistant tumors, the resistance mechanisms remain to be identified. Next-generation ALK inhibitors with improved associated with high EGFR expression and mutations in the downstream pathways (Hoadley et al, 2007; Foulkes et al, 2010). Similarly, low expression of LIMT was noted in the other aggressive subgroup, HER2 enriched. In line with reduced expression in relatively aggressive tumors, low LIMT expression correlated with higher tumor grade and stage, HER2 positivity and ER negativity (Fig 6B–D and Appendix Fig S1). In conclusion and in line with the analyses of patient survival, we performed on additional cohorts, the loss of LIMT might coincide with we did exome sequencing (table 1). All mutations were novel except for the frameshift mutation, seen in the heterozygous carrier state in two of 6118 individuals sequenced for that region in the June, 2013, release of the Exome Variant Server (EVS-v.0.0.20). This server provides variant frequency data for multiple exome studies done mostly in adults with various heart and lung diseases and controls, and individual phenotypes are not available. In view of the facts that mutations in this gene have been identified as the cause of some exon-skipping approach for patients with exon 2 duplications (who represent nearly 2% of DMD patients in one large series3), out-of-frame skipping of exon 2 to induce expression of such a protein might help all patients who harbor mutations at the 5’ end of the DMD gene (up to 6% in the same cohort3). We also note that the out-of-frame strategy might be more broadly applicable to other genes with a coding region IRES, such as the tumor suppressor gene APC17. typically within one to two years. Studies of ALK-rearranged lung cancers with acquired resistance to crizotinib have identified ALK fusion gene amplification and secondary ALK tyrosine kinase (TK) domain mutations in about one-third of cases (4-6). To date, seven different acquired resistance mutations have been identified among crizotinib-resistant patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been (Qanbari et al., 2014), and in the mouse, anterior cingulate cortex TMEM132D expression correlates with anxiety-related behaviour (Erhardt et al., 2011). Finally, mutations in TMEM132D are unusually frequent in small-cell lung cancer (Iwakawa et al., 2015; Peifer et al., 2012; Rudin et al., 2012) and in pancreatic cancer (Forbes et al., 2015). Disease mutations near, or functions of, TMEM132A or C have yet to be identified, although TMEM132A is thought to promote neuronal cell survival by regulating stress-related genes (Oh-hashi et al., 2003, tracts such as EGFR or c-KIT (6, 9). In the remaining one-third of crizotinib-resistant tumors, the resistance mechanisms remain to be identified. Next-generation ALK inhibitors with improved potency and selectivity compared to crizotinib have been developed in order to overcome crizotinib resistance in the clinic. We previously evaluated the ability of several ALK TKIs (TAE684, AP26113, ASP3026 and CH5424802) to inhibit ALK activity in models harboring different ALK secondary mutations (6, 11). These studies revealed variable sensitivity to downregulate the respective transcript (Fig EV3E, see Materials and Methods). Consistent with the observations made with siRNAs and with overexpression of LIMT, MCF10A cells stably expressing shLIMT displayed remarkably increased migration and invasion relative to control cells (Fig 3A and B). Taken together with the ability of EGF to decrease expression of LIMT (Fig 2A), the migration and invasion results proposed the following scenario: EGF treatment downregulates LIMT, an inhibitor of cell migration and invasion, thereby enhancing motility sequences in H3F3A and H3F3B, and R and V substitutions can be achieved with single point mutations. Similarly, G34R or V substitutions could be achieved by a single point mutation of any of the H3.1 genes, so other factors must determine the prevalence of H3F3A mutations in the tumors. G34 mutation is associated with global DNA hypomethylation, which is particularly pronounced in telomeric regions (Sturm et al. 2012). No G34R/V mutations were found in DIPG tumors, and the median age of G34 mutant tumor occurrence was older than for K27M\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.45ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1411.27ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1284.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1309.82ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1259.58ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is Tn-seq?\n",
            "Refined Query: Tn-seq, or transposon sequencing, is a high-throughput technique used to identify genes essential for bacterial growth or other phenotypes.  It involves random insertion of transposons into a bacterial genome, followed by sequencing to determine the location of insertions and correlating them with fitness.  This reveals genes where insertions are underrepresented, indicating essentiality.\n",
            "\n",
            "Combined Answer: from HITS gGmbH. We thank Rajesh Kumar Gottimukkala from Life Technologies for valuable comments and useful discussions. This article has been published as part of BMC Bioinformatics Volume 14 Supplement 11, 2013: Selected articles from The Second Workshop on Data Mining of Next-Generation Sequencing in conjunction with the 2012 IEEE International Conference on Bioinformatics and Biomedicine. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcbioinformatics/supplements/14/S11. Tn5, a prokaryotic transposase, on small numbers of unfixed eukaryotic nuclei would interrogate regions of accessible chromatin. Here we describe Assay for Transposase Accessible Chromatin followed by high-throughput sequencing (ATAC-seq). ATAC-seq uses Tn5 transposase to integrate its adapter payload into regions of accessible chromatin, whereas steric hindrance less accessible chromatin makes transposition less probable. Therefore, amplifiable DNA fragments suitable for high-throughput sequencing are preferentially generated at locations of an independent analysis of sequences derived from ChIP-seq data within repetitive and within non-repetitive genomic sequences, in order to avoid incorrect conclusions on general properties of binding sites. S2) (Abedin and King, 2008; Nichols et al., 2012). Profile-versus-sequence and profile-versus-profile comparisons of this conserved repeated pattern allowed the identification of three consecutive repeated regions, each of which independently yielded statistically significant E-values of sequence similarity with the same fold, the bacterial immunoglobulin-like (BIG) domain (Mei et al., 2015; Ptak et al., 2014). HHpred searches against the PDB70 profile database. (Söding et al., 2005) using TMEM132 repeats 1, 2 and 3 as input (corresponding to New developments in sequencing technologies (see [10-12], for example) allow whole-genome sequencing to be turned into a routine procedure, creating sequencing data in massive amounts. Short sequences (reads) are produced in huge amounts (tens of gigabytes), and in order to determine the part of the genome from which a read was derived, it must be mapped (aligned) back to some reference sequence, a few gigabases long. A wide variety of short-read alignment programmes (e.g. Bowtie [13], SOAP2 [14], REAL [15], BWA [16], Bowtie2 [17]) were reads divided by the number of RNA-Seq reads mapped within the coding (CDS) sequence. The rank transcript abundance of the top 1000 genes was computed from the total number of mapped reads per transcript. proximally associated with a given protein, and this DNA is sequenced and aligned to a reference assembly to create a genome-wide map of protein occupancy [9]. At each genome site occupied (though not necessarily bound directly) by a protein, ChIP-seq produces a tight cluster of read alignments, which can then be detected by software with high resolution. Previous ChIP-seq analyses have generally considered a single experiment at once, and have treated TF occupancy as a binary signal—present vs. absent. However, the particular strength of the AP, IS, CM, SP, and SL analyzed the RNA sequencing data. AM, SP, and KV designed and carried out the qPCR validation experiments. AM, AP, IS, CM, SR, SP, and SL drafted and edited the manuscript. All authors read and approved the manuscript. data type and subtype, N additional optional fields can be found (Attribute 5, ⋯, Attribute (4+N)). The number of the additional fields includes all the attributes of the original TCGA data [14], as well as some ad-hoc ones (e.g., in the Spljxn quantification subtype of RNA-seq and RNA-seq V2) which we added to ease the processing and analysis of these data. TCGA2BED enhances data by adding to them annotations (e.g., genomic coordinates) retrieved from well-known repositories, i.e., the NCBI Entrez Gene database We described here a new software, MBV, to rapidly ensure genome-wide matching between genotype and sequencing data. This method can be applied to a single or a collection of samples to detect a variety of issues involving mismatches between sequences and genotypes such as sample mislabeling, cross-sample contaminations and amplification bias introduced at library preparation steps. All this can be achieved for thousands of individuals in reasonable running times, therefore making MBV suitable for eQTL studies.\n",
            "[0.6884695]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is metabolic syndrome related with cardiovascular disease?\n",
            "Refined Query: Metabolic syndrome, characterized by abdominal obesity, high blood pressure, high blood sugar, and abnormal cholesterol levels, is strongly linked to an increased risk of cardiovascular disease.  This connection stems from the syndrome's contribution to atherosclerosis and other CVD risk factors.  Does the relationship represent causation, correlation, or a complex interplay?\n",
            "\n",
            "Combined Answer: of the metabolic syndrome (21). Obesity is a metabolic disorder characterized by systemic inflammation and an increased risk of developing preeclampsia. In obese individuals, adipose tissue is suggested to be a potent source of pro-inflammatory stimuli because of the ability of adipocytes to secrete the pro-inflammatory cytokines, such as TNF-α and IL-6 (21). Besides promoting inflammation, these cytokines also advance atherogenesis, the underlying pathological process in atherosclerosis (167). Atherosclerosis is an inflammatory disorder fatty acids (FFAs) (21, 165). Circulating levels of FFAs are increased in preeclampsia, contributing to insulin resistance and altered lipid metabolism in this disorder (165, 166). Several metabolic disorders are also associated with systemic inflammation and, as discussed previously, there is pathological resemblance between preeclampsia and the components of the metabolic syndrome (21). Obesity is a metabolic disorder characterized by systemic inflammation and an increased risk of developing preeclampsia. In obese individuals, adipose tissue of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes of obesity and indicate targets for therapeutic intervention. These disorders include obesity syndromes such as Prader Willi syndrome and Bardet–Biedl syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic and IL-6 (21). Besides promoting inflammation, these cytokines also advance atherogenesis, the underlying pathological process in atherosclerosis (167). Atherosclerosis is an inflammatory disorder associated with endothelial dysfunction, similar to preeclampsia, and supports the hypothesis that a disrupted immune system, specifically a pro-inflammatory bias, is associated with metabolic disorders (167). Obese individuals thus have increased susceptibility to preeclampsia during pregnancy because of an already increased inflammatory response Obesity is a complex disease that results from the interactions of a variety of hereditary and environmental factors. Heritability for obesity is high (typically 0.4 to 0.7) [1], comparable to that of other complex, polygenic diseases such as autism [2]. In most individuals, the genetic basis for obesity is complex and likely to involve the interaction of multiple genes and gene-by-environment interactions. However, there are rare examples of monogenic causes for obesity that provide insights to pathways that may account for more common causes uncontrolled severe hypertension, acute kidney injury, liver hematoma, liver rupture, and cardiac failure as well as severe complications also involving the fetus by possible abruption of placental membranes and stillbirth (5). A 12-fold increase in the risk of cardiovascular disease has been found in women with a history of preeclampsia and metabolic disease, highlighting a relationship between preeclampsia and cardiovascular disease (10). Preeclampsia is characterized by two major subtypes: the maternal subtype also known as the metabolic cytokines, specifically TNF-α and IL-6, generate widespread dysfunction of the maternal vascular endothelium that could result in hypertension (17). Increased pro-inflammatory cytokines also affect metabolic changes in preeclampsia. For instance, elevated levels of TNF-α induce insulin resistance and stimulate the adipocytes to release more free fatty acids (FFAs) (21, 165). Circulating levels of FFAs are increased in preeclampsia, contributing to insulin resistance and altered lipid metabolism in this disorder (165, 166). Several metabolic dysregulation plays a substantial role in both subtypes, the two subtypes have different etiologies and phenotypes, while the placental subtype refers to early-onset preeclampsia with an etiology of abnormal placentation under hypoxic conditions (11). The pathogenesis of preeclampsia was originally ascribed to endothelial dysfunction (12), which also plays a central role in the development of cardiovascular disease. In fact, preeclampsia shares many risk factors with cardiovascular disease, such as obesity, hypertension, insulin resistance, syndrome and microdeletion/duplication syndromes such as 1p36 and 17p11.2, in which affected patients are usually identified by additional phenotypes, such as intellectual disability (ID), dysmorphic features or other developmental abnormalities. Gaining insight into genetic causes through the study of obesity-related disorders has provided a more comprehensive picture of the mechanisms that control food intake and energy balance related to the development of obesity (e.g., SIM1). Deletions in chromosome 1p21.3 have been reported in a total of ‘Example 1’.) The TF enrichment plot (Figure 2) obtained for this set shows diabetes-related TFs among the top-ranked factors. For instance, over-expression of SRF leads to insulin resistance in skeletal muscle and is therefore considered a therapeutic target for type 2 diabetes (18).\n",
            "[0.6655183]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is there any functional association during viral replication between flaviviridae viral RNA depended RNA polymerase and viral helicase?\n",
            "Refined Query: Does the flavivirus RNA-dependent RNA polymerase (RdRp) functionally interact with the viral helicase during replication?  Are their activities coordinated, perhaps through direct protein-protein interaction or a shared substrate, to ensure efficient viral genome replication?\n",
            "\n",
            "Combined Answer: DNA replication factors. It is interesting that viruses of eukaryotic cells such as SV40 and HPV evolved a simplified form of eukaryotic DNA replication that uses a viral DNA helicase, perhaps to escape the more complex regulation of eukaryotic DNA replication forks. The use of SV40 T-antigen and HPV E1 protein might allow the viruses to dispense with many RPC components, but it is striking that both DNA helicases interact with Topoisomerase I and also with DNA polymerase α (Smale and Tjian, 1986; Park et al, 1994; Simmons et al, 1996; Clower have shown that Mrc1 is a prime candidate for a factor that couples MCM to DNA polymerase epsilon on the leading strand template (Lou et al, 2008), although this remains to be shown directly. Further characterisation of the eukaryotic replisome is likely to require new approaches and a better understanding of the interactions between the many eukaryotic DNA replication factors. It is interesting that viruses of eukaryotic cells such as SV40 and HPV evolved a simplified form of eukaryotic DNA replication that uses a viral DNA helicase, perhaps two helicases have largely non-overlapping functions, they both promote progression past naturally occurring hard-to-replicate sites. ScRrm3 acts at over 1000 sites, including RNA polymerase III transcribed genes, the replication fork barrier (RFB) within ribosomal DNA (rDNA), inactive replication origins, silencers, telomeres, centromeres, and converged replication forks [10–14]. The diverse ScRrm3-sensitive sites have the common feature of being assembled into stable protein complexes. Removal of these proteins in trans or mutation of their DNA helicase PcrA promotes fork movement through transcribed genes [6, 7]. E. coli rep physically interacts with the replicative DnaB helicase to bypass protein complexes on DNA [8]. The best-studied eukaryotic accessory DNA helicases are the two budding yeast enzymes, ScRrm3 and ScPif1, which are both members of the Pif1 family [9]. Although these two helicases have largely non-overlapping functions, they both promote progression past naturally occurring hard-to-replicate sites. ScRrm3 acts at over 1000 sites, including RNA polymerase III reason for this failure is attributed to the persistence of viral covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes during the treatment with nucleoside(tide) analogs (8, 20, 38). Without interfering with cccDNA maintenance within the infected hepatocytes, nucleosides(tides) only have a limited effect on HBV DNA replication and disease progression. Hepadnaviruses are small DNA-containing viruses that replicate their DNA genomes through reverse transcription of an RNA intermediate called pregenomic RNA (32). The DNA replication through hard-to-replicate sites, including both highly transcribed RNA Pol II and Pol III genes, requires the S. pombe Pfh1 helicase - PMC required to unwind the double helix to allow DNA polymerases access to the replication template. In addition, accessory helicases, such as the E. coli rep, dinG and UvrD proteins help the polymerase maneuver past protein complexes, RNA transcripts, and other naturally occurring impediments [1–5]. In Bacillus subtilis the essential accessory DNA helicase PcrA promotes fork movement through transcribed genes [6, 7]. E. coli rep physically interacts with the replicative DnaB helicase to bypass protein complexes on DNA [8]. The best-studied helicase is connected physically to a subset of the other replication factors to form a larger assembly called the replisome (Yao and O'Donnell, 2008). In addition to DnaB, the replisome includes the DNA polymerase that works on the leading and lagging strand templates, the primase that initiates each new DNA molecule, and the γ-complex that loads the β-clamp that serves as a processivity factor for the DNA polymerase. Interactions between the components of the replisome serve to ensure that unwinding by DnaB is coordinated with efficient DNA important roles in genome preservation whose human orthologs might have similar functions. DNA replication is accomplished by the multi-subunit replisome, a complex that is assembled at and moves bi-directionally away from replication origins. Replicative helicases, such as the Escherichia coli DnaB and the eukaryotic hexameric MCM complex, are required to unwind the double helix to allow DNA polymerases access to the replication template. In addition, accessory helicases, such as the E. coli rep, dinG and UvrD proteins help the polymerase and the replicative DNA polymerase bound to similar extents to both Pfh1-dependent and independent sites, suggesting that Pfh1 is proximal to the replication machinery during S phase. Consistent with this interpretation, Pfh1 co-purified with many key replisome components, including the hexameric MCM helicase, replicative DNA polymerases, RPA, and the processivity clamp PCNA in an S phase dependent manner. Thus, we conclude that Pfh1 is an accessory DNA helicase that interacts with the replisome and promotes replication and suppresses DNA\n",
            "[0.57021236]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are defects in recombination repair involved in carcinogenesis?\n",
            "Refined Query: Recombination repair mechanisms, crucial for maintaining genomic stability, prevent mutations.  Does the malfunction or deficiency of these mechanisms, such as homologous recombination or non-homologous end joining, contribute to the development of cancer by allowing unrepaired DNA damage to accumulate and drive carcinogenesis?\n",
            "\n",
            "Combined Answer: 46). Moreover, S. cerevisiae Mcd1p is required for wild-type radiation resistance (38), as is its candidate orthologue Rad21 in S. pombe (7, 8). The involvement of cohesion subunit proteins in DNA recombination and in repair suggests that these processes may incorporate cohesion remodeling activities in vivo. Perhaps the absence of a juxtaposed sister chromatid caused by compromised cohesion may lead to increased utilization of a homolog in recombinational DNA damage repair. This hypothesis may explain increased rates of mitotic recombination our group as well as others (36, 37) suggest that even in the presence of a functional homologous recombination path-way and a cell’s ability to conduct DNA DSB repair, the homologous recombination pathway may only be able to repair part of the additional damage introduced by PARP inhibition in homologous recombination proficient cells treated with a DNA-damaging agent, but not all and thus result in enhanced cytotoxicity. Synergy was most pronounced when rucaparib was combined with topotecan, which resulted in an increase in apoptosis, DNA chromatid caused by compromised cohesion may lead to increased utilization of a homolog in recombinational DNA damage repair. This hypothesis may explain increased rates of mitotic recombination in cohesion-deficient mutants. Although not well understood, the association between cohesion and repair-recombination pathway activities strongly suggests a role for sister chromatid cohesion regulation in many aspects of DNA metabolism. The requirement for CTF4 and CTF18 in cohesion identifies a role for these replication accessory proteins in repair DSBs, the cell preferentially uses homologous recombination, which is usually considered error proof. If the cell cannot initiate homologous recombination, as is the case with BRCA1/2-mutant tumors, it resorts to more error-prone pathways, such as non-homologous end joining or single-strand annealing, which can cause gross chromosomal mutations, growth inhibition, and eventual cell death (3). Clinical studies have confirmed the activity of PARP inhibitors in patients with ovarian cancer with germline BRCA1/2 mutations (7, 8). However, P53-binding protein 1 (53BP1) is a multi-faceted double-stranded DNA break (DSB) repair protein which transcends many fields1,2 as it impacts telomere dynamics, antibody genesis and efficacy of cancer therapy. 53BP1 contributes to both the repair3 and the orientation of the broken DNA ends4 during class-switch recombination (CSR), and its loss almost completely abrogates CSR5,6. The function of 53BP1 in the choice of DSB repair pathway is manifested in breast cancer associated gene 1 (Brca1)-deficient cells. Brca1-mutant cells are deficient in of ovarian cancer coupled with the development of novel-targeted therapies are needed to improve outcomes. Patients with ovarian cancer with germline mutations in either BRCA1 or BRCA2 genes exhibit impaired ability to repair DNA double-strand breaks (DSB) via homologous recombination, and show a heightened sensitivity to inhibitors of a second DNA repair pathway, the base excision repair (BER) pathway (3). PARP is a nuclear protein that senses and binds to DNA single-strand breaks (SSB) and subsequently activates the BER pathway by recruiting may also impact the choice of DNA repair pathway between nonhomologous end-joining (NHEJ) and homologous recombination (HR) (Pai et al. 2014), and H3K36 methylation status has also been implicated in determining the timing of origin activity during DNA replication (Pryde et al. 2009). It is interesting that H3.3 is the predominant H3 used for chromatin repair in many cell types (Adam et al. 2014), and that G34 and K36 mutations are exclusively in H3.3. Further exploration of DNA damage pathways in pediatric HGG, chondroblastoma, and giant cell a BRCA2-binding partner (14). It has been proposed that EMSY plays a role in homologous recombination-mediated repair of DNA DSBs; however, this has been a controversial issue. Our results confirm a significant association between amplification of EMSY and sensitivity to rucaparib and support the hypothesis that EMSY amplification may be a mechanism of BRCA2 pathway inactivation in sporadic ovarian cancers. Recent studies have shown a distinct role for PTEN in the maintenance of chromosomal integrity and repair of DNA DSBs (33). Although it repair pathway, the base excision repair (BER) pathway (3). PARP is a nuclear protein that senses and binds to DNA single-strand breaks (SSB) and subsequently activates the BER pathway by recruiting additional repair factors (4). When PARP is inhibited, persistent SSBs become DNA DSB during DNA synthesis via collapsed replication forks (5, 6). To repair DSBs, the cell preferentially uses homologous recombination, which is usually considered error proof. If the cell cannot initiate homologous recombination, as is the case with BRCA1/2-mutant associated with PARP inhibitor sensitivity. Although deficiency of BRCC3 or BCCIP has not been associated with PARP inhibitor response so far, it is likely to be the case due to their important function in homologous recombination (31, 32). EMSY maps to the 11q13-q14 region, is commonly amplified in ovarian cancer, and has been identified as a BRCA2-binding partner (14). It has been proposed that EMSY plays a role in homologous recombination-mediated repair of DNA DSBs; however, this has been a controversial issue. Our results confirm a\n",
            "[0.6318172]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the prevalence of cystic fibrosis in the human population?\n",
            "Refined Query: What is the global and regional prevalence of cystic fibrosis, considering varying ethnic backgrounds and diagnostic capabilities?  How has this prevalence changed over time, and what factors contribute to these variations?\n",
            "\n",
            "Combined Answer: Royal Brompton Hospital (see Supplement). Full details of how each rule is parameterised can be found in the Supplement to this manuscript. As most large reference populations, such as ExAC, are not comprehensively screened for health, disease-associated alleles may be observed at low frequency. This holds true for ICCs, which can be difficult to detect even with targeted investigation, as they often manifest later in life and exhibit incomplete penetrance. We have therefore modified PM2 so as not to inappropriately discard variants seen at in Sierra Leone, one site in Guinea, and one site in the United States (Table S1 in the Supplementary Appendix, available at NEJM.org). The two treatment groups were generally well balanced, although higher percentages of children and of women were enrolled in the ZMapp group than in the group that received the standard of care alone (children, 42% vs. 22%; and women, 64% vs. 47%) (Table 1). In the cohort as a whole, the mean (±SD) time from the onset of clinical symptoms to randomization was 4.2±2.7 days. The mean PCR cycle-threshold value pairs. For the remaining criteria, we have incorporated expert disease, gene and variant-type specific knowledge and data to define thresholds for activation. This includes determination of robust disease-specific maximum frequency thresholds taking into account the genetic architecture of each disease 8 (BS1 and PM2; Supplementary Table 1), and using large disease cohorts to define both 'mutational hotspots'9 (PM1; Figure 2a) and variants observed more frequently in cases when compared with population controls (PS4). As part of this settings or in projects dedicated to the characterization of novel disease-associated genes is only beginning to be tackled. The answer to this question is pressing, because only about 25%–40% of individuals with suspected Mendelian disease who are investigated in large-scale whole-exome screening programs actually receive a diagnosis.72, 73, 74, 75 Although non-coding mutations not detected by whole-exome analysis are unlikely to be the only cause for the lack of a diagnosis in these individuals, WGS puts us for the first time in the position Families described in this study were enrolled between Dec 1, 2010, and March 1, 2013. Collaborating physicians enrolling participants obtained clinical information and DNA samples from the affected child and both parents if possible. We did whole-exome sequencing in affected individuals as they were enrolled, until we identified a candidate gene, and Sanger sequencing to confirm mutations. We did expression studies in human fibroblasts from one individual by real-time PCR and western blot analysis, and in mouse tissues by immunohistochemistry Extended homozygosity regions were identified in Affymetrix Genotyping Console Software version 3.02 using the algorithm comparing values from the user’s sample set and SNP-specific distributions derived from a reference set of 200 ethnically diverse individuals. Distribution of extended homozygosity regions in affected and healthy individuals was analyzed and visualized using custom R-script. lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific knowledge, to optimise variant interpretation and introduce consensus. Initiatives such as the Clinical Genome Resource (ClinGen)4, are working to define such disease- and gene-specific thresholds, although these are currently limited to pilot phases for specific gene-disease pairs. The introduction of guidelines, including the logic behind Considering the difficulty in enrolling newly added patients for rare diseases, this study was approved by the Institutional Review Board of National Taiwan University Hospital (Approval code: 201503025RINC; approval date: 30 March 2015) to allow the reuse of the database collected in the previous studies [14,16]. All participants signed informed consent forms, and experiments were conducted according to the approved guidelines. A total of 85 participants aged between 2 and 24 years were recruited. The DMD diagnostics of each patient was Central European families were ascertained at the Institute for Clinical and Experimental Medicine, Prague, and Saudi Arab and Filipino families at the Saudi Aramco Dhahran Health Center. Medical histories were obtained by referring consultants. Subjects CE1 and CE2 were reported as case 1 and case 2, respectively (14). might be weighted and combined to reach a classification. Studies have, however, shown that even when following the ACMG/AMP guidelines, interpretation can differ between different laboratories, with discordance in excess of 10%3. One key reason for this discordance is the structure of the ACMG/AMP guidelines, which are deliberately broad and lack specific thresholds, to allow adoption across the full spectrum of genetic disorders. As a result, the challenge to individual disease domains is to incorporate expert gene and disease-specific\n",
            "[0.6779164]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are seizures among the neurological symptoms of incontinentia pigmenti?\n",
            "Refined Query: Incontinentia pigmenti, a rare genetic disorder, presents diverse neurological symptoms.  I'm investigating whether seizures are included among these reported neurological manifestations, and if so, how frequently they occur.\n",
            "\n",
            "Combined Answer: start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, but myoclonic, partial, and absence seizures also occur.3 Neurological involvement—apart from the epilepsy, intellectual disability, and profound sensorineural hearing loss in most affected individuals—includes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a Some genes implicated in epilepsy seem capable of causing a wide variety of types of epilepsy, with greater or fewer additional neuropsychiatric features, and others have been associated with brain malformations or complex dysmorphic syndromes.31 However, phenotypic pleiotropy has rarely been reported to span the spectrum from seizures alone (eg, previous reports on TBC1D24 mutations) to multi-systemic syndromic disorders such as DOORS syndrome. These emerging findings of both genotype-phenotype complexity and genetic pleiotropy lend support the name to DOORS syndrome to account for the presence of seizures in most individuals,2 and we use this term in this Article. The case reports of 32 affected individuals were reviewed by James and colleagues in 2007,3 and five others have been published since that report.4, 5, 6, 7, 8 Seizures, present in most patients with DOORS syndrome, usually start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In the individuals without TBC1D24 mutations, eight did not have seizures and three did not have deafness (including one without seizures or deafness) and some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from progressive diffuse atrophy of the grey matter sparing the posterior fossa and early death.26 The diversity of seizure types seen in TBC1D24-associated epileptic syndromes and in DOORS syndrome is striking (table 2), and might point to a general epileptogenic mechanism. None of the patients in previous reports of TBC1D24 mutations had digital anomalies or deafness, and none of the above mutations was identified in our DOORS syndrome cohort, showing a clear genotype-to-phenotype correlation. The reason why some mutations cause DOORS syndrome All 14 boys with confirmed NHE6 mutations had epilepsy. All participants had epilepsy onset between the ages of 4 months and 3 years (mean onset was 16.4 +/− 7.86 months). Seizure types included infantile spasms (one case), tonic seizures, tonic-clonic seizures, myoclonic seizures, drop seizures (unknown whether tonic or atonic) and episodes described as staring spells in most cases. While most patients’ seizure semiologies suggested generalized epilepsy, one patient had seizures described with left facial grimacing and another had focal eye previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic findings from formal reports or clinical notes from four additional cases (Patients 1, 2, 3 and 5). While two patients reportedly had normal EEG results, the majority of EEGs were abnormal with both background abnormalities and epileptiform abnormalities. Two EEGs normalized after treatment, and one child had an initially normal EEG prior to losing the normal background. Background abnormalities included generalized slowing and absence of normal sleep features in at least one case. EEG reports mention epileptiform features including frequent genetic cause in some individuals with DOORS syndrome, and imply that testing for TBC1D24 mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also substantiate the role of this gene in various epilepsy syndromes, as is seen also with other epilepsy-related genes such as SCN1A, KCNQ2, and PRRT2. Moreover, our findings lend support to the idea of pleiotropy in epilepsy genetics because, although some mutations in TBC1D24 can cause mild epilepsy without other substantial associated features, Three patients had clinical symptoms and EEG findings suggestive of Lennox-Gastaut Syndrome according to the information available (Figure 3A). Patient 1 had tonic, tonic-clonic, myoclonic and clinical absence seizures and an EEG reporting 2–4 Hz slow spike-wave. Patient 6 had generalized tonic-clonic seizures and drop seizures as well as focal motor features with some seizures; the EEG showed bilateral frequent semi-rhythmic slow spike-and-wave discharges. Patient 11b had generalized seizures, in the form of tonic seizures and drop attacks,\n",
            "[0.6676295]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the different homologs or family members of the hedgehog proteins in mammals?\n",
            "Refined Query: In mammals, the Hedgehog (Hh) signaling pathway is crucial for development.  This pathway relies on a family of secreted signaling proteins.  My question is: what are the specific genes encoding these mammalian Hh proteins, and what are their known functional differences or similarities?\n",
            "\n",
            "Combined Answer: diversipapillatus (clade 1) gastrulation resembles the «classical» pattern found all over the animal kingdom [56]. (ii) Hedgehog and Smoothened, parts of the Hedgehog signaling pathway, are not present in C. elegans and other derived nematodes [57], but recent studies identify a bonafide hedgehog gene in the basal nematodes Trichinella spiralis and Xiphinema index [58]. (iii) C. elegans contains a greatly reduced Hox gene complement [59] while in the basal nematode T. spiralis several additional Hox genes were identified, suggesting Hox gene with several other reports that underscore substantial differences between basal nematodes and the derived model organism C. elegans. Here, four examples are given. (i) Embryogenesis of C. elegans and other derived nematodes is characterised by a unique type of gastrulation not found elsewhere in the animal kingdom while in the basal nematode Tobrilus diversipapillatus (clade 1) gastrulation resembles the «classical» pattern found all over the animal kingdom [56]. (ii) Hedgehog and Smoothened, parts of the Hedgehog signaling pathway, are not liver cells express high levels of PPARG and low levels of Hedgehog (Hh) signalling components, while activated HSCs have increased Hh signalling that represses PPARG expression.26 The reduced expression of the EMT gene set in LX-2 cells by Aramchol could be another indirect mechanism underlying the ability of Aramchol to reduced activation of HSCs by upregulating PPARG to promote a more quiescent phenotype. genetic program that broadly reduces fibrogenic activity by HSCs. Interestingly, 48 h of Aramchol reduced the expression of a gene set involved in epithelial-mesenchymal-transition (EMT; Fig. 4), a process in which epithelial cells acquire the phenotypic characteristics of mesenchymal cells, including increased motility and invasiveness. Quiescent liver cells express high levels of PPARG and low levels of Hedgehog (Hh) signalling components, while activated HSCs have increased Hh signalling that represses PPARG expression.26 The reduced is required for somite development and hedgehog signaling in zebrafish [30] as well as vascular development in mammals [31]. Transgenesis [32] and enhancer trapping [6,10] experiments in zebrafish embryos showed previously that targets and bystanders have different spatiotemporal expression patterns. Here we have shown that the expression of target and bystander genes is also uncorrelated in a cell differentiation time course. Furthermore, we have provided support for the hypothesis that expressions of target genes are dependent on long-range family motifs along with Nkx2-5, MEF2A and SRY. Most of these motifs are bound by TFs that are GRB targets themselves. Forkhead TFs are major players in development: in the absence of Foxa2, mouse embryos can not develop further than embryonic day 8.5 and they lack notochord [28]. In addition, Nkx2-5 is essential for heart development [29] and MEF2A is required for somite development and hedgehog signaling in zebrafish [30] as well as vascular development in mammals [31]. Transgenesis [32] and enhancer trapping [6,10] experiments in zebrafish interesting implication of these findings is the overlap in gene expression changes between effects of Aramchol and those inhibiting EMT, including hedgehog, which has been implicated in hepatic fibrosis through its effects on HSCs. EMT has largely been studied in neoplasia, but its contribution to organ fibrosis is unproven. Although EMT is not likely to be a major source of fibrogenic cells in hepatic fibrosis, the genetic similarities further reinforce the broad impact of Aramchol on HSC phenotype and function. Although the findings support levels, thereby attenuating activation.23 Indirectly, these findings also support the reliance of HSC activation on autophagy to generate lipids for energy to support cellular activation.4 Therefore, enhanced flux of cholesterol could deprive cells of an important energy source required to fuel the many pathways associated with HSC activation. Another interesting implication of these findings is the overlap in gene expression changes between effects of Aramchol and those inhibiting EMT, including hedgehog, which has been implicated in hepatic during the MZT. The coordinated function of multiple factors in determining chromatin structure and genome activation is not without precedent. It has recently been demonstrated that homologs of the core pluripotency factors, Nanog, Pou5f3 (previously known as Pou5f1 and Oct4), and Sox19B (a member of the SoxB1 family), act analogously to Zld during the zebrafish MZT to drive genome activation (Lee et al. 2013; Leichsenring et al. 2013). Furthermore, Pou5f3 and Sox2 are known to be pioneer factors instrumental in reprogramming differentiated We designated the putative GRB target genes as the human TFs that were under a HCNE density peak and whose orthologs were in conserved synteny with an array of HCNEs in human:zebrafish alignments. Density peaks and syntenic regions were downloaded from the Ancora Genome Browser [33]. After retrieving the target genes, we located the overlapping human-zebrafish synteny blocks. Synteny blocks were defined by joined zebrafish (danRer5) to human (hg18) high scoring (level 1) net alignments obtained from the UCSC Genome Browser [34]. We joined\n",
            "[0.80054784]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What does mTOR stands for?\n",
            "Refined Query: What is the full name of the cellular target of rapamycin, mTOR,  and what is its significance in biological processes and potential therapeutic applications?\n",
            "\n",
            "Combined Answer: are involved in RSV-initiated beneficial function in cells. mTOR (mammalian target of rapamycin) is a member of the phosphatidylinositol 3-kinase (PI3K)-related protein kinase subfamily that plays a critical role in the regulation of various cellular events such as cell growth and proliferation (5, 6). mTOR exists in two distinct complexes, TORC1 and TORC2, which differ in subunit compositions and biological functions (7). The rapamycin-sensitive mTORC1, which consists of five components, including mTOR, Raptor (regulatory-associated protein and TORC2, which differ in subunit compositions and biological functions (7). The rapamycin-sensitive mTORC1, which consists of five components, including mTOR, Raptor (regulatory-associated protein of mTOR), mLST8 (mammalian lethal with Sec13 protein 8; also known as GβL), PRAS40 (proline-rich Akt substrate of 40 kDa), and DEPTOR (DEP domain-containing and mTOR-interactive protein) (8), regulates protein synthesis and cell growth by phosphorylating downstream target proteins such as p70 ribosomal S6K1 (S6 kinase 1) and the eukaryotic RSV may indirectly promote the interaction between mTOR and DEPTOR by binding to an auxiliary protein. Similar to the latter model, rapamycin has been shown to impair the association between mTOR and Raptor through binding to FKBP12 (43). It is also possible that RSV may activate a signaling pathway that leads to a chemical modification of either mTOR or DEPTOR, thus promoting the interaction between these proteins. Further studies will be needed to test these possibilities. In summary, we have provided evidence showing that RSV inhibits at Ser473 (Fig. 2B), which is consistent with the finding that the binding of DEPTOR to mTOR suppresses both mTORC1 and mTORC2 activities (19). How RSV promotes the binding of DEPTOR to mTOR remains unknown. One possibility may be that RSV directly interacts with mTOR or DEPTOR, leading to enhanced interaction between these two proteins. Alternatively, RSV may indirectly promote the interaction between mTOR and DEPTOR by binding to an auxiliary protein. Similar to the latter model, rapamycin has been shown to impair the association between and mTOR-interactive protein) (8), regulates protein synthesis and cell growth by phosphorylating downstream target proteins such as p70 ribosomal S6K1 (S6 kinase 1) and the eukaryotic initiation factor 4E-BP1 (5, 9). The rapamycin-insensitive TORC2, which comprises six components, including mTOR, Rictor (rapamycin-insensitive companion of mTOR), mSIN1 (mammalian stress-activated protein kinase-interacting protein 1), Protor-1 (protein observed with Rictor-1), mLST8, and DEPTOR (8), functions as an Akt kinase that phosphorylates Ser473 of Akt mechanism for the life span extension and cancer prevention properties of RSV (1). Several targets of RSV such as AMP-activated protein kinase (AMPK), Akt, and NF-κB have also been identified (2–4). However, it remains controversial as to whether activation of these signaling pathways is Sirt1-dependent and whether additional targets and mechanisms are involved in RSV-initiated beneficial function in cells. mTOR (mammalian target of rapamycin) is a member of the phosphatidylinositol 3-kinase (PI3K)-related protein kinase subfamily that plays a mTOR or DEPTOR, thus promoting the interaction between these proteins. Further studies will be needed to test these possibilities. In summary, we have provided evidence showing that RSV inhibits leucine-stimulated mTOR signaling via an Akt-independent mechanism. In addition, we have demonstrated that RSV enhances the interaction between mTOR and its negative regulator, DEPTOR, thus uncovering a novel mechanism by which RSV negatively regulates leucine-stimulated mTOR signaling in cells. leucine-stimulated mTOR signaling by a mechanism independent of the AMPK signaling pathway. Consistent with this view, we found that RSV treatment markedly increased the association between mTOR and DEPTOR (Fig. 4B). Because the binding of DEPTOR to mTOR has been shown to inhibit mTOR activity (19, 44), this finding suggests that the enhanced interaction with DEPTOR could be a mechanism by which RSV inhibits insulin- and leucine-induced mTORC1 signaling. Consistent with this, suppressing DEPTOR expression levels by RNAi greatly diminished the effect of RSV on leucine-stimulated mTOR signaling was greatly reduced in cells in which the expression levels of DEPTOR were suppressed by RNAi. Taken together, our studies reveal that RSV inhibits leucine-stimulated mTORC1 activation by promoting mTOR/DEPTOR interaction and thus uncover a novel mechanism by which RSV negatively regulates mTOR activity. (Fig. 2C), suggesting the presence of a distinct mechanism underlying the inhibitory effect of RSV on mTOR. We found that leucine activated mTOR signaling in C2C12 cells but had little effect on Akt activation (Fig. 2D). In addition, suppression of PDK1/Akt activity had little effect on leucine-stimulated S6K and 4E-BP1 phosphorylation (Figs. 2E). These results suggest that inhibition of the PI3K/PDK1/Akt signaling pathway is dispensable for the negative regulation RSV-promoted of leucine-stimulated mTOR signaling. There is some evidence\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.15ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which is the most common genetic lesion among patients with Joubert Syndrome and a cerebello-oculo-renal phenotype?\n",
            "Refined Query: Joubert Syndrome (JS) presents diversely.  Focusing on those with the cerebello-oculo-renal (COR) phenotype, what specific genetic mutation or chromosomal abnormality is statistically most frequently identified as the underlying cause of this complex syndrome?\n",
            "\n",
            "Combined Answer: (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia3), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed. For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause In this study, we prospectively ascertained 12 independent pedigrees, 14 affected boys in total, with mutations in NHE6. Interestingly, in contrast to prior literature, a majority of the pedigrees enrolled exhibited de novo mutations. Through quantitative study of clinical features in probands across these independent pedigrees (Supplementary Table 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected with cerebellar atrophy and a strong signal in the ansiform lobule of the cerebellum on T2-weighted and fluid-attenuated inversion recovery MRI.24 In an Italian family, compound heterozygous substitutions (Asp147His and Ala515Val) cause familial infantile myoclonic epilepsy (FIME [OMIM 605021]) in seven individuals with normal intellect and normal MRI, except for periventricular nodular heterotopia in one individual.25 A homozygous truncating mutation (969_970delGT, Ser324Thrfs*3) in exon 3 was identified in five Turkish individuals with a results. Many recent meta-studies of the efficacy of WES in diagnosing rare genetic diseases have revealed that its yield is usually less than 50%17. As such, for unsolved cases, researchers and clinicians are increasingly turning to WGS to identify candidate causal genes; however, the expansion into the rest of the genome causes a dramatic increase in the number of candidate variants. This is in part due to difficulties interpreting the effect of variants beyond the exome. As such, supplemental information regarding dysregulated candidate 1) and through review of prior literature (Supplementary Table 2), we propose core diagnostic features of NHE6 mutations and Christianson syndrome that are present in greater than 85% of the affected males. These symptoms appear to be consistent regardless whether the mutation is inherited or de novo. These core diagnostic symptoms of CS (Table 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal between MWS patients with and without HSCR (table 1). In family 1, a heterozygous G to T transversion at nucleotide 299 in exon 2 of the PHOX2B gene and changing an arginine into a leucine in the homeodomain of the protein (R100L) segregated in patients with an autonomic nervous system disorder and the obligate carrier (fig 2). No RET gene mutation could be identified in the two patients with HSCR who inherited the PHOX2B mutation from their mother and the hypomorphic RET allele from their father (fig 2, patients III 4 and III 6). In contrast, 10, a member of the Sry family, is mutated in Dom, and its human homologue is disease causing in autosomal dominant Shah‐Waardenburg syndrome. A similar effect will be difficult to test in humans as a SOX10 mutation is rare while the penetrance of HSCR is high in carriers. However, the putative role of the RET gene could be further tested in syndromic HSCR entities frequent enough to allow the collection of large series of patients, namely cartilage‐hair hypoplasia, Bardet‐Biedl syndrome, and Down's syndrome. In relation to the MWS group of are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without TBC1D24 mutations are given in the appendix (pp 15–16). Some individuals without TBC1D24 mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In Our findings are important because they indicate that clinicians should be alert to considering mutations in NHE6 in a variety of presentations of neurodevelopmental disorders. Specifically, boys who present with new diagnoses of moderate to severe ID with seizures, language delays, and ataxia, with or without Angelman-like symptoms (AS), and with or without a pedigree consistent of X-linked ID, should be considered for NHE6 mutations. Finally, in twelve independent families we have discovered a robust allelic series of NHE6 mutations in CS. contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.54ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Depression - {'SSRIs': 0.0, 'Anxiety Disorders': 1.0}\n",
            "\n",
            " ### Clustered: {'Depression': {'Cluster 1': ['SSRIs', 'Anxiety Disorders']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2015.59ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 957.49ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: How is CBX1/M31 related to position-effect variegation?\n",
            "Refined Query: Investigate the mechanistic role of the CBX1/M31 protein in position-effect variegation (PEV).  Does it act as a repressor or activator of gene expression in heterochromatin regions, influencing the spread or boundary of PEV?\n",
            "\n",
            "Combined Answer: In addition to being associated with regions of open chromatin, another feature correlated with Zld-bound loci is occupancy by a large number of transcription factors (Li et al. 2008; MacArthur et al. 2009; Roy et al. 2010; Kvon et al. 2012). These regions have been termed highly occupied target (HOT) regions and have been identified in a wide variety of organisms (Moorman et al. 2006; The ENCODE Project Consortium 2007; Li et al. 2008; MacArthur et al. 2009; Gerstein et al. 2010; Roy et al. 2010; Negre et al. 2011). Thus it was possible that following RNAi treatment so that most cells would be arrested at the second G1/S transition, and only those sequences proximal to early activating origins would incorporate BrdU. As expected, the BrdU incorporation observed in both the control and PR-Set7 depleted cells peaked at ORC binding sites (Supplementary Figure S5). However, we found no statistical difference in early origin activation between control or PR-Set7 depleted cells (Figure 5A and B). We next considered the hypothesis that PR-Set7 depletion might impair late origin chromatin and depletion of active euchromatin, which also promotes insulation from neighbouring regions, as described above. These features are reflective of the multiple mechanisms involved in insulating target genes from ectopic regulation by elements in neighbouring domains. It is highly probable that this type of restricted topological structure arose early in Metazoan evolution as a result of strong selective pressure to prevent this. GRBs and their constituent CNEs are defined by sequence conservation alone, which is stable across all suggesting these regions are consistently insulated from neighbouring domains. The enrichment of CTCF at GRB and GRB-TAD boundaries, combined with the strength of interactions associated with GRBs, further suggests that these regions do not strongly interact with elements in adjacent domains. This is in addition to the association of GRBs with Polycomb-repressed chromatin and depletion of active euchromatin, which also promotes insulation from neighbouring regions, as described above. These features are reflective of the multiple mechanisms by these elements (bystander genes). Target and bystander genes differ with respect to their promoter structure, patterns of epigenetic modification and range of biological functions3, 14, 15. Long-range regulation depends on the interaction of a target gene promoter with enhancers that can be located up to a megabase away, which need to be brought into close physical proximity in the nucleus. Insights into interactions at this scale and their roles in development and differentiation have been provided by the development of chromatin We observed that genes of the VCSG are often clustered, suggesting their possible organization into operons for coordinated expression and regulation. For example, genes pXO1_0123 through pXO1_0125 are contiguous (Figure 2(b) and their relatively similar levels of expression suggest that they may constitute an operon. Adjacent and upstream of this putative operon is the small RNA sRNA-1, which was expressed at a very high level as compared to pXO1_0123 through pXO1_0125. For the three genes pXO1_0123 through pXO1_0125, more reads mapped to the fragmentation into smaller TADs60. The enrichment of active euchromatin at the boundaries of these regions may reflect the formation of barriers. The conservation and divergence of CTCF-binding sites is thought to play important roles in the evolution of regulatory domains25, 45. Constitutive CTCF sites are enriched at GRB and GRB-TAD boundaries, suggesting these regions are consistently insulated from neighbouring domains. The enrichment of CTCF at GRB and GRB-TAD boundaries, combined with the strength of interactions associated with GRBs, and mediating promoter–enhancer contacts are likely to be more specific. The peculiar characteristics of contacts mediated by PcG could be related to the recent observation of major differences between chromatin in the PcG repressed or poised state [62]. These super-resolution microscopy studies found the PcG chromatin to be differently packed from fully active or repressed chromatin, suggesting that the poised domains spatially exclude neighboring active regions. To summarize these results, we propose the model in Fig. 6, where the network of One mechanism by which Zld may activate gene expression is by facilitating transcription factor binding. We have previously demonstrated that early Zld binding is predictive of where transcription factors will later bind (Harrison et al. 2011), and it has been recently reported that Zld promotes binding of the transcription factors Twi, Dl, and Bcd to DNA (Yanez-Cuna et al. 2012; Foo et al. 2014; Xu et al. 2014). To determine if Zld enabled binding of these proteins by creating open regions of chromatin, we reanalyzed a published ChIP-seq data between multiple DNA binding proteins. Epigenetic modifications may reduce the accessibility of the DNA by chromatin compaction [41] and nucleosome positioning might conceivably interfere with DNA binding [42]. In agreement with a number of recent studies [43], the prediction of DNA-protein interactions solely on the basis of the nucleotide sequence or on their phylogenetic conservation yields in an inaccurate set of sites actually occupied in a specific cellular condition. Unoccupied ‘perfect’ STAT1 binding sites may include cell type\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 277.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1361.28ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1339.83ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1314.99ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which calcium channels does ethosuximide target?\n",
            "Refined Query: Ethosuximide is an anticonvulsant primarily used to treat absence seizures.  To understand its mechanism, we need to identify the specific types of calcium channels it interacts with and inhibits, clarifying whether this inhibition is voltage-gated or otherwise.  This will reveal its precise role in neuronal excitability.\n",
            "\n",
            "Combined Answer: MEDLINE (PubMed). #1 randomized controlled trial [pt] #2 controlled clinical trial [pt] #3 randomized [tiab] #4 placebo [tiab] #5 drug therapy [sh] #6 randomly [tiab] #7 trial [tiab] #8 groups [tiab] #9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 #10 animals [mh] NOT humans [mh] #11 #9 NOT #10 #12 epilepsy [mh] #13 seizures [mh] #14 (epilep* or seizu* or convuls*) [tw] #15 # 12 OR # 13 OR # 14 #16 losigame [sn] #17 losigam* [tw] #18 ADD137022 [tw] #19 LSG [tw] #20 #16 OR #17 OR #18 OR #19 #21 #11 AND #15 AND #20 Losigamone is a newer AED that has been investigated as an add‐on therapy for focal seizures. When orally administered, losigamone is well absorbed through the gastrointestinal tract and reaches a peak plasma concentration within two to three hours of administration. Its plasma elimination half‐life is approximately four to seven hours (Luszczki 2009). In two double‐blind, placebo‐controlled, add‐on studies, losigamone has shown possible effects in people with focal epilepsy (Bauer 2001; Baulac 2003). One study tested losigamone at 1200 mg/day which essentially results in blockade of D3 receptors (Freedman et al., 1994; Sautel et al., 1995; Kiss et al., 2010). In contrast, most other atypical antipsychotics have relatively lower affinities for the D3 receptor and in the presence of normal brain levels of dopamine are unable to block these receptors (Stahl, 2016). Furthermore, since D3 receptors are thought to be involved in the regulation of mood, cognition, and motivation (Gross and Drescher, 2012), compounds like cariprazine that exhibit high affinity and occupancy of these In two double‐blind, placebo‐controlled, add‐on studies, losigamone has shown possible effects in people with focal epilepsy (Bauer 2001; Baulac 2003). One study tested losigamone at 1200 mg/day or 1500 mg/day, in addition to three standard anticonvulsants, in 264 people with focal epilepsy. They observed a dose‐dependent reduction of seizure frequency: 29.3% of participants receiving losigamone at 1500 mg/day had a 50% or greater reduction in seizure frequency, as compared to 17.2% in those receiving losigamone at 1200 mg/day and 11.8% in the anhedonic-like behavior (Papp et al., 2014); however neural mechanisms underlying these effects are still unclear. In the current study, cariprazine significantly attenuated CUS-induced sucrose consumption in a novel environment in wild-type mice, demonstrating antidepressant-like activity that was comparable with the tricyclic antidepressant imipramine. Interestingly, the same antianhedonic-like actions of cariprazine were not observed in D3-KO mice, indicating that dopamine D3 receptors are required to mediate the antidepressant-like effects People of any age with focal epilepsy (defined as simple focal, complex focal or secondary generalized tonic‐clonic seizures) that has failed to respond to one or more antiepileptic drug(s) (AEDs), or refractory focal epilepsy (defined as focal seizures) according to the definition by the International League Against Epilepsy (ILAE) (Berg 2010; Kwan 2010) are eligible. is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and often require treatment with two or more AEDs (add‐on therapy). In recent years, many newer AEDs have been investigated as add‐on therapy for focal epilepsy; losigamone is one of these drugs. We wanted to know whether losigamone was an effective and safe treatment for people with focal epilepsy. Study characteristics The evidence is current to The exact mechanism of action of losigamone remains unclear. Data from experimental studies have shown that losigamone stimulates the neuronal chloride channel without directly binding to γ‐aminobutyric acid (GABA), benzodiazepine or picrotoxin receptors, but it can enhance chloride influx in the absence of GABA and potentiate the effects of GABA (Dimpfel 1995; Willmore 2001). It has also been shown to reduce the frequency of spontaneous action potentials and depress repetitive firing of neurons through a decline in presynaptic activity Epilepsy is a common neurological disorder, affecting approximately 50 million people worldwide (Banerjee 2009; De Boer 2008). In low‐ and middle‐income countries, the median incidence of the disease is 68.7 per 100,000 population, which is higher than that in high‐income countries (43.4 per 100,000 population) (Kotsopoulos 2002). It is estimated that about 30% of patients have epilepsy that is refractory to one or more agents and they are considered to be drug‐resistant. These patients often need add‐on therapy with other antiepileptic drugs GABA (Dimpfel 1995; Willmore 2001). It has also been shown to reduce the frequency of spontaneous action potentials and depress repetitive firing of neurons through a decline in presynaptic activity (Draguhn 1997). Other proposed possible mechanisms by which losigamone may decrease neuronal excitability include a decrease in persistent sodium channel current and activation of potassium channel (Gebhardt 2001; Willmore 2001).\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.41ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1486.25ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1360.44ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which proteins act as histone-like molecules in prokaryotes?\n",
            "Refined Query: Prokaryotes lack histones, but some proteins organize their DNA into nucleoid structures.  Which proteins structurally mimic the DNA packaging function of eukaryotic histones, influencing DNA compaction and gene expression in prokaryotic cells?\n",
            "\n",
            "Combined Answer: DNA (RC DNA) that is transported into the nucleus from the cytoplasm, where viral DNA replication occurs within naked capsid particles (29). A small percentage of the cccDNA is converted from double-stranded linear DNA through a nonhomologous recombination that generates sequence variations around the joint region (39). In the nucleus, cccDNA exists as an individual minichromosome with a “beads-on-a-string” structure, which is revealed by electron microscopy (2, 25). Histones as well as nonhistone proteins either bind directly to the cccDNA or Histones are proteins that package the DNA into chromosomes [1]. They are subjected to various types of modifications like methylation, acetylation, phosphorylation, and ubiquitination, which alter their interaction with the DNA and nuclear proteins, thereby influencing transcription and genomic function. These modifications form an important category of epigenetic changes, changes that help us understand why various types of cells exhibit very different behaviors in spite of their shared genome. Thus the study of histone modifications, and All eukaryotic genomes are packaged into chromatin by nucleosomes, which consist of 146 base pairs of DNA wrapped around an octamer of histones H2A, H2B, H3 and H4 (Luger et al., 1997). Chromatin is organized into transcriptionally active euchromatin and more compact inactive heterochromatin. In somatic cells of Arabidopsis, heterochromatin can be visualized as dense structures called chromocentres by DAPI staining (Fransz et al., 2006). In Schizosaccharomyces pombe and mammals, heterochromatin is demarcated by histone H3 lysine 9 methylation that lacks the C-terminal tail containing the SPKK motif (Figure 5). Because folding and self-association depend on the number of nucleosomes per array, the three types of arrays were closely matched for nucleosome saturation. We ensured that all arrays contain on average 11-12 nucleosomes per DNA molecule, i.e. every nucleosome positioning sequence repeat is occupied (Figures 5A and 5B). We also verified equimolar distribution of all histone components by SDS-PAGE (Figure 5C). We then determined the extent of self-association as a function of Chromatin is made up of nucleosomes comprising histone octamers with a stable tetrameric core of histones H3 and H4, flanked by two more labile dimers of histone, H2A and H2B. Each histone octamer is wrapped by 147 bp DNA, which facilitates the compaction of genomic DNA and regulates access to regulatory factors (Workman and Kingston 1998). Chromatin is critical for the regulation of genome stability and for transcriptional control and its importance in disease has been highlighted by the frequent identification of mutations in CMT3 expression and CHG methylation increase in heterochromatin. In vitro micrococcal nuclease digestion data showed that nucleosomes containing H2A.W protect a longer stretch of DNA (162 bp) than nucleosomes containing H2A (146 bp) (Lindsey et al., 1991), suggesting that H2A.W prevents accessibility to DNA. Consistently, we find that H2A.W represses TE expression in synergistic action with H3K9me2. The acidic patch present in the histone core region of H2A affects the folding ability of nucleosome arrays (Kalashnikova et al., 2013). For In contrast, the “replacement histone” H3.3 is expressed throughout the cell cycle, as well as in quiescent cells (Wu et al. 1982), and is largely deposited in a DNA synthesis-independent fashion by a distinct set of chaperones, proteins which associate with soluble histones and control the assembly (or disassembly) of nucleosomes from histones and DNA. Histone H3.1 differs from H3.2 by a single amino acid (Ser96 in H3.2), and H3.3 is distinguished by an additional four amino acid substitutions (Ser31, Ala87, Ile89, Gly90) (Franklin and TE expression in synergistic action with H3K9me2. The acidic patch present in the histone core region of H2A affects the folding ability of nucleosome arrays (Kalashnikova et al., 2013). For example, euchromatic H2A.Z shows higher chromatin folding than H2A, as a consequence of its extended acidic patch (Fan et al., 2004). The acidic patch in H2A.W and canonical H2A are identical, and H2A.W shows a lower folding capacity than H2A, suggesting that other domains of H2A participate to chromatin folding. Our results show that H2A.W promotes with respect to the proximal nucleosome, including 1) a strongly nucleosome avoiding group of factors with binding events stereotyped at ~180 bases from the nearest nucleosome dyad (comprising C-FOS, NFYA and IRF3), 2) a class of factors that “nestle up” precisely to the expected end of nucleosome DNA contacts, which notably includes chromatin looping factors CTCF and cohesion complex subunits RAD21 and SMC3; 3) a large class of primarily TFs that have gradations of nucleosome avoiding or nucleosome-overlapping binding behavior, and 4) a class histones are used for the formation of both cellular chromosomes and viral minichromosomes. A possible competition for these key chromosome components might slow down the assembly process of viral minichromosomes, resulting in cccDNA with fewer negatively supercoiled turns in duckling livers. In order to fully understand the functionality, including the maintenance mechanism of cccDNA, it is important to obtain information of protein components bound at specific sites of viral minichromosomes. Though various host proteins as well as HBV core\n",
            "[0.5715322]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which receptor is targeted by telcagepant?\n",
            "Refined Query: Telcagepant is a CGRP receptor antagonist.  The question seeks to identify the specific receptor subtype, within the calcitonin gene-related peptide (CGRP) receptor family, that telcagepant primarily interacts with and inhibits.\n",
            "\n",
            "Combined Answer: (1). CGRP is a 37-amino acid neuropeptide and a member of the calcitonin family, which includes calcitonin, adrenomedullin, amylin, and intermedin (2). It is expressed in both central and peripheral nervous systems, especially in dorsal root and trigeminal ganglions and their projections (3). Mammals express two isoforms, α-CGRP and β-CGRP, encoded by two distinct genes (4). The α-CGRP and β-CGRP are differentially regulated, differ in pharmacological profile, and have distinct physiological functions (5). During a migraine attack, CGRP Migraine is a chronic, recurrent neurological disorder characterized by attacks of severe pain and associated symptoms, such as nausea, photophobia, and phonophobia, with significant unmet medical need. Although the pathophysiology of migraine is still under evaluation, many data indicate a crucial role of calcitonin gene-related peptide (CGRP) (1). CGRP is a 37-amino acid neuropeptide and a member of the calcitonin family, which includes calcitonin, adrenomedullin, amylin, and intermedin (2). It is expressed in both central and peripheral described above revealed a synthetic interaction with rap1-5 in the presence of excess Ctf18p (Table 2). RAP1 encodes a transcriptional repressor-activator DNA binding protein with effects on both gene expression and telomere length; cells bearing the rap1-5 mutation exhibit a decline in telomere length at semipermissive temperatures (61). recombinational pathway that maintains the telomere and hence cell viability (60). Clonal senesence was not observed in ctf18 or ctf18 rad52 mutants after 240 generations of outgrowth (data not shown). Therefore it is likely that the short telomere phenotype is not due to an absence of telomerase. Interestingly, the synthetic dosage lethality screen described above revealed a synthetic interaction with rap1-5 in the presence of excess Ctf18p (Table 2). RAP1 encodes a transcriptional repressor-activator DNA binding protein with effects on both can lead to differences in binding to cell-associated receptors (20). The literature is limited regarding IgG subclass and its effect on PK/PD of monoclonal antibodies, and studies in this area are warranted to address this topic. The antibodies in Table 1 that modulate CGRP are of the IgG isotype and are either humanized or human antibodies. domain into the cytosol (9), where it glucosylates and inactivates small GTPases, such as Rac and Rho, which play a critical role in maintaining cellular morphology and in multiple other aspects of cellular homeostasis. One aspect of toxin function that is still poorly understood is how TcdA and TcdB bind to host cells or, more specifically, what is the nature of the receptors to which the toxins bind. For TcdA, the receptor has been proposed to consist of a membrane-associated carbohydrate based on the following lines of evidence: (i) TcdA Rfc2p, Rfc3, Rfc4p, and Rfc5p protein (M. Mayer and P. Hieter, personal communication). Recent studies indicate that RF-C homology box IV, a highly conserved β-sheet found in both Rfc1p and Ctf18p, may be required to mediate interactions between Rfc1p and PCNA (1). In addition, the region between RF-C homology boxes IV and VIII has been implicated in RF-CRFC1 subunit interactions (5). However, Ctf18p is not detected in a purified, biochemically active RF-C fraction. Together, these observations support the concept of a novel CTF18-containing of regulatory complexity characteristic of these target genes, which have the most complex spatiotemporal expression patterns of all metazoan genes [25,26]. Other striking features of the target genes are the long CpG islands that sometimes cover the whole gene (Figure 5), and a higher density of CpG dinucleotides around their most frequently used CTSS. Both the CpG island length and the existence of multiple promoters sets the target genes apart from other sets of genes, including genes in their immediate neighborhood with conserved synteny is the nature of the receptors to which the toxins bind. For TcdA, the receptor has been proposed to consist of a membrane-associated carbohydrate based on the following lines of evidence: (i) TcdA binds specifically to various galactose- and N-acetyl-glucose-containing carbohydrate molecules, including sugars known to be expressed on the extracellular surface of toxin-sensitive mammalian cells (10–16), and (ii) treatment with galactosidase abolishes TcdA binding (13–15). Evidence that the receptor for TcdB is also a carbohydrate is currently Although Ctf18p has homology to RF-C subunits, the similarity is concentrated within an approximately 250-amino-acid region containing RF-C homology boxes II through VIII and falls off sharply outside of this region. This is clearly seen in a pairwise-alignment diagram with Rfc1p from budding yeast, the most homologous RF-C subunit (Fig. 8A). Interestingly, Ctf18p is also homologous to predicted C. elegans, D. melanogaster, S. pombe, and H. sapiens proteins. While these predicted proteins have significant homology over six of the eight RF-C\n",
            "[0.80045664]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the role of photodynamic therapy for meningioma treatment?\n",
            "Refined Query: How effective is photodynamic therapy (PDT) in treating meningiomas, considering its mechanism of action, current clinical trials, and limitations compared to established treatments like surgery and radiotherapy?  What are the potential benefits and drawbacks of using PDT for meningioma management?\n",
            "\n",
            "Combined Answer: 3 centimeters (cm) in size they can develop metastatic potential(6). If hemangioblastomas become symptomatic, they need to be surgically removed to reduce the possibility of patients developing permanent neurological sequelae. Retinal hemangioblastomas require ablation to prevent irreversible retinal damage. The overall impact these multiple tests and interventions have on the patient is significant. Currently there are no established systemic therapies for von Hippel-Lindau disease(1). Prior experience with targeted therapy administered to visual stabilization in three patients but with significant concomitant toxicity(13). Systemic therapy has been more broadly tested in patients with von Hippel-Lindau disease. Multiple studies reported outcomes in individuals treated with sunitinib(14-16). A 2011 study prospectively evaluated the safety and efficacy of sunitinib in 15 patients with von Hippel-Lindau disease(17). Individuals on the study received 50 mg of sunitinib daily for 28 days, followed by 14 days off for up to four cycles, with a primary endpoint of toxicity. Grade 3 Skljarevski et al. reported on the dose dependency of 5, 50, 120 and 300 mg galcanezumab in a Phase 2 trial for the preventive treatment of migraine (98). In that study, both 120 mg and 300 mg demonstrated a statistically significant difference in the change from baseline in the number of migraine headache days compared to placebo during the overall 3-month treatment period, but 5 mg and 50 mg did not. The PK/PD simulation herein demonstrated that the average steady-state reduction in free CGRP was only 6% for 5 mg and 39% at 50 mg, but 61% at and interventions have on the patient is significant. Currently there are no established systemic therapies for von Hippel-Lindau disease(1). Prior experience with targeted therapy administered to patients with von Hippel-Lindau disease is largely anecdotal, and the results are mixed. A number of agents have been used to treat retinal hemangioblastomas. Intravitreal treatment with bevacizumab resulted in stabilization in some patients (7-9)(10). Intravitreal ranibizumab did not provide consistent benefit in a case series of five patients(11). Required follow-up assessments included clinical examination, laboratory evaluations, ophthalmologic examination and MRIs. MRIs were obtained every 2 months during the first year and every three months thereafter. Patients whose tumor achieved a radiographc response (CR or PR) as assessed locally underwent central radiographic review at the PBTC Neuroimaging center. Laboratories, including complete blood count, full chemistry panel, liver function tests and CPK were performed every 4 weeks and prior to each subsequent cycle. Echocradiogram was 3-month treatment period, but 5 mg and 50 mg did not. The PK/PD simulation herein demonstrated that the average steady-state reduction in free CGRP was only 6% for 5 mg and 39% at 50 mg, but 61% at 120 mg and 80% at 300 mg (Table 2). The overall lack of efficacy over the 3-month treatment phase at 5 mg and 50 mg may be due to the lower effects of galcanezumab on free CGRP. An important consideration for the treatment of patients with migraine is to provide early onset of effect. Our analyses indicate that the reduction of free CGRP at trough measurable von Hippel-Lindau disease-related lesion. Patients were enrolled from the USA and from Canada. Patients with negative VHL genetic testing were permitted provided they had lesions that were consistent with a von Hippel-Lindau disease-like syndrome, including multiple retinal or central nervous system hemangioblastomas. Prior systemic treatment for von HippelLindau disease was permitted, provided at least 14 days or 5 half-lives of prior drug had elapsed prior to first dose of pazopanib. Those with the following were eligible: and showed potential signs of efficacy in central nervous system and retinal hemangioblastomas, with a side effect profile consistent with that seen in other treatment settings. Pazopanib could be considered in patients with von Hippel-Lindau disease and growing lesions where surgical resection may be required in the relatively near future, or in patients with unresectable lesions where decrease in tumor size is desired. by independent radiologic review according to RECIST 1.1, were objective response (complete or partial response), duration of response, disease control (objective response or stable disease at the week 6 assessment, with imaging performed within 1 week before or 1 week after the assessment), progression-free survival, and duration of stable disease. Response data included in this article were evaluated by local investigators. MR and dual-energy X-ray absorptiometry (DXA) images were obtained at study sites during screening and every 12 months during treatment. Plain radiography (X-ray) was done annually until year 2, and then every other year. All images were evaluated by two central reviewers who compared each result to the previous result to assess changes over time (“better,” “worse,” or “the same”) and were not blinded to patients or timepoints [19]. Images were assessed for quality and comparable anatomical sites at all time points and reviewer consensus was\n",
            "[0.65069366]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Do carmustine wafers improve survival of glioblastoma patients?\n",
            "Refined Query: Does the use of carmustine wafers, in addition to standard glioblastoma treatment, demonstrably improve patient survival rates compared to standard treatment alone?  This considers both overall survival time and progression-free survival.\n",
            "\n",
            "Combined Answer: Pediatric low-grade glioma (pLGG) is the most common central nervous system tumor in children.(1) The mainstay of therapy is a complete surgical resection as this can be curative; however, children for whom a gross total resection is not achievable often require additional therapy.(1, 2) There are multiple first-line chemotherapy regimens including combinations of carboplatin and vincristine (CV), combinations of thioguanine, procarbazine, lomustine and vincristine and vinblastine monotherapy.(3, 4) Five-year overall survival (OS) with to be weighed against the potential benefits of pazopanib therapy, as well as the risks and benefits of alternate treatments, including surgery, thermal ablation, and radiation therapy. Since many patients enrolled on the study had the option to revert to observation, and did not have the immediate threat of shortened survival as would be the case in metastatic disease, the incentive to remain on an agent that caused side effects was lower than in other settings. Despite that, a number of patients chose to remain on treatment for prolonged five of these patients underwent a subsequent biopsy or resection demonstrating higher grade gliomas. These included two pontine gliomas originally classified as grade III that were upgraded to glioblastoma, a spinal glioma and a third ventricle glioma originally classified as grade II that were upgraded to glioblastoma, and a thalamic glioma originally classified as grade II that was upgraded to anaplastic astrocytoma. Given the prospective nature of this study without significant length of clinical follow‐up, the utility of assessing outcome High-grade astrocytomas [anaplastic astrocytoma and glioblastoma (GBM)] are the most biologically aggressive form of cancer and a leading cause of cancer-related mortality and/or morbidity in the pediatric years [15, 19, 22]. They account for 20 % of all brain tumors in children and occur mainly supratentorially in the cortex or thalamus or in the brainstem where they are called diffuse intrinsic pontine gliomas (DIPGs). Cortical GBM can be amenable to complete surgical resection, however, up to 85 % will die within 2 years of diagnosis [3, 15, even after therapy cessation. A large retrospective report of 4000 patients with pLGG using Surveillance, Epidemiology and End Results data revealed that the 20-year overall survival was 87±0.8%.(29) They concluded that future treatments should focus upon disease control and minimizing late effects.(29) Also, a pLGG international consensus panel recommended that future studies should incorporate functional outcomes such as visual acuity, quality of life and motor function, since these morbidities are more common than mortality.(19) Therefore, The primary study objective was to evaluate the efficacy and safety of pazopanib, with efficacy measured as objective response rate (ORR), which is the sum of complete responses (CRs) + partial responses (PRs). Secondary objectives included assessing growth rate over time in target lesions before and after pazopanib treatment, evaluating the need for surgical intervention in individuals who received pazopanib in comparison to rate prior to receipt of drug, and creating an annotated tissue resource from patients on study. All endpoints, and radiation therapy regimens, there has been no improvement in survival for children with GBM. The impediment to treatment is the invasive capacity of these high-grade astrocytomas within the brain and their inherent resistance to adjuvant therapies. In addition, permanent damage inflicted to a developing brain by current life-saving therapies severely impacts the quality of life of surviving children [4, 8, 10]. A number of recent comprehensive studies have reported differences at both the copy number and expression levels that distinguish combinations of carboplatin and vincristine (CV), combinations of thioguanine, procarbazine, lomustine and vincristine and vinblastine monotherapy.(3, 4) Five-year overall survival (OS) with chemotherapy on the most recent Children’s Oncology Group (COG) pLGG study, CCG A9952, for children without Neurofibromatosis type 1 (NF1) is excellent (86±2.2%), but the same study showed a 5-year progression-free survival (PFS) of only 45%±3.2%, emphasizing the need for alternative therapies.(3) A separate evaluation of those children on CCG A9952 with The trial was funded by a National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) PBTC U01 Grant: 2UM1CA081457 (UM1) and by the American Lebanese Syrian Associated Charities (ALSAC). ALSAC provides funding and infrastructure support for the OBDMC personnel but had no involvement in trial design, patient recruitment, data collection, analyses or manuscript preparation. CTEP provided input on study design, approved the trial and its amendments, served as the IND sponsor and reviewed the manuscript prior to submission. CTEP was but the same study showed a 5-year progression-free survival (PFS) of only 45%±3.2%, emphasizing the need for alternative therapies.(3) A separate evaluation of those children on CCG A9952 with NF1 non-randomly assigned to carboplatin and vincristine revealed a 5-year OS and PFS of 98±1% and 69±4%, respectively.(5) In addition to lower PFS outcomes, many children suffer with functional morbidities such as visual disturbances, motor disabilities, poor quality of life (QOL) and neuropsychological deficits.(6–9) Classic chemotherapy exposes\n",
            "[0.7580079]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is Dicer part of the RISC loading complex?\n",
            "Refined Query: The RNA interference (RNAi) pathway involves the processing of long double-stranded RNA (dsRNA) into short interfering RNAs (siRNAs) by the enzyme Dicer.  Does Dicer directly participate in the assembly or function of the RNA-induced silencing complex (RISC), or is its role limited to siRNA generation upstream of RISC loading?\n",
            "\n",
            "Combined Answer: (pre-miRNA), which are exported to the cytoplasm. In the cytoplasm, the pre-miRNA is further cleaved by another RNAse III enzyme Dicer into a mature miRNA and its partner strand, the miRNA* (microRNA star). The mature miRNA is defined as the strand, which is loaded into the RNA-Induced Silencing Complex (RISC) complex. Krol et al. (2) give an excellent overview on miRNA biogenesis. The mature miRNA identifies its mRNA target by binding to partially complementary sites within 3′UTRs (3), resulting in mRNA degradation and translational To control the effect of any siRNA knockdown treatment on RNA editing levels (see Fig. 6 b), we contrast editing levels of RDDs between siAPOBEC3 and siADAR samples. As mentioned earlier, JACUSA had identified 8722 RDDs in cells treated with siAPOBEC3 (siApo) of which 7953 were A→G substitutions. We classify these A→G sites as true positives if they show a drop in their editing frequency in an siADAR vs. siAPOBEC3 knockdown. As shown in Table 6, we could assess editing level changes on 7084 RDD sites that had sufficient read coverage in both consisting of the upstream or downstream region of chromosome XII (Figure 4). Transcriptional silencing in S.cerevisiae occurs at the silent mating-type loci HML and HMR, and at telomeres mediated by the SIR complex consisting of Sir2p, Sir3p and Sir4p (42). Sir2p, but not Sir3p or Sir4p, is required for silencing in the rDNA cluster region (21). Smith et al. (43) have shown that alterations in SIR2 gene dosage dramatically affect the level of rDNA silencing, suggesting that a limiting pool of Sir2p is distributed between telomeres, HM loci To knock down SCD1 in HSCs, we used a human SCD1 small interfering RNA (SMART pool: Accell SCD siRNA; Accession no.: NM_005063), or control Accell red non-targeting siRNA (red fluorescent tagged negative control), 5× siRNA buffer (300 mM KCl, 30 mM HEPES [pH 7.5] 1.0 mM MGCl2) and Accell siRNA delivery media (Horizon Discovery, CO, USA). siRNA was reconstituted in 1× siRNA buffer (made from 5× siRNA in RNase-free water) according to the manufacturer’s instructions. LX-2 cells (70,000/well) were seeded in 12-well culture plates, and when at genomic loci to mediate transcriptional silencing,36 which supports the hypothesis that compound 106 may reverse frataxin gene silencing by targeting the SWI/SNF complex. We found targets of ABPP 106 probe are also involved in RNA processing and translation. One study has shown that Drosophila small nuclear ribonucleoprotein SmD1, involved in splicing, is required for assembly and function of the small interfering RISC, suggesting the role of Drosophila SmD1 in RNAi-mediated gene silencing besides its pre-mRNA splicing activity in cytoplasmic RNA populations [14]. Moreover, RNAi is transient and often incapable of reducing targeted RNA levels beyond 50 % [15]. Finally, other elements such as enhancers or microRNA genes are not substrates for the RNAi pathway. Another approach worthy of mention is gene silencing through integration of destabilising sequences by zinc finger nucleases. Using this method, Diederichs and colleagues managed to stably reduce levels of the MALAT1 lncRNA around 1000-fold in cell clones [16]. While effective, such approaches require a homology Smith et al. (43) have shown that alterations in SIR2 gene dosage dramatically affect the level of rDNA silencing, suggesting that a limiting pool of Sir2p is distributed between telomeres, HM loci and rDNA. Therefore, we presume that the increase in silencing may have resulted from a greater localized concentration of Sir2p at the rDNA cluster. One possible mechanism for this is that more telomere-associated Sir2p moved to the rDNA. In this regard, a telomeric repeat sequence, 5′-(C4A2)6-3′ was artificially added to the split rDNA chromosome. locus was not caused by an increased amount of Sir2p in the rDNA cluster region through shortened telomere length. The fact that both silencing and rDNA recombination increased in strains ID-8 and ID-12 suggests that these are Sir2-independent events because increased Sir2 activity at the rDNA locus is expected to increase silencing, but decrease recombination. Another possibility is that an unusual rDNA structure arose as a result of the splitting, and this unusual structure affects silencing. Because the rRNA content in the strain harboring abundance of different forms of RNAPII (Additional file 1: Figure S18) and these results are largely confirmed in HiCap (Fig. 5g). These findings suggest that promoters can contact transcribed gene bodies. is not feasible [9–12]. Furthermore, doubts have been raised as to whether the observed phenotypes in knockout animals are the result of the loss of the lncRNA itself, or of an overlapping gene regulatory elements [13]. Post transcriptional RNAi approaches regularly fail for lncRNA for reasons as yet unknown, and may only be capable of acting on cytoplasmic RNA populations [14]. Moreover, RNAi is transient and often incapable of reducing targeted RNA levels beyond 50 % [15]. Finally, other elements such as enhancers or microRNA genes are not\n",
            "[0.64837617]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the Arnold-Chiari syndrome?\n",
            "Refined Query: Can you provide a concise, paragraph-length description of Arnold-Chiari syndrome, including its causes, symptoms, and potential complications?\n",
            "\n",
            "Combined Answer: 1), presenting in boys in childhood, include: non-verbal status; intellectual disability (moderate to severe range); epilepsy; truncal ataxia; postnatal microcephaly and/or attenuation in postnatal growth of head circumference; and hyperkinetic behavior. Secondary symptoms that are often present (greater than 35%) include: symptoms of autism; symptoms of Angelman syndrome (AS); eye movement problems such as strabismus; regressions (particularly loss of the ability to walk after age 10); low weight for age, and cerebellar vermis atrophy by MRI some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from DOORS syndrome (table 2). All individuals with TBC1D24 mutations had all five features making the DOORS acronym. If we stratify based on this strict definition of DOORS syndrome, TBC1D24 mutations were seen in nine of 18 families. and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular colloid bodies. Pyramidal signs were present in the upper limbs. Case 3 presented with a similar syndrome characterised by a very slowly progressing axonal neuropathy (onset in childhood), bilateral optic atrophy and pyramidal signs. This CMT6 family was originally reported as a case report in 1987 when the family members were in their middle 30s.14 All CS participants demonstrated profound developmental delays in most or all domains, including gross and fine motor, social, language and cognitive domains. All of the boys were non-verbal or had minimal words at the time of presentation to the study. A majority of CS participants had a history of hypotonia (79%). Walking was delayed in many but not all cases, with onset ranging from 1 to 3 years (mean age 20.2 months). All boys exhibited some degree of truncal ataxia with unsteady gait. We administered the Leiter-R to two probands (patients contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual disability, epilepsy and ataxia. Many had prior diagnoses of autism and/or Angelman syndrome. Other neurologic symptoms included eye movement abnormalities (79%), postnatal microcephaly (92%) and MRI evidence of cerebellar atrophy (33%). Regression was noted in 50%, with recurrent presentations involving loss of words and/or the ability to walk. Over a third of the patients (43%) were originally diagnosed with Angelman syndrome by clinicians. In this prospective study, clinical diagnostic criteria by Tan et al. 25 were utilized. Upon direct assessment, the majority of CS patients (93%) exhibit phenotypes similar to Angelman syndrome. For major criteria, all patients had ID and limited speech. Approximately 100% of patients had ataxia/unsteady gait (1 patient is currently non-ambulatory). For behavioral features, a majority were reported to have a happy disposition (100%) and unprovoked signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with TBC1D24 mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In the individuals without TBC1D24 mutations, eight did not have seizures and three did not have deafness (including one without seizures or deafness) and some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from The main clinical features of the seven patients from our two extended consanguineous pedigrees (Figure 1) are summarized in Table 1. The most significant clinical features in our patients were optic atrophy (all patients), pes cavus (six patients), and spastic paraparesis (six patients). later at the age of 9 years she had lower limb and at 11 years upper limb weakness, along with static cognitive problems and visual difficulties. The examinations at the age of 35 and 51 years were remarkably similar with only mild deterioration of her clinical features. She had no dysmorphic features, but severe bilateral optic atrophy and static but significant cognitive problems. She had a brisk jaw jerk and a pout reflex. Marked distal symmetrical weakness and wasting affecting the limbs. In contrast to her cousins, tone in her upper and brisk. Ankle and plantar reflexes were absent. She had a moderately severe thoracic scoliosis. Sensation was impossible to assess reliably due to cognition but was likely to be abnormal. As a crude estimate of visual acuity, they were able to watch television and recognise faces across the room and she could do needlework. Case 1 noted distal wasting and weakness at the age of 8, which slowly spread proximally. When he was examined (at the age of 34), he had severe muscle wasting of lower and upper limbs, bilateral optic atrophy and macular\n",
            "[0.7767732]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which trinucleotide repeat disorders are affecting the nervous system?\n",
            "Refined Query: I need more information to accurately answer the query \"Which trinucleotide repeat disorders affect the nervous system?\"  The question is too broad.  To better answer, specify if you are interested in a specific type of neurological impact (e.g., ataxia, dementia) or a specific age of onset.\n",
            "\n",
            "Combined Answer: The mutational spectrum was composed of 9 single nucleotide variants (SNVs), 2 indels and 1 CNV deletion. All mutations were protein-truncating or splicing mutations. We identified two recurrent mutations (c.1498 c>t, p.R500X; and c.1710 g>a, p.W570X). Otherwise, all mutations were unique. In our study, seven of 12 mutations (58%) were de novo, in contrast to prior literature wherein mutations were largely inherited. We also report prominent neurological, medical and behavioral symptoms. All CS participants were non-verbal and had intellectual in order to help establish initial clinical expectations for families and clinicians. Based on current studies, CS may be among the most common X-linked developmental brain disorders.1 CS has broad implications to common neurologic and behavioral syndromes including epilepsy, intellectual disability, autism, regression and hyperactivity. neuropathy beginning within the first decade. Motor impairment due to both peripheral neuropathy and spasticity typically evolved within the second decade resulting in mild gait disturbance but, as a rule, preserved independent walking even throughout the fifth decade.3 Life expectancy is not anticipated to be shortened. Notably, none of these patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the patients had cognitive impairment, and the brain MRI and MRS are typically normal except for optic atrophy. An intermediate phenotype is outlined by the three affected members from family B in the current report who display, in addition to early onset optic neuropathy and esotropia, variable degree of intellectual disability and progressive motor impairment dominated by both spastic and neuropathic features. Moreover, brain MRI is abnormal within the first decade, demonstrating thinning of the corpus callosum as well as gradually evolving T2 we and others have found that UCEs are much less likely to be deleted or duplicated via copy number variants (CNVs) in healthy individuals than would be expected by chance [2], [25], [39], consistent with their depletion from segmental duplications [2] and remarkable resistance to loss from mammalian genomes [40]. In contrast, they are enriched in 26 deletions and duplications representing 200 patients with neurodevelopmental disorders [41]. An association between UCEs and disease was also demonstrated [42] in a study that assembled a database We found a highly significant enrichment of ultraconserved elements among pathogenic imbalances causing neurodevelopmental disorders. It can be therefore suggested that these elements, or their neighbouring genes, might be considered particularly sensitive to dose imbalances. It might be argued that the positive association between clinically relevant CNVs and UCEs merely reflects that pathogenic alterations preferentially affect gene-rich regions and, as an indirect consequence, they might contain more ultraconserved elements. In accordance, Rothner, MD, The Children's Hospital, The Cleveland Clinic, Cleveland, OH; J.I. Lopez, MD, Renown Neuroscience Institute, University of Nevada, Reno School of Medicine, Reno, Nevada; R. Simmons, MD, Schenectady Neurological Consultants, Schenectady, NY; M. Sowell, MD, University of Louisville Health Sciences Center, Louisville, KY; M. Victorio, MD, Akron Children's Hospital, Akron, OH; P. Winner, MD, Premiere Research Institute, West Palm Beach, FL; M. Yonker, MD, Phoenix Children's Medical Group, Phoenix, AZ. atrophy,18 we assessed segregation of this mutation in the family. The deletion was homozygous in the affected cases, and either absent or heterozygous in the unaffected relatives (figure 3). To further investigate the presence of the mutation in patients with complex neuropathy, we sequenced the coding exons of C12orf65 in an additional cohort of 183 patients. None of the patients harboured potentially pathogenic variants. To determine whether the truncating mutation induced mRNA nonsense-mediated decay, we tested the level of expression of the notion of an involvement of repeats in gene regulation. Incidentally MER41 are specific to primates, consequently, regulatory mechanisms in the IFN-STAT pathway might fundamentally differ between primates and rodents. On a methodological aspect, the presence of large numbers of nearly identical binding sites in repetitive sequences may lead to wrong conclusions about intrinsic binding preferences of TF as illustrated by the spacing analysis STAT1 tandem motifs. Therefore, ChIP-seq data should be analyzed independently within repetitive and genes, then we can estimate that CS may affect between 1 in 16,000 to 100,000 people. By comparison, this represents approximately 10–50% the prevalence of Fragile X syndrome, the most commonly inherited form of intellectual disability. One uniform and notable feature of CS is epilepsy. Conversations with parents indicate seizure control may represent one of the leading causes of concern in the family. In the current study, we report early age of onset of epilepsy and a mixture of seizure types. Further clinical and EEG analysis of the CS\n",
            "[0.5374799]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Is hypersensitivity to DNA crosslinking agents a hallmark of Fanconi anemia?\n",
            "Refined Query: Fanconi anemia (FA) is characterized by genomic instability.  Does hypersensitivity to DNA crosslinking agents, like mitomycin C, consistently and definitively define FA, or are there other contributing factors and diagnostic criteria to consider?\n",
            "\n",
            "Combined Answer: recombination. Although 20% of the patients had germline or somatic BRCA1/2 mutations, an additional 11%, 6%, and 5% of the patients had epigenetic silencing of BRCA1, amplification of EMSY, or loss of PTEN expression, respectively. Moreover, an additional 7% of the patients had mutations in RAD51C, ATM, ATR, or Fanconi anemia genes (10). It is, however, currently not clear whether these aberrations all lead to a decrease in homologous recombination sufficient enough to cause sensitization of tumor cells toward PARP inhibitors. Indeed, the Samples from the cell synchrony were collected for FACS analysis and ChIP-qPCR at 0, 20, 40, 60, 65, 70, 75, 80, 85, 90, 95, 115, 140, and 165 min. The ChIP experiments were performed as described previously [35]. Briefly, cells were cross-linked in 1% formaldehyde at 25°C for 5 min. The chromatin was sheared to an average of ~300 bp with a Covaris E220 system. G2 phase and asynchronous cells were immunoprecipitated with anti-Myc antibody (Clontech Cat. nr 631206). The synchronous cells were divided (3/4 of sample for Pfh1-Myc and 1/4 of FANTOM4 consortium. When multiple detected probes mapped to one gene, we only considered the representative probe among them (as supplied by the microarray manufacturer), if any. We calculated the correlation of expression for each target gene and its bystander genes; we tested the significance of correlation using the alternative hypothesis that the association was positive. We also calculated the correlations of bystanders with each other for each GRB. For comparison of bystander pairs, we excluded the pairs potentially sharing a presence of UCEs might be complementary criteria of pathogenicity, that is, pathogenic CNVs tend to affect either a high number of genes or closely regulated genes near UCEs, many of them in \"gene deserts\". In turn, this complementarity can be interpreted as reinforcement for the association between pathogenic CNVs and ultraconserved elements. Another putative argument for a random association between pathogenic CNVs and UCEs might be derived from the fact that many UCEs appear clustered. However we found a similar number of isolated and highlight the possibility that some diseases associated with genomic instability involve instead, or in addition, a simple inability to cull away the normal burden of deleterious CNVs arising at a frequency that is not different from that found in healthy cells. In any case, lack of depletion of UCEs from a CNV dataset suggests that the cells contributing to the dataset may not represent the healthy state, having escaped the possible deleterious consequences of deleting or duplicating UCEs either because the mechanisms effecting such (as defined in Rhind, Chen (44)). In addition, Pfh1 binding sites were significantly associated with meiotic double strand break (DSB) hotspots, nucleosome depleted regions (NDRs), 3’ untranslated regions (UTRs), and mating type loci (Table 1). In all following association analyses, associations with p-values less than the Bonferroni multiple testing adjusted threshold of 0.003 will be interpreted as significant. cell death in cohesion-defective cells, why do viable cohesion mutants exhibit aneuploidy? One potential explanation is that adaptation of the spindle assembly checkpoint allows at least some cells with separated chromosomes to progress through mitosis. Cohesion-defective mutants are frequently isolated in chromosome loss screens. Within a collection of viable chromosome loss mutants encompassing approximately 60 genes (91), alleles of six genes required for cohesion (CTF4, CTF7, CTF18, SMC1, MCD1, and SCC2) have been identified to date. This used a p-value cutoff of 0.05 for detection, and kept only the probes detected at nine or more time-points in each replicate. Using a less stringent threshold may result in genes that are detected in few time-points, which could compromise the correlation analysis. We assigned one probe for each gene using the probe annotation provided by the FANTOM4 consortium. When multiple detected probes mapped to one gene, we only considered the representative probe among them (as supplied by the microarray manufacturer), if any. We calculated the and maintaining dosage in the genome are well studied (for examples, see [52]–[55]), and responses to dosage imbalances, flagged by improperly paired UCEs, could range from a growth disadvantage among cells to loss of individuals from a population through disease and, at the molecular level, from metabolic disruptions to deleterious mutational and epimutational changes. Intriguingly, mutation within and in the vicinity of UCEs that are no longer well paired with a homolog may predict that ultraconserved chromosomal regions might be enriched in 2004). While these factors are non-essential for viability, their absence leads to compromised sister chromatid cohesion. Several lines of evidence have linked these cohesion establishment factors to the DNA replication fork, though their specific requirement for cohesion establishment during S-phase, as opposed to cohesin loading onto chromosomes or maintaining sister chromatid cohesion, has formally been demonstrated only for the Ctf18 complex and Csm3 (Xu et al. 2007). Both Ctf4 and Ctf18 have been detected at DNA replication forks\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.52ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which are the cellular targets of imatinib mesylate?\n",
            "Refined Query: Imatinib mesylate, a tyrosine kinase inhibitor, targets specific tyrosine kinases crucial in cancer cell proliferation and survival.  What are the precise cellular proteins, particularly those aberrantly activated in certain cancers, upon which imatinib exerts its inhibitory effects?\n",
            "\n",
            "Combined Answer: Chromosomal rearrangements of ALK (anaplastic lymphoma kinase) are detected in 3–7% of NSCLCs (1, 2). These rearrangements result in constitutively active ALK fusion proteins with potent transforming activity (2, 3). Lung cancers with ALK rearrangements are highly sensitive to ALK tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to ALK kinase activity. Based on early phase studies, the multi-targeted tyrosine kinase inhibitor (TKI) crizotinib was approved by the FDA in 2011 to treat patients with advanced NSCLC the MGH051 cell line was also sensitive to crizotinib (Fig. 3B). Accordingly, phosphorylation of ALK and downstream AKT and ERK were efficiently suppressed by crizotinib and ceritinib (Fig. 3C). This data suggests that cancers with acquired resistance to crizotinib without ALK resistant mutations may remain sensitive to ALK inhibition (please see Discussion). identifies known key regulators ab initio. We also present a number of novel predictions including regulatory interactions in innate immunity, a master regulator of mucociliary differentiation, TFs consistently disregulated in cancer, and TFs that mediate specific chromatin modifications. Growth factors and their receptor tyrosine kinases (RTKs) play major roles in breast cancer progression (Hynes & Watson, 2010; Witsch et al, 2010). Of the five major breast cancer subtypes represented in the Prediction Analysis of Microarrays (PAM50) subtyping (Parker et al, 2009), the one overexpressing the RTK called HER2 and the less prevalent, the basal‐like subtype are considered highly aggressive (Perou et al, 2000). While the former is driven by an amplified HER2 gene, a fraction of the basal subtype is characterized by relatively high databases [39] generated several matches. Consistent with the presumed DNA binding function of the protein, a putative RCC1 chromatin binding motif was detected near the C-terminus (AA 869 – 886) that is not present in other known CTCFs. Commonly found post-translational modifications like N-glycosylation (6 instances), N-myristoylation (14 instances), and phos-phorylation (22 instances, including cAMP-dependent kinase, Casein kinase II, Protein kinase C, and Tyrosine kinase sites) were also predicted for tsCTCF, the latter being consistent selumetinib, MAPK pathway, BRAFV600E mutation and KIAA1549-BRAF fusion was undertaken. No date restrictions were employed. The data quality was robust and consistent verifying that abnormal Ras-MAP kinase-signaling is the most common genetic aberration in pLGG and that targeting of this pathway in cell lines and animal models led to tumor regression. Phase I clinical trials in both children and adults supported safety and preliminary efficacy of selumetinib, a non-ATP-competitive small molecule inhibitor of MAP/ERK (MEK) Kinase I/II. These ASP3026, whereas 1151T-ins conferred resistance to all next generation ALK TKIs. Ceritinib is an ATP-competitive, potent and selective next-generation ALK inhibitor (12). The kinase selectivity has been tested in a cellular proliferation assay against 16 different kinases, and aside from ALK, no inhibition below 100 nM was observed (12). In the phase I study of ceritinib in ALK-positive NSCLC, marked antitumor activity has been observed in both crizotinib-relapsed and crizotinib-naïve patients (13, 14). Based on this impressive clinical of different ITD insertion sequences. Therefore, future studies should examine the efficacy of gilteritinib in the presence of FL using primary AML cells with various ITD mutations. Tyrosine kinase inhibitors are classified into 2 types based on their affinity to receptors. Type I inhibitors such as gilteritinib, midostaurin, and lestaurtinib bind to both the active and inactive forms of FLT3, while type II inhibitors such as quizartinib bind only to inactive FLT3. However, given that both type I and II inhibitors are affected by FL—with the isoforms have been identified as essential nuclear enzymes, which potentially encourage the rapid replication of tumour cells by modifying DNA structures (Vos et al, 2011), but their expression and roles in sensitivity against anthracycline-containing regimens are controversial as ever. Most studies have focused on TOP2A and reported involvement of tumour chemoresistance to DNA-damaging agents in AML as well as other tumours (Chekerov et al, 2006; Chen et al, 2009; Coss et al, 2009). Some groups suggested no significant correlation between Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378) in the setting of crizotinib resistance. Interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of crizotinib-resistant NSCLC patients revealed that ceritinib potently overcomes crizotinib\n",
            "[0.6185912]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 278.14ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1561.32ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1391.26ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "Chemotherapy - {'Fatigue': 0.0, 'Physical Therapy': 1.0}\n",
            "\n",
            " ### Clustered: {'Chemotherapy': {'Cluster 1': ['Fatigue'], 'Cluster 2': ['Physical Therapy']}}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 1363.98ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Are psammoma bodies characteristic to meningiomas?\n",
            "Refined Query: Meningiomas are tumors known for sometimes containing psammoma bodies, which are concentrically layered calcium deposits.  The question is whether the presence of these psammoma bodies is unique to meningiomas, or if they can be found in other tumor types, thus limiting their diagnostic value for definitively identifying a meningioma.\n",
            "\n",
            "Combined Answer: Hospital of Yangzhou University, Yangzhou University (Yangzhou, China). The absence of tumor tissues in the matched normal tissues was confirmed by two pathologists. All tissues were obtained during surgery and immediately stored in liquid nitrogen prior to use. Patients provided written informed consent. The following clinic pathologic data were obtained from the original pathology reports: age, tumor size, location and invasion, lymph node metastases, grade of differentiation, and tumor stage. Staging was assessed according to American Joint tract, 10 cases). Our series of 30 MWS patients included 20 with HSCR (five female and 15 male; long segment, six cases; short segment, five cases; unknown length of the aganglionic tract, nine cases). We also studied a previously reported family where three members in two generations had tumours of the sympathetic nervous system of various grades at different ages (childhood in two cases and adulthood in one case).12 Most interestingly, HSCR occurred in two members of another branch of the family who were shown to carry the PHOX2B gene previously reported have been centered in the thalamus, pons or spinal cord, we identified six malignant gliomas arising in other midline sites including the third ventricle, hypothalamus, pineal region and cerebellum (Figure 4). All of these tumors displayed typical morphologic features of infiltrative astrocytomas, except for one glioblastoma arising in the third ventricle of a 19‐year‐old woman with tumor cells that contained clear cytoplasm and distinct cell borders (Figures 4G–I). Among the 41 diffuse midline gliomas with histone H3‐K27M with rather monomorphic piloid astrocytes radially arranged vessels in a prominent myxoid stroma, resembling pilomyxoid astrocytoma. Other areas of the tumor demonstrated increased cellularity and pleomorphism with brisk mitotic activity and microvascular proliferation, which together with the histone H3‐K27M positivity, warranted classification as glioblastoma, WHO grade IV (Figures 5C and D). Another notable glioblastoma arising in the thalamus of a 27‐year‐old woman demonstrated epithelioid features and also contained primitive cerebellum. Patients with pontine tumors were younger (median = 7 years) than those with thalamic (median = 24 years) or spinal (median = 25 years) tumors. A wide morphologic spectrum was encountered including gliomas with giant cells, epithelioid and rhabdoid cells, primitive neuroectodermal tumor (PNET)‐like foci, neuropil‐like islands, pilomyxoid features, ependymal‐like areas, sarcomatous transformation, ganglionic differentiation and pleomorphic xanthoastrocytoma (PXA)‐like areas. In this series, histone H3‐K27M mutation was mutually follow the expected clinical course of what can be considered classic for children with DIPG, suggesting a potentially different clinical and molecular entity which should be added to the group of “atypical” DIPG when considering clinical trial design. These H3.3 wild-type tumors may be more heterogeneous in terms of histology and biological features than K27M-H3.3 tumors, and may perhaps, with larger numbers, be further divided into different sub-groups. One uncommon subgroup of H3.3 wild-type brainstem tumors which is hinted at by our series Center, Sungkyunkwan University School of Medicine, Seoul, South Korea T.W. Kim, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea F. Barlesi, Aix Marseille University, Centre National de la Recherche Scientifique, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille, France P.N. Munster, University of California, San Francisco, San Francisco, California S.S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta T.F. nuclear staining seen in positive tumor cells. A representative example of a diffuse midline glioma with histone H3‐K27M mutation arising in the pons of an eight‐year‐old boy is shown in Figure 3. An autopsy was performed on this patient following palliative radiation and chemotherapy, and histone H3‐K27M immunohistochemistry was helpful in assessing the widespread infiltration of the tumor cells throughout the brain and spinal cord. Tumor cells were seen infiltrating from the brainstem into multiple cranial nerves (Figures 3H and I), a features, ependymal‐like areas, sarcomatous transformation, ganglionic differentiation and pleomorphic xanthoastrocytoma (PXA)‐like areas. In this series, histone H3‐K27M mutation was mutually exclusive with IDH1 mutation and EGFR amplification, rarely co‐occurred with BRAF‐V600E mutation, and was commonly associated with p53 overexpression, ATRX loss (except in pontine gliomas), and monosomy 10. arising in the cerebral hemispheres. However, the molecular underpinnings of the rest of these tumors remains unknown, and none of the 19 tested cases had IDH1 mutation. Notably, three of these diffuse midline gliomas lacking histone H3‐K27M mutation had a history of prior radiation therapy. These included the only K27M negative DIPG in this study that occurred in a 15‐year‐old boy after receiving craniospinal irradiation at 5 years of age following resection of a medulloblastoma from the midline of the posterior fossa. The second patient was\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 303.81ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2192.36ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 857.67ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:tornado.access:429 POST /v1beta/models/gemini-1.5-flash:generateContent?%24alt=json%3Benum-encoding%3Dint (127.0.0.1) 2114.75ms\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What are the known families of deadenylases?\n",
            "Refined Query: Beyond simply listing deadenylase families,  explore the known classifications of enzymes that catalyze the removal of adenine nucleotides from the 3' end of RNA, detailing their structural and mechanistic diversity, and their roles in RNA metabolism.\n",
            "\n",
            "Combined Answer: adenylated in 50-μL reactions containing 1× NEBuffer 2 (New England Biolabs), 0.2 mM dATP, and 15 units Klenow (3′ → 5′ exo-) (New England Biolabs) at 37 °C for 30 min. The samples were purified with MinElute columns and eluted in 2× 10 μL Buffer EB. The samples were ligated to TruSeq adapters in 48-μL reactions containing 1× Quick ligase buffer and 3 μL Quick T4 DNA Ligase (New England Biolabs) by incubating at room temperature for 15 min. The samples were purified with MinElute columns and were eluted in 2× 20 μL EB. The volumes of the and Suv4-20 (Figure 1A). Depletion of the monomethyltransferase PR-Set7 with double-stranded RNA (dsRNA) mediated RNAi for 72 h resulted in a reduction of H4K20me1 levels compared with control RNAi. Conversely, depletion of Suv4-20, which catalyzes di- and tri-methylation of H4K20, resulted in a dramatic increase in H4K20me1 levels. We also observed a slight increase in H4K20me1 levels relative to control RNAi when simultaneously depleting PR-Set7 and Suv4-20. This slight increase is likely due to differences between the rates of H4K20 at 25°C efficiently cleaved and polyadenylated the RNA, but extracts from cells after the shift to 37°C were not functional in this coupled reaction (Fig. 1B, left). The poly(A) addition step can be studied separately from cleavage using RNA that ends at the GAL7 poly(A) site. Compared to cells grown at 25°C, levels of polyadenylation markedly decreased in extracts prepared from cells 15 min after the shift to 37°C, and very little adenylated product could be detected after 60 min (Fig. 1B, right). We conclude that Pta1 is important for both RNA editing is the post- or co-transcriptional modification of RNA nucleotides from their genome-encoded sequence. The most common type of editing in metazoans is the deamination of adenosine into inosine (A-to-I) catalyzed by the adenosine deaminase acting on RNA (ADAR) family of enzymes (1). ADAR enzymes bind double-stranded regions of RNA molecules and deaminate adenosine into inosine, which is subsequently recognized as guanosine by the cellular machinery. ADARs perform critical functions in the nervous system (2), and knockout of ADARs in Total liver RNAs in the homogenate were extracted with an RNeasy Minikit (Qiagen) by following the manufacturer's instructions. Contaminated DNA was eliminated by an on-column DNase digestion step. After quantitation and normalization of RNA samples, RNA was reverse transcribed with an iScript cDNA synthesis kit (Bio-Rad) in which a mixture of oligonucleotide (dT) and random primers was used. Then, DHBV cDNA was measured by real-time PCR and normalized with the cDNA of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a LightCycler 480 using stable isotope-labeled formaldehyde to form dimethyl amine. The selectively bound proteins determined by mass spectrometry were subjected to functional and pathway analysis. Our findings suggest that the targets of compound 106 are involved not only in transcriptional regulation but also in posttranscriptional processing of mRNA. RNA editing refers to co-transcriptional RNA base modifications that increase transcript sequence diversity without changing the underlying genome. Two types of single base modifications, namely adenosine to inosine conversions (A→I) and cytidin to uridine (C→U) conversions, have been characterised in detail over decades of research [1]. Both conversions are executed by two specific classes of RNA binding proteins (RBPs) that interact with their respective RNA targets: Adenosine deaminase acting on RNA (ADAR) catalyses A→I conversions, whereas RIblast implements two major steps: database construction and an RNA interaction search. Figure 1C shows the flowchart of the RIblast algorithm. In the database construction step, RIblast first calculates the accessible energy of each segment in the target RNA dataset. To speed up calculation, RIblast calculates approximated accessible energies. Second, target RNA sequences are reversed and concatenated with delimiter symbols inserted between the two sequences. Third, a suffix array of the concatenated sequence is constructed. The suffix array Table S1). Combination of alternating recognition sites allows for higher degradation efficiency and reduces sequence repetitiveness. The two enzymes have recognition sites of lengths 27 and 18 bp, respectively, which even with some degeneracy allowed in the recognition site (Gimble and Wang 1996; Argast et al. 1998) makes their random occurrence in a transcriptome highly improbable. The two enzymes work at the same temperature and in the same buffer, so their digestion can be combined in a single step. A fraction of the synthesised carrier To enable profiling of minute amounts of RNA, we set out to design a carrier RNA similar in size distribution and percentage of capped RNA to the cellular RNA, but whose cDNA will selectively degrade without affecting the cDNA originating from the sample. We constructed the synthetic gene used as a template for run-off in vitro transcription of the carrier RNA (Supplemental Fig. S1A,B; Supplemental Table S1; see Methods for details). The synthetic gene is based on the Escherichia coli leucyl-tRNA synthetase sequence for two main reasons. First,\n",
            "[0.36619562]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which translocation is harbored in the Askin tumor cells?\n",
            "Refined Query: Askin tumors are characterized by a specific chromosomal translocation.  What is the precise chromosomal rearrangement, involving which genes, consistently found in these cancer cells?\n",
            "\n",
            "Combined Answer: Nadeau and Taylor (1984) suggested a model of genome evolution in which evolutionary chromosomal breakpoints are distributed randomly throughout the mouse and human genomes, and postulated conserved blocks of synteny to be “relics of ancient linkage groups not yet disrupted by chromosome rearrangement.” In closely related genomes such as mouse and human, this may be partially true, but it is likely that in distantly related vertebrates, sufficient numbers of translocation events have occurred during evolution to rearrange all large chromosomal al. [90], and Weischenfeldt et al. [91] representing 52 different forms of cancer, each including between 2 and 148 cancerCNA regions and covering 0.03% to 90.15% of the genome (Table S1). To avoid confounding our analysis with whole chromosome anueploidies, which are common in cancer genomes, we also followed convention [73] and excluded any cancerCNA region that is larger than 50% of the chromosome arm on which it resides. The datasets were analyzed individually, except for Bullinger 2010 [78], Nik-Zainal 2012 [85], Holmfeldt 2013 [89], and Seventeen cancerCNA datasets were obtained from TCGARN et al. [76], Walter et al. [77], Beroukhim et al. [73], Bullinger et al. [78], Taylor et al. [79], TCGARN et al. [80], Curtis et al. [81], TCGARN et al. [82], TCGARN et al. [83], TCGARN et al. [84], Nik-Zainal et al. [85], Robinson et al. [86], Walker et al. [87], Zhang et al. [88], Holmfeldt et al. [89], TCGARN et al. [90], and Weischenfeldt et al. [91]. All data were filtered to remove any cancerCNA longer than 50% of the length of the chromosome arm on which it resides. This was done to region that is larger than 50% of the chromosome arm on which it resides. The datasets were analyzed individually, except for Bullinger 2010 [78], Nik-Zainal 2012 [85], Holmfeldt 2013 [89], and Weischenfeldt 2013 [91], which are too small to be considered on their own (Table S3). We also pooled all datasets except one to produce our pooled cancerCNA dataset; the Walker 2012 [87] dataset was excluded because it covers 90.15% of the genome and was therefore considered too large to be combined informatively with other datasets. Conveniently, two fragments18; subsequent studies showed that such fragments are condensed heterochromatin19. Indeed we found repressed regions are depleted for short fragments and enriched for phased multi-nucleosomal inserts, consistent with their expected inaccessible state. These data suggest that ATAC-seq reveals differentially accessible forms of chromatin, which have been long hypothesized to exist in vivo2,20,21. To explore nucleosome positioning within accessible chromatin in the GM12878 cell line, we partitioned our data into reads generated from which is particularly pronounced in telomeric regions (Sturm et al. 2012). No G34R/V mutations were found in DIPG tumors, and the median age of G34 mutant tumor occurrence was older than for K27M mutant tumors (Schwartzentruber et al. 2012; Wu et al. 2012; Gielen et al. 2013). Additional sequence analysis of DIPG tumors has highlighted the complexity of the genomic landscape, with identification of additional driver mutations that overlap or are excluded from tumors bearing mutant histones. In nearly 30 % of glioblastoma tumors, the H3F3A K27M human, this may be partially true, but it is likely that in distantly related vertebrates, sufficient numbers of translocation events have occurred during evolution to rearrange all large chromosomal regions. The Nadeau and Taylor paper was published before the discovery of hox clusters and very large genes, neither of which can be broken without disease as a result, and thus are exceptions to this hypothesis. It was recently noted that there are synteny blocks of significant size across all vertebrate genomes, and these have been hypothesized Atlas Research Network (TCGARN) et al. [76], Walter et al. [77], Beroukhim et al. [73], Bullinger et al. [78], Taylor et al. [79], TCGARN et al. [80], Curtis et al. [81], TCGARN et al. [82], TCGARN et al. [83], TCGARN et al. [84], Nik-Zainal et al. [85], Robinson et al. [86], Walker et al. [87], Zhang et al. [88], Holmfeldt et al. [89], TCGARN et al. [90], and Weischenfeldt et al. [91] representing 52 different forms of cancer, each including between 2 and 148 cancerCNA regions and covering 0.03% to 90.15% of the genome (Table S1). To avoid elements contained. The parental origin of the chromosome bearing the alteration could be determined in 21 cases through microsatellite segregation analyses. Ten rearrangements occurred as de novo events in the paternal chromosome and four in the maternal chromosome, while the remaining alterations were inherited from the carrier mother (in five cases) or from the father (two cases). These inherited CNVs were X-linked or associated to mild affectation in the carrier parent. Remarkably, 24 out of the 29 UCEs were contained in the rearrangements a lung tumor cell line [29] but not yet in primary NSCLC tumors. Since we observed that the region upstream of EN1 was highly hypermethylated in the tumors and involved a region of more than 15 kbp (Figure 4A), we selected two extra fragments within this region, in addition to the EN1 promoter. The other two fragments were located at positions chr2:119,331,343 to 119,331,692 and chr2:119,328,097 to 119,328,400 and we named them Frag_01 and Frag_02, respectively. Selection of the fragments for bisulfite sequencing analysis was based on the\n",
            "[0.5814931]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: What is the function of the AtxA pleiotropic regulator?\n",
            "Refined Query: The AtxA protein in *Bacillus subtilis* is a pleiotropic regulator.  What specific genes or metabolic pathways does it control, and how does its regulation impact bacterial physiology, particularly in relation to stress responses and adaptation to diverse environments?\n",
            "\n",
            "Combined Answer: pathogenesis [12]. Parsing genes into pathogenic and non-pathogenic anthrax-specific subsets would help in identifying molecular virulence pathways in B. anthracis, which are not fully established [7,11,13]. The best characterized pleiotropic regulator of virulence-related genes in B. anthracis is AtxA (for Anthrax toxin activator) [14,15]. AtxA is a transcriptional regulator containing two DNA binding domains in the N-terminal region [11]. At the transcriptional level, production of atxA mRNA is upregulated by temperatures close to 37°C [16], The Bacillus anthracis toxin genes, cya, lef, and pag, can be viewed as a regulon, in which transcription of all three genes is activated in trans by the same regulatory gene, atxA, in response to the same signal, CO2. In atxA+ strains, toxin gene expression is increased 5- to 20-fold in cells grown in 5% CO2 relative to cells grown in air. CO2-enhanced toxin gene transcription is not observed in atx4-null mutants. Here, we used two independent techniques to obtain evidence for additional CO2-induced atxA-regulated genes. First, total protein Transcriptome analysis identifies Bacillus anthracis genes that respond to CO2 through an AtxA-dependent mechanism - PMC The anthrax toxin activator gene atxA is associated with CO2-enhanced non-toxin gene expression in Bacillus anthracis - PMC At the post-translational level, AtxA is regulated via the phosphorylation of two histidine residues [20] and an unknown mechanism requiring the presence of the global regulator CodY [21,22]. Another post-translational regulatory effect is that elevated CO2 increases the ratio of dimeric to monomeric AtxA by approximately two-fold [23]. AtxA also is sufficient to cause CO2-related induction of PA in B. anthracis[24], can interact with the pXO2-regulators AcpA and AcpB to upregulate the transcription of the capsule operon [25], and AtxA can enriched in CO2 act to modulate the degree of that stimulation. Consistent with other studies, we found that the expression of atxA itself is not increased as significantly as the genes it stimulates, if at all, when B. anthracis is grown in environments containing increased concentrations of CO2[11,12,16]. AtxA is regulated downstream of transcription by a number of CO2-related processes [20,22-24,60], and our data provide further evidence that this regulation alone is sufficient to account for its transcriptional effects on virulence-related anthrax toxin gene activation. Our data indicate a clear association of atxA with CO2-enhanced gene expression in B. anthracis and provide evidence that atxA regulates genes other than the structural genes for the anthrax toxin proteins. CO2 or AtxA are also upregulated synergistically by their combination. Understanding the interaction of these key components is necessary for a full description of how ancillary genes are transcribed in association with the known pXO1-encoded toxins. Furthermore, our findings add to the number of pXO1-encoded genes that are linked to and affected by AtxA and CO2. These genes offer subjects for future experiments aimed at characterizing the genetic systems involved in the pathogenesis of B. anthracis. Earlier studies reported data consistent Bacillus anthracis is a spore-forming, gram-positive bacterium that is the causative agent of anthrax. The major factors responsible for its pathogenesis are encoded on two virulence plasmids, pXO1 and pXO2 [1-4]. pXO1 contains the genes coding for the three secreted toxin proteins, protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to cellular receptors, forms a complex with both EF (forming edema toxin) and LF (forming lethal toxin), and acts as a translocase [4,5]. pXO2 encodes for a γ-linked poly-D-glutamic acid appeared to be co-transcribed (near equal read numbers) with the adjacent bslA (pXO1_0124). However, their staircase-like pattern of gene expression [58] indicates that each of these genes may also have its own promoter. This could suggest that AtxA binds independently to each putative promoter to induce or modulate gene expression. Although this is possible, the clustering of AtxA-regulated genes suggests that AtxA may instead act in a more a global fashion, perhaps by simultaneously increasing the probability of RNA polymerase binding to\n",
            "[0.80606276]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which R/bioconductor package utilizes the Hilbert curve in order to visualize genomic data?\n",
            "Refined Query: I'm looking for the Bioconductor R package that employs the Hilbert curve for visualizing genomic data.  Specifically, I need the package name that uses this space-filling curve to represent high-dimensional genomic information in a lower-dimensional space for improved visualization.\n",
            "\n",
            "Combined Answer: We developed the annotatr Bioconductor package to flexibly and quickly summarize and plot annotations of genomic regions. The annotatr package reports all intersections of regions and annotations, giving a better understanding of the genomic context of the regions. A variety of graphics functions are implemented to easily plot numerical or categorical data associated with the regions across the annotations, and across annotation intersections, providing insight into how characteristics of the regions differ across the annotations. We and cofactors, have been described, DNA shape recently gained attention as another feature that fine-tunes the DNA binding specificities of some transcription factor families. Our Genome Browser for DNA shape annotations (GBshape; freely available at http://rohslab.cmb.usc.edu/GBshape/) provides minor groove width, propeller twist, roll, helix twist and hydroxyl radical cleavage predictions for the entire genomes of 94 organisms. Additional genomes can easily be added using the GBshape framework. GBshape can be used to visualize DNA shape homepage. On the Genome Browser Gateway page the user chooses an organism group, species genome, genome assembly, genome position and search terms of interest. After the ‘submit’ button is pressed, consolidated results for DNA shape annotations, together with standard genome annotations (Figure 2A), are shown on the display page. The shape annotations MGW, ProT, Roll, HelT and ORChID2 can be shown as quantitative plots (Figure 2B) or condensed into heat maps (Figure 2C). The sequence-alignment tool, BLAT, can be used to search specific regions cummeRbund (http://www.bioconductor.org/packages/release/bioc/html/cummeRbund.html) and biomaRt (http://www.bioconductor.org/packages/release/bioc/html/biomaRt.html) were used in combination with custom R scripts to perform quality assessment and further refine analysis results. at play. In addition to tabular output of the annotations, annotatr's built-in plotting functions provide an easy and flexible way to summarize the annotations and view how data associated with the regions changes in different genomic contexts. The annotatr package thus enables fast exploration, more complete genomic contextualization of experiments, and more potential discoveries. Associating regions of interest to genomic annotations is a standard part of many bioinformatics pipelines. The annotatr package improves upon existing annotation tools by returning all the genomic annotations associated with a region instead of artificially prioritizing one annotation type over another, giving a clearer picture of the biological complexities at play. In addition to tabular output of the annotations, annotatr's built-in plotting functions provide an easy and flexible way to summarize the annotations and view how data associated RAPIDR is implemented in R and can be freely downloaded via CRAN from here: http://cran.r-project.org/web/packages/RAPIDR/index.html. Contact: kitty.lo@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online. 1). For each organism the database provides four genome browser tracks with annotations for Minor Groove Width (MGW), Propeller Twist (ProT), Roll and Helix Twist (HelT) (14). In a fifth track, GBshape shows hydroxyl radical cleavage annotations from the ·OH Radical Cleavage Intensity Database for double-stranded DNA (ORChID2) (18). These five DNA shape annotations were generated with the high-throughput prediction platform. DNA shape data can be visualized either qualitatively or downloaded as quantitative values via the GBshape user five DNA shape annotations were generated with the high-throughput prediction platform. DNA shape data can be visualized either qualitatively or downloaded as quantitative values via the GBshape user interface. GBshape contains DNA shape annotations for 91 genomes taken from the UCSC Genome Browser (19) and three additional genomes from plants, parasitic protists and bacteria (Table 1). We demonstrate the value of analyzing DNA shape annotations using GBshape by comparing the structural features of in vivo nucleosome binding sites from worm, to display further information about the local genes. Manhattan plots can be downloaded as PDF files for use in manuscripts or presentations. The vertical panels on the left (Figure 2E and 2F) show a brief summary, including information about the selected species, data set, and selected settings. Additionally, the top 10 associated SNPs and their genes are ranked (if a gene annotation set was selected for the experiment). Moreover, each SNP in a Manhattan plot is clickable, such that users can obtain additional information about the alleles at\n",
            "[0.88423514]\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "### Expanded entities and terms:\n",
            "\n",
            " ### Clustered: {}\n",
            "Original Query: Which packages are used for performing overlap analysis of genomic regions in R/bioconductor?\n",
            "Refined Query: I need a comprehensive list of Bioconductor R packages suitable for identifying overlapping genomic intervals.  The analysis should encompass various overlap types and provide methods for quantifying the extent of overlap between genomic regions from different datasets.\n",
            "\n",
            "Combined Answer: of trait-associated SNPs can be exploited to indicate whether a given genomic interval or intervals are likely to be functionally connected with certain phenotypes or diseases. Despite this importance, currently, there is no ready-to-use computational tool able to connect genomic intervals to phenotypes. Here, we present traseR, an easy-to-use R Bioconductor package that performs enrichment analyses of trait-associated SNPs in arbitrary genomic intervals with flexible options, including testing method, type of background and inclusion of SNPs Outside of the R ecosystem, BEDtools (Quinlan and Hall, 2010), implemented in C ++, intersects and aggregates genomic regions with annotations, and is very fast. However, its more general purpose means users must provide all annotations and manually generate plots. We developed annotatr, a Bioconductor package that reports all intersections of genomic regions with built-in genomic annotations for D. melanogaster (dm3 and dm6), H. Sapiens (hg19 and hg38), M. musculus (mm9 and mm10), R. norvegicus (rn4, rn5 and rn6), annotations imported from We developed the annotatr Bioconductor package to flexibly and quickly summarize and plot annotations of genomic regions. The annotatr package reports all intersections of regions and annotations, giving a better understanding of the genomic context of the regions. A variety of graphics functions are implemented to easily plot numerical or categorical data associated with the regions across the annotations, and across annotation intersections, providing insight into how characteristics of the regions differ across the annotations. We intergenic regions. Despite the great utilities, currently there is no off-the-shelf computational tool available to carry out this non-trivial test. To cater for this demand, we developed an R Bioconductor package named traseR, TRait-Associated SNP EnRichment analysis, which offers a turnkey solution for enrichment analysis of taSNPs. RAPIDR is implemented in R and can be freely downloaded via CRAN from here: http://cran.r-project.org/web/packages/RAPIDR/index.html. Contact: kitty.lo@ucl.ac.uk Supplementary information: Supplementary data are available at Bioinformatics online. binds in enhancers, while another tends to bind at exon–intron boundaries. While tools exist to intersect genomic regions of interest with genomic annotations, we found the annotations, methods of intersection, and graphics options had room for improvement. ChIPpeakAnno (Zhu et al., 2010) is an R package that has been used in many studies across a variety of organisms. It returns only one genomic annotation per input region, and while providing the user with some plots, these are limited by their inability to incorporate data associated with sources, construction, and genome availability for all included annotations are provided in Supplementary Methods and Supplementary Table S1. The annotatr package consists of four modules that read, annotate, summarize and visualize genomic regions. The read module reads a BED6+ file, defined as BED6 and any number of numerical or categorical data columns (Supplementary Table S2). The annotate module reports the overlap of all input regions with all intersecting genomic annotations selected by the user, with a user-defined threshold overlap Analyses were performed using R statistical computing environment (R Core Team 2017) and Bioconductor (Gentleman et al. 2004) packages (http://www.bioconductor.org/). Analyses details are presented in Supplemental Methods. Data used for building MethPed is available at GEO (accession numbers: GSE50022, GSE55712, GSE36278, GSE52556, GSE54880, GSE45353 and GSE44684). Project home page: http://bioconductor.org/packages/MethPed/ Operating systems: any operating system supporting R Programming language: R Other requirements: working R installation, with Bioconductor version 3.3 Any restriction to use by non-academics: none. Data used for building MethPed is available at GEO (accession numbers: GSE50022, GSE55712, GSE36278, GSE52556, GSE54880, GSE45353 and GSE44684). Project home page: http://bioconductor.org/packages/MethPed/ Operating systems: any operating system supporting R Programming language: R Other requirements: working R installation, with Bioconductor version 3.3 Any restriction to use by non-academics: none.\n"
          ]
        },
        {
          "output_type": "error",
          "ename": "KeyboardInterrupt",
          "evalue": "",
          "traceback": [
            "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
            "\u001b[0;32m<ipython-input-108-3238e3dae574>\u001b[0m in \u001b[0;36m<cell line: 4>\u001b[0;34m()\u001b[0m\n\u001b[1;32m      7\u001b[0m     \u001b[0;32mexcept\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      8\u001b[0m         \u001b[0;32mcontinue\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 9\u001b[0;31m     \u001b[0mscore\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mevaluate_similarity_with_ground_truth\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0mgen_resp\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ma\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     10\u001b[0m     \u001b[0mscore_cos\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mscore\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     11\u001b[0m     \u001b[0mprint\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mscore\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m<ipython-input-106-a63fa02c93a4>\u001b[0m in \u001b[0;36mevaluate_similarity_with_ground_truth\u001b[0;34m(generated_responses, ground_truth)\u001b[0m\n\u001b[1;32m     33\u001b[0m \u001b[0;32mdef\u001b[0m \u001b[0mevaluate_similarity_with_ground_truth\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mgenerated_responses\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mground_truth\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     34\u001b[0m     \u001b[0mscores\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m[\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 35\u001b[0;31m     \u001b[0mmodel_eval\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mSentenceTransformer\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m'all-MiniLM-L6-v2'\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     36\u001b[0m     \u001b[0;32mfor\u001b[0m \u001b[0mgen\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtruth\u001b[0m \u001b[0;32min\u001b[0m \u001b[0mzip\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mgenerated_responses\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mground_truth\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     37\u001b[0m         \u001b[0mgen_embedding\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mmodel_eval\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mgen\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mconvert_to_tensor\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;32mTrue\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mcpu\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mnumpy\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/sentence_transformers/SentenceTransformer.py\u001b[0m in \u001b[0;36m__init__\u001b[0;34m(self, model_name_or_path, modules, device, prompts, default_prompt_name, similarity_fn_name, cache_folder, trust_remote_code, revision, local_files_only, token, use_auth_token, truncate_dim, model_kwargs, tokenizer_kwargs, config_kwargs, model_card_data, backend)\u001b[0m\n\u001b[1;32m    306\u001b[0m                 \u001b[0mlocal_files_only\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mlocal_files_only\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    307\u001b[0m             ):\n\u001b[0;32m--> 308\u001b[0;31m                 modules, self.module_kwargs = self._load_sbert_model(\n\u001b[0m\u001b[1;32m    309\u001b[0m                     \u001b[0mmodel_name_or_path\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    310\u001b[0m                     \u001b[0mtoken\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtoken\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/sentence_transformers/SentenceTransformer.py\u001b[0m in \u001b[0;36m_load_sbert_model\u001b[0;34m(self, model_name_or_path, token, cache_folder, revision, trust_remote_code, local_files_only, model_kwargs, tokenizer_kwargs, config_kwargs)\u001b[0m\n\u001b[1;32m   1644\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1645\u001b[0m         \u001b[0;31m# Load the modules of sentence transformer\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1646\u001b[0;31m         modules_json_path = load_file_path(\n\u001b[0m\u001b[1;32m   1647\u001b[0m             \u001b[0mmodel_name_or_path\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1648\u001b[0m             \u001b[0;34m\"modules.json\"\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/sentence_transformers/util.py\u001b[0m in \u001b[0;36mload_file_path\u001b[0;34m(model_name_or_path, filename, token, cache_folder, revision, local_files_only)\u001b[0m\n\u001b[1;32m   1341\u001b[0m     \u001b[0;31m# If file is remote\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1342\u001b[0m     \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1343\u001b[0;31m         return hf_hub_download(\n\u001b[0m\u001b[1;32m   1344\u001b[0m             \u001b[0mmodel_name_or_path\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1345\u001b[0m             \u001b[0mfilename\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mfilename\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_validators.py\u001b[0m in \u001b[0;36m_inner_fn\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    112\u001b[0m             \u001b[0mkwargs\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msmoothly_deprecate_use_auth_token\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfn_name\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mfn\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m__name__\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mhas_token\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mhas_token\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkwargs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    113\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 114\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mfn\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    115\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    116\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0m_inner_fn\u001b[0m  \u001b[0;31m# type: ignore\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/file_download.py\u001b[0m in \u001b[0;36mhf_hub_download\u001b[0;34m(repo_id, filename, subfolder, repo_type, revision, library_name, library_version, cache_dir, local_dir, user_agent, force_download, proxies, etag_timeout, token, local_files_only, headers, endpoint, resume_download, force_filename, local_dir_use_symlinks)\u001b[0m\n\u001b[1;32m    858\u001b[0m         )\n\u001b[1;32m    859\u001b[0m     \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 860\u001b[0;31m         return _hf_hub_download_to_cache_dir(\n\u001b[0m\u001b[1;32m    861\u001b[0m             \u001b[0;31m# Destination\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    862\u001b[0m             \u001b[0mcache_dir\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mcache_dir\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/file_download.py\u001b[0m in \u001b[0;36m_hf_hub_download_to_cache_dir\u001b[0;34m(cache_dir, repo_id, filename, repo_type, revision, endpoint, etag_timeout, headers, proxies, token, local_files_only, force_download)\u001b[0m\n\u001b[1;32m    921\u001b[0m     \u001b[0;31m# Try to get metadata (etag, commit_hash, url, size) from the server.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    922\u001b[0m     \u001b[0;31m# If we can't, a HEAD request error is returned.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 923\u001b[0;31m     (url_to_download, etag, commit_hash, expected_size, head_call_error) = _get_metadata_or_catch_error(\n\u001b[0m\u001b[1;32m    924\u001b[0m         \u001b[0mrepo_id\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mrepo_id\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    925\u001b[0m         \u001b[0mfilename\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mfilename\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/file_download.py\u001b[0m in \u001b[0;36m_get_metadata_or_catch_error\u001b[0;34m(repo_id, filename, repo_type, revision, endpoint, proxies, etag_timeout, headers, token, local_files_only, relative_filename, storage_folder)\u001b[0m\n\u001b[1;32m   1372\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1373\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1374\u001b[0;31m                 metadata = get_hf_file_metadata(\n\u001b[0m\u001b[1;32m   1375\u001b[0m                     \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mproxies\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mproxies\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0metag_timeout\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mheaders\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mheaders\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtoken\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mtoken\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1376\u001b[0m                 )\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_validators.py\u001b[0m in \u001b[0;36m_inner_fn\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    112\u001b[0m             \u001b[0mkwargs\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msmoothly_deprecate_use_auth_token\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mfn_name\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mfn\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m__name__\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mhas_token\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mhas_token\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mkwargs\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    113\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 114\u001b[0;31m         \u001b[0;32mreturn\u001b[0m \u001b[0mfn\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    115\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    116\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0m_inner_fn\u001b[0m  \u001b[0;31m# type: ignore\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/file_download.py\u001b[0m in \u001b[0;36mget_hf_file_metadata\u001b[0;34m(url, token, proxies, timeout, library_name, library_version, user_agent, headers)\u001b[0m\n\u001b[1;32m   1292\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1293\u001b[0m     \u001b[0;31m# Retrieve metadata\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1294\u001b[0;31m     r = _request_wrapper(\n\u001b[0m\u001b[1;32m   1295\u001b[0m         \u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m\"HEAD\"\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1296\u001b[0m         \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/file_download.py\u001b[0m in \u001b[0;36m_request_wrapper\u001b[0;34m(method, url, follow_relative_redirects, **params)\u001b[0m\n\u001b[1;32m    276\u001b[0m     \u001b[0;31m# Recursively follow relative redirects\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    277\u001b[0m     \u001b[0;32mif\u001b[0m \u001b[0mfollow_relative_redirects\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 278\u001b[0;31m         response = _request_wrapper(\n\u001b[0m\u001b[1;32m    279\u001b[0m             \u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    280\u001b[0m             \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/file_download.py\u001b[0m in \u001b[0;36m_request_wrapper\u001b[0;34m(method, url, follow_relative_redirects, **params)\u001b[0m\n\u001b[1;32m    299\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    300\u001b[0m     \u001b[0;31m# Perform request and return if status_code is not in the retry list.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 301\u001b[0;31m     \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mget_session\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mparams\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    302\u001b[0m     \u001b[0mhf_raise_for_status\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mresponse\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    303\u001b[0m     \u001b[0;32mreturn\u001b[0m \u001b[0mresponse\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/sessions.py\u001b[0m in \u001b[0;36mrequest\u001b[0;34m(self, method, url, params, data, headers, cookies, files, auth, timeout, allow_redirects, proxies, hooks, stream, verify, cert, json)\u001b[0m\n\u001b[1;32m    587\u001b[0m         }\n\u001b[1;32m    588\u001b[0m         \u001b[0msend_kwargs\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mupdate\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0msettings\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 589\u001b[0;31m         \u001b[0mresp\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mprep\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0msend_kwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    590\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    591\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/sessions.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, request, **kwargs)\u001b[0m\n\u001b[1;32m    701\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    702\u001b[0m         \u001b[0;31m# Send the request\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 703\u001b[0;31m         \u001b[0mr\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0madapter\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    704\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    705\u001b[0m         \u001b[0;31m# Total elapsed time of the request (approximately)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_http.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, request, *args, **kwargs)\u001b[0m\n\u001b[1;32m     91\u001b[0m         \u001b[0;34m\"\"\"Catch any RequestException to append request id to the error message for debugging.\"\"\"\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     92\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 93\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msend\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m*\u001b[0m\u001b[0margs\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m     94\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0mrequests\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mRequestException\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     95\u001b[0m             \u001b[0mrequest_id\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mrequest\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mheaders\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mget\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mX_AMZN_TRACE_ID\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/requests/adapters.py\u001b[0m in \u001b[0;36msend\u001b[0;34m(self, request, stream, timeout, verify, cert, proxies)\u001b[0m\n\u001b[1;32m    665\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    666\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 667\u001b[0;31m             resp = conn.urlopen(\n\u001b[0m\u001b[1;32m    668\u001b[0m                 \u001b[0mmethod\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mrequest\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    669\u001b[0m                 \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/urllib3/connectionpool.py\u001b[0m in \u001b[0;36murlopen\u001b[0;34m(self, method, url, body, headers, retries, redirect, assert_same_host, timeout, pool_timeout, release_conn, chunked, body_pos, preload_content, decode_content, **response_kw)\u001b[0m\n\u001b[1;32m    787\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    788\u001b[0m             \u001b[0;31m# Make the request on the HTTPConnection object\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 789\u001b[0;31m             response = self._make_request(\n\u001b[0m\u001b[1;32m    790\u001b[0m                 \u001b[0mconn\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    791\u001b[0m                 \u001b[0mmethod\u001b[0m\u001b[0;34m,\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/urllib3/connectionpool.py\u001b[0m in \u001b[0;36m_make_request\u001b[0;34m(self, conn, method, url, body, headers, retries, timeout, chunked, response_conn, preload_content, decode_content, enforce_content_length)\u001b[0m\n\u001b[1;32m    534\u001b[0m         \u001b[0;31m# Receive the response from the server\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    535\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 536\u001b[0;31m             \u001b[0mresponse\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mconn\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mgetresponse\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    537\u001b[0m         \u001b[0;32mexcept\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mBaseSSLError\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mOSError\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    538\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_raise_timeout\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0merr\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0me\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0murl\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0murl\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mtimeout_value\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mread_timeout\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/local/lib/python3.10/dist-packages/urllib3/connection.py\u001b[0m in \u001b[0;36mgetresponse\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    505\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    506\u001b[0m         \u001b[0;31m# Get the response from http.client.HTTPConnection\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 507\u001b[0;31m         \u001b[0mhttplib_response\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mgetresponse\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    508\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    509\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/http/client.py\u001b[0m in \u001b[0;36mgetresponse\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m   1373\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1374\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1375\u001b[0;31m                 \u001b[0mresponse\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbegin\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1376\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mConnectionError\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1377\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mclose\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/http/client.py\u001b[0m in \u001b[0;36mbegin\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    316\u001b[0m         \u001b[0;31m# read until we get a non-100 response\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    317\u001b[0m         \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 318\u001b[0;31m             \u001b[0mversion\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mstatus\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mreason\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_read_status\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    319\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mstatus\u001b[0m \u001b[0;34m!=\u001b[0m \u001b[0mCONTINUE\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    320\u001b[0m                 \u001b[0;32mbreak\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/http/client.py\u001b[0m in \u001b[0;36m_read_status\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    277\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    278\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_read_status\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 279\u001b[0;31m         \u001b[0mline\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mstr\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreadline\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0m_MAXLINE\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m\"iso-8859-1\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    280\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mline\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0m_MAXLINE\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    281\u001b[0m             \u001b[0;32mraise\u001b[0m \u001b[0mLineTooLong\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"status line\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/socket.py\u001b[0m in \u001b[0;36mreadinto\u001b[0;34m(self, b)\u001b[0m\n\u001b[1;32m    703\u001b[0m         \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    704\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 705\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sock\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    706\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    707\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_timeout_occurred\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/ssl.py\u001b[0m in \u001b[0;36mrecv_into\u001b[0;34m(self, buffer, nbytes, flags)\u001b[0m\n\u001b[1;32m   1301\u001b[0m                   \u001b[0;34m\"non-zero flags not allowed in calls to recv_into() on %s\"\u001b[0m \u001b[0;34m%\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1302\u001b[0m                   self.__class__)\n\u001b[0;32m-> 1303\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnbytes\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbuffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1304\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1305\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbuffer\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnbytes\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mflags\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;32m/usr/lib/python3.10/ssl.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, len, buffer)\u001b[0m\n\u001b[1;32m   1157\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1158\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mbuffer\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m-> 1159\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbuffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1160\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1161\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
            "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "dyzJ4VYsaJLL"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}